5.2 Cataracts      Use of corticosteroids may result in posterior subcapsular cataract formation.,result in is not a named entity
5.2 Cataracts      Use of corticosteroids may result in posterior subcapsular cataract formation.,posterior subcapsular cataract is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *   Intraocular pressure (IOP) increase- Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision.",visual acuity is not a named entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *   Intraocular pressure (IOP) increase- Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision.",glaucoma with damage is not a named entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *   Intraocular pressure (IOP) increase- Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision.",damage to the optic nerve is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *   Intraocular pressure (IOP) increase- Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision.",Intraocular pressure increase is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *   Intraocular pressure (IOP) increase- Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision.",defects in visual acuity is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *   Intraocular pressure (IOP) increase- Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision.",defects fields of vision is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *   Intraocular pressure (IOP) increase- Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision.",corticosteroids may is not a named entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *   Intraocular pressure (IOP) increase- Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision.",) increase- Prolonged is not a named entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *   Intraocular pressure (IOP) increase- Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision.",glaucoma is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *   Intraocular pressure (IOP) increase- Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision.",and fields of is not a named entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *   Intraocular pressure (IOP) increase- Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision.",IOP increase is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *   Intraocular pressure (IOP) increase- Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision.",Intraocular pressure ( is not a named entity
"In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids.",perforations is an adverse reaction entity
"In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids.",causing is not a named entity
(  5.2  )     item{ Delayed healing- The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation.,increase bleb formation is an adverse reaction entity
(  5.2  )     item{ Delayed healing- The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation.,use is not a named entity
(  5.2  )     item{ Delayed healing- The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation.,delay healing is an adverse reaction entity
(  5.2  )     item{ Delayed healing- The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation.,of bleb is not a named entity
5.4 Bacterial Infections      Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections.,secondary ocular infections is an adverse reaction entity
5.4 Bacterial Infections      Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections.,ocular infections is not a named entity
5.4 Bacterial Infections      Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections.,increase the is not a named entity
5.4 Bacterial Infections      Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections.,suppress the host response is an adverse reaction entity
"Ocular adverse reactions occurring in < 1% of subjects included application site discomfort or irritation, corneal pigmentation and striae, episcleritis, eye pruritis, eyelid irritation and crusting, foreign body sensation, increased lacrimation, macular edema, sclera hyperemia, and uveitis.",foreign body sensation is an adverse reaction entity
"Ocular adverse reactions occurring in < 1% of subjects included application site discomfort or irritation, corneal pigmentation and striae, episcleritis, eye pruritis, eyelid irritation and crusting, foreign body sensation, increased lacrimation, macular edema, sclera hyperemia, and uveitis.",corneal pigmentation is an adverse reaction entity
"Ocular adverse reactions occurring in < 1% of subjects included application site discomfort or irritation, corneal pigmentation and striae, episcleritis, eye pruritis, eyelid irritation and crusting, foreign body sensation, increased lacrimation, macular edema, sclera hyperemia, and uveitis.","edema , sclera is not a named entity"
"Ocular adverse reactions occurring in < 1% of subjects included application site discomfort or irritation, corneal pigmentation and striae, episcleritis, eye pruritis, eyelid irritation and crusting, foreign body sensation, increased lacrimation, macular edema, sclera hyperemia, and uveitis.",corneal striae is an adverse reaction entity
"Ocular adverse reactions occurring in < 1% of subjects included application site discomfort or irritation, corneal pigmentation and striae, episcleritis, eye pruritis, eyelid irritation and crusting, foreign body sensation, increased lacrimation, macular edema, sclera hyperemia, and uveitis.",or is not a named entity
"Ocular adverse reactions occurring in < 1% of subjects included application site discomfort or irritation, corneal pigmentation and striae, episcleritis, eye pruritis, eyelid irritation and crusting, foreign body sensation, increased lacrimation, macular edema, sclera hyperemia, and uveitis.",episcleritis is an adverse reaction entity
"Ocular adverse reactions occurring in < 1% of subjects included application site discomfort or irritation, corneal pigmentation and striae, episcleritis, eye pruritis, eyelid irritation and crusting, foreign body sensation, increased lacrimation, macular edema, sclera hyperemia, and uveitis.",application site discomfort is an adverse reaction entity
"Ocular adverse reactions occurring in < 1% of subjects included application site discomfort or irritation, corneal pigmentation and striae, episcleritis, eye pruritis, eyelid irritation and crusting, foreign body sensation, increased lacrimation, macular edema, sclera hyperemia, and uveitis.",", increased is not a named entity"
"Ocular adverse reactions occurring in < 1% of subjects included application site discomfort or irritation, corneal pigmentation and striae, episcleritis, eye pruritis, eyelid irritation and crusting, foreign body sensation, increased lacrimation, macular edema, sclera hyperemia, and uveitis.",eye pruritis is an adverse reaction entity
"Ocular adverse reactions occurring in < 1% of subjects included application site discomfort or irritation, corneal pigmentation and striae, episcleritis, eye pruritis, eyelid irritation and crusting, foreign body sensation, increased lacrimation, macular edema, sclera hyperemia, and uveitis.",", macular is not a named entity"
"Ocular adverse reactions occurring in < 1% of subjects included application site discomfort or irritation, corneal pigmentation and striae, episcleritis, eye pruritis, eyelid irritation and crusting, foreign body sensation, increased lacrimation, macular edema, sclera hyperemia, and uveitis.",eyelid irritation is an adverse reaction entity
"Ocular adverse reactions occurring in < 1% of subjects included application site discomfort or irritation, corneal pigmentation and striae, episcleritis, eye pruritis, eyelid irritation and crusting, foreign body sensation, increased lacrimation, macular edema, sclera hyperemia, and uveitis.",reactions occurring in is not a named entity
"Ocular adverse reactions occurring in < 1% of subjects included application site discomfort or irritation, corneal pigmentation and striae, episcleritis, eye pruritis, eyelid irritation and crusting, foreign body sensation, increased lacrimation, macular edema, sclera hyperemia, and uveitis.",% is not a named entity
"Ocular adverse reactions occurring in < 1% of subjects included application site discomfort or irritation, corneal pigmentation and striae, episcleritis, eye pruritis, eyelid irritation and crusting, foreign body sensation, increased lacrimation, macular edema, sclera hyperemia, and uveitis.",", sclera is not a named entity"
"Ocular adverse reactions occurring in < 1% of subjects included application site discomfort or irritation, corneal pigmentation and striae, episcleritis, eye pruritis, eyelid irritation and crusting, foreign body sensation, increased lacrimation, macular edema, sclera hyperemia, and uveitis.",in < is not a named entity
"Ocular adverse reactions occurring in < 1% of subjects included application site discomfort or irritation, corneal pigmentation and striae, episcleritis, eye pruritis, eyelid irritation and crusting, foreign body sensation, increased lacrimation, macular edema, sclera hyperemia, and uveitis.",macular edema is an adverse reaction entity
"Ocular adverse reactions occurring in < 1% of subjects included application site discomfort or irritation, corneal pigmentation and striae, episcleritis, eye pruritis, eyelid irritation and crusting, foreign body sensation, increased lacrimation, macular edema, sclera hyperemia, and uveitis.",", macular is not a named entity"
"Ocular adverse reactions occurring in < 1% of subjects included application site discomfort or irritation, corneal pigmentation and striae, episcleritis, eye pruritis, eyelid irritation and crusting, foreign body sensation, increased lacrimation, macular edema, sclera hyperemia, and uveitis.",", eyelid irritation is not a named entity"
"Ocular adverse reactions occurring in < 1% of subjects included application site discomfort or irritation, corneal pigmentation and striae, episcleritis, eye pruritis, eyelid irritation and crusting, foreign body sensation, increased lacrimation, macular edema, sclera hyperemia, and uveitis.",increased lacrimation is an adverse reaction entity
"Ocular adverse reactions occurring in < 1% of subjects included application site discomfort or irritation, corneal pigmentation and striae, episcleritis, eye pruritis, eyelid irritation and crusting, foreign body sensation, increased lacrimation, macular edema, sclera hyperemia, and uveitis.",application site irritation is an adverse reaction entity
"Ocular adverse reactions occurring in < 1% of subjects included application site discomfort or irritation, corneal pigmentation and striae, episcleritis, eye pruritis, eyelid irritation and crusting, foreign body sensation, increased lacrimation, macular edema, sclera hyperemia, and uveitis.",in < 1 is not a named entity
"Ocular adverse reactions occurring in < 1% of subjects included application site discomfort or irritation, corneal pigmentation and striae, episcleritis, eye pruritis, eyelid irritation and crusting, foreign body sensation, increased lacrimation, macular edema, sclera hyperemia, and uveitis.",eyelid crusting is an adverse reaction entity
"Ocular adverse reactions occurring in < 1% of subjects included application site discomfort or irritation, corneal pigmentation and striae, episcleritis, eye pruritis, eyelid irritation and crusting, foreign body sensation, increased lacrimation, macular edema, sclera hyperemia, and uveitis.",Ocular is not a named entity
"Ocular adverse reactions occurring in < 1% of subjects included application site discomfort or irritation, corneal pigmentation and striae, episcleritis, eye pruritis, eyelid irritation and crusting, foreign body sensation, increased lacrimation, macular edema, sclera hyperemia, and uveitis.",sclera hyperemia is an adverse reaction entity
"Ocular adverse reactions occurring in < 1% of subjects included application site discomfort or irritation, corneal pigmentation and striae, episcleritis, eye pruritis, eyelid irritation and crusting, foreign body sensation, increased lacrimation, macular edema, sclera hyperemia, and uveitis.",uveitis is an adverse reaction entity
"Ocular adverse reactions occurring in < 1% of subjects included application site discomfort or irritation, corneal pigmentation and striae, episcleritis, eye pruritis, eyelid irritation and crusting, foreign body sensation, increased lacrimation, macular edema, sclera hyperemia, and uveitis.",", corneal pigmentation is not a named entity"
"5.1 IOP Increase      Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision.",of is not a named entity
"5.1 IOP Increase      Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision.",defects in visual acuity is an adverse reaction entity
"5.1 IOP Increase      Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision.",glaucoma is an adverse reaction entity
"5.1 IOP Increase      Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision.",use of corticosteroids is not a named entity
"5.1 IOP Increase      Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision.",defects fields of vision is an adverse reaction entity
"5.1 IOP Increase      Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision.",fields of is not a named entity
"5.1 IOP Increase      Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision.",damage to the optic nerve is an adverse reaction entity
"5.1 IOP Increase      Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision.",in visual acuity is not a named entity
(  5.5  )     item{ Fungal infections- Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application.,5.5 ) item is not a named entity
(  5.5  )     item{ Fungal infections- Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application.,Fungal infections of the cornea is an adverse reaction entity
"6 ADVERSE REACTIONS    Adverse reactions associated with ophthalmic steroids include elevated intraocular pressure, which may be associated with optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation; secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera.",of the is not a named entity
"6 ADVERSE REACTIONS    Adverse reactions associated with ophthalmic steroids include elevated intraocular pressure, which may be associated with optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation; secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera.",secondary ocular infection is an adverse reaction entity
"6 ADVERSE REACTIONS    Adverse reactions associated with ophthalmic steroids include elevated intraocular pressure, which may be associated with optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation; secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera.",is thinning of is not a named entity
"6 ADVERSE REACTIONS    Adverse reactions associated with ophthalmic steroids include elevated intraocular pressure, which may be associated with optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation; secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera.",optic nerve damage is an adverse reaction entity
"6 ADVERSE REACTIONS    Adverse reactions associated with ophthalmic steroids include elevated intraocular pressure, which may be associated with optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation; secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera.",of the is not a named entity
"6 ADVERSE REACTIONS    Adverse reactions associated with ophthalmic steroids include elevated intraocular pressure, which may be associated with optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation; secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera.",perforation of the globe is an adverse reaction entity
"6 ADVERSE REACTIONS    Adverse reactions associated with ophthalmic steroids include elevated intraocular pressure, which may be associated with optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation; secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera.",pathogens is not a named entity
"6 ADVERSE REACTIONS    Adverse reactions associated with ophthalmic steroids include elevated intraocular pressure, which may be associated with optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation; secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera.",elevated intraocular pressure is an adverse reaction entity
"6 ADVERSE REACTIONS    Adverse reactions associated with ophthalmic steroids include elevated intraocular pressure, which may be associated with optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation; secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera.",posterior subcapsular cataract formation is an adverse reaction entity
"6 ADVERSE REACTIONS    Adverse reactions associated with ophthalmic steroids include elevated intraocular pressure, which may be associated with optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation; secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera.",cataract is not a named entity
"6 ADVERSE REACTIONS    Adverse reactions associated with ophthalmic steroids include elevated intraocular pressure, which may be associated with optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation; secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera.",visual field defects is an adverse reaction entity
"6 ADVERSE REACTIONS    Adverse reactions associated with ophthalmic steroids include elevated intraocular pressure, which may be associated with optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation; secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera.",steroids include is not a named entity
"6 ADVERSE REACTIONS    Adverse reactions associated with ophthalmic steroids include elevated intraocular pressure, which may be associated with optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation; secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera.",visual acuity defects is an adverse reaction entity
"6 ADVERSE REACTIONS    Adverse reactions associated with ophthalmic steroids include elevated intraocular pressure, which may be associated with optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation; secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera.",secondary ocular infection herpes simplex is an adverse reaction entity
"6 ADVERSE REACTIONS    Adverse reactions associated with ophthalmic steroids include elevated intraocular pressure, which may be associated with optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation; secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera.",may be associated is not a named entity
"6 ADVERSE REACTIONS    Adverse reactions associated with ophthalmic steroids include elevated intraocular pressure, which may be associated with optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation; secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera.",herpes is not a named entity
"Other ocular adverse reactions occurring in 1-5% of subjects included reduced visual acuity, punctate keratitis, eye inflammation, and iritis.",reduced visual acuity is an adverse reaction entity
"Other ocular adverse reactions occurring in 1-5% of subjects included reduced visual acuity, punctate keratitis, eye inflammation, and iritis.",in 1-5 is not a named entity
"Other ocular adverse reactions occurring in 1-5% of subjects included reduced visual acuity, punctate keratitis, eye inflammation, and iritis.",in is not a named entity
"Other ocular adverse reactions occurring in 1-5% of subjects included reduced visual acuity, punctate keratitis, eye inflammation, and iritis.",eye inflammation is an adverse reaction entity
"Other ocular adverse reactions occurring in 1-5% of subjects included reduced visual acuity, punctate keratitis, eye inflammation, and iritis.",punctate keratitis is an adverse reaction entity
"Other ocular adverse reactions occurring in 1-5% of subjects included reduced visual acuity, punctate keratitis, eye inflammation, and iritis.","visual acuity , is not a named entity"
"Other ocular adverse reactions occurring in 1-5% of subjects included reduced visual acuity, punctate keratitis, eye inflammation, and iritis.",visual acuity is not a named entity
"Other ocular adverse reactions occurring in 1-5% of subjects included reduced visual acuity, punctate keratitis, eye inflammation, and iritis.",iritis is an adverse reaction entity
"In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids.",perforations is an adverse reaction entity
"In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids.",", perforations have is not a named entity"
5.6 Fungal Infections      Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application.,of the is not a named entity
5.6 Fungal Infections      Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application.,Fungal infections of the cornea is an adverse reaction entity
"The most common adverse reactions of those exposed to DUREZOL occurring in 5-10% of subjects included blurred vision, eye irritation, eye pain, headache, increased IOP, iritis, limbal and conjunctival hyperemia, punctate keratitis, and uveitis.",limbal hyperemia is an adverse reaction entity
"The most common adverse reactions of those exposed to DUREZOL occurring in 5-10% of subjects included blurred vision, eye irritation, eye pain, headache, increased IOP, iritis, limbal and conjunctival hyperemia, punctate keratitis, and uveitis.","irritation , is not a named entity"
"The most common adverse reactions of those exposed to DUREZOL occurring in 5-10% of subjects included blurred vision, eye irritation, eye pain, headache, increased IOP, iritis, limbal and conjunctival hyperemia, punctate keratitis, and uveitis.",uveitis is an adverse reaction entity
"The most common adverse reactions of those exposed to DUREZOL occurring in 5-10% of subjects included blurred vision, eye irritation, eye pain, headache, increased IOP, iritis, limbal and conjunctival hyperemia, punctate keratitis, and uveitis.",occurring in is not a named entity
"The most common adverse reactions of those exposed to DUREZOL occurring in 5-10% of subjects included blurred vision, eye irritation, eye pain, headache, increased IOP, iritis, limbal and conjunctival hyperemia, punctate keratitis, and uveitis.",punctate keratitis is an adverse reaction entity
"The most common adverse reactions of those exposed to DUREZOL occurring in 5-10% of subjects included blurred vision, eye irritation, eye pain, headache, increased IOP, iritis, limbal and conjunctival hyperemia, punctate keratitis, and uveitis.",reactions is not a named entity
"The most common adverse reactions of those exposed to DUREZOL occurring in 5-10% of subjects included blurred vision, eye irritation, eye pain, headache, increased IOP, iritis, limbal and conjunctival hyperemia, punctate keratitis, and uveitis.",limbal and is not a named entity
"The most common adverse reactions of those exposed to DUREZOL occurring in 5-10% of subjects included blurred vision, eye irritation, eye pain, headache, increased IOP, iritis, limbal and conjunctival hyperemia, punctate keratitis, and uveitis.",conjunctival hyperemia is an adverse reaction entity
"The most common adverse reactions of those exposed to DUREZOL occurring in 5-10% of subjects included blurred vision, eye irritation, eye pain, headache, increased IOP, iritis, limbal and conjunctival hyperemia, punctate keratitis, and uveitis.",", is not a named entity"
"The most common adverse reactions of those exposed to DUREZOL occurring in 5-10% of subjects included blurred vision, eye irritation, eye pain, headache, increased IOP, iritis, limbal and conjunctival hyperemia, punctate keratitis, and uveitis.",eye irritation is an adverse reaction entity
"The most common adverse reactions of those exposed to DUREZOL occurring in 5-10% of subjects included blurred vision, eye irritation, eye pain, headache, increased IOP, iritis, limbal and conjunctival hyperemia, punctate keratitis, and uveitis.",increased IOP is an adverse reaction entity
"The most common adverse reactions of those exposed to DUREZOL occurring in 5-10% of subjects included blurred vision, eye irritation, eye pain, headache, increased IOP, iritis, limbal and conjunctival hyperemia, punctate keratitis, and uveitis.",iritis is an adverse reaction entity
"The most common adverse reactions of those exposed to DUREZOL occurring in 5-10% of subjects included blurred vision, eye irritation, eye pain, headache, increased IOP, iritis, limbal and conjunctival hyperemia, punctate keratitis, and uveitis.",blurred vision is an adverse reaction entity
"The most common adverse reactions of those exposed to DUREZOL occurring in 5-10% of subjects included blurred vision, eye irritation, eye pain, headache, increased IOP, iritis, limbal and conjunctival hyperemia, punctate keratitis, and uveitis.",", is not a named entity"
"The most common adverse reactions of those exposed to DUREZOL occurring in 5-10% of subjects included blurred vision, eye irritation, eye pain, headache, increased IOP, iritis, limbal and conjunctival hyperemia, punctate keratitis, and uveitis.",in 5-10 % is not a named entity
"The most common adverse reactions of those exposed to DUREZOL occurring in 5-10% of subjects included blurred vision, eye irritation, eye pain, headache, increased IOP, iritis, limbal and conjunctival hyperemia, punctate keratitis, and uveitis.",common adverse is not a named entity
"The most common adverse reactions of those exposed to DUREZOL occurring in 5-10% of subjects included blurred vision, eye irritation, eye pain, headache, increased IOP, iritis, limbal and conjunctival hyperemia, punctate keratitis, and uveitis.",eye pain is an adverse reaction entity
"The most common adverse reactions of those exposed to DUREZOL occurring in 5-10% of subjects included blurred vision, eye irritation, eye pain, headache, increased IOP, iritis, limbal and conjunctival hyperemia, punctate keratitis, and uveitis.",headache is an adverse reaction entity
"The most common adverse reactions of those exposed to DUREZOL occurring in 5-10% of subjects included blurred vision, eye irritation, eye pain, headache, increased IOP, iritis, limbal and conjunctival hyperemia, punctate keratitis, and uveitis.","vision , eye is not a named entity"
"The most common adverse reactions of those exposed to DUREZOL occurring in 5-10% of subjects included blurred vision, eye irritation, eye pain, headache, increased IOP, iritis, limbal and conjunctival hyperemia, punctate keratitis, and uveitis.",", and uveitis is not a named entity"
(  5.3  )     item{ Bacterial infections- Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections.,secondary ocular infections is an adverse reaction entity
(  5.3  )     item{ Bacterial infections- Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections.,( 5.3 is not a named entity
(  5.3  )     item{ Bacterial infections- Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections.,suppress the host response is an adverse reaction entity
(  5.3  )     item{ Bacterial infections- Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections.,thus is not a named entity
"It is unknown whether TRULICITY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of dulaglutide-induced rodent thyroid C-cell tumors has not been determined (5.1, 13.1).",C-cell tumors has is not a named entity
"It is unknown whether TRULICITY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of dulaglutide-induced rodent thyroid C-cell tumors has not been determined (5.1, 13.1).",thyroid C-cell tumors is an adverse reaction entity
"It is unknown whether TRULICITY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of dulaglutide-induced rodent thyroid C-cell tumors has not been determined (5.1, 13.1).",thyroid C-cell tumors is an adverse reaction entity
"It is unknown whether TRULICITY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of dulaglutide-induced rodent thyroid C-cell tumors has not been determined (5.1, 13.1).",unknown is not a named entity
"It is unknown whether TRULICITY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of dulaglutide-induced rodent thyroid C-cell tumors has not been determined (5.1, 13.1).",has not is not a named entity
"It is unknown whether TRULICITY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of dulaglutide-induced rodent thyroid C-cell tumors has not been determined (5.1, 13.1).",MTC is an adverse reaction entity
"It is unknown whether TRULICITY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of dulaglutide-induced rodent thyroid C-cell tumors has not been determined (5.1, 13.1).",C-cell tumors has is not a named entity
"It is unknown whether TRULICITY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of dulaglutide-induced rodent thyroid C-cell tumors has not been determined (5.1, 13.1).",medullary thyroid carcinoma is an adverse reaction entity
"Table 1: Adverse Reactions in Placebo-Controlled Trials Reported in >=5% of TRULICITY-Treated Patients    a Includes diarrhea, fecal volume increased, frequent bowel movements.",frequent bowel movements is an adverse reaction entity
"Table 1: Adverse Reactions in Placebo-Controlled Trials Reported in >=5% of TRULICITY-Treated Patients    a Includes diarrhea, fecal volume increased, frequent bowel movements.",fecal volume increased is an adverse reaction entity
"Table 1: Adverse Reactions in Placebo-Controlled Trials Reported in >=5% of TRULICITY-Treated Patients    a Includes diarrhea, fecal volume increased, frequent bowel movements.",: Adverse is not a named entity
"Table 1: Adverse Reactions in Placebo-Controlled Trials Reported in >=5% of TRULICITY-Treated Patients    a Includes diarrhea, fecal volume increased, frequent bowel movements.",diarrhea is an adverse reaction entity
"Table 1: Adverse Reactions in Placebo-Controlled Trials Reported in >=5% of TRULICITY-Treated Patients    a Includes diarrhea, fecal volume increased, frequent bowel movements.",> =5 is not a named entity
"Table 1: Adverse Reactions in Placebo-Controlled Trials Reported in >=5% of TRULICITY-Treated Patients    a Includes diarrhea, fecal volume increased, frequent bowel movements.","diarrhea , is not a named entity"
Other Adverse Reactions           Hypoglycemia         Table 2  summarizes the incidence of documented symptomatic (<=70 mg/dL glucose threshold) and severe hypoglycemia in the placebo-controlled clinical studies.,< is not a named entity
Other Adverse Reactions           Hypoglycemia         Table 2  summarizes the incidence of documented symptomatic (<=70 mg/dL glucose threshold) and severe hypoglycemia in the placebo-controlled clinical studies.,the placebo-controlled is not a named entity
Other Adverse Reactions           Hypoglycemia         Table 2  summarizes the incidence of documented symptomatic (<=70 mg/dL glucose threshold) and severe hypoglycemia in the placebo-controlled clinical studies.,hypoglycemia is an adverse reaction entity
Other Adverse Reactions           Hypoglycemia         Table 2  summarizes the incidence of documented symptomatic (<=70 mg/dL glucose threshold) and severe hypoglycemia in the placebo-controlled clinical studies.,symptomatic hypoglycemia is an adverse reaction entity
More patients receiving TRULICITY 0.75 mg (1.3%) and TRULICITY 1.5 mg (3.5%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.2%).,gastrointestinal adverse reactions is an adverse reaction entity
More patients receiving TRULICITY 0.75 mg (1.3%) and TRULICITY 1.5 mg (3.5%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.2%).,placebo is not a named entity
"5.1 Risk of Thyroid C-cell Tumors         In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure [see Nonclinical Toxicology (  13.1  )]  .",thyroid C-cell tumors is an adverse reaction entity
"5.1 Risk of Thyroid C-cell Tumors         In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure [see Nonclinical Toxicology (  13.1  )]  .",) ] is not a named entity
"5.1 Risk of Thyroid C-cell Tumors         In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure [see Nonclinical Toxicology (  13.1  )]  .",and is not a named entity
"5.1 Risk of Thyroid C-cell Tumors         In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure [see Nonclinical Toxicology (  13.1  )]  .",thyroid C-cell adenomas is an adverse reaction entity
"5.1 Risk of Thyroid C-cell Tumors         In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure [see Nonclinical Toxicology (  13.1  )]  .",thyroid C-cell carcinomas is an adverse reaction entity
"5.1 Risk of Thyroid C-cell Tumors         In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure [see Nonclinical Toxicology (  13.1  )]  .",male is not a named entity
"c Includes abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper, abdominal tenderness, gastrointestinal pain.",upper is not a named entity
"c Includes abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper, abdominal tenderness, gastrointestinal pain.",pain is not a named entity
"c Includes abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper, abdominal tenderness, gastrointestinal pain.","lower , is not a named entity"
"c Includes abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper, abdominal tenderness, gastrointestinal pain.",gastrointestinal pain is an adverse reaction entity
"c Includes abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper, abdominal tenderness, gastrointestinal pain.",abdominal pain upper is an adverse reaction entity
"c Includes abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper, abdominal tenderness, gastrointestinal pain.",abdominal tenderness is an adverse reaction entity
"c Includes abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper, abdominal tenderness, gastrointestinal pain.",abdominal discomfort is an adverse reaction entity
"c Includes abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper, abdominal tenderness, gastrointestinal pain.",c Includes abdominal is not a named entity
"c Includes abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper, abdominal tenderness, gastrointestinal pain.",abdominal pain lower is an adverse reaction entity
"c Includes abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper, abdominal tenderness, gastrointestinal pain.",pain is not a named entity
"c Includes abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper, abdominal tenderness, gastrointestinal pain.",", is not a named entity"
"c Includes abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper, abdominal tenderness, gastrointestinal pain.",abdominal pain is an adverse reaction entity
"Hypersensitivity       Systemic hypersensitivity adverse reactions sometimes severe (e.g., severe urticaria, systemic rash, facial edema, lip swelling) occurred in 0.5% of patients on TRULICITY in the four Phase 2 and five Phase 3 studies.",Systemic hypersensitivity is an adverse reaction entity
"Hypersensitivity       Systemic hypersensitivity adverse reactions sometimes severe (e.g., severe urticaria, systemic rash, facial edema, lip swelling) occurred in 0.5% of patients on TRULICITY in the four Phase 2 and five Phase 3 studies.",lip swelling is an adverse reaction entity
"Hypersensitivity       Systemic hypersensitivity adverse reactions sometimes severe (e.g., severe urticaria, systemic rash, facial edema, lip swelling) occurred in 0.5% of patients on TRULICITY in the four Phase 2 and five Phase 3 studies.",( e.g. is not a named entity
"Hypersensitivity       Systemic hypersensitivity adverse reactions sometimes severe (e.g., severe urticaria, systemic rash, facial edema, lip swelling) occurred in 0.5% of patients on TRULICITY in the four Phase 2 and five Phase 3 studies.",urticaria is an adverse reaction entity
"Hypersensitivity       Systemic hypersensitivity adverse reactions sometimes severe (e.g., severe urticaria, systemic rash, facial edema, lip swelling) occurred in 0.5% of patients on TRULICITY in the four Phase 2 and five Phase 3 studies.",systemic rash is an adverse reaction entity
"Hypersensitivity       Systemic hypersensitivity adverse reactions sometimes severe (e.g., severe urticaria, systemic rash, facial edema, lip swelling) occurred in 0.5% of patients on TRULICITY in the four Phase 2 and five Phase 3 studies.",facial edema is an adverse reaction entity
"Hypersensitivity       Systemic hypersensitivity adverse reactions sometimes severe (e.g., severe urticaria, systemic rash, facial edema, lip swelling) occurred in 0.5% of patients on TRULICITY in the four Phase 2 and five Phase 3 studies.",severe is not a named entity
"Hypersensitivity       Systemic hypersensitivity adverse reactions sometimes severe (e.g., severe urticaria, systemic rash, facial edema, lip swelling) occurred in 0.5% of patients on TRULICITY in the four Phase 2 and five Phase 3 studies.",swelling ) is not a named entity
"Hypersensitivity       Systemic hypersensitivity adverse reactions sometimes severe (e.g., severe urticaria, systemic rash, facial edema, lip swelling) occurred in 0.5% of patients on TRULICITY in the four Phase 2 and five Phase 3 studies.",Systemic hypersensitivity is an adverse reaction entity
"Hypersensitivity       Systemic hypersensitivity adverse reactions sometimes severe (e.g., severe urticaria, systemic rash, facial edema, lip swelling) occurred in 0.5% of patients on TRULICITY in the four Phase 2 and five Phase 3 studies.",", facial edema is not a named entity"
"Hypersensitivity       Systemic hypersensitivity adverse reactions sometimes severe (e.g., severe urticaria, systemic rash, facial edema, lip swelling) occurred in 0.5% of patients on TRULICITY in the four Phase 2 and five Phase 3 studies.",reactions sometimes is not a named entity
"Hypersensitivity       Systemic hypersensitivity adverse reactions sometimes severe (e.g., severe urticaria, systemic rash, facial edema, lip swelling) occurred in 0.5% of patients on TRULICITY in the four Phase 2 and five Phase 3 studies.",2 and five is not a named entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *   Thyroid C-cell Tumors: See Boxed Warning (  5.1  ).,Thyroid C-cell Tumors is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *   Thyroid C-cell Tumors: See Boxed Warning (  5.1  ).,Boxed Warning is not a named entity
"Investigators graded the severity of gastrointestinal adverse reactions occurring on 0.75 mg and 1.5 mg of TRULICITY as ""mild"" in 58% and 48% of cases, respectively, ""moderate"" in 35% and 42% of cases, respectively, or ""severe"" in 7% and 11% of cases, respectively.",gastrointestinal adverse reactions is an adverse reaction entity
"Investigators graded the severity of gastrointestinal adverse reactions occurring on 0.75 mg and 1.5 mg of TRULICITY as ""mild"" in 58% and 48% of cases, respectively, ""moderate"" in 35% and 42% of cases, respectively, or ""severe"" in 7% and 11% of cases, respectively.",of is not a named entity
5.4 Hypersensitivity Reactions      Systemic hypersensitivity reactions were observed in patients receiving TRULICITY in clinical trials [see Adverse Reactions (  6.1  )].,6.1 ) is not a named entity
5.4 Hypersensitivity Reactions      Systemic hypersensitivity reactions were observed in patients receiving TRULICITY in clinical trials [see Adverse Reactions (  6.1  )].,Systemic hypersensitivity is an adverse reaction entity
The long-term clinical effects of the increase in HR have not been established  [see Warnings and Precautions (  5.7  )]  .,increase in HR is an adverse reaction entity
The long-term clinical effects of the increase in HR have not been established  [see Warnings and Precautions (  5.7  )]  .,( 5.7 is not a named entity
"Episodes of sinus tachycardia, associated with a concomitant increase from baseline in heart rate of >=15 beats per minute, were reported in 0.7%, 1.3% and 2.2% of patient treated with placebo, TRULICITY 0.75 mg and TRULICITY 1.5 mg, respectively.",sinus tachycardia is an adverse reaction entity
"Episodes of sinus tachycardia, associated with a concomitant increase from baseline in heart rate of >=15 beats per minute, were reported in 0.7%, 1.3% and 2.2% of patient treated with placebo, TRULICITY 0.75 mg and TRULICITY 1.5 mg, respectively.",increase in heart rate is an adverse reaction entity
"Episodes of sinus tachycardia, associated with a concomitant increase from baseline in heart rate of >=15 beats per minute, were reported in 0.7%, 1.3% and 2.2% of patient treated with placebo, TRULICITY 0.75 mg and TRULICITY 1.5 mg, respectively.",of is not a named entity
"Episodes of sinus tachycardia, associated with a concomitant increase from baseline in heart rate of >=15 beats per minute, were reported in 0.7%, 1.3% and 2.2% of patient treated with placebo, TRULICITY 0.75 mg and TRULICITY 1.5 mg, respectively.",patient treated is not a named entity
"A majority of reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration.",vomiting is an adverse reaction entity
"A majority of reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration.",or dehydration is not a named entity
"A majority of reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration.",diarrhea is an adverse reaction entity
"A majority of reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration.","diarrhea , or is not a named entity"
"A majority of reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration.",majority is not a named entity
"A majority of reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration.",nausea is an adverse reaction entity
"A majority of reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration.",dehydration is an adverse reaction entity
"A majority of reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration.","experienced nausea , is not a named entity"
"Persistence of sinus tachycardia (reported at more than 2 visits) was reported in 0.2%, 0.4% and 1.6% of patients treated with placebo, TRULICITY 0.75 mg and TRULICITY 1.5 mg, respectively.",sinus tachycardia ( is not a named entity
"Persistence of sinus tachycardia (reported at more than 2 visits) was reported in 0.2%, 0.4% and 1.6% of patients treated with placebo, TRULICITY 0.75 mg and TRULICITY 1.5 mg, respectively.",Persistence of sinus tachycardia is an adverse reaction entity
"In the pool of placebo- and active-controlled trials, the types and frequency of common adverse reactions, excluding hypoglycemia, were similar to those listed in  Table 1  .",similar is not a named entity
"In the pool of placebo- and active-controlled trials, the types and frequency of common adverse reactions, excluding hypoglycemia, were similar to those listed in  Table 1  .",hypoglycemia is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *  Risk of Thyroid C-cell Tumors [see Warnings and Precautions (  5.1  )]    *  Pancreatitis [see Warnings and Precautions (  5.2  )]    *  Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (  5.3  )]    *  Hypersensitivity reactions [see Warnings and Precautions (  5.4  )]    *  Renal impairment [see Warnings and Precautions (  5.5  )]    *  Severe Gastrointestinal Disease [see Warnings and Precautions (  5.6  )]         EXCERPT:   The most common adverse reactions, reported in >=5% of patients treated with TRULICITY are: nausea, diarrhea, vomiting, abdominal pain, and decreased appetite (  6.1  ).",vomiting is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *  Risk of Thyroid C-cell Tumors [see Warnings and Precautions (  5.1  )]    *  Pancreatitis [see Warnings and Precautions (  5.2  )]    *  Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (  5.3  )]    *  Hypersensitivity reactions [see Warnings and Precautions (  5.4  )]    *  Renal impairment [see Warnings and Precautions (  5.5  )]    *  Severe Gastrointestinal Disease [see Warnings and Precautions (  5.6  )]         EXCERPT:   The most common adverse reactions, reported in >=5% of patients treated with TRULICITY are: nausea, diarrhea, vomiting, abdominal pain, and decreased appetite (  6.1  ).",Precautions ( 5.3 is not a named entity
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *  Risk of Thyroid C-cell Tumors [see Warnings and Precautions (  5.1  )]    *  Pancreatitis [see Warnings and Precautions (  5.2  )]    *  Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (  5.3  )]    *  Hypersensitivity reactions [see Warnings and Precautions (  5.4  )]    *  Renal impairment [see Warnings and Precautions (  5.5  )]    *  Severe Gastrointestinal Disease [see Warnings and Precautions (  5.6  )]         EXCERPT:   The most common adverse reactions, reported in >=5% of patients treated with TRULICITY are: nausea, diarrhea, vomiting, abdominal pain, and decreased appetite (  6.1  ).",diarrhea is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *  Risk of Thyroid C-cell Tumors [see Warnings and Precautions (  5.1  )]    *  Pancreatitis [see Warnings and Precautions (  5.2  )]    *  Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (  5.3  )]    *  Hypersensitivity reactions [see Warnings and Precautions (  5.4  )]    *  Renal impairment [see Warnings and Precautions (  5.5  )]    *  Severe Gastrointestinal Disease [see Warnings and Precautions (  5.6  )]         EXCERPT:   The most common adverse reactions, reported in >=5% of patients treated with TRULICITY are: nausea, diarrhea, vomiting, abdominal pain, and decreased appetite (  6.1  ).",5.5 is not a named entity
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *  Risk of Thyroid C-cell Tumors [see Warnings and Precautions (  5.1  )]    *  Pancreatitis [see Warnings and Precautions (  5.2  )]    *  Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (  5.3  )]    *  Hypersensitivity reactions [see Warnings and Precautions (  5.4  )]    *  Renal impairment [see Warnings and Precautions (  5.5  )]    *  Severe Gastrointestinal Disease [see Warnings and Precautions (  5.6  )]         EXCERPT:   The most common adverse reactions, reported in >=5% of patients treated with TRULICITY are: nausea, diarrhea, vomiting, abdominal pain, and decreased appetite (  6.1  ).",[ is not a named entity
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *  Risk of Thyroid C-cell Tumors [see Warnings and Precautions (  5.1  )]    *  Pancreatitis [see Warnings and Precautions (  5.2  )]    *  Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (  5.3  )]    *  Hypersensitivity reactions [see Warnings and Precautions (  5.4  )]    *  Renal impairment [see Warnings and Precautions (  5.5  )]    *  Severe Gastrointestinal Disease [see Warnings and Precautions (  5.6  )]         EXCERPT:   The most common adverse reactions, reported in >=5% of patients treated with TRULICITY are: nausea, diarrhea, vomiting, abdominal pain, and decreased appetite (  6.1  ).",Precautions is not a named entity
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *  Risk of Thyroid C-cell Tumors [see Warnings and Precautions (  5.1  )]    *  Pancreatitis [see Warnings and Precautions (  5.2  )]    *  Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (  5.3  )]    *  Hypersensitivity reactions [see Warnings and Precautions (  5.4  )]    *  Renal impairment [see Warnings and Precautions (  5.5  )]    *  Severe Gastrointestinal Disease [see Warnings and Precautions (  5.6  )]         EXCERPT:   The most common adverse reactions, reported in >=5% of patients treated with TRULICITY are: nausea, diarrhea, vomiting, abdominal pain, and decreased appetite (  6.1  ).",Hypersensitivity is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *  Risk of Thyroid C-cell Tumors [see Warnings and Precautions (  5.1  )]    *  Pancreatitis [see Warnings and Precautions (  5.2  )]    *  Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (  5.3  )]    *  Hypersensitivity reactions [see Warnings and Precautions (  5.4  )]    *  Renal impairment [see Warnings and Precautions (  5.5  )]    *  Severe Gastrointestinal Disease [see Warnings and Precautions (  5.6  )]         EXCERPT:   The most common adverse reactions, reported in >=5% of patients treated with TRULICITY are: nausea, diarrhea, vomiting, abdominal pain, and decreased appetite (  6.1  ).",Thyroid C-cell Tumors is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *  Risk of Thyroid C-cell Tumors [see Warnings and Precautions (  5.1  )]    *  Pancreatitis [see Warnings and Precautions (  5.2  )]    *  Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (  5.3  )]    *  Hypersensitivity reactions [see Warnings and Precautions (  5.4  )]    *  Renal impairment [see Warnings and Precautions (  5.5  )]    *  Severe Gastrointestinal Disease [see Warnings and Precautions (  5.6  )]         EXCERPT:   The most common adverse reactions, reported in >=5% of patients treated with TRULICITY are: nausea, diarrhea, vomiting, abdominal pain, and decreased appetite (  6.1  ).",nausea is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *  Risk of Thyroid C-cell Tumors [see Warnings and Precautions (  5.1  )]    *  Pancreatitis [see Warnings and Precautions (  5.2  )]    *  Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (  5.3  )]    *  Hypersensitivity reactions [see Warnings and Precautions (  5.4  )]    *  Renal impairment [see Warnings and Precautions (  5.5  )]    *  Severe Gastrointestinal Disease [see Warnings and Precautions (  5.6  )]         EXCERPT:   The most common adverse reactions, reported in >=5% of patients treated with TRULICITY are: nausea, diarrhea, vomiting, abdominal pain, and decreased appetite (  6.1  ).",abdominal pain is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *  Risk of Thyroid C-cell Tumors [see Warnings and Precautions (  5.1  )]    *  Pancreatitis [see Warnings and Precautions (  5.2  )]    *  Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (  5.3  )]    *  Hypersensitivity reactions [see Warnings and Precautions (  5.4  )]    *  Renal impairment [see Warnings and Precautions (  5.5  )]    *  Severe Gastrointestinal Disease [see Warnings and Precautions (  5.6  )]         EXCERPT:   The most common adverse reactions, reported in >=5% of patients treated with TRULICITY are: nausea, diarrhea, vomiting, abdominal pain, and decreased appetite (  6.1  ).",described below is not a named entity
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *  Risk of Thyroid C-cell Tumors [see Warnings and Precautions (  5.1  )]    *  Pancreatitis [see Warnings and Precautions (  5.2  )]    *  Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (  5.3  )]    *  Hypersensitivity reactions [see Warnings and Precautions (  5.4  )]    *  Renal impairment [see Warnings and Precautions (  5.5  )]    *  Severe Gastrointestinal Disease [see Warnings and Precautions (  5.6  )]         EXCERPT:   The most common adverse reactions, reported in >=5% of patients treated with TRULICITY are: nausea, diarrhea, vomiting, abdominal pain, and decreased appetite (  6.1  ).",Renal impairment is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *  Risk of Thyroid C-cell Tumors [see Warnings and Precautions (  5.1  )]    *  Pancreatitis [see Warnings and Precautions (  5.2  )]    *  Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (  5.3  )]    *  Hypersensitivity reactions [see Warnings and Precautions (  5.4  )]    *  Renal impairment [see Warnings and Precautions (  5.5  )]    *  Severe Gastrointestinal Disease [see Warnings and Precautions (  5.6  )]         EXCERPT:   The most common adverse reactions, reported in >=5% of patients treated with TRULICITY are: nausea, diarrhea, vomiting, abdominal pain, and decreased appetite (  6.1  ).",Hypoglycemia is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *  Risk of Thyroid C-cell Tumors [see Warnings and Precautions (  5.1  )]    *  Pancreatitis [see Warnings and Precautions (  5.2  )]    *  Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (  5.3  )]    *  Hypersensitivity reactions [see Warnings and Precautions (  5.4  )]    *  Renal impairment [see Warnings and Precautions (  5.5  )]    *  Severe Gastrointestinal Disease [see Warnings and Precautions (  5.6  )]         EXCERPT:   The most common adverse reactions, reported in >=5% of patients treated with TRULICITY are: nausea, diarrhea, vomiting, abdominal pain, and decreased appetite (  6.1  ).",Gastrointestinal Disease is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *  Risk of Thyroid C-cell Tumors [see Warnings and Precautions (  5.1  )]    *  Pancreatitis [see Warnings and Precautions (  5.2  )]    *  Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (  5.3  )]    *  Hypersensitivity reactions [see Warnings and Precautions (  5.4  )]    *  Renal impairment [see Warnings and Precautions (  5.5  )]    *  Severe Gastrointestinal Disease [see Warnings and Precautions (  5.6  )]         EXCERPT:   The most common adverse reactions, reported in >=5% of patients treated with TRULICITY are: nausea, diarrhea, vomiting, abdominal pain, and decreased appetite (  6.1  ).",or Insulin [ is not a named entity
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *  Risk of Thyroid C-cell Tumors [see Warnings and Precautions (  5.1  )]    *  Pancreatitis [see Warnings and Precautions (  5.2  )]    *  Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (  5.3  )]    *  Hypersensitivity reactions [see Warnings and Precautions (  5.4  )]    *  Renal impairment [see Warnings and Precautions (  5.5  )]    *  Severe Gastrointestinal Disease [see Warnings and Precautions (  5.6  )]         EXCERPT:   The most common adverse reactions, reported in >=5% of patients treated with TRULICITY are: nausea, diarrhea, vomiting, abdominal pain, and decreased appetite (  6.1  ).",Warnings and is not a named entity
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *  Risk of Thyroid C-cell Tumors [see Warnings and Precautions (  5.1  )]    *  Pancreatitis [see Warnings and Precautions (  5.2  )]    *  Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (  5.3  )]    *  Hypersensitivity reactions [see Warnings and Precautions (  5.4  )]    *  Renal impairment [see Warnings and Precautions (  5.5  )]    *  Severe Gastrointestinal Disease [see Warnings and Precautions (  5.6  )]         EXCERPT:   The most common adverse reactions, reported in >=5% of patients treated with TRULICITY are: nausea, diarrhea, vomiting, abdominal pain, and decreased appetite (  6.1  ).",Pancreatitis is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *  Risk of Thyroid C-cell Tumors [see Warnings and Precautions (  5.1  )]    *  Pancreatitis [see Warnings and Precautions (  5.2  )]    *  Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (  5.3  )]    *  Hypersensitivity reactions [see Warnings and Precautions (  5.4  )]    *  Renal impairment [see Warnings and Precautions (  5.5  )]    *  Severe Gastrointestinal Disease [see Warnings and Precautions (  5.6  )]         EXCERPT:   The most common adverse reactions, reported in >=5% of patients treated with TRULICITY are: nausea, diarrhea, vomiting, abdominal pain, and decreased appetite (  6.1  ).",decreased appetite is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *  Risk of Thyroid C-cell Tumors [see Warnings and Precautions (  5.1  )]    *  Pancreatitis [see Warnings and Precautions (  5.2  )]    *  Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (  5.3  )]    *  Hypersensitivity reactions [see Warnings and Precautions (  5.4  )]    *  Renal impairment [see Warnings and Precautions (  5.5  )]    *  Severe Gastrointestinal Disease [see Warnings and Precautions (  5.6  )]         EXCERPT:   The most common adverse reactions, reported in >=5% of patients treated with TRULICITY are: nausea, diarrhea, vomiting, abdominal pain, and decreased appetite (  6.1  ).",described below or is not a named entity
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *  Risk of Thyroid C-cell Tumors [see Warnings and Precautions (  5.1  )]    *  Pancreatitis [see Warnings and Precautions (  5.2  )]    *  Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (  5.3  )]    *  Hypersensitivity reactions [see Warnings and Precautions (  5.4  )]    *  Renal impairment [see Warnings and Precautions (  5.5  )]    *  Severe Gastrointestinal Disease [see Warnings and Precautions (  5.6  )]         EXCERPT:   The most common adverse reactions, reported in >=5% of patients treated with TRULICITY are: nausea, diarrhea, vomiting, abdominal pain, and decreased appetite (  6.1  ).",see Warnings is not a named entity
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *  Risk of Thyroid C-cell Tumors [see Warnings and Precautions (  5.1  )]    *  Pancreatitis [see Warnings and Precautions (  5.2  )]    *  Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (  5.3  )]    *  Hypersensitivity reactions [see Warnings and Precautions (  5.4  )]    *  Renal impairment [see Warnings and Precautions (  5.5  )]    *  Severe Gastrointestinal Disease [see Warnings and Precautions (  5.6  )]         EXCERPT:   The most common adverse reactions, reported in >=5% of patients treated with TRULICITY are: nausea, diarrhea, vomiting, abdominal pain, and decreased appetite (  6.1  ).",with is not a named entity
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *  Risk of Thyroid C-cell Tumors [see Warnings and Precautions (  5.1  )]    *  Pancreatitis [see Warnings and Precautions (  5.2  )]    *  Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (  5.3  )]    *  Hypersensitivity reactions [see Warnings and Precautions (  5.4  )]    *  Renal impairment [see Warnings and Precautions (  5.5  )]    *  Severe Gastrointestinal Disease [see Warnings and Precautions (  5.6  )]         EXCERPT:   The most common adverse reactions, reported in >=5% of patients treated with TRULICITY are: nausea, diarrhea, vomiting, abdominal pain, and decreased appetite (  6.1  ).",( is not a named entity
"5.6 Severe Gastrointestinal Disease      Use of TRULICITY may be associated with gastrointestinal adverse reactions, sometimes severe [see Adverse Reactions (  6.1  )]  .",TRULICITY may be is not a named entity
"5.6 Severe Gastrointestinal Disease      Use of TRULICITY may be associated with gastrointestinal adverse reactions, sometimes severe [see Adverse Reactions (  6.1  )]  .",gastrointestinal adverse reactions is an adverse reaction entity
"5.6 Severe Gastrointestinal Disease      Use of TRULICITY may be associated with gastrointestinal adverse reactions, sometimes severe [see Adverse Reactions (  6.1  )]  .",TRULICITY may be is not a named entity
"5.6 Severe Gastrointestinal Disease      Use of TRULICITY may be associated with gastrointestinal adverse reactions, sometimes severe [see Adverse Reactions (  6.1  )]  .",gastrointestinal adverse reactions is an adverse reaction entity
"Sinus tachycardia was reported in 3.0%, 2.8%, and 5.6% of patient treated with placebo, TRULICITY 0.75 mg and TRULICITY 1.5 mg, respectively.",Sinus tachycardia is an adverse reaction entity
"Sinus tachycardia was reported in 3.0%, 2.8%, and 5.6% of patient treated with placebo, TRULICITY 0.75 mg and TRULICITY 1.5 mg, respectively.",placebo is not a named entity
"Severe hypoglycemia occurred in 2.4% and 3.4% of patients when TRULICITY 0.75 mg and 1.5 mg, respectively, was co-administered with prandial insulin.",was co-administered with is not a named entity
"Severe hypoglycemia occurred in 2.4% and 3.4% of patients when TRULICITY 0.75 mg and 1.5 mg, respectively, was co-administered with prandial insulin.",hypoglycemia is an adverse reaction entity
"Documented symptomatic hypoglycemia occurred in 85% and 80% of patients when TRULICITY 0.75 mg and 1.5 mg, respectively, was co-administered with prandial insulin.",symptomatic hypoglycemia is an adverse reaction entity
"Documented symptomatic hypoglycemia occurred in 85% and 80% of patients when TRULICITY 0.75 mg and 1.5 mg, respectively, was co-administered with prandial insulin.",TRULICITY 0.75 is not a named entity
"5.2 Pancreatitis      In Phase 2 and Phase 3 clinical studies, 12 (3.4 cases per 1000 patient years) pancreatitis related adverse reactions were reported in patients exposed to TRULICITY versus 3 in non-incretin comparators (2.7 cases per 1000 patient years).",per is not a named entity
"5.2 Pancreatitis      In Phase 2 and Phase 3 clinical studies, 12 (3.4 cases per 1000 patient years) pancreatitis related adverse reactions were reported in patients exposed to TRULICITY versus 3 in non-incretin comparators (2.7 cases per 1000 patient years).",pancreatitis is an adverse reaction entity
"In addition to the reactions in  Table 1  , the following adverse reactions were reported more frequently in TRULICITY-treated patients than placebo (frequencies listed, respectively, as: placebo; 0.75 mg; 1.5 mg): constipation (0.7%, 3.9%, 3.7%), flatulence (1.4%, 1.4%, 3.4%), abdominal distension (0.7%, 2.9%, 2.3%), gastroesophageal reflux disease (0.5%, 1.7%, 2.0%), and eructation (0.2%, 0.6%, 1.6%).",frequently in is not a named entity
"In addition to the reactions in  Table 1  , the following adverse reactions were reported more frequently in TRULICITY-treated patients than placebo (frequencies listed, respectively, as: placebo; 0.75 mg; 1.5 mg): constipation (0.7%, 3.9%, 3.7%), flatulence (1.4%, 1.4%, 3.4%), abdominal distension (0.7%, 2.9%, 2.3%), gastroesophageal reflux disease (0.5%, 1.7%, 2.0%), and eructation (0.2%, 0.6%, 1.6%).",; is not a named entity
"In addition to the reactions in  Table 1  , the following adverse reactions were reported more frequently in TRULICITY-treated patients than placebo (frequencies listed, respectively, as: placebo; 0.75 mg; 1.5 mg): constipation (0.7%, 3.9%, 3.7%), flatulence (1.4%, 1.4%, 3.4%), abdominal distension (0.7%, 2.9%, 2.3%), gastroesophageal reflux disease (0.5%, 1.7%, 2.0%), and eructation (0.2%, 0.6%, 1.6%).",( is not a named entity
"In addition to the reactions in  Table 1  , the following adverse reactions were reported more frequently in TRULICITY-treated patients than placebo (frequencies listed, respectively, as: placebo; 0.75 mg; 1.5 mg): constipation (0.7%, 3.9%, 3.7%), flatulence (1.4%, 1.4%, 3.4%), abdominal distension (0.7%, 2.9%, 2.3%), gastroesophageal reflux disease (0.5%, 1.7%, 2.0%), and eructation (0.2%, 0.6%, 1.6%).",abdominal distension is an adverse reaction entity
"In addition to the reactions in  Table 1  , the following adverse reactions were reported more frequently in TRULICITY-treated patients than placebo (frequencies listed, respectively, as: placebo; 0.75 mg; 1.5 mg): constipation (0.7%, 3.9%, 3.7%), flatulence (1.4%, 1.4%, 3.4%), abdominal distension (0.7%, 2.9%, 2.3%), gastroesophageal reflux disease (0.5%, 1.7%, 2.0%), and eructation (0.2%, 0.6%, 1.6%).",% is not a named entity
"In addition to the reactions in  Table 1  , the following adverse reactions were reported more frequently in TRULICITY-treated patients than placebo (frequencies listed, respectively, as: placebo; 0.75 mg; 1.5 mg): constipation (0.7%, 3.9%, 3.7%), flatulence (1.4%, 1.4%, 3.4%), abdominal distension (0.7%, 2.9%, 2.3%), gastroesophageal reflux disease (0.5%, 1.7%, 2.0%), and eructation (0.2%, 0.6%, 1.6%).",", 3.9 is not a named entity"
"In addition to the reactions in  Table 1  , the following adverse reactions were reported more frequently in TRULICITY-treated patients than placebo (frequencies listed, respectively, as: placebo; 0.75 mg; 1.5 mg): constipation (0.7%, 3.9%, 3.7%), flatulence (1.4%, 1.4%, 3.4%), abdominal distension (0.7%, 2.9%, 2.3%), gastroesophageal reflux disease (0.5%, 1.7%, 2.0%), and eructation (0.2%, 0.6%, 1.6%).",constipation is an adverse reaction entity
"In addition to the reactions in  Table 1  , the following adverse reactions were reported more frequently in TRULICITY-treated patients than placebo (frequencies listed, respectively, as: placebo; 0.75 mg; 1.5 mg): constipation (0.7%, 3.9%, 3.7%), flatulence (1.4%, 1.4%, 3.4%), abdominal distension (0.7%, 2.9%, 2.3%), gastroesophageal reflux disease (0.5%, 1.7%, 2.0%), and eructation (0.2%, 0.6%, 1.6%).",eructation is an adverse reaction entity
"In addition to the reactions in  Table 1  , the following adverse reactions were reported more frequently in TRULICITY-treated patients than placebo (frequencies listed, respectively, as: placebo; 0.75 mg; 1.5 mg): constipation (0.7%, 3.9%, 3.7%), flatulence (1.4%, 1.4%, 3.4%), abdominal distension (0.7%, 2.9%, 2.3%), gastroesophageal reflux disease (0.5%, 1.7%, 2.0%), and eructation (0.2%, 0.6%, 1.6%).",flatulence is an adverse reaction entity
"In addition to the reactions in  Table 1  , the following adverse reactions were reported more frequently in TRULICITY-treated patients than placebo (frequencies listed, respectively, as: placebo; 0.75 mg; 1.5 mg): constipation (0.7%, 3.9%, 3.7%), flatulence (1.4%, 1.4%, 3.4%), abdominal distension (0.7%, 2.9%, 2.3%), gastroesophageal reflux disease (0.5%, 1.7%, 2.0%), and eructation (0.2%, 0.6%, 1.6%).",gastroesophageal reflux disease is an adverse reaction entity
"Amylase and Lipase Increase       Patients exposed to TRULICITY had mean increases from baseline in lipase and/or pancreatic amylase of 14% to 20%, while placebo-treated patients had mean increases of up to 3%.",increases in pancreatic amylase is an adverse reaction entity
"Amylase and Lipase Increase       Patients exposed to TRULICITY had mean increases from baseline in lipase and/or pancreatic amylase of 14% to 20%, while placebo-treated patients had mean increases of up to 3%.",Amylase is not a named entity
"Amylase and Lipase Increase       Patients exposed to TRULICITY had mean increases from baseline in lipase and/or pancreatic amylase of 14% to 20%, while placebo-treated patients had mean increases of up to 3%.",to 3 is not a named entity
"Amylase and Lipase Increase       Patients exposed to TRULICITY had mean increases from baseline in lipase and/or pancreatic amylase of 14% to 20%, while placebo-treated patients had mean increases of up to 3%.",increases in lipase is an adverse reaction entity
Glucagon-like peptide (GLP-1) receptor agonists have induced thyroid C-cell adenomas and carcinomas in mice and rats at clinically relevant exposures.,and rats at is not a named entity
Glucagon-like peptide (GLP-1) receptor agonists have induced thyroid C-cell adenomas and carcinomas in mice and rats at clinically relevant exposures.,thyroid C-cell adenomas is an adverse reaction entity
Glucagon-like peptide (GLP-1) receptor agonists have induced thyroid C-cell adenomas and carcinomas in mice and rats at clinically relevant exposures.,thyroid C-cell carcinomas is an adverse reaction entity
Glucagon-like peptide (GLP-1) receptor agonists have induced thyroid C-cell adenomas and carcinomas in mice and rats at clinically relevant exposures.,in mice and is not a named entity
"5.3 Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin      The risk of hypoglycemia is increased when TRULICITY is used in combination with insulin secretagogues (e.g., sulfonylureas) or insulin.",hypoglycemia is an adverse reaction entity
"5.3 Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin      The risk of hypoglycemia is increased when TRULICITY is used in combination with insulin secretagogues (e.g., sulfonylureas) or insulin.",in is not a named entity
"BOXED WARNING: WARNING: RISK OF THYROID C-CELL TUMORS      WARNING: RISK OF THYROID C-CELL TUMORS        *  In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure.",WARNING is not a named entity
"BOXED WARNING: WARNING: RISK OF THYROID C-CELL TUMORS      WARNING: RISK OF THYROID C-CELL TUMORS        *  In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure.",thyroid C-cell adenomas is an adverse reaction entity
"BOXED WARNING: WARNING: RISK OF THYROID C-CELL TUMORS      WARNING: RISK OF THYROID C-CELL TUMORS        *  In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure.",OF THYROID C-CELL is not a named entity
"BOXED WARNING: WARNING: RISK OF THYROID C-CELL TUMORS      WARNING: RISK OF THYROID C-CELL TUMORS        *  In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure.",* In male is not a named entity
"BOXED WARNING: WARNING: RISK OF THYROID C-CELL TUMORS      WARNING: RISK OF THYROID C-CELL TUMORS        *  In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure.",TUMORS is not a named entity
"BOXED WARNING: WARNING: RISK OF THYROID C-CELL TUMORS      WARNING: RISK OF THYROID C-CELL TUMORS        *  In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure.",C-cell is not a named entity
"BOXED WARNING: WARNING: RISK OF THYROID C-CELL TUMORS      WARNING: RISK OF THYROID C-CELL TUMORS        *  In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure.",THYROID C-CELL TUMORS is an adverse reaction entity
"BOXED WARNING: WARNING: RISK OF THYROID C-CELL TUMORS      WARNING: RISK OF THYROID C-CELL TUMORS        *  In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure.",THYROID C-CELL TUMORS is an adverse reaction entity
"BOXED WARNING: WARNING: RISK OF THYROID C-CELL TUMORS      WARNING: RISK OF THYROID C-CELL TUMORS        *  In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure.",thyroid C-cell carcinomas is an adverse reaction entity
"BOXED WARNING: WARNING: RISK OF THYROID C-CELL TUMORS      WARNING: RISK OF THYROID C-CELL TUMORS        *  In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure.",thyroid C-cell tumors is an adverse reaction entity
"5.5 Renal Impairment      In patients treated with GLP-1 receptor agonists, there have been postmarketing reports of acute renal failure and worsening of chronic renal failure, which may sometimes require hemodialysis.",receptor agonists is not a named entity
"5.5 Renal Impairment      In patients treated with GLP-1 receptor agonists, there have been postmarketing reports of acute renal failure and worsening of chronic renal failure, which may sometimes require hemodialysis.",acute renal failure is an adverse reaction entity
"5.5 Renal Impairment      In patients treated with GLP-1 receptor agonists, there have been postmarketing reports of acute renal failure and worsening of chronic renal failure, which may sometimes require hemodialysis.",and worsening is not a named entity
"5.5 Renal Impairment      In patients treated with GLP-1 receptor agonists, there have been postmarketing reports of acute renal failure and worsening of chronic renal failure, which may sometimes require hemodialysis.",chronic renal failure is an adverse reaction entity
"The adverse reaction of first degree AV block occurred more frequently in patients treated with TRULICITY than placebo (0.9%, 1.7% and 2.3% for placebo, TRULICITY 0.75 mg and TRULICITY 1.5 mg, respectively).",first degree AV block is an adverse reaction entity
"The adverse reaction of first degree AV block occurred more frequently in patients treated with TRULICITY than placebo (0.9%, 1.7% and 2.3% for placebo, TRULICITY 0.75 mg and TRULICITY 1.5 mg, respectively).",% is not a named entity
Adverse reactions of sinus tachycardia were reported more frequently in patients exposed to TRULICITY.,sinus tachycardia is an adverse reaction entity
Adverse reactions of sinus tachycardia were reported more frequently in patients exposed to TRULICITY.,exposed is not a named entity
Elevation of serum iron values and serum bilirubin laboratory values were reported in less than 1% of patients after administration of EOVIST.,Elevation of serum iron is an adverse reaction entity
Elevation of serum iron values and serum bilirubin laboratory values were reported in less than 1% of patients after administration of EOVIST.,patients after is not a named entity
Elevation of serum iron values and serum bilirubin laboratory values were reported in less than 1% of patients after administration of EOVIST.,Elevation of serum bilirubin is an adverse reaction entity
Elevation of serum iron values and serum bilirubin laboratory values were reported in less than 1% of patients after administration of EOVIST.,of is not a named entity
"6 ADVERSE REACTIONS    The following serious adverse reactionsare discussed elsewhere in the labeling:     *    Nephrogenic systemic fibrosis (NSF) [see Boxed Warning and Warnings and Precautions (  5.1  )]    *    Hypersensitivity reactions [see Contraindications (  4  ) and Warnings and Precautions (  5.2  )]         EXCERPT:   Most common adverse reactions (incidence >= 0.5%) are nausea, headache, feeling hot, dizziness, and back pain (  6  )     To report SUSPECTED ADVERSE REACTIONS, contact Bayer HealthCare Pharmaceuticals Inc. at 1-888-84-BAYER (1-888-842-2937) or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",NSF is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactionsare discussed elsewhere in the labeling:     *    Nephrogenic systemic fibrosis (NSF) [see Boxed Warning and Warnings and Precautions (  5.1  )]    *    Hypersensitivity reactions [see Contraindications (  4  ) and Warnings and Precautions (  5.2  )]         EXCERPT:   Most common adverse reactions (incidence >= 0.5%) are nausea, headache, feeling hot, dizziness, and back pain (  6  )     To report SUSPECTED ADVERSE REACTIONS, contact Bayer HealthCare Pharmaceuticals Inc. at 1-888-84-BAYER (1-888-842-2937) or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",( 5.1 ) is not a named entity
"6 ADVERSE REACTIONS    The following serious adverse reactionsare discussed elsewhere in the labeling:     *    Nephrogenic systemic fibrosis (NSF) [see Boxed Warning and Warnings and Precautions (  5.1  )]    *    Hypersensitivity reactions [see Contraindications (  4  ) and Warnings and Precautions (  5.2  )]         EXCERPT:   Most common adverse reactions (incidence >= 0.5%) are nausea, headache, feeling hot, dizziness, and back pain (  6  )     To report SUSPECTED ADVERSE REACTIONS, contact Bayer HealthCare Pharmaceuticals Inc. at 1-888-84-BAYER (1-888-842-2937) or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",back pain is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactionsare discussed elsewhere in the labeling:     *    Nephrogenic systemic fibrosis (NSF) [see Boxed Warning and Warnings and Precautions (  5.1  )]    *    Hypersensitivity reactions [see Contraindications (  4  ) and Warnings and Precautions (  5.2  )]         EXCERPT:   Most common adverse reactions (incidence >= 0.5%) are nausea, headache, feeling hot, dizziness, and back pain (  6  )     To report SUSPECTED ADVERSE REACTIONS, contact Bayer HealthCare Pharmaceuticals Inc. at 1-888-84-BAYER (1-888-842-2937) or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",Nephrogenic systemic fibrosis is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactionsare discussed elsewhere in the labeling:     *    Nephrogenic systemic fibrosis (NSF) [see Boxed Warning and Warnings and Precautions (  5.1  )]    *    Hypersensitivity reactions [see Contraindications (  4  ) and Warnings and Precautions (  5.2  )]         EXCERPT:   Most common adverse reactions (incidence >= 0.5%) are nausea, headache, feeling hot, dizziness, and back pain (  6  )     To report SUSPECTED ADVERSE REACTIONS, contact Bayer HealthCare Pharmaceuticals Inc. at 1-888-84-BAYER (1-888-842-2937) or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",Inc. is not a named entity
"6 ADVERSE REACTIONS    The following serious adverse reactionsare discussed elsewhere in the labeling:     *    Nephrogenic systemic fibrosis (NSF) [see Boxed Warning and Warnings and Precautions (  5.1  )]    *    Hypersensitivity reactions [see Contraindications (  4  ) and Warnings and Precautions (  5.2  )]         EXCERPT:   Most common adverse reactions (incidence >= 0.5%) are nausea, headache, feeling hot, dizziness, and back pain (  6  )     To report SUSPECTED ADVERSE REACTIONS, contact Bayer HealthCare Pharmaceuticals Inc. at 1-888-84-BAYER (1-888-842-2937) or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",1-888-842-2937 is not a named entity
"6 ADVERSE REACTIONS    The following serious adverse reactionsare discussed elsewhere in the labeling:     *    Nephrogenic systemic fibrosis (NSF) [see Boxed Warning and Warnings and Precautions (  5.1  )]    *    Hypersensitivity reactions [see Contraindications (  4  ) and Warnings and Precautions (  5.2  )]         EXCERPT:   Most common adverse reactions (incidence >= 0.5%) are nausea, headache, feeling hot, dizziness, and back pain (  6  )     To report SUSPECTED ADVERSE REACTIONS, contact Bayer HealthCare Pharmaceuticals Inc. at 1-888-84-BAYER (1-888-842-2937) or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",reactions [ see is not a named entity
"6 ADVERSE REACTIONS    The following serious adverse reactionsare discussed elsewhere in the labeling:     *    Nephrogenic systemic fibrosis (NSF) [see Boxed Warning and Warnings and Precautions (  5.1  )]    *    Hypersensitivity reactions [see Contraindications (  4  ) and Warnings and Precautions (  5.2  )]         EXCERPT:   Most common adverse reactions (incidence >= 0.5%) are nausea, headache, feeling hot, dizziness, and back pain (  6  )     To report SUSPECTED ADVERSE REACTIONS, contact Bayer HealthCare Pharmaceuticals Inc. at 1-888-84-BAYER (1-888-842-2937) or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",) [ see is not a named entity
"6 ADVERSE REACTIONS    The following serious adverse reactionsare discussed elsewhere in the labeling:     *    Nephrogenic systemic fibrosis (NSF) [see Boxed Warning and Warnings and Precautions (  5.1  )]    *    Hypersensitivity reactions [see Contraindications (  4  ) and Warnings and Precautions (  5.2  )]         EXCERPT:   Most common adverse reactions (incidence >= 0.5%) are nausea, headache, feeling hot, dizziness, and back pain (  6  )     To report SUSPECTED ADVERSE REACTIONS, contact Bayer HealthCare Pharmaceuticals Inc. at 1-888-84-BAYER (1-888-842-2937) or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",nausea is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactionsare discussed elsewhere in the labeling:     *    Nephrogenic systemic fibrosis (NSF) [see Boxed Warning and Warnings and Precautions (  5.1  )]    *    Hypersensitivity reactions [see Contraindications (  4  ) and Warnings and Precautions (  5.2  )]         EXCERPT:   Most common adverse reactions (incidence >= 0.5%) are nausea, headache, feeling hot, dizziness, and back pain (  6  )     To report SUSPECTED ADVERSE REACTIONS, contact Bayer HealthCare Pharmaceuticals Inc. at 1-888-84-BAYER (1-888-842-2937) or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",and Warnings and is not a named entity
"6 ADVERSE REACTIONS    The following serious adverse reactionsare discussed elsewhere in the labeling:     *    Nephrogenic systemic fibrosis (NSF) [see Boxed Warning and Warnings and Precautions (  5.1  )]    *    Hypersensitivity reactions [see Contraindications (  4  ) and Warnings and Precautions (  5.2  )]         EXCERPT:   Most common adverse reactions (incidence >= 0.5%) are nausea, headache, feeling hot, dizziness, and back pain (  6  )     To report SUSPECTED ADVERSE REACTIONS, contact Bayer HealthCare Pharmaceuticals Inc. at 1-888-84-BAYER (1-888-842-2937) or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",dizziness is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactionsare discussed elsewhere in the labeling:     *    Nephrogenic systemic fibrosis (NSF) [see Boxed Warning and Warnings and Precautions (  5.1  )]    *    Hypersensitivity reactions [see Contraindications (  4  ) and Warnings and Precautions (  5.2  )]         EXCERPT:   Most common adverse reactions (incidence >= 0.5%) are nausea, headache, feeling hot, dizziness, and back pain (  6  )     To report SUSPECTED ADVERSE REACTIONS, contact Bayer HealthCare Pharmaceuticals Inc. at 1-888-84-BAYER (1-888-842-2937) or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",Hypersensitivity reactions is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactionsare discussed elsewhere in the labeling:     *    Nephrogenic systemic fibrosis (NSF) [see Boxed Warning and Warnings and Precautions (  5.1  )]    *    Hypersensitivity reactions [see Contraindications (  4  ) and Warnings and Precautions (  5.2  )]         EXCERPT:   Most common adverse reactions (incidence >= 0.5%) are nausea, headache, feeling hot, dizziness, and back pain (  6  )     To report SUSPECTED ADVERSE REACTIONS, contact Bayer HealthCare Pharmaceuticals Inc. at 1-888-84-BAYER (1-888-842-2937) or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",discussed is not a named entity
"6 ADVERSE REACTIONS    The following serious adverse reactionsare discussed elsewhere in the labeling:     *    Nephrogenic systemic fibrosis (NSF) [see Boxed Warning and Warnings and Precautions (  5.1  )]    *    Hypersensitivity reactions [see Contraindications (  4  ) and Warnings and Precautions (  5.2  )]         EXCERPT:   Most common adverse reactions (incidence >= 0.5%) are nausea, headache, feeling hot, dizziness, and back pain (  6  )     To report SUSPECTED ADVERSE REACTIONS, contact Bayer HealthCare Pharmaceuticals Inc. at 1-888-84-BAYER (1-888-842-2937) or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",Warnings is not a named entity
"6 ADVERSE REACTIONS    The following serious adverse reactionsare discussed elsewhere in the labeling:     *    Nephrogenic systemic fibrosis (NSF) [see Boxed Warning and Warnings and Precautions (  5.1  )]    *    Hypersensitivity reactions [see Contraindications (  4  ) and Warnings and Precautions (  5.2  )]         EXCERPT:   Most common adverse reactions (incidence >= 0.5%) are nausea, headache, feeling hot, dizziness, and back pain (  6  )     To report SUSPECTED ADVERSE REACTIONS, contact Bayer HealthCare Pharmaceuticals Inc. at 1-888-84-BAYER (1-888-842-2937) or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",headache is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactionsare discussed elsewhere in the labeling:     *    Nephrogenic systemic fibrosis (NSF) [see Boxed Warning and Warnings and Precautions (  5.1  )]    *    Hypersensitivity reactions [see Contraindications (  4  ) and Warnings and Precautions (  5.2  )]         EXCERPT:   Most common adverse reactions (incidence >= 0.5%) are nausea, headache, feeling hot, dizziness, and back pain (  6  )     To report SUSPECTED ADVERSE REACTIONS, contact Bayer HealthCare Pharmaceuticals Inc. at 1-888-84-BAYER (1-888-842-2937) or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",feeling hot is an adverse reaction entity
Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs.,of the is not a named entity
Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs.,NSF is an adverse reaction entity
"The most frequent (>= 0.5%) adverse reactions associated with the use of EOVIST were nausea, headache, feeling hot, dizziness, and back pain.",feeling hot is an adverse reaction entity
"The most frequent (>= 0.5%) adverse reactions associated with the use of EOVIST were nausea, headache, feeling hot, dizziness, and back pain.",( is not a named entity
"The most frequent (>= 0.5%) adverse reactions associated with the use of EOVIST were nausea, headache, feeling hot, dizziness, and back pain.",( > = is not a named entity
"The most frequent (>= 0.5%) adverse reactions associated with the use of EOVIST were nausea, headache, feeling hot, dizziness, and back pain.",headache is an adverse reaction entity
"The most frequent (>= 0.5%) adverse reactions associated with the use of EOVIST were nausea, headache, feeling hot, dizziness, and back pain.",of EOVIST were is not a named entity
"The most frequent (>= 0.5%) adverse reactions associated with the use of EOVIST were nausea, headache, feeling hot, dizziness, and back pain.",nausea is an adverse reaction entity
"The most frequent (>= 0.5%) adverse reactions associated with the use of EOVIST were nausea, headache, feeling hot, dizziness, and back pain.",dizziness is an adverse reaction entity
"The most frequent (>= 0.5%) adverse reactions associated with the use of EOVIST were nausea, headache, feeling hot, dizziness, and back pain.",", feeling is not a named entity"
"The most frequent (>= 0.5%) adverse reactions associated with the use of EOVIST were nausea, headache, feeling hot, dizziness, and back pain.",with is not a named entity
"The most frequent (>= 0.5%) adverse reactions associated with the use of EOVIST were nausea, headache, feeling hot, dizziness, and back pain.",back pain is an adverse reaction entity
Monitor patients closely for need of emergency cardiorespiratory support (  5.2  )             5.1 Nephrogenic Systemic Fibrosis (NSF)      Gadolinium-based contrast agents (GBCAs) increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs.,for nephrogenic systemic is not a named entity
Monitor patients closely for need of emergency cardiorespiratory support (  5.2  )             5.1 Nephrogenic Systemic Fibrosis (NSF)      Gadolinium-based contrast agents (GBCAs) increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs.,need of is not a named entity
Monitor patients closely for need of emergency cardiorespiratory support (  5.2  )             5.1 Nephrogenic Systemic Fibrosis (NSF)      Gadolinium-based contrast agents (GBCAs) increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs.,nephrogenic systemic fibrosis is an adverse reaction entity
Monitor patients closely for need of emergency cardiorespiratory support (  5.2  )             5.1 Nephrogenic Systemic Fibrosis (NSF)      Gadolinium-based contrast agents (GBCAs) increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs.,NSF is an adverse reaction entity
"Higher than recommended dosing or repeated dosing appears to increase the risk (  5.1  )   *    Hypersensitivity: anaphylactoid/hypersensitivity reactions with cardiovascular, respiratory and cutaneous manifestations, ranging from mild to severe reactions including shock can occur.",", respiratory and is not a named entity"
"Higher than recommended dosing or repeated dosing appears to increase the risk (  5.1  )   *    Hypersensitivity: anaphylactoid/hypersensitivity reactions with cardiovascular, respiratory and cutaneous manifestations, ranging from mild to severe reactions including shock can occur.",respiratory manifestations is an adverse reaction entity
"Higher than recommended dosing or repeated dosing appears to increase the risk (  5.1  )   *    Hypersensitivity: anaphylactoid/hypersensitivity reactions with cardiovascular, respiratory and cutaneous manifestations, ranging from mild to severe reactions including shock can occur.",cardiovascular manifestations is an adverse reaction entity
"Higher than recommended dosing or repeated dosing appears to increase the risk (  5.1  )   *    Hypersensitivity: anaphylactoid/hypersensitivity reactions with cardiovascular, respiratory and cutaneous manifestations, ranging from mild to severe reactions including shock can occur.",shock is an adverse reaction entity
"Higher than recommended dosing or repeated dosing appears to increase the risk (  5.1  )   *    Hypersensitivity: anaphylactoid/hypersensitivity reactions with cardiovascular, respiratory and cutaneous manifestations, ranging from mild to severe reactions including shock can occur.",cutaneous manifestations is an adverse reaction entity
"Higher than recommended dosing or repeated dosing appears to increase the risk (  5.1  )   *    Hypersensitivity: anaphylactoid/hypersensitivity reactions with cardiovascular, respiratory and cutaneous manifestations, ranging from mild to severe reactions including shock can occur.",repeated dosing is not a named entity
"Higher than recommended dosing or repeated dosing appears to increase the risk (  5.1  )   *    Hypersensitivity: anaphylactoid/hypersensitivity reactions with cardiovascular, respiratory and cutaneous manifestations, ranging from mild to severe reactions including shock can occur.",hypersensitivity reactions is an adverse reaction entity
"Higher than recommended dosing or repeated dosing appears to increase the risk (  5.1  )   *    Hypersensitivity: anaphylactoid/hypersensitivity reactions with cardiovascular, respiratory and cutaneous manifestations, ranging from mild to severe reactions including shock can occur.",manifestations is not a named entity
"Higher than recommended dosing or repeated dosing appears to increase the risk (  5.1  )   *    Hypersensitivity: anaphylactoid/hypersensitivity reactions with cardiovascular, respiratory and cutaneous manifestations, ranging from mild to severe reactions including shock can occur.",recommended dosing or is not a named entity
"Higher than recommended dosing or repeated dosing appears to increase the risk (  5.1  )   *    Hypersensitivity: anaphylactoid/hypersensitivity reactions with cardiovascular, respiratory and cutaneous manifestations, ranging from mild to severe reactions including shock can occur.",shock can occur is not a named entity
"Higher than recommended dosing or repeated dosing appears to increase the risk (  5.1  )   *    Hypersensitivity: anaphylactoid/hypersensitivity reactions with cardiovascular, respiratory and cutaneous manifestations, ranging from mild to severe reactions including shock can occur.",and cutaneous manifestations is not a named entity
"Higher than recommended dosing or repeated dosing appears to increase the risk (  5.1  )   *    Hypersensitivity: anaphylactoid/hypersensitivity reactions with cardiovascular, respiratory and cutaneous manifestations, ranging from mild to severe reactions including shock can occur.",anaphylactoid reactions is an adverse reaction entity
"5.3 Acute Kidney Injury      In patients with chronic renal impairment, acute kidney injury sometimes requiring dialysis has been observed with the use of some GBCAs.",acute kidney injury is an adverse reaction entity
"5.3 Acute Kidney Injury      In patients with chronic renal impairment, acute kidney injury sometimes requiring dialysis has been observed with the use of some GBCAs.",chronic is not a named entity
EXCERPT:   WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)       See full prescribing information for complete boxed warning.,( NSF ) is not a named entity
EXCERPT:   WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)       See full prescribing information for complete boxed warning.,NSF is an adverse reaction entity
EXCERPT:   WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)       See full prescribing information for complete boxed warning.,EXCERPT : is not a named entity
EXCERPT:   WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)       See full prescribing information for complete boxed warning.,NEPHROGENIC SYSTEMIC FIBROSIS is an adverse reaction entity
These patients may have an increased risk for a hypersensitivity reaction to EOVIST.,hypersensitivity reaction is an adverse reaction entity
These patients may have an increased risk for a hypersensitivity reaction to EOVIST.,may have an is not a named entity
BOXED WARNING: WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)    WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)      Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs.,( NSF is not a named entity
BOXED WARNING: WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)    WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)      Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs.,WARNING : is not a named entity
BOXED WARNING: WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)    WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)      Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs.,NEPHROGENIC SYSTEMIC FIBROSIS is an adverse reaction entity
BOXED WARNING: WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)    WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)      Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs.,NEPHROGENIC SYSTEMIC FIBROSIS is an adverse reaction entity
BOXED WARNING: WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)    WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)      Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs.,NSF is an adverse reaction entity
BOXED WARNING: WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)    WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)      Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs.,NSF is an adverse reaction entity
BOXED WARNING: WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)    WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)      Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs.,: is not a named entity
BOXED WARNING: WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)    WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)      Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs.,: is not a named entity
BOXED WARNING: WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)    WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)      Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs.,of is not a named entity
BOXED WARNING: WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)    WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)      Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs.,NSF is an adverse reaction entity
"*    Hypersensitivity reactions (anaphylacticshock, hypotension, pharyngolaryngeal edema, urticaria, face edema, rhinitis, conjunctivitis, abdominal pain, hypoesthesia, sneezing, cough and pallor) [see Warnings and Precautions (  5.2  )]    *    Tachycardia   *    Restlessness",pharyngolaryngeal edema is an adverse reaction entity
"*    Hypersensitivity reactions (anaphylacticshock, hypotension, pharyngolaryngeal edema, urticaria, face edema, rhinitis, conjunctivitis, abdominal pain, hypoesthesia, sneezing, cough and pallor) [see Warnings and Precautions (  5.2  )]    *    Tachycardia   *    Restlessness","conjunctivitis , is not a named entity"
"*    Hypersensitivity reactions (anaphylacticshock, hypotension, pharyngolaryngeal edema, urticaria, face edema, rhinitis, conjunctivitis, abdominal pain, hypoesthesia, sneezing, cough and pallor) [see Warnings and Precautions (  5.2  )]    *    Tachycardia   *    Restlessness",face edema is an adverse reaction entity
"*    Hypersensitivity reactions (anaphylacticshock, hypotension, pharyngolaryngeal edema, urticaria, face edema, rhinitis, conjunctivitis, abdominal pain, hypoesthesia, sneezing, cough and pallor) [see Warnings and Precautions (  5.2  )]    *    Tachycardia   *    Restlessness",", is not a named entity"
"*    Hypersensitivity reactions (anaphylacticshock, hypotension, pharyngolaryngeal edema, urticaria, face edema, rhinitis, conjunctivitis, abdominal pain, hypoesthesia, sneezing, cough and pallor) [see Warnings and Precautions (  5.2  )]    *    Tachycardia   *    Restlessness",urticaria is an adverse reaction entity
"*    Hypersensitivity reactions (anaphylacticshock, hypotension, pharyngolaryngeal edema, urticaria, face edema, rhinitis, conjunctivitis, abdominal pain, hypoesthesia, sneezing, cough and pallor) [see Warnings and Precautions (  5.2  )]    *    Tachycardia   *    Restlessness",sneezing is an adverse reaction entity
"*    Hypersensitivity reactions (anaphylacticshock, hypotension, pharyngolaryngeal edema, urticaria, face edema, rhinitis, conjunctivitis, abdominal pain, hypoesthesia, sneezing, cough and pallor) [see Warnings and Precautions (  5.2  )]    *    Tachycardia   *    Restlessness",anaphylacticshock is an adverse reaction entity
"*    Hypersensitivity reactions (anaphylacticshock, hypotension, pharyngolaryngeal edema, urticaria, face edema, rhinitis, conjunctivitis, abdominal pain, hypoesthesia, sneezing, cough and pallor) [see Warnings and Precautions (  5.2  )]    *    Tachycardia   *    Restlessness","edema , is not a named entity"
"*    Hypersensitivity reactions (anaphylacticshock, hypotension, pharyngolaryngeal edema, urticaria, face edema, rhinitis, conjunctivitis, abdominal pain, hypoesthesia, sneezing, cough and pallor) [see Warnings and Precautions (  5.2  )]    *    Tachycardia   *    Restlessness",conjunctivitis is an adverse reaction entity
"*    Hypersensitivity reactions (anaphylacticshock, hypotension, pharyngolaryngeal edema, urticaria, face edema, rhinitis, conjunctivitis, abdominal pain, hypoesthesia, sneezing, cough and pallor) [see Warnings and Precautions (  5.2  )]    *    Tachycardia   *    Restlessness",) ] * is not a named entity
"*    Hypersensitivity reactions (anaphylacticshock, hypotension, pharyngolaryngeal edema, urticaria, face edema, rhinitis, conjunctivitis, abdominal pain, hypoesthesia, sneezing, cough and pallor) [see Warnings and Precautions (  5.2  )]    *    Tachycardia   *    Restlessness",* is not a named entity
"*    Hypersensitivity reactions (anaphylacticshock, hypotension, pharyngolaryngeal edema, urticaria, face edema, rhinitis, conjunctivitis, abdominal pain, hypoesthesia, sneezing, cough and pallor) [see Warnings and Precautions (  5.2  )]    *    Tachycardia   *    Restlessness","edema , is not a named entity"
"*    Hypersensitivity reactions (anaphylacticshock, hypotension, pharyngolaryngeal edema, urticaria, face edema, rhinitis, conjunctivitis, abdominal pain, hypoesthesia, sneezing, cough and pallor) [see Warnings and Precautions (  5.2  )]    *    Tachycardia   *    Restlessness",rhinitis is an adverse reaction entity
"*    Hypersensitivity reactions (anaphylacticshock, hypotension, pharyngolaryngeal edema, urticaria, face edema, rhinitis, conjunctivitis, abdominal pain, hypoesthesia, sneezing, cough and pallor) [see Warnings and Precautions (  5.2  )]    *    Tachycardia   *    Restlessness",pallor is an adverse reaction entity
"*    Hypersensitivity reactions (anaphylacticshock, hypotension, pharyngolaryngeal edema, urticaria, face edema, rhinitis, conjunctivitis, abdominal pain, hypoesthesia, sneezing, cough and pallor) [see Warnings and Precautions (  5.2  )]    *    Tachycardia   *    Restlessness",cough is an adverse reaction entity
"*    Hypersensitivity reactions (anaphylacticshock, hypotension, pharyngolaryngeal edema, urticaria, face edema, rhinitis, conjunctivitis, abdominal pain, hypoesthesia, sneezing, cough and pallor) [see Warnings and Precautions (  5.2  )]    *    Tachycardia   *    Restlessness",Tachycardia is an adverse reaction entity
"*    Hypersensitivity reactions (anaphylacticshock, hypotension, pharyngolaryngeal edema, urticaria, face edema, rhinitis, conjunctivitis, abdominal pain, hypoesthesia, sneezing, cough and pallor) [see Warnings and Precautions (  5.2  )]    *    Tachycardia   *    Restlessness","urticaria , face is not a named entity"
"*    Hypersensitivity reactions (anaphylacticshock, hypotension, pharyngolaryngeal edema, urticaria, face edema, rhinitis, conjunctivitis, abdominal pain, hypoesthesia, sneezing, cough and pallor) [see Warnings and Precautions (  5.2  )]    *    Tachycardia   *    Restlessness",hypotension is an adverse reaction entity
"*    Hypersensitivity reactions (anaphylacticshock, hypotension, pharyngolaryngeal edema, urticaria, face edema, rhinitis, conjunctivitis, abdominal pain, hypoesthesia, sneezing, cough and pallor) [see Warnings and Precautions (  5.2  )]    *    Tachycardia   *    Restlessness",Hypersensitivity reactions is an adverse reaction entity
"*    Hypersensitivity reactions (anaphylacticshock, hypotension, pharyngolaryngeal edema, urticaria, face edema, rhinitis, conjunctivitis, abdominal pain, hypoesthesia, sneezing, cough and pallor) [see Warnings and Precautions (  5.2  )]    *    Tachycardia   *    Restlessness",Restlessness is an adverse reaction entity
"*    Hypersensitivity reactions (anaphylacticshock, hypotension, pharyngolaryngeal edema, urticaria, face edema, rhinitis, conjunctivitis, abdominal pain, hypoesthesia, sneezing, cough and pallor) [see Warnings and Precautions (  5.2  )]    *    Tachycardia   *    Restlessness",and is not a named entity
"*    Hypersensitivity reactions (anaphylacticshock, hypotension, pharyngolaryngeal edema, urticaria, face edema, rhinitis, conjunctivitis, abdominal pain, hypoesthesia, sneezing, cough and pallor) [see Warnings and Precautions (  5.2  )]    *    Tachycardia   *    Restlessness","hypotension , is not a named entity"
"*    Hypersensitivity reactions (anaphylacticshock, hypotension, pharyngolaryngeal edema, urticaria, face edema, rhinitis, conjunctivitis, abdominal pain, hypoesthesia, sneezing, cough and pallor) [see Warnings and Precautions (  5.2  )]    *    Tachycardia   *    Restlessness","conjunctivitis , is not a named entity"
"*    Hypersensitivity reactions (anaphylacticshock, hypotension, pharyngolaryngeal edema, urticaria, face edema, rhinitis, conjunctivitis, abdominal pain, hypoesthesia, sneezing, cough and pallor) [see Warnings and Precautions (  5.2  )]    *    Tachycardia   *    Restlessness",hypoesthesia is an adverse reaction entity
"*    Hypersensitivity reactions (anaphylacticshock, hypotension, pharyngolaryngeal edema, urticaria, face edema, rhinitis, conjunctivitis, abdominal pain, hypoesthesia, sneezing, cough and pallor) [see Warnings and Precautions (  5.2  )]    *    Tachycardia   *    Restlessness",abdominal pain is an adverse reaction entity
"*    Hypersensitivity reactions (anaphylacticshock, hypotension, pharyngolaryngeal edema, urticaria, face edema, rhinitis, conjunctivitis, abdominal pain, hypoesthesia, sneezing, cough and pallor) [see Warnings and Precautions (  5.2  )]    *    Tachycardia   *    Restlessness",* Tachycardia * is not a named entity
"*    Hypersensitivity reactions (anaphylacticshock, hypotension, pharyngolaryngeal edema, urticaria, face edema, rhinitis, conjunctivitis, abdominal pain, hypoesthesia, sneezing, cough and pallor) [see Warnings and Precautions (  5.2  )]    *    Tachycardia   *    Restlessness",and is not a named entity
"*    Hypersensitivity reactions (anaphylacticshock, hypotension, pharyngolaryngeal edema, urticaria, face edema, rhinitis, conjunctivitis, abdominal pain, hypoesthesia, sneezing, cough and pallor) [see Warnings and Precautions (  5.2  )]    *    Tachycardia   *    Restlessness",) is not a named entity
"*    Hypersensitivity reactions (anaphylacticshock, hypotension, pharyngolaryngeal edema, urticaria, face edema, rhinitis, conjunctivitis, abdominal pain, hypoesthesia, sneezing, cough and pallor) [see Warnings and Precautions (  5.2  )]    *    Tachycardia   *    Restlessness","hypoesthesia , is not a named entity"
"*    Hypersensitivity reactions (anaphylacticshock, hypotension, pharyngolaryngeal edema, urticaria, face edema, rhinitis, conjunctivitis, abdominal pain, hypoesthesia, sneezing, cough and pallor) [see Warnings and Precautions (  5.2  )]    *    Tachycardia   *    Restlessness",and pallor ) is not a named entity
Among the factors that may increase the risk for NSF are repeated or higher than recommended doses of a GBCA and degree of renal impairment at the time of exposure.,NSF is an adverse reaction entity
Among the factors that may increase the risk for NSF are repeated or higher than recommended doses of a GBCA and degree of renal impairment at the time of exposure.,the time of is not a named entity
"*  The risk for NSF appears highest among patients with:oChronic, severe kidney disease (GFR < 30 mL/min/1.73m2), oroAcute kidney injury.",", severe kidney is not a named entity"
"*  The risk for NSF appears highest among patients with:oChronic, severe kidney disease (GFR < 30 mL/min/1.73m2), oroAcute kidney injury.",NSF is an adverse reaction entity
The risk of acute kidney injury might be lower with EOVIST due to its dual excretory pathways.,kidney injury is not a named entity
The risk of acute kidney injury might be lower with EOVIST due to its dual excretory pathways.,acute kidney injury is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Serious infections - do not start CIMZIA during an active infection.,infections is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Serious infections - do not start CIMZIA during an active infection.,WARNINGS is not a named entity
"For some TNF blockers, more cases of malignancies have been observed among patients receiving those TNF blockers compared to control patients  .",malignancies is an adverse reaction entity
"For some TNF blockers, more cases of malignancies have been observed among patients receiving those TNF blockers compared to control patients  .",those TNF blockers is not a named entity
"Serious infections included tuberculosis, pneumonia, cellulitis, and pyelonephritis.",and pyelonephritis is not a named entity
"Serious infections included tuberculosis, pneumonia, cellulitis, and pyelonephritis.",tuberculosis is an adverse reaction entity
"Serious infections included tuberculosis, pneumonia, cellulitis, and pyelonephritis.",and pyelonephritis is not a named entity
"Serious infections included tuberculosis, pneumonia, cellulitis, and pyelonephritis.",", is not a named entity"
"Serious infections included tuberculosis, pneumonia, cellulitis, and pyelonephritis.",cellulitis is an adverse reaction entity
"Serious infections included tuberculosis, pneumonia, cellulitis, and pyelonephritis.",pyelonephritis is an adverse reaction entity
"Serious infections included tuberculosis, pneumonia, cellulitis, and pyelonephritis.",infections is an adverse reaction entity
"Serious infections included tuberculosis, pneumonia, cellulitis, and pyelonephritis.",included tuberculosis is not a named entity
"Serious infections included tuberculosis, pneumonia, cellulitis, and pyelonephritis.",pneumonia is an adverse reaction entity
"Serious infections included tuberculosis, pneumonia, cellulitis, and pyelonephritis.",", pneumonia , is not a named entity"
"[see  Warnings and Precautions (5.2)  ]             Heart Failure         In placebo-controlled and open-label rheumatoid arthritis studies, cases of new or worsening heart failure have been reported for CIMZIA-treated patients.",worsening heart failure is an adverse reaction entity
"[see  Warnings and Precautions (5.2)  ]             Heart Failure         In placebo-controlled and open-label rheumatoid arthritis studies, cases of new or worsening heart failure have been reported for CIMZIA-treated patients.",new heart failure is an adverse reaction entity
"[see  Warnings and Precautions (5.2)  ]             Heart Failure         In placebo-controlled and open-label rheumatoid arthritis studies, cases of new or worsening heart failure have been reported for CIMZIA-treated patients.",have is not a named entity
"[see  Warnings and Precautions (5.2)  ]             Heart Failure         In placebo-controlled and open-label rheumatoid arthritis studies, cases of new or worsening heart failure have been reported for CIMZIA-treated patients.",cases of new is not a named entity
"In some instances, HBV reactivation occurring in conjunction with TNF blocker therapy has been fatal.",", HBV is not a named entity"
"In some instances, HBV reactivation occurring in conjunction with TNF blocker therapy has been fatal.",fatal is an adverse reaction entity
"In some instances, HBV reactivation occurring in conjunction with TNF blocker therapy has been fatal.",with is not a named entity
"In some instances, HBV reactivation occurring in conjunction with TNF blocker therapy has been fatal.",HBV reactivation is an adverse reaction entity
"In premarketing controlled trials of all patient populations combined the most common adverse reactions (>= 8%) were upper respiratory infections (18%), rash (9%) and urinary tract infections (8%).",upper respiratory infections is an adverse reaction entity
"In premarketing controlled trials of all patient populations combined the most common adverse reactions (>= 8%) were upper respiratory infections (18%), rash (9%) and urinary tract infections (8%).",rash is an adverse reaction entity
"In premarketing controlled trials of all patient populations combined the most common adverse reactions (>= 8%) were upper respiratory infections (18%), rash (9%) and urinary tract infections (8%).",were upper is not a named entity
"In premarketing controlled trials of all patient populations combined the most common adverse reactions (>= 8%) were upper respiratory infections (18%), rash (9%) and urinary tract infections (8%).",urinary tract infections is an adverse reaction entity
"In premarketing controlled trials of all patient populations combined the most common adverse reactions (>= 8%) were upper respiratory infections (18%), rash (9%) and urinary tract infections (8%).",infections ( is not a named entity
"In premarketing controlled trials of all patient populations combined the most common adverse reactions (>= 8%) were upper respiratory infections (18%), rash (9%) and urinary tract infections (8%).",controlled is not a named entity
"5.2 Malignancies      In the controlled portions of clinical studies of some TNF blockers, more cases of malignancies have been observed among patients receiving TNF blockers compared to control patients.",malignancies is an adverse reaction entity
"5.2 Malignancies      In the controlled portions of clinical studies of some TNF blockers, more cases of malignancies have been observed among patients receiving TNF blockers compared to control patients.",clinical is not a named entity
"*  Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria.",Bacterial infections is an adverse reaction entity
"*  Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria.",viral infections is an adverse reaction entity
"*  Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria.",to opportunistic pathogens is not a named entity
"*  Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria.","pathogens , including is not a named entity"
"*  Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria.",infections Listeria is an adverse reaction entity
"*  Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria.",* Bacterial is not a named entity
"*  Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria.",and is not a named entity
"*  Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria.",infections Legionella is an adverse reaction entity
"Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma that has a very aggressive disease course and is usually fatal, have been reported in patients treated with TNF blockers, including CIMZIA.",HSTCL is an adverse reaction entity
"Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma that has a very aggressive disease course and is usually fatal, have been reported in patients treated with TNF blockers, including CIMZIA.",hepatosplenic T-cell lymphoma is an adverse reaction entity
"Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma that has a very aggressive disease course and is usually fatal, have been reported in patients treated with TNF blockers, including CIMZIA.",( is not a named entity
"Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma that has a very aggressive disease course and is usually fatal, have been reported in patients treated with TNF blockers, including CIMZIA.",") , a is not a named entity"
"Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma that has a very aggressive disease course and is usually fatal, have been reported in patients treated with TNF blockers, including CIMZIA.",and is usually is not a named entity
"Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma that has a very aggressive disease course and is usually fatal, have been reported in patients treated with TNF blockers, including CIMZIA.",fatal is an adverse reaction entity
"5.5 Hepatitis B Virus Reactivation      Use of TNF blockers, including CIMZIA, has been associated with reactivation of hepatitis B virus (HBV) in patients who are chronic carriers of this virus.",has is not a named entity
"5.5 Hepatitis B Virus Reactivation      Use of TNF blockers, including CIMZIA, has been associated with reactivation of hepatitis B virus (HBV) in patients who are chronic carriers of this virus.",Reactivation is not a named entity
"5.5 Hepatitis B Virus Reactivation      Use of TNF blockers, including CIMZIA, has been associated with reactivation of hepatitis B virus (HBV) in patients who are chronic carriers of this virus.",reactivation of hepatitis B virus is an adverse reaction entity
"5.5 Hepatitis B Virus Reactivation      Use of TNF blockers, including CIMZIA, has been associated with reactivation of hepatitis B virus (HBV) in patients who are chronic carriers of this virus.",reactivation of HBV is an adverse reaction entity
"Four patients out of 2,367 patients treated with CIMZIA in RA clinical studies developed clinical signs suggestive of a lupus-like syndrome.",lupus-like syndrome is an adverse reaction entity
"Four patients out of 2,367 patients treated with CIMZIA in RA clinical studies developed clinical signs suggestive of a lupus-like syndrome.",clinical studies is not a named entity
"Malignancies         In clinical studies of CIMZIA, the overall incidence rate of malignancies was similar for CIMZIA-treated and control patients.",rate is not a named entity
"Malignancies         In clinical studies of CIMZIA, the overall incidence rate of malignancies was similar for CIMZIA-treated and control patients.",malignancies is an adverse reaction entity
"Skin: case of severe skin reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, and new or worsening psoriasis (all sub-types including pustular and palmoplantar) have been identified during post-approval use of TNF blockers.",skin reactions is an adverse reaction entity
"Skin: case of severe skin reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, and new or worsening psoriasis (all sub-types including pustular and palmoplantar) have been identified during post-approval use of TNF blockers.",psoriasis palmoplantar is an adverse reaction entity
"Skin: case of severe skin reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, and new or worsening psoriasis (all sub-types including pustular and palmoplantar) have been identified during post-approval use of TNF blockers.",Stevens-Johnson syndrome is an adverse reaction entity
"Skin: case of severe skin reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, and new or worsening psoriasis (all sub-types including pustular and palmoplantar) have been identified during post-approval use of TNF blockers.",during post-approval is not a named entity
"Skin: case of severe skin reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, and new or worsening psoriasis (all sub-types including pustular and palmoplantar) have been identified during post-approval use of TNF blockers.",psoriasis pustular is an adverse reaction entity
"Skin: case of severe skin reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, and new or worsening psoriasis (all sub-types including pustular and palmoplantar) have been identified during post-approval use of TNF blockers.",epidermal is not a named entity
"Skin: case of severe skin reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, and new or worsening psoriasis (all sub-types including pustular and palmoplantar) have been identified during post-approval use of TNF blockers.",: case of is not a named entity
"Skin: case of severe skin reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, and new or worsening psoriasis (all sub-types including pustular and palmoplantar) have been identified during post-approval use of TNF blockers.",and new or is not a named entity
"Skin: case of severe skin reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, and new or worsening psoriasis (all sub-types including pustular and palmoplantar) have been identified during post-approval use of TNF blockers.",Skin : case is not a named entity
"Skin: case of severe skin reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, and new or worsening psoriasis (all sub-types including pustular and palmoplantar) have been identified during post-approval use of TNF blockers.",erythema multiforme is an adverse reaction entity
"Skin: case of severe skin reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, and new or worsening psoriasis (all sub-types including pustular and palmoplantar) have been identified during post-approval use of TNF blockers.",psoriasis is an adverse reaction entity
"Skin: case of severe skin reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, and new or worsening psoriasis (all sub-types including pustular and palmoplantar) have been identified during post-approval use of TNF blockers.",identified is not a named entity
"Skin: case of severe skin reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, and new or worsening psoriasis (all sub-types including pustular and palmoplantar) have been identified during post-approval use of TNF blockers.",including pustular is not a named entity
"Skin: case of severe skin reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, and new or worsening psoriasis (all sub-types including pustular and palmoplantar) have been identified during post-approval use of TNF blockers.",toxic epidermal necrolysis is an adverse reaction entity
"In the controlled rheumatoid arthritis studies, there were more new cases of serious infection adverse reactions in the CIMZIA treatment groups, compared to the placebo groups (0.06 per patient-year for all CIMZIA doses vs. 0.02 per patient-year for placebo).",infection is an adverse reaction entity
"In the controlled rheumatoid arthritis studies, there were more new cases of serious infection adverse reactions in the CIMZIA treatment groups, compared to the placebo groups (0.06 per patient-year for all CIMZIA doses vs. 0.02 per patient-year for placebo).",the CIMZIA treatment is not a named entity
A higher risk of serious infections was also observed in combination use of TNF blockers with abatacept and rituximab.,and is not a named entity
A higher risk of serious infections was also observed in combination use of TNF blockers with abatacept and rituximab.,infections is an adverse reaction entity
Rates of serious infections in the 200 mg every other week dose group were 0.06 per patient-year and in the 400 mg every 4 weeks dose group were 0.04 per patient-year.,infections is an adverse reaction entity
Rates of serious infections in the 200 mg every other week dose group were 0.06 per patient-year and in the 400 mg every 4 weeks dose group were 0.04 per patient-year.,were 0.06 per is not a named entity
"Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized disease.",fungal infections is not a named entity
"Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized disease.",than localized disease is not a named entity
"Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized disease.",histoplasmosis disseminated is an adverse reaction entity
"Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized disease.",", rather than is not a named entity"
"Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized disease.",", rather is not a named entity"
"Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized disease.",invasive fungal infections is an adverse reaction entity
"Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized disease.",invasive fungal infections disseminated is an adverse reaction entity
"Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized disease.",histoplasmosis is an adverse reaction entity
"*  Increased risk of serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens (5.1).",death is an adverse reaction entity
"*  Increased risk of serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens (5.1).",opportunistic pathogens is not a named entity
"*  Increased risk of serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens (5.1).",histoplasmosis is an adverse reaction entity
"*  Increased risk of serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens (5.1).",tuberculosis is an adverse reaction entity
"*  Increased risk of serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens (5.1).",TB is an adverse reaction entity
"*  Increased risk of serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens (5.1).",infections due to other opportunistic pathogens is an adverse reaction entity
"*  Increased risk of serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens (5.1).",serious infections leading is not a named entity
"*  Increased risk of serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens (5.1).",") , and is not a named entity"
"*  Increased risk of serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens (5.1).",to hospitalization or is not a named entity
"*  Increased risk of serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens (5.1).",* Increased is not a named entity
"*  Increased risk of serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens (5.1).",", bacterial sepsis is not a named entity"
"*  Increased risk of serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens (5.1).",bacterial sepsis is an adverse reaction entity
"*  Increased risk of serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens (5.1).",invasive fungal infections is an adverse reaction entity
"*  Increased risk of serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens (5.1).",to is not a named entity
"*  Increased risk of serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens (5.1).",", and infections is not a named entity"
"*  Increased risk of serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens (5.1).",infections is an adverse reaction entity
"Skin and subcutaneous tissue disorders:  Dermatitis, erythema nodosum, and urticaria.",", and urticaria is not a named entity"
"Skin and subcutaneous tissue disorders:  Dermatitis, erythema nodosum, and urticaria.",", erythema is not a named entity"
"Skin and subcutaneous tissue disorders:  Dermatitis, erythema nodosum, and urticaria.",and is not a named entity
"Skin and subcutaneous tissue disorders:  Dermatitis, erythema nodosum, and urticaria.",erythema nodosum is an adverse reaction entity
"Skin and subcutaneous tissue disorders:  Dermatitis, erythema nodosum, and urticaria.",Dermatitis is an adverse reaction entity
"Skin and subcutaneous tissue disorders:  Dermatitis, erythema nodosum, and urticaria.",urticaria is an adverse reaction entity
Vascular disorder: systemic vasculitis has been identified during post-approval use of TNF blockers.,systemic vasculitis is an adverse reaction entity
Vascular disorder: systemic vasculitis has been identified during post-approval use of TNF blockers.,post-approval use is not a named entity
"The infections consisted primarily of upper respiratory infections (20% for CIMZIA, 13% for placebo).",infections is an adverse reaction entity
"The infections consisted primarily of upper respiratory infections (20% for CIMZIA, 13% for placebo).",", is not a named entity"
"The infections consisted primarily of upper respiratory infections (20% for CIMZIA, 13% for placebo).",upper respiratory infections is an adverse reaction entity
"The infections consisted primarily of upper respiratory infections (20% for CIMZIA, 13% for placebo).",respiratory is not a named entity
"6 ADVERSE REACTIONS    EXCERPT:   The most common adverse reactions (incidence >=7% and higher than placebo): upper respiratory tract infection, rash, and urinary tract infection (  6.1  )  To report SUSPECTED ADVERSE REACTIONS, contact UCB, Inc. at 1-866-822-0068 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.",rash is an adverse reaction entity
"6 ADVERSE REACTIONS    EXCERPT:   The most common adverse reactions (incidence >=7% and higher than placebo): upper respiratory tract infection, rash, and urinary tract infection (  6.1  )  To report SUSPECTED ADVERSE REACTIONS, contact UCB, Inc. at 1-866-822-0068 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.",most common is not a named entity
"6 ADVERSE REACTIONS    EXCERPT:   The most common adverse reactions (incidence >=7% and higher than placebo): upper respiratory tract infection, rash, and urinary tract infection (  6.1  )  To report SUSPECTED ADVERSE REACTIONS, contact UCB, Inc. at 1-866-822-0068 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.",ADVERSE is not a named entity
"6 ADVERSE REACTIONS    EXCERPT:   The most common adverse reactions (incidence >=7% and higher than placebo): upper respiratory tract infection, rash, and urinary tract infection (  6.1  )  To report SUSPECTED ADVERSE REACTIONS, contact UCB, Inc. at 1-866-822-0068 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.",upper respiratory tract infection is an adverse reaction entity
"6 ADVERSE REACTIONS    EXCERPT:   The most common adverse reactions (incidence >=7% and higher than placebo): upper respiratory tract infection, rash, and urinary tract infection (  6.1  )  To report SUSPECTED ADVERSE REACTIONS, contact UCB, Inc. at 1-866-822-0068 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.",most common is not a named entity
"6 ADVERSE REACTIONS    EXCERPT:   The most common adverse reactions (incidence >=7% and higher than placebo): upper respiratory tract infection, rash, and urinary tract infection (  6.1  )  To report SUSPECTED ADVERSE REACTIONS, contact UCB, Inc. at 1-866-822-0068 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.",urinary tract infection is an adverse reaction entity
"5.3 Heart Failure      Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF blockers, including CIMZIA.",worsening congestive heart failure is an adverse reaction entity
"5.3 Heart Failure      Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF blockers, including CIMZIA.",", is not a named entity"
"5.3 Heart Failure      Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF blockers, including CIMZIA.",CHF have is not a named entity
"5.3 Heart Failure      Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF blockers, including CIMZIA.",new onset CHF is an adverse reaction entity
"5.3 Heart Failure      Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF blockers, including CIMZIA.",reported is not a named entity
"5.3 Heart Failure      Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF blockers, including CIMZIA.",worsening CHF is an adverse reaction entity
"Rare cases of neurological disorders, including seizure disorder, optic neuritis, and peripheral neuropathy have been reported in patients treated with CIMZIA [see  Adverse Reactions (6.1)  ]  .","neurological disorders , is not a named entity"
"Rare cases of neurological disorders, including seizure disorder, optic neuritis, and peripheral neuropathy have been reported in patients treated with CIMZIA [see  Adverse Reactions (6.1)  ]  .","neurological disorders , is not a named entity"
"Rare cases of neurological disorders, including seizure disorder, optic neuritis, and peripheral neuropathy have been reported in patients treated with CIMZIA [see  Adverse Reactions (6.1)  ]  .",", including seizure is not a named entity"
"Rare cases of neurological disorders, including seizure disorder, optic neuritis, and peripheral neuropathy have been reported in patients treated with CIMZIA [see  Adverse Reactions (6.1)  ]  .",neurological disorders is an adverse reaction entity
"Rare cases of neurological disorders, including seizure disorder, optic neuritis, and peripheral neuropathy have been reported in patients treated with CIMZIA [see  Adverse Reactions (6.1)  ]  .",seizure disorder is an adverse reaction entity
"Rare cases of neurological disorders, including seizure disorder, optic neuritis, and peripheral neuropathy have been reported in patients treated with CIMZIA [see  Adverse Reactions (6.1)  ]  .",peripheral neuropathy is an adverse reaction entity
"Rare cases of neurological disorders, including seizure disorder, optic neuritis, and peripheral neuropathy have been reported in patients treated with CIMZIA [see  Adverse Reactions (6.1)  ]  .",CIMZIA [ is not a named entity
"Rare cases of neurological disorders, including seizure disorder, optic neuritis, and peripheral neuropathy have been reported in patients treated with CIMZIA [see  Adverse Reactions (6.1)  ]  .",optic neuritis is an adverse reaction entity
"MALIGNANCY         Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which CIMZIA is a member   [see   Warnings and Precautions (5.2)  ].",treated with TNF is not a named entity
"MALIGNANCY         Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which CIMZIA is a member   [see   Warnings and Precautions (5.2)  ].",Lymphoma is an adverse reaction entity
"MALIGNANCY         Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which CIMZIA is a member   [see   Warnings and Precautions (5.2)  ].",and is not a named entity
"MALIGNANCY         Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which CIMZIA is a member   [see   Warnings and Precautions (5.2)  ].",and other is not a named entity
"MALIGNANCY         Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which CIMZIA is a member   [see   Warnings and Precautions (5.2)  ].",fatal is an adverse reaction entity
"MALIGNANCY         Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which CIMZIA is a member   [see   Warnings and Precautions (5.2)  ].",malignancies is an adverse reaction entity
"The infections consisted primarily of upper respiratory tract infections, herpes infections, urinary tract infections, and lower respiratory tract infections.",herpes infections is an adverse reaction entity
"The infections consisted primarily of upper respiratory tract infections, herpes infections, urinary tract infections, and lower respiratory tract infections.",consisted primarily of is not a named entity
"The infections consisted primarily of upper respiratory tract infections, herpes infections, urinary tract infections, and lower respiratory tract infections.",respiratory is not a named entity
"The infections consisted primarily of upper respiratory tract infections, herpes infections, urinary tract infections, and lower respiratory tract infections.",tract is not a named entity
"The infections consisted primarily of upper respiratory tract infections, herpes infections, urinary tract infections, and lower respiratory tract infections.",infections is an adverse reaction entity
"The infections consisted primarily of upper respiratory tract infections, herpes infections, urinary tract infections, and lower respiratory tract infections.",upper respiratory tract infections is an adverse reaction entity
"The infections consisted primarily of upper respiratory tract infections, herpes infections, urinary tract infections, and lower respiratory tract infections.","tract infections , is not a named entity"
"The infections consisted primarily of upper respiratory tract infections, herpes infections, urinary tract infections, and lower respiratory tract infections.",lower respiratory tract infections is an adverse reaction entity
"The infections consisted primarily of upper respiratory tract infections, herpes infections, urinary tract infections, and lower respiratory tract infections.",primarily of upper is not a named entity
"The infections consisted primarily of upper respiratory tract infections, herpes infections, urinary tract infections, and lower respiratory tract infections.",urinary tract infections is an adverse reaction entity
"Other serious or significant adverse reactions reported in controlled and uncontrolled studies in Crohn's disease and other diseases, occurring in patients receiving CIMZIA at doses of 400 mg or other doses include:       Blood and lymphatic system disorders:  Anemia, leukopenia, lymphadenopathy, pancytopenia, and thrombophilia.",disease and other is not a named entity
"Other serious or significant adverse reactions reported in controlled and uncontrolled studies in Crohn's disease and other diseases, occurring in patients receiving CIMZIA at doses of 400 mg or other doses include:       Blood and lymphatic system disorders:  Anemia, leukopenia, lymphadenopathy, pancytopenia, and thrombophilia.",pancytopenia is an adverse reaction entity
"Other serious or significant adverse reactions reported in controlled and uncontrolled studies in Crohn's disease and other diseases, occurring in patients receiving CIMZIA at doses of 400 mg or other doses include:       Blood and lymphatic system disorders:  Anemia, leukopenia, lymphadenopathy, pancytopenia, and thrombophilia.","diseases , occurring is not a named entity"
"Other serious or significant adverse reactions reported in controlled and uncontrolled studies in Crohn's disease and other diseases, occurring in patients receiving CIMZIA at doses of 400 mg or other doses include:       Blood and lymphatic system disorders:  Anemia, leukopenia, lymphadenopathy, pancytopenia, and thrombophilia.",system is not a named entity
"Other serious or significant adverse reactions reported in controlled and uncontrolled studies in Crohn's disease and other diseases, occurring in patients receiving CIMZIA at doses of 400 mg or other doses include:       Blood and lymphatic system disorders:  Anemia, leukopenia, lymphadenopathy, pancytopenia, and thrombophilia.",or significant is not a named entity
"Other serious or significant adverse reactions reported in controlled and uncontrolled studies in Crohn's disease and other diseases, occurring in patients receiving CIMZIA at doses of 400 mg or other doses include:       Blood and lymphatic system disorders:  Anemia, leukopenia, lymphadenopathy, pancytopenia, and thrombophilia.",thrombophilia is an adverse reaction entity
"Other serious or significant adverse reactions reported in controlled and uncontrolled studies in Crohn's disease and other diseases, occurring in patients receiving CIMZIA at doses of 400 mg or other doses include:       Blood and lymphatic system disorders:  Anemia, leukopenia, lymphadenopathy, pancytopenia, and thrombophilia.",leukopenia is an adverse reaction entity
"Other serious or significant adverse reactions reported in controlled and uncontrolled studies in Crohn's disease and other diseases, occurring in patients receiving CIMZIA at doses of 400 mg or other doses include:       Blood and lymphatic system disorders:  Anemia, leukopenia, lymphadenopathy, pancytopenia, and thrombophilia.",", occurring is not a named entity"
"Other serious or significant adverse reactions reported in controlled and uncontrolled studies in Crohn's disease and other diseases, occurring in patients receiving CIMZIA at doses of 400 mg or other doses include:       Blood and lymphatic system disorders:  Anemia, leukopenia, lymphadenopathy, pancytopenia, and thrombophilia.",Anemia is an adverse reaction entity
"Other serious or significant adverse reactions reported in controlled and uncontrolled studies in Crohn's disease and other diseases, occurring in patients receiving CIMZIA at doses of 400 mg or other doses include:       Blood and lymphatic system disorders:  Anemia, leukopenia, lymphadenopathy, pancytopenia, and thrombophilia.",lymphadenopathy is an adverse reaction entity
"The following adverse events were reported in Crohn's disease patients who were antibody-positive (N = 100) at an incidence at least 3% higher compared to antibody-negative patients (N = 1,242): abdominal pain, arthralgia, edema peripheral, erythema nodosum, injection site erythema, injection site pain, pain in extremity, and upper respiratory tract infection.",erythema nodosum is an adverse reaction entity
"The following adverse events were reported in Crohn's disease patients who were antibody-positive (N = 100) at an incidence at least 3% higher compared to antibody-negative patients (N = 1,242): abdominal pain, arthralgia, edema peripheral, erythema nodosum, injection site erythema, injection site pain, pain in extremity, and upper respiratory tract infection.",arthralgia is an adverse reaction entity
"The following adverse events were reported in Crohn's disease patients who were antibody-positive (N = 100) at an incidence at least 3% higher compared to antibody-negative patients (N = 1,242): abdominal pain, arthralgia, edema peripheral, erythema nodosum, injection site erythema, injection site pain, pain in extremity, and upper respiratory tract infection.",", injection site is not a named entity"
"The following adverse events were reported in Crohn's disease patients who were antibody-positive (N = 100) at an incidence at least 3% higher compared to antibody-negative patients (N = 1,242): abdominal pain, arthralgia, edema peripheral, erythema nodosum, injection site erythema, injection site pain, pain in extremity, and upper respiratory tract infection.",pain in extremity is an adverse reaction entity
"The following adverse events were reported in Crohn's disease patients who were antibody-positive (N = 100) at an incidence at least 3% higher compared to antibody-negative patients (N = 1,242): abdominal pain, arthralgia, edema peripheral, erythema nodosum, injection site erythema, injection site pain, pain in extremity, and upper respiratory tract infection.",injection site pain is an adverse reaction entity
"The following adverse events were reported in Crohn's disease patients who were antibody-positive (N = 100) at an incidence at least 3% higher compared to antibody-negative patients (N = 1,242): abdominal pain, arthralgia, edema peripheral, erythema nodosum, injection site erythema, injection site pain, pain in extremity, and upper respiratory tract infection.",least is not a named entity
"The following adverse events were reported in Crohn's disease patients who were antibody-positive (N = 100) at an incidence at least 3% higher compared to antibody-negative patients (N = 1,242): abdominal pain, arthralgia, edema peripheral, erythema nodosum, injection site erythema, injection site pain, pain in extremity, and upper respiratory tract infection.",peripheral is not a named entity
"The following adverse events were reported in Crohn's disease patients who were antibody-positive (N = 100) at an incidence at least 3% higher compared to antibody-negative patients (N = 1,242): abdominal pain, arthralgia, edema peripheral, erythema nodosum, injection site erythema, injection site pain, pain in extremity, and upper respiratory tract infection.",edema peripheral is an adverse reaction entity
"The following adverse events were reported in Crohn's disease patients who were antibody-positive (N = 100) at an incidence at least 3% higher compared to antibody-negative patients (N = 1,242): abdominal pain, arthralgia, edema peripheral, erythema nodosum, injection site erythema, injection site pain, pain in extremity, and upper respiratory tract infection.",upper respiratory tract infection is an adverse reaction entity
"The following adverse events were reported in Crohn's disease patients who were antibody-positive (N = 100) at an incidence at least 3% higher compared to antibody-negative patients (N = 1,242): abdominal pain, arthralgia, edema peripheral, erythema nodosum, injection site erythema, injection site pain, pain in extremity, and upper respiratory tract infection.",following adverse is not a named entity
"The following adverse events were reported in Crohn's disease patients who were antibody-positive (N = 100) at an incidence at least 3% higher compared to antibody-negative patients (N = 1,242): abdominal pain, arthralgia, edema peripheral, erythema nodosum, injection site erythema, injection site pain, pain in extremity, and upper respiratory tract infection.",Crohn 's is not a named entity
"The following adverse events were reported in Crohn's disease patients who were antibody-positive (N = 100) at an incidence at least 3% higher compared to antibody-negative patients (N = 1,242): abdominal pain, arthralgia, edema peripheral, erythema nodosum, injection site erythema, injection site pain, pain in extremity, and upper respiratory tract infection.",abdominal pain is an adverse reaction entity
"The following adverse events were reported in Crohn's disease patients who were antibody-positive (N = 100) at an incidence at least 3% higher compared to antibody-negative patients (N = 1,242): abdominal pain, arthralgia, edema peripheral, erythema nodosum, injection site erythema, injection site pain, pain in extremity, and upper respiratory tract infection.",injection site erythema is an adverse reaction entity
"The following adverse events were reported in Crohn's disease patients who were antibody-positive (N = 100) at an incidence at least 3% higher compared to antibody-negative patients (N = 1,242): abdominal pain, arthralgia, edema peripheral, erythema nodosum, injection site erythema, injection site pain, pain in extremity, and upper respiratory tract infection.","arthralgia , is not a named entity"
"The following adverse events were reported in Crohn's disease patients who were antibody-positive (N = 100) at an incidence at least 3% higher compared to antibody-negative patients (N = 1,242): abdominal pain, arthralgia, edema peripheral, erythema nodosum, injection site erythema, injection site pain, pain in extremity, and upper respiratory tract infection.",following is not a named entity
"The following adverse events were reported in Crohn's disease patients who were antibody-positive (N = 100) at an incidence at least 3% higher compared to antibody-negative patients (N = 1,242): abdominal pain, arthralgia, edema peripheral, erythema nodosum, injection site erythema, injection site pain, pain in extremity, and upper respiratory tract infection.",events were is not a named entity
"6.1 Clinical Trials Experience    The most serious adverse reactions were:     *  Serious Infections [see  Warnings and Precautions (5.1)  ]    *  Malignancies [see  Warnings and Precautions (5.2)  ]    *  Heart Failure [see  Warnings and Precautions (5.3)  ]       Because clinical studies are conducted under widely varying and controlled conditions, adverse reaction rates observed in clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug, and may not predict the rates observed in a broader patient population in clinical practice.",Infections is an adverse reaction entity
"6.1 Clinical Trials Experience    The most serious adverse reactions were:     *  Serious Infections [see  Warnings and Precautions (5.1)  ]    *  Malignancies [see  Warnings and Precautions (5.2)  ]    *  Heart Failure [see  Warnings and Precautions (5.3)  ]       Because clinical studies are conducted under widely varying and controlled conditions, adverse reaction rates observed in clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug, and may not predict the rates observed in a broader patient population in clinical practice.",a broader is not a named entity
"6.1 Clinical Trials Experience    The most serious adverse reactions were:     *  Serious Infections [see  Warnings and Precautions (5.1)  ]    *  Malignancies [see  Warnings and Precautions (5.2)  ]    *  Heart Failure [see  Warnings and Precautions (5.3)  ]       Because clinical studies are conducted under widely varying and controlled conditions, adverse reaction rates observed in clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug, and may not predict the rates observed in a broader patient population in clinical practice.",Heart Failure is an adverse reaction entity
"6.1 Clinical Trials Experience    The most serious adverse reactions were:     *  Serious Infections [see  Warnings and Precautions (5.1)  ]    *  Malignancies [see  Warnings and Precautions (5.2)  ]    *  Heart Failure [see  Warnings and Precautions (5.3)  ]       Because clinical studies are conducted under widely varying and controlled conditions, adverse reaction rates observed in clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug, and may not predict the rates observed in a broader patient population in clinical practice.",Malignancies is an adverse reaction entity
"6.1 Clinical Trials Experience    The most serious adverse reactions were:     *  Serious Infections [see  Warnings and Precautions (5.1)  ]    *  Malignancies [see  Warnings and Precautions (5.2)  ]    *  Heart Failure [see  Warnings and Precautions (5.3)  ]       Because clinical studies are conducted under widely varying and controlled conditions, adverse reaction rates observed in clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug, and may not predict the rates observed in a broader patient population in clinical practice.","drug , is not a named entity"
"6.1 Clinical Trials Experience    The most serious adverse reactions were:     *  Serious Infections [see  Warnings and Precautions (5.1)  ]    *  Malignancies [see  Warnings and Precautions (5.2)  ]    *  Heart Failure [see  Warnings and Precautions (5.3)  ]       Because clinical studies are conducted under widely varying and controlled conditions, adverse reaction rates observed in clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug, and may not predict the rates observed in a broader patient population in clinical practice.",predict the rates is not a named entity
The other cases represented a variety of different malignancies and included rare malignancies usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents.,a variety of is not a named entity
The other cases represented a variety of different malignancies and included rare malignancies usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents.,malignancies is an adverse reaction entity
The other cases represented a variety of different malignancies and included rare malignancies usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents.,usually observed in is not a named entity
The other cases represented a variety of different malignancies and included rare malignancies usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents.,malignancies is an adverse reaction entity
The other cases represented a variety of different malignancies and included rare malignancies usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents.,rare malignancies is an adverse reaction entity
The other cases represented a variety of different malignancies and included rare malignancies usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents.,a is not a named entity
"bladder infection, bacteriuria, cystitis) in 7% of CIMZIA-treated patients and in 6% of placebo-treated patients, and arthralgia (6% CIMZIA, 4% placebo).",arthralgia is an adverse reaction entity
"bladder infection, bacteriuria, cystitis) in 7% of CIMZIA-treated patients and in 6% of placebo-treated patients, and arthralgia (6% CIMZIA, 4% placebo).",6 % is not a named entity
"bladder infection, bacteriuria, cystitis) in 7% of CIMZIA-treated patients and in 6% of placebo-treated patients, and arthralgia (6% CIMZIA, 4% placebo).",in 7 % is not a named entity
"bladder infection, bacteriuria, cystitis) in 7% of CIMZIA-treated patients and in 6% of placebo-treated patients, and arthralgia (6% CIMZIA, 4% placebo).",6 % is not a named entity
"bladder infection, bacteriuria, cystitis) in 7% of CIMZIA-treated patients and in 6% of placebo-treated patients, and arthralgia (6% CIMZIA, 4% placebo).",bacteriuria is an adverse reaction entity
"bladder infection, bacteriuria, cystitis) in 7% of CIMZIA-treated patients and in 6% of placebo-treated patients, and arthralgia (6% CIMZIA, 4% placebo).",6 % CIMZIA is not a named entity
"bladder infection, bacteriuria, cystitis) in 7% of CIMZIA-treated patients and in 6% of placebo-treated patients, and arthralgia (6% CIMZIA, 4% placebo).",bladder infection is an adverse reaction entity
"bladder infection, bacteriuria, cystitis) in 7% of CIMZIA-treated patients and in 6% of placebo-treated patients, and arthralgia (6% CIMZIA, 4% placebo).",cystitis is an adverse reaction entity
"Serious infections observed included bacterial and viral infections, pneumonia, and pyelonephritis.","viral infections , is not a named entity"
"Serious infections observed included bacterial and viral infections, pneumonia, and pyelonephritis.",observed included is not a named entity
"Serious infections observed included bacterial and viral infections, pneumonia, and pyelonephritis.",viral infections is an adverse reaction entity
"Serious infections observed included bacterial and viral infections, pneumonia, and pyelonephritis.",bacterial and is not a named entity
"Serious infections observed included bacterial and viral infections, pneumonia, and pyelonephritis.",pneumonia is an adverse reaction entity
"Serious infections observed included bacterial and viral infections, pneumonia, and pyelonephritis.",bacterial infections is an adverse reaction entity
"Serious infections observed included bacterial and viral infections, pneumonia, and pyelonephritis.",pyelonephritis is an adverse reaction entity
"Serious infections observed included bacterial and viral infections, pneumonia, and pyelonephritis.",", pneumonia , is not a named entity"
"Serious infections observed included bacterial and viral infections, pneumonia, and pyelonephritis.",bacterial and is not a named entity
"Serious infections observed included bacterial and viral infections, pneumonia, and pyelonephritis.",infections is an adverse reaction entity
"The most common adverse reactions (occurring in >= 5% of CIMZIA-treated patients, and with a higher incidence compared to placebo) in controlled clinical studies with CIMZIA were upper respiratory infections (e.g.",upper respiratory infections is an adverse reaction entity
"The most common adverse reactions (occurring in >= 5% of CIMZIA-treated patients, and with a higher incidence compared to placebo) in controlled clinical studies with CIMZIA were upper respiratory infections (e.g.",a higher is not a named entity
"Adverse reactions of the hematologic system, including medically significant cytopenia (e.g., leukopenia, pancytopenia, thrombocytopenia) have been infrequently reported with CIMZIA [see  Adverse Reactions (6.1)  ]  .",cytopenia is an adverse reaction entity
"Adverse reactions of the hematologic system, including medically significant cytopenia (e.g., leukopenia, pancytopenia, thrombocytopenia) have been infrequently reported with CIMZIA [see  Adverse Reactions (6.1)  ]  .",hematologic system is not a named entity
"Adverse reactions of the hematologic system, including medically significant cytopenia (e.g., leukopenia, pancytopenia, thrombocytopenia) have been infrequently reported with CIMZIA [see  Adverse Reactions (6.1)  ]  .",cytopenia ( is not a named entity
"Adverse reactions of the hematologic system, including medically significant cytopenia (e.g., leukopenia, pancytopenia, thrombocytopenia) have been infrequently reported with CIMZIA [see  Adverse Reactions (6.1)  ]  .",infrequently reported with is not a named entity
"Adverse reactions of the hematologic system, including medically significant cytopenia (e.g., leukopenia, pancytopenia, thrombocytopenia) have been infrequently reported with CIMZIA [see  Adverse Reactions (6.1)  ]  .",thrombocytopenia is an adverse reaction entity
"Adverse reactions of the hematologic system, including medically significant cytopenia (e.g., leukopenia, pancytopenia, thrombocytopenia) have been infrequently reported with CIMZIA [see  Adverse Reactions (6.1)  ]  .",Adverse reactions of the hematologic system is an adverse reaction entity
"Adverse reactions of the hematologic system, including medically significant cytopenia (e.g., leukopenia, pancytopenia, thrombocytopenia) have been infrequently reported with CIMZIA [see  Adverse Reactions (6.1)  ]  .",with CIMZIA [ is not a named entity
"Adverse reactions of the hematologic system, including medically significant cytopenia (e.g., leukopenia, pancytopenia, thrombocytopenia) have been infrequently reported with CIMZIA [see  Adverse Reactions (6.1)  ]  .",the is not a named entity
"Adverse reactions of the hematologic system, including medically significant cytopenia (e.g., leukopenia, pancytopenia, thrombocytopenia) have been infrequently reported with CIMZIA [see  Adverse Reactions (6.1)  ]  .",leukopenia is an adverse reaction entity
"Adverse reactions of the hematologic system, including medically significant cytopenia (e.g., leukopenia, pancytopenia, thrombocytopenia) have been infrequently reported with CIMZIA [see  Adverse Reactions (6.1)  ]  .",pancytopenia is an adverse reaction entity
"In the studies with CIMZIA in RA, there were 36 cases of TB among 2,367 exposed patients, including some fatal cases.",TB is an adverse reaction entity
"In the studies with CIMZIA in RA, there were 36 cases of TB among 2,367 exposed patients, including some fatal cases.","patients , including is not a named entity"
"In the studies with CIMZIA in RA, there were 36 cases of TB among 2,367 exposed patients, including some fatal cases.",fatal is an adverse reaction entity
"In the studies with CIMZIA in RA, there were 36 cases of TB among 2,367 exposed patients, including some fatal cases.","exposed patients , is not a named entity"
"The most common adverse reactions leading to the discontinuation of CIMZIA (for at least 2 patients and with a higher incidence than placebo) were abdominal pain (0.4% CIMZIA, 0.2% placebo), diarrhea (0.4% CIMZIA, 0% placebo), and intestinal obstruction (0.4% CIMZIA, 0% placebo).",diarrhea is an adverse reaction entity
"The most common adverse reactions leading to the discontinuation of CIMZIA (for at least 2 patients and with a higher incidence than placebo) were abdominal pain (0.4% CIMZIA, 0.2% placebo), diarrhea (0.4% CIMZIA, 0% placebo), and intestinal obstruction (0.4% CIMZIA, 0% placebo).",CIMZIA is not a named entity
"The most common adverse reactions leading to the discontinuation of CIMZIA (for at least 2 patients and with a higher incidence than placebo) were abdominal pain (0.4% CIMZIA, 0.2% placebo), diarrhea (0.4% CIMZIA, 0% placebo), and intestinal obstruction (0.4% CIMZIA, 0% placebo).",pain ( 0.4 is not a named entity
"The most common adverse reactions leading to the discontinuation of CIMZIA (for at least 2 patients and with a higher incidence than placebo) were abdominal pain (0.4% CIMZIA, 0.2% placebo), diarrhea (0.4% CIMZIA, 0% placebo), and intestinal obstruction (0.4% CIMZIA, 0% placebo).",of is not a named entity
"The most common adverse reactions leading to the discontinuation of CIMZIA (for at least 2 patients and with a higher incidence than placebo) were abdominal pain (0.4% CIMZIA, 0.2% placebo), diarrhea (0.4% CIMZIA, 0% placebo), and intestinal obstruction (0.4% CIMZIA, 0% placebo).",abdominal pain is an adverse reaction entity
"The most common adverse reactions leading to the discontinuation of CIMZIA (for at least 2 patients and with a higher incidence than placebo) were abdominal pain (0.4% CIMZIA, 0.2% placebo), diarrhea (0.4% CIMZIA, 0% placebo), and intestinal obstruction (0.4% CIMZIA, 0% placebo).",intestinal obstruction is an adverse reaction entity
"Approximately half the cases were lymphomas, including Hodgkin's and non-Hodgkin's lymphoma.",half the cases is not a named entity
"Approximately half the cases were lymphomas, including Hodgkin's and non-Hodgkin's lymphoma.",'s and is not a named entity
"Approximately half the cases were lymphomas, including Hodgkin's and non-Hodgkin's lymphoma.",non-Hodgkin's lymphoma is an adverse reaction entity
"Approximately half the cases were lymphomas, including Hodgkin's and non-Hodgkin's lymphoma.",Hodgkin lymphoma is an adverse reaction entity
"Approximately half the cases were lymphomas, including Hodgkin's and non-Hodgkin's lymphoma.",lymphomas is an adverse reaction entity
"Approximately half the cases were lymphomas, including Hodgkin's and non-Hodgkin's lymphoma.","lymphomas , is not a named entity"
"nasopharyngitis, laryngitis, viral infection) in 20% of CIMZIA-treated patients and 13% of placebo-treated patients, urinary tract infections (e.g.",urinary tract infections is an adverse reaction entity
"nasopharyngitis, laryngitis, viral infection) in 20% of CIMZIA-treated patients and 13% of placebo-treated patients, urinary tract infections (e.g.",laryngitis is an adverse reaction entity
"nasopharyngitis, laryngitis, viral infection) in 20% of CIMZIA-treated patients and 13% of placebo-treated patients, urinary tract infections (e.g.",e.g is not a named entity
"nasopharyngitis, laryngitis, viral infection) in 20% of CIMZIA-treated patients and 13% of placebo-treated patients, urinary tract infections (e.g.",nasopharyngitis is an adverse reaction entity
"nasopharyngitis, laryngitis, viral infection) in 20% of CIMZIA-treated patients and 13% of placebo-treated patients, urinary tract infections (e.g.",% of is not a named entity
"nasopharyngitis, laryngitis, viral infection) in 20% of CIMZIA-treated patients and 13% of placebo-treated patients, urinary tract infections (e.g.",", viral is not a named entity"
"nasopharyngitis, laryngitis, viral infection) in 20% of CIMZIA-treated patients and 13% of placebo-treated patients, urinary tract infections (e.g.",placebo-treated patients is not a named entity
"nasopharyngitis, laryngitis, viral infection) in 20% of CIMZIA-treated patients and 13% of placebo-treated patients, urinary tract infections (e.g.",viral infection is an adverse reaction entity
Cases of acute and chronic leukemia have been reported in association with post-marketing TNF-blocker use in RA and other indications.,and other indications is not a named entity
Cases of acute and chronic leukemia have been reported in association with post-marketing TNF-blocker use in RA and other indications.,chronic leukemia is an adverse reaction entity
Cases of acute and chronic leukemia have been reported in association with post-marketing TNF-blocker use in RA and other indications.,acute leukemia is an adverse reaction entity
Cases of acute and chronic leukemia have been reported in association with post-marketing TNF-blocker use in RA and other indications.,leukemia is not a named entity
The incidence of new cases of infections in controlled clinical studies in rheumatoid arthritis was 0.91 per patient-year for all CIMZIA-treated patients and 0.72 per patient-year for placebo-treated patients.,The incidence is not a named entity
The incidence of new cases of infections in controlled clinical studies in rheumatoid arthritis was 0.91 per patient-year for all CIMZIA-treated patients and 0.72 per patient-year for placebo-treated patients.,infections is an adverse reaction entity
The malignancies occurred after a median of 30 months of therapy (range 1 to 84 months).,1 to 84 is not a named entity
The malignancies occurred after a median of 30 months of therapy (range 1 to 84 months).,malignancies is an adverse reaction entity
Infections         The incidence of infections in controlled studies in Crohn's disease was 38% for CIMZIA-treated patients and 30% for placebo-treated patients.,infections is an adverse reaction entity
Infections         The incidence of infections in controlled studies in Crohn's disease was 38% for CIMZIA-treated patients and 30% for placebo-treated patients.,Infections The is not a named entity
"5.4 Hypersensitivity Reactions       The following symptoms that could be compatible with hypersensitivity reactions have been reported rarely following CIMZIA administration to patients: angioedema, dyspnea, hypotension, rash, serum sickness, and urticaria.",hypersensitivity reactions is an adverse reaction entity
"5.4 Hypersensitivity Reactions       The following symptoms that could be compatible with hypersensitivity reactions have been reported rarely following CIMZIA administration to patients: angioedema, dyspnea, hypotension, rash, serum sickness, and urticaria.",5.4 Hypersensitivity Reactions is not a named entity
"5.4 Hypersensitivity Reactions       The following symptoms that could be compatible with hypersensitivity reactions have been reported rarely following CIMZIA administration to patients: angioedema, dyspnea, hypotension, rash, serum sickness, and urticaria.",angioedema is an adverse reaction entity
"5.4 Hypersensitivity Reactions       The following symptoms that could be compatible with hypersensitivity reactions have been reported rarely following CIMZIA administration to patients: angioedema, dyspnea, hypotension, rash, serum sickness, and urticaria.",", dyspnea , is not a named entity"
"5.4 Hypersensitivity Reactions       The following symptoms that could be compatible with hypersensitivity reactions have been reported rarely following CIMZIA administration to patients: angioedema, dyspnea, hypotension, rash, serum sickness, and urticaria.",patients : angioedema is not a named entity
"5.4 Hypersensitivity Reactions       The following symptoms that could be compatible with hypersensitivity reactions have been reported rarely following CIMZIA administration to patients: angioedema, dyspnea, hypotension, rash, serum sickness, and urticaria.",rash is an adverse reaction entity
"5.4 Hypersensitivity Reactions       The following symptoms that could be compatible with hypersensitivity reactions have been reported rarely following CIMZIA administration to patients: angioedema, dyspnea, hypotension, rash, serum sickness, and urticaria.",dyspnea is an adverse reaction entity
"5.4 Hypersensitivity Reactions       The following symptoms that could be compatible with hypersensitivity reactions have been reported rarely following CIMZIA administration to patients: angioedema, dyspnea, hypotension, rash, serum sickness, and urticaria.",", and is not a named entity"
"5.4 Hypersensitivity Reactions       The following symptoms that could be compatible with hypersensitivity reactions have been reported rarely following CIMZIA administration to patients: angioedema, dyspnea, hypotension, rash, serum sickness, and urticaria.",hypotension is an adverse reaction entity
"5.4 Hypersensitivity Reactions       The following symptoms that could be compatible with hypersensitivity reactions have been reported rarely following CIMZIA administration to patients: angioedema, dyspnea, hypotension, rash, serum sickness, and urticaria.",", is not a named entity"
"5.4 Hypersensitivity Reactions       The following symptoms that could be compatible with hypersensitivity reactions have been reported rarely following CIMZIA administration to patients: angioedema, dyspnea, hypotension, rash, serum sickness, and urticaria.",urticaria is an adverse reaction entity
"5.4 Hypersensitivity Reactions       The following symptoms that could be compatible with hypersensitivity reactions have been reported rarely following CIMZIA administration to patients: angioedema, dyspnea, hypotension, rash, serum sickness, and urticaria.",serum sickness is an adverse reaction entity
"5.4 Hypersensitivity Reactions       The following symptoms that could be compatible with hypersensitivity reactions have been reported rarely following CIMZIA administration to patients: angioedema, dyspnea, hypotension, rash, serum sickness, and urticaria.",that could be is not a named entity
"5.4 Hypersensitivity Reactions       The following symptoms that could be compatible with hypersensitivity reactions have been reported rarely following CIMZIA administration to patients: angioedema, dyspnea, hypotension, rash, serum sickness, and urticaria.",rarely is not a named entity
The incidence of serious infections during the controlled clinical studies was 3% per patient-year for CIMZIA-treated patients and 1% for placebo-treated patients.,infections is an adverse reaction entity
The incidence of serious infections during the controlled clinical studies was 3% per patient-year for CIMZIA-treated patients and 1% for placebo-treated patients.,patients and 1 is not a named entity
"The risks and benefits of treatment should be considered prior to initiating therapy in patients:     *  with chronic or recurrent infection   *  who have been exposed to tuberculosis   *  with a history of an opportunistic infection   *  who have resided or traveled in areas of endemic tuberculosis or endemic mycoses, such as histoplasmosis, coccidioidomycosis, or blastomycosis   *  with underlying conditions that may predispose them to infection         Tuberculosis       Cases of reactivation of tuberculosis or new tuberculosis infections have been observed in patients receiving CIMZIA, including patients who have previously received treatment for latent or active tuberculosis.",reactivation of tuberculosis is an adverse reaction entity
"The risks and benefits of treatment should be considered prior to initiating therapy in patients:     *  with chronic or recurrent infection   *  who have been exposed to tuberculosis   *  with a history of an opportunistic infection   *  who have resided or traveled in areas of endemic tuberculosis or endemic mycoses, such as histoplasmosis, coccidioidomycosis, or blastomycosis   *  with underlying conditions that may predispose them to infection         Tuberculosis       Cases of reactivation of tuberculosis or new tuberculosis infections have been observed in patients receiving CIMZIA, including patients who have previously received treatment for latent or active tuberculosis.",been exposed is not a named entity
"The risks and benefits of treatment should be considered prior to initiating therapy in patients:     *  with chronic or recurrent infection   *  who have been exposed to tuberculosis   *  with a history of an opportunistic infection   *  who have resided or traveled in areas of endemic tuberculosis or endemic mycoses, such as histoplasmosis, coccidioidomycosis, or blastomycosis   *  with underlying conditions that may predispose them to infection         Tuberculosis       Cases of reactivation of tuberculosis or new tuberculosis infections have been observed in patients receiving CIMZIA, including patients who have previously received treatment for latent or active tuberculosis.",treatment is not a named entity
"The risks and benefits of treatment should be considered prior to initiating therapy in patients:     *  with chronic or recurrent infection   *  who have been exposed to tuberculosis   *  with a history of an opportunistic infection   *  who have resided or traveled in areas of endemic tuberculosis or endemic mycoses, such as histoplasmosis, coccidioidomycosis, or blastomycosis   *  with underlying conditions that may predispose them to infection         Tuberculosis       Cases of reactivation of tuberculosis or new tuberculosis infections have been observed in patients receiving CIMZIA, including patients who have previously received treatment for latent or active tuberculosis.",tuberculosis infections is an adverse reaction entity
"In the CIMZIA RA clinical trials (placebo-controlled and open label) a total of three cases of lymphoma were observed among 2,367 patients.",three is not a named entity
"In the CIMZIA RA clinical trials (placebo-controlled and open label) a total of three cases of lymphoma were observed among 2,367 patients.",lymphoma is an adverse reaction entity
Rare cases of opportunistic infections have also been reported in these clinical trials.,opportunistic infections is an adverse reaction entity
Rare cases of opportunistic infections have also been reported in these clinical trials.,cases is not a named entity
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis have been reported with TNF blockers.",histoplasmosis is an adverse reaction entity
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis have been reported with TNF blockers.",bacterial is not a named entity
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis have been reported with TNF blockers.",", listeriosis is not a named entity"
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis have been reported with TNF blockers.",opportunistic is not a named entity
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis have been reported with TNF blockers.",coccidioidomycosis is an adverse reaction entity
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis have been reported with TNF blockers.",", mycobacterial is not a named entity"
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis have been reported with TNF blockers.",infections viral is an adverse reaction entity
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis have been reported with TNF blockers.",infections mycobacterial is an adverse reaction entity
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis have been reported with TNF blockers.",to bacterial is not a named entity
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis have been reported with TNF blockers.",legionellosis is an adverse reaction entity
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis have been reported with TNF blockers.",Opportunistic infections is an adverse reaction entity
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis have been reported with TNF blockers.",aspergillosis is an adverse reaction entity
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis have been reported with TNF blockers.",infections bacterial is an adverse reaction entity
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis have been reported with TNF blockers.",", is not a named entity"
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis have been reported with TNF blockers.","fungal , viral is not a named entity"
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis have been reported with TNF blockers.",pneumocystosis is an adverse reaction entity
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis have been reported with TNF blockers.",blockers is not a named entity
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis have been reported with TNF blockers.",including aspergillosis is not a named entity
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis have been reported with TNF blockers.",blastomycosis is an adverse reaction entity
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis have been reported with TNF blockers.",infections invasive fungal is an adverse reaction entity
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis have been reported with TNF blockers.",tuberculosis is an adverse reaction entity
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis have been reported with TNF blockers.",with TNF is not a named entity
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis have been reported with TNF blockers.",", invasive is not a named entity"
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis have been reported with TNF blockers.",pneumocystosis and tuberculosis is not a named entity
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis have been reported with TNF blockers.",listeriosis is an adverse reaction entity
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis have been reported with TNF blockers.",", is not a named entity"
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis have been reported with TNF blockers.",", histoplasmosis , is not a named entity"
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis have been reported with TNF blockers.",candidiasis is an adverse reaction entity
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis have been reported with TNF blockers.",and is not a named entity
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis have been reported with TNF blockers.",infections parasitic is an adverse reaction entity
"The most common adverse reactions leading to discontinuation of CIMZIA were tuberculosis infections (0.5%); and pyrexia, urticaria, pneumonia, and rash (0.3%).",) is not a named entity
"The most common adverse reactions leading to discontinuation of CIMZIA were tuberculosis infections (0.5%); and pyrexia, urticaria, pneumonia, and rash (0.3%).",pneumonia is an adverse reaction entity
"The most common adverse reactions leading to discontinuation of CIMZIA were tuberculosis infections (0.5%); and pyrexia, urticaria, pneumonia, and rash (0.3%).",leading is not a named entity
"The most common adverse reactions leading to discontinuation of CIMZIA were tuberculosis infections (0.5%); and pyrexia, urticaria, pneumonia, and rash (0.3%).",pyrexia is an adverse reaction entity
"The most common adverse reactions leading to discontinuation of CIMZIA were tuberculosis infections (0.5%); and pyrexia, urticaria, pneumonia, and rash (0.3%).",", is not a named entity"
"The most common adverse reactions leading to discontinuation of CIMZIA were tuberculosis infections (0.5%); and pyrexia, urticaria, pneumonia, and rash (0.3%).",urticaria is an adverse reaction entity
"The most common adverse reactions leading to discontinuation of CIMZIA were tuberculosis infections (0.5%); and pyrexia, urticaria, pneumonia, and rash (0.3%).",rash is an adverse reaction entity
"The most common adverse reactions leading to discontinuation of CIMZIA were tuberculosis infections (0.5%); and pyrexia, urticaria, pneumonia, and rash (0.3%).",adverse is not a named entity
"The most common adverse reactions leading to discontinuation of CIMZIA were tuberculosis infections (0.5%); and pyrexia, urticaria, pneumonia, and rash (0.3%).",The most common is not a named entity
"The most common adverse reactions leading to discontinuation of CIMZIA were tuberculosis infections (0.5%); and pyrexia, urticaria, pneumonia, and rash (0.3%).",tuberculosis infections is an adverse reaction entity
"The majority of reports have occurred in patients concomitantly receiving other medications that suppress the immune system, which may also contribute to HBV reactivation.",HBV reactivation is an adverse reaction entity
"The majority of reports have occurred in patients concomitantly receiving other medications that suppress the immune system, which may also contribute to HBV reactivation.",also contribute is not a named entity
Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease.,tuberculosis have is not a named entity
Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease.,extrapulmonary disease is not a named entity
Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease.,tuberculosis extrapulmonary is an adverse reaction entity
Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease.,tuberculosis disseminated is an adverse reaction entity
"5.8 Use with Biological Disease-Modifying Antirheumatic Drugs (Biological DMARDs)      Serious infections were seen in clinical studies with concurrent use of anakinra (an interleukin-1 antagonist) and another TNF blocker, etanercept, with no added benefit compared to etanercept alone.",Use with is not a named entity
"5.8 Use with Biological Disease-Modifying Antirheumatic Drugs (Biological DMARDs)      Serious infections were seen in clinical studies with concurrent use of anakinra (an interleukin-1 antagonist) and another TNF blocker, etanercept, with no added benefit compared to etanercept alone.",infections is an adverse reaction entity
"(  5.1  )   *    Serious Infections: Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents, including BENLYSTA.",Infections is an adverse reaction entity
"(  5.1  )   *    Serious Infections: Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents, including BENLYSTA.",infections is an adverse reaction entity
"(  5.1  )   *    Serious Infections: Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents, including BENLYSTA.",infections is an adverse reaction entity
"(  5.1  )   *    Serious Infections: Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents, including BENLYSTA.",", including BENLYSTA is not a named entity"
"(  5.1  )   *    Serious Infections: Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents, including BENLYSTA.",: is not a named entity
"(  5.1  )   *    Serious Infections: Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents, including BENLYSTA.",agents is not a named entity
"(  5.1  )   *    Serious Infections: Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents, including BENLYSTA.",( 5.1 is not a named entity
"(  5.1  )   *    Serious Infections: Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents, including BENLYSTA.",fatal is an adverse reaction entity
"In the controlled clinical trials, malignancies, excluding non-melanoma skin cancers, were observed in 0.2% (3/1,458) and 0.3% (2/675) of patients receiving BENLYSTA and placebo, respectively.",receiving BENLYSTA and is not a named entity
"In the controlled clinical trials, malignancies, excluding non-melanoma skin cancers, were observed in 0.2% (3/1,458) and 0.3% (2/675) of patients receiving BENLYSTA and placebo, respectively.",malignancies is an adverse reaction entity
"5.5 Infusion Reactions      In the controlled clinical trials, adverse events associated with the infusion (occurring on the same day of the infusion) were reported in 17% (251/1,458) of patients receiving BENLYSTA and 15% (99/675) of patients receiving placebo.",adverse events associated with the infusion is an adverse reaction entity
"5.5 Infusion Reactions      In the controlled clinical trials, adverse events associated with the infusion (occurring on the same day of the infusion) were reported in 17% (251/1,458) of patients receiving BENLYSTA and 15% (99/675) of patients receiving placebo.",the infusion ) is not a named entity
"5.2 Serious Infections      Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents, including BENLYSTA.",immunosuppressive agents is not a named entity
"5.2 Serious Infections      Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents, including BENLYSTA.",infections is an adverse reaction entity
"5.2 Serious Infections      Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents, including BENLYSTA.",sometimes is not a named entity
"5.2 Serious Infections      Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents, including BENLYSTA.",infections is an adverse reaction entity
"5.2 Serious Infections      Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents, including BENLYSTA.",sometimes fatal is not a named entity
"5.2 Serious Infections      Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents, including BENLYSTA.",fatal is an adverse reaction entity
"The most common infusion reactions (>=3% of patients receiving BENLYSTA) were headache, nausea, and skin reactions.",skin reactions is an adverse reaction entity
"The most common infusion reactions (>=3% of patients receiving BENLYSTA) were headache, nausea, and skin reactions.",) were headache is not a named entity
"The most common infusion reactions (>=3% of patients receiving BENLYSTA) were headache, nausea, and skin reactions.",nausea is an adverse reaction entity
"The most common infusion reactions (>=3% of patients receiving BENLYSTA) were headache, nausea, and skin reactions.",headache is an adverse reaction entity
"The most common infusion reactions (>=3% of patients receiving BENLYSTA) were headache, nausea, and skin reactions.",", is not a named entity"
"The most common infusion reactions (>=3% of patients receiving BENLYSTA) were headache, nausea, and skin reactions.",", nausea is not a named entity"
"The most common infusion reactions (>=3% of patients receiving BENLYSTA) were headache, nausea, and skin reactions.",", and is not a named entity"
"The most common infusion reactions (>=3% of patients receiving BENLYSTA) were headache, nausea, and skin reactions.",infusion reactions is an adverse reaction entity
"Infections resulting in death occurred in 0.3% (4/1,458) of patients treated with BENLYSTA and in 0.1% (1/675) of patients receiving placebo.",death is an adverse reaction entity
"Infections resulting in death occurred in 0.3% (4/1,458) of patients treated with BENLYSTA and in 0.1% (1/675) of patients receiving placebo.",Infections is an adverse reaction entity
"Infections resulting in death occurred in 0.3% (4/1,458) of patients treated with BENLYSTA and in 0.1% (1/675) of patients receiving placebo.",1/675 ) of is not a named entity
"Infections resulting in death occurred in 0.3% (4/1,458) of patients treated with BENLYSTA and in 0.1% (1/675) of patients receiving placebo.","4/1,458 is not a named entity"
"Non-acute hypersensitivity reactions including rash, nausea, fatigue, myalgia, headache, and facial edema, have been reported and typically occurred up to a week following the most recent infusion.",and is not a named entity
"Non-acute hypersensitivity reactions including rash, nausea, fatigue, myalgia, headache, and facial edema, have been reported and typically occurred up to a week following the most recent infusion.","headache , and is not a named entity"
"Non-acute hypersensitivity reactions including rash, nausea, fatigue, myalgia, headache, and facial edema, have been reported and typically occurred up to a week following the most recent infusion.",nausea is an adverse reaction entity
"Non-acute hypersensitivity reactions including rash, nausea, fatigue, myalgia, headache, and facial edema, have been reported and typically occurred up to a week following the most recent infusion.",rash is an adverse reaction entity
"Non-acute hypersensitivity reactions including rash, nausea, fatigue, myalgia, headache, and facial edema, have been reported and typically occurred up to a week following the most recent infusion.",hypersensitivity reactions is an adverse reaction entity
"Non-acute hypersensitivity reactions including rash, nausea, fatigue, myalgia, headache, and facial edema, have been reported and typically occurred up to a week following the most recent infusion.",recent is not a named entity
"Non-acute hypersensitivity reactions including rash, nausea, fatigue, myalgia, headache, and facial edema, have been reported and typically occurred up to a week following the most recent infusion.",headache is an adverse reaction entity
"Non-acute hypersensitivity reactions including rash, nausea, fatigue, myalgia, headache, and facial edema, have been reported and typically occurred up to a week following the most recent infusion.",fatigue is an adverse reaction entity
"Non-acute hypersensitivity reactions including rash, nausea, fatigue, myalgia, headache, and facial edema, have been reported and typically occurred up to a week following the most recent infusion.",", fatigue is not a named entity"
"Non-acute hypersensitivity reactions including rash, nausea, fatigue, myalgia, headache, and facial edema, have been reported and typically occurred up to a week following the most recent infusion.","headache , is not a named entity"
"Non-acute hypersensitivity reactions including rash, nausea, fatigue, myalgia, headache, and facial edema, have been reported and typically occurred up to a week following the most recent infusion.",myalgia is an adverse reaction entity
"Non-acute hypersensitivity reactions including rash, nausea, fatigue, myalgia, headache, and facial edema, have been reported and typically occurred up to a week following the most recent infusion.",occurred up is not a named entity
"Non-acute hypersensitivity reactions including rash, nausea, fatigue, myalgia, headache, and facial edema, have been reported and typically occurred up to a week following the most recent infusion.",facial edema is an adverse reaction entity
"Non-acute hypersensitivity reactions including rash, nausea, fatigue, myalgia, headache, and facial edema, have been reported and typically occurred up to a week following the most recent infusion.",reported and typically is not a named entity
The mechanism of action of BENLYSTA could increase the risk for the development of malignancies.,of is not a named entity
The mechanism of action of BENLYSTA could increase the risk for the development of malignancies.,malignancies is an adverse reaction entity
"Due to overlap in signs and symptoms, it was not possible to distinguish between hypersensitivity reactions and infusion reactions in all cases [see  Warnings and Precautions (5.5)  ]  .",infusion reactions is an adverse reaction entity
"Due to overlap in signs and symptoms, it was not possible to distinguish between hypersensitivity reactions and infusion reactions in all cases [see  Warnings and Precautions (5.5)  ]  .",hypersensitivity reactions and is not a named entity
"Due to overlap in signs and symptoms, it was not possible to distinguish between hypersensitivity reactions and infusion reactions in all cases [see  Warnings and Precautions (5.5)  ]  .",was not is not a named entity
"Due to overlap in signs and symptoms, it was not possible to distinguish between hypersensitivity reactions and infusion reactions in all cases [see  Warnings and Precautions (5.5)  ]  .",hypersensitivity reactions is an adverse reaction entity
"Serious psychiatric events were reported in 0.8% of patients receiving BENLYSTA (0.6% and 1.2% with 1 and 10 mg/kg, respectively) and 0.4% of patients receiving placebo.",psychiatric events is an adverse reaction entity
"Serious psychiatric events were reported in 0.8% of patients receiving BENLYSTA (0.6% and 1.2% with 1 and 10 mg/kg, respectively) and 0.4% of patients receiving placebo.",patients receiving placebo is not a named entity
"The most frequent serious infections included pneumonia, urinary tract infection, cellulitis, and bronchitis.","infection , cellulitis is not a named entity"
"The most frequent serious infections included pneumonia, urinary tract infection, cellulitis, and bronchitis.",cellulitis is an adverse reaction entity
"The most frequent serious infections included pneumonia, urinary tract infection, cellulitis, and bronchitis.",infections is an adverse reaction entity
"The most frequent serious infections included pneumonia, urinary tract infection, cellulitis, and bronchitis.",frequent serious infections is not a named entity
"The most frequent serious infections included pneumonia, urinary tract infection, cellulitis, and bronchitis.",", cellulitis is not a named entity"
"The most frequent serious infections included pneumonia, urinary tract infection, cellulitis, and bronchitis.",", urinary tract is not a named entity"
"The most frequent serious infections included pneumonia, urinary tract infection, cellulitis, and bronchitis.",urinary tract infection is an adverse reaction entity
"The most frequent serious infections included pneumonia, urinary tract infection, cellulitis, and bronchitis.",pneumonia is an adverse reaction entity
"The most frequent serious infections included pneumonia, urinary tract infection, cellulitis, and bronchitis.",The most frequent is not a named entity
"The most frequent serious infections included pneumonia, urinary tract infection, cellulitis, and bronchitis.",bronchitis is an adverse reaction entity
"Progressive Multifocal Leukoencephalopathy (PML)       Cases of JC virus-associated PML resulting in neurological deficits, including fatal cases, have been reported in patients with SLE receiving immunosuppressants, including BENLYSTA.","cases , have is not a named entity"
"Progressive Multifocal Leukoencephalopathy (PML)       Cases of JC virus-associated PML resulting in neurological deficits, including fatal cases, have been reported in patients with SLE receiving immunosuppressants, including BENLYSTA.",deficits is not a named entity
"Progressive Multifocal Leukoencephalopathy (PML)       Cases of JC virus-associated PML resulting in neurological deficits, including fatal cases, have been reported in patients with SLE receiving immunosuppressants, including BENLYSTA.",fatal is an adverse reaction entity
"Progressive Multifocal Leukoencephalopathy (PML)       Cases of JC virus-associated PML resulting in neurological deficits, including fatal cases, have been reported in patients with SLE receiving immunosuppressants, including BENLYSTA.",JC virus is an adverse reaction entity
"Progressive Multifocal Leukoencephalopathy (PML)       Cases of JC virus-associated PML resulting in neurological deficits, including fatal cases, have been reported in patients with SLE receiving immunosuppressants, including BENLYSTA.",PML is an adverse reaction entity
"Progressive Multifocal Leukoencephalopathy (PML)       Cases of JC virus-associated PML resulting in neurological deficits, including fatal cases, have been reported in patients with SLE receiving immunosuppressants, including BENLYSTA.",BENLYSTA is not a named entity
"Progressive Multifocal Leukoencephalopathy (PML)       Cases of JC virus-associated PML resulting in neurological deficits, including fatal cases, have been reported in patients with SLE receiving immunosuppressants, including BENLYSTA.",", have is not a named entity"
"Progressive Multifocal Leukoencephalopathy (PML)       Cases of JC virus-associated PML resulting in neurological deficits, including fatal cases, have been reported in patients with SLE receiving immunosuppressants, including BENLYSTA.",neurological deficits is an adverse reaction entity
"The most common adverse reactions resulting in discontinuation of treatment (>=1% of patients receiving BENLYSTA or placebo) were infusion reactions (1.6% BENLYSTA and 0.9% placebo), lupus nephritis (0.7% BENLYSTA and 1.2% placebo), and infections (0.7% BENLYSTA and 1.0% placebo).",BENLYSTA is not a named entity
"The most common adverse reactions resulting in discontinuation of treatment (>=1% of patients receiving BENLYSTA or placebo) were infusion reactions (1.6% BENLYSTA and 0.9% placebo), lupus nephritis (0.7% BENLYSTA and 1.2% placebo), and infections (0.7% BENLYSTA and 1.0% placebo).",treatment ( is not a named entity
"The most common adverse reactions resulting in discontinuation of treatment (>=1% of patients receiving BENLYSTA or placebo) were infusion reactions (1.6% BENLYSTA and 0.9% placebo), lupus nephritis (0.7% BENLYSTA and 1.2% placebo), and infections (0.7% BENLYSTA and 1.0% placebo).",lupus nephritis is an adverse reaction entity
"The most common adverse reactions resulting in discontinuation of treatment (>=1% of patients receiving BENLYSTA or placebo) were infusion reactions (1.6% BENLYSTA and 0.9% placebo), lupus nephritis (0.7% BENLYSTA and 1.2% placebo), and infections (0.7% BENLYSTA and 1.0% placebo).",placebo ) were is not a named entity
"The most common adverse reactions resulting in discontinuation of treatment (>=1% of patients receiving BENLYSTA or placebo) were infusion reactions (1.6% BENLYSTA and 0.9% placebo), lupus nephritis (0.7% BENLYSTA and 1.2% placebo), and infections (0.7% BENLYSTA and 1.0% placebo).",infections is an adverse reaction entity
"The most common adverse reactions resulting in discontinuation of treatment (>=1% of patients receiving BENLYSTA or placebo) were infusion reactions (1.6% BENLYSTA and 0.9% placebo), lupus nephritis (0.7% BENLYSTA and 1.2% placebo), and infections (0.7% BENLYSTA and 1.0% placebo).",infusion reactions is an adverse reaction entity
"The most commonly-reported adverse reactions, occurring in >=5% of patients in clinical trials were nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis.",patients in clinical is not a named entity
"The most commonly-reported adverse reactions, occurring in >=5% of patients in clinical trials were nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis.",most commonly-reported is not a named entity
"The most commonly-reported adverse reactions, occurring in >=5% of patients in clinical trials were nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis.",", insomnia , is not a named entity"
"The most commonly-reported adverse reactions, occurring in >=5% of patients in clinical trials were nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis.",migraine is an adverse reaction entity
"The most commonly-reported adverse reactions, occurring in >=5% of patients in clinical trials were nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis.",", diarrhea is not a named entity"
"The most commonly-reported adverse reactions, occurring in >=5% of patients in clinical trials were nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis.",insomnia is an adverse reaction entity
"The most commonly-reported adverse reactions, occurring in >=5% of patients in clinical trials were nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis.",in clinical trials is not a named entity
"The most commonly-reported adverse reactions, occurring in >=5% of patients in clinical trials were nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis.",pharyngitis is an adverse reaction entity
"The most commonly-reported adverse reactions, occurring in >=5% of patients in clinical trials were nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis.",pyrexia is an adverse reaction entity
"The most commonly-reported adverse reactions, occurring in >=5% of patients in clinical trials were nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis.",", insomnia , is not a named entity"
"The most commonly-reported adverse reactions, occurring in >=5% of patients in clinical trials were nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis.",diarrhea is an adverse reaction entity
"The most commonly-reported adverse reactions, occurring in >=5% of patients in clinical trials were nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis.",nasopharyngitis is an adverse reaction entity
"The most commonly-reported adverse reactions, occurring in >=5% of patients in clinical trials were nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis.",adverse reactions is not a named entity
"The most commonly-reported adverse reactions, occurring in >=5% of patients in clinical trials were nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis.",nausea is an adverse reaction entity
"The most commonly-reported adverse reactions, occurring in >=5% of patients in clinical trials were nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis.",depression is an adverse reaction entity
"The most commonly-reported adverse reactions, occurring in >=5% of patients in clinical trials were nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis.",of patients in is not a named entity
"The most commonly-reported adverse reactions, occurring in >=5% of patients in clinical trials were nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis.",were nausea is not a named entity
"The most commonly-reported adverse reactions, occurring in >=5% of patients in clinical trials were nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis.",bronchitis is an adverse reaction entity
"The most commonly-reported adverse reactions, occurring in >=5% of patients in clinical trials were nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis.",pain in extremity is an adverse reaction entity
"The most commonly-reported adverse reactions, occurring in >=5% of patients in clinical trials were nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis.",trials were nausea is not a named entity
"Due to overlap in signs and symptoms, it was not possible to distinguish between hypersensitivity reactions and infusion reactions in all cases [see  Warnings and Precautions (5.4)  ]  .",between hypersensitivity reactions is not a named entity
"Due to overlap in signs and symptoms, it was not possible to distinguish between hypersensitivity reactions and infusion reactions in all cases [see  Warnings and Precautions (5.4)  ]  .",infusion reactions is an adverse reaction entity
"Due to overlap in signs and symptoms, it was not possible to distinguish between hypersensitivity reactions and infusion reactions in all cases [see  Warnings and Precautions (5.4)  ]  .",hypersensitivity reactions is an adverse reaction entity
"Due to overlap in signs and symptoms, it was not possible to distinguish between hypersensitivity reactions and infusion reactions in all cases [see  Warnings and Precautions (5.4)  ]  .",signs and is not a named entity
"The most common serious adverse reactions were serious infections (6.0% and 5.2% in the groups receiving BENLYSTA and placebo, respectively)  [see Warnings and Precautions (5.2)]  .",( 6.0 is not a named entity
"The most common serious adverse reactions were serious infections (6.0% and 5.2% in the groups receiving BENLYSTA and placebo, respectively)  [see Warnings and Precautions (5.2)]  .",infections is an adverse reaction entity
The majority of patients who reported serious depression or suicidal behavior had a history of depression or other serious psychiatric disorders and most were receiving psychoactive medications.,psychoactive is not a named entity
The majority of patients who reported serious depression or suicidal behavior had a history of depression or other serious psychiatric disorders and most were receiving psychoactive medications.,suicidal behavior is an adverse reaction entity
The majority of patients who reported serious depression or suicidal behavior had a history of depression or other serious psychiatric disorders and most were receiving psychoactive medications.,depression is an adverse reaction entity
The majority of patients who reported serious depression or suicidal behavior had a history of depression or other serious psychiatric disorders and most were receiving psychoactive medications.,depression or suicidal is not a named entity
"In the controlled clinical trials, the overall incidence of infections was 71% in patients treated with BENLYSTA compared with 67% in patients who received placebo.",in patients who is not a named entity
"In the controlled clinical trials, the overall incidence of infections was 71% in patients treated with BENLYSTA compared with 67% in patients who received placebo.",infections is an adverse reaction entity
"In the controlled clinical trials, malignancies (including non-melanoma skin cancers) were reported in 0.4% of patients receiving BENLYSTA and 0.4% of patients receiving placebo.",skin is not a named entity
"In the controlled clinical trials, malignancies (including non-melanoma skin cancers) were reported in 0.4% of patients receiving BENLYSTA and 0.4% of patients receiving placebo.",malignancies is an adverse reaction entity
"In the controlled clinical trials, malignancies (including non-melanoma skin cancers) were reported in 0.4% of patients receiving BENLYSTA and 0.4% of patients receiving placebo.",receiving BENLYSTA is not a named entity
"In the controlled clinical trials, malignancies (including non-melanoma skin cancers) were reported in 0.4% of patients receiving BENLYSTA and 0.4% of patients receiving placebo.",non-melanoma skin cancers is an adverse reaction entity
"In the controlled clinical trials, hypersensitivity reactions (occurring on the same day of infusion) were reported in 13% (191/1,458) of patients receiving BENLYSTA and 11% (76/675) of patients receiving placebo.",hypersensitivity reactions is an adverse reaction entity
"In the controlled clinical trials, hypersensitivity reactions (occurring on the same day of infusion) were reported in 13% (191/1,458) of patients receiving BENLYSTA and 11% (76/675) of patients receiving placebo.",were is not a named entity
"Out of 2,133 patients in 3 clinical trials, a total of 14 deaths occurred during the placebo-controlled, double-blind treatment periods: 3/675 (0.4%), 5/673 (0.7%), 0/111 (0%), and 6/674 (0.9%) deaths in the groups receiving placebo, BENLYSTA 1 mg/kg, BENLYSTA 4 mg/kg, and BENLYSTA 10 mg/kg, respectively.",deaths is an adverse reaction entity
"Out of 2,133 patients in 3 clinical trials, a total of 14 deaths occurred during the placebo-controlled, double-blind treatment periods: 3/675 (0.4%), 5/673 (0.7%), 0/111 (0%), and 6/674 (0.9%) deaths in the groups receiving placebo, BENLYSTA 1 mg/kg, BENLYSTA 4 mg/kg, and BENLYSTA 10 mg/kg, respectively.",0.9 is not a named entity
"Out of 2,133 patients in 3 clinical trials, a total of 14 deaths occurred during the placebo-controlled, double-blind treatment periods: 3/675 (0.4%), 5/673 (0.7%), 0/111 (0%), and 6/674 (0.9%) deaths in the groups receiving placebo, BENLYSTA 1 mg/kg, BENLYSTA 4 mg/kg, and BENLYSTA 10 mg/kg, respectively.","% ) , is not a named entity"
"Out of 2,133 patients in 3 clinical trials, a total of 14 deaths occurred during the placebo-controlled, double-blind treatment periods: 3/675 (0.4%), 5/673 (0.7%), 0/111 (0%), and 6/674 (0.9%) deaths in the groups receiving placebo, BENLYSTA 1 mg/kg, BENLYSTA 4 mg/kg, and BENLYSTA 10 mg/kg, respectively.",deaths is an adverse reaction entity
(  5.2  )   *    Progressive Multifocal Leukoencephalopathy (PML): Patients presenting with new-onset or deteriorating neurological signs and symptoms should be evaluated for PML by an appropriate specialist.,Progressive Multifocal Leukoencephalopathy is an adverse reaction entity
(  5.2  )   *    Progressive Multifocal Leukoencephalopathy (PML): Patients presenting with new-onset or deteriorating neurological signs and symptoms should be evaluated for PML by an appropriate specialist.,Multifocal is not a named entity
(  5.2  )   *    Progressive Multifocal Leukoencephalopathy (PML): Patients presenting with new-onset or deteriorating neurological signs and symptoms should be evaluated for PML by an appropriate specialist.,5.2 is not a named entity
(  5.2  )   *    Progressive Multifocal Leukoencephalopathy (PML): Patients presenting with new-onset or deteriorating neurological signs and symptoms should be evaluated for PML by an appropriate specialist.,PML is an adverse reaction entity
"Hypersensitivity, including serious reactions, has occurred in patients who have previously tolerated infusions of BENLYSTA.",", is not a named entity"
"Hypersensitivity, including serious reactions, has occurred in patients who have previously tolerated infusions of BENLYSTA.",who is not a named entity
"Hypersensitivity, including serious reactions, has occurred in patients who have previously tolerated infusions of BENLYSTA.",Hypersensitivity is an adverse reaction entity
"Hypersensitivity, including serious reactions, has occurred in patients who have previously tolerated infusions of BENLYSTA.",Hypersensitivity is an adverse reaction entity
"(  5.2  )   *    Hypersensitivity Reactions, including Anaphylaxis: Serious and fatal reactions have been reported.",have been is not a named entity
"(  5.2  )   *    Hypersensitivity Reactions, including Anaphylaxis: Serious and fatal reactions have been reported.",fatal is an adverse reaction entity
"(  5.2  )   *    Hypersensitivity Reactions, including Anaphylaxis: Serious and fatal reactions have been reported.",Anaphylaxis is an adverse reaction entity
"(  5.2  )   *    Hypersensitivity Reactions, including Anaphylaxis: Serious and fatal reactions have been reported.",Hypersensitivity Reactions is an adverse reaction entity
"(  5.2  )   *    Hypersensitivity Reactions, including Anaphylaxis: Serious and fatal reactions have been reported.",Serious is not a named entity
"(  5.2  )   *    Hypersensitivity Reactions, including Anaphylaxis: Serious and fatal reactions have been reported.",reactions is not a named entity
"5.6 Depression      In the controlled clinical trials, psychiatric events were reported more frequently with BENLYSTA (16%) than with placebo (12%), related primarily to depression-related events (6.3% BENLYSTA and 4.7% placebo), insomnia (6.0% BENLYSTA and 5.3% placebo), and anxiety (3.9% BENLYSTA and 2.8% placebo).",related primarily to is not a named entity
"5.6 Depression      In the controlled clinical trials, psychiatric events were reported more frequently with BENLYSTA (16%) than with placebo (12%), related primarily to depression-related events (6.3% BENLYSTA and 4.7% placebo), insomnia (6.0% BENLYSTA and 5.3% placebo), and anxiety (3.9% BENLYSTA and 2.8% placebo).",insomnia is an adverse reaction entity
"5.6 Depression      In the controlled clinical trials, psychiatric events were reported more frequently with BENLYSTA (16%) than with placebo (12%), related primarily to depression-related events (6.3% BENLYSTA and 4.7% placebo), insomnia (6.0% BENLYSTA and 5.3% placebo), and anxiety (3.9% BENLYSTA and 2.8% placebo).",depression is an adverse reaction entity
"5.6 Depression      In the controlled clinical trials, psychiatric events were reported more frequently with BENLYSTA (16%) than with placebo (12%), related primarily to depression-related events (6.3% BENLYSTA and 4.7% placebo), insomnia (6.0% BENLYSTA and 5.3% placebo), and anxiety (3.9% BENLYSTA and 2.8% placebo).",", and is not a named entity"
"5.6 Depression      In the controlled clinical trials, psychiatric events were reported more frequently with BENLYSTA (16%) than with placebo (12%), related primarily to depression-related events (6.3% BENLYSTA and 4.7% placebo), insomnia (6.0% BENLYSTA and 5.3% placebo), and anxiety (3.9% BENLYSTA and 2.8% placebo).",anxiety is an adverse reaction entity
"5.6 Depression      In the controlled clinical trials, psychiatric events were reported more frequently with BENLYSTA (16%) than with placebo (12%), related primarily to depression-related events (6.3% BENLYSTA and 4.7% placebo), insomnia (6.0% BENLYSTA and 5.3% placebo), and anxiety (3.9% BENLYSTA and 2.8% placebo).","trials , psychiatric is not a named entity"
"5.6 Depression      In the controlled clinical trials, psychiatric events were reported more frequently with BENLYSTA (16%) than with placebo (12%), related primarily to depression-related events (6.3% BENLYSTA and 4.7% placebo), insomnia (6.0% BENLYSTA and 5.3% placebo), and anxiety (3.9% BENLYSTA and 2.8% placebo).",psychiatric events is an adverse reaction entity
"5.6 Depression      In the controlled clinical trials, psychiatric events were reported more frequently with BENLYSTA (16%) than with placebo (12%), related primarily to depression-related events (6.3% BENLYSTA and 4.7% placebo), insomnia (6.0% BENLYSTA and 5.3% placebo), and anxiety (3.9% BENLYSTA and 2.8% placebo).",with is not a named entity
(  5.7  )             5.1 Mortality      There were more deaths reported with BENLYSTA than with placebo during the controlled period of the clinical trials.,deaths is an adverse reaction entity
(  5.7  )             5.1 Mortality      There were more deaths reported with BENLYSTA than with placebo during the controlled period of the clinical trials.,the clinical is not a named entity
The proportion of patients with elevations in triglycerides >=200 mg/dL (at Endpoint) was 13.2% for SAPHRIS-treated patients versus 10.5% for placebo-treated patients.,The proportion of is not a named entity
The proportion of patients with elevations in triglycerides >=200 mg/dL (at Endpoint) was 13.2% for SAPHRIS-treated patients versus 10.5% for placebo-treated patients.,elevations in triglycerides is an adverse reaction entity
(5.11)   *   Potential for Cognitive and Motor Impairment: Use caution when operating machinery.,5.11 ) * is not a named entity
(5.11)   *   Potential for Cognitive and Motor Impairment: Use caution when operating machinery.,Cognitive Impairment is an adverse reaction entity
(5.11)   *   Potential for Cognitive and Motor Impairment: Use caution when operating machinery.,( 5.11 ) is not a named entity
(5.11)   *   Potential for Cognitive and Motor Impairment: Use caution when operating machinery.,Motor Impairment is an adverse reaction entity
"In a 3-week, placebo-controlled pediatric trial with bipolar I disorder, the mean increases (at Endpoint) in prolactin levels were 3.2 ng/mL for patients treated with SAPHRIS 2.5 mg twice daily, 2.1 ng/mL for patients treated with SAPHRIS 5 mg twice daily, and 6.4 ng/mL for patients treated with SAPHRIS 10 mg twice daily compared to an increase of 2.5 ng/mL for placebo-treated patients.",treated with SAPHRIS is not a named entity
"In a 3-week, placebo-controlled pediatric trial with bipolar I disorder, the mean increases (at Endpoint) in prolactin levels were 3.2 ng/mL for patients treated with SAPHRIS 2.5 mg twice daily, 2.1 ng/mL for patients treated with SAPHRIS 5 mg twice daily, and 6.4 ng/mL for patients treated with SAPHRIS 10 mg twice daily compared to an increase of 2.5 ng/mL for placebo-treated patients.",increases in prolactin levels is an adverse reaction entity
7               15             13               13                       Psychiatric disorders                                                                                             Insomnia                           13              16             15               15                       Vascular disorders                                                                                                Hypertension                       2               2              3                2                                    Dose-Related Adverse Reactions:  In the short term schizophrenia trials the incidence of akathisia appeared to be dose-related (seeTable 8).,akathisia is an adverse reaction entity
7               15             13               13                       Psychiatric disorders                                                                                             Insomnia                           13              16             15               15                       Vascular disorders                                                                                                Hypertension                       2               2              3                2                                    Dose-Related Adverse Reactions:  In the short term schizophrenia trials the incidence of akathisia appeared to be dose-related (seeTable 8).,appeared is not a named entity
7               15             13               13                       Psychiatric disorders                                                                                             Insomnia                           13              16             15               15                       Vascular disorders                                                                                                Hypertension                       2               2              3                2                                    Dose-Related Adverse Reactions:  In the short term schizophrenia trials the incidence of akathisia appeared to be dose-related (seeTable 8).,Insomnia is an adverse reaction entity
7               15             13               13                       Psychiatric disorders                                                                                             Insomnia                           13              16             15               15                       Vascular disorders                                                                                                Hypertension                       2               2              3                2                                    Dose-Related Adverse Reactions:  In the short term schizophrenia trials the incidence of akathisia appeared to be dose-related (seeTable 8).,Hypertension is an adverse reaction entity
7               15             13               13                       Psychiatric disorders                                                                                             Insomnia                           13              16             15               15                       Vascular disorders                                                                                                Hypertension                       2               2              3                2                                    Dose-Related Adverse Reactions:  In the short term schizophrenia trials the incidence of akathisia appeared to be dose-related (seeTable 8).,2 is not a named entity
7               15             13               13                       Psychiatric disorders                                                                                             Insomnia                           13              16             15               15                       Vascular disorders                                                                                                Hypertension                       2               2              3                2                                    Dose-Related Adverse Reactions:  In the short term schizophrenia trials the incidence of akathisia appeared to be dose-related (seeTable 8).,Psychiatric disorders Insomnia is not a named entity
"In the short-term, placebo-controlled schizophrenia adult trials, the incidence of reported EPS-related events, excluding events related to akathisia, for SAPHRIS-treated patients was 10% versus 7% for placebo; and the incidence of akathisia-related events for SAPHRIS-treated patients was 6% versus 3% for placebo.",EPS-related events is an adverse reaction entity
"In the short-term, placebo-controlled schizophrenia adult trials, the incidence of reported EPS-related events, excluding events related to akathisia, for SAPHRIS-treated patients was 10% versus 7% for placebo; and the incidence of akathisia-related events for SAPHRIS-treated patients was 6% versus 3% for placebo.",to akathisia is not a named entity
"In the short-term, placebo-controlled schizophrenia adult trials, the incidence of reported EPS-related events, excluding events related to akathisia, for SAPHRIS-treated patients was 10% versus 7% for placebo; and the incidence of akathisia-related events for SAPHRIS-treated patients was 6% versus 3% for placebo.",% versus is not a named entity
"In the short-term, placebo-controlled schizophrenia adult trials, the incidence of reported EPS-related events, excluding events related to akathisia, for SAPHRIS-treated patients was 10% versus 7% for placebo; and the incidence of akathisia-related events for SAPHRIS-treated patients was 6% versus 3% for placebo.",akathisia is an adverse reaction entity
"In the short-term, placebo-controlled schizophrenia adult trials, the incidence of reported EPS-related events, excluding events related to akathisia, for SAPHRIS-treated patients was 10% versus 7% for placebo; and the incidence of akathisia-related events for SAPHRIS-treated patients was 6% versus 3% for placebo.",for is not a named entity
"In the short-term, placebo-controlled schizophrenia adult trials, the incidence of reported EPS-related events, excluding events related to akathisia, for SAPHRIS-treated patients was 10% versus 7% for placebo; and the incidence of akathisia-related events for SAPHRIS-treated patients was 6% versus 3% for placebo.",akathisia is an adverse reaction entity
"Extrapyramidal symptoms included dystonia, oculogyration, dyskinesia, tardive dyskinesia, muscle rigidity, parkinsonism, tremor, and extrapyramidal disorder (excluding akathisia).",tardive dyskinesia is an adverse reaction entity
"Extrapyramidal symptoms included dystonia, oculogyration, dyskinesia, tardive dyskinesia, muscle rigidity, parkinsonism, tremor, and extrapyramidal disorder (excluding akathisia).",Extrapyramidal symptoms is an adverse reaction entity
"Extrapyramidal symptoms included dystonia, oculogyration, dyskinesia, tardive dyskinesia, muscle rigidity, parkinsonism, tremor, and extrapyramidal disorder (excluding akathisia).",tremor is an adverse reaction entity
"Extrapyramidal symptoms included dystonia, oculogyration, dyskinesia, tardive dyskinesia, muscle rigidity, parkinsonism, tremor, and extrapyramidal disorder (excluding akathisia).",muscle rigidity is an adverse reaction entity
"Extrapyramidal symptoms included dystonia, oculogyration, dyskinesia, tardive dyskinesia, muscle rigidity, parkinsonism, tremor, and extrapyramidal disorder (excluding akathisia).","muscle rigidity , is not a named entity"
"Extrapyramidal symptoms included dystonia, oculogyration, dyskinesia, tardive dyskinesia, muscle rigidity, parkinsonism, tremor, and extrapyramidal disorder (excluding akathisia).",and extrapyramidal is not a named entity
"Extrapyramidal symptoms included dystonia, oculogyration, dyskinesia, tardive dyskinesia, muscle rigidity, parkinsonism, tremor, and extrapyramidal disorder (excluding akathisia).","dyskinesia , is not a named entity"
"Extrapyramidal symptoms included dystonia, oculogyration, dyskinesia, tardive dyskinesia, muscle rigidity, parkinsonism, tremor, and extrapyramidal disorder (excluding akathisia).",akathisia is an adverse reaction entity
"Extrapyramidal symptoms included dystonia, oculogyration, dyskinesia, tardive dyskinesia, muscle rigidity, parkinsonism, tremor, and extrapyramidal disorder (excluding akathisia).","rigidity , is not a named entity"
"Extrapyramidal symptoms included dystonia, oculogyration, dyskinesia, tardive dyskinesia, muscle rigidity, parkinsonism, tremor, and extrapyramidal disorder (excluding akathisia).",included dystonia is not a named entity
"Extrapyramidal symptoms included dystonia, oculogyration, dyskinesia, tardive dyskinesia, muscle rigidity, parkinsonism, tremor, and extrapyramidal disorder (excluding akathisia).","dystonia , oculogyration is not a named entity"
"Extrapyramidal symptoms included dystonia, oculogyration, dyskinesia, tardive dyskinesia, muscle rigidity, parkinsonism, tremor, and extrapyramidal disorder (excluding akathisia).",extrapyramidal disorder is an adverse reaction entity
"Extrapyramidal symptoms included dystonia, oculogyration, dyskinesia, tardive dyskinesia, muscle rigidity, parkinsonism, tremor, and extrapyramidal disorder (excluding akathisia).",and extrapyramidal is not a named entity
"Extrapyramidal symptoms included dystonia, oculogyration, dyskinesia, tardive dyskinesia, muscle rigidity, parkinsonism, tremor, and extrapyramidal disorder (excluding akathisia).",dystonia is an adverse reaction entity
"Extrapyramidal symptoms included dystonia, oculogyration, dyskinesia, tardive dyskinesia, muscle rigidity, parkinsonism, tremor, and extrapyramidal disorder (excluding akathisia).","dystonia , oculogyration is not a named entity"
"Extrapyramidal symptoms included dystonia, oculogyration, dyskinesia, tardive dyskinesia, muscle rigidity, parkinsonism, tremor, and extrapyramidal disorder (excluding akathisia).",parkinsonism is an adverse reaction entity
"Extrapyramidal symptoms included dystonia, oculogyration, dyskinesia, tardive dyskinesia, muscle rigidity, parkinsonism, tremor, and extrapyramidal disorder (excluding akathisia).",oculogyration is an adverse reaction entity
"Extrapyramidal symptoms included dystonia, oculogyration, dyskinesia, tardive dyskinesia, muscle rigidity, parkinsonism, tremor, and extrapyramidal disorder (excluding akathisia).",dyskinesia is an adverse reaction entity
"Extrapyramidal symptoms included dystonia, oculogyration, dyskinesia, tardive dyskinesia, muscle rigidity, parkinsonism, tremor, and extrapyramidal disorder (excluding akathisia).",", is not a named entity"
"Extrapyramidal symptoms included dystonia, oculogyration, dyskinesia, tardive dyskinesia, muscle rigidity, parkinsonism, tremor, and extrapyramidal disorder (excluding akathisia).",akathisia ) is not a named entity
5.12 Potential for Cognitive and Motor Impairment        Somnolence was reported in patients treated with SAPHRIS.,Cognitive is not a named entity
5.12 Potential for Cognitive and Motor Impairment        Somnolence was reported in patients treated with SAPHRIS.,Somnolence is an adverse reaction entity
"No patients treated with SAPHRIS experienced QTc increases >=60 msec from baseline measurements, nor did any patient experience a QTc of >=500 msec.",QTc increases is an adverse reaction entity
"No patients treated with SAPHRIS experienced QTc increases >=60 msec from baseline measurements, nor did any patient experience a QTc of >=500 msec.",experienced QTc is not a named entity
"No patients treated with SAPHRIS experienced QTc increases >=60 msec from baseline measurements, nor did any patient experience a QTc of >=500 msec.",from baseline measurements is not a named entity
"No patients treated with SAPHRIS experienced QTc increases >=60 msec from baseline measurements, nor did any patient experience a QTc of >=500 msec.",QTc of >=500 msec is an adverse reaction entity
"In short-term, placebo-controlled bipolar adult mania trials, the mean increase in transaminase levels for SAPHRIS-treated patients was 8.9 units/L compared to a decrease of 4.9 units/L in placebo-treated patients.",adult is not a named entity
"In short-term, placebo-controlled bipolar adult mania trials, the mean increase in transaminase levels for SAPHRIS-treated patients was 8.9 units/L compared to a decrease of 4.9 units/L in placebo-treated patients.",increase in transaminase levels is an adverse reaction entity
"Somnolence led to discontinuation in 0%, 3%, 1%, and 2% of patients treated with placebo, and SAPHRIS 2.5 mg twice daily, 5 mg twice daily, and 10 mg twice daily, respectively.",", respectively is not a named entity"
"Somnolence led to discontinuation in 0%, 3%, 1%, and 2% of patients treated with placebo, and SAPHRIS 2.5 mg twice daily, 5 mg twice daily, and 10 mg twice daily, respectively.",Somnolence is an adverse reaction entity
5.15 Dysphagia    Esophageal dysmotility and aspiration have been associated with antipsychotic drug use.,with antipsychotic is not a named entity
5.15 Dysphagia    Esophageal dysmotility and aspiration have been associated with antipsychotic drug use.,have is not a named entity
5.15 Dysphagia    Esophageal dysmotility and aspiration have been associated with antipsychotic drug use.,aspiration is an adverse reaction entity
5.15 Dysphagia    Esophageal dysmotility and aspiration have been associated with antipsychotic drug use.,Esophageal dysmotility is an adverse reaction entity
Agranulocytosis (including fatal cases) has been reported with other agents in the class.,Agranulocytosis is an adverse reaction entity
Agranulocytosis (including fatal cases) has been reported with other agents in the class.,cases is not a named entity
Agranulocytosis (including fatal cases) has been reported with other agents in the class.,fatal cases ) is not a named entity
Agranulocytosis (including fatal cases) has been reported with other agents in the class.,fatal is an adverse reaction entity
"These metabolic changes include hyperglycemia, dyslipidemia, and body weight gain.","include hyperglycemia , is not a named entity"
"These metabolic changes include hyperglycemia, dyslipidemia, and body weight gain.",metabolic changes is an adverse reaction entity
"These metabolic changes include hyperglycemia, dyslipidemia, and body weight gain.",changes include is not a named entity
"These metabolic changes include hyperglycemia, dyslipidemia, and body weight gain.",dyslipidemia is an adverse reaction entity
"These metabolic changes include hyperglycemia, dyslipidemia, and body weight gain.",body weight gain is an adverse reaction entity
"These metabolic changes include hyperglycemia, dyslipidemia, and body weight gain.",changes is not a named entity
"These metabolic changes include hyperglycemia, dyslipidemia, and body weight gain.",metabolic changes include is not a named entity
"These metabolic changes include hyperglycemia, dyslipidemia, and body weight gain.",hyperglycemia is an adverse reaction entity
BOXED WARNING: WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS      WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS        Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.,INCREASED MORTALITY is an adverse reaction entity
BOXED WARNING: WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS      WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS        Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.,: is not a named entity
BOXED WARNING: WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS      WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS        Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.,death is an adverse reaction entity
BOXED WARNING: WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS      WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS        Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.,: INCREASED is not a named entity
BOXED WARNING: WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS      WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS        Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.,MORTALITY IN is not a named entity
BOXED WARNING: WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS      WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS        Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.,INCREASED MORTALITY is an adverse reaction entity
"(5.5)   *   Hypersensitivity Reactions: Hypersensitivity reactions, including anaphylaxis and angioedema, have been observed.",5.5 ) * is not a named entity
"(5.5)   *   Hypersensitivity Reactions: Hypersensitivity reactions, including anaphylaxis and angioedema, have been observed.",angioedema is an adverse reaction entity
"(5.5)   *   Hypersensitivity Reactions: Hypersensitivity reactions, including anaphylaxis and angioedema, have been observed.","and angioedema , is not a named entity"
"(5.5)   *   Hypersensitivity Reactions: Hypersensitivity reactions, including anaphylaxis and angioedema, have been observed.",Hypersensitivity reactions is an adverse reaction entity
"(5.5)   *   Hypersensitivity Reactions: Hypersensitivity reactions, including anaphylaxis and angioedema, have been observed.",Hypersensitivity Reactions is an adverse reaction entity
"(5.5)   *   Hypersensitivity Reactions: Hypersensitivity reactions, including anaphylaxis and angioedema, have been observed.","and angioedema , is not a named entity"
"(5.5)   *   Hypersensitivity Reactions: Hypersensitivity reactions, including anaphylaxis and angioedema, have been observed.",reactions is not a named entity
"(5.5)   *   Hypersensitivity Reactions: Hypersensitivity reactions, including anaphylaxis and angioedema, have been observed.",anaphylaxis is an adverse reaction entity
"In short-term, placebo-controlled bipolar mania trials, the proportion of patients with total cholesterol elevations >=240 mg/dL (at Endpoint) was 8.7% for SAPHRIS-treated patients versus 8.6% for placebo-treated patients.",of is not a named entity
"In short-term, placebo-controlled bipolar mania trials, the proportion of patients with total cholesterol elevations >=240 mg/dL (at Endpoint) was 8.7% for SAPHRIS-treated patients versus 8.6% for placebo-treated patients.",total cholesterol elevations is an adverse reaction entity
"During adult pre-marketing clinical trials with SAPHRIS, including long-term trials without comparison to placebo, syncope was reported in 0.6% (11/1953) of patients treated with SAPHRIS.",syncope is an adverse reaction entity
"During adult pre-marketing clinical trials with SAPHRIS, including long-term trials without comparison to placebo, syncope was reported in 0.6% (11/1953) of patients treated with SAPHRIS.",in is not a named entity
"Hyperprolactinemia may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotropin secretion.",resulting in is not a named entity
"Hyperprolactinemia may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotropin secretion.",suppress hypothalamic GnRH is an adverse reaction entity
"Hyperprolactinemia may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotropin secretion.",Hyperprolactinemia may is not a named entity
"Hyperprolactinemia may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotropin secretion.",reduced pituitary gonadotropin secretion is an adverse reaction entity
"Hyperprolactinemia may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotropin secretion.",Hyperprolactinemia is an adverse reaction entity
"Hyperprolactinemia may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotropin secretion.",may is not a named entity
"Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group.","% , is not a named entity"
"Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group.",death is an adverse reaction entity
"5.4 Tardive Dyskinesia        A syndrome of potentially irreversible, involuntary, dyskinetic movements can develop in patients treated with antipsychotic drugs.",treated with is not a named entity
"5.4 Tardive Dyskinesia        A syndrome of potentially irreversible, involuntary, dyskinetic movements can develop in patients treated with antipsychotic drugs.","involuntary, dyskinetic movements is an adverse reaction entity"
The proportion of pediatric patients with ALT elevations >=3 times upper limit of normal (ULN) was 2.4% for patients treated with SAPHRIS 10 mg twice daily versus none for the other SAPHRIS dose groups and placebo-treated patients.,> is not a named entity
The proportion of pediatric patients with ALT elevations >=3 times upper limit of normal (ULN) was 2.4% for patients treated with SAPHRIS 10 mg twice daily versus none for the other SAPHRIS dose groups and placebo-treated patients.,ALT elevations is an adverse reaction entity
"(5.4)   * dispatch: unexpected key: list in dispatch table: {'caption': <function print_caption at 0x1c6c8c0>, 'text': <function print_text at 0x1c6c500>}   Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk.",print_caption is not a named entity
"(5.4)   * dispatch: unexpected key: list in dispatch table: {'caption': <function print_caption at 0x1c6c8c0>, 'text': <function print_text at 0x1c6c500>}   Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk.",metabolic changes is an adverse reaction entity
"(5.4)   * dispatch: unexpected key: list in dispatch table: {'caption': <function print_caption at 0x1c6c8c0>, 'text': <function print_text at 0x1c6c500>}   Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk.",Metabolic Changes is an adverse reaction entity
"(5.4)   * dispatch: unexpected key: list in dispatch table: {'caption': <function print_caption at 0x1c6c8c0>, 'text': <function print_text at 0x1c6c500>}   Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk.",cardiovascular risk is an adverse reaction entity
"(5.4)   * dispatch: unexpected key: list in dispatch table: {'caption': <function print_caption at 0x1c6c8c0>, 'text': <function print_text at 0x1c6c500>}   Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk.",cerebrovascular risk is an adverse reaction entity
"(5.4)   * dispatch: unexpected key: list in dispatch table: {'caption': <function print_caption at 0x1c6c8c0>, 'text': <function print_text at 0x1c6c500>}   Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk.",metabolic changes that is not a named entity
"(5.4)   * dispatch: unexpected key: list in dispatch table: {'caption': <function print_caption at 0x1c6c8c0>, 'text': <function print_text at 0x1c6c500>}   Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk.",Atypical antipsychotic drugs is not a named entity
"(5.4)   * dispatch: unexpected key: list in dispatch table: {'caption': <function print_caption at 0x1c6c8c0>, 'text': <function print_text at 0x1c6c500>}   Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk.",unexpected is not a named entity
"6                      24                                   Psychiatric disorders                                  Anxiety                                     2                      4                                       Depression                                  1                      2                                       Insomnia                                    5                      6                                              Monotherapy in Pediatric Patients with Bipolar Mania:  The following findings are based on a 3-week , placebo-controlled trial for bipolar mania in which SAPHRIS was administered at doses of 2.5 mg, 5 mg, or 10 mg twice daily.",Anxiety is an adverse reaction entity
"6                      24                                   Psychiatric disorders                                  Anxiety                                     2                      4                                       Depression                                  1                      2                                       Insomnia                                    5                      6                                              Monotherapy in Pediatric Patients with Bipolar Mania:  The following findings are based on a 3-week , placebo-controlled trial for bipolar mania in which SAPHRIS was administered at doses of 2.5 mg, 5 mg, or 10 mg twice daily.",10 mg twice is not a named entity
"6                      24                                   Psychiatric disorders                                  Anxiety                                     2                      4                                       Depression                                  1                      2                                       Insomnia                                    5                      6                                              Monotherapy in Pediatric Patients with Bipolar Mania:  The following findings are based on a 3-week , placebo-controlled trial for bipolar mania in which SAPHRIS was administered at doses of 2.5 mg, 5 mg, or 10 mg twice daily.",Monotherapy in Pediatric is not a named entity
"6                      24                                   Psychiatric disorders                                  Anxiety                                     2                      4                                       Depression                                  1                      2                                       Insomnia                                    5                      6                                              Monotherapy in Pediatric Patients with Bipolar Mania:  The following findings are based on a 3-week , placebo-controlled trial for bipolar mania in which SAPHRIS was administered at doses of 2.5 mg, 5 mg, or 10 mg twice daily.",Depression is an adverse reaction entity
"6                      24                                   Psychiatric disorders                                  Anxiety                                     2                      4                                       Depression                                  1                      2                                       Insomnia                                    5                      6                                              Monotherapy in Pediatric Patients with Bipolar Mania:  The following findings are based on a 3-week , placebo-controlled trial for bipolar mania in which SAPHRIS was administered at doses of 2.5 mg, 5 mg, or 10 mg twice daily.",Insomnia is an adverse reaction entity
"6                      24                                   Psychiatric disorders                                  Anxiety                                     2                      4                                       Depression                                  1                      2                                       Insomnia                                    5                      6                                              Monotherapy in Pediatric Patients with Bipolar Mania:  The following findings are based on a 3-week , placebo-controlled trial for bipolar mania in which SAPHRIS was administered at doses of 2.5 mg, 5 mg, or 10 mg twice daily.",are is not a named entity
Table 10: Adverse Reactions Reported in 2% or More of Pediatric Patients (Ages 10 to 17 Years) in Any SAPHRIS Dose Group and Which Occurred at Greater Incidence Than in the Placebo Group in a 3-Week Bipolar Mania Trial    1Includes the preferred terms tachycardia and heart rate increased.,heart rate increased is an adverse reaction entity
Table 10: Adverse Reactions Reported in 2% or More of Pediatric Patients (Ages 10 to 17 Years) in Any SAPHRIS Dose Group and Which Occurred at Greater Incidence Than in the Placebo Group in a 3-Week Bipolar Mania Trial    1Includes the preferred terms tachycardia and heart rate increased.,tachycardia is an adverse reaction entity
Table 10: Adverse Reactions Reported in 2% or More of Pediatric Patients (Ages 10 to 17 Years) in Any SAPHRIS Dose Group and Which Occurred at Greater Incidence Than in the Placebo Group in a 3-Week Bipolar Mania Trial    1Includes the preferred terms tachycardia and heart rate increased.,Which Occurred is not a named entity
Table 10: Adverse Reactions Reported in 2% or More of Pediatric Patients (Ages 10 to 17 Years) in Any SAPHRIS Dose Group and Which Occurred at Greater Incidence Than in the Placebo Group in a 3-Week Bipolar Mania Trial    1Includes the preferred terms tachycardia and heart rate increased.,a 3-Week is not a named entity
"In short-term, placebo-controlled bipolar mania adult trials of therapeutic doses (5-10 mg twice daily), somnolence was reported in 24% (90/379) of patients on SAPHRIS compared to 6% (13/203) of placebo patients.",( is not a named entity
"In short-term, placebo-controlled bipolar mania adult trials of therapeutic doses (5-10 mg twice daily), somnolence was reported in 24% (90/379) of patients on SAPHRIS compared to 6% (13/203) of placebo patients.",somnolence is an adverse reaction entity
"This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.","This , in is not a named entity"
"This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.",function by impairing is not a named entity
"This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.",impairing gonadal steroidogenesis is an adverse reaction entity
"This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.",inhibit reproductive function is an adverse reaction entity
"In SAPHRIS adult clinical trials, the incidences of adverse events related to abnormal prolactin levels were 0.4% versus 0% for placebo.",of adverse is not a named entity
"In SAPHRIS adult clinical trials, the incidences of adverse events related to abnormal prolactin levels were 0.4% versus 0% for placebo.",abnormal prolactin levels is an adverse reaction entity
"These application site reactions included oral ulcers, blisters, peeling/sloughing, and inflammation.",application site blisters is an adverse reaction entity
"These application site reactions included oral ulcers, blisters, peeling/sloughing, and inflammation.",oral ulcers is not a named entity
"These application site reactions included oral ulcers, blisters, peeling/sloughing, and inflammation.",application site inflammation is an adverse reaction entity
"These application site reactions included oral ulcers, blisters, peeling/sloughing, and inflammation.",", peeling/sloughing is not a named entity"
"These application site reactions included oral ulcers, blisters, peeling/sloughing, and inflammation.",peeling/sloughing is not a named entity
"These application site reactions included oral ulcers, blisters, peeling/sloughing, and inflammation.",application site sloughing is an adverse reaction entity
"These application site reactions included oral ulcers, blisters, peeling/sloughing, and inflammation.",These application is not a named entity
"These application site reactions included oral ulcers, blisters, peeling/sloughing, and inflammation.",", is not a named entity"
"These application site reactions included oral ulcers, blisters, peeling/sloughing, and inflammation.",application site reactions is an adverse reaction entity
"These application site reactions included oral ulcers, blisters, peeling/sloughing, and inflammation.",application site oral ulcers is an adverse reaction entity
"These application site reactions included oral ulcers, blisters, peeling/sloughing, and inflammation.",These application is not a named entity
"These application site reactions included oral ulcers, blisters, peeling/sloughing, and inflammation.",application site peeling is an adverse reaction entity
"During clinical trials with SAPHRIS, including long-term trials without comparison to placebo, the incidence of adverse reactions suggestive of body temperature increases (pyrexia and feeling hot) was <=1%.",body temperature increases is an adverse reaction entity
"During clinical trials with SAPHRIS, including long-term trials without comparison to placebo, the incidence of adverse reactions suggestive of body temperature increases (pyrexia and feeling hot) was <=1%.",feeling hot is an adverse reaction entity
"During clinical trials with SAPHRIS, including long-term trials without comparison to placebo, the incidence of adverse reactions suggestive of body temperature increases (pyrexia and feeling hot) was <=1%.",and feeling is not a named entity
"During clinical trials with SAPHRIS, including long-term trials without comparison to placebo, the incidence of adverse reactions suggestive of body temperature increases (pyrexia and feeling hot) was <=1%.",pyrexia is an adverse reaction entity
"During clinical trials with SAPHRIS, including long-term trials without comparison to placebo, the incidence of adverse reactions suggestive of body temperature increases (pyrexia and feeling hot) was <=1%.",temperature increases ( is not a named entity
"During clinical trials with SAPHRIS, including long-term trials without comparison to placebo, the incidence of adverse reactions suggestive of body temperature increases (pyrexia and feeling hot) was <=1%.",", the incidence is not a named entity"
(5.14)              5.1 Increased Mortality in Elderly Patients with Dementia-Related Psychosis        Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.,5.1 Increased is not a named entity
(5.14)              5.1 Increased Mortality in Elderly Patients with Dementia-Related Psychosis        Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.,death is an adverse reaction entity
Precise risk estimates for hyperglycemia-related adverse events in patients treated with atypical antipsychotics are not available.,in is not a named entity
Precise risk estimates for hyperglycemia-related adverse events in patients treated with atypical antipsychotics are not available.,hyperglycemia is an adverse reaction entity
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS         See full prescribing information for complete boxed warning.,MORTALITY is not a named entity
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS         See full prescribing information for complete boxed warning.,INCREASED MORTALITY is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS     EXCERPT:    *   Cerebrovascular Adverse Events: An increased incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack) has been seen in elderly patients with dementia-related psychoses treated with atypical antipsychotic drugs.",patients with dementia-related is not a named entity
"5 WARNINGS AND PRECAUTIONS     EXCERPT:    *   Cerebrovascular Adverse Events: An increased incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack) has been seen in elderly patients with dementia-related psychoses treated with atypical antipsychotic drugs.",EXCERPT : * is not a named entity
"5 WARNINGS AND PRECAUTIONS     EXCERPT:    *   Cerebrovascular Adverse Events: An increased incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack) has been seen in elderly patients with dementia-related psychoses treated with atypical antipsychotic drugs.",stroke is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS     EXCERPT:    *   Cerebrovascular Adverse Events: An increased incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack) has been seen in elderly patients with dementia-related psychoses treated with atypical antipsychotic drugs.",cerebrovascular adverse events is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS     EXCERPT:    *   Cerebrovascular Adverse Events: An increased incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack) has been seen in elderly patients with dementia-related psychoses treated with atypical antipsychotic drugs.",Cerebrovascular Adverse Events is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS     EXCERPT:    *   Cerebrovascular Adverse Events: An increased incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack) has been seen in elderly patients with dementia-related psychoses treated with atypical antipsychotic drugs.",transient ischemic attack is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS     EXCERPT:    *   Cerebrovascular Adverse Events: An increased incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack) has been seen in elderly patients with dementia-related psychoses treated with atypical antipsychotic drugs.",psychoses treated with is not a named entity
"5 WARNINGS AND PRECAUTIONS     EXCERPT:    *   Cerebrovascular Adverse Events: An increased incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack) has been seen in elderly patients with dementia-related psychoses treated with atypical antipsychotic drugs.",attack is not a named entity
"3Includes the preferred terms abdominal pain, abdominal pain upper, abdominal pain lower, and abdominal discomfort.",", and abdominal is not a named entity"
"3Includes the preferred terms abdominal pain, abdominal pain upper, abdominal pain lower, and abdominal discomfort.",abdominal pain lower is an adverse reaction entity
"3Includes the preferred terms abdominal pain, abdominal pain upper, abdominal pain lower, and abdominal discomfort.",abdominal pain is an adverse reaction entity
"3Includes the preferred terms abdominal pain, abdominal pain upper, abdominal pain lower, and abdominal discomfort.",", abdominal is not a named entity"
"3Includes the preferred terms abdominal pain, abdominal pain upper, abdominal pain lower, and abdominal discomfort.",abdominal discomfort is an adverse reaction entity
"3Includes the preferred terms abdominal pain, abdominal pain upper, abdominal pain lower, and abdominal discomfort.","upper , is not a named entity"
"3Includes the preferred terms abdominal pain, abdominal pain upper, abdominal pain lower, and abdominal discomfort.",abdominal pain upper is an adverse reaction entity
"3Includes the preferred terms abdominal pain, abdominal pain upper, abdominal pain lower, and abdominal discomfort.",3Includes the is not a named entity
The proportion of patients with transaminase elevations >=3 times ULN (at Endpoint) was 0.9% for SAPHRIS-treated patients versus 1.3% for placebo-treated patients.,transaminase elevations is an adverse reaction entity
The proportion of patients with transaminase elevations >=3 times ULN (at Endpoint) was 0.9% for SAPHRIS-treated patients versus 1.3% for placebo-treated patients.,for is not a named entity
"The most common adverse reactions associated with discontinuation in subjects treated with SAPHRIS (rates at least 1% and at least twice the placebo rate) were depression (2.5%), suicidal ideation (2.5%), bipolar I disorder (1.9%), insomnia (1.9%) and depressive symptoms (1.3%).",insomnia is an adverse reaction entity
"The most common adverse reactions associated with discontinuation in subjects treated with SAPHRIS (rates at least 1% and at least twice the placebo rate) were depression (2.5%), suicidal ideation (2.5%), bipolar I disorder (1.9%), insomnia (1.9%) and depressive symptoms (1.3%).",placebo is not a named entity
"The most common adverse reactions associated with discontinuation in subjects treated with SAPHRIS (rates at least 1% and at least twice the placebo rate) were depression (2.5%), suicidal ideation (2.5%), bipolar I disorder (1.9%), insomnia (1.9%) and depressive symptoms (1.3%).",) is not a named entity
"The most common adverse reactions associated with discontinuation in subjects treated with SAPHRIS (rates at least 1% and at least twice the placebo rate) were depression (2.5%), suicidal ideation (2.5%), bipolar I disorder (1.9%), insomnia (1.9%) and depressive symptoms (1.3%).",depression is an adverse reaction entity
"The most common adverse reactions associated with discontinuation in subjects treated with SAPHRIS (rates at least 1% and at least twice the placebo rate) were depression (2.5%), suicidal ideation (2.5%), bipolar I disorder (1.9%), insomnia (1.9%) and depressive symptoms (1.3%).",depression ( is not a named entity
"The most common adverse reactions associated with discontinuation in subjects treated with SAPHRIS (rates at least 1% and at least twice the placebo rate) were depression (2.5%), suicidal ideation (2.5%), bipolar I disorder (1.9%), insomnia (1.9%) and depressive symptoms (1.3%).",bipolar I disorder is an adverse reaction entity
"The most common adverse reactions associated with discontinuation in subjects treated with SAPHRIS (rates at least 1% and at least twice the placebo rate) were depression (2.5%), suicidal ideation (2.5%), bipolar I disorder (1.9%), insomnia (1.9%) and depressive symptoms (1.3%).",2.5 % is not a named entity
"The most common adverse reactions associated with discontinuation in subjects treated with SAPHRIS (rates at least 1% and at least twice the placebo rate) were depression (2.5%), suicidal ideation (2.5%), bipolar I disorder (1.9%), insomnia (1.9%) and depressive symptoms (1.3%).",depressive symptoms is an adverse reaction entity
"The most common adverse reactions associated with discontinuation in subjects treated with SAPHRIS (rates at least 1% and at least twice the placebo rate) were depression (2.5%), suicidal ideation (2.5%), bipolar I disorder (1.9%), insomnia (1.9%) and depressive symptoms (1.3%).",rates at is not a named entity
"The most common adverse reactions associated with discontinuation in subjects treated with SAPHRIS (rates at least 1% and at least twice the placebo rate) were depression (2.5%), suicidal ideation (2.5%), bipolar I disorder (1.9%), insomnia (1.9%) and depressive symptoms (1.3%).",suicidal ideation is an adverse reaction entity
There were no reports of Torsade de Pointes or any other adverse reactions associated with delayed ventricular repolarization.,associated with is not a named entity
There were no reports of Torsade de Pointes or any other adverse reactions associated with delayed ventricular repolarization.,Torsade de Pointes is an adverse reaction entity
There were no reports of Torsade de Pointes or any other adverse reactions associated with delayed ventricular repolarization.,There is not a named entity
There were no reports of Torsade de Pointes or any other adverse reactions associated with delayed ventricular repolarization.,delayed ventricular repolarization is an adverse reaction entity
"Extrapyramidal symptoms included: dystonia, parkinsonism, oculogyration, and tremor (excluding akathisia).",tremor is an adverse reaction entity
"Extrapyramidal symptoms included: dystonia, parkinsonism, oculogyration, and tremor (excluding akathisia).",", oculogyration , is not a named entity"
"Extrapyramidal symptoms included: dystonia, parkinsonism, oculogyration, and tremor (excluding akathisia).",dystonia is an adverse reaction entity
"Extrapyramidal symptoms included: dystonia, parkinsonism, oculogyration, and tremor (excluding akathisia).",", and tremor is not a named entity"
"Extrapyramidal symptoms included: dystonia, parkinsonism, oculogyration, and tremor (excluding akathisia).",symptoms included : is not a named entity
"Extrapyramidal symptoms included: dystonia, parkinsonism, oculogyration, and tremor (excluding akathisia).",", oculogyration is not a named entity"
"Extrapyramidal symptoms included: dystonia, parkinsonism, oculogyration, and tremor (excluding akathisia).",oculogyration is an adverse reaction entity
"Extrapyramidal symptoms included: dystonia, parkinsonism, oculogyration, and tremor (excluding akathisia).",Extrapyramidal symptoms is an adverse reaction entity
"Extrapyramidal symptoms included: dystonia, parkinsonism, oculogyration, and tremor (excluding akathisia).",symptoms included is not a named entity
"Extrapyramidal symptoms included: dystonia, parkinsonism, oculogyration, and tremor (excluding akathisia).",", oculogyration is not a named entity"
"Extrapyramidal symptoms included: dystonia, parkinsonism, oculogyration, and tremor (excluding akathisia).",parkinsonism is an adverse reaction entity
"Extrapyramidal symptoms included: dystonia, parkinsonism, oculogyration, and tremor (excluding akathisia).",akathisia is an adverse reaction entity
"Hyperglycemia and Diabetes Mellitus           Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics.",", in is not a named entity"
"Hyperglycemia and Diabetes Mellitus           Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics.",Hyperglycemia is an adverse reaction entity
"Hyperglycemia and Diabetes Mellitus           Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics.",Hyperglycemia is an adverse reaction entity
"Hyperglycemia and Diabetes Mellitus           Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics.",and Diabetes Mellitus is not a named entity
"Hyperglycemia and Diabetes Mellitus           Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics.",hyperosmolar coma is an adverse reaction entity
"Hyperglycemia and Diabetes Mellitus           Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics.",Mellitus Hyperglycemia is not a named entity
"Hyperglycemia and Diabetes Mellitus           Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics.",patients treated with is not a named entity
"Hyperglycemia and Diabetes Mellitus           Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics.",ketoacidosis is an adverse reaction entity
"Hyperglycemia and Diabetes Mellitus           Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics.",death is an adverse reaction entity
"Hyperglycemia and Diabetes Mellitus           Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics.",treated with is not a named entity
"In short-term, placebo-controlled schizophrenia adult trials, the mean increase in transaminase levels for SAPHRIS-treated patients was 1.6 units/L compared to a decrease of 0.4 units/L for placebo-treated patients.",of 0.4 units/L is not a named entity
"In short-term, placebo-controlled schizophrenia adult trials, the mean increase in transaminase levels for SAPHRIS-treated patients was 1.6 units/L compared to a decrease of 0.4 units/L for placebo-treated patients.",increase in transaminase levels is an adverse reaction entity
"The most common adverse reactions that led to discontinuation in pediatric patients treated with SAPHRIS (rates at least 2% in any SAPHRIS arm and at least twice the placebo rate) were somnolence (3% in the 2.5mg twice daily group, 1% in the 5mg twice daily group, and 2% in the 10mg twice daily group), abdominal pain (2% in the 10mg twice daily group), and nausea (2% in the 10mg twice daily group) No placebo-treated patients dropped out for these events.",nausea is an adverse reaction entity
"The most common adverse reactions that led to discontinuation in pediatric patients treated with SAPHRIS (rates at least 2% in any SAPHRIS arm and at least twice the placebo rate) were somnolence (3% in the 2.5mg twice daily group, 1% in the 5mg twice daily group, and 2% in the 10mg twice daily group), abdominal pain (2% in the 10mg twice daily group), and nausea (2% in the 10mg twice daily group) No placebo-treated patients dropped out for these events.",somnolence is an adverse reaction entity
"The most common adverse reactions that led to discontinuation in pediatric patients treated with SAPHRIS (rates at least 2% in any SAPHRIS arm and at least twice the placebo rate) were somnolence (3% in the 2.5mg twice daily group, 1% in the 5mg twice daily group, and 2% in the 10mg twice daily group), abdominal pain (2% in the 10mg twice daily group), and nausea (2% in the 10mg twice daily group) No placebo-treated patients dropped out for these events.",abdominal pain is an adverse reaction entity
"The most common adverse reactions that led to discontinuation in pediatric patients treated with SAPHRIS (rates at least 2% in any SAPHRIS arm and at least twice the placebo rate) were somnolence (3% in the 2.5mg twice daily group, 1% in the 5mg twice daily group, and 2% in the 10mg twice daily group), abdominal pain (2% in the 10mg twice daily group), and nausea (2% in the 10mg twice daily group) No placebo-treated patients dropped out for these events.",10mg is not a named entity
"The most common adverse reactions that led to discontinuation in pediatric patients treated with SAPHRIS (rates at least 2% in any SAPHRIS arm and at least twice the placebo rate) were somnolence (3% in the 2.5mg twice daily group, 1% in the 5mg twice daily group, and 2% in the 10mg twice daily group), abdominal pain (2% in the 10mg twice daily group), and nausea (2% in the 10mg twice daily group) No placebo-treated patients dropped out for these events.",nausea ( is not a named entity
"The most common adverse reactions that led to discontinuation in pediatric patients treated with SAPHRIS (rates at least 2% in any SAPHRIS arm and at least twice the placebo rate) were somnolence (3% in the 2.5mg twice daily group, 1% in the 5mg twice daily group, and 2% in the 10mg twice daily group), abdominal pain (2% in the 10mg twice daily group), and nausea (2% in the 10mg twice daily group) No placebo-treated patients dropped out for these events.",twice daily is not a named entity
(5.12)   *   Suicide: The possibility of a suicide attempt is inherent in schizophrenia and bipolar disorder.,Suicide is an adverse reaction entity
(5.12)   *   Suicide: The possibility of a suicide attempt is inherent in schizophrenia and bipolar disorder.,Suicide : is not a named entity
The proportion of patients with elevations in triglycerides >=200 mg/dL (at Endpoint) was 15.2% for SAPHRIS-treated patients versus 11.4% for placebo-treated patients.,> =200 mg/dL is not a named entity
The proportion of patients with elevations in triglycerides >=200 mg/dL (at Endpoint) was 15.2% for SAPHRIS-treated patients versus 11.4% for placebo-treated patients.,elevations in triglycerides is an adverse reaction entity
"Extrapyramidal symptoms included: dystonia, blepharospasm, torticollis, dyskinesia, tardive dyskinesia, muscle rigidity, parkinsonism, gait disturbance, masked facies, and tremor (excluding akathisia).",parkinsonism is an adverse reaction entity
"Extrapyramidal symptoms included: dystonia, blepharospasm, torticollis, dyskinesia, tardive dyskinesia, muscle rigidity, parkinsonism, gait disturbance, masked facies, and tremor (excluding akathisia).",tremor is an adverse reaction entity
"Extrapyramidal symptoms included: dystonia, blepharospasm, torticollis, dyskinesia, tardive dyskinesia, muscle rigidity, parkinsonism, gait disturbance, masked facies, and tremor (excluding akathisia).",torticollis is an adverse reaction entity
"Extrapyramidal symptoms included: dystonia, blepharospasm, torticollis, dyskinesia, tardive dyskinesia, muscle rigidity, parkinsonism, gait disturbance, masked facies, and tremor (excluding akathisia).",gait disturbance is an adverse reaction entity
"Extrapyramidal symptoms included: dystonia, blepharospasm, torticollis, dyskinesia, tardive dyskinesia, muscle rigidity, parkinsonism, gait disturbance, masked facies, and tremor (excluding akathisia).","masked facies , is not a named entity"
"Extrapyramidal symptoms included: dystonia, blepharospasm, torticollis, dyskinesia, tardive dyskinesia, muscle rigidity, parkinsonism, gait disturbance, masked facies, and tremor (excluding akathisia).",masked facies is an adverse reaction entity
"Extrapyramidal symptoms included: dystonia, blepharospasm, torticollis, dyskinesia, tardive dyskinesia, muscle rigidity, parkinsonism, gait disturbance, masked facies, and tremor (excluding akathisia).",dystonia is an adverse reaction entity
"Extrapyramidal symptoms included: dystonia, blepharospasm, torticollis, dyskinesia, tardive dyskinesia, muscle rigidity, parkinsonism, gait disturbance, masked facies, and tremor (excluding akathisia).",", torticollis is not a named entity"
"Extrapyramidal symptoms included: dystonia, blepharospasm, torticollis, dyskinesia, tardive dyskinesia, muscle rigidity, parkinsonism, gait disturbance, masked facies, and tremor (excluding akathisia).",symptoms included is not a named entity
"Extrapyramidal symptoms included: dystonia, blepharospasm, torticollis, dyskinesia, tardive dyskinesia, muscle rigidity, parkinsonism, gait disturbance, masked facies, and tremor (excluding akathisia).","parkinsonism , is not a named entity"
"Extrapyramidal symptoms included: dystonia, blepharospasm, torticollis, dyskinesia, tardive dyskinesia, muscle rigidity, parkinsonism, gait disturbance, masked facies, and tremor (excluding akathisia).","torticollis , is not a named entity"
"Extrapyramidal symptoms included: dystonia, blepharospasm, torticollis, dyskinesia, tardive dyskinesia, muscle rigidity, parkinsonism, gait disturbance, masked facies, and tremor (excluding akathisia).","torticollis , is not a named entity"
"Extrapyramidal symptoms included: dystonia, blepharospasm, torticollis, dyskinesia, tardive dyskinesia, muscle rigidity, parkinsonism, gait disturbance, masked facies, and tremor (excluding akathisia).",akathisia is an adverse reaction entity
"Extrapyramidal symptoms included: dystonia, blepharospasm, torticollis, dyskinesia, tardive dyskinesia, muscle rigidity, parkinsonism, gait disturbance, masked facies, and tremor (excluding akathisia).",tardive dyskinesia is an adverse reaction entity
"Extrapyramidal symptoms included: dystonia, blepharospasm, torticollis, dyskinesia, tardive dyskinesia, muscle rigidity, parkinsonism, gait disturbance, masked facies, and tremor (excluding akathisia).",blepharospasm is an adverse reaction entity
"Extrapyramidal symptoms included: dystonia, blepharospasm, torticollis, dyskinesia, tardive dyskinesia, muscle rigidity, parkinsonism, gait disturbance, masked facies, and tremor (excluding akathisia).",and is not a named entity
"Extrapyramidal symptoms included: dystonia, blepharospasm, torticollis, dyskinesia, tardive dyskinesia, muscle rigidity, parkinsonism, gait disturbance, masked facies, and tremor (excluding akathisia).",muscle rigidity is an adverse reaction entity
"Extrapyramidal symptoms included: dystonia, blepharospasm, torticollis, dyskinesia, tardive dyskinesia, muscle rigidity, parkinsonism, gait disturbance, masked facies, and tremor (excluding akathisia).","blepharospasm , is not a named entity"
"Extrapyramidal symptoms included: dystonia, blepharospasm, torticollis, dyskinesia, tardive dyskinesia, muscle rigidity, parkinsonism, gait disturbance, masked facies, and tremor (excluding akathisia).",", is not a named entity"
"Extrapyramidal symptoms included: dystonia, blepharospasm, torticollis, dyskinesia, tardive dyskinesia, muscle rigidity, parkinsonism, gait disturbance, masked facies, and tremor (excluding akathisia).",Extrapyramidal symptoms is an adverse reaction entity
"Extrapyramidal symptoms included: dystonia, blepharospasm, torticollis, dyskinesia, tardive dyskinesia, muscle rigidity, parkinsonism, gait disturbance, masked facies, and tremor (excluding akathisia).",", is not a named entity"
"Extrapyramidal symptoms included: dystonia, blepharospasm, torticollis, dyskinesia, tardive dyskinesia, muscle rigidity, parkinsonism, gait disturbance, masked facies, and tremor (excluding akathisia).",dyskinesia is an adverse reaction entity
"Extrapyramidal symptoms included: dystonia, blepharospasm, torticollis, dyskinesia, tardive dyskinesia, muscle rigidity, parkinsonism, gait disturbance, masked facies, and tremor (excluding akathisia).","parkinsonism , gait is not a named entity"
"Extrapyramidal symptoms included: dystonia, blepharospasm, torticollis, dyskinesia, tardive dyskinesia, muscle rigidity, parkinsonism, gait disturbance, masked facies, and tremor (excluding akathisia).","dyskinesia , is not a named entity"
"*   Bipolar Disorder Adults (Monotherapy): somnolence, dizziness, extrapyramidal symptoms other than akathisia, increased weight.",Monotherapy is not a named entity
"*   Bipolar Disorder Adults (Monotherapy): somnolence, dizziness, extrapyramidal symptoms other than akathisia, increased weight.",", extrapyramidal symptoms is not a named entity"
"*   Bipolar Disorder Adults (Monotherapy): somnolence, dizziness, extrapyramidal symptoms other than akathisia, increased weight.",dizziness is an adverse reaction entity
"*   Bipolar Disorder Adults (Monotherapy): somnolence, dizziness, extrapyramidal symptoms other than akathisia, increased weight.",increased weight is an adverse reaction entity
"*   Bipolar Disorder Adults (Monotherapy): somnolence, dizziness, extrapyramidal symptoms other than akathisia, increased weight.",than is not a named entity
"*   Bipolar Disorder Adults (Monotherapy): somnolence, dizziness, extrapyramidal symptoms other than akathisia, increased weight.",extrapyramidal symptoms is an adverse reaction entity
"*   Bipolar Disorder Adults (Monotherapy): somnolence, dizziness, extrapyramidal symptoms other than akathisia, increased weight.",) is not a named entity
"*   Bipolar Disorder Adults (Monotherapy): somnolence, dizziness, extrapyramidal symptoms other than akathisia, increased weight.",somnolence is an adverse reaction entity
"*   Bipolar Disorder Adults (Monotherapy): somnolence, dizziness, extrapyramidal symptoms other than akathisia, increased weight.",akathisia is an adverse reaction entity
"*   Bipolar Disorder Adults (Monotherapy): somnolence, dizziness, extrapyramidal symptoms other than akathisia, increased weight.",* is not a named entity
"During adult pre-marketing clinical trials with SAPHRIS, including long-term trials without comparison to placebo, dysphagia was reported in 0.1% (2/1953) of patients treated with SAPHRIS.",to is not a named entity
"During adult pre-marketing clinical trials with SAPHRIS, including long-term trials without comparison to placebo, dysphagia was reported in 0.1% (2/1953) of patients treated with SAPHRIS.",dysphagia is an adverse reaction entity
"In a 3-week monotherapy trial, the most common adverse reactions (>=5% and at least twice the rate of placebo) reported in pediatric patients with bipolar I disorder treated with SAPHRIS were somnolence, dizziness, dysgeusia, oral paresthesia, nausea, increased appetite, fatigue, and increased weight.",increased weight is an adverse reaction entity
"In a 3-week monotherapy trial, the most common adverse reactions (>=5% and at least twice the rate of placebo) reported in pediatric patients with bipolar I disorder treated with SAPHRIS were somnolence, dizziness, dysgeusia, oral paresthesia, nausea, increased appetite, fatigue, and increased weight.",somnolence is an adverse reaction entity
"In a 3-week monotherapy trial, the most common adverse reactions (>=5% and at least twice the rate of placebo) reported in pediatric patients with bipolar I disorder treated with SAPHRIS were somnolence, dizziness, dysgeusia, oral paresthesia, nausea, increased appetite, fatigue, and increased weight.",dysgeusia is an adverse reaction entity
"In a 3-week monotherapy trial, the most common adverse reactions (>=5% and at least twice the rate of placebo) reported in pediatric patients with bipolar I disorder treated with SAPHRIS were somnolence, dizziness, dysgeusia, oral paresthesia, nausea, increased appetite, fatigue, and increased weight.",nausea is an adverse reaction entity
"In a 3-week monotherapy trial, the most common adverse reactions (>=5% and at least twice the rate of placebo) reported in pediatric patients with bipolar I disorder treated with SAPHRIS were somnolence, dizziness, dysgeusia, oral paresthesia, nausea, increased appetite, fatigue, and increased weight.",reactions ( is not a named entity
"In a 3-week monotherapy trial, the most common adverse reactions (>=5% and at least twice the rate of placebo) reported in pediatric patients with bipolar I disorder treated with SAPHRIS were somnolence, dizziness, dysgeusia, oral paresthesia, nausea, increased appetite, fatigue, and increased weight.",oral paresthesia is an adverse reaction entity
"In a 3-week monotherapy trial, the most common adverse reactions (>=5% and at least twice the rate of placebo) reported in pediatric patients with bipolar I disorder treated with SAPHRIS were somnolence, dizziness, dysgeusia, oral paresthesia, nausea, increased appetite, fatigue, and increased weight.",increased appetite is an adverse reaction entity
"In a 3-week monotherapy trial, the most common adverse reactions (>=5% and at least twice the rate of placebo) reported in pediatric patients with bipolar I disorder treated with SAPHRIS were somnolence, dizziness, dysgeusia, oral paresthesia, nausea, increased appetite, fatigue, and increased weight.",( is not a named entity
"In a 3-week monotherapy trial, the most common adverse reactions (>=5% and at least twice the rate of placebo) reported in pediatric patients with bipolar I disorder treated with SAPHRIS were somnolence, dizziness, dysgeusia, oral paresthesia, nausea, increased appetite, fatigue, and increased weight.",3-week monotherapy is not a named entity
"In a 3-week monotherapy trial, the most common adverse reactions (>=5% and at least twice the rate of placebo) reported in pediatric patients with bipolar I disorder treated with SAPHRIS were somnolence, dizziness, dysgeusia, oral paresthesia, nausea, increased appetite, fatigue, and increased weight.",fatigue is an adverse reaction entity
"In a 3-week monotherapy trial, the most common adverse reactions (>=5% and at least twice the rate of placebo) reported in pediatric patients with bipolar I disorder treated with SAPHRIS were somnolence, dizziness, dysgeusia, oral paresthesia, nausea, increased appetite, fatigue, and increased weight.",dizziness is an adverse reaction entity
"In a 3-week monotherapy trial, the most common adverse reactions (>=5% and at least twice the rate of placebo) reported in pediatric patients with bipolar I disorder treated with SAPHRIS were somnolence, dizziness, dysgeusia, oral paresthesia, nausea, increased appetite, fatigue, and increased weight.",", is not a named entity"
"In a 3-week monotherapy trial, the most common adverse reactions (>=5% and at least twice the rate of placebo) reported in pediatric patients with bipolar I disorder treated with SAPHRIS were somnolence, dizziness, dysgeusia, oral paresthesia, nausea, increased appetite, fatigue, and increased weight.",", is not a named entity"
"In a 3-week monotherapy trial, the most common adverse reactions (>=5% and at least twice the rate of placebo) reported in pediatric patients with bipolar I disorder treated with SAPHRIS were somnolence, dizziness, dysgeusia, oral paresthesia, nausea, increased appetite, fatigue, and increased weight.",", is not a named entity"
"In a 3-week monotherapy trial, the most common adverse reactions (>=5% and at least twice the rate of placebo) reported in pediatric patients with bipolar I disorder treated with SAPHRIS were somnolence, dizziness, dysgeusia, oral paresthesia, nausea, increased appetite, fatigue, and increased weight.","paresthesia , is not a named entity"
"In a 3-week monotherapy trial, the most common adverse reactions (>=5% and at least twice the rate of placebo) reported in pediatric patients with bipolar I disorder treated with SAPHRIS were somnolence, dizziness, dysgeusia, oral paresthesia, nausea, increased appetite, fatigue, and increased weight.",I disorder is not a named entity
"Dysphagia was reported in 0.2% and 0% (1/572, 0/379) of patients treated with therapeutic doses (5-10 mg twice daily) of SAPHRIS as compared to 0% (0/378, 0/203) of patients treated with placebo in short-term schizophrenia and bipolar mania adult trials, respectively.",", is not a named entity"
"Dysphagia was reported in 0.2% and 0% (1/572, 0/379) of patients treated with therapeutic doses (5-10 mg twice daily) of SAPHRIS as compared to 0% (0/378, 0/203) of patients treated with placebo in short-term schizophrenia and bipolar mania adult trials, respectively.",Dysphagia is an adverse reaction entity
"Somnolence includes the following events: somnolence, sedation, and hypersomnia.",hypersomnia is an adverse reaction entity
"Somnolence includes the following events: somnolence, sedation, and hypersomnia.",somnolence is an adverse reaction entity
"Somnolence includes the following events: somnolence, sedation, and hypersomnia.",events : somnolence is not a named entity
"Somnolence includes the following events: somnolence, sedation, and hypersomnia.",sedation is an adverse reaction entity
"Somnolence includes the following events: somnolence, sedation, and hypersomnia.",events is not a named entity
"Somnolence includes the following events: somnolence, sedation, and hypersomnia.",the following events is not a named entity
"Somnolence includes the following events: somnolence, sedation, and hypersomnia.",Somnolence is an adverse reaction entity
"Somnolence includes the following events: somnolence, sedation, and hypersomnia.",": somnolence , is not a named entity"
"EXCERPT:   Commonly observed adverse reactions (incidence >=5% and at least twice that for placebo) were (6.1):     *   Schizophrenia Adults: akathisia, oral hypoesthesia, somnolence.",reactions ( is not a named entity
"EXCERPT:   Commonly observed adverse reactions (incidence >=5% and at least twice that for placebo) were (6.1):     *   Schizophrenia Adults: akathisia, oral hypoesthesia, somnolence.",Adults is not a named entity
"EXCERPT:   Commonly observed adverse reactions (incidence >=5% and at least twice that for placebo) were (6.1):     *   Schizophrenia Adults: akathisia, oral hypoesthesia, somnolence.",oral hypoesthesia is an adverse reaction entity
"EXCERPT:   Commonly observed adverse reactions (incidence >=5% and at least twice that for placebo) were (6.1):     *   Schizophrenia Adults: akathisia, oral hypoesthesia, somnolence.",somnolence is an adverse reaction entity
"EXCERPT:   Commonly observed adverse reactions (incidence >=5% and at least twice that for placebo) were (6.1):     *   Schizophrenia Adults: akathisia, oral hypoesthesia, somnolence.",: * Schizophrenia is not a named entity
"EXCERPT:   Commonly observed adverse reactions (incidence >=5% and at least twice that for placebo) were (6.1):     *   Schizophrenia Adults: akathisia, oral hypoesthesia, somnolence.",akathisia is an adverse reaction entity
"In the short-term placebo-controlled trials for both schizophrenia and acute bipolar disorder, the incidence of adverse reactions suggestive of body temperature increases was low (<=1%) and comparable to placebo (0%).",temperature increases is not a named entity
"In the short-term placebo-controlled trials for both schizophrenia and acute bipolar disorder, the incidence of adverse reactions suggestive of body temperature increases was low (<=1%) and comparable to placebo (0%).",body temperature increases is an adverse reaction entity
"5.10 Hyperprolactinemia        Like other drugs that antagonize dopamine D2receptors, SAPHRIS can elevate prolactin levels, and the elevation can persist during chronic administration.",that antagonize is not a named entity
"5.10 Hyperprolactinemia        Like other drugs that antagonize dopamine D2receptors, SAPHRIS can elevate prolactin levels, and the elevation can persist during chronic administration.",elevate prolactin levels is an adverse reaction entity
Whether antipsychotic drug products differ in their potential to cause Tardive Dyskinesia (TD) is unknown.,to cause Tardive is not a named entity
Whether antipsychotic drug products differ in their potential to cause Tardive Dyskinesia (TD) is unknown.,TD ) is is not a named entity
Whether antipsychotic drug products differ in their potential to cause Tardive Dyskinesia (TD) is unknown.,TD is an adverse reaction entity
Whether antipsychotic drug products differ in their potential to cause Tardive Dyskinesia (TD) is unknown.,Tardive Dyskinesia is an adverse reaction entity
"*   Bipolar Disorder Pediatric Patients (Monotherapy): somnolence, dizziness, dysgeusia, oral paresthesia, nausea, increased appetite, fatigue, increased weight.",dysgeusia is an adverse reaction entity
"*   Bipolar Disorder Pediatric Patients (Monotherapy): somnolence, dizziness, dysgeusia, oral paresthesia, nausea, increased appetite, fatigue, increased weight.",somnolence is an adverse reaction entity
"*   Bipolar Disorder Pediatric Patients (Monotherapy): somnolence, dizziness, dysgeusia, oral paresthesia, nausea, increased appetite, fatigue, increased weight.",increased weight is an adverse reaction entity
"*   Bipolar Disorder Pediatric Patients (Monotherapy): somnolence, dizziness, dysgeusia, oral paresthesia, nausea, increased appetite, fatigue, increased weight.",nausea is an adverse reaction entity
"*   Bipolar Disorder Pediatric Patients (Monotherapy): somnolence, dizziness, dysgeusia, oral paresthesia, nausea, increased appetite, fatigue, increased weight.",", nausea , is not a named entity"
"*   Bipolar Disorder Pediatric Patients (Monotherapy): somnolence, dizziness, dysgeusia, oral paresthesia, nausea, increased appetite, fatigue, increased weight.","fatigue , increased is not a named entity"
"*   Bipolar Disorder Pediatric Patients (Monotherapy): somnolence, dizziness, dysgeusia, oral paresthesia, nausea, increased appetite, fatigue, increased weight.",increased appetite is an adverse reaction entity
"*   Bipolar Disorder Pediatric Patients (Monotherapy): somnolence, dizziness, dysgeusia, oral paresthesia, nausea, increased appetite, fatigue, increased weight.",oral paresthesia is an adverse reaction entity
"*   Bipolar Disorder Pediatric Patients (Monotherapy): somnolence, dizziness, dysgeusia, oral paresthesia, nausea, increased appetite, fatigue, increased weight.",", fatigue is not a named entity"
"*   Bipolar Disorder Pediatric Patients (Monotherapy): somnolence, dizziness, dysgeusia, oral paresthesia, nausea, increased appetite, fatigue, increased weight.",: is not a named entity
"*   Bipolar Disorder Pediatric Patients (Monotherapy): somnolence, dizziness, dysgeusia, oral paresthesia, nausea, increased appetite, fatigue, increased weight.",( Monotherapy is not a named entity
"*   Bipolar Disorder Pediatric Patients (Monotherapy): somnolence, dizziness, dysgeusia, oral paresthesia, nausea, increased appetite, fatigue, increased weight.",fatigue is an adverse reaction entity
"*   Bipolar Disorder Pediatric Patients (Monotherapy): somnolence, dizziness, dysgeusia, oral paresthesia, nausea, increased appetite, fatigue, increased weight.","fatigue , is not a named entity"
"*   Bipolar Disorder Pediatric Patients (Monotherapy): somnolence, dizziness, dysgeusia, oral paresthesia, nausea, increased appetite, fatigue, increased weight.",dizziness is an adverse reaction entity
"*   Bipolar Disorder Pediatric Patients (Monotherapy): somnolence, dizziness, dysgeusia, oral paresthesia, nausea, increased appetite, fatigue, increased weight.","nausea , is not a named entity"
"*   Bipolar Disorder Pediatric Patients (Monotherapy): somnolence, dizziness, dysgeusia, oral paresthesia, nausea, increased appetite, fatigue, increased weight.",": somnolence , is not a named entity"
"Schizophrenia (6-weeks)  Bipolar (3-weeks)     Placebo             SAPHRIS        Placebo       SAPHRIS5 or 10 mgtwice daily         5 mgtwice daily     10 mgtwice daily  5 or 10 mgtwice daily  S       Change from Baseline (kg) (N*)  0.0(348)       1.0(251)      0.9(200)        1.1(532)        0.2(171)      1.3(336)          Proportion of Patients with a >=7% Increase in Body Weight     % with >=7% increase in body weight  1.6%           4.4%          4.8%            4.9%            0.5%          5.8%                                  Adult Patients:  In a 52-week, double-blind, comparator-controlled adult trial that included primarily patients with schizophrenia, the mean weight gain from baseline was 0.9 kg.",daily S is not a named entity
"Schizophrenia (6-weeks)  Bipolar (3-weeks)     Placebo             SAPHRIS        Placebo       SAPHRIS5 or 10 mgtwice daily         5 mgtwice daily     10 mgtwice daily  5 or 10 mgtwice daily  S       Change from Baseline (kg) (N*)  0.0(348)       1.0(251)      0.9(200)        1.1(532)        0.2(171)      1.3(336)          Proportion of Patients with a >=7% Increase in Body Weight     % with >=7% increase in body weight  1.6%           4.4%          4.8%            4.9%            0.5%          5.8%                                  Adult Patients:  In a 52-week, double-blind, comparator-controlled adult trial that included primarily patients with schizophrenia, the mean weight gain from baseline was 0.9 kg.",Increase in Body Weight is an adverse reaction entity
"Schizophrenia (6-weeks)  Bipolar (3-weeks)     Placebo             SAPHRIS        Placebo       SAPHRIS5 or 10 mgtwice daily         5 mgtwice daily     10 mgtwice daily  5 or 10 mgtwice daily  S       Change from Baseline (kg) (N*)  0.0(348)       1.0(251)      0.9(200)        1.1(532)        0.2(171)      1.3(336)          Proportion of Patients with a >=7% Increase in Body Weight     % with >=7% increase in body weight  1.6%           4.4%          4.8%            4.9%            0.5%          5.8%                                  Adult Patients:  In a 52-week, double-blind, comparator-controlled adult trial that included primarily patients with schizophrenia, the mean weight gain from baseline was 0.9 kg.",body is not a named entity
"Schizophrenia (6-weeks)  Bipolar (3-weeks)     Placebo             SAPHRIS        Placebo       SAPHRIS5 or 10 mgtwice daily         5 mgtwice daily     10 mgtwice daily  5 or 10 mgtwice daily  S       Change from Baseline (kg) (N*)  0.0(348)       1.0(251)      0.9(200)        1.1(532)        0.2(171)      1.3(336)          Proportion of Patients with a >=7% Increase in Body Weight     % with >=7% increase in body weight  1.6%           4.4%          4.8%            4.9%            0.5%          5.8%                                  Adult Patients:  In a 52-week, double-blind, comparator-controlled adult trial that included primarily patients with schizophrenia, the mean weight gain from baseline was 0.9 kg.",weight gain is an adverse reaction entity
"Schizophrenia (6-weeks)  Bipolar (3-weeks)     Placebo             SAPHRIS        Placebo       SAPHRIS5 or 10 mgtwice daily         5 mgtwice daily     10 mgtwice daily  5 or 10 mgtwice daily  S       Change from Baseline (kg) (N*)  0.0(348)       1.0(251)      0.9(200)        1.1(532)        0.2(171)      1.3(336)          Proportion of Patients with a >=7% Increase in Body Weight     % with >=7% increase in body weight  1.6%           4.4%          4.8%            4.9%            0.5%          5.8%                                  Adult Patients:  In a 52-week, double-blind, comparator-controlled adult trial that included primarily patients with schizophrenia, the mean weight gain from baseline was 0.9 kg.",( 532 is not a named entity
"Schizophrenia (6-weeks)  Bipolar (3-weeks)     Placebo             SAPHRIS        Placebo       SAPHRIS5 or 10 mgtwice daily         5 mgtwice daily     10 mgtwice daily  5 or 10 mgtwice daily  S       Change from Baseline (kg) (N*)  0.0(348)       1.0(251)      0.9(200)        1.1(532)        0.2(171)      1.3(336)          Proportion of Patients with a >=7% Increase in Body Weight     % with >=7% increase in body weight  1.6%           4.4%          4.8%            4.9%            0.5%          5.8%                                  Adult Patients:  In a 52-week, double-blind, comparator-controlled adult trial that included primarily patients with schizophrenia, the mean weight gain from baseline was 0.9 kg.",increase in body weight is an adverse reaction entity
"Galactorrhea or dysmenorrhea were reported in 0% of patients treated with SAPHRIS 2.5 mg twice daily, 2% of patients treated with SAPHRIS 5 mg twice daily, and 1% of patients treated with SAPHRIS 10 mg twice daily compared to 1% of placebo-treated patients.",with is not a named entity
"Galactorrhea or dysmenorrhea were reported in 0% of patients treated with SAPHRIS 2.5 mg twice daily, 2% of patients treated with SAPHRIS 5 mg twice daily, and 1% of patients treated with SAPHRIS 10 mg twice daily compared to 1% of placebo-treated patients.",dysmenorrhea is an adverse reaction entity
"Galactorrhea or dysmenorrhea were reported in 0% of patients treated with SAPHRIS 2.5 mg twice daily, 2% of patients treated with SAPHRIS 5 mg twice daily, and 1% of patients treated with SAPHRIS 10 mg twice daily compared to 1% of placebo-treated patients.",treated with SAPHRIS is not a named entity
"Galactorrhea or dysmenorrhea were reported in 0% of patients treated with SAPHRIS 2.5 mg twice daily, 2% of patients treated with SAPHRIS 5 mg twice daily, and 1% of patients treated with SAPHRIS 10 mg twice daily compared to 1% of placebo-treated patients.",Galactorrhea is an adverse reaction entity
"Extrapyramidal Symptoms:  In the short-term, placebo-controlled schizophrenia and bipolar mania adult trials, data was objectively collected on the Simpson Angus Rating Scale for extrapyramidal symptoms (EPS), the Barnes Akathisia Scale (for akathisia) and the Assessments of Involuntary Movement Scales (for dyskinesias).",EPS is an adverse reaction entity
"Extrapyramidal Symptoms:  In the short-term, placebo-controlled schizophrenia and bipolar mania adult trials, data was objectively collected on the Simpson Angus Rating Scale for extrapyramidal symptoms (EPS), the Barnes Akathisia Scale (for akathisia) and the Assessments of Involuntary Movement Scales (for dyskinesias).",extrapyramidal symptoms ( is not a named entity
"Extrapyramidal Symptoms:  In the short-term, placebo-controlled schizophrenia and bipolar mania adult trials, data was objectively collected on the Simpson Angus Rating Scale for extrapyramidal symptoms (EPS), the Barnes Akathisia Scale (for akathisia) and the Assessments of Involuntary Movement Scales (for dyskinesias).",was objectively is not a named entity
"Extrapyramidal Symptoms:  In the short-term, placebo-controlled schizophrenia and bipolar mania adult trials, data was objectively collected on the Simpson Angus Rating Scale for extrapyramidal symptoms (EPS), the Barnes Akathisia Scale (for akathisia) and the Assessments of Involuntary Movement Scales (for dyskinesias).",dyskinesias is an adverse reaction entity
"Extrapyramidal Symptoms:  In the short-term, placebo-controlled schizophrenia and bipolar mania adult trials, data was objectively collected on the Simpson Angus Rating Scale for extrapyramidal symptoms (EPS), the Barnes Akathisia Scale (for akathisia) and the Assessments of Involuntary Movement Scales (for dyskinesias).",akathisia is an adverse reaction entity
"Extrapyramidal Symptoms:  In the short-term, placebo-controlled schizophrenia and bipolar mania adult trials, data was objectively collected on the Simpson Angus Rating Scale for extrapyramidal symptoms (EPS), the Barnes Akathisia Scale (for akathisia) and the Assessments of Involuntary Movement Scales (for dyskinesias).",extrapyramidal symptoms is an adverse reaction entity
"Extrapyramidal Symptoms:  In the short-term, placebo-controlled schizophrenia and bipolar mania adult trials, data was objectively collected on the Simpson Angus Rating Scale for extrapyramidal symptoms (EPS), the Barnes Akathisia Scale (for akathisia) and the Assessments of Involuntary Movement Scales (for dyskinesias).",: is not a named entity
"Extrapyramidal Symptoms:  In the short-term, placebo-controlled schizophrenia and bipolar mania adult trials, data was objectively collected on the Simpson Angus Rating Scale for extrapyramidal symptoms (EPS), the Barnes Akathisia Scale (for akathisia) and the Assessments of Involuntary Movement Scales (for dyskinesias).",schizophrenia and is not a named entity
Laboratory Test Abnormalities:           Transaminases:  Transient elevations in serum transaminases (primarily ALT) in the short-term schizophrenia and bipolar mania adult trials were more common in treated patients.,Abnormalities : is not a named entity
Laboratory Test Abnormalities:           Transaminases:  Transient elevations in serum transaminases (primarily ALT) in the short-term schizophrenia and bipolar mania adult trials were more common in treated patients.,were more is not a named entity
Laboratory Test Abnormalities:           Transaminases:  Transient elevations in serum transaminases (primarily ALT) in the short-term schizophrenia and bipolar mania adult trials were more common in treated patients.,elevations in ALT is an adverse reaction entity
Laboratory Test Abnormalities:           Transaminases:  Transient elevations in serum transaminases (primarily ALT) in the short-term schizophrenia and bipolar mania adult trials were more common in treated patients.,elevations in serum transaminases is an adverse reaction entity
"There were no reports of seizures in pediatric patients treated with SAPHRIS in a 3-week-term, bipolar mania trial.",pediatric patients is not a named entity
"There were no reports of seizures in pediatric patients treated with SAPHRIS in a 3-week-term, bipolar mania trial.",seizures is an adverse reaction entity
"Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.",may include elevated is not a named entity
"Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.",and acute is not a named entity
"Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.",", myoglobinuria ( is not a named entity"
"Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.",and is not a named entity
"Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.",myoglobinuria is an adverse reaction entity
"Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.",elevated creatine phosphokinase is an adverse reaction entity
"Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.",rhabdomyolysis is an adverse reaction entity
"Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.",acute renal failure is an adverse reaction entity
The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear.,to some is not a named entity
The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear.,increased mortality is an adverse reaction entity
"Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia).",", and is not a named entity"
"Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia).",", is not a named entity"
"Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia).",irregular pulse is an adverse reaction entity
"Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia).",of autonomic is not a named entity
"Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia).","tachycardia , diaphoresis is not a named entity"
"Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia).",or blood is not a named entity
"Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia).","status , and is not a named entity"
"Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia).","tachycardia , is not a named entity"
"Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia).",instability is not a named entity
"Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia).",irregular blood pressure is an adverse reaction entity
"Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia).",manifestations of NMS is not a named entity
"Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia).",tachycardia is an adverse reaction entity
"Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia).",cardiac dysrhythmia is an adverse reaction entity
"Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia).",diaphoresis is an adverse reaction entity
"Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia).",hyperpyrexia is an adverse reaction entity
"Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia).",autonomic instability is an adverse reaction entity
"Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia).","status , and is not a named entity"
"Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia).",altered mental status is an adverse reaction entity
"Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia).",NMS is an adverse reaction entity
"Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia).",muscle rigidity is an adverse reaction entity
"Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in the drug-treated patients of between 1.6 to 1.7 times that seen in placebo-treated patients.",modal duration of is not a named entity
"Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in the drug-treated patients of between 1.6 to 1.7 times that seen in placebo-treated patients.",death is an adverse reaction entity
"10                    22                                     Psychiatric disorders                                Insomnia                                      8                     10                                     Vascular disorders                                   Hypertension                                  <1                    3                                                Dystonia:  Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment.",22 Psychiatric disorders is not a named entity
"10                    22                                     Psychiatric disorders                                Insomnia                                      8                     10                                     Vascular disorders                                   Hypertension                                  <1                    3                                                Dystonia:  Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment.",dystonia is an adverse reaction entity
"10                    22                                     Psychiatric disorders                                Insomnia                                      8                     10                                     Vascular disorders                                   Hypertension                                  <1                    3                                                Dystonia:  Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment.",may occur is not a named entity
"10                    22                                     Psychiatric disorders                                Insomnia                                      8                     10                                     Vascular disorders                                   Hypertension                                  <1                    3                                                Dystonia:  Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment.",Dystonia is not a named entity
"10                    22                                     Psychiatric disorders                                Insomnia                                      8                     10                                     Vascular disorders                                   Hypertension                                  <1                    3                                                Dystonia:  Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment.",Hypertension is an adverse reaction entity
"10                    22                                     Psychiatric disorders                                Insomnia                                      8                     10                                     Vascular disorders                                   Hypertension                                  <1                    3                                                Dystonia:  Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment.",prolonged abnormal contractions of muscle groups is an adverse reaction entity
"10                    22                                     Psychiatric disorders                                Insomnia                                      8                     10                                     Vascular disorders                                   Hypertension                                  <1                    3                                                Dystonia:  Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment.",", prolonged is not a named entity"
"10                    22                                     Psychiatric disorders                                Insomnia                                      8                     10                                     Vascular disorders                                   Hypertension                                  <1                    3                                                Dystonia:  Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment.",Insomnia is an adverse reaction entity
"*  Choking has been reported by patients, some of whom may have also experienced oropharyngeal muscular dysfunction or hypoesthesia.",muscular is not a named entity
"*  Choking has been reported by patients, some of whom may have also experienced oropharyngeal muscular dysfunction or hypoesthesia.",been reported by is not a named entity
"*  Choking has been reported by patients, some of whom may have also experienced oropharyngeal muscular dysfunction or hypoesthesia.",Choking is an adverse reaction entity
"*  Choking has been reported by patients, some of whom may have also experienced oropharyngeal muscular dysfunction or hypoesthesia.",dysfunction or is not a named entity
"*  Choking has been reported by patients, some of whom may have also experienced oropharyngeal muscular dysfunction or hypoesthesia.",hypoesthesia is an adverse reaction entity
"*  Choking has been reported by patients, some of whom may have also experienced oropharyngeal muscular dysfunction or hypoesthesia.",oropharyngeal muscular dysfunction is an adverse reaction entity
(5.8)   *   QT Prolongation: Increases in QT interval; avoid use with drugs that also increase the QT interval and in patients with risk factors for prolonged QT interval.,risk factors for is not a named entity
(5.8)   *   QT Prolongation: Increases in QT interval; avoid use with drugs that also increase the QT interval and in patients with risk factors for prolonged QT interval.,; avoid use is not a named entity
(5.8)   *   QT Prolongation: Increases in QT interval; avoid use with drugs that also increase the QT interval and in patients with risk factors for prolonged QT interval.,QT Prolongation is an adverse reaction entity
(5.8)   *   QT Prolongation: Increases in QT interval; avoid use with drugs that also increase the QT interval and in patients with risk factors for prolonged QT interval.,Increases in QT interval is an adverse reaction entity
(5.9)   *   Seizures: Use cautiously in patients with a history of seizures or with conditions that lower the seizure threshold.,threshold is not a named entity
(5.9)   *   Seizures: Use cautiously in patients with a history of seizures or with conditions that lower the seizure threshold.,Seizures is an adverse reaction entity
"However, epidemiological studies suggest an increased risk of treatment-emergent hyperglycemia-related adverse events in patients treated with the atypical antipsychotics included in these studies.",adverse events is not a named entity
"However, epidemiological studies suggest an increased risk of treatment-emergent hyperglycemia-related adverse events in patients treated with the atypical antipsychotics included in these studies.",hyperglycemia is an adverse reaction entity
"The proportion of patients with CK elevations >=3 times ULN during a 3-week trial in pediatric bipolar I disorder at any time were 1%, 0%, and 1% for patients treated with SAPHRIS 2.5 mg, 5 mg, and 10 mg twice daily, respectively, versus 3% for placebo-treated patients.",times ULN during is not a named entity
"The proportion of patients with CK elevations >=3 times ULN during a 3-week trial in pediatric bipolar I disorder at any time were 1%, 0%, and 1% for patients treated with SAPHRIS 2.5 mg, 5 mg, and 10 mg twice daily, respectively, versus 3% for placebo-treated patients.",CK elevations is an adverse reaction entity
"5.2 Cerebrovascular Adverse Events, Including Stroke, In Elderly Patients with Dementia-Related Psychosis        In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly subjects with dementia, there was a higher incidence of cerebrovascular adverse reactions (cerebrovascular accidents and transient ischemic attacks) including fatalities compared to placebo-treated subjects.",transient ischemic attacks is an adverse reaction entity
"5.2 Cerebrovascular Adverse Events, Including Stroke, In Elderly Patients with Dementia-Related Psychosis        In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly subjects with dementia, there was a higher incidence of cerebrovascular adverse reactions (cerebrovascular accidents and transient ischemic attacks) including fatalities compared to placebo-treated subjects.",", is not a named entity"
"5.2 Cerebrovascular Adverse Events, Including Stroke, In Elderly Patients with Dementia-Related Psychosis        In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly subjects with dementia, there was a higher incidence of cerebrovascular adverse reactions (cerebrovascular accidents and transient ischemic attacks) including fatalities compared to placebo-treated subjects.",in is not a named entity
"5.2 Cerebrovascular Adverse Events, Including Stroke, In Elderly Patients with Dementia-Related Psychosis        In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly subjects with dementia, there was a higher incidence of cerebrovascular adverse reactions (cerebrovascular accidents and transient ischemic attacks) including fatalities compared to placebo-treated subjects.",subjects with is not a named entity
"5.2 Cerebrovascular Adverse Events, Including Stroke, In Elderly Patients with Dementia-Related Psychosis        In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly subjects with dementia, there was a higher incidence of cerebrovascular adverse reactions (cerebrovascular accidents and transient ischemic attacks) including fatalities compared to placebo-treated subjects.",cerebrovascular adverse reactions is an adverse reaction entity
"5.2 Cerebrovascular Adverse Events, Including Stroke, In Elderly Patients with Dementia-Related Psychosis        In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly subjects with dementia, there was a higher incidence of cerebrovascular adverse reactions (cerebrovascular accidents and transient ischemic attacks) including fatalities compared to placebo-treated subjects.",with is not a named entity
"5.2 Cerebrovascular Adverse Events, Including Stroke, In Elderly Patients with Dementia-Related Psychosis        In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly subjects with dementia, there was a higher incidence of cerebrovascular adverse reactions (cerebrovascular accidents and transient ischemic attacks) including fatalities compared to placebo-treated subjects.",fatalities is an adverse reaction entity
"5.2 Cerebrovascular Adverse Events, Including Stroke, In Elderly Patients with Dementia-Related Psychosis        In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly subjects with dementia, there was a higher incidence of cerebrovascular adverse reactions (cerebrovascular accidents and transient ischemic attacks) including fatalities compared to placebo-treated subjects.",cerebrovascular accidents is an adverse reaction entity
"In short-term bipolar mania adult trials, syncope was reported in 0.3% (1/379) of patients treated with therapeutic doses (5 mg or 10 mg twice daily) of SAPHRIS, compared to 0% (0/203) of patients treated with placebo.",doses ( 5 is not a named entity
"In short-term bipolar mania adult trials, syncope was reported in 0.3% (1/379) of patients treated with therapeutic doses (5 mg or 10 mg twice daily) of SAPHRIS, compared to 0% (0/203) of patients treated with placebo.",syncope is an adverse reaction entity
Bipolar I Disorder (3-weeks)     Placebo           SAPHRIS2.5 mgtwice daily  SAPHRIS5 mgtwice daily  SAPHRIS10 mgtwice daily     Change from Baseline (kg) (N*)  0.5(89)              1.7(92)                1.6(90)               1.4(87)                                     Proportion of Subjects with a >=7% Increase in Body Weight     % with >=7% increase in body weight  1.1%                 12.0%                  8.9%                  8.0%                                      5.6 Hypersensitivity Reactions        Hypersensitivity reactions have been observed in patients treated with SAPHRIS.,a > =7 is not a named entity
Bipolar I Disorder (3-weeks)     Placebo           SAPHRIS2.5 mgtwice daily  SAPHRIS5 mgtwice daily  SAPHRIS10 mgtwice daily     Change from Baseline (kg) (N*)  0.5(89)              1.7(92)                1.6(90)               1.4(87)                                     Proportion of Subjects with a >=7% Increase in Body Weight     % with >=7% increase in body weight  1.1%                 12.0%                  8.9%                  8.0%                                      5.6 Hypersensitivity Reactions        Hypersensitivity reactions have been observed in patients treated with SAPHRIS.,increase in body weight is an adverse reaction entity
Bipolar I Disorder (3-weeks)     Placebo           SAPHRIS2.5 mgtwice daily  SAPHRIS5 mgtwice daily  SAPHRIS10 mgtwice daily     Change from Baseline (kg) (N*)  0.5(89)              1.7(92)                1.6(90)               1.4(87)                                     Proportion of Subjects with a >=7% Increase in Body Weight     % with >=7% increase in body weight  1.1%                 12.0%                  8.9%                  8.0%                                      5.6 Hypersensitivity Reactions        Hypersensitivity reactions have been observed in patients treated with SAPHRIS.,Increase in Body Weight is an adverse reaction entity
Bipolar I Disorder (3-weeks)     Placebo           SAPHRIS2.5 mgtwice daily  SAPHRIS5 mgtwice daily  SAPHRIS10 mgtwice daily     Change from Baseline (kg) (N*)  0.5(89)              1.7(92)                1.6(90)               1.4(87)                                     Proportion of Subjects with a >=7% Increase in Body Weight     % with >=7% increase in body weight  1.1%                 12.0%                  8.9%                  8.0%                                      5.6 Hypersensitivity Reactions        Hypersensitivity reactions have been observed in patients treated with SAPHRIS.,kg is not a named entity
Bipolar I Disorder (3-weeks)     Placebo           SAPHRIS2.5 mgtwice daily  SAPHRIS5 mgtwice daily  SAPHRIS10 mgtwice daily     Change from Baseline (kg) (N*)  0.5(89)              1.7(92)                1.6(90)               1.4(87)                                     Proportion of Subjects with a >=7% Increase in Body Weight     % with >=7% increase in body weight  1.1%                 12.0%                  8.9%                  8.0%                                      5.6 Hypersensitivity Reactions        Hypersensitivity reactions have been observed in patients treated with SAPHRIS.,=7 % is not a named entity
Bipolar I Disorder (3-weeks)     Placebo           SAPHRIS2.5 mgtwice daily  SAPHRIS5 mgtwice daily  SAPHRIS10 mgtwice daily     Change from Baseline (kg) (N*)  0.5(89)              1.7(92)                1.6(90)               1.4(87)                                     Proportion of Subjects with a >=7% Increase in Body Weight     % with >=7% increase in body weight  1.1%                 12.0%                  8.9%                  8.0%                                      5.6 Hypersensitivity Reactions        Hypersensitivity reactions have been observed in patients treated with SAPHRIS.,Hypersensitivity reactions is an adverse reaction entity
"Given these confounders, the relationship between atypical antipsychotic use and hyperglycemia-related adverse reactions is not completely understood.",hyperglycemia is an adverse reaction entity
"Given these confounders, the relationship between atypical antipsychotic use and hyperglycemia-related adverse reactions is not completely understood.",Given is not a named entity
"Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.",infectious ( e.g. is not a named entity
"Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.",sudden death is an adverse reaction entity
"Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.",death is an adverse reaction entity
"Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.",pneumonia is an adverse reaction entity
"Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.",nature is not a named entity
"Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.","( e.g. , is not a named entity"
"Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.","varied , is not a named entity"
"Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.",heart failure is an adverse reaction entity
"Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.",deaths is an adverse reaction entity
"Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.",infectious is not a named entity
Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male subjects.,hyperprolactinemia is an adverse reaction entity
Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male subjects.,hypogonadism is an adverse reaction entity
Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male subjects.,to decreased bone is not a named entity
Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male subjects.,decreased bone density is an adverse reaction entity
Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male subjects.,hyperprolactinemia when associated is not a named entity
Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male subjects.,female and is not a named entity
"Neither clinical studies nor epidemiologic studies conducted to date have shown an association between chronic administration of this class of drugs and tumorigenesis in humans, but the available evidence is too limited to be conclusive.",tumorigenesis in is not a named entity
"Neither clinical studies nor epidemiologic studies conducted to date have shown an association between chronic administration of this class of drugs and tumorigenesis in humans, but the available evidence is too limited to be conclusive.",tumorigenesis is an adverse reaction entity
"While all of the drugs in the class have been shown to produce some metabolic changes, each drug has its own specific risk profile.",metabolic changes is an adverse reaction entity
"While all of the drugs in the class have been shown to produce some metabolic changes, each drug has its own specific risk profile.",specific is not a named entity
"In short-term schizophrenia adult trials, syncope was reported in 0.2% (1/572) of patients treated with therapeutic doses (5 mg or 10 mg twice daily) of SAPHRIS, compared to 0.3% (1/378) of patients treated with placebo.",syncope is an adverse reaction entity
"In short-term schizophrenia adult trials, syncope was reported in 0.2% (1/572) of patients treated with therapeutic doses (5 mg or 10 mg twice daily) of SAPHRIS, compared to 0.3% (1/378) of patients treated with placebo.",reported in is not a named entity
Table 8: Adverse Reactions Reported in 2% or More of Adult Patients in Any SAPHRIS Dose Group and Which Occurred at Greater Incidence Than in the Placebo Group in 6-Week Schizophrenia Trials    * Akathisia includes: akathisia and hyperkinesia.,the Placebo is not a named entity
Table 8: Adverse Reactions Reported in 2% or More of Adult Patients in Any SAPHRIS Dose Group and Which Occurred at Greater Incidence Than in the Placebo Group in 6-Week Schizophrenia Trials    * Akathisia includes: akathisia and hyperkinesia.,akathisia is an adverse reaction entity
Table 8: Adverse Reactions Reported in 2% or More of Adult Patients in Any SAPHRIS Dose Group and Which Occurred at Greater Incidence Than in the Placebo Group in 6-Week Schizophrenia Trials    * Akathisia includes: akathisia and hyperkinesia.,in 2 is not a named entity
Table 8: Adverse Reactions Reported in 2% or More of Adult Patients in Any SAPHRIS Dose Group and Which Occurred at Greater Incidence Than in the Placebo Group in 6-Week Schizophrenia Trials    * Akathisia includes: akathisia and hyperkinesia.,in the is not a named entity
Table 8: Adverse Reactions Reported in 2% or More of Adult Patients in Any SAPHRIS Dose Group and Which Occurred at Greater Incidence Than in the Placebo Group in 6-Week Schizophrenia Trials    * Akathisia includes: akathisia and hyperkinesia.,hyperkinesia is an adverse reaction entity
Table 8: Adverse Reactions Reported in 2% or More of Adult Patients in Any SAPHRIS Dose Group and Which Occurred at Greater Incidence Than in the Placebo Group in 6-Week Schizophrenia Trials    * Akathisia includes: akathisia and hyperkinesia.,Akathisia is an adverse reaction entity
"EPS-related events include: bradykinesia, dyskinesia, dystonia, oromandibular dystonia, muscle contractions involuntary, muscle twitching, musculoskeletal stiffness, parkinsonism, protrusion tongue, resting tremor, and tremor.",", dyskinesia , is not a named entity"
"EPS-related events include: bradykinesia, dyskinesia, dystonia, oromandibular dystonia, muscle contractions involuntary, muscle twitching, musculoskeletal stiffness, parkinsonism, protrusion tongue, resting tremor, and tremor.",", musculoskeletal is not a named entity"
"EPS-related events include: bradykinesia, dyskinesia, dystonia, oromandibular dystonia, muscle contractions involuntary, muscle twitching, musculoskeletal stiffness, parkinsonism, protrusion tongue, resting tremor, and tremor.",musculoskeletal stiffness is an adverse reaction entity
"EPS-related events include: bradykinesia, dyskinesia, dystonia, oromandibular dystonia, muscle contractions involuntary, muscle twitching, musculoskeletal stiffness, parkinsonism, protrusion tongue, resting tremor, and tremor.",muscle contractions involuntary is an adverse reaction entity
"EPS-related events include: bradykinesia, dyskinesia, dystonia, oromandibular dystonia, muscle contractions involuntary, muscle twitching, musculoskeletal stiffness, parkinsonism, protrusion tongue, resting tremor, and tremor.",tremor is an adverse reaction entity
"EPS-related events include: bradykinesia, dyskinesia, dystonia, oromandibular dystonia, muscle contractions involuntary, muscle twitching, musculoskeletal stiffness, parkinsonism, protrusion tongue, resting tremor, and tremor.",tongue is not a named entity
"EPS-related events include: bradykinesia, dyskinesia, dystonia, oromandibular dystonia, muscle contractions involuntary, muscle twitching, musculoskeletal stiffness, parkinsonism, protrusion tongue, resting tremor, and tremor.",parkinsonism is an adverse reaction entity
"EPS-related events include: bradykinesia, dyskinesia, dystonia, oromandibular dystonia, muscle contractions involuntary, muscle twitching, musculoskeletal stiffness, parkinsonism, protrusion tongue, resting tremor, and tremor.",dyskinesia is an adverse reaction entity
"EPS-related events include: bradykinesia, dyskinesia, dystonia, oromandibular dystonia, muscle contractions involuntary, muscle twitching, musculoskeletal stiffness, parkinsonism, protrusion tongue, resting tremor, and tremor.",", resting is not a named entity"
"EPS-related events include: bradykinesia, dyskinesia, dystonia, oromandibular dystonia, muscle contractions involuntary, muscle twitching, musculoskeletal stiffness, parkinsonism, protrusion tongue, resting tremor, and tremor.","dyskinesia , dystonia is not a named entity"
"EPS-related events include: bradykinesia, dyskinesia, dystonia, oromandibular dystonia, muscle contractions involuntary, muscle twitching, musculoskeletal stiffness, parkinsonism, protrusion tongue, resting tremor, and tremor.",bradykinesia is an adverse reaction entity
"EPS-related events include: bradykinesia, dyskinesia, dystonia, oromandibular dystonia, muscle contractions involuntary, muscle twitching, musculoskeletal stiffness, parkinsonism, protrusion tongue, resting tremor, and tremor.",", dystonia is not a named entity"
"EPS-related events include: bradykinesia, dyskinesia, dystonia, oromandibular dystonia, muscle contractions involuntary, muscle twitching, musculoskeletal stiffness, parkinsonism, protrusion tongue, resting tremor, and tremor.",dystonia is an adverse reaction entity
"EPS-related events include: bradykinesia, dyskinesia, dystonia, oromandibular dystonia, muscle contractions involuntary, muscle twitching, musculoskeletal stiffness, parkinsonism, protrusion tongue, resting tremor, and tremor.",protrusion tongue is an adverse reaction entity
"EPS-related events include: bradykinesia, dyskinesia, dystonia, oromandibular dystonia, muscle contractions involuntary, muscle twitching, musculoskeletal stiffness, parkinsonism, protrusion tongue, resting tremor, and tremor.",", and tremor is not a named entity"
"EPS-related events include: bradykinesia, dyskinesia, dystonia, oromandibular dystonia, muscle contractions involuntary, muscle twitching, musculoskeletal stiffness, parkinsonism, protrusion tongue, resting tremor, and tremor.",contractions is not a named entity
"EPS-related events include: bradykinesia, dyskinesia, dystonia, oromandibular dystonia, muscle contractions involuntary, muscle twitching, musculoskeletal stiffness, parkinsonism, protrusion tongue, resting tremor, and tremor.",oromandibular dystonia is an adverse reaction entity
"EPS-related events include: bradykinesia, dyskinesia, dystonia, oromandibular dystonia, muscle contractions involuntary, muscle twitching, musculoskeletal stiffness, parkinsonism, protrusion tongue, resting tremor, and tremor.",", muscle is not a named entity"
"EPS-related events include: bradykinesia, dyskinesia, dystonia, oromandibular dystonia, muscle contractions involuntary, muscle twitching, musculoskeletal stiffness, parkinsonism, protrusion tongue, resting tremor, and tremor.",muscle twitching is an adverse reaction entity
"EPS-related events include: bradykinesia, dyskinesia, dystonia, oromandibular dystonia, muscle contractions involuntary, muscle twitching, musculoskeletal stiffness, parkinsonism, protrusion tongue, resting tremor, and tremor.",", protrusion is not a named entity"
"EPS-related events include: bradykinesia, dyskinesia, dystonia, oromandibular dystonia, muscle contractions involuntary, muscle twitching, musculoskeletal stiffness, parkinsonism, protrusion tongue, resting tremor, and tremor.",events is not a named entity
"EPS-related events include: bradykinesia, dyskinesia, dystonia, oromandibular dystonia, muscle contractions involuntary, muscle twitching, musculoskeletal stiffness, parkinsonism, protrusion tongue, resting tremor, and tremor.",resting tremor is an adverse reaction entity
"EPS-related events include: bradykinesia, dyskinesia, dystonia, oromandibular dystonia, muscle contractions involuntary, muscle twitching, musculoskeletal stiffness, parkinsonism, protrusion tongue, resting tremor, and tremor.",: bradykinesia is not a named entity
"EPS-related events include: bradykinesia, dyskinesia, dystonia, oromandibular dystonia, muscle contractions involuntary, muscle twitching, musculoskeletal stiffness, parkinsonism, protrusion tongue, resting tremor, and tremor.",EPS-related events is an adverse reaction entity
"For events of akathisia, incidences were 2%, 2%, and 1% for patients treated with SAPHRIS 2.5 mg, 5 mg, and 10 mg twice daily, respectively, as compared to 0% for placebo-treated patients.",akathisia is an adverse reaction entity
"For events of akathisia, incidences were 2%, 2%, and 1% for patients treated with SAPHRIS 2.5 mg, 5 mg, and 10 mg twice daily, respectively, as compared to 0% for placebo-treated patients.",0 % is not a named entity
"Table 6: Weight Change Results Categorized by BMI at Baseline: Comparator-Controlled 52-Week Study in Adults with Schizophrenia                                BMI <23    SAPHRIS    N=295      BMI 23 - <=27    SAPHRIS    N=290      BMI >27    SAPHRIS    N=302       Mean change from Baseline (kg)  1.7                        1                          0                             % with >=7% increase in body weight  22%                        13%                        9%                                             Pediatric Patients:  Data on mean changes in body weight and the proportion of pediatric patients meeting a weight gain criterion of >=7% of body weight from the short-term, placebo-controlled bipolar mania trial are presented in  Table 7  .",Patients is not a named entity
"Table 6: Weight Change Results Categorized by BMI at Baseline: Comparator-Controlled 52-Week Study in Adults with Schizophrenia                                BMI <23    SAPHRIS    N=295      BMI 23 - <=27    SAPHRIS    N=290      BMI >27    SAPHRIS    N=302       Mean change from Baseline (kg)  1.7                        1                          0                             % with >=7% increase in body weight  22%                        13%                        9%                                             Pediatric Patients:  Data on mean changes in body weight and the proportion of pediatric patients meeting a weight gain criterion of >=7% of body weight from the short-term, placebo-controlled bipolar mania trial are presented in  Table 7  .",changes in body weight is an adverse reaction entity
"Table 6: Weight Change Results Categorized by BMI at Baseline: Comparator-Controlled 52-Week Study in Adults with Schizophrenia                                BMI <23    SAPHRIS    N=295      BMI 23 - <=27    SAPHRIS    N=290      BMI >27    SAPHRIS    N=302       Mean change from Baseline (kg)  1.7                        1                          0                             % with >=7% increase in body weight  22%                        13%                        9%                                             Pediatric Patients:  Data on mean changes in body weight and the proportion of pediatric patients meeting a weight gain criterion of >=7% of body weight from the short-term, placebo-controlled bipolar mania trial are presented in  Table 7  .",increase in body weight is an adverse reaction entity
"Table 6: Weight Change Results Categorized by BMI at Baseline: Comparator-Controlled 52-Week Study in Adults with Schizophrenia                                BMI <23    SAPHRIS    N=295      BMI 23 - <=27    SAPHRIS    N=290      BMI >27    SAPHRIS    N=302       Mean change from Baseline (kg)  1.7                        1                          0                             % with >=7% increase in body weight  22%                        13%                        9%                                             Pediatric Patients:  Data on mean changes in body weight and the proportion of pediatric patients meeting a weight gain criterion of >=7% of body weight from the short-term, placebo-controlled bipolar mania trial are presented in  Table 7  .",< 23 is not a named entity
"Table 6: Weight Change Results Categorized by BMI at Baseline: Comparator-Controlled 52-Week Study in Adults with Schizophrenia                                BMI <23    SAPHRIS    N=295      BMI 23 - <=27    SAPHRIS    N=290      BMI >27    SAPHRIS    N=302       Mean change from Baseline (kg)  1.7                        1                          0                             % with >=7% increase in body weight  22%                        13%                        9%                                             Pediatric Patients:  Data on mean changes in body weight and the proportion of pediatric patients meeting a weight gain criterion of >=7% of body weight from the short-term, placebo-controlled bipolar mania trial are presented in  Table 7  .",kg ) 1.7 is not a named entity
"Table 6: Weight Change Results Categorized by BMI at Baseline: Comparator-Controlled 52-Week Study in Adults with Schizophrenia                                BMI <23    SAPHRIS    N=295      BMI 23 - <=27    SAPHRIS    N=290      BMI >27    SAPHRIS    N=302       Mean change from Baseline (kg)  1.7                        1                          0                             % with >=7% increase in body weight  22%                        13%                        9%                                             Pediatric Patients:  Data on mean changes in body weight and the proportion of pediatric patients meeting a weight gain criterion of >=7% of body weight from the short-term, placebo-controlled bipolar mania trial are presented in  Table 7  .",weight gain is an adverse reaction entity
"5.3 Neuroleptic Malignant Syndrome        A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with administration of antipsychotic drugs, including SAPHRIS.",association with is not a named entity
"5.3 Neuroleptic Malignant Syndrome        A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with administration of antipsychotic drugs, including SAPHRIS.",NMS is an adverse reaction entity
"5.3 Neuroleptic Malignant Syndrome        A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with administration of antipsychotic drugs, including SAPHRIS.",) has is not a named entity
"5.3 Neuroleptic Malignant Syndrome        A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with administration of antipsychotic drugs, including SAPHRIS.",Malignant Syndrome A is not a named entity
"5.3 Neuroleptic Malignant Syndrome        A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with administration of antipsychotic drugs, including SAPHRIS.",Neuroleptic Malignant Syndrome is an adverse reaction entity
"5.3 Neuroleptic Malignant Syndrome        A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with administration of antipsychotic drugs, including SAPHRIS.",fatal is an adverse reaction entity
The risk of developing TD and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase.,of treatment and is not a named entity
The risk of developing TD and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase.,TD is an adverse reaction entity
The risk of developing TD and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase.,TD is an adverse reaction entity
The risk of developing TD and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase.,it is not a named entity
The most common adverse reactions associated with discontinuation in patients treated with SAPHRIS (rates at least 1% and at least twice the placebo rate) were anxiety (1.1%) and oral hypoesthesia (1.1%) compared to placebo (0%).,The most common is not a named entity
The most common adverse reactions associated with discontinuation in patients treated with SAPHRIS (rates at least 1% and at least twice the placebo rate) were anxiety (1.1%) and oral hypoesthesia (1.1%) compared to placebo (0%).,at least twice is not a named entity
The most common adverse reactions associated with discontinuation in patients treated with SAPHRIS (rates at least 1% and at least twice the placebo rate) were anxiety (1.1%) and oral hypoesthesia (1.1%) compared to placebo (0%).,anxiety is an adverse reaction entity
The most common adverse reactions associated with discontinuation in patients treated with SAPHRIS (rates at least 1% and at least twice the placebo rate) were anxiety (1.1%) and oral hypoesthesia (1.1%) compared to placebo (0%).,oral hypoesthesia is an adverse reaction entity
"These hypersensitivity reactions included: anaphylaxis, angioedema, hypotension, tachycardia, swollen tongue, dyspnea, wheezing and rash.",", is not a named entity"
"These hypersensitivity reactions included: anaphylaxis, angioedema, hypotension, tachycardia, swollen tongue, dyspnea, wheezing and rash.",swollen tongue is an adverse reaction entity
"These hypersensitivity reactions included: anaphylaxis, angioedema, hypotension, tachycardia, swollen tongue, dyspnea, wheezing and rash.",hypotension is an adverse reaction entity
"These hypersensitivity reactions included: anaphylaxis, angioedema, hypotension, tachycardia, swollen tongue, dyspnea, wheezing and rash.",reactions included : is not a named entity
"These hypersensitivity reactions included: anaphylaxis, angioedema, hypotension, tachycardia, swollen tongue, dyspnea, wheezing and rash.",anaphylaxis is an adverse reaction entity
"These hypersensitivity reactions included: anaphylaxis, angioedema, hypotension, tachycardia, swollen tongue, dyspnea, wheezing and rash.",rash is an adverse reaction entity
"These hypersensitivity reactions included: anaphylaxis, angioedema, hypotension, tachycardia, swollen tongue, dyspnea, wheezing and rash.",hypersensitivity reactions included is not a named entity
"These hypersensitivity reactions included: anaphylaxis, angioedema, hypotension, tachycardia, swollen tongue, dyspnea, wheezing and rash.",and is not a named entity
"These hypersensitivity reactions included: anaphylaxis, angioedema, hypotension, tachycardia, swollen tongue, dyspnea, wheezing and rash.",wheezing is an adverse reaction entity
"These hypersensitivity reactions included: anaphylaxis, angioedema, hypotension, tachycardia, swollen tongue, dyspnea, wheezing and rash.",wheezing and is not a named entity
"These hypersensitivity reactions included: anaphylaxis, angioedema, hypotension, tachycardia, swollen tongue, dyspnea, wheezing and rash.",", is not a named entity"
"These hypersensitivity reactions included: anaphylaxis, angioedema, hypotension, tachycardia, swollen tongue, dyspnea, wheezing and rash.",", dyspnea is not a named entity"
"These hypersensitivity reactions included: anaphylaxis, angioedema, hypotension, tachycardia, swollen tongue, dyspnea, wheezing and rash.",tachycardia is an adverse reaction entity
"These hypersensitivity reactions included: anaphylaxis, angioedema, hypotension, tachycardia, swollen tongue, dyspnea, wheezing and rash.","anaphylaxis , is not a named entity"
"These hypersensitivity reactions included: anaphylaxis, angioedema, hypotension, tachycardia, swollen tongue, dyspnea, wheezing and rash.",dyspnea is an adverse reaction entity
"These hypersensitivity reactions included: anaphylaxis, angioedema, hypotension, tachycardia, swollen tongue, dyspnea, wheezing and rash.",hypersensitivity reactions is an adverse reaction entity
"These hypersensitivity reactions included: anaphylaxis, angioedema, hypotension, tachycardia, swollen tongue, dyspnea, wheezing and rash.",", wheezing and is not a named entity"
"These hypersensitivity reactions included: anaphylaxis, angioedema, hypotension, tachycardia, swollen tongue, dyspnea, wheezing and rash.",angioedema is an adverse reaction entity
Most Common Adverse Reactions Occurring More Frequently in the NORTHERA Group                        Study 301 and Study 302    (1 to 2 Weeks Randomized Treatment)        Study 306    (8 to 10 Weeks Randomized Treatment)           Placebo    (N=132)      n (%)        NORTHERA    (N=131)      n (%)        Placebo    (N=108)      n (%)        NORTHERA    (N=114)           n (%)              Headache         4 (3.0)          8 (6.1)          8 (7.4)          15 (13.2)           Dizziness        2 (1.5)          5 (3.8)          5 (4.6)          11 (9.6)            Nausea           2 (1.5)          2 (1.5)          5 (4.6)          10 (8.8)            Hypertension     0                2 (1.5)          1 (0.9)          8 (7.0)                    Note: n=number of patients.,Note : n=number is not a named entity
Most Common Adverse Reactions Occurring More Frequently in the NORTHERA Group                        Study 301 and Study 302    (1 to 2 Weeks Randomized Treatment)        Study 306    (8 to 10 Weeks Randomized Treatment)           Placebo    (N=132)      n (%)        NORTHERA    (N=131)      n (%)        Placebo    (N=108)      n (%)        NORTHERA    (N=114)           n (%)              Headache         4 (3.0)          8 (6.1)          8 (7.4)          15 (13.2)           Dizziness        2 (1.5)          5 (3.8)          5 (4.6)          11 (9.6)            Nausea           2 (1.5)          2 (1.5)          5 (4.6)          10 (8.8)            Hypertension     0                2 (1.5)          1 (0.9)          8 (7.0)                    Note: n=number of patients.,Nausea is an adverse reaction entity
Most Common Adverse Reactions Occurring More Frequently in the NORTHERA Group                        Study 301 and Study 302    (1 to 2 Weeks Randomized Treatment)        Study 306    (8 to 10 Weeks Randomized Treatment)           Placebo    (N=132)      n (%)        NORTHERA    (N=131)      n (%)        Placebo    (N=108)      n (%)        NORTHERA    (N=114)           n (%)              Headache         4 (3.0)          8 (6.1)          8 (7.4)          15 (13.2)           Dizziness        2 (1.5)          5 (3.8)          5 (4.6)          11 (9.6)            Nausea           2 (1.5)          2 (1.5)          5 (4.6)          10 (8.8)            Hypertension     0                2 (1.5)          1 (0.9)          8 (7.0)                    Note: n=number of patients.,Dizziness is an adverse reaction entity
Most Common Adverse Reactions Occurring More Frequently in the NORTHERA Group                        Study 301 and Study 302    (1 to 2 Weeks Randomized Treatment)        Study 306    (8 to 10 Weeks Randomized Treatment)           Placebo    (N=132)      n (%)        NORTHERA    (N=131)      n (%)        Placebo    (N=108)      n (%)        NORTHERA    (N=114)           n (%)              Headache         4 (3.0)          8 (6.1)          8 (7.4)          15 (13.2)           Dizziness        2 (1.5)          5 (3.8)          5 (4.6)          11 (9.6)            Nausea           2 (1.5)          2 (1.5)          5 (4.6)          10 (8.8)            Hypertension     0                2 (1.5)          1 (0.9)          8 (7.0)                    Note: n=number of patients.,Hypertension is an adverse reaction entity
Most Common Adverse Reactions Occurring More Frequently in the NORTHERA Group                        Study 301 and Study 302    (1 to 2 Weeks Randomized Treatment)        Study 306    (8 to 10 Weeks Randomized Treatment)           Placebo    (N=132)      n (%)        NORTHERA    (N=131)      n (%)        Placebo    (N=108)      n (%)        NORTHERA    (N=114)           n (%)              Headache         4 (3.0)          8 (6.1)          8 (7.4)          15 (13.2)           Dizziness        2 (1.5)          5 (3.8)          5 (4.6)          11 (9.6)            Nausea           2 (1.5)          2 (1.5)          5 (4.6)          10 (8.8)            Hypertension     0                2 (1.5)          1 (0.9)          8 (7.0)                    Note: n=number of patients.,Headache is an adverse reaction entity
Most Common Adverse Reactions Occurring More Frequently in the NORTHERA Group                        Study 301 and Study 302    (1 to 2 Weeks Randomized Treatment)        Study 306    (8 to 10 Weeks Randomized Treatment)           Placebo    (N=132)      n (%)        NORTHERA    (N=131)      n (%)        Placebo    (N=108)      n (%)        NORTHERA    (N=114)           n (%)              Headache         4 (3.0)          8 (6.1)          8 (7.4)          15 (13.2)           Dizziness        2 (1.5)          5 (3.8)          5 (4.6)          11 (9.6)            Nausea           2 (1.5)          2 (1.5)          5 (4.6)          10 (8.8)            Hypertension     0                2 (1.5)          1 (0.9)          8 (7.0)                    Note: n=number of patients.,) n ( is not a named entity
Most Common Adverse Reactions Occurring More Frequently in the NORTHERA Group                        Study 301 and Study 302    (1 to 2 Weeks Randomized Treatment)        Study 306    (8 to 10 Weeks Randomized Treatment)           Placebo    (N=132)      n (%)        NORTHERA    (N=131)      n (%)        Placebo    (N=108)      n (%)        NORTHERA    (N=114)           n (%)              Headache         4 (3.0)          8 (6.1)          8 (7.4)          15 (13.2)           Dizziness        2 (1.5)          5 (3.8)          5 (4.6)          11 (9.6)            Nausea           2 (1.5)          2 (1.5)          5 (4.6)          10 (8.8)            Hypertension     0                2 (1.5)          1 (0.9)          8 (7.0)                    Note: n=number of patients.,0 2 is not a named entity
Most Common Adverse Reactions Occurring More Frequently in the NORTHERA Group                        Study 301 and Study 302    (1 to 2 Weeks Randomized Treatment)        Study 306    (8 to 10 Weeks Randomized Treatment)           Placebo    (N=132)      n (%)        NORTHERA    (N=131)      n (%)        Placebo    (N=108)      n (%)        NORTHERA    (N=114)           n (%)              Headache         4 (3.0)          8 (6.1)          8 (7.4)          15 (13.2)           Dizziness        2 (1.5)          5 (3.8)          5 (4.6)          11 (9.6)            Nausea           2 (1.5)          2 (1.5)          5 (4.6)          10 (8.8)            Hypertension     0                2 (1.5)          1 (0.9)          8 (7.0)                    Note: n=number of patients.,) 10 ( is not a named entity
"Placebo-Controlled        Experience         The most commonly observed adverse reactions (those occurring at an incidence of greater than 5%  in the NORTHERA group and with at least a 3% greater incidence in the NORTHERA group than in the placebo group) in NORTHERA-treated patients during the three placebo-controlled trials were headache, dizziness, nausea, hypertension.",headache is an adverse reaction entity
"Placebo-Controlled        Experience         The most commonly observed adverse reactions (those occurring at an incidence of greater than 5%  in the NORTHERA group and with at least a 3% greater incidence in the NORTHERA group than in the placebo group) in NORTHERA-treated patients during the three placebo-controlled trials were headache, dizziness, nausea, hypertension.",5 is not a named entity
"Placebo-Controlled        Experience         The most commonly observed adverse reactions (those occurring at an incidence of greater than 5%  in the NORTHERA group and with at least a 3% greater incidence in the NORTHERA group than in the placebo group) in NORTHERA-treated patients during the three placebo-controlled trials were headache, dizziness, nausea, hypertension.",hypertension is an adverse reaction entity
"Placebo-Controlled        Experience         The most commonly observed adverse reactions (those occurring at an incidence of greater than 5%  in the NORTHERA group and with at least a 3% greater incidence in the NORTHERA group than in the placebo group) in NORTHERA-treated patients during the three placebo-controlled trials were headache, dizziness, nausea, hypertension.",nausea is an adverse reaction entity
"Placebo-Controlled        Experience         The most commonly observed adverse reactions (those occurring at an incidence of greater than 5%  in the NORTHERA group and with at least a 3% greater incidence in the NORTHERA group than in the placebo group) in NORTHERA-treated patients during the three placebo-controlled trials were headache, dizziness, nausea, hypertension.",dizziness is an adverse reaction entity
"Placebo-Controlled        Experience         The most commonly observed adverse reactions (those occurring at an incidence of greater than 5%  in the NORTHERA group and with at least a 3% greater incidence in the NORTHERA group than in the placebo group) in NORTHERA-treated patients during the three placebo-controlled trials were headache, dizziness, nausea, hypertension.",the is not a named entity
"Placebo-Controlled        Experience         The most commonly observed adverse reactions (those occurring at an incidence of greater than 5%  in the NORTHERA group and with at least a 3% greater incidence in the NORTHERA group than in the placebo group) in NORTHERA-treated patients during the three placebo-controlled trials were headache, dizziness, nausea, hypertension.",at is not a named entity
"Placebo-Controlled        Experience         The most commonly observed adverse reactions (those occurring at an incidence of greater than 5%  in the NORTHERA group and with at least a 3% greater incidence in the NORTHERA group than in the placebo group) in NORTHERA-treated patients during the three placebo-controlled trials were headache, dizziness, nausea, hypertension.",group and with is not a named entity
The most common adverse reactions leading to discontinuation from NORTHERA were hypertension or increased blood pressure and nausea.,hypertension is an adverse reaction entity
The most common adverse reactions leading to discontinuation from NORTHERA were hypertension or increased blood pressure and nausea.,adverse reactions is not a named entity
The most common adverse reactions leading to discontinuation from NORTHERA were hypertension or increased blood pressure and nausea.,most common is not a named entity
The most common adverse reactions leading to discontinuation from NORTHERA were hypertension or increased blood pressure and nausea.,common adverse is not a named entity
The most common adverse reactions leading to discontinuation from NORTHERA were hypertension or increased blood pressure and nausea.,nausea is an adverse reaction entity
The most common adverse reactions leading to discontinuation from NORTHERA were hypertension or increased blood pressure and nausea.,increased blood pressure is an adverse reaction entity
"*  Hyperpyrexia and confusion (  5.2  )   *  May exacerbate symptoms in patients with existing ischemic heart disease, arrhythmias, and congestive heart failure (  5.3  )   *  Allergic reactions (  5.4  )             5.1 Supine Hypertension      NORTHERA therapy may cause or exacerbate supine hypertension in patients with NOH.",exacerbate arrhythmias is an adverse reaction entity
"*  Hyperpyrexia and confusion (  5.2  )   *  May exacerbate symptoms in patients with existing ischemic heart disease, arrhythmias, and congestive heart failure (  5.3  )   *  Allergic reactions (  5.4  )             5.1 Supine Hypertension      NORTHERA therapy may cause or exacerbate supine hypertension in patients with NOH.",hypertension in patients is not a named entity
"*  Hyperpyrexia and confusion (  5.2  )   *  May exacerbate symptoms in patients with existing ischemic heart disease, arrhythmias, and congestive heart failure (  5.3  )   *  Allergic reactions (  5.4  )             5.1 Supine Hypertension      NORTHERA therapy may cause or exacerbate supine hypertension in patients with NOH.",5.2 is not a named entity
"*  Hyperpyrexia and confusion (  5.2  )   *  May exacerbate symptoms in patients with existing ischemic heart disease, arrhythmias, and congestive heart failure (  5.3  )   *  Allergic reactions (  5.4  )             5.1 Supine Hypertension      NORTHERA therapy may cause or exacerbate supine hypertension in patients with NOH.",confusion is an adverse reaction entity
"*  Hyperpyrexia and confusion (  5.2  )   *  May exacerbate symptoms in patients with existing ischemic heart disease, arrhythmias, and congestive heart failure (  5.3  )   *  Allergic reactions (  5.4  )             5.1 Supine Hypertension      NORTHERA therapy may cause or exacerbate supine hypertension in patients with NOH.",( is not a named entity
"*  Hyperpyrexia and confusion (  5.2  )   *  May exacerbate symptoms in patients with existing ischemic heart disease, arrhythmias, and congestive heart failure (  5.3  )   *  Allergic reactions (  5.4  )             5.1 Supine Hypertension      NORTHERA therapy may cause or exacerbate supine hypertension in patients with NOH.",Allergic reactions is an adverse reaction entity
"*  Hyperpyrexia and confusion (  5.2  )   *  May exacerbate symptoms in patients with existing ischemic heart disease, arrhythmias, and congestive heart failure (  5.3  )   *  Allergic reactions (  5.4  )             5.1 Supine Hypertension      NORTHERA therapy may cause or exacerbate supine hypertension in patients with NOH.",* Hyperpyrexia and is not a named entity
"*  Hyperpyrexia and confusion (  5.2  )   *  May exacerbate symptoms in patients with existing ischemic heart disease, arrhythmias, and congestive heart failure (  5.3  )   *  Allergic reactions (  5.4  )             5.1 Supine Hypertension      NORTHERA therapy may cause or exacerbate supine hypertension in patients with NOH.",exacerbate ischemic heart disease is an adverse reaction entity
"*  Hyperpyrexia and confusion (  5.2  )   *  May exacerbate symptoms in patients with existing ischemic heart disease, arrhythmias, and congestive heart failure (  5.3  )   *  Allergic reactions (  5.4  )             5.1 Supine Hypertension      NORTHERA therapy may cause or exacerbate supine hypertension in patients with NOH.",in patients is not a named entity
"*  Hyperpyrexia and confusion (  5.2  )   *  May exacerbate symptoms in patients with existing ischemic heart disease, arrhythmias, and congestive heart failure (  5.3  )   *  Allergic reactions (  5.4  )             5.1 Supine Hypertension      NORTHERA therapy may cause or exacerbate supine hypertension in patients with NOH.",) * May is not a named entity
"*  Hyperpyrexia and confusion (  5.2  )   *  May exacerbate symptoms in patients with existing ischemic heart disease, arrhythmias, and congestive heart failure (  5.3  )   *  Allergic reactions (  5.4  )             5.1 Supine Hypertension      NORTHERA therapy may cause or exacerbate supine hypertension in patients with NOH.",Hyperpyrexia is an adverse reaction entity
"*  Hyperpyrexia and confusion (  5.2  )   *  May exacerbate symptoms in patients with existing ischemic heart disease, arrhythmias, and congestive heart failure (  5.3  )   *  Allergic reactions (  5.4  )             5.1 Supine Hypertension      NORTHERA therapy may cause or exacerbate supine hypertension in patients with NOH.",supine hypertension is an adverse reaction entity
"*  Hyperpyrexia and confusion (  5.2  )   *  May exacerbate symptoms in patients with existing ischemic heart disease, arrhythmias, and congestive heart failure (  5.3  )   *  Allergic reactions (  5.4  )             5.1 Supine Hypertension      NORTHERA therapy may cause or exacerbate supine hypertension in patients with NOH.",confusion ( 5.2 is not a named entity
"*  Hyperpyrexia and confusion (  5.2  )   *  May exacerbate symptoms in patients with existing ischemic heart disease, arrhythmias, and congestive heart failure (  5.3  )   *  Allergic reactions (  5.4  )             5.1 Supine Hypertension      NORTHERA therapy may cause or exacerbate supine hypertension in patients with NOH.",exacerbate congestive heart failure is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions with NORTHERA are included in more detail in the Warnings and Precautions section of the label:     *  Supine Hypertension [see Warnings and Precautions (  5.1  )]    *  Hyperpyrexia and Confusion [see Warnings and Precautions (  5.2  )]    *  May exacerbate existing ischemic heart disease, arrhythmias, and congestive heart failure [see Warnings and Precautions (  5.3  )]         EXCERPT:   Headache, dizziness, nausea, hypertension, and fatigue (greater than 5%) (  6.1  )       To report SUSPECTED ADVERSE REACTIONS, contact Lundbeck at 1-800-455-1141 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",with NORTHERA are is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions with NORTHERA are included in more detail in the Warnings and Precautions section of the label:     *  Supine Hypertension [see Warnings and Precautions (  5.1  )]    *  Hyperpyrexia and Confusion [see Warnings and Precautions (  5.2  )]    *  May exacerbate existing ischemic heart disease, arrhythmias, and congestive heart failure [see Warnings and Precautions (  5.3  )]         EXCERPT:   Headache, dizziness, nausea, hypertension, and fatigue (greater than 5%) (  6.1  )       To report SUSPECTED ADVERSE REACTIONS, contact Lundbeck at 1-800-455-1141 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",following adverse is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions with NORTHERA are included in more detail in the Warnings and Precautions section of the label:     *  Supine Hypertension [see Warnings and Precautions (  5.1  )]    *  Hyperpyrexia and Confusion [see Warnings and Precautions (  5.2  )]    *  May exacerbate existing ischemic heart disease, arrhythmias, and congestive heart failure [see Warnings and Precautions (  5.3  )]         EXCERPT:   Headache, dizziness, nausea, hypertension, and fatigue (greater than 5%) (  6.1  )       To report SUSPECTED ADVERSE REACTIONS, contact Lundbeck at 1-800-455-1141 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",exacerbate congestive heart failure is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions with NORTHERA are included in more detail in the Warnings and Precautions section of the label:     *  Supine Hypertension [see Warnings and Precautions (  5.1  )]    *  Hyperpyrexia and Confusion [see Warnings and Precautions (  5.2  )]    *  May exacerbate existing ischemic heart disease, arrhythmias, and congestive heart failure [see Warnings and Precautions (  5.3  )]         EXCERPT:   Headache, dizziness, nausea, hypertension, and fatigue (greater than 5%) (  6.1  )       To report SUSPECTED ADVERSE REACTIONS, contact Lundbeck at 1-800-455-1141 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",] EXCERPT is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions with NORTHERA are included in more detail in the Warnings and Precautions section of the label:     *  Supine Hypertension [see Warnings and Precautions (  5.1  )]    *  Hyperpyrexia and Confusion [see Warnings and Precautions (  5.2  )]    *  May exacerbate existing ischemic heart disease, arrhythmias, and congestive heart failure [see Warnings and Precautions (  5.3  )]         EXCERPT:   Headache, dizziness, nausea, hypertension, and fatigue (greater than 5%) (  6.1  )       To report SUSPECTED ADVERSE REACTIONS, contact Lundbeck at 1-800-455-1141 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",Headache is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions with NORTHERA are included in more detail in the Warnings and Precautions section of the label:     *  Supine Hypertension [see Warnings and Precautions (  5.1  )]    *  Hyperpyrexia and Confusion [see Warnings and Precautions (  5.2  )]    *  May exacerbate existing ischemic heart disease, arrhythmias, and congestive heart failure [see Warnings and Precautions (  5.3  )]         EXCERPT:   Headache, dizziness, nausea, hypertension, and fatigue (greater than 5%) (  6.1  )       To report SUSPECTED ADVERSE REACTIONS, contact Lundbeck at 1-800-455-1141 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",www.fda.gov/medwatch is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions with NORTHERA are included in more detail in the Warnings and Precautions section of the label:     *  Supine Hypertension [see Warnings and Precautions (  5.1  )]    *  Hyperpyrexia and Confusion [see Warnings and Precautions (  5.2  )]    *  May exacerbate existing ischemic heart disease, arrhythmias, and congestive heart failure [see Warnings and Precautions (  5.3  )]         EXCERPT:   Headache, dizziness, nausea, hypertension, and fatigue (greater than 5%) (  6.1  )       To report SUSPECTED ADVERSE REACTIONS, contact Lundbeck at 1-800-455-1141 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",or FDA at is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions with NORTHERA are included in more detail in the Warnings and Precautions section of the label:     *  Supine Hypertension [see Warnings and Precautions (  5.1  )]    *  Hyperpyrexia and Confusion [see Warnings and Precautions (  5.2  )]    *  May exacerbate existing ischemic heart disease, arrhythmias, and congestive heart failure [see Warnings and Precautions (  5.3  )]         EXCERPT:   Headache, dizziness, nausea, hypertension, and fatigue (greater than 5%) (  6.1  )       To report SUSPECTED ADVERSE REACTIONS, contact Lundbeck at 1-800-455-1141 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",ADVERSE REACTIONS The is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions with NORTHERA are included in more detail in the Warnings and Precautions section of the label:     *  Supine Hypertension [see Warnings and Precautions (  5.1  )]    *  Hyperpyrexia and Confusion [see Warnings and Precautions (  5.2  )]    *  May exacerbate existing ischemic heart disease, arrhythmias, and congestive heart failure [see Warnings and Precautions (  5.3  )]         EXCERPT:   Headache, dizziness, nausea, hypertension, and fatigue (greater than 5%) (  6.1  )       To report SUSPECTED ADVERSE REACTIONS, contact Lundbeck at 1-800-455-1141 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",Supine Hypertension is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions with NORTHERA are included in more detail in the Warnings and Precautions section of the label:     *  Supine Hypertension [see Warnings and Precautions (  5.1  )]    *  Hyperpyrexia and Confusion [see Warnings and Precautions (  5.2  )]    *  May exacerbate existing ischemic heart disease, arrhythmias, and congestive heart failure [see Warnings and Precautions (  5.3  )]         EXCERPT:   Headache, dizziness, nausea, hypertension, and fatigue (greater than 5%) (  6.1  )       To report SUSPECTED ADVERSE REACTIONS, contact Lundbeck at 1-800-455-1141 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",Hyperpyrexia is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions with NORTHERA are included in more detail in the Warnings and Precautions section of the label:     *  Supine Hypertension [see Warnings and Precautions (  5.1  )]    *  Hyperpyrexia and Confusion [see Warnings and Precautions (  5.2  )]    *  May exacerbate existing ischemic heart disease, arrhythmias, and congestive heart failure [see Warnings and Precautions (  5.3  )]         EXCERPT:   Headache, dizziness, nausea, hypertension, and fatigue (greater than 5%) (  6.1  )       To report SUSPECTED ADVERSE REACTIONS, contact Lundbeck at 1-800-455-1141 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",exacerbate arrhythmias is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions with NORTHERA are included in more detail in the Warnings and Precautions section of the label:     *  Supine Hypertension [see Warnings and Precautions (  5.1  )]    *  Hyperpyrexia and Confusion [see Warnings and Precautions (  5.2  )]    *  May exacerbate existing ischemic heart disease, arrhythmias, and congestive heart failure [see Warnings and Precautions (  5.3  )]         EXCERPT:   Headache, dizziness, nausea, hypertension, and fatigue (greater than 5%) (  6.1  )       To report SUSPECTED ADVERSE REACTIONS, contact Lundbeck at 1-800-455-1141 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",", is not a named entity"
"6 ADVERSE REACTIONS    The following adverse reactions with NORTHERA are included in more detail in the Warnings and Precautions section of the label:     *  Supine Hypertension [see Warnings and Precautions (  5.1  )]    *  Hyperpyrexia and Confusion [see Warnings and Precautions (  5.2  )]    *  May exacerbate existing ischemic heart disease, arrhythmias, and congestive heart failure [see Warnings and Precautions (  5.3  )]         EXCERPT:   Headache, dizziness, nausea, hypertension, and fatigue (greater than 5%) (  6.1  )       To report SUSPECTED ADVERSE REACTIONS, contact Lundbeck at 1-800-455-1141 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",[ see is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions with NORTHERA are included in more detail in the Warnings and Precautions section of the label:     *  Supine Hypertension [see Warnings and Precautions (  5.1  )]    *  Hyperpyrexia and Confusion [see Warnings and Precautions (  5.2  )]    *  May exacerbate existing ischemic heart disease, arrhythmias, and congestive heart failure [see Warnings and Precautions (  5.3  )]         EXCERPT:   Headache, dizziness, nausea, hypertension, and fatigue (greater than 5%) (  6.1  )       To report SUSPECTED ADVERSE REACTIONS, contact Lundbeck at 1-800-455-1141 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",hypertension is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions with NORTHERA are included in more detail in the Warnings and Precautions section of the label:     *  Supine Hypertension [see Warnings and Precautions (  5.1  )]    *  Hyperpyrexia and Confusion [see Warnings and Precautions (  5.2  )]    *  May exacerbate existing ischemic heart disease, arrhythmias, and congestive heart failure [see Warnings and Precautions (  5.3  )]         EXCERPT:   Headache, dizziness, nausea, hypertension, and fatigue (greater than 5%) (  6.1  )       To report SUSPECTED ADVERSE REACTIONS, contact Lundbeck at 1-800-455-1141 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",ADVERSE REACTIONS is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions with NORTHERA are included in more detail in the Warnings and Precautions section of the label:     *  Supine Hypertension [see Warnings and Precautions (  5.1  )]    *  Hyperpyrexia and Confusion [see Warnings and Precautions (  5.2  )]    *  May exacerbate existing ischemic heart disease, arrhythmias, and congestive heart failure [see Warnings and Precautions (  5.3  )]         EXCERPT:   Headache, dizziness, nausea, hypertension, and fatigue (greater than 5%) (  6.1  )       To report SUSPECTED ADVERSE REACTIONS, contact Lundbeck at 1-800-455-1141 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",( is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions with NORTHERA are included in more detail in the Warnings and Precautions section of the label:     *  Supine Hypertension [see Warnings and Precautions (  5.1  )]    *  Hyperpyrexia and Confusion [see Warnings and Precautions (  5.2  )]    *  May exacerbate existing ischemic heart disease, arrhythmias, and congestive heart failure [see Warnings and Precautions (  5.3  )]         EXCERPT:   Headache, dizziness, nausea, hypertension, and fatigue (greater than 5%) (  6.1  )       To report SUSPECTED ADVERSE REACTIONS, contact Lundbeck at 1-800-455-1141 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",dizziness is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions with NORTHERA are included in more detail in the Warnings and Precautions section of the label:     *  Supine Hypertension [see Warnings and Precautions (  5.1  )]    *  Hyperpyrexia and Confusion [see Warnings and Precautions (  5.2  )]    *  May exacerbate existing ischemic heart disease, arrhythmias, and congestive heart failure [see Warnings and Precautions (  5.3  )]         EXCERPT:   Headache, dizziness, nausea, hypertension, and fatigue (greater than 5%) (  6.1  )       To report SUSPECTED ADVERSE REACTIONS, contact Lundbeck at 1-800-455-1141 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",fatigue is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions with NORTHERA are included in more detail in the Warnings and Precautions section of the label:     *  Supine Hypertension [see Warnings and Precautions (  5.1  )]    *  Hyperpyrexia and Confusion [see Warnings and Precautions (  5.2  )]    *  May exacerbate existing ischemic heart disease, arrhythmias, and congestive heart failure [see Warnings and Precautions (  5.3  )]         EXCERPT:   Headache, dizziness, nausea, hypertension, and fatigue (greater than 5%) (  6.1  )       To report SUSPECTED ADVERSE REACTIONS, contact Lundbeck at 1-800-455-1141 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",( 5.2 is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions with NORTHERA are included in more detail in the Warnings and Precautions section of the label:     *  Supine Hypertension [see Warnings and Precautions (  5.1  )]    *  Hyperpyrexia and Confusion [see Warnings and Precautions (  5.2  )]    *  May exacerbate existing ischemic heart disease, arrhythmias, and congestive heart failure [see Warnings and Precautions (  5.3  )]         EXCERPT:   Headache, dizziness, nausea, hypertension, and fatigue (greater than 5%) (  6.1  )       To report SUSPECTED ADVERSE REACTIONS, contact Lundbeck at 1-800-455-1141 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",nausea is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions with NORTHERA are included in more detail in the Warnings and Precautions section of the label:     *  Supine Hypertension [see Warnings and Precautions (  5.1  )]    *  Hyperpyrexia and Confusion [see Warnings and Precautions (  5.2  )]    *  May exacerbate existing ischemic heart disease, arrhythmias, and congestive heart failure [see Warnings and Precautions (  5.3  )]         EXCERPT:   Headache, dizziness, nausea, hypertension, and fatigue (greater than 5%) (  6.1  )       To report SUSPECTED ADVERSE REACTIONS, contact Lundbeck at 1-800-455-1141 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",Confusion is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions with NORTHERA are included in more detail in the Warnings and Precautions section of the label:     *  Supine Hypertension [see Warnings and Precautions (  5.1  )]    *  Hyperpyrexia and Confusion [see Warnings and Precautions (  5.2  )]    *  May exacerbate existing ischemic heart disease, arrhythmias, and congestive heart failure [see Warnings and Precautions (  5.3  )]         EXCERPT:   Headache, dizziness, nausea, hypertension, and fatigue (greater than 5%) (  6.1  )       To report SUSPECTED ADVERSE REACTIONS, contact Lundbeck at 1-800-455-1141 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",exacerbate ischemic heart disease is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  NORTHERA can cause supine hypertension and may increase cardiovascular risk if supine hypertension is not well-managed (  5.1  ).,AND is not a named entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  NORTHERA can cause supine hypertension and may increase cardiovascular risk if supine hypertension is not well-managed (  5.1  ).,supine hypertension is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  NORTHERA can cause supine hypertension and may increase cardiovascular risk if supine hypertension is not well-managed (  5.1  ).,and is not a named entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  NORTHERA can cause supine hypertension and may increase cardiovascular risk if supine hypertension is not well-managed (  5.1  ).,cardiovascular risk is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  NORTHERA can cause supine hypertension and may increase cardiovascular risk if supine hypertension is not well-managed (  5.1  ).,not well-managed is not a named entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  NORTHERA can cause supine hypertension and may increase cardiovascular risk if supine hypertension is not well-managed (  5.1  ).,supine hypertension is an adverse reaction entity
"The commonly reported adverse events were falls (24%), urinary tract infections (15%), headache (13%), syncope (13%), and dizziness (10%).",falls is an adverse reaction entity
"The commonly reported adverse events were falls (24%), urinary tract infections (15%), headache (13%), syncope (13%), and dizziness (10%).",urinary tract infections is an adverse reaction entity
"The commonly reported adverse events were falls (24%), urinary tract infections (15%), headache (13%), syncope (13%), and dizziness (10%).",13 % ) is not a named entity
"The commonly reported adverse events were falls (24%), urinary tract infections (15%), headache (13%), syncope (13%), and dizziness (10%).",tract infections is not a named entity
"The commonly reported adverse events were falls (24%), urinary tract infections (15%), headache (13%), syncope (13%), and dizziness (10%).",dizziness ( 10 is not a named entity
"The commonly reported adverse events were falls (24%), urinary tract infections (15%), headache (13%), syncope (13%), and dizziness (10%).",headache is an adverse reaction entity
"The commonly reported adverse events were falls (24%), urinary tract infections (15%), headache (13%), syncope (13%), and dizziness (10%).",) is not a named entity
"The commonly reported adverse events were falls (24%), urinary tract infections (15%), headache (13%), syncope (13%), and dizziness (10%).",15 is not a named entity
"The commonly reported adverse events were falls (24%), urinary tract infections (15%), headache (13%), syncope (13%), and dizziness (10%).",dizziness is an adverse reaction entity
"The commonly reported adverse events were falls (24%), urinary tract infections (15%), headache (13%), syncope (13%), and dizziness (10%).",syncope is an adverse reaction entity
EXCERPT:       WARNING: SUPINE HYPERTENSION        See full prescribing information for complete boxed warning.,WARNING : is not a named entity
EXCERPT:       WARNING: SUPINE HYPERTENSION        See full prescribing information for complete boxed warning.,SUPINE HYPERTENSION is an adverse reaction entity
"NMS is an uncommon but life-threatening syndrome characterized by fever or hyperthermia, muscle rigidity, involuntary movements, altered consciousness, and mental status changes.",hyperthermia is an adverse reaction entity
"NMS is an uncommon but life-threatening syndrome characterized by fever or hyperthermia, muscle rigidity, involuntary movements, altered consciousness, and mental status changes.",and mental status is not a named entity
"NMS is an uncommon but life-threatening syndrome characterized by fever or hyperthermia, muscle rigidity, involuntary movements, altered consciousness, and mental status changes.",syndrome is not a named entity
"NMS is an uncommon but life-threatening syndrome characterized by fever or hyperthermia, muscle rigidity, involuntary movements, altered consciousness, and mental status changes.","movements , altered is not a named entity"
"NMS is an uncommon but life-threatening syndrome characterized by fever or hyperthermia, muscle rigidity, involuntary movements, altered consciousness, and mental status changes.",mental status changes is an adverse reaction entity
"NMS is an uncommon but life-threatening syndrome characterized by fever or hyperthermia, muscle rigidity, involuntary movements, altered consciousness, and mental status changes.",and mental is not a named entity
"NMS is an uncommon but life-threatening syndrome characterized by fever or hyperthermia, muscle rigidity, involuntary movements, altered consciousness, and mental status changes.",altered consciousness is an adverse reaction entity
"NMS is an uncommon but life-threatening syndrome characterized by fever or hyperthermia, muscle rigidity, involuntary movements, altered consciousness, and mental status changes.","consciousness , is not a named entity"
"NMS is an uncommon but life-threatening syndrome characterized by fever or hyperthermia, muscle rigidity, involuntary movements, altered consciousness, and mental status changes.",consciousness is not a named entity
"NMS is an uncommon but life-threatening syndrome characterized by fever or hyperthermia, muscle rigidity, involuntary movements, altered consciousness, and mental status changes.",NMS is an adverse reaction entity
"NMS is an uncommon but life-threatening syndrome characterized by fever or hyperthermia, muscle rigidity, involuntary movements, altered consciousness, and mental status changes.",by fever or is not a named entity
"NMS is an uncommon but life-threatening syndrome characterized by fever or hyperthermia, muscle rigidity, involuntary movements, altered consciousness, and mental status changes.",muscle rigidity is an adverse reaction entity
"NMS is an uncommon but life-threatening syndrome characterized by fever or hyperthermia, muscle rigidity, involuntary movements, altered consciousness, and mental status changes.",fever is an adverse reaction entity
"NMS is an uncommon but life-threatening syndrome characterized by fever or hyperthermia, muscle rigidity, involuntary movements, altered consciousness, and mental status changes.",involuntary movements is an adverse reaction entity
"Perform appropriate monitoring and treat hyperglycemia with insulin, as necessary (5.3)   *    Thrombosis, hemorrhage: discontinue ERWINAZE until resolved (5.4)          5.1 Hypersensitivity Reactions      Grade 3 and 4 hypersensitivity reactions after the use of ERWINAZE have occurred in 5% of patients in clinical trials [  see Adverse Reactions (6.1)  ].",Thrombosis is an adverse reaction entity
"Perform appropriate monitoring and treat hyperglycemia with insulin, as necessary (5.3)   *    Thrombosis, hemorrhage: discontinue ERWINAZE until resolved (5.4)          5.1 Hypersensitivity Reactions      Grade 3 and 4 hypersensitivity reactions after the use of ERWINAZE have occurred in 5% of patients in clinical trials [  see Adverse Reactions (6.1)  ].",hemorrhage is an adverse reaction entity
"Perform appropriate monitoring and treat hyperglycemia with insulin, as necessary (5.3)   *    Thrombosis, hemorrhage: discontinue ERWINAZE until resolved (5.4)          5.1 Hypersensitivity Reactions      Grade 3 and 4 hypersensitivity reactions after the use of ERWINAZE have occurred in 5% of patients in clinical trials [  see Adverse Reactions (6.1)  ].",( 6.1 ) is not a named entity
"Perform appropriate monitoring and treat hyperglycemia with insulin, as necessary (5.3)   *    Thrombosis, hemorrhage: discontinue ERWINAZE until resolved (5.4)          5.1 Hypersensitivity Reactions      Grade 3 and 4 hypersensitivity reactions after the use of ERWINAZE have occurred in 5% of patients in clinical trials [  see Adverse Reactions (6.1)  ].",until resolved is not a named entity
"Perform appropriate monitoring and treat hyperglycemia with insulin, as necessary (5.3)   *    Thrombosis, hemorrhage: discontinue ERWINAZE until resolved (5.4)          5.1 Hypersensitivity Reactions      Grade 3 and 4 hypersensitivity reactions after the use of ERWINAZE have occurred in 5% of patients in clinical trials [  see Adverse Reactions (6.1)  ].",hypersensitivity reactions is an adverse reaction entity
"Perform appropriate monitoring and treat hyperglycemia with insulin, as necessary (5.3)   *    Thrombosis, hemorrhage: discontinue ERWINAZE until resolved (5.4)          5.1 Hypersensitivity Reactions      Grade 3 and 4 hypersensitivity reactions after the use of ERWINAZE have occurred in 5% of patients in clinical trials [  see Adverse Reactions (6.1)  ].",clinical trials [ is not a named entity
"Of these 4 patients who developed anti-ERWINAZE antibodies, 3 experienced hypersensitivity reactions (10%, 3 of 30) during the study.",who developed anti-ERWINAZE is not a named entity
"Of these 4 patients who developed anti-ERWINAZE antibodies, 3 experienced hypersensitivity reactions (10%, 3 of 30) during the study.",hypersensitivity reactions is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS     EXCERPT:    *    If the following occur, discontinue ERWINAZE:Serious hypersensitivity reactions, including anaphylaxis (5.1)Severe or hemorrhagic pancreatitis (5.2)   *    Glucose intolerance can occur and, in some cases, may be irreversible.",Glucose intolerance is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS     EXCERPT:    *    If the following occur, discontinue ERWINAZE:Serious hypersensitivity reactions, including anaphylaxis (5.1)Severe or hemorrhagic pancreatitis (5.2)   *    Glucose intolerance can occur and, in some cases, may be irreversible.",hemorrhagic pancreatitis is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS     EXCERPT:    *    If the following occur, discontinue ERWINAZE:Serious hypersensitivity reactions, including anaphylaxis (5.1)Severe or hemorrhagic pancreatitis (5.2)   *    Glucose intolerance can occur and, in some cases, may be irreversible.",in some is not a named entity
"5 WARNINGS AND PRECAUTIONS     EXCERPT:    *    If the following occur, discontinue ERWINAZE:Serious hypersensitivity reactions, including anaphylaxis (5.1)Severe or hemorrhagic pancreatitis (5.2)   *    Glucose intolerance can occur and, in some cases, may be irreversible.",Glucose intolerance is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS     EXCERPT:    *    If the following occur, discontinue ERWINAZE:Serious hypersensitivity reactions, including anaphylaxis (5.1)Severe or hemorrhagic pancreatitis (5.2)   *    Glucose intolerance can occur and, in some cases, may be irreversible.",( is not a named entity
"5 WARNINGS AND PRECAUTIONS     EXCERPT:    *    If the following occur, discontinue ERWINAZE:Serious hypersensitivity reactions, including anaphylaxis (5.1)Severe or hemorrhagic pancreatitis (5.2)   *    Glucose intolerance can occur and, in some cases, may be irreversible.",anaphylaxis is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS     EXCERPT:    *    If the following occur, discontinue ERWINAZE:Serious hypersensitivity reactions, including anaphylaxis (5.1)Severe or hemorrhagic pancreatitis (5.2)   *    Glucose intolerance can occur and, in some cases, may be irreversible.",hypersensitivity reactions is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS     EXCERPT:    *    If the following occur, discontinue ERWINAZE:Serious hypersensitivity reactions, including anaphylaxis (5.1)Severe or hemorrhagic pancreatitis (5.2)   *    Glucose intolerance can occur and, in some cases, may be irreversible.",pancreatitis is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS     EXCERPT:    *    If the following occur, discontinue ERWINAZE:Serious hypersensitivity reactions, including anaphylaxis (5.1)Severe or hemorrhagic pancreatitis (5.2)   *    Glucose intolerance can occur and, in some cases, may be irreversible.",5.2 ) is not a named entity
"5 WARNINGS AND PRECAUTIONS     EXCERPT:    *    If the following occur, discontinue ERWINAZE:Serious hypersensitivity reactions, including anaphylaxis (5.1)Severe or hemorrhagic pancreatitis (5.2)   *    Glucose intolerance can occur and, in some cases, may be irreversible.",( 5.2 ) is not a named entity
"5 WARNINGS AND PRECAUTIONS     EXCERPT:    *    If the following occur, discontinue ERWINAZE:Serious hypersensitivity reactions, including anaphylaxis (5.1)Severe or hemorrhagic pancreatitis (5.2)   *    Glucose intolerance can occur and, in some cases, may be irreversible.",5.2 is not a named entity
"5 WARNINGS AND PRECAUTIONS     EXCERPT:    *    If the following occur, discontinue ERWINAZE:Serious hypersensitivity reactions, including anaphylaxis (5.1)Severe or hemorrhagic pancreatitis (5.2)   *    Glucose intolerance can occur and, in some cases, may be irreversible.",ERWINAZE is not a named entity
"In Study 1, all Grades of adverse events were reported for the following adverse events of special interest: allergy, pancreatitis, coagulopathy (hemorrhage, thrombosis or infarct), hyperbilirubinemia, hyperglycemia, hyperlipidemia, ketoacidosis, and CNS events (hemorrhage, thrombosis or infarction, and cerebral venous thrombosis) and only Grade 3 and 4 events were reported for other adverse events.",events were reported is not a named entity
"In Study 1, all Grades of adverse events were reported for the following adverse events of special interest: allergy, pancreatitis, coagulopathy (hemorrhage, thrombosis or infarct), hyperbilirubinemia, hyperglycemia, hyperlipidemia, ketoacidosis, and CNS events (hemorrhage, thrombosis or infarction, and cerebral venous thrombosis) and only Grade 3 and 4 events were reported for other adverse events.",ketoacidosis is an adverse reaction entity
"In Study 1, all Grades of adverse events were reported for the following adverse events of special interest: allergy, pancreatitis, coagulopathy (hemorrhage, thrombosis or infarct), hyperbilirubinemia, hyperglycemia, hyperlipidemia, ketoacidosis, and CNS events (hemorrhage, thrombosis or infarction, and cerebral venous thrombosis) and only Grade 3 and 4 events were reported for other adverse events.",CNS events is an adverse reaction entity
"In Study 1, all Grades of adverse events were reported for the following adverse events of special interest: allergy, pancreatitis, coagulopathy (hemorrhage, thrombosis or infarct), hyperbilirubinemia, hyperglycemia, hyperlipidemia, ketoacidosis, and CNS events (hemorrhage, thrombosis or infarction, and cerebral venous thrombosis) and only Grade 3 and 4 events were reported for other adverse events.",CNS thrombosis is an adverse reaction entity
"In Study 1, all Grades of adverse events were reported for the following adverse events of special interest: allergy, pancreatitis, coagulopathy (hemorrhage, thrombosis or infarct), hyperbilirubinemia, hyperglycemia, hyperlipidemia, ketoacidosis, and CNS events (hemorrhage, thrombosis or infarction, and cerebral venous thrombosis) and only Grade 3 and 4 events were reported for other adverse events.",were is not a named entity
"In Study 1, all Grades of adverse events were reported for the following adverse events of special interest: allergy, pancreatitis, coagulopathy (hemorrhage, thrombosis or infarct), hyperbilirubinemia, hyperglycemia, hyperlipidemia, ketoacidosis, and CNS events (hemorrhage, thrombosis or infarction, and cerebral venous thrombosis) and only Grade 3 and 4 events were reported for other adverse events.",", is not a named entity"
"In Study 1, all Grades of adverse events were reported for the following adverse events of special interest: allergy, pancreatitis, coagulopathy (hemorrhage, thrombosis or infarct), hyperbilirubinemia, hyperglycemia, hyperlipidemia, ketoacidosis, and CNS events (hemorrhage, thrombosis or infarction, and cerebral venous thrombosis) and only Grade 3 and 4 events were reported for other adverse events.",all is not a named entity
"In Study 1, all Grades of adverse events were reported for the following adverse events of special interest: allergy, pancreatitis, coagulopathy (hemorrhage, thrombosis or infarct), hyperbilirubinemia, hyperglycemia, hyperlipidemia, ketoacidosis, and CNS events (hemorrhage, thrombosis or infarction, and cerebral venous thrombosis) and only Grade 3 and 4 events were reported for other adverse events.",and only Grade is not a named entity
"In Study 1, all Grades of adverse events were reported for the following adverse events of special interest: allergy, pancreatitis, coagulopathy (hemorrhage, thrombosis or infarct), hyperbilirubinemia, hyperglycemia, hyperlipidemia, ketoacidosis, and CNS events (hemorrhage, thrombosis or infarction, and cerebral venous thrombosis) and only Grade 3 and 4 events were reported for other adverse events.",CNS hemorrhage is an adverse reaction entity
"In Study 1, all Grades of adverse events were reported for the following adverse events of special interest: allergy, pancreatitis, coagulopathy (hemorrhage, thrombosis or infarct), hyperbilirubinemia, hyperglycemia, hyperlipidemia, ketoacidosis, and CNS events (hemorrhage, thrombosis or infarction, and cerebral venous thrombosis) and only Grade 3 and 4 events were reported for other adverse events.","infarct ) , is not a named entity"
"In Study 1, all Grades of adverse events were reported for the following adverse events of special interest: allergy, pancreatitis, coagulopathy (hemorrhage, thrombosis or infarct), hyperbilirubinemia, hyperglycemia, hyperlipidemia, ketoacidosis, and CNS events (hemorrhage, thrombosis or infarction, and cerebral venous thrombosis) and only Grade 3 and 4 events were reported for other adverse events.","hemorrhage , is not a named entity"
"In Study 1, all Grades of adverse events were reported for the following adverse events of special interest: allergy, pancreatitis, coagulopathy (hemorrhage, thrombosis or infarct), hyperbilirubinemia, hyperglycemia, hyperlipidemia, ketoacidosis, and CNS events (hemorrhage, thrombosis or infarction, and cerebral venous thrombosis) and only Grade 3 and 4 events were reported for other adverse events.",only Grade is not a named entity
"In Study 1, all Grades of adverse events were reported for the following adverse events of special interest: allergy, pancreatitis, coagulopathy (hemorrhage, thrombosis or infarct), hyperbilirubinemia, hyperglycemia, hyperlipidemia, ketoacidosis, and CNS events (hemorrhage, thrombosis or infarction, and cerebral venous thrombosis) and only Grade 3 and 4 events were reported for other adverse events.",pancreatitis is an adverse reaction entity
"In Study 1, all Grades of adverse events were reported for the following adverse events of special interest: allergy, pancreatitis, coagulopathy (hemorrhage, thrombosis or infarct), hyperbilirubinemia, hyperglycemia, hyperlipidemia, ketoacidosis, and CNS events (hemorrhage, thrombosis or infarction, and cerebral venous thrombosis) and only Grade 3 and 4 events were reported for other adverse events.",") , hyperbilirubinemia is not a named entity"
"In Study 1, all Grades of adverse events were reported for the following adverse events of special interest: allergy, pancreatitis, coagulopathy (hemorrhage, thrombosis or infarct), hyperbilirubinemia, hyperglycemia, hyperlipidemia, ketoacidosis, and CNS events (hemorrhage, thrombosis or infarction, and cerebral venous thrombosis) and only Grade 3 and 4 events were reported for other adverse events.",", and is not a named entity"
"In Study 1, all Grades of adverse events were reported for the following adverse events of special interest: allergy, pancreatitis, coagulopathy (hemorrhage, thrombosis or infarct), hyperbilirubinemia, hyperglycemia, hyperlipidemia, ketoacidosis, and CNS events (hemorrhage, thrombosis or infarction, and cerebral venous thrombosis) and only Grade 3 and 4 events were reported for other adverse events.",cerebral venous thrombosis is an adverse reaction entity
"In Study 1, all Grades of adverse events were reported for the following adverse events of special interest: allergy, pancreatitis, coagulopathy (hemorrhage, thrombosis or infarct), hyperbilirubinemia, hyperglycemia, hyperlipidemia, ketoacidosis, and CNS events (hemorrhage, thrombosis or infarction, and cerebral venous thrombosis) and only Grade 3 and 4 events were reported for other adverse events.",infarct is an adverse reaction entity
"In Study 1, all Grades of adverse events were reported for the following adverse events of special interest: allergy, pancreatitis, coagulopathy (hemorrhage, thrombosis or infarct), hyperbilirubinemia, hyperglycemia, hyperlipidemia, ketoacidosis, and CNS events (hemorrhage, thrombosis or infarction, and cerebral venous thrombosis) and only Grade 3 and 4 events were reported for other adverse events.",allergy is an adverse reaction entity
"In Study 1, all Grades of adverse events were reported for the following adverse events of special interest: allergy, pancreatitis, coagulopathy (hemorrhage, thrombosis or infarct), hyperbilirubinemia, hyperglycemia, hyperlipidemia, ketoacidosis, and CNS events (hemorrhage, thrombosis or infarction, and cerebral venous thrombosis) and only Grade 3 and 4 events were reported for other adverse events.",coagulopathy is an adverse reaction entity
"In Study 1, all Grades of adverse events were reported for the following adverse events of special interest: allergy, pancreatitis, coagulopathy (hemorrhage, thrombosis or infarct), hyperbilirubinemia, hyperglycemia, hyperlipidemia, ketoacidosis, and CNS events (hemorrhage, thrombosis or infarction, and cerebral venous thrombosis) and only Grade 3 and 4 events were reported for other adverse events.",all is not a named entity
"In Study 1, all Grades of adverse events were reported for the following adverse events of special interest: allergy, pancreatitis, coagulopathy (hemorrhage, thrombosis or infarct), hyperbilirubinemia, hyperglycemia, hyperlipidemia, ketoacidosis, and CNS events (hemorrhage, thrombosis or infarction, and cerebral venous thrombosis) and only Grade 3 and 4 events were reported for other adverse events.",thrombosis is an adverse reaction entity
"In Study 1, all Grades of adverse events were reported for the following adverse events of special interest: allergy, pancreatitis, coagulopathy (hemorrhage, thrombosis or infarct), hyperbilirubinemia, hyperglycemia, hyperlipidemia, ketoacidosis, and CNS events (hemorrhage, thrombosis or infarction, and cerebral venous thrombosis) and only Grade 3 and 4 events were reported for other adverse events.",hyperbilirubinemia is an adverse reaction entity
"In Study 1, all Grades of adverse events were reported for the following adverse events of special interest: allergy, pancreatitis, coagulopathy (hemorrhage, thrombosis or infarct), hyperbilirubinemia, hyperglycemia, hyperlipidemia, ketoacidosis, and CNS events (hemorrhage, thrombosis or infarction, and cerebral venous thrombosis) and only Grade 3 and 4 events were reported for other adverse events.",hyperlipidemia is an adverse reaction entity
"In Study 1, all Grades of adverse events were reported for the following adverse events of special interest: allergy, pancreatitis, coagulopathy (hemorrhage, thrombosis or infarct), hyperbilirubinemia, hyperglycemia, hyperlipidemia, ketoacidosis, and CNS events (hemorrhage, thrombosis or infarction, and cerebral venous thrombosis) and only Grade 3 and 4 events were reported for other adverse events.",", coagulopathy is not a named entity"
"In Study 1, all Grades of adverse events were reported for the following adverse events of special interest: allergy, pancreatitis, coagulopathy (hemorrhage, thrombosis or infarct), hyperbilirubinemia, hyperglycemia, hyperlipidemia, ketoacidosis, and CNS events (hemorrhage, thrombosis or infarction, and cerebral venous thrombosis) and only Grade 3 and 4 events were reported for other adverse events.",hemorrhage is an adverse reaction entity
"In Study 1, all Grades of adverse events were reported for the following adverse events of special interest: allergy, pancreatitis, coagulopathy (hemorrhage, thrombosis or infarct), hyperbilirubinemia, hyperglycemia, hyperlipidemia, ketoacidosis, and CNS events (hemorrhage, thrombosis or infarction, and cerebral venous thrombosis) and only Grade 3 and 4 events were reported for other adverse events.",: allergy is not a named entity
"In Study 1, all Grades of adverse events were reported for the following adverse events of special interest: allergy, pancreatitis, coagulopathy (hemorrhage, thrombosis or infarct), hyperbilirubinemia, hyperglycemia, hyperlipidemia, ketoacidosis, and CNS events (hemorrhage, thrombosis or infarction, and cerebral venous thrombosis) and only Grade 3 and 4 events were reported for other adverse events.",or is not a named entity
"In Study 1, all Grades of adverse events were reported for the following adverse events of special interest: allergy, pancreatitis, coagulopathy (hemorrhage, thrombosis or infarct), hyperbilirubinemia, hyperglycemia, hyperlipidemia, ketoacidosis, and CNS events (hemorrhage, thrombosis or infarction, and cerebral venous thrombosis) and only Grade 3 and 4 events were reported for other adverse events.",and is not a named entity
"In Study 1, all Grades of adverse events were reported for the following adverse events of special interest: allergy, pancreatitis, coagulopathy (hemorrhage, thrombosis or infarct), hyperbilirubinemia, hyperglycemia, hyperlipidemia, ketoacidosis, and CNS events (hemorrhage, thrombosis or infarction, and cerebral venous thrombosis) and only Grade 3 and 4 events were reported for other adverse events.",hyperglycemia is an adverse reaction entity
"In Study 1, all Grades of adverse events were reported for the following adverse events of special interest: allergy, pancreatitis, coagulopathy (hemorrhage, thrombosis or infarct), hyperbilirubinemia, hyperglycemia, hyperlipidemia, ketoacidosis, and CNS events (hemorrhage, thrombosis or infarction, and cerebral venous thrombosis) and only Grade 3 and 4 events were reported for other adverse events.",CNS infarction is an adverse reaction entity
"The forms specifically requested information on occurrence of allergic reactions, thrombotic events, hemorrhagic events, hepatobiliary disorders, pancreatic disorders, and hyperglycemia.",occurrence is not a named entity
"The forms specifically requested information on occurrence of allergic reactions, thrombotic events, hemorrhagic events, hepatobiliary disorders, pancreatic disorders, and hyperglycemia.",hyperglycemia is an adverse reaction entity
"The forms specifically requested information on occurrence of allergic reactions, thrombotic events, hemorrhagic events, hepatobiliary disorders, pancreatic disorders, and hyperglycemia.",", is not a named entity"
"The forms specifically requested information on occurrence of allergic reactions, thrombotic events, hemorrhagic events, hepatobiliary disorders, pancreatic disorders, and hyperglycemia.",thrombotic events is an adverse reaction entity
"The forms specifically requested information on occurrence of allergic reactions, thrombotic events, hemorrhagic events, hepatobiliary disorders, pancreatic disorders, and hyperglycemia.",", thrombotic is not a named entity"
"The forms specifically requested information on occurrence of allergic reactions, thrombotic events, hemorrhagic events, hepatobiliary disorders, pancreatic disorders, and hyperglycemia.",", and is not a named entity"
"The forms specifically requested information on occurrence of allergic reactions, thrombotic events, hemorrhagic events, hepatobiliary disorders, pancreatic disorders, and hyperglycemia.",hepatobiliary disorders is an adverse reaction entity
"The forms specifically requested information on occurrence of allergic reactions, thrombotic events, hemorrhagic events, hepatobiliary disorders, pancreatic disorders, and hyperglycemia.",hemorrhagic events is an adverse reaction entity
"The forms specifically requested information on occurrence of allergic reactions, thrombotic events, hemorrhagic events, hepatobiliary disorders, pancreatic disorders, and hyperglycemia.",The forms is not a named entity
"The forms specifically requested information on occurrence of allergic reactions, thrombotic events, hemorrhagic events, hepatobiliary disorders, pancreatic disorders, and hyperglycemia.",", pancreatic disorders is not a named entity"
"The forms specifically requested information on occurrence of allergic reactions, thrombotic events, hemorrhagic events, hepatobiliary disorders, pancreatic disorders, and hyperglycemia.",allergic reactions is an adverse reaction entity
"The forms specifically requested information on occurrence of allergic reactions, thrombotic events, hemorrhagic events, hepatobiliary disorders, pancreatic disorders, and hyperglycemia.",pancreatic disorders is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed in greater detail in other sections of the label:     *    Hypersensitivity reactions [ see Warnings and Precautions (5.1) ]   *    Pancreatitis [ see Warnings and Precautions (5.2) ]   *    Glucose intolerance [ see Warnings and Precautions (5.3) ]   *    Thrombosis and hemorrhage [ see Warnings and Precautions (5.4) ]      The most common adverse reactions (incidence 1% or greater) with ERWINAZE treatment are systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.",vomiting is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed in greater detail in other sections of the label:     *    Hypersensitivity reactions [ see Warnings and Precautions (5.1) ]   *    Pancreatitis [ see Warnings and Precautions (5.2) ]   *    Glucose intolerance [ see Warnings and Precautions (5.3) ]   *    Thrombosis and hemorrhage [ see Warnings and Precautions (5.4) ]      The most common adverse reactions (incidence 1% or greater) with ERWINAZE treatment are systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.",see Warnings and is not a named entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed in greater detail in other sections of the label:     *    Hypersensitivity reactions [ see Warnings and Precautions (5.1) ]   *    Pancreatitis [ see Warnings and Precautions (5.2) ]   *    Glucose intolerance [ see Warnings and Precautions (5.3) ]   *    Thrombosis and hemorrhage [ see Warnings and Precautions (5.4) ]      The most common adverse reactions (incidence 1% or greater) with ERWINAZE treatment are systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.",see Warnings is not a named entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed in greater detail in other sections of the label:     *    Hypersensitivity reactions [ see Warnings and Precautions (5.1) ]   *    Pancreatitis [ see Warnings and Precautions (5.2) ]   *    Glucose intolerance [ see Warnings and Precautions (5.3) ]   *    Thrombosis and hemorrhage [ see Warnings and Precautions (5.4) ]      The most common adverse reactions (incidence 1% or greater) with ERWINAZE treatment are systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.",) is not a named entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed in greater detail in other sections of the label:     *    Hypersensitivity reactions [ see Warnings and Precautions (5.1) ]   *    Pancreatitis [ see Warnings and Precautions (5.2) ]   *    Glucose intolerance [ see Warnings and Precautions (5.3) ]   *    Thrombosis and hemorrhage [ see Warnings and Precautions (5.4) ]      The most common adverse reactions (incidence 1% or greater) with ERWINAZE treatment are systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.",hyperbilirubinemia is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed in greater detail in other sections of the label:     *    Hypersensitivity reactions [ see Warnings and Precautions (5.1) ]   *    Pancreatitis [ see Warnings and Precautions (5.2) ]   *    Glucose intolerance [ see Warnings and Precautions (5.3) ]   *    Thrombosis and hemorrhage [ see Warnings and Precautions (5.4) ]      The most common adverse reactions (incidence 1% or greater) with ERWINAZE treatment are systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.",Glucose intolerance is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed in greater detail in other sections of the label:     *    Hypersensitivity reactions [ see Warnings and Precautions (5.1) ]   *    Pancreatitis [ see Warnings and Precautions (5.2) ]   *    Glucose intolerance [ see Warnings and Precautions (5.3) ]   *    Thrombosis and hemorrhage [ see Warnings and Precautions (5.4) ]      The most common adverse reactions (incidence 1% or greater) with ERWINAZE treatment are systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.","transaminases abnormal , is not a named entity"
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed in greater detail in other sections of the label:     *    Hypersensitivity reactions [ see Warnings and Precautions (5.1) ]   *    Pancreatitis [ see Warnings and Precautions (5.2) ]   *    Glucose intolerance [ see Warnings and Precautions (5.3) ]   *    Thrombosis and hemorrhage [ see Warnings and Precautions (5.4) ]      The most common adverse reactions (incidence 1% or greater) with ERWINAZE treatment are systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.",hemorrhage is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed in greater detail in other sections of the label:     *    Hypersensitivity reactions [ see Warnings and Precautions (5.1) ]   *    Pancreatitis [ see Warnings and Precautions (5.2) ]   *    Glucose intolerance [ see Warnings and Precautions (5.3) ]   *    Thrombosis and hemorrhage [ see Warnings and Precautions (5.4) ]      The most common adverse reactions (incidence 1% or greater) with ERWINAZE treatment are systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.",hyperglycemia is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed in greater detail in other sections of the label:     *    Hypersensitivity reactions [ see Warnings and Precautions (5.1) ]   *    Pancreatitis [ see Warnings and Precautions (5.2) ]   *    Glucose intolerance [ see Warnings and Precautions (5.3) ]   *    Thrombosis and hemorrhage [ see Warnings and Precautions (5.4) ]      The most common adverse reactions (incidence 1% or greater) with ERWINAZE treatment are systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.",", is not a named entity"
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed in greater detail in other sections of the label:     *    Hypersensitivity reactions [ see Warnings and Precautions (5.1) ]   *    Pancreatitis [ see Warnings and Precautions (5.2) ]   *    Glucose intolerance [ see Warnings and Precautions (5.3) ]   *    Thrombosis and hemorrhage [ see Warnings and Precautions (5.4) ]      The most common adverse reactions (incidence 1% or greater) with ERWINAZE treatment are systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.",Pancreatitis [ see is not a named entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed in greater detail in other sections of the label:     *    Hypersensitivity reactions [ see Warnings and Precautions (5.1) ]   *    Pancreatitis [ see Warnings and Precautions (5.2) ]   *    Glucose intolerance [ see Warnings and Precautions (5.3) ]   *    Thrombosis and hemorrhage [ see Warnings and Precautions (5.4) ]      The most common adverse reactions (incidence 1% or greater) with ERWINAZE treatment are systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.",Thrombosis is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed in greater detail in other sections of the label:     *    Hypersensitivity reactions [ see Warnings and Precautions (5.1) ]   *    Pancreatitis [ see Warnings and Precautions (5.2) ]   *    Glucose intolerance [ see Warnings and Precautions (5.3) ]   *    Thrombosis and hemorrhage [ see Warnings and Precautions (5.4) ]      The most common adverse reactions (incidence 1% or greater) with ERWINAZE treatment are systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.",Thrombosis and hemorrhage is not a named entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed in greater detail in other sections of the label:     *    Hypersensitivity reactions [ see Warnings and Precautions (5.1) ]   *    Pancreatitis [ see Warnings and Precautions (5.2) ]   *    Glucose intolerance [ see Warnings and Precautions (5.3) ]   *    Thrombosis and hemorrhage [ see Warnings and Precautions (5.4) ]      The most common adverse reactions (incidence 1% or greater) with ERWINAZE treatment are systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.",are systemic is not a named entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed in greater detail in other sections of the label:     *    Hypersensitivity reactions [ see Warnings and Precautions (5.1) ]   *    Pancreatitis [ see Warnings and Precautions (5.2) ]   *    Glucose intolerance [ see Warnings and Precautions (5.3) ]   *    Thrombosis and hemorrhage [ see Warnings and Precautions (5.4) ]      The most common adverse reactions (incidence 1% or greater) with ERWINAZE treatment are systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.",fever is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed in greater detail in other sections of the label:     *    Hypersensitivity reactions [ see Warnings and Precautions (5.1) ]   *    Pancreatitis [ see Warnings and Precautions (5.2) ]   *    Glucose intolerance [ see Warnings and Precautions (5.3) ]   *    Thrombosis and hemorrhage [ see Warnings and Precautions (5.4) ]      The most common adverse reactions (incidence 1% or greater) with ERWINAZE treatment are systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.",", nausea , is not a named entity"
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed in greater detail in other sections of the label:     *    Hypersensitivity reactions [ see Warnings and Precautions (5.1) ]   *    Pancreatitis [ see Warnings and Precautions (5.2) ]   *    Glucose intolerance [ see Warnings and Precautions (5.3) ]   *    Thrombosis and hemorrhage [ see Warnings and Precautions (5.4) ]      The most common adverse reactions (incidence 1% or greater) with ERWINAZE treatment are systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.",thrombosis is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed in greater detail in other sections of the label:     *    Hypersensitivity reactions [ see Warnings and Precautions (5.1) ]   *    Pancreatitis [ see Warnings and Precautions (5.2) ]   *    Glucose intolerance [ see Warnings and Precautions (5.3) ]   *    Thrombosis and hemorrhage [ see Warnings and Precautions (5.4) ]      The most common adverse reactions (incidence 1% or greater) with ERWINAZE treatment are systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.",) ] The is not a named entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed in greater detail in other sections of the label:     *    Hypersensitivity reactions [ see Warnings and Precautions (5.1) ]   *    Pancreatitis [ see Warnings and Precautions (5.2) ]   *    Glucose intolerance [ see Warnings and Precautions (5.3) ]   *    Thrombosis and hemorrhage [ see Warnings and Precautions (5.4) ]      The most common adverse reactions (incidence 1% or greater) with ERWINAZE treatment are systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.",diarrhea is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed in greater detail in other sections of the label:     *    Hypersensitivity reactions [ see Warnings and Precautions (5.1) ]   *    Pancreatitis [ see Warnings and Precautions (5.2) ]   *    Glucose intolerance [ see Warnings and Precautions (5.3) ]   *    Thrombosis and hemorrhage [ see Warnings and Precautions (5.4) ]      The most common adverse reactions (incidence 1% or greater) with ERWINAZE treatment are systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.",", thrombosis , is not a named entity"
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed in greater detail in other sections of the label:     *    Hypersensitivity reactions [ see Warnings and Precautions (5.1) ]   *    Pancreatitis [ see Warnings and Precautions (5.2) ]   *    Glucose intolerance [ see Warnings and Precautions (5.3) ]   *    Thrombosis and hemorrhage [ see Warnings and Precautions (5.4) ]      The most common adverse reactions (incidence 1% or greater) with ERWINAZE treatment are systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.",abdominal discomfort is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed in greater detail in other sections of the label:     *    Hypersensitivity reactions [ see Warnings and Precautions (5.1) ]   *    Pancreatitis [ see Warnings and Precautions (5.2) ]   *    Glucose intolerance [ see Warnings and Precautions (5.3) ]   *    Thrombosis and hemorrhage [ see Warnings and Precautions (5.4) ]      The most common adverse reactions (incidence 1% or greater) with ERWINAZE treatment are systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.",) ] is not a named entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed in greater detail in other sections of the label:     *    Hypersensitivity reactions [ see Warnings and Precautions (5.1) ]   *    Pancreatitis [ see Warnings and Precautions (5.2) ]   *    Glucose intolerance [ see Warnings and Precautions (5.3) ]   *    Thrombosis and hemorrhage [ see Warnings and Precautions (5.4) ]      The most common adverse reactions (incidence 1% or greater) with ERWINAZE treatment are systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.",systemic hypersensitivity is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed in greater detail in other sections of the label:     *    Hypersensitivity reactions [ see Warnings and Precautions (5.1) ]   *    Pancreatitis [ see Warnings and Precautions (5.2) ]   *    Glucose intolerance [ see Warnings and Precautions (5.3) ]   *    Thrombosis and hemorrhage [ see Warnings and Precautions (5.4) ]      The most common adverse reactions (incidence 1% or greater) with ERWINAZE treatment are systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.",1 is not a named entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed in greater detail in other sections of the label:     *    Hypersensitivity reactions [ see Warnings and Precautions (5.1) ]   *    Pancreatitis [ see Warnings and Precautions (5.2) ]   *    Glucose intolerance [ see Warnings and Precautions (5.3) ]   *    Thrombosis and hemorrhage [ see Warnings and Precautions (5.4) ]      The most common adverse reactions (incidence 1% or greater) with ERWINAZE treatment are systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.",pancreatitis is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed in greater detail in other sections of the label:     *    Hypersensitivity reactions [ see Warnings and Precautions (5.1) ]   *    Pancreatitis [ see Warnings and Precautions (5.2) ]   *    Glucose intolerance [ see Warnings and Precautions (5.3) ]   *    Thrombosis and hemorrhage [ see Warnings and Precautions (5.4) ]      The most common adverse reactions (incidence 1% or greater) with ERWINAZE treatment are systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.",] is not a named entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed in greater detail in other sections of the label:     *    Hypersensitivity reactions [ see Warnings and Precautions (5.1) ]   *    Pancreatitis [ see Warnings and Precautions (5.2) ]   *    Glucose intolerance [ see Warnings and Precautions (5.3) ]   *    Thrombosis and hemorrhage [ see Warnings and Precautions (5.4) ]      The most common adverse reactions (incidence 1% or greater) with ERWINAZE treatment are systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.",] The is not a named entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed in greater detail in other sections of the label:     *    Hypersensitivity reactions [ see Warnings and Precautions (5.1) ]   *    Pancreatitis [ see Warnings and Precautions (5.2) ]   *    Glucose intolerance [ see Warnings and Precautions (5.3) ]   *    Thrombosis and hemorrhage [ see Warnings and Precautions (5.4) ]      The most common adverse reactions (incidence 1% or greater) with ERWINAZE treatment are systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.",[ see is not a named entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed in greater detail in other sections of the label:     *    Hypersensitivity reactions [ see Warnings and Precautions (5.1) ]   *    Pancreatitis [ see Warnings and Precautions (5.2) ]   *    Glucose intolerance [ see Warnings and Precautions (5.3) ]   *    Thrombosis and hemorrhage [ see Warnings and Precautions (5.4) ]      The most common adverse reactions (incidence 1% or greater) with ERWINAZE treatment are systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.",local reactions is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed in greater detail in other sections of the label:     *    Hypersensitivity reactions [ see Warnings and Precautions (5.1) ]   *    Pancreatitis [ see Warnings and Precautions (5.2) ]   *    Glucose intolerance [ see Warnings and Precautions (5.3) ]   *    Thrombosis and hemorrhage [ see Warnings and Precautions (5.4) ]      The most common adverse reactions (incidence 1% or greater) with ERWINAZE treatment are systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.",adverse is not a named entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed in greater detail in other sections of the label:     *    Hypersensitivity reactions [ see Warnings and Precautions (5.1) ]   *    Pancreatitis [ see Warnings and Precautions (5.2) ]   *    Glucose intolerance [ see Warnings and Precautions (5.3) ]   *    Thrombosis and hemorrhage [ see Warnings and Precautions (5.4) ]      The most common adverse reactions (incidence 1% or greater) with ERWINAZE treatment are systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.",Hypersensitivity reactions is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed in greater detail in other sections of the label:     *    Hypersensitivity reactions [ see Warnings and Precautions (5.1) ]   *    Pancreatitis [ see Warnings and Precautions (5.2) ]   *    Glucose intolerance [ see Warnings and Precautions (5.3) ]   *    Thrombosis and hemorrhage [ see Warnings and Precautions (5.4) ]      The most common adverse reactions (incidence 1% or greater) with ERWINAZE treatment are systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.",common is not a named entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed in greater detail in other sections of the label:     *    Hypersensitivity reactions [ see Warnings and Precautions (5.1) ]   *    Pancreatitis [ see Warnings and Precautions (5.2) ]   *    Glucose intolerance [ see Warnings and Precautions (5.3) ]   *    Thrombosis and hemorrhage [ see Warnings and Precautions (5.4) ]      The most common adverse reactions (incidence 1% or greater) with ERWINAZE treatment are systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.",transaminases abnormal is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed in greater detail in other sections of the label:     *    Hypersensitivity reactions [ see Warnings and Precautions (5.1) ]   *    Pancreatitis [ see Warnings and Precautions (5.2) ]   *    Glucose intolerance [ see Warnings and Precautions (5.3) ]   *    Thrombosis and hemorrhage [ see Warnings and Precautions (5.4) ]      The most common adverse reactions (incidence 1% or greater) with ERWINAZE treatment are systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.",Pancreatitis is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed in greater detail in other sections of the label:     *    Hypersensitivity reactions [ see Warnings and Precautions (5.1) ]   *    Pancreatitis [ see Warnings and Precautions (5.2) ]   *    Glucose intolerance [ see Warnings and Precautions (5.3) ]   *    Thrombosis and hemorrhage [ see Warnings and Precautions (5.4) ]      The most common adverse reactions (incidence 1% or greater) with ERWINAZE treatment are systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.",abdominal pain is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed in greater detail in other sections of the label:     *    Hypersensitivity reactions [ see Warnings and Precautions (5.1) ]   *    Pancreatitis [ see Warnings and Precautions (5.2) ]   *    Glucose intolerance [ see Warnings and Precautions (5.3) ]   *    Thrombosis and hemorrhage [ see Warnings and Precautions (5.4) ]      The most common adverse reactions (incidence 1% or greater) with ERWINAZE treatment are systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.",nausea is an adverse reaction entity
"5.4 Thrombosis and Hemorrhage    Serious thrombotic events, including sagittal sinus thrombosis and pulmonary embolism have been reported with both  E. coli  and  Erwinia  -derived L-asparaginase therapy.",thrombotic events is an adverse reaction entity
"5.4 Thrombosis and Hemorrhage    Serious thrombotic events, including sagittal sinus thrombosis and pulmonary embolism have been reported with both  E. coli  and  Erwinia  -derived L-asparaginase therapy.",Serious thrombotic is not a named entity
"5.4 Thrombosis and Hemorrhage    Serious thrombotic events, including sagittal sinus thrombosis and pulmonary embolism have been reported with both  E. coli  and  Erwinia  -derived L-asparaginase therapy.",pulmonary embolism is an adverse reaction entity
"5.4 Thrombosis and Hemorrhage    Serious thrombotic events, including sagittal sinus thrombosis and pulmonary embolism have been reported with both  E. coli  and  Erwinia  -derived L-asparaginase therapy.",sagittal sinus thrombosis is an adverse reaction entity
"5.4 Thrombosis and Hemorrhage    Serious thrombotic events, including sagittal sinus thrombosis and pulmonary embolism have been reported with both  E. coli  and  Erwinia  -derived L-asparaginase therapy.","events , including is not a named entity"
"5.4 Thrombosis and Hemorrhage    Serious thrombotic events, including sagittal sinus thrombosis and pulmonary embolism have been reported with both  E. coli  and  Erwinia  -derived L-asparaginase therapy.",and Erwinia -derived is not a named entity
5.2 Pancreatitis      Pancreatitis has been reported in 4% of patients in clinical trials [  see Adverse Reactions (6.1)  ].,( is not a named entity
5.2 Pancreatitis      Pancreatitis has been reported in 4% of patients in clinical trials [  see Adverse Reactions (6.1)  ].,Pancreatitis is an adverse reaction entity
"The following coagulation proteins were decreased in the majority of patients after a 2-week course of ERWINAZE by intramuscular administration: fibrinogen, protein C activity, protein S activity, and anti-thrombin III.",decreased protein C activity is an adverse reaction entity
"The following coagulation proteins were decreased in the majority of patients after a 2-week course of ERWINAZE by intramuscular administration: fibrinogen, protein C activity, protein S activity, and anti-thrombin III.",decreased anti-thrombin III is an adverse reaction entity
"The following coagulation proteins were decreased in the majority of patients after a 2-week course of ERWINAZE by intramuscular administration: fibrinogen, protein C activity, protein S activity, and anti-thrombin III.",", and is not a named entity"
"The following coagulation proteins were decreased in the majority of patients after a 2-week course of ERWINAZE by intramuscular administration: fibrinogen, protein C activity, protein S activity, and anti-thrombin III.",administration : fibrinogen is not a named entity
"The following coagulation proteins were decreased in the majority of patients after a 2-week course of ERWINAZE by intramuscular administration: fibrinogen, protein C activity, protein S activity, and anti-thrombin III.","fibrinogen , is not a named entity"
"The following coagulation proteins were decreased in the majority of patients after a 2-week course of ERWINAZE by intramuscular administration: fibrinogen, protein C activity, protein S activity, and anti-thrombin III.",", protein C is not a named entity"
"The following coagulation proteins were decreased in the majority of patients after a 2-week course of ERWINAZE by intramuscular administration: fibrinogen, protein C activity, protein S activity, and anti-thrombin III.",decreased fibrinogen is an adverse reaction entity
"The following coagulation proteins were decreased in the majority of patients after a 2-week course of ERWINAZE by intramuscular administration: fibrinogen, protein C activity, protein S activity, and anti-thrombin III.",decreased protein S activity is an adverse reaction entity
"The following coagulation proteins were decreased in the majority of patients after a 2-week course of ERWINAZE by intramuscular administration: fibrinogen, protein C activity, protein S activity, and anti-thrombin III.",administration : is not a named entity
"The following coagulation proteins were decreased in the majority of patients after a 2-week course of ERWINAZE by intramuscular administration: fibrinogen, protein C activity, protein S activity, and anti-thrombin III.",coagulation proteins decreased is an adverse reaction entity
"One subject out of 761 administered Vizamyl experienced a serious hypersensitivity reaction with flushing, dyspnea and chest pressure within minutes following Vizamyl administration and recovered with treatment.",chest pressure is an adverse reaction entity
"One subject out of 761 administered Vizamyl experienced a serious hypersensitivity reaction with flushing, dyspnea and chest pressure within minutes following Vizamyl administration and recovered with treatment.",dyspnea is an adverse reaction entity
"One subject out of 761 administered Vizamyl experienced a serious hypersensitivity reaction with flushing, dyspnea and chest pressure within minutes following Vizamyl administration and recovered with treatment.",and is not a named entity
"One subject out of 761 administered Vizamyl experienced a serious hypersensitivity reaction with flushing, dyspnea and chest pressure within minutes following Vizamyl administration and recovered with treatment.",within is not a named entity
"One subject out of 761 administered Vizamyl experienced a serious hypersensitivity reaction with flushing, dyspnea and chest pressure within minutes following Vizamyl administration and recovered with treatment.",out is not a named entity
"One subject out of 761 administered Vizamyl experienced a serious hypersensitivity reaction with flushing, dyspnea and chest pressure within minutes following Vizamyl administration and recovered with treatment.",flushing is an adverse reaction entity
"One subject out of 761 administered Vizamyl experienced a serious hypersensitivity reaction with flushing, dyspnea and chest pressure within minutes following Vizamyl administration and recovered with treatment.",hypersensitivity reaction is an adverse reaction entity
"One subject out of 761 administered Vizamyl experienced a serious hypersensitivity reaction with flushing, dyspnea and chest pressure within minutes following Vizamyl administration and recovered with treatment.",of 761 is not a named entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Hypersensitivity reactions: Ask patients about prior reactions to Vizamyl.,: * Hypersensitivity is not a named entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Hypersensitivity reactions: Ask patients about prior reactions to Vizamyl.,Hypersensitivity reactions is an adverse reaction entity
Table 2: Adverse Reactions Reported in Clinical Trials of Vizamyl (N = 761 subjects)   Adverse Reaction                                                 N (percent of patients)                      Flushing                                                                 16 (2%)                           Increased blood pressure                                                 13 (2%)                           Headache                                                                 10 (1%)                           Nausea                                                                    8 (1%)                           Dizziness                                                                 8 (1%),Nausea is an adverse reaction entity
Table 2: Adverse Reactions Reported in Clinical Trials of Vizamyl (N = 761 subjects)   Adverse Reaction                                                 N (percent of patients)                      Flushing                                                                 16 (2%)                           Increased blood pressure                                                 13 (2%)                           Headache                                                                 10 (1%)                           Nausea                                                                    8 (1%)                           Dizziness                                                                 8 (1%),of Vizamyl ( is not a named entity
Table 2: Adverse Reactions Reported in Clinical Trials of Vizamyl (N = 761 subjects)   Adverse Reaction                                                 N (percent of patients)                      Flushing                                                                 16 (2%)                           Increased blood pressure                                                 13 (2%)                           Headache                                                                 10 (1%)                           Nausea                                                                    8 (1%)                           Dizziness                                                                 8 (1%),Increased blood pressure is an adverse reaction entity
Table 2: Adverse Reactions Reported in Clinical Trials of Vizamyl (N = 761 subjects)   Adverse Reaction                                                 N (percent of patients)                      Flushing                                                                 16 (2%)                           Increased blood pressure                                                 13 (2%)                           Headache                                                                 10 (1%)                           Nausea                                                                    8 (1%)                           Dizziness                                                                 8 (1%),percent of patients is not a named entity
Table 2: Adverse Reactions Reported in Clinical Trials of Vizamyl (N = 761 subjects)   Adverse Reaction                                                 N (percent of patients)                      Flushing                                                                 16 (2%)                           Increased blood pressure                                                 13 (2%)                           Headache                                                                 10 (1%)                           Nausea                                                                    8 (1%)                           Dizziness                                                                 8 (1%),Headache is an adverse reaction entity
Table 2: Adverse Reactions Reported in Clinical Trials of Vizamyl (N = 761 subjects)   Adverse Reaction                                                 N (percent of patients)                      Flushing                                                                 16 (2%)                           Increased blood pressure                                                 13 (2%)                           Headache                                                                 10 (1%)                           Nausea                                                                    8 (1%)                           Dizziness                                                                 8 (1%),2 is not a named entity
Table 2: Adverse Reactions Reported in Clinical Trials of Vizamyl (N = 761 subjects)   Adverse Reaction                                                 N (percent of patients)                      Flushing                                                                 16 (2%)                           Increased blood pressure                                                 13 (2%)                           Headache                                                                 10 (1%)                           Nausea                                                                    8 (1%)                           Dizziness                                                                 8 (1%),( N is not a named entity
Table 2: Adverse Reactions Reported in Clinical Trials of Vizamyl (N = 761 subjects)   Adverse Reaction                                                 N (percent of patients)                      Flushing                                                                 16 (2%)                           Increased blood pressure                                                 13 (2%)                           Headache                                                                 10 (1%)                           Nausea                                                                    8 (1%)                           Dizziness                                                                 8 (1%),) is not a named entity
Table 2: Adverse Reactions Reported in Clinical Trials of Vizamyl (N = 761 subjects)   Adverse Reaction                                                 N (percent of patients)                      Flushing                                                                 16 (2%)                           Increased blood pressure                                                 13 (2%)                           Headache                                                                 10 (1%)                           Nausea                                                                    8 (1%)                           Dizziness                                                                 8 (1%),Flushing is an adverse reaction entity
Table 2: Adverse Reactions Reported in Clinical Trials of Vizamyl (N = 761 subjects)   Adverse Reaction                                                 N (percent of patients)                      Flushing                                                                 16 (2%)                           Increased blood pressure                                                 13 (2%)                           Headache                                                                 10 (1%)                           Nausea                                                                    8 (1%)                           Dizziness                                                                 8 (1%),Dizziness is an adverse reaction entity
"Have resuscitation equipment and trained personnel available at time of Vizamyl administration (  5.1  )   *  Image interpretation errors (especially false positives) have been observed (  5.2  )   *  Radiation risk: Vizamyl, similar to all radiopharmaceuticals, contributes to a patient's long-term cumulative radiation exposure.",: Vizamyl is not a named entity
"Have resuscitation equipment and trained personnel available at time of Vizamyl administration (  5.1  )   *  Image interpretation errors (especially false positives) have been observed (  5.2  )   *  Radiation risk: Vizamyl, similar to all radiopharmaceuticals, contributes to a patient's long-term cumulative radiation exposure.","all radiopharmaceuticals , is not a named entity"
"Have resuscitation equipment and trained personnel available at time of Vizamyl administration (  5.1  )   *  Image interpretation errors (especially false positives) have been observed (  5.2  )   *  Radiation risk: Vizamyl, similar to all radiopharmaceuticals, contributes to a patient's long-term cumulative radiation exposure.",Radiation risk is an adverse reaction entity
"Have resuscitation equipment and trained personnel available at time of Vizamyl administration (  5.1  )   *  Image interpretation errors (especially false positives) have been observed (  5.2  )   *  Radiation risk: Vizamyl, similar to all radiopharmaceuticals, contributes to a patient's long-term cumulative radiation exposure.",long-term cumulative radiation exposure is an adverse reaction entity
"5.3 Radiation Risk      Vizamyl, similar to other radiopharmaceuticals, contributes to a patient's overall long-term cumulative radiation exposure.",long-term cumulative radiation exposure is an adverse reaction entity
"5.3 Radiation Risk      Vizamyl, similar to other radiopharmaceuticals, contributes to a patient's overall long-term cumulative radiation exposure.",", is not a named entity"
"6 ADVERSE REACTIONS    EXCERPT:   The most common adverse reactions (>=10%) are: fatigue, headache, nausea, diarrhea, back pain, pain in extremities, and upper abdominal pain (  6.1  )  To report SUSPECTED ADVERSE REACTIONS, contact Genzyme Corporation at 1-800-745-4447 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch           6.1 Clinical Trials Experience    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.",headache is an adverse reaction entity
"6 ADVERSE REACTIONS    EXCERPT:   The most common adverse reactions (>=10%) are: fatigue, headache, nausea, diarrhea, back pain, pain in extremities, and upper abdominal pain (  6.1  )  To report SUSPECTED ADVERSE REACTIONS, contact Genzyme Corporation at 1-800-745-4447 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch           6.1 Clinical Trials Experience    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.",rates observed is not a named entity
"6 ADVERSE REACTIONS    EXCERPT:   The most common adverse reactions (>=10%) are: fatigue, headache, nausea, diarrhea, back pain, pain in extremities, and upper abdominal pain (  6.1  )  To report SUSPECTED ADVERSE REACTIONS, contact Genzyme Corporation at 1-800-745-4447 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch           6.1 Clinical Trials Experience    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.",diarrhea is an adverse reaction entity
"6 ADVERSE REACTIONS    EXCERPT:   The most common adverse reactions (>=10%) are: fatigue, headache, nausea, diarrhea, back pain, pain in extremities, and upper abdominal pain (  6.1  )  To report SUSPECTED ADVERSE REACTIONS, contact Genzyme Corporation at 1-800-745-4447 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch           6.1 Clinical Trials Experience    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.",practice is not a named entity
"6 ADVERSE REACTIONS    EXCERPT:   The most common adverse reactions (>=10%) are: fatigue, headache, nausea, diarrhea, back pain, pain in extremities, and upper abdominal pain (  6.1  )  To report SUSPECTED ADVERSE REACTIONS, contact Genzyme Corporation at 1-800-745-4447 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch           6.1 Clinical Trials Experience    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.",", is not a named entity"
"6 ADVERSE REACTIONS    EXCERPT:   The most common adverse reactions (>=10%) are: fatigue, headache, nausea, diarrhea, back pain, pain in extremities, and upper abdominal pain (  6.1  )  To report SUSPECTED ADVERSE REACTIONS, contact Genzyme Corporation at 1-800-745-4447 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch           6.1 Clinical Trials Experience    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.",) is not a named entity
"6 ADVERSE REACTIONS    EXCERPT:   The most common adverse reactions (>=10%) are: fatigue, headache, nausea, diarrhea, back pain, pain in extremities, and upper abdominal pain (  6.1  )  To report SUSPECTED ADVERSE REACTIONS, contact Genzyme Corporation at 1-800-745-4447 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch           6.1 Clinical Trials Experience    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.",", diarrhea is not a named entity"
"6 ADVERSE REACTIONS    EXCERPT:   The most common adverse reactions (>=10%) are: fatigue, headache, nausea, diarrhea, back pain, pain in extremities, and upper abdominal pain (  6.1  )  To report SUSPECTED ADVERSE REACTIONS, contact Genzyme Corporation at 1-800-745-4447 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch           6.1 Clinical Trials Experience    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.",may not is not a named entity
"6 ADVERSE REACTIONS    EXCERPT:   The most common adverse reactions (>=10%) are: fatigue, headache, nausea, diarrhea, back pain, pain in extremities, and upper abdominal pain (  6.1  )  To report SUSPECTED ADVERSE REACTIONS, contact Genzyme Corporation at 1-800-745-4447 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch           6.1 Clinical Trials Experience    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.",back pain is an adverse reaction entity
"6 ADVERSE REACTIONS    EXCERPT:   The most common adverse reactions (>=10%) are: fatigue, headache, nausea, diarrhea, back pain, pain in extremities, and upper abdominal pain (  6.1  )  To report SUSPECTED ADVERSE REACTIONS, contact Genzyme Corporation at 1-800-745-4447 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch           6.1 Clinical Trials Experience    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.",upper abdominal pain is an adverse reaction entity
"6 ADVERSE REACTIONS    EXCERPT:   The most common adverse reactions (>=10%) are: fatigue, headache, nausea, diarrhea, back pain, pain in extremities, and upper abdominal pain (  6.1  )  To report SUSPECTED ADVERSE REACTIONS, contact Genzyme Corporation at 1-800-745-4447 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch           6.1 Clinical Trials Experience    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.",fatigue is an adverse reaction entity
"6 ADVERSE REACTIONS    EXCERPT:   The most common adverse reactions (>=10%) are: fatigue, headache, nausea, diarrhea, back pain, pain in extremities, and upper abdominal pain (  6.1  )  To report SUSPECTED ADVERSE REACTIONS, contact Genzyme Corporation at 1-800-745-4447 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch           6.1 Clinical Trials Experience    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.",pain in extremities is an adverse reaction entity
"6 ADVERSE REACTIONS    EXCERPT:   The most common adverse reactions (>=10%) are: fatigue, headache, nausea, diarrhea, back pain, pain in extremities, and upper abdominal pain (  6.1  )  To report SUSPECTED ADVERSE REACTIONS, contact Genzyme Corporation at 1-800-745-4447 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch           6.1 Clinical Trials Experience    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.",nausea is an adverse reaction entity
"6 ADVERSE REACTIONS    EXCERPT:   The most common adverse reactions (>=10%) are: fatigue, headache, nausea, diarrhea, back pain, pain in extremities, and upper abdominal pain (  6.1  )  To report SUSPECTED ADVERSE REACTIONS, contact Genzyme Corporation at 1-800-745-4447 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch           6.1 Clinical Trials Experience    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.","headache , nausea is not a named entity"
"Because CERDELGA is predicted to cause increases in ECG intervals (PR, QTc, and QRS) at substantially elevated eliglustat plasma concentrations, use of CERDELGA is not recommended in patients with pre-existing cardiac disease (congestive heart failure, recent acute myocardial infarction, bradycardia, heart block, ventricular arrhythmia), long QT syndrome, and in combination with Class IA (e.g., quinidine, procainamide) and Class III (e.g., amiodarone, sotalol) antiarrhythmic medications [see  Clinical Pharmacology (12.2)  ]  .",increases in ECG intervals PR is an adverse reaction entity
"Because CERDELGA is predicted to cause increases in ECG intervals (PR, QTc, and QRS) at substantially elevated eliglustat plasma concentrations, use of CERDELGA is not recommended in patients with pre-existing cardiac disease (congestive heart failure, recent acute myocardial infarction, bradycardia, heart block, ventricular arrhythmia), long QT syndrome, and in combination with Class IA (e.g., quinidine, procainamide) and Class III (e.g., amiodarone, sotalol) antiarrhythmic medications [see  Clinical Pharmacology (12.2)  ]  .",increases in ECG intervals QTc is an adverse reaction entity
"Because CERDELGA is predicted to cause increases in ECG intervals (PR, QTc, and QRS) at substantially elevated eliglustat plasma concentrations, use of CERDELGA is not recommended in patients with pre-existing cardiac disease (congestive heart failure, recent acute myocardial infarction, bradycardia, heart block, ventricular arrhythmia), long QT syndrome, and in combination with Class IA (e.g., quinidine, procainamide) and Class III (e.g., amiodarone, sotalol) antiarrhythmic medications [see  Clinical Pharmacology (12.2)  ]  .",[ see Clinical is not a named entity
"Because CERDELGA is predicted to cause increases in ECG intervals (PR, QTc, and QRS) at substantially elevated eliglustat plasma concentrations, use of CERDELGA is not recommended in patients with pre-existing cardiac disease (congestive heart failure, recent acute myocardial infarction, bradycardia, heart block, ventricular arrhythmia), long QT syndrome, and in combination with Class IA (e.g., quinidine, procainamide) and Class III (e.g., amiodarone, sotalol) antiarrhythmic medications [see  Clinical Pharmacology (12.2)  ]  .",III ( is not a named entity
"Because CERDELGA is predicted to cause increases in ECG intervals (PR, QTc, and QRS) at substantially elevated eliglustat plasma concentrations, use of CERDELGA is not recommended in patients with pre-existing cardiac disease (congestive heart failure, recent acute myocardial infarction, bradycardia, heart block, ventricular arrhythmia), long QT syndrome, and in combination with Class IA (e.g., quinidine, procainamide) and Class III (e.g., amiodarone, sotalol) antiarrhythmic medications [see  Clinical Pharmacology (12.2)  ]  .",) ] is not a named entity
"Because CERDELGA is predicted to cause increases in ECG intervals (PR, QTc, and QRS) at substantially elevated eliglustat plasma concentrations, use of CERDELGA is not recommended in patients with pre-existing cardiac disease (congestive heart failure, recent acute myocardial infarction, bradycardia, heart block, ventricular arrhythmia), long QT syndrome, and in combination with Class IA (e.g., quinidine, procainamide) and Class III (e.g., amiodarone, sotalol) antiarrhythmic medications [see  Clinical Pharmacology (12.2)  ]  .",increases in ECG intervals QRS is an adverse reaction entity
"Drugs that inhibit CYP2D6 and CYP3A metabolism pathways may significantly increase the exposure to eliglustat and result in prolongation of the PR, QTc, and/or QRS cardiac intervals that could result in cardiac arrhythmias [see  Clinical Pharmacology (12.2)  ]  .",could result in is not a named entity
"Drugs that inhibit CYP2D6 and CYP3A metabolism pathways may significantly increase the exposure to eliglustat and result in prolongation of the PR, QTc, and/or QRS cardiac intervals that could result in cardiac arrhythmias [see  Clinical Pharmacology (12.2)  ]  .",could result in is not a named entity
"Drugs that inhibit CYP2D6 and CYP3A metabolism pathways may significantly increase the exposure to eliglustat and result in prolongation of the PR, QTc, and/or QRS cardiac intervals that could result in cardiac arrhythmias [see  Clinical Pharmacology (12.2)  ]  .",prolongation QTc cardiac intervals is an adverse reaction entity
"Drugs that inhibit CYP2D6 and CYP3A metabolism pathways may significantly increase the exposure to eliglustat and result in prolongation of the PR, QTc, and/or QRS cardiac intervals that could result in cardiac arrhythmias [see  Clinical Pharmacology (12.2)  ]  .",may is not a named entity
"Drugs that inhibit CYP2D6 and CYP3A metabolism pathways may significantly increase the exposure to eliglustat and result in prolongation of the PR, QTc, and/or QRS cardiac intervals that could result in cardiac arrhythmias [see  Clinical Pharmacology (12.2)  ]  .",Drugs that is not a named entity
"Drugs that inhibit CYP2D6 and CYP3A metabolism pathways may significantly increase the exposure to eliglustat and result in prolongation of the PR, QTc, and/or QRS cardiac intervals that could result in cardiac arrhythmias [see  Clinical Pharmacology (12.2)  ]  .",prolongation QRS cardiac intervals is an adverse reaction entity
"Drugs that inhibit CYP2D6 and CYP3A metabolism pathways may significantly increase the exposure to eliglustat and result in prolongation of the PR, QTc, and/or QRS cardiac intervals that could result in cardiac arrhythmias [see  Clinical Pharmacology (12.2)  ]  .",cardiac arrhythmias is an adverse reaction entity
"Drugs that inhibit CYP2D6 and CYP3A metabolism pathways may significantly increase the exposure to eliglustat and result in prolongation of the PR, QTc, and/or QRS cardiac intervals that could result in cardiac arrhythmias [see  Clinical Pharmacology (12.2)  ]  .",prolongation PR cardiac intervals is an adverse reaction entity
"Severe hypersensitivity reactions can occur and may include generalized rash/erythema, hypotension and bronchospasm.",hypersensitivity reactions is an adverse reaction entity
"Severe hypersensitivity reactions can occur and may include generalized rash/erythema, hypotension and bronchospasm.",hypotension is an adverse reaction entity
"Severe hypersensitivity reactions can occur and may include generalized rash/erythema, hypotension and bronchospasm.","generalized rash/erythema , is not a named entity"
"Severe hypersensitivity reactions can occur and may include generalized rash/erythema, hypotension and bronchospasm.",generalized rash is an adverse reaction entity
"Severe hypersensitivity reactions can occur and may include generalized rash/erythema, hypotension and bronchospasm.",", is not a named entity"
"Severe hypersensitivity reactions can occur and may include generalized rash/erythema, hypotension and bronchospasm.",erythema is an adverse reaction entity
"Severe hypersensitivity reactions can occur and may include generalized rash/erythema, hypotension and bronchospasm.",bronchospasm is an adverse reaction entity
"Severe hypersensitivity reactions can occur and may include generalized rash/erythema, hypotension and bronchospasm.",occur and is not a named entity
"Severe hypersensitivity reactions can occur and may include generalized rash/erythema, hypotension and bronchospasm.",", is not a named entity"
"Severe hypersensitivity reactions can occur and may include generalized rash/erythema, hypotension and bronchospasm.",Severe hypersensitivity reactions is not a named entity
The most common adverse reactions leading to treatment discontinuation in the JEVTANA group were neutropenia and renal failure.,and renal is not a named entity
The most common adverse reactions leading to treatment discontinuation in the JEVTANA group were neutropenia and renal failure.,renal failure is an adverse reaction entity
The most common adverse reactions leading to treatment discontinuation in the JEVTANA group were neutropenia and renal failure.,neutropenia is an adverse reaction entity
The most common adverse reactions leading to treatment discontinuation in the JEVTANA group were neutropenia and renal failure.,discontinuation in the is not a named entity
"(  5.3  )   *  Renal failure, including cases with fatal outcomes, has been reported.",Renal failure is an adverse reaction entity
"(  5.3  )   *  Renal failure, including cases with fatal outcomes, has been reported.",", is not a named entity"
"(  5.3  )   *  Renal failure, including cases with fatal outcomes, has been reported.",fatal is an adverse reaction entity
"(  5.3  )   *  Renal failure, including cases with fatal outcomes, has been reported.",* Renal is not a named entity
Grade 3-4 neutropenia has been observed in 82% of patients treated with JEVTANA in the randomized trial.,has been observed is not a named entity
Grade 3-4 neutropenia has been observed in 82% of patients treated with JEVTANA in the randomized trial.,neutropenia is an adverse reaction entity
One additional patient's death was attributed to neutropenia without a documented infection.,infection is an adverse reaction entity
One additional patient's death was attributed to neutropenia without a documented infection.,to neutropenia without is not a named entity
One additional patient's death was attributed to neutropenia without a documented infection.,neutropenia is an adverse reaction entity
One additional patient's death was attributed to neutropenia without a documented infection.,patient 's is not a named entity
One additional patient's death was attributed to neutropenia without a documented infection.,death is an adverse reaction entity
One additional patient's death was attributed to neutropenia without a documented infection.,additional is not a named entity
"(  5.7  )(  8.1  )             5.1 Bone Marrow Suppression       Bone marrow suppression manifested as neutropenia, anemia, thrombocytopenia and/or pancytopenia may occur.",Bone is not a named entity
"(  5.7  )(  8.1  )             5.1 Bone Marrow Suppression       Bone marrow suppression manifested as neutropenia, anemia, thrombocytopenia and/or pancytopenia may occur.",neutropenia is an adverse reaction entity
"(  5.7  )(  8.1  )             5.1 Bone Marrow Suppression       Bone marrow suppression manifested as neutropenia, anemia, thrombocytopenia and/or pancytopenia may occur.",thrombocytopenia is an adverse reaction entity
"(  5.7  )(  8.1  )             5.1 Bone Marrow Suppression       Bone marrow suppression manifested as neutropenia, anemia, thrombocytopenia and/or pancytopenia may occur.","as neutropenia , is not a named entity"
"(  5.7  )(  8.1  )             5.1 Bone Marrow Suppression       Bone marrow suppression manifested as neutropenia, anemia, thrombocytopenia and/or pancytopenia may occur.",5.1 is not a named entity
"(  5.7  )(  8.1  )             5.1 Bone Marrow Suppression       Bone marrow suppression manifested as neutropenia, anemia, thrombocytopenia and/or pancytopenia may occur.",occur is not a named entity
"(  5.7  )(  8.1  )             5.1 Bone Marrow Suppression       Bone marrow suppression manifested as neutropenia, anemia, thrombocytopenia and/or pancytopenia may occur.",Bone marrow suppression is an adverse reaction entity
"(  5.7  )(  8.1  )             5.1 Bone Marrow Suppression       Bone marrow suppression manifested as neutropenia, anemia, thrombocytopenia and/or pancytopenia may occur.",anemia is an adverse reaction entity
"(  5.7  )(  8.1  )             5.1 Bone Marrow Suppression       Bone marrow suppression manifested as neutropenia, anemia, thrombocytopenia and/or pancytopenia may occur.",5.7 is not a named entity
"(  5.7  )(  8.1  )             5.1 Bone Marrow Suppression       Bone marrow suppression manifested as neutropenia, anemia, thrombocytopenia and/or pancytopenia may occur.",pancytopenia is an adverse reaction entity
Severe hypersensitivity reactions require immediate discontinuation of the JEVTANA infusion and appropriate therapy.,hypersensitivity reactions is an adverse reaction entity
Severe hypersensitivity reactions require immediate discontinuation of the JEVTANA infusion and appropriate therapy.,and appropriate is not a named entity
The most common fatal adverse reactions in JEVTANA-treated patients were infections (n=5) and renal failure (n=4).,failure is not a named entity
The most common fatal adverse reactions in JEVTANA-treated patients were infections (n=5) and renal failure (n=4).,fatal is an adverse reaction entity
The most common fatal adverse reactions in JEVTANA-treated patients were infections (n=5) and renal failure (n=4).,in is not a named entity
The most common fatal adverse reactions in JEVTANA-treated patients were infections (n=5) and renal failure (n=4).,n=5 ) is not a named entity
The most common fatal adverse reactions in JEVTANA-treated patients were infections (n=5) and renal failure (n=4).,renal failure is an adverse reaction entity
The most common fatal adverse reactions in JEVTANA-treated patients were infections (n=5) and renal failure (n=4).,infections is an adverse reaction entity
"Twenty-two (6%) patients discontinued JEVTANA treatment due to neutropenia, febrile neutropenia, infection, or sepsis.",infection is an adverse reaction entity
"Twenty-two (6%) patients discontinued JEVTANA treatment due to neutropenia, febrile neutropenia, infection, or sepsis.",Twenty-two ( is not a named entity
"Twenty-two (6%) patients discontinued JEVTANA treatment due to neutropenia, febrile neutropenia, infection, or sepsis.",", is not a named entity"
"Twenty-two (6%) patients discontinued JEVTANA treatment due to neutropenia, febrile neutropenia, infection, or sepsis.",discontinued JEVTANA treatment is not a named entity
"Twenty-two (6%) patients discontinued JEVTANA treatment due to neutropenia, febrile neutropenia, infection, or sepsis.","infection , is not a named entity"
"Twenty-two (6%) patients discontinued JEVTANA treatment due to neutropenia, febrile neutropenia, infection, or sepsis.",sepsis is an adverse reaction entity
"Twenty-two (6%) patients discontinued JEVTANA treatment due to neutropenia, febrile neutropenia, infection, or sepsis.",neutropenia is an adverse reaction entity
"Twenty-two (6%) patients discontinued JEVTANA treatment due to neutropenia, febrile neutropenia, infection, or sepsis.",febrile neutropenia is an adverse reaction entity
"The incidence of the following grade 3-4 adverse reactions were higher in patients >= 65 years of age compared to younger patients; neutropenia (87% vs. 74%), and febrile neutropenia (8% vs. 6%)  [see  Use in Specific Populations (8.5)  ]  .",3-4 adverse reactions is not a named entity
"The incidence of the following grade 3-4 adverse reactions were higher in patients >= 65 years of age compared to younger patients; neutropenia (87% vs. 74%), and febrile neutropenia (8% vs. 6%)  [see  Use in Specific Populations (8.5)  ]  .",febrile neutropenia is an adverse reaction entity
"The incidence of the following grade 3-4 adverse reactions were higher in patients >= 65 years of age compared to younger patients; neutropenia (87% vs. 74%), and febrile neutropenia (8% vs. 6%)  [see  Use in Specific Populations (8.5)  ]  .",", and febrile is not a named entity"
"The incidence of the following grade 3-4 adverse reactions were higher in patients >= 65 years of age compared to younger patients; neutropenia (87% vs. 74%), and febrile neutropenia (8% vs. 6%)  [see  Use in Specific Populations (8.5)  ]  .",neutropenia is an adverse reaction entity
BOXED WARNING: WARNING: NEUTROPENIA AND HYPERSENSITIVITY      WARNING: NEUTROPENIA AND HYPERSENSITIVITY      EXCERPT:     WARNING: NEUTROPENIA AND HYPERSENSITIVITY         See full prescribing information for complete boxed warning    .,HYPERSENSITIVITY is an adverse reaction entity
BOXED WARNING: WARNING: NEUTROPENIA AND HYPERSENSITIVITY      WARNING: NEUTROPENIA AND HYPERSENSITIVITY      EXCERPT:     WARNING: NEUTROPENIA AND HYPERSENSITIVITY         See full prescribing information for complete boxed warning    .,NEUTROPENIA is an adverse reaction entity
BOXED WARNING: WARNING: NEUTROPENIA AND HYPERSENSITIVITY      WARNING: NEUTROPENIA AND HYPERSENSITIVITY      EXCERPT:     WARNING: NEUTROPENIA AND HYPERSENSITIVITY         See full prescribing information for complete boxed warning    .,HYPERSENSITIVITY is an adverse reaction entity
BOXED WARNING: WARNING: NEUTROPENIA AND HYPERSENSITIVITY      WARNING: NEUTROPENIA AND HYPERSENSITIVITY      EXCERPT:     WARNING: NEUTROPENIA AND HYPERSENSITIVITY         See full prescribing information for complete boxed warning    .,AND HYPERSENSITIVITY See is not a named entity
BOXED WARNING: WARNING: NEUTROPENIA AND HYPERSENSITIVITY      WARNING: NEUTROPENIA AND HYPERSENSITIVITY      EXCERPT:     WARNING: NEUTROPENIA AND HYPERSENSITIVITY         See full prescribing information for complete boxed warning    .,for complete boxed is not a named entity
BOXED WARNING: WARNING: NEUTROPENIA AND HYPERSENSITIVITY      WARNING: NEUTROPENIA AND HYPERSENSITIVITY      EXCERPT:     WARNING: NEUTROPENIA AND HYPERSENSITIVITY         See full prescribing information for complete boxed warning    .,AND HYPERSENSITIVITY WARNING is not a named entity
BOXED WARNING: WARNING: NEUTROPENIA AND HYPERSENSITIVITY      WARNING: NEUTROPENIA AND HYPERSENSITIVITY      EXCERPT:     WARNING: NEUTROPENIA AND HYPERSENSITIVITY         See full prescribing information for complete boxed warning    .,NEUTROPENIA is an adverse reaction entity
BOXED WARNING: WARNING: NEUTROPENIA AND HYPERSENSITIVITY      WARNING: NEUTROPENIA AND HYPERSENSITIVITY      EXCERPT:     WARNING: NEUTROPENIA AND HYPERSENSITIVITY         See full prescribing information for complete boxed warning    .,: is not a named entity
BOXED WARNING: WARNING: NEUTROPENIA AND HYPERSENSITIVITY      WARNING: NEUTROPENIA AND HYPERSENSITIVITY      EXCERPT:     WARNING: NEUTROPENIA AND HYPERSENSITIVITY         See full prescribing information for complete boxed warning    .,complete boxed warning is not a named entity
BOXED WARNING: WARNING: NEUTROPENIA AND HYPERSENSITIVITY      WARNING: NEUTROPENIA AND HYPERSENSITIVITY      EXCERPT:     WARNING: NEUTROPENIA AND HYPERSENSITIVITY         See full prescribing information for complete boxed warning    .,HYPERSENSITIVITY is an adverse reaction entity
BOXED WARNING: WARNING: NEUTROPENIA AND HYPERSENSITIVITY      WARNING: NEUTROPENIA AND HYPERSENSITIVITY      EXCERPT:     WARNING: NEUTROPENIA AND HYPERSENSITIVITY         See full prescribing information for complete boxed warning    .,NEUTROPENIA is an adverse reaction entity
BOXED WARNING: WARNING: NEUTROPENIA AND HYPERSENSITIVITY      WARNING: NEUTROPENIA AND HYPERSENSITIVITY      EXCERPT:     WARNING: NEUTROPENIA AND HYPERSENSITIVITY         See full prescribing information for complete boxed warning    .,prescribing information for is not a named entity
Death related to diarrhea and electrolyte imbalance occurred in the randomized clinical trial.,Death related is not a named entity
Death related to diarrhea and electrolyte imbalance occurred in the randomized clinical trial.,electrolyte imbalance is an adverse reaction entity
Death related to diarrhea and electrolyte imbalance occurred in the randomized clinical trial.,Death is an adverse reaction entity
Death related to diarrhea and electrolyte imbalance occurred in the randomized clinical trial.,Death related to is not a named entity
Death related to diarrhea and electrolyte imbalance occurred in the randomized clinical trial.,clinical trial is not a named entity
Death related to diarrhea and electrolyte imbalance occurred in the randomized clinical trial.,diarrhea is an adverse reaction entity
"Gastrointestinal (GI) hemorrhage and perforation, ileus, enterocolitis, neutropenic enterocolitis, including fatal outcome, have been reported in patients treated with JEVTANA [see  Adverse Reactions (6.2)  ]  .","ileus , enterocolitis is not a named entity"
"Gastrointestinal (GI) hemorrhage and perforation, ileus, enterocolitis, neutropenic enterocolitis, including fatal outcome, have been reported in patients treated with JEVTANA [see  Adverse Reactions (6.2)  ]  .",Gastrointestinal perforation is an adverse reaction entity
"Gastrointestinal (GI) hemorrhage and perforation, ileus, enterocolitis, neutropenic enterocolitis, including fatal outcome, have been reported in patients treated with JEVTANA [see  Adverse Reactions (6.2)  ]  .",in patients is not a named entity
"Gastrointestinal (GI) hemorrhage and perforation, ileus, enterocolitis, neutropenic enterocolitis, including fatal outcome, have been reported in patients treated with JEVTANA [see  Adverse Reactions (6.2)  ]  .",Gastrointestinal hemorrhage is an adverse reaction entity
"Gastrointestinal (GI) hemorrhage and perforation, ileus, enterocolitis, neutropenic enterocolitis, including fatal outcome, have been reported in patients treated with JEVTANA [see  Adverse Reactions (6.2)  ]  .",in is not a named entity
"Gastrointestinal (GI) hemorrhage and perforation, ileus, enterocolitis, neutropenic enterocolitis, including fatal outcome, have been reported in patients treated with JEVTANA [see  Adverse Reactions (6.2)  ]  .",neutropenic enterocolitis is an adverse reaction entity
"Gastrointestinal (GI) hemorrhage and perforation, ileus, enterocolitis, neutropenic enterocolitis, including fatal outcome, have been reported in patients treated with JEVTANA [see  Adverse Reactions (6.2)  ]  .",ileus is an adverse reaction entity
"Gastrointestinal (GI) hemorrhage and perforation, ileus, enterocolitis, neutropenic enterocolitis, including fatal outcome, have been reported in patients treated with JEVTANA [see  Adverse Reactions (6.2)  ]  .",hemorrhage and perforation is not a named entity
"Gastrointestinal (GI) hemorrhage and perforation, ileus, enterocolitis, neutropenic enterocolitis, including fatal outcome, have been reported in patients treated with JEVTANA [see  Adverse Reactions (6.2)  ]  .",perforation is not a named entity
"Gastrointestinal (GI) hemorrhage and perforation, ileus, enterocolitis, neutropenic enterocolitis, including fatal outcome, have been reported in patients treated with JEVTANA [see  Adverse Reactions (6.2)  ]  .",fatal is an adverse reaction entity
"Gastrointestinal (GI) hemorrhage and perforation, ileus, enterocolitis, neutropenic enterocolitis, including fatal outcome, have been reported in patients treated with JEVTANA [see  Adverse Reactions (6.2)  ]  .","perforation , ileus is not a named entity"
"Gastrointestinal (GI) hemorrhage and perforation, ileus, enterocolitis, neutropenic enterocolitis, including fatal outcome, have been reported in patients treated with JEVTANA [see  Adverse Reactions (6.2)  ]  .",enterocolitis is an adverse reaction entity
"Hematuria:     Adverse events of hematuria, including those requiring medical intervention, were more common in JEVTANA-treated patients.",of hematuria is not a named entity
"Hematuria:     Adverse events of hematuria, including those requiring medical intervention, were more common in JEVTANA-treated patients.",hematuria is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Bone marrow suppression (particularly neutropenia) and its clinical consequences (febrile neutropenia, neutropenic infections): Monitor blood counts frequently to determine if dosage modification or initiation of G-CSF is needed.",needed is not a named entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Bone marrow suppression (particularly neutropenia) and its clinical consequences (febrile neutropenia, neutropenic infections): Monitor blood counts frequently to determine if dosage modification or initiation of G-CSF is needed.",particularly neutropenia is not a named entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Bone marrow suppression (particularly neutropenia) and its clinical consequences (febrile neutropenia, neutropenic infections): Monitor blood counts frequently to determine if dosage modification or initiation of G-CSF is needed.",neutropenic infections is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Bone marrow suppression (particularly neutropenia) and its clinical consequences (febrile neutropenia, neutropenic infections): Monitor blood counts frequently to determine if dosage modification or initiation of G-CSF is needed.",clinical consequences ( is not a named entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Bone marrow suppression (particularly neutropenia) and its clinical consequences (febrile neutropenia, neutropenic infections): Monitor blood counts frequently to determine if dosage modification or initiation of G-CSF is needed.",Bone marrow suppression is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Bone marrow suppression (particularly neutropenia) and its clinical consequences (febrile neutropenia, neutropenic infections): Monitor blood counts frequently to determine if dosage modification or initiation of G-CSF is needed.",neutropenia is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Bone marrow suppression (particularly neutropenia) and its clinical consequences (febrile neutropenia, neutropenic infections): Monitor blood counts frequently to determine if dosage modification or initiation of G-CSF is needed.",of is not a named entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Bone marrow suppression (particularly neutropenia) and its clinical consequences (febrile neutropenia, neutropenic infections): Monitor blood counts frequently to determine if dosage modification or initiation of G-CSF is needed.",febrile neutropenia is an adverse reaction entity
"Elderly Population:     The following grade 1-4 adverse reactions were reported at rates >= 5% higher in patients 65 years of age or greater compared to younger patients: fatigue (40% vs. 30%), neutropenia (97% vs. 89%), asthenia (24% vs. 15%), pyrexia (15% vs. 8%), dizziness (10% vs. 5%), urinary tract infection (10% vs. 3%) and dehydration (7% vs. 2%), respectively.",dehydration is an adverse reaction entity
"Elderly Population:     The following grade 1-4 adverse reactions were reported at rates >= 5% higher in patients 65 years of age or greater compared to younger patients: fatigue (40% vs. 30%), neutropenia (97% vs. 89%), asthenia (24% vs. 15%), pyrexia (15% vs. 8%), dizziness (10% vs. 5%), urinary tract infection (10% vs. 3%) and dehydration (7% vs. 2%), respectively.",dizziness is an adverse reaction entity
"Elderly Population:     The following grade 1-4 adverse reactions were reported at rates >= 5% higher in patients 65 years of age or greater compared to younger patients: fatigue (40% vs. 30%), neutropenia (97% vs. 89%), asthenia (24% vs. 15%), pyrexia (15% vs. 8%), dizziness (10% vs. 5%), urinary tract infection (10% vs. 3%) and dehydration (7% vs. 2%), respectively.",fatigue is an adverse reaction entity
"Elderly Population:     The following grade 1-4 adverse reactions were reported at rates >= 5% higher in patients 65 years of age or greater compared to younger patients: fatigue (40% vs. 30%), neutropenia (97% vs. 89%), asthenia (24% vs. 15%), pyrexia (15% vs. 8%), dizziness (10% vs. 5%), urinary tract infection (10% vs. 3%) and dehydration (7% vs. 2%), respectively.",7 % is not a named entity
"Elderly Population:     The following grade 1-4 adverse reactions were reported at rates >= 5% higher in patients 65 years of age or greater compared to younger patients: fatigue (40% vs. 30%), neutropenia (97% vs. 89%), asthenia (24% vs. 15%), pyrexia (15% vs. 8%), dizziness (10% vs. 5%), urinary tract infection (10% vs. 3%) and dehydration (7% vs. 2%), respectively.",infection is not a named entity
"Elderly Population:     The following grade 1-4 adverse reactions were reported at rates >= 5% higher in patients 65 years of age or greater compared to younger patients: fatigue (40% vs. 30%), neutropenia (97% vs. 89%), asthenia (24% vs. 15%), pyrexia (15% vs. 8%), dizziness (10% vs. 5%), urinary tract infection (10% vs. 3%) and dehydration (7% vs. 2%), respectively.",% ) and is not a named entity
"Elderly Population:     The following grade 1-4 adverse reactions were reported at rates >= 5% higher in patients 65 years of age or greater compared to younger patients: fatigue (40% vs. 30%), neutropenia (97% vs. 89%), asthenia (24% vs. 15%), pyrexia (15% vs. 8%), dizziness (10% vs. 5%), urinary tract infection (10% vs. 3%) and dehydration (7% vs. 2%), respectively.",asthenia is an adverse reaction entity
"Elderly Population:     The following grade 1-4 adverse reactions were reported at rates >= 5% higher in patients 65 years of age or greater compared to younger patients: fatigue (40% vs. 30%), neutropenia (97% vs. 89%), asthenia (24% vs. 15%), pyrexia (15% vs. 8%), dizziness (10% vs. 5%), urinary tract infection (10% vs. 3%) and dehydration (7% vs. 2%), respectively.",7 % vs. is not a named entity
"Elderly Population:     The following grade 1-4 adverse reactions were reported at rates >= 5% higher in patients 65 years of age or greater compared to younger patients: fatigue (40% vs. 30%), neutropenia (97% vs. 89%), asthenia (24% vs. 15%), pyrexia (15% vs. 8%), dizziness (10% vs. 5%), urinary tract infection (10% vs. 3%) and dehydration (7% vs. 2%), respectively.",89 is not a named entity
"Elderly Population:     The following grade 1-4 adverse reactions were reported at rates >= 5% higher in patients 65 years of age or greater compared to younger patients: fatigue (40% vs. 30%), neutropenia (97% vs. 89%), asthenia (24% vs. 15%), pyrexia (15% vs. 8%), dizziness (10% vs. 5%), urinary tract infection (10% vs. 3%) and dehydration (7% vs. 2%), respectively.",neutropenia is an adverse reaction entity
"Elderly Population:     The following grade 1-4 adverse reactions were reported at rates >= 5% higher in patients 65 years of age or greater compared to younger patients: fatigue (40% vs. 30%), neutropenia (97% vs. 89%), asthenia (24% vs. 15%), pyrexia (15% vs. 8%), dizziness (10% vs. 5%), urinary tract infection (10% vs. 3%) and dehydration (7% vs. 2%), respectively.",grade 1-4 adverse is not a named entity
"Elderly Population:     The following grade 1-4 adverse reactions were reported at rates >= 5% higher in patients 65 years of age or greater compared to younger patients: fatigue (40% vs. 30%), neutropenia (97% vs. 89%), asthenia (24% vs. 15%), pyrexia (15% vs. 8%), dizziness (10% vs. 5%), urinary tract infection (10% vs. 3%) and dehydration (7% vs. 2%), respectively.",urinary tract infection is an adverse reaction entity
"Elderly Population:     The following grade 1-4 adverse reactions were reported at rates >= 5% higher in patients 65 years of age or greater compared to younger patients: fatigue (40% vs. 30%), neutropenia (97% vs. 89%), asthenia (24% vs. 15%), pyrexia (15% vs. 8%), dizziness (10% vs. 5%), urinary tract infection (10% vs. 3%) and dehydration (7% vs. 2%), respectively.",pyrexia is an adverse reaction entity
"Elderly Population:     The following grade 1-4 adverse reactions were reported at rates >= 5% higher in patients 65 years of age or greater compared to younger patients: fatigue (40% vs. 30%), neutropenia (97% vs. 89%), asthenia (24% vs. 15%), pyrexia (15% vs. 8%), dizziness (10% vs. 5%), urinary tract infection (10% vs. 3%) and dehydration (7% vs. 2%), respectively.",respectively is not a named entity
(  5.5  )(  6  )(  8.5  )   *  Hepatic impairment: Reduce the JEVTANA dose to 20 mg/m  2  in patients with mild hepatic impairment and to 15 mg/m  2  in patients with moderate hepatic impairment.,Hepatic impairment is an adverse reaction entity
(  5.5  )(  6  )(  8.5  )   *  Hepatic impairment: Reduce the JEVTANA dose to 20 mg/m  2  in patients with mild hepatic impairment and to 15 mg/m  2  in patients with moderate hepatic impairment.,2 is not a named entity
Other factors associated with hematuria were well-balanced between arms and do not account for the increased rate of hematuria on the JEVTANA arm.,between arms is not a named entity
Other factors associated with hematuria were well-balanced between arms and do not account for the increased rate of hematuria on the JEVTANA arm.,not account for is not a named entity
Other factors associated with hematuria were well-balanced between arms and do not account for the increased rate of hematuria on the JEVTANA arm.,hematuria is an adverse reaction entity
Other factors associated with hematuria were well-balanced between arms and do not account for the increased rate of hematuria on the JEVTANA arm.,hematuria is an adverse reaction entity
"Hepatic Laboratory Abnormalities:     The incidences of grade 3-4 increased AST, increased ALT, and increased bilirubin were each <= 1%.","ALT , and is not a named entity"
"Hepatic Laboratory Abnormalities:     The incidences of grade 3-4 increased AST, increased ALT, and increased bilirubin were each <= 1%.",and increased bilirubin is not a named entity
"Hepatic Laboratory Abnormalities:     The incidences of grade 3-4 increased AST, increased ALT, and increased bilirubin were each <= 1%.",increased ALT is an adverse reaction entity
"Hepatic Laboratory Abnormalities:     The incidences of grade 3-4 increased AST, increased ALT, and increased bilirubin were each <= 1%.",: The is not a named entity
"Hepatic Laboratory Abnormalities:     The incidences of grade 3-4 increased AST, increased ALT, and increased bilirubin were each <= 1%.",increased bilirubin is an adverse reaction entity
"Hepatic Laboratory Abnormalities:     The incidences of grade 3-4 increased AST, increased ALT, and increased bilirubin were each <= 1%.",increased AST is an adverse reaction entity
6 ADVERSE REACTIONS    The following serious adverse reactions are discussed in greater detail in another section of the label:     *  Bone Marrow Suppression [see  Warnings and Precautions (5.1)  ] .,Bone Marrow Suppression is an adverse reaction entity
6 ADVERSE REACTIONS    The following serious adverse reactions are discussed in greater detail in another section of the label:     *  Bone Marrow Suppression [see  Warnings and Precautions (5.1)  ] .,in another section is not a named entity
"Patients >= 65 years of age are more likely to experience certain adverse reactions, including neutropenia and febrile neutropenia [see  Adverse Reactions (6)  and  Use in Specific Populations (8.5)  ]  .",neutropenia is an adverse reaction entity
"Patients >= 65 years of age are more likely to experience certain adverse reactions, including neutropenia and febrile neutropenia [see  Adverse Reactions (6)  and  Use in Specific Populations (8.5)  ]  .",and febrile neutropenia is not a named entity
"Patients >= 65 years of age are more likely to experience certain adverse reactions, including neutropenia and febrile neutropenia [see  Adverse Reactions (6)  and  Use in Specific Populations (8.5)  ]  .",febrile neutropenia is an adverse reaction entity
"Patients >= 65 years of age are more likely to experience certain adverse reactions, including neutropenia and febrile neutropenia [see  Adverse Reactions (6)  and  Use in Specific Populations (8.5)  ]  .",adverse is not a named entity
"(  2.2  ) Deaths have occurred due to gastrointestinal hemorrhage, perforation and neutropenic enterocolitis.",gastrointestinal perforation is an adverse reaction entity
"(  2.2  ) Deaths have occurred due to gastrointestinal hemorrhage, perforation and neutropenic enterocolitis.",gastrointestinal hemorrhage is an adverse reaction entity
"(  2.2  ) Deaths have occurred due to gastrointestinal hemorrhage, perforation and neutropenic enterocolitis.",Deaths is an adverse reaction entity
"(  2.2  ) Deaths have occurred due to gastrointestinal hemorrhage, perforation and neutropenic enterocolitis.",due to is not a named entity
"(  2.2  ) Deaths have occurred due to gastrointestinal hemorrhage, perforation and neutropenic enterocolitis.",and neutropenic is not a named entity
"(  2.2  ) Deaths have occurred due to gastrointestinal hemorrhage, perforation and neutropenic enterocolitis.",enterocolitis is not a named entity
"(  2.2  ) Deaths have occurred due to gastrointestinal hemorrhage, perforation and neutropenic enterocolitis.",neutropenic enterocolitis is an adverse reaction entity
"(  2.2  ) Deaths have occurred due to gastrointestinal hemorrhage, perforation and neutropenic enterocolitis.",occurred due to is not a named entity
"Other fatal adverse reactions in JEVTANA-treated patients included ventricular fibrillation, cerebral hemorrhage, and dyspnea.",dyspnea is an adverse reaction entity
"Other fatal adverse reactions in JEVTANA-treated patients included ventricular fibrillation, cerebral hemorrhage, and dyspnea.",", and dyspnea is not a named entity"
"Other fatal adverse reactions in JEVTANA-treated patients included ventricular fibrillation, cerebral hemorrhage, and dyspnea.",reactions in JEVTANA-treated is not a named entity
"Other fatal adverse reactions in JEVTANA-treated patients included ventricular fibrillation, cerebral hemorrhage, and dyspnea.",fatal is an adverse reaction entity
"Other fatal adverse reactions in JEVTANA-treated patients included ventricular fibrillation, cerebral hemorrhage, and dyspnea.",in is not a named entity
"Other fatal adverse reactions in JEVTANA-treated patients included ventricular fibrillation, cerebral hemorrhage, and dyspnea.",Other is not a named entity
"Other fatal adverse reactions in JEVTANA-treated patients included ventricular fibrillation, cerebral hemorrhage, and dyspnea.",ventricular fibrillation is an adverse reaction entity
"Other fatal adverse reactions in JEVTANA-treated patients included ventricular fibrillation, cerebral hemorrhage, and dyspnea.",cerebral hemorrhage is an adverse reaction entity
(  2.3  )   *  JEVTANA can cause fetal harm when administered to a pregnant woman.,2.3 ) * is not a named entity
(  2.3  )   *  JEVTANA can cause fetal harm when administered to a pregnant woman.,fetal harm is an adverse reaction entity
"Most cases occurred in association with sepsis, dehydration, or obstructive uropathy [see  Adverse Reactions (6.1)  ]  .",dehydration is an adverse reaction entity
"Most cases occurred in association with sepsis, dehydration, or obstructive uropathy [see  Adverse Reactions (6.1)  ]  .",sepsis is an adverse reaction entity
"Most cases occurred in association with sepsis, dehydration, or obstructive uropathy [see  Adverse Reactions (6.1)  ]  .",Reactions is not a named entity
"Most cases occurred in association with sepsis, dehydration, or obstructive uropathy [see  Adverse Reactions (6.1)  ]  .",Reactions is not a named entity
"Most cases occurred in association with sepsis, dehydration, or obstructive uropathy [see  Adverse Reactions (6.1)  ]  .",obstructive uropathy is an adverse reaction entity
"Most cases occurred in association with sepsis, dehydration, or obstructive uropathy [see  Adverse Reactions (6.1)  ]  .",cases is not a named entity
Severe hypersensitivity reactions require immediate discontinuation of the JEVTANA infusion and administration of appropriate therapy.,hypersensitivity reactions is an adverse reaction entity
Severe hypersensitivity reactions require immediate discontinuation of the JEVTANA infusion and administration of appropriate therapy.,JEVTANA infusion is not a named entity
"(  5.4  )   *  Elderly patients: Patients >= 65 years of age were more likely to experience fatal outcomes not related to disease progression and certain adverse reactions, including neutropenia and febrile neutropenia.",fatal is an adverse reaction entity
"(  5.4  )   *  Elderly patients: Patients >= 65 years of age were more likely to experience fatal outcomes not related to disease progression and certain adverse reactions, including neutropenia and febrile neutropenia.",neutropenia is an adverse reaction entity
"(  5.4  )   *  Elderly patients: Patients >= 65 years of age were more likely to experience fatal outcomes not related to disease progression and certain adverse reactions, including neutropenia and febrile neutropenia.",more likely to is not a named entity
"(  5.4  )   *  Elderly patients: Patients >= 65 years of age were more likely to experience fatal outcomes not related to disease progression and certain adverse reactions, including neutropenia and febrile neutropenia.",to disease progression is not a named entity
"(  5.4  )   *  Elderly patients: Patients >= 65 years of age were more likely to experience fatal outcomes not related to disease progression and certain adverse reactions, including neutropenia and febrile neutropenia.",febrile neutropenia is an adverse reaction entity
"(  5.4  )   *  Elderly patients: Patients >= 65 years of age were more likely to experience fatal outcomes not related to disease progression and certain adverse reactions, including neutropenia and febrile neutropenia.",of age is not a named entity
"The most common (>= 5%) grade 3-4 adverse reactions in patients who received JEVTANA were neutropenia, leukopenia, anemia, febrile neutropenia, diarrhea, fatigue, and asthenia.",leukopenia is an adverse reaction entity
"The most common (>= 5%) grade 3-4 adverse reactions in patients who received JEVTANA were neutropenia, leukopenia, anemia, febrile neutropenia, diarrhea, fatigue, and asthenia.","neutropenia , is not a named entity"
"The most common (>= 5%) grade 3-4 adverse reactions in patients who received JEVTANA were neutropenia, leukopenia, anemia, febrile neutropenia, diarrhea, fatigue, and asthenia.",", anemia is not a named entity"
"The most common (>= 5%) grade 3-4 adverse reactions in patients who received JEVTANA were neutropenia, leukopenia, anemia, febrile neutropenia, diarrhea, fatigue, and asthenia.",diarrhea is an adverse reaction entity
"The most common (>= 5%) grade 3-4 adverse reactions in patients who received JEVTANA were neutropenia, leukopenia, anemia, febrile neutropenia, diarrhea, fatigue, and asthenia.",neutropenia is an adverse reaction entity
"The most common (>= 5%) grade 3-4 adverse reactions in patients who received JEVTANA were neutropenia, leukopenia, anemia, febrile neutropenia, diarrhea, fatigue, and asthenia.",received JEVTANA is not a named entity
"The most common (>= 5%) grade 3-4 adverse reactions in patients who received JEVTANA were neutropenia, leukopenia, anemia, febrile neutropenia, diarrhea, fatigue, and asthenia.",fatigue is an adverse reaction entity
"The most common (>= 5%) grade 3-4 adverse reactions in patients who received JEVTANA were neutropenia, leukopenia, anemia, febrile neutropenia, diarrhea, fatigue, and asthenia.",) is not a named entity
"The most common (>= 5%) grade 3-4 adverse reactions in patients who received JEVTANA were neutropenia, leukopenia, anemia, febrile neutropenia, diarrhea, fatigue, and asthenia.",common ( > is not a named entity
"The most common (>= 5%) grade 3-4 adverse reactions in patients who received JEVTANA were neutropenia, leukopenia, anemia, febrile neutropenia, diarrhea, fatigue, and asthenia.",asthenia is an adverse reaction entity
"The most common (>= 5%) grade 3-4 adverse reactions in patients who received JEVTANA were neutropenia, leukopenia, anemia, febrile neutropenia, diarrhea, fatigue, and asthenia.",anemia is an adverse reaction entity
"The most common (>= 5%) grade 3-4 adverse reactions in patients who received JEVTANA were neutropenia, leukopenia, anemia, febrile neutropenia, diarrhea, fatigue, and asthenia.","diarrhea , fatigue is not a named entity"
"The most common (>= 5%) grade 3-4 adverse reactions in patients who received JEVTANA were neutropenia, leukopenia, anemia, febrile neutropenia, diarrhea, fatigue, and asthenia.",", fatigue , is not a named entity"
"The most common (>= 5%) grade 3-4 adverse reactions in patients who received JEVTANA were neutropenia, leukopenia, anemia, febrile neutropenia, diarrhea, fatigue, and asthenia.",febrile neutropenia is an adverse reaction entity
"In non-clinical studies in rats and rabbits, cabazitaxel was embryotoxic, fetotoxic, and abortifacient at exposures significantly lower than those expected at the recommended human dose level.",fetotoxic is an adverse reaction entity
"In non-clinical studies in rats and rabbits, cabazitaxel was embryotoxic, fetotoxic, and abortifacient at exposures significantly lower than those expected at the recommended human dose level.",and abortifacient at is not a named entity
"In non-clinical studies in rats and rabbits, cabazitaxel was embryotoxic, fetotoxic, and abortifacient at exposures significantly lower than those expected at the recommended human dose level.",abortifacient at is not a named entity
"In non-clinical studies in rats and rabbits, cabazitaxel was embryotoxic, fetotoxic, and abortifacient at exposures significantly lower than those expected at the recommended human dose level.",exposures significantly is not a named entity
"In non-clinical studies in rats and rabbits, cabazitaxel was embryotoxic, fetotoxic, and abortifacient at exposures significantly lower than those expected at the recommended human dose level.",embryotoxic is an adverse reaction entity
"In non-clinical studies in rats and rabbits, cabazitaxel was embryotoxic, fetotoxic, and abortifacient at exposures significantly lower than those expected at the recommended human dose level.",abortifacient is an adverse reaction entity
"In the randomized trial, five patients (1.3%) experienced fatal infectious adverse events (sepsis or septic shock).",fatal is an adverse reaction entity
"In the randomized trial, five patients (1.3%) experienced fatal infectious adverse events (sepsis or septic shock).",% ) experienced is not a named entity
"In the randomized trial, five patients (1.3%) experienced fatal infectious adverse events (sepsis or septic shock).",the is not a named entity
"In the randomized trial, five patients (1.3%) experienced fatal infectious adverse events (sepsis or septic shock).",infectious adverse events is an adverse reaction entity
"In the randomized trial, five patients (1.3%) experienced fatal infectious adverse events (sepsis or septic shock).",sepsis is an adverse reaction entity
"In the randomized trial, five patients (1.3%) experienced fatal infectious adverse events (sepsis or septic shock).",shock ) is not a named entity
"In the randomized trial, five patients (1.3%) experienced fatal infectious adverse events (sepsis or septic shock).",septic shock is an adverse reaction entity
"In the randomized trial, five patients (1.3%) experienced fatal infectious adverse events (sepsis or septic shock).",) experienced fatal is not a named entity
Treatment discontinuation due to adverse reactions occurred in 35/1300 (2.7%) of patients receiving Teflaro and 48/1297 (3.7%) of patients receiving comparator drugs with the most common adverse reactions leading to discontinuation being hypersensitivity for both treatment groups at a rate of 0.3% in the Teflaro group and 0.5% in comparator group.,most is not a named entity
Treatment discontinuation due to adverse reactions occurred in 35/1300 (2.7%) of patients receiving Teflaro and 48/1297 (3.7%) of patients receiving comparator drugs with the most common adverse reactions leading to discontinuation being hypersensitivity for both treatment groups at a rate of 0.3% in the Teflaro group and 0.5% in comparator group.,hypersensitivity is an adverse reaction entity
"(  5.1  )   *   Clostridium difficile -associated diarrhea (CDAD) has been reported with nearly all systemic antibacterial agents, including Teflaro.",* Clostridium is not a named entity
"(  5.1  )   *   Clostridium difficile -associated diarrhea (CDAD) has been reported with nearly all systemic antibacterial agents, including Teflaro.",nearly is not a named entity
"(  5.1  )   *   Clostridium difficile -associated diarrhea (CDAD) has been reported with nearly all systemic antibacterial agents, including Teflaro.",CDAD is an adverse reaction entity
"(  5.1  )   *   Clostridium difficile -associated diarrhea (CDAD) has been reported with nearly all systemic antibacterial agents, including Teflaro.",Clostridium difficile -associated diarrhea is an adverse reaction entity
(  5.3  )             5.1 Hypersensitivity Reactions      Serious and occasionally fatal hypersensitivity (anaphylactic) reactions and serious skin reactions have been reported in patients receiving beta-lactam antibacterial drugs.,hypersensitivity reactions is an adverse reaction entity
(  5.3  )             5.1 Hypersensitivity Reactions      Serious and occasionally fatal hypersensitivity (anaphylactic) reactions and serious skin reactions have been reported in patients receiving beta-lactam antibacterial drugs.,fatal is an adverse reaction entity
(  5.3  )             5.1 Hypersensitivity Reactions      Serious and occasionally fatal hypersensitivity (anaphylactic) reactions and serious skin reactions have been reported in patients receiving beta-lactam antibacterial drugs.,skin reactions is an adverse reaction entity
(  5.3  )             5.1 Hypersensitivity Reactions      Serious and occasionally fatal hypersensitivity (anaphylactic) reactions and serious skin reactions have been reported in patients receiving beta-lactam antibacterial drugs.,anaphylactic reactions is an adverse reaction entity
(  5.3  )             5.1 Hypersensitivity Reactions      Serious and occasionally fatal hypersensitivity (anaphylactic) reactions and serious skin reactions have been reported in patients receiving beta-lactam antibacterial drugs.,been reported in is not a named entity
(  5.3  )             5.1 Hypersensitivity Reactions      Serious and occasionally fatal hypersensitivity (anaphylactic) reactions and serious skin reactions have been reported in patients receiving beta-lactam antibacterial drugs.,serious skin reactions is not a named entity
(  5.3  )             5.1 Hypersensitivity Reactions      Serious and occasionally fatal hypersensitivity (anaphylactic) reactions and serious skin reactions have been reported in patients receiving beta-lactam antibacterial drugs.,) reactions is not a named entity
(  5.3  )             5.1 Hypersensitivity Reactions      Serious and occasionally fatal hypersensitivity (anaphylactic) reactions and serious skin reactions have been reported in patients receiving beta-lactam antibacterial drugs.,hypersensitivity reactions is an adverse reaction entity
(  5.3  )             5.1 Hypersensitivity Reactions      Serious and occasionally fatal hypersensitivity (anaphylactic) reactions and serious skin reactions have been reported in patients receiving beta-lactam antibacterial drugs.,5.3 ) 5.1 is not a named entity
(  5.3  )             5.1 Hypersensitivity Reactions      Serious and occasionally fatal hypersensitivity (anaphylactic) reactions and serious skin reactions have been reported in patients receiving beta-lactam antibacterial drugs.,( anaphylactic ) is not a named entity
(  5.3  )             5.1 Hypersensitivity Reactions      Serious and occasionally fatal hypersensitivity (anaphylactic) reactions and serious skin reactions have been reported in patients receiving beta-lactam antibacterial drugs.,and serious skin is not a named entity
(  5.3  )             5.1 Hypersensitivity Reactions      Serious and occasionally fatal hypersensitivity (anaphylactic) reactions and serious skin reactions have been reported in patients receiving beta-lactam antibacterial drugs.,anaphylactic reactions is an adverse reaction entity
"The most common adverse reactions occurring in > 2% of patients receiving Teflaro in the pooled phase 3 clinical trials were diarrhea, nausea, and rash.",nausea is an adverse reaction entity
"The most common adverse reactions occurring in > 2% of patients receiving Teflaro in the pooled phase 3 clinical trials were diarrhea, nausea, and rash.",diarrhea is an adverse reaction entity
"The most common adverse reactions occurring in > 2% of patients receiving Teflaro in the pooled phase 3 clinical trials were diarrhea, nausea, and rash.",patients receiving Teflaro is not a named entity
"The most common adverse reactions occurring in > 2% of patients receiving Teflaro in the pooled phase 3 clinical trials were diarrhea, nausea, and rash.",rash is an adverse reaction entity
"The most common adverse reactions occurring in > 2% of patients receiving Teflaro in the pooled phase 3 clinical trials were diarrhea, nausea, and rash.",pooled is not a named entity
"The most common adverse reactions occurring in > 2% of patients receiving Teflaro in the pooled phase 3 clinical trials were diarrhea, nausea, and rash.",were is not a named entity
"WARNINGS AND PRECAUTIONS       EXCERPT:    *  Serious hypersensitivity (anaphylactic) reactions have been reported with beta-lactam antibacterial drugs, including Teflaro.",been reported is not a named entity
"WARNINGS AND PRECAUTIONS       EXCERPT:    *  Serious hypersensitivity (anaphylactic) reactions have been reported with beta-lactam antibacterial drugs, including Teflaro.",have been reported is not a named entity
"WARNINGS AND PRECAUTIONS       EXCERPT:    *  Serious hypersensitivity (anaphylactic) reactions have been reported with beta-lactam antibacterial drugs, including Teflaro.",hypersensitivity reactions is an adverse reaction entity
"WARNINGS AND PRECAUTIONS       EXCERPT:    *  Serious hypersensitivity (anaphylactic) reactions have been reported with beta-lactam antibacterial drugs, including Teflaro.",anaphylactic reactions is an adverse reaction entity
"5.2 Clostridium difficile-Associated Diarrhea       Clostridium difficile  -associated diarrhea (CDAD) has been reported for nearly all systemic antibacterial agents, including Teflaro, and may range in severity from mild diarrhea to fatal colitis.",5.2 Clostridium difficile-Associated is not a named entity
"5.2 Clostridium difficile-Associated Diarrhea       Clostridium difficile  -associated diarrhea (CDAD) has been reported for nearly all systemic antibacterial agents, including Teflaro, and may range in severity from mild diarrhea to fatal colitis.",Teflaro is not a named entity
"5.2 Clostridium difficile-Associated Diarrhea       Clostridium difficile  -associated diarrhea (CDAD) has been reported for nearly all systemic antibacterial agents, including Teflaro, and may range in severity from mild diarrhea to fatal colitis.",fatal is an adverse reaction entity
"5.2 Clostridium difficile-Associated Diarrhea       Clostridium difficile  -associated diarrhea (CDAD) has been reported for nearly all systemic antibacterial agents, including Teflaro, and may range in severity from mild diarrhea to fatal colitis.",agents is not a named entity
"5.2 Clostridium difficile-Associated Diarrhea       Clostridium difficile  -associated diarrhea (CDAD) has been reported for nearly all systemic antibacterial agents, including Teflaro, and may range in severity from mild diarrhea to fatal colitis.",Clostridium difficile -associated diarrhea is an adverse reaction entity
"5.2 Clostridium difficile-Associated Diarrhea       Clostridium difficile  -associated diarrhea (CDAD) has been reported for nearly all systemic antibacterial agents, including Teflaro, and may range in severity from mild diarrhea to fatal colitis.",diarrhea is an adverse reaction entity
"5.2 Clostridium difficile-Associated Diarrhea       Clostridium difficile  -associated diarrhea (CDAD) has been reported for nearly all systemic antibacterial agents, including Teflaro, and may range in severity from mild diarrhea to fatal colitis.",including Teflaro is not a named entity
"5.2 Clostridium difficile-Associated Diarrhea       Clostridium difficile  -associated diarrhea (CDAD) has been reported for nearly all systemic antibacterial agents, including Teflaro, and may range in severity from mild diarrhea to fatal colitis.",to fatal is not a named entity
"5.2 Clostridium difficile-Associated Diarrhea       Clostridium difficile  -associated diarrhea (CDAD) has been reported for nearly all systemic antibacterial agents, including Teflaro, and may range in severity from mild diarrhea to fatal colitis.",CDAD is an adverse reaction entity
"5.2 Clostridium difficile-Associated Diarrhea       Clostridium difficile  -associated diarrhea (CDAD) has been reported for nearly all systemic antibacterial agents, including Teflaro, and may range in severity from mild diarrhea to fatal colitis.",colitis is an adverse reaction entity
"In the pooled Phase 3 CABP trials, 51/520 (9.8%) of Teflaro-treated patients compared to 24/534 (4.5%) of ceftriaxone-treated patients seroconverted from a negative to a positive direct Coombs' test result.",Phase 3 is not a named entity
"In the pooled Phase 3 CABP trials, 51/520 (9.8%) of Teflaro-treated patients compared to 24/534 (4.5%) of ceftriaxone-treated patients seroconverted from a negative to a positive direct Coombs' test result.",seroconverted from a negative to a positive direct Coombs' test result is an adverse reaction entity
"ADVERSE REACTIONS    The following serious adverse reactions are described in greater detail in the Warnings and Precautions section     *  Hypersensitivity Reactions [see Warnings and Precautions (  5.1  )]    *   Clostridium difficile -Associated diarrhea [see Warnings and Precautions (  5.2  )]    *  Direct Coombs' Test Seroconversion [see Warnings and Precautions (  5.3  )]         EXCERPT:   The most common adverse reactions occurring in >2 % of patients are diarrhea, nausea, and rash.",and Precautions is not a named entity
"ADVERSE REACTIONS    The following serious adverse reactions are described in greater detail in the Warnings and Precautions section     *  Hypersensitivity Reactions [see Warnings and Precautions (  5.1  )]    *   Clostridium difficile -Associated diarrhea [see Warnings and Precautions (  5.2  )]    *  Direct Coombs' Test Seroconversion [see Warnings and Precautions (  5.3  )]         EXCERPT:   The most common adverse reactions occurring in >2 % of patients are diarrhea, nausea, and rash.",", and is not a named entity"
"ADVERSE REACTIONS    The following serious adverse reactions are described in greater detail in the Warnings and Precautions section     *  Hypersensitivity Reactions [see Warnings and Precautions (  5.1  )]    *   Clostridium difficile -Associated diarrhea [see Warnings and Precautions (  5.2  )]    *  Direct Coombs' Test Seroconversion [see Warnings and Precautions (  5.3  )]         EXCERPT:   The most common adverse reactions occurring in >2 % of patients are diarrhea, nausea, and rash.",diarrhea is an adverse reaction entity
"ADVERSE REACTIONS    The following serious adverse reactions are described in greater detail in the Warnings and Precautions section     *  Hypersensitivity Reactions [see Warnings and Precautions (  5.1  )]    *   Clostridium difficile -Associated diarrhea [see Warnings and Precautions (  5.2  )]    *  Direct Coombs' Test Seroconversion [see Warnings and Precautions (  5.3  )]         EXCERPT:   The most common adverse reactions occurring in >2 % of patients are diarrhea, nausea, and rash.",diarrhea [ is not a named entity
"ADVERSE REACTIONS    The following serious adverse reactions are described in greater detail in the Warnings and Precautions section     *  Hypersensitivity Reactions [see Warnings and Precautions (  5.1  )]    *   Clostridium difficile -Associated diarrhea [see Warnings and Precautions (  5.2  )]    *  Direct Coombs' Test Seroconversion [see Warnings and Precautions (  5.3  )]         EXCERPT:   The most common adverse reactions occurring in >2 % of patients are diarrhea, nausea, and rash.",Hypersensitivity Reactions is an adverse reaction entity
"ADVERSE REACTIONS    The following serious adverse reactions are described in greater detail in the Warnings and Precautions section     *  Hypersensitivity Reactions [see Warnings and Precautions (  5.1  )]    *   Clostridium difficile -Associated diarrhea [see Warnings and Precautions (  5.2  )]    *  Direct Coombs' Test Seroconversion [see Warnings and Precautions (  5.3  )]         EXCERPT:   The most common adverse reactions occurring in >2 % of patients are diarrhea, nausea, and rash.",see Warnings and is not a named entity
"ADVERSE REACTIONS    The following serious adverse reactions are described in greater detail in the Warnings and Precautions section     *  Hypersensitivity Reactions [see Warnings and Precautions (  5.1  )]    *   Clostridium difficile -Associated diarrhea [see Warnings and Precautions (  5.2  )]    *  Direct Coombs' Test Seroconversion [see Warnings and Precautions (  5.3  )]         EXCERPT:   The most common adverse reactions occurring in >2 % of patients are diarrhea, nausea, and rash.",Direct Coombs' Test Seroconversion is an adverse reaction entity
"ADVERSE REACTIONS    The following serious adverse reactions are described in greater detail in the Warnings and Precautions section     *  Hypersensitivity Reactions [see Warnings and Precautions (  5.1  )]    *   Clostridium difficile -Associated diarrhea [see Warnings and Precautions (  5.2  )]    *  Direct Coombs' Test Seroconversion [see Warnings and Precautions (  5.3  )]         EXCERPT:   The most common adverse reactions occurring in >2 % of patients are diarrhea, nausea, and rash.",Reactions [ is not a named entity
"ADVERSE REACTIONS    The following serious adverse reactions are described in greater detail in the Warnings and Precautions section     *  Hypersensitivity Reactions [see Warnings and Precautions (  5.1  )]    *   Clostridium difficile -Associated diarrhea [see Warnings and Precautions (  5.2  )]    *  Direct Coombs' Test Seroconversion [see Warnings and Precautions (  5.3  )]         EXCERPT:   The most common adverse reactions occurring in >2 % of patients are diarrhea, nausea, and rash.",and Precautions ( is not a named entity
"ADVERSE REACTIONS    The following serious adverse reactions are described in greater detail in the Warnings and Precautions section     *  Hypersensitivity Reactions [see Warnings and Precautions (  5.1  )]    *   Clostridium difficile -Associated diarrhea [see Warnings and Precautions (  5.2  )]    *  Direct Coombs' Test Seroconversion [see Warnings and Precautions (  5.3  )]         EXCERPT:   The most common adverse reactions occurring in >2 % of patients are diarrhea, nausea, and rash.",rash is an adverse reaction entity
"ADVERSE REACTIONS    The following serious adverse reactions are described in greater detail in the Warnings and Precautions section     *  Hypersensitivity Reactions [see Warnings and Precautions (  5.1  )]    *   Clostridium difficile -Associated diarrhea [see Warnings and Precautions (  5.2  )]    *  Direct Coombs' Test Seroconversion [see Warnings and Precautions (  5.3  )]         EXCERPT:   The most common adverse reactions occurring in >2 % of patients are diarrhea, nausea, and rash.",Clostridium difficile -Associated diarrhea is an adverse reaction entity
"ADVERSE REACTIONS    The following serious adverse reactions are described in greater detail in the Warnings and Precautions section     *  Hypersensitivity Reactions [see Warnings and Precautions (  5.1  )]    *   Clostridium difficile -Associated diarrhea [see Warnings and Precautions (  5.2  )]    *  Direct Coombs' Test Seroconversion [see Warnings and Precautions (  5.3  )]         EXCERPT:   The most common adverse reactions occurring in >2 % of patients are diarrhea, nausea, and rash.",nausea is an adverse reaction entity
"5.2             Allergic Reactions        As with any injectable drug product, allergic reactions and anaphylaxis may occur.",", allergic is not a named entity"
"5.2             Allergic Reactions        As with any injectable drug product, allergic reactions and anaphylaxis may occur.",reactions is not a named entity
"5.2             Allergic Reactions        As with any injectable drug product, allergic reactions and anaphylaxis may occur.",anaphylaxis is an adverse reaction entity
"5.2             Allergic Reactions        As with any injectable drug product, allergic reactions and anaphylaxis may occur.",allergic reactions is an adverse reaction entity
"6            ADVERSE REACTIONS      Exclusive of an uncommon, mild injection site reaction, no adverse reactions to  11  C-choline have been reported.",an uncommon is not a named entity
"6            ADVERSE REACTIONS      Exclusive of an uncommon, mild injection site reaction, no adverse reactions to  11  C-choline have been reported.",injection site reaction is an adverse reaction entity
*  Allergic reactions: have emergency resuscitation equipment and personnel readily available (  5.2  ).,have is not a named entity
*  Allergic reactions: have emergency resuscitation equipment and personnel readily available (  5.2  ).,Allergic reactions is an adverse reaction entity
"EXCERPT:   Exclusive of an uncommon, mild injection site reaction, no other adverse reactions have been reported (  6  ).",Exclusive is not a named entity
"EXCERPT:   Exclusive of an uncommon, mild injection site reaction, no other adverse reactions have been reported (  6  ).",injection site reaction is an adverse reaction entity
The discontinuation rate due to bleeding events was 0.7% in the ELIQUIS-treated patients compared to 1.7% in enoxaparin/warfarin-treated patients in the AMPLIFY study.,to bleeding events is not a named entity
The discontinuation rate due to bleeding events was 0.7% in the ELIQUIS-treated patients compared to 1.7% in enoxaparin/warfarin-treated patients in the AMPLIFY study.,bleeding is an adverse reaction entity
WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS(B) SPINAL/EPIDURAL HEMATOMA       See full prescribing information for complete boxed warning.,SPINAL HEMATOMA is an adverse reaction entity
WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS(B) SPINAL/EPIDURAL HEMATOMA       See full prescribing information for complete boxed warning.,THE is not a named entity
WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS(B) SPINAL/EPIDURAL HEMATOMA       See full prescribing information for complete boxed warning.,for complete boxed is not a named entity
WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS(B) SPINAL/EPIDURAL HEMATOMA       See full prescribing information for complete boxed warning.,: ( is not a named entity
WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS(B) SPINAL/EPIDURAL HEMATOMA       See full prescribing information for complete boxed warning.,EPIDURAL HEMATOMA is an adverse reaction entity
WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS(B) SPINAL/EPIDURAL HEMATOMA       See full prescribing information for complete boxed warning.,THROMBOTIC EVENTS is an adverse reaction entity
"Table 7:     Bleeding Results in the AMPLIFY-EXT Study                                 ELIQUIS 2.5 mg bidN=840n (%)  ELIQUIS 5 mg bidN=811n (%)  PlaceboN=826n (%)               *   CRNM = clinically relevant nonmajor bleeding.Events associated with each endpoint were counted once per subject, but subjects may have contributed events to multiple endpoints.",clinically relevant nonmajor bleeding is an adverse reaction entity
"Table 7:     Bleeding Results in the AMPLIFY-EXT Study                                 ELIQUIS 2.5 mg bidN=840n (%)  ELIQUIS 5 mg bidN=811n (%)  PlaceboN=826n (%)               *   CRNM = clinically relevant nonmajor bleeding.Events associated with each endpoint were counted once per subject, but subjects may have contributed events to multiple endpoints.",CRNM is an adverse reaction entity
"Table 7:     Bleeding Results in the AMPLIFY-EXT Study                                 ELIQUIS 2.5 mg bidN=840n (%)  ELIQUIS 5 mg bidN=811n (%)  PlaceboN=826n (%)               *   CRNM = clinically relevant nonmajor bleeding.Events associated with each endpoint were counted once per subject, but subjects may have contributed events to multiple endpoints.",Bleeding is an adverse reaction entity
"Table 7:     Bleeding Results in the AMPLIFY-EXT Study                                 ELIQUIS 2.5 mg bidN=840n (%)  ELIQUIS 5 mg bidN=811n (%)  PlaceboN=826n (%)               *   CRNM = clinically relevant nonmajor bleeding.Events associated with each endpoint were counted once per subject, but subjects may have contributed events to multiple endpoints.",counted once is not a named entity
"Table 7:     Bleeding Results in the AMPLIFY-EXT Study                                 ELIQUIS 2.5 mg bidN=840n (%)  ELIQUIS 5 mg bidN=811n (%)  PlaceboN=826n (%)               *   CRNM = clinically relevant nonmajor bleeding.Events associated with each endpoint were counted once per subject, but subjects may have contributed events to multiple endpoints.",events to multiple is not a named entity
"Table 7:     Bleeding Results in the AMPLIFY-EXT Study                                 ELIQUIS 2.5 mg bidN=840n (%)  ELIQUIS 5 mg bidN=811n (%)  PlaceboN=826n (%)               *   CRNM = clinically relevant nonmajor bleeding.Events associated with each endpoint were counted once per subject, but subjects may have contributed events to multiple endpoints.",", is not a named entity"
"Figure 1:     Major Bleeding Hazard Ratios by Baseline Characteristics - ARISTOTLE Study     Note: The figure above presents effects in various subgroups, all of which are baseline characteristics and all of which were pre-specified, if not the groupings.",Bleeding is an adverse reaction entity
"Figure 1:     Major Bleeding Hazard Ratios by Baseline Characteristics - ARISTOTLE Study     Note: The figure above presents effects in various subgroups, all of which are baseline characteristics and all of which were pre-specified, if not the groupings.",in various subgroups is not a named entity
Bleeding was assessed in each study beginning with the first dose of double-blind study drug.,Bleeding is an adverse reaction entity
Bleeding was assessed in each study beginning with the first dose of double-blind study drug.,dose is not a named entity
"Table 5:     Bleeding Results in the AMPLIFY Study                                  ELIQUISN=2676n (%)        Enoxaparin/WarfarinN=2689n (%)  Relative Risk (95% CI)           *   CRNM = clinically relevant nonmajor bleeding.Events associated with each endpoint were counted once per subject, but subjects may have contributed events to multiple endpoints.",Bleeding is an adverse reaction entity
"Table 5:     Bleeding Results in the AMPLIFY Study                                  ELIQUISN=2676n (%)        Enoxaparin/WarfarinN=2689n (%)  Relative Risk (95% CI)           *   CRNM = clinically relevant nonmajor bleeding.Events associated with each endpoint were counted once per subject, but subjects may have contributed events to multiple endpoints.",subjects may have is not a named entity
"Table 5:     Bleeding Results in the AMPLIFY Study                                  ELIQUISN=2676n (%)        Enoxaparin/WarfarinN=2689n (%)  Relative Risk (95% CI)           *   CRNM = clinically relevant nonmajor bleeding.Events associated with each endpoint were counted once per subject, but subjects may have contributed events to multiple endpoints.","subject , but is not a named entity"
"Table 5:     Bleeding Results in the AMPLIFY Study                                  ELIQUISN=2676n (%)        Enoxaparin/WarfarinN=2689n (%)  Relative Risk (95% CI)           *   CRNM = clinically relevant nonmajor bleeding.Events associated with each endpoint were counted once per subject, but subjects may have contributed events to multiple endpoints.",( 95 % is not a named entity
"Table 5:     Bleeding Results in the AMPLIFY Study                                  ELIQUISN=2676n (%)        Enoxaparin/WarfarinN=2689n (%)  Relative Risk (95% CI)           *   CRNM = clinically relevant nonmajor bleeding.Events associated with each endpoint were counted once per subject, but subjects may have contributed events to multiple endpoints.",CRNM is an adverse reaction entity
"Table 5:     Bleeding Results in the AMPLIFY Study                                  ELIQUISN=2676n (%)        Enoxaparin/WarfarinN=2689n (%)  Relative Risk (95% CI)           *   CRNM = clinically relevant nonmajor bleeding.Events associated with each endpoint were counted once per subject, but subjects may have contributed events to multiple endpoints.",clinically relevant nonmajor bleeding is an adverse reaction entity
"5.2 Bleeding    ELIQUIS increases the risk of bleeding and can cause serious, potentially fatal, bleeding  [see    Dosage and Administration (2.1)    andAdverse Reactions (6.1)]  .",risk of bleeding is not a named entity
"5.2 Bleeding    ELIQUIS increases the risk of bleeding and can cause serious, potentially fatal, bleeding  [see    Dosage and Administration (2.1)    andAdverse Reactions (6.1)]  .",Reactions ( is not a named entity
"5.2 Bleeding    ELIQUIS increases the risk of bleeding and can cause serious, potentially fatal, bleeding  [see    Dosage and Administration (2.1)    andAdverse Reactions (6.1)]  .",bleeding [ is not a named entity
"5.2 Bleeding    ELIQUIS increases the risk of bleeding and can cause serious, potentially fatal, bleeding  [see    Dosage and Administration (2.1)    andAdverse Reactions (6.1)]  .",bleeding is an adverse reaction entity
"5.2 Bleeding    ELIQUIS increases the risk of bleeding and can cause serious, potentially fatal, bleeding  [see    Dosage and Administration (2.1)    andAdverse Reactions (6.1)]  .",bleeding is an adverse reaction entity
"5.2 Bleeding    ELIQUIS increases the risk of bleeding and can cause serious, potentially fatal, bleeding  [see    Dosage and Administration (2.1)    andAdverse Reactions (6.1)]  .",fatal is an adverse reaction entity
"In the AMPLIFY study, ELIQUIS was statistically superior to enoxaparin/warfarin in the primary safety endpoint of major bleeding (relative risk 0.31, 95% CI [0.17, 0.55], P-value <0.0001).",bleeding is an adverse reaction entity
"In the AMPLIFY study, ELIQUIS was statistically superior to enoxaparin/warfarin in the primary safety endpoint of major bleeding (relative risk 0.31, 95% CI [0.17, 0.55], P-value <0.0001).","risk 0.31 , is not a named entity"
Bleeding into an operated joint requiring re-operation or intervention was present in all patients with this category of bleeding.,bleeding is an adverse reaction entity
Bleeding into an operated joint requiring re-operation or intervention was present in all patients with this category of bleeding.,Bleeding into an operated joint is an adverse reaction entity
Bleeding into an operated joint requiring re-operation or intervention was present in all patients with this category of bleeding.,with is not a named entity
Bleeding into an operated joint requiring re-operation or intervention was present in all patients with this category of bleeding.,category is not a named entity
Spinal/epidural anesthesia or puncture [seeWarnings and Precautions (5.3)]         EXCERPT:   Most common adverse reactions (>1%) are related to bleeding.,common adverse is not a named entity
Spinal/epidural anesthesia or puncture [seeWarnings and Precautions (5.3)]         EXCERPT:   Most common adverse reactions (>1%) are related to bleeding.,bleeding is an adverse reaction entity
Table 3:     Bleeding During the Treatment Period in Patients Undergoing Elective Hip or Knee Replacement Surgery     Bleeding Endpoint*      ADVANCE-3Hip Replacement Surgery      ADVANCE-2Knee Replacement Surgery      ADVANCE-1Knee Replacement Surgery          *   All bleeding criteria included surgical site bleeding.,Bleeding is an adverse reaction entity
Table 3:     Bleeding During the Treatment Period in Patients Undergoing Elective Hip or Knee Replacement Surgery     Bleeding Endpoint*      ADVANCE-3Hip Replacement Surgery      ADVANCE-2Knee Replacement Surgery      ADVANCE-1Knee Replacement Surgery          *   All bleeding criteria included surgical site bleeding.,Replacement is not a named entity
Table 3:     Bleeding During the Treatment Period in Patients Undergoing Elective Hip or Knee Replacement Surgery     Bleeding Endpoint*      ADVANCE-3Hip Replacement Surgery      ADVANCE-2Knee Replacement Surgery      ADVANCE-1Knee Replacement Surgery          *   All bleeding criteria included surgical site bleeding.,surgical site bleeding is an adverse reaction entity
Table 3:     Bleeding During the Treatment Period in Patients Undergoing Elective Hip or Knee Replacement Surgery     Bleeding Endpoint*      ADVANCE-3Hip Replacement Surgery      ADVANCE-2Knee Replacement Surgery      ADVANCE-1Knee Replacement Surgery          *   All bleeding criteria included surgical site bleeding.,bleeding is an adverse reaction entity
Table 3:     Bleeding During the Treatment Period in Patients Undergoing Elective Hip or Knee Replacement Surgery     Bleeding Endpoint*      ADVANCE-3Hip Replacement Surgery      ADVANCE-2Knee Replacement Surgery      ADVANCE-1Knee Replacement Surgery          *   All bleeding criteria included surgical site bleeding.,* is not a named entity
Table 3:     Bleeding During the Treatment Period in Patients Undergoing Elective Hip or Knee Replacement Surgery     Bleeding Endpoint*      ADVANCE-3Hip Replacement Surgery      ADVANCE-2Knee Replacement Surgery      ADVANCE-1Knee Replacement Surgery          *   All bleeding criteria included surgical site bleeding.,Undergoing Elective Hip is not a named entity
Bleeding results during the treatment period in the Phase III studies are shown in Table 3.,Bleeding is an adverse reaction entity
Bleeding results during the treatment period in the Phase III studies are shown in Table 3.,during the is not a named entity
Subjects treated with apixaban with diabetes bled more (3.0% per year) than did subjects without diabetes (1.9% per year).,bled is an adverse reaction entity
Subjects treated with apixaban with diabetes bled more (3.0% per year) than did subjects without diabetes (1.9% per year).,subjects is not a named entity
"(A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS: Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events.",thrombotic events is an adverse reaction entity
"(A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS: Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events.",of thrombotic is not a named entity
"(A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS: Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events.",THROMBOTIC EVENTS is an adverse reaction entity
"(A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS: Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events.",RISK is not a named entity
Major                         2 (0.2)                    1 (0.1)                   4 (0.5)                      CRNM*                         25 (3.0)                   34 (4.2)                  19 (2.3)                     Major + CRNM                  27 (3.2)                   35 (4.3)                  22 (2.7)                     Minor                         75 (8.9)                   98 (12.1)                 58 (7.0)                     All                           94 (11.2)                  121 (14.9)                74 (9.0)                             Adverse reactions occurring in >=1% of patients in the AMPLIFY-EXT study are listed in Table 8.,CRNM is an adverse reaction entity
Major                         2 (0.2)                    1 (0.1)                   4 (0.5)                      CRNM*                         25 (3.0)                   34 (4.2)                  19 (2.3)                     Major + CRNM                  27 (3.2)                   35 (4.3)                  22 (2.7)                     Minor                         75 (8.9)                   98 (12.1)                 58 (7.0)                     All                           94 (11.2)                  121 (14.9)                74 (9.0)                             Adverse reactions occurring in >=1% of patients in the AMPLIFY-EXT study are listed in Table 8.,CRNM is an adverse reaction entity
Major                         2 (0.2)                    1 (0.1)                   4 (0.5)                      CRNM*                         25 (3.0)                   34 (4.2)                  19 (2.3)                     Major + CRNM                  27 (3.2)                   35 (4.3)                  22 (2.7)                     Minor                         75 (8.9)                   98 (12.1)                 58 (7.0)                     All                           94 (11.2)                  121 (14.9)                74 (9.0)                             Adverse reactions occurring in >=1% of patients in the AMPLIFY-EXT study are listed in Table 8.,) is not a named entity
Major                         2 (0.2)                    1 (0.1)                   4 (0.5)                      CRNM*                         25 (3.0)                   34 (4.2)                  19 (2.3)                     Major + CRNM                  27 (3.2)                   35 (4.3)                  22 (2.7)                     Minor                         75 (8.9)                   98 (12.1)                 58 (7.0)                     All                           94 (11.2)                  121 (14.9)                74 (9.0)                             Adverse reactions occurring in >=1% of patients in the AMPLIFY-EXT study are listed in Table 8.,12.1 ) 58 is not a named entity
Increased risk of thrombotic events after premature discontinuation [seeWarnings and Precautions (5.1)]    *  ?,thrombotic events is an adverse reaction entity
Increased risk of thrombotic events after premature discontinuation [seeWarnings and Precautions (5.1)]    *  ?,after is not a named entity
Events and event rates include one enoxaparin-treated patient in ADVANCE-1 who also had intracranial hemorrhage.,hemorrhage is not a named entity
Events and event rates include one enoxaparin-treated patient in ADVANCE-1 who also had intracranial hemorrhage.,intracranial hemorrhage is an adverse reaction entity
Includes 5 subjects with major bleeding events that occurred before the first dose of apixaban (administered 12 to 24 hours post surgery).,bleeding is an adverse reaction entity
Includes 5 subjects with major bleeding events that occurred before the first dose of apixaban (administered 12 to 24 hours post surgery).,Includes 5 subjects is not a named entity
"Intracranial bleed includes intracerebral, intraventricular, subdural, and subarachnoid bleeding.",subdural bleeding is an adverse reaction entity
"Intracranial bleed includes intracerebral, intraventricular, subdural, and subarachnoid bleeding.",includes is not a named entity
"Intracranial bleed includes intracerebral, intraventricular, subdural, and subarachnoid bleeding.",intraventricular bleeding is an adverse reaction entity
"Intracranial bleed includes intracerebral, intraventricular, subdural, and subarachnoid bleeding.",", and subarachnoid is not a named entity"
"Intracranial bleed includes intracerebral, intraventricular, subdural, and subarachnoid bleeding.",", intraventricular , is not a named entity"
"Intracranial bleed includes intracerebral, intraventricular, subdural, and subarachnoid bleeding.",Intracranial bleed is an adverse reaction entity
"Intracranial bleed includes intracerebral, intraventricular, subdural, and subarachnoid bleeding.",intracerebral bleeding is an adverse reaction entity
"Intracranial bleed includes intracerebral, intraventricular, subdural, and subarachnoid bleeding.",subarachnoid bleeding is an adverse reaction entity
"Intracranial bleed includes intracerebral, intraventricular, subdural, and subarachnoid bleeding.","subdural , and is not a named entity"
"Intracranial bleed includes intracerebral, intraventricular, subdural, and subarachnoid bleeding.",", and subarachnoid is not a named entity"
"Defined as clinically overt bleeding accompanied by one or more of the following: a decrease in hemoglobin of >=2 g/dL, a transfusion of 2 or more units of packed red blood cells, bleeding at a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal or with fatal outcome.",of the following is not a named entity
"Defined as clinically overt bleeding accompanied by one or more of the following: a decrease in hemoglobin of >=2 g/dL, a transfusion of 2 or more units of packed red blood cells, bleeding at a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal or with fatal outcome.",red blood cells is not a named entity
"Defined as clinically overt bleeding accompanied by one or more of the following: a decrease in hemoglobin of >=2 g/dL, a transfusion of 2 or more units of packed red blood cells, bleeding at a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal or with fatal outcome.",with is not a named entity
"Defined as clinically overt bleeding accompanied by one or more of the following: a decrease in hemoglobin of >=2 g/dL, a transfusion of 2 or more units of packed red blood cells, bleeding at a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal or with fatal outcome.","intraspinal , intraocular is not a named entity"
"Defined as clinically overt bleeding accompanied by one or more of the following: a decrease in hemoglobin of >=2 g/dL, a transfusion of 2 or more units of packed red blood cells, bleeding at a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal or with fatal outcome.",", is not a named entity"
"Defined as clinically overt bleeding accompanied by one or more of the following: a decrease in hemoglobin of >=2 g/dL, a transfusion of 2 or more units of packed red blood cells, bleeding at a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal or with fatal outcome.",bleeding intraocular is an adverse reaction entity
"Defined as clinically overt bleeding accompanied by one or more of the following: a decrease in hemoglobin of >=2 g/dL, a transfusion of 2 or more units of packed red blood cells, bleeding at a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal or with fatal outcome.",bleeding at a critical site is an adverse reaction entity
"Defined as clinically overt bleeding accompanied by one or more of the following: a decrease in hemoglobin of >=2 g/dL, a transfusion of 2 or more units of packed red blood cells, bleeding at a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal or with fatal outcome.",compartment syndrome is an adverse reaction entity
"Defined as clinically overt bleeding accompanied by one or more of the following: a decrease in hemoglobin of >=2 g/dL, a transfusion of 2 or more units of packed red blood cells, bleeding at a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal or with fatal outcome.",bleeding intra-articular is an adverse reaction entity
"Defined as clinically overt bleeding accompanied by one or more of the following: a decrease in hemoglobin of >=2 g/dL, a transfusion of 2 or more units of packed red blood cells, bleeding at a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal or with fatal outcome.",: a is not a named entity
"Defined as clinically overt bleeding accompanied by one or more of the following: a decrease in hemoglobin of >=2 g/dL, a transfusion of 2 or more units of packed red blood cells, bleeding at a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal or with fatal outcome.",bleeding pericardial is an adverse reaction entity
"Defined as clinically overt bleeding accompanied by one or more of the following: a decrease in hemoglobin of >=2 g/dL, a transfusion of 2 or more units of packed red blood cells, bleeding at a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal or with fatal outcome.",bleeding retroperitoneal is an adverse reaction entity
"Defined as clinically overt bleeding accompanied by one or more of the following: a decrease in hemoglobin of >=2 g/dL, a transfusion of 2 or more units of packed red blood cells, bleeding at a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal or with fatal outcome.",bleeding is an adverse reaction entity
"Defined as clinically overt bleeding accompanied by one or more of the following: a decrease in hemoglobin of >=2 g/dL, a transfusion of 2 or more units of packed red blood cells, bleeding at a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal or with fatal outcome.",decrease in hemoglobin is an adverse reaction entity
"Defined as clinically overt bleeding accompanied by one or more of the following: a decrease in hemoglobin of >=2 g/dL, a transfusion of 2 or more units of packed red blood cells, bleeding at a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal or with fatal outcome.",with is not a named entity
"Defined as clinically overt bleeding accompanied by one or more of the following: a decrease in hemoglobin of >=2 g/dL, a transfusion of 2 or more units of packed red blood cells, bleeding at a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal or with fatal outcome.",by one is not a named entity
"Defined as clinically overt bleeding accompanied by one or more of the following: a decrease in hemoglobin of >=2 g/dL, a transfusion of 2 or more units of packed red blood cells, bleeding at a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal or with fatal outcome.",bleeding intracranial is an adverse reaction entity
"Defined as clinically overt bleeding accompanied by one or more of the following: a decrease in hemoglobin of >=2 g/dL, a transfusion of 2 or more units of packed red blood cells, bleeding at a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal or with fatal outcome.",bleeding intramuscular is an adverse reaction entity
"Defined as clinically overt bleeding accompanied by one or more of the following: a decrease in hemoglobin of >=2 g/dL, a transfusion of 2 or more units of packed red blood cells, bleeding at a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal or with fatal outcome.",bleeding intraspinal is an adverse reaction entity
"Defined as clinically overt bleeding accompanied by one or more of the following: a decrease in hemoglobin of >=2 g/dL, a transfusion of 2 or more units of packed red blood cells, bleeding at a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal or with fatal outcome.",fatal outcome is an adverse reaction entity
"Defined as clinically overt bleeding accompanied by one or more of the following: a decrease in hemoglobin of >=2 g/dL, a transfusion of 2 or more units of packed red blood cells, bleeding at a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal or with fatal outcome.",hemoglobin is not a named entity
"Defined as clinically overt bleeding accompanied by one or more of the following: a decrease in hemoglobin of >=2 g/dL, a transfusion of 2 or more units of packed red blood cells, bleeding at a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal or with fatal outcome.",intraspinal is not a named entity
"Defined as clinically overt bleeding accompanied by one or more of the following: a decrease in hemoglobin of >=2 g/dL, a transfusion of 2 or more units of packed red blood cells, bleeding at a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal or with fatal outcome.",blood is not a named entity
"Defined as clinically overt bleeding accompanied by one or more of the following: a decrease in hemoglobin of >=2 g/dL, a transfusion of 2 or more units of packed red blood cells, bleeding at a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal or with fatal outcome.",", intra-articular is not a named entity"
"Major                      45 (1.41)             29 (0.92)             1.54 (0.96, 2.45)     0.07                    Fatal                  5 (0.16)              5 (0.16)              0.99 (0.23, 4.29)     -                       Intracranial           11 (0.34)             11 (0.35)             0.99 (0.39, 2.51)     -                             ARISTOTLE Major Bleeding Forest Plot   Other Adverse Reactions    Hypersensitivity reactions (including drug hypersensitivity, such as skin rash, and anaphylactic reactions, such as allergic edema) and syncope were reported in <1% of patients receiving ELIQUIS.",anaphylactic reactions is an adverse reaction entity
"Major                      45 (1.41)             29 (0.92)             1.54 (0.96, 2.45)     0.07                    Fatal                  5 (0.16)              5 (0.16)              0.99 (0.23, 4.29)     -                       Intracranial           11 (0.34)             11 (0.35)             0.99 (0.39, 2.51)     -                             ARISTOTLE Major Bleeding Forest Plot   Other Adverse Reactions    Hypersensitivity reactions (including drug hypersensitivity, such as skin rash, and anaphylactic reactions, such as allergic edema) and syncope were reported in <1% of patients receiving ELIQUIS.",Hypersensitivity reactions ( is not a named entity
"Major                      45 (1.41)             29 (0.92)             1.54 (0.96, 2.45)     0.07                    Fatal                  5 (0.16)              5 (0.16)              0.99 (0.23, 4.29)     -                       Intracranial           11 (0.34)             11 (0.35)             0.99 (0.39, 2.51)     -                             ARISTOTLE Major Bleeding Forest Plot   Other Adverse Reactions    Hypersensitivity reactions (including drug hypersensitivity, such as skin rash, and anaphylactic reactions, such as allergic edema) and syncope were reported in <1% of patients receiving ELIQUIS.","hypersensitivity , such is not a named entity"
"Major                      45 (1.41)             29 (0.92)             1.54 (0.96, 2.45)     0.07                    Fatal                  5 (0.16)              5 (0.16)              0.99 (0.23, 4.29)     -                       Intracranial           11 (0.34)             11 (0.35)             0.99 (0.39, 2.51)     -                             ARISTOTLE Major Bleeding Forest Plot   Other Adverse Reactions    Hypersensitivity reactions (including drug hypersensitivity, such as skin rash, and anaphylactic reactions, such as allergic edema) and syncope were reported in <1% of patients receiving ELIQUIS.",drug hypersensitivity is an adverse reaction entity
"Major                      45 (1.41)             29 (0.92)             1.54 (0.96, 2.45)     0.07                    Fatal                  5 (0.16)              5 (0.16)              0.99 (0.23, 4.29)     -                       Intracranial           11 (0.34)             11 (0.35)             0.99 (0.39, 2.51)     -                             ARISTOTLE Major Bleeding Forest Plot   Other Adverse Reactions    Hypersensitivity reactions (including drug hypersensitivity, such as skin rash, and anaphylactic reactions, such as allergic edema) and syncope were reported in <1% of patients receiving ELIQUIS.",Forest is not a named entity
"Major                      45 (1.41)             29 (0.92)             1.54 (0.96, 2.45)     0.07                    Fatal                  5 (0.16)              5 (0.16)              0.99 (0.23, 4.29)     -                       Intracranial           11 (0.34)             11 (0.35)             0.99 (0.39, 2.51)     -                             ARISTOTLE Major Bleeding Forest Plot   Other Adverse Reactions    Hypersensitivity reactions (including drug hypersensitivity, such as skin rash, and anaphylactic reactions, such as allergic edema) and syncope were reported in <1% of patients receiving ELIQUIS.",) 0.99 is not a named entity
"Major                      45 (1.41)             29 (0.92)             1.54 (0.96, 2.45)     0.07                    Fatal                  5 (0.16)              5 (0.16)              0.99 (0.23, 4.29)     -                       Intracranial           11 (0.34)             11 (0.35)             0.99 (0.39, 2.51)     -                             ARISTOTLE Major Bleeding Forest Plot   Other Adverse Reactions    Hypersensitivity reactions (including drug hypersensitivity, such as skin rash, and anaphylactic reactions, such as allergic edema) and syncope were reported in <1% of patients receiving ELIQUIS.",5 ( 0.16 is not a named entity
"Major                      45 (1.41)             29 (0.92)             1.54 (0.96, 2.45)     0.07                    Fatal                  5 (0.16)              5 (0.16)              0.99 (0.23, 4.29)     -                       Intracranial           11 (0.34)             11 (0.35)             0.99 (0.39, 2.51)     -                             ARISTOTLE Major Bleeding Forest Plot   Other Adverse Reactions    Hypersensitivity reactions (including drug hypersensitivity, such as skin rash, and anaphylactic reactions, such as allergic edema) and syncope were reported in <1% of patients receiving ELIQUIS.",% of is not a named entity
"Major                      45 (1.41)             29 (0.92)             1.54 (0.96, 2.45)     0.07                    Fatal                  5 (0.16)              5 (0.16)              0.99 (0.23, 4.29)     -                       Intracranial           11 (0.34)             11 (0.35)             0.99 (0.39, 2.51)     -                             ARISTOTLE Major Bleeding Forest Plot   Other Adverse Reactions    Hypersensitivity reactions (including drug hypersensitivity, such as skin rash, and anaphylactic reactions, such as allergic edema) and syncope were reported in <1% of patients receiving ELIQUIS.",Hypersensitivity reactions is an adverse reaction entity
"Major                      45 (1.41)             29 (0.92)             1.54 (0.96, 2.45)     0.07                    Fatal                  5 (0.16)              5 (0.16)              0.99 (0.23, 4.29)     -                       Intracranial           11 (0.34)             11 (0.35)             0.99 (0.39, 2.51)     -                             ARISTOTLE Major Bleeding Forest Plot   Other Adverse Reactions    Hypersensitivity reactions (including drug hypersensitivity, such as skin rash, and anaphylactic reactions, such as allergic edema) and syncope were reported in <1% of patients receiving ELIQUIS.",) 5 is not a named entity
"Major                      45 (1.41)             29 (0.92)             1.54 (0.96, 2.45)     0.07                    Fatal                  5 (0.16)              5 (0.16)              0.99 (0.23, 4.29)     -                       Intracranial           11 (0.34)             11 (0.35)             0.99 (0.39, 2.51)     -                             ARISTOTLE Major Bleeding Forest Plot   Other Adverse Reactions    Hypersensitivity reactions (including drug hypersensitivity, such as skin rash, and anaphylactic reactions, such as allergic edema) and syncope were reported in <1% of patients receiving ELIQUIS.",skin rash is an adverse reaction entity
"Major                      45 (1.41)             29 (0.92)             1.54 (0.96, 2.45)     0.07                    Fatal                  5 (0.16)              5 (0.16)              0.99 (0.23, 4.29)     -                       Intracranial           11 (0.34)             11 (0.35)             0.99 (0.39, 2.51)     -                             ARISTOTLE Major Bleeding Forest Plot   Other Adverse Reactions    Hypersensitivity reactions (including drug hypersensitivity, such as skin rash, and anaphylactic reactions, such as allergic edema) and syncope were reported in <1% of patients receiving ELIQUIS.",syncope is an adverse reaction entity
"Major                      45 (1.41)             29 (0.92)             1.54 (0.96, 2.45)     0.07                    Fatal                  5 (0.16)              5 (0.16)              0.99 (0.23, 4.29)     -                       Intracranial           11 (0.34)             11 (0.35)             0.99 (0.39, 2.51)     -                             ARISTOTLE Major Bleeding Forest Plot   Other Adverse Reactions    Hypersensitivity reactions (including drug hypersensitivity, such as skin rash, and anaphylactic reactions, such as allergic edema) and syncope were reported in <1% of patients receiving ELIQUIS.",Bleeding is an adverse reaction entity
"Major                      45 (1.41)             29 (0.92)             1.54 (0.96, 2.45)     0.07                    Fatal                  5 (0.16)              5 (0.16)              0.99 (0.23, 4.29)     -                       Intracranial           11 (0.34)             11 (0.35)             0.99 (0.39, 2.51)     -                             ARISTOTLE Major Bleeding Forest Plot   Other Adverse Reactions    Hypersensitivity reactions (including drug hypersensitivity, such as skin rash, and anaphylactic reactions, such as allergic edema) and syncope were reported in <1% of patients receiving ELIQUIS.",Fatal is an adverse reaction entity
"Major                      45 (1.41)             29 (0.92)             1.54 (0.96, 2.45)     0.07                    Fatal                  5 (0.16)              5 (0.16)              0.99 (0.23, 4.29)     -                       Intracranial           11 (0.34)             11 (0.35)             0.99 (0.39, 2.51)     -                             ARISTOTLE Major Bleeding Forest Plot   Other Adverse Reactions    Hypersensitivity reactions (including drug hypersensitivity, such as skin rash, and anaphylactic reactions, such as allergic edema) and syncope were reported in <1% of patients receiving ELIQUIS.",) and is not a named entity
"Major                      45 (1.41)             29 (0.92)             1.54 (0.96, 2.45)     0.07                    Fatal                  5 (0.16)              5 (0.16)              0.99 (0.23, 4.29)     -                       Intracranial           11 (0.34)             11 (0.35)             0.99 (0.39, 2.51)     -                             ARISTOTLE Major Bleeding Forest Plot   Other Adverse Reactions    Hypersensitivity reactions (including drug hypersensitivity, such as skin rash, and anaphylactic reactions, such as allergic edema) and syncope were reported in <1% of patients receiving ELIQUIS.",allergic edema is an adverse reaction entity
An increased rate of stroke was observed during the transition from ELIQUIS to warfarin in clinical trials in atrial fibrillation patients.,from is not a named entity
An increased rate of stroke was observed during the transition from ELIQUIS to warfarin in clinical trials in atrial fibrillation patients.,stroke is an adverse reaction entity
Adverse reactions related to bleeding occurred in 219 (13.3%) ELIQUIS-treated patients compared to 72 (8.7%) placebo-treated patients.,bleeding is an adverse reaction entity
Adverse reactions related to bleeding occurred in 219 (13.3%) ELIQUIS-treated patients compared to 72 (8.7%) placebo-treated patients.,Adverse is not a named entity
"(5.4)          5.1 Increased Risk of Thrombotic Events after Premature Discontinuation    Premature discontinuation of any oral anticoagulant, including ELIQUIS, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events.",5.1 Increased Risk is not a named entity
"(5.4)          5.1 Increased Risk of Thrombotic Events after Premature Discontinuation    Premature discontinuation of any oral anticoagulant, including ELIQUIS, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events.",thrombotic events is an adverse reaction entity
"5.3 Spinal/Epidural Anesthesia or Puncture    When neuraxial anesthesia (spinal/epidural anesthesia) or spinal/epidural puncture is employed, patients treated with antithrombotic agents for prevention of thromboembolic complications are at risk of developing an epidural or spinal hematoma which can result in long-term or permanent paralysis.",is is not a named entity
"5.3 Spinal/Epidural Anesthesia or Puncture    When neuraxial anesthesia (spinal/epidural anesthesia) or spinal/epidural puncture is employed, patients treated with antithrombotic agents for prevention of thromboembolic complications are at risk of developing an epidural or spinal hematoma which can result in long-term or permanent paralysis.",spinal hematoma is an adverse reaction entity
"5.3 Spinal/Epidural Anesthesia or Puncture    When neuraxial anesthesia (spinal/epidural anesthesia) or spinal/epidural puncture is employed, patients treated with antithrombotic agents for prevention of thromboembolic complications are at risk of developing an epidural or spinal hematoma which can result in long-term or permanent paralysis.",of developing is not a named entity
"5.3 Spinal/Epidural Anesthesia or Puncture    When neuraxial anesthesia (spinal/epidural anesthesia) or spinal/epidural puncture is employed, patients treated with antithrombotic agents for prevention of thromboembolic complications are at risk of developing an epidural or spinal hematoma which can result in long-term or permanent paralysis.",permanent paralysis is an adverse reaction entity
"5.3 Spinal/Epidural Anesthesia or Puncture    When neuraxial anesthesia (spinal/epidural anesthesia) or spinal/epidural puncture is employed, patients treated with antithrombotic agents for prevention of thromboembolic complications are at risk of developing an epidural or spinal hematoma which can result in long-term or permanent paralysis.",long-term paralysis is an adverse reaction entity
"5.3 Spinal/Epidural Anesthesia or Puncture    When neuraxial anesthesia (spinal/epidural anesthesia) or spinal/epidural puncture is employed, patients treated with antithrombotic agents for prevention of thromboembolic complications are at risk of developing an epidural or spinal hematoma which can result in long-term or permanent paralysis.",epidural hematoma is an adverse reaction entity
"5.3 Spinal/Epidural Anesthesia or Puncture    When neuraxial anesthesia (spinal/epidural anesthesia) or spinal/epidural puncture is employed, patients treated with antithrombotic agents for prevention of thromboembolic complications are at risk of developing an epidural or spinal hematoma which can result in long-term or permanent paralysis.",treated with antithrombotic is not a named entity
"5.3 Spinal/Epidural Anesthesia or Puncture    When neuraxial anesthesia (spinal/epidural anesthesia) or spinal/epidural puncture is employed, patients treated with antithrombotic agents for prevention of thromboembolic complications are at risk of developing an epidural or spinal hematoma which can result in long-term or permanent paralysis.",or is not a named entity
"BOXED WARNING: WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS(B) SPINAL/EPIDURAL HEMATOMA    WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS(B) SPINAL/EPIDURAL HEMATOMA      (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS         Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events.",EPIDURAL HEMATOMA is an adverse reaction entity
"BOXED WARNING: WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS(B) SPINAL/EPIDURAL HEMATOMA    WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS(B) SPINAL/EPIDURAL HEMATOMA      (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS         Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events.",ELIQUIS is not a named entity
"BOXED WARNING: WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS(B) SPINAL/EPIDURAL HEMATOMA    WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS(B) SPINAL/EPIDURAL HEMATOMA      (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS         Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events.",", increases is not a named entity"
"BOXED WARNING: WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS(B) SPINAL/EPIDURAL HEMATOMA    WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS(B) SPINAL/EPIDURAL HEMATOMA      (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS         Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events.",THROMBOTIC EVENTS is an adverse reaction entity
"BOXED WARNING: WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS(B) SPINAL/EPIDURAL HEMATOMA    WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS(B) SPINAL/EPIDURAL HEMATOMA      (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS         Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events.",EVENTS is not a named entity
"BOXED WARNING: WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS(B) SPINAL/EPIDURAL HEMATOMA    WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS(B) SPINAL/EPIDURAL HEMATOMA      (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS         Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events.",THROMBOTIC EVENTS is an adverse reaction entity
"BOXED WARNING: WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS(B) SPINAL/EPIDURAL HEMATOMA    WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS(B) SPINAL/EPIDURAL HEMATOMA      (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS         Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events.",", increases is not a named entity"
"BOXED WARNING: WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS(B) SPINAL/EPIDURAL HEMATOMA    WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS(B) SPINAL/EPIDURAL HEMATOMA      (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS         Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events.",SPINAL HEMATOMA is an adverse reaction entity
"BOXED WARNING: WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS(B) SPINAL/EPIDURAL HEMATOMA    WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS(B) SPINAL/EPIDURAL HEMATOMA      (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS         Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events.",THE RISK OF is not a named entity
"BOXED WARNING: WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS(B) SPINAL/EPIDURAL HEMATOMA    WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS(B) SPINAL/EPIDURAL HEMATOMA      (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS         Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events.",( B is not a named entity
"BOXED WARNING: WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS(B) SPINAL/EPIDURAL HEMATOMA    WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS(B) SPINAL/EPIDURAL HEMATOMA      (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS         Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events.",EPIDURAL HEMATOMA is an adverse reaction entity
"BOXED WARNING: WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS(B) SPINAL/EPIDURAL HEMATOMA    WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS(B) SPINAL/EPIDURAL HEMATOMA      (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS         Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events.",SPINAL HEMATOMA is an adverse reaction entity
"BOXED WARNING: WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS(B) SPINAL/EPIDURAL HEMATOMA    WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS(B) SPINAL/EPIDURAL HEMATOMA      (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS         Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events.",B ) is not a named entity
"BOXED WARNING: WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS(B) SPINAL/EPIDURAL HEMATOMA    WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS(B) SPINAL/EPIDURAL HEMATOMA      (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS         Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events.",thrombotic events is an adverse reaction entity
"BOXED WARNING: WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS(B) SPINAL/EPIDURAL HEMATOMA    WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS(B) SPINAL/EPIDURAL HEMATOMA      (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS         Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events.",THROMBOTIC EVENTS is an adverse reaction entity
"BOXED WARNING: WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS(B) SPINAL/EPIDURAL HEMATOMA    WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS(B) SPINAL/EPIDURAL HEMATOMA      (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS         Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events.",THROMBOTIC EVENTS Premature is not a named entity
"Table 2:      Bleeding Events in Patients with Nonvalvular Atrial Fibrillation in AVERROES                              ELIQUISN=2798n (%/year)  AspirinN=2780n (%/year)  Hazard Ratio(95% CI)  P-value                Events associated with each endpoint were counted once per subject, but subjects may have contributed events to multiple endpoints.",Bleeding is an adverse reaction entity
"Table 2:      Bleeding Events in Patients with Nonvalvular Atrial Fibrillation in AVERROES                              ELIQUISN=2798n (%/year)  AspirinN=2780n (%/year)  Hazard Ratio(95% CI)  P-value                Events associated with each endpoint were counted once per subject, but subjects may have contributed events to multiple endpoints.",AVERROES ELIQUISN=2798n ( is not a named entity
Any type of hemorrhagic stroke was adjudicated and counted as an intracranial major bleed.,as is not a named entity
Any type of hemorrhagic stroke was adjudicated and counted as an intracranial major bleed.,bleed is not a named entity
Any type of hemorrhagic stroke was adjudicated and counted as an intracranial major bleed.,hemorrhagic stroke is an adverse reaction entity
Any type of hemorrhagic stroke was adjudicated and counted as an intracranial major bleed.,intracranial bleed is an adverse reaction entity
"5.4 Local Effects of Inhaled Corticosteroids      In clinical trials, the development of localized infections of the mouth and pharynx with Candida albicans  has occurred in subjects treated with BREO ELLIPTA.",infections of the pharynx with Candida albicans is an adverse reaction entity
"5.4 Local Effects of Inhaled Corticosteroids      In clinical trials, the development of localized infections of the mouth and pharynx with Candida albicans  has occurred in subjects treated with BREO ELLIPTA.",infections of the mouth with Candida albicans is an adverse reaction entity
"5.4 Local Effects of Inhaled Corticosteroids      In clinical trials, the development of localized infections of the mouth and pharynx with Candida albicans  has occurred in subjects treated with BREO ELLIPTA.",Local Effects of is not a named entity
"5.4 Local Effects of Inhaled Corticosteroids      In clinical trials, the development of localized infections of the mouth and pharynx with Candida albicans  has occurred in subjects treated with BREO ELLIPTA.",with BREO is not a named entity
"5.11 Hypersensitivity Reactions, Including Anaphylaxis      Hypersensitivity reactions such as anaphylaxis, angioedema, rash, and urticaria may occur after administration of BREO ELLIPTA.",rash is an adverse reaction entity
"5.11 Hypersensitivity Reactions, Including Anaphylaxis      Hypersensitivity reactions such as anaphylaxis, angioedema, rash, and urticaria may occur after administration of BREO ELLIPTA.",Hypersensitivity reactions is an adverse reaction entity
"5.11 Hypersensitivity Reactions, Including Anaphylaxis      Hypersensitivity reactions such as anaphylaxis, angioedema, rash, and urticaria may occur after administration of BREO ELLIPTA.","as anaphylaxis , is not a named entity"
"5.11 Hypersensitivity Reactions, Including Anaphylaxis      Hypersensitivity reactions such as anaphylaxis, angioedema, rash, and urticaria may occur after administration of BREO ELLIPTA.","angioedema , rash is not a named entity"
"5.11 Hypersensitivity Reactions, Including Anaphylaxis      Hypersensitivity reactions such as anaphylaxis, angioedema, rash, and urticaria may occur after administration of BREO ELLIPTA.",and urticaria is not a named entity
"5.11 Hypersensitivity Reactions, Including Anaphylaxis      Hypersensitivity reactions such as anaphylaxis, angioedema, rash, and urticaria may occur after administration of BREO ELLIPTA.",reactions is not a named entity
"5.11 Hypersensitivity Reactions, Including Anaphylaxis      Hypersensitivity reactions such as anaphylaxis, angioedema, rash, and urticaria may occur after administration of BREO ELLIPTA.",angioedema is an adverse reaction entity
"5.11 Hypersensitivity Reactions, Including Anaphylaxis      Hypersensitivity reactions such as anaphylaxis, angioedema, rash, and urticaria may occur after administration of BREO ELLIPTA.",urticaria is an adverse reaction entity
"5.11 Hypersensitivity Reactions, Including Anaphylaxis      Hypersensitivity reactions such as anaphylaxis, angioedema, rash, and urticaria may occur after administration of BREO ELLIPTA.","Hypersensitivity Reactions , is not a named entity"
"5.11 Hypersensitivity Reactions, Including Anaphylaxis      Hypersensitivity reactions such as anaphylaxis, angioedema, rash, and urticaria may occur after administration of BREO ELLIPTA.",anaphylaxis is an adverse reaction entity
"A 28-week, placebo-controlled, US trial that compared the safety of another LABA (salmeterol) with placebo, each added to usual asthma therapy, showed an increase in asthma-related deaths in subjects receiving salmeterol (13/13,176 in subjects treated with salmeterol vs. 3/13,179 in subjects treated with placebo; relative risk: 4.37 [95% CI: 1.25, 15.34]).",deaths is an adverse reaction entity
"A 28-week, placebo-controlled, US trial that compared the safety of another LABA (salmeterol) with placebo, each added to usual asthma therapy, showed an increase in asthma-related deaths in subjects receiving salmeterol (13/13,176 in subjects treated with salmeterol vs. 3/13,179 in subjects treated with placebo; relative risk: 4.37 [95% CI: 1.25, 15.34]).","13/13,176 in is not a named entity"
"EXCERPT:    *    COPD: Most common adverse reactions (incidence greater than or equal to 3%) are nasopharyngitis, upper respiratory tract infection, headache, and oral candidiasis.",upper respiratory tract infection is an adverse reaction entity
"EXCERPT:    *    COPD: Most common adverse reactions (incidence greater than or equal to 3%) are nasopharyngitis, upper respiratory tract infection, headache, and oral candidiasis.",nasopharyngitis is an adverse reaction entity
"EXCERPT:    *    COPD: Most common adverse reactions (incidence greater than or equal to 3%) are nasopharyngitis, upper respiratory tract infection, headache, and oral candidiasis.",% is not a named entity
"EXCERPT:    *    COPD: Most common adverse reactions (incidence greater than or equal to 3%) are nasopharyngitis, upper respiratory tract infection, headache, and oral candidiasis.",candidiasis is not a named entity
"EXCERPT:    *    COPD: Most common adverse reactions (incidence greater than or equal to 3%) are nasopharyngitis, upper respiratory tract infection, headache, and oral candidiasis.",) is not a named entity
"EXCERPT:    *    COPD: Most common adverse reactions (incidence greater than or equal to 3%) are nasopharyngitis, upper respiratory tract infection, headache, and oral candidiasis.",headache is an adverse reaction entity
"EXCERPT:    *    COPD: Most common adverse reactions (incidence greater than or equal to 3%) are nasopharyngitis, upper respiratory tract infection, headache, and oral candidiasis.",oral candidiasis is an adverse reaction entity
"EXCERPT:    *    COPD: Most common adverse reactions (incidence greater than or equal to 3%) are nasopharyngitis, upper respiratory tract infection, headache, and oral candidiasis.",( incidence is not a named entity
"In addition to the reactions shown in Tables 2 and 3, adverse reactions occurring in greater than or equal to 2% of the subjects treated with BREO ELLIPTA 100/25 or BREO ELLIPTA 200/25 for 12 months included pyrexia, back pain, extrasystoles, upper abdominal pain, respiratory tract infection, allergic rhinitis, pharyngitis, rhinitis, arthralgia, supraventricular extrasystoles, ventricular extrasystoles, acute sinusitis, and pneumonia.",back pain is an adverse reaction entity
"In addition to the reactions shown in Tables 2 and 3, adverse reactions occurring in greater than or equal to 2% of the subjects treated with BREO ELLIPTA 100/25 or BREO ELLIPTA 200/25 for 12 months included pyrexia, back pain, extrasystoles, upper abdominal pain, respiratory tract infection, allergic rhinitis, pharyngitis, rhinitis, arthralgia, supraventricular extrasystoles, ventricular extrasystoles, acute sinusitis, and pneumonia.",", extrasystoles , is not a named entity"
"In addition to the reactions shown in Tables 2 and 3, adverse reactions occurring in greater than or equal to 2% of the subjects treated with BREO ELLIPTA 100/25 or BREO ELLIPTA 200/25 for 12 months included pyrexia, back pain, extrasystoles, upper abdominal pain, respiratory tract infection, allergic rhinitis, pharyngitis, rhinitis, arthralgia, supraventricular extrasystoles, ventricular extrasystoles, acute sinusitis, and pneumonia.",arthralgia is an adverse reaction entity
"In addition to the reactions shown in Tables 2 and 3, adverse reactions occurring in greater than or equal to 2% of the subjects treated with BREO ELLIPTA 100/25 or BREO ELLIPTA 200/25 for 12 months included pyrexia, back pain, extrasystoles, upper abdominal pain, respiratory tract infection, allergic rhinitis, pharyngitis, rhinitis, arthralgia, supraventricular extrasystoles, ventricular extrasystoles, acute sinusitis, and pneumonia.",rhinitis is not a named entity
"In addition to the reactions shown in Tables 2 and 3, adverse reactions occurring in greater than or equal to 2% of the subjects treated with BREO ELLIPTA 100/25 or BREO ELLIPTA 200/25 for 12 months included pyrexia, back pain, extrasystoles, upper abdominal pain, respiratory tract infection, allergic rhinitis, pharyngitis, rhinitis, arthralgia, supraventricular extrasystoles, ventricular extrasystoles, acute sinusitis, and pneumonia.",ventricular extrasystoles is an adverse reaction entity
"In addition to the reactions shown in Tables 2 and 3, adverse reactions occurring in greater than or equal to 2% of the subjects treated with BREO ELLIPTA 100/25 or BREO ELLIPTA 200/25 for 12 months included pyrexia, back pain, extrasystoles, upper abdominal pain, respiratory tract infection, allergic rhinitis, pharyngitis, rhinitis, arthralgia, supraventricular extrasystoles, ventricular extrasystoles, acute sinusitis, and pneumonia.",BREO is not a named entity
"In addition to the reactions shown in Tables 2 and 3, adverse reactions occurring in greater than or equal to 2% of the subjects treated with BREO ELLIPTA 100/25 or BREO ELLIPTA 200/25 for 12 months included pyrexia, back pain, extrasystoles, upper abdominal pain, respiratory tract infection, allergic rhinitis, pharyngitis, rhinitis, arthralgia, supraventricular extrasystoles, ventricular extrasystoles, acute sinusitis, and pneumonia.",pharyngitis is an adverse reaction entity
"In addition to the reactions shown in Tables 2 and 3, adverse reactions occurring in greater than or equal to 2% of the subjects treated with BREO ELLIPTA 100/25 or BREO ELLIPTA 200/25 for 12 months included pyrexia, back pain, extrasystoles, upper abdominal pain, respiratory tract infection, allergic rhinitis, pharyngitis, rhinitis, arthralgia, supraventricular extrasystoles, ventricular extrasystoles, acute sinusitis, and pneumonia.",extrasystoles is not a named entity
"In addition to the reactions shown in Tables 2 and 3, adverse reactions occurring in greater than or equal to 2% of the subjects treated with BREO ELLIPTA 100/25 or BREO ELLIPTA 200/25 for 12 months included pyrexia, back pain, extrasystoles, upper abdominal pain, respiratory tract infection, allergic rhinitis, pharyngitis, rhinitis, arthralgia, supraventricular extrasystoles, ventricular extrasystoles, acute sinusitis, and pneumonia.",extrasystoles is an adverse reaction entity
"In addition to the reactions shown in Tables 2 and 3, adverse reactions occurring in greater than or equal to 2% of the subjects treated with BREO ELLIPTA 100/25 or BREO ELLIPTA 200/25 for 12 months included pyrexia, back pain, extrasystoles, upper abdominal pain, respiratory tract infection, allergic rhinitis, pharyngitis, rhinitis, arthralgia, supraventricular extrasystoles, ventricular extrasystoles, acute sinusitis, and pneumonia.",supraventricular extrasystoles is an adverse reaction entity
"In addition to the reactions shown in Tables 2 and 3, adverse reactions occurring in greater than or equal to 2% of the subjects treated with BREO ELLIPTA 100/25 or BREO ELLIPTA 200/25 for 12 months included pyrexia, back pain, extrasystoles, upper abdominal pain, respiratory tract infection, allergic rhinitis, pharyngitis, rhinitis, arthralgia, supraventricular extrasystoles, ventricular extrasystoles, acute sinusitis, and pneumonia.","extrasystoles , is not a named entity"
"In addition to the reactions shown in Tables 2 and 3, adverse reactions occurring in greater than or equal to 2% of the subjects treated with BREO ELLIPTA 100/25 or BREO ELLIPTA 200/25 for 12 months included pyrexia, back pain, extrasystoles, upper abdominal pain, respiratory tract infection, allergic rhinitis, pharyngitis, rhinitis, arthralgia, supraventricular extrasystoles, ventricular extrasystoles, acute sinusitis, and pneumonia.",", is not a named entity"
"In addition to the reactions shown in Tables 2 and 3, adverse reactions occurring in greater than or equal to 2% of the subjects treated with BREO ELLIPTA 100/25 or BREO ELLIPTA 200/25 for 12 months included pyrexia, back pain, extrasystoles, upper abdominal pain, respiratory tract infection, allergic rhinitis, pharyngitis, rhinitis, arthralgia, supraventricular extrasystoles, ventricular extrasystoles, acute sinusitis, and pneumonia.",100/25 is not a named entity
"In addition to the reactions shown in Tables 2 and 3, adverse reactions occurring in greater than or equal to 2% of the subjects treated with BREO ELLIPTA 100/25 or BREO ELLIPTA 200/25 for 12 months included pyrexia, back pain, extrasystoles, upper abdominal pain, respiratory tract infection, allergic rhinitis, pharyngitis, rhinitis, arthralgia, supraventricular extrasystoles, ventricular extrasystoles, acute sinusitis, and pneumonia.",", is not a named entity"
"In addition to the reactions shown in Tables 2 and 3, adverse reactions occurring in greater than or equal to 2% of the subjects treated with BREO ELLIPTA 100/25 or BREO ELLIPTA 200/25 for 12 months included pyrexia, back pain, extrasystoles, upper abdominal pain, respiratory tract infection, allergic rhinitis, pharyngitis, rhinitis, arthralgia, supraventricular extrasystoles, ventricular extrasystoles, acute sinusitis, and pneumonia.",acute sinusitis is an adverse reaction entity
"In addition to the reactions shown in Tables 2 and 3, adverse reactions occurring in greater than or equal to 2% of the subjects treated with BREO ELLIPTA 100/25 or BREO ELLIPTA 200/25 for 12 months included pyrexia, back pain, extrasystoles, upper abdominal pain, respiratory tract infection, allergic rhinitis, pharyngitis, rhinitis, arthralgia, supraventricular extrasystoles, ventricular extrasystoles, acute sinusitis, and pneumonia.",the reactions shown is not a named entity
"In addition to the reactions shown in Tables 2 and 3, adverse reactions occurring in greater than or equal to 2% of the subjects treated with BREO ELLIPTA 100/25 or BREO ELLIPTA 200/25 for 12 months included pyrexia, back pain, extrasystoles, upper abdominal pain, respiratory tract infection, allergic rhinitis, pharyngitis, rhinitis, arthralgia, supraventricular extrasystoles, ventricular extrasystoles, acute sinusitis, and pneumonia.",rhinitis is an adverse reaction entity
"In addition to the reactions shown in Tables 2 and 3, adverse reactions occurring in greater than or equal to 2% of the subjects treated with BREO ELLIPTA 100/25 or BREO ELLIPTA 200/25 for 12 months included pyrexia, back pain, extrasystoles, upper abdominal pain, respiratory tract infection, allergic rhinitis, pharyngitis, rhinitis, arthralgia, supraventricular extrasystoles, ventricular extrasystoles, acute sinusitis, and pneumonia.",pneumonia is an adverse reaction entity
"In addition to the reactions shown in Tables 2 and 3, adverse reactions occurring in greater than or equal to 2% of the subjects treated with BREO ELLIPTA 100/25 or BREO ELLIPTA 200/25 for 12 months included pyrexia, back pain, extrasystoles, upper abdominal pain, respiratory tract infection, allergic rhinitis, pharyngitis, rhinitis, arthralgia, supraventricular extrasystoles, ventricular extrasystoles, acute sinusitis, and pneumonia.","extrasystoles , upper is not a named entity"
"In addition to the reactions shown in Tables 2 and 3, adverse reactions occurring in greater than or equal to 2% of the subjects treated with BREO ELLIPTA 100/25 or BREO ELLIPTA 200/25 for 12 months included pyrexia, back pain, extrasystoles, upper abdominal pain, respiratory tract infection, allergic rhinitis, pharyngitis, rhinitis, arthralgia, supraventricular extrasystoles, ventricular extrasystoles, acute sinusitis, and pneumonia.",allergic rhinitis is an adverse reaction entity
"In addition to the reactions shown in Tables 2 and 3, adverse reactions occurring in greater than or equal to 2% of the subjects treated with BREO ELLIPTA 100/25 or BREO ELLIPTA 200/25 for 12 months included pyrexia, back pain, extrasystoles, upper abdominal pain, respiratory tract infection, allergic rhinitis, pharyngitis, rhinitis, arthralgia, supraventricular extrasystoles, ventricular extrasystoles, acute sinusitis, and pneumonia.",upper abdominal pain is an adverse reaction entity
"In addition to the reactions shown in Tables 2 and 3, adverse reactions occurring in greater than or equal to 2% of the subjects treated with BREO ELLIPTA 100/25 or BREO ELLIPTA 200/25 for 12 months included pyrexia, back pain, extrasystoles, upper abdominal pain, respiratory tract infection, allergic rhinitis, pharyngitis, rhinitis, arthralgia, supraventricular extrasystoles, ventricular extrasystoles, acute sinusitis, and pneumonia.","pain , is not a named entity"
"In addition to the reactions shown in Tables 2 and 3, adverse reactions occurring in greater than or equal to 2% of the subjects treated with BREO ELLIPTA 100/25 or BREO ELLIPTA 200/25 for 12 months included pyrexia, back pain, extrasystoles, upper abdominal pain, respiratory tract infection, allergic rhinitis, pharyngitis, rhinitis, arthralgia, supraventricular extrasystoles, ventricular extrasystoles, acute sinusitis, and pneumonia.",respiratory tract infection is an adverse reaction entity
"In addition to the reactions shown in Tables 2 and 3, adverse reactions occurring in greater than or equal to 2% of the subjects treated with BREO ELLIPTA 100/25 or BREO ELLIPTA 200/25 for 12 months included pyrexia, back pain, extrasystoles, upper abdominal pain, respiratory tract infection, allergic rhinitis, pharyngitis, rhinitis, arthralgia, supraventricular extrasystoles, ventricular extrasystoles, acute sinusitis, and pneumonia.",pyrexia is an adverse reaction entity
"In addition to the reactions shown in Tables 2 and 3, adverse reactions occurring in greater than or equal to 2% of the subjects treated with BREO ELLIPTA 100/25 or BREO ELLIPTA 200/25 for 12 months included pyrexia, back pain, extrasystoles, upper abdominal pain, respiratory tract infection, allergic rhinitis, pharyngitis, rhinitis, arthralgia, supraventricular extrasystoles, ventricular extrasystoles, acute sinusitis, and pneumonia.",equal to 2 is not a named entity
"In addition to the reactions shown in Tables 2 and 3, adverse reactions occurring in greater than or equal to 2% of the subjects treated with BREO ELLIPTA 100/25 or BREO ELLIPTA 200/25 for 12 months included pyrexia, back pain, extrasystoles, upper abdominal pain, respiratory tract infection, allergic rhinitis, pharyngitis, rhinitis, arthralgia, supraventricular extrasystoles, ventricular extrasystoles, acute sinusitis, and pneumonia.",subjects treated with is not a named entity
Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs.,fatalities is an adverse reaction entity
Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs.,Clinically significant cardiovascular is not a named entity
"5.10 Paradoxical Bronchospasm      As with other inhaled medicines, BREO ELLIPTA can produce paradoxical bronchospasm, which may be life threatening.",paradoxical bronchospasm is an adverse reaction entity
"5.10 Paradoxical Bronchospasm      As with other inhaled medicines, BREO ELLIPTA can produce paradoxical bronchospasm, which may be life threatening.",paradoxical bronchospasm is an adverse reaction entity
"5.10 Paradoxical Bronchospasm      As with other inhaled medicines, BREO ELLIPTA can produce paradoxical bronchospasm, which may be life threatening.",", which is not a named entity"
"5.10 Paradoxical Bronchospasm      As with other inhaled medicines, BREO ELLIPTA can produce paradoxical bronchospasm, which may be life threatening.",produce paradoxical bronchospasm is not a named entity
"In healthy subjects, large doses of inhaled fluticasone furoate/vilanterol (4 times the recommended dose of vilanterol, representing a 12- or 10-fold higher systemic exposure than seen in subjects with COPD or asthma, respectively) have been associated with clinically significant prolongation of the QTc interval, which has the potential for producing ventricular arrhythmias.",ventricular arrhythmias is an adverse reaction entity
"In healthy subjects, large doses of inhaled fluticasone furoate/vilanterol (4 times the recommended dose of vilanterol, representing a 12- or 10-fold higher systemic exposure than seen in subjects with COPD or asthma, respectively) have been associated with clinically significant prolongation of the QTc interval, which has the potential for producing ventricular arrhythmias.",QTc interval is not a named entity
"In healthy subjects, large doses of inhaled fluticasone furoate/vilanterol (4 times the recommended dose of vilanterol, representing a 12- or 10-fold higher systemic exposure than seen in subjects with COPD or asthma, respectively) have been associated with clinically significant prolongation of the QTc interval, which has the potential for producing ventricular arrhythmias.",prolongation of the QTc interval is an adverse reaction entity
"In healthy subjects, large doses of inhaled fluticasone furoate/vilanterol (4 times the recommended dose of vilanterol, representing a 12- or 10-fold higher systemic exposure than seen in subjects with COPD or asthma, respectively) have been associated with clinically significant prolongation of the QTc interval, which has the potential for producing ventricular arrhythmias.",furoate/vilanterol ( is not a named entity
"Chickenpox and measles, for example, can have a more serious or even fatal course in susceptible children or adults using corticosteroids.",fatal is an adverse reaction entity
"Chickenpox and measles, for example, can have a more serious or even fatal course in susceptible children or adults using corticosteroids.",Chickenpox is an adverse reaction entity
"Chickenpox and measles, for example, can have a more serious or even fatal course in susceptible children or adults using corticosteroids.",even fatal course is not a named entity
"Chickenpox and measles, for example, can have a more serious or even fatal course in susceptible children or adults using corticosteroids.",have a is not a named entity
"Chickenpox and measles, for example, can have a more serious or even fatal course in susceptible children or adults using corticosteroids.",children is not a named entity
"Chickenpox and measles, for example, can have a more serious or even fatal course in susceptible children or adults using corticosteroids.",measles is an adverse reaction entity
5.13 Reduction in Bone Mineral Density      Decreases in bone mineral density (BMD) have been observed with long-term administration of products containing inhaled corticosteroids.,containing is not a named entity
5.13 Reduction in Bone Mineral Density      Decreases in bone mineral density (BMD) have been observed with long-term administration of products containing inhaled corticosteroids.,Bone Mineral Density is not a named entity
5.13 Reduction in Bone Mineral Density      Decreases in bone mineral density (BMD) have been observed with long-term administration of products containing inhaled corticosteroids.,Decreases in BMD is an adverse reaction entity
5.13 Reduction in Bone Mineral Density      Decreases in bone mineral density (BMD) have been observed with long-term administration of products containing inhaled corticosteroids.,Decreases in bone mineral density is an adverse reaction entity
"The increased risk of asthma-related death is considered a class effect of LABA, including vilanterol, one of the active ingredients in BREO ELLIPTA.",death is an adverse reaction entity
"The increased risk of asthma-related death is considered a class effect of LABA, including vilanterol, one of the active ingredients in BREO ELLIPTA.",including vilanterol is not a named entity
"*  Long-acting beta2-adrenergic agonists (LABA), such as vilanterol, increase the risk of asthma-related death.",* Long-acting is not a named entity
"*  Long-acting beta2-adrenergic agonists (LABA), such as vilanterol, increase the risk of asthma-related death.",death is an adverse reaction entity
"5.16 Hypokalemia and Hyperglycemia      Beta-adrenergic agonist medicines may produce significant hypokalemia in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects.",5.16 Hypokalemia is not a named entity
"5.16 Hypokalemia and Hyperglycemia      Beta-adrenergic agonist medicines may produce significant hypokalemia in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects.",hypokalemia is an adverse reaction entity
A placebo-controlled trial with another LABA (salmeterol) showed an increase in asthma-related deaths.,deaths is an adverse reaction entity
A placebo-controlled trial with another LABA (salmeterol) showed an increase in asthma-related deaths.,salmeterol ) is not a named entity
"BOXED WARNING: WARNING: ASTHMA-RELATED DEATH    WARNING: ASTHMA-RELATED DEATH      Long-acting beta2-adrenergic agonists (LABA), such as vilanterol, one of the active ingredients in BREO ELLIPTA, increase the risk of asthma-related death.",DEATH is an adverse reaction entity
"BOXED WARNING: WARNING: ASTHMA-RELATED DEATH    WARNING: ASTHMA-RELATED DEATH      Long-acting beta2-adrenergic agonists (LABA), such as vilanterol, one of the active ingredients in BREO ELLIPTA, increase the risk of asthma-related death.",DEATH is an adverse reaction entity
"BOXED WARNING: WARNING: ASTHMA-RELATED DEATH    WARNING: ASTHMA-RELATED DEATH      Long-acting beta2-adrenergic agonists (LABA), such as vilanterol, one of the active ingredients in BREO ELLIPTA, increase the risk of asthma-related death.","BREO ELLIPTA , is not a named entity"
"BOXED WARNING: WARNING: ASTHMA-RELATED DEATH    WARNING: ASTHMA-RELATED DEATH      Long-acting beta2-adrenergic agonists (LABA), such as vilanterol, one of the active ingredients in BREO ELLIPTA, increase the risk of asthma-related death.",ingredients in BREO is not a named entity
"BOXED WARNING: WARNING: ASTHMA-RELATED DEATH    WARNING: ASTHMA-RELATED DEATH      Long-acting beta2-adrenergic agonists (LABA), such as vilanterol, one of the active ingredients in BREO ELLIPTA, increase the risk of asthma-related death.",death is an adverse reaction entity
"BOXED WARNING: WARNING: ASTHMA-RELATED DEATH    WARNING: ASTHMA-RELATED DEATH      Long-acting beta2-adrenergic agonists (LABA), such as vilanterol, one of the active ingredients in BREO ELLIPTA, increase the risk of asthma-related death.",one is not a named entity
No trial adequate to determine whether the rate of asthma-related death is increased in subjects treated with BREO ELLIPTA has been conducted.,with is not a named entity
No trial adequate to determine whether the rate of asthma-related death is increased in subjects treated with BREO ELLIPTA has been conducted.,death is an adverse reaction entity
"6 ADVERSE REACTIONS      LABA, such as vilanterol, one of the active ingredients in BREO ELLIPTA, increase the risk of asthma-related death.",death is an adverse reaction entity
"6 ADVERSE REACTIONS      LABA, such as vilanterol, one of the active ingredients in BREO ELLIPTA, increase the risk of asthma-related death.",vilanterol is not a named entity
"5.14 Glaucoma and Cataracts      Glaucoma, increased intraocular pressure, and cataracts have been reported in patients with COPD or asthma following the long-term administration of inhaled corticosteroids.",long-term is not a named entity
"5.14 Glaucoma and Cataracts      Glaucoma, increased intraocular pressure, and cataracts have been reported in patients with COPD or asthma following the long-term administration of inhaled corticosteroids.",increased intraocular pressure is an adverse reaction entity
"5.14 Glaucoma and Cataracts      Glaucoma, increased intraocular pressure, and cataracts have been reported in patients with COPD or asthma following the long-term administration of inhaled corticosteroids.",asthma is not a named entity
"5.14 Glaucoma and Cataracts      Glaucoma, increased intraocular pressure, and cataracts have been reported in patients with COPD or asthma following the long-term administration of inhaled corticosteroids.",cataracts is an adverse reaction entity
"5.14 Glaucoma and Cataracts      Glaucoma, increased intraocular pressure, and cataracts have been reported in patients with COPD or asthma following the long-term administration of inhaled corticosteroids.",pressure is not a named entity
"5.14 Glaucoma and Cataracts      Glaucoma, increased intraocular pressure, and cataracts have been reported in patients with COPD or asthma following the long-term administration of inhaled corticosteroids.",Glaucoma is an adverse reaction entity
5.6 Immunosuppression      Persons who are using drugs that suppress the immune system are more susceptible to infections than healthy individuals.,that suppress is not a named entity
5.6 Immunosuppression      Persons who are using drugs that suppress the immune system are more susceptible to infections than healthy individuals.,infections is an adverse reaction entity
"(  5.5  )   *    Potential worsening of infections (e.g., existing tuberculosis; fungal, bacterial, viral, or parasitic infections; ocular herpes simplex).",* is not a named entity
"(  5.5  )   *    Potential worsening of infections (e.g., existing tuberculosis; fungal, bacterial, viral, or parasitic infections; ocular herpes simplex).",worsening existing tuberculosis is an adverse reaction entity
"(  5.5  )   *    Potential worsening of infections (e.g., existing tuberculosis; fungal, bacterial, viral, or parasitic infections; ocular herpes simplex).",worsening ocular herpes simplex is an adverse reaction entity
"(  5.5  )   *    Potential worsening of infections (e.g., existing tuberculosis; fungal, bacterial, viral, or parasitic infections; ocular herpes simplex).",existing is not a named entity
"(  5.5  )   *    Potential worsening of infections (e.g., existing tuberculosis; fungal, bacterial, viral, or parasitic infections; ocular herpes simplex).",simplex ) is not a named entity
"(  5.5  )   *    Potential worsening of infections (e.g., existing tuberculosis; fungal, bacterial, viral, or parasitic infections; ocular herpes simplex).",worsening of infections is an adverse reaction entity
"(  5.5  )   *    Potential worsening of infections (e.g., existing tuberculosis; fungal, bacterial, viral, or parasitic infections; ocular herpes simplex).",worsening fungal infections is an adverse reaction entity
"(  5.5  )   *    Potential worsening of infections (e.g., existing tuberculosis; fungal, bacterial, viral, or parasitic infections; ocular herpes simplex).","fungal , is not a named entity"
"(  5.5  )   *    Potential worsening of infections (e.g., existing tuberculosis; fungal, bacterial, viral, or parasitic infections; ocular herpes simplex).",worsening viral infections is an adverse reaction entity
"(  5.5  )   *    Potential worsening of infections (e.g., existing tuberculosis; fungal, bacterial, viral, or parasitic infections; ocular herpes simplex).",", is not a named entity"
"(  5.5  )   *    Potential worsening of infections (e.g., existing tuberculosis; fungal, bacterial, viral, or parasitic infections; ocular herpes simplex).",Potential worsening is not a named entity
"(  5.5  )   *    Potential worsening of infections (e.g., existing tuberculosis; fungal, bacterial, viral, or parasitic infections; ocular herpes simplex).",worsening bacterial infections is an adverse reaction entity
"(  5.5  )   *    Potential worsening of infections (e.g., existing tuberculosis; fungal, bacterial, viral, or parasitic infections; ocular herpes simplex).",; is not a named entity
"(  5.5  )   *    Potential worsening of infections (e.g., existing tuberculosis; fungal, bacterial, viral, or parasitic infections; ocular herpes simplex).",worsening parasitic infections is an adverse reaction entity
5.17 Effect on Growth      Orally inhaled corticosteroids may cause a reduction in growth velocity when administered to children and adolescents.,Growth Orally is not a named entity
5.17 Effect on Growth      Orally inhaled corticosteroids may cause a reduction in growth velocity when administered to children and adolescents.,reduction in growth velocity is an adverse reaction entity
Data from a large placebo-controlled US trial that compared the safety of another LABA (salmeterol) with placebo added to usual asthma therapy showed an increase in asthma-related deaths in subjects receiving salmeterol.,deaths is an adverse reaction entity
Data from a large placebo-controlled US trial that compared the safety of another LABA (salmeterol) with placebo added to usual asthma therapy showed an increase in asthma-related deaths in subjects receiving salmeterol.,another is not a named entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *    LABA increase the risk of asthma-related death and asthma-related hospitalizations.,WARNINGS AND is not a named entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *    LABA increase the risk of asthma-related death and asthma-related hospitalizations.,death is an adverse reaction entity
"In replicate 12-month trials in 3,255 subjects with COPD who had experienced a COPD exacerbation in the previous year, there was a higher incidence of pneumonia reported in subjects receiving fluticasone furoate/vilanterol 50 mcg/25 mcg: 6% (48 of 820 subjects); BREO ELLIPTA 100/25: 6% (51 of 806 subjects); or BREO ELLIPTA 200/25: 7% (55 of 811 subjects) than in subjects receiving vilanterol 25 mcg: 3% (27 of 818 subjects).",subjects is not a named entity
"In replicate 12-month trials in 3,255 subjects with COPD who had experienced a COPD exacerbation in the previous year, there was a higher incidence of pneumonia reported in subjects receiving fluticasone furoate/vilanterol 50 mcg/25 mcg: 6% (48 of 820 subjects); BREO ELLIPTA 100/25: 6% (51 of 806 subjects); or BREO ELLIPTA 200/25: 7% (55 of 811 subjects) than in subjects receiving vilanterol 25 mcg: 3% (27 of 818 subjects).",pneumonia is an adverse reaction entity
Data from a large placebo-controlled US trial that compared the safety of another LABA (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in subjects receiving salmeterol.,deaths is an adverse reaction entity
Data from a large placebo-controlled US trial that compared the safety of another LABA (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in subjects receiving salmeterol.,or is not a named entity
Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs.,use of is not a named entity
Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs.,Fatalities is an adverse reaction entity
"In addition to the reactions shown in Tables 2 and 3, adverse reactions occurring in greater than or equal to 2% of subjects treated with BREO ELLIPTA 200/25 included viral respiratory tract infection, pharyngitis, pyrexia, and arthralgia.",pharyngitis is an adverse reaction entity
"In addition to the reactions shown in Tables 2 and 3, adverse reactions occurring in greater than or equal to 2% of subjects treated with BREO ELLIPTA 200/25 included viral respiratory tract infection, pharyngitis, pyrexia, and arthralgia.",equal to is not a named entity
"In addition to the reactions shown in Tables 2 and 3, adverse reactions occurring in greater than or equal to 2% of subjects treated with BREO ELLIPTA 200/25 included viral respiratory tract infection, pharyngitis, pyrexia, and arthralgia.",viral respiratory tract infection is an adverse reaction entity
"In addition to the reactions shown in Tables 2 and 3, adverse reactions occurring in greater than or equal to 2% of subjects treated with BREO ELLIPTA 200/25 included viral respiratory tract infection, pharyngitis, pyrexia, and arthralgia.",addition to is not a named entity
"In addition to the reactions shown in Tables 2 and 3, adverse reactions occurring in greater than or equal to 2% of subjects treated with BREO ELLIPTA 200/25 included viral respiratory tract infection, pharyngitis, pyrexia, and arthralgia.",pyrexia is an adverse reaction entity
"In addition to the reactions shown in Tables 2 and 3, adverse reactions occurring in greater than or equal to 2% of subjects treated with BREO ELLIPTA 200/25 included viral respiratory tract infection, pharyngitis, pyrexia, and arthralgia.",and arthralgia is not a named entity
"In addition to the reactions shown in Tables 2 and 3, adverse reactions occurring in greater than or equal to 2% of subjects treated with BREO ELLIPTA 200/25 included viral respiratory tract infection, pharyngitis, pyrexia, and arthralgia.",reactions is not a named entity
"In addition to the reactions shown in Tables 2 and 3, adverse reactions occurring in greater than or equal to 2% of subjects treated with BREO ELLIPTA 200/25 included viral respiratory tract infection, pharyngitis, pyrexia, and arthralgia.",arthralgia is an adverse reaction entity
Currently available data are inadequate to determine whether concurrent use of inhaled corticosteroids or other long-term asthma control drugs mitigates the increased risk of asthma-related death from LABA.,death is an adverse reaction entity
Currently available data are inadequate to determine whether concurrent use of inhaled corticosteroids or other long-term asthma control drugs mitigates the increased risk of asthma-related death from LABA.,risk of asthma-related is not a named entity
"There have been reports of anaphylactic reactions in patients with severe milk protein allergy after inhalation of other powder medications containing lactose; therefore, patients with severe milk protein allergy should not use BREO ELLIPTA [see Contraindications (4)]  .",anaphylactic reactions is an adverse reaction entity
"There have been reports of anaphylactic reactions in patients with severe milk protein allergy after inhalation of other powder medications containing lactose; therefore, patients with severe milk protein allergy should not use BREO ELLIPTA [see Contraindications (4)]  .",not use BREO is not a named entity
Currently available data are inadequate to determine whether concurrent use of inhaled corticosteroids (ICS) or other long-term asthma control drugs mitigates the increased risk of asthma-related death from LABA.,Currently available data is not a named entity
Currently available data are inadequate to determine whether concurrent use of inhaled corticosteroids (ICS) or other long-term asthma control drugs mitigates the increased risk of asthma-related death from LABA.,death is an adverse reaction entity
More serious or even fatal course of chickenpox or measles can occur in susceptible patients.,chickenpox is an adverse reaction entity
More serious or even fatal course of chickenpox or measles can occur in susceptible patients.,occur is not a named entity
More serious or even fatal course of chickenpox or measles can occur in susceptible patients.,fatal is an adverse reaction entity
More serious or even fatal course of chickenpox or measles can occur in susceptible patients.,course of is not a named entity
More serious or even fatal course of chickenpox or measles can occur in susceptible patients.,serious or even is not a named entity
More serious or even fatal course of chickenpox or measles can occur in susceptible patients.,measles is an adverse reaction entity
There was no fatal pneumonia in subjects receiving vilanterol or fluticasone furoate/vilanterol 50 mcg/25 mcg.,pneumonia is an adverse reaction entity
There was no fatal pneumonia in subjects receiving vilanterol or fluticasone furoate/vilanterol 50 mcg/25 mcg.,fatal is an adverse reaction entity
There was no fatal pneumonia in subjects receiving vilanterol or fluticasone furoate/vilanterol 50 mcg/25 mcg.,pneumonia in is not a named entity
There was no fatal pneumonia in subjects receiving vilanterol or fluticasone furoate/vilanterol 50 mcg/25 mcg.,furoate/vilanterol 50 is not a named entity
It is possible that systemic corticosteroid effects such as hypercorticism and adrenal suppression (including adrenal crisis) may appear in a small number of patients who are sensitive to these effects.,hypercorticism is an adverse reaction entity
It is possible that systemic corticosteroid effects such as hypercorticism and adrenal suppression (including adrenal crisis) may appear in a small number of patients who are sensitive to these effects.,adrenal suppression is an adverse reaction entity
It is possible that systemic corticosteroid effects such as hypercorticism and adrenal suppression (including adrenal crisis) may appear in a small number of patients who are sensitive to these effects.,corticosteroid effects such is not a named entity
It is possible that systemic corticosteroid effects such as hypercorticism and adrenal suppression (including adrenal crisis) may appear in a small number of patients who are sensitive to these effects.,small number of is not a named entity
It is possible that systemic corticosteroid effects such as hypercorticism and adrenal suppression (including adrenal crisis) may appear in a small number of patients who are sensitive to these effects.,crisis is not a named entity
It is possible that systemic corticosteroid effects such as hypercorticism and adrenal suppression (including adrenal crisis) may appear in a small number of patients who are sensitive to these effects.,adrenal crisis is an adverse reaction entity
Currently available data are inadequate to determine whether concurrent use of inhaled corticosteroids (ICS) or other long-term asthma control drugs mitigates the increased risk of asthma-related death from LABA.,from is not a named entity
Currently available data are inadequate to determine whether concurrent use of inhaled corticosteroids (ICS) or other long-term asthma control drugs mitigates the increased risk of asthma-related death from LABA.,death is an adverse reaction entity
Data are not available to determine whether the rate of death in patients with COPD is increased by LABA.,death is an adverse reaction entity
Data are not available to determine whether the rate of death in patients with COPD is increased by LABA.,of is not a named entity
"In addition to the reactions shown in Table 1, adverse reactions occurring in greater than or equal to 3% of the subjects treated with BREO ELLIPTA 100/25 (n = 806) for 12 months included back pain, pneumonia  [see Warnings and Precautions (5.5)]  , bronchitis, sinusitis, cough, oropharyngeal pain, arthralgia, influenza, pharyngitis, and pyrexia.",bronchitis is an adverse reaction entity
"In addition to the reactions shown in Table 1, adverse reactions occurring in greater than or equal to 3% of the subjects treated with BREO ELLIPTA 100/25 (n = 806) for 12 months included back pain, pneumonia  [see Warnings and Precautions (5.5)]  , bronchitis, sinusitis, cough, oropharyngeal pain, arthralgia, influenza, pharyngitis, and pyrexia.",pain is not a named entity
"In addition to the reactions shown in Table 1, adverse reactions occurring in greater than or equal to 3% of the subjects treated with BREO ELLIPTA 100/25 (n = 806) for 12 months included back pain, pneumonia  [see Warnings and Precautions (5.5)]  , bronchitis, sinusitis, cough, oropharyngeal pain, arthralgia, influenza, pharyngitis, and pyrexia.",pneumonia is an adverse reaction entity
"In addition to the reactions shown in Table 1, adverse reactions occurring in greater than or equal to 3% of the subjects treated with BREO ELLIPTA 100/25 (n = 806) for 12 months included back pain, pneumonia  [see Warnings and Precautions (5.5)]  , bronchitis, sinusitis, cough, oropharyngeal pain, arthralgia, influenza, pharyngitis, and pyrexia.",greater is not a named entity
"In addition to the reactions shown in Table 1, adverse reactions occurring in greater than or equal to 3% of the subjects treated with BREO ELLIPTA 100/25 (n = 806) for 12 months included back pain, pneumonia  [see Warnings and Precautions (5.5)]  , bronchitis, sinusitis, cough, oropharyngeal pain, arthralgia, influenza, pharyngitis, and pyrexia.",oropharyngeal pain is an adverse reaction entity
"In addition to the reactions shown in Table 1, adverse reactions occurring in greater than or equal to 3% of the subjects treated with BREO ELLIPTA 100/25 (n = 806) for 12 months included back pain, pneumonia  [see Warnings and Precautions (5.5)]  , bronchitis, sinusitis, cough, oropharyngeal pain, arthralgia, influenza, pharyngitis, and pyrexia.",arthralgia is an adverse reaction entity
"In addition to the reactions shown in Table 1, adverse reactions occurring in greater than or equal to 3% of the subjects treated with BREO ELLIPTA 100/25 (n = 806) for 12 months included back pain, pneumonia  [see Warnings and Precautions (5.5)]  , bronchitis, sinusitis, cough, oropharyngeal pain, arthralgia, influenza, pharyngitis, and pyrexia.",pyrexia is an adverse reaction entity
"In addition to the reactions shown in Table 1, adverse reactions occurring in greater than or equal to 3% of the subjects treated with BREO ELLIPTA 100/25 (n = 806) for 12 months included back pain, pneumonia  [see Warnings and Precautions (5.5)]  , bronchitis, sinusitis, cough, oropharyngeal pain, arthralgia, influenza, pharyngitis, and pyrexia.",", sinusitis is not a named entity"
"In addition to the reactions shown in Table 1, adverse reactions occurring in greater than or equal to 3% of the subjects treated with BREO ELLIPTA 100/25 (n = 806) for 12 months included back pain, pneumonia  [see Warnings and Precautions (5.5)]  , bronchitis, sinusitis, cough, oropharyngeal pain, arthralgia, influenza, pharyngitis, and pyrexia.",3 is not a named entity
"In addition to the reactions shown in Table 1, adverse reactions occurring in greater than or equal to 3% of the subjects treated with BREO ELLIPTA 100/25 (n = 806) for 12 months included back pain, pneumonia  [see Warnings and Precautions (5.5)]  , bronchitis, sinusitis, cough, oropharyngeal pain, arthralgia, influenza, pharyngitis, and pyrexia.",to 3 is not a named entity
"In addition to the reactions shown in Table 1, adverse reactions occurring in greater than or equal to 3% of the subjects treated with BREO ELLIPTA 100/25 (n = 806) for 12 months included back pain, pneumonia  [see Warnings and Precautions (5.5)]  , bronchitis, sinusitis, cough, oropharyngeal pain, arthralgia, influenza, pharyngitis, and pyrexia.",In addition to is not a named entity
"In addition to the reactions shown in Table 1, adverse reactions occurring in greater than or equal to 3% of the subjects treated with BREO ELLIPTA 100/25 (n = 806) for 12 months included back pain, pneumonia  [see Warnings and Precautions (5.5)]  , bronchitis, sinusitis, cough, oropharyngeal pain, arthralgia, influenza, pharyngitis, and pyrexia.",12 months included is not a named entity
"In addition to the reactions shown in Table 1, adverse reactions occurring in greater than or equal to 3% of the subjects treated with BREO ELLIPTA 100/25 (n = 806) for 12 months included back pain, pneumonia  [see Warnings and Precautions (5.5)]  , bronchitis, sinusitis, cough, oropharyngeal pain, arthralgia, influenza, pharyngitis, and pyrexia.",cough is an adverse reaction entity
"In addition to the reactions shown in Table 1, adverse reactions occurring in greater than or equal to 3% of the subjects treated with BREO ELLIPTA 100/25 (n = 806) for 12 months included back pain, pneumonia  [see Warnings and Precautions (5.5)]  , bronchitis, sinusitis, cough, oropharyngeal pain, arthralgia, influenza, pharyngitis, and pyrexia.",influenza is an adverse reaction entity
"In addition to the reactions shown in Table 1, adverse reactions occurring in greater than or equal to 3% of the subjects treated with BREO ELLIPTA 100/25 (n = 806) for 12 months included back pain, pneumonia  [see Warnings and Precautions (5.5)]  , bronchitis, sinusitis, cough, oropharyngeal pain, arthralgia, influenza, pharyngitis, and pyrexia.",Precautions ( 5.5 is not a named entity
"In addition to the reactions shown in Table 1, adverse reactions occurring in greater than or equal to 3% of the subjects treated with BREO ELLIPTA 100/25 (n = 806) for 12 months included back pain, pneumonia  [see Warnings and Precautions (5.5)]  , bronchitis, sinusitis, cough, oropharyngeal pain, arthralgia, influenza, pharyngitis, and pyrexia.",pharyngitis is an adverse reaction entity
"In addition to the reactions shown in Table 1, adverse reactions occurring in greater than or equal to 3% of the subjects treated with BREO ELLIPTA 100/25 (n = 806) for 12 months included back pain, pneumonia  [see Warnings and Precautions (5.5)]  , bronchitis, sinusitis, cough, oropharyngeal pain, arthralgia, influenza, pharyngitis, and pyrexia.",back pain is an adverse reaction entity
"In addition to the reactions shown in Table 1, adverse reactions occurring in greater than or equal to 3% of the subjects treated with BREO ELLIPTA 100/25 (n = 806) for 12 months included back pain, pneumonia  [see Warnings and Precautions (5.5)]  , bronchitis, sinusitis, cough, oropharyngeal pain, arthralgia, influenza, pharyngitis, and pyrexia.",", sinusitis , is not a named entity"
"In addition to the reactions shown in Table 1, adverse reactions occurring in greater than or equal to 3% of the subjects treated with BREO ELLIPTA 100/25 (n = 806) for 12 months included back pain, pneumonia  [see Warnings and Precautions (5.5)]  , bronchitis, sinusitis, cough, oropharyngeal pain, arthralgia, influenza, pharyngitis, and pyrexia.",sinusitis is an adverse reaction entity
"In addition to the reactions shown in Table 1, adverse reactions occurring in greater than or equal to 3% of the subjects treated with BREO ELLIPTA 100/25 (n = 806) for 12 months included back pain, pneumonia  [see Warnings and Precautions (5.5)]  , bronchitis, sinusitis, cough, oropharyngeal pain, arthralgia, influenza, pharyngitis, and pyrexia.",[ see is not a named entity
(  5.6  )   *    Risk of impaired adrenal function when transferring from systemic corticosteroids.,( 5.6 ) is not a named entity
(  5.6  )   *    Risk of impaired adrenal function when transferring from systemic corticosteroids.,impaired adrenal function is an adverse reaction entity
5.6 Embryo-fetal Toxicity      Beleodaq can cause fetal harm when administered to a pregnant woman.,fetal harm is an adverse reaction entity
5.6 Embryo-fetal Toxicity      Beleodaq can cause fetal harm when administered to a pregnant woman.,Toxicity Beleodaq is not a named entity
"(   2.2  ,  5.1   )   *    Infection: Serious and fatal infections (e.g., pneumonia and sepsis).",Infection is an adverse reaction entity
"(   2.2  ,  5.1   )   *    Infection: Serious and fatal infections (e.g., pneumonia and sepsis).",5.1 ) is not a named entity
"(   2.2  ,  5.1   )   *    Infection: Serious and fatal infections (e.g., pneumonia and sepsis).",fatal is an adverse reaction entity
"(   2.2  ,  5.1   )   *    Infection: Serious and fatal infections (e.g., pneumonia and sepsis).",sepsis ) is not a named entity
"(   2.2  ,  5.1   )   *    Infection: Serious and fatal infections (e.g., pneumonia and sepsis).",Serious and is not a named entity
"(   2.2  ,  5.1   )   *    Infection: Serious and fatal infections (e.g., pneumonia and sepsis).",infections is an adverse reaction entity
"(   2.2  ,  5.1   )   *    Infection: Serious and fatal infections (e.g., pneumonia and sepsis).",sepsis is an adverse reaction entity
"(   2.2  ,  5.1   )   *    Infection: Serious and fatal infections (e.g., pneumonia and sepsis).",infections is an adverse reaction entity
"(   2.2  ,  5.1   )   *    Infection: Serious and fatal infections (e.g., pneumonia and sepsis).",", pneumonia and is not a named entity"
"(   2.2  ,  5.1   )   *    Infection: Serious and fatal infections (e.g., pneumonia and sepsis).",and is not a named entity
"(   2.2  ,  5.1   )   *    Infection: Serious and fatal infections (e.g., pneumonia and sepsis).",pneumonia is an adverse reaction entity
"(   2.2  ,  5.1   )   *    Infection: Serious and fatal infections (e.g., pneumonia and sepsis).","( e.g. , is not a named entity"
5.3 Hepatotoxicity      Beleodaq can cause fatal hepatotoxicity and liver function test abnormalities  [see Adverse Reactions  (   6.1  )]  .,function is not a named entity
5.3 Hepatotoxicity      Beleodaq can cause fatal hepatotoxicity and liver function test abnormalities  [see Adverse Reactions  (   6.1  )]  .,fatal is an adverse reaction entity
5.3 Hepatotoxicity      Beleodaq can cause fatal hepatotoxicity and liver function test abnormalities  [see Adverse Reactions  (   6.1  )]  .,liver function test abnormalities is an adverse reaction entity
5.3 Hepatotoxicity      Beleodaq can cause fatal hepatotoxicity and liver function test abnormalities  [see Adverse Reactions  (   6.1  )]  .,hepatotoxicity is an adverse reaction entity
5.3 Hepatotoxicity      Beleodaq can cause fatal hepatotoxicity and liver function test abnormalities  [see Adverse Reactions  (   6.1  )]  .,Beleodaq is not a named entity
5.3 Hepatotoxicity      Beleodaq can cause fatal hepatotoxicity and liver function test abnormalities  [see Adverse Reactions  (   6.1  )]  .,5.3 Hepatotoxicity is not a named entity
"5.2 Infections      Serious and sometimes fatal infections, including pneumonia and sepsis, have occurred with Beleodaq.",pneumonia is an adverse reaction entity
"5.2 Infections      Serious and sometimes fatal infections, including pneumonia and sepsis, have occurred with Beleodaq.",", including is not a named entity"
"5.2 Infections      Serious and sometimes fatal infections, including pneumonia and sepsis, have occurred with Beleodaq.",and is not a named entity
"5.2 Infections      Serious and sometimes fatal infections, including pneumonia and sepsis, have occurred with Beleodaq.",including pneumonia and is not a named entity
"5.2 Infections      Serious and sometimes fatal infections, including pneumonia and sepsis, have occurred with Beleodaq.",infections is an adverse reaction entity
"5.2 Infections      Serious and sometimes fatal infections, including pneumonia and sepsis, have occurred with Beleodaq.",occurred with Beleodaq is not a named entity
"5.2 Infections      Serious and sometimes fatal infections, including pneumonia and sepsis, have occurred with Beleodaq.",fatal is an adverse reaction entity
"5.2 Infections      Serious and sometimes fatal infections, including pneumonia and sepsis, have occurred with Beleodaq.",sepsis is an adverse reaction entity
"5.2 Infections      Serious and sometimes fatal infections, including pneumonia and sepsis, have occurred with Beleodaq.","fatal infections , is not a named entity"
"5.2 Infections      Serious and sometimes fatal infections, including pneumonia and sepsis, have occurred with Beleodaq.",infections is an adverse reaction entity
(   5.2   )   *    Hepatotoxicity: Beleodaq may cause hepatic toxicity and liver function test abnormalities.,liver function test abnormalities is an adverse reaction entity
(   5.2   )   *    Hepatotoxicity: Beleodaq may cause hepatic toxicity and liver function test abnormalities.,Hepatotoxicity is an adverse reaction entity
(   5.2   )   *    Hepatotoxicity: Beleodaq may cause hepatic toxicity and liver function test abnormalities.,hepatic toxicity is an adverse reaction entity
(   5.2   )   *    Hepatotoxicity: Beleodaq may cause hepatic toxicity and liver function test abnormalities.,cause hepatic is not a named entity
(   5.2   )   *    Hepatotoxicity: Beleodaq may cause hepatic toxicity and liver function test abnormalities.,5.2 ) is not a named entity
(   5.2   )   *    Hepatotoxicity: Beleodaq may cause hepatic toxicity and liver function test abnormalities.,cause is not a named entity
A treatment-related death from ventricular fibrillation was reported in another monotherapy clinical trial with Beleodaq.,in is not a named entity
A treatment-related death from ventricular fibrillation was reported in another monotherapy clinical trial with Beleodaq.,another monotherapy is not a named entity
A treatment-related death from ventricular fibrillation was reported in another monotherapy clinical trial with Beleodaq.,death is an adverse reaction entity
A treatment-related death from ventricular fibrillation was reported in another monotherapy clinical trial with Beleodaq.,ventricular fibrillation is an adverse reaction entity
"EXCERPT:   The most common adverse reactions (>25%) are nausea, fatigue, pyrexia, anemia, and vomiting.",fatigue is an adverse reaction entity
"EXCERPT:   The most common adverse reactions (>25%) are nausea, fatigue, pyrexia, anemia, and vomiting.",anemia is an adverse reaction entity
"EXCERPT:   The most common adverse reactions (>25%) are nausea, fatigue, pyrexia, anemia, and vomiting.",> 25 % is not a named entity
"EXCERPT:   The most common adverse reactions (>25%) are nausea, fatigue, pyrexia, anemia, and vomiting.",nausea is an adverse reaction entity
"EXCERPT:   The most common adverse reactions (>25%) are nausea, fatigue, pyrexia, anemia, and vomiting.","pyrexia , anemia is not a named entity"
"EXCERPT:   The most common adverse reactions (>25%) are nausea, fatigue, pyrexia, anemia, and vomiting.",vomiting is an adverse reaction entity
"EXCERPT:   The most common adverse reactions (>25%) are nausea, fatigue, pyrexia, anemia, and vomiting.",The most is not a named entity
"EXCERPT:   The most common adverse reactions (>25%) are nausea, fatigue, pyrexia, anemia, and vomiting.",pyrexia is an adverse reaction entity
"EXCERPT:   The most common adverse reactions (>25%) are nausea, fatigue, pyrexia, anemia, and vomiting.",", pyrexia , is not a named entity"
"EXCERPT:   The most common adverse reactions (>25%) are nausea, fatigue, pyrexia, anemia, and vomiting.",most common adverse is not a named entity
"(   2.2  ,  5.3   )   *    Tumor lysis syndrome: Monitor patients with advanced stage disease and/or high tumor burden and take appropriate precautions.",Tumor lysis syndrome is an adverse reaction entity
"(   2.2  ,  5.3   )   *    Tumor lysis syndrome: Monitor patients with advanced stage disease and/or high tumor burden and take appropriate precautions.",Monitor patients with is not a named entity
"5.5 Gastrointestinal Toxicity      Nausea, vomiting and diarrhea occur with Beleodaq  [see Adverse Reactions (  6.1  )]  and may require the use of antiemetic and antidiarrheal medications.",diarrhea is an adverse reaction entity
"5.5 Gastrointestinal Toxicity      Nausea, vomiting and diarrhea occur with Beleodaq  [see Adverse Reactions (  6.1  )]  and may require the use of antiemetic and antidiarrheal medications.",( 6.1 ) is not a named entity
"5.5 Gastrointestinal Toxicity      Nausea, vomiting and diarrhea occur with Beleodaq  [see Adverse Reactions (  6.1  )]  and may require the use of antiemetic and antidiarrheal medications.",vomiting is an adverse reaction entity
"5.5 Gastrointestinal Toxicity      Nausea, vomiting and diarrhea occur with Beleodaq  [see Adverse Reactions (  6.1  )]  and may require the use of antiemetic and antidiarrheal medications.",Nausea is an adverse reaction entity
"5.5 Gastrointestinal Toxicity      Nausea, vomiting and diarrhea occur with Beleodaq  [see Adverse Reactions (  6.1  )]  and may require the use of antiemetic and antidiarrheal medications.",of antiemetic and is not a named entity
"5.5 Gastrointestinal Toxicity      Nausea, vomiting and diarrhea occur with Beleodaq  [see Adverse Reactions (  6.1  )]  and may require the use of antiemetic and antidiarrheal medications.",Toxicity is not a named entity
"(   5.6   )             5.1 Hematologic Toxicity      Beleodaq can cause thrombocytopenia, leukopenia (neutropenia and lymphopenia), and/or anemia; monitor blood counts weekly during treatment, and modify dosage as necessary  [see Dosage and Administration (  2.2    ) and Adverse Reactions   (  6.1  )]  .",lymphopenia is an adverse reaction entity
"(   5.6   )             5.1 Hematologic Toxicity      Beleodaq can cause thrombocytopenia, leukopenia (neutropenia and lymphopenia), and/or anemia; monitor blood counts weekly during treatment, and modify dosage as necessary  [see Dosage and Administration (  2.2    ) and Adverse Reactions   (  6.1  )]  .",Beleodaq can is not a named entity
"(   5.6   )             5.1 Hematologic Toxicity      Beleodaq can cause thrombocytopenia, leukopenia (neutropenia and lymphopenia), and/or anemia; monitor blood counts weekly during treatment, and modify dosage as necessary  [see Dosage and Administration (  2.2    ) and Adverse Reactions   (  6.1  )]  .",can cause is not a named entity
"(   5.6   )             5.1 Hematologic Toxicity      Beleodaq can cause thrombocytopenia, leukopenia (neutropenia and lymphopenia), and/or anemia; monitor blood counts weekly during treatment, and modify dosage as necessary  [see Dosage and Administration (  2.2    ) and Adverse Reactions   (  6.1  )]  .",leukopenia is an adverse reaction entity
"(   5.6   )             5.1 Hematologic Toxicity      Beleodaq can cause thrombocytopenia, leukopenia (neutropenia and lymphopenia), and/or anemia; monitor blood counts weekly during treatment, and modify dosage as necessary  [see Dosage and Administration (  2.2    ) and Adverse Reactions   (  6.1  )]  .",) 5.1 is not a named entity
"(   5.6   )             5.1 Hematologic Toxicity      Beleodaq can cause thrombocytopenia, leukopenia (neutropenia and lymphopenia), and/or anemia; monitor blood counts weekly during treatment, and modify dosage as necessary  [see Dosage and Administration (  2.2    ) and Adverse Reactions   (  6.1  )]  .",thrombocytopenia is an adverse reaction entity
"(   5.6   )             5.1 Hematologic Toxicity      Beleodaq can cause thrombocytopenia, leukopenia (neutropenia and lymphopenia), and/or anemia; monitor blood counts weekly during treatment, and modify dosage as necessary  [see Dosage and Administration (  2.2    ) and Adverse Reactions   (  6.1  )]  .",anemia is an adverse reaction entity
"(   5.6   )             5.1 Hematologic Toxicity      Beleodaq can cause thrombocytopenia, leukopenia (neutropenia and lymphopenia), and/or anemia; monitor blood counts weekly during treatment, and modify dosage as necessary  [see Dosage and Administration (  2.2    ) and Adverse Reactions   (  6.1  )]  .",neutropenia is an adverse reaction entity
"(   5.6   )             5.1 Hematologic Toxicity      Beleodaq can cause thrombocytopenia, leukopenia (neutropenia and lymphopenia), and/or anemia; monitor blood counts weekly during treatment, and modify dosage as necessary  [see Dosage and Administration (  2.2    ) and Adverse Reactions   (  6.1  )]  .",counts is not a named entity
"(   5.6   )             5.1 Hematologic Toxicity      Beleodaq can cause thrombocytopenia, leukopenia (neutropenia and lymphopenia), and/or anemia; monitor blood counts weekly during treatment, and modify dosage as necessary  [see Dosage and Administration (  2.2    ) and Adverse Reactions   (  6.1  )]  .",Reactions ( 6.1 is not a named entity
"The adverse reactions reported most frequently as the reason for discontinuation of treatment included anemia, febrile neutropenia, fatigue, and multi-organ failure.",anemia is an adverse reaction entity
"The adverse reactions reported most frequently as the reason for discontinuation of treatment included anemia, febrile neutropenia, fatigue, and multi-organ failure.",multi-organ failure is an adverse reaction entity
"The adverse reactions reported most frequently as the reason for discontinuation of treatment included anemia, febrile neutropenia, fatigue, and multi-organ failure.",fatigue is an adverse reaction entity
"The adverse reactions reported most frequently as the reason for discontinuation of treatment included anemia, febrile neutropenia, fatigue, and multi-organ failure.",frequently as the is not a named entity
"The adverse reactions reported most frequently as the reason for discontinuation of treatment included anemia, febrile neutropenia, fatigue, and multi-organ failure.",adverse reactions reported is not a named entity
"The adverse reactions reported most frequently as the reason for discontinuation of treatment included anemia, febrile neutropenia, fatigue, and multi-organ failure.",reactions reported most is not a named entity
"The adverse reactions reported most frequently as the reason for discontinuation of treatment included anemia, febrile neutropenia, fatigue, and multi-organ failure.",reason for discontinuation is not a named entity
"The adverse reactions reported most frequently as the reason for discontinuation of treatment included anemia, febrile neutropenia, fatigue, and multi-organ failure.",febrile neutropenia is an adverse reaction entity
One patient with baseline hyperuricemia and bulky disease experienced Grade 4 tumor lysis syndrome during the first cycle of treatment and died due to multi-organ failure.,during the is not a named entity
One patient with baseline hyperuricemia and bulky disease experienced Grade 4 tumor lysis syndrome during the first cycle of treatment and died due to multi-organ failure.,tumor lysis syndrome is an adverse reaction entity
One patient with baseline hyperuricemia and bulky disease experienced Grade 4 tumor lysis syndrome during the first cycle of treatment and died due to multi-organ failure.,with is not a named entity
One patient with baseline hyperuricemia and bulky disease experienced Grade 4 tumor lysis syndrome during the first cycle of treatment and died due to multi-organ failure.,4 is not a named entity
One patient with baseline hyperuricemia and bulky disease experienced Grade 4 tumor lysis syndrome during the first cycle of treatment and died due to multi-organ failure.,multi-organ failure is an adverse reaction entity
One patient with baseline hyperuricemia and bulky disease experienced Grade 4 tumor lysis syndrome during the first cycle of treatment and died due to multi-organ failure.,died is an adverse reaction entity
Beleodaq may cause teratogenicity and/or embryo-fetal lethality because it is genotoxic and targets actively dividing cells  [see Nonclinical Toxicology  (   13.1    ) ]  .,Toxicology is not a named entity
Beleodaq may cause teratogenicity and/or embryo-fetal lethality because it is genotoxic and targets actively dividing cells  [see Nonclinical Toxicology  (   13.1    ) ]  .,actively is not a named entity
Beleodaq may cause teratogenicity and/or embryo-fetal lethality because it is genotoxic and targets actively dividing cells  [see Nonclinical Toxicology  (   13.1    ) ]  .,embryo-fetal lethality is an adverse reaction entity
Beleodaq may cause teratogenicity and/or embryo-fetal lethality because it is genotoxic and targets actively dividing cells  [see Nonclinical Toxicology  (   13.1    ) ]  .,teratogenicity is an adverse reaction entity
Beleodaq may cause teratogenicity and/or embryo-fetal lethality because it is genotoxic and targets actively dividing cells  [see Nonclinical Toxicology  (   13.1    ) ]  .,lethality is not a named entity
Beleodaq may cause teratogenicity and/or embryo-fetal lethality because it is genotoxic and targets actively dividing cells  [see Nonclinical Toxicology  (   13.1    ) ]  .,genotoxic is an adverse reaction entity
"In patients with permanent AF, MULTAQ doubles the risk of death, stroke, and hospitalization for heart failure.",of death is not a named entity
"In patients with permanent AF, MULTAQ doubles the risk of death, stroke, and hospitalization for heart failure.",of is not a named entity
"In patients with permanent AF, MULTAQ doubles the risk of death, stroke, and hospitalization for heart failure.","stroke , and is not a named entity"
"In patients with permanent AF, MULTAQ doubles the risk of death, stroke, and hospitalization for heart failure.",heart failure is an adverse reaction entity
"In patients with permanent AF, MULTAQ doubles the risk of death, stroke, and hospitalization for heart failure.",death is an adverse reaction entity
"In patients with permanent AF, MULTAQ doubles the risk of death, stroke, and hospitalization for heart failure.",stroke is an adverse reaction entity
5.7 Hypokalemia and Hypomagnesemia with Potassium-Depleting Diuretics      Hypokalemia or hypomagnesemia may occur with concomitant administration of potassium-depleting diuretics.,Hypokalemia is an adverse reaction entity
5.7 Hypokalemia and Hypomagnesemia with Potassium-Depleting Diuretics      Hypokalemia or hypomagnesemia may occur with concomitant administration of potassium-depleting diuretics.,and Hypomagnesemia with is not a named entity
5.7 Hypokalemia and Hypomagnesemia with Potassium-Depleting Diuretics      Hypokalemia or hypomagnesemia may occur with concomitant administration of potassium-depleting diuretics.,concomitant administration of is not a named entity
5.7 Hypokalemia and Hypomagnesemia with Potassium-Depleting Diuretics      Hypokalemia or hypomagnesemia may occur with concomitant administration of potassium-depleting diuretics.,hypomagnesemia is an adverse reaction entity
5.8 QT Interval Prolongation      Dronedarone induces a moderate (average of about 10 ms but much greater effects have been observed) QTc (Bazett) prolongation [see  Clinical Pharmacology (12.2)  and  Clinical Studies (14.1)  ]  .,QTc prolongation is an adverse reaction entity
5.8 QT Interval Prolongation      Dronedarone induces a moderate (average of about 10 ms but much greater effects have been observed) QTc (Bazett) prolongation [see  Clinical Pharmacology (12.2)  and  Clinical Studies (14.1)  ]  .,much greater effects is not a named entity
"5.3 Increased Risk of Stroke in Permanent AF      In a placebo-controlled study in patients with permanent atrial fibrillation, dronedarone was associated with an increased risk of stroke, particularly in the first two weeks of therapy [   see Clinical Studies (14.4)    ].",stroke is an adverse reaction entity
"5.3 Increased Risk of Stroke in Permanent AF      In a placebo-controlled study in patients with permanent atrial fibrillation, dronedarone was associated with an increased risk of stroke, particularly in the first two weeks of therapy [   see Clinical Studies (14.4)    ].",atrial is not a named entity
"(  4  ,   5.1  )         In patients with permanent atrial fibrillation, MULTAQ doubles the risk of death, stroke and hospitalization for heart failure.","4 , 5.1 is not a named entity"
"(  4  ,   5.1  )         In patients with permanent atrial fibrillation, MULTAQ doubles the risk of death, stroke and hospitalization for heart failure.",heart failure is an adverse reaction entity
"(  4  ,   5.1  )         In patients with permanent atrial fibrillation, MULTAQ doubles the risk of death, stroke and hospitalization for heart failure.",stroke is an adverse reaction entity
"(  4  ,   5.1  )         In patients with permanent atrial fibrillation, MULTAQ doubles the risk of death, stroke and hospitalization for heart failure.",MULTAQ doubles is not a named entity
"(  4  ,   5.1  )         In patients with permanent atrial fibrillation, MULTAQ doubles the risk of death, stroke and hospitalization for heart failure.",death is an adverse reaction entity
"(  4  ,   5.1  )         In patients with permanent atrial fibrillation, MULTAQ doubles the risk of death, stroke and hospitalization for heart failure.",and hospitalization is not a named entity
"Hepatic:  Liver Injury  [see  Warnings and Precautions (5.5)  ]           Respiratory:  Interstitial lung disease including pneumonitis and pulmonary fibrosis  [see  Warnings and Precautions (5.6)  ]           Immune:  Anaphylactic reactions including angioedema         Vascular:  Vasculitis, including leukocytoclastic vasculitis",5.5 ) is not a named entity
"Hepatic:  Liver Injury  [see  Warnings and Precautions (5.5)  ]           Respiratory:  Interstitial lung disease including pneumonitis and pulmonary fibrosis  [see  Warnings and Precautions (5.6)  ]           Immune:  Anaphylactic reactions including angioedema         Vascular:  Vasculitis, including leukocytoclastic vasculitis",: Interstitial is not a named entity
"Hepatic:  Liver Injury  [see  Warnings and Precautions (5.5)  ]           Respiratory:  Interstitial lung disease including pneumonitis and pulmonary fibrosis  [see  Warnings and Precautions (5.6)  ]           Immune:  Anaphylactic reactions including angioedema         Vascular:  Vasculitis, including leukocytoclastic vasculitis",Anaphylactic reactions is an adverse reaction entity
"Hepatic:  Liver Injury  [see  Warnings and Precautions (5.5)  ]           Respiratory:  Interstitial lung disease including pneumonitis and pulmonary fibrosis  [see  Warnings and Precautions (5.6)  ]           Immune:  Anaphylactic reactions including angioedema         Vascular:  Vasculitis, including leukocytoclastic vasculitis",leukocytoclastic vasculitis is an adverse reaction entity
"Hepatic:  Liver Injury  [see  Warnings and Precautions (5.5)  ]           Respiratory:  Interstitial lung disease including pneumonitis and pulmonary fibrosis  [see  Warnings and Precautions (5.6)  ]           Immune:  Anaphylactic reactions including angioedema         Vascular:  Vasculitis, including leukocytoclastic vasculitis",Liver Injury is an adverse reaction entity
"Hepatic:  Liver Injury  [see  Warnings and Precautions (5.5)  ]           Respiratory:  Interstitial lung disease including pneumonitis and pulmonary fibrosis  [see  Warnings and Precautions (5.6)  ]           Immune:  Anaphylactic reactions including angioedema         Vascular:  Vasculitis, including leukocytoclastic vasculitis",pneumonitis is an adverse reaction entity
"Hepatic:  Liver Injury  [see  Warnings and Precautions (5.5)  ]           Respiratory:  Interstitial lung disease including pneumonitis and pulmonary fibrosis  [see  Warnings and Precautions (5.6)  ]           Immune:  Anaphylactic reactions including angioedema         Vascular:  Vasculitis, including leukocytoclastic vasculitis",angioedema is an adverse reaction entity
"Hepatic:  Liver Injury  [see  Warnings and Precautions (5.5)  ]           Respiratory:  Interstitial lung disease including pneumonitis and pulmonary fibrosis  [see  Warnings and Precautions (5.6)  ]           Immune:  Anaphylactic reactions including angioedema         Vascular:  Vasculitis, including leukocytoclastic vasculitis",] Respiratory : is not a named entity
"Hepatic:  Liver Injury  [see  Warnings and Precautions (5.5)  ]           Respiratory:  Interstitial lung disease including pneumonitis and pulmonary fibrosis  [see  Warnings and Precautions (5.6)  ]           Immune:  Anaphylactic reactions including angioedema         Vascular:  Vasculitis, including leukocytoclastic vasculitis",lung disease including is not a named entity
"Hepatic:  Liver Injury  [see  Warnings and Precautions (5.5)  ]           Respiratory:  Interstitial lung disease including pneumonitis and pulmonary fibrosis  [see  Warnings and Precautions (5.6)  ]           Immune:  Anaphylactic reactions including angioedema         Vascular:  Vasculitis, including leukocytoclastic vasculitis",] is not a named entity
"Hepatic:  Liver Injury  [see  Warnings and Precautions (5.5)  ]           Respiratory:  Interstitial lung disease including pneumonitis and pulmonary fibrosis  [see  Warnings and Precautions (5.6)  ]           Immune:  Anaphylactic reactions including angioedema         Vascular:  Vasculitis, including leukocytoclastic vasculitis",Precautions ( is not a named entity
"Hepatic:  Liver Injury  [see  Warnings and Precautions (5.5)  ]           Respiratory:  Interstitial lung disease including pneumonitis and pulmonary fibrosis  [see  Warnings and Precautions (5.6)  ]           Immune:  Anaphylactic reactions including angioedema         Vascular:  Vasculitis, including leukocytoclastic vasculitis",Vasculitis is an adverse reaction entity
"Hepatic:  Liver Injury  [see  Warnings and Precautions (5.5)  ]           Respiratory:  Interstitial lung disease including pneumonitis and pulmonary fibrosis  [see  Warnings and Precautions (5.6)  ]           Immune:  Anaphylactic reactions including angioedema         Vascular:  Vasculitis, including leukocytoclastic vasculitis",Interstitial lung disease is an adverse reaction entity
"Hepatic:  Liver Injury  [see  Warnings and Precautions (5.5)  ]           Respiratory:  Interstitial lung disease including pneumonitis and pulmonary fibrosis  [see  Warnings and Precautions (5.6)  ]           Immune:  Anaphylactic reactions including angioedema         Vascular:  Vasculitis, including leukocytoclastic vasculitis",pulmonary fibrosis is an adverse reaction entity
"Hepatic:  Liver Injury  [see  Warnings and Precautions (5.5)  ]           Respiratory:  Interstitial lung disease including pneumonitis and pulmonary fibrosis  [see  Warnings and Precautions (5.6)  ]           Immune:  Anaphylactic reactions including angioedema         Vascular:  Vasculitis, including leukocytoclastic vasculitis",: Interstitial is not a named entity
"Hepatic:  Liver Injury  [see  Warnings and Precautions (5.5)  ]           Respiratory:  Interstitial lung disease including pneumonitis and pulmonary fibrosis  [see  Warnings and Precautions (5.6)  ]           Immune:  Anaphylactic reactions including angioedema         Vascular:  Vasculitis, including leukocytoclastic vasculitis",reactions is not a named entity
"The most frequent adverse reactions observed with MULTAQ 400 mg twice daily in the 5 studies were diarrhea, nausea, abdominal pain, vomiting, and asthenia.",asthenia is an adverse reaction entity
"The most frequent adverse reactions observed with MULTAQ 400 mg twice daily in the 5 studies were diarrhea, nausea, abdominal pain, vomiting, and asthenia.",abdominal pain is an adverse reaction entity
"The most frequent adverse reactions observed with MULTAQ 400 mg twice daily in the 5 studies were diarrhea, nausea, abdominal pain, vomiting, and asthenia.",most is not a named entity
"The most frequent adverse reactions observed with MULTAQ 400 mg twice daily in the 5 studies were diarrhea, nausea, abdominal pain, vomiting, and asthenia.",the 5 is not a named entity
"The most frequent adverse reactions observed with MULTAQ 400 mg twice daily in the 5 studies were diarrhea, nausea, abdominal pain, vomiting, and asthenia.",diarrhea is an adverse reaction entity
"The most frequent adverse reactions observed with MULTAQ 400 mg twice daily in the 5 studies were diarrhea, nausea, abdominal pain, vomiting, and asthenia.",the is not a named entity
"The most frequent adverse reactions observed with MULTAQ 400 mg twice daily in the 5 studies were diarrhea, nausea, abdominal pain, vomiting, and asthenia.",vomiting is an adverse reaction entity
"The most frequent adverse reactions observed with MULTAQ 400 mg twice daily in the 5 studies were diarrhea, nausea, abdominal pain, vomiting, and asthenia.","vomiting , is not a named entity"
"The most frequent adverse reactions observed with MULTAQ 400 mg twice daily in the 5 studies were diarrhea, nausea, abdominal pain, vomiting, and asthenia.",reactions is not a named entity
"The most frequent adverse reactions observed with MULTAQ 400 mg twice daily in the 5 studies were diarrhea, nausea, abdominal pain, vomiting, and asthenia.",nausea is an adverse reaction entity
The most common reasons for discontinuation of therapy with MULTAQ were gastrointestinal disorders (3.2 % versus 1.8% in the placebo group) and QT prolongation (1.5% versus 0.5% in the placebo group).,QT prolongation is an adverse reaction entity
The most common reasons for discontinuation of therapy with MULTAQ were gastrointestinal disorders (3.2 % versus 1.8% in the placebo group) and QT prolongation (1.5% versus 0.5% in the placebo group).,% versus is not a named entity
The most common reasons for discontinuation of therapy with MULTAQ were gastrointestinal disorders (3.2 % versus 1.8% in the placebo group) and QT prolongation (1.5% versus 0.5% in the placebo group).,of therapy is not a named entity
The most common reasons for discontinuation of therapy with MULTAQ were gastrointestinal disorders (3.2 % versus 1.8% in the placebo group) and QT prolongation (1.5% versus 0.5% in the placebo group).,gastrointestinal disorders is an adverse reaction entity
"(  4  ,   5.2  )         EXCERPT:   WARNING: INCREASED RISK OF DEATH, STROKE AND HEART FAILURE IN PATIENTS WITH DECOMPENSATED HEART FAILURE OR PERMANENT ATRIAL FIBRILLATION             MULTAQ is contraindicated in patients with symptomatic heart failure with recent decompensation requiring hospitalization or NYHA Class IV heart failure.",STROKE is an adverse reaction entity
"(  4  ,   5.2  )         EXCERPT:   WARNING: INCREASED RISK OF DEATH, STROKE AND HEART FAILURE IN PATIENTS WITH DECOMPENSATED HEART FAILURE OR PERMANENT ATRIAL FIBRILLATION             MULTAQ is contraindicated in patients with symptomatic heart failure with recent decompensation requiring hospitalization or NYHA Class IV heart failure.",HEART FAILURE is an adverse reaction entity
"(  4  ,   5.2  )         EXCERPT:   WARNING: INCREASED RISK OF DEATH, STROKE AND HEART FAILURE IN PATIENTS WITH DECOMPENSATED HEART FAILURE OR PERMANENT ATRIAL FIBRILLATION             MULTAQ is contraindicated in patients with symptomatic heart failure with recent decompensation requiring hospitalization or NYHA Class IV heart failure.",DEATH is an adverse reaction entity
"(  4  ,   5.2  )         EXCERPT:   WARNING: INCREASED RISK OF DEATH, STROKE AND HEART FAILURE IN PATIENTS WITH DECOMPENSATED HEART FAILURE OR PERMANENT ATRIAL FIBRILLATION             MULTAQ is contraindicated in patients with symptomatic heart failure with recent decompensation requiring hospitalization or NYHA Class IV heart failure.",or NYHA Class is not a named entity
"(  4  ,   5.2  )         EXCERPT:   WARNING: INCREASED RISK OF DEATH, STROKE AND HEART FAILURE IN PATIENTS WITH DECOMPENSATED HEART FAILURE OR PERMANENT ATRIAL FIBRILLATION             MULTAQ is contraindicated in patients with symptomatic heart failure with recent decompensation requiring hospitalization or NYHA Class IV heart failure.",: INCREASED is not a named entity
"(  4  ,   5.2  )         EXCERPT:   WARNING: INCREASED RISK OF DEATH, STROKE AND HEART FAILURE IN PATIENTS WITH DECOMPENSATED HEART FAILURE OR PERMANENT ATRIAL FIBRILLATION             MULTAQ is contraindicated in patients with symptomatic heart failure with recent decompensation requiring hospitalization or NYHA Class IV heart failure.",STROKE AND HEART is not a named entity
Cardiac:  New or worsening heart failure  [see  Warnings and Precautions (5.4)  ]       Atrial flutter with 1:1 atrioventricular conduction has been reported very rarely.,atrioventricular is not a named entity
Cardiac:  New or worsening heart failure  [see  Warnings and Precautions (5.4)  ]       Atrial flutter with 1:1 atrioventricular conduction has been reported very rarely.,Atrial flutter with 1:1 atrioventricular conduction is an adverse reaction entity
Cardiac:  New or worsening heart failure  [see  Warnings and Precautions (5.4)  ]       Atrial flutter with 1:1 atrioventricular conduction has been reported very rarely.,or worsening is not a named entity
Cardiac:  New or worsening heart failure  [see  Warnings and Precautions (5.4)  ]       Atrial flutter with 1:1 atrioventricular conduction has been reported very rarely.,been reported is not a named entity
Cardiac:  New or worsening heart failure  [see  Warnings and Precautions (5.4)  ]       Atrial flutter with 1:1 atrioventricular conduction has been reported very rarely.,Atrial flutter is an adverse reaction entity
Cardiac:  New or worsening heart failure  [see  Warnings and Precautions (5.4)  ]       Atrial flutter with 1:1 atrioventricular conduction has been reported very rarely.,heart failure is an adverse reaction entity
"5.5 Liver Injury        *     Hepatocellular liver injury, including acute liver failure requiring transplant, has been reported in patients treated with MULTAQ in the postmarketing setting.",Hepatocellular liver injury is an adverse reaction entity
"5.5 Liver Injury        *     Hepatocellular liver injury, including acute liver failure requiring transplant, has been reported in patients treated with MULTAQ in the postmarketing setting.","liver injury , is not a named entity"
"5.5 Liver Injury        *     Hepatocellular liver injury, including acute liver failure requiring transplant, has been reported in patients treated with MULTAQ in the postmarketing setting.",treated with is not a named entity
"5.5 Liver Injury        *     Hepatocellular liver injury, including acute liver failure requiring transplant, has been reported in patients treated with MULTAQ in the postmarketing setting.",acute liver failure is an adverse reaction entity
"BOXED WARNING: WARNING: INCREASED RISK OF DEATH, STROKE AND HEART FAILURE IN PATIENTS WITH DECOMPENSATED HEART FAILURE OR PERMANENT ATRIAL FIBRILLATION      WARNING: INCREASED RISK OF DEATH, STROKE AND HEART FAILURE IN PATIENTS WITH DECOMPENSATED HEART FAILURE OR PERMANENT ATRIAL FIBRILLATION        In patients with symptomatic heart failure and recent decompensation requiring hospitalization or NYHA Class IV heart failure; MULTAQ doubles the risk of death.",STROKE is an adverse reaction entity
"BOXED WARNING: WARNING: INCREASED RISK OF DEATH, STROKE AND HEART FAILURE IN PATIENTS WITH DECOMPENSATED HEART FAILURE OR PERMANENT ATRIAL FIBRILLATION      WARNING: INCREASED RISK OF DEATH, STROKE AND HEART FAILURE IN PATIENTS WITH DECOMPENSATED HEART FAILURE OR PERMANENT ATRIAL FIBRILLATION        In patients with symptomatic heart failure and recent decompensation requiring hospitalization or NYHA Class IV heart failure; MULTAQ doubles the risk of death.",the risk is not a named entity
"BOXED WARNING: WARNING: INCREASED RISK OF DEATH, STROKE AND HEART FAILURE IN PATIENTS WITH DECOMPENSATED HEART FAILURE OR PERMANENT ATRIAL FIBRILLATION      WARNING: INCREASED RISK OF DEATH, STROKE AND HEART FAILURE IN PATIENTS WITH DECOMPENSATED HEART FAILURE OR PERMANENT ATRIAL FIBRILLATION        In patients with symptomatic heart failure and recent decompensation requiring hospitalization or NYHA Class IV heart failure; MULTAQ doubles the risk of death.",: INCREASED RISK is not a named entity
"BOXED WARNING: WARNING: INCREASED RISK OF DEATH, STROKE AND HEART FAILURE IN PATIENTS WITH DECOMPENSATED HEART FAILURE OR PERMANENT ATRIAL FIBRILLATION      WARNING: INCREASED RISK OF DEATH, STROKE AND HEART FAILURE IN PATIENTS WITH DECOMPENSATED HEART FAILURE OR PERMANENT ATRIAL FIBRILLATION        In patients with symptomatic heart failure and recent decompensation requiring hospitalization or NYHA Class IV heart failure; MULTAQ doubles the risk of death.",DEATH is an adverse reaction entity
"BOXED WARNING: WARNING: INCREASED RISK OF DEATH, STROKE AND HEART FAILURE IN PATIENTS WITH DECOMPENSATED HEART FAILURE OR PERMANENT ATRIAL FIBRILLATION      WARNING: INCREASED RISK OF DEATH, STROKE AND HEART FAILURE IN PATIENTS WITH DECOMPENSATED HEART FAILURE OR PERMANENT ATRIAL FIBRILLATION        In patients with symptomatic heart failure and recent decompensation requiring hospitalization or NYHA Class IV heart failure; MULTAQ doubles the risk of death.",", is not a named entity"
"BOXED WARNING: WARNING: INCREASED RISK OF DEATH, STROKE AND HEART FAILURE IN PATIENTS WITH DECOMPENSATED HEART FAILURE OR PERMANENT ATRIAL FIBRILLATION      WARNING: INCREASED RISK OF DEATH, STROKE AND HEART FAILURE IN PATIENTS WITH DECOMPENSATED HEART FAILURE OR PERMANENT ATRIAL FIBRILLATION        In patients with symptomatic heart failure and recent decompensation requiring hospitalization or NYHA Class IV heart failure; MULTAQ doubles the risk of death.",DEATH is an adverse reaction entity
"BOXED WARNING: WARNING: INCREASED RISK OF DEATH, STROKE AND HEART FAILURE IN PATIENTS WITH DECOMPENSATED HEART FAILURE OR PERMANENT ATRIAL FIBRILLATION      WARNING: INCREASED RISK OF DEATH, STROKE AND HEART FAILURE IN PATIENTS WITH DECOMPENSATED HEART FAILURE OR PERMANENT ATRIAL FIBRILLATION        In patients with symptomatic heart failure and recent decompensation requiring hospitalization or NYHA Class IV heart failure; MULTAQ doubles the risk of death.",HEART FAILURE is an adverse reaction entity
"BOXED WARNING: WARNING: INCREASED RISK OF DEATH, STROKE AND HEART FAILURE IN PATIENTS WITH DECOMPENSATED HEART FAILURE OR PERMANENT ATRIAL FIBRILLATION      WARNING: INCREASED RISK OF DEATH, STROKE AND HEART FAILURE IN PATIENTS WITH DECOMPENSATED HEART FAILURE OR PERMANENT ATRIAL FIBRILLATION        In patients with symptomatic heart failure and recent decompensation requiring hospitalization or NYHA Class IV heart failure; MULTAQ doubles the risk of death.",death is an adverse reaction entity
"BOXED WARNING: WARNING: INCREASED RISK OF DEATH, STROKE AND HEART FAILURE IN PATIENTS WITH DECOMPENSATED HEART FAILURE OR PERMANENT ATRIAL FIBRILLATION      WARNING: INCREASED RISK OF DEATH, STROKE AND HEART FAILURE IN PATIENTS WITH DECOMPENSATED HEART FAILURE OR PERMANENT ATRIAL FIBRILLATION        In patients with symptomatic heart failure and recent decompensation requiring hospitalization or NYHA Class IV heart failure; MULTAQ doubles the risk of death.",HEART FAILURE is an adverse reaction entity
"BOXED WARNING: WARNING: INCREASED RISK OF DEATH, STROKE AND HEART FAILURE IN PATIENTS WITH DECOMPENSATED HEART FAILURE OR PERMANENT ATRIAL FIBRILLATION      WARNING: INCREASED RISK OF DEATH, STROKE AND HEART FAILURE IN PATIENTS WITH DECOMPENSATED HEART FAILURE OR PERMANENT ATRIAL FIBRILLATION        In patients with symptomatic heart failure and recent decompensation requiring hospitalization or NYHA Class IV heart failure; MULTAQ doubles the risk of death.",STROKE is an adverse reaction entity
"BOXED WARNING: WARNING: INCREASED RISK OF DEATH, STROKE AND HEART FAILURE IN PATIENTS WITH DECOMPENSATED HEART FAILURE OR PERMANENT ATRIAL FIBRILLATION      WARNING: INCREASED RISK OF DEATH, STROKE AND HEART FAILURE IN PATIENTS WITH DECOMPENSATED HEART FAILURE OR PERMANENT ATRIAL FIBRILLATION        In patients with symptomatic heart failure and recent decompensation requiring hospitalization or NYHA Class IV heart failure; MULTAQ doubles the risk of death.",OR PERMANENT is not a named entity
"BOXED WARNING: WARNING: INCREASED RISK OF DEATH, STROKE AND HEART FAILURE IN PATIENTS WITH DECOMPENSATED HEART FAILURE OR PERMANENT ATRIAL FIBRILLATION      WARNING: INCREASED RISK OF DEATH, STROKE AND HEART FAILURE IN PATIENTS WITH DECOMPENSATED HEART FAILURE OR PERMANENT ATRIAL FIBRILLATION        In patients with symptomatic heart failure and recent decompensation requiring hospitalization or NYHA Class IV heart failure; MULTAQ doubles the risk of death.",INCREASED is not a named entity
"BOXED WARNING: WARNING: INCREASED RISK OF DEATH, STROKE AND HEART FAILURE IN PATIENTS WITH DECOMPENSATED HEART FAILURE OR PERMANENT ATRIAL FIBRILLATION      WARNING: INCREASED RISK OF DEATH, STROKE AND HEART FAILURE IN PATIENTS WITH DECOMPENSATED HEART FAILURE OR PERMANENT ATRIAL FIBRILLATION        In patients with symptomatic heart failure and recent decompensation requiring hospitalization or NYHA Class IV heart failure; MULTAQ doubles the risk of death.",WARNING is not a named entity
"BOXED WARNING: WARNING: INCREASED RISK OF DEATH, STROKE AND HEART FAILURE IN PATIENTS WITH DECOMPENSATED HEART FAILURE OR PERMANENT ATRIAL FIBRILLATION      WARNING: INCREASED RISK OF DEATH, STROKE AND HEART FAILURE IN PATIENTS WITH DECOMPENSATED HEART FAILURE OR PERMANENT ATRIAL FIBRILLATION        In patients with symptomatic heart failure and recent decompensation requiring hospitalization or NYHA Class IV heart failure; MULTAQ doubles the risk of death.",OR is not a named entity
5.4 New Onset or Worsening Heart Failure      New onset or worsening of heart failure has been reported during treatment with MULTAQ in the postmarketing setting.,5.4 New is not a named entity
5.4 New Onset or Worsening Heart Failure      New onset or worsening of heart failure has been reported during treatment with MULTAQ in the postmarketing setting.,has is not a named entity
5.4 New Onset or Worsening Heart Failure      New onset or worsening of heart failure has been reported during treatment with MULTAQ in the postmarketing setting.,New onset heart failure is an adverse reaction entity
5.4 New Onset or Worsening Heart Failure      New onset or worsening of heart failure has been reported during treatment with MULTAQ in the postmarketing setting.,worsening of heart failure is an adverse reaction entity
"(  5.3  )   *   Clostridium difficile -associated diarrhea (CDAD) has been reported with nearly all systemic antibacterial agents, including DALVANCE.",CDAD is an adverse reaction entity
"(  5.3  )   *   Clostridium difficile -associated diarrhea (CDAD) has been reported with nearly all systemic antibacterial agents, including DALVANCE.",Clostridium difficile -associated diarrhea is an adverse reaction entity
"(  5.3  )   *   Clostridium difficile -associated diarrhea (CDAD) has been reported with nearly all systemic antibacterial agents, including DALVANCE.",systemic is not a named entity
"(  5.3  )   *   Clostridium difficile -associated diarrhea (CDAD) has been reported with nearly all systemic antibacterial agents, including DALVANCE.",nearly is not a named entity
"5.4 Clostridium difficile-Associated Diarrhea       Clostridium difficile  -associated diarrhea (CDAD) has been reported in users of nearly all systemic antibacterial drugs, including DALVANCE, with severity ranging from mild diarrhea to fatal colitis.",diarrhea is an adverse reaction entity
"5.4 Clostridium difficile-Associated Diarrhea       Clostridium difficile  -associated diarrhea (CDAD) has been reported in users of nearly all systemic antibacterial drugs, including DALVANCE, with severity ranging from mild diarrhea to fatal colitis.",-associated diarrhea ( is not a named entity
"5.4 Clostridium difficile-Associated Diarrhea       Clostridium difficile  -associated diarrhea (CDAD) has been reported in users of nearly all systemic antibacterial drugs, including DALVANCE, with severity ranging from mild diarrhea to fatal colitis.",users of is not a named entity
"5.4 Clostridium difficile-Associated Diarrhea       Clostridium difficile  -associated diarrhea (CDAD) has been reported in users of nearly all systemic antibacterial drugs, including DALVANCE, with severity ranging from mild diarrhea to fatal colitis.",Clostridium difficile -associated diarrhea is an adverse reaction entity
"5.4 Clostridium difficile-Associated Diarrhea       Clostridium difficile  -associated diarrhea (CDAD) has been reported in users of nearly all systemic antibacterial drugs, including DALVANCE, with severity ranging from mild diarrhea to fatal colitis.",fatal is an adverse reaction entity
"5.4 Clostridium difficile-Associated Diarrhea       Clostridium difficile  -associated diarrhea (CDAD) has been reported in users of nearly all systemic antibacterial drugs, including DALVANCE, with severity ranging from mild diarrhea to fatal colitis.",mild diarrhea is not a named entity
"5.4 Clostridium difficile-Associated Diarrhea       Clostridium difficile  -associated diarrhea (CDAD) has been reported in users of nearly all systemic antibacterial drugs, including DALVANCE, with severity ranging from mild diarrhea to fatal colitis.",5.4 Clostridium difficile-Associated is not a named entity
"5.4 Clostridium difficile-Associated Diarrhea       Clostridium difficile  -associated diarrhea (CDAD) has been reported in users of nearly all systemic antibacterial drugs, including DALVANCE, with severity ranging from mild diarrhea to fatal colitis.","DALVANCE , is not a named entity"
"5.4 Clostridium difficile-Associated Diarrhea       Clostridium difficile  -associated diarrhea (CDAD) has been reported in users of nearly all systemic antibacterial drugs, including DALVANCE, with severity ranging from mild diarrhea to fatal colitis.",CDAD is an adverse reaction entity
"5.4 Clostridium difficile-Associated Diarrhea       Clostridium difficile  -associated diarrhea (CDAD) has been reported in users of nearly all systemic antibacterial drugs, including DALVANCE, with severity ranging from mild diarrhea to fatal colitis.",colitis is an adverse reaction entity
(  5.1  )   *  Rapid intravenous infusion of glycopeptide antibacterial agents can cause reactions.,infusion reactions is an adverse reaction entity
(  5.1  )   *  Rapid intravenous infusion of glycopeptide antibacterial agents can cause reactions.,glycopeptide antibacterial is not a named entity
(  5.4  )             5.1 Hypersensitivity Reactions      Serious hypersensitivity (anaphylactic) and skin reactions have been reported in patients treated with DALVANCE.,( 5.4 ) is not a named entity
(  5.4  )             5.1 Hypersensitivity Reactions      Serious hypersensitivity (anaphylactic) and skin reactions have been reported in patients treated with DALVANCE.,( is not a named entity
(  5.4  )             5.1 Hypersensitivity Reactions      Serious hypersensitivity (anaphylactic) and skin reactions have been reported in patients treated with DALVANCE.,anaphylactic reactions is an adverse reaction entity
(  5.4  )             5.1 Hypersensitivity Reactions      Serious hypersensitivity (anaphylactic) and skin reactions have been reported in patients treated with DALVANCE.,reported in is not a named entity
(  5.4  )             5.1 Hypersensitivity Reactions      Serious hypersensitivity (anaphylactic) and skin reactions have been reported in patients treated with DALVANCE.,hypersensitivity reactions is an adverse reaction entity
(  5.4  )             5.1 Hypersensitivity Reactions      Serious hypersensitivity (anaphylactic) and skin reactions have been reported in patients treated with DALVANCE.,skin reactions is an adverse reaction entity
"Most Common Adverse Reactions       The most common adverse reactions in patients treated with DALVANCE were nausea (5.5%), headache (4.7%), and diarrhea (4.4%).",headache is an adverse reaction entity
"Most Common Adverse Reactions       The most common adverse reactions in patients treated with DALVANCE were nausea (5.5%), headache (4.7%), and diarrhea (4.4%).",diarrhea is an adverse reaction entity
"Most Common Adverse Reactions       The most common adverse reactions in patients treated with DALVANCE were nausea (5.5%), headache (4.7%), and diarrhea (4.4%).",", headache ( is not a named entity"
"Most Common Adverse Reactions       The most common adverse reactions in patients treated with DALVANCE were nausea (5.5%), headache (4.7%), and diarrhea (4.4%).",Common Adverse Reactions is not a named entity
"Most Common Adverse Reactions       The most common adverse reactions in patients treated with DALVANCE were nausea (5.5%), headache (4.7%), and diarrhea (4.4%).",adverse reactions in is not a named entity
"Most Common Adverse Reactions       The most common adverse reactions in patients treated with DALVANCE were nausea (5.5%), headache (4.7%), and diarrhea (4.4%).",nausea is an adverse reaction entity
"Selected Adverse Reactions in Phase 2/3 Trials  (Number (%) of Patients)                         Dalbavancin       Comparator*                         (N = 1778)       (N = 1224)           Nausea           98 (5.5)         78 (6.4)            Vomiting         50 (2.8)         37 (3)              Diarrhea         79 (4.4)         72 (5.9)            Headache         83 (4.7)         59 (4.8)            Rash             48 (2.7)         30 (2.4)            Pruritus         38 (2.1)         41 (3.3)            * Comparators included linezolid, cefazolin, cephalexin, and vancomycin.",( 3 ) is not a named entity
"Selected Adverse Reactions in Phase 2/3 Trials  (Number (%) of Patients)                         Dalbavancin       Comparator*                         (N = 1778)       (N = 1224)           Nausea           98 (5.5)         78 (6.4)            Vomiting         50 (2.8)         37 (3)              Diarrhea         79 (4.4)         72 (5.9)            Headache         83 (4.7)         59 (4.8)            Rash             48 (2.7)         30 (2.4)            Pruritus         38 (2.1)         41 (3.3)            * Comparators included linezolid, cefazolin, cephalexin, and vancomycin.",) is not a named entity
"Selected Adverse Reactions in Phase 2/3 Trials  (Number (%) of Patients)                         Dalbavancin       Comparator*                         (N = 1778)       (N = 1224)           Nausea           98 (5.5)         78 (6.4)            Vomiting         50 (2.8)         37 (3)              Diarrhea         79 (4.4)         72 (5.9)            Headache         83 (4.7)         59 (4.8)            Rash             48 (2.7)         30 (2.4)            Pruritus         38 (2.1)         41 (3.3)            * Comparators included linezolid, cefazolin, cephalexin, and vancomycin.",Headache is an adverse reaction entity
"Selected Adverse Reactions in Phase 2/3 Trials  (Number (%) of Patients)                         Dalbavancin       Comparator*                         (N = 1778)       (N = 1224)           Nausea           98 (5.5)         78 (6.4)            Vomiting         50 (2.8)         37 (3)              Diarrhea         79 (4.4)         72 (5.9)            Headache         83 (4.7)         59 (4.8)            Rash             48 (2.7)         30 (2.4)            Pruritus         38 (2.1)         41 (3.3)            * Comparators included linezolid, cefazolin, cephalexin, and vancomycin.",Pruritus is an adverse reaction entity
"Selected Adverse Reactions in Phase 2/3 Trials  (Number (%) of Patients)                         Dalbavancin       Comparator*                         (N = 1778)       (N = 1224)           Nausea           98 (5.5)         78 (6.4)            Vomiting         50 (2.8)         37 (3)              Diarrhea         79 (4.4)         72 (5.9)            Headache         83 (4.7)         59 (4.8)            Rash             48 (2.7)         30 (2.4)            Pruritus         38 (2.1)         41 (3.3)            * Comparators included linezolid, cefazolin, cephalexin, and vancomycin.",1224 ) Nausea is not a named entity
"Selected Adverse Reactions in Phase 2/3 Trials  (Number (%) of Patients)                         Dalbavancin       Comparator*                         (N = 1778)       (N = 1224)           Nausea           98 (5.5)         78 (6.4)            Vomiting         50 (2.8)         37 (3)              Diarrhea         79 (4.4)         72 (5.9)            Headache         83 (4.7)         59 (4.8)            Rash             48 (2.7)         30 (2.4)            Pruritus         38 (2.1)         41 (3.3)            * Comparators included linezolid, cefazolin, cephalexin, and vancomycin.",Rash is an adverse reaction entity
"Selected Adverse Reactions in Phase 2/3 Trials  (Number (%) of Patients)                         Dalbavancin       Comparator*                         (N = 1778)       (N = 1224)           Nausea           98 (5.5)         78 (6.4)            Vomiting         50 (2.8)         37 (3)              Diarrhea         79 (4.4)         72 (5.9)            Headache         83 (4.7)         59 (4.8)            Rash             48 (2.7)         30 (2.4)            Pruritus         38 (2.1)         41 (3.3)            * Comparators included linezolid, cefazolin, cephalexin, and vancomycin.",Vomiting is an adverse reaction entity
"Selected Adverse Reactions in Phase 2/3 Trials  (Number (%) of Patients)                         Dalbavancin       Comparator*                         (N = 1778)       (N = 1224)           Nausea           98 (5.5)         78 (6.4)            Vomiting         50 (2.8)         37 (3)              Diarrhea         79 (4.4)         72 (5.9)            Headache         83 (4.7)         59 (4.8)            Rash             48 (2.7)         30 (2.4)            Pruritus         38 (2.1)         41 (3.3)            * Comparators included linezolid, cefazolin, cephalexin, and vancomycin.",) is not a named entity
"Selected Adverse Reactions in Phase 2/3 Trials  (Number (%) of Patients)                         Dalbavancin       Comparator*                         (N = 1778)       (N = 1224)           Nausea           98 (5.5)         78 (6.4)            Vomiting         50 (2.8)         37 (3)              Diarrhea         79 (4.4)         72 (5.9)            Headache         83 (4.7)         59 (4.8)            Rash             48 (2.7)         30 (2.4)            Pruritus         38 (2.1)         41 (3.3)            * Comparators included linezolid, cefazolin, cephalexin, and vancomycin.",Diarrhea is an adverse reaction entity
"Selected Adverse Reactions in Phase 2/3 Trials  (Number (%) of Patients)                         Dalbavancin       Comparator*                         (N = 1778)       (N = 1224)           Nausea           98 (5.5)         78 (6.4)            Vomiting         50 (2.8)         37 (3)              Diarrhea         79 (4.4)         72 (5.9)            Headache         83 (4.7)         59 (4.8)            Rash             48 (2.7)         30 (2.4)            Pruritus         38 (2.1)         41 (3.3)            * Comparators included linezolid, cefazolin, cephalexin, and vancomycin.",) ( is not a named entity
"Selected Adverse Reactions in Phase 2/3 Trials  (Number (%) of Patients)                         Dalbavancin       Comparator*                         (N = 1778)       (N = 1224)           Nausea           98 (5.5)         78 (6.4)            Vomiting         50 (2.8)         37 (3)              Diarrhea         79 (4.4)         72 (5.9)            Headache         83 (4.7)         59 (4.8)            Rash             48 (2.7)         30 (2.4)            Pruritus         38 (2.1)         41 (3.3)            * Comparators included linezolid, cefazolin, cephalexin, and vancomycin.",Nausea is an adverse reaction entity
"Selected Adverse Reactions in Phase 2/3 Trials  (Number (%) of Patients)                         Dalbavancin       Comparator*                         (N = 1778)       (N = 1224)           Nausea           98 (5.5)         78 (6.4)            Vomiting         50 (2.8)         37 (3)              Diarrhea         79 (4.4)         72 (5.9)            Headache         83 (4.7)         59 (4.8)            Rash             48 (2.7)         30 (2.4)            Pruritus         38 (2.1)         41 (3.3)            * Comparators included linezolid, cefazolin, cephalexin, and vancomycin.",) * Comparators is not a named entity
"5.3 Hepatic Effects      In Phase 2 and 3 clinical trials, more DALVANCE- than comparator-treated subjects with normal baseline transaminase levels had post-baseline alanine aminotransferase (ALT) elevation greater than 3 times the upper limit of normal (ULN).",ALT elevation is an adverse reaction entity
"5.3 Hepatic Effects      In Phase 2 and 3 clinical trials, more DALVANCE- than comparator-treated subjects with normal baseline transaminase levels had post-baseline alanine aminotransferase (ALT) elevation greater than 3 times the upper limit of normal (ULN).",times the is not a named entity
"5.3 Hepatic Effects      In Phase 2 and 3 clinical trials, more DALVANCE- than comparator-treated subjects with normal baseline transaminase levels had post-baseline alanine aminotransferase (ALT) elevation greater than 3 times the upper limit of normal (ULN).",alanine aminotransferase elevation is an adverse reaction entity
"5.3 Hepatic Effects      In Phase 2 and 3 clinical trials, more DALVANCE- than comparator-treated subjects with normal baseline transaminase levels had post-baseline alanine aminotransferase (ALT) elevation greater than 3 times the upper limit of normal (ULN).",3 clinical is not a named entity
"Rapid intravenous infusions of DALVANCE can cause reactions that resemble ""Red-Man Syndrome,"" including flushing of the upper body, urticaria, pruritus, and/or rash.",rash is an adverse reaction entity
"Rapid intravenous infusions of DALVANCE can cause reactions that resemble ""Red-Man Syndrome,"" including flushing of the upper body, urticaria, pruritus, and/or rash.","pruritus , and/or is not a named entity"
"Rapid intravenous infusions of DALVANCE can cause reactions that resemble ""Red-Man Syndrome,"" including flushing of the upper body, urticaria, pruritus, and/or rash.",pruritus is an adverse reaction entity
"Rapid intravenous infusions of DALVANCE can cause reactions that resemble ""Red-Man Syndrome,"" including flushing of the upper body, urticaria, pruritus, and/or rash.",", and/or rash is not a named entity"
"Rapid intravenous infusions of DALVANCE can cause reactions that resemble ""Red-Man Syndrome,"" including flushing of the upper body, urticaria, pruritus, and/or rash.",including flushing of is not a named entity
"Rapid intravenous infusions of DALVANCE can cause reactions that resemble ""Red-Man Syndrome,"" including flushing of the upper body, urticaria, pruritus, and/or rash.",urticaria is an adverse reaction entity
"Rapid intravenous infusions of DALVANCE can cause reactions that resemble ""Red-Man Syndrome,"" including flushing of the upper body, urticaria, pruritus, and/or rash.",DALVANCE can cause is not a named entity
"Rapid intravenous infusions of DALVANCE can cause reactions that resemble ""Red-Man Syndrome,"" including flushing of the upper body, urticaria, pruritus, and/or rash.",Red-Man Syndrome is an adverse reaction entity
"Rapid intravenous infusions of DALVANCE can cause reactions that resemble ""Red-Man Syndrome,"" including flushing of the upper body, urticaria, pruritus, and/or rash.",flushing of the upper body is an adverse reaction entity
"Rapid intravenous infusions of DALVANCE can cause reactions that resemble ""Red-Man Syndrome,"" including flushing of the upper body, urticaria, pruritus, and/or rash.","upper body , is not a named entity"
"In addition, one DALVANCE-treated subject in a Phase 1 trial had post-baseline ALT elevations greater than 20 times ULN.",1 trial had is not a named entity
"In addition, one DALVANCE-treated subject in a Phase 1 trial had post-baseline ALT elevations greater than 20 times ULN.",ALT elevations is an adverse reaction entity
(  5.2  )   *  ALT elevations with DALVANCE treatment were reported in clinical trials.,reported is not a named entity
(  5.2  )   *  ALT elevations with DALVANCE treatment were reported in clinical trials.,ALT elevations is an adverse reaction entity
The most common (per patient incidence >= 10%) adverse reactions reported with Prolia in patients with bone loss receiving androgen deprivation therapy for prostate cancer or adjuvant aromatase inhibitor therapy for breast cancer are arthralgia and back pain.,) is not a named entity
The most common (per patient incidence >= 10%) adverse reactions reported with Prolia in patients with bone loss receiving androgen deprivation therapy for prostate cancer or adjuvant aromatase inhibitor therapy for breast cancer are arthralgia and back pain.,back pain is an adverse reaction entity
The most common (per patient incidence >= 10%) adverse reactions reported with Prolia in patients with bone loss receiving androgen deprivation therapy for prostate cancer or adjuvant aromatase inhibitor therapy for breast cancer are arthralgia and back pain.,per patient is not a named entity
The most common (per patient incidence >= 10%) adverse reactions reported with Prolia in patients with bone loss receiving androgen deprivation therapy for prostate cancer or adjuvant aromatase inhibitor therapy for breast cancer are arthralgia and back pain.,arthralgia is an adverse reaction entity
"EXCERPT:    *  Postmenopausal osteoporosis: Most common adverse reactions (> 5% and more common than placebo) were: back pain, pain in extremity, hypercholesterolemia, musculoskeletal pain, and cystitis.",Postmenopausal is not a named entity
"EXCERPT:    *  Postmenopausal osteoporosis: Most common adverse reactions (> 5% and more common than placebo) were: back pain, pain in extremity, hypercholesterolemia, musculoskeletal pain, and cystitis.",were : back is not a named entity
"EXCERPT:    *  Postmenopausal osteoporosis: Most common adverse reactions (> 5% and more common than placebo) were: back pain, pain in extremity, hypercholesterolemia, musculoskeletal pain, and cystitis.",cystitis is an adverse reaction entity
"EXCERPT:    *  Postmenopausal osteoporosis: Most common adverse reactions (> 5% and more common than placebo) were: back pain, pain in extremity, hypercholesterolemia, musculoskeletal pain, and cystitis.","pain , is not a named entity"
"EXCERPT:    *  Postmenopausal osteoporosis: Most common adverse reactions (> 5% and more common than placebo) were: back pain, pain in extremity, hypercholesterolemia, musculoskeletal pain, and cystitis.",", is not a named entity"
"EXCERPT:    *  Postmenopausal osteoporosis: Most common adverse reactions (> 5% and more common than placebo) were: back pain, pain in extremity, hypercholesterolemia, musculoskeletal pain, and cystitis.",musculoskeletal pain is an adverse reaction entity
"EXCERPT:    *  Postmenopausal osteoporosis: Most common adverse reactions (> 5% and more common than placebo) were: back pain, pain in extremity, hypercholesterolemia, musculoskeletal pain, and cystitis.",pain in extremity is an adverse reaction entity
"EXCERPT:    *  Postmenopausal osteoporosis: Most common adverse reactions (> 5% and more common than placebo) were: back pain, pain in extremity, hypercholesterolemia, musculoskeletal pain, and cystitis.",more common than is not a named entity
"EXCERPT:    *  Postmenopausal osteoporosis: Most common adverse reactions (> 5% and more common than placebo) were: back pain, pain in extremity, hypercholesterolemia, musculoskeletal pain, and cystitis.",hypercholesterolemia is an adverse reaction entity
"EXCERPT:    *  Postmenopausal osteoporosis: Most common adverse reactions (> 5% and more common than placebo) were: back pain, pain in extremity, hypercholesterolemia, musculoskeletal pain, and cystitis.",back pain is an adverse reaction entity
"5.9 Suppression of Bone Turnover      In clinical trials in women with postmenopausal osteoporosis, treatment with Prolia resulted in significant suppression of bone remodeling as evidenced by markers of bone turnover and bone histomorphometry [see Clinical Pharmacology (  12.2  ) and Clinical Studies (  14.1  )]  .",of is not a named entity
"5.9 Suppression of Bone Turnover      In clinical trials in women with postmenopausal osteoporosis, treatment with Prolia resulted in significant suppression of bone remodeling as evidenced by markers of bone turnover and bone histomorphometry [see Clinical Pharmacology (  12.2  ) and Clinical Studies (  14.1  )]  .",suppression of bone remodeling is an adverse reaction entity
"5.6 Serious Infections      In a clinical trial of over 7800 women with postmenopausal osteoporosis, serious infections leading to hospitalization were reported more frequently in the Prolia group than in the placebo group [see Adverse Reactions (  6.1  )]  .",infections is an adverse reaction entity
"5.6 Serious Infections      In a clinical trial of over 7800 women with postmenopausal osteoporosis, serious infections leading to hospitalization were reported more frequently in the Prolia group than in the placebo group [see Adverse Reactions (  6.1  )]  .",in the is not a named entity
Pain in extremity and musculoskeletal pain have also been reported in clinical trials.,Pain in extremity is an adverse reaction entity
Pain in extremity and musculoskeletal pain have also been reported in clinical trials.,musculoskeletal pain is an adverse reaction entity
Pain in extremity and musculoskeletal pain have also been reported in clinical trials.,clinical trials is not a named entity
Pain in extremity and musculoskeletal pain have also been reported in clinical trials.,musculoskeletal pain have is not a named entity
"5.8 Musculoskeletal Pain       In post-marketing experience, severe and occasionally incapacitating bone, joint, and/or muscle pain has been reported in patients taking Prolia [see Adverse Reactions (  6.2  )]  .",muscle pain is an adverse reaction entity
"5.8 Musculoskeletal Pain       In post-marketing experience, severe and occasionally incapacitating bone, joint, and/or muscle pain has been reported in patients taking Prolia [see Adverse Reactions (  6.2  )]  .",joint pain is an adverse reaction entity
"5.8 Musculoskeletal Pain       In post-marketing experience, severe and occasionally incapacitating bone, joint, and/or muscle pain has been reported in patients taking Prolia [see Adverse Reactions (  6.2  )]  .",[ is not a named entity
"5.8 Musculoskeletal Pain       In post-marketing experience, severe and occasionally incapacitating bone, joint, and/or muscle pain has been reported in patients taking Prolia [see Adverse Reactions (  6.2  )]  .",and is not a named entity
"5.8 Musculoskeletal Pain       In post-marketing experience, severe and occasionally incapacitating bone, joint, and/or muscle pain has been reported in patients taking Prolia [see Adverse Reactions (  6.2  )]  .",severe is not a named entity
"5.8 Musculoskeletal Pain       In post-marketing experience, severe and occasionally incapacitating bone, joint, and/or muscle pain has been reported in patients taking Prolia [see Adverse Reactions (  6.2  )]  .",bone pain is an adverse reaction entity
ONJ has been reported in patients receiving denosumab [see Adverse Reactions (  6.1  )].,( 6.1 ) is not a named entity
ONJ has been reported in patients receiving denosumab [see Adverse Reactions (  6.1  )].,ONJ is an adverse reaction entity
Serious Infections    S  erious infection was reported in 1 patient (0.8%) in the placebo group and no patients in the Prolia group.,infection is an adverse reaction entity
Serious Infections    S  erious infection was reported in 1 patient (0.8%) in the placebo group and no patients in the Prolia group.,) in is not a named entity
"Pain in extremity and musculoskeletal pain have also been reported in clinical trials (  6.1  )        To report SUSPECTED ADVERSE REACTIONS, contact Amgen Inc. at 1-800-77-AMGEN (1-800-772-6436) or FDA at 1-800-FDA-1088 or    www.fda.gov/medwatch      .",extremity is not a named entity
"Pain in extremity and musculoskeletal pain have also been reported in clinical trials (  6.1  )        To report SUSPECTED ADVERSE REACTIONS, contact Amgen Inc. at 1-800-77-AMGEN (1-800-772-6436) or FDA at 1-800-FDA-1088 or    www.fda.gov/medwatch      .",musculoskeletal pain is an adverse reaction entity
"Pain in extremity and musculoskeletal pain have also been reported in clinical trials (  6.1  )        To report SUSPECTED ADVERSE REACTIONS, contact Amgen Inc. at 1-800-77-AMGEN (1-800-772-6436) or FDA at 1-800-FDA-1088 or    www.fda.gov/medwatch      .",Pain in extremity is an adverse reaction entity
"Pain in extremity and musculoskeletal pain have also been reported in clinical trials (  6.1  )        To report SUSPECTED ADVERSE REACTIONS, contact Amgen Inc. at 1-800-77-AMGEN (1-800-772-6436) or FDA at 1-800-FDA-1088 or    www.fda.gov/medwatch      .",www.fda.gov/medwatch is not a named entity
Endocarditis was reported in no placebo patients and 3 patients receiving Prolia.,Endocarditis is an adverse reaction entity
Endocarditis was reported in no placebo patients and 3 patients receiving Prolia.,patients and 3 is not a named entity
"Skin infections, including erysipelas and cellulitis, leading to hospitalization were reported more frequently in patients treated with Prolia (< 0.1% placebo vs. 0.4% Prolia).",% placebo vs. is not a named entity
"Skin infections, including erysipelas and cellulitis, leading to hospitalization were reported more frequently in patients treated with Prolia (< 0.1% placebo vs. 0.4% Prolia).",cellulitis is an adverse reaction entity
"Skin infections, including erysipelas and cellulitis, leading to hospitalization were reported more frequently in patients treated with Prolia (< 0.1% placebo vs. 0.4% Prolia).",Skin infections is an adverse reaction entity
"Skin infections, including erysipelas and cellulitis, leading to hospitalization were reported more frequently in patients treated with Prolia (< 0.1% placebo vs. 0.4% Prolia).",vs. 0.4 is not a named entity
"Skin infections, including erysipelas and cellulitis, leading to hospitalization were reported more frequently in patients treated with Prolia (< 0.1% placebo vs. 0.4% Prolia).","Skin infections , is not a named entity"
"Skin infections, including erysipelas and cellulitis, leading to hospitalization were reported more frequently in patients treated with Prolia (< 0.1% placebo vs. 0.4% Prolia).",erysipelas is an adverse reaction entity
"Of these reports, 1 patient in the placebo group and all 8 patients in the Prolia group had serious events, including one death in the Prolia group.",patient is not a named entity
"Of these reports, 1 patient in the placebo group and all 8 patients in the Prolia group had serious events, including one death in the Prolia group.",death is an adverse reaction entity
Atypical femoral fractures most commonly occur with minimal or no trauma to the affected area.,minimal is not a named entity
Atypical femoral fractures most commonly occur with minimal or no trauma to the affected area.,Atypical femoral fractures is an adverse reaction entity
"Evaluate patients with thigh or groin pain to rule out a femoral fracture (  5.5  )   *  Serious infections including skin infections: May occur, including those leading to hospitalization.",infections is an adverse reaction entity
"Evaluate patients with thigh or groin pain to rule out a femoral fracture (  5.5  )   *  Serious infections including skin infections: May occur, including those leading to hospitalization.",with is not a named entity
"Evaluate patients with thigh or groin pain to rule out a femoral fracture (  5.5  )   *  Serious infections including skin infections: May occur, including those leading to hospitalization.",fracture is not a named entity
"Evaluate patients with thigh or groin pain to rule out a femoral fracture (  5.5  )   *  Serious infections including skin infections: May occur, including those leading to hospitalization.",skin infections is an adverse reaction entity
The incidence of opportunistic infections was similar to that reported with placebo.,opportunistic infections is an adverse reaction entity
The incidence of opportunistic infections was similar to that reported with placebo.,similar to that is not a named entity
The incidence of all-cause mortality was 0.8% (n = 1) in the placebo group and 0.8% (n = 1) in the Prolia group.,% ( n is not a named entity
The incidence of all-cause mortality was 0.8% (n = 1) in the placebo group and 0.8% (n = 1) in the Prolia group.,mortality is an adverse reaction entity
"5.7 Dermatologic Adverse Reactions      In a large clinical trial of over 7800 women with postmenopausal osteoporosis, epidermal and dermal adverse events such as dermatitis, eczema, and rashes occurred at a significantly higher rate in the Prolia group compared to the placebo group.",rashes occurred at is not a named entity
"5.7 Dermatologic Adverse Reactions      In a large clinical trial of over 7800 women with postmenopausal osteoporosis, epidermal and dermal adverse events such as dermatitis, eczema, and rashes occurred at a significantly higher rate in the Prolia group compared to the placebo group.",Reactions is not a named entity
"5.7 Dermatologic Adverse Reactions      In a large clinical trial of over 7800 women with postmenopausal osteoporosis, epidermal and dermal adverse events such as dermatitis, eczema, and rashes occurred at a significantly higher rate in the Prolia group compared to the placebo group.",rashes is an adverse reaction entity
"5.7 Dermatologic Adverse Reactions      In a large clinical trial of over 7800 women with postmenopausal osteoporosis, epidermal and dermal adverse events such as dermatitis, eczema, and rashes occurred at a significantly higher rate in the Prolia group compared to the placebo group.",5.7 Dermatologic is not a named entity
"5.7 Dermatologic Adverse Reactions      In a large clinical trial of over 7800 women with postmenopausal osteoporosis, epidermal and dermal adverse events such as dermatitis, eczema, and rashes occurred at a significantly higher rate in the Prolia group compared to the placebo group.",eczema is an adverse reaction entity
"5.7 Dermatologic Adverse Reactions      In a large clinical trial of over 7800 women with postmenopausal osteoporosis, epidermal and dermal adverse events such as dermatitis, eczema, and rashes occurred at a significantly higher rate in the Prolia group compared to the placebo group.",epidermal adverse events is an adverse reaction entity
"5.7 Dermatologic Adverse Reactions      In a large clinical trial of over 7800 women with postmenopausal osteoporosis, epidermal and dermal adverse events such as dermatitis, eczema, and rashes occurred at a significantly higher rate in the Prolia group compared to the placebo group.",Dermatologic is not a named entity
"5.7 Dermatologic Adverse Reactions      In a large clinical trial of over 7800 women with postmenopausal osteoporosis, epidermal and dermal adverse events such as dermatitis, eczema, and rashes occurred at a significantly higher rate in the Prolia group compared to the placebo group.",large clinical trial is not a named entity
"5.7 Dermatologic Adverse Reactions      In a large clinical trial of over 7800 women with postmenopausal osteoporosis, epidermal and dermal adverse events such as dermatitis, eczema, and rashes occurred at a significantly higher rate in the Prolia group compared to the placebo group.",dermal adverse events is an adverse reaction entity
"5.7 Dermatologic Adverse Reactions      In a large clinical trial of over 7800 women with postmenopausal osteoporosis, epidermal and dermal adverse events such as dermatitis, eczema, and rashes occurred at a significantly higher rate in the Prolia group compared to the placebo group.",dermatitis is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed below and also elsewhere in the labeling:     *  Hypocalcemia [see Warnings and Precautions (  5.3  )]    *  Serious Infections [see Warnings and Precautions (  5.6  )]    *  Dermatologic Adverse Reactions [see Warnings and Precautions (  5.7  )]    *  Osteonecrosis of the Jaw [see Warnings and Precautions (  5.4  )]    *  Atypical Subtrochanteric and Diaphyseal Femoral Fractures [see Warnings and Precautions (  5.5  )]       The most common adverse reactions reported with Prolia in patients with postmenopausal osteoporosis are back pain, pain in extremity, musculoskeletal pain, hypercholesterolemia, and cystitis.",pain in extremity is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed below and also elsewhere in the labeling:     *  Hypocalcemia [see Warnings and Precautions (  5.3  )]    *  Serious Infections [see Warnings and Precautions (  5.6  )]    *  Dermatologic Adverse Reactions [see Warnings and Precautions (  5.7  )]    *  Osteonecrosis of the Jaw [see Warnings and Precautions (  5.4  )]    *  Atypical Subtrochanteric and Diaphyseal Femoral Fractures [see Warnings and Precautions (  5.5  )]       The most common adverse reactions reported with Prolia in patients with postmenopausal osteoporosis are back pain, pain in extremity, musculoskeletal pain, hypercholesterolemia, and cystitis.",cystitis is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed below and also elsewhere in the labeling:     *  Hypocalcemia [see Warnings and Precautions (  5.3  )]    *  Serious Infections [see Warnings and Precautions (  5.6  )]    *  Dermatologic Adverse Reactions [see Warnings and Precautions (  5.7  )]    *  Osteonecrosis of the Jaw [see Warnings and Precautions (  5.4  )]    *  Atypical Subtrochanteric and Diaphyseal Femoral Fractures [see Warnings and Precautions (  5.5  )]       The most common adverse reactions reported with Prolia in patients with postmenopausal osteoporosis are back pain, pain in extremity, musculoskeletal pain, hypercholesterolemia, and cystitis.",and is not a named entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed below and also elsewhere in the labeling:     *  Hypocalcemia [see Warnings and Precautions (  5.3  )]    *  Serious Infections [see Warnings and Precautions (  5.6  )]    *  Dermatologic Adverse Reactions [see Warnings and Precautions (  5.7  )]    *  Osteonecrosis of the Jaw [see Warnings and Precautions (  5.4  )]    *  Atypical Subtrochanteric and Diaphyseal Femoral Fractures [see Warnings and Precautions (  5.5  )]       The most common adverse reactions reported with Prolia in patients with postmenopausal osteoporosis are back pain, pain in extremity, musculoskeletal pain, hypercholesterolemia, and cystitis.",hypercholesterolemia is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed below and also elsewhere in the labeling:     *  Hypocalcemia [see Warnings and Precautions (  5.3  )]    *  Serious Infections [see Warnings and Precautions (  5.6  )]    *  Dermatologic Adverse Reactions [see Warnings and Precautions (  5.7  )]    *  Osteonecrosis of the Jaw [see Warnings and Precautions (  5.4  )]    *  Atypical Subtrochanteric and Diaphyseal Femoral Fractures [see Warnings and Precautions (  5.5  )]       The most common adverse reactions reported with Prolia in patients with postmenopausal osteoporosis are back pain, pain in extremity, musculoskeletal pain, hypercholesterolemia, and cystitis.",with is not a named entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed below and also elsewhere in the labeling:     *  Hypocalcemia [see Warnings and Precautions (  5.3  )]    *  Serious Infections [see Warnings and Precautions (  5.6  )]    *  Dermatologic Adverse Reactions [see Warnings and Precautions (  5.7  )]    *  Osteonecrosis of the Jaw [see Warnings and Precautions (  5.4  )]    *  Atypical Subtrochanteric and Diaphyseal Femoral Fractures [see Warnings and Precautions (  5.5  )]       The most common adverse reactions reported with Prolia in patients with postmenopausal osteoporosis are back pain, pain in extremity, musculoskeletal pain, hypercholesterolemia, and cystitis.",Hypocalcemia is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed below and also elsewhere in the labeling:     *  Hypocalcemia [see Warnings and Precautions (  5.3  )]    *  Serious Infections [see Warnings and Precautions (  5.6  )]    *  Dermatologic Adverse Reactions [see Warnings and Precautions (  5.7  )]    *  Osteonecrosis of the Jaw [see Warnings and Precautions (  5.4  )]    *  Atypical Subtrochanteric and Diaphyseal Femoral Fractures [see Warnings and Precautions (  5.5  )]       The most common adverse reactions reported with Prolia in patients with postmenopausal osteoporosis are back pain, pain in extremity, musculoskeletal pain, hypercholesterolemia, and cystitis.",Precautions ( 5.4 is not a named entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed below and also elsewhere in the labeling:     *  Hypocalcemia [see Warnings and Precautions (  5.3  )]    *  Serious Infections [see Warnings and Precautions (  5.6  )]    *  Dermatologic Adverse Reactions [see Warnings and Precautions (  5.7  )]    *  Osteonecrosis of the Jaw [see Warnings and Precautions (  5.4  )]    *  Atypical Subtrochanteric and Diaphyseal Femoral Fractures [see Warnings and Precautions (  5.5  )]       The most common adverse reactions reported with Prolia in patients with postmenopausal osteoporosis are back pain, pain in extremity, musculoskeletal pain, hypercholesterolemia, and cystitis.",and is not a named entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed below and also elsewhere in the labeling:     *  Hypocalcemia [see Warnings and Precautions (  5.3  )]    *  Serious Infections [see Warnings and Precautions (  5.6  )]    *  Dermatologic Adverse Reactions [see Warnings and Precautions (  5.7  )]    *  Osteonecrosis of the Jaw [see Warnings and Precautions (  5.4  )]    *  Atypical Subtrochanteric and Diaphyseal Femoral Fractures [see Warnings and Precautions (  5.5  )]       The most common adverse reactions reported with Prolia in patients with postmenopausal osteoporosis are back pain, pain in extremity, musculoskeletal pain, hypercholesterolemia, and cystitis.",] is not a named entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed below and also elsewhere in the labeling:     *  Hypocalcemia [see Warnings and Precautions (  5.3  )]    *  Serious Infections [see Warnings and Precautions (  5.6  )]    *  Dermatologic Adverse Reactions [see Warnings and Precautions (  5.7  )]    *  Osteonecrosis of the Jaw [see Warnings and Precautions (  5.4  )]    *  Atypical Subtrochanteric and Diaphyseal Femoral Fractures [see Warnings and Precautions (  5.5  )]       The most common adverse reactions reported with Prolia in patients with postmenopausal osteoporosis are back pain, pain in extremity, musculoskeletal pain, hypercholesterolemia, and cystitis.",Warnings and is not a named entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed below and also elsewhere in the labeling:     *  Hypocalcemia [see Warnings and Precautions (  5.3  )]    *  Serious Infections [see Warnings and Precautions (  5.6  )]    *  Dermatologic Adverse Reactions [see Warnings and Precautions (  5.7  )]    *  Osteonecrosis of the Jaw [see Warnings and Precautions (  5.4  )]    *  Atypical Subtrochanteric and Diaphyseal Femoral Fractures [see Warnings and Precautions (  5.5  )]       The most common adverse reactions reported with Prolia in patients with postmenopausal osteoporosis are back pain, pain in extremity, musculoskeletal pain, hypercholesterolemia, and cystitis.",are back is not a named entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed below and also elsewhere in the labeling:     *  Hypocalcemia [see Warnings and Precautions (  5.3  )]    *  Serious Infections [see Warnings and Precautions (  5.6  )]    *  Dermatologic Adverse Reactions [see Warnings and Precautions (  5.7  )]    *  Osteonecrosis of the Jaw [see Warnings and Precautions (  5.4  )]    *  Atypical Subtrochanteric and Diaphyseal Femoral Fractures [see Warnings and Precautions (  5.5  )]       The most common adverse reactions reported with Prolia in patients with postmenopausal osteoporosis are back pain, pain in extremity, musculoskeletal pain, hypercholesterolemia, and cystitis.",Atypical Diaphyseal Femoral Fractures is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed below and also elsewhere in the labeling:     *  Hypocalcemia [see Warnings and Precautions (  5.3  )]    *  Serious Infections [see Warnings and Precautions (  5.6  )]    *  Dermatologic Adverse Reactions [see Warnings and Precautions (  5.7  )]    *  Osteonecrosis of the Jaw [see Warnings and Precautions (  5.4  )]    *  Atypical Subtrochanteric and Diaphyseal Femoral Fractures [see Warnings and Precautions (  5.5  )]       The most common adverse reactions reported with Prolia in patients with postmenopausal osteoporosis are back pain, pain in extremity, musculoskeletal pain, hypercholesterolemia, and cystitis.",see Warnings is not a named entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed below and also elsewhere in the labeling:     *  Hypocalcemia [see Warnings and Precautions (  5.3  )]    *  Serious Infections [see Warnings and Precautions (  5.6  )]    *  Dermatologic Adverse Reactions [see Warnings and Precautions (  5.7  )]    *  Osteonecrosis of the Jaw [see Warnings and Precautions (  5.4  )]    *  Atypical Subtrochanteric and Diaphyseal Femoral Fractures [see Warnings and Precautions (  5.5  )]       The most common adverse reactions reported with Prolia in patients with postmenopausal osteoporosis are back pain, pain in extremity, musculoskeletal pain, hypercholesterolemia, and cystitis.",Osteonecrosis of the Jaw is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed below and also elsewhere in the labeling:     *  Hypocalcemia [see Warnings and Precautions (  5.3  )]    *  Serious Infections [see Warnings and Precautions (  5.6  )]    *  Dermatologic Adverse Reactions [see Warnings and Precautions (  5.7  )]    *  Osteonecrosis of the Jaw [see Warnings and Precautions (  5.4  )]    *  Atypical Subtrochanteric and Diaphyseal Femoral Fractures [see Warnings and Precautions (  5.5  )]       The most common adverse reactions reported with Prolia in patients with postmenopausal osteoporosis are back pain, pain in extremity, musculoskeletal pain, hypercholesterolemia, and cystitis.",) is not a named entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed below and also elsewhere in the labeling:     *  Hypocalcemia [see Warnings and Precautions (  5.3  )]    *  Serious Infections [see Warnings and Precautions (  5.6  )]    *  Dermatologic Adverse Reactions [see Warnings and Precautions (  5.7  )]    *  Osteonecrosis of the Jaw [see Warnings and Precautions (  5.4  )]    *  Atypical Subtrochanteric and Diaphyseal Femoral Fractures [see Warnings and Precautions (  5.5  )]       The most common adverse reactions reported with Prolia in patients with postmenopausal osteoporosis are back pain, pain in extremity, musculoskeletal pain, hypercholesterolemia, and cystitis.",Dermatologic Adverse Reactions is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed below and also elsewhere in the labeling:     *  Hypocalcemia [see Warnings and Precautions (  5.3  )]    *  Serious Infections [see Warnings and Precautions (  5.6  )]    *  Dermatologic Adverse Reactions [see Warnings and Precautions (  5.7  )]    *  Osteonecrosis of the Jaw [see Warnings and Precautions (  5.4  )]    *  Atypical Subtrochanteric and Diaphyseal Femoral Fractures [see Warnings and Precautions (  5.5  )]       The most common adverse reactions reported with Prolia in patients with postmenopausal osteoporosis are back pain, pain in extremity, musculoskeletal pain, hypercholesterolemia, and cystitis.",back pain is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed below and also elsewhere in the labeling:     *  Hypocalcemia [see Warnings and Precautions (  5.3  )]    *  Serious Infections [see Warnings and Precautions (  5.6  )]    *  Dermatologic Adverse Reactions [see Warnings and Precautions (  5.7  )]    *  Osteonecrosis of the Jaw [see Warnings and Precautions (  5.4  )]    *  Atypical Subtrochanteric and Diaphyseal Femoral Fractures [see Warnings and Precautions (  5.5  )]       The most common adverse reactions reported with Prolia in patients with postmenopausal osteoporosis are back pain, pain in extremity, musculoskeletal pain, hypercholesterolemia, and cystitis.",Atypical Subtrochanteric Femoral Fractures is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed below and also elsewhere in the labeling:     *  Hypocalcemia [see Warnings and Precautions (  5.3  )]    *  Serious Infections [see Warnings and Precautions (  5.6  )]    *  Dermatologic Adverse Reactions [see Warnings and Precautions (  5.7  )]    *  Osteonecrosis of the Jaw [see Warnings and Precautions (  5.4  )]    *  Atypical Subtrochanteric and Diaphyseal Femoral Fractures [see Warnings and Precautions (  5.5  )]       The most common adverse reactions reported with Prolia in patients with postmenopausal osteoporosis are back pain, pain in extremity, musculoskeletal pain, hypercholesterolemia, and cystitis.",musculoskeletal pain is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed below and also elsewhere in the labeling:     *  Hypocalcemia [see Warnings and Precautions (  5.3  )]    *  Serious Infections [see Warnings and Precautions (  5.6  )]    *  Dermatologic Adverse Reactions [see Warnings and Precautions (  5.7  )]    *  Osteonecrosis of the Jaw [see Warnings and Precautions (  5.4  )]    *  Atypical Subtrochanteric and Diaphyseal Femoral Fractures [see Warnings and Precautions (  5.5  )]       The most common adverse reactions reported with Prolia in patients with postmenopausal osteoporosis are back pain, pain in extremity, musculoskeletal pain, hypercholesterolemia, and cystitis.",elsewhere in is not a named entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed below and also elsewhere in the labeling:     *  Hypocalcemia [see Warnings and Precautions (  5.3  )]    *  Serious Infections [see Warnings and Precautions (  5.6  )]    *  Dermatologic Adverse Reactions [see Warnings and Precautions (  5.7  )]    *  Osteonecrosis of the Jaw [see Warnings and Precautions (  5.4  )]    *  Atypical Subtrochanteric and Diaphyseal Femoral Fractures [see Warnings and Precautions (  5.5  )]       The most common adverse reactions reported with Prolia in patients with postmenopausal osteoporosis are back pain, pain in extremity, musculoskeletal pain, hypercholesterolemia, and cystitis.",Infections is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed below and also elsewhere in the labeling:     *  Hypocalcemia [see Warnings and Precautions (  5.3  )]    *  Serious Infections [see Warnings and Precautions (  5.6  )]    *  Dermatologic Adverse Reactions [see Warnings and Precautions (  5.7  )]    *  Osteonecrosis of the Jaw [see Warnings and Precautions (  5.4  )]    *  Atypical Subtrochanteric and Diaphyseal Femoral Fractures [see Warnings and Precautions (  5.5  )]       The most common adverse reactions reported with Prolia in patients with postmenopausal osteoporosis are back pain, pain in extremity, musculoskeletal pain, hypercholesterolemia, and cystitis.",below and also is not a named entity
5.2 Hypersensitivity      Clinically significant hypersensitivity including anaphylaxis has been reported with Prolia.,hypersensitivity is an adverse reaction entity
5.2 Hypersensitivity      Clinically significant hypersensitivity including anaphylaxis has been reported with Prolia.,anaphylaxis is an adverse reaction entity
5.2 Hypersensitivity      Clinically significant hypersensitivity including anaphylaxis has been reported with Prolia.,Clinically significant hypersensitivity is not a named entity
5.2 Hypersensitivity      Clinically significant hypersensitivity including anaphylaxis has been reported with Prolia.,5.2 Hypersensitivity Clinically is not a named entity
"Consider discontinuing Prolia if severe symptoms develop (  5.7  )   *  Severe Bone, Joint, Muscle Pain may occur.",Bone Pain is an adverse reaction entity
"Consider discontinuing Prolia if severe symptoms develop (  5.7  )   *  Severe Bone, Joint, Muscle Pain may occur.",discontinuing Prolia if is not a named entity
"Consider discontinuing Prolia if severe symptoms develop (  5.7  )   *  Severe Bone, Joint, Muscle Pain may occur.",severe symptoms develop is not a named entity
"Consider discontinuing Prolia if severe symptoms develop (  5.7  )   *  Severe Bone, Joint, Muscle Pain may occur.",Muscle Pain is an adverse reaction entity
"Consider discontinuing Prolia if severe symptoms develop (  5.7  )   *  Severe Bone, Joint, Muscle Pain may occur.",Joint Pain is an adverse reaction entity
"Consider discontinuing Prolia if severe symptoms develop (  5.7  )   *  Severe Bone, Joint, Muscle Pain may occur.",( 5.7 is not a named entity
Hypocalcemia (serum calcium < 8.4 mg/dL) was reported only in Prolia-treated patients (2.4% vs. 0%) at the month 1 visit.,was reported only is not a named entity
Hypocalcemia (serum calcium < 8.4 mg/dL) was reported only in Prolia-treated patients (2.4% vs. 0%) at the month 1 visit.,Hypocalcemia is an adverse reaction entity
5.3 Hypocalcemia and Mineral Metabolism       Hypocalcemia may be exacerbated by the use of Prolia.,exacerbated by is not a named entity
5.3 Hypocalcemia and Mineral Metabolism       Hypocalcemia may be exacerbated by the use of Prolia.,Hypocalcemia exacerbated is an adverse reaction entity
"Dermatologic Reactions  A significantly higher number of patients treated with Prolia developed epidermal and dermal adverse events (such as dermatitis, eczema, and rashes), with these events reported in 8.2% of the placebo and 10.8% of the Prolia groups (p < 0.0001).",of is not a named entity
"Dermatologic Reactions  A significantly higher number of patients treated with Prolia developed epidermal and dermal adverse events (such as dermatitis, eczema, and rashes), with these events reported in 8.2% of the placebo and 10.8% of the Prolia groups (p < 0.0001).",dermatitis is an adverse reaction entity
"Dermatologic Reactions  A significantly higher number of patients treated with Prolia developed epidermal and dermal adverse events (such as dermatitis, eczema, and rashes), with these events reported in 8.2% of the placebo and 10.8% of the Prolia groups (p < 0.0001).",such as dermatitis is not a named entity
"Dermatologic Reactions  A significantly higher number of patients treated with Prolia developed epidermal and dermal adverse events (such as dermatitis, eczema, and rashes), with these events reported in 8.2% of the placebo and 10.8% of the Prolia groups (p < 0.0001).",and dermal adverse is not a named entity
"Dermatologic Reactions  A significantly higher number of patients treated with Prolia developed epidermal and dermal adverse events (such as dermatitis, eczema, and rashes), with these events reported in 8.2% of the placebo and 10.8% of the Prolia groups (p < 0.0001).",eczema is an adverse reaction entity
"Dermatologic Reactions  A significantly higher number of patients treated with Prolia developed epidermal and dermal adverse events (such as dermatitis, eczema, and rashes), with these events reported in 8.2% of the placebo and 10.8% of the Prolia groups (p < 0.0001).","dermatitis , eczema is not a named entity"
"Dermatologic Reactions  A significantly higher number of patients treated with Prolia developed epidermal and dermal adverse events (such as dermatitis, eczema, and rashes), with these events reported in 8.2% of the placebo and 10.8% of the Prolia groups (p < 0.0001).",Prolia groups is not a named entity
"Dermatologic Reactions  A significantly higher number of patients treated with Prolia developed epidermal and dermal adverse events (such as dermatitis, eczema, and rashes), with these events reported in 8.2% of the placebo and 10.8% of the Prolia groups (p < 0.0001).",dermal adverse events is an adverse reaction entity
"Dermatologic Reactions  A significantly higher number of patients treated with Prolia developed epidermal and dermal adverse events (such as dermatitis, eczema, and rashes), with these events reported in 8.2% of the placebo and 10.8% of the Prolia groups (p < 0.0001).",epidermal adverse events is an adverse reaction entity
"Dermatologic Reactions  A significantly higher number of patients treated with Prolia developed epidermal and dermal adverse events (such as dermatitis, eczema, and rashes), with these events reported in 8.2% of the placebo and 10.8% of the Prolia groups (p < 0.0001).",rashes is an adverse reaction entity
"The following adverse reactions have been identified during post approval use of Prolia:     *  Drug-related hypersensitivity reactions: anaphylaxis, rash, urticaria, facial swelling, and erythema     *  Hypocalcemia: severe symptomatic hypocalcemia   *  Musculoskeletal pain, including severe cases   *  Parathyroid Hormone (PTH): Marked elevation in serum PTH in patients with severe renal impairment (creatinine clearance < 30 mL/min) or receiving dialysis.",with severe renal is not a named entity
"The following adverse reactions have been identified during post approval use of Prolia:     *  Drug-related hypersensitivity reactions: anaphylaxis, rash, urticaria, facial swelling, and erythema     *  Hypocalcemia: severe symptomatic hypocalcemia   *  Musculoskeletal pain, including severe cases   *  Parathyroid Hormone (PTH): Marked elevation in serum PTH in patients with severe renal impairment (creatinine clearance < 30 mL/min) or receiving dialysis.",rash is an adverse reaction entity
"The following adverse reactions have been identified during post approval use of Prolia:     *  Drug-related hypersensitivity reactions: anaphylaxis, rash, urticaria, facial swelling, and erythema     *  Hypocalcemia: severe symptomatic hypocalcemia   *  Musculoskeletal pain, including severe cases   *  Parathyroid Hormone (PTH): Marked elevation in serum PTH in patients with severe renal impairment (creatinine clearance < 30 mL/min) or receiving dialysis.",urticaria is an adverse reaction entity
"The following adverse reactions have been identified during post approval use of Prolia:     *  Drug-related hypersensitivity reactions: anaphylaxis, rash, urticaria, facial swelling, and erythema     *  Hypocalcemia: severe symptomatic hypocalcemia   *  Musculoskeletal pain, including severe cases   *  Parathyroid Hormone (PTH): Marked elevation in serum PTH in patients with severe renal impairment (creatinine clearance < 30 mL/min) or receiving dialysis.",PTH in is not a named entity
"The following adverse reactions have been identified during post approval use of Prolia:     *  Drug-related hypersensitivity reactions: anaphylaxis, rash, urticaria, facial swelling, and erythema     *  Hypocalcemia: severe symptomatic hypocalcemia   *  Musculoskeletal pain, including severe cases   *  Parathyroid Hormone (PTH): Marked elevation in serum PTH in patients with severe renal impairment (creatinine clearance < 30 mL/min) or receiving dialysis.",) or is not a named entity
"The following adverse reactions have been identified during post approval use of Prolia:     *  Drug-related hypersensitivity reactions: anaphylaxis, rash, urticaria, facial swelling, and erythema     *  Hypocalcemia: severe symptomatic hypocalcemia   *  Musculoskeletal pain, including severe cases   *  Parathyroid Hormone (PTH): Marked elevation in serum PTH in patients with severe renal impairment (creatinine clearance < 30 mL/min) or receiving dialysis.",anaphylaxis is an adverse reaction entity
"The following adverse reactions have been identified during post approval use of Prolia:     *  Drug-related hypersensitivity reactions: anaphylaxis, rash, urticaria, facial swelling, and erythema     *  Hypocalcemia: severe symptomatic hypocalcemia   *  Musculoskeletal pain, including severe cases   *  Parathyroid Hormone (PTH): Marked elevation in serum PTH in patients with severe renal impairment (creatinine clearance < 30 mL/min) or receiving dialysis.",erythema is an adverse reaction entity
"The following adverse reactions have been identified during post approval use of Prolia:     *  Drug-related hypersensitivity reactions: anaphylaxis, rash, urticaria, facial swelling, and erythema     *  Hypocalcemia: severe symptomatic hypocalcemia   *  Musculoskeletal pain, including severe cases   *  Parathyroid Hormone (PTH): Marked elevation in serum PTH in patients with severe renal impairment (creatinine clearance < 30 mL/min) or receiving dialysis.",use of Prolia is not a named entity
"The following adverse reactions have been identified during post approval use of Prolia:     *  Drug-related hypersensitivity reactions: anaphylaxis, rash, urticaria, facial swelling, and erythema     *  Hypocalcemia: severe symptomatic hypocalcemia   *  Musculoskeletal pain, including severe cases   *  Parathyroid Hormone (PTH): Marked elevation in serum PTH in patients with severe renal impairment (creatinine clearance < 30 mL/min) or receiving dialysis.",serum is not a named entity
"The following adverse reactions have been identified during post approval use of Prolia:     *  Drug-related hypersensitivity reactions: anaphylaxis, rash, urticaria, facial swelling, and erythema     *  Hypocalcemia: severe symptomatic hypocalcemia   *  Musculoskeletal pain, including severe cases   *  Parathyroid Hormone (PTH): Marked elevation in serum PTH in patients with severe renal impairment (creatinine clearance < 30 mL/min) or receiving dialysis.",", rash is not a named entity"
"The following adverse reactions have been identified during post approval use of Prolia:     *  Drug-related hypersensitivity reactions: anaphylaxis, rash, urticaria, facial swelling, and erythema     *  Hypocalcemia: severe symptomatic hypocalcemia   *  Musculoskeletal pain, including severe cases   *  Parathyroid Hormone (PTH): Marked elevation in serum PTH in patients with severe renal impairment (creatinine clearance < 30 mL/min) or receiving dialysis.",facial swelling is an adverse reaction entity
"The following adverse reactions have been identified during post approval use of Prolia:     *  Drug-related hypersensitivity reactions: anaphylaxis, rash, urticaria, facial swelling, and erythema     *  Hypocalcemia: severe symptomatic hypocalcemia   *  Musculoskeletal pain, including severe cases   *  Parathyroid Hormone (PTH): Marked elevation in serum PTH in patients with severe renal impairment (creatinine clearance < 30 mL/min) or receiving dialysis.","rash , is not a named entity"
"The following adverse reactions have been identified during post approval use of Prolia:     *  Drug-related hypersensitivity reactions: anaphylaxis, rash, urticaria, facial swelling, and erythema     *  Hypocalcemia: severe symptomatic hypocalcemia   *  Musculoskeletal pain, including severe cases   *  Parathyroid Hormone (PTH): Marked elevation in serum PTH in patients with severe renal impairment (creatinine clearance < 30 mL/min) or receiving dialysis.",and erythema is not a named entity
"The following adverse reactions have been identified during post approval use of Prolia:     *  Drug-related hypersensitivity reactions: anaphylaxis, rash, urticaria, facial swelling, and erythema     *  Hypocalcemia: severe symptomatic hypocalcemia   *  Musculoskeletal pain, including severe cases   *  Parathyroid Hormone (PTH): Marked elevation in serum PTH in patients with severe renal impairment (creatinine clearance < 30 mL/min) or receiving dialysis.",hypersensitivity reactions is an adverse reaction entity
"The following adverse reactions have been identified during post approval use of Prolia:     *  Drug-related hypersensitivity reactions: anaphylaxis, rash, urticaria, facial swelling, and erythema     *  Hypocalcemia: severe symptomatic hypocalcemia   *  Musculoskeletal pain, including severe cases   *  Parathyroid Hormone (PTH): Marked elevation in serum PTH in patients with severe renal impairment (creatinine clearance < 30 mL/min) or receiving dialysis.",hypocalcemia is an adverse reaction entity
"The following adverse reactions have been identified during post approval use of Prolia:     *  Drug-related hypersensitivity reactions: anaphylaxis, rash, urticaria, facial swelling, and erythema     *  Hypocalcemia: severe symptomatic hypocalcemia   *  Musculoskeletal pain, including severe cases   *  Parathyroid Hormone (PTH): Marked elevation in serum PTH in patients with severe renal impairment (creatinine clearance < 30 mL/min) or receiving dialysis.",elevation in serum PTH is an adverse reaction entity
"The following adverse reactions have been identified during post approval use of Prolia:     *  Drug-related hypersensitivity reactions: anaphylaxis, rash, urticaria, facial swelling, and erythema     *  Hypocalcemia: severe symptomatic hypocalcemia   *  Musculoskeletal pain, including severe cases   *  Parathyroid Hormone (PTH): Marked elevation in serum PTH in patients with severe renal impairment (creatinine clearance < 30 mL/min) or receiving dialysis.",Musculoskeletal pain is an adverse reaction entity
"The following adverse reactions have been identified during post approval use of Prolia:     *  Drug-related hypersensitivity reactions: anaphylaxis, rash, urticaria, facial swelling, and erythema     *  Hypocalcemia: severe symptomatic hypocalcemia   *  Musculoskeletal pain, including severe cases   *  Parathyroid Hormone (PTH): Marked elevation in serum PTH in patients with severe renal impairment (creatinine clearance < 30 mL/min) or receiving dialysis.",Hypocalcemia : is not a named entity
"The following adverse reactions have been identified during post approval use of Prolia:     *  Drug-related hypersensitivity reactions: anaphylaxis, rash, urticaria, facial swelling, and erythema     *  Hypocalcemia: severe symptomatic hypocalcemia   *  Musculoskeletal pain, including severe cases   *  Parathyroid Hormone (PTH): Marked elevation in serum PTH in patients with severe renal impairment (creatinine clearance < 30 mL/min) or receiving dialysis.",PTH in is not a named entity
"The following adverse reactions have been identified during post approval use of Prolia:     *  Drug-related hypersensitivity reactions: anaphylaxis, rash, urticaria, facial swelling, and erythema     *  Hypocalcemia: severe symptomatic hypocalcemia   *  Musculoskeletal pain, including severe cases   *  Parathyroid Hormone (PTH): Marked elevation in serum PTH in patients with severe renal impairment (creatinine clearance < 30 mL/min) or receiving dialysis.",symptomatic hypocalcemia is an adverse reaction entity
"The following adverse reactions have been identified during post approval use of Prolia:     *  Drug-related hypersensitivity reactions: anaphylaxis, rash, urticaria, facial swelling, and erythema     *  Hypocalcemia: severe symptomatic hypocalcemia   *  Musculoskeletal pain, including severe cases   *  Parathyroid Hormone (PTH): Marked elevation in serum PTH in patients with severe renal impairment (creatinine clearance < 30 mL/min) or receiving dialysis.",Hypocalcemia is an adverse reaction entity
"The following adverse reactions have been identified during post approval use of Prolia:     *  Drug-related hypersensitivity reactions: anaphylaxis, rash, urticaria, facial swelling, and erythema     *  Hypocalcemia: severe symptomatic hypocalcemia   *  Musculoskeletal pain, including severe cases   *  Parathyroid Hormone (PTH): Marked elevation in serum PTH in patients with severe renal impairment (creatinine clearance < 30 mL/min) or receiving dialysis.",or receiving is not a named entity
"Advise patients to seek prompt medical attention if they develop signs or symptoms of infection, including cellulitis (  5.6  )   *  Dermatologic reactions: Dermatitis, rashes, and eczema have been reported.",Dermatitis is an adverse reaction entity
"Advise patients to seek prompt medical attention if they develop signs or symptoms of infection, including cellulitis (  5.6  )   *  Dermatologic reactions: Dermatitis, rashes, and eczema have been reported.",patients is not a named entity
"Advise patients to seek prompt medical attention if they develop signs or symptoms of infection, including cellulitis (  5.6  )   *  Dermatologic reactions: Dermatitis, rashes, and eczema have been reported.",seek prompt is not a named entity
"Advise patients to seek prompt medical attention if they develop signs or symptoms of infection, including cellulitis (  5.6  )   *  Dermatologic reactions: Dermatitis, rashes, and eczema have been reported.",rashes is an adverse reaction entity
"Advise patients to seek prompt medical attention if they develop signs or symptoms of infection, including cellulitis (  5.6  )   *  Dermatologic reactions: Dermatitis, rashes, and eczema have been reported.",if is not a named entity
"Advise patients to seek prompt medical attention if they develop signs or symptoms of infection, including cellulitis (  5.6  )   *  Dermatologic reactions: Dermatitis, rashes, and eczema have been reported.",reactions : Dermatitis is not a named entity
"Advise patients to seek prompt medical attention if they develop signs or symptoms of infection, including cellulitis (  5.6  )   *  Dermatologic reactions: Dermatitis, rashes, and eczema have been reported.",eczema is an adverse reaction entity
"Advise patients to seek prompt medical attention if they develop signs or symptoms of infection, including cellulitis (  5.6  )   *  Dermatologic reactions: Dermatitis, rashes, and eczema have been reported.",Dermatologic reactions is an adverse reaction entity
Discontinue use if severe symptoms develop (  5.8  )   *  Suppression of bone turnover: Significant suppression has been demonstrated.,Suppression of bone turnover is an adverse reaction entity
Discontinue use if severe symptoms develop (  5.8  )   *  Suppression of bone turnover: Significant suppression has been demonstrated.,: Significant is not a named entity
Adequately supplement patients with calcium and vitamin D (  5.3  )   *  Osteonecrosis of the jaw: Has been reported with Prolia.,Osteonecrosis of the jaw is an adverse reaction entity
Adequately supplement patients with calcium and vitamin D (  5.3  )   *  Osteonecrosis of the jaw: Has been reported with Prolia.,patients with is not a named entity
"Pancreatitis has been reported in clinical trials (  6.1  )   *  Male Osteoporosis: Most common adverse reactions (> 5% and more common than placebo) were: back pain, arthralgia, and nasopharyngitis (  6.1  )   *  Bone loss due to hormone ablation for cancer: Most common adverse reactions (>= 10% and more common than placebo) were: arthralgia and back pain.",ablation is not a named entity
"Pancreatitis has been reported in clinical trials (  6.1  )   *  Male Osteoporosis: Most common adverse reactions (> 5% and more common than placebo) were: back pain, arthralgia, and nasopharyngitis (  6.1  )   *  Bone loss due to hormone ablation for cancer: Most common adverse reactions (>= 10% and more common than placebo) were: arthralgia and back pain.",= 10 is not a named entity
"Pancreatitis has been reported in clinical trials (  6.1  )   *  Male Osteoporosis: Most common adverse reactions (> 5% and more common than placebo) were: back pain, arthralgia, and nasopharyngitis (  6.1  )   *  Bone loss due to hormone ablation for cancer: Most common adverse reactions (>= 10% and more common than placebo) were: arthralgia and back pain.",pain is not a named entity
"Pancreatitis has been reported in clinical trials (  6.1  )   *  Male Osteoporosis: Most common adverse reactions (> 5% and more common than placebo) were: back pain, arthralgia, and nasopharyngitis (  6.1  )   *  Bone loss due to hormone ablation for cancer: Most common adverse reactions (>= 10% and more common than placebo) were: arthralgia and back pain.",nasopharyngitis is an adverse reaction entity
"Pancreatitis has been reported in clinical trials (  6.1  )   *  Male Osteoporosis: Most common adverse reactions (> 5% and more common than placebo) were: back pain, arthralgia, and nasopharyngitis (  6.1  )   *  Bone loss due to hormone ablation for cancer: Most common adverse reactions (>= 10% and more common than placebo) were: arthralgia and back pain.",common adverse reactions is not a named entity
"Pancreatitis has been reported in clinical trials (  6.1  )   *  Male Osteoporosis: Most common adverse reactions (> 5% and more common than placebo) were: back pain, arthralgia, and nasopharyngitis (  6.1  )   *  Bone loss due to hormone ablation for cancer: Most common adverse reactions (>= 10% and more common than placebo) were: arthralgia and back pain.",Pancreatitis is an adverse reaction entity
"Pancreatitis has been reported in clinical trials (  6.1  )   *  Male Osteoporosis: Most common adverse reactions (> 5% and more common than placebo) were: back pain, arthralgia, and nasopharyngitis (  6.1  )   *  Bone loss due to hormone ablation for cancer: Most common adverse reactions (>= 10% and more common than placebo) were: arthralgia and back pain.",were is not a named entity
"Pancreatitis has been reported in clinical trials (  6.1  )   *  Male Osteoporosis: Most common adverse reactions (> 5% and more common than placebo) were: back pain, arthralgia, and nasopharyngitis (  6.1  )   *  Bone loss due to hormone ablation for cancer: Most common adverse reactions (>= 10% and more common than placebo) were: arthralgia and back pain.",arthralgia is an adverse reaction entity
"Pancreatitis has been reported in clinical trials (  6.1  )   *  Male Osteoporosis: Most common adverse reactions (> 5% and more common than placebo) were: back pain, arthralgia, and nasopharyngitis (  6.1  )   *  Bone loss due to hormone ablation for cancer: Most common adverse reactions (>= 10% and more common than placebo) were: arthralgia and back pain.",arthralgia is an adverse reaction entity
"Pancreatitis has been reported in clinical trials (  6.1  )   *  Male Osteoporosis: Most common adverse reactions (> 5% and more common than placebo) were: back pain, arthralgia, and nasopharyngitis (  6.1  )   *  Bone loss due to hormone ablation for cancer: Most common adverse reactions (>= 10% and more common than placebo) were: arthralgia and back pain.",Male Osteoporosis : is not a named entity
"Pancreatitis has been reported in clinical trials (  6.1  )   *  Male Osteoporosis: Most common adverse reactions (> 5% and more common than placebo) were: back pain, arthralgia, and nasopharyngitis (  6.1  )   *  Bone loss due to hormone ablation for cancer: Most common adverse reactions (>= 10% and more common than placebo) were: arthralgia and back pain.",back pain is an adverse reaction entity
"Pancreatitis has been reported in clinical trials (  6.1  )   *  Male Osteoporosis: Most common adverse reactions (> 5% and more common than placebo) were: back pain, arthralgia, and nasopharyngitis (  6.1  )   *  Bone loss due to hormone ablation for cancer: Most common adverse reactions (>= 10% and more common than placebo) were: arthralgia and back pain.",back pain is an adverse reaction entity
Discontinue permanently if a clinically significant reaction occurs (  5.2  )   *  Hypocalcemia: Must be corrected before initiating Prolia.,Hypocalcemia is an adverse reaction entity
Discontinue permanently if a clinically significant reaction occurs (  5.2  )   *  Hypocalcemia: Must be corrected before initiating Prolia.,a clinically is not a named entity
The duration of Prolia exposure to time of atypical femoral fracture diagnosis was as early as 21/2 years  [see Warnings and Precautions (  5.5  )]  .,Precautions ( is not a named entity
The duration of Prolia exposure to time of atypical femoral fracture diagnosis was as early as 21/2 years  [see Warnings and Precautions (  5.5  )]  .,atypical femoral fracture is an adverse reaction entity
"In some postmarketing cases, hypocalcemia persisted for weeks or months and required frequent monitoring and intravenous and/or oral calcium replacement, with or without vitamin D.       Hypocalcemia following Prolia administration is a significant risk in patients with severe renal impairment [creatinine clearance < 30 mL/min] or receiving dialysis.",Hypocalcemia is an adverse reaction entity
"In some postmarketing cases, hypocalcemia persisted for weeks or months and required frequent monitoring and intravenous and/or oral calcium replacement, with or without vitamin D.       Hypocalcemia following Prolia administration is a significant risk in patients with severe renal impairment [creatinine clearance < 30 mL/min] or receiving dialysis.",and/or oral is not a named entity
"In some postmarketing cases, hypocalcemia persisted for weeks or months and required frequent monitoring and intravenous and/or oral calcium replacement, with or without vitamin D.       Hypocalcemia following Prolia administration is a significant risk in patients with severe renal impairment [creatinine clearance < 30 mL/min] or receiving dialysis.",with severe is not a named entity
"In some postmarketing cases, hypocalcemia persisted for weeks or months and required frequent monitoring and intravenous and/or oral calcium replacement, with or without vitamin D.       Hypocalcemia following Prolia administration is a significant risk in patients with severe renal impairment [creatinine clearance < 30 mL/min] or receiving dialysis.",hypocalcemia is an adverse reaction entity
Osteonecrosis of the Jaw  ONJ has been reported in the osteoporosis clinical trial program in patients treated with Prolia  [see Warnings and Precautions (  5.4  )].,Osteonecrosis of the Jaw is an adverse reaction entity
Osteonecrosis of the Jaw  ONJ has been reported in the osteoporosis clinical trial program in patients treated with Prolia  [see Warnings and Precautions (  5.4  )].,in the osteoporosis is not a named entity
Osteonecrosis of the Jaw  ONJ has been reported in the osteoporosis clinical trial program in patients treated with Prolia  [see Warnings and Precautions (  5.4  )].,ONJ is an adverse reaction entity
Osteonecrosis of the Jaw  ONJ has been reported in the osteoporosis clinical trial program in patients treated with Prolia  [see Warnings and Precautions (  5.4  )].,Prolia [ see is not a named entity
Monitor for symptoms (  5.4  )   *  Atypical femoral fractures: Have been reported.,: Have been is not a named entity
Monitor for symptoms (  5.4  )   *  Atypical femoral fractures: Have been reported.,Atypical femoral fractures is an adverse reaction entity
"In a study of 55 subjects with varying degrees of renal function, serum calcium levels < 7.5 mg/dL or symptomatic hypocalcemia were observed in 5 subjects.",symptomatic hypocalcemia is an adverse reaction entity
"In a study of 55 subjects with varying degrees of renal function, serum calcium levels < 7.5 mg/dL or symptomatic hypocalcemia were observed in 5 subjects.",observed in 5 is not a named entity
"New Malignancies  New malignancies were reported in no patients in the placebo group and 4 (3.3%) patients (3 prostate cancers, 1 basal cell carcinoma) in the Prolia group.",prostate cancers is an adverse reaction entity
"New Malignancies  New malignancies were reported in no patients in the placebo group and 4 (3.3%) patients (3 prostate cancers, 1 basal cell carcinoma) in the Prolia group.",carcinoma ) is not a named entity
"New Malignancies  New malignancies were reported in no patients in the placebo group and 4 (3.3%) patients (3 prostate cancers, 1 basal cell carcinoma) in the Prolia group.",basal cell carcinoma is an adverse reaction entity
"New Malignancies  New malignancies were reported in no patients in the placebo group and 4 (3.3%) patients (3 prostate cancers, 1 basal cell carcinoma) in the Prolia group.",malignancies is an adverse reaction entity
"New Malignancies  New malignancies were reported in no patients in the placebo group and 4 (3.3%) patients (3 prostate cancers, 1 basal cell carcinoma) in the Prolia group.",3.3 % is not a named entity
"New Malignancies  New malignancies were reported in no patients in the placebo group and 4 (3.3%) patients (3 prostate cancers, 1 basal cell carcinoma) in the Prolia group.",group is not a named entity
"New malignancies related to the breast (0.7% placebo vs. 0.9% Prolia), reproductive system (0.2% placebo vs. 0.5% Prolia), and gastrointestinal system (0.6% placebo vs. 0.9% Prolia) were reported.",Prolia ) is not a named entity
"New malignancies related to the breast (0.7% placebo vs. 0.9% Prolia), reproductive system (0.2% placebo vs. 0.5% Prolia), and gastrointestinal system (0.6% placebo vs. 0.9% Prolia) were reported.",malignancies to the breast is an adverse reaction entity
"New malignancies related to the breast (0.7% placebo vs. 0.9% Prolia), reproductive system (0.2% placebo vs. 0.5% Prolia), and gastrointestinal system (0.6% placebo vs. 0.9% Prolia) were reported.",malignancies to the gastrointestinal system is an adverse reaction entity
"New malignancies related to the breast (0.7% placebo vs. 0.9% Prolia), reproductive system (0.2% placebo vs. 0.5% Prolia), and gastrointestinal system (0.6% placebo vs. 0.9% Prolia) were reported.",malignancies to the reproductive system is an adverse reaction entity
"New malignancies related to the breast (0.7% placebo vs. 0.9% Prolia), reproductive system (0.2% placebo vs. 0.5% Prolia), and gastrointestinal system (0.6% placebo vs. 0.9% Prolia) were reported.",0.2 is not a named entity
"New malignancies related to the breast (0.7% placebo vs. 0.9% Prolia), reproductive system (0.2% placebo vs. 0.5% Prolia), and gastrointestinal system (0.6% placebo vs. 0.9% Prolia) were reported.",vs. is not a named entity
"Symptoms have included hypotension, dyspnea, throat tightness, facial and upper airway edema, pruritus, and urticaria.",facial edema is an adverse reaction entity
"Symptoms have included hypotension, dyspnea, throat tightness, facial and upper airway edema, pruritus, and urticaria.",", is not a named entity"
"Symptoms have included hypotension, dyspnea, throat tightness, facial and upper airway edema, pruritus, and urticaria.",", throat is not a named entity"
"Symptoms have included hypotension, dyspnea, throat tightness, facial and upper airway edema, pruritus, and urticaria.",urticaria is an adverse reaction entity
"Symptoms have included hypotension, dyspnea, throat tightness, facial and upper airway edema, pruritus, and urticaria.",upper airway edema is an adverse reaction entity
"Symptoms have included hypotension, dyspnea, throat tightness, facial and upper airway edema, pruritus, and urticaria.",pruritus is an adverse reaction entity
"Symptoms have included hypotension, dyspnea, throat tightness, facial and upper airway edema, pruritus, and urticaria.",dyspnea is an adverse reaction entity
"Symptoms have included hypotension, dyspnea, throat tightness, facial and upper airway edema, pruritus, and urticaria.",hypotension is an adverse reaction entity
"Symptoms have included hypotension, dyspnea, throat tightness, facial and upper airway edema, pruritus, and urticaria.",have included hypotension is not a named entity
"Symptoms have included hypotension, dyspnea, throat tightness, facial and upper airway edema, pruritus, and urticaria.",", throat tightness is not a named entity"
"Symptoms have included hypotension, dyspnea, throat tightness, facial and upper airway edema, pruritus, and urticaria.","hypotension , is not a named entity"
"Symptoms have included hypotension, dyspnea, throat tightness, facial and upper airway edema, pruritus, and urticaria.",have included is not a named entity
"Symptoms have included hypotension, dyspnea, throat tightness, facial and upper airway edema, pruritus, and urticaria.","included hypotension , is not a named entity"
"Symptoms have included hypotension, dyspnea, throat tightness, facial and upper airway edema, pruritus, and urticaria.",throat tightness is an adverse reaction entity
"Adverse reactions reported in >= 5% of men with osteoporosis and more frequently with Prolia than in the placebo-treated patients were: back pain (6.7% placebo vs. 8.3% Prolia), arthralgia (5.8% placebo vs. 6.7% Prolia), and nasopharyngitis (5.8% placebo vs. 6.7% Prolia).",nasopharyngitis is an adverse reaction entity
"Adverse reactions reported in >= 5% of men with osteoporosis and more frequently with Prolia than in the placebo-treated patients were: back pain (6.7% placebo vs. 8.3% Prolia), arthralgia (5.8% placebo vs. 6.7% Prolia), and nasopharyngitis (5.8% placebo vs. 6.7% Prolia).",back pain is an adverse reaction entity
"Adverse reactions reported in >= 5% of men with osteoporosis and more frequently with Prolia than in the placebo-treated patients were: back pain (6.7% placebo vs. 8.3% Prolia), arthralgia (5.8% placebo vs. 6.7% Prolia), and nasopharyngitis (5.8% placebo vs. 6.7% Prolia).",osteoporosis and more is not a named entity
"Adverse reactions reported in >= 5% of men with osteoporosis and more frequently with Prolia than in the placebo-treated patients were: back pain (6.7% placebo vs. 8.3% Prolia), arthralgia (5.8% placebo vs. 6.7% Prolia), and nasopharyngitis (5.8% placebo vs. 6.7% Prolia).",arthralgia is an adverse reaction entity
"Adverse reactions reported in >= 5% of men with osteoporosis and more frequently with Prolia than in the placebo-treated patients were: back pain (6.7% placebo vs. 8.3% Prolia), arthralgia (5.8% placebo vs. 6.7% Prolia), and nasopharyngitis (5.8% placebo vs. 6.7% Prolia).",of men is not a named entity
"Adverse reactions reported in >= 5% of men with osteoporosis and more frequently with Prolia than in the placebo-treated patients were: back pain (6.7% placebo vs. 8.3% Prolia), arthralgia (5.8% placebo vs. 6.7% Prolia), and nasopharyngitis (5.8% placebo vs. 6.7% Prolia).",= 5 % is not a named entity
Pancreatitis  Pancreatitis was reported in 4 patients (0.1%) in the placebo and 8 patients (0.2%) in the Prolia groups.,Pancreatitis is an adverse reaction entity
Pancreatitis  Pancreatitis was reported in 4 patients (0.1%) in the placebo and 8 patients (0.2%) in the Prolia groups.,Pancreatitis was is not a named entity
"Dermatologic Reactions  Epidermal and dermal adverse events (such as dermatitis, eczema, and rashes) were reported in 4 patients (3.3%) in the placebo group and 5 patients (4.2%) in the Prolia group.",rashes is an adverse reaction entity
"Dermatologic Reactions  Epidermal and dermal adverse events (such as dermatitis, eczema, and rashes) were reported in 4 patients (3.3%) in the placebo group and 5 patients (4.2%) in the Prolia group.",", eczema , is not a named entity"
"Dermatologic Reactions  Epidermal and dermal adverse events (such as dermatitis, eczema, and rashes) were reported in 4 patients (3.3%) in the placebo group and 5 patients (4.2%) in the Prolia group.",placebo is not a named entity
"Dermatologic Reactions  Epidermal and dermal adverse events (such as dermatitis, eczema, and rashes) were reported in 4 patients (3.3%) in the placebo group and 5 patients (4.2%) in the Prolia group.",eczema is an adverse reaction entity
"Dermatologic Reactions  Epidermal and dermal adverse events (such as dermatitis, eczema, and rashes) were reported in 4 patients (3.3%) in the placebo group and 5 patients (4.2%) in the Prolia group.",dermal adverse events is an adverse reaction entity
"Dermatologic Reactions  Epidermal and dermal adverse events (such as dermatitis, eczema, and rashes) were reported in 4 patients (3.3%) in the placebo group and 5 patients (4.2%) in the Prolia group.",dermatitis is an adverse reaction entity
"Dermatologic Reactions  Epidermal and dermal adverse events (such as dermatitis, eczema, and rashes) were reported in 4 patients (3.3%) in the placebo group and 5 patients (4.2%) in the Prolia group.",( 3.3 % is not a named entity
"Dermatologic Reactions  Epidermal and dermal adverse events (such as dermatitis, eczema, and rashes) were reported in 4 patients (3.3%) in the placebo group and 5 patients (4.2%) in the Prolia group.",the Prolia is not a named entity
"Dermatologic Reactions  Epidermal and dermal adverse events (such as dermatitis, eczema, and rashes) were reported in 4 patients (3.3%) in the placebo group and 5 patients (4.2%) in the Prolia group.",% is not a named entity
"Dermatologic Reactions  Epidermal and dermal adverse events (such as dermatitis, eczema, and rashes) were reported in 4 patients (3.3%) in the placebo group and 5 patients (4.2%) in the Prolia group.",Epidermal adverse events is an adverse reaction entity
"Additionally in Prolia-treated men with nonmetastatic prostate cancer receiving ADT, a greater incidence of cataracts was observed (1.2% placebo vs. 4.7% Prolia).",cataracts is an adverse reaction entity
"Additionally in Prolia-treated men with nonmetastatic prostate cancer receiving ADT, a greater incidence of cataracts was observed (1.2% placebo vs. 4.7% Prolia).",men with nonmetastatic is not a named entity
These patients may also develop marked elevations of serum parathyroid hormone (PTH).,elevations of serum parathyroid hormone is an adverse reaction entity
These patients may also develop marked elevations of serum parathyroid hormone (PTH).,PTH is not a named entity
"5.7  Extravasation Injury      TREANDA extravasations have been reported in post marketing resulting in hospitalizations from erythema, marked swelling, and pain.",Injury is not a named entity
"5.7  Extravasation Injury      TREANDA extravasations have been reported in post marketing resulting in hospitalizations from erythema, marked swelling, and pain.",swelling is an adverse reaction entity
"5.7  Extravasation Injury      TREANDA extravasations have been reported in post marketing resulting in hospitalizations from erythema, marked swelling, and pain.",resulting is not a named entity
"5.7  Extravasation Injury      TREANDA extravasations have been reported in post marketing resulting in hospitalizations from erythema, marked swelling, and pain.",erythema is an adverse reaction entity
"5.7  Extravasation Injury      TREANDA extravasations have been reported in post marketing resulting in hospitalizations from erythema, marked swelling, and pain.",from erythema is not a named entity
"5.7  Extravasation Injury      TREANDA extravasations have been reported in post marketing resulting in hospitalizations from erythema, marked swelling, and pain.",pain is an adverse reaction entity
"5.7  Extravasation Injury      TREANDA extravasations have been reported in post marketing resulting in hospitalizations from erythema, marked swelling, and pain.",Extravasation Injury is not a named entity
"5.7  Extravasation Injury      TREANDA extravasations have been reported in post marketing resulting in hospitalizations from erythema, marked swelling, and pain.",extravasations is an adverse reaction entity
"Hematologic toxicities, based on laboratory values and CTC grade, in NHL patients treated in both single arm studies combined are described in Table 4.","grade , is not a named entity"
"Hematologic toxicities, based on laboratory values and CTC grade, in NHL patients treated in both single arm studies combined are described in Table 4.",Hematologic toxicities is an adverse reaction entity
"Other adverse reactions seen frequently in one or more studies included asthenia, fatigue, malaise, and weakness; dry mouth; somnolence; cough; constipation; headache; mucosal inflammation and stomatitis.",", and is not a named entity"
"Other adverse reactions seen frequently in one or more studies included asthenia, fatigue, malaise, and weakness; dry mouth; somnolence; cough; constipation; headache; mucosal inflammation and stomatitis.",dry mouth is an adverse reaction entity
"Other adverse reactions seen frequently in one or more studies included asthenia, fatigue, malaise, and weakness; dry mouth; somnolence; cough; constipation; headache; mucosal inflammation and stomatitis.",and is not a named entity
"Other adverse reactions seen frequently in one or more studies included asthenia, fatigue, malaise, and weakness; dry mouth; somnolence; cough; constipation; headache; mucosal inflammation and stomatitis.",", malaise is not a named entity"
"Other adverse reactions seen frequently in one or more studies included asthenia, fatigue, malaise, and weakness; dry mouth; somnolence; cough; constipation; headache; mucosal inflammation and stomatitis.",constipation is an adverse reaction entity
"Other adverse reactions seen frequently in one or more studies included asthenia, fatigue, malaise, and weakness; dry mouth; somnolence; cough; constipation; headache; mucosal inflammation and stomatitis.",fatigue is an adverse reaction entity
"Other adverse reactions seen frequently in one or more studies included asthenia, fatigue, malaise, and weakness; dry mouth; somnolence; cough; constipation; headache; mucosal inflammation and stomatitis.",; constipation is not a named entity
"Other adverse reactions seen frequently in one or more studies included asthenia, fatigue, malaise, and weakness; dry mouth; somnolence; cough; constipation; headache; mucosal inflammation and stomatitis.",studies included asthenia is not a named entity
"Other adverse reactions seen frequently in one or more studies included asthenia, fatigue, malaise, and weakness; dry mouth; somnolence; cough; constipation; headache; mucosal inflammation and stomatitis.",malaise is an adverse reaction entity
"Other adverse reactions seen frequently in one or more studies included asthenia, fatigue, malaise, and weakness; dry mouth; somnolence; cough; constipation; headache; mucosal inflammation and stomatitis.",weakness is an adverse reaction entity
"Other adverse reactions seen frequently in one or more studies included asthenia, fatigue, malaise, and weakness; dry mouth; somnolence; cough; constipation; headache; mucosal inflammation and stomatitis.",; cough is not a named entity
"Other adverse reactions seen frequently in one or more studies included asthenia, fatigue, malaise, and weakness; dry mouth; somnolence; cough; constipation; headache; mucosal inflammation and stomatitis.",constipation ; is not a named entity
"Other adverse reactions seen frequently in one or more studies included asthenia, fatigue, malaise, and weakness; dry mouth; somnolence; cough; constipation; headache; mucosal inflammation and stomatitis.",in one is not a named entity
"Other adverse reactions seen frequently in one or more studies included asthenia, fatigue, malaise, and weakness; dry mouth; somnolence; cough; constipation; headache; mucosal inflammation and stomatitis.",headache is an adverse reaction entity
"Other adverse reactions seen frequently in one or more studies included asthenia, fatigue, malaise, and weakness; dry mouth; somnolence; cough; constipation; headache; mucosal inflammation and stomatitis.",cough is an adverse reaction entity
"Other adverse reactions seen frequently in one or more studies included asthenia, fatigue, malaise, and weakness; dry mouth; somnolence; cough; constipation; headache; mucosal inflammation and stomatitis.",Other adverse reactions is not a named entity
"Other adverse reactions seen frequently in one or more studies included asthenia, fatigue, malaise, and weakness; dry mouth; somnolence; cough; constipation; headache; mucosal inflammation and stomatitis.",somnolence is an adverse reaction entity
"Other adverse reactions seen frequently in one or more studies included asthenia, fatigue, malaise, and weakness; dry mouth; somnolence; cough; constipation; headache; mucosal inflammation and stomatitis.",included is not a named entity
"Other adverse reactions seen frequently in one or more studies included asthenia, fatigue, malaise, and weakness; dry mouth; somnolence; cough; constipation; headache; mucosal inflammation and stomatitis.",mucosal inflammation is an adverse reaction entity
"Other adverse reactions seen frequently in one or more studies included asthenia, fatigue, malaise, and weakness; dry mouth; somnolence; cough; constipation; headache; mucosal inflammation and stomatitis.",stomatitis is an adverse reaction entity
"Other adverse reactions seen frequently in one or more studies included asthenia, fatigue, malaise, and weakness; dry mouth; somnolence; cough; constipation; headache; mucosal inflammation and stomatitis.",", malaise , is not a named entity"
"Other adverse reactions seen frequently in one or more studies included asthenia, fatigue, malaise, and weakness; dry mouth; somnolence; cough; constipation; headache; mucosal inflammation and stomatitis.",asthenia is an adverse reaction entity
5.4  Tumor Lysis Syndrome      Tumor lysis syndrome associated with TREANDA treatment has occurred in patients in clinical trials and in postmarketing reports.,Tumor lysis syndrome is an adverse reaction entity
5.4  Tumor Lysis Syndrome      Tumor lysis syndrome associated with TREANDA treatment has occurred in patients in clinical trials and in postmarketing reports.,has occurred is not a named entity
The most frequent adverse reactions leading to study withdrawal for patients receiving TREANDA were hypersensitivity (2%) and pyrexia (1%).,and pyrexia is not a named entity
The most frequent adverse reactions leading to study withdrawal for patients receiving TREANDA were hypersensitivity (2%) and pyrexia (1%).,receiving TREANDA is not a named entity
The most frequent adverse reactions leading to study withdrawal for patients receiving TREANDA were hypersensitivity (2%) and pyrexia (1%).,hypersensitivity is an adverse reaction entity
The most frequent adverse reactions leading to study withdrawal for patients receiving TREANDA were hypersensitivity (2%) and pyrexia (1%).,pyrexia is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *    Myelosuppression:  Delay or reduce dose.,Myelosuppression is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *    Myelosuppression:  Delay or reduce dose.,WARNINGS is not a named entity
Worsening hypertension was reported in 4 patients treated with TREANDA in the CLL trial and in none treated with chlorambucil.,in none treated is not a named entity
Worsening hypertension was reported in 4 patients treated with TREANDA in the CLL trial and in none treated with chlorambucil.,Worsening hypertension is an adverse reaction entity
"The most common non-hematologic Grade 3 or 4 adverse reactions (>=5%) were fatigue (11%), febrile neutropenia (6%), and pneumonia, hypokalemia and dehydration, each reported in 5% of patients.",", febrile is not a named entity"
"The most common non-hematologic Grade 3 or 4 adverse reactions (>=5%) were fatigue (11%), febrile neutropenia (6%), and pneumonia, hypokalemia and dehydration, each reported in 5% of patients.",dehydration is an adverse reaction entity
"The most common non-hematologic Grade 3 or 4 adverse reactions (>=5%) were fatigue (11%), febrile neutropenia (6%), and pneumonia, hypokalemia and dehydration, each reported in 5% of patients.",febrile neutropenia is an adverse reaction entity
"The most common non-hematologic Grade 3 or 4 adverse reactions (>=5%) were fatigue (11%), febrile neutropenia (6%), and pneumonia, hypokalemia and dehydration, each reported in 5% of patients.",hypokalemia is an adverse reaction entity
"The most common non-hematologic Grade 3 or 4 adverse reactions (>=5%) were fatigue (11%), febrile neutropenia (6%), and pneumonia, hypokalemia and dehydration, each reported in 5% of patients.",") , febrile is not a named entity"
"The most common non-hematologic Grade 3 or 4 adverse reactions (>=5%) were fatigue (11%), febrile neutropenia (6%), and pneumonia, hypokalemia and dehydration, each reported in 5% of patients.",Grade 3 is not a named entity
"The most common non-hematologic Grade 3 or 4 adverse reactions (>=5%) were fatigue (11%), febrile neutropenia (6%), and pneumonia, hypokalemia and dehydration, each reported in 5% of patients.",each is not a named entity
"The most common non-hematologic Grade 3 or 4 adverse reactions (>=5%) were fatigue (11%), febrile neutropenia (6%), and pneumonia, hypokalemia and dehydration, each reported in 5% of patients.",% is not a named entity
"The most common non-hematologic Grade 3 or 4 adverse reactions (>=5%) were fatigue (11%), febrile neutropenia (6%), and pneumonia, hypokalemia and dehydration, each reported in 5% of patients.",fatigue is an adverse reaction entity
"The most common non-hematologic Grade 3 or 4 adverse reactions (>=5%) were fatigue (11%), febrile neutropenia (6%), and pneumonia, hypokalemia and dehydration, each reported in 5% of patients.",pneumonia is an adverse reaction entity
(  5.2  )   *    Anaphylaxis and Infusion Reactions: Severe and anaphylactic reactions have occurred; monitor clinically and discontinue TREANDA.,Anaphylaxis and Infusion is not a named entity
(  5.2  )   *    Anaphylaxis and Infusion Reactions: Severe and anaphylactic reactions have occurred; monitor clinically and discontinue TREANDA.,* is not a named entity
(  5.2  )   *    Anaphylaxis and Infusion Reactions: Severe and anaphylactic reactions have occurred; monitor clinically and discontinue TREANDA.,have occurred ; is not a named entity
(  5.2  )   *    Anaphylaxis and Infusion Reactions: Severe and anaphylactic reactions have occurred; monitor clinically and discontinue TREANDA.,Infusion Reactions is an adverse reaction entity
(  5.2  )   *    Anaphylaxis and Infusion Reactions: Severe and anaphylactic reactions have occurred; monitor clinically and discontinue TREANDA.,anaphylactic reactions is an adverse reaction entity
(  5.2  )   *    Anaphylaxis and Infusion Reactions: Severe and anaphylactic reactions have occurred; monitor clinically and discontinue TREANDA.,Anaphylaxis is an adverse reaction entity
5.8  Embryo-fetal Toxicity      TREANDA can cause fetal harm when administered to a pregnant woman.,Toxicity TREANDA can is not a named entity
5.8  Embryo-fetal Toxicity      TREANDA can cause fetal harm when administered to a pregnant woman.,fetal harm is an adverse reaction entity
"The onset tends to be within the first treatment cycle of TREANDA and, without intervention, may lead to acute renal failure and death.",of TREANDA is not a named entity
"The onset tends to be within the first treatment cycle of TREANDA and, without intervention, may lead to acute renal failure and death.",death is an adverse reaction entity
"The onset tends to be within the first treatment cycle of TREANDA and, without intervention, may lead to acute renal failure and death.",within the first is not a named entity
"The onset tends to be within the first treatment cycle of TREANDA and, without intervention, may lead to acute renal failure and death.",acute renal failure is an adverse reaction entity
(  5.6  )   *    Extravasation: Assure good venous access and monitor infusion site during and after administration.,Extravasation is an adverse reaction entity
(  5.6  )   *    Extravasation: Assure good venous access and monitor infusion site during and after administration.,and after administration is not a named entity
(  5.7  )   *    Embryo-fetal toxicity:  Fetal harm can occur when administered to a pregnant woman.,a pregnant is not a named entity
(  5.7  )   *    Embryo-fetal toxicity:  Fetal harm can occur when administered to a pregnant woman.,occur is not a named entity
(  5.7  )   *    Embryo-fetal toxicity:  Fetal harm can occur when administered to a pregnant woman.,Embryo-fetal toxicity is an adverse reaction entity
(  5.7  )   *    Embryo-fetal toxicity:  Fetal harm can occur when administered to a pregnant woman.,Fetal harm is an adverse reaction entity
5.3  Anaphylaxis and Infusion Reactions      Infusion reactions to TREANDA have occurred commonly in clinical trials.,trials is not a named entity
5.3  Anaphylaxis and Infusion Reactions      Infusion reactions to TREANDA have occurred commonly in clinical trials.,Infusion reactions is an adverse reaction entity
"However, there may be an increased risk of severe skin toxicity when TREANDA and allopurinol are administered concomitantly [see  Warnings and Precautions  (  5.5  )]  .",skin toxicity is an adverse reaction entity
"However, there may be an increased risk of severe skin toxicity when TREANDA and allopurinol are administered concomitantly [see  Warnings and Precautions  (  5.5  )]  .",Precautions is not a named entity
"Cases of SJS and TEN, some fatal, have been reported when TREANDA was administered concomitantly with allopurinol and other medications known to cause these syndromes.",TEN is an adverse reaction entity
"Cases of SJS and TEN, some fatal, have been reported when TREANDA was administered concomitantly with allopurinol and other medications known to cause these syndromes.",SJS is an adverse reaction entity
"Cases of SJS and TEN, some fatal, have been reported when TREANDA was administered concomitantly with allopurinol and other medications known to cause these syndromes.",known to cause is not a named entity
"Cases of SJS and TEN, some fatal, have been reported when TREANDA was administered concomitantly with allopurinol and other medications known to cause these syndromes.",medications known is not a named entity
"Cases of SJS and TEN, some fatal, have been reported when TREANDA was administered concomitantly with allopurinol and other medications known to cause these syndromes.",to is not a named entity
"Cases of SJS and TEN, some fatal, have been reported when TREANDA was administered concomitantly with allopurinol and other medications known to cause these syndromes.",fatal is an adverse reaction entity
"Where skin reactions occur, they may be progressive and increase in severity with further treatment.",in severity is not a named entity
"Where skin reactions occur, they may be progressive and increase in severity with further treatment.",skin reactions is an adverse reaction entity
"(  6.1  )      *    Most common hematologic abnormalities for both indications (frequency >= 15%) are lymphopenia, anemia, leukopenia, thrombocytopenia, and neutropenia.",hematologic abnormalities is an adverse reaction entity
"(  6.1  )      *    Most common hematologic abnormalities for both indications (frequency >= 15%) are lymphopenia, anemia, leukopenia, thrombocytopenia, and neutropenia.",thrombocytopenia is an adverse reaction entity
"(  6.1  )      *    Most common hematologic abnormalities for both indications (frequency >= 15%) are lymphopenia, anemia, leukopenia, thrombocytopenia, and neutropenia.",% is not a named entity
"(  6.1  )      *    Most common hematologic abnormalities for both indications (frequency >= 15%) are lymphopenia, anemia, leukopenia, thrombocytopenia, and neutropenia.",lymphopenia is an adverse reaction entity
"(  6.1  )      *    Most common hematologic abnormalities for both indications (frequency >= 15%) are lymphopenia, anemia, leukopenia, thrombocytopenia, and neutropenia.",leukopenia is an adverse reaction entity
"(  6.1  )      *    Most common hematologic abnormalities for both indications (frequency >= 15%) are lymphopenia, anemia, leukopenia, thrombocytopenia, and neutropenia.",indications is not a named entity
"(  6.1  )      *    Most common hematologic abnormalities for both indications (frequency >= 15%) are lymphopenia, anemia, leukopenia, thrombocytopenia, and neutropenia.",) * Most is not a named entity
"(  6.1  )      *    Most common hematologic abnormalities for both indications (frequency >= 15%) are lymphopenia, anemia, leukopenia, thrombocytopenia, and neutropenia.",both indications ( is not a named entity
"(  6.1  )      *    Most common hematologic abnormalities for both indications (frequency >= 15%) are lymphopenia, anemia, leukopenia, thrombocytopenia, and neutropenia.",) is not a named entity
"(  6.1  )      *    Most common hematologic abnormalities for both indications (frequency >= 15%) are lymphopenia, anemia, leukopenia, thrombocytopenia, and neutropenia.",15 % is not a named entity
"(  6.1  )      *    Most common hematologic abnormalities for both indications (frequency >= 15%) are lymphopenia, anemia, leukopenia, thrombocytopenia, and neutropenia.",neutropenia is an adverse reaction entity
"(  6.1  )      *    Most common hematologic abnormalities for both indications (frequency >= 15%) are lymphopenia, anemia, leukopenia, thrombocytopenia, and neutropenia.",anemia is an adverse reaction entity
"(  6.1  )     *    Most common non-hematologic adverse reactions for NHL (frequency >= 15%) are nausea, fatigue, vomiting, diarrhea, pyrexia, constipation, anorexia, cough, headache, weight decreased, dyspnea, rash, and stomatitis.",vomiting is an adverse reaction entity
"(  6.1  )     *    Most common non-hematologic adverse reactions for NHL (frequency >= 15%) are nausea, fatigue, vomiting, diarrhea, pyrexia, constipation, anorexia, cough, headache, weight decreased, dyspnea, rash, and stomatitis.",fatigue is an adverse reaction entity
"(  6.1  )     *    Most common non-hematologic adverse reactions for NHL (frequency >= 15%) are nausea, fatigue, vomiting, diarrhea, pyrexia, constipation, anorexia, cough, headache, weight decreased, dyspnea, rash, and stomatitis.",pyrexia is an adverse reaction entity
"(  6.1  )     *    Most common non-hematologic adverse reactions for NHL (frequency >= 15%) are nausea, fatigue, vomiting, diarrhea, pyrexia, constipation, anorexia, cough, headache, weight decreased, dyspnea, rash, and stomatitis.",% ) is not a named entity
"(  6.1  )     *    Most common non-hematologic adverse reactions for NHL (frequency >= 15%) are nausea, fatigue, vomiting, diarrhea, pyrexia, constipation, anorexia, cough, headache, weight decreased, dyspnea, rash, and stomatitis.","vomiting , is not a named entity"
"(  6.1  )     *    Most common non-hematologic adverse reactions for NHL (frequency >= 15%) are nausea, fatigue, vomiting, diarrhea, pyrexia, constipation, anorexia, cough, headache, weight decreased, dyspnea, rash, and stomatitis.",", is not a named entity"
"(  6.1  )     *    Most common non-hematologic adverse reactions for NHL (frequency >= 15%) are nausea, fatigue, vomiting, diarrhea, pyrexia, constipation, anorexia, cough, headache, weight decreased, dyspnea, rash, and stomatitis.",decreased is not a named entity
"(  6.1  )     *    Most common non-hematologic adverse reactions for NHL (frequency >= 15%) are nausea, fatigue, vomiting, diarrhea, pyrexia, constipation, anorexia, cough, headache, weight decreased, dyspnea, rash, and stomatitis.",constipation is an adverse reaction entity
"(  6.1  )     *    Most common non-hematologic adverse reactions for NHL (frequency >= 15%) are nausea, fatigue, vomiting, diarrhea, pyrexia, constipation, anorexia, cough, headache, weight decreased, dyspnea, rash, and stomatitis.",rash is an adverse reaction entity
"(  6.1  )     *    Most common non-hematologic adverse reactions for NHL (frequency >= 15%) are nausea, fatigue, vomiting, diarrhea, pyrexia, constipation, anorexia, cough, headache, weight decreased, dyspnea, rash, and stomatitis.",cough is an adverse reaction entity
"(  6.1  )     *    Most common non-hematologic adverse reactions for NHL (frequency >= 15%) are nausea, fatigue, vomiting, diarrhea, pyrexia, constipation, anorexia, cough, headache, weight decreased, dyspnea, rash, and stomatitis.",Most common is not a named entity
"(  6.1  )     *    Most common non-hematologic adverse reactions for NHL (frequency >= 15%) are nausea, fatigue, vomiting, diarrhea, pyrexia, constipation, anorexia, cough, headache, weight decreased, dyspnea, rash, and stomatitis.",", diarrhea is not a named entity"
"(  6.1  )     *    Most common non-hematologic adverse reactions for NHL (frequency >= 15%) are nausea, fatigue, vomiting, diarrhea, pyrexia, constipation, anorexia, cough, headache, weight decreased, dyspnea, rash, and stomatitis.",", is not a named entity"
"(  6.1  )     *    Most common non-hematologic adverse reactions for NHL (frequency >= 15%) are nausea, fatigue, vomiting, diarrhea, pyrexia, constipation, anorexia, cough, headache, weight decreased, dyspnea, rash, and stomatitis.",stomatitis is an adverse reaction entity
"(  6.1  )     *    Most common non-hematologic adverse reactions for NHL (frequency >= 15%) are nausea, fatigue, vomiting, diarrhea, pyrexia, constipation, anorexia, cough, headache, weight decreased, dyspnea, rash, and stomatitis.",diarrhea is an adverse reaction entity
"(  6.1  )     *    Most common non-hematologic adverse reactions for NHL (frequency >= 15%) are nausea, fatigue, vomiting, diarrhea, pyrexia, constipation, anorexia, cough, headache, weight decreased, dyspnea, rash, and stomatitis.","fatigue , vomiting is not a named entity"
"(  6.1  )     *    Most common non-hematologic adverse reactions for NHL (frequency >= 15%) are nausea, fatigue, vomiting, diarrhea, pyrexia, constipation, anorexia, cough, headache, weight decreased, dyspnea, rash, and stomatitis.",headache is an adverse reaction entity
"(  6.1  )     *    Most common non-hematologic adverse reactions for NHL (frequency >= 15%) are nausea, fatigue, vomiting, diarrhea, pyrexia, constipation, anorexia, cough, headache, weight decreased, dyspnea, rash, and stomatitis.",common is not a named entity
"(  6.1  )     *    Most common non-hematologic adverse reactions for NHL (frequency >= 15%) are nausea, fatigue, vomiting, diarrhea, pyrexia, constipation, anorexia, cough, headache, weight decreased, dyspnea, rash, and stomatitis.",anorexia is an adverse reaction entity
"(  6.1  )     *    Most common non-hematologic adverse reactions for NHL (frequency >= 15%) are nausea, fatigue, vomiting, diarrhea, pyrexia, constipation, anorexia, cough, headache, weight decreased, dyspnea, rash, and stomatitis.",nausea is an adverse reaction entity
"(  6.1  )     *    Most common non-hematologic adverse reactions for NHL (frequency >= 15%) are nausea, fatigue, vomiting, diarrhea, pyrexia, constipation, anorexia, cough, headache, weight decreased, dyspnea, rash, and stomatitis.",dyspnea is an adverse reaction entity
"(  6.1  )     *    Most common non-hematologic adverse reactions for NHL (frequency >= 15%) are nausea, fatigue, vomiting, diarrhea, pyrexia, constipation, anorexia, cough, headache, weight decreased, dyspnea, rash, and stomatitis.","rash , is not a named entity"
"(  6.1  )     *    Most common non-hematologic adverse reactions for NHL (frequency >= 15%) are nausea, fatigue, vomiting, diarrhea, pyrexia, constipation, anorexia, cough, headache, weight decreased, dyspnea, rash, and stomatitis.",", and stomatitis is not a named entity"
"(  6.1  )     *    Most common non-hematologic adverse reactions for NHL (frequency >= 15%) are nausea, fatigue, vomiting, diarrhea, pyrexia, constipation, anorexia, cough, headache, weight decreased, dyspnea, rash, and stomatitis.",common non-hematologic is not a named entity
"(  6.1  )     *    Most common non-hematologic adverse reactions for NHL (frequency >= 15%) are nausea, fatigue, vomiting, diarrhea, pyrexia, constipation, anorexia, cough, headache, weight decreased, dyspnea, rash, and stomatitis.",weight decreased is an adverse reaction entity
"(  6.1  )     *    Most common non-hematologic adverse reactions for NHL (frequency >= 15%) are nausea, fatigue, vomiting, diarrhea, pyrexia, constipation, anorexia, cough, headache, weight decreased, dyspnea, rash, and stomatitis.",) * is not a named entity
"Three patients (2%) died from myelosuppression-related adverse reactions; one each from neutropenic sepsis, diffuse alveolar hemorrhage with Grade 3 thrombocytopenia, and pneumonia from an opportunistic infection (CMV).",an opportunistic is not a named entity
"Three patients (2%) died from myelosuppression-related adverse reactions; one each from neutropenic sepsis, diffuse alveolar hemorrhage with Grade 3 thrombocytopenia, and pneumonia from an opportunistic infection (CMV).",infection CMV is an adverse reaction entity
"Three patients (2%) died from myelosuppression-related adverse reactions; one each from neutropenic sepsis, diffuse alveolar hemorrhage with Grade 3 thrombocytopenia, and pneumonia from an opportunistic infection (CMV).",) died is not a named entity
"Three patients (2%) died from myelosuppression-related adverse reactions; one each from neutropenic sepsis, diffuse alveolar hemorrhage with Grade 3 thrombocytopenia, and pneumonia from an opportunistic infection (CMV).",diffuse alveolar hemorrhage is an adverse reaction entity
"Three patients (2%) died from myelosuppression-related adverse reactions; one each from neutropenic sepsis, diffuse alveolar hemorrhage with Grade 3 thrombocytopenia, and pneumonia from an opportunistic infection (CMV).",; is not a named entity
"Three patients (2%) died from myelosuppression-related adverse reactions; one each from neutropenic sepsis, diffuse alveolar hemorrhage with Grade 3 thrombocytopenia, and pneumonia from an opportunistic infection (CMV).",pneumonia is an adverse reaction entity
"Three patients (2%) died from myelosuppression-related adverse reactions; one each from neutropenic sepsis, diffuse alveolar hemorrhage with Grade 3 thrombocytopenia, and pneumonia from an opportunistic infection (CMV).",", diffuse is not a named entity"
"Three patients (2%) died from myelosuppression-related adverse reactions; one each from neutropenic sepsis, diffuse alveolar hemorrhage with Grade 3 thrombocytopenia, and pneumonia from an opportunistic infection (CMV).",thrombocytopenia is an adverse reaction entity
"Three patients (2%) died from myelosuppression-related adverse reactions; one each from neutropenic sepsis, diffuse alveolar hemorrhage with Grade 3 thrombocytopenia, and pneumonia from an opportunistic infection (CMV).",died is an adverse reaction entity
"Three patients (2%) died from myelosuppression-related adverse reactions; one each from neutropenic sepsis, diffuse alveolar hemorrhage with Grade 3 thrombocytopenia, and pneumonia from an opportunistic infection (CMV).",infection ( CMV is not a named entity
"Three patients (2%) died from myelosuppression-related adverse reactions; one each from neutropenic sepsis, diffuse alveolar hemorrhage with Grade 3 thrombocytopenia, and pneumonia from an opportunistic infection (CMV).",( CMV is not a named entity
"Three patients (2%) died from myelosuppression-related adverse reactions; one each from neutropenic sepsis, diffuse alveolar hemorrhage with Grade 3 thrombocytopenia, and pneumonia from an opportunistic infection (CMV).",neutropenic sepsis is an adverse reaction entity
"Three patients (2%) died from myelosuppression-related adverse reactions; one each from neutropenic sepsis, diffuse alveolar hemorrhage with Grade 3 thrombocytopenia, and pneumonia from an opportunistic infection (CMV).",myelosuppression-related adverse reactions is an adverse reaction entity
"Three patients (2%) died from myelosuppression-related adverse reactions; one each from neutropenic sepsis, diffuse alveolar hemorrhage with Grade 3 thrombocytopenia, and pneumonia from an opportunistic infection (CMV).",( is not a named entity
"Three patients (2%) died from myelosuppression-related adverse reactions; one each from neutropenic sepsis, diffuse alveolar hemorrhage with Grade 3 thrombocytopenia, and pneumonia from an opportunistic infection (CMV).",( 2 % is not a named entity
"Three patients (2%) died from myelosuppression-related adverse reactions; one each from neutropenic sepsis, diffuse alveolar hemorrhage with Grade 3 thrombocytopenia, and pneumonia from an opportunistic infection (CMV).",opportunistic infection is an adverse reaction entity
"Table 4:  Incidence of Hematology Laboratory Abnormalities in Patients Who Received TREANDA in the NHL Studies                             Percent of patients       Hematology variable      All Grades     Grades 3/4        Lymphocytes Decreased    99             94                Leukocytes Decreased     94             56                Hemoglobin Decreased     88             11                Neutrophils Decreased    86             60                Platelets Decreased      86             25                       In both studies, serious adverse reactions, regardless of causality, were reported in 37% of patients receiving TREANDA.",reported in is not a named entity
"Table 4:  Incidence of Hematology Laboratory Abnormalities in Patients Who Received TREANDA in the NHL Studies                             Percent of patients       Hematology variable      All Grades     Grades 3/4        Lymphocytes Decreased    99             94                Leukocytes Decreased     94             56                Hemoglobin Decreased     88             11                Neutrophils Decreased    86             60                Platelets Decreased      86             25                       In both studies, serious adverse reactions, regardless of causality, were reported in 37% of patients receiving TREANDA.",99 is not a named entity
"Table 4:  Incidence of Hematology Laboratory Abnormalities in Patients Who Received TREANDA in the NHL Studies                             Percent of patients       Hematology variable      All Grades     Grades 3/4        Lymphocytes Decreased    99             94                Leukocytes Decreased     94             56                Hemoglobin Decreased     88             11                Neutrophils Decreased    86             60                Platelets Decreased      86             25                       In both studies, serious adverse reactions, regardless of causality, were reported in 37% of patients receiving TREANDA.",Lymphocytes Decreased is an adverse reaction entity
"Table 4:  Incidence of Hematology Laboratory Abnormalities in Patients Who Received TREANDA in the NHL Studies                             Percent of patients       Hematology variable      All Grades     Grades 3/4        Lymphocytes Decreased    99             94                Leukocytes Decreased     94             56                Hemoglobin Decreased     88             11                Neutrophils Decreased    86             60                Platelets Decreased      86             25                       In both studies, serious adverse reactions, regardless of causality, were reported in 37% of patients receiving TREANDA.",Platelets Decreased is an adverse reaction entity
"Table 4:  Incidence of Hematology Laboratory Abnormalities in Patients Who Received TREANDA in the NHL Studies                             Percent of patients       Hematology variable      All Grades     Grades 3/4        Lymphocytes Decreased    99             94                Leukocytes Decreased     94             56                Hemoglobin Decreased     88             11                Neutrophils Decreased    86             60                Platelets Decreased      86             25                       In both studies, serious adverse reactions, regardless of causality, were reported in 37% of patients receiving TREANDA.",Neutrophils Decreased is an adverse reaction entity
"Table 4:  Incidence of Hematology Laboratory Abnormalities in Patients Who Received TREANDA in the NHL Studies                             Percent of patients       Hematology variable      All Grades     Grades 3/4        Lymphocytes Decreased    99             94                Leukocytes Decreased     94             56                Hemoglobin Decreased     88             11                Neutrophils Decreased    86             60                Platelets Decreased      86             25                       In both studies, serious adverse reactions, regardless of causality, were reported in 37% of patients receiving TREANDA.",Patients is not a named entity
"Table 4:  Incidence of Hematology Laboratory Abnormalities in Patients Who Received TREANDA in the NHL Studies                             Percent of patients       Hematology variable      All Grades     Grades 3/4        Lymphocytes Decreased    99             94                Leukocytes Decreased     94             56                Hemoglobin Decreased     88             11                Neutrophils Decreased    86             60                Platelets Decreased      86             25                       In both studies, serious adverse reactions, regardless of causality, were reported in 37% of patients receiving TREANDA.",regardless is not a named entity
"Table 4:  Incidence of Hematology Laboratory Abnormalities in Patients Who Received TREANDA in the NHL Studies                             Percent of patients       Hematology variable      All Grades     Grades 3/4        Lymphocytes Decreased    99             94                Leukocytes Decreased     94             56                Hemoglobin Decreased     88             11                Neutrophils Decreased    86             60                Platelets Decreased      86             25                       In both studies, serious adverse reactions, regardless of causality, were reported in 37% of patients receiving TREANDA.",Hemoglobin Decreased is an adverse reaction entity
"Table 4:  Incidence of Hematology Laboratory Abnormalities in Patients Who Received TREANDA in the NHL Studies                             Percent of patients       Hematology variable      All Grades     Grades 3/4        Lymphocytes Decreased    99             94                Leukocytes Decreased     94             56                Hemoglobin Decreased     88             11                Neutrophils Decreased    86             60                Platelets Decreased      86             25                       In both studies, serious adverse reactions, regardless of causality, were reported in 37% of patients receiving TREANDA.",of causality is not a named entity
"Table 4:  Incidence of Hematology Laboratory Abnormalities in Patients Who Received TREANDA in the NHL Studies                             Percent of patients       Hematology variable      All Grades     Grades 3/4        Lymphocytes Decreased    99             94                Leukocytes Decreased     94             56                Hemoglobin Decreased     88             11                Neutrophils Decreased    86             60                Platelets Decreased      86             25                       In both studies, serious adverse reactions, regardless of causality, were reported in 37% of patients receiving TREANDA.",Leukocytes Decreased is an adverse reaction entity
"Increases in AST and ALT of Grade 3 or 4 were limited to 1% and 3% of patients, respectively.",and ALT of is not a named entity
"Increases in AST and ALT of Grade 3 or 4 were limited to 1% and 3% of patients, respectively.",Increases in ALT is an adverse reaction entity
"Increases in AST and ALT of Grade 3 or 4 were limited to 1% and 3% of patients, respectively.",Increases in AST is an adverse reaction entity
"Increases in AST and ALT of Grade 3 or 4 were limited to 1% and 3% of patients, respectively.","of patients , is not a named entity"
These findings confirm the myelosuppressive effects seen in patients treated with TREANDA.,myelosuppressive effects is an adverse reaction entity
These findings confirm the myelosuppressive effects seen in patients treated with TREANDA.,confirm is not a named entity
"(  5.8  ,  8.1  )             5.1  Myelosuppression      TREANDA caused severe myelosuppression (Grade 3-4) in 98% of patients in the two NHL studies (see Table 4).",myelosuppression is an adverse reaction entity
"(  5.8  ,  8.1  )             5.1  Myelosuppression      TREANDA caused severe myelosuppression (Grade 3-4) in 98% of patients in the two NHL studies (see Table 4).",Table 4 is not a named entity
Three of these 4 adverse reactions were described as a hypertensive crisis and were managed with oral medications and resolved.,a hypertensive crisis is not a named entity
Three of these 4 adverse reactions were described as a hypertensive crisis and were managed with oral medications and resolved.,hypertensive crisis is an adverse reaction entity
"The most common non-hematologic adverse reactions (>=30%) were nausea (75%), fatigue (57%), vomiting (40%), diarrhea (37%) and pyrexia (34%).",", is not a named entity"
"The most common non-hematologic adverse reactions (>=30%) were nausea (75%), fatigue (57%), vomiting (40%), diarrhea (37%) and pyrexia (34%).",diarrhea is an adverse reaction entity
"The most common non-hematologic adverse reactions (>=30%) were nausea (75%), fatigue (57%), vomiting (40%), diarrhea (37%) and pyrexia (34%).",% is not a named entity
"The most common non-hematologic adverse reactions (>=30%) were nausea (75%), fatigue (57%), vomiting (40%), diarrhea (37%) and pyrexia (34%).",% ) is not a named entity
"The most common non-hematologic adverse reactions (>=30%) were nausea (75%), fatigue (57%), vomiting (40%), diarrhea (37%) and pyrexia (34%).",vomiting is an adverse reaction entity
"The most common non-hematologic adverse reactions (>=30%) were nausea (75%), fatigue (57%), vomiting (40%), diarrhea (37%) and pyrexia (34%).",") , is not a named entity"
"The most common non-hematologic adverse reactions (>=30%) were nausea (75%), fatigue (57%), vomiting (40%), diarrhea (37%) and pyrexia (34%).",fatigue is an adverse reaction entity
"The most common non-hematologic adverse reactions (>=30%) were nausea (75%), fatigue (57%), vomiting (40%), diarrhea (37%) and pyrexia (34%).",) were is not a named entity
"The most common non-hematologic adverse reactions (>=30%) were nausea (75%), fatigue (57%), vomiting (40%), diarrhea (37%) and pyrexia (34%).",nausea is an adverse reaction entity
"The most common non-hematologic adverse reactions (>=30%) were nausea (75%), fatigue (57%), vomiting (40%), diarrhea (37%) and pyrexia (34%).",pyrexia is an adverse reaction entity
"*    Myelosuppression [see  Warnings and Precautions  (  5.1  )]    *    Infections [see  Warnings and Precautions  (  5.2  )]    *    Anaphylaxis and Infusion Reactions [see  Warnings and Precautions  (  5.3  )]    *    Tumor Lysis Syndrome [see  Warnings and Precautions  (  5.4  )]    *    Skin Reactions [see  Warnings and Precautions  (  5.5  )]    *    Other Malignancies [see  Warnings and Precautions  (  5.6  )]    *    Extravasation injury [see  Warnings and Precautions (5.7)]        *         *    Most common non-hematologic adverse reactions for CLL (frequency >= 15%) are pyrexia, nausea, and vomiting.",pyrexia is an adverse reaction entity
"*    Myelosuppression [see  Warnings and Precautions  (  5.1  )]    *    Infections [see  Warnings and Precautions  (  5.2  )]    *    Anaphylaxis and Infusion Reactions [see  Warnings and Precautions  (  5.3  )]    *    Tumor Lysis Syndrome [see  Warnings and Precautions  (  5.4  )]    *    Skin Reactions [see  Warnings and Precautions  (  5.5  )]    *    Other Malignancies [see  Warnings and Precautions  (  5.6  )]    *    Extravasation injury [see  Warnings and Precautions (5.7)]        *         *    Most common non-hematologic adverse reactions for CLL (frequency >= 15%) are pyrexia, nausea, and vomiting.",] * Other is not a named entity
"*    Myelosuppression [see  Warnings and Precautions  (  5.1  )]    *    Infections [see  Warnings and Precautions  (  5.2  )]    *    Anaphylaxis and Infusion Reactions [see  Warnings and Precautions  (  5.3  )]    *    Tumor Lysis Syndrome [see  Warnings and Precautions  (  5.4  )]    *    Skin Reactions [see  Warnings and Precautions  (  5.5  )]    *    Other Malignancies [see  Warnings and Precautions  (  5.6  )]    *    Extravasation injury [see  Warnings and Precautions (5.7)]        *         *    Most common non-hematologic adverse reactions for CLL (frequency >= 15%) are pyrexia, nausea, and vomiting.",non-hematologic is not a named entity
"*    Myelosuppression [see  Warnings and Precautions  (  5.1  )]    *    Infections [see  Warnings and Precautions  (  5.2  )]    *    Anaphylaxis and Infusion Reactions [see  Warnings and Precautions  (  5.3  )]    *    Tumor Lysis Syndrome [see  Warnings and Precautions  (  5.4  )]    *    Skin Reactions [see  Warnings and Precautions  (  5.5  )]    *    Other Malignancies [see  Warnings and Precautions  (  5.6  )]    *    Extravasation injury [see  Warnings and Precautions (5.7)]        *         *    Most common non-hematologic adverse reactions for CLL (frequency >= 15%) are pyrexia, nausea, and vomiting.",vomiting is an adverse reaction entity
"*    Myelosuppression [see  Warnings and Precautions  (  5.1  )]    *    Infections [see  Warnings and Precautions  (  5.2  )]    *    Anaphylaxis and Infusion Reactions [see  Warnings and Precautions  (  5.3  )]    *    Tumor Lysis Syndrome [see  Warnings and Precautions  (  5.4  )]    *    Skin Reactions [see  Warnings and Precautions  (  5.5  )]    *    Other Malignancies [see  Warnings and Precautions  (  5.6  )]    *    Extravasation injury [see  Warnings and Precautions (5.7)]        *         *    Most common non-hematologic adverse reactions for CLL (frequency >= 15%) are pyrexia, nausea, and vomiting.",Anaphylaxis is an adverse reaction entity
"*    Myelosuppression [see  Warnings and Precautions  (  5.1  )]    *    Infections [see  Warnings and Precautions  (  5.2  )]    *    Anaphylaxis and Infusion Reactions [see  Warnings and Precautions  (  5.3  )]    *    Tumor Lysis Syndrome [see  Warnings and Precautions  (  5.4  )]    *    Skin Reactions [see  Warnings and Precautions  (  5.5  )]    *    Other Malignancies [see  Warnings and Precautions  (  5.6  )]    *    Extravasation injury [see  Warnings and Precautions (5.7)]        *         *    Most common non-hematologic adverse reactions for CLL (frequency >= 15%) are pyrexia, nausea, and vomiting.",Myelosuppression is an adverse reaction entity
"*    Myelosuppression [see  Warnings and Precautions  (  5.1  )]    *    Infections [see  Warnings and Precautions  (  5.2  )]    *    Anaphylaxis and Infusion Reactions [see  Warnings and Precautions  (  5.3  )]    *    Tumor Lysis Syndrome [see  Warnings and Precautions  (  5.4  )]    *    Skin Reactions [see  Warnings and Precautions  (  5.5  )]    *    Other Malignancies [see  Warnings and Precautions  (  5.6  )]    *    Extravasation injury [see  Warnings and Precautions (5.7)]        *         *    Most common non-hematologic adverse reactions for CLL (frequency >= 15%) are pyrexia, nausea, and vomiting.",Warnings and Precautions is not a named entity
"*    Myelosuppression [see  Warnings and Precautions  (  5.1  )]    *    Infections [see  Warnings and Precautions  (  5.2  )]    *    Anaphylaxis and Infusion Reactions [see  Warnings and Precautions  (  5.3  )]    *    Tumor Lysis Syndrome [see  Warnings and Precautions  (  5.4  )]    *    Skin Reactions [see  Warnings and Precautions  (  5.5  )]    *    Other Malignancies [see  Warnings and Precautions  (  5.6  )]    *    Extravasation injury [see  Warnings and Precautions (5.7)]        *         *    Most common non-hematologic adverse reactions for CLL (frequency >= 15%) are pyrexia, nausea, and vomiting.",Infections is an adverse reaction entity
"*    Myelosuppression [see  Warnings and Precautions  (  5.1  )]    *    Infections [see  Warnings and Precautions  (  5.2  )]    *    Anaphylaxis and Infusion Reactions [see  Warnings and Precautions  (  5.3  )]    *    Tumor Lysis Syndrome [see  Warnings and Precautions  (  5.4  )]    *    Skin Reactions [see  Warnings and Precautions  (  5.5  )]    *    Other Malignancies [see  Warnings and Precautions  (  5.6  )]    *    Extravasation injury [see  Warnings and Precautions (5.7)]        *         *    Most common non-hematologic adverse reactions for CLL (frequency >= 15%) are pyrexia, nausea, and vomiting.",see Warnings and is not a named entity
"*    Myelosuppression [see  Warnings and Precautions  (  5.1  )]    *    Infections [see  Warnings and Precautions  (  5.2  )]    *    Anaphylaxis and Infusion Reactions [see  Warnings and Precautions  (  5.3  )]    *    Tumor Lysis Syndrome [see  Warnings and Precautions  (  5.4  )]    *    Skin Reactions [see  Warnings and Precautions  (  5.5  )]    *    Other Malignancies [see  Warnings and Precautions  (  5.6  )]    *    Extravasation injury [see  Warnings and Precautions (5.7)]        *         *    Most common non-hematologic adverse reactions for CLL (frequency >= 15%) are pyrexia, nausea, and vomiting.",for CLL is not a named entity
"*    Myelosuppression [see  Warnings and Precautions  (  5.1  )]    *    Infections [see  Warnings and Precautions  (  5.2  )]    *    Anaphylaxis and Infusion Reactions [see  Warnings and Precautions  (  5.3  )]    *    Tumor Lysis Syndrome [see  Warnings and Precautions  (  5.4  )]    *    Skin Reactions [see  Warnings and Precautions  (  5.5  )]    *    Other Malignancies [see  Warnings and Precautions  (  5.6  )]    *    Extravasation injury [see  Warnings and Precautions (5.7)]        *         *    Most common non-hematologic adverse reactions for CLL (frequency >= 15%) are pyrexia, nausea, and vomiting.",nausea is an adverse reaction entity
"*    Myelosuppression [see  Warnings and Precautions  (  5.1  )]    *    Infections [see  Warnings and Precautions  (  5.2  )]    *    Anaphylaxis and Infusion Reactions [see  Warnings and Precautions  (  5.3  )]    *    Tumor Lysis Syndrome [see  Warnings and Precautions  (  5.4  )]    *    Skin Reactions [see  Warnings and Precautions  (  5.5  )]    *    Other Malignancies [see  Warnings and Precautions  (  5.6  )]    *    Extravasation injury [see  Warnings and Precautions (5.7)]        *         *    Most common non-hematologic adverse reactions for CLL (frequency >= 15%) are pyrexia, nausea, and vomiting.",Tumor Lysis Syndrome is an adverse reaction entity
"*    Myelosuppression [see  Warnings and Precautions  (  5.1  )]    *    Infections [see  Warnings and Precautions  (  5.2  )]    *    Anaphylaxis and Infusion Reactions [see  Warnings and Precautions  (  5.3  )]    *    Tumor Lysis Syndrome [see  Warnings and Precautions  (  5.4  )]    *    Skin Reactions [see  Warnings and Precautions  (  5.5  )]    *    Other Malignancies [see  Warnings and Precautions  (  5.6  )]    *    Extravasation injury [see  Warnings and Precautions (5.7)]        *         *    Most common non-hematologic adverse reactions for CLL (frequency >= 15%) are pyrexia, nausea, and vomiting.",and Precautions ( is not a named entity
"*    Myelosuppression [see  Warnings and Precautions  (  5.1  )]    *    Infections [see  Warnings and Precautions  (  5.2  )]    *    Anaphylaxis and Infusion Reactions [see  Warnings and Precautions  (  5.3  )]    *    Tumor Lysis Syndrome [see  Warnings and Precautions  (  5.4  )]    *    Skin Reactions [see  Warnings and Precautions  (  5.5  )]    *    Other Malignancies [see  Warnings and Precautions  (  5.6  )]    *    Extravasation injury [see  Warnings and Precautions (5.7)]        *         *    Most common non-hematologic adverse reactions for CLL (frequency >= 15%) are pyrexia, nausea, and vomiting.",Skin Reactions is an adverse reaction entity
"*    Myelosuppression [see  Warnings and Precautions  (  5.1  )]    *    Infections [see  Warnings and Precautions  (  5.2  )]    *    Anaphylaxis and Infusion Reactions [see  Warnings and Precautions  (  5.3  )]    *    Tumor Lysis Syndrome [see  Warnings and Precautions  (  5.4  )]    *    Skin Reactions [see  Warnings and Precautions  (  5.5  )]    *    Other Malignancies [see  Warnings and Precautions  (  5.6  )]    *    Extravasation injury [see  Warnings and Precautions (5.7)]        *         *    Most common non-hematologic adverse reactions for CLL (frequency >= 15%) are pyrexia, nausea, and vomiting.",see is not a named entity
"*    Myelosuppression [see  Warnings and Precautions  (  5.1  )]    *    Infections [see  Warnings and Precautions  (  5.2  )]    *    Anaphylaxis and Infusion Reactions [see  Warnings and Precautions  (  5.3  )]    *    Tumor Lysis Syndrome [see  Warnings and Precautions  (  5.4  )]    *    Skin Reactions [see  Warnings and Precautions  (  5.5  )]    *    Other Malignancies [see  Warnings and Precautions  (  5.6  )]    *    Extravasation injury [see  Warnings and Precautions (5.7)]        *         *    Most common non-hematologic adverse reactions for CLL (frequency >= 15%) are pyrexia, nausea, and vomiting.",Malignancies is an adverse reaction entity
"*    Myelosuppression [see  Warnings and Precautions  (  5.1  )]    *    Infections [see  Warnings and Precautions  (  5.2  )]    *    Anaphylaxis and Infusion Reactions [see  Warnings and Precautions  (  5.3  )]    *    Tumor Lysis Syndrome [see  Warnings and Precautions  (  5.4  )]    *    Skin Reactions [see  Warnings and Precautions  (  5.5  )]    *    Other Malignancies [see  Warnings and Precautions  (  5.6  )]    *    Extravasation injury [see  Warnings and Precautions (5.7)]        *         *    Most common non-hematologic adverse reactions for CLL (frequency >= 15%) are pyrexia, nausea, and vomiting.",5.1 ) ] is not a named entity
"*    Myelosuppression [see  Warnings and Precautions  (  5.1  )]    *    Infections [see  Warnings and Precautions  (  5.2  )]    *    Anaphylaxis and Infusion Reactions [see  Warnings and Precautions  (  5.3  )]    *    Tumor Lysis Syndrome [see  Warnings and Precautions  (  5.4  )]    *    Skin Reactions [see  Warnings and Precautions  (  5.5  )]    *    Other Malignancies [see  Warnings and Precautions  (  5.6  )]    *    Extravasation injury [see  Warnings and Precautions (5.7)]        *         *    Most common non-hematologic adverse reactions for CLL (frequency >= 15%) are pyrexia, nausea, and vomiting.",Extravasation injury is an adverse reaction entity
"*    Myelosuppression [see  Warnings and Precautions  (  5.1  )]    *    Infections [see  Warnings and Precautions  (  5.2  )]    *    Anaphylaxis and Infusion Reactions [see  Warnings and Precautions  (  5.3  )]    *    Tumor Lysis Syndrome [see  Warnings and Precautions  (  5.4  )]    *    Skin Reactions [see  Warnings and Precautions  (  5.5  )]    *    Other Malignancies [see  Warnings and Precautions  (  5.6  )]    *    Extravasation injury [see  Warnings and Precautions (5.7)]        *         *    Most common non-hematologic adverse reactions for CLL (frequency >= 15%) are pyrexia, nausea, and vomiting.",5.5 ) is not a named entity
"*    Myelosuppression [see  Warnings and Precautions  (  5.1  )]    *    Infections [see  Warnings and Precautions  (  5.2  )]    *    Anaphylaxis and Infusion Reactions [see  Warnings and Precautions  (  5.3  )]    *    Tumor Lysis Syndrome [see  Warnings and Precautions  (  5.4  )]    *    Skin Reactions [see  Warnings and Precautions  (  5.5  )]    *    Other Malignancies [see  Warnings and Precautions  (  5.6  )]    *    Extravasation injury [see  Warnings and Precautions (5.7)]        *         *    Most common non-hematologic adverse reactions for CLL (frequency >= 15%) are pyrexia, nausea, and vomiting.",) is not a named entity
"*    Myelosuppression [see  Warnings and Precautions  (  5.1  )]    *    Infections [see  Warnings and Precautions  (  5.2  )]    *    Anaphylaxis and Infusion Reactions [see  Warnings and Precautions  (  5.3  )]    *    Tumor Lysis Syndrome [see  Warnings and Precautions  (  5.4  )]    *    Skin Reactions [see  Warnings and Precautions  (  5.5  )]    *    Other Malignancies [see  Warnings and Precautions  (  5.6  )]    *    Extravasation injury [see  Warnings and Precautions (5.7)]        *         *    Most common non-hematologic adverse reactions for CLL (frequency >= 15%) are pyrexia, nausea, and vomiting.",and Precautions is not a named entity
"*    Myelosuppression [see  Warnings and Precautions  (  5.1  )]    *    Infections [see  Warnings and Precautions  (  5.2  )]    *    Anaphylaxis and Infusion Reactions [see  Warnings and Precautions  (  5.3  )]    *    Tumor Lysis Syndrome [see  Warnings and Precautions  (  5.4  )]    *    Skin Reactions [see  Warnings and Precautions  (  5.5  )]    *    Other Malignancies [see  Warnings and Precautions  (  5.6  )]    *    Extravasation injury [see  Warnings and Precautions (5.7)]        *         *    Most common non-hematologic adverse reactions for CLL (frequency >= 15%) are pyrexia, nausea, and vomiting.",Infusion Reactions is an adverse reaction entity
"Single intraperitoneal doses of bendamustine in mice and rats administered during organogenesis caused an increase in resorptions, skeletal and visceral malformations, and decreased fetal body weights.",in resorptions is not a named entity
"Single intraperitoneal doses of bendamustine in mice and rats administered during organogenesis caused an increase in resorptions, skeletal and visceral malformations, and decreased fetal body weights.",skeletal malformations is an adverse reaction entity
"Single intraperitoneal doses of bendamustine in mice and rats administered during organogenesis caused an increase in resorptions, skeletal and visceral malformations, and decreased fetal body weights.",and visceral malformations is not a named entity
"Single intraperitoneal doses of bendamustine in mice and rats administered during organogenesis caused an increase in resorptions, skeletal and visceral malformations, and decreased fetal body weights.",", skeletal and is not a named entity"
"Single intraperitoneal doses of bendamustine in mice and rats administered during organogenesis caused an increase in resorptions, skeletal and visceral malformations, and decreased fetal body weights.",increase in resorptions is an adverse reaction entity
"Single intraperitoneal doses of bendamustine in mice and rats administered during organogenesis caused an increase in resorptions, skeletal and visceral malformations, and decreased fetal body weights.",decreased fetal body weights is an adverse reaction entity
"Single intraperitoneal doses of bendamustine in mice and rats administered during organogenesis caused an increase in resorptions, skeletal and visceral malformations, and decreased fetal body weights.",visceral malformations is an adverse reaction entity
"Single intraperitoneal doses of bendamustine in mice and rats administered during organogenesis caused an increase in resorptions, skeletal and visceral malformations, and decreased fetal body weights.",in is not a named entity
(  5.1  )   *    Infections:  Monitor for fever and other signs of infection and treat promptly.,Infections is an adverse reaction entity
(  5.1  )   *    Infections:  Monitor for fever and other signs of infection and treat promptly.,Monitor for is not a named entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: anaphylaxis; and injection or infusion site reactions including phlebitis, pruritus, irritation, pain, and swelling; pneumocystis jiroveci pneumonia and pneumonitis.",injection site reactions is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: anaphylaxis; and injection or infusion site reactions including phlebitis, pruritus, irritation, pain, and swelling; pneumocystis jiroveci pneumonia and pneumonitis.","phlebitis , pruritus is not a named entity"
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: anaphylaxis; and injection or infusion site reactions including phlebitis, pruritus, irritation, pain, and swelling; pneumocystis jiroveci pneumonia and pneumonitis.",infusion site pruritus is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: anaphylaxis; and injection or infusion site reactions including phlebitis, pruritus, irritation, pain, and swelling; pneumocystis jiroveci pneumonia and pneumonitis.",injection site irritation is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: anaphylaxis; and injection or infusion site reactions including phlebitis, pruritus, irritation, pain, and swelling; pneumocystis jiroveci pneumonia and pneumonitis.",it is is not a named entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: anaphylaxis; and injection or infusion site reactions including phlebitis, pruritus, irritation, pain, and swelling; pneumocystis jiroveci pneumonia and pneumonitis.",causal relationship to is not a named entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: anaphylaxis; and injection or infusion site reactions including phlebitis, pruritus, irritation, pain, and swelling; pneumocystis jiroveci pneumonia and pneumonitis.",anaphylaxis is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: anaphylaxis; and injection or infusion site reactions including phlebitis, pruritus, irritation, pain, and swelling; pneumocystis jiroveci pneumonia and pneumonitis.",drug exposure is not a named entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: anaphylaxis; and injection or infusion site reactions including phlebitis, pruritus, irritation, pain, and swelling; pneumocystis jiroveci pneumonia and pneumonitis.",a is not a named entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: anaphylaxis; and injection or infusion site reactions including phlebitis, pruritus, irritation, pain, and swelling; pneumocystis jiroveci pneumonia and pneumonitis.",injection site pain is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: anaphylaxis; and injection or infusion site reactions including phlebitis, pruritus, irritation, pain, and swelling; pneumocystis jiroveci pneumonia and pneumonitis.",pneumocystis jiroveci pneumonia is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: anaphylaxis; and injection or infusion site reactions including phlebitis, pruritus, irritation, pain, and swelling; pneumocystis jiroveci pneumonia and pneumonitis.",infusion site pain is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: anaphylaxis; and injection or infusion site reactions including phlebitis, pruritus, irritation, pain, and swelling; pneumocystis jiroveci pneumonia and pneumonitis.",drug exposure is not a named entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: anaphylaxis; and injection or infusion site reactions including phlebitis, pruritus, irritation, pain, and swelling; pneumocystis jiroveci pneumonia and pneumonitis.","size , it is not a named entity"
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: anaphylaxis; and injection or infusion site reactions including phlebitis, pruritus, irritation, pain, and swelling; pneumocystis jiroveci pneumonia and pneumonitis.",injection site pruritus is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: anaphylaxis; and injection or infusion site reactions including phlebitis, pruritus, irritation, pain, and swelling; pneumocystis jiroveci pneumonia and pneumonitis.",a is not a named entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: anaphylaxis; and injection or infusion site reactions including phlebitis, pruritus, irritation, pain, and swelling; pneumocystis jiroveci pneumonia and pneumonitis.",infusion site swelling is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: anaphylaxis; and injection or infusion site reactions including phlebitis, pruritus, irritation, pain, and swelling; pneumocystis jiroveci pneumonia and pneumonitis.",infusion site phlebitis is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: anaphylaxis; and injection or infusion site reactions including phlebitis, pruritus, irritation, pain, and swelling; pneumocystis jiroveci pneumonia and pneumonitis.",injection site swelling is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: anaphylaxis; and injection or infusion site reactions including phlebitis, pruritus, irritation, pain, and swelling; pneumocystis jiroveci pneumonia and pneumonitis.",pneumonia and is not a named entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: anaphylaxis; and injection or infusion site reactions including phlebitis, pruritus, irritation, pain, and swelling; pneumocystis jiroveci pneumonia and pneumonitis.",infusion site reactions is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: anaphylaxis; and injection or infusion site reactions including phlebitis, pruritus, irritation, pain, and swelling; pneumocystis jiroveci pneumonia and pneumonitis.",to drug exposure is not a named entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: anaphylaxis; and injection or infusion site reactions including phlebitis, pruritus, irritation, pain, and swelling; pneumocystis jiroveci pneumonia and pneumonitis.","irritation , is not a named entity"
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: anaphylaxis; and injection or infusion site reactions including phlebitis, pruritus, irritation, pain, and swelling; pneumocystis jiroveci pneumonia and pneumonitis.",injection site phlebitis is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: anaphylaxis; and injection or infusion site reactions including phlebitis, pruritus, irritation, pain, and swelling; pneumocystis jiroveci pneumonia and pneumonitis.",; and is not a named entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: anaphylaxis; and injection or infusion site reactions including phlebitis, pruritus, irritation, pain, and swelling; pneumocystis jiroveci pneumonia and pneumonitis.",pneumonitis is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: anaphylaxis; and injection or infusion site reactions including phlebitis, pruritus, irritation, pain, and swelling; pneumocystis jiroveci pneumonia and pneumonitis.","pruritus , irritation is not a named entity"
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: anaphylaxis; and injection or infusion site reactions including phlebitis, pruritus, irritation, pain, and swelling; pneumocystis jiroveci pneumonia and pneumonitis.",infusion site irritation is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: anaphylaxis; and injection or infusion site reactions including phlebitis, pruritus, irritation, pain, and swelling; pneumocystis jiroveci pneumonia and pneumonitis.","phlebitis , is not a named entity"
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: anaphylaxis; and injection or infusion site reactions including phlebitis, pruritus, irritation, pain, and swelling; pneumocystis jiroveci pneumonia and pneumonitis.",jiroveci pneumonia and is not a named entity
(  5.5  )   *    Other Malignancies: Pre-malignant and malignant diseases have been reported.,Malignancies is an adverse reaction entity
(  5.5  )   *    Other Malignancies: Pre-malignant and malignant diseases have been reported.,: Pre-malignant is not a named entity
(  5.5  )   *    Other Malignancies: Pre-malignant and malignant diseases have been reported.,Pre-malignant diseases is an adverse reaction entity
(  5.5  )   *    Other Malignancies: Pre-malignant and malignant diseases have been reported.,malignant diseases is an adverse reaction entity
(  5.5  )   *    Other Malignancies: Pre-malignant and malignant diseases have been reported.,have is not a named entity
(  5.5  )   *    Other Malignancies: Pre-malignant and malignant diseases have been reported.,5.5 ) * is not a named entity
"Neuraceq, like all radiopharmaceuticals, contributes to a patient's long-term cumulative radiation exposure.",like all radiopharmaceuticals is not a named entity
"Neuraceq, like all radiopharmaceuticals, contributes to a patient's long-term cumulative radiation exposure.",long-term cumulative radiation exposure is an adverse reaction entity
"The most frequently observed adverse drug reactions in subjects receiving Neuraceq were injection site reactions consisting of erythema, irritation and pain.",in subjects receiving is not a named entity
"The most frequently observed adverse drug reactions in subjects receiving Neuraceq were injection site reactions consisting of erythema, irritation and pain.",drug reactions in is not a named entity
"The most frequently observed adverse drug reactions in subjects receiving Neuraceq were injection site reactions consisting of erythema, irritation and pain.",injection site erythema is an adverse reaction entity
"The most frequently observed adverse drug reactions in subjects receiving Neuraceq were injection site reactions consisting of erythema, irritation and pain.",injection site pain is an adverse reaction entity
"The most frequently observed adverse drug reactions in subjects receiving Neuraceq were injection site reactions consisting of erythema, irritation and pain.","erythema , is not a named entity"
"The most frequently observed adverse drug reactions in subjects receiving Neuraceq were injection site reactions consisting of erythema, irritation and pain.",injection site reactions is an adverse reaction entity
"The most frequently observed adverse drug reactions in subjects receiving Neuraceq were injection site reactions consisting of erythema, irritation and pain.",injection site irritation is an adverse reaction entity
"The most frequently observed adverse drug reactions in subjects receiving Neuraceq were injection site reactions consisting of erythema, irritation and pain.",irritation and is not a named entity
"6 ADVERSE REACTIONS           EXCERPT:   The most commonly reported adverse reactions were: injection site reaction consisting of erythema (1.7 %), irritation (1.2 %), and pain (3.9 %).",EXCERPT is not a named entity
"6 ADVERSE REACTIONS           EXCERPT:   The most commonly reported adverse reactions were: injection site reaction consisting of erythema (1.7 %), irritation (1.2 %), and pain (3.9 %).",injection site reaction is an adverse reaction entity
"6 ADVERSE REACTIONS           EXCERPT:   The most commonly reported adverse reactions were: injection site reaction consisting of erythema (1.7 %), irritation (1.2 %), and pain (3.9 %).",injection site pain is an adverse reaction entity
"6 ADVERSE REACTIONS           EXCERPT:   The most commonly reported adverse reactions were: injection site reaction consisting of erythema (1.7 %), irritation (1.2 %), and pain (3.9 %).",injection site irritation is an adverse reaction entity
"6 ADVERSE REACTIONS           EXCERPT:   The most commonly reported adverse reactions were: injection site reaction consisting of erythema (1.7 %), irritation (1.2 %), and pain (3.9 %).",: The is not a named entity
"6 ADVERSE REACTIONS           EXCERPT:   The most commonly reported adverse reactions were: injection site reaction consisting of erythema (1.7 %), irritation (1.2 %), and pain (3.9 %).",3.9 is not a named entity
"6 ADVERSE REACTIONS           EXCERPT:   The most commonly reported adverse reactions were: injection site reaction consisting of erythema (1.7 %), irritation (1.2 %), and pain (3.9 %).",injection site erythema is an adverse reaction entity
"6 ADVERSE REACTIONS           EXCERPT:   The most commonly reported adverse reactions were: injection site reaction consisting of erythema (1.7 %), irritation (1.2 %), and pain (3.9 %).",") , is not a named entity"
Long-term cumulative radiation exposure is associated with an increased risk of cancer.,of cancer is not a named entity
Long-term cumulative radiation exposure is associated with an increased risk of cancer.,radiation exposure is not a named entity
Long-term cumulative radiation exposure is associated with an increased risk of cancer.,cancer is an adverse reaction entity
Long-term cumulative radiation exposure is associated with an increased risk of cancer.,Long-term cumulative radiation exposure is an adverse reaction entity
"Among ENTEREG-treated patients undergoing surgeries that included a bowel resection, the most common adverse reaction (incidence >=1.5%) occurring with a higher frequency than placebo was dyspepsia (ENTEREG, 1.5%; placebo, 0.8%).",dyspepsia is an adverse reaction entity
"Among ENTEREG-treated patients undergoing surgeries that included a bowel resection, the most common adverse reaction (incidence >=1.5%) occurring with a higher frequency than placebo was dyspepsia (ENTEREG, 1.5%; placebo, 0.8%).",a bowel resection is not a named entity
6 ADVERSE REACTIONS    EXCERPT:   The most common adverse reaction (incidence >=1.5%) occurring with a higher frequency than placebo among ENTEREG-treated patients undergoing surgeries that included a bowel resection was dyspepsia.,6 ADVERSE is not a named entity
6 ADVERSE REACTIONS    EXCERPT:   The most common adverse reaction (incidence >=1.5%) occurring with a higher frequency than placebo among ENTEREG-treated patients undergoing surgeries that included a bowel resection was dyspepsia.,dyspepsia is an adverse reaction entity
"In this study, the majority of myocardial infarctions occurred between 1 and 4 months after initiation of treatment.",of is not a named entity
"In this study, the majority of myocardial infarctions occurred between 1 and 4 months after initiation of treatment.",myocardial infarctions is an adverse reaction entity
"Since ENTEREG acts peripherally, clinical signs and symptoms of increased sensitivity would be related to the gastrointestinal tract (e.g., abdominal pain, nausea and vomiting, diarrhea).",nausea is an adverse reaction entity
"Since ENTEREG acts peripherally, clinical signs and symptoms of increased sensitivity would be related to the gastrointestinal tract (e.g., abdominal pain, nausea and vomiting, diarrhea).",vomiting is an adverse reaction entity
"Since ENTEREG acts peripherally, clinical signs and symptoms of increased sensitivity would be related to the gastrointestinal tract (e.g., abdominal pain, nausea and vomiting, diarrhea).",clinical signs is not a named entity
"Since ENTEREG acts peripherally, clinical signs and symptoms of increased sensitivity would be related to the gastrointestinal tract (e.g., abdominal pain, nausea and vomiting, diarrhea).",", clinical is not a named entity"
"Since ENTEREG acts peripherally, clinical signs and symptoms of increased sensitivity would be related to the gastrointestinal tract (e.g., abdominal pain, nausea and vomiting, diarrhea).",ENTEREG acts is not a named entity
"Since ENTEREG acts peripherally, clinical signs and symptoms of increased sensitivity would be related to the gastrointestinal tract (e.g., abdominal pain, nausea and vomiting, diarrhea).",abdominal pain is an adverse reaction entity
"Since ENTEREG acts peripherally, clinical signs and symptoms of increased sensitivity would be related to the gastrointestinal tract (e.g., abdominal pain, nausea and vomiting, diarrhea).",gastrointestinal tract is not a named entity
"Since ENTEREG acts peripherally, clinical signs and symptoms of increased sensitivity would be related to the gastrointestinal tract (e.g., abdominal pain, nausea and vomiting, diarrhea).",increased sensitivity to the gastrointestinal tract is an adverse reaction entity
"Since ENTEREG acts peripherally, clinical signs and symptoms of increased sensitivity would be related to the gastrointestinal tract (e.g., abdominal pain, nausea and vomiting, diarrhea).",diarrhea is an adverse reaction entity
"Since ENTEREG acts peripherally, clinical signs and symptoms of increased sensitivity would be related to the gastrointestinal tract (e.g., abdominal pain, nausea and vomiting, diarrhea).",", clinical is not a named entity"
WARNING:  POTENTIAL RISK OF MYOCARDIAL INFARCTION WITH LONG-TERM USE: FOR SHORT-TERM HOSPITAL USE ONLY         See full prescribing information for complete boxed warning.,MYOCARDIAL INFARCTION is an adverse reaction entity
WARNING:  POTENTIAL RISK OF MYOCARDIAL INFARCTION WITH LONG-TERM USE: FOR SHORT-TERM HOSPITAL USE ONLY         See full prescribing information for complete boxed warning.,for is not a named entity
"(5.7)          5.1 Potential Risk of Myocardial Infarction with Long-term Use    There were more reports of myocardial infarctions in patients treated with alvimopan 0.5 mg twice daily compared with placebo-treated patients in a 12-month study of patients treated with opioids for chronic non-cancer pain (alvimopan 0.5 mg, n = 538; placebo, n = 267).",infarctions is not a named entity
"(5.7)          5.1 Potential Risk of Myocardial Infarction with Long-term Use    There were more reports of myocardial infarctions in patients treated with alvimopan 0.5 mg twice daily compared with placebo-treated patients in a 12-month study of patients treated with opioids for chronic non-cancer pain (alvimopan 0.5 mg, n = 538; placebo, n = 267).",myocardial infarctions is an adverse reaction entity
"BOXED WARNING: WARNING: POTENTIAL RISK OF MYOCARDIAL INFARCTION WITH LONG-TERM USE: FOR SHORT-TERM HOSPITAL USE ONLY      WARNING: POTENTIAL RISK OF MYOCARDIAL INFARCTION WITH LONG-TERM USE: FOR SHORT-TERM HOSPITAL USE ONLY        There was a greater incidence of myocardial infarction in alvimopan-treated patients compared to placebo-treated patients in a 12-month clinical trial, although a causal relationship has not been established.",USE ONLY is not a named entity
"BOXED WARNING: WARNING: POTENTIAL RISK OF MYOCARDIAL INFARCTION WITH LONG-TERM USE: FOR SHORT-TERM HOSPITAL USE ONLY      WARNING: POTENTIAL RISK OF MYOCARDIAL INFARCTION WITH LONG-TERM USE: FOR SHORT-TERM HOSPITAL USE ONLY        There was a greater incidence of myocardial infarction in alvimopan-treated patients compared to placebo-treated patients in a 12-month clinical trial, although a causal relationship has not been established.",myocardial infarction is an adverse reaction entity
"BOXED WARNING: WARNING: POTENTIAL RISK OF MYOCARDIAL INFARCTION WITH LONG-TERM USE: FOR SHORT-TERM HOSPITAL USE ONLY      WARNING: POTENTIAL RISK OF MYOCARDIAL INFARCTION WITH LONG-TERM USE: FOR SHORT-TERM HOSPITAL USE ONLY        There was a greater incidence of myocardial infarction in alvimopan-treated patients compared to placebo-treated patients in a 12-month clinical trial, although a causal relationship has not been established.",MYOCARDIAL INFARCTION is an adverse reaction entity
"BOXED WARNING: WARNING: POTENTIAL RISK OF MYOCARDIAL INFARCTION WITH LONG-TERM USE: FOR SHORT-TERM HOSPITAL USE ONLY      WARNING: POTENTIAL RISK OF MYOCARDIAL INFARCTION WITH LONG-TERM USE: FOR SHORT-TERM HOSPITAL USE ONLY        There was a greater incidence of myocardial infarction in alvimopan-treated patients compared to placebo-treated patients in a 12-month clinical trial, although a causal relationship has not been established.",: is not a named entity
"BOXED WARNING: WARNING: POTENTIAL RISK OF MYOCARDIAL INFARCTION WITH LONG-TERM USE: FOR SHORT-TERM HOSPITAL USE ONLY      WARNING: POTENTIAL RISK OF MYOCARDIAL INFARCTION WITH LONG-TERM USE: FOR SHORT-TERM HOSPITAL USE ONLY        There was a greater incidence of myocardial infarction in alvimopan-treated patients compared to placebo-treated patients in a 12-month clinical trial, although a causal relationship has not been established.",MYOCARDIAL INFARCTION is an adverse reaction entity
"BOXED WARNING: WARNING: POTENTIAL RISK OF MYOCARDIAL INFARCTION WITH LONG-TERM USE: FOR SHORT-TERM HOSPITAL USE ONLY      WARNING: POTENTIAL RISK OF MYOCARDIAL INFARCTION WITH LONG-TERM USE: FOR SHORT-TERM HOSPITAL USE ONLY        There was a greater incidence of myocardial infarction in alvimopan-treated patients compared to placebo-treated patients in a 12-month clinical trial, although a causal relationship has not been established.",myocardial infarction in is not a named entity
"5 WARNINGS AND PRECAUTIONS     EXCERPT:    *  A higher number of myocardial infarctions was reported in patients treated with alvimopan 0.5 mg twice daily compared with placebo in a 12-month study in patients treated with opioids for chronic non-cancer pain, although a causal relationship with long-term use has not been established.",myocardial infarctions is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS     EXCERPT:    *  A higher number of myocardial infarctions was reported in patients treated with alvimopan 0.5 mg twice daily compared with placebo in a 12-month study in patients treated with opioids for chronic non-cancer pain, although a causal relationship with long-term use has not been established.",* A higher is not a named entity
"The following adverse reactions are described in more detail in the Warnings and Precautions section of the label: Seizures, Anaphylaxis, and Urinary Tract Infections.",described is not a named entity
"The following adverse reactions are described in more detail in the Warnings and Precautions section of the label: Seizures, Anaphylaxis, and Urinary Tract Infections.",Seizures is an adverse reaction entity
"The following adverse reactions are described in more detail in the Warnings and Precautions section of the label: Seizures, Anaphylaxis, and Urinary Tract Infections.",Urinary Tract Infections is an adverse reaction entity
"The following adverse reactions are described in more detail in the Warnings and Precautions section of the label: Seizures, Anaphylaxis, and Urinary Tract Infections.","Seizures , is not a named entity"
"The following adverse reactions are described in more detail in the Warnings and Precautions section of the label: Seizures, Anaphylaxis, and Urinary Tract Infections.",reactions are described is not a named entity
"The following adverse reactions are described in more detail in the Warnings and Precautions section of the label: Seizures, Anaphylaxis, and Urinary Tract Infections.",Anaphylaxis is an adverse reaction entity
"Signs and symptoms have included respiratory compromise, urticaria, and angioedema of the throat and or tongue.",urticaria is an adverse reaction entity
"Signs and symptoms have included respiratory compromise, urticaria, and angioedema of the throat and or tongue.",angioedema of the tongue is an adverse reaction entity
"Signs and symptoms have included respiratory compromise, urticaria, and angioedema of the throat and or tongue.",angioedema of the throat is an adverse reaction entity
"Signs and symptoms have included respiratory compromise, urticaria, and angioedema of the throat and or tongue.",", urticaria , is not a named entity"
"Signs and symptoms have included respiratory compromise, urticaria, and angioedema of the throat and or tongue.",the is not a named entity
"Signs and symptoms have included respiratory compromise, urticaria, and angioedema of the throat and or tongue.",respiratory compromise is an adverse reaction entity
"Signs and symptoms have included respiratory compromise, urticaria, and angioedema of the throat and or tongue.",of the is not a named entity
"Signs and symptoms have included respiratory compromise, urticaria, and angioedema of the throat and or tongue.",", and is not a named entity"
"In open label extension trials in MS patients, the incidence of seizures during treatment with dalfampridine 15 mg twice daily (1.7/100PY) was over 4 times higher than the incidence during treatment with 10 mg twice daily (0.4/100PY).",dalfampridine 15 is not a named entity
"In open label extension trials in MS patients, the incidence of seizures during treatment with dalfampridine 15 mg twice daily (1.7/100PY) was over 4 times higher than the incidence during treatment with 10 mg twice daily (0.4/100PY).",seizures is an adverse reaction entity
"As in controlled clinical trials, a dose-dependent increase in the incidence of seizures has been observed in open-label clinical trials with AMPYRA in patients with MS as follows: AMPYRA 10 mg twice daily 0.41 per 100 person-years (95% confidence interval 0.13-0.96); dalfampridine 15 mg twice daily 1.7 per 100 person-years (95% confidence interval 0.21-6.28).",10 is not a named entity
"As in controlled clinical trials, a dose-dependent increase in the incidence of seizures has been observed in open-label clinical trials with AMPYRA in patients with MS as follows: AMPYRA 10 mg twice daily 0.41 per 100 person-years (95% confidence interval 0.13-0.96); dalfampridine 15 mg twice daily 1.7 per 100 person-years (95% confidence interval 0.21-6.28).",seizures is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  AMPYRA can cause seizures; the risk of seizures increases with increasing AMPYRA doses; discontinue AMPYRA and do not restart if a seizure occurs (  5.1  )   *  AMPYRA should not be taken with other forms of 4-aminopyridine (4-AP, fampridine), since the active ingredient is the same (  5.3  )   *  AMPYRA can cause anaphylaxis.",seizures is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  AMPYRA can cause seizures; the risk of seizures increases with increasing AMPYRA doses; discontinue AMPYRA and do not restart if a seizure occurs (  5.1  )   *  AMPYRA should not be taken with other forms of 4-aminopyridine (4-AP, fampridine), since the active ingredient is the same (  5.3  )   *  AMPYRA can cause anaphylaxis.",: * AMPYRA is not a named entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  AMPYRA can cause seizures; the risk of seizures increases with increasing AMPYRA doses; discontinue AMPYRA and do not restart if a seizure occurs (  5.1  )   *  AMPYRA should not be taken with other forms of 4-aminopyridine (4-AP, fampridine), since the active ingredient is the same (  5.3  )   *  AMPYRA can cause anaphylaxis.",seizures is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  AMPYRA can cause seizures; the risk of seizures increases with increasing AMPYRA doses; discontinue AMPYRA and do not restart if a seizure occurs (  5.1  )   *  AMPYRA should not be taken with other forms of 4-aminopyridine (4-AP, fampridine), since the active ingredient is the same (  5.3  )   *  AMPYRA can cause anaphylaxis.",risk is not a named entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  AMPYRA can cause seizures; the risk of seizures increases with increasing AMPYRA doses; discontinue AMPYRA and do not restart if a seizure occurs (  5.1  )   *  AMPYRA should not be taken with other forms of 4-aminopyridine (4-AP, fampridine), since the active ingredient is the same (  5.3  )   *  AMPYRA can cause anaphylaxis.",anaphylaxis is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  AMPYRA can cause seizures; the risk of seizures increases with increasing AMPYRA doses; discontinue AMPYRA and do not restart if a seizure occurs (  5.1  )   *  AMPYRA should not be taken with other forms of 4-aminopyridine (4-AP, fampridine), since the active ingredient is the same (  5.3  )   *  AMPYRA can cause anaphylaxis.",discontinue AMPYRA and is not a named entity
"In patients with mild renal impairment (CrCl 51-80 mL/min), AMPYRA plasma levels may approach those seen at a dose of 15 mg twice daily, a dose that may be associated with an increased risk of seizures [see  Warnings and Precautions (5.1)  ]  .",a dose is not a named entity
"In patients with mild renal impairment (CrCl 51-80 mL/min), AMPYRA plasma levels may approach those seen at a dose of 15 mg twice daily, a dose that may be associated with an increased risk of seizures [see  Warnings and Precautions (5.1)  ]  .",seizures is an adverse reaction entity
"EXCERPT:   The most common adverse events (incidence >=2% and at a rate greater than the placebo rate) for AMPYRA were urinary tract infection, insomnia, dizziness, headache, nausea, asthenia, back pain, balance disorder, multiple sclerosis relapse, paresthesia, nasopharyngitis, constipation, dyspepsia, and pharyngolaryngeal pain (  6.1  ).",pharyngolaryngeal pain is an adverse reaction entity
"EXCERPT:   The most common adverse events (incidence >=2% and at a rate greater than the placebo rate) for AMPYRA were urinary tract infection, insomnia, dizziness, headache, nausea, asthenia, back pain, balance disorder, multiple sclerosis relapse, paresthesia, nasopharyngitis, constipation, dyspepsia, and pharyngolaryngeal pain (  6.1  ).",urinary tract infection is an adverse reaction entity
"EXCERPT:   The most common adverse events (incidence >=2% and at a rate greater than the placebo rate) for AMPYRA were urinary tract infection, insomnia, dizziness, headache, nausea, asthenia, back pain, balance disorder, multiple sclerosis relapse, paresthesia, nasopharyngitis, constipation, dyspepsia, and pharyngolaryngeal pain (  6.1  ).",constipation is an adverse reaction entity
"EXCERPT:   The most common adverse events (incidence >=2% and at a rate greater than the placebo rate) for AMPYRA were urinary tract infection, insomnia, dizziness, headache, nausea, asthenia, back pain, balance disorder, multiple sclerosis relapse, paresthesia, nasopharyngitis, constipation, dyspepsia, and pharyngolaryngeal pain (  6.1  ).",common adverse events is not a named entity
"EXCERPT:   The most common adverse events (incidence >=2% and at a rate greater than the placebo rate) for AMPYRA were urinary tract infection, insomnia, dizziness, headache, nausea, asthenia, back pain, balance disorder, multiple sclerosis relapse, paresthesia, nasopharyngitis, constipation, dyspepsia, and pharyngolaryngeal pain (  6.1  ).",back pain is an adverse reaction entity
"EXCERPT:   The most common adverse events (incidence >=2% and at a rate greater than the placebo rate) for AMPYRA were urinary tract infection, insomnia, dizziness, headache, nausea, asthenia, back pain, balance disorder, multiple sclerosis relapse, paresthesia, nasopharyngitis, constipation, dyspepsia, and pharyngolaryngeal pain (  6.1  ).",insomnia is an adverse reaction entity
"EXCERPT:   The most common adverse events (incidence >=2% and at a rate greater than the placebo rate) for AMPYRA were urinary tract infection, insomnia, dizziness, headache, nausea, asthenia, back pain, balance disorder, multiple sclerosis relapse, paresthesia, nasopharyngitis, constipation, dyspepsia, and pharyngolaryngeal pain (  6.1  ).",events is not a named entity
"EXCERPT:   The most common adverse events (incidence >=2% and at a rate greater than the placebo rate) for AMPYRA were urinary tract infection, insomnia, dizziness, headache, nausea, asthenia, back pain, balance disorder, multiple sclerosis relapse, paresthesia, nasopharyngitis, constipation, dyspepsia, and pharyngolaryngeal pain (  6.1  ).",", and pharyngolaryngeal is not a named entity"
"EXCERPT:   The most common adverse events (incidence >=2% and at a rate greater than the placebo rate) for AMPYRA were urinary tract infection, insomnia, dizziness, headache, nausea, asthenia, back pain, balance disorder, multiple sclerosis relapse, paresthesia, nasopharyngitis, constipation, dyspepsia, and pharyngolaryngeal pain (  6.1  ).",paresthesia is an adverse reaction entity
"EXCERPT:   The most common adverse events (incidence >=2% and at a rate greater than the placebo rate) for AMPYRA were urinary tract infection, insomnia, dizziness, headache, nausea, asthenia, back pain, balance disorder, multiple sclerosis relapse, paresthesia, nasopharyngitis, constipation, dyspepsia, and pharyngolaryngeal pain (  6.1  ).",: The most is not a named entity
"EXCERPT:   The most common adverse events (incidence >=2% and at a rate greater than the placebo rate) for AMPYRA were urinary tract infection, insomnia, dizziness, headache, nausea, asthenia, back pain, balance disorder, multiple sclerosis relapse, paresthesia, nasopharyngitis, constipation, dyspepsia, and pharyngolaryngeal pain (  6.1  ).",dyspepsia is an adverse reaction entity
"EXCERPT:   The most common adverse events (incidence >=2% and at a rate greater than the placebo rate) for AMPYRA were urinary tract infection, insomnia, dizziness, headache, nausea, asthenia, back pain, balance disorder, multiple sclerosis relapse, paresthesia, nasopharyngitis, constipation, dyspepsia, and pharyngolaryngeal pain (  6.1  ).",", dyspepsia , is not a named entity"
"EXCERPT:   The most common adverse events (incidence >=2% and at a rate greater than the placebo rate) for AMPYRA were urinary tract infection, insomnia, dizziness, headache, nausea, asthenia, back pain, balance disorder, multiple sclerosis relapse, paresthesia, nasopharyngitis, constipation, dyspepsia, and pharyngolaryngeal pain (  6.1  ).",and is not a named entity
"EXCERPT:   The most common adverse events (incidence >=2% and at a rate greater than the placebo rate) for AMPYRA were urinary tract infection, insomnia, dizziness, headache, nausea, asthenia, back pain, balance disorder, multiple sclerosis relapse, paresthesia, nasopharyngitis, constipation, dyspepsia, and pharyngolaryngeal pain (  6.1  ).",", is not a named entity"
"EXCERPT:   The most common adverse events (incidence >=2% and at a rate greater than the placebo rate) for AMPYRA were urinary tract infection, insomnia, dizziness, headache, nausea, asthenia, back pain, balance disorder, multiple sclerosis relapse, paresthesia, nasopharyngitis, constipation, dyspepsia, and pharyngolaryngeal pain (  6.1  ).",asthenia is an adverse reaction entity
"EXCERPT:   The most common adverse events (incidence >=2% and at a rate greater than the placebo rate) for AMPYRA were urinary tract infection, insomnia, dizziness, headache, nausea, asthenia, back pain, balance disorder, multiple sclerosis relapse, paresthesia, nasopharyngitis, constipation, dyspepsia, and pharyngolaryngeal pain (  6.1  ).",were urinary is not a named entity
"EXCERPT:   The most common adverse events (incidence >=2% and at a rate greater than the placebo rate) for AMPYRA were urinary tract infection, insomnia, dizziness, headache, nausea, asthenia, back pain, balance disorder, multiple sclerosis relapse, paresthesia, nasopharyngitis, constipation, dyspepsia, and pharyngolaryngeal pain (  6.1  ).",", is not a named entity"
"EXCERPT:   The most common adverse events (incidence >=2% and at a rate greater than the placebo rate) for AMPYRA were urinary tract infection, insomnia, dizziness, headache, nausea, asthenia, back pain, balance disorder, multiple sclerosis relapse, paresthesia, nasopharyngitis, constipation, dyspepsia, and pharyngolaryngeal pain (  6.1  ).",headache is an adverse reaction entity
"EXCERPT:   The most common adverse events (incidence >=2% and at a rate greater than the placebo rate) for AMPYRA were urinary tract infection, insomnia, dizziness, headache, nausea, asthenia, back pain, balance disorder, multiple sclerosis relapse, paresthesia, nasopharyngitis, constipation, dyspepsia, and pharyngolaryngeal pain (  6.1  ).","relapse , paresthesia is not a named entity"
"EXCERPT:   The most common adverse events (incidence >=2% and at a rate greater than the placebo rate) for AMPYRA were urinary tract infection, insomnia, dizziness, headache, nausea, asthenia, back pain, balance disorder, multiple sclerosis relapse, paresthesia, nasopharyngitis, constipation, dyspepsia, and pharyngolaryngeal pain (  6.1  ).",AMPYRA were is not a named entity
"EXCERPT:   The most common adverse events (incidence >=2% and at a rate greater than the placebo rate) for AMPYRA were urinary tract infection, insomnia, dizziness, headache, nausea, asthenia, back pain, balance disorder, multiple sclerosis relapse, paresthesia, nasopharyngitis, constipation, dyspepsia, and pharyngolaryngeal pain (  6.1  ).",balance disorder is an adverse reaction entity
"EXCERPT:   The most common adverse events (incidence >=2% and at a rate greater than the placebo rate) for AMPYRA were urinary tract infection, insomnia, dizziness, headache, nausea, asthenia, back pain, balance disorder, multiple sclerosis relapse, paresthesia, nasopharyngitis, constipation, dyspepsia, and pharyngolaryngeal pain (  6.1  ).",multiple sclerosis relapse is an adverse reaction entity
"EXCERPT:   The most common adverse events (incidence >=2% and at a rate greater than the placebo rate) for AMPYRA were urinary tract infection, insomnia, dizziness, headache, nausea, asthenia, back pain, balance disorder, multiple sclerosis relapse, paresthesia, nasopharyngitis, constipation, dyspepsia, and pharyngolaryngeal pain (  6.1  ).",at a is not a named entity
"EXCERPT:   The most common adverse events (incidence >=2% and at a rate greater than the placebo rate) for AMPYRA were urinary tract infection, insomnia, dizziness, headache, nausea, asthenia, back pain, balance disorder, multiple sclerosis relapse, paresthesia, nasopharyngitis, constipation, dyspepsia, and pharyngolaryngeal pain (  6.1  ).",dizziness is an adverse reaction entity
"EXCERPT:   The most common adverse events (incidence >=2% and at a rate greater than the placebo rate) for AMPYRA were urinary tract infection, insomnia, dizziness, headache, nausea, asthenia, back pain, balance disorder, multiple sclerosis relapse, paresthesia, nasopharyngitis, constipation, dyspepsia, and pharyngolaryngeal pain (  6.1  ).",placebo rate is not a named entity
"EXCERPT:   The most common adverse events (incidence >=2% and at a rate greater than the placebo rate) for AMPYRA were urinary tract infection, insomnia, dizziness, headache, nausea, asthenia, back pain, balance disorder, multiple sclerosis relapse, paresthesia, nasopharyngitis, constipation, dyspepsia, and pharyngolaryngeal pain (  6.1  ).",nasopharyngitis is an adverse reaction entity
"EXCERPT:   The most common adverse events (incidence >=2% and at a rate greater than the placebo rate) for AMPYRA were urinary tract infection, insomnia, dizziness, headache, nausea, asthenia, back pain, balance disorder, multiple sclerosis relapse, paresthesia, nasopharyngitis, constipation, dyspepsia, and pharyngolaryngeal pain (  6.1  ).",nausea is an adverse reaction entity
"EXCERPT:   The most common adverse events (incidence >=2% and at a rate greater than the placebo rate) for AMPYRA were urinary tract infection, insomnia, dizziness, headache, nausea, asthenia, back pain, balance disorder, multiple sclerosis relapse, paresthesia, nasopharyngitis, constipation, dyspepsia, and pharyngolaryngeal pain (  6.1  ).",) is not a named entity
"The treatment emergent adverse events leading to discontinuation of at least 2 patients treated with AMPYRA and that led to discontinuation more frequently compared to placebo were headache (AMPYRA 0.5%, placebo 0%), balance disorder (AMPYRA 0.5%, placebo 0%), dizziness (AMPYRA 0.5%, placebo 0%), and confusional state (AMPYRA 0.3%, placebo 0%).",and that is not a named entity
"The treatment emergent adverse events leading to discontinuation of at least 2 patients treated with AMPYRA and that led to discontinuation more frequently compared to placebo were headache (AMPYRA 0.5%, placebo 0%), balance disorder (AMPYRA 0.5%, placebo 0%), dizziness (AMPYRA 0.5%, placebo 0%), and confusional state (AMPYRA 0.3%, placebo 0%).",dizziness is an adverse reaction entity
"The treatment emergent adverse events leading to discontinuation of at least 2 patients treated with AMPYRA and that led to discontinuation more frequently compared to placebo were headache (AMPYRA 0.5%, placebo 0%), balance disorder (AMPYRA 0.5%, placebo 0%), dizziness (AMPYRA 0.5%, placebo 0%), and confusional state (AMPYRA 0.3%, placebo 0%).",headache is an adverse reaction entity
"The treatment emergent adverse events leading to discontinuation of at least 2 patients treated with AMPYRA and that led to discontinuation more frequently compared to placebo were headache (AMPYRA 0.5%, placebo 0%), balance disorder (AMPYRA 0.5%, placebo 0%), dizziness (AMPYRA 0.5%, placebo 0%), and confusional state (AMPYRA 0.3%, placebo 0%).",balance disorder is an adverse reaction entity
"The treatment emergent adverse events leading to discontinuation of at least 2 patients treated with AMPYRA and that led to discontinuation more frequently compared to placebo were headache (AMPYRA 0.5%, placebo 0%), balance disorder (AMPYRA 0.5%, placebo 0%), dizziness (AMPYRA 0.5%, placebo 0%), and confusional state (AMPYRA 0.3%, placebo 0%).",2 is not a named entity
"The treatment emergent adverse events leading to discontinuation of at least 2 patients treated with AMPYRA and that led to discontinuation more frequently compared to placebo were headache (AMPYRA 0.5%, placebo 0%), balance disorder (AMPYRA 0.5%, placebo 0%), dizziness (AMPYRA 0.5%, placebo 0%), and confusional state (AMPYRA 0.3%, placebo 0%).",confusional state is an adverse reaction entity
"The treatment emergent adverse events leading to discontinuation of at least 2 patients treated with AMPYRA and that led to discontinuation more frequently compared to placebo were headache (AMPYRA 0.5%, placebo 0%), balance disorder (AMPYRA 0.5%, placebo 0%), dizziness (AMPYRA 0.5%, placebo 0%), and confusional state (AMPYRA 0.3%, placebo 0%).","% , is not a named entity"
"The treatment emergent adverse events leading to discontinuation of at least 2 patients treated with AMPYRA and that led to discontinuation more frequently compared to placebo were headache (AMPYRA 0.5%, placebo 0%), balance disorder (AMPYRA 0.5%, placebo 0%), dizziness (AMPYRA 0.5%, placebo 0%), and confusional state (AMPYRA 0.3%, placebo 0%).",AMPYRA 0.5 is not a named entity
5.5 Urinary Tract Infections      Urinary tract infections (UTIs) were reported more frequently as adverse reactions in controlled studies in patients receiving AMPYRA 10 mg twice daily (12%) as compared to placebo (8%).,Urinary tract infections is an adverse reaction entity
5.5 Urinary Tract Infections      Urinary tract infections (UTIs) were reported more frequently as adverse reactions in controlled studies in patients receiving AMPYRA 10 mg twice daily (12%) as compared to placebo (8%).,AMPYRA 10 mg is not a named entity
5.5 Urinary Tract Infections      Urinary tract infections (UTIs) were reported more frequently as adverse reactions in controlled studies in patients receiving AMPYRA 10 mg twice daily (12%) as compared to placebo (8%).,UTIs is an adverse reaction entity
5.5 Urinary Tract Infections      Urinary tract infections (UTIs) were reported more frequently as adverse reactions in controlled studies in patients receiving AMPYRA 10 mg twice daily (12%) as compared to placebo (8%).,10 mg twice is not a named entity
"There were four suicides in drug-treated patients in the trials and none in placebo-treated patients, but the number of events is too small to allow any conclusion about drug effect on suicide.",suicide is an adverse reaction entity
"There were four suicides in drug-treated patients in the trials and none in placebo-treated patients, but the number of events is too small to allow any conclusion about drug effect on suicide.",suicides is an adverse reaction entity
"There were four suicides in drug-treated patients in the trials and none in placebo-treated patients, but the number of events is too small to allow any conclusion about drug effect on suicide.",is too small is not a named entity
"There were four suicides in drug-treated patients in the trials and none in placebo-treated patients, but the number of events is too small to allow any conclusion about drug effect on suicide.",drug effect on is not a named entity
5.2 Serious Dermatologic Reactions      Serious dermatologic reactions including Stevens-Johnson Syndrome (SJS) have been reported in association with APTIOM use.,have been is not a named entity
5.2 Serious Dermatologic Reactions      Serious dermatologic reactions including Stevens-Johnson Syndrome (SJS) have been reported in association with APTIOM use.,5.2 Serious Dermatologic is not a named entity
5.2 Serious Dermatologic Reactions      Serious dermatologic reactions including Stevens-Johnson Syndrome (SJS) have been reported in association with APTIOM use.,reported in is not a named entity
5.2 Serious Dermatologic Reactions      Serious dermatologic reactions including Stevens-Johnson Syndrome (SJS) have been reported in association with APTIOM use.,dermatologic reactions is an adverse reaction entity
5.2 Serious Dermatologic Reactions      Serious dermatologic reactions including Stevens-Johnson Syndrome (SJS) have been reported in association with APTIOM use.,SJS is an adverse reaction entity
5.2 Serious Dermatologic Reactions      Serious dermatologic reactions including Stevens-Johnson Syndrome (SJS) have been reported in association with APTIOM use.,Stevens-Johnson Syndrome is an adverse reaction entity
"The adverse reactions most commonly (>=1% in any APTIOM treatment group, and greater than placebo) leading to discontinuation, in descending order of frequency, were dizziness, nausea, vomiting, ataxia, diplopia, somnolence, headache, blurred vision, vertigo, asthenia, fatigue, rash, dysarthria, and tremor.",somnolence is an adverse reaction entity
"The adverse reactions most commonly (>=1% in any APTIOM treatment group, and greater than placebo) leading to discontinuation, in descending order of frequency, were dizziness, nausea, vomiting, ataxia, diplopia, somnolence, headache, blurred vision, vertigo, asthenia, fatigue, rash, dysarthria, and tremor.",blurred vision is an adverse reaction entity
"The adverse reactions most commonly (>=1% in any APTIOM treatment group, and greater than placebo) leading to discontinuation, in descending order of frequency, were dizziness, nausea, vomiting, ataxia, diplopia, somnolence, headache, blurred vision, vertigo, asthenia, fatigue, rash, dysarthria, and tremor.",nausea is an adverse reaction entity
"The adverse reactions most commonly (>=1% in any APTIOM treatment group, and greater than placebo) leading to discontinuation, in descending order of frequency, were dizziness, nausea, vomiting, ataxia, diplopia, somnolence, headache, blurred vision, vertigo, asthenia, fatigue, rash, dysarthria, and tremor.",were dizziness is not a named entity
"The adverse reactions most commonly (>=1% in any APTIOM treatment group, and greater than placebo) leading to discontinuation, in descending order of frequency, were dizziness, nausea, vomiting, ataxia, diplopia, somnolence, headache, blurred vision, vertigo, asthenia, fatigue, rash, dysarthria, and tremor.",vomiting is an adverse reaction entity
"The adverse reactions most commonly (>=1% in any APTIOM treatment group, and greater than placebo) leading to discontinuation, in descending order of frequency, were dizziness, nausea, vomiting, ataxia, diplopia, somnolence, headache, blurred vision, vertigo, asthenia, fatigue, rash, dysarthria, and tremor.","treatment group , is not a named entity"
"The adverse reactions most commonly (>=1% in any APTIOM treatment group, and greater than placebo) leading to discontinuation, in descending order of frequency, were dizziness, nausea, vomiting, ataxia, diplopia, somnolence, headache, blurred vision, vertigo, asthenia, fatigue, rash, dysarthria, and tremor.","vomiting , ataxia is not a named entity"
"The adverse reactions most commonly (>=1% in any APTIOM treatment group, and greater than placebo) leading to discontinuation, in descending order of frequency, were dizziness, nausea, vomiting, ataxia, diplopia, somnolence, headache, blurred vision, vertigo, asthenia, fatigue, rash, dysarthria, and tremor.",dizziness is an adverse reaction entity
"The adverse reactions most commonly (>=1% in any APTIOM treatment group, and greater than placebo) leading to discontinuation, in descending order of frequency, were dizziness, nausea, vomiting, ataxia, diplopia, somnolence, headache, blurred vision, vertigo, asthenia, fatigue, rash, dysarthria, and tremor.",headache is an adverse reaction entity
"The adverse reactions most commonly (>=1% in any APTIOM treatment group, and greater than placebo) leading to discontinuation, in descending order of frequency, were dizziness, nausea, vomiting, ataxia, diplopia, somnolence, headache, blurred vision, vertigo, asthenia, fatigue, rash, dysarthria, and tremor.","dizziness , nausea is not a named entity"
"The adverse reactions most commonly (>=1% in any APTIOM treatment group, and greater than placebo) leading to discontinuation, in descending order of frequency, were dizziness, nausea, vomiting, ataxia, diplopia, somnolence, headache, blurred vision, vertigo, asthenia, fatigue, rash, dysarthria, and tremor.",tremor is an adverse reaction entity
"The adverse reactions most commonly (>=1% in any APTIOM treatment group, and greater than placebo) leading to discontinuation, in descending order of frequency, were dizziness, nausea, vomiting, ataxia, diplopia, somnolence, headache, blurred vision, vertigo, asthenia, fatigue, rash, dysarthria, and tremor.",asthenia is an adverse reaction entity
"The adverse reactions most commonly (>=1% in any APTIOM treatment group, and greater than placebo) leading to discontinuation, in descending order of frequency, were dizziness, nausea, vomiting, ataxia, diplopia, somnolence, headache, blurred vision, vertigo, asthenia, fatigue, rash, dysarthria, and tremor.",rash is an adverse reaction entity
"The adverse reactions most commonly (>=1% in any APTIOM treatment group, and greater than placebo) leading to discontinuation, in descending order of frequency, were dizziness, nausea, vomiting, ataxia, diplopia, somnolence, headache, blurred vision, vertigo, asthenia, fatigue, rash, dysarthria, and tremor.",", were dizziness is not a named entity"
"The adverse reactions most commonly (>=1% in any APTIOM treatment group, and greater than placebo) leading to discontinuation, in descending order of frequency, were dizziness, nausea, vomiting, ataxia, diplopia, somnolence, headache, blurred vision, vertigo, asthenia, fatigue, rash, dysarthria, and tremor.",diplopia is an adverse reaction entity
"The adverse reactions most commonly (>=1% in any APTIOM treatment group, and greater than placebo) leading to discontinuation, in descending order of frequency, were dizziness, nausea, vomiting, ataxia, diplopia, somnolence, headache, blurred vision, vertigo, asthenia, fatigue, rash, dysarthria, and tremor.","ataxia , is not a named entity"
"The adverse reactions most commonly (>=1% in any APTIOM treatment group, and greater than placebo) leading to discontinuation, in descending order of frequency, were dizziness, nausea, vomiting, ataxia, diplopia, somnolence, headache, blurred vision, vertigo, asthenia, fatigue, rash, dysarthria, and tremor.","asthenia , fatigue is not a named entity"
"The adverse reactions most commonly (>=1% in any APTIOM treatment group, and greater than placebo) leading to discontinuation, in descending order of frequency, were dizziness, nausea, vomiting, ataxia, diplopia, somnolence, headache, blurred vision, vertigo, asthenia, fatigue, rash, dysarthria, and tremor.",ataxia is an adverse reaction entity
"The adverse reactions most commonly (>=1% in any APTIOM treatment group, and greater than placebo) leading to discontinuation, in descending order of frequency, were dizziness, nausea, vomiting, ataxia, diplopia, somnolence, headache, blurred vision, vertigo, asthenia, fatigue, rash, dysarthria, and tremor.",descending order is not a named entity
"The adverse reactions most commonly (>=1% in any APTIOM treatment group, and greater than placebo) leading to discontinuation, in descending order of frequency, were dizziness, nausea, vomiting, ataxia, diplopia, somnolence, headache, blurred vision, vertigo, asthenia, fatigue, rash, dysarthria, and tremor.","vertigo , asthenia is not a named entity"
"The adverse reactions most commonly (>=1% in any APTIOM treatment group, and greater than placebo) leading to discontinuation, in descending order of frequency, were dizziness, nausea, vomiting, ataxia, diplopia, somnolence, headache, blurred vision, vertigo, asthenia, fatigue, rash, dysarthria, and tremor.",vertigo is an adverse reaction entity
"The adverse reactions most commonly (>=1% in any APTIOM treatment group, and greater than placebo) leading to discontinuation, in descending order of frequency, were dizziness, nausea, vomiting, ataxia, diplopia, somnolence, headache, blurred vision, vertigo, asthenia, fatigue, rash, dysarthria, and tremor.","diplopia , is not a named entity"
"The adverse reactions most commonly (>=1% in any APTIOM treatment group, and greater than placebo) leading to discontinuation, in descending order of frequency, were dizziness, nausea, vomiting, ataxia, diplopia, somnolence, headache, blurred vision, vertigo, asthenia, fatigue, rash, dysarthria, and tremor.",than placebo ) is not a named entity
"The adverse reactions most commonly (>=1% in any APTIOM treatment group, and greater than placebo) leading to discontinuation, in descending order of frequency, were dizziness, nausea, vomiting, ataxia, diplopia, somnolence, headache, blurred vision, vertigo, asthenia, fatigue, rash, dysarthria, and tremor.",placebo ) is not a named entity
"The adverse reactions most commonly (>=1% in any APTIOM treatment group, and greater than placebo) leading to discontinuation, in descending order of frequency, were dizziness, nausea, vomiting, ataxia, diplopia, somnolence, headache, blurred vision, vertigo, asthenia, fatigue, rash, dysarthria, and tremor.",fatigue is an adverse reaction entity
"The adverse reactions most commonly (>=1% in any APTIOM treatment group, and greater than placebo) leading to discontinuation, in descending order of frequency, were dizziness, nausea, vomiting, ataxia, diplopia, somnolence, headache, blurred vision, vertigo, asthenia, fatigue, rash, dysarthria, and tremor.",dysarthria is an adverse reaction entity
"The adverse reactions most commonly (>=1% in any APTIOM treatment group, and greater than placebo) leading to discontinuation, in descending order of frequency, were dizziness, nausea, vomiting, ataxia, diplopia, somnolence, headache, blurred vision, vertigo, asthenia, fatigue, rash, dysarthria, and tremor.","discontinuation , is not a named entity"
"The adverse reactions most commonly (>=1% in any APTIOM treatment group, and greater than placebo) leading to discontinuation, in descending order of frequency, were dizziness, nausea, vomiting, ataxia, diplopia, somnolence, headache, blurred vision, vertigo, asthenia, fatigue, rash, dysarthria, and tremor.",The is not a named entity
"Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed.",most trials is not a named entity
"Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed.",suicidal thoughts is an adverse reaction entity
"Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed.",could not is not a named entity
"Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed.",suicidal behavior is an adverse reaction entity
"It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident.",lymphadenopathy is an adverse reaction entity
"It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident.",It is not a named entity
"It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident.",hypersensitivity is an adverse reaction entity
"It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident.",be present even is not a named entity
"It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident.",or lymphadenopathy is not a named entity
"It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident.",fever is an adverse reaction entity
"It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident.",rash is an adverse reaction entity
"It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident.",", is not a named entity"
"Serious and sometimes fatal dermatologic reactions, including toxic epidermal necrolysis (TEN) and SJS, have been reported in patients using oxcarbazepine or carbamazepine which are chemically related to APTIOM.",dermatologic reactions is an adverse reaction entity
"Serious and sometimes fatal dermatologic reactions, including toxic epidermal necrolysis (TEN) and SJS, have been reported in patients using oxcarbazepine or carbamazepine which are chemically related to APTIOM.",fatal is an adverse reaction entity
"Serious and sometimes fatal dermatologic reactions, including toxic epidermal necrolysis (TEN) and SJS, have been reported in patients using oxcarbazepine or carbamazepine which are chemically related to APTIOM.",reported in patients is not a named entity
"Serious and sometimes fatal dermatologic reactions, including toxic epidermal necrolysis (TEN) and SJS, have been reported in patients using oxcarbazepine or carbamazepine which are chemically related to APTIOM.",and is not a named entity
"Serious and sometimes fatal dermatologic reactions, including toxic epidermal necrolysis (TEN) and SJS, have been reported in patients using oxcarbazepine or carbamazepine which are chemically related to APTIOM.",toxic epidermal necrolysis is an adverse reaction entity
"Serious and sometimes fatal dermatologic reactions, including toxic epidermal necrolysis (TEN) and SJS, have been reported in patients using oxcarbazepine or carbamazepine which are chemically related to APTIOM.",carbamazepine is not a named entity
"Serious and sometimes fatal dermatologic reactions, including toxic epidermal necrolysis (TEN) and SJS, have been reported in patients using oxcarbazepine or carbamazepine which are chemically related to APTIOM.",SJS is an adverse reaction entity
"Serious and sometimes fatal dermatologic reactions, including toxic epidermal necrolysis (TEN) and SJS, have been reported in patients using oxcarbazepine or carbamazepine which are chemically related to APTIOM.",TEN is an adverse reaction entity
"Serious and sometimes fatal dermatologic reactions, including toxic epidermal necrolysis (TEN) and SJS, have been reported in patients using oxcarbazepine or carbamazepine which are chemically related to APTIOM.",which is not a named entity
"Serious and sometimes fatal dermatologic reactions, including toxic epidermal necrolysis (TEN) and SJS, have been reported in patients using oxcarbazepine or carbamazepine which are chemically related to APTIOM.","SJS , have is not a named entity"
"Dizziness, nausea, somnolence, and fatigue were all reported at lower incidences during the AED Withdrawal Phase and Monotherapy Phase compared with the Titration Phase.",nausea is an adverse reaction entity
"Dizziness, nausea, somnolence, and fatigue were all reported at lower incidences during the AED Withdrawal Phase and Monotherapy Phase compared with the Titration Phase.",Dizziness is an adverse reaction entity
"Dizziness, nausea, somnolence, and fatigue were all reported at lower incidences during the AED Withdrawal Phase and Monotherapy Phase compared with the Titration Phase.",were is not a named entity
"Dizziness, nausea, somnolence, and fatigue were all reported at lower incidences during the AED Withdrawal Phase and Monotherapy Phase compared with the Titration Phase.",fatigue is an adverse reaction entity
"Dizziness, nausea, somnolence, and fatigue were all reported at lower incidences during the AED Withdrawal Phase and Monotherapy Phase compared with the Titration Phase.",somnolence is an adverse reaction entity
"Dizziness, nausea, somnolence, and fatigue were all reported at lower incidences during the AED Withdrawal Phase and Monotherapy Phase compared with the Titration Phase.",reported at is not a named entity
"Dizziness, nausea, somnolence, and fatigue were all reported at lower incidences during the AED Withdrawal Phase and Monotherapy Phase compared with the Titration Phase.",with the Titration is not a named entity
"Dizziness, nausea, somnolence, and fatigue were all reported at lower incidences during the AED Withdrawal Phase and Monotherapy Phase compared with the Titration Phase.",Phase is not a named entity
"Events related to dizziness and disturbance in gait and coordination were more often serious in APTIOM-treated patients than in placebo-treated patients (2% vs. 0%), and more often led to study withdrawal in APTIOM-treated patients than in placebo-treated patients (9% vs. 0.7%).",in APTIOM-treated patients is not a named entity
"Events related to dizziness and disturbance in gait and coordination were more often serious in APTIOM-treated patients than in placebo-treated patients (2% vs. 0%), and more often led to study withdrawal in APTIOM-treated patients than in placebo-treated patients (9% vs. 0.7%).",dizziness is an adverse reaction entity
"Events related to dizziness and disturbance in gait and coordination were more often serious in APTIOM-treated patients than in placebo-treated patients (2% vs. 0%), and more often led to study withdrawal in APTIOM-treated patients than in placebo-treated patients (9% vs. 0.7%).",% is not a named entity
"Events related to dizziness and disturbance in gait and coordination were more often serious in APTIOM-treated patients than in placebo-treated patients (2% vs. 0%), and more often led to study withdrawal in APTIOM-treated patients than in placebo-treated patients (9% vs. 0.7%).",and coordination is not a named entity
"Events related to dizziness and disturbance in gait and coordination were more often serious in APTIOM-treated patients than in placebo-treated patients (2% vs. 0%), and more often led to study withdrawal in APTIOM-treated patients than in placebo-treated patients (9% vs. 0.7%).",disturbance in coordination is an adverse reaction entity
"Events related to dizziness and disturbance in gait and coordination were more often serious in APTIOM-treated patients than in placebo-treated patients (2% vs. 0%), and more often led to study withdrawal in APTIOM-treated patients than in placebo-treated patients (9% vs. 0.7%).",disturbance in gait is an adverse reaction entity
"Cognitive Dysfunction       APTIOM causes dose-dependent increases in cognitive dysfunction-related events (memory impairment, disturbance in attention, amnesia, confusional state, aphasia, speech disorder, slowness of thought, disorientation, and psychomotor retardation).",", aphasia , is not a named entity"
"Cognitive Dysfunction       APTIOM causes dose-dependent increases in cognitive dysfunction-related events (memory impairment, disturbance in attention, amnesia, confusional state, aphasia, speech disorder, slowness of thought, disorientation, and psychomotor retardation).",memory impairment is an adverse reaction entity
"Cognitive Dysfunction       APTIOM causes dose-dependent increases in cognitive dysfunction-related events (memory impairment, disturbance in attention, amnesia, confusional state, aphasia, speech disorder, slowness of thought, disorientation, and psychomotor retardation).",psychomotor retardation is an adverse reaction entity
"Cognitive Dysfunction       APTIOM causes dose-dependent increases in cognitive dysfunction-related events (memory impairment, disturbance in attention, amnesia, confusional state, aphasia, speech disorder, slowness of thought, disorientation, and psychomotor retardation).",", is not a named entity"
"Cognitive Dysfunction       APTIOM causes dose-dependent increases in cognitive dysfunction-related events (memory impairment, disturbance in attention, amnesia, confusional state, aphasia, speech disorder, slowness of thought, disorientation, and psychomotor retardation).","impairment , disturbance is not a named entity"
"Cognitive Dysfunction       APTIOM causes dose-dependent increases in cognitive dysfunction-related events (memory impairment, disturbance in attention, amnesia, confusional state, aphasia, speech disorder, slowness of thought, disorientation, and psychomotor retardation).",amnesia is an adverse reaction entity
"Cognitive Dysfunction       APTIOM causes dose-dependent increases in cognitive dysfunction-related events (memory impairment, disturbance in attention, amnesia, confusional state, aphasia, speech disorder, slowness of thought, disorientation, and psychomotor retardation).",disorder is not a named entity
"Cognitive Dysfunction       APTIOM causes dose-dependent increases in cognitive dysfunction-related events (memory impairment, disturbance in attention, amnesia, confusional state, aphasia, speech disorder, slowness of thought, disorientation, and psychomotor retardation).",aphasia is an adverse reaction entity
"Cognitive Dysfunction       APTIOM causes dose-dependent increases in cognitive dysfunction-related events (memory impairment, disturbance in attention, amnesia, confusional state, aphasia, speech disorder, slowness of thought, disorientation, and psychomotor retardation).",", disorientation , is not a named entity"
"Cognitive Dysfunction       APTIOM causes dose-dependent increases in cognitive dysfunction-related events (memory impairment, disturbance in attention, amnesia, confusional state, aphasia, speech disorder, slowness of thought, disorientation, and psychomotor retardation).",confusional state is an adverse reaction entity
"Cognitive Dysfunction       APTIOM causes dose-dependent increases in cognitive dysfunction-related events (memory impairment, disturbance in attention, amnesia, confusional state, aphasia, speech disorder, slowness of thought, disorientation, and psychomotor retardation).",disorientation is an adverse reaction entity
"Cognitive Dysfunction       APTIOM causes dose-dependent increases in cognitive dysfunction-related events (memory impairment, disturbance in attention, amnesia, confusional state, aphasia, speech disorder, slowness of thought, disorientation, and psychomotor retardation).",speech disorder is an adverse reaction entity
"Cognitive Dysfunction       APTIOM causes dose-dependent increases in cognitive dysfunction-related events (memory impairment, disturbance in attention, amnesia, confusional state, aphasia, speech disorder, slowness of thought, disorientation, and psychomotor retardation).",disturbance in attention is an adverse reaction entity
"Cognitive Dysfunction       APTIOM causes dose-dependent increases in cognitive dysfunction-related events (memory impairment, disturbance in attention, amnesia, confusional state, aphasia, speech disorder, slowness of thought, disorientation, and psychomotor retardation).",cognitive dysfunction is an adverse reaction entity
"Cognitive Dysfunction       APTIOM causes dose-dependent increases in cognitive dysfunction-related events (memory impairment, disturbance in attention, amnesia, confusional state, aphasia, speech disorder, slowness of thought, disorientation, and psychomotor retardation).",APTIOM causes dose-dependent is not a named entity
"Cognitive Dysfunction       APTIOM causes dose-dependent increases in cognitive dysfunction-related events (memory impairment, disturbance in attention, amnesia, confusional state, aphasia, speech disorder, slowness of thought, disorientation, and psychomotor retardation).",Cognitive Dysfunction is not a named entity
"Cognitive Dysfunction       APTIOM causes dose-dependent increases in cognitive dysfunction-related events (memory impairment, disturbance in attention, amnesia, confusional state, aphasia, speech disorder, slowness of thought, disorientation, and psychomotor retardation).",slowness of thought is an adverse reaction entity
"Cognitive Dysfunction       APTIOM causes dose-dependent increases in cognitive dysfunction-related events (memory impairment, disturbance in attention, amnesia, confusional state, aphasia, speech disorder, slowness of thought, disorientation, and psychomotor retardation).","disorientation , and is not a named entity"
"Cognitive Dysfunction       APTIOM causes dose-dependent increases in cognitive dysfunction-related events (memory impairment, disturbance in attention, amnesia, confusional state, aphasia, speech disorder, slowness of thought, disorientation, and psychomotor retardation).","aphasia , is not a named entity"
"Cognitive Dysfunction       APTIOM causes dose-dependent increases in cognitive dysfunction-related events (memory impairment, disturbance in attention, amnesia, confusional state, aphasia, speech disorder, slowness of thought, disorientation, and psychomotor retardation).",", speech disorder is not a named entity"
Somnolence and fatigue-related events were serious in 0.3% of APTIOM-treated patients (and 0 placebo patients) and led to discontinuation in 3% of APTIOM-treated patients (and 0.7% of placebo-treated patients).,and 0.7 % is not a named entity
Somnolence and fatigue-related events were serious in 0.3% of APTIOM-treated patients (and 0 placebo patients) and led to discontinuation in 3% of APTIOM-treated patients (and 0.7% of placebo-treated patients).,fatigue-related events is an adverse reaction entity
Somnolence and fatigue-related events were serious in 0.3% of APTIOM-treated patients (and 0 placebo patients) and led to discontinuation in 3% of APTIOM-treated patients (and 0.7% of placebo-treated patients).,placebo patients ) is not a named entity
Somnolence and fatigue-related events were serious in 0.3% of APTIOM-treated patients (and 0 placebo patients) and led to discontinuation in 3% of APTIOM-treated patients (and 0.7% of placebo-treated patients).,Somnolence is an adverse reaction entity
A higher percentage of APTIOM-treated patients (5.1%) than placebo-treated patients (0.7%) experienced decreases in sodium values of more than 10 mEq/L.,values is not a named entity
A higher percentage of APTIOM-treated patients (5.1%) than placebo-treated patients (0.7%) experienced decreases in sodium values of more than 10 mEq/L.,decreases in sodium values is an adverse reaction entity
5.9 Abnormal Thyroid Function Tests      Dose-dependent decreases in serum T3 and T4 (free and total) values have been observed in patients taking APTIOM.,Tests Dose-dependent decreases is not a named entity
5.9 Abnormal Thyroid Function Tests      Dose-dependent decreases in serum T3 and T4 (free and total) values have been observed in patients taking APTIOM.,decreases in serum T3 free is an adverse reaction entity
5.9 Abnormal Thyroid Function Tests      Dose-dependent decreases in serum T3 and T4 (free and total) values have been observed in patients taking APTIOM.,observed is not a named entity
5.9 Abnormal Thyroid Function Tests      Dose-dependent decreases in serum T3 and T4 (free and total) values have been observed in patients taking APTIOM.,decreases in serum T4 total is an adverse reaction entity
5.9 Abnormal Thyroid Function Tests      Dose-dependent decreases in serum T3 and T4 (free and total) values have been observed in patients taking APTIOM.,decreases in serum T4 free is an adverse reaction entity
5.9 Abnormal Thyroid Function Tests      Dose-dependent decreases in serum T3 and T4 (free and total) values have been observed in patients taking APTIOM.,T4 ( is not a named entity
5.9 Abnormal Thyroid Function Tests      Dose-dependent decreases in serum T3 and T4 (free and total) values have been observed in patients taking APTIOM.,decreases in serum T3 total is an adverse reaction entity
5.9 Abnormal Thyroid Function Tests      Dose-dependent decreases in serum T3 and T4 (free and total) values have been observed in patients taking APTIOM.,total is not a named entity
"(  5.2  ,  5.3  ,  5.4  )   *  Hyponatremia: Monitor sodium levels in patients at risk or patients experiencing hyponatremia symptoms.",Hyponatremia is an adverse reaction entity
"(  5.2  ,  5.3  ,  5.4  )   *  Hyponatremia: Monitor sodium levels in patients at risk or patients experiencing hyponatremia symptoms.",or patients is not a named entity
"Serious, life-threatening complications were reported with APTIOM-associated hyponatremia (as low as 112 mEq/L) including seizures, severe nausea/vomiting leading to dehydration, severe gait instability, and injury.",dehydration is an adverse reaction entity
"Serious, life-threatening complications were reported with APTIOM-associated hyponatremia (as low as 112 mEq/L) including seizures, severe nausea/vomiting leading to dehydration, severe gait instability, and injury.",mEq/L ) including is not a named entity
"Serious, life-threatening complications were reported with APTIOM-associated hyponatremia (as low as 112 mEq/L) including seizures, severe nausea/vomiting leading to dehydration, severe gait instability, and injury.",seizures is an adverse reaction entity
"Serious, life-threatening complications were reported with APTIOM-associated hyponatremia (as low as 112 mEq/L) including seizures, severe nausea/vomiting leading to dehydration, severe gait instability, and injury.",as is not a named entity
"Serious, life-threatening complications were reported with APTIOM-associated hyponatremia (as low as 112 mEq/L) including seizures, severe nausea/vomiting leading to dehydration, severe gait instability, and injury.",with APTIOM-associated hyponatremia is not a named entity
"Serious, life-threatening complications were reported with APTIOM-associated hyponatremia (as low as 112 mEq/L) including seizures, severe nausea/vomiting leading to dehydration, severe gait instability, and injury.",nausea is an adverse reaction entity
"Serious, life-threatening complications were reported with APTIOM-associated hyponatremia (as low as 112 mEq/L) including seizures, severe nausea/vomiting leading to dehydration, severe gait instability, and injury.",", severe nausea/vomiting is not a named entity"
"Serious, life-threatening complications were reported with APTIOM-associated hyponatremia (as low as 112 mEq/L) including seizures, severe nausea/vomiting leading to dehydration, severe gait instability, and injury.",hyponatremia is an adverse reaction entity
"Serious, life-threatening complications were reported with APTIOM-associated hyponatremia (as low as 112 mEq/L) including seizures, severe nausea/vomiting leading to dehydration, severe gait instability, and injury.",hyponatremia is an adverse reaction entity
"Serious, life-threatening complications were reported with APTIOM-associated hyponatremia (as low as 112 mEq/L) including seizures, severe nausea/vomiting leading to dehydration, severe gait instability, and injury.",", is not a named entity"
"Serious, life-threatening complications were reported with APTIOM-associated hyponatremia (as low as 112 mEq/L) including seizures, severe nausea/vomiting leading to dehydration, severe gait instability, and injury.","instability , and is not a named entity"
"Serious, life-threatening complications were reported with APTIOM-associated hyponatremia (as low as 112 mEq/L) including seizures, severe nausea/vomiting leading to dehydration, severe gait instability, and injury.",gait instability is an adverse reaction entity
"Serious, life-threatening complications were reported with APTIOM-associated hyponatremia (as low as 112 mEq/L) including seizures, severe nausea/vomiting leading to dehydration, severe gait instability, and injury.",as low is not a named entity
"Serious, life-threatening complications were reported with APTIOM-associated hyponatremia (as low as 112 mEq/L) including seizures, severe nausea/vomiting leading to dehydration, severe gait instability, and injury.",leading to is not a named entity
"Serious, life-threatening complications were reported with APTIOM-associated hyponatremia (as low as 112 mEq/L) including seizures, severe nausea/vomiting leading to dehydration, severe gait instability, and injury.",injury is an adverse reaction entity
"Serious, life-threatening complications were reported with APTIOM-associated hyponatremia (as low as 112 mEq/L) including seizures, severe nausea/vomiting leading to dehydration, severe gait instability, and injury.",vomiting is an adverse reaction entity
The adverse reaction most commonly (>=1% on APTIOM) leading to discontinuation was hyponatremia.,> is not a named entity
The adverse reaction most commonly (>=1% on APTIOM) leading to discontinuation was hyponatremia.,hyponatremia is an adverse reaction entity
Risk factors for development of serious dermatologic reactions with APTIOM use have not been identified.,dermatologic reactions is an adverse reaction entity
Risk factors for development of serious dermatologic reactions with APTIOM use have not been identified.,APTIOM use is not a named entity
Dizziness and disturbance in gait and coordination were also observed in monotherapy trials.,and coordination is not a named entity
Dizziness and disturbance in gait and coordination were also observed in monotherapy trials.,trials is not a named entity
Dizziness and disturbance in gait and coordination were also observed in monotherapy trials.,in monotherapy is not a named entity
Dizziness and disturbance in gait and coordination were also observed in monotherapy trials.,disturbance in gait is an adverse reaction entity
Dizziness and disturbance in gait and coordination were also observed in monotherapy trials.,Dizziness is an adverse reaction entity
Dizziness and disturbance in gait and coordination were also observed in monotherapy trials.,disturbance in coordination is an adverse reaction entity
The combination of transaminase elevations and elevated bilirubin without evidence of obstruction is generally recognized as an important predictor of severe liver injury.,evidence of is not a named entity
The combination of transaminase elevations and elevated bilirubin without evidence of obstruction is generally recognized as an important predictor of severe liver injury.,The combination is not a named entity
The combination of transaminase elevations and elevated bilirubin without evidence of obstruction is generally recognized as an important predictor of severe liver injury.,liver injury is an adverse reaction entity
The combination of transaminase elevations and elevated bilirubin without evidence of obstruction is generally recognized as an important predictor of severe liver injury.,transaminase elevations is an adverse reaction entity
The combination of transaminase elevations and elevated bilirubin without evidence of obstruction is generally recognized as an important predictor of severe liver injury.,elevated bilirubin is an adverse reaction entity
The combination of transaminase elevations and elevated bilirubin without evidence of obstruction is generally recognized as an important predictor of severe liver injury.,is generally is not a named entity
"The incidence of dizziness was greater with the concomitant use of APTIOM and carbamazepine compared to the use of APTIOM without carbamazepine (up to 37% vs. 19%, respectively).",dizziness is an adverse reaction entity
"The incidence of dizziness was greater with the concomitant use of APTIOM and carbamazepine compared to the use of APTIOM without carbamazepine (up to 37% vs. 19%, respectively).",", respectively ) is not a named entity"
Cognitive dysfunction-related events were serious in 0.2% of APTIOM-treated patients (and 0.2% of placebo patients) and led to discontinuation in 1% of APTIOM-treated patients (and 0.5% of placebo-treated patients).,Cognitive dysfunction is an adverse reaction entity
Cognitive dysfunction-related events were serious in 0.2% of APTIOM-treated patients (and 0.2% of placebo patients) and led to discontinuation in 1% of APTIOM-treated patients (and 0.5% of placebo-treated patients).,and 0.5 % is not a named entity
Cognitive dysfunction-related events were serious in 0.2% of APTIOM-treated patients (and 0.2% of placebo patients) and led to discontinuation in 1% of APTIOM-treated patients (and 0.5% of placebo-treated patients).,Cognitive dysfunction is an adverse reaction entity
Cognitive dysfunction-related events were serious in 0.2% of APTIOM-treated patients (and 0.2% of placebo patients) and led to discontinuation in 1% of APTIOM-treated patients (and 0.5% of placebo-treated patients).,to discontinuation is not a named entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Suicidal Behavior and Ideation: Monitor for suicidal thoughts or behavior.,Suicidal Behavior is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Suicidal Behavior and Ideation: Monitor for suicidal thoughts or behavior.,Suicidal Ideation is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Suicidal Behavior and Ideation: Monitor for suicidal thoughts or behavior.,Suicidal Behavior and is not a named entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Suicidal Behavior and Ideation: Monitor for suicidal thoughts or behavior.,5 WARNINGS AND is not a named entity
"(  5.1  )   *  Serious Dermatologic Reactions, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), Anaphylactic Reactions and Angioedema: Monitor and discontinue if another cause cannot be established.",Anaphylactic Reactions is an adverse reaction entity
"(  5.1  )   *  Serious Dermatologic Reactions, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), Anaphylactic Reactions and Angioedema: Monitor and discontinue if another cause cannot be established.",not be established is not a named entity
"(  5.1  )   *  Serious Dermatologic Reactions, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), Anaphylactic Reactions and Angioedema: Monitor and discontinue if another cause cannot be established.",: Monitor is not a named entity
"(  5.1  )   *  Serious Dermatologic Reactions, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), Anaphylactic Reactions and Angioedema: Monitor and discontinue if another cause cannot be established.",DRESS is an adverse reaction entity
"(  5.1  )   *  Serious Dermatologic Reactions, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), Anaphylactic Reactions and Angioedema: Monitor and discontinue if another cause cannot be established.",can not is not a named entity
"(  5.1  )   *  Serious Dermatologic Reactions, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), Anaphylactic Reactions and Angioedema: Monitor and discontinue if another cause cannot be established.",Dermatologic Reactions is an adverse reaction entity
"(  5.1  )   *  Serious Dermatologic Reactions, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), Anaphylactic Reactions and Angioedema: Monitor and discontinue if another cause cannot be established.",Drug Reaction with Eosinophilia and Systemic Symptoms is an adverse reaction entity
"(  5.1  )   *  Serious Dermatologic Reactions, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), Anaphylactic Reactions and Angioedema: Monitor and discontinue if another cause cannot be established.",Angioedema is an adverse reaction entity
"(  5.1  )   *  Serious Dermatologic Reactions, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), Anaphylactic Reactions and Angioedema: Monitor and discontinue if another cause cannot be established.",5.1 ) * is not a named entity
"(  5.1  )   *  Serious Dermatologic Reactions, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), Anaphylactic Reactions and Angioedema: Monitor and discontinue if another cause cannot be established.",if another cause is not a named entity
"5.6 Neurological Adverse Reactions       Dizziness and Disturbance in Gait and Coordination       APTIOM causes dose-related increases in adverse reactions related to dizziness and disturbance in gait and coordination (dizziness, ataxia, vertigo, balance disorder, gait disturbance, nystagmus, and abnormal coordination) [see Adverse Reactions (  6.1  )]  .",and is not a named entity
"5.6 Neurological Adverse Reactions       Dizziness and Disturbance in Gait and Coordination       APTIOM causes dose-related increases in adverse reactions related to dizziness and disturbance in gait and coordination (dizziness, ataxia, vertigo, balance disorder, gait disturbance, nystagmus, and abnormal coordination) [see Adverse Reactions (  6.1  )]  .",coordination is not a named entity
"5.6 Neurological Adverse Reactions       Dizziness and Disturbance in Gait and Coordination       APTIOM causes dose-related increases in adverse reactions related to dizziness and disturbance in gait and coordination (dizziness, ataxia, vertigo, balance disorder, gait disturbance, nystagmus, and abnormal coordination) [see Adverse Reactions (  6.1  )]  .",abnormal coordination is an adverse reaction entity
"5.6 Neurological Adverse Reactions       Dizziness and Disturbance in Gait and Coordination       APTIOM causes dose-related increases in adverse reactions related to dizziness and disturbance in gait and coordination (dizziness, ataxia, vertigo, balance disorder, gait disturbance, nystagmus, and abnormal coordination) [see Adverse Reactions (  6.1  )]  .",gait disturbance is an adverse reaction entity
"5.6 Neurological Adverse Reactions       Dizziness and Disturbance in Gait and Coordination       APTIOM causes dose-related increases in adverse reactions related to dizziness and disturbance in gait and coordination (dizziness, ataxia, vertigo, balance disorder, gait disturbance, nystagmus, and abnormal coordination) [see Adverse Reactions (  6.1  )]  .",nystagmus is an adverse reaction entity
"5.6 Neurological Adverse Reactions       Dizziness and Disturbance in Gait and Coordination       APTIOM causes dose-related increases in adverse reactions related to dizziness and disturbance in gait and coordination (dizziness, ataxia, vertigo, balance disorder, gait disturbance, nystagmus, and abnormal coordination) [see Adverse Reactions (  6.1  )]  .",", vertigo , is not a named entity"
"5.6 Neurological Adverse Reactions       Dizziness and Disturbance in Gait and Coordination       APTIOM causes dose-related increases in adverse reactions related to dizziness and disturbance in gait and coordination (dizziness, ataxia, vertigo, balance disorder, gait disturbance, nystagmus, and abnormal coordination) [see Adverse Reactions (  6.1  )]  .",Coordination APTIOM causes is not a named entity
"5.6 Neurological Adverse Reactions       Dizziness and Disturbance in Gait and Coordination       APTIOM causes dose-related increases in adverse reactions related to dizziness and disturbance in gait and coordination (dizziness, ataxia, vertigo, balance disorder, gait disturbance, nystagmus, and abnormal coordination) [see Adverse Reactions (  6.1  )]  .",abnormal coordination ) is not a named entity
"5.6 Neurological Adverse Reactions       Dizziness and Disturbance in Gait and Coordination       APTIOM causes dose-related increases in adverse reactions related to dizziness and disturbance in gait and coordination (dizziness, ataxia, vertigo, balance disorder, gait disturbance, nystagmus, and abnormal coordination) [see Adverse Reactions (  6.1  )]  .",vertigo is an adverse reaction entity
"5.6 Neurological Adverse Reactions       Dizziness and Disturbance in Gait and Coordination       APTIOM causes dose-related increases in adverse reactions related to dizziness and disturbance in gait and coordination (dizziness, ataxia, vertigo, balance disorder, gait disturbance, nystagmus, and abnormal coordination) [see Adverse Reactions (  6.1  )]  .",dose-related is not a named entity
"5.6 Neurological Adverse Reactions       Dizziness and Disturbance in Gait and Coordination       APTIOM causes dose-related increases in adverse reactions related to dizziness and disturbance in gait and coordination (dizziness, ataxia, vertigo, balance disorder, gait disturbance, nystagmus, and abnormal coordination) [see Adverse Reactions (  6.1  )]  .",dizziness is an adverse reaction entity
"5.6 Neurological Adverse Reactions       Dizziness and Disturbance in Gait and Coordination       APTIOM causes dose-related increases in adverse reactions related to dizziness and disturbance in gait and coordination (dizziness, ataxia, vertigo, balance disorder, gait disturbance, nystagmus, and abnormal coordination) [see Adverse Reactions (  6.1  )]  .",ataxia is an adverse reaction entity
"5.6 Neurological Adverse Reactions       Dizziness and Disturbance in Gait and Coordination       APTIOM causes dose-related increases in adverse reactions related to dizziness and disturbance in gait and coordination (dizziness, ataxia, vertigo, balance disorder, gait disturbance, nystagmus, and abnormal coordination) [see Adverse Reactions (  6.1  )]  .",gait is not a named entity
"5.6 Neurological Adverse Reactions       Dizziness and Disturbance in Gait and Coordination       APTIOM causes dose-related increases in adverse reactions related to dizziness and disturbance in gait and coordination (dizziness, ataxia, vertigo, balance disorder, gait disturbance, nystagmus, and abnormal coordination) [see Adverse Reactions (  6.1  )]  .",balance disorder is an adverse reaction entity
"5.6 Neurological Adverse Reactions       Dizziness and Disturbance in Gait and Coordination       APTIOM causes dose-related increases in adverse reactions related to dizziness and disturbance in gait and coordination (dizziness, ataxia, vertigo, balance disorder, gait disturbance, nystagmus, and abnormal coordination) [see Adverse Reactions (  6.1  )]  .",disturbance in gait is an adverse reaction entity
"5.6 Neurological Adverse Reactions       Dizziness and Disturbance in Gait and Coordination       APTIOM causes dose-related increases in adverse reactions related to dizziness and disturbance in gait and coordination (dizziness, ataxia, vertigo, balance disorder, gait disturbance, nystagmus, and abnormal coordination) [see Adverse Reactions (  6.1  )]  .",", ataxia is not a named entity"
"5.6 Neurological Adverse Reactions       Dizziness and Disturbance in Gait and Coordination       APTIOM causes dose-related increases in adverse reactions related to dizziness and disturbance in gait and coordination (dizziness, ataxia, vertigo, balance disorder, gait disturbance, nystagmus, and abnormal coordination) [see Adverse Reactions (  6.1  )]  .",disturbance in coordination is an adverse reaction entity
"5.6 Neurological Adverse Reactions       Dizziness and Disturbance in Gait and Coordination       APTIOM causes dose-related increases in adverse reactions related to dizziness and disturbance in gait and coordination (dizziness, ataxia, vertigo, balance disorder, gait disturbance, nystagmus, and abnormal coordination) [see Adverse Reactions (  6.1  )]  .",", gait disturbance is not a named entity"
"5.6 Neurological Adverse Reactions       Dizziness and Disturbance in Gait and Coordination       APTIOM causes dose-related increases in adverse reactions related to dizziness and disturbance in gait and coordination (dizziness, ataxia, vertigo, balance disorder, gait disturbance, nystagmus, and abnormal coordination) [see Adverse Reactions (  6.1  )]  .","dizziness , ataxia is not a named entity"
"5.6 Neurological Adverse Reactions       Dizziness and Disturbance in Gait and Coordination       APTIOM causes dose-related increases in adverse reactions related to dizziness and disturbance in gait and coordination (dizziness, ataxia, vertigo, balance disorder, gait disturbance, nystagmus, and abnormal coordination) [see Adverse Reactions (  6.1  )]  .",dizziness is an adverse reaction entity
"The most frequently reported adverse reactions in patients receiving APTIOM at doses of 800 mg or 1200 mg (>=4% and >=2% greater than placebo) were dizziness, somnolence, nausea, headache, diplopia, vomiting, fatigue, vertigo, ataxia, blurred vision, and tremor.",nausea is an adverse reaction entity
"The most frequently reported adverse reactions in patients receiving APTIOM at doses of 800 mg or 1200 mg (>=4% and >=2% greater than placebo) were dizziness, somnolence, nausea, headache, diplopia, vomiting, fatigue, vertigo, ataxia, blurred vision, and tremor.",vomiting is an adverse reaction entity
"The most frequently reported adverse reactions in patients receiving APTIOM at doses of 800 mg or 1200 mg (>=4% and >=2% greater than placebo) were dizziness, somnolence, nausea, headache, diplopia, vomiting, fatigue, vertigo, ataxia, blurred vision, and tremor.",vertigo is an adverse reaction entity
"The most frequently reported adverse reactions in patients receiving APTIOM at doses of 800 mg or 1200 mg (>=4% and >=2% greater than placebo) were dizziness, somnolence, nausea, headache, diplopia, vomiting, fatigue, vertigo, ataxia, blurred vision, and tremor.",placebo ) were is not a named entity
"The most frequently reported adverse reactions in patients receiving APTIOM at doses of 800 mg or 1200 mg (>=4% and >=2% greater than placebo) were dizziness, somnolence, nausea, headache, diplopia, vomiting, fatigue, vertigo, ataxia, blurred vision, and tremor.",tremor is an adverse reaction entity
"The most frequently reported adverse reactions in patients receiving APTIOM at doses of 800 mg or 1200 mg (>=4% and >=2% greater than placebo) were dizziness, somnolence, nausea, headache, diplopia, vomiting, fatigue, vertigo, ataxia, blurred vision, and tremor.",blurred vision is an adverse reaction entity
"The most frequently reported adverse reactions in patients receiving APTIOM at doses of 800 mg or 1200 mg (>=4% and >=2% greater than placebo) were dizziness, somnolence, nausea, headache, diplopia, vomiting, fatigue, vertigo, ataxia, blurred vision, and tremor.",somnolence is an adverse reaction entity
"The most frequently reported adverse reactions in patients receiving APTIOM at doses of 800 mg or 1200 mg (>=4% and >=2% greater than placebo) were dizziness, somnolence, nausea, headache, diplopia, vomiting, fatigue, vertigo, ataxia, blurred vision, and tremor.",( is not a named entity
"The most frequently reported adverse reactions in patients receiving APTIOM at doses of 800 mg or 1200 mg (>=4% and >=2% greater than placebo) were dizziness, somnolence, nausea, headache, diplopia, vomiting, fatigue, vertigo, ataxia, blurred vision, and tremor.",> =4 is not a named entity
"The most frequently reported adverse reactions in patients receiving APTIOM at doses of 800 mg or 1200 mg (>=4% and >=2% greater than placebo) were dizziness, somnolence, nausea, headache, diplopia, vomiting, fatigue, vertigo, ataxia, blurred vision, and tremor.",800 mg is not a named entity
"The most frequently reported adverse reactions in patients receiving APTIOM at doses of 800 mg or 1200 mg (>=4% and >=2% greater than placebo) were dizziness, somnolence, nausea, headache, diplopia, vomiting, fatigue, vertigo, ataxia, blurred vision, and tremor.",ataxia is an adverse reaction entity
"The most frequently reported adverse reactions in patients receiving APTIOM at doses of 800 mg or 1200 mg (>=4% and >=2% greater than placebo) were dizziness, somnolence, nausea, headache, diplopia, vomiting, fatigue, vertigo, ataxia, blurred vision, and tremor.","ataxia , blurred is not a named entity"
"The most frequently reported adverse reactions in patients receiving APTIOM at doses of 800 mg or 1200 mg (>=4% and >=2% greater than placebo) were dizziness, somnolence, nausea, headache, diplopia, vomiting, fatigue, vertigo, ataxia, blurred vision, and tremor.",APTIOM at doses is not a named entity
"The most frequently reported adverse reactions in patients receiving APTIOM at doses of 800 mg or 1200 mg (>=4% and >=2% greater than placebo) were dizziness, somnolence, nausea, headache, diplopia, vomiting, fatigue, vertigo, ataxia, blurred vision, and tremor.",diplopia is an adverse reaction entity
"The most frequently reported adverse reactions in patients receiving APTIOM at doses of 800 mg or 1200 mg (>=4% and >=2% greater than placebo) were dizziness, somnolence, nausea, headache, diplopia, vomiting, fatigue, vertigo, ataxia, blurred vision, and tremor.",fatigue is an adverse reaction entity
"The most frequently reported adverse reactions in patients receiving APTIOM at doses of 800 mg or 1200 mg (>=4% and >=2% greater than placebo) were dizziness, somnolence, nausea, headache, diplopia, vomiting, fatigue, vertigo, ataxia, blurred vision, and tremor.","nausea , headache is not a named entity"
"The most frequently reported adverse reactions in patients receiving APTIOM at doses of 800 mg or 1200 mg (>=4% and >=2% greater than placebo) were dizziness, somnolence, nausea, headache, diplopia, vomiting, fatigue, vertigo, ataxia, blurred vision, and tremor.","somnolence , is not a named entity"
"The most frequently reported adverse reactions in patients receiving APTIOM at doses of 800 mg or 1200 mg (>=4% and >=2% greater than placebo) were dizziness, somnolence, nausea, headache, diplopia, vomiting, fatigue, vertigo, ataxia, blurred vision, and tremor.",headache is an adverse reaction entity
"The most frequently reported adverse reactions in patients receiving APTIOM at doses of 800 mg or 1200 mg (>=4% and >=2% greater than placebo) were dizziness, somnolence, nausea, headache, diplopia, vomiting, fatigue, vertigo, ataxia, blurred vision, and tremor.",dizziness is an adverse reaction entity
"The most frequently reported adverse reactions in patients receiving APTIOM at doses of 800 mg or 1200 mg (>=4% and >=2% greater than placebo) were dizziness, somnolence, nausea, headache, diplopia, vomiting, fatigue, vertigo, ataxia, blurred vision, and tremor.",reactions in is not a named entity
"The most frequently reported adverse reactions in patients receiving APTIOM at doses of 800 mg or 1200 mg (>=4% and >=2% greater than placebo) were dizziness, somnolence, nausea, headache, diplopia, vomiting, fatigue, vertigo, ataxia, blurred vision, and tremor.",", is not a named entity"
"The most frequently reported adverse reactions in patients receiving APTIOM at doses of 800 mg or 1200 mg (>=4% and >=2% greater than placebo) were dizziness, somnolence, nausea, headache, diplopia, vomiting, fatigue, vertigo, ataxia, blurred vision, and tremor.",800 mg or is not a named entity
"5.8 Drug Induced Liver Injury      Hepatic effects, ranging from mild to moderate elevations in transaminases (>3 times the upper limit of normal) to rare cases with concomitant elevations of total bilirubin (>2 times the upper limit of normal) have been reported with APTIOM use.",elevations of total bilirubin is an adverse reaction entity
"5.8 Drug Induced Liver Injury      Hepatic effects, ranging from mild to moderate elevations in transaminases (>3 times the upper limit of normal) to rare cases with concomitant elevations of total bilirubin (>2 times the upper limit of normal) have been reported with APTIOM use.",> 3 is not a named entity
"5.8 Drug Induced Liver Injury      Hepatic effects, ranging from mild to moderate elevations in transaminases (>3 times the upper limit of normal) to rare cases with concomitant elevations of total bilirubin (>2 times the upper limit of normal) have been reported with APTIOM use.",Injury Hepatic effects is not a named entity
"5.8 Drug Induced Liver Injury      Hepatic effects, ranging from mild to moderate elevations in transaminases (>3 times the upper limit of normal) to rare cases with concomitant elevations of total bilirubin (>2 times the upper limit of normal) have been reported with APTIOM use.",elevations in transaminases is an adverse reaction entity
"(  2.6  ,  5.7  )   *  Drug Induced Liver Injury: Discontinue APTIOM in patients with jaundice or evidence of significant liver injury.",or evidence is not a named entity
"(  2.6  ,  5.7  )   *  Drug Induced Liver Injury: Discontinue APTIOM in patients with jaundice or evidence of significant liver injury.",Drug Induced Liver Injury is an adverse reaction entity
Epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.,illnesses for which is not a named entity
Epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.,Epilepsy and many is not a named entity
Epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.,morbidity is an adverse reaction entity
Epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.,and mortality and is not a named entity
Epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.,and many is not a named entity
Epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.,suicidal thoughts is an adverse reaction entity
Epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.,suicidal behavior is an adverse reaction entity
Epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.,mortality is an adverse reaction entity
"Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% confidence interval [CI]: 1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo.",suicidal behavior is an adverse reaction entity
"Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% confidence interval [CI]: 1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo.",2.7 ) of is not a named entity
"Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% confidence interval [CI]: 1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo.",approximately twice the is not a named entity
"Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% confidence interval [CI]: 1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo.",suicidal thinking is an adverse reaction entity
"(5.4)   *    Immediate hypersensitivity reactions: Discontinue TUDORZA PRESSAIR at once and consider alternatives if immediate hypersensitivity reactions, including angioedema, bronchospasm, or anaphylaxis, occur.",hypersensitivity reactions is an adverse reaction entity
"(5.4)   *    Immediate hypersensitivity reactions: Discontinue TUDORZA PRESSAIR at once and consider alternatives if immediate hypersensitivity reactions, including angioedema, bronchospasm, or anaphylaxis, occur.","reactions , including is not a named entity"
"In postmarketing experience with TUDORZA PRESSAIR, immediate hypersensitivity reactions, including anaphylaxis, angioedema (including swelling of the lips, tongue, or throat), urticaria, rash, bronchospasm, or itching have been reported.",", bronchospasm is not a named entity"
"In postmarketing experience with TUDORZA PRESSAIR, immediate hypersensitivity reactions, including anaphylaxis, angioedema (including swelling of the lips, tongue, or throat), urticaria, rash, bronchospasm, or itching have been reported.",postmarketing experience with is not a named entity
"In postmarketing experience with TUDORZA PRESSAIR, immediate hypersensitivity reactions, including anaphylaxis, angioedema (including swelling of the lips, tongue, or throat), urticaria, rash, bronchospasm, or itching have been reported.",rash is an adverse reaction entity
"In postmarketing experience with TUDORZA PRESSAIR, immediate hypersensitivity reactions, including anaphylaxis, angioedema (including swelling of the lips, tongue, or throat), urticaria, rash, bronchospasm, or itching have been reported.",swelling of the lips is an adverse reaction entity
"In postmarketing experience with TUDORZA PRESSAIR, immediate hypersensitivity reactions, including anaphylaxis, angioedema (including swelling of the lips, tongue, or throat), urticaria, rash, bronchospasm, or itching have been reported.",urticaria is an adverse reaction entity
"In postmarketing experience with TUDORZA PRESSAIR, immediate hypersensitivity reactions, including anaphylaxis, angioedema (including swelling of the lips, tongue, or throat), urticaria, rash, bronchospasm, or itching have been reported.",", tongue , is not a named entity"
"In postmarketing experience with TUDORZA PRESSAIR, immediate hypersensitivity reactions, including anaphylaxis, angioedema (including swelling of the lips, tongue, or throat), urticaria, rash, bronchospasm, or itching have been reported.",including is not a named entity
"In postmarketing experience with TUDORZA PRESSAIR, immediate hypersensitivity reactions, including anaphylaxis, angioedema (including swelling of the lips, tongue, or throat), urticaria, rash, bronchospasm, or itching have been reported.",", is not a named entity"
"In postmarketing experience with TUDORZA PRESSAIR, immediate hypersensitivity reactions, including anaphylaxis, angioedema (including swelling of the lips, tongue, or throat), urticaria, rash, bronchospasm, or itching have been reported.",angioedema ( is not a named entity
"In postmarketing experience with TUDORZA PRESSAIR, immediate hypersensitivity reactions, including anaphylaxis, angioedema (including swelling of the lips, tongue, or throat), urticaria, rash, bronchospasm, or itching have been reported.",anaphylaxis is an adverse reaction entity
"In postmarketing experience with TUDORZA PRESSAIR, immediate hypersensitivity reactions, including anaphylaxis, angioedema (including swelling of the lips, tongue, or throat), urticaria, rash, bronchospasm, or itching have been reported.",itching is an adverse reaction entity
"In postmarketing experience with TUDORZA PRESSAIR, immediate hypersensitivity reactions, including anaphylaxis, angioedema (including swelling of the lips, tongue, or throat), urticaria, rash, bronchospasm, or itching have been reported.",swelling of the tongue is an adverse reaction entity
"In postmarketing experience with TUDORZA PRESSAIR, immediate hypersensitivity reactions, including anaphylaxis, angioedema (including swelling of the lips, tongue, or throat), urticaria, rash, bronchospasm, or itching have been reported.",swelling of the throat is an adverse reaction entity
"In postmarketing experience with TUDORZA PRESSAIR, immediate hypersensitivity reactions, including anaphylaxis, angioedema (including swelling of the lips, tongue, or throat), urticaria, rash, bronchospasm, or itching have been reported.",angioedema is an adverse reaction entity
"In postmarketing experience with TUDORZA PRESSAIR, immediate hypersensitivity reactions, including anaphylaxis, angioedema (including swelling of the lips, tongue, or throat), urticaria, rash, bronchospasm, or itching have been reported.",bronchospasm is an adverse reaction entity
"In postmarketing experience with TUDORZA PRESSAIR, immediate hypersensitivity reactions, including anaphylaxis, angioedema (including swelling of the lips, tongue, or throat), urticaria, rash, bronchospasm, or itching have been reported.",", angioedema is not a named entity"
"In postmarketing experience with TUDORZA PRESSAIR, immediate hypersensitivity reactions, including anaphylaxis, angioedema (including swelling of the lips, tongue, or throat), urticaria, rash, bronchospasm, or itching have been reported.",postmarketing experience with is not a named entity
"In postmarketing experience with TUDORZA PRESSAIR, immediate hypersensitivity reactions, including anaphylaxis, angioedema (including swelling of the lips, tongue, or throat), urticaria, rash, bronchospasm, or itching have been reported.","tongue , is not a named entity"
"In postmarketing experience with TUDORZA PRESSAIR, immediate hypersensitivity reactions, including anaphylaxis, angioedema (including swelling of the lips, tongue, or throat), urticaria, rash, bronchospasm, or itching have been reported.",", tongue is not a named entity"
"In postmarketing experience with TUDORZA PRESSAIR, immediate hypersensitivity reactions, including anaphylaxis, angioedema (including swelling of the lips, tongue, or throat), urticaria, rash, bronchospasm, or itching have been reported.",immediate hypersensitivity reactions is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are described in greater detail in other sections:     *    Paradoxical bronchospasm [see Warnings and Precautions (5.2)]    *    Worsening of narrow-angle glaucoma [see Warnings and Precautions (5.3)]    *    Worsening of urinary retention [see Warnings and Precautions (5.4)]    *    Immediate Hypersensitivity Reactions [ see Warnings and Precautions (5.5) ]        EXCERPT:   Most common adverse reactions (>=3% incidence and greater than placebo) are headache, nasopharyngitis and cough.",Worsening of narrow-angle glaucoma is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are described in greater detail in other sections:     *    Paradoxical bronchospasm [see Warnings and Precautions (5.2)]    *    Worsening of narrow-angle glaucoma [see Warnings and Precautions (5.3)]    *    Worsening of urinary retention [see Warnings and Precautions (5.4)]    *    Immediate Hypersensitivity Reactions [ see Warnings and Precautions (5.5) ]        EXCERPT:   Most common adverse reactions (>=3% incidence and greater than placebo) are headache, nasopharyngitis and cough.",Immediate Hypersensitivity Reactions is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are described in greater detail in other sections:     *    Paradoxical bronchospasm [see Warnings and Precautions (5.2)]    *    Worsening of narrow-angle glaucoma [see Warnings and Precautions (5.3)]    *    Worsening of urinary retention [see Warnings and Precautions (5.4)]    *    Immediate Hypersensitivity Reactions [ see Warnings and Precautions (5.5) ]        EXCERPT:   Most common adverse reactions (>=3% incidence and greater than placebo) are headache, nasopharyngitis and cough.",glaucoma [ see is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions are described in greater detail in other sections:     *    Paradoxical bronchospasm [see Warnings and Precautions (5.2)]    *    Worsening of narrow-angle glaucoma [see Warnings and Precautions (5.3)]    *    Worsening of urinary retention [see Warnings and Precautions (5.4)]    *    Immediate Hypersensitivity Reactions [ see Warnings and Precautions (5.5) ]        EXCERPT:   Most common adverse reactions (>=3% incidence and greater than placebo) are headache, nasopharyngitis and cough.",EXCERPT : Most is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions are described in greater detail in other sections:     *    Paradoxical bronchospasm [see Warnings and Precautions (5.2)]    *    Worsening of narrow-angle glaucoma [see Warnings and Precautions (5.3)]    *    Worsening of urinary retention [see Warnings and Precautions (5.4)]    *    Immediate Hypersensitivity Reactions [ see Warnings and Precautions (5.5) ]        EXCERPT:   Most common adverse reactions (>=3% incidence and greater than placebo) are headache, nasopharyngitis and cough.",[ is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions are described in greater detail in other sections:     *    Paradoxical bronchospasm [see Warnings and Precautions (5.2)]    *    Worsening of narrow-angle glaucoma [see Warnings and Precautions (5.3)]    *    Worsening of urinary retention [see Warnings and Precautions (5.4)]    *    Immediate Hypersensitivity Reactions [ see Warnings and Precautions (5.5) ]        EXCERPT:   Most common adverse reactions (>=3% incidence and greater than placebo) are headache, nasopharyngitis and cough.",( is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions are described in greater detail in other sections:     *    Paradoxical bronchospasm [see Warnings and Precautions (5.2)]    *    Worsening of narrow-angle glaucoma [see Warnings and Precautions (5.3)]    *    Worsening of urinary retention [see Warnings and Precautions (5.4)]    *    Immediate Hypersensitivity Reactions [ see Warnings and Precautions (5.5) ]        EXCERPT:   Most common adverse reactions (>=3% incidence and greater than placebo) are headache, nasopharyngitis and cough.",Paradoxical bronchospasm is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are described in greater detail in other sections:     *    Paradoxical bronchospasm [see Warnings and Precautions (5.2)]    *    Worsening of narrow-angle glaucoma [see Warnings and Precautions (5.3)]    *    Worsening of urinary retention [see Warnings and Precautions (5.4)]    *    Immediate Hypersensitivity Reactions [ see Warnings and Precautions (5.5) ]        EXCERPT:   Most common adverse reactions (>=3% incidence and greater than placebo) are headache, nasopharyngitis and cough.",Worsening of urinary retention is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are described in greater detail in other sections:     *    Paradoxical bronchospasm [see Warnings and Precautions (5.2)]    *    Worsening of narrow-angle glaucoma [see Warnings and Precautions (5.3)]    *    Worsening of urinary retention [see Warnings and Precautions (5.4)]    *    Immediate Hypersensitivity Reactions [ see Warnings and Precautions (5.5) ]        EXCERPT:   Most common adverse reactions (>=3% incidence and greater than placebo) are headache, nasopharyngitis and cough.",", nasopharyngitis is not a named entity"
"6 ADVERSE REACTIONS    The following adverse reactions are described in greater detail in other sections:     *    Paradoxical bronchospasm [see Warnings and Precautions (5.2)]    *    Worsening of narrow-angle glaucoma [see Warnings and Precautions (5.3)]    *    Worsening of urinary retention [see Warnings and Precautions (5.4)]    *    Immediate Hypersensitivity Reactions [ see Warnings and Precautions (5.5) ]        EXCERPT:   Most common adverse reactions (>=3% incidence and greater than placebo) are headache, nasopharyngitis and cough.",nasopharyngitis is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are described in greater detail in other sections:     *    Paradoxical bronchospasm [see Warnings and Precautions (5.2)]    *    Worsening of narrow-angle glaucoma [see Warnings and Precautions (5.3)]    *    Worsening of urinary retention [see Warnings and Precautions (5.4)]    *    Immediate Hypersensitivity Reactions [ see Warnings and Precautions (5.5) ]        EXCERPT:   Most common adverse reactions (>=3% incidence and greater than placebo) are headache, nasopharyngitis and cough.",cough is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are described in greater detail in other sections:     *    Paradoxical bronchospasm [see Warnings and Precautions (5.2)]    *    Worsening of narrow-angle glaucoma [see Warnings and Precautions (5.3)]    *    Worsening of urinary retention [see Warnings and Precautions (5.4)]    *    Immediate Hypersensitivity Reactions [ see Warnings and Precautions (5.5) ]        EXCERPT:   Most common adverse reactions (>=3% incidence and greater than placebo) are headache, nasopharyngitis and cough.",headache is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are described in greater detail in other sections:     *    Paradoxical bronchospasm [see Warnings and Precautions (5.2)]    *    Worsening of narrow-angle glaucoma [see Warnings and Precautions (5.3)]    *    Worsening of urinary retention [see Warnings and Precautions (5.4)]    *    Immediate Hypersensitivity Reactions [ see Warnings and Precautions (5.5) ]        EXCERPT:   Most common adverse reactions (>=3% incidence and greater than placebo) are headache, nasopharyngitis and cough.",5.4 ) is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions are described in greater detail in other sections:     *    Paradoxical bronchospasm [see Warnings and Precautions (5.2)]    *    Worsening of narrow-angle glaucoma [see Warnings and Precautions (5.3)]    *    Worsening of urinary retention [see Warnings and Precautions (5.4)]    *    Immediate Hypersensitivity Reactions [ see Warnings and Precautions (5.5) ]        EXCERPT:   Most common adverse reactions (>=3% incidence and greater than placebo) are headache, nasopharyngitis and cough.",Warnings and Precautions is not a named entity
"5.2 Paradoxical Bronchospasm    Inhaled medicines, including TUDORZA PRESSAIR, may cause paradoxical bronchospasm.",paradoxical bronchospasm is an adverse reaction entity
"5.2 Paradoxical Bronchospasm    Inhaled medicines, including TUDORZA PRESSAIR, may cause paradoxical bronchospasm.",may cause is not a named entity
Peripheral neuropathy was the most common toxicity leading to discontinuation of HALAVEN (5% of patients; 24/503).,HALAVEN ( is not a named entity
Peripheral neuropathy was the most common toxicity leading to discontinuation of HALAVEN (5% of patients; 24/503).,Peripheral neuropathy is an adverse reaction entity
"Avoid in patients with congenital long QT syndrome (  5.4  )              5.1   Neutropenia        Severe neutropenia (ANC < 500/mm  3  ) lasting more than one week occurred in 12% (62/503) of patients in Study 1, leading to discontinuation in <1% of patients [ see Adverse Reactions (     6     )  ].",than one is not a named entity
"Avoid in patients with congenital long QT syndrome (  5.4  )              5.1   Neutropenia        Severe neutropenia (ANC < 500/mm  3  ) lasting more than one week occurred in 12% (62/503) of patients in Study 1, leading to discontinuation in <1% of patients [ see Adverse Reactions (     6     )  ].",neutropenia is an adverse reaction entity
"5.2   Peripheral Neuropathy        Grade 3 peripheral neuropathy occurred in 8% (40/503) of patients, and Grade 4 in 0.4% (2/503) of patients in Study 1.",and Grade 4 is not a named entity
"5.2   Peripheral Neuropathy        Grade 3 peripheral neuropathy occurred in 8% (40/503) of patients, and Grade 4 in 0.4% (2/503) of patients in Study 1.",peripheral neuropathy is an adverse reaction entity
"5.2   Peripheral Neuropathy        Grade 3 peripheral neuropathy occurred in 8% (40/503) of patients, and Grade 4 in 0.4% (2/503) of patients in Study 1.",Peripheral Neuropathy Grade is not a named entity
"5.2   Peripheral Neuropathy        Grade 3 peripheral neuropathy occurred in 8% (40/503) of patients, and Grade 4 in 0.4% (2/503) of patients in Study 1.",peripheral neuropathy is an adverse reaction entity
"Manage with dose delay and adjustment (  2.2  ,  5.2  ,  6  )   *   Embryo-Fetal Toxicity : Fetal harm can occur when administered to a pregnant woman (  5.3  ) (  8.1  )   *   QT Prolongation : Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities.",QT Prolongation is an adverse reaction entity
"Manage with dose delay and adjustment (  2.2  ,  5.2  ,  6  )   *   Embryo-Fetal Toxicity : Fetal harm can occur when administered to a pregnant woman (  5.3  ) (  8.1  )   *   QT Prolongation : Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities.",", bradyarrhythmias is not a named entity"
"Manage with dose delay and adjustment (  2.2  ,  5.2  ,  6  )   *   Embryo-Fetal Toxicity : Fetal harm can occur when administered to a pregnant woman (  5.3  ) (  8.1  )   *   QT Prolongation : Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities.",Fetal harm is an adverse reaction entity
"Manage with dose delay and adjustment (  2.2  ,  5.2  ,  6  )   *   Embryo-Fetal Toxicity : Fetal harm can occur when administered to a pregnant woman (  5.3  ) (  8.1  )   *   QT Prolongation : Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities.",6 is not a named entity
"Manage with dose delay and adjustment (  2.2  ,  5.2  ,  6  )   *   Embryo-Fetal Toxicity : Fetal harm can occur when administered to a pregnant woman (  5.3  ) (  8.1  )   *   QT Prolongation : Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities.",Embryo-Fetal Toxicity is an adverse reaction entity
"Manage with dose delay and adjustment (  2.2  ,  5.2  ,  6  )   *   Embryo-Fetal Toxicity : Fetal harm can occur when administered to a pregnant woman (  5.3  ) (  8.1  )   *   QT Prolongation : Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities.",patients with is not a named entity
"b  includes neuropathy peripheral, neuropathy, peripheral motor neuropathy, polyneuropathy, peripheral sensoryneuropathy, and paraesthesia.",neuropathy peripheral is an adverse reaction entity
"b  includes neuropathy peripheral, neuropathy, peripheral motor neuropathy, polyneuropathy, peripheral sensoryneuropathy, and paraesthesia.",includes is not a named entity
"b  includes neuropathy peripheral, neuropathy, peripheral motor neuropathy, polyneuropathy, peripheral sensoryneuropathy, and paraesthesia.",polyneuropathy is an adverse reaction entity
"b  includes neuropathy peripheral, neuropathy, peripheral motor neuropathy, polyneuropathy, peripheral sensoryneuropathy, and paraesthesia.",paraesthesia is an adverse reaction entity
"b  includes neuropathy peripheral, neuropathy, peripheral motor neuropathy, polyneuropathy, peripheral sensoryneuropathy, and paraesthesia.",peripheral sensoryneuropathy is an adverse reaction entity
"b  includes neuropathy peripheral, neuropathy, peripheral motor neuropathy, polyneuropathy, peripheral sensoryneuropathy, and paraesthesia.","motor neuropathy , is not a named entity"
"b  includes neuropathy peripheral, neuropathy, peripheral motor neuropathy, polyneuropathy, peripheral sensoryneuropathy, and paraesthesia.","sensoryneuropathy , is not a named entity"
"b  includes neuropathy peripheral, neuropathy, peripheral motor neuropathy, polyneuropathy, peripheral sensoryneuropathy, and paraesthesia.",", peripheral is not a named entity"
"b  includes neuropathy peripheral, neuropathy, peripheral motor neuropathy, polyneuropathy, peripheral sensoryneuropathy, and paraesthesia.",", peripheral motor is not a named entity"
"b  includes neuropathy peripheral, neuropathy, peripheral motor neuropathy, polyneuropathy, peripheral sensoryneuropathy, and paraesthesia.",peripheral motor neuropathy is an adverse reaction entity
"b  includes neuropathy peripheral, neuropathy, peripheral motor neuropathy, polyneuropathy, peripheral sensoryneuropathy, and paraesthesia.",neuropathy is an adverse reaction entity
"b  includes neuropathy peripheral, neuropathy, peripheral motor neuropathy, polyneuropathy, peripheral sensoryneuropathy, and paraesthesia.","motor neuropathy , is not a named entity"
Dose reduction due to neutropenia was required in 12% (62/503) of patients and discontinuation was required in <1% of patients.,was required in is not a named entity
Dose reduction due to neutropenia was required in 12% (62/503) of patients and discontinuation was required in <1% of patients.,neutropenia is an adverse reaction entity
Embryo-fetal toxicity and teratogenicity occurred in rats that received eribulin mesylate at approximately half of the recommended human dose based on body surface area.,Embryo-fetal toxicity is an adverse reaction entity
Embryo-fetal toxicity and teratogenicity occurred in rats that received eribulin mesylate at approximately half of the recommended human dose based on body surface area.,half is not a named entity
Embryo-fetal toxicity and teratogenicity occurred in rats that received eribulin mesylate at approximately half of the recommended human dose based on body surface area.,teratogenicity is an adverse reaction entity
Embryo-fetal toxicity and teratogenicity occurred in rats that received eribulin mesylate at approximately half of the recommended human dose based on body surface area.,mesylate is not a named entity
Twenty-two percent (109/503) of patients developed a new or worsening neuropathy that had not recovered within a median follow-up duration of 269 days (range 25-662 days).,not is not a named entity
Twenty-two percent (109/503) of patients developed a new or worsening neuropathy that had not recovered within a median follow-up duration of 269 days (range 25-662 days).,neuropathy is an adverse reaction entity
"5   WARNINGS AND PRECAUTIONS         EXCERPT:    *   Neutropenia : Monitor peripheral blood cell counts and adjust dose as appropriate (  2.2  ,  5.1  ,  6  )   *   Peripheral Neuropathy : Monitor for signs of neuropathy.",6 is not a named entity
"5   WARNINGS AND PRECAUTIONS         EXCERPT:    *   Neutropenia : Monitor peripheral blood cell counts and adjust dose as appropriate (  2.2  ,  5.1  ,  6  )   *   Peripheral Neuropathy : Monitor for signs of neuropathy.",Peripheral Neuropathy is an adverse reaction entity
"5   WARNINGS AND PRECAUTIONS         EXCERPT:    *   Neutropenia : Monitor peripheral blood cell counts and adjust dose as appropriate (  2.2  ,  5.1  ,  6  )   *   Peripheral Neuropathy : Monitor for signs of neuropathy.",Neutropenia is an adverse reaction entity
"5   WARNINGS AND PRECAUTIONS         EXCERPT:    *   Neutropenia : Monitor peripheral blood cell counts and adjust dose as appropriate (  2.2  ,  5.1  ,  6  )   *   Peripheral Neuropathy : Monitor for signs of neuropathy.","5.1 , 6 is not a named entity"
"Peripheral Neuropathy:  In Study 1, 17 % of enrolled patients had Grade 1 peripheral neuropathy and 3% of patients had Grade 2 peripheral neuropathy at baseline.",peripheral neuropathy is an adverse reaction entity
"Peripheral Neuropathy:  In Study 1, 17 % of enrolled patients had Grade 1 peripheral neuropathy and 3% of patients had Grade 2 peripheral neuropathy at baseline.",peripheral neuropathy is an adverse reaction entity
"Peripheral Neuropathy:  In Study 1, 17 % of enrolled patients had Grade 1 peripheral neuropathy and 3% of patients had Grade 2 peripheral neuropathy at baseline.",Grade 1 peripheral is not a named entity
"Peripheral Neuropathy:  In Study 1, 17 % of enrolled patients had Grade 1 peripheral neuropathy and 3% of patients had Grade 2 peripheral neuropathy at baseline.",patients is not a named entity
The following adverse reactions are discussed in detail in other sections of the labeling:     *  Neutropenia [ see Warnings and Precautions (    5.1    ) ].,Neutropenia is an adverse reaction entity
The following adverse reactions are discussed in detail in other sections of the labeling:     *  Neutropenia [ see Warnings and Precautions (    5.1    ) ].,: is not a named entity
"HALAVEN is a microtubule inhibitor; therefore, it is expected to cause fetal harm when administered to a pregnant woman.",therefore is not a named entity
"HALAVEN is a microtubule inhibitor; therefore, it is expected to cause fetal harm when administered to a pregnant woman.",fetal harm is an adverse reaction entity
"5.4   QT Prolongation        In an uncontrolled open-label ECG study in 26 patients, QT prolongation was observed on Day 8, independent of eribulin concentration, with no QT prolongation observed on Day 1.",an uncontrolled open-label is not a named entity
"5.4   QT Prolongation        In an uncontrolled open-label ECG study in 26 patients, QT prolongation was observed on Day 8, independent of eribulin concentration, with no QT prolongation observed on Day 1.",QT prolongation is an adverse reaction entity
"5.4   QT Prolongation        In an uncontrolled open-label ECG study in 26 patients, QT prolongation was observed on Day 8, independent of eribulin concentration, with no QT prolongation observed on Day 1.",QT prolongation is an adverse reaction entity
"5.4   QT Prolongation        In an uncontrolled open-label ECG study in 26 patients, QT prolongation was observed on Day 8, independent of eribulin concentration, with no QT prolongation observed on Day 1.",concentration is not a named entity
c        not applicable; (grading system does not specify > Grade 2 for alopecia).,alopecia is an adverse reaction entity
c        not applicable; (grading system does not specify > Grade 2 for alopecia).,applicable ; ( is not a named entity
"Liver Function Test Abnormalities:  Among patients with Grade 0 or 1 ALT levels at baseline, 18% of HALAVEN-treated patients experienced Grade 2 or greater ALT elevation.",% of HALAVEN-treated is not a named entity
"Liver Function Test Abnormalities:  Among patients with Grade 0 or 1 ALT levels at baseline, 18% of HALAVEN-treated patients experienced Grade 2 or greater ALT elevation.",ALT elevation is an adverse reaction entity
The most common serious adverse reactions reported in patients receiving HALAVEN were febrile neutropenia (4%) and neutropenia (2%).,neutropenia is an adverse reaction entity
The most common serious adverse reactions reported in patients receiving HALAVEN were febrile neutropenia (4%) and neutropenia (2%).,febrile neutropenia is an adverse reaction entity
The most common serious adverse reactions reported in patients receiving HALAVEN were febrile neutropenia (4%) and neutropenia (2%).,) is not a named entity
The most common serious adverse reactions reported in patients receiving HALAVEN were febrile neutropenia (4%) and neutropenia (2%).,reported is not a named entity
"*   Blood and Lymphatic System Disorders: lymphopenia   *   Gastrointestinal Disorders: pancreatitis   *   Hepatobiliary Disorders: hepatotoxicity   *   Immune System Disorders: drug hypersensitivity   *   Infections and Infestations: pneumonia, sepsis/neutropenic sepsis   *   Metabolism and Nutrition Disorders: hypomagnesemia, dehydration   *   Respiratory, thoracic and mediastinal disorders: interstitial lung disease   *   Skin and Subcutaneous Tissue Disorders: pruritus",pneumonia is an adverse reaction entity
"*   Blood and Lymphatic System Disorders: lymphopenia   *   Gastrointestinal Disorders: pancreatitis   *   Hepatobiliary Disorders: hepatotoxicity   *   Immune System Disorders: drug hypersensitivity   *   Infections and Infestations: pneumonia, sepsis/neutropenic sepsis   *   Metabolism and Nutrition Disorders: hypomagnesemia, dehydration   *   Respiratory, thoracic and mediastinal disorders: interstitial lung disease   *   Skin and Subcutaneous Tissue Disorders: pruritus",sepsis is an adverse reaction entity
"*   Blood and Lymphatic System Disorders: lymphopenia   *   Gastrointestinal Disorders: pancreatitis   *   Hepatobiliary Disorders: hepatotoxicity   *   Immune System Disorders: drug hypersensitivity   *   Infections and Infestations: pneumonia, sepsis/neutropenic sepsis   *   Metabolism and Nutrition Disorders: hypomagnesemia, dehydration   *   Respiratory, thoracic and mediastinal disorders: interstitial lung disease   *   Skin and Subcutaneous Tissue Disorders: pruritus",pancreatitis is an adverse reaction entity
"*   Blood and Lymphatic System Disorders: lymphopenia   *   Gastrointestinal Disorders: pancreatitis   *   Hepatobiliary Disorders: hepatotoxicity   *   Immune System Disorders: drug hypersensitivity   *   Infections and Infestations: pneumonia, sepsis/neutropenic sepsis   *   Metabolism and Nutrition Disorders: hypomagnesemia, dehydration   *   Respiratory, thoracic and mediastinal disorders: interstitial lung disease   *   Skin and Subcutaneous Tissue Disorders: pruritus",interstitial lung disease is an adverse reaction entity
"*   Blood and Lymphatic System Disorders: lymphopenia   *   Gastrointestinal Disorders: pancreatitis   *   Hepatobiliary Disorders: hepatotoxicity   *   Immune System Disorders: drug hypersensitivity   *   Infections and Infestations: pneumonia, sepsis/neutropenic sepsis   *   Metabolism and Nutrition Disorders: hypomagnesemia, dehydration   *   Respiratory, thoracic and mediastinal disorders: interstitial lung disease   *   Skin and Subcutaneous Tissue Disorders: pruritus",", is not a named entity"
"*   Blood and Lymphatic System Disorders: lymphopenia   *   Gastrointestinal Disorders: pancreatitis   *   Hepatobiliary Disorders: hepatotoxicity   *   Immune System Disorders: drug hypersensitivity   *   Infections and Infestations: pneumonia, sepsis/neutropenic sepsis   *   Metabolism and Nutrition Disorders: hypomagnesemia, dehydration   *   Respiratory, thoracic and mediastinal disorders: interstitial lung disease   *   Skin and Subcutaneous Tissue Disorders: pruritus",Infections and Infestations is not a named entity
"*   Blood and Lymphatic System Disorders: lymphopenia   *   Gastrointestinal Disorders: pancreatitis   *   Hepatobiliary Disorders: hepatotoxicity   *   Immune System Disorders: drug hypersensitivity   *   Infections and Infestations: pneumonia, sepsis/neutropenic sepsis   *   Metabolism and Nutrition Disorders: hypomagnesemia, dehydration   *   Respiratory, thoracic and mediastinal disorders: interstitial lung disease   *   Skin and Subcutaneous Tissue Disorders: pruritus",Infestations : pneumonia is not a named entity
"*   Blood and Lymphatic System Disorders: lymphopenia   *   Gastrointestinal Disorders: pancreatitis   *   Hepatobiliary Disorders: hepatotoxicity   *   Immune System Disorders: drug hypersensitivity   *   Infections and Infestations: pneumonia, sepsis/neutropenic sepsis   *   Metabolism and Nutrition Disorders: hypomagnesemia, dehydration   *   Respiratory, thoracic and mediastinal disorders: interstitial lung disease   *   Skin and Subcutaneous Tissue Disorders: pruritus",pruritus is an adverse reaction entity
"*   Blood and Lymphatic System Disorders: lymphopenia   *   Gastrointestinal Disorders: pancreatitis   *   Hepatobiliary Disorders: hepatotoxicity   *   Immune System Disorders: drug hypersensitivity   *   Infections and Infestations: pneumonia, sepsis/neutropenic sepsis   *   Metabolism and Nutrition Disorders: hypomagnesemia, dehydration   *   Respiratory, thoracic and mediastinal disorders: interstitial lung disease   *   Skin and Subcutaneous Tissue Disorders: pruritus",hypersensitivity is an adverse reaction entity
"*   Blood and Lymphatic System Disorders: lymphopenia   *   Gastrointestinal Disorders: pancreatitis   *   Hepatobiliary Disorders: hepatotoxicity   *   Immune System Disorders: drug hypersensitivity   *   Infections and Infestations: pneumonia, sepsis/neutropenic sepsis   *   Metabolism and Nutrition Disorders: hypomagnesemia, dehydration   *   Respiratory, thoracic and mediastinal disorders: interstitial lung disease   *   Skin and Subcutaneous Tissue Disorders: pruritus",", thoracic and is not a named entity"
"*   Blood and Lymphatic System Disorders: lymphopenia   *   Gastrointestinal Disorders: pancreatitis   *   Hepatobiliary Disorders: hepatotoxicity   *   Immune System Disorders: drug hypersensitivity   *   Infections and Infestations: pneumonia, sepsis/neutropenic sepsis   *   Metabolism and Nutrition Disorders: hypomagnesemia, dehydration   *   Respiratory, thoracic and mediastinal disorders: interstitial lung disease   *   Skin and Subcutaneous Tissue Disorders: pruritus",Subcutaneous Tissue Disorders is not a named entity
"*   Blood and Lymphatic System Disorders: lymphopenia   *   Gastrointestinal Disorders: pancreatitis   *   Hepatobiliary Disorders: hepatotoxicity   *   Immune System Disorders: drug hypersensitivity   *   Infections and Infestations: pneumonia, sepsis/neutropenic sepsis   *   Metabolism and Nutrition Disorders: hypomagnesemia, dehydration   *   Respiratory, thoracic and mediastinal disorders: interstitial lung disease   *   Skin and Subcutaneous Tissue Disorders: pruritus",Nutrition Disorders is not a named entity
"*   Blood and Lymphatic System Disorders: lymphopenia   *   Gastrointestinal Disorders: pancreatitis   *   Hepatobiliary Disorders: hepatotoxicity   *   Immune System Disorders: drug hypersensitivity   *   Infections and Infestations: pneumonia, sepsis/neutropenic sepsis   *   Metabolism and Nutrition Disorders: hypomagnesemia, dehydration   *   Respiratory, thoracic and mediastinal disorders: interstitial lung disease   *   Skin and Subcutaneous Tissue Disorders: pruritus",neutropenic sepsis is an adverse reaction entity
"*   Blood and Lymphatic System Disorders: lymphopenia   *   Gastrointestinal Disorders: pancreatitis   *   Hepatobiliary Disorders: hepatotoxicity   *   Immune System Disorders: drug hypersensitivity   *   Infections and Infestations: pneumonia, sepsis/neutropenic sepsis   *   Metabolism and Nutrition Disorders: hypomagnesemia, dehydration   *   Respiratory, thoracic and mediastinal disorders: interstitial lung disease   *   Skin and Subcutaneous Tissue Disorders: pruritus",": pneumonia , is not a named entity"
"*   Blood and Lymphatic System Disorders: lymphopenia   *   Gastrointestinal Disorders: pancreatitis   *   Hepatobiliary Disorders: hepatotoxicity   *   Immune System Disorders: drug hypersensitivity   *   Infections and Infestations: pneumonia, sepsis/neutropenic sepsis   *   Metabolism and Nutrition Disorders: hypomagnesemia, dehydration   *   Respiratory, thoracic and mediastinal disorders: interstitial lung disease   *   Skin and Subcutaneous Tissue Disorders: pruritus",* Blood is not a named entity
"*   Blood and Lymphatic System Disorders: lymphopenia   *   Gastrointestinal Disorders: pancreatitis   *   Hepatobiliary Disorders: hepatotoxicity   *   Immune System Disorders: drug hypersensitivity   *   Infections and Infestations: pneumonia, sepsis/neutropenic sepsis   *   Metabolism and Nutrition Disorders: hypomagnesemia, dehydration   *   Respiratory, thoracic and mediastinal disorders: interstitial lung disease   *   Skin and Subcutaneous Tissue Disorders: pruritus",Blood is not a named entity
"*   Blood and Lymphatic System Disorders: lymphopenia   *   Gastrointestinal Disorders: pancreatitis   *   Hepatobiliary Disorders: hepatotoxicity   *   Immune System Disorders: drug hypersensitivity   *   Infections and Infestations: pneumonia, sepsis/neutropenic sepsis   *   Metabolism and Nutrition Disorders: hypomagnesemia, dehydration   *   Respiratory, thoracic and mediastinal disorders: interstitial lung disease   *   Skin and Subcutaneous Tissue Disorders: pruritus",Immune is not a named entity
"*   Blood and Lymphatic System Disorders: lymphopenia   *   Gastrointestinal Disorders: pancreatitis   *   Hepatobiliary Disorders: hepatotoxicity   *   Immune System Disorders: drug hypersensitivity   *   Infections and Infestations: pneumonia, sepsis/neutropenic sepsis   *   Metabolism and Nutrition Disorders: hypomagnesemia, dehydration   *   Respiratory, thoracic and mediastinal disorders: interstitial lung disease   *   Skin and Subcutaneous Tissue Disorders: pruritus",Disorders is not a named entity
"*   Blood and Lymphatic System Disorders: lymphopenia   *   Gastrointestinal Disorders: pancreatitis   *   Hepatobiliary Disorders: hepatotoxicity   *   Immune System Disorders: drug hypersensitivity   *   Infections and Infestations: pneumonia, sepsis/neutropenic sepsis   *   Metabolism and Nutrition Disorders: hypomagnesemia, dehydration   *   Respiratory, thoracic and mediastinal disorders: interstitial lung disease   *   Skin and Subcutaneous Tissue Disorders: pruritus",lymphopenia is an adverse reaction entity
"*   Blood and Lymphatic System Disorders: lymphopenia   *   Gastrointestinal Disorders: pancreatitis   *   Hepatobiliary Disorders: hepatotoxicity   *   Immune System Disorders: drug hypersensitivity   *   Infections and Infestations: pneumonia, sepsis/neutropenic sepsis   *   Metabolism and Nutrition Disorders: hypomagnesemia, dehydration   *   Respiratory, thoracic and mediastinal disorders: interstitial lung disease   *   Skin and Subcutaneous Tissue Disorders: pruritus",hepatotoxicity is an adverse reaction entity
"*   Blood and Lymphatic System Disorders: lymphopenia   *   Gastrointestinal Disorders: pancreatitis   *   Hepatobiliary Disorders: hepatotoxicity   *   Immune System Disorders: drug hypersensitivity   *   Infections and Infestations: pneumonia, sepsis/neutropenic sepsis   *   Metabolism and Nutrition Disorders: hypomagnesemia, dehydration   *   Respiratory, thoracic and mediastinal disorders: interstitial lung disease   *   Skin and Subcutaneous Tissue Disorders: pruritus",dehydration is an adverse reaction entity
"*   Blood and Lymphatic System Disorders: lymphopenia   *   Gastrointestinal Disorders: pancreatitis   *   Hepatobiliary Disorders: hepatotoxicity   *   Immune System Disorders: drug hypersensitivity   *   Infections and Infestations: pneumonia, sepsis/neutropenic sepsis   *   Metabolism and Nutrition Disorders: hypomagnesemia, dehydration   *   Respiratory, thoracic and mediastinal disorders: interstitial lung disease   *   Skin and Subcutaneous Tissue Disorders: pruritus",hypomagnesemia is an adverse reaction entity
Dose reduction due to peripheral neuropathy was required by 3% (14/503) of patients who received HALAVEN.,peripheral neuropathy is an adverse reaction entity
Dose reduction due to peripheral neuropathy was required by 3% (14/503) of patients who received HALAVEN.,neuropathy was required is not a named entity
Patients with alanine aminotransferase or aspartate aminotransferase > 3 * ULN (upper limit of normal) experienced a higher incidence of Grade 4 neutropenia and febrile neutropenia than patients with normal aminotransferase levels.,normal aminotransferase is not a named entity
Patients with alanine aminotransferase or aspartate aminotransferase > 3 * ULN (upper limit of normal) experienced a higher incidence of Grade 4 neutropenia and febrile neutropenia than patients with normal aminotransferase levels.,febrile neutropenia is an adverse reaction entity
Patients with alanine aminotransferase or aspartate aminotransferase > 3 * ULN (upper limit of normal) experienced a higher incidence of Grade 4 neutropenia and febrile neutropenia than patients with normal aminotransferase levels.,higher is not a named entity
Patients with alanine aminotransferase or aspartate aminotransferase > 3 * ULN (upper limit of normal) experienced a higher incidence of Grade 4 neutropenia and febrile neutropenia than patients with normal aminotransferase levels.,neutropenia is an adverse reaction entity
The most common adverse reaction resulting in discontinuation of HALAVEN was peripheral neuropathy (5%).,common adverse reaction is not a named entity
The most common adverse reaction resulting in discontinuation of HALAVEN was peripheral neuropathy (5%).,peripheral neuropathy is an adverse reaction entity
"In addition, because ILARIS may interfere with normal immune response to new antigens, vaccinations may not be effective in patients receiving ILARIS.",interfere with normal immune response is an adverse reaction entity
"In addition, because ILARIS may interfere with normal immune response to new antigens, vaccinations may not be effective in patients receiving ILARIS.","new antigens , is not a named entity"
"The most commonly reported adverse reactions associated with ILARIS treatment in the CAPS patients were nasopharyngitis, diarrhea, influenza, headache, and nausea.",ILARIS treatment is not a named entity
"The most commonly reported adverse reactions associated with ILARIS treatment in the CAPS patients were nasopharyngitis, diarrhea, influenza, headache, and nausea.",nausea is an adverse reaction entity
"The most commonly reported adverse reactions associated with ILARIS treatment in the CAPS patients were nasopharyngitis, diarrhea, influenza, headache, and nausea.",headache is an adverse reaction entity
"The most commonly reported adverse reactions associated with ILARIS treatment in the CAPS patients were nasopharyngitis, diarrhea, influenza, headache, and nausea.",influenza is an adverse reaction entity
"The most commonly reported adverse reactions associated with ILARIS treatment in the CAPS patients were nasopharyngitis, diarrhea, influenza, headache, and nausea.",", headache is not a named entity"
"The most commonly reported adverse reactions associated with ILARIS treatment in the CAPS patients were nasopharyngitis, diarrhea, influenza, headache, and nausea.",diarrhea is an adverse reaction entity
"The most commonly reported adverse reactions associated with ILARIS treatment in the CAPS patients were nasopharyngitis, diarrhea, influenza, headache, and nausea.",treatment in the is not a named entity
"The most commonly reported adverse reactions associated with ILARIS treatment in the CAPS patients were nasopharyngitis, diarrhea, influenza, headache, and nausea.",nasopharyngitis is an adverse reaction entity
"The most commonly reported adverse reactions associated with ILARIS treatment in the CAPS patients were nasopharyngitis, diarrhea, influenza, headache, and nausea.",treatment is not a named entity
"The most commonly reported adverse reactions associated with ILARIS treatment in the CAPS patients were nasopharyngitis, diarrhea, influenza, headache, and nausea.",patients were is not a named entity
(  5.4  )             5.1     Serious Infections      ILARIS has been associated with an increased risk of serious infections.,with an is not a named entity
(  5.4  )             5.1     Serious Infections      ILARIS has been associated with an increased risk of serious infections.,infections is an adverse reaction entity
Hepatic Transaminases       Elevations of transaminases have been observed in patients treated with ILARIS.,Elevations of transaminases is an adverse reaction entity
Hepatic Transaminases       Elevations of transaminases have been observed in patients treated with ILARIS.,Transaminases Elevations of is not a named entity
"Based on the clinical trial experience, ILARIS does not appear to increase the incidence of MAS in SJIA patients, but no definitive conclusion can be made.",MAS is an adverse reaction entity
"Based on the clinical trial experience, ILARIS does not appear to increase the incidence of MAS in SJIA patients, but no definitive conclusion can be made.",clinical trial is not a named entity
"However, treatment with immunosuppressants, including ILARIS, may result in an increase in the risk of malignancies.",malignancies is an adverse reaction entity
"However, treatment with immunosuppressants, including ILARIS, may result in an increase in the risk of malignancies.",increase is not a named entity
"The adverse drug reactions associated with ILARIS treatment in SJIA patients were infections, abdominal pain, and injection site reactions.",in SJIA is not a named entity
"The adverse drug reactions associated with ILARIS treatment in SJIA patients were infections, abdominal pain, and injection site reactions.",treatment in is not a named entity
"The adverse drug reactions associated with ILARIS treatment in SJIA patients were infections, abdominal pain, and injection site reactions.",injection site reactions is an adverse reaction entity
"The adverse drug reactions associated with ILARIS treatment in SJIA patients were infections, abdominal pain, and injection site reactions.",infections is an adverse reaction entity
"The adverse drug reactions associated with ILARIS treatment in SJIA patients were infections, abdominal pain, and injection site reactions.",treatment is not a named entity
"The adverse drug reactions associated with ILARIS treatment in SJIA patients were infections, abdominal pain, and injection site reactions.",abdominal pain is an adverse reaction entity
"Infections, predominantly of the upper respiratory tract, in some instances serious, have been reported with ILARIS.",", is not a named entity"
"Infections, predominantly of the upper respiratory tract, in some instances serious, have been reported with ILARIS.",Infections is an adverse reaction entity
"Infections, predominantly of the upper respiratory tract, in some instances serious, have been reported with ILARIS.",ILARIS is not a named entity
"Infections, predominantly of the upper respiratory tract, in some instances serious, have been reported with ILARIS.",", have is not a named entity"
"Infections, predominantly of the upper respiratory tract, in some instances serious, have been reported with ILARIS.",Infections of the upper respiratory tract is an adverse reaction entity
"Infections, predominantly of the upper respiratory tract, in some instances serious, have been reported with ILARIS.",Infections is an adverse reaction entity
"Infections, predominantly of the upper respiratory tract, in some instances serious, have been reported with ILARIS.",Infections of the upper respiratory tract is an adverse reaction entity
"Infections, predominantly of the upper respiratory tract, in some instances serious, have been reported with ILARIS.",in some is not a named entity
Eleven cases of MAS were observed in 201 SJIA patients treated with canakinumab in clinical trials.,SJIA patients is not a named entity
Eleven cases of MAS were observed in 201 SJIA patients treated with canakinumab in clinical trials.,MAS is an adverse reaction entity
Mild (less than LLN and greater than 75x10  9  /L) and transient decreases in platelet counts were observed in 3 (6.3%) ILARIS treated patients versus 1 (2.0%) placebo-treated patient.,( 2.0 is not a named entity
Mild (less than LLN and greater than 75x10  9  /L) and transient decreases in platelet counts were observed in 3 (6.3%) ILARIS treated patients versus 1 (2.0%) placebo-treated patient.,decreases in platelet counts is an adverse reaction entity
"(  6  )       SJIA:  The most common adverse drug reactions greater than 10% reported by patients with SJIA treated with ILARIS are infections (nasopharyngitis and upper respiratory tract infections), abdominal pain and injection site reactions.",tract infections ) is not a named entity
"(  6  )       SJIA:  The most common adverse drug reactions greater than 10% reported by patients with SJIA treated with ILARIS are infections (nasopharyngitis and upper respiratory tract infections), abdominal pain and injection site reactions.",injection site reactions is an adverse reaction entity
"(  6  )       SJIA:  The most common adverse drug reactions greater than 10% reported by patients with SJIA treated with ILARIS are infections (nasopharyngitis and upper respiratory tract infections), abdominal pain and injection site reactions.",greater than is not a named entity
"(  6  )       SJIA:  The most common adverse drug reactions greater than 10% reported by patients with SJIA treated with ILARIS are infections (nasopharyngitis and upper respiratory tract infections), abdominal pain and injection site reactions.",reactions greater is not a named entity
"(  6  )       SJIA:  The most common adverse drug reactions greater than 10% reported by patients with SJIA treated with ILARIS are infections (nasopharyngitis and upper respiratory tract infections), abdominal pain and injection site reactions.",site is not a named entity
"(  6  )       SJIA:  The most common adverse drug reactions greater than 10% reported by patients with SJIA treated with ILARIS are infections (nasopharyngitis and upper respiratory tract infections), abdominal pain and injection site reactions.",nasopharyngitis is an adverse reaction entity
"(  6  )       SJIA:  The most common adverse drug reactions greater than 10% reported by patients with SJIA treated with ILARIS are infections (nasopharyngitis and upper respiratory tract infections), abdominal pain and injection site reactions.",drug reactions greater is not a named entity
"(  6  )       SJIA:  The most common adverse drug reactions greater than 10% reported by patients with SJIA treated with ILARIS are infections (nasopharyngitis and upper respiratory tract infections), abdominal pain and injection site reactions.",abdominal pain is an adverse reaction entity
"(  6  )       SJIA:  The most common adverse drug reactions greater than 10% reported by patients with SJIA treated with ILARIS are infections (nasopharyngitis and upper respiratory tract infections), abdominal pain and injection site reactions.",infections is an adverse reaction entity
"(  6  )       SJIA:  The most common adverse drug reactions greater than 10% reported by patients with SJIA treated with ILARIS are infections (nasopharyngitis and upper respiratory tract infections), abdominal pain and injection site reactions.",upper respiratory tract infections is an adverse reaction entity
It is possible that use of IL-1 inhibitors such as ILARIS increases the risk of reactivation of tuberculosis or of opportunistic infections.,ILARIS increases is not a named entity
It is possible that use of IL-1 inhibitors such as ILARIS increases the risk of reactivation of tuberculosis or of opportunistic infections.,opportunistic infections is an adverse reaction entity
It is possible that use of IL-1 inhibitors such as ILARIS increases the risk of reactivation of tuberculosis or of opportunistic infections.,reactivation of tuberculosis is an adverse reaction entity
It is possible that use of IL-1 inhibitors such as ILARIS increases the risk of reactivation of tuberculosis or of opportunistic infections.,the is not a named entity
"Serious infections (e.g., pneumonia, varicella, gastroenteritis, measles, sepsis, otitis media, sinusitis, adenovirus, lymph node abscess, pharyngitis) were observed in approximately 4% to 5% (0.02 to 0.17 per 100 patient-days) of patients receiving ILARIS in both studies.",infections is an adverse reaction entity
"Serious infections (e.g., pneumonia, varicella, gastroenteritis, measles, sepsis, otitis media, sinusitis, adenovirus, lymph node abscess, pharyngitis) were observed in approximately 4% to 5% (0.02 to 0.17 per 100 patient-days) of patients receiving ILARIS in both studies.",", is not a named entity"
"Serious infections (e.g., pneumonia, varicella, gastroenteritis, measles, sepsis, otitis media, sinusitis, adenovirus, lymph node abscess, pharyngitis) were observed in approximately 4% to 5% (0.02 to 0.17 per 100 patient-days) of patients receiving ILARIS in both studies.",0.02 to 0.17 is not a named entity
"Serious infections (e.g., pneumonia, varicella, gastroenteritis, measles, sepsis, otitis media, sinusitis, adenovirus, lymph node abscess, pharyngitis) were observed in approximately 4% to 5% (0.02 to 0.17 per 100 patient-days) of patients receiving ILARIS in both studies.",adenovirus is an adverse reaction entity
"Serious infections (e.g., pneumonia, varicella, gastroenteritis, measles, sepsis, otitis media, sinusitis, adenovirus, lymph node abscess, pharyngitis) were observed in approximately 4% to 5% (0.02 to 0.17 per 100 patient-days) of patients receiving ILARIS in both studies.",measles is an adverse reaction entity
"Serious infections (e.g., pneumonia, varicella, gastroenteritis, measles, sepsis, otitis media, sinusitis, adenovirus, lymph node abscess, pharyngitis) were observed in approximately 4% to 5% (0.02 to 0.17 per 100 patient-days) of patients receiving ILARIS in both studies.",pharyngitis is an adverse reaction entity
"Serious infections (e.g., pneumonia, varicella, gastroenteritis, measles, sepsis, otitis media, sinusitis, adenovirus, lymph node abscess, pharyngitis) were observed in approximately 4% to 5% (0.02 to 0.17 per 100 patient-days) of patients receiving ILARIS in both studies.",", measles is not a named entity"
"Serious infections (e.g., pneumonia, varicella, gastroenteritis, measles, sepsis, otitis media, sinusitis, adenovirus, lymph node abscess, pharyngitis) were observed in approximately 4% to 5% (0.02 to 0.17 per 100 patient-days) of patients receiving ILARIS in both studies.",", measles is not a named entity"
"Serious infections (e.g., pneumonia, varicella, gastroenteritis, measles, sepsis, otitis media, sinusitis, adenovirus, lymph node abscess, pharyngitis) were observed in approximately 4% to 5% (0.02 to 0.17 per 100 patient-days) of patients receiving ILARIS in both studies.",sinusitis is an adverse reaction entity
"Serious infections (e.g., pneumonia, varicella, gastroenteritis, measles, sepsis, otitis media, sinusitis, adenovirus, lymph node abscess, pharyngitis) were observed in approximately 4% to 5% (0.02 to 0.17 per 100 patient-days) of patients receiving ILARIS in both studies.",) were is not a named entity
"Serious infections (e.g., pneumonia, varicella, gastroenteritis, measles, sepsis, otitis media, sinusitis, adenovirus, lymph node abscess, pharyngitis) were observed in approximately 4% to 5% (0.02 to 0.17 per 100 patient-days) of patients receiving ILARIS in both studies.",lymph node abscess is an adverse reaction entity
"Serious infections (e.g., pneumonia, varicella, gastroenteritis, measles, sepsis, otitis media, sinusitis, adenovirus, lymph node abscess, pharyngitis) were observed in approximately 4% to 5% (0.02 to 0.17 per 100 patient-days) of patients receiving ILARIS in both studies.",varicella is an adverse reaction entity
"Serious infections (e.g., pneumonia, varicella, gastroenteritis, measles, sepsis, otitis media, sinusitis, adenovirus, lymph node abscess, pharyngitis) were observed in approximately 4% to 5% (0.02 to 0.17 per 100 patient-days) of patients receiving ILARIS in both studies.",sepsis is an adverse reaction entity
"Serious infections (e.g., pneumonia, varicella, gastroenteritis, measles, sepsis, otitis media, sinusitis, adenovirus, lymph node abscess, pharyngitis) were observed in approximately 4% to 5% (0.02 to 0.17 per 100 patient-days) of patients receiving ILARIS in both studies.",in approximately is not a named entity
"Serious infections (e.g., pneumonia, varicella, gastroenteritis, measles, sepsis, otitis media, sinusitis, adenovirus, lymph node abscess, pharyngitis) were observed in approximately 4% to 5% (0.02 to 0.17 per 100 patient-days) of patients receiving ILARIS in both studies.",in is not a named entity
"Serious infections (e.g., pneumonia, varicella, gastroenteritis, measles, sepsis, otitis media, sinusitis, adenovirus, lymph node abscess, pharyngitis) were observed in approximately 4% to 5% (0.02 to 0.17 per 100 patient-days) of patients receiving ILARIS in both studies.",gastroenteritis is an adverse reaction entity
"Serious infections (e.g., pneumonia, varicella, gastroenteritis, measles, sepsis, otitis media, sinusitis, adenovirus, lymph node abscess, pharyngitis) were observed in approximately 4% to 5% (0.02 to 0.17 per 100 patient-days) of patients receiving ILARIS in both studies.",pneumonia is an adverse reaction entity
"Serious infections (e.g., pneumonia, varicella, gastroenteritis, measles, sepsis, otitis media, sinusitis, adenovirus, lymph node abscess, pharyngitis) were observed in approximately 4% to 5% (0.02 to 0.17 per 100 patient-days) of patients receiving ILARIS in both studies.",to 0.17 per is not a named entity
"Serious infections (e.g., pneumonia, varicella, gastroenteritis, measles, sepsis, otitis media, sinusitis, adenovirus, lymph node abscess, pharyngitis) were observed in approximately 4% to 5% (0.02 to 0.17 per 100 patient-days) of patients receiving ILARIS in both studies.",node is not a named entity
"Serious infections (e.g., pneumonia, varicella, gastroenteritis, measles, sepsis, otitis media, sinusitis, adenovirus, lymph node abscess, pharyngitis) were observed in approximately 4% to 5% (0.02 to 0.17 per 100 patient-days) of patients receiving ILARIS in both studies.",otitis media is an adverse reaction entity
"Serious infections (e.g., pneumonia, varicella, gastroenteritis, measles, sepsis, otitis media, sinusitis, adenovirus, lymph node abscess, pharyngitis) were observed in approximately 4% to 5% (0.02 to 0.17 per 100 patient-days) of patients receiving ILARIS in both studies.",0.02 to is not a named entity
"Serious infections (e.g., pneumonia, varicella, gastroenteritis, measles, sepsis, otitis media, sinusitis, adenovirus, lymph node abscess, pharyngitis) were observed in approximately 4% to 5% (0.02 to 0.17 per 100 patient-days) of patients receiving ILARIS in both studies.",", measles , is not a named entity"
An increased incidence of serious infections has been associated with administration of another IL-1 blocker in combination with TNF inhibitors.,with TNF inhibitors is not a named entity
An increased incidence of serious infections has been associated with administration of another IL-1 blocker in combination with TNF inhibitors.,infections is an adverse reaction entity
Opportunistic infections have also been reported in patients treated with ILARIS  [see Warnings and Precautions (5.1)]  .,Opportunistic infections is an adverse reaction entity
Opportunistic infections have also been reported in patients treated with ILARIS  [see Warnings and Precautions (5.1)]  .,and is not a named entity
"Injection Site Reactions       In CAPS Study 1, subcutaneous injection site reactions were observed in 9% of patients in Part 1 with mild tolerability reactions; in Part 2, one patient each (7%) had a mild or a moderate tolerability reaction and, in Part 3, one patient had a mild local tolerability reaction.",subcutaneous injection site reactions is an adverse reaction entity
"Injection Site Reactions       In CAPS Study 1, subcutaneous injection site reactions were observed in 9% of patients in Part 1 with mild tolerability reactions; in Part 2, one patient each (7%) had a mild or a moderate tolerability reaction and, in Part 3, one patient had a mild local tolerability reaction.",Study 1 is not a named entity
"Injection Site Reactions       In CAPS Study 1, subcutaneous injection site reactions were observed in 9% of patients in Part 1 with mild tolerability reactions; in Part 2, one patient each (7%) had a mild or a moderate tolerability reaction and, in Part 3, one patient had a mild local tolerability reaction.",tolerability is not a named entity
"Injection Site Reactions       In CAPS Study 1, subcutaneous injection site reactions were observed in 9% of patients in Part 1 with mild tolerability reactions; in Part 2, one patient each (7%) had a mild or a moderate tolerability reaction and, in Part 3, one patient had a mild local tolerability reaction.",local tolerability reaction is an adverse reaction entity
"In the randomized, placebo-controlled portion of SJIA Study 2 decreased white blood cell counts (WBC) less than or equal to 0.8 times lower limit of normal (LLN) were reported in 5 patients (10.4%)in the ILARIS group compared to 2 (4.0%) in the placebo group.",decreased WBC is an adverse reaction entity
"In the randomized, placebo-controlled portion of SJIA Study 2 decreased white blood cell counts (WBC) less than or equal to 0.8 times lower limit of normal (LLN) were reported in 5 patients (10.4%)in the ILARIS group compared to 2 (4.0%) in the placebo group.","randomized , placebo-controlled is not a named entity"
"In the randomized, placebo-controlled portion of SJIA Study 2 decreased white blood cell counts (WBC) less than or equal to 0.8 times lower limit of normal (LLN) were reported in 5 patients (10.4%)in the ILARIS group compared to 2 (4.0%) in the placebo group.",decreased white blood cell counts is an adverse reaction entity
"In the randomized, placebo-controlled portion of SJIA Study 2 decreased white blood cell counts (WBC) less than or equal to 0.8 times lower limit of normal (LLN) were reported in 5 patients (10.4%)in the ILARIS group compared to 2 (4.0%) in the placebo group.",LLN ) were is not a named entity
In CAPS trials one patient discontinued and in SJIA trials no patients discontinued due to hypersensitivity reactions.,one patient discontinued is not a named entity
In CAPS trials one patient discontinued and in SJIA trials no patients discontinued due to hypersensitivity reactions.,hypersensitivity reactions is an adverse reaction entity
Bilirubin       Asymptomatic and mild elevations of serum bilirubin have been observed in patients treated with ILARIS without concomitant elevations of transaminases.,serum is not a named entity
Bilirubin       Asymptomatic and mild elevations of serum bilirubin have been observed in patients treated with ILARIS without concomitant elevations of transaminases.,elevations of serum bilirubin is an adverse reaction entity
Bilirubin       Asymptomatic and mild elevations of serum bilirubin have been observed in patients treated with ILARIS without concomitant elevations of transaminases.,without is not a named entity
Bilirubin       Asymptomatic and mild elevations of serum bilirubin have been observed in patients treated with ILARIS without concomitant elevations of transaminases.,elevations of transaminases is an adverse reaction entity
One case of ANC less than 0.5x10  9  /L was observed in the ILARIS group and none in the placebo group.,and none is not a named entity
One case of ANC less than 0.5x10  9  /L was observed in the ILARIS group and none in the placebo group.,ANC less than 0.5x10 9 /L is an adverse reaction entity
"Among these were vertigo (2 patients), infections (3 patients), including intra-abdominal abscess following appendectomy (1 patient).",vertigo is an adverse reaction entity
"Among these were vertigo (2 patients), infections (3 patients), including intra-abdominal abscess following appendectomy (1 patient).",intra-abdominal abscess is an adverse reaction entity
"Among these were vertigo (2 patients), infections (3 patients), including intra-abdominal abscess following appendectomy (1 patient).",appendectomy ( 1 is not a named entity
"Among these were vertigo (2 patients), infections (3 patients), including intra-abdominal abscess following appendectomy (1 patient).",infections ( 3 is not a named entity
"Among these were vertigo (2 patients), infections (3 patients), including intra-abdominal abscess following appendectomy (1 patient).",infections is an adverse reaction entity
"Among these were vertigo (2 patients), infections (3 patients), including intra-abdominal abscess following appendectomy (1 patient).",Among these is not a named entity
Patients experiencing seizure were permanently discontinued from therapy and all seizure events resolved.,seizure is an adverse reaction entity
Patients experiencing seizure were permanently discontinued from therapy and all seizure events resolved.,seizure is not a named entity
Grade 1-4 elevations in ALT occurred in 10% of patients treated with XTANDI (0.2% Grade 3-4) and 16% of patients treated with placebo (0.2% Grade 3-4).,treated is not a named entity
Grade 1-4 elevations in ALT occurred in 10% of patients treated with XTANDI (0.2% Grade 3-4) and 16% of patients treated with placebo (0.2% Grade 3-4).,elevations in ALT is an adverse reaction entity
Grade 1-4 elevations in ALT occurred in 10% of patients treated with XTANDI (0.2% Grade 3-4) and 16% of patients treated with placebo (0.2% Grade 3-4).,elevations in ALT is an adverse reaction entity
Grade 1-4 elevations in ALT occurred in 10% of patients treated with XTANDI (0.2% Grade 3-4) and 16% of patients treated with placebo (0.2% Grade 3-4).,in is not a named entity
Grade 1-4 elevations in ALT occurred in 10% of patients treated with XTANDI (0.2% Grade 3-4) and 16% of patients treated with placebo (0.2% Grade 3-4).,Grade 3-4 ) is not a named entity
Grade 1-4 elevations in ALT occurred in 10% of patients treated with XTANDI (0.2% Grade 3-4) and 16% of patients treated with placebo (0.2% Grade 3-4).,elevations in ALT is an adverse reaction entity
"Laboratory Abnormalities  In the two randomized clinical trials, Grade 1-4 neutropenia occurred in 15% of patients treated with XTANDI (1% Grade 3-4) and in 6% of patients treated with placebo (0.5% Grade 3-4).",neutropenia is an adverse reaction entity
"Laboratory Abnormalities  In the two randomized clinical trials, Grade 1-4 neutropenia occurred in 15% of patients treated with XTANDI (1% Grade 3-4) and in 6% of patients treated with placebo (0.5% Grade 3-4).",neutropenia is an adverse reaction entity
"Laboratory Abnormalities  In the two randomized clinical trials, Grade 1-4 neutropenia occurred in 15% of patients treated with XTANDI (1% Grade 3-4) and in 6% of patients treated with placebo (0.5% Grade 3-4).",% of patients is not a named entity
"Laboratory Abnormalities  In the two randomized clinical trials, Grade 1-4 neutropenia occurred in 15% of patients treated with XTANDI (1% Grade 3-4) and in 6% of patients treated with placebo (0.5% Grade 3-4).",3-4 is not a named entity
"Laboratory Abnormalities  In the two randomized clinical trials, Grade 1-4 neutropenia occurred in 15% of patients treated with XTANDI (1% Grade 3-4) and in 6% of patients treated with placebo (0.5% Grade 3-4).",neutropenia is an adverse reaction entity
"Laboratory Abnormalities  In the two randomized clinical trials, Grade 1-4 neutropenia occurred in 15% of patients treated with XTANDI (1% Grade 3-4) and in 6% of patients treated with placebo (0.5% Grade 3-4).",neutropenia occurred in is not a named entity
"Fall-related injuries were more severe in patients treated with XTANDI and included non-pathologic fractures, joint injuries, and hematomas.","joint injuries , is not a named entity"
"Fall-related injuries were more severe in patients treated with XTANDI and included non-pathologic fractures, joint injuries, and hematomas.",Fall-related injuries is an adverse reaction entity
"Fall-related injuries were more severe in patients treated with XTANDI and included non-pathologic fractures, joint injuries, and hematomas.",joint injuries is an adverse reaction entity
"Fall-related injuries were more severe in patients treated with XTANDI and included non-pathologic fractures, joint injuries, and hematomas.",with XTANDI and is not a named entity
"Fall-related injuries were more severe in patients treated with XTANDI and included non-pathologic fractures, joint injuries, and hematomas.",", is not a named entity"
"Fall-related injuries were more severe in patients treated with XTANDI and included non-pathologic fractures, joint injuries, and hematomas.",hematomas is an adverse reaction entity
"Fall-related injuries were more severe in patients treated with XTANDI and included non-pathologic fractures, joint injuries, and hematomas.",non-pathologic fractures is an adverse reaction entity
"Fall-related injuries were more severe in patients treated with XTANDI and included non-pathologic fractures, joint injuries, and hematomas.","non-pathologic fractures , is not a named entity"
"The most common adverse reaction leading to treatment discontinuation was fatigue/asthenia, which occurred in 1% of patients on each treatment arm.",fatigue is an adverse reaction entity
"The most common adverse reaction leading to treatment discontinuation was fatigue/asthenia, which occurred in 1% of patients on each treatment arm.",asthenia is an adverse reaction entity
"The most common adverse reaction leading to treatment discontinuation was fatigue/asthenia, which occurred in 1% of patients on each treatment arm.",occurred in 1 is not a named entity
"The most common adverse reaction leading to treatment discontinuation was fatigue/asthenia, which occurred in 1% of patients on each treatment arm.",discontinuation was is not a named entity
"The most common adverse reactions (>= 10%) that occurred more commonly (>= 2% over placebo) in the XTANDI-treated patients from the two randomized clinical trials were asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",the is not a named entity
"The most common adverse reactions (>= 10%) that occurred more commonly (>= 2% over placebo) in the XTANDI-treated patients from the two randomized clinical trials were asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",", is not a named entity"
"The most common adverse reactions (>= 10%) that occurred more commonly (>= 2% over placebo) in the XTANDI-treated patients from the two randomized clinical trials were asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",musculoskeletal pain is an adverse reaction entity
"The most common adverse reactions (>= 10%) that occurred more commonly (>= 2% over placebo) in the XTANDI-treated patients from the two randomized clinical trials were asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",", hot is not a named entity"
"The most common adverse reactions (>= 10%) that occurred more commonly (>= 2% over placebo) in the XTANDI-treated patients from the two randomized clinical trials were asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",peripheral edema is an adverse reaction entity
"The most common adverse reactions (>= 10%) that occurred more commonly (>= 2% over placebo) in the XTANDI-treated patients from the two randomized clinical trials were asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.","dyspnea , musculoskeletal is not a named entity"
"The most common adverse reactions (>= 10%) that occurred more commonly (>= 2% over placebo) in the XTANDI-treated patients from the two randomized clinical trials were asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",vertigo is an adverse reaction entity
"The most common adverse reactions (>= 10%) that occurred more commonly (>= 2% over placebo) in the XTANDI-treated patients from the two randomized clinical trials were asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",dyspnea is an adverse reaction entity
"The most common adverse reactions (>= 10%) that occurred more commonly (>= 2% over placebo) in the XTANDI-treated patients from the two randomized clinical trials were asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",hot flush is an adverse reaction entity
"The most common adverse reactions (>= 10%) that occurred more commonly (>= 2% over placebo) in the XTANDI-treated patients from the two randomized clinical trials were asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",dizziness is an adverse reaction entity
"The most common adverse reactions (>= 10%) that occurred more commonly (>= 2% over placebo) in the XTANDI-treated patients from the two randomized clinical trials were asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.","back pain , is not a named entity"
"The most common adverse reactions (>= 10%) that occurred more commonly (>= 2% over placebo) in the XTANDI-treated patients from the two randomized clinical trials were asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",that is not a named entity
"The most common adverse reactions (>= 10%) that occurred more commonly (>= 2% over placebo) in the XTANDI-treated patients from the two randomized clinical trials were asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",", constipation , is not a named entity"
"The most common adverse reactions (>= 10%) that occurred more commonly (>= 2% over placebo) in the XTANDI-treated patients from the two randomized clinical trials were asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",back pain is an adverse reaction entity
"The most common adverse reactions (>= 10%) that occurred more commonly (>= 2% over placebo) in the XTANDI-treated patients from the two randomized clinical trials were asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",upper respiratory tract infection is an adverse reaction entity
"The most common adverse reactions (>= 10%) that occurred more commonly (>= 2% over placebo) in the XTANDI-treated patients from the two randomized clinical trials were asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",", diarrhea is not a named entity"
"The most common adverse reactions (>= 10%) that occurred more commonly (>= 2% over placebo) in the XTANDI-treated patients from the two randomized clinical trials were asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",", is not a named entity"
"The most common adverse reactions (>= 10%) that occurred more commonly (>= 2% over placebo) in the XTANDI-treated patients from the two randomized clinical trials were asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",XTANDI-treated is not a named entity
"The most common adverse reactions (>= 10%) that occurred more commonly (>= 2% over placebo) in the XTANDI-treated patients from the two randomized clinical trials were asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",weight decreased is an adverse reaction entity
"The most common adverse reactions (>= 10%) that occurred more commonly (>= 2% over placebo) in the XTANDI-treated patients from the two randomized clinical trials were asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",hypertension is an adverse reaction entity
"The most common adverse reactions (>= 10%) that occurred more commonly (>= 2% over placebo) in the XTANDI-treated patients from the two randomized clinical trials were asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",) in the is not a named entity
"The most common adverse reactions (>= 10%) that occurred more commonly (>= 2% over placebo) in the XTANDI-treated patients from the two randomized clinical trials were asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",fatigue is an adverse reaction entity
"The most common adverse reactions (>= 10%) that occurred more commonly (>= 2% over placebo) in the XTANDI-treated patients from the two randomized clinical trials were asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",arthralgia is an adverse reaction entity
"The most common adverse reactions (>= 10%) that occurred more commonly (>= 2% over placebo) in the XTANDI-treated patients from the two randomized clinical trials were asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",) that occurred is not a named entity
"The most common adverse reactions (>= 10%) that occurred more commonly (>= 2% over placebo) in the XTANDI-treated patients from the two randomized clinical trials were asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",asthenia is an adverse reaction entity
"The most common adverse reactions (>= 10%) that occurred more commonly (>= 2% over placebo) in the XTANDI-treated patients from the two randomized clinical trials were asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",decreased appetite is an adverse reaction entity
"The most common adverse reactions (>= 10%) that occurred more commonly (>= 2% over placebo) in the XTANDI-treated patients from the two randomized clinical trials were asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",= 10 % is not a named entity
"The most common adverse reactions (>= 10%) that occurred more commonly (>= 2% over placebo) in the XTANDI-treated patients from the two randomized clinical trials were asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",two randomized clinical is not a named entity
"The most common adverse reactions (>= 10%) that occurred more commonly (>= 2% over placebo) in the XTANDI-treated patients from the two randomized clinical trials were asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",common adverse reactions is not a named entity
"The most common adverse reactions (>= 10%) that occurred more commonly (>= 2% over placebo) in the XTANDI-treated patients from the two randomized clinical trials were asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",diarrhea is an adverse reaction entity
"The most common adverse reactions (>= 10%) that occurred more commonly (>= 2% over placebo) in the XTANDI-treated patients from the two randomized clinical trials were asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",headache is an adverse reaction entity
"The most common adverse reactions (>= 10%) that occurred more commonly (>= 2% over placebo) in the XTANDI-treated patients from the two randomized clinical trials were asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.","headache , hypertension is not a named entity"
"The most common adverse reactions (>= 10%) that occurred more commonly (>= 2% over placebo) in the XTANDI-treated patients from the two randomized clinical trials were asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",randomized clinical is not a named entity
"The most common adverse reactions (>= 10%) that occurred more commonly (>= 2% over placebo) in the XTANDI-treated patients from the two randomized clinical trials were asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",constipation is an adverse reaction entity
"Hypertension  In the two randomized trials, hypertension was reported in 11% of patients receiving XTANDI and 4% of patients receiving placebo.",Hypertension is an adverse reaction entity
"Hypertension  In the two randomized trials, hypertension was reported in 11% of patients receiving XTANDI and 4% of patients receiving placebo.",in 11 % is not a named entity
"Hypertension  In the two randomized trials, hypertension was reported in 11% of patients receiving XTANDI and 4% of patients receiving placebo.",and is not a named entity
"Hypertension  In the two randomized trials, hypertension was reported in 11% of patients receiving XTANDI and 4% of patients receiving placebo.",hypertension is an adverse reaction entity
"The most common adverse reaction leading to treatment discontinuation was seizure, which occurred in 0.9% of the XTANDI-treated patients compared to none (0%) of the placebo-treated patients.",seizure is an adverse reaction entity
"The most common adverse reaction leading to treatment discontinuation was seizure, which occurred in 0.9% of the XTANDI-treated patients compared to none (0%) of the placebo-treated patients.",% of is not a named entity
5 WARNINGS AND PRECAUTIONS      EXCERPT:   Seizure occurred in 0.9% of patients receiving XTANDI who previously received docetaxel and in 0.1% of patients who were chemotherapy-naive.,Seizure is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS      EXCERPT:   Seizure occurred in 0.9% of patients receiving XTANDI who previously received docetaxel and in 0.1% of patients who were chemotherapy-naive.,docetaxel and in is not a named entity
"In Study 2, 1 patient in each treatment group (0.1%) had an infection resulting in death.",death is an adverse reaction entity
"In Study 2, 1 patient in each treatment group (0.1%) had an infection resulting in death.",infection is an adverse reaction entity
"In Study 2, 1 patient in each treatment group (0.1%) had an infection resulting in death.",had is not a named entity
"In Study 2, 1 patient in each treatment group (0.1%) had an infection resulting in death.",", 1 patient is not a named entity"
"(  5.1  )            5.1 Seizure       In Study 1, which enrolled patients who previously received docetaxel, 7 of 800 (0.9%) patients treated with XTANDI experienced a seizure and no patients treated with placebo experienced a seizure.",800 ( 0.9 is not a named entity
"(  5.1  )            5.1 Seizure       In Study 1, which enrolled patients who previously received docetaxel, 7 of 800 (0.9%) patients treated with XTANDI experienced a seizure and no patients treated with placebo experienced a seizure.",seizure is an adverse reaction entity
"(  5.1  )            5.1 Seizure       In Study 1, which enrolled patients who previously received docetaxel, 7 of 800 (0.9%) patients treated with XTANDI experienced a seizure and no patients treated with placebo experienced a seizure.",patients treated with is not a named entity
"(  5.1  )            5.1 Seizure       In Study 1, which enrolled patients who previously received docetaxel, 7 of 800 (0.9%) patients treated with XTANDI experienced a seizure and no patients treated with placebo experienced a seizure.",seizure is an adverse reaction entity
"Grade 3 or higher (severe, life-threatening, or fatal) neurological toxicities following initiation of BLINCYTO administration occurred in approximately 15% of patients and included encephalopathy, convulsions, speech disorders, disturbances in consciousness, confusion and disorientation, and coordination and balance disorders.",initiation is not a named entity
"Grade 3 or higher (severe, life-threatening, or fatal) neurological toxicities following initiation of BLINCYTO administration occurred in approximately 15% of patients and included encephalopathy, convulsions, speech disorders, disturbances in consciousness, confusion and disorientation, and coordination and balance disorders.",confusion is an adverse reaction entity
"Grade 3 or higher (severe, life-threatening, or fatal) neurological toxicities following initiation of BLINCYTO administration occurred in approximately 15% of patients and included encephalopathy, convulsions, speech disorders, disturbances in consciousness, confusion and disorientation, and coordination and balance disorders.",fatal is an adverse reaction entity
"Grade 3 or higher (severe, life-threatening, or fatal) neurological toxicities following initiation of BLINCYTO administration occurred in approximately 15% of patients and included encephalopathy, convulsions, speech disorders, disturbances in consciousness, confusion and disorientation, and coordination and balance disorders.",and is not a named entity
"Grade 3 or higher (severe, life-threatening, or fatal) neurological toxicities following initiation of BLINCYTO administration occurred in approximately 15% of patients and included encephalopathy, convulsions, speech disorders, disturbances in consciousness, confusion and disorientation, and coordination and balance disorders.",initiation is not a named entity
"Grade 3 or higher (severe, life-threatening, or fatal) neurological toxicities following initiation of BLINCYTO administration occurred in approximately 15% of patients and included encephalopathy, convulsions, speech disorders, disturbances in consciousness, confusion and disorientation, and coordination and balance disorders.",disorientation is an adverse reaction entity
"Grade 3 or higher (severe, life-threatening, or fatal) neurological toxicities following initiation of BLINCYTO administration occurred in approximately 15% of patients and included encephalopathy, convulsions, speech disorders, disturbances in consciousness, confusion and disorientation, and coordination and balance disorders.",balance disorders is an adverse reaction entity
"Grade 3 or higher (severe, life-threatening, or fatal) neurological toxicities following initiation of BLINCYTO administration occurred in approximately 15% of patients and included encephalopathy, convulsions, speech disorders, disturbances in consciousness, confusion and disorientation, and coordination and balance disorders.",disturbances in consciousness is an adverse reaction entity
"Grade 3 or higher (severe, life-threatening, or fatal) neurological toxicities following initiation of BLINCYTO administration occurred in approximately 15% of patients and included encephalopathy, convulsions, speech disorders, disturbances in consciousness, confusion and disorientation, and coordination and balance disorders.",coordination disorders is an adverse reaction entity
"Grade 3 or higher (severe, life-threatening, or fatal) neurological toxicities following initiation of BLINCYTO administration occurred in approximately 15% of patients and included encephalopathy, convulsions, speech disorders, disturbances in consciousness, confusion and disorientation, and coordination and balance disorders.",neurological toxicities is an adverse reaction entity
"Grade 3 or higher (severe, life-threatening, or fatal) neurological toxicities following initiation of BLINCYTO administration occurred in approximately 15% of patients and included encephalopathy, convulsions, speech disorders, disturbances in consciousness, confusion and disorientation, and coordination and balance disorders.",convulsions is an adverse reaction entity
"Grade 3 or higher (severe, life-threatening, or fatal) neurological toxicities following initiation of BLINCYTO administration occurred in approximately 15% of patients and included encephalopathy, convulsions, speech disorders, disturbances in consciousness, confusion and disorientation, and coordination and balance disorders.",confusion and is not a named entity
"Grade 3 or higher (severe, life-threatening, or fatal) neurological toxicities following initiation of BLINCYTO administration occurred in approximately 15% of patients and included encephalopathy, convulsions, speech disorders, disturbances in consciousness, confusion and disorientation, and coordination and balance disorders.",encephalopathy is an adverse reaction entity
"Grade 3 or higher (severe, life-threatening, or fatal) neurological toxicities following initiation of BLINCYTO administration occurred in approximately 15% of patients and included encephalopathy, convulsions, speech disorders, disturbances in consciousness, confusion and disorientation, and coordination and balance disorders.",of is not a named entity
"Grade 3 or higher (severe, life-threatening, or fatal) neurological toxicities following initiation of BLINCYTO administration occurred in approximately 15% of patients and included encephalopathy, convulsions, speech disorders, disturbances in consciousness, confusion and disorientation, and coordination and balance disorders.",", convulsions , is not a named entity"
"Grade 3 or higher (severe, life-threatening, or fatal) neurological toxicities following initiation of BLINCYTO administration occurred in approximately 15% of patients and included encephalopathy, convulsions, speech disorders, disturbances in consciousness, confusion and disorientation, and coordination and balance disorders.",approximately is not a named entity
"Grade 3 or higher (severe, life-threatening, or fatal) neurological toxicities following initiation of BLINCYTO administration occurred in approximately 15% of patients and included encephalopathy, convulsions, speech disorders, disturbances in consciousness, confusion and disorientation, and coordination and balance disorders.",of BLINCYTO is not a named entity
"Grade 3 or higher (severe, life-threatening, or fatal) neurological toxicities following initiation of BLINCYTO administration occurred in approximately 15% of patients and included encephalopathy, convulsions, speech disorders, disturbances in consciousness, confusion and disorientation, and coordination and balance disorders.",15 % of is not a named entity
"Grade 3 or higher (severe, life-threatening, or fatal) neurological toxicities following initiation of BLINCYTO administration occurred in approximately 15% of patients and included encephalopathy, convulsions, speech disorders, disturbances in consciousness, confusion and disorientation, and coordination and balance disorders.",occurred in approximately is not a named entity
"Grade 3 or higher (severe, life-threatening, or fatal) neurological toxicities following initiation of BLINCYTO administration occurred in approximately 15% of patients and included encephalopathy, convulsions, speech disorders, disturbances in consciousness, confusion and disorientation, and coordination and balance disorders.",speech disorders is an adverse reaction entity
"1915        05       Skin and subcutaneous tissue disorders       RashRash includes the following terms: erythema, rash, erythematous rash, generalized rash, macular rash, maculo-papular rash, papular rash, and vesicular rash.",erythematous rash is an adverse reaction entity
"1915        05       Skin and subcutaneous tissue disorders       RashRash includes the following terms: erythema, rash, erythematous rash, generalized rash, macular rash, maculo-papular rash, papular rash, and vesicular rash.",and is not a named entity
"1915        05       Skin and subcutaneous tissue disorders       RashRash includes the following terms: erythema, rash, erythematous rash, generalized rash, macular rash, maculo-papular rash, papular rash, and vesicular rash.",Rash is an adverse reaction entity
"1915        05       Skin and subcutaneous tissue disorders       RashRash includes the following terms: erythema, rash, erythematous rash, generalized rash, macular rash, maculo-papular rash, papular rash, and vesicular rash.",rash is an adverse reaction entity
"1915        05       Skin and subcutaneous tissue disorders       RashRash includes the following terms: erythema, rash, erythematous rash, generalized rash, macular rash, maculo-papular rash, papular rash, and vesicular rash.",Rash is an adverse reaction entity
"1915        05       Skin and subcutaneous tissue disorders       RashRash includes the following terms: erythema, rash, erythematous rash, generalized rash, macular rash, maculo-papular rash, papular rash, and vesicular rash.",": erythema , is not a named entity"
"1915        05       Skin and subcutaneous tissue disorders       RashRash includes the following terms: erythema, rash, erythematous rash, generalized rash, macular rash, maculo-papular rash, papular rash, and vesicular rash.",", is not a named entity"
"1915        05       Skin and subcutaneous tissue disorders       RashRash includes the following terms: erythema, rash, erythematous rash, generalized rash, macular rash, maculo-papular rash, papular rash, and vesicular rash.",subcutaneous is not a named entity
"1915        05       Skin and subcutaneous tissue disorders       RashRash includes the following terms: erythema, rash, erythematous rash, generalized rash, macular rash, maculo-papular rash, papular rash, and vesicular rash.",rash is not a named entity
"1915        05       Skin and subcutaneous tissue disorders       RashRash includes the following terms: erythema, rash, erythematous rash, generalized rash, macular rash, maculo-papular rash, papular rash, and vesicular rash.",vesicular rash is an adverse reaction entity
"1915        05       Skin and subcutaneous tissue disorders       RashRash includes the following terms: erythema, rash, erythematous rash, generalized rash, macular rash, maculo-papular rash, papular rash, and vesicular rash.",05 Skin and is not a named entity
"1915        05       Skin and subcutaneous tissue disorders       RashRash includes the following terms: erythema, rash, erythematous rash, generalized rash, macular rash, maculo-papular rash, papular rash, and vesicular rash.",maculo-papular rash is an adverse reaction entity
"1915        05       Skin and subcutaneous tissue disorders       RashRash includes the following terms: erythema, rash, erythematous rash, generalized rash, macular rash, maculo-papular rash, papular rash, and vesicular rash.",disorders is not a named entity
"1915        05       Skin and subcutaneous tissue disorders       RashRash includes the following terms: erythema, rash, erythematous rash, generalized rash, macular rash, maculo-papular rash, papular rash, and vesicular rash.",macular rash is an adverse reaction entity
"1915        05       Skin and subcutaneous tissue disorders       RashRash includes the following terms: erythema, rash, erythematous rash, generalized rash, macular rash, maculo-papular rash, papular rash, and vesicular rash.",", macular rash is not a named entity"
"1915        05       Skin and subcutaneous tissue disorders       RashRash includes the following terms: erythema, rash, erythematous rash, generalized rash, macular rash, maculo-papular rash, papular rash, and vesicular rash.",erythema is an adverse reaction entity
"1915        05       Skin and subcutaneous tissue disorders       RashRash includes the following terms: erythema, rash, erythematous rash, generalized rash, macular rash, maculo-papular rash, papular rash, and vesicular rash.",RashRash includes is not a named entity
"1915        05       Skin and subcutaneous tissue disorders       RashRash includes the following terms: erythema, rash, erythematous rash, generalized rash, macular rash, maculo-papular rash, papular rash, and vesicular rash.",papular rash is an adverse reaction entity
"1915        05       Skin and subcutaneous tissue disorders       RashRash includes the following terms: erythema, rash, erythematous rash, generalized rash, macular rash, maculo-papular rash, papular rash, and vesicular rash.",generalized rash is an adverse reaction entity
"1915        05       Skin and subcutaneous tissue disorders       RashRash includes the following terms: erythema, rash, erythematous rash, generalized rash, macular rash, maculo-papular rash, papular rash, and vesicular rash.",: is not a named entity
5.7     Elevated Liver Enzymes      Treatment with BLINCYTO was associated with transient elevations in liver enzymes.,BLINCYTO is not a named entity
5.7     Elevated Liver Enzymes      Treatment with BLINCYTO was associated with transient elevations in liver enzymes.,elevations in liver enzymes is an adverse reaction entity
"5.3     Infections      In patients receiving BLINCYTO in clinical trials, serious infections such as sepsis, pneumonia, bacteremia, opportunistic infections, and catheter-site infections were observed in approximately 25% of patients, some of which were life-threatening or fatal.",25 % of is not a named entity
"5.3     Infections      In patients receiving BLINCYTO in clinical trials, serious infections such as sepsis, pneumonia, bacteremia, opportunistic infections, and catheter-site infections were observed in approximately 25% of patients, some of which were life-threatening or fatal.",BLINCYTO in is not a named entity
"5.3     Infections      In patients receiving BLINCYTO in clinical trials, serious infections such as sepsis, pneumonia, bacteremia, opportunistic infections, and catheter-site infections were observed in approximately 25% of patients, some of which were life-threatening or fatal.",approximately 25 is not a named entity
"5.3     Infections      In patients receiving BLINCYTO in clinical trials, serious infections such as sepsis, pneumonia, bacteremia, opportunistic infections, and catheter-site infections were observed in approximately 25% of patients, some of which were life-threatening or fatal.",pneumonia is an adverse reaction entity
"5.3     Infections      In patients receiving BLINCYTO in clinical trials, serious infections such as sepsis, pneumonia, bacteremia, opportunistic infections, and catheter-site infections were observed in approximately 25% of patients, some of which were life-threatening or fatal.",", pneumonia is not a named entity"
"5.3     Infections      In patients receiving BLINCYTO in clinical trials, serious infections such as sepsis, pneumonia, bacteremia, opportunistic infections, and catheter-site infections were observed in approximately 25% of patients, some of which were life-threatening or fatal.",patients is not a named entity
"5.3     Infections      In patients receiving BLINCYTO in clinical trials, serious infections such as sepsis, pneumonia, bacteremia, opportunistic infections, and catheter-site infections were observed in approximately 25% of patients, some of which were life-threatening or fatal.",catheter-site infections is an adverse reaction entity
"5.3     Infections      In patients receiving BLINCYTO in clinical trials, serious infections such as sepsis, pneumonia, bacteremia, opportunistic infections, and catheter-site infections were observed in approximately 25% of patients, some of which were life-threatening or fatal.",patients is not a named entity
"5.3     Infections      In patients receiving BLINCYTO in clinical trials, serious infections such as sepsis, pneumonia, bacteremia, opportunistic infections, and catheter-site infections were observed in approximately 25% of patients, some of which were life-threatening or fatal.",sepsis is an adverse reaction entity
"5.3     Infections      In patients receiving BLINCYTO in clinical trials, serious infections such as sepsis, pneumonia, bacteremia, opportunistic infections, and catheter-site infections were observed in approximately 25% of patients, some of which were life-threatening or fatal.",life-threatening or fatal is not a named entity
"5.3     Infections      In patients receiving BLINCYTO in clinical trials, serious infections such as sepsis, pneumonia, bacteremia, opportunistic infections, and catheter-site infections were observed in approximately 25% of patients, some of which were life-threatening or fatal.",of which were is not a named entity
"5.3     Infections      In patients receiving BLINCYTO in clinical trials, serious infections such as sepsis, pneumonia, bacteremia, opportunistic infections, and catheter-site infections were observed in approximately 25% of patients, some of which were life-threatening or fatal.",sepsis is an adverse reaction entity
"5.3     Infections      In patients receiving BLINCYTO in clinical trials, serious infections such as sepsis, pneumonia, bacteremia, opportunistic infections, and catheter-site infections were observed in approximately 25% of patients, some of which were life-threatening or fatal.",in is not a named entity
"5.3     Infections      In patients receiving BLINCYTO in clinical trials, serious infections such as sepsis, pneumonia, bacteremia, opportunistic infections, and catheter-site infections were observed in approximately 25% of patients, some of which were life-threatening or fatal.",bacteremia is an adverse reaction entity
"5.3     Infections      In patients receiving BLINCYTO in clinical trials, serious infections such as sepsis, pneumonia, bacteremia, opportunistic infections, and catheter-site infections were observed in approximately 25% of patients, some of which were life-threatening or fatal.",5.3 Infections In is not a named entity
"5.3     Infections      In patients receiving BLINCYTO in clinical trials, serious infections such as sepsis, pneumonia, bacteremia, opportunistic infections, and catheter-site infections were observed in approximately 25% of patients, some of which were life-threatening or fatal.","sepsis , is not a named entity"
"5.3     Infections      In patients receiving BLINCYTO in clinical trials, serious infections such as sepsis, pneumonia, bacteremia, opportunistic infections, and catheter-site infections were observed in approximately 25% of patients, some of which were life-threatening or fatal.",BLINCYTO is not a named entity
"5.3     Infections      In patients receiving BLINCYTO in clinical trials, serious infections such as sepsis, pneumonia, bacteremia, opportunistic infections, and catheter-site infections were observed in approximately 25% of patients, some of which were life-threatening or fatal.",infections is an adverse reaction entity
"5.3     Infections      In patients receiving BLINCYTO in clinical trials, serious infections such as sepsis, pneumonia, bacteremia, opportunistic infections, and catheter-site infections were observed in approximately 25% of patients, some of which were life-threatening or fatal.",fatal is an adverse reaction entity
"5.3     Infections      In patients receiving BLINCYTO in clinical trials, serious infections such as sepsis, pneumonia, bacteremia, opportunistic infections, and catheter-site infections were observed in approximately 25% of patients, some of which were life-threatening or fatal.",catheter-site infections is an adverse reaction entity
"5.3     Infections      In patients receiving BLINCYTO in clinical trials, serious infections such as sepsis, pneumonia, bacteremia, opportunistic infections, and catheter-site infections were observed in approximately 25% of patients, some of which were life-threatening or fatal.",pneumonia is an adverse reaction entity
"5.3     Infections      In patients receiving BLINCYTO in clinical trials, serious infections such as sepsis, pneumonia, bacteremia, opportunistic infections, and catheter-site infections were observed in approximately 25% of patients, some of which were life-threatening or fatal.",opportunistic infections is an adverse reaction entity
"5.3     Infections      In patients receiving BLINCYTO in clinical trials, serious infections such as sepsis, pneumonia, bacteremia, opportunistic infections, and catheter-site infections were observed in approximately 25% of patients, some of which were life-threatening or fatal.",bacteremia is an adverse reaction entity
"5.3     Infections      In patients receiving BLINCYTO in clinical trials, serious infections such as sepsis, pneumonia, bacteremia, opportunistic infections, and catheter-site infections were observed in approximately 25% of patients, some of which were life-threatening or fatal.",opportunistic infections is an adverse reaction entity
"The most common serious adverse reactions (>= 2%) included febrile neutropenia, pyrexia, pneumonia, sepsis, neutropenia, device-related infection, tremor, encephalopathy, infection, overdose, confusion,  Staphylococcal  bacteremia, and headache.",encephalopathy is an adverse reaction entity
"The most common serious adverse reactions (>= 2%) included febrile neutropenia, pyrexia, pneumonia, sepsis, neutropenia, device-related infection, tremor, encephalopathy, infection, overdose, confusion,  Staphylococcal  bacteremia, and headache.",infection is an adverse reaction entity
"The most common serious adverse reactions (>= 2%) included febrile neutropenia, pyrexia, pneumonia, sepsis, neutropenia, device-related infection, tremor, encephalopathy, infection, overdose, confusion,  Staphylococcal  bacteremia, and headache.",febrile neutropenia is an adverse reaction entity
"The most common serious adverse reactions (>= 2%) included febrile neutropenia, pyrexia, pneumonia, sepsis, neutropenia, device-related infection, tremor, encephalopathy, infection, overdose, confusion,  Staphylococcal  bacteremia, and headache.",", neutropenia , is not a named entity"
"The most common serious adverse reactions (>= 2%) included febrile neutropenia, pyrexia, pneumonia, sepsis, neutropenia, device-related infection, tremor, encephalopathy, infection, overdose, confusion,  Staphylococcal  bacteremia, and headache.",adverse reactions ( is not a named entity
"The most common serious adverse reactions (>= 2%) included febrile neutropenia, pyrexia, pneumonia, sepsis, neutropenia, device-related infection, tremor, encephalopathy, infection, overdose, confusion,  Staphylococcal  bacteremia, and headache.",pyrexia is an adverse reaction entity
"The most common serious adverse reactions (>= 2%) included febrile neutropenia, pyrexia, pneumonia, sepsis, neutropenia, device-related infection, tremor, encephalopathy, infection, overdose, confusion,  Staphylococcal  bacteremia, and headache.",tremor is an adverse reaction entity
"The most common serious adverse reactions (>= 2%) included febrile neutropenia, pyrexia, pneumonia, sepsis, neutropenia, device-related infection, tremor, encephalopathy, infection, overdose, confusion,  Staphylococcal  bacteremia, and headache.",confusion is an adverse reaction entity
"The most common serious adverse reactions (>= 2%) included febrile neutropenia, pyrexia, pneumonia, sepsis, neutropenia, device-related infection, tremor, encephalopathy, infection, overdose, confusion,  Staphylococcal  bacteremia, and headache.",) included is not a named entity
"The most common serious adverse reactions (>= 2%) included febrile neutropenia, pyrexia, pneumonia, sepsis, neutropenia, device-related infection, tremor, encephalopathy, infection, overdose, confusion,  Staphylococcal  bacteremia, and headache.",pneumonia is an adverse reaction entity
"The most common serious adverse reactions (>= 2%) included febrile neutropenia, pyrexia, pneumonia, sepsis, neutropenia, device-related infection, tremor, encephalopathy, infection, overdose, confusion,  Staphylococcal  bacteremia, and headache.","pyrexia , pneumonia is not a named entity"
"The most common serious adverse reactions (>= 2%) included febrile neutropenia, pyrexia, pneumonia, sepsis, neutropenia, device-related infection, tremor, encephalopathy, infection, overdose, confusion,  Staphylococcal  bacteremia, and headache.",common is not a named entity
"The most common serious adverse reactions (>= 2%) included febrile neutropenia, pyrexia, pneumonia, sepsis, neutropenia, device-related infection, tremor, encephalopathy, infection, overdose, confusion,  Staphylococcal  bacteremia, and headache.",", is not a named entity"
"The most common serious adverse reactions (>= 2%) included febrile neutropenia, pyrexia, pneumonia, sepsis, neutropenia, device-related infection, tremor, encephalopathy, infection, overdose, confusion,  Staphylococcal  bacteremia, and headache.",device-related infection is an adverse reaction entity
"The most common serious adverse reactions (>= 2%) included febrile neutropenia, pyrexia, pneumonia, sepsis, neutropenia, device-related infection, tremor, encephalopathy, infection, overdose, confusion,  Staphylococcal  bacteremia, and headache.",overdose is an adverse reaction entity
"The most common serious adverse reactions (>= 2%) included febrile neutropenia, pyrexia, pneumonia, sepsis, neutropenia, device-related infection, tremor, encephalopathy, infection, overdose, confusion,  Staphylococcal  bacteremia, and headache.",", sepsis is not a named entity"
"The most common serious adverse reactions (>= 2%) included febrile neutropenia, pyrexia, pneumonia, sepsis, neutropenia, device-related infection, tremor, encephalopathy, infection, overdose, confusion,  Staphylococcal  bacteremia, and headache.",The most is not a named entity
"The most common serious adverse reactions (>= 2%) included febrile neutropenia, pyrexia, pneumonia, sepsis, neutropenia, device-related infection, tremor, encephalopathy, infection, overdose, confusion,  Staphylococcal  bacteremia, and headache.",neutropenia is an adverse reaction entity
"The most common serious adverse reactions (>= 2%) included febrile neutropenia, pyrexia, pneumonia, sepsis, neutropenia, device-related infection, tremor, encephalopathy, infection, overdose, confusion,  Staphylococcal  bacteremia, and headache.",Staphylococcal bacteremia is an adverse reaction entity
"The most common serious adverse reactions (>= 2%) included febrile neutropenia, pyrexia, pneumonia, sepsis, neutropenia, device-related infection, tremor, encephalopathy, infection, overdose, confusion,  Staphylococcal  bacteremia, and headache.",headache is an adverse reaction entity
"The most common serious adverse reactions (>= 2%) included febrile neutropenia, pyrexia, pneumonia, sepsis, neutropenia, device-related infection, tremor, encephalopathy, infection, overdose, confusion,  Staphylococcal  bacteremia, and headache.",sepsis is an adverse reaction entity
"The most common serious adverse reactions (>= 2%) included febrile neutropenia, pyrexia, pneumonia, sepsis, neutropenia, device-related infection, tremor, encephalopathy, infection, overdose, confusion,  Staphylococcal  bacteremia, and headache.",common is not a named entity
"The most common serious adverse reactions (>= 2%) included febrile neutropenia, pyrexia, pneumonia, sepsis, neutropenia, device-related infection, tremor, encephalopathy, infection, overdose, confusion,  Staphylococcal  bacteremia, and headache.",serious adverse reactions is not a named entity
"The most common serious adverse reactions (>= 2%) included febrile neutropenia, pyrexia, pneumonia, sepsis, neutropenia, device-related infection, tremor, encephalopathy, infection, overdose, confusion,  Staphylococcal  bacteremia, and headache.",", device-related is not a named entity"
"The most common serious adverse reactions (>= 2%) included febrile neutropenia, pyrexia, pneumonia, sepsis, neutropenia, device-related infection, tremor, encephalopathy, infection, overdose, confusion,  Staphylococcal  bacteremia, and headache.",", pyrexia is not a named entity"
"The most common serious adverse reactions (>= 2%) included febrile neutropenia, pyrexia, pneumonia, sepsis, neutropenia, device-related infection, tremor, encephalopathy, infection, overdose, confusion,  Staphylococcal  bacteremia, and headache.",", confusion , is not a named entity"
The adverse reactions reported most frequently as the reason for discontinuation of treatment included encephalopathy and sepsis.,sepsis is an adverse reaction entity
The adverse reactions reported most frequently as the reason for discontinuation of treatment included encephalopathy and sepsis.,as the reason is not a named entity
The adverse reactions reported most frequently as the reason for discontinuation of treatment included encephalopathy and sepsis.,frequently as is not a named entity
The adverse reactions reported most frequently as the reason for discontinuation of treatment included encephalopathy and sepsis.,encephalopathy is an adverse reaction entity
"The most common adverse reactions (>= 20%) were pyrexia (62%), headache (36%), peripheral edema (25%), febrile neutropenia (25%), nausea (25%), hypokalemia (23%), and constipation (20%).",hypokalemia is an adverse reaction entity
"The most common adverse reactions (>= 20%) were pyrexia (62%), headache (36%), peripheral edema (25%), febrile neutropenia (25%), nausea (25%), hypokalemia (23%), and constipation (20%).",adverse reactions ( is not a named entity
"The most common adverse reactions (>= 20%) were pyrexia (62%), headache (36%), peripheral edema (25%), febrile neutropenia (25%), nausea (25%), hypokalemia (23%), and constipation (20%).","% ) , is not a named entity"
"The most common adverse reactions (>= 20%) were pyrexia (62%), headache (36%), peripheral edema (25%), febrile neutropenia (25%), nausea (25%), hypokalemia (23%), and constipation (20%).","% ) , is not a named entity"
"The most common adverse reactions (>= 20%) were pyrexia (62%), headache (36%), peripheral edema (25%), febrile neutropenia (25%), nausea (25%), hypokalemia (23%), and constipation (20%).",nausea is an adverse reaction entity
"The most common adverse reactions (>= 20%) were pyrexia (62%), headache (36%), peripheral edema (25%), febrile neutropenia (25%), nausea (25%), hypokalemia (23%), and constipation (20%).",headache is an adverse reaction entity
"The most common adverse reactions (>= 20%) were pyrexia (62%), headache (36%), peripheral edema (25%), febrile neutropenia (25%), nausea (25%), hypokalemia (23%), and constipation (20%).",", hypokalemia ( is not a named entity"
"The most common adverse reactions (>= 20%) were pyrexia (62%), headache (36%), peripheral edema (25%), febrile neutropenia (25%), nausea (25%), hypokalemia (23%), and constipation (20%).",") , peripheral is not a named entity"
"The most common adverse reactions (>= 20%) were pyrexia (62%), headache (36%), peripheral edema (25%), febrile neutropenia (25%), nausea (25%), hypokalemia (23%), and constipation (20%).",febrile neutropenia is an adverse reaction entity
"The most common adverse reactions (>= 20%) were pyrexia (62%), headache (36%), peripheral edema (25%), febrile neutropenia (25%), nausea (25%), hypokalemia (23%), and constipation (20%).",and constipation is not a named entity
"The most common adverse reactions (>= 20%) were pyrexia (62%), headache (36%), peripheral edema (25%), febrile neutropenia (25%), nausea (25%), hypokalemia (23%), and constipation (20%).",pyrexia is an adverse reaction entity
"The most common adverse reactions (>= 20%) were pyrexia (62%), headache (36%), peripheral edema (25%), febrile neutropenia (25%), nausea (25%), hypokalemia (23%), and constipation (20%).",constipation is an adverse reaction entity
"The most common adverse reactions (>= 20%) were pyrexia (62%), headache (36%), peripheral edema (25%), febrile neutropenia (25%), nausea (25%), hypokalemia (23%), and constipation (20%).",peripheral edema is an adverse reaction entity
"The most common adverse reactions (>= 20%) were pyrexia (62%), headache (36%), peripheral edema (25%), febrile neutropenia (25%), nausea (25%), hypokalemia (23%), and constipation (20%).",25 is not a named entity
Hypersensitivity reactions related to BLINCYTO treatment were hypersensitivity (1%) and bronchospasm (< 1%).,1 is not a named entity
Hypersensitivity reactions related to BLINCYTO treatment were hypersensitivity (1%) and bronchospasm (< 1%).,bronchospasm is an adverse reaction entity
Hypersensitivity reactions related to BLINCYTO treatment were hypersensitivity (1%) and bronchospasm (< 1%).,Hypersensitivity reactions related is not a named entity
Hypersensitivity reactions related to BLINCYTO treatment were hypersensitivity (1%) and bronchospasm (< 1%).,Hypersensitivity reactions is an adverse reaction entity
Hypersensitivity reactions related to BLINCYTO treatment were hypersensitivity (1%) and bronchospasm (< 1%).,hypersensitivity is an adverse reaction entity
Hypersensitivity reactions related to BLINCYTO treatment were hypersensitivity (1%) and bronchospasm (< 1%).,treatment were hypersensitivity is not a named entity
"In patients receiving BLINCYTO in clinical trials, Grade 3 or greater elevations in liver enzymes occurred in approximately 6% of patients outside the setting of CRS and resulted in treatment discontinuation in less than 1% of patients.",CRS is an adverse reaction entity
"In patients receiving BLINCYTO in clinical trials, Grade 3 or greater elevations in liver enzymes occurred in approximately 6% of patients outside the setting of CRS and resulted in treatment discontinuation in less than 1% of patients.",elevations in liver enzymes is an adverse reaction entity
"In patients receiving BLINCYTO in clinical trials, Grade 3 or greater elevations in liver enzymes occurred in approximately 6% of patients outside the setting of CRS and resulted in treatment discontinuation in less than 1% of patients.",In is not a named entity
"In patients receiving BLINCYTO in clinical trials, Grade 3 or greater elevations in liver enzymes occurred in approximately 6% of patients outside the setting of CRS and resulted in treatment discontinuation in less than 1% of patients.",enzymes occurred in is not a named entity
"5.4     Tumor Lysis Syndrome      Tumor lysis syndrome (TLS), which may be life-threatening or fatal, has been observed in patients receiving BLINCYTO.","or fatal , is not a named entity"
"5.4     Tumor Lysis Syndrome      Tumor lysis syndrome (TLS), which may be life-threatening or fatal, has been observed in patients receiving BLINCYTO.",TLS is an adverse reaction entity
"5.4     Tumor Lysis Syndrome      Tumor lysis syndrome (TLS), which may be life-threatening or fatal, has been observed in patients receiving BLINCYTO.",Tumor lysis syndrome is an adverse reaction entity
"5.4     Tumor Lysis Syndrome      Tumor lysis syndrome (TLS), which may be life-threatening or fatal, has been observed in patients receiving BLINCYTO.",syndrome ( is not a named entity
"5.4     Tumor Lysis Syndrome      Tumor lysis syndrome (TLS), which may be life-threatening or fatal, has been observed in patients receiving BLINCYTO.",Syndrome Tumor lysis is not a named entity
"5.4     Tumor Lysis Syndrome      Tumor lysis syndrome (TLS), which may be life-threatening or fatal, has been observed in patients receiving BLINCYTO.",Tumor lysis syndrome is an adverse reaction entity
"5.4     Tumor Lysis Syndrome      Tumor lysis syndrome (TLS), which may be life-threatening or fatal, has been observed in patients receiving BLINCYTO.",( TLS ) is not a named entity
"5.4     Tumor Lysis Syndrome      Tumor lysis syndrome (TLS), which may be life-threatening or fatal, has been observed in patients receiving BLINCYTO.",fatal is an adverse reaction entity
"5.4     Tumor Lysis Syndrome      Tumor lysis syndrome (TLS), which may be life-threatening or fatal, has been observed in patients receiving BLINCYTO.",TLS is an adverse reaction entity
"5.4     Tumor Lysis Syndrome      Tumor lysis syndrome (TLS), which may be life-threatening or fatal, has been observed in patients receiving BLINCYTO.",observed in is not a named entity
"In some cases, disseminated intravascular coagulation (DIC), capillary leak syndrome (CLS), and hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) have been reported in the setting of CRS.",coagulation is not a named entity
"In some cases, disseminated intravascular coagulation (DIC), capillary leak syndrome (CLS), and hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) have been reported in the setting of CRS.",hemophagocytic lymphohistiocytosis is an adverse reaction entity
"In some cases, disseminated intravascular coagulation (DIC), capillary leak syndrome (CLS), and hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) have been reported in the setting of CRS.",in the is not a named entity
"In some cases, disseminated intravascular coagulation (DIC), capillary leak syndrome (CLS), and hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) have been reported in the setting of CRS.","cases , disseminated is not a named entity"
"In some cases, disseminated intravascular coagulation (DIC), capillary leak syndrome (CLS), and hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) have been reported in the setting of CRS.",DIC is an adverse reaction entity
"In some cases, disseminated intravascular coagulation (DIC), capillary leak syndrome (CLS), and hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) have been reported in the setting of CRS.",activation syndrome is not a named entity
"In some cases, disseminated intravascular coagulation (DIC), capillary leak syndrome (CLS), and hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) have been reported in the setting of CRS.",MAS is an adverse reaction entity
"In some cases, disseminated intravascular coagulation (DIC), capillary leak syndrome (CLS), and hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) have been reported in the setting of CRS.",", capillary is not a named entity"
"In some cases, disseminated intravascular coagulation (DIC), capillary leak syndrome (CLS), and hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) have been reported in the setting of CRS.",CRS is an adverse reaction entity
"In some cases, disseminated intravascular coagulation (DIC), capillary leak syndrome (CLS), and hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) have been reported in the setting of CRS.",disseminated intravascular coagulation is an adverse reaction entity
"In some cases, disseminated intravascular coagulation (DIC), capillary leak syndrome (CLS), and hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) have been reported in the setting of CRS.",HLH is an adverse reaction entity
"In some cases, disseminated intravascular coagulation (DIC), capillary leak syndrome (CLS), and hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) have been reported in the setting of CRS.",the setting of is not a named entity
"In some cases, disseminated intravascular coagulation (DIC), capillary leak syndrome (CLS), and hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) have been reported in the setting of CRS.",macrophage activation syndrome is an adverse reaction entity
"In some cases, disseminated intravascular coagulation (DIC), capillary leak syndrome (CLS), and hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) have been reported in the setting of CRS.",lymphohistiocytosis/macrophage activation syndrome is not a named entity
"In some cases, disseminated intravascular coagulation (DIC), capillary leak syndrome (CLS), and hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) have been reported in the setting of CRS.",CLS is an adverse reaction entity
"In some cases, disseminated intravascular coagulation (DIC), capillary leak syndrome (CLS), and hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) have been reported in the setting of CRS.",( is not a named entity
"In some cases, disseminated intravascular coagulation (DIC), capillary leak syndrome (CLS), and hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) have been reported in the setting of CRS.",) is not a named entity
"In some cases, disseminated intravascular coagulation (DIC), capillary leak syndrome (CLS), and hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) have been reported in the setting of CRS.",capillary leak syndrome is an adverse reaction entity
"(  5.9  )             5.1     Cytokine Release Syndrome      Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO.",Cytokine Release Syndrome is an adverse reaction entity
"(  5.9  )             5.1     Cytokine Release Syndrome      Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO.",Cytokine Release Syndrome is an adverse reaction entity
"(  5.9  )             5.1     Cytokine Release Syndrome      Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO.",CRS is an adverse reaction entity
"(  5.9  )             5.1     Cytokine Release Syndrome      Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO.",Syndrome Cytokine is not a named entity
"(  5.9  )             5.1     Cytokine Release Syndrome      Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO.",CRS is an adverse reaction entity
"(  5.9  )             5.1     Cytokine Release Syndrome      Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO.","fatal , occurred is not a named entity"
"(  5.9  )             5.1     Cytokine Release Syndrome      Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO.",fatal is an adverse reaction entity
"(  5.9  )             5.1     Cytokine Release Syndrome      Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO.",in is not a named entity
"(  5.9  )             5.1     Cytokine Release Syndrome      Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO.",) 5.1 Cytokine is not a named entity
"(  5.9  )             5.1     Cytokine Release Syndrome      Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO.",in patients receiving is not a named entity
Infusion reactions have occurred with the BLINCYTO infusion and may be clinically indistinguishable from manifestations of CRS .,with is not a named entity
Infusion reactions have occurred with the BLINCYTO infusion and may be clinically indistinguishable from manifestations of CRS .,Infusion reactions is an adverse reaction entity
EXCERPT:     WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES      See full prescribing information for complete boxed warning.,EXCERPT is not a named entity
EXCERPT:     WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES      See full prescribing information for complete boxed warning.,CYTOKINE RELEASE SYNDROME is an adverse reaction entity
EXCERPT:     WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES      See full prescribing information for complete boxed warning.,full prescribing information is not a named entity
EXCERPT:     WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES      See full prescribing information for complete boxed warning.,NEUROLOGICAL TOXICITIES is an adverse reaction entity
"Although the majority of these events were observed in the setting of CRS, some were observed outside of this setting.",outside of this is not a named entity
"Although the majority of these events were observed in the setting of CRS, some were observed outside of this setting.",CRS is an adverse reaction entity
"*  Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO.",fatal is an adverse reaction entity
"*  Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO.",Cytokine Release Syndrome is an adverse reaction entity
"*  Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO.",CRS is an adverse reaction entity
"*  Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO.",Syndrome is not a named entity
"*  Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO.",", occurred is not a named entity"
"*  Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO.",occurred is not a named entity
"*  Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO.",Cytokine Release Syndrome is an adverse reaction entity
"*  Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO.",which may is not a named entity
"*  Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO.",") , is not a named entity"
"*  Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO.",CRS is an adverse reaction entity
"5.6     Effects on Ability to Drive and Use Machines      Due to the potential for neurologic events, including seizures, patients receiving BLINCYTO are at risk for loss of consciousness [see Warnings and Precautions (  5.2  )]  .",neurologic events is an adverse reaction entity
"5.6     Effects on Ability to Drive and Use Machines      Due to the potential for neurologic events, including seizures, patients receiving BLINCYTO are at risk for loss of consciousness [see Warnings and Precautions (  5.2  )]  .",receiving BLINCYTO is not a named entity
"5.6     Effects on Ability to Drive and Use Machines      Due to the potential for neurologic events, including seizures, patients receiving BLINCYTO are at risk for loss of consciousness [see Warnings and Precautions (  5.2  )]  .",loss of consciousness is an adverse reaction entity
"5.6     Effects on Ability to Drive and Use Machines      Due to the potential for neurologic events, including seizures, patients receiving BLINCYTO are at risk for loss of consciousness [see Warnings and Precautions (  5.2  )]  .",the potential for is not a named entity
"5.6     Effects on Ability to Drive and Use Machines      Due to the potential for neurologic events, including seizures, patients receiving BLINCYTO are at risk for loss of consciousness [see Warnings and Precautions (  5.2  )]  .",seizures is an adverse reaction entity
"5.6     Effects on Ability to Drive and Use Machines      Due to the potential for neurologic events, including seizures, patients receiving BLINCYTO are at risk for loss of consciousness [see Warnings and Precautions (  5.2  )]  .",patients is not a named entity
"5.2     Neurological Toxicities      In patients receiving BLINCYTO in clinical trials, neurological toxicities have occurred in approximately 50% of patients.",trials is not a named entity
"5.2     Neurological Toxicities      In patients receiving BLINCYTO in clinical trials, neurological toxicities have occurred in approximately 50% of patients.",neurological toxicities is an adverse reaction entity
"Serious adverse events that may be associated with CRS included pyrexia, headache, nausea, asthenia, hypotension, increased alanine aminotransferase, increased aspartate aminotransferase, and increased total bilirubin; these events infrequently led to BLINCYTO discontinuation.",CRS is an adverse reaction entity
"Serious adverse events that may be associated with CRS included pyrexia, headache, nausea, asthenia, hypotension, increased alanine aminotransferase, increased aspartate aminotransferase, and increased total bilirubin; these events infrequently led to BLINCYTO discontinuation.",to BLINCYTO discontinuation is not a named entity
"Serious adverse events that may be associated with CRS included pyrexia, headache, nausea, asthenia, hypotension, increased alanine aminotransferase, increased aspartate aminotransferase, and increased total bilirubin; these events infrequently led to BLINCYTO discontinuation.",increased alanine aminotransferase is an adverse reaction entity
"Serious adverse events that may be associated with CRS included pyrexia, headache, nausea, asthenia, hypotension, increased alanine aminotransferase, increased aspartate aminotransferase, and increased total bilirubin; these events infrequently led to BLINCYTO discontinuation.",to BLINCYTO discontinuation is not a named entity
"Serious adverse events that may be associated with CRS included pyrexia, headache, nausea, asthenia, hypotension, increased alanine aminotransferase, increased aspartate aminotransferase, and increased total bilirubin; these events infrequently led to BLINCYTO discontinuation.",increased aspartate aminotransferase is an adverse reaction entity
"Serious adverse events that may be associated with CRS included pyrexia, headache, nausea, asthenia, hypotension, increased alanine aminotransferase, increased aspartate aminotransferase, and increased total bilirubin; these events infrequently led to BLINCYTO discontinuation.","aminotransferase , is not a named entity"
"Serious adverse events that may be associated with CRS included pyrexia, headache, nausea, asthenia, hypotension, increased alanine aminotransferase, increased aspartate aminotransferase, and increased total bilirubin; these events infrequently led to BLINCYTO discontinuation.",discontinuation is not a named entity
"Serious adverse events that may be associated with CRS included pyrexia, headache, nausea, asthenia, hypotension, increased alanine aminotransferase, increased aspartate aminotransferase, and increased total bilirubin; these events infrequently led to BLINCYTO discontinuation.",these events infrequently is not a named entity
"Serious adverse events that may be associated with CRS included pyrexia, headache, nausea, asthenia, hypotension, increased alanine aminotransferase, increased aspartate aminotransferase, and increased total bilirubin; these events infrequently led to BLINCYTO discontinuation.",nausea is an adverse reaction entity
"Serious adverse events that may be associated with CRS included pyrexia, headache, nausea, asthenia, hypotension, increased alanine aminotransferase, increased aspartate aminotransferase, and increased total bilirubin; these events infrequently led to BLINCYTO discontinuation.",headache is an adverse reaction entity
"Serious adverse events that may be associated with CRS included pyrexia, headache, nausea, asthenia, hypotension, increased alanine aminotransferase, increased aspartate aminotransferase, and increased total bilirubin; these events infrequently led to BLINCYTO discontinuation.",asthenia is an adverse reaction entity
"Serious adverse events that may be associated with CRS included pyrexia, headache, nausea, asthenia, hypotension, increased alanine aminotransferase, increased aspartate aminotransferase, and increased total bilirubin; these events infrequently led to BLINCYTO discontinuation.",hypotension is an adverse reaction entity
"Serious adverse events that may be associated with CRS included pyrexia, headache, nausea, asthenia, hypotension, increased alanine aminotransferase, increased aspartate aminotransferase, and increased total bilirubin; these events infrequently led to BLINCYTO discontinuation.",pyrexia is an adverse reaction entity
"Serious adverse events that may be associated with CRS included pyrexia, headache, nausea, asthenia, hypotension, increased alanine aminotransferase, increased aspartate aminotransferase, and increased total bilirubin; these events infrequently led to BLINCYTO discontinuation.",increased total bilirubin is an adverse reaction entity
"Serious adverse events that may be associated with CRS included pyrexia, headache, nausea, asthenia, hypotension, increased alanine aminotransferase, increased aspartate aminotransferase, and increased total bilirubin; these events infrequently led to BLINCYTO discontinuation.",events is not a named entity
"Serious adverse events that may be associated with CRS included pyrexia, headache, nausea, asthenia, hypotension, increased alanine aminotransferase, increased aspartate aminotransferase, and increased total bilirubin; these events infrequently led to BLINCYTO discontinuation.",included pyrexia is not a named entity
"Serious adverse events that may be associated with CRS included pyrexia, headache, nausea, asthenia, hypotension, increased alanine aminotransferase, increased aspartate aminotransferase, and increased total bilirubin; these events infrequently led to BLINCYTO discontinuation.",infrequently is not a named entity
"Serious adverse events that may be associated with CRS included pyrexia, headache, nausea, asthenia, hypotension, increased alanine aminotransferase, increased aspartate aminotransferase, and increased total bilirubin; these events infrequently led to BLINCYTO discontinuation.","asthenia , is not a named entity"
"BOXED WARNING: WARNING: CYTOKINE RELEASE SYNDROME and  NEUROLOGICAL TOXICITIES      WARNING: CYTOKINE RELEASE SYNDROME and  NEUROLOGICAL TOXICITIES        *  Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO.",Cytokine Release Syndrome is an adverse reaction entity
"BOXED WARNING: WARNING: CYTOKINE RELEASE SYNDROME and  NEUROLOGICAL TOXICITIES      WARNING: CYTOKINE RELEASE SYNDROME and  NEUROLOGICAL TOXICITIES        *  Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO.",NEUROLOGICAL TOXICITIES is an adverse reaction entity
"BOXED WARNING: WARNING: CYTOKINE RELEASE SYNDROME and  NEUROLOGICAL TOXICITIES      WARNING: CYTOKINE RELEASE SYNDROME and  NEUROLOGICAL TOXICITIES        *  Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO.",CRS is an adverse reaction entity
"BOXED WARNING: WARNING: CYTOKINE RELEASE SYNDROME and  NEUROLOGICAL TOXICITIES      WARNING: CYTOKINE RELEASE SYNDROME and  NEUROLOGICAL TOXICITIES        *  Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO.",Cytokine Release Syndrome is an adverse reaction entity
"BOXED WARNING: WARNING: CYTOKINE RELEASE SYNDROME and  NEUROLOGICAL TOXICITIES      WARNING: CYTOKINE RELEASE SYNDROME and  NEUROLOGICAL TOXICITIES        *  Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO.",") , is not a named entity"
"BOXED WARNING: WARNING: CYTOKINE RELEASE SYNDROME and  NEUROLOGICAL TOXICITIES      WARNING: CYTOKINE RELEASE SYNDROME and  NEUROLOGICAL TOXICITIES        *  Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO.",Release is not a named entity
"BOXED WARNING: WARNING: CYTOKINE RELEASE SYNDROME and  NEUROLOGICAL TOXICITIES      WARNING: CYTOKINE RELEASE SYNDROME and  NEUROLOGICAL TOXICITIES        *  Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO.",WARNING : is not a named entity
"BOXED WARNING: WARNING: CYTOKINE RELEASE SYNDROME and  NEUROLOGICAL TOXICITIES      WARNING: CYTOKINE RELEASE SYNDROME and  NEUROLOGICAL TOXICITIES        *  Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO.",which may be is not a named entity
"BOXED WARNING: WARNING: CYTOKINE RELEASE SYNDROME and  NEUROLOGICAL TOXICITIES      WARNING: CYTOKINE RELEASE SYNDROME and  NEUROLOGICAL TOXICITIES        *  Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO.",", occurred is not a named entity"
"BOXED WARNING: WARNING: CYTOKINE RELEASE SYNDROME and  NEUROLOGICAL TOXICITIES      WARNING: CYTOKINE RELEASE SYNDROME and  NEUROLOGICAL TOXICITIES        *  Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO.",fatal is an adverse reaction entity
"BOXED WARNING: WARNING: CYTOKINE RELEASE SYNDROME and  NEUROLOGICAL TOXICITIES      WARNING: CYTOKINE RELEASE SYNDROME and  NEUROLOGICAL TOXICITIES        *  Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO.",NEUROLOGICAL TOXICITIES is an adverse reaction entity
"BOXED WARNING: WARNING: CYTOKINE RELEASE SYNDROME and  NEUROLOGICAL TOXICITIES      WARNING: CYTOKINE RELEASE SYNDROME and  NEUROLOGICAL TOXICITIES        *  Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO.",WARNING : is not a named entity
"BOXED WARNING: WARNING: CYTOKINE RELEASE SYNDROME and  NEUROLOGICAL TOXICITIES      WARNING: CYTOKINE RELEASE SYNDROME and  NEUROLOGICAL TOXICITIES        *  Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO.",CYTOKINE RELEASE SYNDROME is an adverse reaction entity
"BOXED WARNING: WARNING: CYTOKINE RELEASE SYNDROME and  NEUROLOGICAL TOXICITIES      WARNING: CYTOKINE RELEASE SYNDROME and  NEUROLOGICAL TOXICITIES        *  Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO.",which may be is not a named entity
"BOXED WARNING: WARNING: CYTOKINE RELEASE SYNDROME and  NEUROLOGICAL TOXICITIES      WARNING: CYTOKINE RELEASE SYNDROME and  NEUROLOGICAL TOXICITIES        *  Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO.",WARNING is not a named entity
"BOXED WARNING: WARNING: CYTOKINE RELEASE SYNDROME and  NEUROLOGICAL TOXICITIES      WARNING: CYTOKINE RELEASE SYNDROME and  NEUROLOGICAL TOXICITIES        *  Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO.",CYTOKINE RELEASE SYNDROME is an adverse reaction entity
"BOXED WARNING: WARNING: CYTOKINE RELEASE SYNDROME and  NEUROLOGICAL TOXICITIES      WARNING: CYTOKINE RELEASE SYNDROME and  NEUROLOGICAL TOXICITIES        *  Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO.",CRS is an adverse reaction entity
"BOXED WARNING: WARNING: CYTOKINE RELEASE SYNDROME and  NEUROLOGICAL TOXICITIES      WARNING: CYTOKINE RELEASE SYNDROME and  NEUROLOGICAL TOXICITIES        *  Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO.",", occurred is not a named entity"
"During the clinical trials, 0.1% (1/1308) of subjects treated with OTEZLA discontinued treatment due to depression compared with none in placebo-treated subjects(0/506).",depression is an adverse reaction entity
"During the clinical trials, 0.1% (1/1308) of subjects treated with OTEZLA discontinued treatment due to depression compared with none in placebo-treated subjects(0/506).",in placebo-treated subjects is not a named entity
"In the clinical trials, one subject treated with OTEZLA attempted suicide while one who received placebo committed suicide.",suicide while one is not a named entity
"In the clinical trials, one subject treated with OTEZLA attempted suicide while one who received placebo committed suicide.",attempted suicide is an adverse reaction entity
"In the clinical trials, one subject treated with OTEZLA attempted suicide while one who received placebo committed suicide.",In is not a named entity
"In the clinical trials, one subject treated with OTEZLA attempted suicide while one who received placebo committed suicide.",suicide is an adverse reaction entity
"Diarrhea, nausea, and upper respiratory tract infection were the most commonly reported adverse reactions.",upper respiratory tract infection is an adverse reaction entity
"Diarrhea, nausea, and upper respiratory tract infection were the most commonly reported adverse reactions.",adverse reactions is not a named entity
"Diarrhea, nausea, and upper respiratory tract infection were the most commonly reported adverse reactions.",reactions is not a named entity
"Diarrhea, nausea, and upper respiratory tract infection were the most commonly reported adverse reactions.",Diarrhea is an adverse reaction entity
"Diarrhea, nausea, and upper respiratory tract infection were the most commonly reported adverse reactions.",", and upper is not a named entity"
"Diarrhea, nausea, and upper respiratory tract infection were the most commonly reported adverse reactions.",nausea is an adverse reaction entity
Table 3: Adverse Reactions Reported in >=1% of Subjects on OTEZLA and With Greater Frequency Than in Subjects on Placebo; up to Day 112 (Week 16)     *  Two subjects treated with OTEZLA experienced serious adverse reaction of abdominal pain.,abdominal pain is an adverse reaction entity
Table 3: Adverse Reactions Reported in >=1% of Subjects on OTEZLA and With Greater Frequency Than in Subjects on Placebo; up to Day 112 (Week 16)     *  Two subjects treated with OTEZLA experienced serious adverse reaction of abdominal pain.,OTEZLA and is not a named entity
"5.2 Weight Decrease    During the controlled period of the studies in psoriatic arthritis (PsA), weight decrease between 5%-10% of body weight was reported in 10% (49/497) of subjects treated with OTEZLA 30 mg twice daily compared to 3.3% (16/495) treated with placebo [  see Adverse Reactions (6.1)  ].",( 6.1 ) is not a named entity
"5.2 Weight Decrease    During the controlled period of the studies in psoriatic arthritis (PsA), weight decrease between 5%-10% of body weight was reported in 10% (49/497) of subjects treated with OTEZLA 30 mg twice daily compared to 3.3% (16/495) treated with placebo [  see Adverse Reactions (6.1)  ].",weight decrease is an adverse reaction entity
"Instances of suicidal behavior have been observed in 0.1% (1/1308) of subjects while receiving OTEZLA, compared to 0.2% (1/506) in placebo-treated subjects.",observed is not a named entity
"Instances of suicidal behavior have been observed in 0.1% (1/1308) of subjects while receiving OTEZLA, compared to 0.2% (1/506) in placebo-treated subjects.",suicidal behavior is an adverse reaction entity
"In the clinical trials, 2 subjects who received placebo committed suicide compared to none in OTEZLA-treated subjects.",none is not a named entity
"In the clinical trials, 2 subjects who received placebo committed suicide compared to none in OTEZLA-treated subjects.",suicide is an adverse reaction entity
Weight decrease of >=10% of body weight occurred in 2% (16/784) of subjects treated with OTEZLA 30 mg twice daily compared to 1% (3/382) subjects treated with placebo.,Weight decrease is an adverse reaction entity
Weight decrease of >=10% of body weight occurred in 2% (16/784) of subjects treated with OTEZLA 30 mg twice daily compared to 1% (3/382) subjects treated with placebo.,occurred is not a named entity
"During the clinical trials, 0.3% (4/1441) of subjects treated with OTEZLA discontinued treatment due to depression or depressed mood compared with none in placebo treated subjects (0/495).",OTEZLA discontinued treatment is not a named entity
"During the clinical trials, 0.3% (4/1441) of subjects treated with OTEZLA discontinued treatment due to depression or depressed mood compared with none in placebo treated subjects (0/495).",depressed mood is an adverse reaction entity
"During the clinical trials, 0.3% (4/1441) of subjects treated with OTEZLA discontinued treatment due to depression or depressed mood compared with none in placebo treated subjects (0/495).",depression is an adverse reaction entity
"During the clinical trials, 0.3% (4/1441) of subjects treated with OTEZLA discontinued treatment due to depression or depressed mood compared with none in placebo treated subjects (0/495).",4/1441 ) is not a named entity
"6 ADVERSE REACTIONS     EXCERPT:    *   Psoriatic Arthritis : The most common adverse reactions (>=5%) are diarrhea, nausea, and headache (6.1)   *   Psoriasis : The most common adverse reactions (>=5%) are diarrhea, nausea, upper respiratory tract infection, and headache, including tension headache (6.1)      To report SUSPECTED ADVERSE REACTIONS, contact Celgene Corporation at 1-888-423-5436 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch         6.1 Clinical Trials Experience    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trial of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.","are diarrhea , is not a named entity"
"6 ADVERSE REACTIONS     EXCERPT:    *   Psoriatic Arthritis : The most common adverse reactions (>=5%) are diarrhea, nausea, and headache (6.1)   *   Psoriasis : The most common adverse reactions (>=5%) are diarrhea, nausea, upper respiratory tract infection, and headache, including tension headache (6.1)      To report SUSPECTED ADVERSE REACTIONS, contact Celgene Corporation at 1-888-423-5436 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch         6.1 Clinical Trials Experience    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trial of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.",", and is not a named entity"
"6 ADVERSE REACTIONS     EXCERPT:    *   Psoriatic Arthritis : The most common adverse reactions (>=5%) are diarrhea, nausea, and headache (6.1)   *   Psoriasis : The most common adverse reactions (>=5%) are diarrhea, nausea, upper respiratory tract infection, and headache, including tension headache (6.1)      To report SUSPECTED ADVERSE REACTIONS, contact Celgene Corporation at 1-888-423-5436 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch         6.1 Clinical Trials Experience    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trial of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.",tension headache is an adverse reaction entity
"6 ADVERSE REACTIONS     EXCERPT:    *   Psoriatic Arthritis : The most common adverse reactions (>=5%) are diarrhea, nausea, and headache (6.1)   *   Psoriasis : The most common adverse reactions (>=5%) are diarrhea, nausea, upper respiratory tract infection, and headache, including tension headache (6.1)      To report SUSPECTED ADVERSE REACTIONS, contact Celgene Corporation at 1-888-423-5436 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch         6.1 Clinical Trials Experience    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trial of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.",upper respiratory tract infection is an adverse reaction entity
"6 ADVERSE REACTIONS     EXCERPT:    *   Psoriatic Arthritis : The most common adverse reactions (>=5%) are diarrhea, nausea, and headache (6.1)   *   Psoriasis : The most common adverse reactions (>=5%) are diarrhea, nausea, upper respiratory tract infection, and headache, including tension headache (6.1)      To report SUSPECTED ADVERSE REACTIONS, contact Celgene Corporation at 1-888-423-5436 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch         6.1 Clinical Trials Experience    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trial of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.",nausea is an adverse reaction entity
"6 ADVERSE REACTIONS     EXCERPT:    *   Psoriatic Arthritis : The most common adverse reactions (>=5%) are diarrhea, nausea, and headache (6.1)   *   Psoriasis : The most common adverse reactions (>=5%) are diarrhea, nausea, upper respiratory tract infection, and headache, including tension headache (6.1)      To report SUSPECTED ADVERSE REACTIONS, contact Celgene Corporation at 1-888-423-5436 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch         6.1 Clinical Trials Experience    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trial of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.",may not is not a named entity
"6 ADVERSE REACTIONS     EXCERPT:    *   Psoriatic Arthritis : The most common adverse reactions (>=5%) are diarrhea, nausea, and headache (6.1)   *   Psoriasis : The most common adverse reactions (>=5%) are diarrhea, nausea, upper respiratory tract infection, and headache, including tension headache (6.1)      To report SUSPECTED ADVERSE REACTIONS, contact Celgene Corporation at 1-888-423-5436 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch         6.1 Clinical Trials Experience    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trial of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.",% ) is not a named entity
"6 ADVERSE REACTIONS     EXCERPT:    *   Psoriatic Arthritis : The most common adverse reactions (>=5%) are diarrhea, nausea, and headache (6.1)   *   Psoriasis : The most common adverse reactions (>=5%) are diarrhea, nausea, upper respiratory tract infection, and headache, including tension headache (6.1)      To report SUSPECTED ADVERSE REACTIONS, contact Celgene Corporation at 1-888-423-5436 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch         6.1 Clinical Trials Experience    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trial of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.",Corporation at 1-888-423-5436 is not a named entity
"6 ADVERSE REACTIONS     EXCERPT:    *   Psoriatic Arthritis : The most common adverse reactions (>=5%) are diarrhea, nausea, and headache (6.1)   *   Psoriasis : The most common adverse reactions (>=5%) are diarrhea, nausea, upper respiratory tract infection, and headache, including tension headache (6.1)      To report SUSPECTED ADVERSE REACTIONS, contact Celgene Corporation at 1-888-423-5436 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch         6.1 Clinical Trials Experience    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trial of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.",headache is an adverse reaction entity
"6 ADVERSE REACTIONS     EXCERPT:    *   Psoriatic Arthritis : The most common adverse reactions (>=5%) are diarrhea, nausea, and headache (6.1)   *   Psoriasis : The most common adverse reactions (>=5%) are diarrhea, nausea, upper respiratory tract infection, and headache, including tension headache (6.1)      To report SUSPECTED ADVERSE REACTIONS, contact Celgene Corporation at 1-888-423-5436 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch         6.1 Clinical Trials Experience    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trial of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.","conditions , is not a named entity"
"6 ADVERSE REACTIONS     EXCERPT:    *   Psoriatic Arthritis : The most common adverse reactions (>=5%) are diarrhea, nausea, and headache (6.1)   *   Psoriasis : The most common adverse reactions (>=5%) are diarrhea, nausea, upper respiratory tract infection, and headache, including tension headache (6.1)      To report SUSPECTED ADVERSE REACTIONS, contact Celgene Corporation at 1-888-423-5436 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch         6.1 Clinical Trials Experience    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trial of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.",Because clinical trials is not a named entity
"6 ADVERSE REACTIONS     EXCERPT:    *   Psoriatic Arthritis : The most common adverse reactions (>=5%) are diarrhea, nausea, and headache (6.1)   *   Psoriasis : The most common adverse reactions (>=5%) are diarrhea, nausea, upper respiratory tract infection, and headache, including tension headache (6.1)      To report SUSPECTED ADVERSE REACTIONS, contact Celgene Corporation at 1-888-423-5436 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch         6.1 Clinical Trials Experience    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trial of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.",headache is an adverse reaction entity
"6 ADVERSE REACTIONS     EXCERPT:    *   Psoriatic Arthritis : The most common adverse reactions (>=5%) are diarrhea, nausea, and headache (6.1)   *   Psoriasis : The most common adverse reactions (>=5%) are diarrhea, nausea, upper respiratory tract infection, and headache, including tension headache (6.1)      To report SUSPECTED ADVERSE REACTIONS, contact Celgene Corporation at 1-888-423-5436 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch         6.1 Clinical Trials Experience    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trial of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.",nausea is an adverse reaction entity
"6 ADVERSE REACTIONS     EXCERPT:    *   Psoriatic Arthritis : The most common adverse reactions (>=5%) are diarrhea, nausea, and headache (6.1)   *   Psoriasis : The most common adverse reactions (>=5%) are diarrhea, nausea, upper respiratory tract infection, and headache, including tension headache (6.1)      To report SUSPECTED ADVERSE REACTIONS, contact Celgene Corporation at 1-888-423-5436 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch         6.1 Clinical Trials Experience    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trial of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.",diarrhea is an adverse reaction entity
"6 ADVERSE REACTIONS     EXCERPT:    *   Psoriatic Arthritis : The most common adverse reactions (>=5%) are diarrhea, nausea, and headache (6.1)   *   Psoriasis : The most common adverse reactions (>=5%) are diarrhea, nausea, upper respiratory tract infection, and headache, including tension headache (6.1)      To report SUSPECTED ADVERSE REACTIONS, contact Celgene Corporation at 1-888-423-5436 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch         6.1 Clinical Trials Experience    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trial of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.",the is not a named entity
"6 ADVERSE REACTIONS     EXCERPT:    *   Psoriatic Arthritis : The most common adverse reactions (>=5%) are diarrhea, nausea, and headache (6.1)   *   Psoriasis : The most common adverse reactions (>=5%) are diarrhea, nausea, upper respiratory tract infection, and headache, including tension headache (6.1)      To report SUSPECTED ADVERSE REACTIONS, contact Celgene Corporation at 1-888-423-5436 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch         6.1 Clinical Trials Experience    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trial of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.",diarrhea is an adverse reaction entity
"During the controlled period of the trials in psoriasis, weight decrease between 5%-10% of body weight occurred in 12% (96/784) of subjects treated with OTEZLA compared to 5% (19/382) treated with placebo.",5 % -10 is not a named entity
"During the controlled period of the trials in psoriasis, weight decrease between 5%-10% of body weight occurred in 12% (96/784) of subjects treated with OTEZLA compared to 5% (19/382) treated with placebo.",weight decrease is an adverse reaction entity
"Depression was reported as serious in 0.1% (1/1308) of subjects exposed to OTEZLA, compared to none in placebo-treated subjects (0/506).",Depression is an adverse reaction entity
"Depression was reported as serious in 0.1% (1/1308) of subjects exposed to OTEZLA, compared to none in placebo-treated subjects (0/506).",", is not a named entity"
"Psoriatic arthritis  : During the 0 to 16 week placebo-controlled period of the 3 controlled clinical trials, 1.0% (10/998) of subjects treated with OTEZLA reported depression or depressed mood compared to 0.8% (4/495) treated with placebo.",depressed mood is an adverse reaction entity
"Psoriatic arthritis  : During the 0 to 16 week placebo-controlled period of the 3 controlled clinical trials, 1.0% (10/998) of subjects treated with OTEZLA reported depression or depressed mood compared to 0.8% (4/495) treated with placebo.",controlled clinical is not a named entity
"Psoriatic arthritis  : During the 0 to 16 week placebo-controlled period of the 3 controlled clinical trials, 1.0% (10/998) of subjects treated with OTEZLA reported depression or depressed mood compared to 0.8% (4/495) treated with placebo.",subjects treated is not a named entity
"Psoriatic arthritis  : During the 0 to 16 week placebo-controlled period of the 3 controlled clinical trials, 1.0% (10/998) of subjects treated with OTEZLA reported depression or depressed mood compared to 0.8% (4/495) treated with placebo.",depression is an adverse reaction entity
"Psoriasis  : During the 0 to 16 week placebo-controlled period of the 3 controlled clinical trials, 1.3% (12/920) of subjects treated with OTEZLA reported depression compared to 0.4% (2/506) treated with placebo.",depression is an adverse reaction entity
"Psoriasis  : During the 0 to 16 week placebo-controlled period of the 3 controlled clinical trials, 1.3% (12/920) of subjects treated with OTEZLA reported depression compared to 0.4% (2/506) treated with placebo.",0.4 % ( is not a named entity
"The most common adverse reactions leading to discontinuation for patients taking OTEZLA were nausea (1.8%), diarrhea (1.8%), and headache (1.2%).",headache is an adverse reaction entity
"The most common adverse reactions leading to discontinuation for patients taking OTEZLA were nausea (1.8%), diarrhea (1.8%), and headache (1.2%).",common adverse is not a named entity
"The most common adverse reactions leading to discontinuation for patients taking OTEZLA were nausea (1.8%), diarrhea (1.8%), and headache (1.2%).",diarrhea is an adverse reaction entity
"The most common adverse reactions leading to discontinuation for patients taking OTEZLA were nausea (1.8%), diarrhea (1.8%), and headache (1.2%).",1.8 % ) is not a named entity
"The most common adverse reactions leading to discontinuation for patients taking OTEZLA were nausea (1.8%), diarrhea (1.8%), and headache (1.2%).",( is not a named entity
"The most common adverse reactions leading to discontinuation for patients taking OTEZLA were nausea (1.8%), diarrhea (1.8%), and headache (1.2%).",nausea is an adverse reaction entity
"Across 8 Phase III clinical trials  [see Clinical Studies (14)]  , MTC was diagnosed in 1 patient receiving TANZEUM and 1 patient receiving placebo.",MTC is an adverse reaction entity
"Across 8 Phase III clinical trials  [see Clinical Studies (14)]  , MTC was diagnosed in 1 patient receiving TANZEUM and 1 patient receiving placebo.","] , MTC is not a named entity"
"5.3 Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin    The risk of hypoglycemia is increased when TANZEUM is used in combination with insulin secretagogues (e.g., sulfonylureas) or insulin.",increased when is not a named entity
"5.3 Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin    The risk of hypoglycemia is increased when TANZEUM is used in combination with insulin secretagogues (e.g., sulfonylureas) or insulin.",hypoglycemia is an adverse reaction entity
"5.2 Acute Pancreatitis    In clinical trials, acute pancreatitis has been reported in association with TANZEUM.",acute pancreatitis is an adverse reaction entity
"5.2 Acute Pancreatitis    In clinical trials, acute pancreatitis has been reported in association with TANZEUM.",reported is not a named entity
"The majority of injection site reactions were judged as ""mild"" by investigators in both groups (73% for TANZEUM versus 94% for placebo).",injection site reactions is an adverse reaction entity
"The majority of injection site reactions were judged as ""mild"" by investigators in both groups (73% for TANZEUM versus 94% for placebo).",groups is not a named entity
"The majority of injection site reactions were judged as ""mild"" by investigators in both groups (73% for TANZEUM versus 94% for placebo).",groups ( is not a named entity
"The majority of injection site reactions were judged as ""mild"" by investigators in both groups (73% for TANZEUM versus 94% for placebo).",injection site reactions is an adverse reaction entity
"Appendicitis       In the pool of placebo- and active-controlled trials, serious events of appendicitis occurred in 0.3% of patients treated with TANZEUM compared with 0% among all comparators.",appendicitis is an adverse reaction entity
"Appendicitis       In the pool of placebo- and active-controlled trials, serious events of appendicitis occurred in 0.3% of patients treated with TANZEUM compared with 0% among all comparators.",TANZEUM compared is not a named entity
"In the third case, elevation in ALT (10 times the upper limit of normal) was accompanied by an increase in total bilirubin (4 times the upper limit of normal) and occurred 8 days after the first dose of TANZEUM.",elevation in ALT is an adverse reaction entity
"In the third case, elevation in ALT (10 times the upper limit of normal) was accompanied by an increase in total bilirubin (4 times the upper limit of normal) and occurred 8 days after the first dose of TANZEUM.",4 times the is not a named entity
"In the third case, elevation in ALT (10 times the upper limit of normal) was accompanied by an increase in total bilirubin (4 times the upper limit of normal) and occurred 8 days after the first dose of TANZEUM.",increase in total bilirubin is an adverse reaction entity
"In the third case, elevation in ALT (10 times the upper limit of normal) was accompanied by an increase in total bilirubin (4 times the upper limit of normal) and occurred 8 days after the first dose of TANZEUM.",) was accompanied is not a named entity
More cases of pneumonia in the group receiving TANZEUM were serious (0.4% for TANZEUM versus 0.1% for all comparators).,for TANZEUM versus is not a named entity
More cases of pneumonia in the group receiving TANZEUM were serious (0.4% for TANZEUM versus 0.1% for all comparators).,pneumonia is an adverse reaction entity
"Pneumonia       In the pool of 7 placebo- and active-controlled trials, the adverse reaction of pneumonia was reported more frequently in patients receiving TANZEUM (1.8%) than in patients in the all-comparators group (0.8%).",1.8 % is not a named entity
"Pneumonia       In the pool of 7 placebo- and active-controlled trials, the adverse reaction of pneumonia was reported more frequently in patients receiving TANZEUM (1.8%) than in patients in the all-comparators group (0.8%).",pneumonia is an adverse reaction entity
"Heart Rate Increase       In the pool of placebo-controlled trials, mean heart rate in patients treated with TANZEUM was higher by an average of 1 to 2 bpm compared with mean heart rate in patients treated with placebo across study visits.",mean heart rate higher by an average of 1 to 2 bpm is an adverse reaction entity
"Heart Rate Increase       In the pool of placebo-controlled trials, mean heart rate in patients treated with TANZEUM was higher by an average of 1 to 2 bpm compared with mean heart rate in patients treated with placebo across study visits.",. is not a named entity
"Gastrointestinal Adverse Reactions       In the pool of placebo-controlled trials, gastrointestinal complaints occurred more frequently among patients receiving TANZEUM (39%) than patients receiving placebo (33%).",than is not a named entity
"Gastrointestinal Adverse Reactions       In the pool of placebo-controlled trials, gastrointestinal complaints occurred more frequently among patients receiving TANZEUM (39%) than patients receiving placebo (33%).",gastrointestinal complaints is an adverse reaction entity
*       c  Plasma glucose concentration <=70 mg/dL and presence of hypoglycemic symptoms.,Plasma glucose concentration <=70 mg/dL is an adverse reaction entity
*       c  Plasma glucose concentration <=70 mg/dL and presence of hypoglycemic symptoms.,glucose concentration is not a named entity
*       c  Plasma glucose concentration <=70 mg/dL and presence of hypoglycemic symptoms.,hypoglycemic symptoms is an adverse reaction entity
*       c  Plasma glucose concentration <=70 mg/dL and presence of hypoglycemic symptoms.,=70 is not a named entity
"In the group treated with TANZEUM, investigators graded the severity of GI reactions as ""mild"" in 56% of cases, ""moderate"" in 37% of cases, and ""severe"" in 7% of cases.",and `` severe is not a named entity
"In the group treated with TANZEUM, investigators graded the severity of GI reactions as ""mild"" in 56% of cases, ""moderate"" in 37% of cases, and ""severe"" in 7% of cases.",GI reactions is an adverse reaction entity
"Liver Enzyme Abnormalities       In the pool of placebo- and active-controlled trials, a similar proportion of patients experienced at least one event of alanine aminotransferase (ALT) increase of 3-fold or greater above the upper limit of normal (0.9% and 0.9% for all comparators versus TANZEUM).",% and 0.9 is not a named entity
"Liver Enzyme Abnormalities       In the pool of placebo- and active-controlled trials, a similar proportion of patients experienced at least one event of alanine aminotransferase (ALT) increase of 3-fold or greater above the upper limit of normal (0.9% and 0.9% for all comparators versus TANZEUM).",alanine aminotransferase increase is an adverse reaction entity
"Liver Enzyme Abnormalities       In the pool of placebo- and active-controlled trials, a similar proportion of patients experienced at least one event of alanine aminotransferase (ALT) increase of 3-fold or greater above the upper limit of normal (0.9% and 0.9% for all comparators versus TANZEUM).",the upper is not a named entity
"Liver Enzyme Abnormalities       In the pool of placebo- and active-controlled trials, a similar proportion of patients experienced at least one event of alanine aminotransferase (ALT) increase of 3-fold or greater above the upper limit of normal (0.9% and 0.9% for all comparators versus TANZEUM).",ALT increase is an adverse reaction entity
"Cases of MTC in patients treated with liraglutide, another GLP-1 receptor agonist, have been reported in the postmarketing period; the data in these reports are insufficient to establish or exclude a causal relationship between MTC and GLP-1 receptor agonist use in humans.","liraglutide , is not a named entity"
"Cases of MTC in patients treated with liraglutide, another GLP-1 receptor agonist, have been reported in the postmarketing period; the data in these reports are insufficient to establish or exclude a causal relationship between MTC and GLP-1 receptor agonist use in humans.",MTC is an adverse reaction entity
"Cases of MTC in patients treated with liraglutide, another GLP-1 receptor agonist, have been reported in the postmarketing period; the data in these reports are insufficient to establish or exclude a causal relationship between MTC and GLP-1 receptor agonist use in humans.",to establish is not a named entity
"Cases of MTC in patients treated with liraglutide, another GLP-1 receptor agonist, have been reported in the postmarketing period; the data in these reports are insufficient to establish or exclude a causal relationship between MTC and GLP-1 receptor agonist use in humans.",MTC is an adverse reaction entity
"A majority of reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration.",vomiting is an adverse reaction entity
"A majority of reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration.",diarrhea is an adverse reaction entity
"A majority of reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration.","nausea , vomiting is not a named entity"
"A majority of reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration.",", vomiting is not a named entity"
"A majority of reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration.",dehydration is an adverse reaction entity
"A majority of reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration.",nausea is an adverse reaction entity
"A majority of reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration.","experienced nausea , is not a named entity"
"A majority of reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration.",", is not a named entity"
"In addition to diarrhea and nausea (see Table 1), the following gastrointestinal adverse reactions also occurred more frequently in patients receiving TANZEUM: vomiting (2.6% versus 4.2% for placebo versus TANZEUM), gastroesophageal reflux disease (1.9% versus 3.5% for placebo versus TANZEUM), and dyspepsia (2.8% versus 3.4% for placebo versus TANZEUM).",diarrhea is an adverse reaction entity
"In addition to diarrhea and nausea (see Table 1), the following gastrointestinal adverse reactions also occurred more frequently in patients receiving TANZEUM: vomiting (2.6% versus 4.2% for placebo versus TANZEUM), gastroesophageal reflux disease (1.9% versus 3.5% for placebo versus TANZEUM), and dyspepsia (2.8% versus 3.4% for placebo versus TANZEUM).",vomiting is an adverse reaction entity
"In addition to diarrhea and nausea (see Table 1), the following gastrointestinal adverse reactions also occurred more frequently in patients receiving TANZEUM: vomiting (2.6% versus 4.2% for placebo versus TANZEUM), gastroesophageal reflux disease (1.9% versus 3.5% for placebo versus TANZEUM), and dyspepsia (2.8% versus 3.4% for placebo versus TANZEUM).",% is not a named entity
"In addition to diarrhea and nausea (see Table 1), the following gastrointestinal adverse reactions also occurred more frequently in patients receiving TANZEUM: vomiting (2.6% versus 4.2% for placebo versus TANZEUM), gastroesophageal reflux disease (1.9% versus 3.5% for placebo versus TANZEUM), and dyspepsia (2.8% versus 3.4% for placebo versus TANZEUM).",dyspepsia is an adverse reaction entity
"In addition to diarrhea and nausea (see Table 1), the following gastrointestinal adverse reactions also occurred more frequently in patients receiving TANZEUM: vomiting (2.6% versus 4.2% for placebo versus TANZEUM), gastroesophageal reflux disease (1.9% versus 3.5% for placebo versus TANZEUM), and dyspepsia (2.8% versus 3.4% for placebo versus TANZEUM).",( 1.9 % is not a named entity
"In addition to diarrhea and nausea (see Table 1), the following gastrointestinal adverse reactions also occurred more frequently in patients receiving TANZEUM: vomiting (2.6% versus 4.2% for placebo versus TANZEUM), gastroesophageal reflux disease (1.9% versus 3.5% for placebo versus TANZEUM), and dyspepsia (2.8% versus 3.4% for placebo versus TANZEUM).",for placebo is not a named entity
"In addition to diarrhea and nausea (see Table 1), the following gastrointestinal adverse reactions also occurred more frequently in patients receiving TANZEUM: vomiting (2.6% versus 4.2% for placebo versus TANZEUM), gastroesophageal reflux disease (1.9% versus 3.5% for placebo versus TANZEUM), and dyspepsia (2.8% versus 3.4% for placebo versus TANZEUM).","TANZEUM ) , is not a named entity"
"In addition to diarrhea and nausea (see Table 1), the following gastrointestinal adverse reactions also occurred more frequently in patients receiving TANZEUM: vomiting (2.6% versus 4.2% for placebo versus TANZEUM), gastroesophageal reflux disease (1.9% versus 3.5% for placebo versus TANZEUM), and dyspepsia (2.8% versus 3.4% for placebo versus TANZEUM).",1.9 % versus is not a named entity
"In addition to diarrhea and nausea (see Table 1), the following gastrointestinal adverse reactions also occurred more frequently in patients receiving TANZEUM: vomiting (2.6% versus 4.2% for placebo versus TANZEUM), gastroesophageal reflux disease (1.9% versus 3.5% for placebo versus TANZEUM), and dyspepsia (2.8% versus 3.4% for placebo versus TANZEUM).",also occurred is not a named entity
"In addition to diarrhea and nausea (see Table 1), the following gastrointestinal adverse reactions also occurred more frequently in patients receiving TANZEUM: vomiting (2.6% versus 4.2% for placebo versus TANZEUM), gastroesophageal reflux disease (1.9% versus 3.5% for placebo versus TANZEUM), and dyspepsia (2.8% versus 3.4% for placebo versus TANZEUM).",gastroesophageal reflux disease is an adverse reaction entity
"In addition to diarrhea and nausea (see Table 1), the following gastrointestinal adverse reactions also occurred more frequently in patients receiving TANZEUM: vomiting (2.6% versus 4.2% for placebo versus TANZEUM), gastroesophageal reflux disease (1.9% versus 3.5% for placebo versus TANZEUM), and dyspepsia (2.8% versus 3.4% for placebo versus TANZEUM).",gastrointestinal adverse reactions is an adverse reaction entity
"In addition to diarrhea and nausea (see Table 1), the following gastrointestinal adverse reactions also occurred more frequently in patients receiving TANZEUM: vomiting (2.6% versus 4.2% for placebo versus TANZEUM), gastroesophageal reflux disease (1.9% versus 3.5% for placebo versus TANZEUM), and dyspepsia (2.8% versus 3.4% for placebo versus TANZEUM).",nausea is an adverse reaction entity
Other GLP-1 receptor agonists have caused dose-related and treatment-duration-dependent thyroid C-cell tumors (adenomas or carcinomas) in rodents.,thyroid C-cell adenomas is an adverse reaction entity
Other GLP-1 receptor agonists have caused dose-related and treatment-duration-dependent thyroid C-cell tumors (adenomas or carcinomas) in rodents.,thyroid C-cell carcinomas is an adverse reaction entity
Other GLP-1 receptor agonists have caused dose-related and treatment-duration-dependent thyroid C-cell tumors (adenomas or carcinomas) in rodents.,thyroid C-cell tumors is an adverse reaction entity
Other GLP-1 receptor agonists have caused dose-related and treatment-duration-dependent thyroid C-cell tumors (adenomas or carcinomas) in rodents.,agonists have caused is not a named entity
Other GLP-1 receptor agonists have caused dose-related and treatment-duration-dependent thyroid C-cell tumors (adenomas or carcinomas) in rodents.,GLP-1 is not a named entity
Other GLP-1 receptor agonists have caused dose-related and treatment-duration-dependent thyroid C-cell tumors (adenomas or carcinomas) in rodents.,rodents is not a named entity
"Gamma Glutamyltransferase (GGT) Increase       In the pool of placebo-controlled trials, the adverse event of increased GGT occurred more frequently in the group treated with TANZEUM (0.9% and 1.5% for placebo versus TANZEUM).",% and is not a named entity
"Gamma Glutamyltransferase (GGT) Increase       In the pool of placebo-controlled trials, the adverse event of increased GGT occurred more frequently in the group treated with TANZEUM (0.9% and 1.5% for placebo versus TANZEUM).",increased GGT is an adverse reaction entity
(5.4)   *     Renal Impairment: Monitor renal function in patients with renal impairment reporting severe adverse gastrointestinal reactions.,impairment reporting severe is not a named entity
(5.4)   *     Renal Impairment: Monitor renal function in patients with renal impairment reporting severe adverse gastrointestinal reactions.,Renal Impairment is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *    Risk of Thyroid C-cell Tumors [see Warnings and Precautions (5.1)]    *    Acute Pancreatitis [see Warnings and Precautions (5.2)]    *    Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (5.3)]    *    Hypersensitivity Reactions [see Warnings and Precautions (5.4)]    *    Renal Impairment [see Warnings and Precautions (5.5)]         EXCERPT:   Adverse reactions, reported in >=5% of patients treated with TANZEUM and more frequently than in patients on placebo, were upper respiratory tract infection, diarrhea, nausea, injection site reaction, cough, back pain, arthralgia, sinusitis, and influenza.",Warnings is not a named entity
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *    Risk of Thyroid C-cell Tumors [see Warnings and Precautions (5.1)]    *    Acute Pancreatitis [see Warnings and Precautions (5.2)]    *    Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (5.3)]    *    Hypersensitivity Reactions [see Warnings and Precautions (5.4)]    *    Renal Impairment [see Warnings and Precautions (5.5)]         EXCERPT:   Adverse reactions, reported in >=5% of patients treated with TANZEUM and more frequently than in patients on placebo, were upper respiratory tract infection, diarrhea, nausea, injection site reaction, cough, back pain, arthralgia, sinusitis, and influenza.",Acute Pancreatitis is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *    Risk of Thyroid C-cell Tumors [see Warnings and Precautions (5.1)]    *    Acute Pancreatitis [see Warnings and Precautions (5.2)]    *    Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (5.3)]    *    Hypersensitivity Reactions [see Warnings and Precautions (5.4)]    *    Renal Impairment [see Warnings and Precautions (5.5)]         EXCERPT:   Adverse reactions, reported in >=5% of patients treated with TANZEUM and more frequently than in patients on placebo, were upper respiratory tract infection, diarrhea, nausea, injection site reaction, cough, back pain, arthralgia, sinusitis, and influenza.",nausea is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *    Risk of Thyroid C-cell Tumors [see Warnings and Precautions (5.1)]    *    Acute Pancreatitis [see Warnings and Precautions (5.2)]    *    Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (5.3)]    *    Hypersensitivity Reactions [see Warnings and Precautions (5.4)]    *    Renal Impairment [see Warnings and Precautions (5.5)]         EXCERPT:   Adverse reactions, reported in >=5% of patients treated with TANZEUM and more frequently than in patients on placebo, were upper respiratory tract infection, diarrhea, nausea, injection site reaction, cough, back pain, arthralgia, sinusitis, and influenza.",back pain is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *    Risk of Thyroid C-cell Tumors [see Warnings and Precautions (5.1)]    *    Acute Pancreatitis [see Warnings and Precautions (5.2)]    *    Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (5.3)]    *    Hypersensitivity Reactions [see Warnings and Precautions (5.4)]    *    Renal Impairment [see Warnings and Precautions (5.5)]         EXCERPT:   Adverse reactions, reported in >=5% of patients treated with TANZEUM and more frequently than in patients on placebo, were upper respiratory tract infection, diarrhea, nausea, injection site reaction, cough, back pain, arthralgia, sinusitis, and influenza.",respiratory is not a named entity
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *    Risk of Thyroid C-cell Tumors [see Warnings and Precautions (5.1)]    *    Acute Pancreatitis [see Warnings and Precautions (5.2)]    *    Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (5.3)]    *    Hypersensitivity Reactions [see Warnings and Precautions (5.4)]    *    Renal Impairment [see Warnings and Precautions (5.5)]         EXCERPT:   Adverse reactions, reported in >=5% of patients treated with TANZEUM and more frequently than in patients on placebo, were upper respiratory tract infection, diarrhea, nausea, injection site reaction, cough, back pain, arthralgia, sinusitis, and influenza.",injection site reaction is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *    Risk of Thyroid C-cell Tumors [see Warnings and Precautions (5.1)]    *    Acute Pancreatitis [see Warnings and Precautions (5.2)]    *    Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (5.3)]    *    Hypersensitivity Reactions [see Warnings and Precautions (5.4)]    *    Renal Impairment [see Warnings and Precautions (5.5)]         EXCERPT:   Adverse reactions, reported in >=5% of patients treated with TANZEUM and more frequently than in patients on placebo, were upper respiratory tract infection, diarrhea, nausea, injection site reaction, cough, back pain, arthralgia, sinusitis, and influenza.","diarrhea , is not a named entity"
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *    Risk of Thyroid C-cell Tumors [see Warnings and Precautions (5.1)]    *    Acute Pancreatitis [see Warnings and Precautions (5.2)]    *    Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (5.3)]    *    Hypersensitivity Reactions [see Warnings and Precautions (5.4)]    *    Renal Impairment [see Warnings and Precautions (5.5)]         EXCERPT:   Adverse reactions, reported in >=5% of patients treated with TANZEUM and more frequently than in patients on placebo, were upper respiratory tract infection, diarrhea, nausea, injection site reaction, cough, back pain, arthralgia, sinusitis, and influenza.",influenza is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *    Risk of Thyroid C-cell Tumors [see Warnings and Precautions (5.1)]    *    Acute Pancreatitis [see Warnings and Precautions (5.2)]    *    Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (5.3)]    *    Hypersensitivity Reactions [see Warnings and Precautions (5.4)]    *    Renal Impairment [see Warnings and Precautions (5.5)]         EXCERPT:   Adverse reactions, reported in >=5% of patients treated with TANZEUM and more frequently than in patients on placebo, were upper respiratory tract infection, diarrhea, nausea, injection site reaction, cough, back pain, arthralgia, sinusitis, and influenza.",Hypersensitivity Reactions is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *    Risk of Thyroid C-cell Tumors [see Warnings and Precautions (5.1)]    *    Acute Pancreatitis [see Warnings and Precautions (5.2)]    *    Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (5.3)]    *    Hypersensitivity Reactions [see Warnings and Precautions (5.4)]    *    Renal Impairment [see Warnings and Precautions (5.5)]         EXCERPT:   Adverse reactions, reported in >=5% of patients treated with TANZEUM and more frequently than in patients on placebo, were upper respiratory tract infection, diarrhea, nausea, injection site reaction, cough, back pain, arthralgia, sinusitis, and influenza.",sinusitis is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *    Risk of Thyroid C-cell Tumors [see Warnings and Precautions (5.1)]    *    Acute Pancreatitis [see Warnings and Precautions (5.2)]    *    Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (5.3)]    *    Hypersensitivity Reactions [see Warnings and Precautions (5.4)]    *    Renal Impairment [see Warnings and Precautions (5.5)]         EXCERPT:   Adverse reactions, reported in >=5% of patients treated with TANZEUM and more frequently than in patients on placebo, were upper respiratory tract infection, diarrhea, nausea, injection site reaction, cough, back pain, arthralgia, sinusitis, and influenza.",", were upper is not a named entity"
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *    Risk of Thyroid C-cell Tumors [see Warnings and Precautions (5.1)]    *    Acute Pancreatitis [see Warnings and Precautions (5.2)]    *    Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (5.3)]    *    Hypersensitivity Reactions [see Warnings and Precautions (5.4)]    *    Renal Impairment [see Warnings and Precautions (5.5)]         EXCERPT:   Adverse reactions, reported in >=5% of patients treated with TANZEUM and more frequently than in patients on placebo, were upper respiratory tract infection, diarrhea, nausea, injection site reaction, cough, back pain, arthralgia, sinusitis, and influenza.",Thyroid C-cell Tumors is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *    Risk of Thyroid C-cell Tumors [see Warnings and Precautions (5.1)]    *    Acute Pancreatitis [see Warnings and Precautions (5.2)]    *    Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (5.3)]    *    Hypersensitivity Reactions [see Warnings and Precautions (5.4)]    *    Renal Impairment [see Warnings and Precautions (5.5)]         EXCERPT:   Adverse reactions, reported in >=5% of patients treated with TANZEUM and more frequently than in patients on placebo, were upper respiratory tract infection, diarrhea, nausea, injection site reaction, cough, back pain, arthralgia, sinusitis, and influenza.",diarrhea is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *    Risk of Thyroid C-cell Tumors [see Warnings and Precautions (5.1)]    *    Acute Pancreatitis [see Warnings and Precautions (5.2)]    *    Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (5.3)]    *    Hypersensitivity Reactions [see Warnings and Precautions (5.4)]    *    Renal Impairment [see Warnings and Precautions (5.5)]         EXCERPT:   Adverse reactions, reported in >=5% of patients treated with TANZEUM and more frequently than in patients on placebo, were upper respiratory tract infection, diarrhea, nausea, injection site reaction, cough, back pain, arthralgia, sinusitis, and influenza.",cough is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *    Risk of Thyroid C-cell Tumors [see Warnings and Precautions (5.1)]    *    Acute Pancreatitis [see Warnings and Precautions (5.2)]    *    Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (5.3)]    *    Hypersensitivity Reactions [see Warnings and Precautions (5.4)]    *    Renal Impairment [see Warnings and Precautions (5.5)]         EXCERPT:   Adverse reactions, reported in >=5% of patients treated with TANZEUM and more frequently than in patients on placebo, were upper respiratory tract infection, diarrhea, nausea, injection site reaction, cough, back pain, arthralgia, sinusitis, and influenza.",", is not a named entity"
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *    Risk of Thyroid C-cell Tumors [see Warnings and Precautions (5.1)]    *    Acute Pancreatitis [see Warnings and Precautions (5.2)]    *    Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (5.3)]    *    Hypersensitivity Reactions [see Warnings and Precautions (5.4)]    *    Renal Impairment [see Warnings and Precautions (5.5)]         EXCERPT:   Adverse reactions, reported in >=5% of patients treated with TANZEUM and more frequently than in patients on placebo, were upper respiratory tract infection, diarrhea, nausea, injection site reaction, cough, back pain, arthralgia, sinusitis, and influenza.",upper respiratory tract infection is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *    Risk of Thyroid C-cell Tumors [see Warnings and Precautions (5.1)]    *    Acute Pancreatitis [see Warnings and Precautions (5.2)]    *    Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (5.3)]    *    Hypersensitivity Reactions [see Warnings and Precautions (5.4)]    *    Renal Impairment [see Warnings and Precautions (5.5)]         EXCERPT:   Adverse reactions, reported in >=5% of patients treated with TANZEUM and more frequently than in patients on placebo, were upper respiratory tract infection, diarrhea, nausea, injection site reaction, cough, back pain, arthralgia, sinusitis, and influenza.",infection is not a named entity
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *    Risk of Thyroid C-cell Tumors [see Warnings and Precautions (5.1)]    *    Acute Pancreatitis [see Warnings and Precautions (5.2)]    *    Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (5.3)]    *    Hypersensitivity Reactions [see Warnings and Precautions (5.4)]    *    Renal Impairment [see Warnings and Precautions (5.5)]         EXCERPT:   Adverse reactions, reported in >=5% of patients treated with TANZEUM and more frequently than in patients on placebo, were upper respiratory tract infection, diarrhea, nausea, injection site reaction, cough, back pain, arthralgia, sinusitis, and influenza.",", back pain is not a named entity"
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *    Risk of Thyroid C-cell Tumors [see Warnings and Precautions (5.1)]    *    Acute Pancreatitis [see Warnings and Precautions (5.2)]    *    Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (5.3)]    *    Hypersensitivity Reactions [see Warnings and Precautions (5.4)]    *    Renal Impairment [see Warnings and Precautions (5.5)]         EXCERPT:   Adverse reactions, reported in >=5% of patients treated with TANZEUM and more frequently than in patients on placebo, were upper respiratory tract infection, diarrhea, nausea, injection site reaction, cough, back pain, arthralgia, sinusitis, and influenza.",Adverse is not a named entity
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *    Risk of Thyroid C-cell Tumors [see Warnings and Precautions (5.1)]    *    Acute Pancreatitis [see Warnings and Precautions (5.2)]    *    Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (5.3)]    *    Hypersensitivity Reactions [see Warnings and Precautions (5.4)]    *    Renal Impairment [see Warnings and Precautions (5.5)]         EXCERPT:   Adverse reactions, reported in >=5% of patients treated with TANZEUM and more frequently than in patients on placebo, were upper respiratory tract infection, diarrhea, nausea, injection site reaction, cough, back pain, arthralgia, sinusitis, and influenza.",arthralgia is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *    Risk of Thyroid C-cell Tumors [see Warnings and Precautions (5.1)]    *    Acute Pancreatitis [see Warnings and Precautions (5.2)]    *    Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (5.3)]    *    Hypersensitivity Reactions [see Warnings and Precautions (5.4)]    *    Renal Impairment [see Warnings and Precautions (5.5)]         EXCERPT:   Adverse reactions, reported in >=5% of patients treated with TANZEUM and more frequently than in patients on placebo, were upper respiratory tract infection, diarrhea, nausea, injection site reaction, cough, back pain, arthralgia, sinusitis, and influenza.",Precautions ( is not a named entity
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *    Risk of Thyroid C-cell Tumors [see Warnings and Precautions (5.1)]    *    Acute Pancreatitis [see Warnings and Precautions (5.2)]    *    Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (5.3)]    *    Hypersensitivity Reactions [see Warnings and Precautions (5.4)]    *    Renal Impairment [see Warnings and Precautions (5.5)]         EXCERPT:   Adverse reactions, reported in >=5% of patients treated with TANZEUM and more frequently than in patients on placebo, were upper respiratory tract infection, diarrhea, nausea, injection site reaction, cough, back pain, arthralgia, sinusitis, and influenza.","reactions , reported is not a named entity"
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *    Risk of Thyroid C-cell Tumors [see Warnings and Precautions (5.1)]    *    Acute Pancreatitis [see Warnings and Precautions (5.2)]    *    Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (5.3)]    *    Hypersensitivity Reactions [see Warnings and Precautions (5.4)]    *    Renal Impairment [see Warnings and Precautions (5.5)]         EXCERPT:   Adverse reactions, reported in >=5% of patients treated with TANZEUM and more frequently than in patients on placebo, were upper respiratory tract infection, diarrhea, nausea, injection site reaction, cough, back pain, arthralgia, sinusitis, and influenza.",Hypoglycemia is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *    Risk of Thyroid C-cell Tumors [see Warnings and Precautions (5.1)]    *    Acute Pancreatitis [see Warnings and Precautions (5.2)]    *    Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (5.3)]    *    Hypersensitivity Reactions [see Warnings and Precautions (5.4)]    *    Renal Impairment [see Warnings and Precautions (5.5)]         EXCERPT:   Adverse reactions, reported in >=5% of patients treated with TANZEUM and more frequently than in patients on placebo, were upper respiratory tract infection, diarrhea, nausea, injection site reaction, cough, back pain, arthralgia, sinusitis, and influenza.",REACTIONS The following is not a named entity
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *    Risk of Thyroid C-cell Tumors [see Warnings and Precautions (5.1)]    *    Acute Pancreatitis [see Warnings and Precautions (5.2)]    *    Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (5.3)]    *    Hypersensitivity Reactions [see Warnings and Precautions (5.4)]    *    Renal Impairment [see Warnings and Precautions (5.5)]         EXCERPT:   Adverse reactions, reported in >=5% of patients treated with TANZEUM and more frequently than in patients on placebo, were upper respiratory tract infection, diarrhea, nausea, injection site reaction, cough, back pain, arthralgia, sinusitis, and influenza.",prescribing is not a named entity
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *    Risk of Thyroid C-cell Tumors [see Warnings and Precautions (5.1)]    *    Acute Pancreatitis [see Warnings and Precautions (5.2)]    *    Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (5.3)]    *    Hypersensitivity Reactions [see Warnings and Precautions (5.4)]    *    Renal Impairment [see Warnings and Precautions (5.5)]         EXCERPT:   Adverse reactions, reported in >=5% of patients treated with TANZEUM and more frequently than in patients on placebo, were upper respiratory tract infection, diarrhea, nausea, injection site reaction, cough, back pain, arthralgia, sinusitis, and influenza.",C-cell Tumors [ is not a named entity
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *    Risk of Thyroid C-cell Tumors [see Warnings and Precautions (5.1)]    *    Acute Pancreatitis [see Warnings and Precautions (5.2)]    *    Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (5.3)]    *    Hypersensitivity Reactions [see Warnings and Precautions (5.4)]    *    Renal Impairment [see Warnings and Precautions (5.5)]         EXCERPT:   Adverse reactions, reported in >=5% of patients treated with TANZEUM and more frequently than in patients on placebo, were upper respiratory tract infection, diarrhea, nausea, injection site reaction, cough, back pain, arthralgia, sinusitis, and influenza.",5.2 ) ] is not a named entity
"6 ADVERSE REACTIONS    The following serious reactions are described below or elsewhere in the prescribing information:     *    Risk of Thyroid C-cell Tumors [see Warnings and Precautions (5.1)]    *    Acute Pancreatitis [see Warnings and Precautions (5.2)]    *    Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (5.3)]    *    Hypersensitivity Reactions [see Warnings and Precautions (5.4)]    *    Renal Impairment [see Warnings and Precautions (5.5)]         EXCERPT:   Adverse reactions, reported in >=5% of patients treated with TANZEUM and more frequently than in patients on placebo, were upper respiratory tract infection, diarrhea, nausea, injection site reaction, cough, back pain, arthralgia, sinusitis, and influenza.",Renal Impairment is an adverse reaction entity
"It is unknown whether TANZEUM(r) causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans [see Warnings and Precautions (5.1), Nonclinical Toxicology (13.1)].",thyroid C-cell tumors is an adverse reaction entity
"It is unknown whether TANZEUM(r) causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans [see Warnings and Precautions (5.1), Nonclinical Toxicology (13.1)].",MTC is an adverse reaction entity
"It is unknown whether TANZEUM(r) causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans [see Warnings and Precautions (5.1), Nonclinical Toxicology (13.1)].",Precautions is not a named entity
"It is unknown whether TANZEUM(r) causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans [see Warnings and Precautions (5.1), Nonclinical Toxicology (13.1)].",medullary thyroid carcinoma is an adverse reaction entity
"It is unknown whether TANZEUM(r) causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans [see Warnings and Precautions (5.1), Nonclinical Toxicology (13.1)].",unknown whether is not a named entity
"It is unknown whether TANZEUM(r) causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans [see Warnings and Precautions (5.1), Nonclinical Toxicology (13.1)].",unknown whether is not a named entity
Other Adverse Reactions         Hypoglycemia       The proportion of patients experiencing at least one documented symptomatic hypoglycemic episode on TANZEUM and the proportion of patients experiencing at least one severe hypoglycemic episode on TANZEUM in clinical trials  [see Clinical Studies (14)]  is shown in Table 2.,hypoglycemic episode is an adverse reaction entity
Other Adverse Reactions         Hypoglycemia       The proportion of patients experiencing at least one documented symptomatic hypoglycemic episode on TANZEUM and the proportion of patients experiencing at least one severe hypoglycemic episode on TANZEUM in clinical trials  [see Clinical Studies (14)]  is shown in Table 2.,shown is not a named entity
Other Adverse Reactions         Hypoglycemia       The proportion of patients experiencing at least one documented symptomatic hypoglycemic episode on TANZEUM and the proportion of patients experiencing at least one severe hypoglycemic episode on TANZEUM in clinical trials  [see Clinical Studies (14)]  is shown in Table 2.,( 14 ) is not a named entity
Other Adverse Reactions         Hypoglycemia       The proportion of patients experiencing at least one documented symptomatic hypoglycemic episode on TANZEUM and the proportion of patients experiencing at least one severe hypoglycemic episode on TANZEUM in clinical trials  [see Clinical Studies (14)]  is shown in Table 2.,hypoglycemic episode is an adverse reaction entity
"More patients on TANZEUM than on placebo: discontinued due to an injection site reaction (2% versus 0.2%), experienced more than 2 reactions (38% versus 20%), had a reaction judged by investigators to be ""moderate"" or ""severe"" (27% versus 6%) and required local or systemic treatment for the reactions (36% versus 11%).",injection site reaction is an adverse reaction entity
"More patients on TANZEUM than on placebo: discontinued due to an injection site reaction (2% versus 0.2%), experienced more than 2 reactions (38% versus 20%), had a reaction judged by investigators to be ""moderate"" or ""severe"" (27% versus 6%) and required local or systemic treatment for the reactions (36% versus 11%).",reaction is not a named entity
"It is unknown whether TANZEUM causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans.",causes thyroid C-cell is not a named entity
"It is unknown whether TANZEUM causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans.",MTC is an adverse reaction entity
"It is unknown whether TANZEUM causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans.",C-cell is not a named entity
"It is unknown whether TANZEUM causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans.",", is not a named entity"
"It is unknown whether TANZEUM causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans.",medullary thyroid carcinoma is an adverse reaction entity
"It is unknown whether TANZEUM causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans.",thyroid C-cell tumors is an adverse reaction entity
The etiology of hepatocellular injury was possibly related to TANZEUM but direct attribution to TANZEUM was confounded by the presence of gallstone disease diagnosed on ultrasound 3 weeks after the event  .,etiology of hepatocellular is not a named entity
The etiology of hepatocellular injury was possibly related to TANZEUM but direct attribution to TANZEUM was confounded by the presence of gallstone disease diagnosed on ultrasound 3 weeks after the event  .,hepatocellular injury is an adverse reaction entity
"BOXED WARNING: WARNING: RISK OF THYROID C-CELL TUMORS    WARNING: RISK OF THYROID C-CELL TUMORS      *  Carcinogenicity of albiglutide could not be assessed in rodents, but other glucagon-like peptide-1 (GLP-1) receptor agonists have caused thyroid C-cell tumors in rodents at clinically relevant exposures.",thyroid C-cell tumors is an adverse reaction entity
"BOXED WARNING: WARNING: RISK OF THYROID C-CELL TUMORS    WARNING: RISK OF THYROID C-CELL TUMORS      *  Carcinogenicity of albiglutide could not be assessed in rodents, but other glucagon-like peptide-1 (GLP-1) receptor agonists have caused thyroid C-cell tumors in rodents at clinically relevant exposures.",peptide-1 ( GLP-1 is not a named entity
"BOXED WARNING: WARNING: RISK OF THYROID C-CELL TUMORS    WARNING: RISK OF THYROID C-CELL TUMORS      *  Carcinogenicity of albiglutide could not be assessed in rodents, but other glucagon-like peptide-1 (GLP-1) receptor agonists have caused thyroid C-cell tumors in rodents at clinically relevant exposures.",THYROID C-CELL TUMORS is an adverse reaction entity
"BOXED WARNING: WARNING: RISK OF THYROID C-CELL TUMORS    WARNING: RISK OF THYROID C-CELL TUMORS      *  Carcinogenicity of albiglutide could not be assessed in rodents, but other glucagon-like peptide-1 (GLP-1) receptor agonists have caused thyroid C-cell tumors in rodents at clinically relevant exposures.",THYROID C-CELL TUMORS is an adverse reaction entity
"BOXED WARNING: WARNING: RISK OF THYROID C-CELL TUMORS    WARNING: RISK OF THYROID C-CELL TUMORS      *  Carcinogenicity of albiglutide could not be assessed in rodents, but other glucagon-like peptide-1 (GLP-1) receptor agonists have caused thyroid C-cell tumors in rodents at clinically relevant exposures.",: WARNING is not a named entity
"BOXED WARNING: WARNING: RISK OF THYROID C-CELL TUMORS    WARNING: RISK OF THYROID C-CELL TUMORS      *  Carcinogenicity of albiglutide could not be assessed in rodents, but other glucagon-like peptide-1 (GLP-1) receptor agonists have caused thyroid C-cell tumors in rodents at clinically relevant exposures.",in rodents is not a named entity
"Injection Site Reactions       In the pool of placebo-controlled trials, injection site reactions occurred more frequently on TANZEUM (18%) than on placebo (8%).",injection site reactions is an adverse reaction entity
"Injection Site Reactions       In the pool of placebo-controlled trials, injection site reactions occurred more frequently on TANZEUM (18%) than on placebo (8%).",% ) is not a named entity
"In a trial of TANZEUM in patients with renal impairment  [see Clinical Studies (14.3)]  , the frequency of such gastrointestinal reactions increased as renal function declined  [see Use in Specific Populations (8.6)]  .",trial of is not a named entity
"In a trial of TANZEUM in patients with renal impairment  [see Clinical Studies (14.3)]  , the frequency of such gastrointestinal reactions increased as renal function declined  [see Use in Specific Populations (8.6)]  .",renal function declined is an adverse reaction entity
"In a trial of TANZEUM in patients with renal impairment  [see Clinical Studies (14.3)]  , the frequency of such gastrointestinal reactions increased as renal function declined  [see Use in Specific Populations (8.6)]  .",Use in is not a named entity
"In a trial of TANZEUM in patients with renal impairment  [see Clinical Studies (14.3)]  , the frequency of such gastrointestinal reactions increased as renal function declined  [see Use in Specific Populations (8.6)]  .",gastrointestinal reactions is an adverse reaction entity
Table 1 shows common adverse reactions excluding hypoglycemia associated with the use of TANZEUM in the pool of placebo-controlled trials.,pool of is not a named entity
Table 1 shows common adverse reactions excluding hypoglycemia associated with the use of TANZEUM in the pool of placebo-controlled trials.,hypoglycemia is an adverse reaction entity
"Therefore, patients may require a lower dose of sulfonylurea or insulin to reduce the risk of hypoglycemia in this setting  [see Dosage and Administration (2.2), Adverse Reactions (6.1)]  .",hypoglycemia is an adverse reaction entity
"Therefore, patients may require a lower dose of sulfonylurea or insulin to reduce the risk of hypoglycemia in this setting  [see Dosage and Administration (2.2), Adverse Reactions (6.1)]  .",Therefore is not a named entity
Hypoglycemia was more frequent when TANZEUM was added to sulfonylurea or insulin  [see Warnings and Precautions (5.3)]  .,Hypoglycemia is an adverse reaction entity
Hypoglycemia was more frequent when TANZEUM was added to sulfonylurea or insulin  [see Warnings and Precautions (5.3)]  .,sulfonylurea or is not a named entity
"It is unknown whether TANZEUM causes thyroid C-cell tumors, including MTC, in humans  [see Boxed Warning, Contraindications (4.1)]  .",", is not a named entity"
"It is unknown whether TANZEUM causes thyroid C-cell tumors, including MTC, in humans  [see Boxed Warning, Contraindications (4.1)]  .",MTC is an adverse reaction entity
"It is unknown whether TANZEUM causes thyroid C-cell tumors, including MTC, in humans  [see Boxed Warning, Contraindications (4.1)]  .",Warning is not a named entity
"It is unknown whether TANZEUM causes thyroid C-cell tumors, including MTC, in humans  [see Boxed Warning, Contraindications (4.1)]  .",thyroid C-cell tumors is an adverse reaction entity
Three subjects on TANZEUM and one subject in the all-comparator group experienced at least one event of ALT increase of 10-fold or greater above the upper limit of normal  .,ALT increase is an adverse reaction entity
Three subjects on TANZEUM and one subject in the all-comparator group experienced at least one event of ALT increase of 10-fold or greater above the upper limit of normal  .,above is not a named entity
Human relevance of GLP-1 receptor agonist induced C-cell tumors in rodents has not been determined.,in is not a named entity
Human relevance of GLP-1 receptor agonist induced C-cell tumors in rodents has not been determined.,C-cell tumors is an adverse reaction entity
"In clinical trials with Vimizim, 44 of 235 (18.7%) patients experienced hypersensitivity reactions, including anaphylaxis.",% ) is not a named entity
"In clinical trials with Vimizim, 44 of 235 (18.7%) patients experienced hypersensitivity reactions, including anaphylaxis.",hypersensitivity is an adverse reaction entity
"In clinical trials with Vimizim, 44 of 235 (18.7%) patients experienced hypersensitivity reactions, including anaphylaxis.",anaphylaxis is an adverse reaction entity
"In clinical trials with Vimizim, 44 of 235 (18.7%) patients experienced hypersensitivity reactions, including anaphylaxis.",( 18.7 % is not a named entity
Anaphylaxis and Hypersensitivity Reactions: Life-threatening anaphylaxis and hypersensitivity reactions have been observed in some patients during treatment with Vimizim.,Anaphylaxis is an adverse reaction entity
Anaphylaxis and Hypersensitivity Reactions: Life-threatening anaphylaxis and hypersensitivity reactions have been observed in some patients during treatment with Vimizim.,anaphylaxis is an adverse reaction entity
Anaphylaxis and Hypersensitivity Reactions: Life-threatening anaphylaxis and hypersensitivity reactions have been observed in some patients during treatment with Vimizim.,Life-threatening is not a named entity
Anaphylaxis and Hypersensitivity Reactions: Life-threatening anaphylaxis and hypersensitivity reactions have been observed in some patients during treatment with Vimizim.,Hypersensitivity Reactions is an adverse reaction entity
Anaphylaxis and Hypersensitivity Reactions: Life-threatening anaphylaxis and hypersensitivity reactions have been observed in some patients during treatment with Vimizim.,and Hypersensitivity Reactions is not a named entity
Anaphylaxis and Hypersensitivity Reactions: Life-threatening anaphylaxis and hypersensitivity reactions have been observed in some patients during treatment with Vimizim.,Anaphylaxis and Hypersensitivity is not a named entity
Anaphylaxis and Hypersensitivity Reactions: Life-threatening anaphylaxis and hypersensitivity reactions have been observed in some patients during treatment with Vimizim.,: Life-threatening is not a named entity
Anaphylaxis and Hypersensitivity Reactions: Life-threatening anaphylaxis and hypersensitivity reactions have been observed in some patients during treatment with Vimizim.,hypersensitivity is an adverse reaction entity
Life-threatening anaphylactic reactions have occurred in some patients during Vimizim infusions.,in is not a named entity
Life-threatening anaphylactic reactions have occurred in some patients during Vimizim infusions.,anaphylactic reactions is an adverse reaction entity
"These 18 patients experienced 26 anaphylactic reactions during infusion with signs and symptoms including cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria.",rash is an adverse reaction entity
"These 18 patients experienced 26 anaphylactic reactions during infusion with signs and symptoms including cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria.",and gastrointestinal is not a named entity
"These 18 patients experienced 26 anaphylactic reactions during infusion with signs and symptoms including cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria.",in conjunction is not a named entity
"These 18 patients experienced 26 anaphylactic reactions during infusion with signs and symptoms including cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria.",gastrointestinal symptoms is an adverse reaction entity
"These 18 patients experienced 26 anaphylactic reactions during infusion with signs and symptoms including cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria.",", and gastrointestinal is not a named entity"
"These 18 patients experienced 26 anaphylactic reactions during infusion with signs and symptoms including cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria.",abdominal pain is an adverse reaction entity
"These 18 patients experienced 26 anaphylactic reactions during infusion with signs and symptoms including cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria.",", flushing is not a named entity"
"These 18 patients experienced 26 anaphylactic reactions during infusion with signs and symptoms including cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria.",with urticaria is not a named entity
"These 18 patients experienced 26 anaphylactic reactions during infusion with signs and symptoms including cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria.","tightness , is not a named entity"
"These 18 patients experienced 26 anaphylactic reactions during infusion with signs and symptoms including cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria.",flushing is an adverse reaction entity
"These 18 patients experienced 26 anaphylactic reactions during infusion with signs and symptoms including cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria.",", is not a named entity"
"These 18 patients experienced 26 anaphylactic reactions during infusion with signs and symptoms including cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria.",dyspnea is an adverse reaction entity
"These 18 patients experienced 26 anaphylactic reactions during infusion with signs and symptoms including cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria.",( is not a named entity
"These 18 patients experienced 26 anaphylactic reactions during infusion with signs and symptoms including cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria.",retching is an adverse reaction entity
"These 18 patients experienced 26 anaphylactic reactions during infusion with signs and symptoms including cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria.",urticaria is an adverse reaction entity
"These 18 patients experienced 26 anaphylactic reactions during infusion with signs and symptoms including cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria.",", rash is not a named entity"
"These 18 patients experienced 26 anaphylactic reactions during infusion with signs and symptoms including cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria.",cough is an adverse reaction entity
"These 18 patients experienced 26 anaphylactic reactions during infusion with signs and symptoms including cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria.","pain , retching is not a named entity"
"These 18 patients experienced 26 anaphylactic reactions during infusion with signs and symptoms including cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria.",and is not a named entity
"These 18 patients experienced 26 anaphylactic reactions during infusion with signs and symptoms including cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria.","cyanosis , hypotension is not a named entity"
"These 18 patients experienced 26 anaphylactic reactions during infusion with signs and symptoms including cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria.","dyspnea , chest is not a named entity"
"These 18 patients experienced 26 anaphylactic reactions during infusion with signs and symptoms including cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria.",urticaria is an adverse reaction entity
"These 18 patients experienced 26 anaphylactic reactions during infusion with signs and symptoms including cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria.",", throat tightness is not a named entity"
"These 18 patients experienced 26 anaphylactic reactions during infusion with signs and symptoms including cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria.",nausea is an adverse reaction entity
"These 18 patients experienced 26 anaphylactic reactions during infusion with signs and symptoms including cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria.","including cough , is not a named entity"
"These 18 patients experienced 26 anaphylactic reactions during infusion with signs and symptoms including cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria.",cyanosis is an adverse reaction entity
"These 18 patients experienced 26 anaphylactic reactions during infusion with signs and symptoms including cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria.",hypotension is an adverse reaction entity
"These 18 patients experienced 26 anaphylactic reactions during infusion with signs and symptoms including cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria.",chest discomfort is an adverse reaction entity
"These 18 patients experienced 26 anaphylactic reactions during infusion with signs and symptoms including cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria.",", dyspnea , is not a named entity"
"These 18 patients experienced 26 anaphylactic reactions during infusion with signs and symptoms including cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria.",", cyanosis , is not a named entity"
"These 18 patients experienced 26 anaphylactic reactions during infusion with signs and symptoms including cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria.",anaphylactic reactions is an adverse reaction entity
"These 18 patients experienced 26 anaphylactic reactions during infusion with signs and symptoms including cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria.",vomiting is an adverse reaction entity
"These 18 patients experienced 26 anaphylactic reactions during infusion with signs and symptoms including cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria.",erythema is an adverse reaction entity
"These 18 patients experienced 26 anaphylactic reactions during infusion with signs and symptoms including cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria.",throat tightness is an adverse reaction entity
BOXED WARNING: WARNING: RISK OF ANAPHYLAXIS      WARNING: RISK OF ANAPHYLAXIS        Life-threatening anaphylactic reactions have occurred in some patients during Vimizim infusions.,ANAPHYLAXIS is an adverse reaction entity
BOXED WARNING: WARNING: RISK OF ANAPHYLAXIS      WARNING: RISK OF ANAPHYLAXIS        Life-threatening anaphylactic reactions have occurred in some patients during Vimizim infusions.,anaphylactic reactions is an adverse reaction entity
BOXED WARNING: WARNING: RISK OF ANAPHYLAXIS      WARNING: RISK OF ANAPHYLAXIS        Life-threatening anaphylactic reactions have occurred in some patients during Vimizim infusions.,have occurred in is not a named entity
BOXED WARNING: WARNING: RISK OF ANAPHYLAXIS      WARNING: RISK OF ANAPHYLAXIS        Life-threatening anaphylactic reactions have occurred in some patients during Vimizim infusions.,ANAPHYLAXIS is an adverse reaction entity
BOXED WARNING: WARNING: RISK OF ANAPHYLAXIS      WARNING: RISK OF ANAPHYLAXIS        Life-threatening anaphylactic reactions have occurred in some patients during Vimizim infusions.,occurred in some is not a named entity
BOXED WARNING: WARNING: RISK OF ANAPHYLAXIS      WARNING: RISK OF ANAPHYLAXIS        Life-threatening anaphylactic reactions have occurred in some patients during Vimizim infusions.,ANAPHYLAXIS Life-threatening anaphylactic is not a named entity
5.2 Risk of Acute Respiratory Complications      Patients with acute febrile or respiratory illness at the time of Vimizim infusion may be at higher risk of life-threatening complications from hypersensitivity reactions.,from is not a named entity
5.2 Risk of Acute Respiratory Complications      Patients with acute febrile or respiratory illness at the time of Vimizim infusion may be at higher risk of life-threatening complications from hypersensitivity reactions.,hypersensitivity reactions is an adverse reaction entity
"Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms in conjunction with urticaria, have been reported to occur during infusions, regardless of duration of the course of treatment.","erythema , throat is not a named entity"
"Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms in conjunction with urticaria, have been reported to occur during infusions, regardless of duration of the course of treatment.","hypotension , rash is not a named entity"
"Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms in conjunction with urticaria, have been reported to occur during infusions, regardless of duration of the course of treatment.",", flushing , is not a named entity"
"Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms in conjunction with urticaria, have been reported to occur during infusions, regardless of duration of the course of treatment.","hypotension , rash is not a named entity"
"Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms in conjunction with urticaria, have been reported to occur during infusions, regardless of duration of the course of treatment.","throat tightness , is not a named entity"
"Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms in conjunction with urticaria, have been reported to occur during infusions, regardless of duration of the course of treatment.",presenting as cough is not a named entity
"Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms in conjunction with urticaria, have been reported to occur during infusions, regardless of duration of the course of treatment.",symptoms in is not a named entity
"Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms in conjunction with urticaria, have been reported to occur during infusions, regardless of duration of the course of treatment.",erythema is an adverse reaction entity
"Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms in conjunction with urticaria, have been reported to occur during infusions, regardless of duration of the course of treatment.",Anaphylaxis is an adverse reaction entity
"Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms in conjunction with urticaria, have been reported to occur during infusions, regardless of duration of the course of treatment.",hypotension is an adverse reaction entity
"Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms in conjunction with urticaria, have been reported to occur during infusions, regardless of duration of the course of treatment.",rash is an adverse reaction entity
"Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms in conjunction with urticaria, have been reported to occur during infusions, regardless of duration of the course of treatment.",urticaria is an adverse reaction entity
"Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms in conjunction with urticaria, have been reported to occur during infusions, regardless of duration of the course of treatment.",urticaria is an adverse reaction entity
"Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms in conjunction with urticaria, have been reported to occur during infusions, regardless of duration of the course of treatment.",", hypotension , is not a named entity"
"Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms in conjunction with urticaria, have been reported to occur during infusions, regardless of duration of the course of treatment.",cough is an adverse reaction entity
"Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms in conjunction with urticaria, have been reported to occur during infusions, regardless of duration of the course of treatment.",throat tightness is an adverse reaction entity
"Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms in conjunction with urticaria, have been reported to occur during infusions, regardless of duration of the course of treatment.",chest discomfort is an adverse reaction entity
"Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms in conjunction with urticaria, have been reported to occur during infusions, regardless of duration of the course of treatment.",", presenting is not a named entity"
"Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms in conjunction with urticaria, have been reported to occur during infusions, regardless of duration of the course of treatment.",symptoms is not a named entity
"Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms in conjunction with urticaria, have been reported to occur during infusions, regardless of duration of the course of treatment.",dyspnea is an adverse reaction entity
"Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms in conjunction with urticaria, have been reported to occur during infusions, regardless of duration of the course of treatment.",gastrointestinal symptoms is an adverse reaction entity
"Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms in conjunction with urticaria, have been reported to occur during infusions, regardless of duration of the course of treatment.",flushing is an adverse reaction entity
"Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms in conjunction with urticaria, have been reported to occur during infusions, regardless of duration of the course of treatment.",been reported is not a named entity
"Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms in conjunction with urticaria, have been reported to occur during infusions, regardless of duration of the course of treatment.",treatment is not a named entity
"Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms in conjunction with urticaria, have been reported to occur during infusions, regardless of duration of the course of treatment.",cyanosis is an adverse reaction entity
"Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms in conjunction with urticaria, have been reported to occur during infusions, regardless of duration of the course of treatment.",presenting as cough is not a named entity
EXCERPT:     WARNING: RISK OF ANAPHYLAXIS           See full prescribing information for complete boxed warning    .,information for complete is not a named entity
EXCERPT:     WARNING: RISK OF ANAPHYLAXIS           See full prescribing information for complete boxed warning    .,ANAPHYLAXIS is an adverse reaction entity
Hypersensitivity reactions have occurred as early as 30 minutes from the start of infusion but as late as six days after infusion.,Hypersensitivity is an adverse reaction entity
Hypersensitivity reactions have occurred as early as 30 minutes from the start of infusion but as late as six days after infusion.,infusion is not a named entity
Risk of Acute Respiratory Complications: Patients with acute febrile or respiratory illness may be at higher risk of life-threatening complications from hypersensitivity reactions.,hypersensitivity reactions is an adverse reaction entity
Risk of Acute Respiratory Complications: Patients with acute febrile or respiratory illness may be at higher risk of life-threatening complications from hypersensitivity reactions.,Acute Respiratory Complications is an adverse reaction entity
Risk of Acute Respiratory Complications: Patients with acute febrile or respiratory illness may be at higher risk of life-threatening complications from hypersensitivity reactions.,life-threatening is not a named entity
Risk of Acute Respiratory Complications: Patients with acute febrile or respiratory illness may be at higher risk of life-threatening complications from hypersensitivity reactions.,risk of life-threatening is not a named entity
"Frequent symptoms of hypersensitivity reactions (occurring in more than 2 patients) included anaphylactic reactions, urticaria, peripheral edema, cough, dyspnea, and flushing.",peripheral edema is an adverse reaction entity
"Frequent symptoms of hypersensitivity reactions (occurring in more than 2 patients) included anaphylactic reactions, urticaria, peripheral edema, cough, dyspnea, and flushing.",dyspnea is an adverse reaction entity
"Frequent symptoms of hypersensitivity reactions (occurring in more than 2 patients) included anaphylactic reactions, urticaria, peripheral edema, cough, dyspnea, and flushing.",in more than is not a named entity
"Frequent symptoms of hypersensitivity reactions (occurring in more than 2 patients) included anaphylactic reactions, urticaria, peripheral edema, cough, dyspnea, and flushing.",) included anaphylactic is not a named entity
"Frequent symptoms of hypersensitivity reactions (occurring in more than 2 patients) included anaphylactic reactions, urticaria, peripheral edema, cough, dyspnea, and flushing.",hypersensitivity is an adverse reaction entity
"Frequent symptoms of hypersensitivity reactions (occurring in more than 2 patients) included anaphylactic reactions, urticaria, peripheral edema, cough, dyspnea, and flushing.",reactions is not a named entity
"Frequent symptoms of hypersensitivity reactions (occurring in more than 2 patients) included anaphylactic reactions, urticaria, peripheral edema, cough, dyspnea, and flushing.",flushing is an adverse reaction entity
"Frequent symptoms of hypersensitivity reactions (occurring in more than 2 patients) included anaphylactic reactions, urticaria, peripheral edema, cough, dyspnea, and flushing.",occurring in is not a named entity
"Frequent symptoms of hypersensitivity reactions (occurring in more than 2 patients) included anaphylactic reactions, urticaria, peripheral edema, cough, dyspnea, and flushing.","dyspnea , is not a named entity"
"Frequent symptoms of hypersensitivity reactions (occurring in more than 2 patients) included anaphylactic reactions, urticaria, peripheral edema, cough, dyspnea, and flushing.","peripheral edema , is not a named entity"
"Frequent symptoms of hypersensitivity reactions (occurring in more than 2 patients) included anaphylactic reactions, urticaria, peripheral edema, cough, dyspnea, and flushing.",urticaria is an adverse reaction entity
"Frequent symptoms of hypersensitivity reactions (occurring in more than 2 patients) included anaphylactic reactions, urticaria, peripheral edema, cough, dyspnea, and flushing.",cough is an adverse reaction entity
"Frequent symptoms of hypersensitivity reactions (occurring in more than 2 patients) included anaphylactic reactions, urticaria, peripheral edema, cough, dyspnea, and flushing.","reactions , is not a named entity"
"Frequent symptoms of hypersensitivity reactions (occurring in more than 2 patients) included anaphylactic reactions, urticaria, peripheral edema, cough, dyspnea, and flushing.",anaphylactic reactions is an adverse reaction entity
"6     ADVERSE REACTIONS      EXCERPT:   The most common adverse reactions in adults (>30%) are headache, anorexia, dizziness, asthenia, arthralgia and myalgia.",) are is not a named entity
"6     ADVERSE REACTIONS      EXCERPT:   The most common adverse reactions in adults (>30%) are headache, anorexia, dizziness, asthenia, arthralgia and myalgia.",adverse reactions in is not a named entity
"6     ADVERSE REACTIONS      EXCERPT:   The most common adverse reactions in adults (>30%) are headache, anorexia, dizziness, asthenia, arthralgia and myalgia.",30 % is not a named entity
"6     ADVERSE REACTIONS      EXCERPT:   The most common adverse reactions in adults (>30%) are headache, anorexia, dizziness, asthenia, arthralgia and myalgia.",arthralgia is an adverse reaction entity
"6     ADVERSE REACTIONS      EXCERPT:   The most common adverse reactions in adults (>30%) are headache, anorexia, dizziness, asthenia, arthralgia and myalgia.",REACTIONS is not a named entity
"6     ADVERSE REACTIONS      EXCERPT:   The most common adverse reactions in adults (>30%) are headache, anorexia, dizziness, asthenia, arthralgia and myalgia.",anorexia is an adverse reaction entity
"6     ADVERSE REACTIONS      EXCERPT:   The most common adverse reactions in adults (>30%) are headache, anorexia, dizziness, asthenia, arthralgia and myalgia.","headache , is not a named entity"
"6     ADVERSE REACTIONS      EXCERPT:   The most common adverse reactions in adults (>30%) are headache, anorexia, dizziness, asthenia, arthralgia and myalgia.",headache is an adverse reaction entity
"6     ADVERSE REACTIONS      EXCERPT:   The most common adverse reactions in adults (>30%) are headache, anorexia, dizziness, asthenia, arthralgia and myalgia.",myalgia is an adverse reaction entity
"6     ADVERSE REACTIONS      EXCERPT:   The most common adverse reactions in adults (>30%) are headache, anorexia, dizziness, asthenia, arthralgia and myalgia.",EXCERPT : The is not a named entity
"6     ADVERSE REACTIONS      EXCERPT:   The most common adverse reactions in adults (>30%) are headache, anorexia, dizziness, asthenia, arthralgia and myalgia.",asthenia is an adverse reaction entity
"6     ADVERSE REACTIONS      EXCERPT:   The most common adverse reactions in adults (>30%) are headache, anorexia, dizziness, asthenia, arthralgia and myalgia.",dizziness is an adverse reaction entity
"The most common adverse reactions in children (>12%) are pyrexia, cough, vomiting, anorexia, and headache.",", and is not a named entity"
"The most common adverse reactions in children (>12%) are pyrexia, cough, vomiting, anorexia, and headache.",( > is not a named entity
"The most common adverse reactions in children (>12%) are pyrexia, cough, vomiting, anorexia, and headache.",reactions in is not a named entity
"The most common adverse reactions in children (>12%) are pyrexia, cough, vomiting, anorexia, and headache.",vomiting is an adverse reaction entity
"The most common adverse reactions in children (>12%) are pyrexia, cough, vomiting, anorexia, and headache.",anorexia is an adverse reaction entity
"The most common adverse reactions in children (>12%) are pyrexia, cough, vomiting, anorexia, and headache.",% ) are is not a named entity
"The most common adverse reactions in children (>12%) are pyrexia, cough, vomiting, anorexia, and headache.",pyrexia is an adverse reaction entity
"The most common adverse reactions in children (>12%) are pyrexia, cough, vomiting, anorexia, and headache.","anorexia , is not a named entity"
"The most common adverse reactions in children (>12%) are pyrexia, cough, vomiting, anorexia, and headache.",headache is an adverse reaction entity
"The most common adverse reactions in children (>12%) are pyrexia, cough, vomiting, anorexia, and headache.",cough is an adverse reaction entity
"In adults, the most frequently reported adverse reactions were headache, anorexia, dizziness, and asthenia.",reactions is not a named entity
"In adults, the most frequently reported adverse reactions were headache, anorexia, dizziness, and asthenia.",", the most is not a named entity"
"In adults, the most frequently reported adverse reactions were headache, anorexia, dizziness, and asthenia.",dizziness is an adverse reaction entity
"In adults, the most frequently reported adverse reactions were headache, anorexia, dizziness, and asthenia.",", is not a named entity"
"In adults, the most frequently reported adverse reactions were headache, anorexia, dizziness, and asthenia.",asthenia is an adverse reaction entity
"In adults, the most frequently reported adverse reactions were headache, anorexia, dizziness, and asthenia.",anorexia is an adverse reaction entity
"In adults, the most frequently reported adverse reactions were headache, anorexia, dizziness, and asthenia.",headache is an adverse reaction entity
"In adults, the most frequently reported adverse reactions were headache, anorexia, dizziness, and asthenia.",", anorexia , is not a named entity"
"(6.2)       To report SUSPECTED ADVERSE REACTIONS, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch           6.1     Serious Adverse Reactions    The following serious and otherwise important adverse reactions are discussed in greater detail in other sections of labeling:     *  Hypersensitivity Reactions [see Contraindications (4) and Adverse Reactions (6.3)] .",) To report is not a named entity
"(6.2)       To report SUSPECTED ADVERSE REACTIONS, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch           6.1     Serious Adverse Reactions    The following serious and otherwise important adverse reactions are discussed in greater detail in other sections of labeling:     *  Hypersensitivity Reactions [see Contraindications (4) and Adverse Reactions (6.3)] .",Hypersensitivity Reactions is an adverse reaction entity
"*  Hypersensitivity reactions: anaphylaxis, urticaria, angioedema, and serious skin reactions (bullous eruption) have been reported.",angioedema is an adverse reaction entity
"*  Hypersensitivity reactions: anaphylaxis, urticaria, angioedema, and serious skin reactions (bullous eruption) have been reported.",anaphylaxis is an adverse reaction entity
"*  Hypersensitivity reactions: anaphylaxis, urticaria, angioedema, and serious skin reactions (bullous eruption) have been reported.",", angioedema is not a named entity"
"*  Hypersensitivity reactions: anaphylaxis, urticaria, angioedema, and serious skin reactions (bullous eruption) have been reported.",reactions ( is not a named entity
"*  Hypersensitivity reactions: anaphylaxis, urticaria, angioedema, and serious skin reactions (bullous eruption) have been reported.",bullous eruption is an adverse reaction entity
"*  Hypersensitivity reactions: anaphylaxis, urticaria, angioedema, and serious skin reactions (bullous eruption) have been reported.",urticaria is an adverse reaction entity
"*  Hypersensitivity reactions: anaphylaxis, urticaria, angioedema, and serious skin reactions (bullous eruption) have been reported.",": anaphylaxis , is not a named entity"
"*  Hypersensitivity reactions: anaphylaxis, urticaria, angioedema, and serious skin reactions (bullous eruption) have been reported.",skin reactions is an adverse reaction entity
"*  Hypersensitivity reactions: anaphylaxis, urticaria, angioedema, and serious skin reactions (bullous eruption) have been reported.",( bullous is not a named entity
"*  Hypersensitivity reactions: anaphylaxis, urticaria, angioedema, and serious skin reactions (bullous eruption) have been reported.",and is not a named entity
"In some patients infected with HBV and treated with EMTRIVA, the exacerbations of hepatitis B were associated with liver decompensation and liver failure.",and is not a named entity
"In some patients infected with HBV and treated with EMTRIVA, the exacerbations of hepatitis B were associated with liver decompensation and liver failure.",liver decompensation is an adverse reaction entity
"In some patients infected with HBV and treated with EMTRIVA, the exacerbations of hepatitis B were associated with liver decompensation and liver failure.",exacerbations of hepatitis B is an adverse reaction entity
"In some patients infected with HBV and treated with EMTRIVA, the exacerbations of hepatitis B were associated with liver decompensation and liver failure.",associated with liver is not a named entity
"In some patients infected with HBV and treated with EMTRIVA, the exacerbations of hepatitis B were associated with liver decompensation and liver failure.",liver failure is an adverse reaction entity
"In some patients infected with HBV and treated with EMTRIVA, the exacerbations of hepatitis B were associated with liver decompensation and liver failure.",with is not a named entity
(  5.7  )   *  Immune reconstitution syndrome: May necessitate further evaluation and treatment.,further is not a named entity
(  5.7  )   *  Immune reconstitution syndrome: May necessitate further evaluation and treatment.,Immune reconstitution syndrome is an adverse reaction entity
"5.7 Fat Redistribution      Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and ""cushingoid appearance"" have been observed in patients receiving antiretroviral therapy.",and `` cushingoid is not a named entity
"5.7 Fat Redistribution      Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and ""cushingoid appearance"" have been observed in patients receiving antiretroviral therapy.",facial wasting is an adverse reaction entity
"5.7 Fat Redistribution      Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and ""cushingoid appearance"" have been observed in patients receiving antiretroviral therapy.",breast enlargement is an adverse reaction entity
"5.7 Fat Redistribution      Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and ""cushingoid appearance"" have been observed in patients receiving antiretroviral therapy.",peripheral wasting is not a named entity
"5.7 Fat Redistribution      Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and ""cushingoid appearance"" have been observed in patients receiving antiretroviral therapy.",body fat peripheral wasting is an adverse reaction entity
"5.7 Fat Redistribution      Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and ""cushingoid appearance"" have been observed in patients receiving antiretroviral therapy.",") , peripheral is not a named entity"
"5.7 Fat Redistribution      Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and ""cushingoid appearance"" have been observed in patients receiving antiretroviral therapy.","wasting , is not a named entity"
"5.7 Fat Redistribution      Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and ""cushingoid appearance"" have been observed in patients receiving antiretroviral therapy.",dorsocervical fat enlargement is an adverse reaction entity
"5.7 Fat Redistribution      Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and ""cushingoid appearance"" have been observed in patients receiving antiretroviral therapy.",central obesity is an adverse reaction entity
"5.7 Fat Redistribution      Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and ""cushingoid appearance"" have been observed in patients receiving antiretroviral therapy.",", is not a named entity"
"5.7 Fat Redistribution      Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and ""cushingoid appearance"" have been observed in patients receiving antiretroviral therapy.",cushingoid appearance is an adverse reaction entity
"5.7 Fat Redistribution      Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and ""cushingoid appearance"" have been observed in patients receiving antiretroviral therapy.",", facial wasting is not a named entity"
"5.7 Fat Redistribution      Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and ""cushingoid appearance"" have been observed in patients receiving antiretroviral therapy.",body fat is not a named entity
"5.7 Fat Redistribution      Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and ""cushingoid appearance"" have been observed in patients receiving antiretroviral therapy.",buffalo hump is an adverse reaction entity
"5.7 Fat Redistribution      Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and ""cushingoid appearance"" have been observed in patients receiving antiretroviral therapy.",patients receiving antiretroviral is not a named entity
"5.7 Fat Redistribution      Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and ""cushingoid appearance"" have been observed in patients receiving antiretroviral therapy.",obesity is not a named entity
"5.7 Fat Redistribution      Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and ""cushingoid appearance"" have been observed in patients receiving antiretroviral therapy.",accumulation of body fat is an adverse reaction entity
"5.7 Fat Redistribution      Redistribution/accumulation of body fat including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and ""cushingoid appearance"" have been observed in patients receiving antiretroviral therapy.",Redistribution of body fat is an adverse reaction entity
"5.3 New Onset or Worsening Renal Impairment      Renal impairment, including cases of acute renal failure and Fanconi syndrome (renal tubular injury with severe hypophosphatemia), has been reported with the use of tenofovir DF, a component of STRIBILD, and with the use of STRIBILD [see  Adverse Reactions (6.2)  ]  .","impairment , is not a named entity"
"5.3 New Onset or Worsening Renal Impairment      Renal impairment, including cases of acute renal failure and Fanconi syndrome (renal tubular injury with severe hypophosphatemia), has been reported with the use of tenofovir DF, a component of STRIBILD, and with the use of STRIBILD [see  Adverse Reactions (6.2)  ]  .",acute renal failure is an adverse reaction entity
"5.3 New Onset or Worsening Renal Impairment      Renal impairment, including cases of acute renal failure and Fanconi syndrome (renal tubular injury with severe hypophosphatemia), has been reported with the use of tenofovir DF, a component of STRIBILD, and with the use of STRIBILD [see  Adverse Reactions (6.2)  ]  .",6.2 ) is not a named entity
"5.3 New Onset or Worsening Renal Impairment      Renal impairment, including cases of acute renal failure and Fanconi syndrome (renal tubular injury with severe hypophosphatemia), has been reported with the use of tenofovir DF, a component of STRIBILD, and with the use of STRIBILD [see  Adverse Reactions (6.2)  ]  .",[ see is not a named entity
"5.3 New Onset or Worsening Renal Impairment      Renal impairment, including cases of acute renal failure and Fanconi syndrome (renal tubular injury with severe hypophosphatemia), has been reported with the use of tenofovir DF, a component of STRIBILD, and with the use of STRIBILD [see  Adverse Reactions (6.2)  ]  .",Renal impairment is an adverse reaction entity
"5.3 New Onset or Worsening Renal Impairment      Renal impairment, including cases of acute renal failure and Fanconi syndrome (renal tubular injury with severe hypophosphatemia), has been reported with the use of tenofovir DF, a component of STRIBILD, and with the use of STRIBILD [see  Adverse Reactions (6.2)  ]  .",and with is not a named entity
"5.3 New Onset or Worsening Renal Impairment      Renal impairment, including cases of acute renal failure and Fanconi syndrome (renal tubular injury with severe hypophosphatemia), has been reported with the use of tenofovir DF, a component of STRIBILD, and with the use of STRIBILD [see  Adverse Reactions (6.2)  ]  .",renal tubular injury is an adverse reaction entity
"5.3 New Onset or Worsening Renal Impairment      Renal impairment, including cases of acute renal failure and Fanconi syndrome (renal tubular injury with severe hypophosphatemia), has been reported with the use of tenofovir DF, a component of STRIBILD, and with the use of STRIBILD [see  Adverse Reactions (6.2)  ]  .",hypophosphatemia is an adverse reaction entity
"5.3 New Onset or Worsening Renal Impairment      Renal impairment, including cases of acute renal failure and Fanconi syndrome (renal tubular injury with severe hypophosphatemia), has been reported with the use of tenofovir DF, a component of STRIBILD, and with the use of STRIBILD [see  Adverse Reactions (6.2)  ]  .",Fanconi syndrome is an adverse reaction entity
"5.3 New Onset or Worsening Renal Impairment      Renal impairment, including cases of acute renal failure and Fanconi syndrome (renal tubular injury with severe hypophosphatemia), has been reported with the use of tenofovir DF, a component of STRIBILD, and with the use of STRIBILD [see  Adverse Reactions (6.2)  ]  .","Renal impairment , is not a named entity"
"Adverse Reactions from Clinical Trials of the Components of STRIBILD           Emtricitabine and Tenofovir Disoproxil Fumarate:  In addition to the adverse reactions observed with STRIBILD, the following adverse reactions occurred in at least 5% of treatment-experienced or treatment-naive subjects receiving emtricitabine or tenofovir DF with other antiretroviral agents in other clinical trials: depression, abdominal pain, dyspepsia, vomiting, fever, pain, nasopharyngitis, pneumonia, sinusitis, upper respiratory tract infection, arthralgia, back pain, myalgia, paresthesia, peripheral neuropathy (including peripheral neuritis and neuropathy), anxiety, increased cough, and rhinitis.",5 % is not a named entity
"Adverse Reactions from Clinical Trials of the Components of STRIBILD           Emtricitabine and Tenofovir Disoproxil Fumarate:  In addition to the adverse reactions observed with STRIBILD, the following adverse reactions occurred in at least 5% of treatment-experienced or treatment-naive subjects receiving emtricitabine or tenofovir DF with other antiretroviral agents in other clinical trials: depression, abdominal pain, dyspepsia, vomiting, fever, pain, nasopharyngitis, pneumonia, sinusitis, upper respiratory tract infection, arthralgia, back pain, myalgia, paresthesia, peripheral neuropathy (including peripheral neuritis and neuropathy), anxiety, increased cough, and rhinitis.",or treatment-naive is not a named entity
"Adverse Reactions from Clinical Trials of the Components of STRIBILD           Emtricitabine and Tenofovir Disoproxil Fumarate:  In addition to the adverse reactions observed with STRIBILD, the following adverse reactions occurred in at least 5% of treatment-experienced or treatment-naive subjects receiving emtricitabine or tenofovir DF with other antiretroviral agents in other clinical trials: depression, abdominal pain, dyspepsia, vomiting, fever, pain, nasopharyngitis, pneumonia, sinusitis, upper respiratory tract infection, arthralgia, back pain, myalgia, paresthesia, peripheral neuropathy (including peripheral neuritis and neuropathy), anxiety, increased cough, and rhinitis.",: is not a named entity
"Adverse Reactions from Clinical Trials of the Components of STRIBILD           Emtricitabine and Tenofovir Disoproxil Fumarate:  In addition to the adverse reactions observed with STRIBILD, the following adverse reactions occurred in at least 5% of treatment-experienced or treatment-naive subjects receiving emtricitabine or tenofovir DF with other antiretroviral agents in other clinical trials: depression, abdominal pain, dyspepsia, vomiting, fever, pain, nasopharyngitis, pneumonia, sinusitis, upper respiratory tract infection, arthralgia, back pain, myalgia, paresthesia, peripheral neuropathy (including peripheral neuritis and neuropathy), anxiety, increased cough, and rhinitis.",", is not a named entity"
"Adverse Reactions from Clinical Trials of the Components of STRIBILD           Emtricitabine and Tenofovir Disoproxil Fumarate:  In addition to the adverse reactions observed with STRIBILD, the following adverse reactions occurred in at least 5% of treatment-experienced or treatment-naive subjects receiving emtricitabine or tenofovir DF with other antiretroviral agents in other clinical trials: depression, abdominal pain, dyspepsia, vomiting, fever, pain, nasopharyngitis, pneumonia, sinusitis, upper respiratory tract infection, arthralgia, back pain, myalgia, paresthesia, peripheral neuropathy (including peripheral neuritis and neuropathy), anxiety, increased cough, and rhinitis.",increased cough is an adverse reaction entity
"Adverse Reactions from Clinical Trials of the Components of STRIBILD           Emtricitabine and Tenofovir Disoproxil Fumarate:  In addition to the adverse reactions observed with STRIBILD, the following adverse reactions occurred in at least 5% of treatment-experienced or treatment-naive subjects receiving emtricitabine or tenofovir DF with other antiretroviral agents in other clinical trials: depression, abdominal pain, dyspepsia, vomiting, fever, pain, nasopharyngitis, pneumonia, sinusitis, upper respiratory tract infection, arthralgia, back pain, myalgia, paresthesia, peripheral neuropathy (including peripheral neuritis and neuropathy), anxiety, increased cough, and rhinitis.",myalgia is an adverse reaction entity
"Adverse Reactions from Clinical Trials of the Components of STRIBILD           Emtricitabine and Tenofovir Disoproxil Fumarate:  In addition to the adverse reactions observed with STRIBILD, the following adverse reactions occurred in at least 5% of treatment-experienced or treatment-naive subjects receiving emtricitabine or tenofovir DF with other antiretroviral agents in other clinical trials: depression, abdominal pain, dyspepsia, vomiting, fever, pain, nasopharyngitis, pneumonia, sinusitis, upper respiratory tract infection, arthralgia, back pain, myalgia, paresthesia, peripheral neuropathy (including peripheral neuritis and neuropathy), anxiety, increased cough, and rhinitis.",at least 5 is not a named entity
"Adverse Reactions from Clinical Trials of the Components of STRIBILD           Emtricitabine and Tenofovir Disoproxil Fumarate:  In addition to the adverse reactions observed with STRIBILD, the following adverse reactions occurred in at least 5% of treatment-experienced or treatment-naive subjects receiving emtricitabine or tenofovir DF with other antiretroviral agents in other clinical trials: depression, abdominal pain, dyspepsia, vomiting, fever, pain, nasopharyngitis, pneumonia, sinusitis, upper respiratory tract infection, arthralgia, back pain, myalgia, paresthesia, peripheral neuropathy (including peripheral neuritis and neuropathy), anxiety, increased cough, and rhinitis.",peripheral neuropathy is an adverse reaction entity
"Adverse Reactions from Clinical Trials of the Components of STRIBILD           Emtricitabine and Tenofovir Disoproxil Fumarate:  In addition to the adverse reactions observed with STRIBILD, the following adverse reactions occurred in at least 5% of treatment-experienced or treatment-naive subjects receiving emtricitabine or tenofovir DF with other antiretroviral agents in other clinical trials: depression, abdominal pain, dyspepsia, vomiting, fever, pain, nasopharyngitis, pneumonia, sinusitis, upper respiratory tract infection, arthralgia, back pain, myalgia, paresthesia, peripheral neuropathy (including peripheral neuritis and neuropathy), anxiety, increased cough, and rhinitis.",dyspepsia is an adverse reaction entity
"Adverse Reactions from Clinical Trials of the Components of STRIBILD           Emtricitabine and Tenofovir Disoproxil Fumarate:  In addition to the adverse reactions observed with STRIBILD, the following adverse reactions occurred in at least 5% of treatment-experienced or treatment-naive subjects receiving emtricitabine or tenofovir DF with other antiretroviral agents in other clinical trials: depression, abdominal pain, dyspepsia, vomiting, fever, pain, nasopharyngitis, pneumonia, sinusitis, upper respiratory tract infection, arthralgia, back pain, myalgia, paresthesia, peripheral neuropathy (including peripheral neuritis and neuropathy), anxiety, increased cough, and rhinitis.",peripheral neuritis is an adverse reaction entity
"Adverse Reactions from Clinical Trials of the Components of STRIBILD           Emtricitabine and Tenofovir Disoproxil Fumarate:  In addition to the adverse reactions observed with STRIBILD, the following adverse reactions occurred in at least 5% of treatment-experienced or treatment-naive subjects receiving emtricitabine or tenofovir DF with other antiretroviral agents in other clinical trials: depression, abdominal pain, dyspepsia, vomiting, fever, pain, nasopharyngitis, pneumonia, sinusitis, upper respiratory tract infection, arthralgia, back pain, myalgia, paresthesia, peripheral neuropathy (including peripheral neuritis and neuropathy), anxiety, increased cough, and rhinitis.",treatment-naive is not a named entity
"Adverse Reactions from Clinical Trials of the Components of STRIBILD           Emtricitabine and Tenofovir Disoproxil Fumarate:  In addition to the adverse reactions observed with STRIBILD, the following adverse reactions occurred in at least 5% of treatment-experienced or treatment-naive subjects receiving emtricitabine or tenofovir DF with other antiretroviral agents in other clinical trials: depression, abdominal pain, dyspepsia, vomiting, fever, pain, nasopharyngitis, pneumonia, sinusitis, upper respiratory tract infection, arthralgia, back pain, myalgia, paresthesia, peripheral neuropathy (including peripheral neuritis and neuropathy), anxiety, increased cough, and rhinitis.",Fumarate : In is not a named entity
"Adverse Reactions from Clinical Trials of the Components of STRIBILD           Emtricitabine and Tenofovir Disoproxil Fumarate:  In addition to the adverse reactions observed with STRIBILD, the following adverse reactions occurred in at least 5% of treatment-experienced or treatment-naive subjects receiving emtricitabine or tenofovir DF with other antiretroviral agents in other clinical trials: depression, abdominal pain, dyspepsia, vomiting, fever, pain, nasopharyngitis, pneumonia, sinusitis, upper respiratory tract infection, arthralgia, back pain, myalgia, paresthesia, peripheral neuropathy (including peripheral neuritis and neuropathy), anxiety, increased cough, and rhinitis.",": depression , is not a named entity"
"Adverse Reactions from Clinical Trials of the Components of STRIBILD           Emtricitabine and Tenofovir Disoproxil Fumarate:  In addition to the adverse reactions observed with STRIBILD, the following adverse reactions occurred in at least 5% of treatment-experienced or treatment-naive subjects receiving emtricitabine or tenofovir DF with other antiretroviral agents in other clinical trials: depression, abdominal pain, dyspepsia, vomiting, fever, pain, nasopharyngitis, pneumonia, sinusitis, upper respiratory tract infection, arthralgia, back pain, myalgia, paresthesia, peripheral neuropathy (including peripheral neuritis and neuropathy), anxiety, increased cough, and rhinitis.",depression is an adverse reaction entity
"Adverse Reactions from Clinical Trials of the Components of STRIBILD           Emtricitabine and Tenofovir Disoproxil Fumarate:  In addition to the adverse reactions observed with STRIBILD, the following adverse reactions occurred in at least 5% of treatment-experienced or treatment-naive subjects receiving emtricitabine or tenofovir DF with other antiretroviral agents in other clinical trials: depression, abdominal pain, dyspepsia, vomiting, fever, pain, nasopharyngitis, pneumonia, sinusitis, upper respiratory tract infection, arthralgia, back pain, myalgia, paresthesia, peripheral neuropathy (including peripheral neuritis and neuropathy), anxiety, increased cough, and rhinitis.",and rhinitis is not a named entity
"Adverse Reactions from Clinical Trials of the Components of STRIBILD           Emtricitabine and Tenofovir Disoproxil Fumarate:  In addition to the adverse reactions observed with STRIBILD, the following adverse reactions occurred in at least 5% of treatment-experienced or treatment-naive subjects receiving emtricitabine or tenofovir DF with other antiretroviral agents in other clinical trials: depression, abdominal pain, dyspepsia, vomiting, fever, pain, nasopharyngitis, pneumonia, sinusitis, upper respiratory tract infection, arthralgia, back pain, myalgia, paresthesia, peripheral neuropathy (including peripheral neuritis and neuropathy), anxiety, increased cough, and rhinitis.",emtricitabine is not a named entity
"Adverse Reactions from Clinical Trials of the Components of STRIBILD           Emtricitabine and Tenofovir Disoproxil Fumarate:  In addition to the adverse reactions observed with STRIBILD, the following adverse reactions occurred in at least 5% of treatment-experienced or treatment-naive subjects receiving emtricitabine or tenofovir DF with other antiretroviral agents in other clinical trials: depression, abdominal pain, dyspepsia, vomiting, fever, pain, nasopharyngitis, pneumonia, sinusitis, upper respiratory tract infection, arthralgia, back pain, myalgia, paresthesia, peripheral neuropathy (including peripheral neuritis and neuropathy), anxiety, increased cough, and rhinitis.",pain is an adverse reaction entity
"Adverse Reactions from Clinical Trials of the Components of STRIBILD           Emtricitabine and Tenofovir Disoproxil Fumarate:  In addition to the adverse reactions observed with STRIBILD, the following adverse reactions occurred in at least 5% of treatment-experienced or treatment-naive subjects receiving emtricitabine or tenofovir DF with other antiretroviral agents in other clinical trials: depression, abdominal pain, dyspepsia, vomiting, fever, pain, nasopharyngitis, pneumonia, sinusitis, upper respiratory tract infection, arthralgia, back pain, myalgia, paresthesia, peripheral neuropathy (including peripheral neuritis and neuropathy), anxiety, increased cough, and rhinitis.",abdominal pain is an adverse reaction entity
"Adverse Reactions from Clinical Trials of the Components of STRIBILD           Emtricitabine and Tenofovir Disoproxil Fumarate:  In addition to the adverse reactions observed with STRIBILD, the following adverse reactions occurred in at least 5% of treatment-experienced or treatment-naive subjects receiving emtricitabine or tenofovir DF with other antiretroviral agents in other clinical trials: depression, abdominal pain, dyspepsia, vomiting, fever, pain, nasopharyngitis, pneumonia, sinusitis, upper respiratory tract infection, arthralgia, back pain, myalgia, paresthesia, peripheral neuropathy (including peripheral neuritis and neuropathy), anxiety, increased cough, and rhinitis.",arthralgia is an adverse reaction entity
"Adverse Reactions from Clinical Trials of the Components of STRIBILD           Emtricitabine and Tenofovir Disoproxil Fumarate:  In addition to the adverse reactions observed with STRIBILD, the following adverse reactions occurred in at least 5% of treatment-experienced or treatment-naive subjects receiving emtricitabine or tenofovir DF with other antiretroviral agents in other clinical trials: depression, abdominal pain, dyspepsia, vomiting, fever, pain, nasopharyngitis, pneumonia, sinusitis, upper respiratory tract infection, arthralgia, back pain, myalgia, paresthesia, peripheral neuropathy (including peripheral neuritis and neuropathy), anxiety, increased cough, and rhinitis.",", is not a named entity"
"Adverse Reactions from Clinical Trials of the Components of STRIBILD           Emtricitabine and Tenofovir Disoproxil Fumarate:  In addition to the adverse reactions observed with STRIBILD, the following adverse reactions occurred in at least 5% of treatment-experienced or treatment-naive subjects receiving emtricitabine or tenofovir DF with other antiretroviral agents in other clinical trials: depression, abdominal pain, dyspepsia, vomiting, fever, pain, nasopharyngitis, pneumonia, sinusitis, upper respiratory tract infection, arthralgia, back pain, myalgia, paresthesia, peripheral neuropathy (including peripheral neuritis and neuropathy), anxiety, increased cough, and rhinitis.",peripheral neuropathy is an adverse reaction entity
"Adverse Reactions from Clinical Trials of the Components of STRIBILD           Emtricitabine and Tenofovir Disoproxil Fumarate:  In addition to the adverse reactions observed with STRIBILD, the following adverse reactions occurred in at least 5% of treatment-experienced or treatment-naive subjects receiving emtricitabine or tenofovir DF with other antiretroviral agents in other clinical trials: depression, abdominal pain, dyspepsia, vomiting, fever, pain, nasopharyngitis, pneumonia, sinusitis, upper respiratory tract infection, arthralgia, back pain, myalgia, paresthesia, peripheral neuropathy (including peripheral neuritis and neuropathy), anxiety, increased cough, and rhinitis.",Disoproxil is not a named entity
"Adverse Reactions from Clinical Trials of the Components of STRIBILD           Emtricitabine and Tenofovir Disoproxil Fumarate:  In addition to the adverse reactions observed with STRIBILD, the following adverse reactions occurred in at least 5% of treatment-experienced or treatment-naive subjects receiving emtricitabine or tenofovir DF with other antiretroviral agents in other clinical trials: depression, abdominal pain, dyspepsia, vomiting, fever, pain, nasopharyngitis, pneumonia, sinusitis, upper respiratory tract infection, arthralgia, back pain, myalgia, paresthesia, peripheral neuropathy (including peripheral neuritis and neuropathy), anxiety, increased cough, and rhinitis.",trials is not a named entity
"Adverse Reactions from Clinical Trials of the Components of STRIBILD           Emtricitabine and Tenofovir Disoproxil Fumarate:  In addition to the adverse reactions observed with STRIBILD, the following adverse reactions occurred in at least 5% of treatment-experienced or treatment-naive subjects receiving emtricitabine or tenofovir DF with other antiretroviral agents in other clinical trials: depression, abdominal pain, dyspepsia, vomiting, fever, pain, nasopharyngitis, pneumonia, sinusitis, upper respiratory tract infection, arthralgia, back pain, myalgia, paresthesia, peripheral neuropathy (including peripheral neuritis and neuropathy), anxiety, increased cough, and rhinitis.",clinical is not a named entity
"Adverse Reactions from Clinical Trials of the Components of STRIBILD           Emtricitabine and Tenofovir Disoproxil Fumarate:  In addition to the adverse reactions observed with STRIBILD, the following adverse reactions occurred in at least 5% of treatment-experienced or treatment-naive subjects receiving emtricitabine or tenofovir DF with other antiretroviral agents in other clinical trials: depression, abdominal pain, dyspepsia, vomiting, fever, pain, nasopharyngitis, pneumonia, sinusitis, upper respiratory tract infection, arthralgia, back pain, myalgia, paresthesia, peripheral neuropathy (including peripheral neuritis and neuropathy), anxiety, increased cough, and rhinitis.",nasopharyngitis is an adverse reaction entity
"Adverse Reactions from Clinical Trials of the Components of STRIBILD           Emtricitabine and Tenofovir Disoproxil Fumarate:  In addition to the adverse reactions observed with STRIBILD, the following adverse reactions occurred in at least 5% of treatment-experienced or treatment-naive subjects receiving emtricitabine or tenofovir DF with other antiretroviral agents in other clinical trials: depression, abdominal pain, dyspepsia, vomiting, fever, pain, nasopharyngitis, pneumonia, sinusitis, upper respiratory tract infection, arthralgia, back pain, myalgia, paresthesia, peripheral neuropathy (including peripheral neuritis and neuropathy), anxiety, increased cough, and rhinitis.","abdominal pain , is not a named entity"
"Adverse Reactions from Clinical Trials of the Components of STRIBILD           Emtricitabine and Tenofovir Disoproxil Fumarate:  In addition to the adverse reactions observed with STRIBILD, the following adverse reactions occurred in at least 5% of treatment-experienced or treatment-naive subjects receiving emtricitabine or tenofovir DF with other antiretroviral agents in other clinical trials: depression, abdominal pain, dyspepsia, vomiting, fever, pain, nasopharyngitis, pneumonia, sinusitis, upper respiratory tract infection, arthralgia, back pain, myalgia, paresthesia, peripheral neuropathy (including peripheral neuritis and neuropathy), anxiety, increased cough, and rhinitis.",and is not a named entity
"Adverse Reactions from Clinical Trials of the Components of STRIBILD           Emtricitabine and Tenofovir Disoproxil Fumarate:  In addition to the adverse reactions observed with STRIBILD, the following adverse reactions occurred in at least 5% of treatment-experienced or treatment-naive subjects receiving emtricitabine or tenofovir DF with other antiretroviral agents in other clinical trials: depression, abdominal pain, dyspepsia, vomiting, fever, pain, nasopharyngitis, pneumonia, sinusitis, upper respiratory tract infection, arthralgia, back pain, myalgia, paresthesia, peripheral neuropathy (including peripheral neuritis and neuropathy), anxiety, increased cough, and rhinitis.",", is not a named entity"
"Adverse Reactions from Clinical Trials of the Components of STRIBILD           Emtricitabine and Tenofovir Disoproxil Fumarate:  In addition to the adverse reactions observed with STRIBILD, the following adverse reactions occurred in at least 5% of treatment-experienced or treatment-naive subjects receiving emtricitabine or tenofovir DF with other antiretroviral agents in other clinical trials: depression, abdominal pain, dyspepsia, vomiting, fever, pain, nasopharyngitis, pneumonia, sinusitis, upper respiratory tract infection, arthralgia, back pain, myalgia, paresthesia, peripheral neuropathy (including peripheral neuritis and neuropathy), anxiety, increased cough, and rhinitis.",pneumonia is an adverse reaction entity
"Adverse Reactions from Clinical Trials of the Components of STRIBILD           Emtricitabine and Tenofovir Disoproxil Fumarate:  In addition to the adverse reactions observed with STRIBILD, the following adverse reactions occurred in at least 5% of treatment-experienced or treatment-naive subjects receiving emtricitabine or tenofovir DF with other antiretroviral agents in other clinical trials: depression, abdominal pain, dyspepsia, vomiting, fever, pain, nasopharyngitis, pneumonia, sinusitis, upper respiratory tract infection, arthralgia, back pain, myalgia, paresthesia, peripheral neuropathy (including peripheral neuritis and neuropathy), anxiety, increased cough, and rhinitis.",adverse is not a named entity
"Adverse Reactions from Clinical Trials of the Components of STRIBILD           Emtricitabine and Tenofovir Disoproxil Fumarate:  In addition to the adverse reactions observed with STRIBILD, the following adverse reactions occurred in at least 5% of treatment-experienced or treatment-naive subjects receiving emtricitabine or tenofovir DF with other antiretroviral agents in other clinical trials: depression, abdominal pain, dyspepsia, vomiting, fever, pain, nasopharyngitis, pneumonia, sinusitis, upper respiratory tract infection, arthralgia, back pain, myalgia, paresthesia, peripheral neuropathy (including peripheral neuritis and neuropathy), anxiety, increased cough, and rhinitis.",back pain is an adverse reaction entity
"Adverse Reactions from Clinical Trials of the Components of STRIBILD           Emtricitabine and Tenofovir Disoproxil Fumarate:  In addition to the adverse reactions observed with STRIBILD, the following adverse reactions occurred in at least 5% of treatment-experienced or treatment-naive subjects receiving emtricitabine or tenofovir DF with other antiretroviral agents in other clinical trials: depression, abdominal pain, dyspepsia, vomiting, fever, pain, nasopharyngitis, pneumonia, sinusitis, upper respiratory tract infection, arthralgia, back pain, myalgia, paresthesia, peripheral neuropathy (including peripheral neuritis and neuropathy), anxiety, increased cough, and rhinitis.",anxiety is an adverse reaction entity
"Adverse Reactions from Clinical Trials of the Components of STRIBILD           Emtricitabine and Tenofovir Disoproxil Fumarate:  In addition to the adverse reactions observed with STRIBILD, the following adverse reactions occurred in at least 5% of treatment-experienced or treatment-naive subjects receiving emtricitabine or tenofovir DF with other antiretroviral agents in other clinical trials: depression, abdominal pain, dyspepsia, vomiting, fever, pain, nasopharyngitis, pneumonia, sinusitis, upper respiratory tract infection, arthralgia, back pain, myalgia, paresthesia, peripheral neuropathy (including peripheral neuritis and neuropathy), anxiety, increased cough, and rhinitis.","dyspepsia , vomiting is not a named entity"
"Adverse Reactions from Clinical Trials of the Components of STRIBILD           Emtricitabine and Tenofovir Disoproxil Fumarate:  In addition to the adverse reactions observed with STRIBILD, the following adverse reactions occurred in at least 5% of treatment-experienced or treatment-naive subjects receiving emtricitabine or tenofovir DF with other antiretroviral agents in other clinical trials: depression, abdominal pain, dyspepsia, vomiting, fever, pain, nasopharyngitis, pneumonia, sinusitis, upper respiratory tract infection, arthralgia, back pain, myalgia, paresthesia, peripheral neuropathy (including peripheral neuritis and neuropathy), anxiety, increased cough, and rhinitis.",vomiting is an adverse reaction entity
"Adverse Reactions from Clinical Trials of the Components of STRIBILD           Emtricitabine and Tenofovir Disoproxil Fumarate:  In addition to the adverse reactions observed with STRIBILD, the following adverse reactions occurred in at least 5% of treatment-experienced or treatment-naive subjects receiving emtricitabine or tenofovir DF with other antiretroviral agents in other clinical trials: depression, abdominal pain, dyspepsia, vomiting, fever, pain, nasopharyngitis, pneumonia, sinusitis, upper respiratory tract infection, arthralgia, back pain, myalgia, paresthesia, peripheral neuropathy (including peripheral neuritis and neuropathy), anxiety, increased cough, and rhinitis.",rhinitis is an adverse reaction entity
"Adverse Reactions from Clinical Trials of the Components of STRIBILD           Emtricitabine and Tenofovir Disoproxil Fumarate:  In addition to the adverse reactions observed with STRIBILD, the following adverse reactions occurred in at least 5% of treatment-experienced or treatment-naive subjects receiving emtricitabine or tenofovir DF with other antiretroviral agents in other clinical trials: depression, abdominal pain, dyspepsia, vomiting, fever, pain, nasopharyngitis, pneumonia, sinusitis, upper respiratory tract infection, arthralgia, back pain, myalgia, paresthesia, peripheral neuropathy (including peripheral neuritis and neuropathy), anxiety, increased cough, and rhinitis.",sinusitis is an adverse reaction entity
"Adverse Reactions from Clinical Trials of the Components of STRIBILD           Emtricitabine and Tenofovir Disoproxil Fumarate:  In addition to the adverse reactions observed with STRIBILD, the following adverse reactions occurred in at least 5% of treatment-experienced or treatment-naive subjects receiving emtricitabine or tenofovir DF with other antiretroviral agents in other clinical trials: depression, abdominal pain, dyspepsia, vomiting, fever, pain, nasopharyngitis, pneumonia, sinusitis, upper respiratory tract infection, arthralgia, back pain, myalgia, paresthesia, peripheral neuropathy (including peripheral neuritis and neuropathy), anxiety, increased cough, and rhinitis.",paresthesia is an adverse reaction entity
"Adverse Reactions from Clinical Trials of the Components of STRIBILD           Emtricitabine and Tenofovir Disoproxil Fumarate:  In addition to the adverse reactions observed with STRIBILD, the following adverse reactions occurred in at least 5% of treatment-experienced or treatment-naive subjects receiving emtricitabine or tenofovir DF with other antiretroviral agents in other clinical trials: depression, abdominal pain, dyspepsia, vomiting, fever, pain, nasopharyngitis, pneumonia, sinusitis, upper respiratory tract infection, arthralgia, back pain, myalgia, paresthesia, peripheral neuropathy (including peripheral neuritis and neuropathy), anxiety, increased cough, and rhinitis.",fever is an adverse reaction entity
"Adverse Reactions from Clinical Trials of the Components of STRIBILD           Emtricitabine and Tenofovir Disoproxil Fumarate:  In addition to the adverse reactions observed with STRIBILD, the following adverse reactions occurred in at least 5% of treatment-experienced or treatment-naive subjects receiving emtricitabine or tenofovir DF with other antiretroviral agents in other clinical trials: depression, abdominal pain, dyspepsia, vomiting, fever, pain, nasopharyngitis, pneumonia, sinusitis, upper respiratory tract infection, arthralgia, back pain, myalgia, paresthesia, peripheral neuropathy (including peripheral neuritis and neuropathy), anxiety, increased cough, and rhinitis.",other clinical is not a named entity
"Adverse Reactions from Clinical Trials of the Components of STRIBILD           Emtricitabine and Tenofovir Disoproxil Fumarate:  In addition to the adverse reactions observed with STRIBILD, the following adverse reactions occurred in at least 5% of treatment-experienced or treatment-naive subjects receiving emtricitabine or tenofovir DF with other antiretroviral agents in other clinical trials: depression, abdominal pain, dyspepsia, vomiting, fever, pain, nasopharyngitis, pneumonia, sinusitis, upper respiratory tract infection, arthralgia, back pain, myalgia, paresthesia, peripheral neuropathy (including peripheral neuritis and neuropathy), anxiety, increased cough, and rhinitis.",upper respiratory tract infection is an adverse reaction entity
"Mineralization Defects:       Cases of osteomalacia associated with proximal renal tubulopathy, manifested as bone pain or pain in extremities and which may contribute to fractures, have been reported in association with the use of tenofovir DF [see  Adverse Reactions (6.2)  ]  .",been reported is not a named entity
"Mineralization Defects:       Cases of osteomalacia associated with proximal renal tubulopathy, manifested as bone pain or pain in extremities and which may contribute to fractures, have been reported in association with the use of tenofovir DF [see  Adverse Reactions (6.2)  ]  .",with the use is not a named entity
"Mineralization Defects:       Cases of osteomalacia associated with proximal renal tubulopathy, manifested as bone pain or pain in extremities and which may contribute to fractures, have been reported in association with the use of tenofovir DF [see  Adverse Reactions (6.2)  ]  .",", is not a named entity"
"Mineralization Defects:       Cases of osteomalacia associated with proximal renal tubulopathy, manifested as bone pain or pain in extremities and which may contribute to fractures, have been reported in association with the use of tenofovir DF [see  Adverse Reactions (6.2)  ]  .",pain in extremities is an adverse reaction entity
"Mineralization Defects:       Cases of osteomalacia associated with proximal renal tubulopathy, manifested as bone pain or pain in extremities and which may contribute to fractures, have been reported in association with the use of tenofovir DF [see  Adverse Reactions (6.2)  ]  .",bone pain is an adverse reaction entity
"Mineralization Defects:       Cases of osteomalacia associated with proximal renal tubulopathy, manifested as bone pain or pain in extremities and which may contribute to fractures, have been reported in association with the use of tenofovir DF [see  Adverse Reactions (6.2)  ]  .",pain or is not a named entity
"Mineralization Defects:       Cases of osteomalacia associated with proximal renal tubulopathy, manifested as bone pain or pain in extremities and which may contribute to fractures, have been reported in association with the use of tenofovir DF [see  Adverse Reactions (6.2)  ]  .",osteomalacia is an adverse reaction entity
"Mineralization Defects:       Cases of osteomalacia associated with proximal renal tubulopathy, manifested as bone pain or pain in extremities and which may contribute to fractures, have been reported in association with the use of tenofovir DF [see  Adverse Reactions (6.2)  ]  .",proximal renal tubulopathy is an adverse reaction entity
"Mineralization Defects:       Cases of osteomalacia associated with proximal renal tubulopathy, manifested as bone pain or pain in extremities and which may contribute to fractures, have been reported in association with the use of tenofovir DF [see  Adverse Reactions (6.2)  ]  .",osteomalacia associated is not a named entity
"Mineralization Defects:       Cases of osteomalacia associated with proximal renal tubulopathy, manifested as bone pain or pain in extremities and which may contribute to fractures, have been reported in association with the use of tenofovir DF [see  Adverse Reactions (6.2)  ]  .",fractures is an adverse reaction entity
Four (0.6%) subjects who received STRIBILD developed laboratory findings consistent with proximal renal tubular dysfunction leading to discontinuation of STRIBILD during the first 48 weeks of treatment.,proximal renal tubular dysfunction is an adverse reaction entity
Four (0.6%) subjects who received STRIBILD developed laboratory findings consistent with proximal renal tubular dysfunction leading to discontinuation of STRIBILD during the first 48 weeks of treatment.,first 48 is not a named entity
"During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections [such as Mycobacterium avium  infection, cytomegalovirus, Pneumocystis jirovecii  pneumonia (PCP), or tuberculosis], which may necessitate further evaluation and treatment.",cytomegalovirus is an adverse reaction entity
"During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections [such as Mycobacterium avium  infection, cytomegalovirus, Pneumocystis jirovecii  pneumonia (PCP), or tuberculosis], which may necessitate further evaluation and treatment.",system responds is not a named entity
"During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections [such as Mycobacterium avium  infection, cytomegalovirus, Pneumocystis jirovecii  pneumonia (PCP), or tuberculosis], which may necessitate further evaluation and treatment.",phase of is not a named entity
"During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections [such as Mycobacterium avium  infection, cytomegalovirus, Pneumocystis jirovecii  pneumonia (PCP), or tuberculosis], which may necessitate further evaluation and treatment.",or residual is not a named entity
"During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections [such as Mycobacterium avium  infection, cytomegalovirus, Pneumocystis jirovecii  pneumonia (PCP), or tuberculosis], which may necessitate further evaluation and treatment.",PCP is an adverse reaction entity
"During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections [such as Mycobacterium avium  infection, cytomegalovirus, Pneumocystis jirovecii  pneumonia (PCP), or tuberculosis], which may necessitate further evaluation and treatment.",indolent is not a named entity
"During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections [such as Mycobacterium avium  infection, cytomegalovirus, Pneumocystis jirovecii  pneumonia (PCP), or tuberculosis], which may necessitate further evaluation and treatment.",to indolent is not a named entity
"During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections [such as Mycobacterium avium  infection, cytomegalovirus, Pneumocystis jirovecii  pneumonia (PCP), or tuberculosis], which may necessitate further evaluation and treatment.",infections [ such is not a named entity
"During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections [such as Mycobacterium avium  infection, cytomegalovirus, Pneumocystis jirovecii  pneumonia (PCP), or tuberculosis], which may necessitate further evaluation and treatment.",residual opportunistic infections is an adverse reaction entity
"During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections [such as Mycobacterium avium  infection, cytomegalovirus, Pneumocystis jirovecii  pneumonia (PCP), or tuberculosis], which may necessitate further evaluation and treatment.",Pneumocystis jirovecii pneumonia is an adverse reaction entity
"During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections [such as Mycobacterium avium  infection, cytomegalovirus, Pneumocystis jirovecii  pneumonia (PCP), or tuberculosis], which may necessitate further evaluation and treatment.",tuberculosis is an adverse reaction entity
"During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections [such as Mycobacterium avium  infection, cytomegalovirus, Pneumocystis jirovecii  pneumonia (PCP), or tuberculosis], which may necessitate further evaluation and treatment.",Mycobacterium avium infection is an adverse reaction entity
"In Studies 102 and 103, increases in serum creatinine and decreases in estimated creatinine clearance occurred early in treatment with STRIBILD, after which they stabilized.",decreases in estimated creatinine clearance is an adverse reaction entity
"In Studies 102 and 103, increases in serum creatinine and decreases in estimated creatinine clearance occurred early in treatment with STRIBILD, after which they stabilized.",increases in serum creatinine is an adverse reaction entity
"In Studies 102 and 103, increases in serum creatinine and decreases in estimated creatinine clearance occurred early in treatment with STRIBILD, after which they stabilized.",they stabilized is not a named entity
"In Studies 102 and 103, increases in serum creatinine and decreases in estimated creatinine clearance occurred early in treatment with STRIBILD, after which they stabilized.",creatinine clearance occurred is not a named entity
(  5.6  )   *  Redistribution/accumulation of body fat: Observed in patients receiving antiretroviral therapy.,accumulation of body fat is an adverse reaction entity
(  5.6  )   *  Redistribution/accumulation of body fat: Observed in patients receiving antiretroviral therapy.,* Redistribution/accumulation is not a named entity
(  5.6  )   *  Redistribution/accumulation of body fat: Observed in patients receiving antiretroviral therapy.,Redistribution of body fat is an adverse reaction entity
(  5.6  )   *  Redistribution/accumulation of body fat: Observed in patients receiving antiretroviral therapy.,therapy is not a named entity
"EXCERPT:   Most common adverse drug reactions to STRIBILD (incidence greater than or equal to 10%, all grades) are nausea and diarrhea.",diarrhea is an adverse reaction entity
"EXCERPT:   Most common adverse drug reactions to STRIBILD (incidence greater than or equal to 10%, all grades) are nausea and diarrhea.",nausea is an adverse reaction entity
"EXCERPT:   Most common adverse drug reactions to STRIBILD (incidence greater than or equal to 10%, all grades) are nausea and diarrhea.",% is not a named entity
"EXCERPT:   Most common adverse drug reactions to STRIBILD (incidence greater than or equal to 10%, all grades) are nausea and diarrhea.",nausea and is not a named entity
"5.6 Bone Effects of Tenofovir DF       Bone Mineral Density:       In clinical trials in HIV-1 infected adults, tenofovir DF (a component of STRIBILD) was associated with slightly greater decreases in bone mineral density (BMD) and increases in biochemical markers of bone metabolism, suggesting increased bone turnover relative to comparators.",increased bone turnover is an adverse reaction entity
"5.6 Bone Effects of Tenofovir DF       Bone Mineral Density:       In clinical trials in HIV-1 infected adults, tenofovir DF (a component of STRIBILD) was associated with slightly greater decreases in bone mineral density (BMD) and increases in biochemical markers of bone metabolism, suggesting increased bone turnover relative to comparators.",) was is not a named entity
"5.6 Bone Effects of Tenofovir DF       Bone Mineral Density:       In clinical trials in HIV-1 infected adults, tenofovir DF (a component of STRIBILD) was associated with slightly greater decreases in bone mineral density (BMD) and increases in biochemical markers of bone metabolism, suggesting increased bone turnover relative to comparators.",decreases in bone mineral density is an adverse reaction entity
"5.6 Bone Effects of Tenofovir DF       Bone Mineral Density:       In clinical trials in HIV-1 infected adults, tenofovir DF (a component of STRIBILD) was associated with slightly greater decreases in bone mineral density (BMD) and increases in biochemical markers of bone metabolism, suggesting increased bone turnover relative to comparators.",increases in biochemical markers of bone metabolism is an adverse reaction entity
"5.6 Bone Effects of Tenofovir DF       Bone Mineral Density:       In clinical trials in HIV-1 infected adults, tenofovir DF (a component of STRIBILD) was associated with slightly greater decreases in bone mineral density (BMD) and increases in biochemical markers of bone metabolism, suggesting increased bone turnover relative to comparators.",decreases in BMD is an adverse reaction entity
"5.6 Bone Effects of Tenofovir DF       Bone Mineral Density:       In clinical trials in HIV-1 infected adults, tenofovir DF (a component of STRIBILD) was associated with slightly greater decreases in bone mineral density (BMD) and increases in biochemical markers of bone metabolism, suggesting increased bone turnover relative to comparators.",adults is not a named entity
"5.6 Bone Effects of Tenofovir DF       Bone Mineral Density:       In clinical trials in HIV-1 infected adults, tenofovir DF (a component of STRIBILD) was associated with slightly greater decreases in bone mineral density (BMD) and increases in biochemical markers of bone metabolism, suggesting increased bone turnover relative to comparators.",of bone is not a named entity
"5.6 Bone Effects of Tenofovir DF       Bone Mineral Density:       In clinical trials in HIV-1 infected adults, tenofovir DF (a component of STRIBILD) was associated with slightly greater decreases in bone mineral density (BMD) and increases in biochemical markers of bone metabolism, suggesting increased bone turnover relative to comparators.","metabolism , is not a named entity"
EXCERPT:   WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B       See full prescribing information for complete boxed warning.,HEPATOMEGALY WITH is not a named entity
EXCERPT:   WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B       See full prescribing information for complete boxed warning.,: WARNING : is not a named entity
EXCERPT:   WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B       See full prescribing information for complete boxed warning.,STEATOSIS is an adverse reaction entity
EXCERPT:   WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B       See full prescribing information for complete boxed warning.,HEPATITIS is not a named entity
EXCERPT:   WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B       See full prescribing information for complete boxed warning.,ACUTE EXACERBATION OF HEPATITIS B is an adverse reaction entity
EXCERPT:   WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B       See full prescribing information for complete boxed warning.,LACTIC ACIDOSIS is an adverse reaction entity
EXCERPT:   WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B       See full prescribing information for complete boxed warning.,HEPATOMEGALY is an adverse reaction entity
EXCERPT:   WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B       See full prescribing information for complete boxed warning.,full prescribing is not a named entity
*  New Onset or Worsening Renal Impairment [see  Warnings and Precautions (5.3)  ] .,New Onset Renal Impairment is an adverse reaction entity
*  New Onset or Worsening Renal Impairment [see  Warnings and Precautions (5.3)  ] .,Worsening Renal Impairment is an adverse reaction entity
*  New Onset or Worsening Renal Impairment [see  Warnings and Precautions (5.3)  ] .,Renal is not a named entity
*  New Onset or Worsening Renal Impairment [see  Warnings and Precautions (5.3)  ] .,New Onset or is not a named entity
"Severe acute exacerbations of hepatitis B have been reported in patients who are coinfected with HBV and human immunodeficiency virus-1 (HIV-1) and have discontinued EMTRIVA or VIREAD, which are components of STRIBILD.",are components is not a named entity
"Severe acute exacerbations of hepatitis B have been reported in patients who are coinfected with HBV and human immunodeficiency virus-1 (HIV-1) and have discontinued EMTRIVA or VIREAD, which are components of STRIBILD.",acute exacerbations of hepatitis B is an adverse reaction entity
"BOXED WARNING: WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B      WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B        Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including tenofovir disoproxil fumarate, a component of STRIBILD, in combination with other antiretrovirals   [see   Warnings and Precautions (5.1)  ]  .",LACTIC ACIDOSIS is an adverse reaction entity
"BOXED WARNING: WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B      WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B        Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including tenofovir disoproxil fumarate, a component of STRIBILD, in combination with other antiretrovirals   [see   Warnings and Precautions (5.1)  ]  .",STEATOSIS is an adverse reaction entity
"BOXED WARNING: WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B      WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B        Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including tenofovir disoproxil fumarate, a component of STRIBILD, in combination with other antiretrovirals   [see   Warnings and Precautions (5.1)  ]  .",hepatomegaly is an adverse reaction entity
"BOXED WARNING: WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B      WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B        Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including tenofovir disoproxil fumarate, a component of STRIBILD, in combination with other antiretrovirals   [see   Warnings and Precautions (5.1)  ]  .",ACUTE EXACERBATION OF HEPATITIS B is an adverse reaction entity
"BOXED WARNING: WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B      WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B        Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including tenofovir disoproxil fumarate, a component of STRIBILD, in combination with other antiretrovirals   [see   Warnings and Precautions (5.1)  ]  .",STEATOSIS and POST is not a named entity
"BOXED WARNING: WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B      WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B        Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including tenofovir disoproxil fumarate, a component of STRIBILD, in combination with other antiretrovirals   [see   Warnings and Precautions (5.1)  ]  .",LACTIC ACIDOSIS is an adverse reaction entity
"BOXED WARNING: WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B      WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B        Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including tenofovir disoproxil fumarate, a component of STRIBILD, in combination with other antiretrovirals   [see   Warnings and Precautions (5.1)  ]  .",HEPATOMEGALY is an adverse reaction entity
"BOXED WARNING: WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B      WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B        Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including tenofovir disoproxil fumarate, a component of STRIBILD, in combination with other antiretrovirals   [see   Warnings and Precautions (5.1)  ]  .",fatal is an adverse reaction entity
"BOXED WARNING: WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B      WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B        Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including tenofovir disoproxil fumarate, a component of STRIBILD, in combination with other antiretrovirals   [see   Warnings and Precautions (5.1)  ]  .",Lactic acidosis is an adverse reaction entity
"BOXED WARNING: WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B      WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B        Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including tenofovir disoproxil fumarate, a component of STRIBILD, in combination with other antiretrovirals   [see   Warnings and Precautions (5.1)  ]  .",of nucleoside analogs is not a named entity
"BOXED WARNING: WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B      WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B        Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including tenofovir disoproxil fumarate, a component of STRIBILD, in combination with other antiretrovirals   [see   Warnings and Precautions (5.1)  ]  .",", including tenofovir is not a named entity"
"BOXED WARNING: WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B      WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B        Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including tenofovir disoproxil fumarate, a component of STRIBILD, in combination with other antiretrovirals   [see   Warnings and Precautions (5.1)  ]  .",OF HEPATITIS is not a named entity
"BOXED WARNING: WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B      WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B        Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including tenofovir disoproxil fumarate, a component of STRIBILD, in combination with other antiretrovirals   [see   Warnings and Precautions (5.1)  ]  .",STEATOSIS is an adverse reaction entity
"BOXED WARNING: WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B      WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B        Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including tenofovir disoproxil fumarate, a component of STRIBILD, in combination with other antiretrovirals   [see   Warnings and Precautions (5.1)  ]  .",disoproxil is not a named entity
"BOXED WARNING: WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B      WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B        Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including tenofovir disoproxil fumarate, a component of STRIBILD, in combination with other antiretrovirals   [see   Warnings and Precautions (5.1)  ]  .",", is not a named entity"
"BOXED WARNING: WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B      WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B        Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including tenofovir disoproxil fumarate, a component of STRIBILD, in combination with other antiretrovirals   [see   Warnings and Precautions (5.1)  ]  .",HEPATOMEGALY is an adverse reaction entity
"BOXED WARNING: WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B      WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B        Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including tenofovir disoproxil fumarate, a component of STRIBILD, in combination with other antiretrovirals   [see   Warnings and Precautions (5.1)  ]  .",B Lactic acidosis is not a named entity
"BOXED WARNING: WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B      WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B        Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including tenofovir disoproxil fumarate, a component of STRIBILD, in combination with other antiretrovirals   [see   Warnings and Precautions (5.1)  ]  .",steatosis is an adverse reaction entity
"BOXED WARNING: WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B      WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B        Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including tenofovir disoproxil fumarate, a component of STRIBILD, in combination with other antiretrovirals   [see   Warnings and Precautions (5.1)  ]  .",ACIDOSIS/SEVERE HEPATOMEGALY is not a named entity
"BOXED WARNING: WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B      WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B        Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including tenofovir disoproxil fumarate, a component of STRIBILD, in combination with other antiretrovirals   [see   Warnings and Precautions (5.1)  ]  .",TREATMENT ACUTE EXACERBATION is not a named entity
"BOXED WARNING: WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B      WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B        Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including tenofovir disoproxil fumarate, a component of STRIBILD, in combination with other antiretrovirals   [see   Warnings and Precautions (5.1)  ]  .",ACUTE EXACERBATION OF HEPATITIS B is an adverse reaction entity
"BOXED WARNING: WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B      WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B        Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including tenofovir disoproxil fumarate, a component of STRIBILD, in combination with other antiretrovirals   [see   Warnings and Precautions (5.1)  ]  .","fumarate , a is not a named entity"
"BOXED WARNING: WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B      WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B        Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including tenofovir disoproxil fumarate, a component of STRIBILD, in combination with other antiretrovirals   [see   Warnings and Precautions (5.1)  ]  .",been is not a named entity
"BOXED WARNING: WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B      WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B        Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including tenofovir disoproxil fumarate, a component of STRIBILD, in combination with other antiretrovirals   [see   Warnings and Precautions (5.1)  ]  .",and severe hepatomegaly is not a named entity
"In the clinical trials of STRIBILD over 144 weeks, 13 (1.9%) subjects in the STRIBILD group (N=701), 8 (2.3%) subjects in the ATV + RTV + TRUVADA group (N=355) and no subjects in the ATRIPLA group (N = 352) discontinued study drug due to a renal adverse reaction.",renal adverse reaction is an adverse reaction entity
"In the clinical trials of STRIBILD over 144 weeks, 13 (1.9%) subjects in the STRIBILD group (N=701), 8 (2.3%) subjects in the ATV + RTV + TRUVADA group (N=355) and no subjects in the ATRIPLA group (N = 352) discontinued study drug due to a renal adverse reaction.",over 144 weeks is not a named entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  New onset or worsening renal impairment: Can include acute renal failure and Fanconi syndrome.,: is not a named entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  New onset or worsening renal impairment: Can include acute renal failure and Fanconi syndrome.,EXCERPT is not a named entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  New onset or worsening renal impairment: Can include acute renal failure and Fanconi syndrome.,acute renal failure is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  New onset or worsening renal impairment: Can include acute renal failure and Fanconi syndrome.,AND PRECAUTIONS EXCERPT is not a named entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  New onset or worsening renal impairment: Can include acute renal failure and Fanconi syndrome.,Fanconi syndrome is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  New onset or worsening renal impairment: Can include acute renal failure and Fanconi syndrome.,New onset renal impairment is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  New onset or worsening renal impairment: Can include acute renal failure and Fanconi syndrome.,WARNINGS is not a named entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  New onset or worsening renal impairment: Can include acute renal failure and Fanconi syndrome.,worsening renal impairment is an adverse reaction entity
"Additional adverse drug reactions observed with STRIBILD included suicidal ideation and suicide attempt (0.3%), all in subjects with a pre-existing history of depression or psychiatric illness.",suicide attempt is an adverse reaction entity
"Additional adverse drug reactions observed with STRIBILD included suicidal ideation and suicide attempt (0.3%), all in subjects with a pre-existing history of depression or psychiatric illness.",of depression or is not a named entity
"Additional adverse drug reactions observed with STRIBILD included suicidal ideation and suicide attempt (0.3%), all in subjects with a pre-existing history of depression or psychiatric illness.",suicidal ideation is an adverse reaction entity
"Additional adverse drug reactions observed with STRIBILD included suicidal ideation and suicide attempt (0.3%), all in subjects with a pre-existing history of depression or psychiatric illness.",) is not a named entity
One (0.3%) subject who received ATV + RTV + TRUVADA developed laboratory findings consistent with proximal renal tubular dysfunction leading to discontinuation of ATV + RTV + TRUVADA after Week 96.,0.3 % ) is not a named entity
One (0.3%) subject who received ATV + RTV + TRUVADA developed laboratory findings consistent with proximal renal tubular dysfunction leading to discontinuation of ATV + RTV + TRUVADA after Week 96.,proximal renal tubular dysfunction is an adverse reaction entity
Table 4 displays the mean changes in serum creatinine and eGFR levels at Week 144 and the percentage of subjects with elevations in serum creatinine (All Grades).,elevations in serum creatinine is an adverse reaction entity
Table 4 displays the mean changes in serum creatinine and eGFR levels at Week 144 and the percentage of subjects with elevations in serum creatinine (All Grades).,levels at is not a named entity
Skin discoloration has been reported with higher frequency among emtricitabine-treated subjects; it was manifested by hyperpigmentation on the palms and/or soles and was generally mild and asymptomatic.,hyperpigmentation on the soles is an adverse reaction entity
Skin discoloration has been reported with higher frequency among emtricitabine-treated subjects; it was manifested by hyperpigmentation on the palms and/or soles and was generally mild and asymptomatic.,the is not a named entity
Skin discoloration has been reported with higher frequency among emtricitabine-treated subjects; it was manifested by hyperpigmentation on the palms and/or soles and was generally mild and asymptomatic.,with higher frequency is not a named entity
Skin discoloration has been reported with higher frequency among emtricitabine-treated subjects; it was manifested by hyperpigmentation on the palms and/or soles and was generally mild and asymptomatic.,hyperpigmentation on the palms is an adverse reaction entity
Skin discoloration has been reported with higher frequency among emtricitabine-treated subjects; it was manifested by hyperpigmentation on the palms and/or soles and was generally mild and asymptomatic.,emtricitabine-treated is not a named entity
Skin discoloration has been reported with higher frequency among emtricitabine-treated subjects; it was manifested by hyperpigmentation on the palms and/or soles and was generally mild and asymptomatic.,Skin discoloration is an adverse reaction entity
"Autoimmune disorders (such as Graves' disease, polymyositis, and Guillain-Barre syndrome) have also been reported to occur in the setting of immune reconstitution, however, the time to onset is more variable, and can occur many months after initiation of treatment.",polymyositis is an adverse reaction entity
"Autoimmune disorders (such as Graves' disease, polymyositis, and Guillain-Barre syndrome) have also been reported to occur in the setting of immune reconstitution, however, the time to onset is more variable, and can occur many months after initiation of treatment.",in is not a named entity
"Autoimmune disorders (such as Graves' disease, polymyositis, and Guillain-Barre syndrome) have also been reported to occur in the setting of immune reconstitution, however, the time to onset is more variable, and can occur many months after initiation of treatment.",occur many months is not a named entity
"Autoimmune disorders (such as Graves' disease, polymyositis, and Guillain-Barre syndrome) have also been reported to occur in the setting of immune reconstitution, however, the time to onset is more variable, and can occur many months after initiation of treatment.",Autoimmune disorders is an adverse reaction entity
"Autoimmune disorders (such as Graves' disease, polymyositis, and Guillain-Barre syndrome) have also been reported to occur in the setting of immune reconstitution, however, the time to onset is more variable, and can occur many months after initiation of treatment.",months is not a named entity
"Autoimmune disorders (such as Graves' disease, polymyositis, and Guillain-Barre syndrome) have also been reported to occur in the setting of immune reconstitution, however, the time to onset is more variable, and can occur many months after initiation of treatment.",Guillain-Barre syndrome is an adverse reaction entity
"Autoimmune disorders (such as Graves' disease, polymyositis, and Guillain-Barre syndrome) have also been reported to occur in the setting of immune reconstitution, however, the time to onset is more variable, and can occur many months after initiation of treatment.",Graves' disease is an adverse reaction entity
"Autoimmune disorders (such as Graves' disease, polymyositis, and Guillain-Barre syndrome) have also been reported to occur in the setting of immune reconstitution, however, the time to onset is more variable, and can occur many months after initiation of treatment.",immune is not a named entity
"Common adverse reactions that occurred in greater than or equal to 2% of subjects switching to STRIBILD were nausea (4%), flatulence (2%), and headache (2%).",headache is an adverse reaction entity
"Common adverse reactions that occurred in greater than or equal to 2% of subjects switching to STRIBILD were nausea (4%), flatulence (2%), and headache (2%).",", flatulence ( is not a named entity"
"Common adverse reactions that occurred in greater than or equal to 2% of subjects switching to STRIBILD were nausea (4%), flatulence (2%), and headache (2%).",occurred is not a named entity
"Common adverse reactions that occurred in greater than or equal to 2% of subjects switching to STRIBILD were nausea (4%), flatulence (2%), and headache (2%).",flatulence ( 2 is not a named entity
"Common adverse reactions that occurred in greater than or equal to 2% of subjects switching to STRIBILD were nausea (4%), flatulence (2%), and headache (2%).",flatulence is an adverse reaction entity
"Common adverse reactions that occurred in greater than or equal to 2% of subjects switching to STRIBILD were nausea (4%), flatulence (2%), and headache (2%).",nausea is an adverse reaction entity
"Mean percentage decreases in BMD from baseline to Week 144 in the STRIBILD group were comparable to the ATV + RTV + TRUVADA group at the lumbar spine (-1.43% versus -3.68%, respectively) and at the hip (-2.83% versus -3.77%, respectively).",respectively is not a named entity
"Mean percentage decreases in BMD from baseline to Week 144 in the STRIBILD group were comparable to the ATV + RTV + TRUVADA group at the lumbar spine (-1.43% versus -3.68%, respectively) and at the hip (-2.83% versus -3.77%, respectively).",decreases in BMD is an adverse reaction entity
"The decrease in serum potassium is usually transient, not requiring supplementation.",potassium is usually is not a named entity
"The decrease in serum potassium is usually transient, not requiring supplementation.",decrease in serum potassium is an adverse reaction entity
"(  5.6  ,  5.7  )              5.1     Asthma-Related Death [See Boxed Warning]          *   Data from a large placebo-controlled study in asthma patients showed that long-acting beta  2  -adrenergic agonists may increase the risk of asthma-related death.",death is an adverse reaction entity
"(  5.6  ,  5.7  )              5.1     Asthma-Related Death [See Boxed Warning]          *   Data from a large placebo-controlled study in asthma patients showed that long-acting beta  2  -adrenergic agonists may increase the risk of asthma-related death.",the risk of is not a named entity
5.4     Immediate Hypersensitivity Reactions       Immediate hypersensitivity reactions may occur after administration of ARCAPTA NEOHALER.,5.4 Immediate is not a named entity
5.4     Immediate Hypersensitivity Reactions       Immediate hypersensitivity reactions may occur after administration of ARCAPTA NEOHALER.,hypersensitivity reactions is an adverse reaction entity
"These adverse reactions are: hypersensitivity reactions, paradoxical bronchospasm, tachycardia/heart rate increase/palpitations, pruritus/rash and dizziness.",rash is an adverse reaction entity
"These adverse reactions are: hypersensitivity reactions, paradoxical bronchospasm, tachycardia/heart rate increase/palpitations, pruritus/rash and dizziness.",dizziness is an adverse reaction entity
"These adverse reactions are: hypersensitivity reactions, paradoxical bronchospasm, tachycardia/heart rate increase/palpitations, pruritus/rash and dizziness.","increase/palpitations , pruritus/rash is not a named entity"
"These adverse reactions are: hypersensitivity reactions, paradoxical bronchospasm, tachycardia/heart rate increase/palpitations, pruritus/rash and dizziness.",paradoxical bronchospasm is an adverse reaction entity
"These adverse reactions are: hypersensitivity reactions, paradoxical bronchospasm, tachycardia/heart rate increase/palpitations, pruritus/rash and dizziness.",", tachycardia/heart is not a named entity"
"These adverse reactions are: hypersensitivity reactions, paradoxical bronchospasm, tachycardia/heart rate increase/palpitations, pruritus/rash and dizziness.",", is not a named entity"
"These adverse reactions are: hypersensitivity reactions, paradoxical bronchospasm, tachycardia/heart rate increase/palpitations, pruritus/rash and dizziness.",are is not a named entity
"These adverse reactions are: hypersensitivity reactions, paradoxical bronchospasm, tachycardia/heart rate increase/palpitations, pruritus/rash and dizziness.",", is not a named entity"
"These adverse reactions are: hypersensitivity reactions, paradoxical bronchospasm, tachycardia/heart rate increase/palpitations, pruritus/rash and dizziness.",pruritus/rash and is not a named entity
"These adverse reactions are: hypersensitivity reactions, paradoxical bronchospasm, tachycardia/heart rate increase/palpitations, pruritus/rash and dizziness.",reactions are is not a named entity
"These adverse reactions are: hypersensitivity reactions, paradoxical bronchospasm, tachycardia/heart rate increase/palpitations, pruritus/rash and dizziness.",heart rate increase is an adverse reaction entity
"These adverse reactions are: hypersensitivity reactions, paradoxical bronchospasm, tachycardia/heart rate increase/palpitations, pruritus/rash and dizziness.",hypersensitivity reactions is an adverse reaction entity
"These adverse reactions are: hypersensitivity reactions, paradoxical bronchospasm, tachycardia/heart rate increase/palpitations, pruritus/rash and dizziness.",tachycardia is an adverse reaction entity
"These adverse reactions are: hypersensitivity reactions, paradoxical bronchospasm, tachycardia/heart rate increase/palpitations, pruritus/rash and dizziness.",palpitations is an adverse reaction entity
"These adverse reactions are: hypersensitivity reactions, paradoxical bronchospasm, tachycardia/heart rate increase/palpitations, pruritus/rash and dizziness.",rate increase/palpitations is not a named entity
"These adverse reactions are: hypersensitivity reactions, paradoxical bronchospasm, tachycardia/heart rate increase/palpitations, pruritus/rash and dizziness.",pruritus is an adverse reaction entity
"5.5     Paradoxical Bronchospasm      As with other inhaled beta2-agonists, ARCAPTA NEOHALER may produce paradoxical bronchospasm that may be life-threatening.",As with is not a named entity
"5.5     Paradoxical Bronchospasm      As with other inhaled beta2-agonists, ARCAPTA NEOHALER may produce paradoxical bronchospasm that may be life-threatening.",paradoxical bronchospasm is an adverse reaction entity
Clinically notable decreases in serum potassium or changes in blood glucose were infrequent during clinical studies with long-term administration of ARCAPTA NEOHALER with the rates similar to those for placebo controls.,serum is not a named entity
Clinically notable decreases in serum potassium or changes in blood glucose were infrequent during clinical studies with long-term administration of ARCAPTA NEOHALER with the rates similar to those for placebo controls.,decreases in serum potassium is an adverse reaction entity
Clinically notable decreases in serum potassium or changes in blood glucose were infrequent during clinical studies with long-term administration of ARCAPTA NEOHALER with the rates similar to those for placebo controls.,changes in blood glucose is an adverse reaction entity
Clinically notable decreases in serum potassium or changes in blood glucose were infrequent during clinical studies with long-term administration of ARCAPTA NEOHALER with the rates similar to those for placebo controls.,during clinical studies is not a named entity
"*   A 28-week, placebo-controlled US study comparing the safety of another long-acting beta  2  -adrenergic agonist (  salmeterol  ) with placebo, each added to usual asthma therapy, showed an increase in asthma-related deaths in patients receiving salmeterol (13/13,176 in patients treated with salmeterol vs. 3/13,179 in patients treated with placebo; RR 4.37, 95% CI 1.25, 15.34).",deaths is an adverse reaction entity
"*   A 28-week, placebo-controlled US study comparing the safety of another long-acting beta  2  -adrenergic agonist (  salmeterol  ) with placebo, each added to usual asthma therapy, showed an increase in asthma-related deaths in patients receiving salmeterol (13/13,176 in patients treated with salmeterol vs. 3/13,179 in patients treated with placebo; RR 4.37, 95% CI 1.25, 15.34).",vs. is not a named entity
"5.6     Cardiovascular Effects      ARCAPTA NEOHALER, like other beta2-agonists, can produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, systolic or diastolic blood pressure, or symptoms.",Effects is not a named entity
"5.6     Cardiovascular Effects      ARCAPTA NEOHALER, like other beta2-agonists, can produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, systolic or diastolic blood pressure, or symptoms.",clinically significant cardiovascular is not a named entity
"5.6     Cardiovascular Effects      ARCAPTA NEOHALER, like other beta2-agonists, can produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, systolic or diastolic blood pressure, or symptoms.",or is not a named entity
"5.6     Cardiovascular Effects      ARCAPTA NEOHALER, like other beta2-agonists, can produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, systolic or diastolic blood pressure, or symptoms.",increases in pulse rate is an adverse reaction entity
"5.6     Cardiovascular Effects      ARCAPTA NEOHALER, like other beta2-agonists, can produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, systolic or diastolic blood pressure, or symptoms.",increases in diastolic blood pressure is an adverse reaction entity
"5.6     Cardiovascular Effects      ARCAPTA NEOHALER, like other beta2-agonists, can produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, systolic or diastolic blood pressure, or symptoms.","beta2-agonists , can is not a named entity"
"5.6     Cardiovascular Effects      ARCAPTA NEOHALER, like other beta2-agonists, can produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, systolic or diastolic blood pressure, or symptoms.",cardiovascular effect is an adverse reaction entity
"5.6     Cardiovascular Effects      ARCAPTA NEOHALER, like other beta2-agonists, can produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, systolic or diastolic blood pressure, or symptoms.",increases in systolic blood pressure is an adverse reaction entity
"Doses of the related beta2-agonist albuterol, when administered intravenously, have been reported to aggravate pre-existing diabetes mellitus and ketoacidosis.",of the related is not a named entity
"Doses of the related beta2-agonist albuterol, when administered intravenously, have been reported to aggravate pre-existing diabetes mellitus and ketoacidosis.",", when is not a named entity"
"Doses of the related beta2-agonist albuterol, when administered intravenously, have been reported to aggravate pre-existing diabetes mellitus and ketoacidosis.",aggravate ketoacidosis is an adverse reaction entity
"Doses of the related beta2-agonist albuterol, when administered intravenously, have been reported to aggravate pre-existing diabetes mellitus and ketoacidosis.",aggravate pre-existing diabetes mellitus is an adverse reaction entity
The most common adverse reactions that lead to discontinuation of ARCAPTA NEOHALER were COPD and dyspnea.,most is not a named entity
The most common adverse reactions that lead to discontinuation of ARCAPTA NEOHALER were COPD and dyspnea.,COPD is an adverse reaction entity
The most common adverse reactions that lead to discontinuation of ARCAPTA NEOHALER were COPD and dyspnea.,dyspnea is an adverse reaction entity
The most common adverse reactions that lead to discontinuation of ARCAPTA NEOHALER were COPD and dyspnea.,COPD and dyspnea is not a named entity
BOXED WARNING: WARNING: ASTHMA-RELATED DEATH      WARNING    : ASTHMA-RELATED DEATH        L    ong-acting beta    2    -adrenergic agonist    s         (LABA)     increase the risk of asthma-related death.,increase is not a named entity
BOXED WARNING: WARNING: ASTHMA-RELATED DEATH      WARNING    : ASTHMA-RELATED DEATH        L    ong-acting beta    2    -adrenergic agonist    s         (LABA)     increase the risk of asthma-related death.,DEATH is an adverse reaction entity
BOXED WARNING: WARNING: ASTHMA-RELATED DEATH      WARNING    : ASTHMA-RELATED DEATH        L    ong-acting beta    2    -adrenergic agonist    s         (LABA)     increase the risk of asthma-related death.,) increase is not a named entity
BOXED WARNING: WARNING: ASTHMA-RELATED DEATH      WARNING    : ASTHMA-RELATED DEATH        L    ong-acting beta    2    -adrenergic agonist    s         (LABA)     increase the risk of asthma-related death.,-adrenergic is not a named entity
BOXED WARNING: WARNING: ASTHMA-RELATED DEATH      WARNING    : ASTHMA-RELATED DEATH        L    ong-acting beta    2    -adrenergic agonist    s         (LABA)     increase the risk of asthma-related death.,death is an adverse reaction entity
BOXED WARNING: WARNING: ASTHMA-RELATED DEATH      WARNING    : ASTHMA-RELATED DEATH        L    ong-acting beta    2    -adrenergic agonist    s         (LABA)     increase the risk of asthma-related death.,DEATH is an adverse reaction entity
Inhalation of high doses of beta2-adrenergic agonists may produce increases in plasma glucose.,increases in plasma glucose is an adverse reaction entity
Inhalation of high doses of beta2-adrenergic agonists may produce increases in plasma glucose.,in plasma is not a named entity
"Cough following inhalation in clinical trials was not associated with bronchospasm, exacerbations, deteriorations of disease or loss of efficacy.",clinical trials was is not a named entity
"Cough following inhalation in clinical trials was not associated with bronchospasm, exacerbations, deteriorations of disease or loss of efficacy.",not is not a named entity
"Cough following inhalation in clinical trials was not associated with bronchospasm, exacerbations, deteriorations of disease or loss of efficacy.",Cough is an adverse reaction entity
"Cough following inhalation in clinical trials was not associated with bronchospasm, exacerbations, deteriorations of disease or loss of efficacy.","bronchospasm , exacerbations is not a named entity"
"Cough following inhalation in clinical trials was not associated with bronchospasm, exacerbations, deteriorations of disease or loss of efficacy.",bronchospasm is an adverse reaction entity
"Cough following inhalation in clinical trials was not associated with bronchospasm, exacerbations, deteriorations of disease or loss of efficacy.",loss of efficacy is an adverse reaction entity
*  A placebo-controlled study with another long-acting beta2-adrenergic agonist (salmeterol) showed an increase in asthma-related deaths in patients receiving salmeterol.,deaths is an adverse reaction entity
*  A placebo-controlled study with another long-acting beta2-adrenergic agonist (salmeterol) showed an increase in asthma-related deaths in patients receiving salmeterol.,study with another is not a named entity
Data from a large placebo-controlled US study that compared the safety of another long-acting beta    2    -adrenergic agonist (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol.,deaths is an adverse reaction entity
Data from a large placebo-controlled US study that compared the safety of another long-acting beta    2    -adrenergic agonist (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol.,an increase in is not a named entity
"EXCERPT:   Most common adverse reactions (>2% and more common than placebo) are cough, oropharyngeal pain, nasopharyngitis, headache and nausea.",cough is an adverse reaction entity
"EXCERPT:   Most common adverse reactions (>2% and more common than placebo) are cough, oropharyngeal pain, nasopharyngitis, headache and nausea.",than placebo ) is not a named entity
"EXCERPT:   Most common adverse reactions (>2% and more common than placebo) are cough, oropharyngeal pain, nasopharyngitis, headache and nausea.",headache is an adverse reaction entity
"EXCERPT:   Most common adverse reactions (>2% and more common than placebo) are cough, oropharyngeal pain, nasopharyngitis, headache and nausea.",EXCERPT : Most is not a named entity
"EXCERPT:   Most common adverse reactions (>2% and more common than placebo) are cough, oropharyngeal pain, nasopharyngitis, headache and nausea.",> 2 % is not a named entity
"EXCERPT:   Most common adverse reactions (>2% and more common than placebo) are cough, oropharyngeal pain, nasopharyngitis, headache and nausea.",nausea is an adverse reaction entity
"EXCERPT:   Most common adverse reactions (>2% and more common than placebo) are cough, oropharyngeal pain, nasopharyngitis, headache and nausea.",oropharyngeal pain is an adverse reaction entity
"EXCERPT:   Most common adverse reactions (>2% and more common than placebo) are cough, oropharyngeal pain, nasopharyngitis, headache and nausea.",placebo ) are is not a named entity
"EXCERPT:   Most common adverse reactions (>2% and more common than placebo) are cough, oropharyngeal pain, nasopharyngitis, headache and nausea.",( is not a named entity
"EXCERPT:   Most common adverse reactions (>2% and more common than placebo) are cough, oropharyngeal pain, nasopharyngitis, headache and nausea.",nasopharyngitis is an adverse reaction entity
"The most common serious adverse reactions were COPD exacerbation, pneumonia, angina pectoris, and atrial fibrillation, which occurred at similar rates across treatment groups.",were COPD exacerbation is not a named entity
"The most common serious adverse reactions were COPD exacerbation, pneumonia, angina pectoris, and atrial fibrillation, which occurred at similar rates across treatment groups.",atrial fibrillation is an adverse reaction entity
"The most common serious adverse reactions were COPD exacerbation, pneumonia, angina pectoris, and atrial fibrillation, which occurred at similar rates across treatment groups.",angina pectoris is an adverse reaction entity
"The most common serious adverse reactions were COPD exacerbation, pneumonia, angina pectoris, and atrial fibrillation, which occurred at similar rates across treatment groups.",similar rates is not a named entity
"The most common serious adverse reactions were COPD exacerbation, pneumonia, angina pectoris, and atrial fibrillation, which occurred at similar rates across treatment groups.",pneumonia is an adverse reaction entity
"The most common serious adverse reactions were COPD exacerbation, pneumonia, angina pectoris, and atrial fibrillation, which occurred at similar rates across treatment groups.",COPD exacerbation is an adverse reaction entity
"The most common serious adverse reactions were COPD exacerbation, pneumonia, angina pectoris, and atrial fibrillation, which occurred at similar rates across treatment groups.",fibrillation is not a named entity
"The most common serious adverse reactions were COPD exacerbation, pneumonia, angina pectoris, and atrial fibrillation, which occurred at similar rates across treatment groups.",", angina pectoris is not a named entity"
There were no deaths in the ARCAPTA NEOHALER 600 mcg dose group or in the salmeterol active control group.,deaths is an adverse reaction entity
There were no deaths in the ARCAPTA NEOHALER 600 mcg dose group or in the salmeterol active control group.,group or is not a named entity
"Serious adverse reactions related to asthma exacerbation were reported for 2 patients in the indacaterol 300 mcg group, 3 patients in the indacaterol 600 mcg group, and no patients in the salmeterol active control group.",asthma exacerbation is an adverse reaction entity
"Serious adverse reactions related to asthma exacerbation were reported for 2 patients in the indacaterol 300 mcg group, 3 patients in the indacaterol 600 mcg group, and no patients in the salmeterol active control group.",indacaterol 600 mcg is not a named entity
"5.8     Hypokalemia and Hyperglycemia      Beta2-agonist medications may produce significant hypokalemia in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects [ see Clinical Pharmacology (12.2)  ].",has is not a named entity
"5.8     Hypokalemia and Hyperglycemia      Beta2-agonist medications may produce significant hypokalemia in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects [ see Clinical Pharmacology (12.2)  ].",adverse cardiovascular effects is an adverse reaction entity
"5.8     Hypokalemia and Hyperglycemia      Beta2-agonist medications may produce significant hypokalemia in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects [ see Clinical Pharmacology (12.2)  ].",hypokalemia is an adverse reaction entity
"5.8     Hypokalemia and Hyperglycemia      Beta2-agonist medications may produce significant hypokalemia in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects [ see Clinical Pharmacology (12.2)  ].",has the potential is not a named entity
"6 ADVERSE REACTIONS    The following risk is discussed elsewhere in the labeling:     *  Hypotension and Reflex Tachycardia   [see Warnings and Precautions (5.2)]           EXCERPT:   Most common adverse reactions (>2%) are headache, nausea, and vomiting.",6 is not a named entity
"6 ADVERSE REACTIONS    The following risk is discussed elsewhere in the labeling:     *  Hypotension and Reflex Tachycardia   [see Warnings and Precautions (5.2)]           EXCERPT:   Most common adverse reactions (>2%) are headache, nausea, and vomiting.",Reflex Tachycardia is an adverse reaction entity
"6 ADVERSE REACTIONS    The following risk is discussed elsewhere in the labeling:     *  Hypotension and Reflex Tachycardia   [see Warnings and Precautions (5.2)]           EXCERPT:   Most common adverse reactions (>2%) are headache, nausea, and vomiting.",vomiting is an adverse reaction entity
"6 ADVERSE REACTIONS    The following risk is discussed elsewhere in the labeling:     *  Hypotension and Reflex Tachycardia   [see Warnings and Precautions (5.2)]           EXCERPT:   Most common adverse reactions (>2%) are headache, nausea, and vomiting.",headache is an adverse reaction entity
"6 ADVERSE REACTIONS    The following risk is discussed elsewhere in the labeling:     *  Hypotension and Reflex Tachycardia   [see Warnings and Precautions (5.2)]           EXCERPT:   Most common adverse reactions (>2%) are headache, nausea, and vomiting.",Hypotension is an adverse reaction entity
"6 ADVERSE REACTIONS    The following risk is discussed elsewhere in the labeling:     *  Hypotension and Reflex Tachycardia   [see Warnings and Precautions (5.2)]           EXCERPT:   Most common adverse reactions (>2%) are headache, nausea, and vomiting.",are is not a named entity
"6 ADVERSE REACTIONS    The following risk is discussed elsewhere in the labeling:     *  Hypotension and Reflex Tachycardia   [see Warnings and Precautions (5.2)]           EXCERPT:   Most common adverse reactions (>2%) are headache, nausea, and vomiting.",EXCERPT : Most is not a named entity
"6 ADVERSE REACTIONS    The following risk is discussed elsewhere in the labeling:     *  Hypotension and Reflex Tachycardia   [see Warnings and Precautions (5.2)]           EXCERPT:   Most common adverse reactions (>2%) are headache, nausea, and vomiting.",nausea is an adverse reaction entity
"6 ADVERSE REACTIONS    The following risk is discussed elsewhere in the labeling:     *  Hypotension and Reflex Tachycardia   [see Warnings and Precautions (5.2)]           EXCERPT:   Most common adverse reactions (>2%) are headache, nausea, and vomiting.","nausea , and is not a named entity"
"6 ADVERSE REACTIONS    The following risk is discussed elsewhere in the labeling:     *  Hypotension and Reflex Tachycardia   [see Warnings and Precautions (5.2)]           EXCERPT:   Most common adverse reactions (>2%) are headache, nausea, and vomiting.",% is not a named entity
"Less Common Adverse Reactions in Patients with Severe or Essential Hypertension       Adverse reactions that were reported in <1% of patients with severe or essential hypertension included:Cardiac: myocardial infarction, cardiac arrestNervous system: syncopeRespiratory: dyspnea       6.2 Post-Marketing and Other Clinical Experience    Because adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or to establish a causal relationship to drug exposure.",of patients with is not a named entity
"Less Common Adverse Reactions in Patients with Severe or Essential Hypertension       Adverse reactions that were reported in <1% of patients with severe or essential hypertension included:Cardiac: myocardial infarction, cardiac arrestNervous system: syncopeRespiratory: dyspnea       6.2 Post-Marketing and Other Clinical Experience    Because adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or to establish a causal relationship to drug exposure.",were reported is not a named entity
"Less Common Adverse Reactions in Patients with Severe or Essential Hypertension       Adverse reactions that were reported in <1% of patients with severe or essential hypertension included:Cardiac: myocardial infarction, cardiac arrestNervous system: syncopeRespiratory: dyspnea       6.2 Post-Marketing and Other Clinical Experience    Because adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or to establish a causal relationship to drug exposure.",< 1 is not a named entity
"Less Common Adverse Reactions in Patients with Severe or Essential Hypertension       Adverse reactions that were reported in <1% of patients with severe or essential hypertension included:Cardiac: myocardial infarction, cardiac arrestNervous system: syncopeRespiratory: dyspnea       6.2 Post-Marketing and Other Clinical Experience    Because adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or to establish a causal relationship to drug exposure.",in is not a named entity
"Less Common Adverse Reactions in Patients with Severe or Essential Hypertension       Adverse reactions that were reported in <1% of patients with severe or essential hypertension included:Cardiac: myocardial infarction, cardiac arrestNervous system: syncopeRespiratory: dyspnea       6.2 Post-Marketing and Other Clinical Experience    Because adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or to establish a causal relationship to drug exposure.",cardiac arrest is an adverse reaction entity
"Less Common Adverse Reactions in Patients with Severe or Essential Hypertension       Adverse reactions that were reported in <1% of patients with severe or essential hypertension included:Cardiac: myocardial infarction, cardiac arrestNervous system: syncopeRespiratory: dyspnea       6.2 Post-Marketing and Other Clinical Experience    Because adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or to establish a causal relationship to drug exposure.",myocardial infarction is an adverse reaction entity
"Less Common Adverse Reactions in Patients with Severe or Essential Hypertension       Adverse reactions that were reported in <1% of patients with severe or essential hypertension included:Cardiac: myocardial infarction, cardiac arrestNervous system: syncopeRespiratory: dyspnea       6.2 Post-Marketing and Other Clinical Experience    Because adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or to establish a causal relationship to drug exposure.",syncope is an adverse reaction entity
"Less Common Adverse Reactions in Patients with Severe or Essential Hypertension       Adverse reactions that were reported in <1% of patients with severe or essential hypertension included:Cardiac: myocardial infarction, cardiac arrestNervous system: syncopeRespiratory: dyspnea       6.2 Post-Marketing and Other Clinical Experience    Because adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or to establish a causal relationship to drug exposure.",dyspnea is an adverse reaction entity
5.2 Hypotension and Reflex Tachycardia      Cleviprex may produce systemic hypotension and reflex tachycardia.,reflex tachycardia is an adverse reaction entity
5.2 Hypotension and Reflex Tachycardia      Cleviprex may produce systemic hypotension and reflex tachycardia.,may is not a named entity
5.2 Hypotension and Reflex Tachycardia      Cleviprex may produce systemic hypotension and reflex tachycardia.,Tachycardia is not a named entity
5.2 Hypotension and Reflex Tachycardia      Cleviprex may produce systemic hypotension and reflex tachycardia.,systemic hypotension is an adverse reaction entity
"The common adverse reactions for Cleviprex in severe hypertension included headache (6.3%), nausea (4.8%), and vomiting (3.2%).",common is not a named entity
"The common adverse reactions for Cleviprex in severe hypertension included headache (6.3%), nausea (4.8%), and vomiting (3.2%).",headache is an adverse reaction entity
"The common adverse reactions for Cleviprex in severe hypertension included headache (6.3%), nausea (4.8%), and vomiting (3.2%).",vomiting is an adverse reaction entity
"The common adverse reactions for Cleviprex in severe hypertension included headache (6.3%), nausea (4.8%), and vomiting (3.2%).",adverse reactions is not a named entity
"The common adverse reactions for Cleviprex in severe hypertension included headache (6.3%), nausea (4.8%), and vomiting (3.2%).",nausea is an adverse reaction entity
"The common adverse reactions for Cleviprex in severe hypertension included headache (6.3%), nausea (4.8%), and vomiting (3.2%).","% ) , is not a named entity"
5.4 Negative Inotropy      Dihydropyridine calcium channel blockers can produce negative inotropic effects and exacerbate heart failure.,channel blockers can is not a named entity
5.4 Negative Inotropy      Dihydropyridine calcium channel blockers can produce negative inotropic effects and exacerbate heart failure.,negative inotropic effects is an adverse reaction entity
5.4 Negative Inotropy      Dihydropyridine calcium channel blockers can produce negative inotropic effects and exacerbate heart failure.,Dihydropyridine is not a named entity
5.4 Negative Inotropy      Dihydropyridine calcium channel blockers can produce negative inotropic effects and exacerbate heart failure.,exacerbate heart failure is an adverse reaction entity
"(  2.4  ,  5.2  )   *  Hepatic Toxicity: Monitor liver enzymes at least monthly for the first three months and as needed.",* is not a named entity
"(  2.4  ,  5.2  )   *  Hepatic Toxicity: Monitor liver enzymes at least monthly for the first three months and as needed.",Hepatic Toxicity is an adverse reaction entity
"Specifically, 9 patients had a Grade 3 or 4 pleural effusion, 3 patients experienced both Grade 3 or Grade 4 pleural and pericardial effusions, 1 patient experienced Grade 3 peripheral and pulmonary edema, and 1 patient had a Grade 3 edema.",", 1 is not a named entity"
"Specifically, 9 patients had a Grade 3 or 4 pleural effusion, 3 patients experienced both Grade 3 or Grade 4 pleural and pericardial effusions, 1 patient experienced Grade 3 peripheral and pulmonary edema, and 1 patient had a Grade 3 edema.",pulmonary edema is an adverse reaction entity
"Specifically, 9 patients had a Grade 3 or 4 pleural effusion, 3 patients experienced both Grade 3 or Grade 4 pleural and pericardial effusions, 1 patient experienced Grade 3 peripheral and pulmonary edema, and 1 patient had a Grade 3 edema.",pleural effusions is an adverse reaction entity
"Specifically, 9 patients had a Grade 3 or 4 pleural effusion, 3 patients experienced both Grade 3 or Grade 4 pleural and pericardial effusions, 1 patient experienced Grade 3 peripheral and pulmonary edema, and 1 patient had a Grade 3 edema.",peripheral and pulmonary is not a named entity
"Specifically, 9 patients had a Grade 3 or 4 pleural effusion, 3 patients experienced both Grade 3 or Grade 4 pleural and pericardial effusions, 1 patient experienced Grade 3 peripheral and pulmonary edema, and 1 patient had a Grade 3 edema.",had a Grade is not a named entity
"Specifically, 9 patients had a Grade 3 or 4 pleural effusion, 3 patients experienced both Grade 3 or Grade 4 pleural and pericardial effusions, 1 patient experienced Grade 3 peripheral and pulmonary edema, and 1 patient had a Grade 3 edema.",pleural effusion is an adverse reaction entity
"Specifically, 9 patients had a Grade 3 or 4 pleural effusion, 3 patients experienced both Grade 3 or Grade 4 pleural and pericardial effusions, 1 patient experienced Grade 3 peripheral and pulmonary edema, and 1 patient had a Grade 3 edema.",both is not a named entity
"Specifically, 9 patients had a Grade 3 or 4 pleural effusion, 3 patients experienced both Grade 3 or Grade 4 pleural and pericardial effusions, 1 patient experienced Grade 3 peripheral and pulmonary edema, and 1 patient had a Grade 3 edema.",peripheral edema is an adverse reaction entity
"Specifically, 9 patients had a Grade 3 or 4 pleural effusion, 3 patients experienced both Grade 3 or Grade 4 pleural and pericardial effusions, 1 patient experienced Grade 3 peripheral and pulmonary edema, and 1 patient had a Grade 3 edema.",had is not a named entity
"Specifically, 9 patients had a Grade 3 or 4 pleural effusion, 3 patients experienced both Grade 3 or Grade 4 pleural and pericardial effusions, 1 patient experienced Grade 3 peripheral and pulmonary edema, and 1 patient had a Grade 3 edema.",pericardial effusions is an adverse reaction entity
"Specifically, 9 patients had a Grade 3 or 4 pleural effusion, 3 patients experienced both Grade 3 or Grade 4 pleural and pericardial effusions, 1 patient experienced Grade 3 peripheral and pulmonary edema, and 1 patient had a Grade 3 edema.",a Grade is not a named entity
"Specifically, 9 patients had a Grade 3 or 4 pleural effusion, 3 patients experienced both Grade 3 or Grade 4 pleural and pericardial effusions, 1 patient experienced Grade 3 peripheral and pulmonary edema, and 1 patient had a Grade 3 edema.",edema is an adverse reaction entity
*  Hepatic toxicity [see  Dosage and Administration (2.5)  and  Warnings and Precautions (5.3)  ] .,toxicity [ is not a named entity
*  Hepatic toxicity [see  Dosage and Administration (2.5)  and  Warnings and Precautions (5.3)  ] .,Hepatic toxicity is an adverse reaction entity
6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the labeling:     *  Gastrointestinal toxicity [see  Dosage and Administration (2.3)  and  Warnings and Precautions (5.1)  ] .,Gastrointestinal toxicity is an adverse reaction entity
6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the labeling:     *  Gastrointestinal toxicity [see  Dosage and Administration (2.3)  and  Warnings and Precautions (5.1)  ] .,REACTIONS The following is not a named entity
"In the 546 patients from the safety population, the incidence of ALT elevation was 17% and AST elevation was 14%.",ALT elevation is an adverse reaction entity
"In the 546 patients from the safety population, the incidence of ALT elevation was 17% and AST elevation was 14%.",the 546 is not a named entity
"In the 546 patients from the safety population, the incidence of ALT elevation was 17% and AST elevation was 14%.",and AST elevation is not a named entity
"In the 546 patients from the safety population, the incidence of ALT elevation was 17% and AST elevation was 14%.",AST elevation is an adverse reaction entity
Bosutinib caused embryofetal toxicities in rabbits at maternal exposures that were greater than the clinical exposure at the recommended bosutinib dose of 500 mg/day.,embryofetal toxicities is an adverse reaction entity
Bosutinib caused embryofetal toxicities in rabbits at maternal exposures that were greater than the clinical exposure at the recommended bosutinib dose of 500 mg/day.,the clinical is not a named entity
"(  2.3  ,  5.1  )   *  Myelosuppression: Monitor blood counts and manage as necessary.",Myelosuppression is an adverse reaction entity
"(  2.3  ,  5.1  )   *  Myelosuppression: Monitor blood counts and manage as necessary.",manage as necessary is not a named entity
"EXCERPT:   Most common adverse reactions (incidence greater than 20%) are diarrhea, nausea, thrombocytopenia, vomiting, abdominal pain, rash, anemia, pyrexia, and fatigue.",nausea is an adverse reaction entity
"EXCERPT:   Most common adverse reactions (incidence greater than 20%) are diarrhea, nausea, thrombocytopenia, vomiting, abdominal pain, rash, anemia, pyrexia, and fatigue.",adverse reactions is not a named entity
"EXCERPT:   Most common adverse reactions (incidence greater than 20%) are diarrhea, nausea, thrombocytopenia, vomiting, abdominal pain, rash, anemia, pyrexia, and fatigue.",: is not a named entity
"EXCERPT:   Most common adverse reactions (incidence greater than 20%) are diarrhea, nausea, thrombocytopenia, vomiting, abdominal pain, rash, anemia, pyrexia, and fatigue.",rash is an adverse reaction entity
"EXCERPT:   Most common adverse reactions (incidence greater than 20%) are diarrhea, nausea, thrombocytopenia, vomiting, abdominal pain, rash, anemia, pyrexia, and fatigue.",fatigue is an adverse reaction entity
"EXCERPT:   Most common adverse reactions (incidence greater than 20%) are diarrhea, nausea, thrombocytopenia, vomiting, abdominal pain, rash, anemia, pyrexia, and fatigue.","pain , rash is not a named entity"
"EXCERPT:   Most common adverse reactions (incidence greater than 20%) are diarrhea, nausea, thrombocytopenia, vomiting, abdominal pain, rash, anemia, pyrexia, and fatigue.",vomiting is an adverse reaction entity
"EXCERPT:   Most common adverse reactions (incidence greater than 20%) are diarrhea, nausea, thrombocytopenia, vomiting, abdominal pain, rash, anemia, pyrexia, and fatigue.","pyrexia , is not a named entity"
"EXCERPT:   Most common adverse reactions (incidence greater than 20%) are diarrhea, nausea, thrombocytopenia, vomiting, abdominal pain, rash, anemia, pyrexia, and fatigue.",diarrhea is an adverse reaction entity
"EXCERPT:   Most common adverse reactions (incidence greater than 20%) are diarrhea, nausea, thrombocytopenia, vomiting, abdominal pain, rash, anemia, pyrexia, and fatigue.",incidence greater is not a named entity
"EXCERPT:   Most common adverse reactions (incidence greater than 20%) are diarrhea, nausea, thrombocytopenia, vomiting, abdominal pain, rash, anemia, pyrexia, and fatigue.",20 % is not a named entity
"EXCERPT:   Most common adverse reactions (incidence greater than 20%) are diarrhea, nausea, thrombocytopenia, vomiting, abdominal pain, rash, anemia, pyrexia, and fatigue.",abdominal pain is an adverse reaction entity
"EXCERPT:   Most common adverse reactions (incidence greater than 20%) are diarrhea, nausea, thrombocytopenia, vomiting, abdominal pain, rash, anemia, pyrexia, and fatigue.","pain , rash is not a named entity"
"EXCERPT:   Most common adverse reactions (incidence greater than 20%) are diarrhea, nausea, thrombocytopenia, vomiting, abdominal pain, rash, anemia, pyrexia, and fatigue.",pyrexia is an adverse reaction entity
"EXCERPT:   Most common adverse reactions (incidence greater than 20%) are diarrhea, nausea, thrombocytopenia, vomiting, abdominal pain, rash, anemia, pyrexia, and fatigue.",20 is not a named entity
"EXCERPT:   Most common adverse reactions (incidence greater than 20%) are diarrhea, nausea, thrombocytopenia, vomiting, abdominal pain, rash, anemia, pyrexia, and fatigue.",anemia is an adverse reaction entity
"EXCERPT:   Most common adverse reactions (incidence greater than 20%) are diarrhea, nausea, thrombocytopenia, vomiting, abdominal pain, rash, anemia, pyrexia, and fatigue.",", and fatigue is not a named entity"
"EXCERPT:   Most common adverse reactions (incidence greater than 20%) are diarrhea, nausea, thrombocytopenia, vomiting, abdominal pain, rash, anemia, pyrexia, and fatigue.",thrombocytopenia is an adverse reaction entity
"(  5.6  )             5.1 Gastrointestinal Toxicity      Diarrhea, nausea, vomiting, and abdominal pain occur with BOSULIF treatment.",occur with is not a named entity
"(  5.6  )             5.1 Gastrointestinal Toxicity      Diarrhea, nausea, vomiting, and abdominal pain occur with BOSULIF treatment.",Diarrhea is an adverse reaction entity
"(  5.6  )             5.1 Gastrointestinal Toxicity      Diarrhea, nausea, vomiting, and abdominal pain occur with BOSULIF treatment.",nausea is an adverse reaction entity
"(  5.6  )             5.1 Gastrointestinal Toxicity      Diarrhea, nausea, vomiting, and abdominal pain occur with BOSULIF treatment.",and abdominal is not a named entity
"(  5.6  )             5.1 Gastrointestinal Toxicity      Diarrhea, nausea, vomiting, and abdominal pain occur with BOSULIF treatment.",5.1 Gastrointestinal Toxicity is not a named entity
"(  5.6  )             5.1 Gastrointestinal Toxicity      Diarrhea, nausea, vomiting, and abdominal pain occur with BOSULIF treatment.","vomiting , is not a named entity"
"(  5.6  )             5.1 Gastrointestinal Toxicity      Diarrhea, nausea, vomiting, and abdominal pain occur with BOSULIF treatment.",abdominal pain is an adverse reaction entity
"(  5.6  )             5.1 Gastrointestinal Toxicity      Diarrhea, nausea, vomiting, and abdominal pain occur with BOSULIF treatment.",vomiting is an adverse reaction entity
"5.4 Fluid Retention      Fluid retention occurs with BOSULIF and may manifest as pericardial effusion, pleural effusion, pulmonary edema, and/or peripheral edema.","effusion , is not a named entity"
"5.4 Fluid Retention      Fluid retention occurs with BOSULIF and may manifest as pericardial effusion, pleural effusion, pulmonary edema, and/or peripheral edema.",Fluid retention is an adverse reaction entity
"5.4 Fluid Retention      Fluid retention occurs with BOSULIF and may manifest as pericardial effusion, pleural effusion, pulmonary edema, and/or peripheral edema.",edema is not a named entity
"5.4 Fluid Retention      Fluid retention occurs with BOSULIF and may manifest as pericardial effusion, pleural effusion, pulmonary edema, and/or peripheral edema.",occurs with BOSULIF is not a named entity
"5.4 Fluid Retention      Fluid retention occurs with BOSULIF and may manifest as pericardial effusion, pleural effusion, pulmonary edema, and/or peripheral edema.",occurs is not a named entity
"5.4 Fluid Retention      Fluid retention occurs with BOSULIF and may manifest as pericardial effusion, pleural effusion, pulmonary edema, and/or peripheral edema.",pericardial effusion is an adverse reaction entity
"5.4 Fluid Retention      Fluid retention occurs with BOSULIF and may manifest as pericardial effusion, pleural effusion, pulmonary edema, and/or peripheral edema.",peripheral edema is an adverse reaction entity
"5.4 Fluid Retention      Fluid retention occurs with BOSULIF and may manifest as pericardial effusion, pleural effusion, pulmonary edema, and/or peripheral edema.",pleural effusion is an adverse reaction entity
"5.4 Fluid Retention      Fluid retention occurs with BOSULIF and may manifest as pericardial effusion, pleural effusion, pulmonary edema, and/or peripheral edema.",pulmonary edema is an adverse reaction entity
"5.4 Fluid Retention      Fluid retention occurs with BOSULIF and may manifest as pericardial effusion, pleural effusion, pulmonary edema, and/or peripheral edema.","edema , and/or is not a named entity"
"In the single-arm Phase 1/2 clinical trial in 546 patients with CML treated with prior therapy, severe fluid retention was reported in 14 patients (3%).",3 % ) is not a named entity
"In the single-arm Phase 1/2 clinical trial in 546 patients with CML treated with prior therapy, severe fluid retention was reported in 14 patients (3%).",fluid retention is an adverse reaction entity
"5.2 Myelosuppression      Thrombocytopenia, anemia and neutropenia occur with BOSULIF treatment.",anemia is an adverse reaction entity
"5.2 Myelosuppression      Thrombocytopenia, anemia and neutropenia occur with BOSULIF treatment.",neutropenia is an adverse reaction entity
"5.2 Myelosuppression      Thrombocytopenia, anemia and neutropenia occur with BOSULIF treatment.",", is not a named entity"
"5.2 Myelosuppression      Thrombocytopenia, anemia and neutropenia occur with BOSULIF treatment.",neutropenia occur is not a named entity
"5.2 Myelosuppression      Thrombocytopenia, anemia and neutropenia occur with BOSULIF treatment.",Thrombocytopenia is an adverse reaction entity
"5.2 Myelosuppression      Thrombocytopenia, anemia and neutropenia occur with BOSULIF treatment.",5.2 Myelosuppression Thrombocytopenia is not a named entity
"Most cases of transaminase elevations occurred early in treatment; of patients who experienced transaminase elevations of any grade, more than 80% experienced their first event within the first 3 months.",transaminase elevations is an adverse reaction entity
"Most cases of transaminase elevations occurred early in treatment; of patients who experienced transaminase elevations of any grade, more than 80% experienced their first event within the first 3 months.",early in treatment is not a named entity
"Most cases of transaminase elevations occurred early in treatment; of patients who experienced transaminase elevations of any grade, more than 80% experienced their first event within the first 3 months.",; of patients is not a named entity
"Most cases of transaminase elevations occurred early in treatment; of patients who experienced transaminase elevations of any grade, more than 80% experienced their first event within the first 3 months.",transaminase elevations is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Gastrointestinal Toxicity: Monitor and manage as necessary.,Gastrointestinal Toxicity is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Gastrointestinal Toxicity: Monitor and manage as necessary.,: is not a named entity
*  Myelosuppression [see  Dosage and Administration (2.4)  and  Warnings and Precautions (5.2)  ] .,Myelosuppression is an adverse reaction entity
*  Myelosuppression [see  Dosage and Administration (2.4)  and  Warnings and Precautions (5.2)  ] .,Administration ( is not a named entity
"Adverse reactions of any toxicity grade reported for greater than 20% of patients in the Phase 1/2 safety population (n=546) were diarrhea (82%), nausea (46%), thrombocytopenia (41%), vomiting (39%), abdominal pain (37%), rash (35%), anemia (27%), pyrexia (26%), and fatigue (24%)  [see  Clinical Studies (14)  ]  .",pyrexia is an adverse reaction entity
"Adverse reactions of any toxicity grade reported for greater than 20% of patients in the Phase 1/2 safety population (n=546) were diarrhea (82%), nausea (46%), thrombocytopenia (41%), vomiting (39%), abdominal pain (37%), rash (35%), anemia (27%), pyrexia (26%), and fatigue (24%)  [see  Clinical Studies (14)  ]  .",rash is an adverse reaction entity
"Adverse reactions of any toxicity grade reported for greater than 20% of patients in the Phase 1/2 safety population (n=546) were diarrhea (82%), nausea (46%), thrombocytopenia (41%), vomiting (39%), abdominal pain (37%), rash (35%), anemia (27%), pyrexia (26%), and fatigue (24%)  [see  Clinical Studies (14)  ]  .",vomiting is an adverse reaction entity
"Adverse reactions of any toxicity grade reported for greater than 20% of patients in the Phase 1/2 safety population (n=546) were diarrhea (82%), nausea (46%), thrombocytopenia (41%), vomiting (39%), abdominal pain (37%), rash (35%), anemia (27%), pyrexia (26%), and fatigue (24%)  [see  Clinical Studies (14)  ]  .",( is not a named entity
"Adverse reactions of any toxicity grade reported for greater than 20% of patients in the Phase 1/2 safety population (n=546) were diarrhea (82%), nausea (46%), thrombocytopenia (41%), vomiting (39%), abdominal pain (37%), rash (35%), anemia (27%), pyrexia (26%), and fatigue (24%)  [see  Clinical Studies (14)  ]  .",37 % is not a named entity
"Adverse reactions of any toxicity grade reported for greater than 20% of patients in the Phase 1/2 safety population (n=546) were diarrhea (82%), nausea (46%), thrombocytopenia (41%), vomiting (39%), abdominal pain (37%), rash (35%), anemia (27%), pyrexia (26%), and fatigue (24%)  [see  Clinical Studies (14)  ]  .",thrombocytopenia is an adverse reaction entity
"Adverse reactions of any toxicity grade reported for greater than 20% of patients in the Phase 1/2 safety population (n=546) were diarrhea (82%), nausea (46%), thrombocytopenia (41%), vomiting (39%), abdominal pain (37%), rash (35%), anemia (27%), pyrexia (26%), and fatigue (24%)  [see  Clinical Studies (14)  ]  .",pyrexia ( is not a named entity
"Adverse reactions of any toxicity grade reported for greater than 20% of patients in the Phase 1/2 safety population (n=546) were diarrhea (82%), nausea (46%), thrombocytopenia (41%), vomiting (39%), abdominal pain (37%), rash (35%), anemia (27%), pyrexia (26%), and fatigue (24%)  [see  Clinical Studies (14)  ]  .",anemia is an adverse reaction entity
"Adverse reactions of any toxicity grade reported for greater than 20% of patients in the Phase 1/2 safety population (n=546) were diarrhea (82%), nausea (46%), thrombocytopenia (41%), vomiting (39%), abdominal pain (37%), rash (35%), anemia (27%), pyrexia (26%), and fatigue (24%)  [see  Clinical Studies (14)  ]  .",] is not a named entity
"Adverse reactions of any toxicity grade reported for greater than 20% of patients in the Phase 1/2 safety population (n=546) were diarrhea (82%), nausea (46%), thrombocytopenia (41%), vomiting (39%), abdominal pain (37%), rash (35%), anemia (27%), pyrexia (26%), and fatigue (24%)  [see  Clinical Studies (14)  ]  .",", rash ( is not a named entity"
"Adverse reactions of any toxicity grade reported for greater than 20% of patients in the Phase 1/2 safety population (n=546) were diarrhea (82%), nausea (46%), thrombocytopenia (41%), vomiting (39%), abdominal pain (37%), rash (35%), anemia (27%), pyrexia (26%), and fatigue (24%)  [see  Clinical Studies (14)  ]  .",abdominal pain is an adverse reaction entity
"Adverse reactions of any toxicity grade reported for greater than 20% of patients in the Phase 1/2 safety population (n=546) were diarrhea (82%), nausea (46%), thrombocytopenia (41%), vomiting (39%), abdominal pain (37%), rash (35%), anemia (27%), pyrexia (26%), and fatigue (24%)  [see  Clinical Studies (14)  ]  .",nausea is an adverse reaction entity
"Adverse reactions of any toxicity grade reported for greater than 20% of patients in the Phase 1/2 safety population (n=546) were diarrhea (82%), nausea (46%), thrombocytopenia (41%), vomiting (39%), abdominal pain (37%), rash (35%), anemia (27%), pyrexia (26%), and fatigue (24%)  [see  Clinical Studies (14)  ]  .",") , vomiting is not a named entity"
"Adverse reactions of any toxicity grade reported for greater than 20% of patients in the Phase 1/2 safety population (n=546) were diarrhea (82%), nausea (46%), thrombocytopenia (41%), vomiting (39%), abdominal pain (37%), rash (35%), anemia (27%), pyrexia (26%), and fatigue (24%)  [see  Clinical Studies (14)  ]  .",diarrhea is an adverse reaction entity
"Adverse reactions of any toxicity grade reported for greater than 20% of patients in the Phase 1/2 safety population (n=546) were diarrhea (82%), nausea (46%), thrombocytopenia (41%), vomiting (39%), abdominal pain (37%), rash (35%), anemia (27%), pyrexia (26%), and fatigue (24%)  [see  Clinical Studies (14)  ]  .",greater than is not a named entity
"Adverse reactions of any toxicity grade reported for greater than 20% of patients in the Phase 1/2 safety population (n=546) were diarrhea (82%), nausea (46%), thrombocytopenia (41%), vomiting (39%), abdominal pain (37%), rash (35%), anemia (27%), pyrexia (26%), and fatigue (24%)  [see  Clinical Studies (14)  ]  .",Adverse is not a named entity
"Adverse reactions of any toxicity grade reported for greater than 20% of patients in the Phase 1/2 safety population (n=546) were diarrhea (82%), nausea (46%), thrombocytopenia (41%), vomiting (39%), abdominal pain (37%), rash (35%), anemia (27%), pyrexia (26%), and fatigue (24%)  [see  Clinical Studies (14)  ]  .",fatigue is an adverse reaction entity
"Adverse reactions of any toxicity grade reported for greater than 20% of patients in the Phase 1/2 safety population (n=546) were diarrhea (82%), nausea (46%), thrombocytopenia (41%), vomiting (39%), abdominal pain (37%), rash (35%), anemia (27%), pyrexia (26%), and fatigue (24%)  [see  Clinical Studies (14)  ]  .",( 82 % is not a named entity
"5.2 Hypersensitivity Reactions      Acute hypersensitivity reactions, including dyspnea, rash pruritus, and angioedema of the mouth, throat, and face have been reported with fidaxomicin.",the is not a named entity
"5.2 Hypersensitivity Reactions      Acute hypersensitivity reactions, including dyspnea, rash pruritus, and angioedema of the mouth, throat, and face have been reported with fidaxomicin.",Acute hypersensitivity reactions is an adverse reaction entity
"5.2 Hypersensitivity Reactions      Acute hypersensitivity reactions, including dyspnea, rash pruritus, and angioedema of the mouth, throat, and face have been reported with fidaxomicin.",of the is not a named entity
"5.2 Hypersensitivity Reactions      Acute hypersensitivity reactions, including dyspnea, rash pruritus, and angioedema of the mouth, throat, and face have been reported with fidaxomicin.",been reported with is not a named entity
"5.2 Hypersensitivity Reactions      Acute hypersensitivity reactions, including dyspnea, rash pruritus, and angioedema of the mouth, throat, and face have been reported with fidaxomicin.",pruritus is an adverse reaction entity
"5.2 Hypersensitivity Reactions      Acute hypersensitivity reactions, including dyspnea, rash pruritus, and angioedema of the mouth, throat, and face have been reported with fidaxomicin.",Hypersensitivity is not a named entity
"5.2 Hypersensitivity Reactions      Acute hypersensitivity reactions, including dyspnea, rash pruritus, and angioedema of the mouth, throat, and face have been reported with fidaxomicin.",and angioedema of is not a named entity
"5.2 Hypersensitivity Reactions      Acute hypersensitivity reactions, including dyspnea, rash pruritus, and angioedema of the mouth, throat, and face have been reported with fidaxomicin.",Hypersensitivity Reactions Acute is not a named entity
"5.2 Hypersensitivity Reactions      Acute hypersensitivity reactions, including dyspnea, rash pruritus, and angioedema of the mouth, throat, and face have been reported with fidaxomicin.",rash is an adverse reaction entity
"5.2 Hypersensitivity Reactions      Acute hypersensitivity reactions, including dyspnea, rash pruritus, and angioedema of the mouth, throat, and face have been reported with fidaxomicin.",angioedema of the face is an adverse reaction entity
"5.2 Hypersensitivity Reactions      Acute hypersensitivity reactions, including dyspnea, rash pruritus, and angioedema of the mouth, throat, and face have been reported with fidaxomicin.",dyspnea is an adverse reaction entity
"5.2 Hypersensitivity Reactions      Acute hypersensitivity reactions, including dyspnea, rash pruritus, and angioedema of the mouth, throat, and face have been reported with fidaxomicin.",Hypersensitivity Reactions is not a named entity
"5.2 Hypersensitivity Reactions      Acute hypersensitivity reactions, including dyspnea, rash pruritus, and angioedema of the mouth, throat, and face have been reported with fidaxomicin.",angioedema of the mouth is an adverse reaction entity
"5.2 Hypersensitivity Reactions      Acute hypersensitivity reactions, including dyspnea, rash pruritus, and angioedema of the mouth, throat, and face have been reported with fidaxomicin.",angioedema of the throat is an adverse reaction entity
Some patients with hypersensitivity reactions also reported a history of allergy to other macrolides.,reactions is not a named entity
Some patients with hypersensitivity reactions also reported a history of allergy to other macrolides.,hypersensitivity reactions is an adverse reaction entity
Vomiting was the primary adverse reaction leading to discontinuation of dosing; this occurred at an incidence of 0.5% in both the fidaxomicin and vancomycin patients in Phase 3 studies.,Vomiting is an adverse reaction entity
Vomiting was the primary adverse reaction leading to discontinuation of dosing; this occurred at an incidence of 0.5% in both the fidaxomicin and vancomycin patients in Phase 3 studies.,primary adverse reaction is not a named entity
"6 ADVERSE REACTIONS    EXCERPT:   The most common adverse reactions are nausea (11%), vomiting (7%), abdominal pain (6%), gastrointestinal hemorrhage (4%), anemia (2%), and neutropenia (2%) (  6  ).",neutropenia is an adverse reaction entity
"6 ADVERSE REACTIONS    EXCERPT:   The most common adverse reactions are nausea (11%), vomiting (7%), abdominal pain (6%), gastrointestinal hemorrhage (4%), anemia (2%), and neutropenia (2%) (  6  ).",abdominal pain is an adverse reaction entity
"6 ADVERSE REACTIONS    EXCERPT:   The most common adverse reactions are nausea (11%), vomiting (7%), abdominal pain (6%), gastrointestinal hemorrhage (4%), anemia (2%), and neutropenia (2%) (  6  ).",nausea is an adverse reaction entity
"6 ADVERSE REACTIONS    EXCERPT:   The most common adverse reactions are nausea (11%), vomiting (7%), abdominal pain (6%), gastrointestinal hemorrhage (4%), anemia (2%), and neutropenia (2%) (  6  ).",vomiting is an adverse reaction entity
"6 ADVERSE REACTIONS    EXCERPT:   The most common adverse reactions are nausea (11%), vomiting (7%), abdominal pain (6%), gastrointestinal hemorrhage (4%), anemia (2%), and neutropenia (2%) (  6  ).",( is not a named entity
"6 ADVERSE REACTIONS    EXCERPT:   The most common adverse reactions are nausea (11%), vomiting (7%), abdominal pain (6%), gastrointestinal hemorrhage (4%), anemia (2%), and neutropenia (2%) (  6  ).",: The most is not a named entity
"6 ADVERSE REACTIONS    EXCERPT:   The most common adverse reactions are nausea (11%), vomiting (7%), abdominal pain (6%), gastrointestinal hemorrhage (4%), anemia (2%), and neutropenia (2%) (  6  ).",gastrointestinal hemorrhage is an adverse reaction entity
"6 ADVERSE REACTIONS    EXCERPT:   The most common adverse reactions are nausea (11%), vomiting (7%), abdominal pain (6%), gastrointestinal hemorrhage (4%), anemia (2%), and neutropenia (2%) (  6  ).",7 % is not a named entity
"6 ADVERSE REACTIONS    EXCERPT:   The most common adverse reactions are nausea (11%), vomiting (7%), abdominal pain (6%), gastrointestinal hemorrhage (4%), anemia (2%), and neutropenia (2%) (  6  ).",( 7 is not a named entity
"6 ADVERSE REACTIONS    EXCERPT:   The most common adverse reactions are nausea (11%), vomiting (7%), abdominal pain (6%), gastrointestinal hemorrhage (4%), anemia (2%), and neutropenia (2%) (  6  ).",: The is not a named entity
"6 ADVERSE REACTIONS    EXCERPT:   The most common adverse reactions are nausea (11%), vomiting (7%), abdominal pain (6%), gastrointestinal hemorrhage (4%), anemia (2%), and neutropenia (2%) (  6  ).",anemia is an adverse reaction entity
"6 ADVERSE REACTIONS    EXCERPT:   The most common adverse reactions are nausea (11%), vomiting (7%), abdominal pain (6%), gastrointestinal hemorrhage (4%), anemia (2%), and neutropenia (2%) (  6  ).",reactions are is not a named entity
patients less than 1 month of age or preterm infants with a corrected age of less than 44 weeks) could be at risk for gasping syndrome if treated with ULESFIA   (r)     Lotion  [see     Use in Specific Populations     (     8.4     )]  .,gasping syndrome is an adverse reaction entity
patients less than 1 month of age or preterm infants with a corrected age of less than 44 weeks) could be at risk for gasping syndrome if treated with ULESFIA   (r)     Lotion  [see     Use in Specific Populations     (     8.4     )]  .,ULESFIA ( is not a named entity
"1           Neonatal Toxicity              Intravenous administration of products containing benzyl alcohol has been associated with neonatal gasping syndrome consisting of severe metabolic acidosis, gasping respirations, progressive hypotension, seizures, central nervous system depression, intraventricular hemorrhage, and death in preterm, low birth weight infants.",progressive hypotension is an adverse reaction entity
"1           Neonatal Toxicity              Intravenous administration of products containing benzyl alcohol has been associated with neonatal gasping syndrome consisting of severe metabolic acidosis, gasping respirations, progressive hypotension, seizures, central nervous system depression, intraventricular hemorrhage, and death in preterm, low birth weight infants.",seizures is an adverse reaction entity
"1           Neonatal Toxicity              Intravenous administration of products containing benzyl alcohol has been associated with neonatal gasping syndrome consisting of severe metabolic acidosis, gasping respirations, progressive hypotension, seizures, central nervous system depression, intraventricular hemorrhage, and death in preterm, low birth weight infants.",with neonatal is not a named entity
"1           Neonatal Toxicity              Intravenous administration of products containing benzyl alcohol has been associated with neonatal gasping syndrome consisting of severe metabolic acidosis, gasping respirations, progressive hypotension, seizures, central nervous system depression, intraventricular hemorrhage, and death in preterm, low birth weight infants.",and death is not a named entity
"1           Neonatal Toxicity              Intravenous administration of products containing benzyl alcohol has been associated with neonatal gasping syndrome consisting of severe metabolic acidosis, gasping respirations, progressive hypotension, seizures, central nervous system depression, intraventricular hemorrhage, and death in preterm, low birth weight infants.",central nervous system depression is an adverse reaction entity
"1           Neonatal Toxicity              Intravenous administration of products containing benzyl alcohol has been associated with neonatal gasping syndrome consisting of severe metabolic acidosis, gasping respirations, progressive hypotension, seizures, central nervous system depression, intraventricular hemorrhage, and death in preterm, low birth weight infants.",neonatal gasping syndrome is an adverse reaction entity
"1           Neonatal Toxicity              Intravenous administration of products containing benzyl alcohol has been associated with neonatal gasping syndrome consisting of severe metabolic acidosis, gasping respirations, progressive hypotension, seizures, central nervous system depression, intraventricular hemorrhage, and death in preterm, low birth weight infants.",containing is not a named entity
"1           Neonatal Toxicity              Intravenous administration of products containing benzyl alcohol has been associated with neonatal gasping syndrome consisting of severe metabolic acidosis, gasping respirations, progressive hypotension, seizures, central nervous system depression, intraventricular hemorrhage, and death in preterm, low birth weight infants.",metabolic acidosis is an adverse reaction entity
"1           Neonatal Toxicity              Intravenous administration of products containing benzyl alcohol has been associated with neonatal gasping syndrome consisting of severe metabolic acidosis, gasping respirations, progressive hypotension, seizures, central nervous system depression, intraventricular hemorrhage, and death in preterm, low birth weight infants.",", is not a named entity"
"1           Neonatal Toxicity              Intravenous administration of products containing benzyl alcohol has been associated with neonatal gasping syndrome consisting of severe metabolic acidosis, gasping respirations, progressive hypotension, seizures, central nervous system depression, intraventricular hemorrhage, and death in preterm, low birth weight infants.",", and death is not a named entity"
"1           Neonatal Toxicity              Intravenous administration of products containing benzyl alcohol has been associated with neonatal gasping syndrome consisting of severe metabolic acidosis, gasping respirations, progressive hypotension, seizures, central nervous system depression, intraventricular hemorrhage, and death in preterm, low birth weight infants.",Neonatal Toxicity is not a named entity
"1           Neonatal Toxicity              Intravenous administration of products containing benzyl alcohol has been associated with neonatal gasping syndrome consisting of severe metabolic acidosis, gasping respirations, progressive hypotension, seizures, central nervous system depression, intraventricular hemorrhage, and death in preterm, low birth weight infants.",intraventricular hemorrhage is an adverse reaction entity
"1           Neonatal Toxicity              Intravenous administration of products containing benzyl alcohol has been associated with neonatal gasping syndrome consisting of severe metabolic acidosis, gasping respirations, progressive hypotension, seizures, central nervous system depression, intraventricular hemorrhage, and death in preterm, low birth weight infants.",gasping respirations is an adverse reaction entity
"1           Neonatal Toxicity              Intravenous administration of products containing benzyl alcohol has been associated with neonatal gasping syndrome consisting of severe metabolic acidosis, gasping respirations, progressive hypotension, seizures, central nervous system depression, intraventricular hemorrhage, and death in preterm, low birth weight infants.",death is an adverse reaction entity
"1           Neonatal Toxicity              Intravenous administration of products containing benzyl alcohol has been associated with neonatal gasping syndrome consisting of severe metabolic acidosis, gasping respirations, progressive hypotension, seizures, central nervous system depression, intraventricular hemorrhage, and death in preterm, low birth weight infants.",", is not a named entity"
"1           Neonatal Toxicity              Intravenous administration of products containing benzyl alcohol has been associated with neonatal gasping syndrome consisting of severe metabolic acidosis, gasping respirations, progressive hypotension, seizures, central nervous system depression, intraventricular hemorrhage, and death in preterm, low birth weight infants.","depression , intraventricular is not a named entity"
"Table 2: Monitored Adverse Reactions - Application Site Symptoms   Event            ULESFIA    (r)    Lotion  Vehicle             Application site Irritation  2% (11/478)      1% (2/336)         Application site anesthesia &hypoesthesia  2% (10/478)      0% (0/336)         Pain             1% (5/478)       0% (1/336)                        The subset of subjects who did not have pruritus, erythema, edema or pyoderma of skin and scalp, or ocular irritation prior to treatment were assessed for these signs and symptoms after treatment; the results are presented in Table 3.",Application site anesthesia is an adverse reaction entity
"Table 2: Monitored Adverse Reactions - Application Site Symptoms   Event            ULESFIA    (r)    Lotion  Vehicle             Application site Irritation  2% (11/478)      1% (2/336)         Application site anesthesia &hypoesthesia  2% (10/478)      0% (0/336)         Pain             1% (5/478)       0% (1/336)                        The subset of subjects who did not have pruritus, erythema, edema or pyoderma of skin and scalp, or ocular irritation prior to treatment were assessed for these signs and symptoms after treatment; the results are presented in Table 3.",subjects who did is not a named entity
"Table 2: Monitored Adverse Reactions - Application Site Symptoms   Event            ULESFIA    (r)    Lotion  Vehicle             Application site Irritation  2% (11/478)      1% (2/336)         Application site anesthesia &hypoesthesia  2% (10/478)      0% (0/336)         Pain             1% (5/478)       0% (1/336)                        The subset of subjects who did not have pruritus, erythema, edema or pyoderma of skin and scalp, or ocular irritation prior to treatment were assessed for these signs and symptoms after treatment; the results are presented in Table 3.",Application site Irritation is an adverse reaction entity
"Table 2: Monitored Adverse Reactions - Application Site Symptoms   Event            ULESFIA    (r)    Lotion  Vehicle             Application site Irritation  2% (11/478)      1% (2/336)         Application site anesthesia &hypoesthesia  2% (10/478)      0% (0/336)         Pain             1% (5/478)       0% (1/336)                        The subset of subjects who did not have pruritus, erythema, edema or pyoderma of skin and scalp, or ocular irritation prior to treatment were assessed for these signs and symptoms after treatment; the results are presented in Table 3.",who is not a named entity
"Table 2: Monitored Adverse Reactions - Application Site Symptoms   Event            ULESFIA    (r)    Lotion  Vehicle             Application site Irritation  2% (11/478)      1% (2/336)         Application site anesthesia &hypoesthesia  2% (10/478)      0% (0/336)         Pain             1% (5/478)       0% (1/336)                        The subset of subjects who did not have pruritus, erythema, edema or pyoderma of skin and scalp, or ocular irritation prior to treatment were assessed for these signs and symptoms after treatment; the results are presented in Table 3.",2 is not a named entity
"Table 2: Monitored Adverse Reactions - Application Site Symptoms   Event            ULESFIA    (r)    Lotion  Vehicle             Application site Irritation  2% (11/478)      1% (2/336)         Application site anesthesia &hypoesthesia  2% (10/478)      0% (0/336)         Pain             1% (5/478)       0% (1/336)                        The subset of subjects who did not have pruritus, erythema, edema or pyoderma of skin and scalp, or ocular irritation prior to treatment were assessed for these signs and symptoms after treatment; the results are presented in Table 3.",Pain is an adverse reaction entity
"Table 2: Monitored Adverse Reactions - Application Site Symptoms   Event            ULESFIA    (r)    Lotion  Vehicle             Application site Irritation  2% (11/478)      1% (2/336)         Application site anesthesia &hypoesthesia  2% (10/478)      0% (0/336)         Pain             1% (5/478)       0% (1/336)                        The subset of subjects who did not have pruritus, erythema, edema or pyoderma of skin and scalp, or ocular irritation prior to treatment were assessed for these signs and symptoms after treatment; the results are presented in Table 3.",) 0 % is not a named entity
"Table 2: Monitored Adverse Reactions - Application Site Symptoms   Event            ULESFIA    (r)    Lotion  Vehicle             Application site Irritation  2% (11/478)      1% (2/336)         Application site anesthesia &hypoesthesia  2% (10/478)      0% (0/336)         Pain             1% (5/478)       0% (1/336)                        The subset of subjects who did not have pruritus, erythema, edema or pyoderma of skin and scalp, or ocular irritation prior to treatment were assessed for these signs and symptoms after treatment; the results are presented in Table 3.",Application site hypoesthesia is an adverse reaction entity
3           Contact Dermatitis              ULESFIA   (r)     Lotion may cause allergic or irritant dermatitis.,may cause is not a named entity
3           Contact Dermatitis              ULESFIA   (r)     Lotion may cause allergic or irritant dermatitis.,irritant dermatitis is an adverse reaction entity
3           Contact Dermatitis              ULESFIA   (r)     Lotion may cause allergic or irritant dermatitis.,allergic dermatitis is an adverse reaction entity
3           Contact Dermatitis              ULESFIA   (r)     Lotion may cause allergic or irritant dermatitis.,cause allergic or is not a named entity
A total of 2.2% of HIV-1-infected subjects receiving INTELENCE  (r)  discontinued from Phase 3 trials due to rash [ see  Adverse Reactions (6)    ].,of 2.2 % is not a named entity
A total of 2.2% of HIV-1-infected subjects receiving INTELENCE  (r)  discontinued from Phase 3 trials due to rash [ see  Adverse Reactions (6)    ].,rash is an adverse reaction entity
6 ADVERSE REACTIONS    The following adverse reactions are described in greater detail in other sections:     *  Severe skin and hypersensitivity reactions [ see  Warnings and Precautions (5.1)   ].,skin reactions is an adverse reaction entity
6 ADVERSE REACTIONS    The following adverse reactions are described in greater detail in other sections:     *  Severe skin and hypersensitivity reactions [ see  Warnings and Precautions (5.1)   ].,hypersensitivity reactions is an adverse reaction entity
6 ADVERSE REACTIONS    The following adverse reactions are described in greater detail in other sections:     *  Severe skin and hypersensitivity reactions [ see  Warnings and Precautions (5.1)   ].,5.1 ) ] is not a named entity
6 ADVERSE REACTIONS    The following adverse reactions are described in greater detail in other sections:     *  Severe skin and hypersensitivity reactions [ see  Warnings and Precautions (5.1)   ].,see Warnings is not a named entity
"5 WARNINGS AND PRECAUTIONS      EXCERPT:   Severe, potentially life threatening and fatal skin reactions have been reported.",been reported is not a named entity
"5 WARNINGS AND PRECAUTIONS      EXCERPT:   Severe, potentially life threatening and fatal skin reactions have been reported.",fatal is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS      EXCERPT:   Severe, potentially life threatening and fatal skin reactions have been reported.",potentially life threatening is not a named entity
"5 WARNINGS AND PRECAUTIONS      EXCERPT:   Severe, potentially life threatening and fatal skin reactions have been reported.",skin reactions is an adverse reaction entity
A total of 2.2% of HIV-1-infected subjects in Phase 3 trials receiving INTELENCE  (r)  discontinued due to rash.,rash is an adverse reaction entity
A total of 2.2% of HIV-1-infected subjects in Phase 3 trials receiving INTELENCE  (r)  discontinued due to rash.,of 2.2 is not a named entity
"The frequency, type and severity of adverse drug reactions in pediatric subjects were comparable to those observed in adult subjects, except for rash which was observed more frequently in pediatric subjects.",rash is an adverse reaction entity
"The frequency, type and severity of adverse drug reactions in pediatric subjects were comparable to those observed in adult subjects, except for rash which was observed more frequently in pediatric subjects.","frequency , is not a named entity"
"During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium  infection, cytomegalovirus, Pneumocystis jiroveci  pneumonia (PCP) or tuberculosis), which may necessitate further evaluation and treatment.",patients whose immune is not a named entity
"During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium  infection, cytomegalovirus, Pneumocystis jiroveci  pneumonia (PCP) or tuberculosis), which may necessitate further evaluation and treatment.",responds may develop is not a named entity
"During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium  infection, cytomegalovirus, Pneumocystis jiroveci  pneumonia (PCP) or tuberculosis), which may necessitate further evaluation and treatment.",inflammatory response is an adverse reaction entity
"During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium  infection, cytomegalovirus, Pneumocystis jiroveci  pneumonia (PCP) or tuberculosis), which may necessitate further evaluation and treatment.",cytomegalovirus is an adverse reaction entity
"During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium  infection, cytomegalovirus, Pneumocystis jiroveci  pneumonia (PCP) or tuberculosis), which may necessitate further evaluation and treatment.",opportunistic infections ( is not a named entity
"During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium  infection, cytomegalovirus, Pneumocystis jiroveci  pneumonia (PCP) or tuberculosis), which may necessitate further evaluation and treatment.",as is not a named entity
"During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium  infection, cytomegalovirus, Pneumocystis jiroveci  pneumonia (PCP) or tuberculosis), which may necessitate further evaluation and treatment.",tuberculosis is an adverse reaction entity
"During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium  infection, cytomegalovirus, Pneumocystis jiroveci  pneumonia (PCP) or tuberculosis), which may necessitate further evaluation and treatment.",PCP is an adverse reaction entity
"During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium  infection, cytomegalovirus, Pneumocystis jiroveci  pneumonia (PCP) or tuberculosis), which may necessitate further evaluation and treatment.",Mycobacterium avium infection is an adverse reaction entity
"During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium  infection, cytomegalovirus, Pneumocystis jiroveci  pneumonia (PCP) or tuberculosis), which may necessitate further evaluation and treatment.",phase of is not a named entity
"During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium  infection, cytomegalovirus, Pneumocystis jiroveci  pneumonia (PCP) or tuberculosis), which may necessitate further evaluation and treatment.",responds may is not a named entity
"During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium  infection, cytomegalovirus, Pneumocystis jiroveci  pneumonia (PCP) or tuberculosis), which may necessitate further evaluation and treatment.",opportunistic infections is an adverse reaction entity
"During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium  infection, cytomegalovirus, Pneumocystis jiroveci  pneumonia (PCP) or tuberculosis), which may necessitate further evaluation and treatment.",Pneumocystis jiroveci pneumonia is an adverse reaction entity
"During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium  infection, cytomegalovirus, Pneumocystis jiroveci  pneumonia (PCP) or tuberculosis), which may necessitate further evaluation and treatment.",phase is not a named entity
"The incidence of rash was higher in females [ see  Adverse Reactions (6)    ]     Discontinue INTELENCE  (r)  immediately if signs or symptoms of severe skin reactions or hypersensitivity reactions develop (including, but not limited to, severe rash or rash accompanied by fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, facial edema, hepatitis, eosinophilia, angioedema).",rash is an adverse reaction entity
"The incidence of rash was higher in females [ see  Adverse Reactions (6)    ]     Discontinue INTELENCE  (r)  immediately if signs or symptoms of severe skin reactions or hypersensitivity reactions develop (including, but not limited to, severe rash or rash accompanied by fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, facial edema, hepatitis, eosinophilia, angioedema).",) immediately if is not a named entity
"5.3 Immune Reconstitution Syndrome      Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy, including INTELENCE  (r)  .",therapy is not a named entity
"5.3 Immune Reconstitution Syndrome      Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy, including INTELENCE  (r)  .",Immune reconstitution syndrome is an adverse reaction entity
"In general, in clinical trials, rash was mild to moderate, occurred primarily in the second week of therapy, and was infrequent after Week 4.",rash is an adverse reaction entity
"In general, in clinical trials, rash was mild to moderate, occurred primarily in the second week of therapy, and was infrequent after Week 4.",of is not a named entity
Patients with a history of NNRTI-related rash did not appear to be at increased risk for the development of INTELENCE  (r)  -related rash compared to patients without a history of NNRTI-related rash.,r is not a named entity
Patients with a history of NNRTI-related rash did not appear to be at increased risk for the development of INTELENCE  (r)  -related rash compared to patients without a history of NNRTI-related rash.,at is not a named entity
Patients with a history of NNRTI-related rash did not appear to be at increased risk for the development of INTELENCE  (r)  -related rash compared to patients without a history of NNRTI-related rash.,rash is an adverse reaction entity
Patients with a history of NNRTI-related rash did not appear to be at increased risk for the development of INTELENCE  (r)  -related rash compared to patients without a history of NNRTI-related rash.,rash is an adverse reaction entity
Patients with a history of NNRTI-related rash did not appear to be at increased risk for the development of INTELENCE  (r)  -related rash compared to patients without a history of NNRTI-related rash.,) -related rash is not a named entity
Patients with a history of NNRTI-related rash did not appear to be at increased risk for the development of INTELENCE  (r)  -related rash compared to patients without a history of NNRTI-related rash.,rash is an adverse reaction entity
Musculoskeletal and Connective Tissue Disorders  : rhabdomyolysis       Skin and Subcutaneous Tissue Disorders  : Fatal cases of toxic epidermal necrolysis have been reported [  see  Warnings and Precautions (5.1)    ].,rhabdomyolysis is an adverse reaction entity
Musculoskeletal and Connective Tissue Disorders  : rhabdomyolysis       Skin and Subcutaneous Tissue Disorders  : Fatal cases of toxic epidermal necrolysis have been reported [  see  Warnings and Precautions (5.1)    ].,cases is not a named entity
Musculoskeletal and Connective Tissue Disorders  : rhabdomyolysis       Skin and Subcutaneous Tissue Disorders  : Fatal cases of toxic epidermal necrolysis have been reported [  see  Warnings and Precautions (5.1)    ].,Fatal is an adverse reaction entity
Musculoskeletal and Connective Tissue Disorders  : rhabdomyolysis       Skin and Subcutaneous Tissue Disorders  : Fatal cases of toxic epidermal necrolysis have been reported [  see  Warnings and Precautions (5.1)    ].,toxic epidermal necrolysis is an adverse reaction entity
Musculoskeletal and Connective Tissue Disorders  : rhabdomyolysis       Skin and Subcutaneous Tissue Disorders  : Fatal cases of toxic epidermal necrolysis have been reported [  see  Warnings and Precautions (5.1)    ].,Tissue is not a named entity
Musculoskeletal and Connective Tissue Disorders  : rhabdomyolysis       Skin and Subcutaneous Tissue Disorders  : Fatal cases of toxic epidermal necrolysis have been reported [  see  Warnings and Precautions (5.1)    ].,see is not a named entity
Rash was reported more frequently in female subjects than in male subjects (rash >= Grade 2 was reported in 13/64 [20.3%] females versus 2/37 [5.4%] males; discontinuations due to rash were reported in 4/64 [6.3%] females versus 0/37 [0%] males).,females is not a named entity
Rash was reported more frequently in female subjects than in male subjects (rash >= Grade 2 was reported in 13/64 [20.3%] females versus 2/37 [5.4%] males; discontinuations due to rash were reported in 4/64 [6.3%] females versus 0/37 [0%] males).,rash is an adverse reaction entity
Rash was reported more frequently in female subjects than in male subjects (rash >= Grade 2 was reported in 13/64 [20.3%] females versus 2/37 [5.4%] males; discontinuations due to rash were reported in 4/64 [6.3%] females versus 0/37 [0%] males).,female is not a named entity
Rash was reported more frequently in female subjects than in male subjects (rash >= Grade 2 was reported in 13/64 [20.3%] females versus 2/37 [5.4%] males; discontinuations due to rash were reported in 4/64 [6.3%] females versus 0/37 [0%] males).,Rash is an adverse reaction entity
Rash was reported more frequently in female subjects than in male subjects (rash >= Grade 2 was reported in 13/64 [20.3%] females versus 2/37 [5.4%] males; discontinuations due to rash were reported in 4/64 [6.3%] females versus 0/37 [0%] males).,rash is an adverse reaction entity
Rash was reported more frequently in female subjects than in male subjects (rash >= Grade 2 was reported in 13/64 [20.3%] females versus 2/37 [5.4%] males; discontinuations due to rash were reported in 4/64 [6.3%] females versus 0/37 [0%] males).,6.3 % is not a named entity
"Stevens-Johnson syndrome, drug hypersensitivity reaction and erythema multiforme were reported in less than 0.1% of subjects during clinical development with INTELENCE  (r)  [  see  Warnings and Precautions (5.1)    ].",Stevens-Johnson syndrome is an adverse reaction entity
"Stevens-Johnson syndrome, drug hypersensitivity reaction and erythema multiforme were reported in less than 0.1% of subjects during clinical development with INTELENCE  (r)  [  see  Warnings and Precautions (5.1)    ].",[ see is not a named entity
"Stevens-Johnson syndrome, drug hypersensitivity reaction and erythema multiforme were reported in less than 0.1% of subjects during clinical development with INTELENCE  (r)  [  see  Warnings and Precautions (5.1)    ].",hypersensitivity is an adverse reaction entity
"Stevens-Johnson syndrome, drug hypersensitivity reaction and erythema multiforme were reported in less than 0.1% of subjects during clinical development with INTELENCE  (r)  [  see  Warnings and Precautions (5.1)    ].",Warnings and Precautions is not a named entity
"Stevens-Johnson syndrome, drug hypersensitivity reaction and erythema multiforme were reported in less than 0.1% of subjects during clinical development with INTELENCE  (r)  [  see  Warnings and Precautions (5.1)    ].",erythema multiforme is an adverse reaction entity
"Stevens-Johnson syndrome, drug hypersensitivity reaction and erythema multiforme were reported in less than 0.1% of subjects during clinical development with INTELENCE  (r)  [  see  Warnings and Precautions (5.1)    ].",Precautions ( 5.1 is not a named entity
(  6.1  )     The most common adverse drug reactions in at least 2% of pediatric patients are rash and diarrhea.,rash is an adverse reaction entity
(  6.1  )     The most common adverse drug reactions in at least 2% of pediatric patients are rash and diarrhea.,least 2 is not a named entity
(  6.1  )     The most common adverse drug reactions in at least 2% of pediatric patients are rash and diarrhea.,diarrhea is an adverse reaction entity
(  6.1  )     The most common adverse drug reactions in at least 2% of pediatric patients are rash and diarrhea.,reactions in at is not a named entity
"(  5.1  )            5.1 Severe Skin and Hypersensitivity Reactions      Severe, potentially life-threatening, and fatal skin reactions have been reported.",skin reactions is an adverse reaction entity
"(  5.1  )            5.1 Severe Skin and Hypersensitivity Reactions      Severe, potentially life-threatening, and fatal skin reactions have been reported.",fatal is an adverse reaction entity
"(  5.1  )            5.1 Severe Skin and Hypersensitivity Reactions      Severe, potentially life-threatening, and fatal skin reactions have been reported.",and fatal is not a named entity
"(  5.1  )            5.1 Severe Skin and Hypersensitivity Reactions      Severe, potentially life-threatening, and fatal skin reactions have been reported.",have been is not a named entity
"These include cases of Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme.",necrolysis and is not a named entity
"These include cases of Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme.",erythema multiforme is an adverse reaction entity
"These include cases of Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme.",epidermal is not a named entity
"These include cases of Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme.",", is not a named entity"
"These include cases of Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme.",toxic epidermal necrolysis is an adverse reaction entity
"These include cases of Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme.",Stevens-Johnson syndrome is an adverse reaction entity
The incidence of rash was higher in women compared to men in the INTELENCE  (r)  arm in the Phase 3 trials (rash >= Grade 2 was reported in 9/60 [15.0%] women versus 51/539 [9.5%] men; discontinuations due to rash were reported in 3/60 [5.0%] women versus 10/539 [1.9%] men) [  see  Warnings and Precautions (5.1)    ].,women compared is not a named entity
The incidence of rash was higher in women compared to men in the INTELENCE  (r)  arm in the Phase 3 trials (rash >= Grade 2 was reported in 9/60 [15.0%] women versus 51/539 [9.5%] men; discontinuations due to rash were reported in 3/60 [5.0%] women versus 10/539 [1.9%] men) [  see  Warnings and Precautions (5.1)    ].,rash is an adverse reaction entity
The incidence of rash was higher in women compared to men in the INTELENCE  (r)  arm in the Phase 3 trials (rash >= Grade 2 was reported in 9/60 [15.0%] women versus 51/539 [9.5%] men; discontinuations due to rash were reported in 3/60 [5.0%] women versus 10/539 [1.9%] men) [  see  Warnings and Precautions (5.1)    ].,rash is an adverse reaction entity
The incidence of rash was higher in women compared to men in the INTELENCE  (r)  arm in the Phase 3 trials (rash >= Grade 2 was reported in 9/60 [15.0%] women versus 51/539 [9.5%] men; discontinuations due to rash were reported in 3/60 [5.0%] women versus 10/539 [1.9%] men) [  see  Warnings and Precautions (5.1)    ].,rash is an adverse reaction entity
The incidence of rash was higher in women compared to men in the INTELENCE  (r)  arm in the Phase 3 trials (rash >= Grade 2 was reported in 9/60 [15.0%] women versus 51/539 [9.5%] men; discontinuations due to rash were reported in 3/60 [5.0%] women versus 10/539 [1.9%] men) [  see  Warnings and Precautions (5.1)    ].,5.1 is not a named entity
The incidence of rash was higher in women compared to men in the INTELENCE  (r)  arm in the Phase 3 trials (rash >= Grade 2 was reported in 9/60 [15.0%] women versus 51/539 [9.5%] men; discontinuations due to rash were reported in 3/60 [5.0%] women versus 10/539 [1.9%] men) [  see  Warnings and Precautions (5.1)    ].,arm in is not a named entity
"Grade 2 or higher laboratory abnormalities that represent a worsening from baseline of AST, ALT or total bilirubin occurred in 27.8%, 25.0% and 7.1% respectively, of INTELENCE  (r)  -treated co-infected subjects as compared to 6.7%, 7.5% and 1.8% of non-co-infected INTELENCE  (r)  -treated subjects.",INTELENCE ( r is not a named entity
"Grade 2 or higher laboratory abnormalities that represent a worsening from baseline of AST, ALT or total bilirubin occurred in 27.8%, 25.0% and 7.1% respectively, of INTELENCE  (r)  -treated co-infected subjects as compared to 6.7%, 7.5% and 1.8% of non-co-infected INTELENCE  (r)  -treated subjects.",abnormalities of AST is an adverse reaction entity
"Grade 2 or higher laboratory abnormalities that represent a worsening from baseline of AST, ALT or total bilirubin occurred in 27.8%, 25.0% and 7.1% respectively, of INTELENCE  (r)  -treated co-infected subjects as compared to 6.7%, 7.5% and 1.8% of non-co-infected INTELENCE  (r)  -treated subjects.",abnormalities of ALT is an adverse reaction entity
"Grade 2 or higher laboratory abnormalities that represent a worsening from baseline of AST, ALT or total bilirubin occurred in 27.8%, 25.0% and 7.1% respectively, of INTELENCE  (r)  -treated co-infected subjects as compared to 6.7%, 7.5% and 1.8% of non-co-infected INTELENCE  (r)  -treated subjects.",% is not a named entity
"Grade 2 or higher laboratory abnormalities that represent a worsening from baseline of AST, ALT or total bilirubin occurred in 27.8%, 25.0% and 7.1% respectively, of INTELENCE  (r)  -treated co-infected subjects as compared to 6.7%, 7.5% and 1.8% of non-co-infected INTELENCE  (r)  -treated subjects.",co-infected subjects is not a named entity
"Grade 2 or higher laboratory abnormalities that represent a worsening from baseline of AST, ALT or total bilirubin occurred in 27.8%, 25.0% and 7.1% respectively, of INTELENCE  (r)  -treated co-infected subjects as compared to 6.7%, 7.5% and 1.8% of non-co-infected INTELENCE  (r)  -treated subjects.",abnormalities of total bilirubin is an adverse reaction entity
"5.2 Fat Redistribution      Redistribution/accumulation of body fat, including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and ""cushingoid appearance"" have been observed in patients receiving antiretroviral therapy.",have is not a named entity
"5.2 Fat Redistribution      Redistribution/accumulation of body fat, including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and ""cushingoid appearance"" have been observed in patients receiving antiretroviral therapy.",cushingoid appearance is an adverse reaction entity
"5.2 Fat Redistribution      Redistribution/accumulation of body fat, including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and ""cushingoid appearance"" have been observed in patients receiving antiretroviral therapy.",body fat peripheral wasting is an adverse reaction entity
"5.2 Fat Redistribution      Redistribution/accumulation of body fat, including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and ""cushingoid appearance"" have been observed in patients receiving antiretroviral therapy.","facial wasting , is not a named entity"
"5.2 Fat Redistribution      Redistribution/accumulation of body fat, including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and ""cushingoid appearance"" have been observed in patients receiving antiretroviral therapy.",'' have been is not a named entity
"5.2 Fat Redistribution      Redistribution/accumulation of body fat, including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and ""cushingoid appearance"" have been observed in patients receiving antiretroviral therapy.",accumulation of body fat is an adverse reaction entity
"5.2 Fat Redistribution      Redistribution/accumulation of body fat, including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and ""cushingoid appearance"" have been observed in patients receiving antiretroviral therapy.",dorsocervical fat enlargement is an adverse reaction entity
"5.2 Fat Redistribution      Redistribution/accumulation of body fat, including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and ""cushingoid appearance"" have been observed in patients receiving antiretroviral therapy.",central obesity is an adverse reaction entity
"5.2 Fat Redistribution      Redistribution/accumulation of body fat, including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and ""cushingoid appearance"" have been observed in patients receiving antiretroviral therapy.",fat enlargement is not a named entity
"5.2 Fat Redistribution      Redistribution/accumulation of body fat, including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and ""cushingoid appearance"" have been observed in patients receiving antiretroviral therapy.",have been observed is not a named entity
"5.2 Fat Redistribution      Redistribution/accumulation of body fat, including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and ""cushingoid appearance"" have been observed in patients receiving antiretroviral therapy.","wasting , facial is not a named entity"
"5.2 Fat Redistribution      Redistribution/accumulation of body fat, including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and ""cushingoid appearance"" have been observed in patients receiving antiretroviral therapy.",Redistribution of body fat is an adverse reaction entity
"5.2 Fat Redistribution      Redistribution/accumulation of body fat, including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and ""cushingoid appearance"" have been observed in patients receiving antiretroviral therapy.",buffalo hump is an adverse reaction entity
"5.2 Fat Redistribution      Redistribution/accumulation of body fat, including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and ""cushingoid appearance"" have been observed in patients receiving antiretroviral therapy.",", breast is not a named entity"
"5.2 Fat Redistribution      Redistribution/accumulation of body fat, including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and ""cushingoid appearance"" have been observed in patients receiving antiretroviral therapy.",and is not a named entity
"5.2 Fat Redistribution      Redistribution/accumulation of body fat, including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and ""cushingoid appearance"" have been observed in patients receiving antiretroviral therapy.",", including is not a named entity"
"5.2 Fat Redistribution      Redistribution/accumulation of body fat, including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and ""cushingoid appearance"" have been observed in patients receiving antiretroviral therapy.",facial wasting is an adverse reaction entity
"5.2 Fat Redistribution      Redistribution/accumulation of body fat, including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and ""cushingoid appearance"" have been observed in patients receiving antiretroviral therapy.",breast enlargement is an adverse reaction entity
EXCERPT:   The most common adverse drug reactions of moderate to severe intensity (at least 2%) which occurred at a higher rate than placebo in adults are rash and peripheral neuropathy.,adults is not a named entity
EXCERPT:   The most common adverse drug reactions of moderate to severe intensity (at least 2%) which occurred at a higher rate than placebo in adults are rash and peripheral neuropathy.,% ) is not a named entity
EXCERPT:   The most common adverse drug reactions of moderate to severe intensity (at least 2%) which occurred at a higher rate than placebo in adults are rash and peripheral neuropathy.,rash is an adverse reaction entity
EXCERPT:   The most common adverse drug reactions of moderate to severe intensity (at least 2%) which occurred at a higher rate than placebo in adults are rash and peripheral neuropathy.,peripheral neuropathy is an adverse reaction entity
"Bleeding events of any grade, including bruising and petechiae, occurred in approximately half of patients treated with IMBRUVICA.",bruising is an adverse reaction entity
"Bleeding events of any grade, including bruising and petechiae, occurred in approximately half of patients treated with IMBRUVICA.",petechiae is an adverse reaction entity
"Bleeding events of any grade, including bruising and petechiae, occurred in approximately half of patients treated with IMBRUVICA.",IMBRUVICA is not a named entity
"Bleeding events of any grade, including bruising and petechiae, occurred in approximately half of patients treated with IMBRUVICA.",any is not a named entity
"Bleeding events of any grade, including bruising and petechiae, occurred in approximately half of patients treated with IMBRUVICA.",of any grade is not a named entity
"Bleeding events of any grade, including bruising and petechiae, occurred in approximately half of patients treated with IMBRUVICA.",Bleeding is an adverse reaction entity
*  Infections: Monitor patients for fever and infections and evaluate promptly (  5.2  ).,Infections is an adverse reaction entity
*  Infections: Monitor patients for fever and infections and evaluate promptly (  5.2  ).,* Infections is not a named entity
"5.4 Atrial Fibrillation      Atrial fibrillation and atrial flutter (range, 6 to 9%) have occurred in patients treated with IMBRUVICA, particularly in patients with cardiac risk factors, acute infections, and a previous history of atrial fibrillation.",6 is not a named entity
"5.4 Atrial Fibrillation      Atrial fibrillation and atrial flutter (range, 6 to 9%) have occurred in patients treated with IMBRUVICA, particularly in patients with cardiac risk factors, acute infections, and a previous history of atrial fibrillation.",previous history is not a named entity
"5.4 Atrial Fibrillation      Atrial fibrillation and atrial flutter (range, 6 to 9%) have occurred in patients treated with IMBRUVICA, particularly in patients with cardiac risk factors, acute infections, and a previous history of atrial fibrillation.",atrial flutter is an adverse reaction entity
"5.4 Atrial Fibrillation      Atrial fibrillation and atrial flutter (range, 6 to 9%) have occurred in patients treated with IMBRUVICA, particularly in patients with cardiac risk factors, acute infections, and a previous history of atrial fibrillation.",Atrial fibrillation is an adverse reaction entity
"Decrease of Hemoglobin, Platelets, or Neutrophils in Patients with WM (N=63)                                          Percent of Patients (N=63)         All Grades (%)                              Grade 3 or 4 (%)                 Platelets Decreased                                43                                 13                     Neutrophils Decreased                              44                                 19                     Hemoglobin Decreased                               13                                  8                               6.",Hemoglobin Decreased is an adverse reaction entity
"Decrease of Hemoglobin, Platelets, or Neutrophils in Patients with WM (N=63)                                          Percent of Patients (N=63)         All Grades (%)                              Grade 3 or 4 (%)                 Platelets Decreased                                43                                 13                     Neutrophils Decreased                              44                                 19                     Hemoglobin Decreased                               13                                  8                               6.",) is not a named entity
"Decrease of Hemoglobin, Platelets, or Neutrophils in Patients with WM (N=63)                                          Percent of Patients (N=63)         All Grades (%)                              Grade 3 or 4 (%)                 Platelets Decreased                                43                                 13                     Neutrophils Decreased                              44                                 19                     Hemoglobin Decreased                               13                                  8                               6.",in is not a named entity
"Decrease of Hemoglobin, Platelets, or Neutrophils in Patients with WM (N=63)                                          Percent of Patients (N=63)         All Grades (%)                              Grade 3 or 4 (%)                 Platelets Decreased                                43                                 13                     Neutrophils Decreased                              44                                 19                     Hemoglobin Decreased                               13                                  8                               6.",N=63 is not a named entity
"Decrease of Hemoglobin, Platelets, or Neutrophils in Patients with WM (N=63)                                          Percent of Patients (N=63)         All Grades (%)                              Grade 3 or 4 (%)                 Platelets Decreased                                43                                 13                     Neutrophils Decreased                              44                                 19                     Hemoglobin Decreased                               13                                  8                               6.",) Percent of is not a named entity
"Decrease of Hemoglobin, Platelets, or Neutrophils in Patients with WM (N=63)                                          Percent of Patients (N=63)         All Grades (%)                              Grade 3 or 4 (%)                 Platelets Decreased                                43                                 13                     Neutrophils Decreased                              44                                 19                     Hemoglobin Decreased                               13                                  8                               6.",Decrease of Neutrophils is an adverse reaction entity
"Decrease of Hemoglobin, Platelets, or Neutrophils in Patients with WM (N=63)                                          Percent of Patients (N=63)         All Grades (%)                              Grade 3 or 4 (%)                 Platelets Decreased                                43                                 13                     Neutrophils Decreased                              44                                 19                     Hemoglobin Decreased                               13                                  8                               6.",43 13 Neutrophils is not a named entity
"Decrease of Hemoglobin, Platelets, or Neutrophils in Patients with WM (N=63)                                          Percent of Patients (N=63)         All Grades (%)                              Grade 3 or 4 (%)                 Platelets Decreased                                43                                 13                     Neutrophils Decreased                              44                                 19                     Hemoglobin Decreased                               13                                  8                               6.",Decrease of Platelets is an adverse reaction entity
"Decrease of Hemoglobin, Platelets, or Neutrophils in Patients with WM (N=63)                                          Percent of Patients (N=63)         All Grades (%)                              Grade 3 or 4 (%)                 Platelets Decreased                                43                                 13                     Neutrophils Decreased                              44                                 19                     Hemoglobin Decreased                               13                                  8                               6.",Platelets Decreased is an adverse reaction entity
"Decrease of Hemoglobin, Platelets, or Neutrophils in Patients with WM (N=63)                                          Percent of Patients (N=63)         All Grades (%)                              Grade 3 or 4 (%)                 Platelets Decreased                                43                                 13                     Neutrophils Decreased                              44                                 19                     Hemoglobin Decreased                               13                                  8                               6.",43 13 Neutrophils is not a named entity
"Decrease of Hemoglobin, Platelets, or Neutrophils in Patients with WM (N=63)                                          Percent of Patients (N=63)         All Grades (%)                              Grade 3 or 4 (%)                 Platelets Decreased                                43                                 13                     Neutrophils Decreased                              44                                 19                     Hemoglobin Decreased                               13                                  8                               6.",Neutrophils Decreased is an adverse reaction entity
"Decrease of Hemoglobin, Platelets, or Neutrophils in Patients with WM (N=63)                                          Percent of Patients (N=63)         All Grades (%)                              Grade 3 or 4 (%)                 Platelets Decreased                                43                                 13                     Neutrophils Decreased                              44                                 19                     Hemoglobin Decreased                               13                                  8                               6.",Decrease of Hemoglobin is an adverse reaction entity
"5.3 Cytopenias      Treatment-emergent Grade 3 or 4 cytopenias including neutropenia (range, 19 to 29%), thrombocytopenia (range, 5 to 17%), and anemia (range, 0 to 9%) occurred in patients treated with IMBRUVICA.",", thrombocytopenia ( is not a named entity"
"5.3 Cytopenias      Treatment-emergent Grade 3 or 4 cytopenias including neutropenia (range, 19 to 29%), thrombocytopenia (range, 5 to 17%), and anemia (range, 0 to 9%) occurred in patients treated with IMBRUVICA.",cytopenias is an adverse reaction entity
"5.3 Cytopenias      Treatment-emergent Grade 3 or 4 cytopenias including neutropenia (range, 19 to 29%), thrombocytopenia (range, 5 to 17%), and anemia (range, 0 to 9%) occurred in patients treated with IMBRUVICA.",thrombocytopenia is an adverse reaction entity
"5.3 Cytopenias      Treatment-emergent Grade 3 or 4 cytopenias including neutropenia (range, 19 to 29%), thrombocytopenia (range, 5 to 17%), and anemia (range, 0 to 9%) occurred in patients treated with IMBRUVICA.",neutropenia is an adverse reaction entity
"5.3 Cytopenias      Treatment-emergent Grade 3 or 4 cytopenias including neutropenia (range, 19 to 29%), thrombocytopenia (range, 5 to 17%), and anemia (range, 0 to 9%) occurred in patients treated with IMBRUVICA.",cytopenias is an adverse reaction entity
"5.3 Cytopenias      Treatment-emergent Grade 3 or 4 cytopenias including neutropenia (range, 19 to 29%), thrombocytopenia (range, 5 to 17%), and anemia (range, 0 to 9%) occurred in patients treated with IMBRUVICA.",5.3 is not a named entity
"5.3 Cytopenias      Treatment-emergent Grade 3 or 4 cytopenias including neutropenia (range, 19 to 29%), thrombocytopenia (range, 5 to 17%), and anemia (range, 0 to 9%) occurred in patients treated with IMBRUVICA.",patients treated is not a named entity
"5.3 Cytopenias      Treatment-emergent Grade 3 or 4 cytopenias including neutropenia (range, 19 to 29%), thrombocytopenia (range, 5 to 17%), and anemia (range, 0 to 9%) occurred in patients treated with IMBRUVICA.",anemia is an adverse reaction entity
"5.3 Cytopenias      Treatment-emergent Grade 3 or 4 cytopenias including neutropenia (range, 19 to 29%), thrombocytopenia (range, 5 to 17%), and anemia (range, 0 to 9%) occurred in patients treated with IMBRUVICA.",17 % is not a named entity
"5.3 Cytopenias      Treatment-emergent Grade 3 or 4 cytopenias including neutropenia (range, 19 to 29%), thrombocytopenia (range, 5 to 17%), and anemia (range, 0 to 9%) occurred in patients treated with IMBRUVICA.","range , 0 is not a named entity"
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in more detail in other sections of the labeling:     *  Hemorrhage [see  Warnings and Precautions (5.1)  ]    *  Infections [see  Warnings and Precautions (5.2)  ]    *  Cytopenias [see  Warnings and Precautions (5.3)  ]    *  Atrial Fibrillation [see  Warnings and Precautions (5.4)  ]    *  Second Primary Malignancies [see  Warnings and Precautions (5.5)  ]    *  Tumor Lysis Syndrome [see  Warnings and Precautions (5.6)  ]       Because clinical trials are conducted under widely variable conditions, adverse event rates observed in clinical trials of a drug cannot be directly compared with rates of clinical trials of another drug and may not reflect the rates observed in practice.",Atrial Fibrillation is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in more detail in other sections of the labeling:     *  Hemorrhage [see  Warnings and Precautions (5.1)  ]    *  Infections [see  Warnings and Precautions (5.2)  ]    *  Cytopenias [see  Warnings and Precautions (5.3)  ]    *  Atrial Fibrillation [see  Warnings and Precautions (5.4)  ]    *  Second Primary Malignancies [see  Warnings and Precautions (5.5)  ]    *  Tumor Lysis Syndrome [see  Warnings and Precautions (5.6)  ]       Because clinical trials are conducted under widely variable conditions, adverse event rates observed in clinical trials of a drug cannot be directly compared with rates of clinical trials of another drug and may not reflect the rates observed in practice.",Warnings is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in more detail in other sections of the labeling:     *  Hemorrhage [see  Warnings and Precautions (5.1)  ]    *  Infections [see  Warnings and Precautions (5.2)  ]    *  Cytopenias [see  Warnings and Precautions (5.3)  ]    *  Atrial Fibrillation [see  Warnings and Precautions (5.4)  ]    *  Second Primary Malignancies [see  Warnings and Precautions (5.5)  ]    *  Tumor Lysis Syndrome [see  Warnings and Precautions (5.6)  ]       Because clinical trials are conducted under widely variable conditions, adverse event rates observed in clinical trials of a drug cannot be directly compared with rates of clinical trials of another drug and may not reflect the rates observed in practice.",6 is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in more detail in other sections of the labeling:     *  Hemorrhage [see  Warnings and Precautions (5.1)  ]    *  Infections [see  Warnings and Precautions (5.2)  ]    *  Cytopenias [see  Warnings and Precautions (5.3)  ]    *  Atrial Fibrillation [see  Warnings and Precautions (5.4)  ]    *  Second Primary Malignancies [see  Warnings and Precautions (5.5)  ]    *  Tumor Lysis Syndrome [see  Warnings and Precautions (5.6)  ]       Because clinical trials are conducted under widely variable conditions, adverse event rates observed in clinical trials of a drug cannot be directly compared with rates of clinical trials of another drug and may not reflect the rates observed in practice.",Warnings and Precautions is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in more detail in other sections of the labeling:     *  Hemorrhage [see  Warnings and Precautions (5.1)  ]    *  Infections [see  Warnings and Precautions (5.2)  ]    *  Cytopenias [see  Warnings and Precautions (5.3)  ]    *  Atrial Fibrillation [see  Warnings and Precautions (5.4)  ]    *  Second Primary Malignancies [see  Warnings and Precautions (5.5)  ]    *  Tumor Lysis Syndrome [see  Warnings and Precautions (5.6)  ]       Because clinical trials are conducted under widely variable conditions, adverse event rates observed in clinical trials of a drug cannot be directly compared with rates of clinical trials of another drug and may not reflect the rates observed in practice.",Tumor Lysis Syndrome is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in more detail in other sections of the labeling:     *  Hemorrhage [see  Warnings and Precautions (5.1)  ]    *  Infections [see  Warnings and Precautions (5.2)  ]    *  Cytopenias [see  Warnings and Precautions (5.3)  ]    *  Atrial Fibrillation [see  Warnings and Precautions (5.4)  ]    *  Second Primary Malignancies [see  Warnings and Precautions (5.5)  ]    *  Tumor Lysis Syndrome [see  Warnings and Precautions (5.6)  ]       Because clinical trials are conducted under widely variable conditions, adverse event rates observed in clinical trials of a drug cannot be directly compared with rates of clinical trials of another drug and may not reflect the rates observed in practice.",Cytopenias is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in more detail in other sections of the labeling:     *  Hemorrhage [see  Warnings and Precautions (5.1)  ]    *  Infections [see  Warnings and Precautions (5.2)  ]    *  Cytopenias [see  Warnings and Precautions (5.3)  ]    *  Atrial Fibrillation [see  Warnings and Precautions (5.4)  ]    *  Second Primary Malignancies [see  Warnings and Precautions (5.5)  ]    *  Tumor Lysis Syndrome [see  Warnings and Precautions (5.6)  ]       Because clinical trials are conducted under widely variable conditions, adverse event rates observed in clinical trials of a drug cannot be directly compared with rates of clinical trials of another drug and may not reflect the rates observed in practice.",Infections is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in more detail in other sections of the labeling:     *  Hemorrhage [see  Warnings and Precautions (5.1)  ]    *  Infections [see  Warnings and Precautions (5.2)  ]    *  Cytopenias [see  Warnings and Precautions (5.3)  ]    *  Atrial Fibrillation [see  Warnings and Precautions (5.4)  ]    *  Second Primary Malignancies [see  Warnings and Precautions (5.5)  ]    *  Tumor Lysis Syndrome [see  Warnings and Precautions (5.6)  ]       Because clinical trials are conducted under widely variable conditions, adverse event rates observed in clinical trials of a drug cannot be directly compared with rates of clinical trials of another drug and may not reflect the rates observed in practice.",5.5 ) ] is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in more detail in other sections of the labeling:     *  Hemorrhage [see  Warnings and Precautions (5.1)  ]    *  Infections [see  Warnings and Precautions (5.2)  ]    *  Cytopenias [see  Warnings and Precautions (5.3)  ]    *  Atrial Fibrillation [see  Warnings and Precautions (5.4)  ]    *  Second Primary Malignancies [see  Warnings and Precautions (5.5)  ]    *  Tumor Lysis Syndrome [see  Warnings and Precautions (5.6)  ]       Because clinical trials are conducted under widely variable conditions, adverse event rates observed in clinical trials of a drug cannot be directly compared with rates of clinical trials of another drug and may not reflect the rates observed in practice.",Second Primary Malignancies is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in more detail in other sections of the labeling:     *  Hemorrhage [see  Warnings and Precautions (5.1)  ]    *  Infections [see  Warnings and Precautions (5.2)  ]    *  Cytopenias [see  Warnings and Precautions (5.3)  ]    *  Atrial Fibrillation [see  Warnings and Precautions (5.4)  ]    *  Second Primary Malignancies [see  Warnings and Precautions (5.5)  ]    *  Tumor Lysis Syndrome [see  Warnings and Precautions (5.6)  ]       Because clinical trials are conducted under widely variable conditions, adverse event rates observed in clinical trials of a drug cannot be directly compared with rates of clinical trials of another drug and may not reflect the rates observed in practice.",( 5.4 ) is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in more detail in other sections of the labeling:     *  Hemorrhage [see  Warnings and Precautions (5.1)  ]    *  Infections [see  Warnings and Precautions (5.2)  ]    *  Cytopenias [see  Warnings and Precautions (5.3)  ]    *  Atrial Fibrillation [see  Warnings and Precautions (5.4)  ]    *  Second Primary Malignancies [see  Warnings and Precautions (5.5)  ]    *  Tumor Lysis Syndrome [see  Warnings and Precautions (5.6)  ]       Because clinical trials are conducted under widely variable conditions, adverse event rates observed in clinical trials of a drug cannot be directly compared with rates of clinical trials of another drug and may not reflect the rates observed in practice.",Hemorrhage is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in more detail in other sections of the labeling:     *  Hemorrhage [see  Warnings and Precautions (5.1)  ]    *  Infections [see  Warnings and Precautions (5.2)  ]    *  Cytopenias [see  Warnings and Precautions (5.3)  ]    *  Atrial Fibrillation [see  Warnings and Precautions (5.4)  ]    *  Second Primary Malignancies [see  Warnings and Precautions (5.5)  ]    *  Tumor Lysis Syndrome [see  Warnings and Precautions (5.6)  ]       Because clinical trials are conducted under widely variable conditions, adverse event rates observed in clinical trials of a drug cannot be directly compared with rates of clinical trials of another drug and may not reflect the rates observed in practice.",observed is not a named entity
"5.7 Embryo-Fetal Toxicity      Based on findings in animals, IMBRUVICA can cause fetal harm when administered to a pregnant woman.",fetal harm is an adverse reaction entity
"5.7 Embryo-Fetal Toxicity      Based on findings in animals, IMBRUVICA can cause fetal harm when administered to a pregnant woman.",when is not a named entity
5.1 Hemorrhage       Fatal bleeding events have occurred in patients treated with IMBRUVICA.,occurred in patients is not a named entity
5.1 Hemorrhage       Fatal bleeding events have occurred in patients treated with IMBRUVICA.,5.1 Hemorrhage Fatal is not a named entity
5.1 Hemorrhage       Fatal bleeding events have occurred in patients treated with IMBRUVICA.,bleeding events is an adverse reaction entity
5.1 Hemorrhage       Fatal bleeding events have occurred in patients treated with IMBRUVICA.,Fatal is an adverse reaction entity
The most frequent adverse reaction leading to treatment discontinuation was subdural hematoma (1.8%).,subdural hematoma is an adverse reaction entity
The most frequent adverse reaction leading to treatment discontinuation was subdural hematoma (1.8%).,treatment discontinuation is not a named entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Hemorrhage: Monitor for bleeding (  5.1  ).,bleeding is not a named entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Hemorrhage: Monitor for bleeding (  5.1  ).,Hemorrhage is an adverse reaction entity
Increases in creatinine 1.5 to 3 times the upper limit of normal occurred in 9% of patients.,9 % is not a named entity
Increases in creatinine 1.5 to 3 times the upper limit of normal occurred in 9% of patients.,Increases in creatinine is an adverse reaction entity
"Hypersensitivity reactions including anaphylactic shock (fatal), urticaria, and angioedema have been reported.",urticaria is an adverse reaction entity
"Hypersensitivity reactions including anaphylactic shock (fatal), urticaria, and angioedema have been reported.",Hypersensitivity reactions is an adverse reaction entity
"Hypersensitivity reactions including anaphylactic shock (fatal), urticaria, and angioedema have been reported.",anaphylactic shock is an adverse reaction entity
"Hypersensitivity reactions including anaphylactic shock (fatal), urticaria, and angioedema have been reported.",shock is not a named entity
"Hypersensitivity reactions including anaphylactic shock (fatal), urticaria, and angioedema have been reported.",shock ( fatal is not a named entity
"Hypersensitivity reactions including anaphylactic shock (fatal), urticaria, and angioedema have been reported.","fatal ) , is not a named entity"
"Hypersensitivity reactions including anaphylactic shock (fatal), urticaria, and angioedema have been reported.",angioedema is an adverse reaction entity
"Hypersensitivity reactions including anaphylactic shock (fatal), urticaria, and angioedema have been reported.",", urticaria is not a named entity"
"Hypersensitivity reactions including anaphylactic shock (fatal), urticaria, and angioedema have been reported.",fatal ) is not a named entity
"Hypersensitivity reactions including anaphylactic shock (fatal), urticaria, and angioedema have been reported.",fatal is an adverse reaction entity
Forty percent of patients had elevated uric acid levels on study including 13% with values above 10 mg/dL.,above is not a named entity
Forty percent of patients had elevated uric acid levels on study including 13% with values above 10 mg/dL.,Forty percent is not a named entity
Forty percent of patients had elevated uric acid levels on study including 13% with values above 10 mg/dL.,elevated uric acid levels is an adverse reaction entity
Forty percent of patients had elevated uric acid levels on study including 13% with values above 10 mg/dL.,elevated uric acid levels is an adverse reaction entity
"EXCERPT:   The most common adverse reactions (>=25%) in patients with B-cell malignancies (MCL, CLL, WM) were thrombocytopenia, neutropenia, diarrhea, anemia, fatigue, musculoskeletal pain, bruising, nausea, upper respiratory tract infection, and rash.",respiratory tract is not a named entity
"EXCERPT:   The most common adverse reactions (>=25%) in patients with B-cell malignancies (MCL, CLL, WM) were thrombocytopenia, neutropenia, diarrhea, anemia, fatigue, musculoskeletal pain, bruising, nausea, upper respiratory tract infection, and rash.",", musculoskeletal is not a named entity"
"EXCERPT:   The most common adverse reactions (>=25%) in patients with B-cell malignancies (MCL, CLL, WM) were thrombocytopenia, neutropenia, diarrhea, anemia, fatigue, musculoskeletal pain, bruising, nausea, upper respiratory tract infection, and rash.",anemia is an adverse reaction entity
"EXCERPT:   The most common adverse reactions (>=25%) in patients with B-cell malignancies (MCL, CLL, WM) were thrombocytopenia, neutropenia, diarrhea, anemia, fatigue, musculoskeletal pain, bruising, nausea, upper respiratory tract infection, and rash.",adverse reactions ( is not a named entity
"EXCERPT:   The most common adverse reactions (>=25%) in patients with B-cell malignancies (MCL, CLL, WM) were thrombocytopenia, neutropenia, diarrhea, anemia, fatigue, musculoskeletal pain, bruising, nausea, upper respiratory tract infection, and rash.",rash is an adverse reaction entity
"EXCERPT:   The most common adverse reactions (>=25%) in patients with B-cell malignancies (MCL, CLL, WM) were thrombocytopenia, neutropenia, diarrhea, anemia, fatigue, musculoskeletal pain, bruising, nausea, upper respiratory tract infection, and rash.","CLL , is not a named entity"
"EXCERPT:   The most common adverse reactions (>=25%) in patients with B-cell malignancies (MCL, CLL, WM) were thrombocytopenia, neutropenia, diarrhea, anemia, fatigue, musculoskeletal pain, bruising, nausea, upper respiratory tract infection, and rash.",thrombocytopenia is an adverse reaction entity
"EXCERPT:   The most common adverse reactions (>=25%) in patients with B-cell malignancies (MCL, CLL, WM) were thrombocytopenia, neutropenia, diarrhea, anemia, fatigue, musculoskeletal pain, bruising, nausea, upper respiratory tract infection, and rash.",musculoskeletal pain is an adverse reaction entity
"EXCERPT:   The most common adverse reactions (>=25%) in patients with B-cell malignancies (MCL, CLL, WM) were thrombocytopenia, neutropenia, diarrhea, anemia, fatigue, musculoskeletal pain, bruising, nausea, upper respiratory tract infection, and rash.",nausea is an adverse reaction entity
"EXCERPT:   The most common adverse reactions (>=25%) in patients with B-cell malignancies (MCL, CLL, WM) were thrombocytopenia, neutropenia, diarrhea, anemia, fatigue, musculoskeletal pain, bruising, nausea, upper respiratory tract infection, and rash.",> =25 is not a named entity
"EXCERPT:   The most common adverse reactions (>=25%) in patients with B-cell malignancies (MCL, CLL, WM) were thrombocytopenia, neutropenia, diarrhea, anemia, fatigue, musculoskeletal pain, bruising, nausea, upper respiratory tract infection, and rash.",( is not a named entity
"EXCERPT:   The most common adverse reactions (>=25%) in patients with B-cell malignancies (MCL, CLL, WM) were thrombocytopenia, neutropenia, diarrhea, anemia, fatigue, musculoskeletal pain, bruising, nausea, upper respiratory tract infection, and rash.",upper respiratory tract infection is an adverse reaction entity
"EXCERPT:   The most common adverse reactions (>=25%) in patients with B-cell malignancies (MCL, CLL, WM) were thrombocytopenia, neutropenia, diarrhea, anemia, fatigue, musculoskeletal pain, bruising, nausea, upper respiratory tract infection, and rash.",", neutropenia is not a named entity"
"EXCERPT:   The most common adverse reactions (>=25%) in patients with B-cell malignancies (MCL, CLL, WM) were thrombocytopenia, neutropenia, diarrhea, anemia, fatigue, musculoskeletal pain, bruising, nausea, upper respiratory tract infection, and rash.",fatigue is an adverse reaction entity
"EXCERPT:   The most common adverse reactions (>=25%) in patients with B-cell malignancies (MCL, CLL, WM) were thrombocytopenia, neutropenia, diarrhea, anemia, fatigue, musculoskeletal pain, bruising, nausea, upper respiratory tract infection, and rash.",common is not a named entity
"EXCERPT:   The most common adverse reactions (>=25%) in patients with B-cell malignancies (MCL, CLL, WM) were thrombocytopenia, neutropenia, diarrhea, anemia, fatigue, musculoskeletal pain, bruising, nausea, upper respiratory tract infection, and rash.",neutropenia is an adverse reaction entity
"EXCERPT:   The most common adverse reactions (>=25%) in patients with B-cell malignancies (MCL, CLL, WM) were thrombocytopenia, neutropenia, diarrhea, anemia, fatigue, musculoskeletal pain, bruising, nausea, upper respiratory tract infection, and rash.",bruising is an adverse reaction entity
"EXCERPT:   The most common adverse reactions (>=25%) in patients with B-cell malignancies (MCL, CLL, WM) were thrombocytopenia, neutropenia, diarrhea, anemia, fatigue, musculoskeletal pain, bruising, nausea, upper respiratory tract infection, and rash.","nausea , upper is not a named entity"
"EXCERPT:   The most common adverse reactions (>=25%) in patients with B-cell malignancies (MCL, CLL, WM) were thrombocytopenia, neutropenia, diarrhea, anemia, fatigue, musculoskeletal pain, bruising, nausea, upper respiratory tract infection, and rash.",patients with is not a named entity
"EXCERPT:   The most common adverse reactions (>=25%) in patients with B-cell malignancies (MCL, CLL, WM) were thrombocytopenia, neutropenia, diarrhea, anemia, fatigue, musculoskeletal pain, bruising, nausea, upper respiratory tract infection, and rash.",diarrhea is an adverse reaction entity
5.6 Tumor Lysis Syndrome       Tumor lysis syndrome has been reported with IMBRUVICA therapy.,lysis syndrome has is not a named entity
5.6 Tumor Lysis Syndrome       Tumor lysis syndrome has been reported with IMBRUVICA therapy.,Tumor lysis syndrome is an adverse reaction entity
"5.5 Second Primary Malignancies      Other malignancies (range, 5 to 14%) including non-skin carcinomas (range, 1 to 3%) have occurred in patients treated with IMBRUVICA.",malignancies is an adverse reaction entity
"5.5 Second Primary Malignancies      Other malignancies (range, 5 to 14%) including non-skin carcinomas (range, 1 to 3%) have occurred in patients treated with IMBRUVICA.",5.5 Second Primary is not a named entity
"5.5 Second Primary Malignancies      Other malignancies (range, 5 to 14%) including non-skin carcinomas (range, 1 to 3%) have occurred in patients treated with IMBRUVICA.",non-skin carcinomas is an adverse reaction entity
"5.5 Second Primary Malignancies      Other malignancies (range, 5 to 14%) including non-skin carcinomas (range, 1 to 3%) have occurred in patients treated with IMBRUVICA.",( is not a named entity
IMBRUVICA may increase the risk of hemorrhage in patients receiving antiplatelet or anticoagulant therapies.,increase the risk is not a named entity
IMBRUVICA may increase the risk of hemorrhage in patients receiving antiplatelet or anticoagulant therapies.,hemorrhage is an adverse reaction entity
"The most commonly occurring adverse reactions (>= 20%) were thrombocytopenia, diarrhea, neutropenia, anemia, fatigue, musculoskeletal pain, peripheral edema, upper respiratory tract infection, nausea, bruising, dyspnea, constipation, rash, abdominal pain, vomiting and decreased appetite (see  Tables 1  and  2  ).",most is not a named entity
"The most commonly occurring adverse reactions (>= 20%) were thrombocytopenia, diarrhea, neutropenia, anemia, fatigue, musculoskeletal pain, peripheral edema, upper respiratory tract infection, nausea, bruising, dyspnea, constipation, rash, abdominal pain, vomiting and decreased appetite (see  Tables 1  and  2  ).",", rash , is not a named entity"
"The most commonly occurring adverse reactions (>= 20%) were thrombocytopenia, diarrhea, neutropenia, anemia, fatigue, musculoskeletal pain, peripheral edema, upper respiratory tract infection, nausea, bruising, dyspnea, constipation, rash, abdominal pain, vomiting and decreased appetite (see  Tables 1  and  2  ).",bruising is an adverse reaction entity
"The most commonly occurring adverse reactions (>= 20%) were thrombocytopenia, diarrhea, neutropenia, anemia, fatigue, musculoskeletal pain, peripheral edema, upper respiratory tract infection, nausea, bruising, dyspnea, constipation, rash, abdominal pain, vomiting and decreased appetite (see  Tables 1  and  2  ).",nausea is an adverse reaction entity
"The most commonly occurring adverse reactions (>= 20%) were thrombocytopenia, diarrhea, neutropenia, anemia, fatigue, musculoskeletal pain, peripheral edema, upper respiratory tract infection, nausea, bruising, dyspnea, constipation, rash, abdominal pain, vomiting and decreased appetite (see  Tables 1  and  2  ).",dyspnea is an adverse reaction entity
"The most commonly occurring adverse reactions (>= 20%) were thrombocytopenia, diarrhea, neutropenia, anemia, fatigue, musculoskeletal pain, peripheral edema, upper respiratory tract infection, nausea, bruising, dyspnea, constipation, rash, abdominal pain, vomiting and decreased appetite (see  Tables 1  and  2  ).",Tables is not a named entity
"The most commonly occurring adverse reactions (>= 20%) were thrombocytopenia, diarrhea, neutropenia, anemia, fatigue, musculoskeletal pain, peripheral edema, upper respiratory tract infection, nausea, bruising, dyspnea, constipation, rash, abdominal pain, vomiting and decreased appetite (see  Tables 1  and  2  ).",neutropenia is an adverse reaction entity
"The most commonly occurring adverse reactions (>= 20%) were thrombocytopenia, diarrhea, neutropenia, anemia, fatigue, musculoskeletal pain, peripheral edema, upper respiratory tract infection, nausea, bruising, dyspnea, constipation, rash, abdominal pain, vomiting and decreased appetite (see  Tables 1  and  2  ).","dyspnea , constipation is not a named entity"
"The most commonly occurring adverse reactions (>= 20%) were thrombocytopenia, diarrhea, neutropenia, anemia, fatigue, musculoskeletal pain, peripheral edema, upper respiratory tract infection, nausea, bruising, dyspnea, constipation, rash, abdominal pain, vomiting and decreased appetite (see  Tables 1  and  2  ).",constipation is an adverse reaction entity
"The most commonly occurring adverse reactions (>= 20%) were thrombocytopenia, diarrhea, neutropenia, anemia, fatigue, musculoskeletal pain, peripheral edema, upper respiratory tract infection, nausea, bruising, dyspnea, constipation, rash, abdominal pain, vomiting and decreased appetite (see  Tables 1  and  2  ).",anemia is an adverse reaction entity
"The most commonly occurring adverse reactions (>= 20%) were thrombocytopenia, diarrhea, neutropenia, anemia, fatigue, musculoskeletal pain, peripheral edema, upper respiratory tract infection, nausea, bruising, dyspnea, constipation, rash, abdominal pain, vomiting and decreased appetite (see  Tables 1  and  2  ).",most is not a named entity
"The most commonly occurring adverse reactions (>= 20%) were thrombocytopenia, diarrhea, neutropenia, anemia, fatigue, musculoskeletal pain, peripheral edema, upper respiratory tract infection, nausea, bruising, dyspnea, constipation, rash, abdominal pain, vomiting and decreased appetite (see  Tables 1  and  2  ).",fatigue is an adverse reaction entity
"The most commonly occurring adverse reactions (>= 20%) were thrombocytopenia, diarrhea, neutropenia, anemia, fatigue, musculoskeletal pain, peripheral edema, upper respiratory tract infection, nausea, bruising, dyspnea, constipation, rash, abdominal pain, vomiting and decreased appetite (see  Tables 1  and  2  ).",and 2 is not a named entity
"The most commonly occurring adverse reactions (>= 20%) were thrombocytopenia, diarrhea, neutropenia, anemia, fatigue, musculoskeletal pain, peripheral edema, upper respiratory tract infection, nausea, bruising, dyspnea, constipation, rash, abdominal pain, vomiting and decreased appetite (see  Tables 1  and  2  ).",% ) is not a named entity
"The most commonly occurring adverse reactions (>= 20%) were thrombocytopenia, diarrhea, neutropenia, anemia, fatigue, musculoskeletal pain, peripheral edema, upper respiratory tract infection, nausea, bruising, dyspnea, constipation, rash, abdominal pain, vomiting and decreased appetite (see  Tables 1  and  2  ).",decreased appetite is an adverse reaction entity
"The most commonly occurring adverse reactions (>= 20%) were thrombocytopenia, diarrhea, neutropenia, anemia, fatigue, musculoskeletal pain, peripheral edema, upper respiratory tract infection, nausea, bruising, dyspnea, constipation, rash, abdominal pain, vomiting and decreased appetite (see  Tables 1  and  2  ).",tract is not a named entity
"The most commonly occurring adverse reactions (>= 20%) were thrombocytopenia, diarrhea, neutropenia, anemia, fatigue, musculoskeletal pain, peripheral edema, upper respiratory tract infection, nausea, bruising, dyspnea, constipation, rash, abdominal pain, vomiting and decreased appetite (see  Tables 1  and  2  ).","pain , is not a named entity"
"The most commonly occurring adverse reactions (>= 20%) were thrombocytopenia, diarrhea, neutropenia, anemia, fatigue, musculoskeletal pain, peripheral edema, upper respiratory tract infection, nausea, bruising, dyspnea, constipation, rash, abdominal pain, vomiting and decreased appetite (see  Tables 1  and  2  ).",", rash is not a named entity"
"The most commonly occurring adverse reactions (>= 20%) were thrombocytopenia, diarrhea, neutropenia, anemia, fatigue, musculoskeletal pain, peripheral edema, upper respiratory tract infection, nausea, bruising, dyspnea, constipation, rash, abdominal pain, vomiting and decreased appetite (see  Tables 1  and  2  ).",upper respiratory tract infection is an adverse reaction entity
"The most commonly occurring adverse reactions (>= 20%) were thrombocytopenia, diarrhea, neutropenia, anemia, fatigue, musculoskeletal pain, peripheral edema, upper respiratory tract infection, nausea, bruising, dyspnea, constipation, rash, abdominal pain, vomiting and decreased appetite (see  Tables 1  and  2  ).",rash is an adverse reaction entity
"The most commonly occurring adverse reactions (>= 20%) were thrombocytopenia, diarrhea, neutropenia, anemia, fatigue, musculoskeletal pain, peripheral edema, upper respiratory tract infection, nausea, bruising, dyspnea, constipation, rash, abdominal pain, vomiting and decreased appetite (see  Tables 1  and  2  ).","tract infection , is not a named entity"
"The most commonly occurring adverse reactions (>= 20%) were thrombocytopenia, diarrhea, neutropenia, anemia, fatigue, musculoskeletal pain, peripheral edema, upper respiratory tract infection, nausea, bruising, dyspnea, constipation, rash, abdominal pain, vomiting and decreased appetite (see  Tables 1  and  2  ).","diarrhea , neutropenia is not a named entity"
"The most commonly occurring adverse reactions (>= 20%) were thrombocytopenia, diarrhea, neutropenia, anemia, fatigue, musculoskeletal pain, peripheral edema, upper respiratory tract infection, nausea, bruising, dyspnea, constipation, rash, abdominal pain, vomiting and decreased appetite (see  Tables 1  and  2  ).",peripheral edema is an adverse reaction entity
"The most commonly occurring adverse reactions (>= 20%) were thrombocytopenia, diarrhea, neutropenia, anemia, fatigue, musculoskeletal pain, peripheral edema, upper respiratory tract infection, nausea, bruising, dyspnea, constipation, rash, abdominal pain, vomiting and decreased appetite (see  Tables 1  and  2  ).","edema , upper is not a named entity"
"The most commonly occurring adverse reactions (>= 20%) were thrombocytopenia, diarrhea, neutropenia, anemia, fatigue, musculoskeletal pain, peripheral edema, upper respiratory tract infection, nausea, bruising, dyspnea, constipation, rash, abdominal pain, vomiting and decreased appetite (see  Tables 1  and  2  ).",musculoskeletal pain is an adverse reaction entity
"The most commonly occurring adverse reactions (>= 20%) were thrombocytopenia, diarrhea, neutropenia, anemia, fatigue, musculoskeletal pain, peripheral edema, upper respiratory tract infection, nausea, bruising, dyspnea, constipation, rash, abdominal pain, vomiting and decreased appetite (see  Tables 1  and  2  ).",thrombocytopenia is an adverse reaction entity
"The most commonly occurring adverse reactions (>= 20%) were thrombocytopenia, diarrhea, neutropenia, anemia, fatigue, musculoskeletal pain, peripheral edema, upper respiratory tract infection, nausea, bruising, dyspnea, constipation, rash, abdominal pain, vomiting and decreased appetite (see  Tables 1  and  2  ).",abdominal pain is an adverse reaction entity
"The most commonly occurring adverse reactions (>= 20%) were thrombocytopenia, diarrhea, neutropenia, anemia, fatigue, musculoskeletal pain, peripheral edema, upper respiratory tract infection, nausea, bruising, dyspnea, constipation, rash, abdominal pain, vomiting and decreased appetite (see  Tables 1  and  2  ).",", is not a named entity"
"The most commonly occurring adverse reactions (>= 20%) were thrombocytopenia, diarrhea, neutropenia, anemia, fatigue, musculoskeletal pain, peripheral edema, upper respiratory tract infection, nausea, bruising, dyspnea, constipation, rash, abdominal pain, vomiting and decreased appetite (see  Tables 1  and  2  ).",", is not a named entity"
"The most commonly occurring adverse reactions (>= 20%) were thrombocytopenia, diarrhea, neutropenia, anemia, fatigue, musculoskeletal pain, peripheral edema, upper respiratory tract infection, nausea, bruising, dyspnea, constipation, rash, abdominal pain, vomiting and decreased appetite (see  Tables 1  and  2  ).",diarrhea is an adverse reaction entity
"The most commonly occurring adverse reactions (>= 20%) were thrombocytopenia, diarrhea, neutropenia, anemia, fatigue, musculoskeletal pain, peripheral edema, upper respiratory tract infection, nausea, bruising, dyspnea, constipation, rash, abdominal pain, vomiting and decreased appetite (see  Tables 1  and  2  ).",", nausea is not a named entity"
"The most commonly occurring adverse reactions (>= 20%) were thrombocytopenia, diarrhea, neutropenia, anemia, fatigue, musculoskeletal pain, peripheral edema, upper respiratory tract infection, nausea, bruising, dyspnea, constipation, rash, abdominal pain, vomiting and decreased appetite (see  Tables 1  and  2  ).",vomiting is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *     Gout Flare : An increase in gout flares is frequently observed during initiation of anti-hyperuricemic agents, including ULORIC.",gout flares is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *     Gout Flare : An increase in gout flares is frequently observed during initiation of anti-hyperuricemic agents, including ULORIC.",5 is not a named entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *     Gout Flare : An increase in gout flares is frequently observed during initiation of anti-hyperuricemic agents, including ULORIC.",Gout Flare is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *     Gout Flare : An increase in gout flares is frequently observed during initiation of anti-hyperuricemic agents, including ULORIC.",in gout flares is not a named entity
"Blood and Lymphatic System Disorders  : anemia, idiopathic thrombocytopenic purpura, leukocytosis/leukopenia, neutropenia, pancytopenia, splenomegaly, thrombocytopenia.",pancytopenia is an adverse reaction entity
"Blood and Lymphatic System Disorders  : anemia, idiopathic thrombocytopenic purpura, leukocytosis/leukopenia, neutropenia, pancytopenia, splenomegaly, thrombocytopenia.",", thrombocytopenia is not a named entity"
"Blood and Lymphatic System Disorders  : anemia, idiopathic thrombocytopenic purpura, leukocytosis/leukopenia, neutropenia, pancytopenia, splenomegaly, thrombocytopenia.",leukopenia is an adverse reaction entity
"Blood and Lymphatic System Disorders  : anemia, idiopathic thrombocytopenic purpura, leukocytosis/leukopenia, neutropenia, pancytopenia, splenomegaly, thrombocytopenia.",leukocytosis is an adverse reaction entity
"Blood and Lymphatic System Disorders  : anemia, idiopathic thrombocytopenic purpura, leukocytosis/leukopenia, neutropenia, pancytopenia, splenomegaly, thrombocytopenia.","anemia , idiopathic is not a named entity"
"Blood and Lymphatic System Disorders  : anemia, idiopathic thrombocytopenic purpura, leukocytosis/leukopenia, neutropenia, pancytopenia, splenomegaly, thrombocytopenia.",splenomegaly is an adverse reaction entity
"Blood and Lymphatic System Disorders  : anemia, idiopathic thrombocytopenic purpura, leukocytosis/leukopenia, neutropenia, pancytopenia, splenomegaly, thrombocytopenia.",and is not a named entity
"Blood and Lymphatic System Disorders  : anemia, idiopathic thrombocytopenic purpura, leukocytosis/leukopenia, neutropenia, pancytopenia, splenomegaly, thrombocytopenia.",System is not a named entity
"Blood and Lymphatic System Disorders  : anemia, idiopathic thrombocytopenic purpura, leukocytosis/leukopenia, neutropenia, pancytopenia, splenomegaly, thrombocytopenia.",idiopathic thrombocytopenic purpura is an adverse reaction entity
"Blood and Lymphatic System Disorders  : anemia, idiopathic thrombocytopenic purpura, leukocytosis/leukopenia, neutropenia, pancytopenia, splenomegaly, thrombocytopenia.",thrombocytopenia is an adverse reaction entity
"Blood and Lymphatic System Disorders  : anemia, idiopathic thrombocytopenic purpura, leukocytosis/leukopenia, neutropenia, pancytopenia, splenomegaly, thrombocytopenia.","pancytopenia , is not a named entity"
"Blood and Lymphatic System Disorders  : anemia, idiopathic thrombocytopenic purpura, leukocytosis/leukopenia, neutropenia, pancytopenia, splenomegaly, thrombocytopenia.",thrombocytopenic is not a named entity
"Blood and Lymphatic System Disorders  : anemia, idiopathic thrombocytopenic purpura, leukocytosis/leukopenia, neutropenia, pancytopenia, splenomegaly, thrombocytopenia.",neutropenia is an adverse reaction entity
"Blood and Lymphatic System Disorders  : anemia, idiopathic thrombocytopenic purpura, leukocytosis/leukopenia, neutropenia, pancytopenia, splenomegaly, thrombocytopenia.",purpura is not a named entity
"Blood and Lymphatic System Disorders  : anemia, idiopathic thrombocytopenic purpura, leukocytosis/leukopenia, neutropenia, pancytopenia, splenomegaly, thrombocytopenia.",anemia is an adverse reaction entity
"Blood and Lymphatic System Disorders  : anemia, idiopathic thrombocytopenic purpura, leukocytosis/leukopenia, neutropenia, pancytopenia, splenomegaly, thrombocytopenia.",: is not a named entity
"(N=134)                        40 mg daily(N=757)             80 mg daily(N=1279)    (N=1277)           Liver Function Abnormalities    0.7%                           6.6%            4.6%            4.2%                Nausea                         0.7%                           1.1%            1.3%            0.8%                Arthralgia                      0%                            1.1%            0.7%            0.7%                Rash                           0.7%                           0.5%            1.6%            1.6%                         The most common adverse reaction leading to discontinuation from therapy was liver function abnormalities in 1.8% of ULORIC 40 mg, 1.2% of ULORIC 80 mg, and in 0.9% of allopurinol-treated subjects.",( N=757 ) is not a named entity
"(N=134)                        40 mg daily(N=757)             80 mg daily(N=1279)    (N=1277)           Liver Function Abnormalities    0.7%                           6.6%            4.6%            4.2%                Nausea                         0.7%                           1.1%            1.3%            0.8%                Arthralgia                      0%                            1.1%            0.7%            0.7%                Rash                           0.7%                           0.5%            1.6%            1.6%                         The most common adverse reaction leading to discontinuation from therapy was liver function abnormalities in 1.8% of ULORIC 40 mg, 1.2% of ULORIC 80 mg, and in 0.9% of allopurinol-treated subjects.",Arthralgia is an adverse reaction entity
"(N=134)                        40 mg daily(N=757)             80 mg daily(N=1279)    (N=1277)           Liver Function Abnormalities    0.7%                           6.6%            4.6%            4.2%                Nausea                         0.7%                           1.1%            1.3%            0.8%                Arthralgia                      0%                            1.1%            0.7%            0.7%                Rash                           0.7%                           0.5%            1.6%            1.6%                         The most common adverse reaction leading to discontinuation from therapy was liver function abnormalities in 1.8% of ULORIC 40 mg, 1.2% of ULORIC 80 mg, and in 0.9% of allopurinol-treated subjects.",Rash is an adverse reaction entity
"(N=134)                        40 mg daily(N=757)             80 mg daily(N=1279)    (N=1277)           Liver Function Abnormalities    0.7%                           6.6%            4.6%            4.2%                Nausea                         0.7%                           1.1%            1.3%            0.8%                Arthralgia                      0%                            1.1%            0.7%            0.7%                Rash                           0.7%                           0.5%            1.6%            1.6%                         The most common adverse reaction leading to discontinuation from therapy was liver function abnormalities in 1.8% of ULORIC 40 mg, 1.2% of ULORIC 80 mg, and in 0.9% of allopurinol-treated subjects.",Nausea is an adverse reaction entity
"(N=134)                        40 mg daily(N=757)             80 mg daily(N=1279)    (N=1277)           Liver Function Abnormalities    0.7%                           6.6%            4.6%            4.2%                Nausea                         0.7%                           1.1%            1.3%            0.8%                Arthralgia                      0%                            1.1%            0.7%            0.7%                Rash                           0.7%                           0.5%            1.6%            1.6%                         The most common adverse reaction leading to discontinuation from therapy was liver function abnormalities in 1.8% of ULORIC 40 mg, 1.2% of ULORIC 80 mg, and in 0.9% of allopurinol-treated subjects.",liver function abnormalities is an adverse reaction entity
"(N=134)                        40 mg daily(N=757)             80 mg daily(N=1279)    (N=1277)           Liver Function Abnormalities    0.7%                           6.6%            4.6%            4.2%                Nausea                         0.7%                           1.1%            1.3%            0.8%                Arthralgia                      0%                            1.1%            0.7%            0.7%                Rash                           0.7%                           0.5%            1.6%            1.6%                         The most common adverse reaction leading to discontinuation from therapy was liver function abnormalities in 1.8% of ULORIC 40 mg, 1.2% of ULORIC 80 mg, and in 0.9% of allopurinol-treated subjects.",( N=1279 ) is not a named entity
"(N=134)                        40 mg daily(N=757)             80 mg daily(N=1279)    (N=1277)           Liver Function Abnormalities    0.7%                           6.6%            4.6%            4.2%                Nausea                         0.7%                           1.1%            1.3%            0.8%                Arthralgia                      0%                            1.1%            0.7%            0.7%                Rash                           0.7%                           0.5%            1.6%            1.6%                         The most common adverse reaction leading to discontinuation from therapy was liver function abnormalities in 1.8% of ULORIC 40 mg, 1.2% of ULORIC 80 mg, and in 0.9% of allopurinol-treated subjects.",N=1279 ) ( is not a named entity
"(N=134)                        40 mg daily(N=757)             80 mg daily(N=1279)    (N=1277)           Liver Function Abnormalities    0.7%                           6.6%            4.6%            4.2%                Nausea                         0.7%                           1.1%            1.3%            0.8%                Arthralgia                      0%                            1.1%            0.7%            0.7%                Rash                           0.7%                           0.5%            1.6%            1.6%                         The most common adverse reaction leading to discontinuation from therapy was liver function abnormalities in 1.8% of ULORIC 40 mg, 1.2% of ULORIC 80 mg, and in 0.9% of allopurinol-treated subjects.",Liver Function Abnormalities is an adverse reaction entity
"(N=134)                        40 mg daily(N=757)             80 mg daily(N=1279)    (N=1277)           Liver Function Abnormalities    0.7%                           6.6%            4.6%            4.2%                Nausea                         0.7%                           1.1%            1.3%            0.8%                Arthralgia                      0%                            1.1%            0.7%            0.7%                Rash                           0.7%                           0.5%            1.6%            1.6%                         The most common adverse reaction leading to discontinuation from therapy was liver function abnormalities in 1.8% of ULORIC 40 mg, 1.2% of ULORIC 80 mg, and in 0.9% of allopurinol-treated subjects.",mg is not a named entity
"(N=134)                        40 mg daily(N=757)             80 mg daily(N=1279)    (N=1277)           Liver Function Abnormalities    0.7%                           6.6%            4.6%            4.2%                Nausea                         0.7%                           1.1%            1.3%            0.8%                Arthralgia                      0%                            1.1%            0.7%            0.7%                Rash                           0.7%                           0.5%            1.6%            1.6%                         The most common adverse reaction leading to discontinuation from therapy was liver function abnormalities in 1.8% of ULORIC 40 mg, 1.2% of ULORIC 80 mg, and in 0.9% of allopurinol-treated subjects.",1.6 % is not a named entity
"6 ADVERSE REACTIONS    EXCERPT:   Adverse reactions occurring in at least 1% of ULORIC-treated patients, and at least 0.5% greater than placebo, are liver function abnormalities, nausea, arthralgia, and rash.",least is not a named entity
"6 ADVERSE REACTIONS    EXCERPT:   Adverse reactions occurring in at least 1% of ULORIC-treated patients, and at least 0.5% greater than placebo, are liver function abnormalities, nausea, arthralgia, and rash.",rash is an adverse reaction entity
"6 ADVERSE REACTIONS    EXCERPT:   Adverse reactions occurring in at least 1% of ULORIC-treated patients, and at least 0.5% greater than placebo, are liver function abnormalities, nausea, arthralgia, and rash.",nausea is an adverse reaction entity
"6 ADVERSE REACTIONS    EXCERPT:   Adverse reactions occurring in at least 1% of ULORIC-treated patients, and at least 0.5% greater than placebo, are liver function abnormalities, nausea, arthralgia, and rash.",arthralgia is an adverse reaction entity
"6 ADVERSE REACTIONS    EXCERPT:   Adverse reactions occurring in at least 1% of ULORIC-treated patients, and at least 0.5% greater than placebo, are liver function abnormalities, nausea, arthralgia, and rash.",ADVERSE REACTIONS is not a named entity
"6 ADVERSE REACTIONS    EXCERPT:   Adverse reactions occurring in at least 1% of ULORIC-treated patients, and at least 0.5% greater than placebo, are liver function abnormalities, nausea, arthralgia, and rash.",and is not a named entity
"6 ADVERSE REACTIONS    EXCERPT:   Adverse reactions occurring in at least 1% of ULORIC-treated patients, and at least 0.5% greater than placebo, are liver function abnormalities, nausea, arthralgia, and rash.",liver function abnormalities is an adverse reaction entity
"6 ADVERSE REACTIONS    EXCERPT:   Adverse reactions occurring in at least 1% of ULORIC-treated patients, and at least 0.5% greater than placebo, are liver function abnormalities, nausea, arthralgia, and rash.",greater than is not a named entity
"Renal and Urinary Disorders  : hematuria, nephrolithiasis, pollakiuria, proteinuria, renal failure, renal insufficiency, urgency, incontinence.",and Urinary is not a named entity
"Renal and Urinary Disorders  : hematuria, nephrolithiasis, pollakiuria, proteinuria, renal failure, renal insufficiency, urgency, incontinence.",hematuria is an adverse reaction entity
"Renal and Urinary Disorders  : hematuria, nephrolithiasis, pollakiuria, proteinuria, renal failure, renal insufficiency, urgency, incontinence.",", nephrolithiasis , is not a named entity"
"Renal and Urinary Disorders  : hematuria, nephrolithiasis, pollakiuria, proteinuria, renal failure, renal insufficiency, urgency, incontinence.",", proteinuria is not a named entity"
"Renal and Urinary Disorders  : hematuria, nephrolithiasis, pollakiuria, proteinuria, renal failure, renal insufficiency, urgency, incontinence.","failure , renal is not a named entity"
"Renal and Urinary Disorders  : hematuria, nephrolithiasis, pollakiuria, proteinuria, renal failure, renal insufficiency, urgency, incontinence.",Disorders : is not a named entity
"Renal and Urinary Disorders  : hematuria, nephrolithiasis, pollakiuria, proteinuria, renal failure, renal insufficiency, urgency, incontinence.",Urinary incontinence is an adverse reaction entity
"Renal and Urinary Disorders  : hematuria, nephrolithiasis, pollakiuria, proteinuria, renal failure, renal insufficiency, urgency, incontinence.",nephrolithiasis is an adverse reaction entity
"Renal and Urinary Disorders  : hematuria, nephrolithiasis, pollakiuria, proteinuria, renal failure, renal insufficiency, urgency, incontinence.",renal insufficiency is an adverse reaction entity
"Renal and Urinary Disorders  : hematuria, nephrolithiasis, pollakiuria, proteinuria, renal failure, renal insufficiency, urgency, incontinence.",renal failure is an adverse reaction entity
"Renal and Urinary Disorders  : hematuria, nephrolithiasis, pollakiuria, proteinuria, renal failure, renal insufficiency, urgency, incontinence.",pollakiuria is an adverse reaction entity
"Renal and Urinary Disorders  : hematuria, nephrolithiasis, pollakiuria, proteinuria, renal failure, renal insufficiency, urgency, incontinence.",", renal is not a named entity"
"Renal and Urinary Disorders  : hematuria, nephrolithiasis, pollakiuria, proteinuria, renal failure, renal insufficiency, urgency, incontinence.",proteinuria is an adverse reaction entity
"Renal and Urinary Disorders  : hematuria, nephrolithiasis, pollakiuria, proteinuria, renal failure, renal insufficiency, urgency, incontinence.",Urinary urgency is an adverse reaction entity
"Renal and Urinary Disorders  : hematuria, nephrolithiasis, pollakiuria, proteinuria, renal failure, renal insufficiency, urgency, incontinence.","nephrolithiasis , pollakiuria is not a named entity"
"Renal and Urinary Disorders  : hematuria, nephrolithiasis, pollakiuria, proteinuria, renal failure, renal insufficiency, urgency, incontinence.",urgency is not a named entity
"General Disorders and Administration Site Conditions  : asthenia, chest pain/discomfort, edema, fatigue, feeling abnormal, gait disturbance, influenza-like symptoms, mass, pain, thirst.",fatigue is an adverse reaction entity
"General Disorders and Administration Site Conditions  : asthenia, chest pain/discomfort, edema, fatigue, feeling abnormal, gait disturbance, influenza-like symptoms, mass, pain, thirst.",Disorders and Administration is not a named entity
"General Disorders and Administration Site Conditions  : asthenia, chest pain/discomfort, edema, fatigue, feeling abnormal, gait disturbance, influenza-like symptoms, mass, pain, thirst.",gait disturbance is an adverse reaction entity
"General Disorders and Administration Site Conditions  : asthenia, chest pain/discomfort, edema, fatigue, feeling abnormal, gait disturbance, influenza-like symptoms, mass, pain, thirst.",asthenia is an adverse reaction entity
"General Disorders and Administration Site Conditions  : asthenia, chest pain/discomfort, edema, fatigue, feeling abnormal, gait disturbance, influenza-like symptoms, mass, pain, thirst.",pain is an adverse reaction entity
"General Disorders and Administration Site Conditions  : asthenia, chest pain/discomfort, edema, fatigue, feeling abnormal, gait disturbance, influenza-like symptoms, mass, pain, thirst.",disturbance is not a named entity
"General Disorders and Administration Site Conditions  : asthenia, chest pain/discomfort, edema, fatigue, feeling abnormal, gait disturbance, influenza-like symptoms, mass, pain, thirst.",feeling abnormal is an adverse reaction entity
"General Disorders and Administration Site Conditions  : asthenia, chest pain/discomfort, edema, fatigue, feeling abnormal, gait disturbance, influenza-like symptoms, mass, pain, thirst.",chest pain is an adverse reaction entity
"General Disorders and Administration Site Conditions  : asthenia, chest pain/discomfort, edema, fatigue, feeling abnormal, gait disturbance, influenza-like symptoms, mass, pain, thirst.",mass is an adverse reaction entity
"General Disorders and Administration Site Conditions  : asthenia, chest pain/discomfort, edema, fatigue, feeling abnormal, gait disturbance, influenza-like symptoms, mass, pain, thirst.",thirst is an adverse reaction entity
"General Disorders and Administration Site Conditions  : asthenia, chest pain/discomfort, edema, fatigue, feeling abnormal, gait disturbance, influenza-like symptoms, mass, pain, thirst.",General Disorders and is not a named entity
"General Disorders and Administration Site Conditions  : asthenia, chest pain/discomfort, edema, fatigue, feeling abnormal, gait disturbance, influenza-like symptoms, mass, pain, thirst.","fatigue , is not a named entity"
"General Disorders and Administration Site Conditions  : asthenia, chest pain/discomfort, edema, fatigue, feeling abnormal, gait disturbance, influenza-like symptoms, mass, pain, thirst.","symptoms , mass is not a named entity"
"General Disorders and Administration Site Conditions  : asthenia, chest pain/discomfort, edema, fatigue, feeling abnormal, gait disturbance, influenza-like symptoms, mass, pain, thirst.",Administration is not a named entity
"General Disorders and Administration Site Conditions  : asthenia, chest pain/discomfort, edema, fatigue, feeling abnormal, gait disturbance, influenza-like symptoms, mass, pain, thirst.",and Administration Site is not a named entity
"General Disorders and Administration Site Conditions  : asthenia, chest pain/discomfort, edema, fatigue, feeling abnormal, gait disturbance, influenza-like symptoms, mass, pain, thirst.",: asthenia is not a named entity
"General Disorders and Administration Site Conditions  : asthenia, chest pain/discomfort, edema, fatigue, feeling abnormal, gait disturbance, influenza-like symptoms, mass, pain, thirst.",chest discomfort is an adverse reaction entity
"General Disorders and Administration Site Conditions  : asthenia, chest pain/discomfort, edema, fatigue, feeling abnormal, gait disturbance, influenza-like symptoms, mass, pain, thirst.",", feeling abnormal is not a named entity"
"General Disorders and Administration Site Conditions  : asthenia, chest pain/discomfort, edema, fatigue, feeling abnormal, gait disturbance, influenza-like symptoms, mass, pain, thirst.",influenza-like symptoms is an adverse reaction entity
"General Disorders and Administration Site Conditions  : asthenia, chest pain/discomfort, edema, fatigue, feeling abnormal, gait disturbance, influenza-like symptoms, mass, pain, thirst.","asthenia , chest is not a named entity"
"General Disorders and Administration Site Conditions  : asthenia, chest pain/discomfort, edema, fatigue, feeling abnormal, gait disturbance, influenza-like symptoms, mass, pain, thirst.",edema is an adverse reaction entity
"General Disorders and Administration Site Conditions  : asthenia, chest pain/discomfort, edema, fatigue, feeling abnormal, gait disturbance, influenza-like symptoms, mass, pain, thirst.",: is not a named entity
"(  5.3  )             5.1 Gout Flare      After initiation of ULORIC, an increase in gout flares is frequently observed.",flares is not a named entity
"(  5.3  )             5.1 Gout Flare      After initiation of ULORIC, an increase in gout flares is frequently observed.",gout flares is an adverse reaction entity
"Reproductive System and Breast Changes  : breast pain, erectile dysfunction, gynecomastia.",breast pain is an adverse reaction entity
"Reproductive System and Breast Changes  : breast pain, erectile dysfunction, gynecomastia.",and is not a named entity
"Reproductive System and Breast Changes  : breast pain, erectile dysfunction, gynecomastia.","pain , erectile is not a named entity"
"Reproductive System and Breast Changes  : breast pain, erectile dysfunction, gynecomastia.",gynecomastia is an adverse reaction entity
"Reproductive System and Breast Changes  : breast pain, erectile dysfunction, gynecomastia.",and is not a named entity
"Reproductive System and Breast Changes  : breast pain, erectile dysfunction, gynecomastia.",erectile dysfunction is an adverse reaction entity
"Hepatobiliary Disorders  : cholelithiasis/cholecystitis, hepatic steatosis, hepatitis, hepatomegaly.",", hepatomegaly is not a named entity"
"Hepatobiliary Disorders  : cholelithiasis/cholecystitis, hepatic steatosis, hepatitis, hepatomegaly.","steatosis , is not a named entity"
"Hepatobiliary Disorders  : cholelithiasis/cholecystitis, hepatic steatosis, hepatitis, hepatomegaly.",cholelithiasis is an adverse reaction entity
"Hepatobiliary Disorders  : cholelithiasis/cholecystitis, hepatic steatosis, hepatitis, hepatomegaly.",hepatomegaly is an adverse reaction entity
"Hepatobiliary Disorders  : cholelithiasis/cholecystitis, hepatic steatosis, hepatitis, hepatomegaly.",", hepatitis , is not a named entity"
"Hepatobiliary Disorders  : cholelithiasis/cholecystitis, hepatic steatosis, hepatitis, hepatomegaly.","steatosis , is not a named entity"
"Hepatobiliary Disorders  : cholelithiasis/cholecystitis, hepatic steatosis, hepatitis, hepatomegaly.","cholelithiasis/cholecystitis , is not a named entity"
"Hepatobiliary Disorders  : cholelithiasis/cholecystitis, hepatic steatosis, hepatitis, hepatomegaly.",hepatic steatosis is an adverse reaction entity
"Hepatobiliary Disorders  : cholelithiasis/cholecystitis, hepatic steatosis, hepatitis, hepatomegaly.",hepatitis is an adverse reaction entity
"Hepatobiliary Disorders  : cholelithiasis/cholecystitis, hepatic steatosis, hepatitis, hepatomegaly.",cholecystitis is an adverse reaction entity
"Nervous System Disorders  : altered taste, balance disorder, cerebrovascular accident, Guillain-Barre syndrome, headache, hemiparesis, hypoesthesia, hyposmia, lacunar infarction, lethargy, mental impairment, migraine, paresthesia, somnolence, transient ischemic attack, tremor.",balance disorder is an adverse reaction entity
"Nervous System Disorders  : altered taste, balance disorder, cerebrovascular accident, Guillain-Barre syndrome, headache, hemiparesis, hypoesthesia, hyposmia, lacunar infarction, lethargy, mental impairment, migraine, paresthesia, somnolence, transient ischemic attack, tremor.",paresthesia is an adverse reaction entity
"Nervous System Disorders  : altered taste, balance disorder, cerebrovascular accident, Guillain-Barre syndrome, headache, hemiparesis, hypoesthesia, hyposmia, lacunar infarction, lethargy, mental impairment, migraine, paresthesia, somnolence, transient ischemic attack, tremor.",cerebrovascular accident is an adverse reaction entity
"Nervous System Disorders  : altered taste, balance disorder, cerebrovascular accident, Guillain-Barre syndrome, headache, hemiparesis, hypoesthesia, hyposmia, lacunar infarction, lethargy, mental impairment, migraine, paresthesia, somnolence, transient ischemic attack, tremor.",System Disorders is not a named entity
"Nervous System Disorders  : altered taste, balance disorder, cerebrovascular accident, Guillain-Barre syndrome, headache, hemiparesis, hypoesthesia, hyposmia, lacunar infarction, lethargy, mental impairment, migraine, paresthesia, somnolence, transient ischemic attack, tremor.",transient ischemic attack is an adverse reaction entity
"Nervous System Disorders  : altered taste, balance disorder, cerebrovascular accident, Guillain-Barre syndrome, headache, hemiparesis, hypoesthesia, hyposmia, lacunar infarction, lethargy, mental impairment, migraine, paresthesia, somnolence, transient ischemic attack, tremor.",mental impairment is an adverse reaction entity
"Nervous System Disorders  : altered taste, balance disorder, cerebrovascular accident, Guillain-Barre syndrome, headache, hemiparesis, hypoesthesia, hyposmia, lacunar infarction, lethargy, mental impairment, migraine, paresthesia, somnolence, transient ischemic attack, tremor.",syndrome is not a named entity
"Nervous System Disorders  : altered taste, balance disorder, cerebrovascular accident, Guillain-Barre syndrome, headache, hemiparesis, hypoesthesia, hyposmia, lacunar infarction, lethargy, mental impairment, migraine, paresthesia, somnolence, transient ischemic attack, tremor.",ischemic attack is not a named entity
"Nervous System Disorders  : altered taste, balance disorder, cerebrovascular accident, Guillain-Barre syndrome, headache, hemiparesis, hypoesthesia, hyposmia, lacunar infarction, lethargy, mental impairment, migraine, paresthesia, somnolence, transient ischemic attack, tremor.",Guillain-Barre syndrome is an adverse reaction entity
"Nervous System Disorders  : altered taste, balance disorder, cerebrovascular accident, Guillain-Barre syndrome, headache, hemiparesis, hypoesthesia, hyposmia, lacunar infarction, lethargy, mental impairment, migraine, paresthesia, somnolence, transient ischemic attack, tremor.",", balance disorder is not a named entity"
"Nervous System Disorders  : altered taste, balance disorder, cerebrovascular accident, Guillain-Barre syndrome, headache, hemiparesis, hypoesthesia, hyposmia, lacunar infarction, lethargy, mental impairment, migraine, paresthesia, somnolence, transient ischemic attack, tremor.",somnolence is an adverse reaction entity
"Nervous System Disorders  : altered taste, balance disorder, cerebrovascular accident, Guillain-Barre syndrome, headache, hemiparesis, hypoesthesia, hyposmia, lacunar infarction, lethargy, mental impairment, migraine, paresthesia, somnolence, transient ischemic attack, tremor.",hemiparesis is an adverse reaction entity
"Nervous System Disorders  : altered taste, balance disorder, cerebrovascular accident, Guillain-Barre syndrome, headache, hemiparesis, hypoesthesia, hyposmia, lacunar infarction, lethargy, mental impairment, migraine, paresthesia, somnolence, transient ischemic attack, tremor.",lethargy is an adverse reaction entity
"Nervous System Disorders  : altered taste, balance disorder, cerebrovascular accident, Guillain-Barre syndrome, headache, hemiparesis, hypoesthesia, hyposmia, lacunar infarction, lethargy, mental impairment, migraine, paresthesia, somnolence, transient ischemic attack, tremor.",altered taste is an adverse reaction entity
"Nervous System Disorders  : altered taste, balance disorder, cerebrovascular accident, Guillain-Barre syndrome, headache, hemiparesis, hypoesthesia, hyposmia, lacunar infarction, lethargy, mental impairment, migraine, paresthesia, somnolence, transient ischemic attack, tremor.",accident is not a named entity
"Nervous System Disorders  : altered taste, balance disorder, cerebrovascular accident, Guillain-Barre syndrome, headache, hemiparesis, hypoesthesia, hyposmia, lacunar infarction, lethargy, mental impairment, migraine, paresthesia, somnolence, transient ischemic attack, tremor.",hyposmia is an adverse reaction entity
"Nervous System Disorders  : altered taste, balance disorder, cerebrovascular accident, Guillain-Barre syndrome, headache, hemiparesis, hypoesthesia, hyposmia, lacunar infarction, lethargy, mental impairment, migraine, paresthesia, somnolence, transient ischemic attack, tremor.",", lacunar infarction is not a named entity"
"Nervous System Disorders  : altered taste, balance disorder, cerebrovascular accident, Guillain-Barre syndrome, headache, hemiparesis, hypoesthesia, hyposmia, lacunar infarction, lethargy, mental impairment, migraine, paresthesia, somnolence, transient ischemic attack, tremor.",accident is not a named entity
"Nervous System Disorders  : altered taste, balance disorder, cerebrovascular accident, Guillain-Barre syndrome, headache, hemiparesis, hypoesthesia, hyposmia, lacunar infarction, lethargy, mental impairment, migraine, paresthesia, somnolence, transient ischemic attack, tremor.","ischemic attack , is not a named entity"
"Nervous System Disorders  : altered taste, balance disorder, cerebrovascular accident, Guillain-Barre syndrome, headache, hemiparesis, hypoesthesia, hyposmia, lacunar infarction, lethargy, mental impairment, migraine, paresthesia, somnolence, transient ischemic attack, tremor.","syndrome , is not a named entity"
"Nervous System Disorders  : altered taste, balance disorder, cerebrovascular accident, Guillain-Barre syndrome, headache, hemiparesis, hypoesthesia, hyposmia, lacunar infarction, lethargy, mental impairment, migraine, paresthesia, somnolence, transient ischemic attack, tremor.",headache is an adverse reaction entity
"Nervous System Disorders  : altered taste, balance disorder, cerebrovascular accident, Guillain-Barre syndrome, headache, hemiparesis, hypoesthesia, hyposmia, lacunar infarction, lethargy, mental impairment, migraine, paresthesia, somnolence, transient ischemic attack, tremor.","cerebrovascular accident , is not a named entity"
"Nervous System Disorders  : altered taste, balance disorder, cerebrovascular accident, Guillain-Barre syndrome, headache, hemiparesis, hypoesthesia, hyposmia, lacunar infarction, lethargy, mental impairment, migraine, paresthesia, somnolence, transient ischemic attack, tremor.",", hemiparesis , is not a named entity"
"Nervous System Disorders  : altered taste, balance disorder, cerebrovascular accident, Guillain-Barre syndrome, headache, hemiparesis, hypoesthesia, hyposmia, lacunar infarction, lethargy, mental impairment, migraine, paresthesia, somnolence, transient ischemic attack, tremor.",hypoesthesia is an adverse reaction entity
"Nervous System Disorders  : altered taste, balance disorder, cerebrovascular accident, Guillain-Barre syndrome, headache, hemiparesis, hypoesthesia, hyposmia, lacunar infarction, lethargy, mental impairment, migraine, paresthesia, somnolence, transient ischemic attack, tremor.","hemiparesis , hypoesthesia is not a named entity"
"Nervous System Disorders  : altered taste, balance disorder, cerebrovascular accident, Guillain-Barre syndrome, headache, hemiparesis, hypoesthesia, hyposmia, lacunar infarction, lethargy, mental impairment, migraine, paresthesia, somnolence, transient ischemic attack, tremor.",", headache is not a named entity"
"Nervous System Disorders  : altered taste, balance disorder, cerebrovascular accident, Guillain-Barre syndrome, headache, hemiparesis, hypoesthesia, hyposmia, lacunar infarction, lethargy, mental impairment, migraine, paresthesia, somnolence, transient ischemic attack, tremor.",", mental impairment is not a named entity"
"Nervous System Disorders  : altered taste, balance disorder, cerebrovascular accident, Guillain-Barre syndrome, headache, hemiparesis, hypoesthesia, hyposmia, lacunar infarction, lethargy, mental impairment, migraine, paresthesia, somnolence, transient ischemic attack, tremor.",lacunar infarction is an adverse reaction entity
"Nervous System Disorders  : altered taste, balance disorder, cerebrovascular accident, Guillain-Barre syndrome, headache, hemiparesis, hypoesthesia, hyposmia, lacunar infarction, lethargy, mental impairment, migraine, paresthesia, somnolence, transient ischemic attack, tremor.",: is not a named entity
"Nervous System Disorders  : altered taste, balance disorder, cerebrovascular accident, Guillain-Barre syndrome, headache, hemiparesis, hypoesthesia, hyposmia, lacunar infarction, lethargy, mental impairment, migraine, paresthesia, somnolence, transient ischemic attack, tremor.",migraine is an adverse reaction entity
"Nervous System Disorders  : altered taste, balance disorder, cerebrovascular accident, Guillain-Barre syndrome, headache, hemiparesis, hypoesthesia, hyposmia, lacunar infarction, lethargy, mental impairment, migraine, paresthesia, somnolence, transient ischemic attack, tremor.",accident is not a named entity
"Nervous System Disorders  : altered taste, balance disorder, cerebrovascular accident, Guillain-Barre syndrome, headache, hemiparesis, hypoesthesia, hyposmia, lacunar infarction, lethargy, mental impairment, migraine, paresthesia, somnolence, transient ischemic attack, tremor.",tremor is an adverse reaction entity
"5.2 Cardiovascular Events      In the randomized controlled studies, there was a higher rate of cardiovascular thromboembolic events (cardiovascular deaths, non-fatal myocardial infarctions, and non-fatal strokes) in patients treated with ULORIC (0.74 per 100 P-Y [95% Confidence Interval (CI) 0.36-1.37]) than allopurinol (0.60 per 100 P-Y [95% CI 0.16-1.53]) [see  Adverse Reactions (6.1)  ]  .",) [ see is not a named entity
"5.2 Cardiovascular Events      In the randomized controlled studies, there was a higher rate of cardiovascular thromboembolic events (cardiovascular deaths, non-fatal myocardial infarctions, and non-fatal strokes) in patients treated with ULORIC (0.74 per 100 P-Y [95% Confidence Interval (CI) 0.36-1.37]) than allopurinol (0.60 per 100 P-Y [95% CI 0.16-1.53]) [see  Adverse Reactions (6.1)  ]  .",P-Y [ is not a named entity
"5.2 Cardiovascular Events      In the randomized controlled studies, there was a higher rate of cardiovascular thromboembolic events (cardiovascular deaths, non-fatal myocardial infarctions, and non-fatal strokes) in patients treated with ULORIC (0.74 per 100 P-Y [95% Confidence Interval (CI) 0.36-1.37]) than allopurinol (0.60 per 100 P-Y [95% CI 0.16-1.53]) [see  Adverse Reactions (6.1)  ]  .",strokes is an adverse reaction entity
"5.2 Cardiovascular Events      In the randomized controlled studies, there was a higher rate of cardiovascular thromboembolic events (cardiovascular deaths, non-fatal myocardial infarctions, and non-fatal strokes) in patients treated with ULORIC (0.74 per 100 P-Y [95% Confidence Interval (CI) 0.36-1.37]) than allopurinol (0.60 per 100 P-Y [95% CI 0.16-1.53]) [see  Adverse Reactions (6.1)  ]  .",myocardial infarctions is an adverse reaction entity
"5.2 Cardiovascular Events      In the randomized controlled studies, there was a higher rate of cardiovascular thromboembolic events (cardiovascular deaths, non-fatal myocardial infarctions, and non-fatal strokes) in patients treated with ULORIC (0.74 per 100 P-Y [95% Confidence Interval (CI) 0.36-1.37]) than allopurinol (0.60 per 100 P-Y [95% CI 0.16-1.53]) [see  Adverse Reactions (6.1)  ]  .",100 is not a named entity
"5.2 Cardiovascular Events      In the randomized controlled studies, there was a higher rate of cardiovascular thromboembolic events (cardiovascular deaths, non-fatal myocardial infarctions, and non-fatal strokes) in patients treated with ULORIC (0.74 per 100 P-Y [95% Confidence Interval (CI) 0.36-1.37]) than allopurinol (0.60 per 100 P-Y [95% CI 0.16-1.53]) [see  Adverse Reactions (6.1)  ]  .",cardiovascular thromboembolic events is an adverse reaction entity
"5.2 Cardiovascular Events      In the randomized controlled studies, there was a higher rate of cardiovascular thromboembolic events (cardiovascular deaths, non-fatal myocardial infarctions, and non-fatal strokes) in patients treated with ULORIC (0.74 per 100 P-Y [95% Confidence Interval (CI) 0.36-1.37]) than allopurinol (0.60 per 100 P-Y [95% CI 0.16-1.53]) [see  Adverse Reactions (6.1)  ]  .",cardiovascular deaths is an adverse reaction entity
"5.2 Cardiovascular Events      In the randomized controlled studies, there was a higher rate of cardiovascular thromboembolic events (cardiovascular deaths, non-fatal myocardial infarctions, and non-fatal strokes) in patients treated with ULORIC (0.74 per 100 P-Y [95% Confidence Interval (CI) 0.36-1.37]) than allopurinol (0.60 per 100 P-Y [95% CI 0.16-1.53]) [see  Adverse Reactions (6.1)  ]  .",Cardiovascular Events is not a named entity
"Cardiovascular Safety       Cardiovascular events and deaths were adjudicated to one of the pre-defined endpoints from the Anti-Platelet Trialists' Collaborations (APTC) (cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke) in the randomized controlled and long-term extension studies.",stroke is an adverse reaction entity
"Cardiovascular Safety       Cardiovascular events and deaths were adjudicated to one of the pre-defined endpoints from the Anti-Platelet Trialists' Collaborations (APTC) (cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke) in the randomized controlled and long-term extension studies.",Cardiovascular events is an adverse reaction entity
"Cardiovascular Safety       Cardiovascular events and deaths were adjudicated to one of the pre-defined endpoints from the Anti-Platelet Trialists' Collaborations (APTC) (cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke) in the randomized controlled and long-term extension studies.",Safety Cardiovascular events is not a named entity
"Cardiovascular Safety       Cardiovascular events and deaths were adjudicated to one of the pre-defined endpoints from the Anti-Platelet Trialists' Collaborations (APTC) (cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke) in the randomized controlled and long-term extension studies.",in the randomized is not a named entity
"Cardiovascular Safety       Cardiovascular events and deaths were adjudicated to one of the pre-defined endpoints from the Anti-Platelet Trialists' Collaborations (APTC) (cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke) in the randomized controlled and long-term extension studies.",", is not a named entity"
"Cardiovascular Safety       Cardiovascular events and deaths were adjudicated to one of the pre-defined endpoints from the Anti-Platelet Trialists' Collaborations (APTC) (cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke) in the randomized controlled and long-term extension studies.",deaths is an adverse reaction entity
"Cardiovascular Safety       Cardiovascular events and deaths were adjudicated to one of the pre-defined endpoints from the Anti-Platelet Trialists' Collaborations (APTC) (cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke) in the randomized controlled and long-term extension studies.",controlled and is not a named entity
"Cardiovascular Safety       Cardiovascular events and deaths were adjudicated to one of the pre-defined endpoints from the Anti-Platelet Trialists' Collaborations (APTC) (cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke) in the randomized controlled and long-term extension studies.",and non-fatal is not a named entity
"Cardiovascular Safety       Cardiovascular events and deaths were adjudicated to one of the pre-defined endpoints from the Anti-Platelet Trialists' Collaborations (APTC) (cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke) in the randomized controlled and long-term extension studies.",myocardial infarction is an adverse reaction entity
"Cardiovascular Safety       Cardiovascular events and deaths were adjudicated to one of the pre-defined endpoints from the Anti-Platelet Trialists' Collaborations (APTC) (cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke) in the randomized controlled and long-term extension studies.",cardiovascular death is an adverse reaction entity
"Skin and Subcutaneous Tissue Disorders  : alopecia, angio-edema, dermatitis, dermographism, ecchymosis, eczema, hair color changes, hair growth abnormal, hyperhidrosis  ,  peeling skin, petechiae, photosensitivity, pruritus, purpura, skin discoloration/altered pigmentation, skin lesion, skin odor abnormal, urticaria.",dermatitis is an adverse reaction entity
"Skin and Subcutaneous Tissue Disorders  : alopecia, angio-edema, dermatitis, dermographism, ecchymosis, eczema, hair color changes, hair growth abnormal, hyperhidrosis  ,  peeling skin, petechiae, photosensitivity, pruritus, purpura, skin discoloration/altered pigmentation, skin lesion, skin odor abnormal, urticaria.",skin odor abnormal is an adverse reaction entity
"Skin and Subcutaneous Tissue Disorders  : alopecia, angio-edema, dermatitis, dermographism, ecchymosis, eczema, hair color changes, hair growth abnormal, hyperhidrosis  ,  peeling skin, petechiae, photosensitivity, pruritus, purpura, skin discoloration/altered pigmentation, skin lesion, skin odor abnormal, urticaria.","growth abnormal , is not a named entity"
"Skin and Subcutaneous Tissue Disorders  : alopecia, angio-edema, dermatitis, dermographism, ecchymosis, eczema, hair color changes, hair growth abnormal, hyperhidrosis  ,  peeling skin, petechiae, photosensitivity, pruritus, purpura, skin discoloration/altered pigmentation, skin lesion, skin odor abnormal, urticaria.","abnormal , hyperhidrosis is not a named entity"
"Skin and Subcutaneous Tissue Disorders  : alopecia, angio-edema, dermatitis, dermographism, ecchymosis, eczema, hair color changes, hair growth abnormal, hyperhidrosis  ,  peeling skin, petechiae, photosensitivity, pruritus, purpura, skin discoloration/altered pigmentation, skin lesion, skin odor abnormal, urticaria.",urticaria is an adverse reaction entity
"Skin and Subcutaneous Tissue Disorders  : alopecia, angio-edema, dermatitis, dermographism, ecchymosis, eczema, hair color changes, hair growth abnormal, hyperhidrosis  ,  peeling skin, petechiae, photosensitivity, pruritus, purpura, skin discoloration/altered pigmentation, skin lesion, skin odor abnormal, urticaria.",", is not a named entity"
"Skin and Subcutaneous Tissue Disorders  : alopecia, angio-edema, dermatitis, dermographism, ecchymosis, eczema, hair color changes, hair growth abnormal, hyperhidrosis  ,  peeling skin, petechiae, photosensitivity, pruritus, purpura, skin discoloration/altered pigmentation, skin lesion, skin odor abnormal, urticaria.","growth abnormal , is not a named entity"
"Skin and Subcutaneous Tissue Disorders  : alopecia, angio-edema, dermatitis, dermographism, ecchymosis, eczema, hair color changes, hair growth abnormal, hyperhidrosis  ,  peeling skin, petechiae, photosensitivity, pruritus, purpura, skin discoloration/altered pigmentation, skin lesion, skin odor abnormal, urticaria.",abnormal is not a named entity
"Skin and Subcutaneous Tissue Disorders  : alopecia, angio-edema, dermatitis, dermographism, ecchymosis, eczema, hair color changes, hair growth abnormal, hyperhidrosis  ,  peeling skin, petechiae, photosensitivity, pruritus, purpura, skin discoloration/altered pigmentation, skin lesion, skin odor abnormal, urticaria.",", peeling is not a named entity"
"Skin and Subcutaneous Tissue Disorders  : alopecia, angio-edema, dermatitis, dermographism, ecchymosis, eczema, hair color changes, hair growth abnormal, hyperhidrosis  ,  peeling skin, petechiae, photosensitivity, pruritus, purpura, skin discoloration/altered pigmentation, skin lesion, skin odor abnormal, urticaria.",peeling skin is an adverse reaction entity
"Skin and Subcutaneous Tissue Disorders  : alopecia, angio-edema, dermatitis, dermographism, ecchymosis, eczema, hair color changes, hair growth abnormal, hyperhidrosis  ,  peeling skin, petechiae, photosensitivity, pruritus, purpura, skin discoloration/altered pigmentation, skin lesion, skin odor abnormal, urticaria.",pruritus is an adverse reaction entity
"Skin and Subcutaneous Tissue Disorders  : alopecia, angio-edema, dermatitis, dermographism, ecchymosis, eczema, hair color changes, hair growth abnormal, hyperhidrosis  ,  peeling skin, petechiae, photosensitivity, pruritus, purpura, skin discoloration/altered pigmentation, skin lesion, skin odor abnormal, urticaria.","eczema , is not a named entity"
"Skin and Subcutaneous Tissue Disorders  : alopecia, angio-edema, dermatitis, dermographism, ecchymosis, eczema, hair color changes, hair growth abnormal, hyperhidrosis  ,  peeling skin, petechiae, photosensitivity, pruritus, purpura, skin discoloration/altered pigmentation, skin lesion, skin odor abnormal, urticaria.",hair color changes is an adverse reaction entity
"Skin and Subcutaneous Tissue Disorders  : alopecia, angio-edema, dermatitis, dermographism, ecchymosis, eczema, hair color changes, hair growth abnormal, hyperhidrosis  ,  peeling skin, petechiae, photosensitivity, pruritus, purpura, skin discoloration/altered pigmentation, skin lesion, skin odor abnormal, urticaria.",petechiae is an adverse reaction entity
"Skin and Subcutaneous Tissue Disorders  : alopecia, angio-edema, dermatitis, dermographism, ecchymosis, eczema, hair color changes, hair growth abnormal, hyperhidrosis  ,  peeling skin, petechiae, photosensitivity, pruritus, purpura, skin discoloration/altered pigmentation, skin lesion, skin odor abnormal, urticaria.",angio-edema is an adverse reaction entity
"Skin and Subcutaneous Tissue Disorders  : alopecia, angio-edema, dermatitis, dermographism, ecchymosis, eczema, hair color changes, hair growth abnormal, hyperhidrosis  ,  peeling skin, petechiae, photosensitivity, pruritus, purpura, skin discoloration/altered pigmentation, skin lesion, skin odor abnormal, urticaria.",", hair growth is not a named entity"
"Skin and Subcutaneous Tissue Disorders  : alopecia, angio-edema, dermatitis, dermographism, ecchymosis, eczema, hair color changes, hair growth abnormal, hyperhidrosis  ,  peeling skin, petechiae, photosensitivity, pruritus, purpura, skin discoloration/altered pigmentation, skin lesion, skin odor abnormal, urticaria.",eczema is an adverse reaction entity
"Skin and Subcutaneous Tissue Disorders  : alopecia, angio-edema, dermatitis, dermographism, ecchymosis, eczema, hair color changes, hair growth abnormal, hyperhidrosis  ,  peeling skin, petechiae, photosensitivity, pruritus, purpura, skin discoloration/altered pigmentation, skin lesion, skin odor abnormal, urticaria.",", is not a named entity"
"Skin and Subcutaneous Tissue Disorders  : alopecia, angio-edema, dermatitis, dermographism, ecchymosis, eczema, hair color changes, hair growth abnormal, hyperhidrosis  ,  peeling skin, petechiae, photosensitivity, pruritus, purpura, skin discoloration/altered pigmentation, skin lesion, skin odor abnormal, urticaria.",", skin is not a named entity"
"Skin and Subcutaneous Tissue Disorders  : alopecia, angio-edema, dermatitis, dermographism, ecchymosis, eczema, hair color changes, hair growth abnormal, hyperhidrosis  ,  peeling skin, petechiae, photosensitivity, pruritus, purpura, skin discoloration/altered pigmentation, skin lesion, skin odor abnormal, urticaria.","lesion , skin is not a named entity"
"Skin and Subcutaneous Tissue Disorders  : alopecia, angio-edema, dermatitis, dermographism, ecchymosis, eczema, hair color changes, hair growth abnormal, hyperhidrosis  ,  peeling skin, petechiae, photosensitivity, pruritus, purpura, skin discoloration/altered pigmentation, skin lesion, skin odor abnormal, urticaria.",dermographism is an adverse reaction entity
"Skin and Subcutaneous Tissue Disorders  : alopecia, angio-edema, dermatitis, dermographism, ecchymosis, eczema, hair color changes, hair growth abnormal, hyperhidrosis  ,  peeling skin, petechiae, photosensitivity, pruritus, purpura, skin discoloration/altered pigmentation, skin lesion, skin odor abnormal, urticaria.","ecchymosis , is not a named entity"
"Skin and Subcutaneous Tissue Disorders  : alopecia, angio-edema, dermatitis, dermographism, ecchymosis, eczema, hair color changes, hair growth abnormal, hyperhidrosis  ,  peeling skin, petechiae, photosensitivity, pruritus, purpura, skin discoloration/altered pigmentation, skin lesion, skin odor abnormal, urticaria.","eczema , is not a named entity"
"Skin and Subcutaneous Tissue Disorders  : alopecia, angio-edema, dermatitis, dermographism, ecchymosis, eczema, hair color changes, hair growth abnormal, hyperhidrosis  ,  peeling skin, petechiae, photosensitivity, pruritus, purpura, skin discoloration/altered pigmentation, skin lesion, skin odor abnormal, urticaria.",abnormal is not a named entity
"Skin and Subcutaneous Tissue Disorders  : alopecia, angio-edema, dermatitis, dermographism, ecchymosis, eczema, hair color changes, hair growth abnormal, hyperhidrosis  ,  peeling skin, petechiae, photosensitivity, pruritus, purpura, skin discoloration/altered pigmentation, skin lesion, skin odor abnormal, urticaria.",skin discoloration is an adverse reaction entity
"Skin and Subcutaneous Tissue Disorders  : alopecia, angio-edema, dermatitis, dermographism, ecchymosis, eczema, hair color changes, hair growth abnormal, hyperhidrosis  ,  peeling skin, petechiae, photosensitivity, pruritus, purpura, skin discoloration/altered pigmentation, skin lesion, skin odor abnormal, urticaria.","pigmentation , is not a named entity"
"Skin and Subcutaneous Tissue Disorders  : alopecia, angio-edema, dermatitis, dermographism, ecchymosis, eczema, hair color changes, hair growth abnormal, hyperhidrosis  ,  peeling skin, petechiae, photosensitivity, pruritus, purpura, skin discoloration/altered pigmentation, skin lesion, skin odor abnormal, urticaria.",purpura is an adverse reaction entity
"Skin and Subcutaneous Tissue Disorders  : alopecia, angio-edema, dermatitis, dermographism, ecchymosis, eczema, hair color changes, hair growth abnormal, hyperhidrosis  ,  peeling skin, petechiae, photosensitivity, pruritus, purpura, skin discoloration/altered pigmentation, skin lesion, skin odor abnormal, urticaria.",", photosensitivity , is not a named entity"
"Skin and Subcutaneous Tissue Disorders  : alopecia, angio-edema, dermatitis, dermographism, ecchymosis, eczema, hair color changes, hair growth abnormal, hyperhidrosis  ,  peeling skin, petechiae, photosensitivity, pruritus, purpura, skin discoloration/altered pigmentation, skin lesion, skin odor abnormal, urticaria.","dermatitis , dermographism is not a named entity"
"Skin and Subcutaneous Tissue Disorders  : alopecia, angio-edema, dermatitis, dermographism, ecchymosis, eczema, hair color changes, hair growth abnormal, hyperhidrosis  ,  peeling skin, petechiae, photosensitivity, pruritus, purpura, skin discoloration/altered pigmentation, skin lesion, skin odor abnormal, urticaria.",skin altered pigmentation is an adverse reaction entity
"Skin and Subcutaneous Tissue Disorders  : alopecia, angio-edema, dermatitis, dermographism, ecchymosis, eczema, hair color changes, hair growth abnormal, hyperhidrosis  ,  peeling skin, petechiae, photosensitivity, pruritus, purpura, skin discoloration/altered pigmentation, skin lesion, skin odor abnormal, urticaria.",", is not a named entity"
"Skin and Subcutaneous Tissue Disorders  : alopecia, angio-edema, dermatitis, dermographism, ecchymosis, eczema, hair color changes, hair growth abnormal, hyperhidrosis  ,  peeling skin, petechiae, photosensitivity, pruritus, purpura, skin discoloration/altered pigmentation, skin lesion, skin odor abnormal, urticaria.",photosensitivity is an adverse reaction entity
"Skin and Subcutaneous Tissue Disorders  : alopecia, angio-edema, dermatitis, dermographism, ecchymosis, eczema, hair color changes, hair growth abnormal, hyperhidrosis  ,  peeling skin, petechiae, photosensitivity, pruritus, purpura, skin discoloration/altered pigmentation, skin lesion, skin odor abnormal, urticaria.",: alopecia is not a named entity
"Skin and Subcutaneous Tissue Disorders  : alopecia, angio-edema, dermatitis, dermographism, ecchymosis, eczema, hair color changes, hair growth abnormal, hyperhidrosis  ,  peeling skin, petechiae, photosensitivity, pruritus, purpura, skin discoloration/altered pigmentation, skin lesion, skin odor abnormal, urticaria.",alopecia is an adverse reaction entity
"Skin and Subcutaneous Tissue Disorders  : alopecia, angio-edema, dermatitis, dermographism, ecchymosis, eczema, hair color changes, hair growth abnormal, hyperhidrosis  ,  peeling skin, petechiae, photosensitivity, pruritus, purpura, skin discoloration/altered pigmentation, skin lesion, skin odor abnormal, urticaria.",hair growth abnormal is an adverse reaction entity
"Skin and Subcutaneous Tissue Disorders  : alopecia, angio-edema, dermatitis, dermographism, ecchymosis, eczema, hair color changes, hair growth abnormal, hyperhidrosis  ,  peeling skin, petechiae, photosensitivity, pruritus, purpura, skin discoloration/altered pigmentation, skin lesion, skin odor abnormal, urticaria.",hyperhidrosis is an adverse reaction entity
"Skin and Subcutaneous Tissue Disorders  : alopecia, angio-edema, dermatitis, dermographism, ecchymosis, eczema, hair color changes, hair growth abnormal, hyperhidrosis  ,  peeling skin, petechiae, photosensitivity, pruritus, purpura, skin discoloration/altered pigmentation, skin lesion, skin odor abnormal, urticaria.",ecchymosis is an adverse reaction entity
"Skin and Subcutaneous Tissue Disorders  : alopecia, angio-edema, dermatitis, dermographism, ecchymosis, eczema, hair color changes, hair growth abnormal, hyperhidrosis  ,  peeling skin, petechiae, photosensitivity, pruritus, purpura, skin discoloration/altered pigmentation, skin lesion, skin odor abnormal, urticaria.",skin lesion is an adverse reaction entity
"Hepatobiliary Disorders:  hepatic failure (some fatal), jaundice, serious cases of abnormal liver function test results, liver disorder.",fatal is an adverse reaction entity
"Hepatobiliary Disorders:  hepatic failure (some fatal), jaundice, serious cases of abnormal liver function test results, liver disorder.",hepatic failure is an adverse reaction entity
"Hepatobiliary Disorders:  hepatic failure (some fatal), jaundice, serious cases of abnormal liver function test results, liver disorder.",liver function test is not a named entity
"Hepatobiliary Disorders:  hepatic failure (some fatal), jaundice, serious cases of abnormal liver function test results, liver disorder.","jaundice , is not a named entity"
"Hepatobiliary Disorders:  hepatic failure (some fatal), jaundice, serious cases of abnormal liver function test results, liver disorder.",abnormal liver function is an adverse reaction entity
"Hepatobiliary Disorders:  hepatic failure (some fatal), jaundice, serious cases of abnormal liver function test results, liver disorder.",jaundice is an adverse reaction entity
"Hepatobiliary Disorders:  hepatic failure (some fatal), jaundice, serious cases of abnormal liver function test results, liver disorder.",liver disorder is an adverse reaction entity
"Hepatobiliary Disorders:  hepatic failure (some fatal), jaundice, serious cases of abnormal liver function test results, liver disorder.",Disorders is not a named entity
"Hepatobiliary Disorders:  hepatic failure (some fatal), jaundice, serious cases of abnormal liver function test results, liver disorder.","fatal ) , is not a named entity"
"Hepatobiliary Disorders:  hepatic failure (some fatal), jaundice, serious cases of abnormal liver function test results, liver disorder.",function test is not a named entity
"Gastrointestinal Disorders  : abdominal distention, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, frequent stools, gastritis, gastroesophageal reflux disease, gastrointestinal discomfort, gingival pain, haematemesis, hyperchlorhydria, hematochezia, mouth ulceration, pancreatitis, peptic ulcer, vomiting.",", is not a named entity"
"Gastrointestinal Disorders  : abdominal distention, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, frequent stools, gastritis, gastroesophageal reflux disease, gastrointestinal discomfort, gingival pain, haematemesis, hyperchlorhydria, hematochezia, mouth ulceration, pancreatitis, peptic ulcer, vomiting.",hyperchlorhydria is an adverse reaction entity
"Gastrointestinal Disorders  : abdominal distention, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, frequent stools, gastritis, gastroesophageal reflux disease, gastrointestinal discomfort, gingival pain, haematemesis, hyperchlorhydria, hematochezia, mouth ulceration, pancreatitis, peptic ulcer, vomiting.",gastroesophageal reflux disease is an adverse reaction entity
"Gastrointestinal Disorders  : abdominal distention, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, frequent stools, gastritis, gastroesophageal reflux disease, gastrointestinal discomfort, gingival pain, haematemesis, hyperchlorhydria, hematochezia, mouth ulceration, pancreatitis, peptic ulcer, vomiting.","discomfort , gingival is not a named entity"
"Gastrointestinal Disorders  : abdominal distention, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, frequent stools, gastritis, gastroesophageal reflux disease, gastrointestinal discomfort, gingival pain, haematemesis, hyperchlorhydria, hematochezia, mouth ulceration, pancreatitis, peptic ulcer, vomiting.",dry mouth is an adverse reaction entity
"Gastrointestinal Disorders  : abdominal distention, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, frequent stools, gastritis, gastroesophageal reflux disease, gastrointestinal discomfort, gingival pain, haematemesis, hyperchlorhydria, hematochezia, mouth ulceration, pancreatitis, peptic ulcer, vomiting.",flatulence is an adverse reaction entity
"Gastrointestinal Disorders  : abdominal distention, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, frequent stools, gastritis, gastroesophageal reflux disease, gastrointestinal discomfort, gingival pain, haematemesis, hyperchlorhydria, hematochezia, mouth ulceration, pancreatitis, peptic ulcer, vomiting.","stools , gastritis is not a named entity"
"Gastrointestinal Disorders  : abdominal distention, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, frequent stools, gastritis, gastroesophageal reflux disease, gastrointestinal discomfort, gingival pain, haematemesis, hyperchlorhydria, hematochezia, mouth ulceration, pancreatitis, peptic ulcer, vomiting.",", is not a named entity"
"Gastrointestinal Disorders  : abdominal distention, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, frequent stools, gastritis, gastroesophageal reflux disease, gastrointestinal discomfort, gingival pain, haematemesis, hyperchlorhydria, hematochezia, mouth ulceration, pancreatitis, peptic ulcer, vomiting.",", gastroesophageal reflux is not a named entity"
"Gastrointestinal Disorders  : abdominal distention, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, frequent stools, gastritis, gastroesophageal reflux disease, gastrointestinal discomfort, gingival pain, haematemesis, hyperchlorhydria, hematochezia, mouth ulceration, pancreatitis, peptic ulcer, vomiting.",", is not a named entity"
"Gastrointestinal Disorders  : abdominal distention, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, frequent stools, gastritis, gastroesophageal reflux disease, gastrointestinal discomfort, gingival pain, haematemesis, hyperchlorhydria, hematochezia, mouth ulceration, pancreatitis, peptic ulcer, vomiting.",abdominal distention is an adverse reaction entity
"Gastrointestinal Disorders  : abdominal distention, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, frequent stools, gastritis, gastroesophageal reflux disease, gastrointestinal discomfort, gingival pain, haematemesis, hyperchlorhydria, hematochezia, mouth ulceration, pancreatitis, peptic ulcer, vomiting.","mouth , is not a named entity"
"Gastrointestinal Disorders  : abdominal distention, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, frequent stools, gastritis, gastroesophageal reflux disease, gastrointestinal discomfort, gingival pain, haematemesis, hyperchlorhydria, hematochezia, mouth ulceration, pancreatitis, peptic ulcer, vomiting.","dry mouth , is not a named entity"
"Gastrointestinal Disorders  : abdominal distention, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, frequent stools, gastritis, gastroesophageal reflux disease, gastrointestinal discomfort, gingival pain, haematemesis, hyperchlorhydria, hematochezia, mouth ulceration, pancreatitis, peptic ulcer, vomiting.",frequent stools is an adverse reaction entity
"Gastrointestinal Disorders  : abdominal distention, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, frequent stools, gastritis, gastroesophageal reflux disease, gastrointestinal discomfort, gingival pain, haematemesis, hyperchlorhydria, hematochezia, mouth ulceration, pancreatitis, peptic ulcer, vomiting.",", vomiting is not a named entity"
"Gastrointestinal Disorders  : abdominal distention, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, frequent stools, gastritis, gastroesophageal reflux disease, gastrointestinal discomfort, gingival pain, haematemesis, hyperchlorhydria, hematochezia, mouth ulceration, pancreatitis, peptic ulcer, vomiting.","ulceration , pancreatitis is not a named entity"
"Gastrointestinal Disorders  : abdominal distention, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, frequent stools, gastritis, gastroesophageal reflux disease, gastrointestinal discomfort, gingival pain, haematemesis, hyperchlorhydria, hematochezia, mouth ulceration, pancreatitis, peptic ulcer, vomiting.","peptic ulcer , is not a named entity"
"Gastrointestinal Disorders  : abdominal distention, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, frequent stools, gastritis, gastroesophageal reflux disease, gastrointestinal discomfort, gingival pain, haematemesis, hyperchlorhydria, hematochezia, mouth ulceration, pancreatitis, peptic ulcer, vomiting.",gastrointestinal discomfort is an adverse reaction entity
"Gastrointestinal Disorders  : abdominal distention, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, frequent stools, gastritis, gastroesophageal reflux disease, gastrointestinal discomfort, gingival pain, haematemesis, hyperchlorhydria, hematochezia, mouth ulceration, pancreatitis, peptic ulcer, vomiting.",", is not a named entity"
"Gastrointestinal Disorders  : abdominal distention, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, frequent stools, gastritis, gastroesophageal reflux disease, gastrointestinal discomfort, gingival pain, haematemesis, hyperchlorhydria, hematochezia, mouth ulceration, pancreatitis, peptic ulcer, vomiting.",gastritis is an adverse reaction entity
"Gastrointestinal Disorders  : abdominal distention, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, frequent stools, gastritis, gastroesophageal reflux disease, gastrointestinal discomfort, gingival pain, haematemesis, hyperchlorhydria, hematochezia, mouth ulceration, pancreatitis, peptic ulcer, vomiting.",", gastritis is not a named entity"
"Gastrointestinal Disorders  : abdominal distention, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, frequent stools, gastritis, gastroesophageal reflux disease, gastrointestinal discomfort, gingival pain, haematemesis, hyperchlorhydria, hematochezia, mouth ulceration, pancreatitis, peptic ulcer, vomiting.",pancreatitis is an adverse reaction entity
"Gastrointestinal Disorders  : abdominal distention, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, frequent stools, gastritis, gastroesophageal reflux disease, gastrointestinal discomfort, gingival pain, haematemesis, hyperchlorhydria, hematochezia, mouth ulceration, pancreatitis, peptic ulcer, vomiting.",", gastroesophageal reflux is not a named entity"
"Gastrointestinal Disorders  : abdominal distention, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, frequent stools, gastritis, gastroesophageal reflux disease, gastrointestinal discomfort, gingival pain, haematemesis, hyperchlorhydria, hematochezia, mouth ulceration, pancreatitis, peptic ulcer, vomiting.",gingival pain is an adverse reaction entity
"Gastrointestinal Disorders  : abdominal distention, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, frequent stools, gastritis, gastroesophageal reflux disease, gastrointestinal discomfort, gingival pain, haematemesis, hyperchlorhydria, hematochezia, mouth ulceration, pancreatitis, peptic ulcer, vomiting.",abdominal pain is an adverse reaction entity
"Gastrointestinal Disorders  : abdominal distention, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, frequent stools, gastritis, gastroesophageal reflux disease, gastrointestinal discomfort, gingival pain, haematemesis, hyperchlorhydria, hematochezia, mouth ulceration, pancreatitis, peptic ulcer, vomiting.",haematemesis is an adverse reaction entity
"Gastrointestinal Disorders  : abdominal distention, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, frequent stools, gastritis, gastroesophageal reflux disease, gastrointestinal discomfort, gingival pain, haematemesis, hyperchlorhydria, hematochezia, mouth ulceration, pancreatitis, peptic ulcer, vomiting.",vomiting is an adverse reaction entity
"Gastrointestinal Disorders  : abdominal distention, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, frequent stools, gastritis, gastroesophageal reflux disease, gastrointestinal discomfort, gingival pain, haematemesis, hyperchlorhydria, hematochezia, mouth ulceration, pancreatitis, peptic ulcer, vomiting.",reflux is not a named entity
"Gastrointestinal Disorders  : abdominal distention, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, frequent stools, gastritis, gastroesophageal reflux disease, gastrointestinal discomfort, gingival pain, haematemesis, hyperchlorhydria, hematochezia, mouth ulceration, pancreatitis, peptic ulcer, vomiting.",: abdominal is not a named entity
"Gastrointestinal Disorders  : abdominal distention, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, frequent stools, gastritis, gastroesophageal reflux disease, gastrointestinal discomfort, gingival pain, haematemesis, hyperchlorhydria, hematochezia, mouth ulceration, pancreatitis, peptic ulcer, vomiting.",dyspepsia is an adverse reaction entity
"Gastrointestinal Disorders  : abdominal distention, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, frequent stools, gastritis, gastroesophageal reflux disease, gastrointestinal discomfort, gingival pain, haematemesis, hyperchlorhydria, hematochezia, mouth ulceration, pancreatitis, peptic ulcer, vomiting.",peptic ulcer is an adverse reaction entity
"Gastrointestinal Disorders  : abdominal distention, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, frequent stools, gastritis, gastroesophageal reflux disease, gastrointestinal discomfort, gingival pain, haematemesis, hyperchlorhydria, hematochezia, mouth ulceration, pancreatitis, peptic ulcer, vomiting.",mouth ulceration is an adverse reaction entity
"Gastrointestinal Disorders  : abdominal distention, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, frequent stools, gastritis, gastroesophageal reflux disease, gastrointestinal discomfort, gingival pain, haematemesis, hyperchlorhydria, hematochezia, mouth ulceration, pancreatitis, peptic ulcer, vomiting.","pain , is not a named entity"
"Gastrointestinal Disorders  : abdominal distention, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, frequent stools, gastritis, gastroesophageal reflux disease, gastrointestinal discomfort, gingival pain, haematemesis, hyperchlorhydria, hematochezia, mouth ulceration, pancreatitis, peptic ulcer, vomiting.",hematochezia is an adverse reaction entity
"Gastrointestinal Disorders  : abdominal distention, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, frequent stools, gastritis, gastroesophageal reflux disease, gastrointestinal discomfort, gingival pain, haematemesis, hyperchlorhydria, hematochezia, mouth ulceration, pancreatitis, peptic ulcer, vomiting.",constipation is an adverse reaction entity
"Gastrointestinal Disorders  : abdominal distention, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, frequent stools, gastritis, gastroesophageal reflux disease, gastrointestinal discomfort, gingival pain, haematemesis, hyperchlorhydria, hematochezia, mouth ulceration, pancreatitis, peptic ulcer, vomiting.",", flatulence is not a named entity"
"Skin and Subcutaneous Tissue Disorders:  generalized rash, Stevens Johnson Syndrome, hypersensitivity skin reactions.",hypersensitivity skin reactions is an adverse reaction entity
"Skin and Subcutaneous Tissue Disorders:  generalized rash, Stevens Johnson Syndrome, hypersensitivity skin reactions.",", is not a named entity"
"Skin and Subcutaneous Tissue Disorders:  generalized rash, Stevens Johnson Syndrome, hypersensitivity skin reactions.",and Subcutaneous is not a named entity
"Skin and Subcutaneous Tissue Disorders:  generalized rash, Stevens Johnson Syndrome, hypersensitivity skin reactions.",Tissue Disorders is not a named entity
"Skin and Subcutaneous Tissue Disorders:  generalized rash, Stevens Johnson Syndrome, hypersensitivity skin reactions.",Stevens Johnson Syndrome is an adverse reaction entity
"Skin and Subcutaneous Tissue Disorders:  generalized rash, Stevens Johnson Syndrome, hypersensitivity skin reactions.",generalized rash is an adverse reaction entity
"Metabolism and Nutrition Disorders  : anorexia, appetite decreased/increased, dehydration, diabetes mellitus, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypokalemia, weight decreased/increased.",", hypertriglyceridemia , is not a named entity"
"Metabolism and Nutrition Disorders  : anorexia, appetite decreased/increased, dehydration, diabetes mellitus, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypokalemia, weight decreased/increased.",weight decreased is an adverse reaction entity
"Metabolism and Nutrition Disorders  : anorexia, appetite decreased/increased, dehydration, diabetes mellitus, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypokalemia, weight decreased/increased.",hypercholesterolemia is an adverse reaction entity
"Metabolism and Nutrition Disorders  : anorexia, appetite decreased/increased, dehydration, diabetes mellitus, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypokalemia, weight decreased/increased.","hyperglycemia , hyperlipidemia is not a named entity"
"Metabolism and Nutrition Disorders  : anorexia, appetite decreased/increased, dehydration, diabetes mellitus, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypokalemia, weight decreased/increased.",hypokalemia is an adverse reaction entity
"Metabolism and Nutrition Disorders  : anorexia, appetite decreased/increased, dehydration, diabetes mellitus, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypokalemia, weight decreased/increased.","anorexia , appetite is not a named entity"
"Metabolism and Nutrition Disorders  : anorexia, appetite decreased/increased, dehydration, diabetes mellitus, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypokalemia, weight decreased/increased.",weight increased is an adverse reaction entity
"Metabolism and Nutrition Disorders  : anorexia, appetite decreased/increased, dehydration, diabetes mellitus, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypokalemia, weight decreased/increased.",hyperglycemia is an adverse reaction entity
"Metabolism and Nutrition Disorders  : anorexia, appetite decreased/increased, dehydration, diabetes mellitus, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypokalemia, weight decreased/increased.",", is not a named entity"
"Metabolism and Nutrition Disorders  : anorexia, appetite decreased/increased, dehydration, diabetes mellitus, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypokalemia, weight decreased/increased.",", hyperglycemia is not a named entity"
"Metabolism and Nutrition Disorders  : anorexia, appetite decreased/increased, dehydration, diabetes mellitus, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypokalemia, weight decreased/increased.",", diabetes mellitus is not a named entity"
"Metabolism and Nutrition Disorders  : anorexia, appetite decreased/increased, dehydration, diabetes mellitus, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypokalemia, weight decreased/increased.",hypertriglyceridemia is an adverse reaction entity
"Metabolism and Nutrition Disorders  : anorexia, appetite decreased/increased, dehydration, diabetes mellitus, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypokalemia, weight decreased/increased.",dehydration is an adverse reaction entity
"Metabolism and Nutrition Disorders  : anorexia, appetite decreased/increased, dehydration, diabetes mellitus, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypokalemia, weight decreased/increased.",appetite decreased is an adverse reaction entity
"Metabolism and Nutrition Disorders  : anorexia, appetite decreased/increased, dehydration, diabetes mellitus, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypokalemia, weight decreased/increased.",decreased/increased is not a named entity
"Metabolism and Nutrition Disorders  : anorexia, appetite decreased/increased, dehydration, diabetes mellitus, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypokalemia, weight decreased/increased.",Metabolism and is not a named entity
"Metabolism and Nutrition Disorders  : anorexia, appetite decreased/increased, dehydration, diabetes mellitus, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypokalemia, weight decreased/increased.",anorexia is an adverse reaction entity
"Metabolism and Nutrition Disorders  : anorexia, appetite decreased/increased, dehydration, diabetes mellitus, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypokalemia, weight decreased/increased.",diabetes mellitus is an adverse reaction entity
"Metabolism and Nutrition Disorders  : anorexia, appetite decreased/increased, dehydration, diabetes mellitus, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypokalemia, weight decreased/increased.",", is not a named entity"
"Metabolism and Nutrition Disorders  : anorexia, appetite decreased/increased, dehydration, diabetes mellitus, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypokalemia, weight decreased/increased.","diabetes mellitus , is not a named entity"
"Metabolism and Nutrition Disorders  : anorexia, appetite decreased/increased, dehydration, diabetes mellitus, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypokalemia, weight decreased/increased.",appetite increased is an adverse reaction entity
"Metabolism and Nutrition Disorders  : anorexia, appetite decreased/increased, dehydration, diabetes mellitus, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypokalemia, weight decreased/increased.",", is not a named entity"
"Metabolism and Nutrition Disorders  : anorexia, appetite decreased/increased, dehydration, diabetes mellitus, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypokalemia, weight decreased/increased.",hyperlipidemia is an adverse reaction entity
"Metabolism and Nutrition Disorders  : anorexia, appetite decreased/increased, dehydration, diabetes mellitus, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypokalemia, weight decreased/increased.",", hypertriglyceridemia , is not a named entity"
"(  5.5  )             5.1 Tendon Rupture or Other Serious Injury to the Injected Finger/Hand in the Treatment of Dupuytren's Contracture      In the controlled and uncontrolled portions of clinical trials in Dupuytren's contracture, flexor tendon ruptures occurred after XIAFLEX injection   [see Adverse Reactions (6.1)]    .",Finger/Hand in the is not a named entity
"(  5.5  )             5.1 Tendon Rupture or Other Serious Injury to the Injected Finger/Hand in the Treatment of Dupuytren's Contracture      In the controlled and uncontrolled portions of clinical trials in Dupuytren's contracture, flexor tendon ruptures occurred after XIAFLEX injection   [see Adverse Reactions (6.1)]    .",flexor tendon ruptures is an adverse reaction entity
"5.5 Risk of bleeding in Patients with Abnormal Coagulation      In the XIAFLEX trials in Dupuytren's contracture (Studies 1 and 2), 70% and 38% of XIAFLEX-treated patients developed an ecchymosis/contusion or an injection site hemorrhage, respectively (see Table 3).",( is not a named entity
"5.5 Risk of bleeding in Patients with Abnormal Coagulation      In the XIAFLEX trials in Dupuytren's contracture (Studies 1 and 2), 70% and 38% of XIAFLEX-treated patients developed an ecchymosis/contusion or an injection site hemorrhage, respectively (see Table 3).",the is not a named entity
"5.5 Risk of bleeding in Patients with Abnormal Coagulation      In the XIAFLEX trials in Dupuytren's contracture (Studies 1 and 2), 70% and 38% of XIAFLEX-treated patients developed an ecchymosis/contusion or an injection site hemorrhage, respectively (see Table 3).",with Abnormal Coagulation is not a named entity
"5.5 Risk of bleeding in Patients with Abnormal Coagulation      In the XIAFLEX trials in Dupuytren's contracture (Studies 1 and 2), 70% and 38% of XIAFLEX-treated patients developed an ecchymosis/contusion or an injection site hemorrhage, respectively (see Table 3).",contusion is an adverse reaction entity
"5.5 Risk of bleeding in Patients with Abnormal Coagulation      In the XIAFLEX trials in Dupuytren's contracture (Studies 1 and 2), 70% and 38% of XIAFLEX-treated patients developed an ecchymosis/contusion or an injection site hemorrhage, respectively (see Table 3).",ecchymosis is an adverse reaction entity
"5.5 Risk of bleeding in Patients with Abnormal Coagulation      In the XIAFLEX trials in Dupuytren's contracture (Studies 1 and 2), 70% and 38% of XIAFLEX-treated patients developed an ecchymosis/contusion or an injection site hemorrhage, respectively (see Table 3).",injection site hemorrhage is an adverse reaction entity
"*  In other XIAFLEX-treated patients (9 of 1044; 0.9%), a combination of penile ecchymoses or hematoma, sudden penile detumescence, and/or a penile ""popping"" sound or sensation was reported, and in these cases, a diagnosis of corporal rupture cannot be excluded.",penile detumescence is an adverse reaction entity
"*  In other XIAFLEX-treated patients (9 of 1044; 0.9%), a combination of penile ecchymoses or hematoma, sudden penile detumescence, and/or a penile ""popping"" sound or sensation was reported, and in these cases, a diagnosis of corporal rupture cannot be excluded.",penile hematoma is an adverse reaction entity
"*  In other XIAFLEX-treated patients (9 of 1044; 0.9%), a combination of penile ecchymoses or hematoma, sudden penile detumescence, and/or a penile ""popping"" sound or sensation was reported, and in these cases, a diagnosis of corporal rupture cannot be excluded.",be is not a named entity
"*  In other XIAFLEX-treated patients (9 of 1044; 0.9%), a combination of penile ecchymoses or hematoma, sudden penile detumescence, and/or a penile ""popping"" sound or sensation was reported, and in these cases, a diagnosis of corporal rupture cannot be excluded.","penile ""popping"" sensation is an adverse reaction entity"
"*  In other XIAFLEX-treated patients (9 of 1044; 0.9%), a combination of penile ecchymoses or hematoma, sudden penile detumescence, and/or a penile ""popping"" sound or sensation was reported, and in these cases, a diagnosis of corporal rupture cannot be excluded.","detumescence , is not a named entity"
"*  In other XIAFLEX-treated patients (9 of 1044; 0.9%), a combination of penile ecchymoses or hematoma, sudden penile detumescence, and/or a penile ""popping"" sound or sensation was reported, and in these cases, a diagnosis of corporal rupture cannot be excluded.",", and in is not a named entity"
"*  In other XIAFLEX-treated patients (9 of 1044; 0.9%), a combination of penile ecchymoses or hematoma, sudden penile detumescence, and/or a penile ""popping"" sound or sensation was reported, and in these cases, a diagnosis of corporal rupture cannot be excluded.",sudden is not a named entity
"*  In other XIAFLEX-treated patients (9 of 1044; 0.9%), a combination of penile ecchymoses or hematoma, sudden penile detumescence, and/or a penile ""popping"" sound or sensation was reported, and in these cases, a diagnosis of corporal rupture cannot be excluded.","was reported , is not a named entity"
"*  In other XIAFLEX-treated patients (9 of 1044; 0.9%), a combination of penile ecchymoses or hematoma, sudden penile detumescence, and/or a penile ""popping"" sound or sensation was reported, and in these cases, a diagnosis of corporal rupture cannot be excluded.",penile ecchymoses is an adverse reaction entity
"*  In other XIAFLEX-treated patients (9 of 1044; 0.9%), a combination of penile ecchymoses or hematoma, sudden penile detumescence, and/or a penile ""popping"" sound or sensation was reported, and in these cases, a diagnosis of corporal rupture cannot be excluded.",of is not a named entity
"*  In other XIAFLEX-treated patients (9 of 1044; 0.9%), a combination of penile ecchymoses or hematoma, sudden penile detumescence, and/or a penile ""popping"" sound or sensation was reported, and in these cases, a diagnosis of corporal rupture cannot be excluded.",corporal rupture is an adverse reaction entity
"*  In other XIAFLEX-treated patients (9 of 1044; 0.9%), a combination of penile ecchymoses or hematoma, sudden penile detumescence, and/or a penile ""popping"" sound or sensation was reported, and in these cases, a diagnosis of corporal rupture cannot be excluded.","penile ""popping"" sound is an adverse reaction entity"
"Other XIAFLEX-associated serious local adverse reactions included pulley rupture, ligament injury, complex regional pain syndrome (CRPS), sensory abnormality of the hand, and skin laceration (tear).",skin tear is an adverse reaction entity
"Other XIAFLEX-associated serious local adverse reactions included pulley rupture, ligament injury, complex regional pain syndrome (CRPS), sensory abnormality of the hand, and skin laceration (tear).",complex regional pain syndrome is an adverse reaction entity
"Other XIAFLEX-associated serious local adverse reactions included pulley rupture, ligament injury, complex regional pain syndrome (CRPS), sensory abnormality of the hand, and skin laceration (tear).",skin laceration is an adverse reaction entity
"Other XIAFLEX-associated serious local adverse reactions included pulley rupture, ligament injury, complex regional pain syndrome (CRPS), sensory abnormality of the hand, and skin laceration (tear).",( CRPS is not a named entity
"Other XIAFLEX-associated serious local adverse reactions included pulley rupture, ligament injury, complex regional pain syndrome (CRPS), sensory abnormality of the hand, and skin laceration (tear).",pulley rupture is an adverse reaction entity
"Other XIAFLEX-associated serious local adverse reactions included pulley rupture, ligament injury, complex regional pain syndrome (CRPS), sensory abnormality of the hand, and skin laceration (tear).",the is not a named entity
"Other XIAFLEX-associated serious local adverse reactions included pulley rupture, ligament injury, complex regional pain syndrome (CRPS), sensory abnormality of the hand, and skin laceration (tear).",local is not a named entity
"Other XIAFLEX-associated serious local adverse reactions included pulley rupture, ligament injury, complex regional pain syndrome (CRPS), sensory abnormality of the hand, and skin laceration (tear).",sensory abnormality of the hand is an adverse reaction entity
"Other XIAFLEX-associated serious local adverse reactions included pulley rupture, ligament injury, complex regional pain syndrome (CRPS), sensory abnormality of the hand, and skin laceration (tear).",CRPS is an adverse reaction entity
"Other XIAFLEX-associated serious local adverse reactions included pulley rupture, ligament injury, complex regional pain syndrome (CRPS), sensory abnormality of the hand, and skin laceration (tear).",ligament injury is an adverse reaction entity
"Other XIAFLEX-associated serious local adverse reactions included pulley rupture, ligament injury, complex regional pain syndrome (CRPS), sensory abnormality of the hand, and skin laceration (tear).",) is not a named entity
"Other XIAFLEX-associated serious local adverse reactions included pulley rupture, ligament injury, complex regional pain syndrome (CRPS), sensory abnormality of the hand, and skin laceration (tear).",( tear ) is not a named entity
"Other XIAFLEX-associated serious local adverse reactions included pulley rupture, ligament injury, complex regional pain syndrome (CRPS), sensory abnormality of the hand, and skin laceration (tear).",syndrome ( CRPS is not a named entity
"Other XIAFLEX-associated serious local adverse reactions included pulley rupture, ligament injury, complex regional pain syndrome (CRPS), sensory abnormality of the hand, and skin laceration (tear).","the hand , is not a named entity"
The incidence of XIAFLEX-associated pruritus was similar after each injection regardless of the number of injections administered.,pruritus is an adverse reaction entity
The incidence of XIAFLEX-associated pruritus was similar after each injection regardless of the number of injections administered.,was is not a named entity
The incidence of XIAFLEX-associated pruritus increased after more XIAFLEX injections in patients with Dupuytren's contracture.,pruritus is an adverse reaction entity
The incidence of XIAFLEX-associated pruritus increased after more XIAFLEX injections in patients with Dupuytren's contracture.,The incidence is not a named entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Tendon rupture or serious injury to the injected finger/hand: Avoid injecting XIAFLEX into tendons, nerves, blood vessels, or other collagen-containing structure of the hand.",injury to the injected hand is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Tendon rupture or serious injury to the injected finger/hand: Avoid injecting XIAFLEX into tendons, nerves, blood vessels, or other collagen-containing structure of the hand.",or serious is not a named entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Tendon rupture or serious injury to the injected finger/hand: Avoid injecting XIAFLEX into tendons, nerves, blood vessels, or other collagen-containing structure of the hand.",Tendon rupture is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Tendon rupture or serious injury to the injected finger/hand: Avoid injecting XIAFLEX into tendons, nerves, blood vessels, or other collagen-containing structure of the hand.",injury to the injected finger is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Tendon rupture or serious injury to the injected finger/hand: Avoid injecting XIAFLEX into tendons, nerves, blood vessels, or other collagen-containing structure of the hand.","nerves , blood is not a named entity"
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Tendon rupture or serious injury to the injected finger/hand: Avoid injecting XIAFLEX into tendons, nerves, blood vessels, or other collagen-containing structure of the hand.",serious injury to is not a named entity
EXCERPT:   WARNING: CORPORAL RUPTURE (PENILE FRACTURE) OR OTHER SERIOUS PENILE INJURY IN THE TREATMENT OF PEYRONIE'S DISEASE       See full prescribing information for complete   boxed warning         *  Corporal rupture (penile fracture) was reported as an adverse reaction in 5 of 1044 (0.5%) XIAFLEX-treated patients in clinical studies.,Corporal rupture is an adverse reaction entity
EXCERPT:   WARNING: CORPORAL RUPTURE (PENILE FRACTURE) OR OTHER SERIOUS PENILE INJURY IN THE TREATMENT OF PEYRONIE'S DISEASE       See full prescribing information for complete   boxed warning         *  Corporal rupture (penile fracture) was reported as an adverse reaction in 5 of 1044 (0.5%) XIAFLEX-treated patients in clinical studies.,clinical studies is not a named entity
EXCERPT:   WARNING: CORPORAL RUPTURE (PENILE FRACTURE) OR OTHER SERIOUS PENILE INJURY IN THE TREATMENT OF PEYRONIE'S DISEASE       See full prescribing information for complete   boxed warning         *  Corporal rupture (penile fracture) was reported as an adverse reaction in 5 of 1044 (0.5%) XIAFLEX-treated patients in clinical studies.,OF PEYRONIE is not a named entity
EXCERPT:   WARNING: CORPORAL RUPTURE (PENILE FRACTURE) OR OTHER SERIOUS PENILE INJURY IN THE TREATMENT OF PEYRONIE'S DISEASE       See full prescribing information for complete   boxed warning         *  Corporal rupture (penile fracture) was reported as an adverse reaction in 5 of 1044 (0.5%) XIAFLEX-treated patients in clinical studies.,CORPORAL RUPTURE is an adverse reaction entity
EXCERPT:   WARNING: CORPORAL RUPTURE (PENILE FRACTURE) OR OTHER SERIOUS PENILE INJURY IN THE TREATMENT OF PEYRONIE'S DISEASE       See full prescribing information for complete   boxed warning         *  Corporal rupture (penile fracture) was reported as an adverse reaction in 5 of 1044 (0.5%) XIAFLEX-treated patients in clinical studies.,PENILE INJURY is an adverse reaction entity
EXCERPT:   WARNING: CORPORAL RUPTURE (PENILE FRACTURE) OR OTHER SERIOUS PENILE INJURY IN THE TREATMENT OF PEYRONIE'S DISEASE       See full prescribing information for complete   boxed warning         *  Corporal rupture (penile fracture) was reported as an adverse reaction in 5 of 1044 (0.5%) XIAFLEX-treated patients in clinical studies.,PENILE FRACTURE is an adverse reaction entity
EXCERPT:   WARNING: CORPORAL RUPTURE (PENILE FRACTURE) OR OTHER SERIOUS PENILE INJURY IN THE TREATMENT OF PEYRONIE'S DISEASE       See full prescribing information for complete   boxed warning         *  Corporal rupture (penile fracture) was reported as an adverse reaction in 5 of 1044 (0.5%) XIAFLEX-treated patients in clinical studies.,0.5 % is not a named entity
EXCERPT:   WARNING: CORPORAL RUPTURE (PENILE FRACTURE) OR OTHER SERIOUS PENILE INJURY IN THE TREATMENT OF PEYRONIE'S DISEASE       See full prescribing information for complete   boxed warning         *  Corporal rupture (penile fracture) was reported as an adverse reaction in 5 of 1044 (0.5%) XIAFLEX-treated patients in clinical studies.,RUPTURE ( is not a named entity
EXCERPT:   WARNING: CORPORAL RUPTURE (PENILE FRACTURE) OR OTHER SERIOUS PENILE INJURY IN THE TREATMENT OF PEYRONIE'S DISEASE       See full prescribing information for complete   boxed warning         *  Corporal rupture (penile fracture) was reported as an adverse reaction in 5 of 1044 (0.5%) XIAFLEX-treated patients in clinical studies.,was reported as is not a named entity
EXCERPT:   WARNING: CORPORAL RUPTURE (PENILE FRACTURE) OR OTHER SERIOUS PENILE INJURY IN THE TREATMENT OF PEYRONIE'S DISEASE       See full prescribing information for complete   boxed warning         *  Corporal rupture (penile fracture) was reported as an adverse reaction in 5 of 1044 (0.5%) XIAFLEX-treated patients in clinical studies.,penile fracture is an adverse reaction entity
"Peyronie's Disease (  6.2  )       The most frequently reported adverse drug reactions reported with >= 25% of patients treated with XIAFLEX and at an incidence greater than placebo were penile hematoma, penile swelling and penile pain.",and penile is not a named entity
"Peyronie's Disease (  6.2  )       The most frequently reported adverse drug reactions reported with >= 25% of patients treated with XIAFLEX and at an incidence greater than placebo were penile hematoma, penile swelling and penile pain.",penile swelling is an adverse reaction entity
"Peyronie's Disease (  6.2  )       The most frequently reported adverse drug reactions reported with >= 25% of patients treated with XIAFLEX and at an incidence greater than placebo were penile hematoma, penile swelling and penile pain.",treated with XIAFLEX is not a named entity
"Peyronie's Disease (  6.2  )       The most frequently reported adverse drug reactions reported with >= 25% of patients treated with XIAFLEX and at an incidence greater than placebo were penile hematoma, penile swelling and penile pain.",penile pain is an adverse reaction entity
"Peyronie's Disease (  6.2  )       The most frequently reported adverse drug reactions reported with >= 25% of patients treated with XIAFLEX and at an incidence greater than placebo were penile hematoma, penile swelling and penile pain.",penile hematoma is an adverse reaction entity
"Peyronie's Disease (  6.2  )       The most frequently reported adverse drug reactions reported with >= 25% of patients treated with XIAFLEX and at an incidence greater than placebo were penile hematoma, penile swelling and penile pain.",The most is not a named entity
Severe penile hematoma was also reported as an adverse reaction in 39 of 1044 patients (3.7%) in the controlled and uncontrolled clinical trials in Peyronie's disease [ see Adverse Reactions (  6  )  ].,in the is not a named entity
Severe penile hematoma was also reported as an adverse reaction in 39 of 1044 patients (3.7%) in the controlled and uncontrolled clinical trials in Peyronie's disease [ see Adverse Reactions (  6  )  ].,penile hematoma is an adverse reaction entity
"b  Includes: injection site swelling, penile edema, penile swelling, local swelling, scrotal swelling, and injection site edema.",and injection is not a named entity
"b  Includes: injection site swelling, penile edema, penile swelling, local swelling, scrotal swelling, and injection site edema.",penile edema is an adverse reaction entity
"b  Includes: injection site swelling, penile edema, penile swelling, local swelling, scrotal swelling, and injection site edema.",swelling is not a named entity
"b  Includes: injection site swelling, penile edema, penile swelling, local swelling, scrotal swelling, and injection site edema.",local swelling is an adverse reaction entity
"b  Includes: injection site swelling, penile edema, penile swelling, local swelling, scrotal swelling, and injection site edema.","swelling , is not a named entity"
"b  Includes: injection site swelling, penile edema, penile swelling, local swelling, scrotal swelling, and injection site edema.",", local is not a named entity"
"b  Includes: injection site swelling, penile edema, penile swelling, local swelling, scrotal swelling, and injection site edema.",penile swelling is an adverse reaction entity
"b  Includes: injection site swelling, penile edema, penile swelling, local swelling, scrotal swelling, and injection site edema.","edema , penile is not a named entity"
"b  Includes: injection site swelling, penile edema, penile swelling, local swelling, scrotal swelling, and injection site edema.",injection site swelling is an adverse reaction entity
"b  Includes: injection site swelling, penile edema, penile swelling, local swelling, scrotal swelling, and injection site edema.",b Includes : is not a named entity
"b  Includes: injection site swelling, penile edema, penile swelling, local swelling, scrotal swelling, and injection site edema.",scrotal swelling is an adverse reaction entity
"b  Includes: injection site swelling, penile edema, penile swelling, local swelling, scrotal swelling, and injection site edema.",injection site edema is an adverse reaction entity
"Because of the risks of corporal rupture or other serious penile injury, XIAFLEX is available for the treatment of Peyronie's disease only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the XIAFLEX REMS Program   [see Warnings and Precautions (5.3)]  .",penile injury is an adverse reaction entity
"Because of the risks of corporal rupture or other serious penile injury, XIAFLEX is available for the treatment of Peyronie's disease only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the XIAFLEX REMS Program   [see Warnings and Precautions (5.3)]  .",of is not a named entity
"Because of the risks of corporal rupture or other serious penile injury, XIAFLEX is available for the treatment of Peyronie's disease only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the XIAFLEX REMS Program   [see Warnings and Precautions (5.3)]  .",corporal rupture is an adverse reaction entity
"Because of the risks of corporal rupture or other serious penile injury, XIAFLEX is available for the treatment of Peyronie's disease only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the XIAFLEX REMS Program   [see Warnings and Precautions (5.3)]  .",of corporal rupture is not a named entity
Severe penile hematoma was also reported as an adverse reaction in 39 of 1044 (3.7%) XIAFLEX-treated patients   [see Warnings and Precautions (5.2)]  .,39 of 1044 is not a named entity
Severe penile hematoma was also reported as an adverse reaction in 39 of 1044 (3.7%) XIAFLEX-treated patients   [see Warnings and Precautions (5.2)]  .,penile hematoma is an adverse reaction entity
Corporal Rupture and Other Serious Penile Injury       *  Corporal rupture was reported as an adverse reaction after XIAFLEX injections in 5 of 1044 (0.5%) XIAFLEX treated patients.,as an is not a named entity
Corporal Rupture and Other Serious Penile Injury       *  Corporal rupture was reported as an adverse reaction after XIAFLEX injections in 5 of 1044 (0.5%) XIAFLEX treated patients.,Corporal rupture is an adverse reaction entity
*  Severe penile hematoma was also reported as an adverse reaction in 39 of 1044 patients (3.7%) in the controlled and uncontrolled clinical trials in Peyronie's disease   [see Adverse Reactions (6)].,in is not a named entity
*  Severe penile hematoma was also reported as an adverse reaction in 39 of 1044 patients (3.7%) in the controlled and uncontrolled clinical trials in Peyronie's disease   [see Adverse Reactions (6)].,penile hematoma is an adverse reaction entity
"Out of 715 patients who received two concurrent injections of XIAFLEX 0.58 mg in the same hand (1450 XIAFLEX injections) in Study 3, one (0.1%) patient experienced a tendon rupture of the treated finger within 3 days of the injection.",715 patients is not a named entity
"Out of 715 patients who received two concurrent injections of XIAFLEX 0.58 mg in the same hand (1450 XIAFLEX injections) in Study 3, one (0.1%) patient experienced a tendon rupture of the treated finger within 3 days of the injection.",tendon rupture of the finger is an adverse reaction entity
Adverse Reactions Occurring in >= 1% of XIAFLEX-Treated Patients with Peyronie's disease and at a Greater Incidence than Placebo After Up to Four Treatment Cycles in Studies 1 and 2 Combined      a  Includes: injection site hematoma and penile hematoma were reported with the verbatim term of penile bruising or injection site bruising in 87% of subjects.,with Peyronie 's is not a named entity
Adverse Reactions Occurring in >= 1% of XIAFLEX-Treated Patients with Peyronie's disease and at a Greater Incidence than Placebo After Up to Four Treatment Cycles in Studies 1 and 2 Combined      a  Includes: injection site hematoma and penile hematoma were reported with the verbatim term of penile bruising or injection site bruising in 87% of subjects.,disease and is not a named entity
Adverse Reactions Occurring in >= 1% of XIAFLEX-Treated Patients with Peyronie's disease and at a Greater Incidence than Placebo After Up to Four Treatment Cycles in Studies 1 and 2 Combined      a  Includes: injection site hematoma and penile hematoma were reported with the verbatim term of penile bruising or injection site bruising in 87% of subjects.,were reported with is not a named entity
Adverse Reactions Occurring in >= 1% of XIAFLEX-Treated Patients with Peyronie's disease and at a Greater Incidence than Placebo After Up to Four Treatment Cycles in Studies 1 and 2 Combined      a  Includes: injection site hematoma and penile hematoma were reported with the verbatim term of penile bruising or injection site bruising in 87% of subjects.,injection site bruising is an adverse reaction entity
Adverse Reactions Occurring in >= 1% of XIAFLEX-Treated Patients with Peyronie's disease and at a Greater Incidence than Placebo After Up to Four Treatment Cycles in Studies 1 and 2 Combined      a  Includes: injection site hematoma and penile hematoma were reported with the verbatim term of penile bruising or injection site bruising in 87% of subjects.,injection site hematoma is an adverse reaction entity
Adverse Reactions Occurring in >= 1% of XIAFLEX-Treated Patients with Peyronie's disease and at a Greater Incidence than Placebo After Up to Four Treatment Cycles in Studies 1 and 2 Combined      a  Includes: injection site hematoma and penile hematoma were reported with the verbatim term of penile bruising or injection site bruising in 87% of subjects.,> = 1 is not a named entity
Adverse Reactions Occurring in >= 1% of XIAFLEX-Treated Patients with Peyronie's disease and at a Greater Incidence than Placebo After Up to Four Treatment Cycles in Studies 1 and 2 Combined      a  Includes: injection site hematoma and penile hematoma were reported with the verbatim term of penile bruising or injection site bruising in 87% of subjects.,penile hematoma is an adverse reaction entity
Adverse Reactions Occurring in >= 1% of XIAFLEX-Treated Patients with Peyronie's disease and at a Greater Incidence than Placebo After Up to Four Treatment Cycles in Studies 1 and 2 Combined      a  Includes: injection site hematoma and penile hematoma were reported with the verbatim term of penile bruising or injection site bruising in 87% of subjects.,penile bruising is an adverse reaction entity
Severe penile hematoma was also reported as an adverse reaction in 39 of 1044 (3.7%) XIAFLEX-treated patients (5.2).,of 1044 is not a named entity
Severe penile hematoma was also reported as an adverse reaction in 39 of 1044 (3.7%) XIAFLEX-treated patients (5.2).,penile hematoma is an adverse reaction entity
"Out of 1082 patients who received 0.58 mg of XIAFLEX in the controlled and uncontrolled portions of the XIAFLEX studies (2630 XIAFLEX injections), 3 (0.3%) patients had a flexor tendon rupture of the treated finger within 7 days of the injection.",flexor tendon rupture of the finger is an adverse reaction entity
"Out of 1082 patients who received 0.58 mg of XIAFLEX in the controlled and uncontrolled portions of the XIAFLEX studies (2630 XIAFLEX injections), 3 (0.3%) patients had a flexor tendon rupture of the treated finger within 7 days of the injection.",0.3 % ) is not a named entity
Cases of skin laceration requiring skin graft after finger extension procedures have been reported post-marketing.,procedures have been is not a named entity
Cases of skin laceration requiring skin graft after finger extension procedures have been reported post-marketing.,skin laceration is an adverse reaction entity
"5.4 Hypersensitivity Reactions, Including Anaphylaxis      In the controlled portions of the clinical trials in Dupuytren's contracture (Studies 1 and 2), a greater proportion of XIAFLEX-treated patients (15%) compared to placebo-treated patients (1%) had mild allergic reactions (pruritus) after up to 3 injections.",in Dupuytren 's is not a named entity
"5.4 Hypersensitivity Reactions, Including Anaphylaxis      In the controlled portions of the clinical trials in Dupuytren's contracture (Studies 1 and 2), a greater proportion of XIAFLEX-treated patients (15%) compared to placebo-treated patients (1%) had mild allergic reactions (pruritus) after up to 3 injections.",pruritus is an adverse reaction entity
"5.4 Hypersensitivity Reactions, Including Anaphylaxis      In the controlled portions of the clinical trials in Dupuytren's contracture (Studies 1 and 2), a greater proportion of XIAFLEX-treated patients (15%) compared to placebo-treated patients (1%) had mild allergic reactions (pruritus) after up to 3 injections.",'s is not a named entity
"5.4 Hypersensitivity Reactions, Including Anaphylaxis      In the controlled portions of the clinical trials in Dupuytren's contracture (Studies 1 and 2), a greater proportion of XIAFLEX-treated patients (15%) compared to placebo-treated patients (1%) had mild allergic reactions (pruritus) after up to 3 injections.",allergic reactions is an adverse reaction entity
"In a historically controlled post-marketing trial, the incidence of skin laceration (22%) was higher for subjects treated with two concurrent injections of XIAFLEX compared with subjects treated with up to three single injections in the placebo-controlled premarketing trials (9%).",skin laceration is an adverse reaction entity
"In a historically controlled post-marketing trial, the incidence of skin laceration (22%) was higher for subjects treated with two concurrent injections of XIAFLEX compared with subjects treated with up to three single injections in the placebo-controlled premarketing trials (9%).",single injections is not a named entity
"In other XIAFLEX-treated patients (9 of 1044; 0.9%), a combination of penile ecchymoses or hematoma, sudden penile detumescence, and/or a penile ""popping"" sound or sensation was reported, and in these cases, a diagnosis of corporal rupture cannot be excluded.",penile detumescence is an adverse reaction entity
"In other XIAFLEX-treated patients (9 of 1044; 0.9%), a combination of penile ecchymoses or hematoma, sudden penile detumescence, and/or a penile ""popping"" sound or sensation was reported, and in these cases, a diagnosis of corporal rupture cannot be excluded.","or hematoma , is not a named entity"
"In other XIAFLEX-treated patients (9 of 1044; 0.9%), a combination of penile ecchymoses or hematoma, sudden penile detumescence, and/or a penile ""popping"" sound or sensation was reported, and in these cases, a diagnosis of corporal rupture cannot be excluded.","penile ""popping"" sound is an adverse reaction entity"
"In other XIAFLEX-treated patients (9 of 1044; 0.9%), a combination of penile ecchymoses or hematoma, sudden penile detumescence, and/or a penile ""popping"" sound or sensation was reported, and in these cases, a diagnosis of corporal rupture cannot be excluded.","penile ""popping"" sensation is an adverse reaction entity"
"In other XIAFLEX-treated patients (9 of 1044; 0.9%), a combination of penile ecchymoses or hematoma, sudden penile detumescence, and/or a penile ""popping"" sound or sensation was reported, and in these cases, a diagnosis of corporal rupture cannot be excluded.",can not be is not a named entity
"In other XIAFLEX-treated patients (9 of 1044; 0.9%), a combination of penile ecchymoses or hematoma, sudden penile detumescence, and/or a penile ""popping"" sound or sensation was reported, and in these cases, a diagnosis of corporal rupture cannot be excluded.",penile hematoma is an adverse reaction entity
"In other XIAFLEX-treated patients (9 of 1044; 0.9%), a combination of penile ecchymoses or hematoma, sudden penile detumescence, and/or a penile ""popping"" sound or sensation was reported, and in these cases, a diagnosis of corporal rupture cannot be excluded.",penile ecchymoses is an adverse reaction entity
"In other XIAFLEX-treated patients (9 of 1044; 0.9%), a combination of penile ecchymoses or hematoma, sudden penile detumescence, and/or a penile ""popping"" sound or sensation was reported, and in these cases, a diagnosis of corporal rupture cannot be excluded.",a combination is not a named entity
"In other XIAFLEX-treated patients (9 of 1044; 0.9%), a combination of penile ecchymoses or hematoma, sudden penile detumescence, and/or a penile ""popping"" sound or sensation was reported, and in these cases, a diagnosis of corporal rupture cannot be excluded.",corporal rupture is an adverse reaction entity
"In other XIAFLEX-treated patients (9 of 1044; 0.9%), a combination of penile ecchymoses or hematoma, sudden penile detumescence, and/or a penile ""popping"" sound or sensation was reported, and in these cases, a diagnosis of corporal rupture cannot be excluded.",( 9 is not a named entity
"In other XIAFLEX-treated patients (9 of 1044; 0.9%), a combination of penile ecchymoses or hematoma, sudden penile detumescence, and/or a penile ""popping"" sound or sensation was reported, and in these cases, a diagnosis of corporal rupture cannot be excluded.","% ) , is not a named entity"
"In other XIAFLEX-treated patients (9 of 1044; 0.9%), a combination of penile ecchymoses or hematoma, sudden penile detumescence, and/or a penile ""popping"" sound or sensation was reported, and in these cases, a diagnosis of corporal rupture cannot be excluded.",", is not a named entity"
Injection of XIAFLEX into collagen-containing structures such as the corpora cavernosa of the penis may result in damage to those structures and possible injury such as corporal rupture (penile fracture).,structures and is not a named entity
Injection of XIAFLEX into collagen-containing structures such as the corpora cavernosa of the penis may result in damage to those structures and possible injury such as corporal rupture (penile fracture).,of the penis is not a named entity
Injection of XIAFLEX into collagen-containing structures such as the corpora cavernosa of the penis may result in damage to those structures and possible injury such as corporal rupture (penile fracture).,penile fracture is an adverse reaction entity
Injection of XIAFLEX into collagen-containing structures such as the corpora cavernosa of the penis may result in damage to those structures and possible injury such as corporal rupture (penile fracture).,collagen-containing structures damage is an adverse reaction entity
Injection of XIAFLEX into collagen-containing structures such as the corpora cavernosa of the penis may result in damage to those structures and possible injury such as corporal rupture (penile fracture).,Injection of XIAFLEX is not a named entity
Injection of XIAFLEX into collagen-containing structures such as the corpora cavernosa of the penis may result in damage to those structures and possible injury such as corporal rupture (penile fracture).,corpora cavernosa of the penis damage is an adverse reaction entity
Injection of XIAFLEX into collagen-containing structures such as the corpora cavernosa of the penis may result in damage to those structures and possible injury such as corporal rupture (penile fracture).,) is not a named entity
Injection of XIAFLEX into collagen-containing structures such as the corpora cavernosa of the penis may result in damage to those structures and possible injury such as corporal rupture (penile fracture).,corporal rupture is an adverse reaction entity
"In the double-blind, placebo-controlled portions of the clinical trials in Peyronie's disease (Studies 1 and 2), a greater proportion of XIAFLEX-treated patients (4%) compared to placebo-treated patients (1%) had localized pruritus after up to 4 treatment cycles (involving up to 8 XIAFLEX injection procedures).",procedures is not a named entity
"In the double-blind, placebo-controlled portions of the clinical trials in Peyronie's disease (Studies 1 and 2), a greater proportion of XIAFLEX-treated patients (4%) compared to placebo-treated patients (1%) had localized pruritus after up to 4 treatment cycles (involving up to 8 XIAFLEX injection procedures).",localized pruritus is an adverse reaction entity
"(  5.2  )   *  Hypersensitivity reactions, including anaphylaxis: Healthcare providers should be prepared to address hypersensitivity reactions, including anaphylaxis, following XIAFLEX injections.",Hypersensitivity reactions is an adverse reaction entity
"(  5.2  )   *  Hypersensitivity reactions, including anaphylaxis: Healthcare providers should be prepared to address hypersensitivity reactions, including anaphylaxis, following XIAFLEX injections.",: is not a named entity
"(  5.2  )   *  Hypersensitivity reactions, including anaphylaxis: Healthcare providers should be prepared to address hypersensitivity reactions, including anaphylaxis, following XIAFLEX injections.",anaphylaxis is an adverse reaction entity
"(  5.2  )   *  Hypersensitivity reactions, including anaphylaxis: Healthcare providers should be prepared to address hypersensitivity reactions, including anaphylaxis, following XIAFLEX injections.",) is not a named entity
"In other XIAFLEX-treated patients (9 of 1044; 0.9%), a diagnosis of corporal rupture cannot be excluded.",diagnosis of corporal is not a named entity
"In other XIAFLEX-treated patients (9 of 1044; 0.9%), a diagnosis of corporal rupture cannot be excluded.",corporal rupture is an adverse reaction entity
Over 95% of XIAFLEX-treated patients had an adverse reaction of the injected extremity after up to 3 injections.,patients had is not a named entity
Over 95% of XIAFLEX-treated patients had an adverse reaction of the injected extremity after up to 3 injections.,adverse reaction of the injected extremity is an adverse reaction entity
"The most frequently reported adverse drug reactions (>= 25%) in the XIAFLEX clinical trials in patients with Dupuytren's contracture included edema peripheral (mostly swelling of the injected hand), contusion, injection site hemorrhage, injection site reaction, and pain in the treated extremity.",", and pain is not a named entity"
"The most frequently reported adverse drug reactions (>= 25%) in the XIAFLEX clinical trials in patients with Dupuytren's contracture included edema peripheral (mostly swelling of the injected hand), contusion, injection site hemorrhage, injection site reaction, and pain in the treated extremity.",25 % is not a named entity
"The most frequently reported adverse drug reactions (>= 25%) in the XIAFLEX clinical trials in patients with Dupuytren's contracture included edema peripheral (mostly swelling of the injected hand), contusion, injection site hemorrhage, injection site reaction, and pain in the treated extremity.",edema peripheral is an adverse reaction entity
"The most frequently reported adverse drug reactions (>= 25%) in the XIAFLEX clinical trials in patients with Dupuytren's contracture included edema peripheral (mostly swelling of the injected hand), contusion, injection site hemorrhage, injection site reaction, and pain in the treated extremity.",injection site hemorrhage is an adverse reaction entity
"The most frequently reported adverse drug reactions (>= 25%) in the XIAFLEX clinical trials in patients with Dupuytren's contracture included edema peripheral (mostly swelling of the injected hand), contusion, injection site hemorrhage, injection site reaction, and pain in the treated extremity.",injection site reaction is an adverse reaction entity
"The most frequently reported adverse drug reactions (>= 25%) in the XIAFLEX clinical trials in patients with Dupuytren's contracture included edema peripheral (mostly swelling of the injected hand), contusion, injection site hemorrhage, injection site reaction, and pain in the treated extremity.",pain in the treated extremity is an adverse reaction entity
"The most frequently reported adverse drug reactions (>= 25%) in the XIAFLEX clinical trials in patients with Dupuytren's contracture included edema peripheral (mostly swelling of the injected hand), contusion, injection site hemorrhage, injection site reaction, and pain in the treated extremity.",contracture included is not a named entity
"The most frequently reported adverse drug reactions (>= 25%) in the XIAFLEX clinical trials in patients with Dupuytren's contracture included edema peripheral (mostly swelling of the injected hand), contusion, injection site hemorrhage, injection site reaction, and pain in the treated extremity.",contusion is an adverse reaction entity
"The most frequently reported adverse drug reactions (>= 25%) in the XIAFLEX clinical trials in patients with Dupuytren's contracture included edema peripheral (mostly swelling of the injected hand), contusion, injection site hemorrhage, injection site reaction, and pain in the treated extremity.",( mostly swelling is not a named entity
"The most frequently reported adverse drug reactions (>= 25%) in the XIAFLEX clinical trials in patients with Dupuytren's contracture included edema peripheral (mostly swelling of the injected hand), contusion, injection site hemorrhage, injection site reaction, and pain in the treated extremity.",most frequently is not a named entity
"The most frequently reported adverse drug reactions (>= 25%) in the XIAFLEX clinical trials in patients with Dupuytren's contracture included edema peripheral (mostly swelling of the injected hand), contusion, injection site hemorrhage, injection site reaction, and pain in the treated extremity.",swelling of the injected hand is an adverse reaction entity
"The most frequently reported adverse drug reactions (>= 25%) in the XIAFLEX clinical trials in patients with Dupuytren's contracture included edema peripheral (mostly swelling of the injected hand), contusion, injection site hemorrhage, injection site reaction, and pain in the treated extremity.",and pain in is not a named entity
"However, the incidence of pruritus increased with more injections    [see Warnings and Precautions (5.4)].",pruritus is an adverse reaction entity
"However, the incidence of pruritus increased with more injections    [see Warnings and Precautions (5.4)].",increased is not a named entity
WARNING: FETAL TOXICITY         See full prescribing information for complete boxed warning.,FETAL TOXICITY See is not a named entity
WARNING: FETAL TOXICITY         See full prescribing information for complete boxed warning.,FETAL TOXICITY is an adverse reaction entity
"In addition, patients taking Edarbi who had moderate to severe renal impairment at baseline or who were >75 years of age were more likely to report serum creatinine increases.",serum creatinine increases is an adverse reaction entity
"In addition, patients taking Edarbi who had moderate to severe renal impairment at baseline or who were >75 years of age were more likely to report serum creatinine increases.",severe renal is not a named entity
(5.3)          5.1 Fetal Toxicity    Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.,Fetal Toxicity is not a named entity
(5.3)          5.1 Fetal Toxicity    Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.,and increases fetal is not a named entity
(5.3)          5.1 Fetal Toxicity    Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.,Use of is not a named entity
(5.3)          5.1 Fetal Toxicity    Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.,fetal morbidity is an adverse reaction entity
(5.3)          5.1 Fetal Toxicity    Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.,system is not a named entity
(5.3)          5.1 Fetal Toxicity    Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.,and is not a named entity
(5.3)          5.1 Fetal Toxicity    Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.,neonatal morbidity is an adverse reaction entity
(5.3)          5.1 Fetal Toxicity    Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.,reduces fetal renal function is an adverse reaction entity
(5.3)          5.1 Fetal Toxicity    Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.,neonatal death is an adverse reaction entity
(5.3)          5.1 Fetal Toxicity    Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.,fetal death is an adverse reaction entity
"BOXED WARNING: WARNING: FETAL TOXICITY      WARNING: FETAL TOXICITY        *  When pregnancy is detected, discontinue Edarbi as soon as possible [see Warnings and Precautions (5.1)].",FETAL TOXICITY is an adverse reaction entity
"BOXED WARNING: WARNING: FETAL TOXICITY      WARNING: FETAL TOXICITY        *  When pregnancy is detected, discontinue Edarbi as soon as possible [see Warnings and Precautions (5.1)].",FETAL TOXICITY is an adverse reaction entity
"BOXED WARNING: WARNING: FETAL TOXICITY      WARNING: FETAL TOXICITY        *  When pregnancy is detected, discontinue Edarbi as soon as possible [see Warnings and Precautions (5.1)].",TOXICITY * is not a named entity
"BOXED WARNING: WARNING: FETAL TOXICITY      WARNING: FETAL TOXICITY        *  When pregnancy is detected, discontinue Edarbi as soon as possible [see Warnings and Precautions (5.1)].",as possible is not a named entity
(5.1)   *  Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.,system is not a named entity
(5.1)   *  Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.,injury to the developing fetus is an adverse reaction entity
(5.1)   *  Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.,death to the developing fetus is an adverse reaction entity
(5.1)   *  Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.,the developing is not a named entity
"Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death.",", is not a named entity"
"Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death.",skull is not a named entity
"Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death.",neonatal renal failure is an adverse reaction entity
"Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death.",death is not a named entity
"Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death.",neonatal skull hypoplasia is an adverse reaction entity
"Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death.",neonatal anuria is an adverse reaction entity
"Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death.",neonatal death is an adverse reaction entity
"Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death.","hypoplasia , anuria is not a named entity"
"Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death.",neonatal hypotension is an adverse reaction entity
"Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death.",neonatal adverse effects is an adverse reaction entity
"Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death.",Potential neonatal is not a named entity
"Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death.","hypotension , renal is not a named entity"
"Hemoglobin/Hematocrit       Low hemoglobin, hematocrit, and RBC counts were observed in 0.2%, 0.4%, and 0.3% of Edarbi-treated subjects, respectively.",Low RBC counts is an adverse reaction entity
"Hemoglobin/Hematocrit       Low hemoglobin, hematocrit, and RBC counts were observed in 0.2%, 0.4%, and 0.3% of Edarbi-treated subjects, respectively.",Low hematocrit is an adverse reaction entity
"Hemoglobin/Hematocrit       Low hemoglobin, hematocrit, and RBC counts were observed in 0.2%, 0.4%, and 0.3% of Edarbi-treated subjects, respectively.",% of Edarbi-treated is not a named entity
"Hemoglobin/Hematocrit       Low hemoglobin, hematocrit, and RBC counts were observed in 0.2%, 0.4%, and 0.3% of Edarbi-treated subjects, respectively.",Low hemoglobin is an adverse reaction entity
"Hemoglobin/Hematocrit       Low hemoglobin, hematocrit, and RBC counts were observed in 0.2%, 0.4%, and 0.3% of Edarbi-treated subjects, respectively.",were is not a named entity
"Hemoglobin/Hematocrit       Low hemoglobin, hematocrit, and RBC counts were observed in 0.2%, 0.4%, and 0.3% of Edarbi-treated subjects, respectively.",", and is not a named entity"
"5.3 Impaired Renal Function    As a consequence of inhibiting the renin-angiotensin system, changes in renal function may be anticipated in susceptible individuals treated with Edarbi.",changes in renal function is an adverse reaction entity
"5.3 Impaired Renal Function    As a consequence of inhibiting the renin-angiotensin system, changes in renal function may be anticipated in susceptible individuals treated with Edarbi.",the is not a named entity
Serum creatinine       Small reversible increases in serum creatinine are seen in patients receiving 80 mg of Edarbi.,reversible is not a named entity
Serum creatinine       Small reversible increases in serum creatinine are seen in patients receiving 80 mg of Edarbi.,increases in serum creatinine is an adverse reaction entity
"In patients whose renal function may depend on the activity of the renin-angiotensin system (e.g., patients with severe congestive heart failure, renal artery stenosis, or volume depletion), treatment with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers has been associated with oliguria or progressive azotemia and rarely with acute renal failure and death.",artery is not a named entity
"In patients whose renal function may depend on the activity of the renin-angiotensin system (e.g., patients with severe congestive heart failure, renal artery stenosis, or volume depletion), treatment with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers has been associated with oliguria or progressive azotemia and rarely with acute renal failure and death.",death is an adverse reaction entity
"In patients whose renal function may depend on the activity of the renin-angiotensin system (e.g., patients with severe congestive heart failure, renal artery stenosis, or volume depletion), treatment with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers has been associated with oliguria or progressive azotemia and rarely with acute renal failure and death.",activity is not a named entity
"In patients whose renal function may depend on the activity of the renin-angiotensin system (e.g., patients with severe congestive heart failure, renal artery stenosis, or volume depletion), treatment with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers has been associated with oliguria or progressive azotemia and rarely with acute renal failure and death.",oliguria is an adverse reaction entity
"In patients whose renal function may depend on the activity of the renin-angiotensin system (e.g., patients with severe congestive heart failure, renal artery stenosis, or volume depletion), treatment with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers has been associated with oliguria or progressive azotemia and rarely with acute renal failure and death.",azotemia and is not a named entity
"In patients whose renal function may depend on the activity of the renin-angiotensin system (e.g., patients with severe congestive heart failure, renal artery stenosis, or volume depletion), treatment with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers has been associated with oliguria or progressive azotemia and rarely with acute renal failure and death.",progressive azotemia is an adverse reaction entity
"In patients whose renal function may depend on the activity of the renin-angiotensin system (e.g., patients with severe congestive heart failure, renal artery stenosis, or volume depletion), treatment with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers has been associated with oliguria or progressive azotemia and rarely with acute renal failure and death.",acute renal failure is an adverse reaction entity
"In patients whose renal function may depend on the activity of the renin-angiotensin system (e.g., patients with severe congestive heart failure, renal artery stenosis, or volume depletion), treatment with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers has been associated with oliguria or progressive azotemia and rarely with acute renal failure and death.",( e.g. is not a named entity
"5.2 Hypotension in Volume- or Salt-Depleted Patients    In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with Edarbi.",or Salt-Depleted is not a named entity
"5.2 Hypotension in Volume- or Salt-Depleted Patients    In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with Edarbi.",symptomatic hypotension is an adverse reaction entity
"In placebo-controlled monotherapy trials, diarrhea was reported up to 2% in patients treated with Edarbi 80 mg daily compared with 0.5% of patients on placebo.",Edarbi is not a named entity
"In placebo-controlled monotherapy trials, diarrhea was reported up to 2% in patients treated with Edarbi 80 mg daily compared with 0.5% of patients on placebo.",diarrhea is an adverse reaction entity
*  Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions (5.1)].,5.1 ) is not a named entity
*  Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions (5.1)].,the is not a named entity
*  Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions (5.1)].,death to the developing fetus is an adverse reaction entity
*  Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions (5.1)].,injury to the developing fetus is an adverse reaction entity
"Table 1: Adverse Reactions Reported by at Least 1% of Subjects Treated for up to 48 Weeks    Adverse Event, n (%)     JUBLIAN = 1227           VehicleN = 413              Ingrown toenail          28 (2.3%)                3 (0.7%)                    Application site dermatitis    27 (2.2%)                1 (0.2%)                    Application site vesicles    20 (1.6%)                0 (0.0%)                    Application site pain    13 (1.1%)                1 (0.2%)",Ingrown toenail is an adverse reaction entity
"Table 1: Adverse Reactions Reported by at Least 1% of Subjects Treated for up to 48 Weeks    Adverse Event, n (%)     JUBLIAN = 1227           VehicleN = 413              Ingrown toenail          28 (2.3%)                3 (0.7%)                    Application site dermatitis    27 (2.2%)                1 (0.2%)                    Application site vesicles    20 (1.6%)                0 (0.0%)                    Application site pain    13 (1.1%)                1 (0.2%)",Application site vesicles is an adverse reaction entity
"Table 1: Adverse Reactions Reported by at Least 1% of Subjects Treated for up to 48 Weeks    Adverse Event, n (%)     JUBLIAN = 1227           VehicleN = 413              Ingrown toenail          28 (2.3%)                3 (0.7%)                    Application site dermatitis    27 (2.2%)                1 (0.2%)                    Application site vesicles    20 (1.6%)                0 (0.0%)                    Application site pain    13 (1.1%)                1 (0.2%)",) 0 ( is not a named entity
"Table 1: Adverse Reactions Reported by at Least 1% of Subjects Treated for up to 48 Weeks    Adverse Event, n (%)     JUBLIAN = 1227           VehicleN = 413              Ingrown toenail          28 (2.3%)                3 (0.7%)                    Application site dermatitis    27 (2.2%)                1 (0.2%)                    Application site vesicles    20 (1.6%)                0 (0.0%)                    Application site pain    13 (1.1%)                1 (0.2%)",Application site pain is an adverse reaction entity
"Table 1: Adverse Reactions Reported by at Least 1% of Subjects Treated for up to 48 Weeks    Adverse Event, n (%)     JUBLIAN = 1227           VehicleN = 413              Ingrown toenail          28 (2.3%)                3 (0.7%)                    Application site dermatitis    27 (2.2%)                1 (0.2%)                    Application site vesicles    20 (1.6%)                0 (0.0%)                    Application site pain    13 (1.1%)                1 (0.2%)",dermatitis is not a named entity
"Table 1: Adverse Reactions Reported by at Least 1% of Subjects Treated for up to 48 Weeks    Adverse Event, n (%)     JUBLIAN = 1227           VehicleN = 413              Ingrown toenail          28 (2.3%)                3 (0.7%)                    Application site dermatitis    27 (2.2%)                1 (0.2%)                    Application site vesicles    20 (1.6%)                0 (0.0%)                    Application site pain    13 (1.1%)                1 (0.2%)",VehicleN = 413 is not a named entity
"Table 1: Adverse Reactions Reported by at Least 1% of Subjects Treated for up to 48 Weeks    Adverse Event, n (%)     JUBLIAN = 1227           VehicleN = 413              Ingrown toenail          28 (2.3%)                3 (0.7%)                    Application site dermatitis    27 (2.2%)                1 (0.2%)                    Application site vesicles    20 (1.6%)                0 (0.0%)                    Application site pain    13 (1.1%)                1 (0.2%)",% is not a named entity
"Table 1: Adverse Reactions Reported by at Least 1% of Subjects Treated for up to 48 Weeks    Adverse Event, n (%)     JUBLIAN = 1227           VehicleN = 413              Ingrown toenail          28 (2.3%)                3 (0.7%)                    Application site dermatitis    27 (2.2%)                1 (0.2%)                    Application site vesicles    20 (1.6%)                0 (0.0%)                    Application site pain    13 (1.1%)                1 (0.2%)",Application site dermatitis is an adverse reaction entity
"6 ADVERSE REACTIONS    EXCERPT:   The most common adverse reactions (incidence >1%) were ingrown toenails, application site dermatitis, application site vesicles, and application site pain.",application site vesicles is an adverse reaction entity
"6 ADVERSE REACTIONS    EXCERPT:   The most common adverse reactions (incidence >1%) were ingrown toenails, application site dermatitis, application site vesicles, and application site pain.",and application site is not a named entity
"6 ADVERSE REACTIONS    EXCERPT:   The most common adverse reactions (incidence >1%) were ingrown toenails, application site dermatitis, application site vesicles, and application site pain.",) were is not a named entity
"6 ADVERSE REACTIONS    EXCERPT:   The most common adverse reactions (incidence >1%) were ingrown toenails, application site dermatitis, application site vesicles, and application site pain.",application site pain is an adverse reaction entity
"6 ADVERSE REACTIONS    EXCERPT:   The most common adverse reactions (incidence >1%) were ingrown toenails, application site dermatitis, application site vesicles, and application site pain.",1 % ) is not a named entity
"6 ADVERSE REACTIONS    EXCERPT:   The most common adverse reactions (incidence >1%) were ingrown toenails, application site dermatitis, application site vesicles, and application site pain.",ingrown toenails is an adverse reaction entity
"6 ADVERSE REACTIONS    EXCERPT:   The most common adverse reactions (incidence >1%) were ingrown toenails, application site dermatitis, application site vesicles, and application site pain.",application site dermatitis is an adverse reaction entity
"6 ADVERSE REACTIONS    EXCERPT:   The most common adverse reactions (incidence >1%) were ingrown toenails, application site dermatitis, application site vesicles, and application site pain.",most common adverse is not a named entity
"(  6.1  )   *    In pediatric patients age 6 years and older with ITP, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were upper respiratory tract infection, nasopharyngitis, and rhinitis.",upper respiratory tract infection is an adverse reaction entity
"(  6.1  )   *    In pediatric patients age 6 years and older with ITP, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were upper respiratory tract infection, nasopharyngitis, and rhinitis.",nasopharyngitis is an adverse reaction entity
"(  6.1  )   *    In pediatric patients age 6 years and older with ITP, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were upper respiratory tract infection, nasopharyngitis, and rhinitis.",the most is not a named entity
"(  6.1  )   *    In pediatric patients age 6 years and older with ITP, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were upper respiratory tract infection, nasopharyngitis, and rhinitis.",rhinitis is an adverse reaction entity
"(  6.1  )   *    In pediatric patients age 6 years and older with ITP, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were upper respiratory tract infection, nasopharyngitis, and rhinitis.",pediatric is not a named entity
"(  6.1  )   *    In pediatric patients age 6 years and older with ITP, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were upper respiratory tract infection, nasopharyngitis, and rhinitis.",) were upper is not a named entity
"In patients with chronic hepatitis C, PROMACTA in combination with interferon and ribavirin may increase the risk of hepatic decompensation.",hepatic decompensation is an adverse reaction entity
"In patients with chronic hepatitis C, PROMACTA in combination with interferon and ribavirin may increase the risk of hepatic decompensation.",risk of hepatic is not a named entity
"(  6.1  )   *    In patients with chronic hepatitis C-associated thrombocytopenia, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were: anemia, pyrexia, fatigue, headache, nausea, diarrhea, decreased appetite, influenza-like illness, asthenia, insomnia, cough, pruritus, chills, myalgia, alopecia, and peripheral edema.","alopecia , and is not a named entity"
"(  6.1  )   *    In patients with chronic hepatitis C-associated thrombocytopenia, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were: anemia, pyrexia, fatigue, headache, nausea, diarrhea, decreased appetite, influenza-like illness, asthenia, insomnia, cough, pruritus, chills, myalgia, alopecia, and peripheral edema.",headache is an adverse reaction entity
"(  6.1  )   *    In patients with chronic hepatitis C-associated thrombocytopenia, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were: anemia, pyrexia, fatigue, headache, nausea, diarrhea, decreased appetite, influenza-like illness, asthenia, insomnia, cough, pruritus, chills, myalgia, alopecia, and peripheral edema.",myalgia is an adverse reaction entity
"(  6.1  )   *    In patients with chronic hepatitis C-associated thrombocytopenia, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were: anemia, pyrexia, fatigue, headache, nausea, diarrhea, decreased appetite, influenza-like illness, asthenia, insomnia, cough, pruritus, chills, myalgia, alopecia, and peripheral edema.",", is not a named entity"
"(  6.1  )   *    In patients with chronic hepatitis C-associated thrombocytopenia, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were: anemia, pyrexia, fatigue, headache, nausea, diarrhea, decreased appetite, influenza-like illness, asthenia, insomnia, cough, pruritus, chills, myalgia, alopecia, and peripheral edema.",", influenza-like is not a named entity"
"(  6.1  )   *    In patients with chronic hepatitis C-associated thrombocytopenia, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were: anemia, pyrexia, fatigue, headache, nausea, diarrhea, decreased appetite, influenza-like illness, asthenia, insomnia, cough, pruritus, chills, myalgia, alopecia, and peripheral edema.",greater than placebo is not a named entity
"(  6.1  )   *    In patients with chronic hepatitis C-associated thrombocytopenia, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were: anemia, pyrexia, fatigue, headache, nausea, diarrhea, decreased appetite, influenza-like illness, asthenia, insomnia, cough, pruritus, chills, myalgia, alopecia, and peripheral edema.",equal is not a named entity
"(  6.1  )   *    In patients with chronic hepatitis C-associated thrombocytopenia, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were: anemia, pyrexia, fatigue, headache, nausea, diarrhea, decreased appetite, influenza-like illness, asthenia, insomnia, cough, pruritus, chills, myalgia, alopecia, and peripheral edema.",anemia is an adverse reaction entity
"(  6.1  )   *    In patients with chronic hepatitis C-associated thrombocytopenia, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were: anemia, pyrexia, fatigue, headache, nausea, diarrhea, decreased appetite, influenza-like illness, asthenia, insomnia, cough, pruritus, chills, myalgia, alopecia, and peripheral edema.",insomnia is an adverse reaction entity
"(  6.1  )   *    In patients with chronic hepatitis C-associated thrombocytopenia, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were: anemia, pyrexia, fatigue, headache, nausea, diarrhea, decreased appetite, influenza-like illness, asthenia, insomnia, cough, pruritus, chills, myalgia, alopecia, and peripheral edema.",greater than is not a named entity
"(  6.1  )   *    In patients with chronic hepatitis C-associated thrombocytopenia, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were: anemia, pyrexia, fatigue, headache, nausea, diarrhea, decreased appetite, influenza-like illness, asthenia, insomnia, cough, pruritus, chills, myalgia, alopecia, and peripheral edema.",cough is an adverse reaction entity
"(  6.1  )   *    In patients with chronic hepatitis C-associated thrombocytopenia, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were: anemia, pyrexia, fatigue, headache, nausea, diarrhea, decreased appetite, influenza-like illness, asthenia, insomnia, cough, pruritus, chills, myalgia, alopecia, and peripheral edema.",influenza-like illness is an adverse reaction entity
"(  6.1  )   *    In patients with chronic hepatitis C-associated thrombocytopenia, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were: anemia, pyrexia, fatigue, headache, nausea, diarrhea, decreased appetite, influenza-like illness, asthenia, insomnia, cough, pruritus, chills, myalgia, alopecia, and peripheral edema.",most is not a named entity
"(  6.1  )   *    In patients with chronic hepatitis C-associated thrombocytopenia, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were: anemia, pyrexia, fatigue, headache, nausea, diarrhea, decreased appetite, influenza-like illness, asthenia, insomnia, cough, pruritus, chills, myalgia, alopecia, and peripheral edema.",", pyrexia , is not a named entity"
"(  6.1  )   *    In patients with chronic hepatitis C-associated thrombocytopenia, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were: anemia, pyrexia, fatigue, headache, nausea, diarrhea, decreased appetite, influenza-like illness, asthenia, insomnia, cough, pruritus, chills, myalgia, alopecia, and peripheral edema.",adverse reactions ( is not a named entity
"(  6.1  )   *    In patients with chronic hepatitis C-associated thrombocytopenia, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were: anemia, pyrexia, fatigue, headache, nausea, diarrhea, decreased appetite, influenza-like illness, asthenia, insomnia, cough, pruritus, chills, myalgia, alopecia, and peripheral edema.","headache , nausea is not a named entity"
"(  6.1  )   *    In patients with chronic hepatitis C-associated thrombocytopenia, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were: anemia, pyrexia, fatigue, headache, nausea, diarrhea, decreased appetite, influenza-like illness, asthenia, insomnia, cough, pruritus, chills, myalgia, alopecia, and peripheral edema.",", diarrhea , is not a named entity"
"(  6.1  )   *    In patients with chronic hepatitis C-associated thrombocytopenia, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were: anemia, pyrexia, fatigue, headache, nausea, diarrhea, decreased appetite, influenza-like illness, asthenia, insomnia, cough, pruritus, chills, myalgia, alopecia, and peripheral edema.",diarrhea is an adverse reaction entity
"(  6.1  )   *    In patients with chronic hepatitis C-associated thrombocytopenia, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were: anemia, pyrexia, fatigue, headache, nausea, diarrhea, decreased appetite, influenza-like illness, asthenia, insomnia, cough, pruritus, chills, myalgia, alopecia, and peripheral edema.",and peripheral edema is not a named entity
"(  6.1  )   *    In patients with chronic hepatitis C-associated thrombocytopenia, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were: anemia, pyrexia, fatigue, headache, nausea, diarrhea, decreased appetite, influenza-like illness, asthenia, insomnia, cough, pruritus, chills, myalgia, alopecia, and peripheral edema.",chills is an adverse reaction entity
"(  6.1  )   *    In patients with chronic hepatitis C-associated thrombocytopenia, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were: anemia, pyrexia, fatigue, headache, nausea, diarrhea, decreased appetite, influenza-like illness, asthenia, insomnia, cough, pruritus, chills, myalgia, alopecia, and peripheral edema.",pyrexia is an adverse reaction entity
"(  6.1  )   *    In patients with chronic hepatitis C-associated thrombocytopenia, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were: anemia, pyrexia, fatigue, headache, nausea, diarrhea, decreased appetite, influenza-like illness, asthenia, insomnia, cough, pruritus, chills, myalgia, alopecia, and peripheral edema.",fatigue is an adverse reaction entity
"(  6.1  )   *    In patients with chronic hepatitis C-associated thrombocytopenia, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were: anemia, pyrexia, fatigue, headache, nausea, diarrhea, decreased appetite, influenza-like illness, asthenia, insomnia, cough, pruritus, chills, myalgia, alopecia, and peripheral edema.",nausea is an adverse reaction entity
"(  6.1  )   *    In patients with chronic hepatitis C-associated thrombocytopenia, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were: anemia, pyrexia, fatigue, headache, nausea, diarrhea, decreased appetite, influenza-like illness, asthenia, insomnia, cough, pruritus, chills, myalgia, alopecia, and peripheral edema.",to is not a named entity
"(  6.1  )   *    In patients with chronic hepatitis C-associated thrombocytopenia, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were: anemia, pyrexia, fatigue, headache, nausea, diarrhea, decreased appetite, influenza-like illness, asthenia, insomnia, cough, pruritus, chills, myalgia, alopecia, and peripheral edema.",pruritus is an adverse reaction entity
"(  6.1  )   *    In patients with chronic hepatitis C-associated thrombocytopenia, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were: anemia, pyrexia, fatigue, headache, nausea, diarrhea, decreased appetite, influenza-like illness, asthenia, insomnia, cough, pruritus, chills, myalgia, alopecia, and peripheral edema.",decreased appetite is an adverse reaction entity
"(  6.1  )   *    In patients with chronic hepatitis C-associated thrombocytopenia, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were: anemia, pyrexia, fatigue, headache, nausea, diarrhea, decreased appetite, influenza-like illness, asthenia, insomnia, cough, pruritus, chills, myalgia, alopecia, and peripheral edema.","pruritus , chills is not a named entity"
"(  6.1  )   *    In patients with chronic hepatitis C-associated thrombocytopenia, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were: anemia, pyrexia, fatigue, headache, nausea, diarrhea, decreased appetite, influenza-like illness, asthenia, insomnia, cough, pruritus, chills, myalgia, alopecia, and peripheral edema.",peripheral edema is an adverse reaction entity
"(  6.1  )   *    In patients with chronic hepatitis C-associated thrombocytopenia, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were: anemia, pyrexia, fatigue, headache, nausea, diarrhea, decreased appetite, influenza-like illness, asthenia, insomnia, cough, pruritus, chills, myalgia, alopecia, and peripheral edema.","pruritus , is not a named entity"
"(  6.1  )   *    In patients with chronic hepatitis C-associated thrombocytopenia, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were: anemia, pyrexia, fatigue, headache, nausea, diarrhea, decreased appetite, influenza-like illness, asthenia, insomnia, cough, pruritus, chills, myalgia, alopecia, and peripheral edema.",adverse reactions is not a named entity
"(  6.1  )   *    In patients with chronic hepatitis C-associated thrombocytopenia, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were: anemia, pyrexia, fatigue, headache, nausea, diarrhea, decreased appetite, influenza-like illness, asthenia, insomnia, cough, pruritus, chills, myalgia, alopecia, and peripheral edema.",asthenia is an adverse reaction entity
"(  6.1  )   *    In patients with chronic hepatitis C-associated thrombocytopenia, the most common adverse reactions (greater than or equal to 10% and greater than placebo) were: anemia, pyrexia, fatigue, headache, nausea, diarrhea, decreased appetite, influenza-like illness, asthenia, insomnia, cough, pruritus, chills, myalgia, alopecia, and peripheral edema.",alopecia is an adverse reaction entity
Four patients (1%) treated with PROMACTA and three patients in the placebo group (2%) discontinued treatment due to hepatobiliary laboratory abnormalities.,the placebo group is not a named entity
Four patients (1%) treated with PROMACTA and three patients in the placebo group (2%) discontinued treatment due to hepatobiliary laboratory abnormalities.,hepatobiliary laboratory abnormalities is an adverse reaction entity
"(  5.3  )             5.1 Hepatic Decompensation in Patients with Chronic Hepatitis C      In patients with chronic hepatitis C, PROMACTA in combination with interferon and ribavirin may increase the risk of hepatic decompensation.",risk of hepatic is not a named entity
"(  5.3  )             5.1 Hepatic Decompensation in Patients with Chronic Hepatitis C      In patients with chronic hepatitis C, PROMACTA in combination with interferon and ribavirin may increase the risk of hepatic decompensation.",hepatic decompensation is an adverse reaction entity
Seven of the patients treated with PROMACTA in the controlled trials with hepatobiliary laboratory abnormalities were re-exposed to PROMACTA in the extension trial.,PROMACTA is not a named entity
Seven of the patients treated with PROMACTA in the controlled trials with hepatobiliary laboratory abnormalities were re-exposed to PROMACTA in the extension trial.,hepatobiliary laboratory abnormalities is an adverse reaction entity
"Chronic Immune (Idiopathic) Thrombocytopenia:    Adults:  In clinical trials, hemorrhage was the most common serious adverse reaction and most hemorrhagic reactions followed discontinuation of PROMACTA.",Chronic is not a named entity
"Chronic Immune (Idiopathic) Thrombocytopenia:    Adults:  In clinical trials, hemorrhage was the most common serious adverse reaction and most hemorrhagic reactions followed discontinuation of PROMACTA.",serious is not a named entity
"Chronic Immune (Idiopathic) Thrombocytopenia:    Adults:  In clinical trials, hemorrhage was the most common serious adverse reaction and most hemorrhagic reactions followed discontinuation of PROMACTA.",hemorrhagic reactions is an adverse reaction entity
"Chronic Immune (Idiopathic) Thrombocytopenia:    Adults:  In clinical trials, hemorrhage was the most common serious adverse reaction and most hemorrhagic reactions followed discontinuation of PROMACTA.",hemorrhage is an adverse reaction entity
"Total bilirubin greater than or equal to 1.5 x ULN was reported in 76% and 50% of patients receiving PROMACTA and placebo, respectively.",Total bilirubin greater than or equal to 1.5 x ULN is an adverse reaction entity
"Total bilirubin greater than or equal to 1.5 x ULN was reported in 76% and 50% of patients receiving PROMACTA and placebo, respectively.",than or equal is not a named entity
"The most common adverse reactions (greater than or equal to 20%) were nausea, fatigue, cough, diarrhea, and headache.",equal to is not a named entity
"The most common adverse reactions (greater than or equal to 20%) were nausea, fatigue, cough, diarrhea, and headache.",cough is an adverse reaction entity
"The most common adverse reactions (greater than or equal to 20%) were nausea, fatigue, cough, diarrhea, and headache.",headache is an adverse reaction entity
"The most common adverse reactions (greater than or equal to 20%) were nausea, fatigue, cough, diarrhea, and headache.",( greater is not a named entity
"The most common adverse reactions (greater than or equal to 20%) were nausea, fatigue, cough, diarrhea, and headache.",fatigue is an adverse reaction entity
"The most common adverse reactions (greater than or equal to 20%) were nausea, fatigue, cough, diarrhea, and headache.",nausea is an adverse reaction entity
"The most common adverse reactions (greater than or equal to 20%) were nausea, fatigue, cough, diarrhea, and headache.",or equal to is not a named entity
"The most common adverse reactions (greater than or equal to 20%) were nausea, fatigue, cough, diarrhea, and headache.",", is not a named entity"
"The most common adverse reactions (greater than or equal to 20%) were nausea, fatigue, cough, diarrhea, and headache.",were nausea is not a named entity
"The most common adverse reactions (greater than or equal to 20%) were nausea, fatigue, cough, diarrhea, and headache.",diarrhea is an adverse reaction entity
5.2 Hepatotoxicity      PROMACTA can cause liver enzyme elevations [see Adverse Reactions (6.1)]  .,liver enzyme elevations is an adverse reaction entity
5.2 Hepatotoxicity      PROMACTA can cause liver enzyme elevations [see Adverse Reactions (6.1)]  .,cause liver enzyme is not a named entity
"*    Hepatic Decompensation in Patients with Chronic Hepatitis C [see Warnings and Precautions (5.1)]    *    Hepatotoxicity [see Warnings and Precautions (5.2)]    *    Thrombotic/Thromboembolic Complications [see Warnings and Precautions (5.3)]    *    Cataracts [see Warnings and Precautions (5.4)]      *    In adult patients with ITP, the most common adverse reactions (greater than or equal to 5% and greater than placebo) were: nausea, diarrhea, upper respiratory tract infection, vomiting, increased ALT, myalgia, and urinary tract infection.",Thrombotic Complications is an adverse reaction entity
"*    Hepatic Decompensation in Patients with Chronic Hepatitis C [see Warnings and Precautions (5.1)]    *    Hepatotoxicity [see Warnings and Precautions (5.2)]    *    Thrombotic/Thromboembolic Complications [see Warnings and Precautions (5.3)]    *    Cataracts [see Warnings and Precautions (5.4)]      *    In adult patients with ITP, the most common adverse reactions (greater than or equal to 5% and greater than placebo) were: nausea, diarrhea, upper respiratory tract infection, vomiting, increased ALT, myalgia, and urinary tract infection.",upper respiratory tract infection is an adverse reaction entity
"*    Hepatic Decompensation in Patients with Chronic Hepatitis C [see Warnings and Precautions (5.1)]    *    Hepatotoxicity [see Warnings and Precautions (5.2)]    *    Thrombotic/Thromboembolic Complications [see Warnings and Precautions (5.3)]    *    Cataracts [see Warnings and Precautions (5.4)]      *    In adult patients with ITP, the most common adverse reactions (greater than or equal to 5% and greater than placebo) were: nausea, diarrhea, upper respiratory tract infection, vomiting, increased ALT, myalgia, and urinary tract infection.",urinary tract infection is an adverse reaction entity
"*    Hepatic Decompensation in Patients with Chronic Hepatitis C [see Warnings and Precautions (5.1)]    *    Hepatotoxicity [see Warnings and Precautions (5.2)]    *    Thrombotic/Thromboembolic Complications [see Warnings and Precautions (5.3)]    *    Cataracts [see Warnings and Precautions (5.4)]      *    In adult patients with ITP, the most common adverse reactions (greater than or equal to 5% and greater than placebo) were: nausea, diarrhea, upper respiratory tract infection, vomiting, increased ALT, myalgia, and urinary tract infection.",Cataracts is an adverse reaction entity
"*    Hepatic Decompensation in Patients with Chronic Hepatitis C [see Warnings and Precautions (5.1)]    *    Hepatotoxicity [see Warnings and Precautions (5.2)]    *    Thrombotic/Thromboembolic Complications [see Warnings and Precautions (5.3)]    *    Cataracts [see Warnings and Precautions (5.4)]      *    In adult patients with ITP, the most common adverse reactions (greater than or equal to 5% and greater than placebo) were: nausea, diarrhea, upper respiratory tract infection, vomiting, increased ALT, myalgia, and urinary tract infection.",increased ALT is an adverse reaction entity
"*    Hepatic Decompensation in Patients with Chronic Hepatitis C [see Warnings and Precautions (5.1)]    *    Hepatotoxicity [see Warnings and Precautions (5.2)]    *    Thrombotic/Thromboembolic Complications [see Warnings and Precautions (5.3)]    *    Cataracts [see Warnings and Precautions (5.4)]      *    In adult patients with ITP, the most common adverse reactions (greater than or equal to 5% and greater than placebo) were: nausea, diarrhea, upper respiratory tract infection, vomiting, increased ALT, myalgia, and urinary tract infection.",common is not a named entity
"*    Hepatic Decompensation in Patients with Chronic Hepatitis C [see Warnings and Precautions (5.1)]    *    Hepatotoxicity [see Warnings and Precautions (5.2)]    *    Thrombotic/Thromboembolic Complications [see Warnings and Precautions (5.3)]    *    Cataracts [see Warnings and Precautions (5.4)]      *    In adult patients with ITP, the most common adverse reactions (greater than or equal to 5% and greater than placebo) were: nausea, diarrhea, upper respiratory tract infection, vomiting, increased ALT, myalgia, and urinary tract infection.",Hepatotoxicity is an adverse reaction entity
"*    Hepatic Decompensation in Patients with Chronic Hepatitis C [see Warnings and Precautions (5.1)]    *    Hepatotoxicity [see Warnings and Precautions (5.2)]    *    Thrombotic/Thromboembolic Complications [see Warnings and Precautions (5.3)]    *    Cataracts [see Warnings and Precautions (5.4)]      *    In adult patients with ITP, the most common adverse reactions (greater than or equal to 5% and greater than placebo) were: nausea, diarrhea, upper respiratory tract infection, vomiting, increased ALT, myalgia, and urinary tract infection.",vomiting is an adverse reaction entity
"*    Hepatic Decompensation in Patients with Chronic Hepatitis C [see Warnings and Precautions (5.1)]    *    Hepatotoxicity [see Warnings and Precautions (5.2)]    *    Thrombotic/Thromboembolic Complications [see Warnings and Precautions (5.3)]    *    Cataracts [see Warnings and Precautions (5.4)]      *    In adult patients with ITP, the most common adverse reactions (greater than or equal to 5% and greater than placebo) were: nausea, diarrhea, upper respiratory tract infection, vomiting, increased ALT, myalgia, and urinary tract infection.",adult is not a named entity
"*    Hepatic Decompensation in Patients with Chronic Hepatitis C [see Warnings and Precautions (5.1)]    *    Hepatotoxicity [see Warnings and Precautions (5.2)]    *    Thrombotic/Thromboembolic Complications [see Warnings and Precautions (5.3)]    *    Cataracts [see Warnings and Precautions (5.4)]      *    In adult patients with ITP, the most common adverse reactions (greater than or equal to 5% and greater than placebo) were: nausea, diarrhea, upper respiratory tract infection, vomiting, increased ALT, myalgia, and urinary tract infection.",and Precautions is not a named entity
"*    Hepatic Decompensation in Patients with Chronic Hepatitis C [see Warnings and Precautions (5.1)]    *    Hepatotoxicity [see Warnings and Precautions (5.2)]    *    Thrombotic/Thromboembolic Complications [see Warnings and Precautions (5.3)]    *    Cataracts [see Warnings and Precautions (5.4)]      *    In adult patients with ITP, the most common adverse reactions (greater than or equal to 5% and greater than placebo) were: nausea, diarrhea, upper respiratory tract infection, vomiting, increased ALT, myalgia, and urinary tract infection.",ITP is not a named entity
"*    Hepatic Decompensation in Patients with Chronic Hepatitis C [see Warnings and Precautions (5.1)]    *    Hepatotoxicity [see Warnings and Precautions (5.2)]    *    Thrombotic/Thromboembolic Complications [see Warnings and Precautions (5.3)]    *    Cataracts [see Warnings and Precautions (5.4)]      *    In adult patients with ITP, the most common adverse reactions (greater than or equal to 5% and greater than placebo) were: nausea, diarrhea, upper respiratory tract infection, vomiting, increased ALT, myalgia, and urinary tract infection.",or is not a named entity
"*    Hepatic Decompensation in Patients with Chronic Hepatitis C [see Warnings and Precautions (5.1)]    *    Hepatotoxicity [see Warnings and Precautions (5.2)]    *    Thrombotic/Thromboembolic Complications [see Warnings and Precautions (5.3)]    *    Cataracts [see Warnings and Precautions (5.4)]      *    In adult patients with ITP, the most common adverse reactions (greater than or equal to 5% and greater than placebo) were: nausea, diarrhea, upper respiratory tract infection, vomiting, increased ALT, myalgia, and urinary tract infection.",) is not a named entity
"*    Hepatic Decompensation in Patients with Chronic Hepatitis C [see Warnings and Precautions (5.1)]    *    Hepatotoxicity [see Warnings and Precautions (5.2)]    *    Thrombotic/Thromboembolic Complications [see Warnings and Precautions (5.3)]    *    Cataracts [see Warnings and Precautions (5.4)]      *    In adult patients with ITP, the most common adverse reactions (greater than or equal to 5% and greater than placebo) were: nausea, diarrhea, upper respiratory tract infection, vomiting, increased ALT, myalgia, and urinary tract infection.",Thromboembolic Complications is an adverse reaction entity
"*    Hepatic Decompensation in Patients with Chronic Hepatitis C [see Warnings and Precautions (5.1)]    *    Hepatotoxicity [see Warnings and Precautions (5.2)]    *    Thrombotic/Thromboembolic Complications [see Warnings and Precautions (5.3)]    *    Cataracts [see Warnings and Precautions (5.4)]      *    In adult patients with ITP, the most common adverse reactions (greater than or equal to 5% and greater than placebo) were: nausea, diarrhea, upper respiratory tract infection, vomiting, increased ALT, myalgia, and urinary tract infection.",diarrhea is an adverse reaction entity
"*    Hepatic Decompensation in Patients with Chronic Hepatitis C [see Warnings and Precautions (5.1)]    *    Hepatotoxicity [see Warnings and Precautions (5.2)]    *    Thrombotic/Thromboembolic Complications [see Warnings and Precautions (5.3)]    *    Cataracts [see Warnings and Precautions (5.4)]      *    In adult patients with ITP, the most common adverse reactions (greater than or equal to 5% and greater than placebo) were: nausea, diarrhea, upper respiratory tract infection, vomiting, increased ALT, myalgia, and urinary tract infection.","myalgia , is not a named entity"
"*    Hepatic Decompensation in Patients with Chronic Hepatitis C [see Warnings and Precautions (5.1)]    *    Hepatotoxicity [see Warnings and Precautions (5.2)]    *    Thrombotic/Thromboembolic Complications [see Warnings and Precautions (5.3)]    *    Cataracts [see Warnings and Precautions (5.4)]      *    In adult patients with ITP, the most common adverse reactions (greater than or equal to 5% and greater than placebo) were: nausea, diarrhea, upper respiratory tract infection, vomiting, increased ALT, myalgia, and urinary tract infection.",] * is not a named entity
"*    Hepatic Decompensation in Patients with Chronic Hepatitis C [see Warnings and Precautions (5.1)]    *    Hepatotoxicity [see Warnings and Precautions (5.2)]    *    Thrombotic/Thromboembolic Complications [see Warnings and Precautions (5.3)]    *    Cataracts [see Warnings and Precautions (5.4)]      *    In adult patients with ITP, the most common adverse reactions (greater than or equal to 5% and greater than placebo) were: nausea, diarrhea, upper respiratory tract infection, vomiting, increased ALT, myalgia, and urinary tract infection.",and is not a named entity
"*    Hepatic Decompensation in Patients with Chronic Hepatitis C [see Warnings and Precautions (5.1)]    *    Hepatotoxicity [see Warnings and Precautions (5.2)]    *    Thrombotic/Thromboembolic Complications [see Warnings and Precautions (5.3)]    *    Cataracts [see Warnings and Precautions (5.4)]      *    In adult patients with ITP, the most common adverse reactions (greater than or equal to 5% and greater than placebo) were: nausea, diarrhea, upper respiratory tract infection, vomiting, increased ALT, myalgia, and urinary tract infection.",", and urinary is not a named entity"
"*    Hepatic Decompensation in Patients with Chronic Hepatitis C [see Warnings and Precautions (5.1)]    *    Hepatotoxicity [see Warnings and Precautions (5.2)]    *    Thrombotic/Thromboembolic Complications [see Warnings and Precautions (5.3)]    *    Cataracts [see Warnings and Precautions (5.4)]      *    In adult patients with ITP, the most common adverse reactions (greater than or equal to 5% and greater than placebo) were: nausea, diarrhea, upper respiratory tract infection, vomiting, increased ALT, myalgia, and urinary tract infection.",* is not a named entity
"*    Hepatic Decompensation in Patients with Chronic Hepatitis C [see Warnings and Precautions (5.1)]    *    Hepatotoxicity [see Warnings and Precautions (5.2)]    *    Thrombotic/Thromboembolic Complications [see Warnings and Precautions (5.3)]    *    Cataracts [see Warnings and Precautions (5.4)]      *    In adult patients with ITP, the most common adverse reactions (greater than or equal to 5% and greater than placebo) were: nausea, diarrhea, upper respiratory tract infection, vomiting, increased ALT, myalgia, and urinary tract infection.",Hepatic Decompensation is an adverse reaction entity
"*    Hepatic Decompensation in Patients with Chronic Hepatitis C [see Warnings and Precautions (5.1)]    *    Hepatotoxicity [see Warnings and Precautions (5.2)]    *    Thrombotic/Thromboembolic Complications [see Warnings and Precautions (5.3)]    *    Cataracts [see Warnings and Precautions (5.4)]      *    In adult patients with ITP, the most common adverse reactions (greater than or equal to 5% and greater than placebo) were: nausea, diarrhea, upper respiratory tract infection, vomiting, increased ALT, myalgia, and urinary tract infection.",( 5.2 is not a named entity
"*    Hepatic Decompensation in Patients with Chronic Hepatitis C [see Warnings and Precautions (5.1)]    *    Hepatotoxicity [see Warnings and Precautions (5.2)]    *    Thrombotic/Thromboembolic Complications [see Warnings and Precautions (5.3)]    *    Cataracts [see Warnings and Precautions (5.4)]      *    In adult patients with ITP, the most common adverse reactions (greater than or equal to 5% and greater than placebo) were: nausea, diarrhea, upper respiratory tract infection, vomiting, increased ALT, myalgia, and urinary tract infection.",myalgia is an adverse reaction entity
"*    Hepatic Decompensation in Patients with Chronic Hepatitis C [see Warnings and Precautions (5.1)]    *    Hepatotoxicity [see Warnings and Precautions (5.2)]    *    Thrombotic/Thromboembolic Complications [see Warnings and Precautions (5.3)]    *    Cataracts [see Warnings and Precautions (5.4)]      *    In adult patients with ITP, the most common adverse reactions (greater than or equal to 5% and greater than placebo) were: nausea, diarrhea, upper respiratory tract infection, vomiting, increased ALT, myalgia, and urinary tract infection.",nausea is an adverse reaction entity
"In the extension trial, cataracts developed or worsened in 4% of patients who underwent ocular examination prior to therapy with PROMACTA.",cataracts is an adverse reaction entity
"In the extension trial, cataracts developed or worsened in 4% of patients who underwent ocular examination prior to therapy with PROMACTA.",in 4 % is not a named entity
"Eight patients had a new cytogenetic abnormality reported on therapy, including 5 patients who had complex changes in chromosome 7.",changes in chromosome 7 is an adverse reaction entity
"Eight patients had a new cytogenetic abnormality reported on therapy, including 5 patients who had complex changes in chromosome 7.",new cytogenetic is not a named entity
"Eight patients had a new cytogenetic abnormality reported on therapy, including 5 patients who had complex changes in chromosome 7.",cytogenetic abnormality is an adverse reaction entity
"Eight patients had a new cytogenetic abnormality reported on therapy, including 5 patients who had complex changes in chromosome 7.",patients had is not a named entity
The risk of portal venous thrombosis was increased in thrombocytopenic patients with chronic liver disease treated with 75 mg of PROMACTA once daily for 2 weeks in preparation for invasive procedures.,with is not a named entity
The risk of portal venous thrombosis was increased in thrombocytopenic patients with chronic liver disease treated with 75 mg of PROMACTA once daily for 2 weeks in preparation for invasive procedures.,portal venous thrombosis is an adverse reaction entity
"ALT or AST greater than or equal to 3 x ULN was reported in 34% and 38% of patients for PROMACTA and placebo, respectively.",3 is not a named entity
"ALT or AST greater than or equal to 3 x ULN was reported in 34% and 38% of patients for PROMACTA and placebo, respectively.",% of patients is not a named entity
"ALT or AST greater than or equal to 3 x ULN was reported in 34% and 38% of patients for PROMACTA and placebo, respectively.",ALT greater than or equal to 3 x ULN is an adverse reaction entity
"ALT or AST greater than or equal to 3 x ULN was reported in 34% and 38% of patients for PROMACTA and placebo, respectively.",AST greater than or equal to 3 x ULN is an adverse reaction entity
"In two controlled clinical trials in patients with chronic hepatitis C and thrombocytopenia, ascites and encephalopathy occurred more frequently on the arm receiving treatment with PROMACTA plus antivirals (7%) than the placebo plus antivirals arm (4%).",encephalopathy is an adverse reaction entity
"In two controlled clinical trials in patients with chronic hepatitis C and thrombocytopenia, ascites and encephalopathy occurred more frequently on the arm receiving treatment with PROMACTA plus antivirals (7%) than the placebo plus antivirals arm (4%).",ascites is an adverse reaction entity
"In two controlled clinical trials in patients with chronic hepatitis C and thrombocytopenia, ascites and encephalopathy occurred more frequently on the arm receiving treatment with PROMACTA plus antivirals (7%) than the placebo plus antivirals arm (4%).",plus antivirals is not a named entity
"In two controlled clinical trials in patients with chronic hepatitis C and thrombocytopenia, ascites and encephalopathy occurred more frequently on the arm receiving treatment with PROMACTA plus antivirals (7%) than the placebo plus antivirals arm (4%).",receiving treatment is not a named entity
EXCERPT:   WARNING: RISK FOR HEPATIC DECOMPENSATION IN PATIENTS WITH CHRONIC HEPATITIS C       See full prescribing information for complete boxed warning.,DECOMPENSATION IN PATIENTS is not a named entity
EXCERPT:   WARNING: RISK FOR HEPATIC DECOMPENSATION IN PATIENTS WITH CHRONIC HEPATITIS C       See full prescribing information for complete boxed warning.,HEPATIC DECOMPENSATION is an adverse reaction entity
"5.4 Cataracts      In the three controlled clinical trials in adults with chronic ITP, cataracts developed or worsened in 15 (7%) patients who received 50 mg of PROMACTA daily and 8 (7%) placebo-group patients.",7 % is not a named entity
"5.4 Cataracts      In the three controlled clinical trials in adults with chronic ITP, cataracts developed or worsened in 15 (7%) patients who received 50 mg of PROMACTA daily and 8 (7%) placebo-group patients.",cataracts is an adverse reaction entity
Thrombotic/thromboembolic complications may result from increases in platelet counts with PROMACTA.,Thrombotic complications is an adverse reaction entity
Thrombotic/thromboembolic complications may result from increases in platelet counts with PROMACTA.,may result is not a named entity
Thrombotic/thromboembolic complications may result from increases in platelet counts with PROMACTA.,platelet is not a named entity
Thrombotic/thromboembolic complications may result from increases in platelet counts with PROMACTA.,increases in platelet counts is an adverse reaction entity
Thrombotic/thromboembolic complications may result from increases in platelet counts with PROMACTA.,thromboembolic complications is an adverse reaction entity
Thrombotic/thromboembolic complications may result from increases in platelet counts with PROMACTA.,may result from is not a named entity
(  5.2  )   *    Thrombotic/Thromboembolic Complications: Portal vein thrombosis has been reported in patients with chronic liver disease receiving PROMACTA.,receiving is not a named entity
(  5.2  )   *    Thrombotic/Thromboembolic Complications: Portal vein thrombosis has been reported in patients with chronic liver disease receiving PROMACTA.,Thromboembolic Complications is an adverse reaction entity
(  5.2  )   *    Thrombotic/Thromboembolic Complications: Portal vein thrombosis has been reported in patients with chronic liver disease receiving PROMACTA.,Thrombotic Complications is an adverse reaction entity
(  5.2  )   *    Thrombotic/Thromboembolic Complications: Portal vein thrombosis has been reported in patients with chronic liver disease receiving PROMACTA.,thrombosis has is not a named entity
(  5.2  )   *    Thrombotic/Thromboembolic Complications: Portal vein thrombosis has been reported in patients with chronic liver disease receiving PROMACTA.,Portal vein thrombosis is an adverse reaction entity
(  5.2  )   *    Thrombotic/Thromboembolic Complications: Portal vein thrombosis has been reported in patients with chronic liver disease receiving PROMACTA.,* is not a named entity
Six of these patients again experienced liver test abnormalities (predominantly Grade 1) resulting in discontinuation of PROMACTA in one patient.,predominantly is not a named entity
Six of these patients again experienced liver test abnormalities (predominantly Grade 1) resulting in discontinuation of PROMACTA in one patient.,liver test abnormalities is an adverse reaction entity
Six of these patients again experienced liver test abnormalities (predominantly Grade 1) resulting in discontinuation of PROMACTA in one patient.,liver test abnormalities is an adverse reaction entity
Six of these patients again experienced liver test abnormalities (predominantly Grade 1) resulting in discontinuation of PROMACTA in one patient.,test abnormalities is not a named entity
Patients with low albumin levels (less than 3.5 g/dL) or Model for End-Stage Liver Disease (MELD) score greater than or equal to 10 at baseline had a greater risk for hepatic decompensation on the arm receiving treatment with PROMACTA plus antivirals.,hepatic decompensation is an adverse reaction entity
Patients with low albumin levels (less than 3.5 g/dL) or Model for End-Stage Liver Disease (MELD) score greater than or equal to 10 at baseline had a greater risk for hepatic decompensation on the arm receiving treatment with PROMACTA plus antivirals.,) score is not a named entity
"In the two controlled clinical trials in patients with chronic hepatitis C and thrombocytopenia, cataracts developed or worsened in 8% patients treated with PROMACTA and 5% patients treated with placebo.",cataracts is an adverse reaction entity
"In the two controlled clinical trials in patients with chronic hepatitis C and thrombocytopenia, cataracts developed or worsened in 8% patients treated with PROMACTA and 5% patients treated with placebo.",with is not a named entity
Other serious adverse reactions included thrombotic/thromboembolic complications  [see Warnings and Precautions (5.3)]  .,Other serious is not a named entity
Other serious adverse reactions included thrombotic/thromboembolic complications  [see Warnings and Precautions (5.3)]  .,Precautions ( 5.3 is not a named entity
Other serious adverse reactions included thrombotic/thromboembolic complications  [see Warnings and Precautions (5.3)]  .,thromboembolic complications is an adverse reaction entity
Other serious adverse reactions included thrombotic/thromboembolic complications  [see Warnings and Precautions (5.3)]  .,thrombotic complications is an adverse reaction entity
"In the extension chronic ITP trial, one additional patient had PROMACTA discontinued due to liver test abnormalities (less than or equal to Grade 3).",Grade 3 is not a named entity
"In the extension chronic ITP trial, one additional patient had PROMACTA discontinued due to liver test abnormalities (less than or equal to Grade 3).",liver test abnormalities is an adverse reaction entity
"In the extension chronic ITP trial, one additional patient had PROMACTA discontinued due to liver test abnormalities (less than or equal to Grade 3).",liver test abnormalities is an adverse reaction entity
"In the extension chronic ITP trial, one additional patient had PROMACTA discontinued due to liver test abnormalities (less than or equal to Grade 3).",3 ) is not a named entity
"Other common adverse reactions occurring in greater than 1% of patients included pyrexia, transaminase increase, dizziness, and rash.",common adverse reactions is not a named entity
"Other common adverse reactions occurring in greater than 1% of patients included pyrexia, transaminase increase, dizziness, and rash.",rash is an adverse reaction entity
"Other common adverse reactions occurring in greater than 1% of patients included pyrexia, transaminase increase, dizziness, and rash.","pyrexia , transaminase is not a named entity"
"Other common adverse reactions occurring in greater than 1% of patients included pyrexia, transaminase increase, dizziness, and rash.",adverse reactions occurring is not a named entity
"Other common adverse reactions occurring in greater than 1% of patients included pyrexia, transaminase increase, dizziness, and rash.",dizziness is an adverse reaction entity
"Other common adverse reactions occurring in greater than 1% of patients included pyrexia, transaminase increase, dizziness, and rash.",transaminase increase is an adverse reaction entity
"Other common adverse reactions occurring in greater than 1% of patients included pyrexia, transaminase increase, dizziness, and rash.",Other common is not a named entity
"Other common adverse reactions occurring in greater than 1% of patients included pyrexia, transaminase increase, dizziness, and rash.",pyrexia is an adverse reaction entity
"Other adverse reactions reported included rash, nausea, and headache in patients exposed to FIRAZYR.",rash is an adverse reaction entity
"Other adverse reactions reported included rash, nausea, and headache in patients exposed to FIRAZYR.",nausea is an adverse reaction entity
"Other adverse reactions reported included rash, nausea, and headache in patients exposed to FIRAZYR.","rash , is not a named entity"
"Other adverse reactions reported included rash, nausea, and headache in patients exposed to FIRAZYR.",headache is an adverse reaction entity
"Other adverse reactions reported included rash, nausea, and headache in patients exposed to FIRAZYR.",Other is not a named entity
"Other adverse reactions reported included rash, nausea, and headache in patients exposed to FIRAZYR.",exposed to FIRAZYR is not a named entity
"5.7     Geriatric Patients      In the randomized advanced hormone receptor-positive, HER2-negative breast cancer study, the incidence of deaths due to any cause within 28 days of the last AFINITOR dose was 6% in patients >= 65 years of age compared to 2% in patients < 65 years of age.",in patients > is not a named entity
"5.7     Geriatric Patients      In the randomized advanced hormone receptor-positive, HER2-negative breast cancer study, the incidence of deaths due to any cause within 28 days of the last AFINITOR dose was 6% in patients >= 65 years of age compared to 2% in patients < 65 years of age.",deaths is an adverse reaction entity
"Table 6: Adverse Reactions Reported in at Least 10% of Patients with RCC and at a Higher Rate in the AFINITOR Arm than in the Placebo Arm   Grading according to CTCAE Version 3.0  a  Stomatitis (including aphthous stomatitis), and mouth and tongue ulceration.",mouth ulceration is an adverse reaction entity
"Table 6: Adverse Reactions Reported in at Least 10% of Patients with RCC and at a Higher Rate in the AFINITOR Arm than in the Placebo Arm   Grading according to CTCAE Version 3.0  a  Stomatitis (including aphthous stomatitis), and mouth and tongue ulceration.",CTCAE is not a named entity
"Table 6: Adverse Reactions Reported in at Least 10% of Patients with RCC and at a Higher Rate in the AFINITOR Arm than in the Placebo Arm   Grading according to CTCAE Version 3.0  a  Stomatitis (including aphthous stomatitis), and mouth and tongue ulceration.",tongue ulceration is an adverse reaction entity
"Table 6: Adverse Reactions Reported in at Least 10% of Patients with RCC and at a Higher Rate in the AFINITOR Arm than in the Placebo Arm   Grading according to CTCAE Version 3.0  a  Stomatitis (including aphthous stomatitis), and mouth and tongue ulceration.",) is not a named entity
"Table 6: Adverse Reactions Reported in at Least 10% of Patients with RCC and at a Higher Rate in the AFINITOR Arm than in the Placebo Arm   Grading according to CTCAE Version 3.0  a  Stomatitis (including aphthous stomatitis), and mouth and tongue ulceration.",( including aphthous is not a named entity
"Table 6: Adverse Reactions Reported in at Least 10% of Patients with RCC and at a Higher Rate in the AFINITOR Arm than in the Placebo Arm   Grading according to CTCAE Version 3.0  a  Stomatitis (including aphthous stomatitis), and mouth and tongue ulceration.",aphthous stomatitis is an adverse reaction entity
"Table 6: Adverse Reactions Reported in at Least 10% of Patients with RCC and at a Higher Rate in the AFINITOR Arm than in the Placebo Arm   Grading according to CTCAE Version 3.0  a  Stomatitis (including aphthous stomatitis), and mouth and tongue ulceration.",the is not a named entity
"Table 6: Adverse Reactions Reported in at Least 10% of Patients with RCC and at a Higher Rate in the AFINITOR Arm than in the Placebo Arm   Grading according to CTCAE Version 3.0  a  Stomatitis (including aphthous stomatitis), and mouth and tongue ulceration.",Stomatitis is an adverse reaction entity
"Causes of death on the AFINITOR arm included one case of each of the following: acute renal failure, acute respiratory distress, cardiac arrest, death (cause unknown), hepatic failure, pneumonia, and sepsis.",hepatic failure is an adverse reaction entity
"Causes of death on the AFINITOR arm included one case of each of the following: acute renal failure, acute respiratory distress, cardiac arrest, death (cause unknown), hepatic failure, pneumonia, and sepsis.",death is an adverse reaction entity
"Causes of death on the AFINITOR arm included one case of each of the following: acute renal failure, acute respiratory distress, cardiac arrest, death (cause unknown), hepatic failure, pneumonia, and sepsis.",arrest is not a named entity
"Causes of death on the AFINITOR arm included one case of each of the following: acute renal failure, acute respiratory distress, cardiac arrest, death (cause unknown), hepatic failure, pneumonia, and sepsis.",and is not a named entity
"Causes of death on the AFINITOR arm included one case of each of the following: acute renal failure, acute respiratory distress, cardiac arrest, death (cause unknown), hepatic failure, pneumonia, and sepsis.",failure is not a named entity
"Causes of death on the AFINITOR arm included one case of each of the following: acute renal failure, acute respiratory distress, cardiac arrest, death (cause unknown), hepatic failure, pneumonia, and sepsis.",sepsis is an adverse reaction entity
"Causes of death on the AFINITOR arm included one case of each of the following: acute renal failure, acute respiratory distress, cardiac arrest, death (cause unknown), hepatic failure, pneumonia, and sepsis.",", and sepsis is not a named entity"
"Causes of death on the AFINITOR arm included one case of each of the following: acute renal failure, acute respiratory distress, cardiac arrest, death (cause unknown), hepatic failure, pneumonia, and sepsis.",", acute respiratory is not a named entity"
"Causes of death on the AFINITOR arm included one case of each of the following: acute renal failure, acute respiratory distress, cardiac arrest, death (cause unknown), hepatic failure, pneumonia, and sepsis.",death is an adverse reaction entity
"Causes of death on the AFINITOR arm included one case of each of the following: acute renal failure, acute respiratory distress, cardiac arrest, death (cause unknown), hepatic failure, pneumonia, and sepsis.",", pneumonia , is not a named entity"
"Causes of death on the AFINITOR arm included one case of each of the following: acute renal failure, acute respiratory distress, cardiac arrest, death (cause unknown), hepatic failure, pneumonia, and sepsis.",unknown is not a named entity
"Causes of death on the AFINITOR arm included one case of each of the following: acute renal failure, acute respiratory distress, cardiac arrest, death (cause unknown), hepatic failure, pneumonia, and sepsis.",acute respiratory distress is an adverse reaction entity
"Causes of death on the AFINITOR arm included one case of each of the following: acute renal failure, acute respiratory distress, cardiac arrest, death (cause unknown), hepatic failure, pneumonia, and sepsis.",of is not a named entity
"Causes of death on the AFINITOR arm included one case of each of the following: acute renal failure, acute respiratory distress, cardiac arrest, death (cause unknown), hepatic failure, pneumonia, and sepsis.",acute renal failure is an adverse reaction entity
"Causes of death on the AFINITOR arm included one case of each of the following: acute renal failure, acute respiratory distress, cardiac arrest, death (cause unknown), hepatic failure, pneumonia, and sepsis.",cardiac arrest is an adverse reaction entity
"Causes of death on the AFINITOR arm included one case of each of the following: acute renal failure, acute respiratory distress, cardiac arrest, death (cause unknown), hepatic failure, pneumonia, and sepsis.",pneumonia is an adverse reaction entity
The most common Grade 3-4 adverse reactions (incidence >= 2%) were stomatitis and amenorrhea.,stomatitis is an adverse reaction entity
The most common Grade 3-4 adverse reactions (incidence >= 2%) were stomatitis and amenorrhea.,The is not a named entity
The most common Grade 3-4 adverse reactions (incidence >= 2%) were stomatitis and amenorrhea.,amenorrhea is an adverse reaction entity
The most common Grade 3-4 adverse reactions (incidence >= 2%) were stomatitis and amenorrhea.,2 % is not a named entity
The most common adverse reactions reported for AFINITOR (incidence >= 30%) were stomatitis and respiratory tract infection.,most common adverse is not a named entity
The most common adverse reactions reported for AFINITOR (incidence >= 30%) were stomatitis and respiratory tract infection.,stomatitis is an adverse reaction entity
The most common adverse reactions reported for AFINITOR (incidence >= 30%) were stomatitis and respiratory tract infection.,tract is not a named entity
The most common adverse reactions reported for AFINITOR (incidence >= 30%) were stomatitis and respiratory tract infection.,respiratory tract infection is an adverse reaction entity
"(  5.3  )   *  Oral ulceration: Mouth ulcers, stomatitis, and oral mucositis are common.",stomatitis is an adverse reaction entity
"(  5.3  )   *  Oral ulceration: Mouth ulcers, stomatitis, and oral mucositis are common.",", and oral is not a named entity"
"(  5.3  )   *  Oral ulceration: Mouth ulcers, stomatitis, and oral mucositis are common.",", stomatitis , is not a named entity"
"(  5.3  )   *  Oral ulceration: Mouth ulcers, stomatitis, and oral mucositis are common.",Oral ulceration is an adverse reaction entity
"(  5.3  )   *  Oral ulceration: Mouth ulcers, stomatitis, and oral mucositis are common.",Mouth ulcers is an adverse reaction entity
"(  5.3  )   *  Oral ulceration: Mouth ulcers, stomatitis, and oral mucositis are common.",mucositis are common is not a named entity
"(  5.3  )   *  Oral ulceration: Mouth ulcers, stomatitis, and oral mucositis are common.","Mouth ulcers , is not a named entity"
"(  5.3  )   *  Oral ulceration: Mouth ulcers, stomatitis, and oral mucositis are common.",oral mucositis is an adverse reaction entity
*  Angioedema with concomitant use of ACE inhibitors [see Warnings and Precautions (5.3)] .,* Angioedema is not a named entity
*  Angioedema with concomitant use of ACE inhibitors [see Warnings and Precautions (5.3)] .,Angioedema is an adverse reaction entity
"The most common Grade 3-4 adverse reactions (incidence >= 2%) were stomatitis, pyrexia, pneumonia, gastroenteritis, aggression, agitation, and amenorrhea.","agitation , and is not a named entity"
"The most common Grade 3-4 adverse reactions (incidence >= 2%) were stomatitis, pyrexia, pneumonia, gastroenteritis, aggression, agitation, and amenorrhea.",stomatitis is an adverse reaction entity
"The most common Grade 3-4 adverse reactions (incidence >= 2%) were stomatitis, pyrexia, pneumonia, gastroenteritis, aggression, agitation, and amenorrhea.",Grade is not a named entity
"The most common Grade 3-4 adverse reactions (incidence >= 2%) were stomatitis, pyrexia, pneumonia, gastroenteritis, aggression, agitation, and amenorrhea.",( incidence > is not a named entity
"The most common Grade 3-4 adverse reactions (incidence >= 2%) were stomatitis, pyrexia, pneumonia, gastroenteritis, aggression, agitation, and amenorrhea.",aggression is an adverse reaction entity
"The most common Grade 3-4 adverse reactions (incidence >= 2%) were stomatitis, pyrexia, pneumonia, gastroenteritis, aggression, agitation, and amenorrhea.",gastroenteritis is an adverse reaction entity
"The most common Grade 3-4 adverse reactions (incidence >= 2%) were stomatitis, pyrexia, pneumonia, gastroenteritis, aggression, agitation, and amenorrhea.",pneumonia is an adverse reaction entity
"The most common Grade 3-4 adverse reactions (incidence >= 2%) were stomatitis, pyrexia, pneumonia, gastroenteritis, aggression, agitation, and amenorrhea.",Grade 3-4 adverse is not a named entity
"The most common Grade 3-4 adverse reactions (incidence >= 2%) were stomatitis, pyrexia, pneumonia, gastroenteritis, aggression, agitation, and amenorrhea.",", is not a named entity"
"The most common Grade 3-4 adverse reactions (incidence >= 2%) were stomatitis, pyrexia, pneumonia, gastroenteritis, aggression, agitation, and amenorrhea.",( incidence > is not a named entity
"The most common Grade 3-4 adverse reactions (incidence >= 2%) were stomatitis, pyrexia, pneumonia, gastroenteritis, aggression, agitation, and amenorrhea.",% ) were is not a named entity
"The most common Grade 3-4 adverse reactions (incidence >= 2%) were stomatitis, pyrexia, pneumonia, gastroenteritis, aggression, agitation, and amenorrhea.",amenorrhea is an adverse reaction entity
"The most common Grade 3-4 adverse reactions (incidence >= 2%) were stomatitis, pyrexia, pneumonia, gastroenteritis, aggression, agitation, and amenorrhea.",pyrexia is an adverse reaction entity
"The most common Grade 3-4 adverse reactions (incidence >= 2%) were stomatitis, pyrexia, pneumonia, gastroenteritis, aggression, agitation, and amenorrhea.",agitation is an adverse reaction entity
"c  Includes pneumonitis, interstitial lung disease, lung infiltration, pulmonary alveolar hemorrhage, pulmonary toxicity, and alveolitis.",pneumonitis is an adverse reaction entity
"c  Includes pneumonitis, interstitial lung disease, lung infiltration, pulmonary alveolar hemorrhage, pulmonary toxicity, and alveolitis.",pulmonary alveolar hemorrhage is an adverse reaction entity
"c  Includes pneumonitis, interstitial lung disease, lung infiltration, pulmonary alveolar hemorrhage, pulmonary toxicity, and alveolitis.","infiltration , pulmonary is not a named entity"
"c  Includes pneumonitis, interstitial lung disease, lung infiltration, pulmonary alveolar hemorrhage, pulmonary toxicity, and alveolitis.",lung infiltration is an adverse reaction entity
"c  Includes pneumonitis, interstitial lung disease, lung infiltration, pulmonary alveolar hemorrhage, pulmonary toxicity, and alveolitis.",disease is not a named entity
"c  Includes pneumonitis, interstitial lung disease, lung infiltration, pulmonary alveolar hemorrhage, pulmonary toxicity, and alveolitis.","disease , is not a named entity"
"c  Includes pneumonitis, interstitial lung disease, lung infiltration, pulmonary alveolar hemorrhage, pulmonary toxicity, and alveolitis.",c Includes is not a named entity
"c  Includes pneumonitis, interstitial lung disease, lung infiltration, pulmonary alveolar hemorrhage, pulmonary toxicity, and alveolitis.",interstitial lung disease is an adverse reaction entity
"c  Includes pneumonitis, interstitial lung disease, lung infiltration, pulmonary alveolar hemorrhage, pulmonary toxicity, and alveolitis.",pulmonary toxicity is an adverse reaction entity
"c  Includes pneumonitis, interstitial lung disease, lung infiltration, pulmonary alveolar hemorrhage, pulmonary toxicity, and alveolitis.",alveolitis is an adverse reaction entity
"c  Includes pneumonitis, interstitial lung disease, lung infiltration, pulmonary alveolar hemorrhage, pulmonary toxicity, and alveolitis.",", interstitial lung is not a named entity"
"c  Includes pneumonitis, interstitial lung disease, lung infiltration, pulmonary alveolar hemorrhage, pulmonary toxicity, and alveolitis.","pneumonitis , interstitial is not a named entity"
"5.3     Angioedema with Concomitant Use of Angiotensin-Converting Enzyme (ACE) Inhibitors       Patients taking concomitant ACE inhibitor therapy may be at increased risk for angioedema (e.g., swelling of the airways or tongue, with or without respiratory impairment).",swelling of the airways is an adverse reaction entity
"5.3     Angioedema with Concomitant Use of Angiotensin-Converting Enzyme (ACE) Inhibitors       Patients taking concomitant ACE inhibitor therapy may be at increased risk for angioedema (e.g., swelling of the airways or tongue, with or without respiratory impairment).",swelling of the tongue is an adverse reaction entity
"5.3     Angioedema with Concomitant Use of Angiotensin-Converting Enzyme (ACE) Inhibitors       Patients taking concomitant ACE inhibitor therapy may be at increased risk for angioedema (e.g., swelling of the airways or tongue, with or without respiratory impairment).",without respiratory impairment is not a named entity
"5.3     Angioedema with Concomitant Use of Angiotensin-Converting Enzyme (ACE) Inhibitors       Patients taking concomitant ACE inhibitor therapy may be at increased risk for angioedema (e.g., swelling of the airways or tongue, with or without respiratory impairment).",respiratory impairment is an adverse reaction entity
"5.3     Angioedema with Concomitant Use of Angiotensin-Converting Enzyme (ACE) Inhibitors       Patients taking concomitant ACE inhibitor therapy may be at increased risk for angioedema (e.g., swelling of the airways or tongue, with or without respiratory impairment).",angioedema ( e.g. is not a named entity
"5.3     Angioedema with Concomitant Use of Angiotensin-Converting Enzyme (ACE) Inhibitors       Patients taking concomitant ACE inhibitor therapy may be at increased risk for angioedema (e.g., swelling of the airways or tongue, with or without respiratory impairment).",increased risk is not a named entity
"5.3     Angioedema with Concomitant Use of Angiotensin-Converting Enzyme (ACE) Inhibitors       Patients taking concomitant ACE inhibitor therapy may be at increased risk for angioedema (e.g., swelling of the airways or tongue, with or without respiratory impairment).",Patients is not a named entity
"5.3     Angioedema with Concomitant Use of Angiotensin-Converting Enzyme (ACE) Inhibitors       Patients taking concomitant ACE inhibitor therapy may be at increased risk for angioedema (e.g., swelling of the airways or tongue, with or without respiratory impairment).",angioedema is an adverse reaction entity
The most common adverse reaction reported for AFINITOR (incidence >= 30%) was stomatitis.,stomatitis is an adverse reaction entity
The most common adverse reaction reported for AFINITOR (incidence >= 30%) was stomatitis.,reaction reported is not a named entity
The most common adverse reactions (irrespective of causality) leading to treatment discontinuation were pneumonitis and dyspnea.,dyspnea is an adverse reaction entity
The most common adverse reactions (irrespective of causality) leading to treatment discontinuation were pneumonitis and dyspnea.,adverse is not a named entity
The most common adverse reactions (irrespective of causality) leading to treatment discontinuation were pneumonitis and dyspnea.,pneumonitis is an adverse reaction entity
The most common adverse reactions (irrespective of causality) leading to treatment discontinuation were pneumonitis and dyspnea.,reactions is not a named entity
"5.5     Renal Failure      Cases of renal failure (including acute renal failure), some with a fatal outcome, have been observed in patients treated with AFINITOR [see Laboratory Tests and Monitoring (5.8)]  .",fatal is an adverse reaction entity
"5.5     Renal Failure      Cases of renal failure (including acute renal failure), some with a fatal outcome, have been observed in patients treated with AFINITOR [see Laboratory Tests and Monitoring (5.8)]  .",have is not a named entity
"5.5     Renal Failure      Cases of renal failure (including acute renal failure), some with a fatal outcome, have been observed in patients treated with AFINITOR [see Laboratory Tests and Monitoring (5.8)]  .",acute renal failure is an adverse reaction entity
"5.5     Renal Failure      Cases of renal failure (including acute renal failure), some with a fatal outcome, have been observed in patients treated with AFINITOR [see Laboratory Tests and Monitoring (5.8)]  .",renal failure is an adverse reaction entity
"5.5     Renal Failure      Cases of renal failure (including acute renal failure), some with a fatal outcome, have been observed in patients treated with AFINITOR [see Laboratory Tests and Monitoring (5.8)]  .",patients is not a named entity
"5.5     Renal Failure      Cases of renal failure (including acute renal failure), some with a fatal outcome, have been observed in patients treated with AFINITOR [see Laboratory Tests and Monitoring (5.8)]  .","failure ) , is not a named entity"
"(  5.12  ,  8.1  )             5.1     Non-infectious Pneumonitis      Non-infectious pneumonitis is a class effect of rapamycin derivatives, including AFINITOR.",Non-infectious pneumonitis is an adverse reaction entity
"(  5.12  ,  8.1  )             5.1     Non-infectious Pneumonitis      Non-infectious pneumonitis is a class effect of rapamycin derivatives, including AFINITOR.",pneumonitis is a is not a named entity
5     WARNINGS AND PRECAUTIONS       EXCERPT:    *  Non-infectious pneumonitis: Monitor for clinical symptoms or radiological changes; fatal cases have occurred.,fatal is an adverse reaction entity
5     WARNINGS AND PRECAUTIONS       EXCERPT:    *  Non-infectious pneumonitis: Monitor for clinical symptoms or radiological changes; fatal cases have occurred.,or radiological is not a named entity
5     WARNINGS AND PRECAUTIONS       EXCERPT:    *  Non-infectious pneumonitis: Monitor for clinical symptoms or radiological changes; fatal cases have occurred.,WARNINGS is not a named entity
5     WARNINGS AND PRECAUTIONS       EXCERPT:    *  Non-infectious pneumonitis: Monitor for clinical symptoms or radiological changes; fatal cases have occurred.,Non-infectious pneumonitis is an adverse reaction entity
"EXCERPT:   Advanced HR+ BC, advanced PNET, advanced RCC: Most common adverse reactions (incidence >=30%) include stomatitis, infections, rash, fatigue, diarrhea, edema, abdominal pain, nausea, fever, asthenia, cough, headache and decreased appetite.",=30 % is not a named entity
"EXCERPT:   Advanced HR+ BC, advanced PNET, advanced RCC: Most common adverse reactions (incidence >=30%) include stomatitis, infections, rash, fatigue, diarrhea, edema, abdominal pain, nausea, fever, asthenia, cough, headache and decreased appetite.",common adverse reactions is not a named entity
"EXCERPT:   Advanced HR+ BC, advanced PNET, advanced RCC: Most common adverse reactions (incidence >=30%) include stomatitis, infections, rash, fatigue, diarrhea, edema, abdominal pain, nausea, fever, asthenia, cough, headache and decreased appetite.",abdominal pain is an adverse reaction entity
"EXCERPT:   Advanced HR+ BC, advanced PNET, advanced RCC: Most common adverse reactions (incidence >=30%) include stomatitis, infections, rash, fatigue, diarrhea, edema, abdominal pain, nausea, fever, asthenia, cough, headache and decreased appetite.",asthenia is an adverse reaction entity
"EXCERPT:   Advanced HR+ BC, advanced PNET, advanced RCC: Most common adverse reactions (incidence >=30%) include stomatitis, infections, rash, fatigue, diarrhea, edema, abdominal pain, nausea, fever, asthenia, cough, headache and decreased appetite.",fatigue is an adverse reaction entity
"EXCERPT:   Advanced HR+ BC, advanced PNET, advanced RCC: Most common adverse reactions (incidence >=30%) include stomatitis, infections, rash, fatigue, diarrhea, edema, abdominal pain, nausea, fever, asthenia, cough, headache and decreased appetite.",> =30 % is not a named entity
"EXCERPT:   Advanced HR+ BC, advanced PNET, advanced RCC: Most common adverse reactions (incidence >=30%) include stomatitis, infections, rash, fatigue, diarrhea, edema, abdominal pain, nausea, fever, asthenia, cough, headache and decreased appetite.",", fatigue , is not a named entity"
"EXCERPT:   Advanced HR+ BC, advanced PNET, advanced RCC: Most common adverse reactions (incidence >=30%) include stomatitis, infections, rash, fatigue, diarrhea, edema, abdominal pain, nausea, fever, asthenia, cough, headache and decreased appetite.",diarrhea is an adverse reaction entity
"EXCERPT:   Advanced HR+ BC, advanced PNET, advanced RCC: Most common adverse reactions (incidence >=30%) include stomatitis, infections, rash, fatigue, diarrhea, edema, abdominal pain, nausea, fever, asthenia, cough, headache and decreased appetite.",( incidence is not a named entity
"EXCERPT:   Advanced HR+ BC, advanced PNET, advanced RCC: Most common adverse reactions (incidence >=30%) include stomatitis, infections, rash, fatigue, diarrhea, edema, abdominal pain, nausea, fever, asthenia, cough, headache and decreased appetite.",stomatitis is an adverse reaction entity
"EXCERPT:   Advanced HR+ BC, advanced PNET, advanced RCC: Most common adverse reactions (incidence >=30%) include stomatitis, infections, rash, fatigue, diarrhea, edema, abdominal pain, nausea, fever, asthenia, cough, headache and decreased appetite.",fever is an adverse reaction entity
"EXCERPT:   Advanced HR+ BC, advanced PNET, advanced RCC: Most common adverse reactions (incidence >=30%) include stomatitis, infections, rash, fatigue, diarrhea, edema, abdominal pain, nausea, fever, asthenia, cough, headache and decreased appetite.",appetite is not a named entity
"EXCERPT:   Advanced HR+ BC, advanced PNET, advanced RCC: Most common adverse reactions (incidence >=30%) include stomatitis, infections, rash, fatigue, diarrhea, edema, abdominal pain, nausea, fever, asthenia, cough, headache and decreased appetite.",: is not a named entity
"EXCERPT:   Advanced HR+ BC, advanced PNET, advanced RCC: Most common adverse reactions (incidence >=30%) include stomatitis, infections, rash, fatigue, diarrhea, edema, abdominal pain, nausea, fever, asthenia, cough, headache and decreased appetite.",common adverse is not a named entity
"EXCERPT:   Advanced HR+ BC, advanced PNET, advanced RCC: Most common adverse reactions (incidence >=30%) include stomatitis, infections, rash, fatigue, diarrhea, edema, abdominal pain, nausea, fever, asthenia, cough, headache and decreased appetite.",( incidence is not a named entity
"EXCERPT:   Advanced HR+ BC, advanced PNET, advanced RCC: Most common adverse reactions (incidence >=30%) include stomatitis, infections, rash, fatigue, diarrhea, edema, abdominal pain, nausea, fever, asthenia, cough, headache and decreased appetite.",edema is an adverse reaction entity
"EXCERPT:   Advanced HR+ BC, advanced PNET, advanced RCC: Most common adverse reactions (incidence >=30%) include stomatitis, infections, rash, fatigue, diarrhea, edema, abdominal pain, nausea, fever, asthenia, cough, headache and decreased appetite.",adverse is not a named entity
"EXCERPT:   Advanced HR+ BC, advanced PNET, advanced RCC: Most common adverse reactions (incidence >=30%) include stomatitis, infections, rash, fatigue, diarrhea, edema, abdominal pain, nausea, fever, asthenia, cough, headache and decreased appetite.",", cough is not a named entity"
"EXCERPT:   Advanced HR+ BC, advanced PNET, advanced RCC: Most common adverse reactions (incidence >=30%) include stomatitis, infections, rash, fatigue, diarrhea, edema, abdominal pain, nausea, fever, asthenia, cough, headache and decreased appetite.",appetite is not a named entity
"EXCERPT:   Advanced HR+ BC, advanced PNET, advanced RCC: Most common adverse reactions (incidence >=30%) include stomatitis, infections, rash, fatigue, diarrhea, edema, abdominal pain, nausea, fever, asthenia, cough, headache and decreased appetite.",rash is an adverse reaction entity
"EXCERPT:   Advanced HR+ BC, advanced PNET, advanced RCC: Most common adverse reactions (incidence >=30%) include stomatitis, infections, rash, fatigue, diarrhea, edema, abdominal pain, nausea, fever, asthenia, cough, headache and decreased appetite.",nausea is an adverse reaction entity
"EXCERPT:   Advanced HR+ BC, advanced PNET, advanced RCC: Most common adverse reactions (incidence >=30%) include stomatitis, infections, rash, fatigue, diarrhea, edema, abdominal pain, nausea, fever, asthenia, cough, headache and decreased appetite.",cough is an adverse reaction entity
"EXCERPT:   Advanced HR+ BC, advanced PNET, advanced RCC: Most common adverse reactions (incidence >=30%) include stomatitis, infections, rash, fatigue, diarrhea, edema, abdominal pain, nausea, fever, asthenia, cough, headache and decreased appetite.",headache is an adverse reaction entity
"EXCERPT:   Advanced HR+ BC, advanced PNET, advanced RCC: Most common adverse reactions (incidence >=30%) include stomatitis, infections, rash, fatigue, diarrhea, edema, abdominal pain, nausea, fever, asthenia, cough, headache and decreased appetite.",infections is an adverse reaction entity
"EXCERPT:   Advanced HR+ BC, advanced PNET, advanced RCC: Most common adverse reactions (incidence >=30%) include stomatitis, infections, rash, fatigue, diarrhea, edema, abdominal pain, nausea, fever, asthenia, cough, headache and decreased appetite.",common is not a named entity
"EXCERPT:   Advanced HR+ BC, advanced PNET, advanced RCC: Most common adverse reactions (incidence >=30%) include stomatitis, infections, rash, fatigue, diarrhea, edema, abdominal pain, nausea, fever, asthenia, cough, headache and decreased appetite.",decreased appetite is an adverse reaction entity
"The most common adverse reactions (incidence >= 30%) were stomatitis, infections, rash, fatigue, diarrhea, and decreased appetite.",", diarrhea is not a named entity"
"The most common adverse reactions (incidence >= 30%) were stomatitis, infections, rash, fatigue, diarrhea, and decreased appetite.",30 is not a named entity
"The most common adverse reactions (incidence >= 30%) were stomatitis, infections, rash, fatigue, diarrhea, and decreased appetite.",decreased appetite is an adverse reaction entity
"The most common adverse reactions (incidence >= 30%) were stomatitis, infections, rash, fatigue, diarrhea, and decreased appetite.",stomatitis is an adverse reaction entity
"The most common adverse reactions (incidence >= 30%) were stomatitis, infections, rash, fatigue, diarrhea, and decreased appetite.",rash is an adverse reaction entity
"The most common adverse reactions (incidence >= 30%) were stomatitis, infections, rash, fatigue, diarrhea, and decreased appetite.",common adverse is not a named entity
"The most common adverse reactions (incidence >= 30%) were stomatitis, infections, rash, fatigue, diarrhea, and decreased appetite.",diarrhea is an adverse reaction entity
"The most common adverse reactions (incidence >= 30%) were stomatitis, infections, rash, fatigue, diarrhea, and decreased appetite.",", infections , is not a named entity"
"The most common adverse reactions (incidence >= 30%) were stomatitis, infections, rash, fatigue, diarrhea, and decreased appetite.",= 30 % is not a named entity
"The most common adverse reactions (incidence >= 30%) were stomatitis, infections, rash, fatigue, diarrhea, and decreased appetite.",infections is an adverse reaction entity
"The most common adverse reactions (incidence >= 30%) were stomatitis, infections, rash, fatigue, diarrhea, and decreased appetite.",> = 30 is not a named entity
"The most common adverse reactions (incidence >= 30%) were stomatitis, infections, rash, fatigue, diarrhea, and decreased appetite.",fatigue is an adverse reaction entity
"5.4     Oral Ulceration      Mouth ulcers, stomatitis, and oral mucositis have occurred in patients treated with AFINITOR at an incidence ranging from 44%-78% across the clinical trial experience.",mucositis have is not a named entity
"5.4     Oral Ulceration      Mouth ulcers, stomatitis, and oral mucositis have occurred in patients treated with AFINITOR at an incidence ranging from 44%-78% across the clinical trial experience.",Mouth ulcers is an adverse reaction entity
"5.4     Oral Ulceration      Mouth ulcers, stomatitis, and oral mucositis have occurred in patients treated with AFINITOR at an incidence ranging from 44%-78% across the clinical trial experience.",oral mucositis is an adverse reaction entity
"5.4     Oral Ulceration      Mouth ulcers, stomatitis, and oral mucositis have occurred in patients treated with AFINITOR at an incidence ranging from 44%-78% across the clinical trial experience.",stomatitis is an adverse reaction entity
"5.4     Oral Ulceration      Mouth ulcers, stomatitis, and oral mucositis have occurred in patients treated with AFINITOR at an incidence ranging from 44%-78% across the clinical trial experience.",have occurred is not a named entity
"5.4     Oral Ulceration      Mouth ulcers, stomatitis, and oral mucositis have occurred in patients treated with AFINITOR at an incidence ranging from 44%-78% across the clinical trial experience.",and oral mucositis is not a named entity
(  5.2  )   *  Angioedema: Patients taking concomitant ACE inhibitor therapy may be at increased risk for angioedema.,risk for is not a named entity
(  5.2  )   *  Angioedema: Patients taking concomitant ACE inhibitor therapy may be at increased risk for angioedema.,Angioedema is an adverse reaction entity
The most common Grade 3-4 laboratory abnormality (incidence >= 3%) was hypophosphatemia.,= 3 is not a named entity
The most common Grade 3-4 laboratory abnormality (incidence >= 3%) was hypophosphatemia.,hypophosphatemia is an adverse reaction entity
"5.2     Infections      AFINITOR has immunosuppressive properties and may predispose patients to bacterial, fungal, viral, or protozoal infections, including infections with opportunistic pathogens [see Adverse Reactions (6.1, 6.2, 6.3, 6.4, 6.5)]  .",[ is not a named entity
"5.2     Infections      AFINITOR has immunosuppressive properties and may predispose patients to bacterial, fungal, viral, or protozoal infections, including infections with opportunistic pathogens [see Adverse Reactions (6.1, 6.2, 6.3, 6.4, 6.5)]  .",with is not a named entity
"5.2     Infections      AFINITOR has immunosuppressive properties and may predispose patients to bacterial, fungal, viral, or protozoal infections, including infections with opportunistic pathogens [see Adverse Reactions (6.1, 6.2, 6.3, 6.4, 6.5)]  .",viral infections is an adverse reaction entity
"5.2     Infections      AFINITOR has immunosuppressive properties and may predispose patients to bacterial, fungal, viral, or protozoal infections, including infections with opportunistic pathogens [see Adverse Reactions (6.1, 6.2, 6.3, 6.4, 6.5)]  .",protozoal infections is an adverse reaction entity
"5.2     Infections      AFINITOR has immunosuppressive properties and may predispose patients to bacterial, fungal, viral, or protozoal infections, including infections with opportunistic pathogens [see Adverse Reactions (6.1, 6.2, 6.3, 6.4, 6.5)]  .",Infections AFINITOR has is not a named entity
"5.2     Infections      AFINITOR has immunosuppressive properties and may predispose patients to bacterial, fungal, viral, or protozoal infections, including infections with opportunistic pathogens [see Adverse Reactions (6.1, 6.2, 6.3, 6.4, 6.5)]  .",infections with opportunistic pathogens is an adverse reaction entity
"5.2     Infections      AFINITOR has immunosuppressive properties and may predispose patients to bacterial, fungal, viral, or protozoal infections, including infections with opportunistic pathogens [see Adverse Reactions (6.1, 6.2, 6.3, 6.4, 6.5)]  .",to bacterial is not a named entity
"5.2     Infections      AFINITOR has immunosuppressive properties and may predispose patients to bacterial, fungal, viral, or protozoal infections, including infections with opportunistic pathogens [see Adverse Reactions (6.1, 6.2, 6.3, 6.4, 6.5)]  .",bacterial infections is an adverse reaction entity
"5.2     Infections      AFINITOR has immunosuppressive properties and may predispose patients to bacterial, fungal, viral, or protozoal infections, including infections with opportunistic pathogens [see Adverse Reactions (6.1, 6.2, 6.3, 6.4, 6.5)]  .",immunosuppressive is not a named entity
"5.2     Infections      AFINITOR has immunosuppressive properties and may predispose patients to bacterial, fungal, viral, or protozoal infections, including infections with opportunistic pathogens [see Adverse Reactions (6.1, 6.2, 6.3, 6.4, 6.5)]  .",fungal infections is an adverse reaction entity
"The most common laboratory abnormalities (incidence >= 50%) were decreased hemoglobin, hyperglycemia, alkaline phosphatase increased, hypercholesterolemia, bicarbonate decreased, and increased aspartate transaminase (AST).",common laboratory abnormalities is not a named entity
"The most common laboratory abnormalities (incidence >= 50%) were decreased hemoglobin, hyperglycemia, alkaline phosphatase increased, hypercholesterolemia, bicarbonate decreased, and increased aspartate transaminase (AST).",alkaline phosphatase increased is an adverse reaction entity
"The most common laboratory abnormalities (incidence >= 50%) were decreased hemoglobin, hyperglycemia, alkaline phosphatase increased, hypercholesterolemia, bicarbonate decreased, and increased aspartate transaminase (AST).",decreased hemoglobin is an adverse reaction entity
"The most common laboratory abnormalities (incidence >= 50%) were decreased hemoglobin, hyperglycemia, alkaline phosphatase increased, hypercholesterolemia, bicarbonate decreased, and increased aspartate transaminase (AST).",increased AST is an adverse reaction entity
"The most common laboratory abnormalities (incidence >= 50%) were decreased hemoglobin, hyperglycemia, alkaline phosphatase increased, hypercholesterolemia, bicarbonate decreased, and increased aspartate transaminase (AST).",", hypercholesterolemia , is not a named entity"
"The most common laboratory abnormalities (incidence >= 50%) were decreased hemoglobin, hyperglycemia, alkaline phosphatase increased, hypercholesterolemia, bicarbonate decreased, and increased aspartate transaminase (AST).","hypercholesterolemia , is not a named entity"
"The most common laboratory abnormalities (incidence >= 50%) were decreased hemoglobin, hyperglycemia, alkaline phosphatase increased, hypercholesterolemia, bicarbonate decreased, and increased aspartate transaminase (AST).",were decreased hemoglobin is not a named entity
"The most common laboratory abnormalities (incidence >= 50%) were decreased hemoglobin, hyperglycemia, alkaline phosphatase increased, hypercholesterolemia, bicarbonate decreased, and increased aspartate transaminase (AST).",were decreased is not a named entity
"The most common laboratory abnormalities (incidence >= 50%) were decreased hemoglobin, hyperglycemia, alkaline phosphatase increased, hypercholesterolemia, bicarbonate decreased, and increased aspartate transaminase (AST).",bicarbonate decreased is an adverse reaction entity
"The most common laboratory abnormalities (incidence >= 50%) were decreased hemoglobin, hyperglycemia, alkaline phosphatase increased, hypercholesterolemia, bicarbonate decreased, and increased aspartate transaminase (AST).",hypercholesterolemia is an adverse reaction entity
"The most common laboratory abnormalities (incidence >= 50%) were decreased hemoglobin, hyperglycemia, alkaline phosphatase increased, hypercholesterolemia, bicarbonate decreased, and increased aspartate transaminase (AST).",increased aspartate transaminase is an adverse reaction entity
"The most common laboratory abnormalities (incidence >= 50%) were decreased hemoglobin, hyperglycemia, alkaline phosphatase increased, hypercholesterolemia, bicarbonate decreased, and increased aspartate transaminase (AST).",hyperglycemia is an adverse reaction entity
"The most common laboratory abnormalities (incidence >= 50%) were decreased hemoglobin, hyperglycemia, alkaline phosphatase increased, hypercholesterolemia, bicarbonate decreased, and increased aspartate transaminase (AST).","hypercholesterolemia , is not a named entity"
"The most common laboratory abnormalities (incidence >= 50%) were decreased hemoglobin, hyperglycemia, alkaline phosphatase increased, hypercholesterolemia, bicarbonate decreased, and increased aspartate transaminase (AST).",", and increased is not a named entity"
"c  Includes pneumonitis, interstitial lung disease, pulmonary fibrosis and restrictive pulmonary disease.",disease is not a named entity
"c  Includes pneumonitis, interstitial lung disease, pulmonary fibrosis and restrictive pulmonary disease.",pneumonitis is an adverse reaction entity
"c  Includes pneumonitis, interstitial lung disease, pulmonary fibrosis and restrictive pulmonary disease.",lung is not a named entity
"c  Includes pneumonitis, interstitial lung disease, pulmonary fibrosis and restrictive pulmonary disease.",restrictive pulmonary disease is an adverse reaction entity
"c  Includes pneumonitis, interstitial lung disease, pulmonary fibrosis and restrictive pulmonary disease.",", interstitial lung is not a named entity"
"c  Includes pneumonitis, interstitial lung disease, pulmonary fibrosis and restrictive pulmonary disease.",pulmonary fibrosis is an adverse reaction entity
"c  Includes pneumonitis, interstitial lung disease, pulmonary fibrosis and restrictive pulmonary disease.",interstitial lung disease is an adverse reaction entity
"c  Includes pneumonitis, interstitial lung disease, pulmonary fibrosis and restrictive pulmonary disease.",c is not a named entity
"The most common laboratory abnormalities (incidence >= 50%) were anemia, hypercholesterolemia, hypertriglyceridemia, hyperglycemia, lymphopenia, and increased creatinine.",( incidence is not a named entity
"The most common laboratory abnormalities (incidence >= 50%) were anemia, hypercholesterolemia, hypertriglyceridemia, hyperglycemia, lymphopenia, and increased creatinine.",lymphopenia is an adverse reaction entity
"The most common laboratory abnormalities (incidence >= 50%) were anemia, hypercholesterolemia, hypertriglyceridemia, hyperglycemia, lymphopenia, and increased creatinine.",hypercholesterolemia is an adverse reaction entity
"The most common laboratory abnormalities (incidence >= 50%) were anemia, hypercholesterolemia, hypertriglyceridemia, hyperglycemia, lymphopenia, and increased creatinine.",laboratory abnormalities ( is not a named entity
"The most common laboratory abnormalities (incidence >= 50%) were anemia, hypercholesterolemia, hypertriglyceridemia, hyperglycemia, lymphopenia, and increased creatinine.",The most common is not a named entity
"The most common laboratory abnormalities (incidence >= 50%) were anemia, hypercholesterolemia, hypertriglyceridemia, hyperglycemia, lymphopenia, and increased creatinine.",increased creatinine is an adverse reaction entity
"The most common laboratory abnormalities (incidence >= 50%) were anemia, hypercholesterolemia, hypertriglyceridemia, hyperglycemia, lymphopenia, and increased creatinine.",common laboratory abnormalities is not a named entity
"The most common laboratory abnormalities (incidence >= 50%) were anemia, hypercholesterolemia, hypertriglyceridemia, hyperglycemia, lymphopenia, and increased creatinine.","hypercholesterolemia , hypertriglyceridemia is not a named entity"
"The most common laboratory abnormalities (incidence >= 50%) were anemia, hypercholesterolemia, hypertriglyceridemia, hyperglycemia, lymphopenia, and increased creatinine.",anemia is an adverse reaction entity
"The most common laboratory abnormalities (incidence >= 50%) were anemia, hypercholesterolemia, hypertriglyceridemia, hyperglycemia, lymphopenia, and increased creatinine.",hyperglycemia is an adverse reaction entity
"The most common medical interventions required during AFINITOR treatment were for infections, anemia, and stomatitis.",anemia is an adverse reaction entity
"The most common medical interventions required during AFINITOR treatment were for infections, anemia, and stomatitis.",stomatitis is an adverse reaction entity
"The most common medical interventions required during AFINITOR treatment were for infections, anemia, and stomatitis.",infections is an adverse reaction entity
"The most common medical interventions required during AFINITOR treatment were for infections, anemia, and stomatitis.",treatment were for is not a named entity
"The most common medical interventions required during AFINITOR treatment were for infections, anemia, and stomatitis.",most common is not a named entity
"The most common medical interventions required during AFINITOR treatment were for infections, anemia, and stomatitis.",common medical is not a named entity
(  5.11  )   *  Embryo-fetal toxicity: Fetal harm can occur when administered to a pregnant woman.,Embryo-fetal toxicity is an adverse reaction entity
(  5.11  )   *  Embryo-fetal toxicity: Fetal harm can occur when administered to a pregnant woman.,Fetal harm is an adverse reaction entity
(  5.11  )   *  Embryo-fetal toxicity: Fetal harm can occur when administered to a pregnant woman.,a pregnant woman is not a named entity
(  5.11  )   *  Embryo-fetal toxicity: Fetal harm can occur when administered to a pregnant woman.,) is not a named entity
"5.8     Laboratory Tests and Monitoring       Renal Function       Elevations of serum creatinine and proteinuria have been reported in patients taking AFINITOR [see Adverse Reactions (6.1, 6.2, 6.3, 6.4, 6.5)]  .",Laboratory Tests and is not a named entity
"5.8     Laboratory Tests and Monitoring       Renal Function       Elevations of serum creatinine and proteinuria have been reported in patients taking AFINITOR [see Adverse Reactions (6.1, 6.2, 6.3, 6.4, 6.5)]  .",proteinuria is an adverse reaction entity
"5.8     Laboratory Tests and Monitoring       Renal Function       Elevations of serum creatinine and proteinuria have been reported in patients taking AFINITOR [see Adverse Reactions (6.1, 6.2, 6.3, 6.4, 6.5)]  .",of serum creatinine is not a named entity
"5.8     Laboratory Tests and Monitoring       Renal Function       Elevations of serum creatinine and proteinuria have been reported in patients taking AFINITOR [see Adverse Reactions (6.1, 6.2, 6.3, 6.4, 6.5)]  .",Elevations of serum creatinine is an adverse reaction entity
"Pneumocystis jiroveci pneumonia, some with a fatal outcome, has been reported in patients who received everolimus.",patients who is not a named entity
"Pneumocystis jiroveci pneumonia, some with a fatal outcome, has been reported in patients who received everolimus.",Pneumocystis jiroveci pneumonia is an adverse reaction entity
"Pneumocystis jiroveci pneumonia, some with a fatal outcome, has been reported in patients who received everolimus.",been is not a named entity
"Pneumocystis jiroveci pneumonia, some with a fatal outcome, has been reported in patients who received everolimus.",fatal is an adverse reaction entity
"Adverse reactions leading to permanent discontinuation in the AFINITOR arm were hypersensitivity/angioedema/bronchospasm, convulsion, and hypophosphatemia.",convulsion is an adverse reaction entity
"Adverse reactions leading to permanent discontinuation in the AFINITOR arm were hypersensitivity/angioedema/bronchospasm, convulsion, and hypophosphatemia.",arm were hypersensitivity/angioedema/bronchospasm is not a named entity
"Adverse reactions leading to permanent discontinuation in the AFINITOR arm were hypersensitivity/angioedema/bronchospasm, convulsion, and hypophosphatemia.",Adverse reactions leading is not a named entity
"Adverse reactions leading to permanent discontinuation in the AFINITOR arm were hypersensitivity/angioedema/bronchospasm, convulsion, and hypophosphatemia.",bronchospasm is an adverse reaction entity
"Adverse reactions leading to permanent discontinuation in the AFINITOR arm were hypersensitivity/angioedema/bronchospasm, convulsion, and hypophosphatemia.",hypophosphatemia is an adverse reaction entity
"Adverse reactions leading to permanent discontinuation in the AFINITOR arm were hypersensitivity/angioedema/bronchospasm, convulsion, and hypophosphatemia.",angioedema is an adverse reaction entity
"Adverse reactions leading to permanent discontinuation in the AFINITOR arm were hypersensitivity/angioedema/bronchospasm, convulsion, and hypophosphatemia.","hypersensitivity/angioedema/bronchospasm , is not a named entity"
"Adverse reactions leading to permanent discontinuation in the AFINITOR arm were hypersensitivity/angioedema/bronchospasm, convulsion, and hypophosphatemia.",", convulsion , is not a named entity"
"Adverse reactions leading to permanent discontinuation in the AFINITOR arm were hypersensitivity/angioedema/bronchospasm, convulsion, and hypophosphatemia.",AFINITOR arm were is not a named entity
"Adverse reactions leading to permanent discontinuation in the AFINITOR arm were hypersensitivity/angioedema/bronchospasm, convulsion, and hypophosphatemia.",hypersensitivity is an adverse reaction entity
Thrombotic events included five patients with pulmonary embolus in the everolimus arm and one in the placebo arm as well as three patients with thrombosis in the everolimus arm and two in the placebo arm.,everolimus arm is not a named entity
Thrombotic events included five patients with pulmonary embolus in the everolimus arm and one in the placebo arm as well as three patients with thrombosis in the everolimus arm and two in the placebo arm.,pulmonary embolus is an adverse reaction entity
Thrombotic events included five patients with pulmonary embolus in the everolimus arm and one in the placebo arm as well as three patients with thrombosis in the everolimus arm and two in the placebo arm.,events is not a named entity
Thrombotic events included five patients with pulmonary embolus in the everolimus arm and one in the placebo arm as well as three patients with thrombosis in the everolimus arm and two in the placebo arm.,thrombosis is an adverse reaction entity
Thrombotic events included five patients with pulmonary embolus in the everolimus arm and one in the placebo arm as well as three patients with thrombosis in the everolimus arm and two in the placebo arm.,five patients is not a named entity
Thrombotic events included five patients with pulmonary embolus in the everolimus arm and one in the placebo arm as well as three patients with thrombosis in the everolimus arm and two in the placebo arm.,Thrombotic events is an adverse reaction entity
"Table 2: Adverse Reactions Reported >= 10% of Patients with Advanced HR+ BC*   Grading according to CTCAE Version 3.0  *  160 patients (33.2%) were exposed to AFINITOR therapy for a period of >= 32 weeks  a  Exemestane (25 mg/day)  b  Includes stomatitis, mouth ulceration, aphthous stomatitis, glossodynia, gingival pain, glossitis and lip ulceration  c  Includes all preferred terms within the 'infections and infestations' system organ class, the most common being nasopharyngitis (10%), urinary tract infection (10%), upper respiratory tract infection (5%), pneumonia (4%), bronchitis (4%), cystitis (3%), sinusitis (3%), and also including candidiasis (<1%), and sepsis (<1%), and hepatitis C (<1%).",bronchitis is an adverse reaction entity
"Table 2: Adverse Reactions Reported >= 10% of Patients with Advanced HR+ BC*   Grading according to CTCAE Version 3.0  *  160 patients (33.2%) were exposed to AFINITOR therapy for a period of >= 32 weeks  a  Exemestane (25 mg/day)  b  Includes stomatitis, mouth ulceration, aphthous stomatitis, glossodynia, gingival pain, glossitis and lip ulceration  c  Includes all preferred terms within the 'infections and infestations' system organ class, the most common being nasopharyngitis (10%), urinary tract infection (10%), upper respiratory tract infection (5%), pneumonia (4%), bronchitis (4%), cystitis (3%), sinusitis (3%), and also including candidiasis (<1%), and sepsis (<1%), and hepatitis C (<1%).",gingival pain is an adverse reaction entity
"Table 2: Adverse Reactions Reported >= 10% of Patients with Advanced HR+ BC*   Grading according to CTCAE Version 3.0  *  160 patients (33.2%) were exposed to AFINITOR therapy for a period of >= 32 weeks  a  Exemestane (25 mg/day)  b  Includes stomatitis, mouth ulceration, aphthous stomatitis, glossodynia, gingival pain, glossitis and lip ulceration  c  Includes all preferred terms within the 'infections and infestations' system organ class, the most common being nasopharyngitis (10%), urinary tract infection (10%), upper respiratory tract infection (5%), pneumonia (4%), bronchitis (4%), cystitis (3%), sinusitis (3%), and also including candidiasis (<1%), and sepsis (<1%), and hepatitis C (<1%).",infestations ' system is not a named entity
"Table 2: Adverse Reactions Reported >= 10% of Patients with Advanced HR+ BC*   Grading according to CTCAE Version 3.0  *  160 patients (33.2%) were exposed to AFINITOR therapy for a period of >= 32 weeks  a  Exemestane (25 mg/day)  b  Includes stomatitis, mouth ulceration, aphthous stomatitis, glossodynia, gingival pain, glossitis and lip ulceration  c  Includes all preferred terms within the 'infections and infestations' system organ class, the most common being nasopharyngitis (10%), urinary tract infection (10%), upper respiratory tract infection (5%), pneumonia (4%), bronchitis (4%), cystitis (3%), sinusitis (3%), and also including candidiasis (<1%), and sepsis (<1%), and hepatitis C (<1%).",to is not a named entity
"Table 2: Adverse Reactions Reported >= 10% of Patients with Advanced HR+ BC*   Grading according to CTCAE Version 3.0  *  160 patients (33.2%) were exposed to AFINITOR therapy for a period of >= 32 weeks  a  Exemestane (25 mg/day)  b  Includes stomatitis, mouth ulceration, aphthous stomatitis, glossodynia, gingival pain, glossitis and lip ulceration  c  Includes all preferred terms within the 'infections and infestations' system organ class, the most common being nasopharyngitis (10%), urinary tract infection (10%), upper respiratory tract infection (5%), pneumonia (4%), bronchitis (4%), cystitis (3%), sinusitis (3%), and also including candidiasis (<1%), and sepsis (<1%), and hepatitis C (<1%).",Table 2 : is not a named entity
"Table 2: Adverse Reactions Reported >= 10% of Patients with Advanced HR+ BC*   Grading according to CTCAE Version 3.0  *  160 patients (33.2%) were exposed to AFINITOR therapy for a period of >= 32 weeks  a  Exemestane (25 mg/day)  b  Includes stomatitis, mouth ulceration, aphthous stomatitis, glossodynia, gingival pain, glossitis and lip ulceration  c  Includes all preferred terms within the 'infections and infestations' system organ class, the most common being nasopharyngitis (10%), urinary tract infection (10%), upper respiratory tract infection (5%), pneumonia (4%), bronchitis (4%), cystitis (3%), sinusitis (3%), and also including candidiasis (<1%), and sepsis (<1%), and hepatitis C (<1%).",urinary tract infection is an adverse reaction entity
"Table 2: Adverse Reactions Reported >= 10% of Patients with Advanced HR+ BC*   Grading according to CTCAE Version 3.0  *  160 patients (33.2%) were exposed to AFINITOR therapy for a period of >= 32 weeks  a  Exemestane (25 mg/day)  b  Includes stomatitis, mouth ulceration, aphthous stomatitis, glossodynia, gingival pain, glossitis and lip ulceration  c  Includes all preferred terms within the 'infections and infestations' system organ class, the most common being nasopharyngitis (10%), urinary tract infection (10%), upper respiratory tract infection (5%), pneumonia (4%), bronchitis (4%), cystitis (3%), sinusitis (3%), and also including candidiasis (<1%), and sepsis (<1%), and hepatitis C (<1%).",% is not a named entity
"Table 2: Adverse Reactions Reported >= 10% of Patients with Advanced HR+ BC*   Grading according to CTCAE Version 3.0  *  160 patients (33.2%) were exposed to AFINITOR therapy for a period of >= 32 weeks  a  Exemestane (25 mg/day)  b  Includes stomatitis, mouth ulceration, aphthous stomatitis, glossodynia, gingival pain, glossitis and lip ulceration  c  Includes all preferred terms within the 'infections and infestations' system organ class, the most common being nasopharyngitis (10%), urinary tract infection (10%), upper respiratory tract infection (5%), pneumonia (4%), bronchitis (4%), cystitis (3%), sinusitis (3%), and also including candidiasis (<1%), and sepsis (<1%), and hepatitis C (<1%).",pneumonia is an adverse reaction entity
"Table 2: Adverse Reactions Reported >= 10% of Patients with Advanced HR+ BC*   Grading according to CTCAE Version 3.0  *  160 patients (33.2%) were exposed to AFINITOR therapy for a period of >= 32 weeks  a  Exemestane (25 mg/day)  b  Includes stomatitis, mouth ulceration, aphthous stomatitis, glossodynia, gingival pain, glossitis and lip ulceration  c  Includes all preferred terms within the 'infections and infestations' system organ class, the most common being nasopharyngitis (10%), urinary tract infection (10%), upper respiratory tract infection (5%), pneumonia (4%), bronchitis (4%), cystitis (3%), sinusitis (3%), and also including candidiasis (<1%), and sepsis (<1%), and hepatitis C (<1%).",aphthous stomatitis is an adverse reaction entity
"Table 2: Adverse Reactions Reported >= 10% of Patients with Advanced HR+ BC*   Grading according to CTCAE Version 3.0  *  160 patients (33.2%) were exposed to AFINITOR therapy for a period of >= 32 weeks  a  Exemestane (25 mg/day)  b  Includes stomatitis, mouth ulceration, aphthous stomatitis, glossodynia, gingival pain, glossitis and lip ulceration  c  Includes all preferred terms within the 'infections and infestations' system organ class, the most common being nasopharyngitis (10%), urinary tract infection (10%), upper respiratory tract infection (5%), pneumonia (4%), bronchitis (4%), cystitis (3%), sinusitis (3%), and also including candidiasis (<1%), and sepsis (<1%), and hepatitis C (<1%).","ulceration , aphthous is not a named entity"
"Table 2: Adverse Reactions Reported >= 10% of Patients with Advanced HR+ BC*   Grading according to CTCAE Version 3.0  *  160 patients (33.2%) were exposed to AFINITOR therapy for a period of >= 32 weeks  a  Exemestane (25 mg/day)  b  Includes stomatitis, mouth ulceration, aphthous stomatitis, glossodynia, gingival pain, glossitis and lip ulceration  c  Includes all preferred terms within the 'infections and infestations' system organ class, the most common being nasopharyngitis (10%), urinary tract infection (10%), upper respiratory tract infection (5%), pneumonia (4%), bronchitis (4%), cystitis (3%), sinusitis (3%), and also including candidiasis (<1%), and sepsis (<1%), and hepatitis C (<1%).",therapy is not a named entity
"Table 2: Adverse Reactions Reported >= 10% of Patients with Advanced HR+ BC*   Grading according to CTCAE Version 3.0  *  160 patients (33.2%) were exposed to AFINITOR therapy for a period of >= 32 weeks  a  Exemestane (25 mg/day)  b  Includes stomatitis, mouth ulceration, aphthous stomatitis, glossodynia, gingival pain, glossitis and lip ulceration  c  Includes all preferred terms within the 'infections and infestations' system organ class, the most common being nasopharyngitis (10%), urinary tract infection (10%), upper respiratory tract infection (5%), pneumonia (4%), bronchitis (4%), cystitis (3%), sinusitis (3%), and also including candidiasis (<1%), and sepsis (<1%), and hepatitis C (<1%).",( is not a named entity
"Table 2: Adverse Reactions Reported >= 10% of Patients with Advanced HR+ BC*   Grading according to CTCAE Version 3.0  *  160 patients (33.2%) were exposed to AFINITOR therapy for a period of >= 32 weeks  a  Exemestane (25 mg/day)  b  Includes stomatitis, mouth ulceration, aphthous stomatitis, glossodynia, gingival pain, glossitis and lip ulceration  c  Includes all preferred terms within the 'infections and infestations' system organ class, the most common being nasopharyngitis (10%), urinary tract infection (10%), upper respiratory tract infection (5%), pneumonia (4%), bronchitis (4%), cystitis (3%), sinusitis (3%), and also including candidiasis (<1%), and sepsis (<1%), and hepatitis C (<1%).",patients ( is not a named entity
"Table 2: Adverse Reactions Reported >= 10% of Patients with Advanced HR+ BC*   Grading according to CTCAE Version 3.0  *  160 patients (33.2%) were exposed to AFINITOR therapy for a period of >= 32 weeks  a  Exemestane (25 mg/day)  b  Includes stomatitis, mouth ulceration, aphthous stomatitis, glossodynia, gingival pain, glossitis and lip ulceration  c  Includes all preferred terms within the 'infections and infestations' system organ class, the most common being nasopharyngitis (10%), urinary tract infection (10%), upper respiratory tract infection (5%), pneumonia (4%), bronchitis (4%), cystitis (3%), sinusitis (3%), and also including candidiasis (<1%), and sepsis (<1%), and hepatitis C (<1%).",Table is not a named entity
"Table 2: Adverse Reactions Reported >= 10% of Patients with Advanced HR+ BC*   Grading according to CTCAE Version 3.0  *  160 patients (33.2%) were exposed to AFINITOR therapy for a period of >= 32 weeks  a  Exemestane (25 mg/day)  b  Includes stomatitis, mouth ulceration, aphthous stomatitis, glossodynia, gingival pain, glossitis and lip ulceration  c  Includes all preferred terms within the 'infections and infestations' system organ class, the most common being nasopharyngitis (10%), urinary tract infection (10%), upper respiratory tract infection (5%), pneumonia (4%), bronchitis (4%), cystitis (3%), sinusitis (3%), and also including candidiasis (<1%), and sepsis (<1%), and hepatitis C (<1%).",sinusitis is an adverse reaction entity
"Table 2: Adverse Reactions Reported >= 10% of Patients with Advanced HR+ BC*   Grading according to CTCAE Version 3.0  *  160 patients (33.2%) were exposed to AFINITOR therapy for a period of >= 32 weeks  a  Exemestane (25 mg/day)  b  Includes stomatitis, mouth ulceration, aphthous stomatitis, glossodynia, gingival pain, glossitis and lip ulceration  c  Includes all preferred terms within the 'infections and infestations' system organ class, the most common being nasopharyngitis (10%), urinary tract infection (10%), upper respiratory tract infection (5%), pneumonia (4%), bronchitis (4%), cystitis (3%), sinusitis (3%), and also including candidiasis (<1%), and sepsis (<1%), and hepatitis C (<1%).",160 patients ( is not a named entity
"Table 2: Adverse Reactions Reported >= 10% of Patients with Advanced HR+ BC*   Grading according to CTCAE Version 3.0  *  160 patients (33.2%) were exposed to AFINITOR therapy for a period of >= 32 weeks  a  Exemestane (25 mg/day)  b  Includes stomatitis, mouth ulceration, aphthous stomatitis, glossodynia, gingival pain, glossitis and lip ulceration  c  Includes all preferred terms within the 'infections and infestations' system organ class, the most common being nasopharyngitis (10%), urinary tract infection (10%), upper respiratory tract infection (5%), pneumonia (4%), bronchitis (4%), cystitis (3%), sinusitis (3%), and also including candidiasis (<1%), and sepsis (<1%), and hepatitis C (<1%).",cystitis is an adverse reaction entity
"Table 2: Adverse Reactions Reported >= 10% of Patients with Advanced HR+ BC*   Grading according to CTCAE Version 3.0  *  160 patients (33.2%) were exposed to AFINITOR therapy for a period of >= 32 weeks  a  Exemestane (25 mg/day)  b  Includes stomatitis, mouth ulceration, aphthous stomatitis, glossodynia, gingival pain, glossitis and lip ulceration  c  Includes all preferred terms within the 'infections and infestations' system organ class, the most common being nasopharyngitis (10%), urinary tract infection (10%), upper respiratory tract infection (5%), pneumonia (4%), bronchitis (4%), cystitis (3%), sinusitis (3%), and also including candidiasis (<1%), and sepsis (<1%), and hepatitis C (<1%).",glossitis is an adverse reaction entity
"Table 2: Adverse Reactions Reported >= 10% of Patients with Advanced HR+ BC*   Grading according to CTCAE Version 3.0  *  160 patients (33.2%) were exposed to AFINITOR therapy for a period of >= 32 weeks  a  Exemestane (25 mg/day)  b  Includes stomatitis, mouth ulceration, aphthous stomatitis, glossodynia, gingival pain, glossitis and lip ulceration  c  Includes all preferred terms within the 'infections and infestations' system organ class, the most common being nasopharyngitis (10%), urinary tract infection (10%), upper respiratory tract infection (5%), pneumonia (4%), bronchitis (4%), cystitis (3%), sinusitis (3%), and also including candidiasis (<1%), and sepsis (<1%), and hepatitis C (<1%).",and sepsis is not a named entity
"Table 2: Adverse Reactions Reported >= 10% of Patients with Advanced HR+ BC*   Grading according to CTCAE Version 3.0  *  160 patients (33.2%) were exposed to AFINITOR therapy for a period of >= 32 weeks  a  Exemestane (25 mg/day)  b  Includes stomatitis, mouth ulceration, aphthous stomatitis, glossodynia, gingival pain, glossitis and lip ulceration  c  Includes all preferred terms within the 'infections and infestations' system organ class, the most common being nasopharyngitis (10%), urinary tract infection (10%), upper respiratory tract infection (5%), pneumonia (4%), bronchitis (4%), cystitis (3%), sinusitis (3%), and also including candidiasis (<1%), and sepsis (<1%), and hepatitis C (<1%).",sepsis is an adverse reaction entity
"Table 2: Adverse Reactions Reported >= 10% of Patients with Advanced HR+ BC*   Grading according to CTCAE Version 3.0  *  160 patients (33.2%) were exposed to AFINITOR therapy for a period of >= 32 weeks  a  Exemestane (25 mg/day)  b  Includes stomatitis, mouth ulceration, aphthous stomatitis, glossodynia, gingival pain, glossitis and lip ulceration  c  Includes all preferred terms within the 'infections and infestations' system organ class, the most common being nasopharyngitis (10%), urinary tract infection (10%), upper respiratory tract infection (5%), pneumonia (4%), bronchitis (4%), cystitis (3%), sinusitis (3%), and also including candidiasis (<1%), and sepsis (<1%), and hepatitis C (<1%).",mouth ulceration is an adverse reaction entity
"Table 2: Adverse Reactions Reported >= 10% of Patients with Advanced HR+ BC*   Grading according to CTCAE Version 3.0  *  160 patients (33.2%) were exposed to AFINITOR therapy for a period of >= 32 weeks  a  Exemestane (25 mg/day)  b  Includes stomatitis, mouth ulceration, aphthous stomatitis, glossodynia, gingival pain, glossitis and lip ulceration  c  Includes all preferred terms within the 'infections and infestations' system organ class, the most common being nasopharyngitis (10%), urinary tract infection (10%), upper respiratory tract infection (5%), pneumonia (4%), bronchitis (4%), cystitis (3%), sinusitis (3%), and also including candidiasis (<1%), and sepsis (<1%), and hepatitis C (<1%).",nasopharyngitis is an adverse reaction entity
"Table 2: Adverse Reactions Reported >= 10% of Patients with Advanced HR+ BC*   Grading according to CTCAE Version 3.0  *  160 patients (33.2%) were exposed to AFINITOR therapy for a period of >= 32 weeks  a  Exemestane (25 mg/day)  b  Includes stomatitis, mouth ulceration, aphthous stomatitis, glossodynia, gingival pain, glossitis and lip ulceration  c  Includes all preferred terms within the 'infections and infestations' system organ class, the most common being nasopharyngitis (10%), urinary tract infection (10%), upper respiratory tract infection (5%), pneumonia (4%), bronchitis (4%), cystitis (3%), sinusitis (3%), and also including candidiasis (<1%), and sepsis (<1%), and hepatitis C (<1%).",upper respiratory tract infection is an adverse reaction entity
"Table 2: Adverse Reactions Reported >= 10% of Patients with Advanced HR+ BC*   Grading according to CTCAE Version 3.0  *  160 patients (33.2%) were exposed to AFINITOR therapy for a period of >= 32 weeks  a  Exemestane (25 mg/day)  b  Includes stomatitis, mouth ulceration, aphthous stomatitis, glossodynia, gingival pain, glossitis and lip ulceration  c  Includes all preferred terms within the 'infections and infestations' system organ class, the most common being nasopharyngitis (10%), urinary tract infection (10%), upper respiratory tract infection (5%), pneumonia (4%), bronchitis (4%), cystitis (3%), sinusitis (3%), and also including candidiasis (<1%), and sepsis (<1%), and hepatitis C (<1%).",Includes all is not a named entity
"Table 2: Adverse Reactions Reported >= 10% of Patients with Advanced HR+ BC*   Grading according to CTCAE Version 3.0  *  160 patients (33.2%) were exposed to AFINITOR therapy for a period of >= 32 weeks  a  Exemestane (25 mg/day)  b  Includes stomatitis, mouth ulceration, aphthous stomatitis, glossodynia, gingival pain, glossitis and lip ulceration  c  Includes all preferred terms within the 'infections and infestations' system organ class, the most common being nasopharyngitis (10%), urinary tract infection (10%), upper respiratory tract infection (5%), pneumonia (4%), bronchitis (4%), cystitis (3%), sinusitis (3%), and also including candidiasis (<1%), and sepsis (<1%), and hepatitis C (<1%).",glossodynia is an adverse reaction entity
"Table 2: Adverse Reactions Reported >= 10% of Patients with Advanced HR+ BC*   Grading according to CTCAE Version 3.0  *  160 patients (33.2%) were exposed to AFINITOR therapy for a period of >= 32 weeks  a  Exemestane (25 mg/day)  b  Includes stomatitis, mouth ulceration, aphthous stomatitis, glossodynia, gingival pain, glossitis and lip ulceration  c  Includes all preferred terms within the 'infections and infestations' system organ class, the most common being nasopharyngitis (10%), urinary tract infection (10%), upper respiratory tract infection (5%), pneumonia (4%), bronchitis (4%), cystitis (3%), sinusitis (3%), and also including candidiasis (<1%), and sepsis (<1%), and hepatitis C (<1%).",stomatitis is an adverse reaction entity
"Table 2: Adverse Reactions Reported >= 10% of Patients with Advanced HR+ BC*   Grading according to CTCAE Version 3.0  *  160 patients (33.2%) were exposed to AFINITOR therapy for a period of >= 32 weeks  a  Exemestane (25 mg/day)  b  Includes stomatitis, mouth ulceration, aphthous stomatitis, glossodynia, gingival pain, glossitis and lip ulceration  c  Includes all preferred terms within the 'infections and infestations' system organ class, the most common being nasopharyngitis (10%), urinary tract infection (10%), upper respiratory tract infection (5%), pneumonia (4%), bronchitis (4%), cystitis (3%), sinusitis (3%), and also including candidiasis (<1%), and sepsis (<1%), and hepatitis C (<1%).",", upper is not a named entity"
"Table 2: Adverse Reactions Reported >= 10% of Patients with Advanced HR+ BC*   Grading according to CTCAE Version 3.0  *  160 patients (33.2%) were exposed to AFINITOR therapy for a period of >= 32 weeks  a  Exemestane (25 mg/day)  b  Includes stomatitis, mouth ulceration, aphthous stomatitis, glossodynia, gingival pain, glossitis and lip ulceration  c  Includes all preferred terms within the 'infections and infestations' system organ class, the most common being nasopharyngitis (10%), urinary tract infection (10%), upper respiratory tract infection (5%), pneumonia (4%), bronchitis (4%), cystitis (3%), sinusitis (3%), and also including candidiasis (<1%), and sepsis (<1%), and hepatitis C (<1%).",lip ulceration is an adverse reaction entity
"Table 2: Adverse Reactions Reported >= 10% of Patients with Advanced HR+ BC*   Grading according to CTCAE Version 3.0  *  160 patients (33.2%) were exposed to AFINITOR therapy for a period of >= 32 weeks  a  Exemestane (25 mg/day)  b  Includes stomatitis, mouth ulceration, aphthous stomatitis, glossodynia, gingival pain, glossitis and lip ulceration  c  Includes all preferred terms within the 'infections and infestations' system organ class, the most common being nasopharyngitis (10%), urinary tract infection (10%), upper respiratory tract infection (5%), pneumonia (4%), bronchitis (4%), cystitis (3%), sinusitis (3%), and also including candidiasis (<1%), and sepsis (<1%), and hepatitis C (<1%).",hepatitis C is an adverse reaction entity
"Table 2: Adverse Reactions Reported >= 10% of Patients with Advanced HR+ BC*   Grading according to CTCAE Version 3.0  *  160 patients (33.2%) were exposed to AFINITOR therapy for a period of >= 32 weeks  a  Exemestane (25 mg/day)  b  Includes stomatitis, mouth ulceration, aphthous stomatitis, glossodynia, gingival pain, glossitis and lip ulceration  c  Includes all preferred terms within the 'infections and infestations' system organ class, the most common being nasopharyngitis (10%), urinary tract infection (10%), upper respiratory tract infection (5%), pneumonia (4%), bronchitis (4%), cystitis (3%), sinusitis (3%), and also including candidiasis (<1%), and sepsis (<1%), and hepatitis C (<1%).",") , upper is not a named entity"
"Table 2: Adverse Reactions Reported >= 10% of Patients with Advanced HR+ BC*   Grading according to CTCAE Version 3.0  *  160 patients (33.2%) were exposed to AFINITOR therapy for a period of >= 32 weeks  a  Exemestane (25 mg/day)  b  Includes stomatitis, mouth ulceration, aphthous stomatitis, glossodynia, gingival pain, glossitis and lip ulceration  c  Includes all preferred terms within the 'infections and infestations' system organ class, the most common being nasopharyngitis (10%), urinary tract infection (10%), upper respiratory tract infection (5%), pneumonia (4%), bronchitis (4%), cystitis (3%), sinusitis (3%), and also including candidiasis (<1%), and sepsis (<1%), and hepatitis C (<1%).",C is not a named entity
"Table 2: Adverse Reactions Reported >= 10% of Patients with Advanced HR+ BC*   Grading according to CTCAE Version 3.0  *  160 patients (33.2%) were exposed to AFINITOR therapy for a period of >= 32 weeks  a  Exemestane (25 mg/day)  b  Includes stomatitis, mouth ulceration, aphthous stomatitis, glossodynia, gingival pain, glossitis and lip ulceration  c  Includes all preferred terms within the 'infections and infestations' system organ class, the most common being nasopharyngitis (10%), urinary tract infection (10%), upper respiratory tract infection (5%), pneumonia (4%), bronchitis (4%), cystitis (3%), sinusitis (3%), and also including candidiasis (<1%), and sepsis (<1%), and hepatitis C (<1%).",candidiasis is an adverse reaction entity
"Table 2: Adverse Reactions Reported >= 10% of Patients with Advanced HR+ BC*   Grading according to CTCAE Version 3.0  *  160 patients (33.2%) were exposed to AFINITOR therapy for a period of >= 32 weeks  a  Exemestane (25 mg/day)  b  Includes stomatitis, mouth ulceration, aphthous stomatitis, glossodynia, gingival pain, glossitis and lip ulceration  c  Includes all preferred terms within the 'infections and infestations' system organ class, the most common being nasopharyngitis (10%), urinary tract infection (10%), upper respiratory tract infection (5%), pneumonia (4%), bronchitis (4%), cystitis (3%), sinusitis (3%), and also including candidiasis (<1%), and sepsis (<1%), and hepatitis C (<1%).",32 weeks is not a named entity
"Table 2: Adverse Reactions Reported >= 10% of Patients with Advanced HR+ BC*   Grading according to CTCAE Version 3.0  *  160 patients (33.2%) were exposed to AFINITOR therapy for a period of >= 32 weeks  a  Exemestane (25 mg/day)  b  Includes stomatitis, mouth ulceration, aphthous stomatitis, glossodynia, gingival pain, glossitis and lip ulceration  c  Includes all preferred terms within the 'infections and infestations' system organ class, the most common being nasopharyngitis (10%), urinary tract infection (10%), upper respiratory tract infection (5%), pneumonia (4%), bronchitis (4%), cystitis (3%), sinusitis (3%), and also including candidiasis (<1%), and sepsis (<1%), and hepatitis C (<1%).",) b Includes is not a named entity
"The incidence of Common Terminology Criteria (CTC) Grade 3 and 4 non-infectious pneumonitis was up to 4.0% and up to 0.2%, respectively  [see Adverse Reactions (6.1, 6.2, 6.3, 6.4, 6.5)]  .","6.1 , is not a named entity"
"The incidence of Common Terminology Criteria (CTC) Grade 3 and 4 non-infectious pneumonitis was up to 4.0% and up to 0.2%, respectively  [see Adverse Reactions (6.1, 6.2, 6.3, 6.4, 6.5)]  .",non-infectious pneumonitis is an adverse reaction entity
"The incidence of Common Terminology Criteria (CTC) Grade 3 and 4 non-infectious pneumonitis was up to 4.0% and up to 0.2%, respectively  [see Adverse Reactions (6.1, 6.2, 6.3, 6.4, 6.5)]  .",see Adverse is not a named entity
"The incidence of Common Terminology Criteria (CTC) Grade 3 and 4 non-infectious pneumonitis was up to 4.0% and up to 0.2%, respectively  [see Adverse Reactions (6.1, 6.2, 6.3, 6.4, 6.5)]  .",non-infectious pneumonitis is an adverse reaction entity
"Table 8: Adverse Reactions Reported in >= 10% of AFINITOR-treated Patients with Renal Angiomyolipoma   Grading according to CTCAE Version 3.0  a  Includes stomatitis, aphthous stomatitis, mouth ulceration, gingival pain, glossitis, and glossodynia.",Reactions Reported in is not a named entity
"Table 8: Adverse Reactions Reported in >= 10% of AFINITOR-treated Patients with Renal Angiomyolipoma   Grading according to CTCAE Version 3.0  a  Includes stomatitis, aphthous stomatitis, mouth ulceration, gingival pain, glossitis, and glossodynia.",and glossodynia is not a named entity
"Table 8: Adverse Reactions Reported in >= 10% of AFINITOR-treated Patients with Renal Angiomyolipoma   Grading according to CTCAE Version 3.0  a  Includes stomatitis, aphthous stomatitis, mouth ulceration, gingival pain, glossitis, and glossodynia.",mouth ulceration is an adverse reaction entity
"Table 8: Adverse Reactions Reported in >= 10% of AFINITOR-treated Patients with Renal Angiomyolipoma   Grading according to CTCAE Version 3.0  a  Includes stomatitis, aphthous stomatitis, mouth ulceration, gingival pain, glossitis, and glossodynia.",Angiomyolipoma Grading according is not a named entity
"Table 8: Adverse Reactions Reported in >= 10% of AFINITOR-treated Patients with Renal Angiomyolipoma   Grading according to CTCAE Version 3.0  a  Includes stomatitis, aphthous stomatitis, mouth ulceration, gingival pain, glossitis, and glossodynia.",glossodynia is an adverse reaction entity
"Table 8: Adverse Reactions Reported in >= 10% of AFINITOR-treated Patients with Renal Angiomyolipoma   Grading according to CTCAE Version 3.0  a  Includes stomatitis, aphthous stomatitis, mouth ulceration, gingival pain, glossitis, and glossodynia.","glossitis , is not a named entity"
"Table 8: Adverse Reactions Reported in >= 10% of AFINITOR-treated Patients with Renal Angiomyolipoma   Grading according to CTCAE Version 3.0  a  Includes stomatitis, aphthous stomatitis, mouth ulceration, gingival pain, glossitis, and glossodynia.",aphthous stomatitis is an adverse reaction entity
"Table 8: Adverse Reactions Reported in >= 10% of AFINITOR-treated Patients with Renal Angiomyolipoma   Grading according to CTCAE Version 3.0  a  Includes stomatitis, aphthous stomatitis, mouth ulceration, gingival pain, glossitis, and glossodynia.","pain , glossitis is not a named entity"
"Table 8: Adverse Reactions Reported in >= 10% of AFINITOR-treated Patients with Renal Angiomyolipoma   Grading according to CTCAE Version 3.0  a  Includes stomatitis, aphthous stomatitis, mouth ulceration, gingival pain, glossitis, and glossodynia.",Renal Angiomyolipoma is not a named entity
"Table 8: Adverse Reactions Reported in >= 10% of AFINITOR-treated Patients with Renal Angiomyolipoma   Grading according to CTCAE Version 3.0  a  Includes stomatitis, aphthous stomatitis, mouth ulceration, gingival pain, glossitis, and glossodynia.",glossitis is an adverse reaction entity
"Table 8: Adverse Reactions Reported in >= 10% of AFINITOR-treated Patients with Renal Angiomyolipoma   Grading according to CTCAE Version 3.0  a  Includes stomatitis, aphthous stomatitis, mouth ulceration, gingival pain, glossitis, and glossodynia.",stomatitis is an adverse reaction entity
"Table 8: Adverse Reactions Reported in >= 10% of AFINITOR-treated Patients with Renal Angiomyolipoma   Grading according to CTCAE Version 3.0  a  Includes stomatitis, aphthous stomatitis, mouth ulceration, gingival pain, glossitis, and glossodynia.",gingival pain is an adverse reaction entity
"The most common laboratory abnormalities (incidence >= 50%) were hypercholesterolemia, hypertriglyceridemia, and anemia.",( incidence is not a named entity
"The most common laboratory abnormalities (incidence >= 50%) were hypercholesterolemia, hypertriglyceridemia, and anemia.",laboratory is not a named entity
"The most common laboratory abnormalities (incidence >= 50%) were hypercholesterolemia, hypertriglyceridemia, and anemia.",hypertriglyceridemia is an adverse reaction entity
"The most common laboratory abnormalities (incidence >= 50%) were hypercholesterolemia, hypertriglyceridemia, and anemia.",anemia is an adverse reaction entity
"The most common laboratory abnormalities (incidence >= 50%) were hypercholesterolemia, hypertriglyceridemia, and anemia.",common is not a named entity
"The most common laboratory abnormalities (incidence >= 50%) were hypercholesterolemia, hypertriglyceridemia, and anemia.",hypercholesterolemia is an adverse reaction entity
"The most common Grade 3-4 laboratory abnormalities (incidence >= 3%) were lymphopenia, hyperglycemia, anemia, hypophosphatemia, and hypercholesterolemia.",The is not a named entity
"The most common Grade 3-4 laboratory abnormalities (incidence >= 3%) were lymphopenia, hyperglycemia, anemia, hypophosphatemia, and hypercholesterolemia.",hypercholesterolemia is an adverse reaction entity
"The most common Grade 3-4 laboratory abnormalities (incidence >= 3%) were lymphopenia, hyperglycemia, anemia, hypophosphatemia, and hypercholesterolemia.",hypophosphatemia is an adverse reaction entity
"The most common Grade 3-4 laboratory abnormalities (incidence >= 3%) were lymphopenia, hyperglycemia, anemia, hypophosphatemia, and hypercholesterolemia.",lymphopenia is an adverse reaction entity
"The most common Grade 3-4 laboratory abnormalities (incidence >= 3%) were lymphopenia, hyperglycemia, anemia, hypophosphatemia, and hypercholesterolemia.",> is not a named entity
"The most common Grade 3-4 laboratory abnormalities (incidence >= 3%) were lymphopenia, hyperglycemia, anemia, hypophosphatemia, and hypercholesterolemia.",were lymphopenia is not a named entity
"The most common Grade 3-4 laboratory abnormalities (incidence >= 3%) were lymphopenia, hyperglycemia, anemia, hypophosphatemia, and hypercholesterolemia.",most common Grade is not a named entity
"The most common Grade 3-4 laboratory abnormalities (incidence >= 3%) were lymphopenia, hyperglycemia, anemia, hypophosphatemia, and hypercholesterolemia.",anemia is an adverse reaction entity
"The most common Grade 3-4 laboratory abnormalities (incidence >= 3%) were lymphopenia, hyperglycemia, anemia, hypophosphatemia, and hypercholesterolemia.",> = is not a named entity
"The most common Grade 3-4 laboratory abnormalities (incidence >= 3%) were lymphopenia, hyperglycemia, anemia, hypophosphatemia, and hypercholesterolemia.",hyperglycemia is an adverse reaction entity
"(  5.4  )   *  Renal failure: Cases of renal failure (including acute renal failure), some with a fatal outcome, have been observed.",fatal is an adverse reaction entity
"(  5.4  )   *  Renal failure: Cases of renal failure (including acute renal failure), some with a fatal outcome, have been observed.",5.4 is not a named entity
"(  5.4  )   *  Renal failure: Cases of renal failure (including acute renal failure), some with a fatal outcome, have been observed.",acute renal failure is an adverse reaction entity
"(  5.4  )   *  Renal failure: Cases of renal failure (including acute renal failure), some with a fatal outcome, have been observed.",been observed is not a named entity
"(  5.4  )   *  Renal failure: Cases of renal failure (including acute renal failure), some with a fatal outcome, have been observed.",renal failure is an adverse reaction entity
"(  5.4  )   *  Renal failure: Cases of renal failure (including acute renal failure), some with a fatal outcome, have been observed.",failure ) is not a named entity
"(  5.4  )   *  Renal failure: Cases of renal failure (including acute renal failure), some with a fatal outcome, have been observed.",Cases of is not a named entity
"(  5.4  )   *  Renal failure: Cases of renal failure (including acute renal failure), some with a fatal outcome, have been observed.",Renal failure is an adverse reaction entity
"In a pooled analysis of randomized double-blind oncology clinical trials, the incidence of angioedema in patients taking everolimus with an ACE inhibitor was 6.8% compared to 1.3% in the control arm with an ACE inhibitor.",in the control is not a named entity
"In a pooled analysis of randomized double-blind oncology clinical trials, the incidence of angioedema in patients taking everolimus with an ACE inhibitor was 6.8% compared to 1.3% in the control arm with an ACE inhibitor.",angioedema is an adverse reaction entity
"Infections, stomatitis, and pneumonitis were the most common reasons for treatment delay or dose reduction.",stomatitis is an adverse reaction entity
"Infections, stomatitis, and pneumonitis were the most common reasons for treatment delay or dose reduction.",were the is not a named entity
"Infections, stomatitis, and pneumonitis were the most common reasons for treatment delay or dose reduction.",pneumonitis is an adverse reaction entity
"Infections, stomatitis, and pneumonitis were the most common reasons for treatment delay or dose reduction.",", and pneumonitis is not a named entity"
"Infections, stomatitis, and pneumonitis were the most common reasons for treatment delay or dose reduction.",Infections is an adverse reaction entity
"Infections, stomatitis, and pneumonitis were the most common reasons for treatment delay or dose reduction.",reasons is not a named entity
"Deaths due to acute respiratory failure (0.7%), infection (0.7%), and acute renal failure (0.4%) were observed on the AFINITOR arm but none on the placebo arm.",acute renal failure is an adverse reaction entity
"Deaths due to acute respiratory failure (0.7%), infection (0.7%), and acute renal failure (0.4%) were observed on the AFINITOR arm but none on the placebo arm.",observed on the is not a named entity
"Deaths due to acute respiratory failure (0.7%), infection (0.7%), and acute renal failure (0.4%) were observed on the AFINITOR arm but none on the placebo arm.",0.7 is not a named entity
"Deaths due to acute respiratory failure (0.7%), infection (0.7%), and acute renal failure (0.4%) were observed on the AFINITOR arm but none on the placebo arm.",infection is an adverse reaction entity
"Deaths due to acute respiratory failure (0.7%), infection (0.7%), and acute renal failure (0.4%) were observed on the AFINITOR arm but none on the placebo arm.",failure ( is not a named entity
"Deaths due to acute respiratory failure (0.7%), infection (0.7%), and acute renal failure (0.4%) were observed on the AFINITOR arm but none on the placebo arm.",arm but none is not a named entity
"Deaths due to acute respiratory failure (0.7%), infection (0.7%), and acute renal failure (0.4%) were observed on the AFINITOR arm but none on the placebo arm.",acute respiratory failure is an adverse reaction entity
"Deaths due to acute respiratory failure (0.7%), infection (0.7%), and acute renal failure (0.4%) were observed on the AFINITOR arm but none on the placebo arm.",Deaths is an adverse reaction entity
"The most common Grade 3/4 adverse reactions (incidence >= 2%) were stomatitis, infections, hyperglycemia, fatigue, dyspnea, pneumonitis, and diarrhea.",", dyspnea is not a named entity"
"The most common Grade 3/4 adverse reactions (incidence >= 2%) were stomatitis, infections, hyperglycemia, fatigue, dyspnea, pneumonitis, and diarrhea.",pneumonitis is an adverse reaction entity
"The most common Grade 3/4 adverse reactions (incidence >= 2%) were stomatitis, infections, hyperglycemia, fatigue, dyspnea, pneumonitis, and diarrhea.",diarrhea is an adverse reaction entity
"The most common Grade 3/4 adverse reactions (incidence >= 2%) were stomatitis, infections, hyperglycemia, fatigue, dyspnea, pneumonitis, and diarrhea.",The most is not a named entity
"The most common Grade 3/4 adverse reactions (incidence >= 2%) were stomatitis, infections, hyperglycemia, fatigue, dyspnea, pneumonitis, and diarrhea.",", pneumonitis , is not a named entity"
"The most common Grade 3/4 adverse reactions (incidence >= 2%) were stomatitis, infections, hyperglycemia, fatigue, dyspnea, pneumonitis, and diarrhea.",stomatitis is an adverse reaction entity
"The most common Grade 3/4 adverse reactions (incidence >= 2%) were stomatitis, infections, hyperglycemia, fatigue, dyspnea, pneumonitis, and diarrhea.",common Grade 3/4 is not a named entity
"The most common Grade 3/4 adverse reactions (incidence >= 2%) were stomatitis, infections, hyperglycemia, fatigue, dyspnea, pneumonitis, and diarrhea.",adverse reactions ( is not a named entity
"The most common Grade 3/4 adverse reactions (incidence >= 2%) were stomatitis, infections, hyperglycemia, fatigue, dyspnea, pneumonitis, and diarrhea.",most is not a named entity
"The most common Grade 3/4 adverse reactions (incidence >= 2%) were stomatitis, infections, hyperglycemia, fatigue, dyspnea, pneumonitis, and diarrhea.",", is not a named entity"
"The most common Grade 3/4 adverse reactions (incidence >= 2%) were stomatitis, infections, hyperglycemia, fatigue, dyspnea, pneumonitis, and diarrhea.",infections is an adverse reaction entity
"The most common Grade 3/4 adverse reactions (incidence >= 2%) were stomatitis, infections, hyperglycemia, fatigue, dyspnea, pneumonitis, and diarrhea.",fatigue is an adverse reaction entity
"The most common Grade 3/4 adverse reactions (incidence >= 2%) were stomatitis, infections, hyperglycemia, fatigue, dyspnea, pneumonitis, and diarrhea.",dyspnea is an adverse reaction entity
"The most common Grade 3/4 adverse reactions (incidence >= 2%) were stomatitis, infections, hyperglycemia, fatigue, dyspnea, pneumonitis, and diarrhea.",hyperglycemia is an adverse reaction entity
"Hematologic Parameters       Decreased hemoglobin, lymphocytes, neutrophils, and platelets have been reported in patients taking AFINITOR [see Adverse Reactions (6.1, 6.2, 6.3, 6.4, 6.5)]  .",Decreased neutrophils is an adverse reaction entity
"Hematologic Parameters       Decreased hemoglobin, lymphocytes, neutrophils, and platelets have been reported in patients taking AFINITOR [see Adverse Reactions (6.1, 6.2, 6.3, 6.4, 6.5)]  .","6.1 , is not a named entity"
"Hematologic Parameters       Decreased hemoglobin, lymphocytes, neutrophils, and platelets have been reported in patients taking AFINITOR [see Adverse Reactions (6.1, 6.2, 6.3, 6.4, 6.5)]  .",Hematologic Parameters is not a named entity
"Hematologic Parameters       Decreased hemoglobin, lymphocytes, neutrophils, and platelets have been reported in patients taking AFINITOR [see Adverse Reactions (6.1, 6.2, 6.3, 6.4, 6.5)]  .","neutrophils , is not a named entity"
"Hematologic Parameters       Decreased hemoglobin, lymphocytes, neutrophils, and platelets have been reported in patients taking AFINITOR [see Adverse Reactions (6.1, 6.2, 6.3, 6.4, 6.5)]  .",Decreased hemoglobin is an adverse reaction entity
"Hematologic Parameters       Decreased hemoglobin, lymphocytes, neutrophils, and platelets have been reported in patients taking AFINITOR [see Adverse Reactions (6.1, 6.2, 6.3, 6.4, 6.5)]  .",Decreased lymphocytes is an adverse reaction entity
"Hematologic Parameters       Decreased hemoglobin, lymphocytes, neutrophils, and platelets have been reported in patients taking AFINITOR [see Adverse Reactions (6.1, 6.2, 6.3, 6.4, 6.5)]  .",Decreased platelets is an adverse reaction entity
"Hematologic Parameters       Decreased hemoglobin, lymphocytes, neutrophils, and platelets have been reported in patients taking AFINITOR [see Adverse Reactions (6.1, 6.2, 6.3, 6.4, 6.5)]  .",Reactions is not a named entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate frequency or establish a causal relationship to drug exposure: acute pancreatitis, cholecystitis, cholelithiasis, arterial thrombotic events and reflex sympathetic dystrophy.",cholecystitis is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate frequency or establish a causal relationship to drug exposure: acute pancreatitis, cholecystitis, cholelithiasis, arterial thrombotic events and reflex sympathetic dystrophy.",acute pancreatitis is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate frequency or establish a causal relationship to drug exposure: acute pancreatitis, cholecystitis, cholelithiasis, arterial thrombotic events and reflex sympathetic dystrophy.",cholelithiasis is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate frequency or establish a causal relationship to drug exposure: acute pancreatitis, cholecystitis, cholelithiasis, arterial thrombotic events and reflex sympathetic dystrophy.",relationship to drug is not a named entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate frequency or establish a causal relationship to drug exposure: acute pancreatitis, cholecystitis, cholelithiasis, arterial thrombotic events and reflex sympathetic dystrophy.",it is not a named entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate frequency or establish a causal relationship to drug exposure: acute pancreatitis, cholecystitis, cholelithiasis, arterial thrombotic events and reflex sympathetic dystrophy.",of uncertain size is not a named entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate frequency or establish a causal relationship to drug exposure: acute pancreatitis, cholecystitis, cholelithiasis, arterial thrombotic events and reflex sympathetic dystrophy.",", arterial is not a named entity"
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate frequency or establish a causal relationship to drug exposure: acute pancreatitis, cholecystitis, cholelithiasis, arterial thrombotic events and reflex sympathetic dystrophy.",reflex sympathetic dystrophy is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate frequency or establish a causal relationship to drug exposure: acute pancreatitis, cholecystitis, cholelithiasis, arterial thrombotic events and reflex sympathetic dystrophy.",arterial thrombotic events is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate frequency or establish a causal relationship to drug exposure: acute pancreatitis, cholecystitis, cholelithiasis, arterial thrombotic events and reflex sympathetic dystrophy.",sympathetic dystrophy is not a named entity
Fatal adverse reactions occurred more frequently in patients who received AFINITOR plus exemestane (2%) compared to patients on the placebo plus exemestane arm (0.4%).,patients is not a named entity
Fatal adverse reactions occurred more frequently in patients who received AFINITOR plus exemestane (2%) compared to patients on the placebo plus exemestane arm (0.4%).,Fatal is an adverse reaction entity
"The most common Grade 3-4 laboratory abnormalities (incidence >= 3%) were hyperglycemia, lymphopenia, decreased hemoglobin, hypophosphatemia, increased alkaline phosphatase, neutropenia, increased aspartate transaminase (AST), potassium decreased, and thrombocytopenia.",most common Grade is not a named entity
"The most common Grade 3-4 laboratory abnormalities (incidence >= 3%) were hyperglycemia, lymphopenia, decreased hemoglobin, hypophosphatemia, increased alkaline phosphatase, neutropenia, increased aspartate transaminase (AST), potassium decreased, and thrombocytopenia.",increased AST is an adverse reaction entity
"The most common Grade 3-4 laboratory abnormalities (incidence >= 3%) were hyperglycemia, lymphopenia, decreased hemoglobin, hypophosphatemia, increased alkaline phosphatase, neutropenia, increased aspartate transaminase (AST), potassium decreased, and thrombocytopenia.",hypophosphatemia is an adverse reaction entity
"The most common Grade 3-4 laboratory abnormalities (incidence >= 3%) were hyperglycemia, lymphopenia, decreased hemoglobin, hypophosphatemia, increased alkaline phosphatase, neutropenia, increased aspartate transaminase (AST), potassium decreased, and thrombocytopenia.","lymphopenia , is not a named entity"
"The most common Grade 3-4 laboratory abnormalities (incidence >= 3%) were hyperglycemia, lymphopenia, decreased hemoglobin, hypophosphatemia, increased alkaline phosphatase, neutropenia, increased aspartate transaminase (AST), potassium decreased, and thrombocytopenia.","phosphatase , neutropenia is not a named entity"
"The most common Grade 3-4 laboratory abnormalities (incidence >= 3%) were hyperglycemia, lymphopenia, decreased hemoglobin, hypophosphatemia, increased alkaline phosphatase, neutropenia, increased aspartate transaminase (AST), potassium decreased, and thrombocytopenia.",", decreased hemoglobin is not a named entity"
"The most common Grade 3-4 laboratory abnormalities (incidence >= 3%) were hyperglycemia, lymphopenia, decreased hemoglobin, hypophosphatemia, increased alkaline phosphatase, neutropenia, increased aspartate transaminase (AST), potassium decreased, and thrombocytopenia.",decreased hemoglobin is an adverse reaction entity
"The most common Grade 3-4 laboratory abnormalities (incidence >= 3%) were hyperglycemia, lymphopenia, decreased hemoglobin, hypophosphatemia, increased alkaline phosphatase, neutropenia, increased aspartate transaminase (AST), potassium decreased, and thrombocytopenia.",potassium decreased is an adverse reaction entity
"The most common Grade 3-4 laboratory abnormalities (incidence >= 3%) were hyperglycemia, lymphopenia, decreased hemoglobin, hypophosphatemia, increased alkaline phosphatase, neutropenia, increased aspartate transaminase (AST), potassium decreased, and thrombocytopenia.","neutropenia , increased is not a named entity"
"The most common Grade 3-4 laboratory abnormalities (incidence >= 3%) were hyperglycemia, lymphopenia, decreased hemoglobin, hypophosphatemia, increased alkaline phosphatase, neutropenia, increased aspartate transaminase (AST), potassium decreased, and thrombocytopenia.",AST ) is not a named entity
"The most common Grade 3-4 laboratory abnormalities (incidence >= 3%) were hyperglycemia, lymphopenia, decreased hemoglobin, hypophosphatemia, increased alkaline phosphatase, neutropenia, increased aspartate transaminase (AST), potassium decreased, and thrombocytopenia.",Grade is not a named entity
"The most common Grade 3-4 laboratory abnormalities (incidence >= 3%) were hyperglycemia, lymphopenia, decreased hemoglobin, hypophosphatemia, increased alkaline phosphatase, neutropenia, increased aspartate transaminase (AST), potassium decreased, and thrombocytopenia.",neutropenia is an adverse reaction entity
"The most common Grade 3-4 laboratory abnormalities (incidence >= 3%) were hyperglycemia, lymphopenia, decreased hemoglobin, hypophosphatemia, increased alkaline phosphatase, neutropenia, increased aspartate transaminase (AST), potassium decreased, and thrombocytopenia.","decreased , is not a named entity"
"The most common Grade 3-4 laboratory abnormalities (incidence >= 3%) were hyperglycemia, lymphopenia, decreased hemoglobin, hypophosphatemia, increased alkaline phosphatase, neutropenia, increased aspartate transaminase (AST), potassium decreased, and thrombocytopenia.","decreased hemoglobin , is not a named entity"
"The most common Grade 3-4 laboratory abnormalities (incidence >= 3%) were hyperglycemia, lymphopenia, decreased hemoglobin, hypophosphatemia, increased alkaline phosphatase, neutropenia, increased aspartate transaminase (AST), potassium decreased, and thrombocytopenia.",thrombocytopenia is an adverse reaction entity
"The most common Grade 3-4 laboratory abnormalities (incidence >= 3%) were hyperglycemia, lymphopenia, decreased hemoglobin, hypophosphatemia, increased alkaline phosphatase, neutropenia, increased aspartate transaminase (AST), potassium decreased, and thrombocytopenia.",incidence is not a named entity
"The most common Grade 3-4 laboratory abnormalities (incidence >= 3%) were hyperglycemia, lymphopenia, decreased hemoglobin, hypophosphatemia, increased alkaline phosphatase, neutropenia, increased aspartate transaminase (AST), potassium decreased, and thrombocytopenia.",increased aspartate transaminase is an adverse reaction entity
"The most common Grade 3-4 laboratory abnormalities (incidence >= 3%) were hyperglycemia, lymphopenia, decreased hemoglobin, hypophosphatemia, increased alkaline phosphatase, neutropenia, increased aspartate transaminase (AST), potassium decreased, and thrombocytopenia.",lymphopenia is an adverse reaction entity
"The most common Grade 3-4 laboratory abnormalities (incidence >= 3%) were hyperglycemia, lymphopenia, decreased hemoglobin, hypophosphatemia, increased alkaline phosphatase, neutropenia, increased aspartate transaminase (AST), potassium decreased, and thrombocytopenia.",increased alkaline phosphatase is an adverse reaction entity
"The most common Grade 3-4 laboratory abnormalities (incidence >= 3%) were hyperglycemia, lymphopenia, decreased hemoglobin, hypophosphatemia, increased alkaline phosphatase, neutropenia, increased aspartate transaminase (AST), potassium decreased, and thrombocytopenia.",hyperglycemia is an adverse reaction entity
"The most common Grade 3/4 laboratory abnormalities (incidence >= 3%) were lymphopenia, hyperglycemia, anemia, decreased potassium, increased AST, increased ALT, and thrombocytopenia.",increased AST is an adverse reaction entity
"The most common Grade 3/4 laboratory abnormalities (incidence >= 3%) were lymphopenia, hyperglycemia, anemia, decreased potassium, increased AST, increased ALT, and thrombocytopenia.",common Grade is not a named entity
"The most common Grade 3/4 laboratory abnormalities (incidence >= 3%) were lymphopenia, hyperglycemia, anemia, decreased potassium, increased AST, increased ALT, and thrombocytopenia.",lymphopenia is an adverse reaction entity
"The most common Grade 3/4 laboratory abnormalities (incidence >= 3%) were lymphopenia, hyperglycemia, anemia, decreased potassium, increased AST, increased ALT, and thrombocytopenia.",most common is not a named entity
"The most common Grade 3/4 laboratory abnormalities (incidence >= 3%) were lymphopenia, hyperglycemia, anemia, decreased potassium, increased AST, increased ALT, and thrombocytopenia.","potassium , increased is not a named entity"
"The most common Grade 3/4 laboratory abnormalities (incidence >= 3%) were lymphopenia, hyperglycemia, anemia, decreased potassium, increased AST, increased ALT, and thrombocytopenia.",", anemia , is not a named entity"
"The most common Grade 3/4 laboratory abnormalities (incidence >= 3%) were lymphopenia, hyperglycemia, anemia, decreased potassium, increased AST, increased ALT, and thrombocytopenia.",anemia is an adverse reaction entity
"The most common Grade 3/4 laboratory abnormalities (incidence >= 3%) were lymphopenia, hyperglycemia, anemia, decreased potassium, increased AST, increased ALT, and thrombocytopenia.",were lymphopenia is not a named entity
"The most common Grade 3/4 laboratory abnormalities (incidence >= 3%) were lymphopenia, hyperglycemia, anemia, decreased potassium, increased AST, increased ALT, and thrombocytopenia.",thrombocytopenia is an adverse reaction entity
"The most common Grade 3/4 laboratory abnormalities (incidence >= 3%) were lymphopenia, hyperglycemia, anemia, decreased potassium, increased AST, increased ALT, and thrombocytopenia.",increased ALT is an adverse reaction entity
"The most common Grade 3/4 laboratory abnormalities (incidence >= 3%) were lymphopenia, hyperglycemia, anemia, decreased potassium, increased AST, increased ALT, and thrombocytopenia.",hyperglycemia is an adverse reaction entity
"The most common Grade 3/4 laboratory abnormalities (incidence >= 3%) were lymphopenia, hyperglycemia, anemia, decreased potassium, increased AST, increased ALT, and thrombocytopenia.",decreased potassium is an adverse reaction entity
"The most common Grade 3/4 laboratory abnormalities (incidence >= 3%) were lymphopenia, hyperglycemia, anemia, decreased potassium, increased AST, increased ALT, and thrombocytopenia.","were lymphopenia , is not a named entity"
"The most common Grade 3/4 laboratory abnormalities (incidence >= 3%) were lymphopenia, hyperglycemia, anemia, decreased potassium, increased AST, increased ALT, and thrombocytopenia.",( is not a named entity
The most common Grade 3-4 laboratory abnormality (incidence >= 3%) was neutropenia.,neutropenia is an adverse reaction entity
The most common Grade 3-4 laboratory abnormality (incidence >= 3%) was neutropenia.,laboratory abnormality is not a named entity
Grade 3-4 renal failure occurred in six patients in the everolimus arm and three patients in the placebo arm.,renal failure is an adverse reaction entity
Grade 3-4 renal failure occurred in six patients in the everolimus arm and three patients in the placebo arm.,the placebo arm is not a named entity
The most common Grade 3-4 adverse reactions (incidence >= 5%) were stomatitis and diarrhea.,stomatitis is an adverse reaction entity
The most common Grade 3-4 adverse reactions (incidence >= 5%) were stomatitis and diarrhea.,( incidence is not a named entity
The most common Grade 3-4 adverse reactions (incidence >= 5%) were stomatitis and diarrhea.,diarrhea is an adverse reaction entity
The most common Grade 3-4 adverse reactions (incidence >= 5%) were stomatitis and diarrhea.,stomatitis and diarrhea is not a named entity
5.10     Hepatic Impairment      Exposure to everolimus was increased in patients with hepatic impairment  [see Clinical Pharmacology (12.3)]  .,impairment [ is not a named entity
5.10     Hepatic Impairment      Exposure to everolimus was increased in patients with hepatic impairment  [see Clinical Pharmacology (12.3)]  .,hepatic impairment is an adverse reaction entity
"For this same group of AFINITOR-treated females, the following menstrual abnormalities were reported: dysmenorrhea (6%), menorrhagia (6%), metrorrhagia (6%), and unspecified menstrual irregularity (6%).",same group is not a named entity
"For this same group of AFINITOR-treated females, the following menstrual abnormalities were reported: dysmenorrhea (6%), menorrhagia (6%), metrorrhagia (6%), and unspecified menstrual irregularity (6%).",following menstrual abnormalities is not a named entity
"For this same group of AFINITOR-treated females, the following menstrual abnormalities were reported: dysmenorrhea (6%), menorrhagia (6%), metrorrhagia (6%), and unspecified menstrual irregularity (6%).",menstrual abnormalities is an adverse reaction entity
"For this same group of AFINITOR-treated females, the following menstrual abnormalities were reported: dysmenorrhea (6%), menorrhagia (6%), metrorrhagia (6%), and unspecified menstrual irregularity (6%).",", the is not a named entity"
"For this same group of AFINITOR-treated females, the following menstrual abnormalities were reported: dysmenorrhea (6%), menorrhagia (6%), metrorrhagia (6%), and unspecified menstrual irregularity (6%).",dysmenorrhea is an adverse reaction entity
"For this same group of AFINITOR-treated females, the following menstrual abnormalities were reported: dysmenorrhea (6%), menorrhagia (6%), metrorrhagia (6%), and unspecified menstrual irregularity (6%).",metrorrhagia is an adverse reaction entity
"For this same group of AFINITOR-treated females, the following menstrual abnormalities were reported: dysmenorrhea (6%), menorrhagia (6%), metrorrhagia (6%), and unspecified menstrual irregularity (6%).",menorrhagia is an adverse reaction entity
"For this same group of AFINITOR-treated females, the following menstrual abnormalities were reported: dysmenorrhea (6%), menorrhagia (6%), metrorrhagia (6%), and unspecified menstrual irregularity (6%).",", the is not a named entity"
"For this same group of AFINITOR-treated females, the following menstrual abnormalities were reported: dysmenorrhea (6%), menorrhagia (6%), metrorrhagia (6%), and unspecified menstrual irregularity (6%).",females is not a named entity
"For this same group of AFINITOR-treated females, the following menstrual abnormalities were reported: dysmenorrhea (6%), menorrhagia (6%), metrorrhagia (6%), and unspecified menstrual irregularity (6%).",unspecified menstrual irregularity is an adverse reaction entity
Deaths during double-blind treatment where an adverse event was the primary cause occurred in seven patients on AFINITOR and one patient on placebo.,Deaths is an adverse reaction entity
Deaths during double-blind treatment where an adverse event was the primary cause occurred in seven patients on AFINITOR and one patient on placebo.,primary cause occurred is not a named entity
"The most common Grade 3-4 adverse reactions (incidence >= 3%) were infections, dyspnea, fatigue, stomatitis, dehydration, pneumonitis, abdominal pain, and asthenia.",pneumonitis is an adverse reaction entity
"The most common Grade 3-4 adverse reactions (incidence >= 3%) were infections, dyspnea, fatigue, stomatitis, dehydration, pneumonitis, abdominal pain, and asthenia.",abdominal pain is an adverse reaction entity
"The most common Grade 3-4 adverse reactions (incidence >= 3%) were infections, dyspnea, fatigue, stomatitis, dehydration, pneumonitis, abdominal pain, and asthenia.",dyspnea is an adverse reaction entity
"The most common Grade 3-4 adverse reactions (incidence >= 3%) were infections, dyspnea, fatigue, stomatitis, dehydration, pneumonitis, abdominal pain, and asthenia.",stomatitis is an adverse reaction entity
"The most common Grade 3-4 adverse reactions (incidence >= 3%) were infections, dyspnea, fatigue, stomatitis, dehydration, pneumonitis, abdominal pain, and asthenia.",) were infections is not a named entity
"The most common Grade 3-4 adverse reactions (incidence >= 3%) were infections, dyspnea, fatigue, stomatitis, dehydration, pneumonitis, abdominal pain, and asthenia.","stomatitis , dehydration is not a named entity"
"The most common Grade 3-4 adverse reactions (incidence >= 3%) were infections, dyspnea, fatigue, stomatitis, dehydration, pneumonitis, abdominal pain, and asthenia.",common Grade 3-4 is not a named entity
"The most common Grade 3-4 adverse reactions (incidence >= 3%) were infections, dyspnea, fatigue, stomatitis, dehydration, pneumonitis, abdominal pain, and asthenia.","pain , and is not a named entity"
"The most common Grade 3-4 adverse reactions (incidence >= 3%) were infections, dyspnea, fatigue, stomatitis, dehydration, pneumonitis, abdominal pain, and asthenia.",infections is an adverse reaction entity
"The most common Grade 3-4 adverse reactions (incidence >= 3%) were infections, dyspnea, fatigue, stomatitis, dehydration, pneumonitis, abdominal pain, and asthenia.",fatigue is an adverse reaction entity
"The most common Grade 3-4 adverse reactions (incidence >= 3%) were infections, dyspnea, fatigue, stomatitis, dehydration, pneumonitis, abdominal pain, and asthenia.",", is not a named entity"
"The most common Grade 3-4 adverse reactions (incidence >= 3%) were infections, dyspnea, fatigue, stomatitis, dehydration, pneumonitis, abdominal pain, and asthenia.",incidence > is not a named entity
"The most common Grade 3-4 adverse reactions (incidence >= 3%) were infections, dyspnea, fatigue, stomatitis, dehydration, pneumonitis, abdominal pain, and asthenia.",dehydration is an adverse reaction entity
"The most common Grade 3-4 adverse reactions (incidence >= 3%) were infections, dyspnea, fatigue, stomatitis, dehydration, pneumonitis, abdominal pain, and asthenia.",asthenia is an adverse reaction entity
"The most common Grade 3-4 adverse reactions (incidence >= 3%) were infections, dyspnea, fatigue, stomatitis, dehydration, pneumonitis, abdominal pain, and asthenia.",% ) is not a named entity
"The most common Grade 3-4 adverse reactions (incidence >= 3%) were infections, dyspnea, fatigue, stomatitis, dehydration, pneumonitis, abdominal pain, and asthenia.",incidence > is not a named entity
"The most common laboratory abnormalities (incidence >= 50%) were hypercholesterolemia, hyperglycemia, increased aspartate transaminase (AST), anemia, leukopenia, thrombocytopenia, lymphopenia, increased alanine transaminase (ALT), and hypertriglyceridemia.",increased ALT is an adverse reaction entity
"The most common laboratory abnormalities (incidence >= 50%) were hypercholesterolemia, hyperglycemia, increased aspartate transaminase (AST), anemia, leukopenia, thrombocytopenia, lymphopenia, increased alanine transaminase (ALT), and hypertriglyceridemia.",transaminase ( is not a named entity
"The most common laboratory abnormalities (incidence >= 50%) were hypercholesterolemia, hyperglycemia, increased aspartate transaminase (AST), anemia, leukopenia, thrombocytopenia, lymphopenia, increased alanine transaminase (ALT), and hypertriglyceridemia.","lymphopenia , is not a named entity"
"The most common laboratory abnormalities (incidence >= 50%) were hypercholesterolemia, hyperglycemia, increased aspartate transaminase (AST), anemia, leukopenia, thrombocytopenia, lymphopenia, increased alanine transaminase (ALT), and hypertriglyceridemia.",laboratory abnormalities is not a named entity
"The most common laboratory abnormalities (incidence >= 50%) were hypercholesterolemia, hyperglycemia, increased aspartate transaminase (AST), anemia, leukopenia, thrombocytopenia, lymphopenia, increased alanine transaminase (ALT), and hypertriglyceridemia.",hypercholesterolemia is an adverse reaction entity
"The most common laboratory abnormalities (incidence >= 50%) were hypercholesterolemia, hyperglycemia, increased aspartate transaminase (AST), anemia, leukopenia, thrombocytopenia, lymphopenia, increased alanine transaminase (ALT), and hypertriglyceridemia.",aspartate transaminase ( is not a named entity
"The most common laboratory abnormalities (incidence >= 50%) were hypercholesterolemia, hyperglycemia, increased aspartate transaminase (AST), anemia, leukopenia, thrombocytopenia, lymphopenia, increased alanine transaminase (ALT), and hypertriglyceridemia.",hypertriglyceridemia is an adverse reaction entity
"The most common laboratory abnormalities (incidence >= 50%) were hypercholesterolemia, hyperglycemia, increased aspartate transaminase (AST), anemia, leukopenia, thrombocytopenia, lymphopenia, increased alanine transaminase (ALT), and hypertriglyceridemia.",", hyperglycemia , is not a named entity"
"The most common laboratory abnormalities (incidence >= 50%) were hypercholesterolemia, hyperglycemia, increased aspartate transaminase (AST), anemia, leukopenia, thrombocytopenia, lymphopenia, increased alanine transaminase (ALT), and hypertriglyceridemia.",increased alanine transaminase is an adverse reaction entity
"The most common laboratory abnormalities (incidence >= 50%) were hypercholesterolemia, hyperglycemia, increased aspartate transaminase (AST), anemia, leukopenia, thrombocytopenia, lymphopenia, increased alanine transaminase (ALT), and hypertriglyceridemia.","lymphopenia , is not a named entity"
"The most common laboratory abnormalities (incidence >= 50%) were hypercholesterolemia, hyperglycemia, increased aspartate transaminase (AST), anemia, leukopenia, thrombocytopenia, lymphopenia, increased alanine transaminase (ALT), and hypertriglyceridemia.",leukopenia is an adverse reaction entity
"The most common laboratory abnormalities (incidence >= 50%) were hypercholesterolemia, hyperglycemia, increased aspartate transaminase (AST), anemia, leukopenia, thrombocytopenia, lymphopenia, increased alanine transaminase (ALT), and hypertriglyceridemia.",The most common is not a named entity
"The most common laboratory abnormalities (incidence >= 50%) were hypercholesterolemia, hyperglycemia, increased aspartate transaminase (AST), anemia, leukopenia, thrombocytopenia, lymphopenia, increased alanine transaminase (ALT), and hypertriglyceridemia.",alanine transaminase is not a named entity
"The most common laboratory abnormalities (incidence >= 50%) were hypercholesterolemia, hyperglycemia, increased aspartate transaminase (AST), anemia, leukopenia, thrombocytopenia, lymphopenia, increased alanine transaminase (ALT), and hypertriglyceridemia.",increased aspartate transaminase is an adverse reaction entity
"The most common laboratory abnormalities (incidence >= 50%) were hypercholesterolemia, hyperglycemia, increased aspartate transaminase (AST), anemia, leukopenia, thrombocytopenia, lymphopenia, increased alanine transaminase (ALT), and hypertriglyceridemia.",were hypercholesterolemia is not a named entity
"The most common laboratory abnormalities (incidence >= 50%) were hypercholesterolemia, hyperglycemia, increased aspartate transaminase (AST), anemia, leukopenia, thrombocytopenia, lymphopenia, increased alanine transaminase (ALT), and hypertriglyceridemia.",hyperglycemia is an adverse reaction entity
"The most common laboratory abnormalities (incidence >= 50%) were hypercholesterolemia, hyperglycemia, increased aspartate transaminase (AST), anemia, leukopenia, thrombocytopenia, lymphopenia, increased alanine transaminase (ALT), and hypertriglyceridemia.",common laboratory is not a named entity
"The most common laboratory abnormalities (incidence >= 50%) were hypercholesterolemia, hyperglycemia, increased aspartate transaminase (AST), anemia, leukopenia, thrombocytopenia, lymphopenia, increased alanine transaminase (ALT), and hypertriglyceridemia.",anemia is an adverse reaction entity
"The most common laboratory abnormalities (incidence >= 50%) were hypercholesterolemia, hyperglycemia, increased aspartate transaminase (AST), anemia, leukopenia, thrombocytopenia, lymphopenia, increased alanine transaminase (ALT), and hypertriglyceridemia.",thrombocytopenia is an adverse reaction entity
"The most common laboratory abnormalities (incidence >= 50%) were hypercholesterolemia, hyperglycemia, increased aspartate transaminase (AST), anemia, leukopenia, thrombocytopenia, lymphopenia, increased alanine transaminase (ALT), and hypertriglyceridemia.",lymphopenia is an adverse reaction entity
"The most common laboratory abnormalities (incidence >= 50%) were hypercholesterolemia, hyperglycemia, increased aspartate transaminase (AST), anemia, leukopenia, thrombocytopenia, lymphopenia, increased alanine transaminase (ALT), and hypertriglyceridemia.",increased AST is an adverse reaction entity
"The most common laboratory abnormalities (incidence >= 50%) were hypercholesterolemia, hyperglycemia, increased aspartate transaminase (AST), anemia, leukopenia, thrombocytopenia, lymphopenia, increased alanine transaminase (ALT), and hypertriglyceridemia.",( incidence is not a named entity
Non-infectious pneumonitis was reported in up to 19% of patients treated with AFINITOR in clinical trials.,AFINITOR in clinical is not a named entity
Non-infectious pneumonitis was reported in up to 19% of patients treated with AFINITOR in clinical trials.,Non-infectious pneumonitis is an adverse reaction entity
"5.6     Impaired Wound Healing      Everolimus delays wound healing and increases the occurrence of wound-related complications like wound dehiscence, wound infection, incisional hernia, lymphocele, and seroma.",wound infection is an adverse reaction entity
"5.6     Impaired Wound Healing      Everolimus delays wound healing and increases the occurrence of wound-related complications like wound dehiscence, wound infection, incisional hernia, lymphocele, and seroma.",", wound infection is not a named entity"
"5.6     Impaired Wound Healing      Everolimus delays wound healing and increases the occurrence of wound-related complications like wound dehiscence, wound infection, incisional hernia, lymphocele, and seroma.",lymphocele is an adverse reaction entity
"5.6     Impaired Wound Healing      Everolimus delays wound healing and increases the occurrence of wound-related complications like wound dehiscence, wound infection, incisional hernia, lymphocele, and seroma.",seroma is an adverse reaction entity
"5.6     Impaired Wound Healing      Everolimus delays wound healing and increases the occurrence of wound-related complications like wound dehiscence, wound infection, incisional hernia, lymphocele, and seroma.",increases the is not a named entity
"5.6     Impaired Wound Healing      Everolimus delays wound healing and increases the occurrence of wound-related complications like wound dehiscence, wound infection, incisional hernia, lymphocele, and seroma.",Everolimus delays is not a named entity
"5.6     Impaired Wound Healing      Everolimus delays wound healing and increases the occurrence of wound-related complications like wound dehiscence, wound infection, incisional hernia, lymphocele, and seroma.","lymphocele , is not a named entity"
"5.6     Impaired Wound Healing      Everolimus delays wound healing and increases the occurrence of wound-related complications like wound dehiscence, wound infection, incisional hernia, lymphocele, and seroma.",wound-related complications like is not a named entity
"5.6     Impaired Wound Healing      Everolimus delays wound healing and increases the occurrence of wound-related complications like wound dehiscence, wound infection, incisional hernia, lymphocele, and seroma.",incisional hernia is an adverse reaction entity
"5.6     Impaired Wound Healing      Everolimus delays wound healing and increases the occurrence of wound-related complications like wound dehiscence, wound infection, incisional hernia, lymphocele, and seroma.",delays wound healing is an adverse reaction entity
"5.6     Impaired Wound Healing      Everolimus delays wound healing and increases the occurrence of wound-related complications like wound dehiscence, wound infection, incisional hernia, lymphocele, and seroma.",wound-related complications is an adverse reaction entity
"5.6     Impaired Wound Healing      Everolimus delays wound healing and increases the occurrence of wound-related complications like wound dehiscence, wound infection, incisional hernia, lymphocele, and seroma.",wound healing is not a named entity
"5.6     Impaired Wound Healing      Everolimus delays wound healing and increases the occurrence of wound-related complications like wound dehiscence, wound infection, incisional hernia, lymphocele, and seroma.",", is not a named entity"
"5.6     Impaired Wound Healing      Everolimus delays wound healing and increases the occurrence of wound-related complications like wound dehiscence, wound infection, incisional hernia, lymphocele, and seroma.",wound dehiscence is an adverse reaction entity
"RE-ALIGN was terminated early due to the occurrence of significantly more thromboembolic events (valve thrombosis, stroke, transient ischemic attack, and myocardial infarction) and an excess of major bleeding (predominantly post-operative pericardial effusions requiring intervention for hemodynamic compromise) in the PRADAXA treatment arm as compared to the warfarin treatment arm.",and an excess is not a named entity
"RE-ALIGN was terminated early due to the occurrence of significantly more thromboembolic events (valve thrombosis, stroke, transient ischemic attack, and myocardial infarction) and an excess of major bleeding (predominantly post-operative pericardial effusions requiring intervention for hemodynamic compromise) in the PRADAXA treatment arm as compared to the warfarin treatment arm.",myocardial infarction is an adverse reaction entity
"RE-ALIGN was terminated early due to the occurrence of significantly more thromboembolic events (valve thrombosis, stroke, transient ischemic attack, and myocardial infarction) and an excess of major bleeding (predominantly post-operative pericardial effusions requiring intervention for hemodynamic compromise) in the PRADAXA treatment arm as compared to the warfarin treatment arm.",) in the is not a named entity
"RE-ALIGN was terminated early due to the occurrence of significantly more thromboembolic events (valve thrombosis, stroke, transient ischemic attack, and myocardial infarction) and an excess of major bleeding (predominantly post-operative pericardial effusions requiring intervention for hemodynamic compromise) in the PRADAXA treatment arm as compared to the warfarin treatment arm.",infarction ) is not a named entity
"RE-ALIGN was terminated early due to the occurrence of significantly more thromboembolic events (valve thrombosis, stroke, transient ischemic attack, and myocardial infarction) and an excess of major bleeding (predominantly post-operative pericardial effusions requiring intervention for hemodynamic compromise) in the PRADAXA treatment arm as compared to the warfarin treatment arm.",pericardial effusions is an adverse reaction entity
"RE-ALIGN was terminated early due to the occurrence of significantly more thromboembolic events (valve thrombosis, stroke, transient ischemic attack, and myocardial infarction) and an excess of major bleeding (predominantly post-operative pericardial effusions requiring intervention for hemodynamic compromise) in the PRADAXA treatment arm as compared to the warfarin treatment arm.",transient ischemic attack is an adverse reaction entity
"RE-ALIGN was terminated early due to the occurrence of significantly more thromboembolic events (valve thrombosis, stroke, transient ischemic attack, and myocardial infarction) and an excess of major bleeding (predominantly post-operative pericardial effusions requiring intervention for hemodynamic compromise) in the PRADAXA treatment arm as compared to the warfarin treatment arm.",thromboembolic events is an adverse reaction entity
"RE-ALIGN was terminated early due to the occurrence of significantly more thromboembolic events (valve thrombosis, stroke, transient ischemic attack, and myocardial infarction) and an excess of major bleeding (predominantly post-operative pericardial effusions requiring intervention for hemodynamic compromise) in the PRADAXA treatment arm as compared to the warfarin treatment arm.",bleeding is an adverse reaction entity
"RE-ALIGN was terminated early due to the occurrence of significantly more thromboembolic events (valve thrombosis, stroke, transient ischemic attack, and myocardial infarction) and an excess of major bleeding (predominantly post-operative pericardial effusions requiring intervention for hemodynamic compromise) in the PRADAXA treatment arm as compared to the warfarin treatment arm.",thromboembolic stroke is an adverse reaction entity
"RE-ALIGN was terminated early due to the occurrence of significantly more thromboembolic events (valve thrombosis, stroke, transient ischemic attack, and myocardial infarction) and an excess of major bleeding (predominantly post-operative pericardial effusions requiring intervention for hemodynamic compromise) in the PRADAXA treatment arm as compared to the warfarin treatment arm.",bleeding ( predominantly is not a named entity
"RE-ALIGN was terminated early due to the occurrence of significantly more thromboembolic events (valve thrombosis, stroke, transient ischemic attack, and myocardial infarction) and an excess of major bleeding (predominantly post-operative pericardial effusions requiring intervention for hemodynamic compromise) in the PRADAXA treatment arm as compared to the warfarin treatment arm.",excess of major is not a named entity
"RE-ALIGN was terminated early due to the occurrence of significantly more thromboembolic events (valve thrombosis, stroke, transient ischemic attack, and myocardial infarction) and an excess of major bleeding (predominantly post-operative pericardial effusions requiring intervention for hemodynamic compromise) in the PRADAXA treatment arm as compared to the warfarin treatment arm.",compromise is not a named entity
"Hypersensitivity Reactions           In the RE-LY study, drug hypersensitivity (including urticaria, rash, and pruritus), allergic edema, anaphylactic reaction, and anaphylactic shock were reported in <0.1% of patients receiving PRADAXA.",hypersensitivity is an adverse reaction entity
"Hypersensitivity Reactions           In the RE-LY study, drug hypersensitivity (including urticaria, rash, and pruritus), allergic edema, anaphylactic reaction, and anaphylactic shock were reported in <0.1% of patients receiving PRADAXA.",and anaphylactic is not a named entity
"Hypersensitivity Reactions           In the RE-LY study, drug hypersensitivity (including urticaria, rash, and pruritus), allergic edema, anaphylactic reaction, and anaphylactic shock were reported in <0.1% of patients receiving PRADAXA.",( is not a named entity
"Hypersensitivity Reactions           In the RE-LY study, drug hypersensitivity (including urticaria, rash, and pruritus), allergic edema, anaphylactic reaction, and anaphylactic shock were reported in <0.1% of patients receiving PRADAXA.",anaphylactic reaction is an adverse reaction entity
"Hypersensitivity Reactions           In the RE-LY study, drug hypersensitivity (including urticaria, rash, and pruritus), allergic edema, anaphylactic reaction, and anaphylactic shock were reported in <0.1% of patients receiving PRADAXA.",urticaria is an adverse reaction entity
"Hypersensitivity Reactions           In the RE-LY study, drug hypersensitivity (including urticaria, rash, and pruritus), allergic edema, anaphylactic reaction, and anaphylactic shock were reported in <0.1% of patients receiving PRADAXA.",rash is an adverse reaction entity
"Hypersensitivity Reactions           In the RE-LY study, drug hypersensitivity (including urticaria, rash, and pruritus), allergic edema, anaphylactic reaction, and anaphylactic shock were reported in <0.1% of patients receiving PRADAXA.",hypersensitivity ( is not a named entity
"Hypersensitivity Reactions           In the RE-LY study, drug hypersensitivity (including urticaria, rash, and pruritus), allergic edema, anaphylactic reaction, and anaphylactic shock were reported in <0.1% of patients receiving PRADAXA.","pruritus ) , is not a named entity"
"Hypersensitivity Reactions           In the RE-LY study, drug hypersensitivity (including urticaria, rash, and pruritus), allergic edema, anaphylactic reaction, and anaphylactic shock were reported in <0.1% of patients receiving PRADAXA.",shock is not a named entity
"Hypersensitivity Reactions           In the RE-LY study, drug hypersensitivity (including urticaria, rash, and pruritus), allergic edema, anaphylactic reaction, and anaphylactic shock were reported in <0.1% of patients receiving PRADAXA.",pruritus is an adverse reaction entity
"Hypersensitivity Reactions           In the RE-LY study, drug hypersensitivity (including urticaria, rash, and pruritus), allergic edema, anaphylactic reaction, and anaphylactic shock were reported in <0.1% of patients receiving PRADAXA.",") , is not a named entity"
"Hypersensitivity Reactions           In the RE-LY study, drug hypersensitivity (including urticaria, rash, and pruritus), allergic edema, anaphylactic reaction, and anaphylactic shock were reported in <0.1% of patients receiving PRADAXA.",anaphylactic shock is an adverse reaction entity
"Hypersensitivity Reactions           In the RE-LY study, drug hypersensitivity (including urticaria, rash, and pruritus), allergic edema, anaphylactic reaction, and anaphylactic shock were reported in <0.1% of patients receiving PRADAXA.",drug hypersensitivity is not a named entity
"Hypersensitivity Reactions           In the RE-LY study, drug hypersensitivity (including urticaria, rash, and pruritus), allergic edema, anaphylactic reaction, and anaphylactic shock were reported in <0.1% of patients receiving PRADAXA.",allergic edema is an adverse reaction entity
"BOXED WARNING: WARNING: (A) PREMATURE DISCONTINUATION OF PRADAXA INCREASES THE RISK  OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA    WARNING: (A) PREMATURE DISCONTINUATION OF PRADAXA INCREASES THE RISK  OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA      (A) PREMATURE DISCONTINUATION  OF PRADAXA INCREASES THE RISK OF THROMBOTIC EVENTSPremature  discontinuation of any oral anticoagulant, including PRADAXA, increases  the risk of thrombotic events.",BOXED is not a named entity
"BOXED WARNING: WARNING: (A) PREMATURE DISCONTINUATION OF PRADAXA INCREASES THE RISK  OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA    WARNING: (A) PREMATURE DISCONTINUATION OF PRADAXA INCREASES THE RISK  OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA      (A) PREMATURE DISCONTINUATION  OF PRADAXA INCREASES THE RISK OF THROMBOTIC EVENTSPremature  discontinuation of any oral anticoagulant, including PRADAXA, increases  the risk of thrombotic events.",SPINAL HEMATOMA is an adverse reaction entity
"BOXED WARNING: WARNING: (A) PREMATURE DISCONTINUATION OF PRADAXA INCREASES THE RISK  OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA    WARNING: (A) PREMATURE DISCONTINUATION OF PRADAXA INCREASES THE RISK  OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA      (A) PREMATURE DISCONTINUATION  OF PRADAXA INCREASES THE RISK OF THROMBOTIC EVENTSPremature  discontinuation of any oral anticoagulant, including PRADAXA, increases  the risk of thrombotic events.",PREMATURE DISCONTINUATION OF is not a named entity
"BOXED WARNING: WARNING: (A) PREMATURE DISCONTINUATION OF PRADAXA INCREASES THE RISK  OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA    WARNING: (A) PREMATURE DISCONTINUATION OF PRADAXA INCREASES THE RISK  OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA      (A) PREMATURE DISCONTINUATION  OF PRADAXA INCREASES THE RISK OF THROMBOTIC EVENTSPremature  discontinuation of any oral anticoagulant, including PRADAXA, increases  the risk of thrombotic events.",) PREMATURE is not a named entity
"BOXED WARNING: WARNING: (A) PREMATURE DISCONTINUATION OF PRADAXA INCREASES THE RISK  OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA    WARNING: (A) PREMATURE DISCONTINUATION OF PRADAXA INCREASES THE RISK  OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA      (A) PREMATURE DISCONTINUATION  OF PRADAXA INCREASES THE RISK OF THROMBOTIC EVENTSPremature  discontinuation of any oral anticoagulant, including PRADAXA, increases  the risk of thrombotic events.",EPIDURAL HEMATOMA is an adverse reaction entity
"BOXED WARNING: WARNING: (A) PREMATURE DISCONTINUATION OF PRADAXA INCREASES THE RISK  OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA    WARNING: (A) PREMATURE DISCONTINUATION OF PRADAXA INCREASES THE RISK  OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA      (A) PREMATURE DISCONTINUATION  OF PRADAXA INCREASES THE RISK OF THROMBOTIC EVENTSPremature  discontinuation of any oral anticoagulant, including PRADAXA, increases  the risk of thrombotic events.",EPIDURAL HEMATOMA is an adverse reaction entity
"BOXED WARNING: WARNING: (A) PREMATURE DISCONTINUATION OF PRADAXA INCREASES THE RISK  OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA    WARNING: (A) PREMATURE DISCONTINUATION OF PRADAXA INCREASES THE RISK  OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA      (A) PREMATURE DISCONTINUATION  OF PRADAXA INCREASES THE RISK OF THROMBOTIC EVENTSPremature  discontinuation of any oral anticoagulant, including PRADAXA, increases  the risk of thrombotic events.",PRADAXA is not a named entity
"BOXED WARNING: WARNING: (A) PREMATURE DISCONTINUATION OF PRADAXA INCREASES THE RISK  OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA    WARNING: (A) PREMATURE DISCONTINUATION OF PRADAXA INCREASES THE RISK  OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA      (A) PREMATURE DISCONTINUATION  OF PRADAXA INCREASES THE RISK OF THROMBOTIC EVENTSPremature  discontinuation of any oral anticoagulant, including PRADAXA, increases  the risk of thrombotic events.",SPINAL HEMATOMA is an adverse reaction entity
"Major bleeding is defined as bleeding accompanied by one or more of the following: a decrease in hemoglobin of >=2 g/dL, a transfusion of >=2 units of packed red blood cells, bleeding at a critical site or with a fatal outcome.",one or more is not a named entity
"Major bleeding is defined as bleeding accompanied by one or more of the following: a decrease in hemoglobin of >=2 g/dL, a transfusion of >=2 units of packed red blood cells, bleeding at a critical site or with a fatal outcome.",bleeding is an adverse reaction entity
"Major bleeding is defined as bleeding accompanied by one or more of the following: a decrease in hemoglobin of >=2 g/dL, a transfusion of >=2 units of packed red blood cells, bleeding at a critical site or with a fatal outcome.",bleeding is an adverse reaction entity
"Major bleeding is defined as bleeding accompanied by one or more of the following: a decrease in hemoglobin of >=2 g/dL, a transfusion of >=2 units of packed red blood cells, bleeding at a critical site or with a fatal outcome.",fatal is an adverse reaction entity
"Major bleeding is defined as bleeding accompanied by one or more of the following: a decrease in hemoglobin of >=2 g/dL, a transfusion of >=2 units of packed red blood cells, bleeding at a critical site or with a fatal outcome.",in hemoglobin is not a named entity
"Major bleeding is defined as bleeding accompanied by one or more of the following: a decrease in hemoglobin of >=2 g/dL, a transfusion of >=2 units of packed red blood cells, bleeding at a critical site or with a fatal outcome.",a is not a named entity
"Major bleeding is defined as bleeding accompanied by one or more of the following: a decrease in hemoglobin of >=2 g/dL, a transfusion of >=2 units of packed red blood cells, bleeding at a critical site or with a fatal outcome.",bleeding at a critical site is an adverse reaction entity
"Major bleeding is defined as bleeding accompanied by one or more of the following: a decrease in hemoglobin of >=2 g/dL, a transfusion of >=2 units of packed red blood cells, bleeding at a critical site or with a fatal outcome.",decrease in hemoglobin is an adverse reaction entity
"Major bleeding is defined as bleeding accompanied by one or more of the following: a decrease in hemoglobin of >=2 g/dL, a transfusion of >=2 units of packed red blood cells, bleeding at a critical site or with a fatal outcome.",one is not a named entity
"Major bleeding is defined as bleeding accompanied by one or more of the following: a decrease in hemoglobin of >=2 g/dL, a transfusion of >=2 units of packed red blood cells, bleeding at a critical site or with a fatal outcome.",one or is not a named entity
"The following adverse reactions have been identified during post approval use of PRADAXA: angioedema, thrombocytopenia, esophageal ulcer.",angioedema is an adverse reaction entity
"The following adverse reactions have been identified during post approval use of PRADAXA: angioedema, thrombocytopenia, esophageal ulcer.",thrombocytopenia is an adverse reaction entity
"The following adverse reactions have been identified during post approval use of PRADAXA: angioedema, thrombocytopenia, esophageal ulcer.",esophageal ulcer is an adverse reaction entity
"The following adverse reactions have been identified during post approval use of PRADAXA: angioedema, thrombocytopenia, esophageal ulcer.",during is not a named entity
"The following adverse reactions have been identified during post approval use of PRADAXA: angioedema, thrombocytopenia, esophageal ulcer.",following adverse is not a named entity
"The following adverse reactions have been identified during post approval use of PRADAXA: angioedema, thrombocytopenia, esophageal ulcer.",adverse reactions have is not a named entity
(B) SPINAL/EPIDURAL HEMATOMA: Epidural or spinal hematomas  may occur in patients treated with PRADAXA who are receiving neuraxial  anesthesia or undergoing spinal puncture.,occur in is not a named entity
(B) SPINAL/EPIDURAL HEMATOMA: Epidural or spinal hematomas  may occur in patients treated with PRADAXA who are receiving neuraxial  anesthesia or undergoing spinal puncture.,spinal hematomas is an adverse reaction entity
(B) SPINAL/EPIDURAL HEMATOMA: Epidural or spinal hematomas  may occur in patients treated with PRADAXA who are receiving neuraxial  anesthesia or undergoing spinal puncture.,Epidural hematomas is an adverse reaction entity
(B) SPINAL/EPIDURAL HEMATOMA: Epidural or spinal hematomas  may occur in patients treated with PRADAXA who are receiving neuraxial  anesthesia or undergoing spinal puncture.,in patients is not a named entity
"Intracranial hemorrhage included intracerebral (hemorrhagic stroke), subarachnoid, and subdural bleeds.",included intracerebral ( is not a named entity
"Intracranial hemorrhage included intracerebral (hemorrhagic stroke), subarachnoid, and subdural bleeds.",intracerebral bleeds is an adverse reaction entity
"Intracranial hemorrhage included intracerebral (hemorrhagic stroke), subarachnoid, and subdural bleeds.",and is not a named entity
"Intracranial hemorrhage included intracerebral (hemorrhagic stroke), subarachnoid, and subdural bleeds.",") , subarachnoid is not a named entity"
"Intracranial hemorrhage included intracerebral (hemorrhagic stroke), subarachnoid, and subdural bleeds.",subdural bleeds is an adverse reaction entity
"Intracranial hemorrhage included intracerebral (hemorrhagic stroke), subarachnoid, and subdural bleeds.",subarachnoid bleeds is an adverse reaction entity
"Intracranial hemorrhage included intracerebral (hemorrhagic stroke), subarachnoid, and subdural bleeds.",", subarachnoid , is not a named entity"
"Intracranial hemorrhage included intracerebral (hemorrhagic stroke), subarachnoid, and subdural bleeds.",( hemorrhagic stroke is not a named entity
"Intracranial hemorrhage included intracerebral (hemorrhagic stroke), subarachnoid, and subdural bleeds.",Intracranial hemorrhage is an adverse reaction entity
"Intracranial hemorrhage included intracerebral (hemorrhagic stroke), subarachnoid, and subdural bleeds.",hemorrhagic stroke is an adverse reaction entity
Figure 1 Adjudicated Major Bleeding by Baseline Characteristics Including Hemorrhagic Stroke Treated Patients       Note: The figure above presents effects in various subgroups all of which are baseline characteristics and all of which were pre-specified.,and is not a named entity
Figure 1 Adjudicated Major Bleeding by Baseline Characteristics Including Hemorrhagic Stroke Treated Patients       Note: The figure above presents effects in various subgroups all of which are baseline characteristics and all of which were pre-specified.,Bleeding is an adverse reaction entity
"c  Confidence interval                               Patients         Major bleeding event  a                                               Clinically relevant non-major bleeding      Any bleeding            In the RE-SONATE study, the rate of any gastrointestinal bleeds in patients receiving PRADAXA 150 mg was 0.7% (0.3% on placebo).",study is not a named entity
"c  Confidence interval                               Patients         Major bleeding event  a                                               Clinically relevant non-major bleeding      Any bleeding            In the RE-SONATE study, the rate of any gastrointestinal bleeds in patients receiving PRADAXA 150 mg was 0.7% (0.3% on placebo).",bleeding is an adverse reaction entity
"c  Confidence interval                               Patients         Major bleeding event  a                                               Clinically relevant non-major bleeding      Any bleeding            In the RE-SONATE study, the rate of any gastrointestinal bleeds in patients receiving PRADAXA 150 mg was 0.7% (0.3% on placebo).",bleeding is an adverse reaction entity
"c  Confidence interval                               Patients         Major bleeding event  a                                               Clinically relevant non-major bleeding      Any bleeding            In the RE-SONATE study, the rate of any gastrointestinal bleeds in patients receiving PRADAXA 150 mg was 0.7% (0.3% on placebo).",bleeding is an adverse reaction entity
"c  Confidence interval                               Patients         Major bleeding event  a                                               Clinically relevant non-major bleeding      Any bleeding            In the RE-SONATE study, the rate of any gastrointestinal bleeds in patients receiving PRADAXA 150 mg was 0.7% (0.3% on placebo).",gastrointestinal bleeds is an adverse reaction entity
"c  Confidence interval                               Patients         Major bleeding event  a                                               Clinically relevant non-major bleeding      Any bleeding            In the RE-SONATE study, the rate of any gastrointestinal bleeds in patients receiving PRADAXA 150 mg was 0.7% (0.3% on placebo).",In the is not a named entity
"c  Confidence interval                               Patients         Major bleeding event  a                                               Clinically relevant non-major bleeding      Any bleeding            In the RE-SONATE study, the rate of any gastrointestinal bleeds in patients receiving PRADAXA 150 mg was 0.7% (0.3% on placebo).",the RE-SONATE is not a named entity
"c  Confidence interval                               Patients         Major bleeding event  a                                               Clinically relevant non-major bleeding      Any bleeding            In the RE-SONATE study, the rate of any gastrointestinal bleeds in patients receiving PRADAXA 150 mg was 0.7% (0.3% on placebo).",Patients is not a named entity
"Gastrointestinal Adverse Reactions  In the four pivotal studies, patients on PRADAXA 150 mg had a similar incidence of gastrointestinal adverse reactions (24.7% vs. 22.7% on warfarin).",similar incidence of is not a named entity
"Gastrointestinal Adverse Reactions  In the four pivotal studies, patients on PRADAXA 150 mg had a similar incidence of gastrointestinal adverse reactions (24.7% vs. 22.7% on warfarin).",gastrointestinal adverse reactions is an adverse reaction entity
"The risk of major bleeds was similar with PRADAXA 150 mg and warfarin across major subgroups defined by baseline characteristics (see Figure 1), with the exception of age, where there was a trend towards a higher incidence of major bleeding on PRADAXA (hazard ratio 1.2, 95% CI: 1.0 to 1.5) for patients >=75 years of age.",bleeds is an adverse reaction entity
"The risk of major bleeds was similar with PRADAXA 150 mg and warfarin across major subgroups defined by baseline characteristics (see Figure 1), with the exception of age, where there was a trend towards a higher incidence of major bleeding on PRADAXA (hazard ratio 1.2, 95% CI: 1.0 to 1.5) for patients >=75 years of age.",of major is not a named entity
"The risk of major bleeds was similar with PRADAXA 150 mg and warfarin across major subgroups defined by baseline characteristics (see Figure 1), with the exception of age, where there was a trend towards a higher incidence of major bleeding on PRADAXA (hazard ratio 1.2, 95% CI: 1.0 to 1.5) for patients >=75 years of age.",bleeding is an adverse reaction entity
"The risk of major bleeds was similar with PRADAXA 150 mg and warfarin across major subgroups defined by baseline characteristics (see Figure 1), with the exception of age, where there was a trend towards a higher incidence of major bleeding on PRADAXA (hazard ratio 1.2, 95% CI: 1.0 to 1.5) for patients >=75 years of age.",1.5 ) for is not a named entity
"These were commonly dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) and gastritis-like symptoms (including GERD, esophagitis, erosive gastritis, gastric hemorrhage, hemorrhagic gastritis, hemorrhagic erosive gastritis, and gastrointestinal ulcer).",and epigastric is not a named entity
"These were commonly dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) and gastritis-like symptoms (including GERD, esophagitis, erosive gastritis, gastric hemorrhage, hemorrhagic gastritis, hemorrhagic erosive gastritis, and gastrointestinal ulcer).",gastritis is not a named entity
"These were commonly dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) and gastritis-like symptoms (including GERD, esophagitis, erosive gastritis, gastric hemorrhage, hemorrhagic gastritis, hemorrhagic erosive gastritis, and gastrointestinal ulcer).",", is not a named entity"
"These were commonly dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) and gastritis-like symptoms (including GERD, esophagitis, erosive gastritis, gastric hemorrhage, hemorrhagic gastritis, hemorrhagic erosive gastritis, and gastrointestinal ulcer).",hemorrhagic gastritis is an adverse reaction entity
"These were commonly dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) and gastritis-like symptoms (including GERD, esophagitis, erosive gastritis, gastric hemorrhage, hemorrhagic gastritis, hemorrhagic erosive gastritis, and gastrointestinal ulcer).",hemorrhagic erosive gastritis is an adverse reaction entity
"These were commonly dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) and gastritis-like symptoms (including GERD, esophagitis, erosive gastritis, gastric hemorrhage, hemorrhagic gastritis, hemorrhagic erosive gastritis, and gastrointestinal ulcer).",", hemorrhagic is not a named entity"
"These were commonly dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) and gastritis-like symptoms (including GERD, esophagitis, erosive gastritis, gastric hemorrhage, hemorrhagic gastritis, hemorrhagic erosive gastritis, and gastrointestinal ulcer).",and is not a named entity
"These were commonly dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) and gastritis-like symptoms (including GERD, esophagitis, erosive gastritis, gastric hemorrhage, hemorrhagic gastritis, hemorrhagic erosive gastritis, and gastrointestinal ulcer).",", and epigastric is not a named entity"
"These were commonly dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) and gastritis-like symptoms (including GERD, esophagitis, erosive gastritis, gastric hemorrhage, hemorrhagic gastritis, hemorrhagic erosive gastritis, and gastrointestinal ulcer).",GERD is an adverse reaction entity
"These were commonly dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) and gastritis-like symptoms (including GERD, esophagitis, erosive gastritis, gastric hemorrhage, hemorrhagic gastritis, hemorrhagic erosive gastritis, and gastrointestinal ulcer).",abdominal pain is an adverse reaction entity
"These were commonly dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) and gastritis-like symptoms (including GERD, esophagitis, erosive gastritis, gastric hemorrhage, hemorrhagic gastritis, hemorrhagic erosive gastritis, and gastrointestinal ulcer).",These were commonly is not a named entity
"These were commonly dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) and gastritis-like symptoms (including GERD, esophagitis, erosive gastritis, gastric hemorrhage, hemorrhagic gastritis, hemorrhagic erosive gastritis, and gastrointestinal ulcer).",epigastric discomfort is an adverse reaction entity
"These were commonly dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) and gastritis-like symptoms (including GERD, esophagitis, erosive gastritis, gastric hemorrhage, hemorrhagic gastritis, hemorrhagic erosive gastritis, and gastrointestinal ulcer).",", is not a named entity"
"These were commonly dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) and gastritis-like symptoms (including GERD, esophagitis, erosive gastritis, gastric hemorrhage, hemorrhagic gastritis, hemorrhagic erosive gastritis, and gastrointestinal ulcer).",were commonly dyspepsia is not a named entity
"These were commonly dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) and gastritis-like symptoms (including GERD, esophagitis, erosive gastritis, gastric hemorrhage, hemorrhagic gastritis, hemorrhagic erosive gastritis, and gastrointestinal ulcer).",erosive gastritis is an adverse reaction entity
"These were commonly dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) and gastritis-like symptoms (including GERD, esophagitis, erosive gastritis, gastric hemorrhage, hemorrhagic gastritis, hemorrhagic erosive gastritis, and gastrointestinal ulcer).",and gastrointestinal ulcer is not a named entity
"These were commonly dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) and gastritis-like symptoms (including GERD, esophagitis, erosive gastritis, gastric hemorrhage, hemorrhagic gastritis, hemorrhagic erosive gastritis, and gastrointestinal ulcer).",gastrointestinal ulcer is an adverse reaction entity
"These were commonly dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) and gastritis-like symptoms (including GERD, esophagitis, erosive gastritis, gastric hemorrhage, hemorrhagic gastritis, hemorrhagic erosive gastritis, and gastrointestinal ulcer).",gastritis is an adverse reaction entity
"These were commonly dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) and gastritis-like symptoms (including GERD, esophagitis, erosive gastritis, gastric hemorrhage, hemorrhagic gastritis, hemorrhagic erosive gastritis, and gastrointestinal ulcer).",dyspepsia is an adverse reaction entity
"These were commonly dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) and gastritis-like symptoms (including GERD, esophagitis, erosive gastritis, gastric hemorrhage, hemorrhagic gastritis, hemorrhagic erosive gastritis, and gastrointestinal ulcer).",gastric hemorrhage is an adverse reaction entity
"These were commonly dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) and gastritis-like symptoms (including GERD, esophagitis, erosive gastritis, gastric hemorrhage, hemorrhagic gastritis, hemorrhagic erosive gastritis, and gastrointestinal ulcer).",and is not a named entity
"These were commonly dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) and gastritis-like symptoms (including GERD, esophagitis, erosive gastritis, gastric hemorrhage, hemorrhagic gastritis, hemorrhagic erosive gastritis, and gastrointestinal ulcer).",abdominal discomfort is an adverse reaction entity
"These were commonly dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) and gastritis-like symptoms (including GERD, esophagitis, erosive gastritis, gastric hemorrhage, hemorrhagic gastritis, hemorrhagic erosive gastritis, and gastrointestinal ulcer).","abdominal pain , is not a named entity"
"These were commonly dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) and gastritis-like symptoms (including GERD, esophagitis, erosive gastritis, gastric hemorrhage, hemorrhagic gastritis, hemorrhagic erosive gastritis, and gastrointestinal ulcer).",abdominal pain upper is an adverse reaction entity
"These were commonly dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) and gastritis-like symptoms (including GERD, esophagitis, erosive gastritis, gastric hemorrhage, hemorrhagic gastritis, hemorrhagic erosive gastritis, and gastrointestinal ulcer).",esophagitis is an adverse reaction entity
"These were commonly dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) and gastritis-like symptoms (including GERD, esophagitis, erosive gastritis, gastric hemorrhage, hemorrhagic gastritis, hemorrhagic erosive gastritis, and gastrointestinal ulcer).",", is not a named entity"
(B) SPINAL/EPIDURAL  HEMATOMAEpidural or spinal hematomas may occur in patients  treated with PRADAXA who are receiving neuraxial anesthesia or undergoing  spinal puncture.,PRADAXA who is not a named entity
(B) SPINAL/EPIDURAL  HEMATOMAEpidural or spinal hematomas may occur in patients  treated with PRADAXA who are receiving neuraxial anesthesia or undergoing  spinal puncture.,Epidural hematomas is an adverse reaction entity
(B) SPINAL/EPIDURAL  HEMATOMAEpidural or spinal hematomas may occur in patients  treated with PRADAXA who are receiving neuraxial anesthesia or undergoing  spinal puncture.,HEMATOMAEpidural is not a named entity
(B) SPINAL/EPIDURAL  HEMATOMAEpidural or spinal hematomas may occur in patients  treated with PRADAXA who are receiving neuraxial anesthesia or undergoing  spinal puncture.,spinal hematomas is an adverse reaction entity
"Bleeding events for the 4 pivotal studies were classified as major bleeding events if at least one of the following criteria applied: fatal bleeding, symptomatic bleeding in a critical area or organ (intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding, or pericardial bleeding), bleeding causing a fall in hemoglobin level of 2.0 g/dL (1.24 mmol/L or more, or leading to transfusion of 2 or more units of whole blood or red cells).",of the is not a named entity
"Bleeding events for the 4 pivotal studies were classified as major bleeding events if at least one of the following criteria applied: fatal bleeding, symptomatic bleeding in a critical area or organ (intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding, or pericardial bleeding), bleeding causing a fall in hemoglobin level of 2.0 g/dL (1.24 mmol/L or more, or leading to transfusion of 2 or more units of whole blood or red cells).",bleeding is an adverse reaction entity
"Bleeding events for the 4 pivotal studies were classified as major bleeding events if at least one of the following criteria applied: fatal bleeding, symptomatic bleeding in a critical area or organ (intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding, or pericardial bleeding), bleeding causing a fall in hemoglobin level of 2.0 g/dL (1.24 mmol/L or more, or leading to transfusion of 2 or more units of whole blood or red cells).",intramuscular is not a named entity
"Bleeding events for the 4 pivotal studies were classified as major bleeding events if at least one of the following criteria applied: fatal bleeding, symptomatic bleeding in a critical area or organ (intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding, or pericardial bleeding), bleeding causing a fall in hemoglobin level of 2.0 g/dL (1.24 mmol/L or more, or leading to transfusion of 2 or more units of whole blood or red cells).",of 2.0 g/dL is not a named entity
"Bleeding events for the 4 pivotal studies were classified as major bleeding events if at least one of the following criteria applied: fatal bleeding, symptomatic bleeding in a critical area or organ (intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding, or pericardial bleeding), bleeding causing a fall in hemoglobin level of 2.0 g/dL (1.24 mmol/L or more, or leading to transfusion of 2 or more units of whole blood or red cells).",in a is not a named entity
"Bleeding events for the 4 pivotal studies were classified as major bleeding events if at least one of the following criteria applied: fatal bleeding, symptomatic bleeding in a critical area or organ (intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding, or pericardial bleeding), bleeding causing a fall in hemoglobin level of 2.0 g/dL (1.24 mmol/L or more, or leading to transfusion of 2 or more units of whole blood or red cells).",", intraspinal or is not a named entity"
"Bleeding events for the 4 pivotal studies were classified as major bleeding events if at least one of the following criteria applied: fatal bleeding, symptomatic bleeding in a critical area or organ (intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding, or pericardial bleeding), bleeding causing a fall in hemoglobin level of 2.0 g/dL (1.24 mmol/L or more, or leading to transfusion of 2 or more units of whole blood or red cells).",or is not a named entity
"Bleeding events for the 4 pivotal studies were classified as major bleeding events if at least one of the following criteria applied: fatal bleeding, symptomatic bleeding in a critical area or organ (intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding, or pericardial bleeding), bleeding causing a fall in hemoglobin level of 2.0 g/dL (1.24 mmol/L or more, or leading to transfusion of 2 or more units of whole blood or red cells).",intramuscular with compartment is not a named entity
"Bleeding events for the 4 pivotal studies were classified as major bleeding events if at least one of the following criteria applied: fatal bleeding, symptomatic bleeding in a critical area or organ (intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding, or pericardial bleeding), bleeding causing a fall in hemoglobin level of 2.0 g/dL (1.24 mmol/L or more, or leading to transfusion of 2 or more units of whole blood or red cells).",bleeding intracranial is an adverse reaction entity
"Bleeding events for the 4 pivotal studies were classified as major bleeding events if at least one of the following criteria applied: fatal bleeding, symptomatic bleeding in a critical area or organ (intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding, or pericardial bleeding), bleeding causing a fall in hemoglobin level of 2.0 g/dL (1.24 mmol/L or more, or leading to transfusion of 2 or more units of whole blood or red cells).",Bleeding is an adverse reaction entity
"Bleeding events for the 4 pivotal studies were classified as major bleeding events if at least one of the following criteria applied: fatal bleeding, symptomatic bleeding in a critical area or organ (intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding, or pericardial bleeding), bleeding causing a fall in hemoglobin level of 2.0 g/dL (1.24 mmol/L or more, or leading to transfusion of 2 or more units of whole blood or red cells).",bleeding intramuscular is an adverse reaction entity
"Bleeding events for the 4 pivotal studies were classified as major bleeding events if at least one of the following criteria applied: fatal bleeding, symptomatic bleeding in a critical area or organ (intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding, or pericardial bleeding), bleeding causing a fall in hemoglobin level of 2.0 g/dL (1.24 mmol/L or more, or leading to transfusion of 2 or more units of whole blood or red cells).",fatal is an adverse reaction entity
"Bleeding events for the 4 pivotal studies were classified as major bleeding events if at least one of the following criteria applied: fatal bleeding, symptomatic bleeding in a critical area or organ (intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding, or pericardial bleeding), bleeding causing a fall in hemoglobin level of 2.0 g/dL (1.24 mmol/L or more, or leading to transfusion of 2 or more units of whole blood or red cells).",4 is not a named entity
"Bleeding events for the 4 pivotal studies were classified as major bleeding events if at least one of the following criteria applied: fatal bleeding, symptomatic bleeding in a critical area or organ (intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding, or pericardial bleeding), bleeding causing a fall in hemoglobin level of 2.0 g/dL (1.24 mmol/L or more, or leading to transfusion of 2 or more units of whole blood or red cells).",g/dL ( 1.24 is not a named entity
"Bleeding events for the 4 pivotal studies were classified as major bleeding events if at least one of the following criteria applied: fatal bleeding, symptomatic bleeding in a critical area or organ (intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding, or pericardial bleeding), bleeding causing a fall in hemoglobin level of 2.0 g/dL (1.24 mmol/L or more, or leading to transfusion of 2 or more units of whole blood or red cells).",symptomatic bleeding in a critical area is an adverse reaction entity
"Bleeding events for the 4 pivotal studies were classified as major bleeding events if at least one of the following criteria applied: fatal bleeding, symptomatic bleeding in a critical area or organ (intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding, or pericardial bleeding), bleeding causing a fall in hemoglobin level of 2.0 g/dL (1.24 mmol/L or more, or leading to transfusion of 2 or more units of whole blood or red cells).",area is not a named entity
"Bleeding events for the 4 pivotal studies were classified as major bleeding events if at least one of the following criteria applied: fatal bleeding, symptomatic bleeding in a critical area or organ (intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding, or pericardial bleeding), bleeding causing a fall in hemoglobin level of 2.0 g/dL (1.24 mmol/L or more, or leading to transfusion of 2 or more units of whole blood or red cells).",organ ( is not a named entity
"Bleeding events for the 4 pivotal studies were classified as major bleeding events if at least one of the following criteria applied: fatal bleeding, symptomatic bleeding in a critical area or organ (intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding, or pericardial bleeding), bleeding causing a fall in hemoglobin level of 2.0 g/dL (1.24 mmol/L or more, or leading to transfusion of 2 or more units of whole blood or red cells).",classified as major is not a named entity
"Bleeding events for the 4 pivotal studies were classified as major bleeding events if at least one of the following criteria applied: fatal bleeding, symptomatic bleeding in a critical area or organ (intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding, or pericardial bleeding), bleeding causing a fall in hemoglobin level of 2.0 g/dL (1.24 mmol/L or more, or leading to transfusion of 2 or more units of whole blood or red cells).",bleeding intraspinal is an adverse reaction entity
"Bleeding events for the 4 pivotal studies were classified as major bleeding events if at least one of the following criteria applied: fatal bleeding, symptomatic bleeding in a critical area or organ (intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding, or pericardial bleeding), bleeding causing a fall in hemoglobin level of 2.0 g/dL (1.24 mmol/L or more, or leading to transfusion of 2 or more units of whole blood or red cells).",bleeding intraocular is an adverse reaction entity
"Bleeding events for the 4 pivotal studies were classified as major bleeding events if at least one of the following criteria applied: fatal bleeding, symptomatic bleeding in a critical area or organ (intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding, or pericardial bleeding), bleeding causing a fall in hemoglobin level of 2.0 g/dL (1.24 mmol/L or more, or leading to transfusion of 2 or more units of whole blood or red cells).",retroperitoneal bleeding is an adverse reaction entity
"Bleeding events for the 4 pivotal studies were classified as major bleeding events if at least one of the following criteria applied: fatal bleeding, symptomatic bleeding in a critical area or organ (intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding, or pericardial bleeding), bleeding causing a fall in hemoglobin level of 2.0 g/dL (1.24 mmol/L or more, or leading to transfusion of 2 or more units of whole blood or red cells).",", intra-articular bleeding is not a named entity"
"Bleeding events for the 4 pivotal studies were classified as major bleeding events if at least one of the following criteria applied: fatal bleeding, symptomatic bleeding in a critical area or organ (intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding, or pericardial bleeding), bleeding causing a fall in hemoglobin level of 2.0 g/dL (1.24 mmol/L or more, or leading to transfusion of 2 or more units of whole blood or red cells).",pericardial bleeding is an adverse reaction entity
"Bleeding events for the 4 pivotal studies were classified as major bleeding events if at least one of the following criteria applied: fatal bleeding, symptomatic bleeding in a critical area or organ (intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding, or pericardial bleeding), bleeding causing a fall in hemoglobin level of 2.0 g/dL (1.24 mmol/L or more, or leading to transfusion of 2 or more units of whole blood or red cells).",compartment syndrome is an adverse reaction entity
"Bleeding events for the 4 pivotal studies were classified as major bleeding events if at least one of the following criteria applied: fatal bleeding, symptomatic bleeding in a critical area or organ (intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding, or pericardial bleeding), bleeding causing a fall in hemoglobin level of 2.0 g/dL (1.24 mmol/L or more, or leading to transfusion of 2 or more units of whole blood or red cells).",in is not a named entity
"Bleeding events for the 4 pivotal studies were classified as major bleeding events if at least one of the following criteria applied: fatal bleeding, symptomatic bleeding in a critical area or organ (intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding, or pericardial bleeding), bleeding causing a fall in hemoglobin level of 2.0 g/dL (1.24 mmol/L or more, or leading to transfusion of 2 or more units of whole blood or red cells).",bleeding in is not a named entity
"Bleeding events for the 4 pivotal studies were classified as major bleeding events if at least one of the following criteria applied: fatal bleeding, symptomatic bleeding in a critical area or organ (intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding, or pericardial bleeding), bleeding causing a fall in hemoglobin level of 2.0 g/dL (1.24 mmol/L or more, or leading to transfusion of 2 or more units of whole blood or red cells).",symptomatic bleeding in a critical organ is an adverse reaction entity
"Bleeding events for the 4 pivotal studies were classified as major bleeding events if at least one of the following criteria applied: fatal bleeding, symptomatic bleeding in a critical area or organ (intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding, or pericardial bleeding), bleeding causing a fall in hemoglobin level of 2.0 g/dL (1.24 mmol/L or more, or leading to transfusion of 2 or more units of whole blood or red cells).",critical is not a named entity
"Bleeding events for the 4 pivotal studies were classified as major bleeding events if at least one of the following criteria applied: fatal bleeding, symptomatic bleeding in a critical area or organ (intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding, or pericardial bleeding), bleeding causing a fall in hemoglobin level of 2.0 g/dL (1.24 mmol/L or more, or leading to transfusion of 2 or more units of whole blood or red cells).",fall in hemoglobin level is an adverse reaction entity
"Bleeding events for the 4 pivotal studies were classified as major bleeding events if at least one of the following criteria applied: fatal bleeding, symptomatic bleeding in a critical area or organ (intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding, or pericardial bleeding), bleeding causing a fall in hemoglobin level of 2.0 g/dL (1.24 mmol/L or more, or leading to transfusion of 2 or more units of whole blood or red cells).",bleeding is an adverse reaction entity
"Bleeding events for the 4 pivotal studies were classified as major bleeding events if at least one of the following criteria applied: fatal bleeding, symptomatic bleeding in a critical area or organ (intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding, or pericardial bleeding), bleeding causing a fall in hemoglobin level of 2.0 g/dL (1.24 mmol/L or more, or leading to transfusion of 2 or more units of whole blood or red cells).",intra-articular bleeding is an adverse reaction entity
"Bleeding events for the 4 pivotal studies were classified as major bleeding events if at least one of the following criteria applied: fatal bleeding, symptomatic bleeding in a critical area or organ (intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding, or pericardial bleeding), bleeding causing a fall in hemoglobin level of 2.0 g/dL (1.24 mmol/L or more, or leading to transfusion of 2 or more units of whole blood or red cells).",bleeding is an adverse reaction entity
"5.2 Risk of Bleeding      PRADAXA increases the risk of bleeding and can cause significant and, sometimes, fatal bleeding.",bleeding is an adverse reaction entity
"5.2 Risk of Bleeding      PRADAXA increases the risk of bleeding and can cause significant and, sometimes, fatal bleeding.",cause significant and is not a named entity
"5.2 Risk of Bleeding      PRADAXA increases the risk of bleeding and can cause significant and, sometimes, fatal bleeding.",risk is not a named entity
"5.2 Risk of Bleeding      PRADAXA increases the risk of bleeding and can cause significant and, sometimes, fatal bleeding.",bleeding is an adverse reaction entity
"5.2 Risk of Bleeding      PRADAXA increases the risk of bleeding and can cause significant and, sometimes, fatal bleeding.",fatal is an adverse reaction entity
"5.2 Risk of Bleeding      PRADAXA increases the risk of bleeding and can cause significant and, sometimes, fatal bleeding.",Bleeding PRADAXA is not a named entity
"5.2 Risk of Bleeding      PRADAXA increases the risk of bleeding and can cause significant and, sometimes, fatal bleeding.",of is not a named entity
"5.2 Risk of Bleeding      PRADAXA increases the risk of bleeding and can cause significant and, sometimes, fatal bleeding.",bleeding is an adverse reaction entity
"cDefined as bleeding accompanied by one or more of the following: a decrease in hemoglobin of >=2 g/dL, a transfusion of 2 or more units of packed red blood cells, bleeding at a critical site or with fatal outcome.",bleeding is an adverse reaction entity
"cDefined as bleeding accompanied by one or more of the following: a decrease in hemoglobin of >=2 g/dL, a transfusion of 2 or more units of packed red blood cells, bleeding at a critical site or with fatal outcome.",transfusion of 2 is not a named entity
"cDefined as bleeding accompanied by one or more of the following: a decrease in hemoglobin of >=2 g/dL, a transfusion of 2 or more units of packed red blood cells, bleeding at a critical site or with fatal outcome.",or more units is not a named entity
"cDefined as bleeding accompanied by one or more of the following: a decrease in hemoglobin of >=2 g/dL, a transfusion of 2 or more units of packed red blood cells, bleeding at a critical site or with fatal outcome.",bleeding at a critical site is an adverse reaction entity
"cDefined as bleeding accompanied by one or more of the following: a decrease in hemoglobin of >=2 g/dL, a transfusion of 2 or more units of packed red blood cells, bleeding at a critical site or with fatal outcome.",a decrease is not a named entity
"cDefined as bleeding accompanied by one or more of the following: a decrease in hemoglobin of >=2 g/dL, a transfusion of 2 or more units of packed red blood cells, bleeding at a critical site or with fatal outcome.",of 2 or is not a named entity
"cDefined as bleeding accompanied by one or more of the following: a decrease in hemoglobin of >=2 g/dL, a transfusion of 2 or more units of packed red blood cells, bleeding at a critical site or with fatal outcome.",decrease in hemoglobin is an adverse reaction entity
"cDefined as bleeding accompanied by one or more of the following: a decrease in hemoglobin of >=2 g/dL, a transfusion of 2 or more units of packed red blood cells, bleeding at a critical site or with fatal outcome.",fatal is an adverse reaction entity
"5.3 Spinal/Epidural Anesthesia or Puncture      When neuraxial anesthesia (spinal/epidural anesthesia) or spinal puncture is employed, patients treated with anticoagulant agents are at risk of developing an epidural or spinal hematoma which can result in long-term or permanent paralysis [see  Boxed Warning  ]  .",which can result is not a named entity
"5.3 Spinal/Epidural Anesthesia or Puncture      When neuraxial anesthesia (spinal/epidural anesthesia) or spinal puncture is employed, patients treated with anticoagulant agents are at risk of developing an epidural or spinal hematoma which can result in long-term or permanent paralysis [see  Boxed Warning  ]  .",puncture is not a named entity
"5.3 Spinal/Epidural Anesthesia or Puncture      When neuraxial anesthesia (spinal/epidural anesthesia) or spinal puncture is employed, patients treated with anticoagulant agents are at risk of developing an epidural or spinal hematoma which can result in long-term or permanent paralysis [see  Boxed Warning  ]  .",paralysis is an adverse reaction entity
"5.3 Spinal/Epidural Anesthesia or Puncture      When neuraxial anesthesia (spinal/epidural anesthesia) or spinal puncture is employed, patients treated with anticoagulant agents are at risk of developing an epidural or spinal hematoma which can result in long-term or permanent paralysis [see  Boxed Warning  ]  .",developing is not a named entity
"5.3 Spinal/Epidural Anesthesia or Puncture      When neuraxial anesthesia (spinal/epidural anesthesia) or spinal puncture is employed, patients treated with anticoagulant agents are at risk of developing an epidural or spinal hematoma which can result in long-term or permanent paralysis [see  Boxed Warning  ]  .",epidural hematoma is an adverse reaction entity
"5.3 Spinal/Epidural Anesthesia or Puncture      When neuraxial anesthesia (spinal/epidural anesthesia) or spinal puncture is employed, patients treated with anticoagulant agents are at risk of developing an epidural or spinal hematoma which can result in long-term or permanent paralysis [see  Boxed Warning  ]  .",spinal hematoma is an adverse reaction entity
"5.3 Spinal/Epidural Anesthesia or Puncture      When neuraxial anesthesia (spinal/epidural anesthesia) or spinal puncture is employed, patients treated with anticoagulant agents are at risk of developing an epidural or spinal hematoma which can result in long-term or permanent paralysis [see  Boxed Warning  ]  .",permanent paralysis is an adverse reaction entity
"5.3 Spinal/Epidural Anesthesia or Puncture      When neuraxial anesthesia (spinal/epidural anesthesia) or spinal puncture is employed, patients treated with anticoagulant agents are at risk of developing an epidural or spinal hematoma which can result in long-term or permanent paralysis [see  Boxed Warning  ]  .",in long-term or is not a named entity
6  ADVERSE REACTIONS    The most serious adverse reactions reported with PRADAXA were related to bleeding  [see Warnings and Precautions  (5.2)  ]  .,bleeding is an adverse reaction entity
6  ADVERSE REACTIONS    The most serious adverse reactions reported with PRADAXA were related to bleeding  [see Warnings and Precautions  (5.2)  ]  .,) is not a named entity
Figure 1             Gastrointestinal Adverse Reactions           Patients on PRADAXA 150 mg had an increased incidence of gastrointestinal adverse reactions (35% vs. 24% on warfarin).,% vs. 24 is not a named entity
Figure 1             Gastrointestinal Adverse Reactions           Patients on PRADAXA 150 mg had an increased incidence of gastrointestinal adverse reactions (35% vs. 24% on warfarin).,gastrointestinal adverse reactions is an adverse reaction entity
fFatal bleed: Adjudicated major bleed as defined above with investigator reported fatal outcome and adjudicated death with primary cause from bleeding.,bleeding is an adverse reaction entity
fFatal bleed: Adjudicated major bleed as defined above with investigator reported fatal outcome and adjudicated death with primary cause from bleeding.,bleed is an adverse reaction entity
fFatal bleed: Adjudicated major bleed as defined above with investigator reported fatal outcome and adjudicated death with primary cause from bleeding.,as defined above is not a named entity
fFatal bleed: Adjudicated major bleed as defined above with investigator reported fatal outcome and adjudicated death with primary cause from bleeding.,Adjudicated is not a named entity
fFatal bleed: Adjudicated major bleed as defined above with investigator reported fatal outcome and adjudicated death with primary cause from bleeding.,bleed is an adverse reaction entity
fFatal bleed: Adjudicated major bleed as defined above with investigator reported fatal outcome and adjudicated death with primary cause from bleeding.,Fatal is an adverse reaction entity
fFatal bleed: Adjudicated major bleed as defined above with investigator reported fatal outcome and adjudicated death with primary cause from bleeding.,: is not a named entity
fFatal bleed: Adjudicated major bleed as defined above with investigator reported fatal outcome and adjudicated death with primary cause from bleeding.,fatal is an adverse reaction entity
fFatal bleed: Adjudicated major bleed as defined above with investigator reported fatal outcome and adjudicated death with primary cause from bleeding.,above is not a named entity
fFatal bleed: Adjudicated major bleed as defined above with investigator reported fatal outcome and adjudicated death with primary cause from bleeding.,investigator reported is not a named entity
fFatal bleed: Adjudicated major bleed as defined above with investigator reported fatal outcome and adjudicated death with primary cause from bleeding.,death is an adverse reaction entity
fFatal bleed: Adjudicated major bleed as defined above with investigator reported fatal outcome and adjudicated death with primary cause from bleeding.,as is not a named entity
Table 3 Bleeding Events in RE-COVER and RE-COVER II Treated Patients   Note: MBE can belong to more than one criterion.,MBE is an adverse reaction entity
Table 3 Bleeding Events in RE-COVER and RE-COVER II Treated Patients   Note: MBE can belong to more than one criterion.,Patients Note : is not a named entity
Table 3 Bleeding Events in RE-COVER and RE-COVER II Treated Patients   Note: MBE can belong to more than one criterion.,Bleeding is an adverse reaction entity
Table 3 Bleeding Events in RE-COVER and RE-COVER II Treated Patients   Note: MBE can belong to more than one criterion.,3 is not a named entity
"Hypersensitivity Reactions  In the 4 pivotal studies, drug hypersensitivity (including urticaria, rash, and pruritus), allergic edema, anaphylactic reaction, and anaphylactic shock were reported in 0.1% of patients receiving PRADAXA.",% of patients is not a named entity
"Hypersensitivity Reactions  In the 4 pivotal studies, drug hypersensitivity (including urticaria, rash, and pruritus), allergic edema, anaphylactic reaction, and anaphylactic shock were reported in 0.1% of patients receiving PRADAXA.",") , allergic is not a named entity"
"Hypersensitivity Reactions  In the 4 pivotal studies, drug hypersensitivity (including urticaria, rash, and pruritus), allergic edema, anaphylactic reaction, and anaphylactic shock were reported in 0.1% of patients receiving PRADAXA.",anaphylactic shock is an adverse reaction entity
"Hypersensitivity Reactions  In the 4 pivotal studies, drug hypersensitivity (including urticaria, rash, and pruritus), allergic edema, anaphylactic reaction, and anaphylactic shock were reported in 0.1% of patients receiving PRADAXA.",allergic edema is an adverse reaction entity
"Hypersensitivity Reactions  In the 4 pivotal studies, drug hypersensitivity (including urticaria, rash, and pruritus), allergic edema, anaphylactic reaction, and anaphylactic shock were reported in 0.1% of patients receiving PRADAXA.",% of patients is not a named entity
"Hypersensitivity Reactions  In the 4 pivotal studies, drug hypersensitivity (including urticaria, rash, and pruritus), allergic edema, anaphylactic reaction, and anaphylactic shock were reported in 0.1% of patients receiving PRADAXA.",hypersensitivity is an adverse reaction entity
"Hypersensitivity Reactions  In the 4 pivotal studies, drug hypersensitivity (including urticaria, rash, and pruritus), allergic edema, anaphylactic reaction, and anaphylactic shock were reported in 0.1% of patients receiving PRADAXA.",0.1 % is not a named entity
"Hypersensitivity Reactions  In the 4 pivotal studies, drug hypersensitivity (including urticaria, rash, and pruritus), allergic edema, anaphylactic reaction, and anaphylactic shock were reported in 0.1% of patients receiving PRADAXA.",patients is not a named entity
"Hypersensitivity Reactions  In the 4 pivotal studies, drug hypersensitivity (including urticaria, rash, and pruritus), allergic edema, anaphylactic reaction, and anaphylactic shock were reported in 0.1% of patients receiving PRADAXA.",hypersensitivity ( is not a named entity
"Hypersensitivity Reactions  In the 4 pivotal studies, drug hypersensitivity (including urticaria, rash, and pruritus), allergic edema, anaphylactic reaction, and anaphylactic shock were reported in 0.1% of patients receiving PRADAXA.",rash is an adverse reaction entity
"Hypersensitivity Reactions  In the 4 pivotal studies, drug hypersensitivity (including urticaria, rash, and pruritus), allergic edema, anaphylactic reaction, and anaphylactic shock were reported in 0.1% of patients receiving PRADAXA.",anaphylactic reaction is an adverse reaction entity
"Hypersensitivity Reactions  In the 4 pivotal studies, drug hypersensitivity (including urticaria, rash, and pruritus), allergic edema, anaphylactic reaction, and anaphylactic shock were reported in 0.1% of patients receiving PRADAXA.",Reactions is not a named entity
"Hypersensitivity Reactions  In the 4 pivotal studies, drug hypersensitivity (including urticaria, rash, and pruritus), allergic edema, anaphylactic reaction, and anaphylactic shock were reported in 0.1% of patients receiving PRADAXA.",pruritus is an adverse reaction entity
"Hypersensitivity Reactions  In the 4 pivotal studies, drug hypersensitivity (including urticaria, rash, and pruritus), allergic edema, anaphylactic reaction, and anaphylactic shock were reported in 0.1% of patients receiving PRADAXA.",urticaria is an adverse reaction entity
"These bleeding and thromboembolic events were seen both in patients who were initiated on PRADAXA post-operatively within three days of mechanical bileaflet valve implantation, as well as in patients whose valves had been implanted more than three months prior to enrollment.",bleeding is an adverse reaction entity
"These bleeding and thromboembolic events were seen both in patients who were initiated on PRADAXA post-operatively within three days of mechanical bileaflet valve implantation, as well as in patients whose valves had been implanted more than three months prior to enrollment.",thromboembolic events is an adverse reaction entity
"These bleeding and thromboembolic events were seen both in patients who were initiated on PRADAXA post-operatively within three days of mechanical bileaflet valve implantation, as well as in patients whose valves had been implanted more than three months prior to enrollment.",three days of is not a named entity
"These bleeding and thromboembolic events were seen both in patients who were initiated on PRADAXA post-operatively within three days of mechanical bileaflet valve implantation, as well as in patients whose valves had been implanted more than three months prior to enrollment.",prior to enrollment is not a named entity
Table 4 Bleeding Events in RE-MEDY Treated Patients   Note: MBE can belong to more than one criterion.,one is not a named entity
Table 4 Bleeding Events in RE-MEDY Treated Patients   Note: MBE can belong to more than one criterion.,Table 4 is not a named entity
Table 4 Bleeding Events in RE-MEDY Treated Patients   Note: MBE can belong to more than one criterion.,Bleeding is an adverse reaction entity
Table 4 Bleeding Events in RE-MEDY Treated Patients   Note: MBE can belong to more than one criterion.,MBE is an adverse reaction entity
"In the placebo-controlled study, a similar rate of non-fatal and fatal clinical myocardial infarction was reported in patients who received PRADAXA [1 (0.32 per 100 patient-years)] and in those who received placebo [1 (0.34 per 100 patient-years)].",myocardial infarction is an adverse reaction entity
"In the placebo-controlled study, a similar rate of non-fatal and fatal clinical myocardial infarction was reported in patients who received PRADAXA [1 (0.32 per 100 patient-years)] and in those who received placebo [1 (0.34 per 100 patient-years)].",100 is not a named entity
"In the placebo-controlled study, a similar rate of non-fatal and fatal clinical myocardial infarction was reported in patients who received PRADAXA [1 (0.32 per 100 patient-years)] and in those who received placebo [1 (0.34 per 100 patient-years)].",and fatal clinical is not a named entity
"In the placebo-controlled study, a similar rate of non-fatal and fatal clinical myocardial infarction was reported in patients who received PRADAXA [1 (0.32 per 100 patient-years)] and in those who received placebo [1 (0.34 per 100 patient-years)].",1 ( is not a named entity
"In the placebo-controlled study, a similar rate of non-fatal and fatal clinical myocardial infarction was reported in patients who received PRADAXA [1 (0.32 per 100 patient-years)] and in those who received placebo [1 (0.34 per 100 patient-years)].",myocardial infarction is an adverse reaction entity
"In the placebo-controlled study, a similar rate of non-fatal and fatal clinical myocardial infarction was reported in patients who received PRADAXA [1 (0.32 per 100 patient-years)] and in those who received placebo [1 (0.34 per 100 patient-years)].",fatal is an adverse reaction entity
"Major bleeding events within each subcategory were counted once per patient, but patients may have contributed events to multiple subcategories.",bleeding is an adverse reaction entity
"Major bleeding events within each subcategory were counted once per patient, but patients may have contributed events to multiple subcategories.",have contributed is not a named entity
"EXCERPT:     WARNING: (A) PREMATURE DISCONTINUATION  OF PRADAXA INCREASES THE RISK OF THROMBOTIC EVENTS, and (B) SPINAL/EPIDURAL  HEMATOMA    See full prescribing information  for complete boxed warning    (A)  PREMATURE DISCONTINUATION OF PRADAXA INCREASES THE RISK OF THROMBOTIC  EVENTS: Premature discontinuation of any oral anticoagulant, including  PRADAXA, increases the risk of thrombotic events.",SPINAL HEMATOMA is an adverse reaction entity
"EXCERPT:     WARNING: (A) PREMATURE DISCONTINUATION  OF PRADAXA INCREASES THE RISK OF THROMBOTIC EVENTS, and (B) SPINAL/EPIDURAL  HEMATOMA    See full prescribing information  for complete boxed warning    (A)  PREMATURE DISCONTINUATION OF PRADAXA INCREASES THE RISK OF THROMBOTIC  EVENTS: Premature discontinuation of any oral anticoagulant, including  PRADAXA, increases the risk of thrombotic events.",EPIDURAL HEMATOMA is an adverse reaction entity
"EXCERPT:     WARNING: (A) PREMATURE DISCONTINUATION  OF PRADAXA INCREASES THE RISK OF THROMBOTIC EVENTS, and (B) SPINAL/EPIDURAL  HEMATOMA    See full prescribing information  for complete boxed warning    (A)  PREMATURE DISCONTINUATION OF PRADAXA INCREASES THE RISK OF THROMBOTIC  EVENTS: Premature discontinuation of any oral anticoagulant, including  PRADAXA, increases the risk of thrombotic events.",OF is not a named entity
"EXCERPT:     WARNING: (A) PREMATURE DISCONTINUATION  OF PRADAXA INCREASES THE RISK OF THROMBOTIC EVENTS, and (B) SPINAL/EPIDURAL  HEMATOMA    See full prescribing information  for complete boxed warning    (A)  PREMATURE DISCONTINUATION OF PRADAXA INCREASES THE RISK OF THROMBOTIC  EVENTS: Premature discontinuation of any oral anticoagulant, including  PRADAXA, increases the risk of thrombotic events.",OF THROMBOTIC is not a named entity
"Local skin reactions typically occurred within 1 day of treatment initiation, peaked in intensity up to 1 week following completion of treatment, and resolved within 2 weeks for areas treated on the face and scalp, and within 4 weeks for areas treated on the trunk and extremities.",1 day is not a named entity
"Local skin reactions typically occurred within 1 day of treatment initiation, peaked in intensity up to 1 week following completion of treatment, and resolved within 2 weeks for areas treated on the face and scalp, and within 4 weeks for areas treated on the trunk and extremities.",Local skin reactions is an adverse reaction entity
"Eye disorders, including severe eye pain, chemical conjunctivitis, corneal burn, eyelid edema, eyelid ptosis, periorbital edema can occur after exposure.",eyelid ptosis is an adverse reaction entity
"Eye disorders, including severe eye pain, chemical conjunctivitis, corneal burn, eyelid edema, eyelid ptosis, periorbital edema can occur after exposure.",", eyelid is not a named entity"
"Eye disorders, including severe eye pain, chemical conjunctivitis, corneal burn, eyelid edema, eyelid ptosis, periorbital edema can occur after exposure.",Eye disorders is an adverse reaction entity
"Eye disorders, including severe eye pain, chemical conjunctivitis, corneal burn, eyelid edema, eyelid ptosis, periorbital edema can occur after exposure.",disorders is not a named entity
"Eye disorders, including severe eye pain, chemical conjunctivitis, corneal burn, eyelid edema, eyelid ptosis, periorbital edema can occur after exposure.",burn is not a named entity
"Eye disorders, including severe eye pain, chemical conjunctivitis, corneal burn, eyelid edema, eyelid ptosis, periorbital edema can occur after exposure.",eyelid edema is an adverse reaction entity
"Eye disorders, including severe eye pain, chemical conjunctivitis, corneal burn, eyelid edema, eyelid ptosis, periorbital edema can occur after exposure.",eye pain is an adverse reaction entity
"Eye disorders, including severe eye pain, chemical conjunctivitis, corneal burn, eyelid edema, eyelid ptosis, periorbital edema can occur after exposure.","burn , eyelid is not a named entity"
"Eye disorders, including severe eye pain, chemical conjunctivitis, corneal burn, eyelid edema, eyelid ptosis, periorbital edema can occur after exposure.",periorbital edema is an adverse reaction entity
"Eye disorders, including severe eye pain, chemical conjunctivitis, corneal burn, eyelid edema, eyelid ptosis, periorbital edema can occur after exposure.",including severe eye is not a named entity
"Eye disorders, including severe eye pain, chemical conjunctivitis, corneal burn, eyelid edema, eyelid ptosis, periorbital edema can occur after exposure.",chemical conjunctivitis is an adverse reaction entity
"Eye disorders, including severe eye pain, chemical conjunctivitis, corneal burn, eyelid edema, eyelid ptosis, periorbital edema can occur after exposure.",", eyelid is not a named entity"
"Eye disorders, including severe eye pain, chemical conjunctivitis, corneal burn, eyelid edema, eyelid ptosis, periorbital edema can occur after exposure.","conjunctivitis , corneal is not a named entity"
"Eye disorders, including severe eye pain, chemical conjunctivitis, corneal burn, eyelid edema, eyelid ptosis, periorbital edema can occur after exposure.",corneal burn is an adverse reaction entity
"5.2 Hypersensitivity Reactions      Hypersensitivity reactions, including anaphylaxis and allergic contact dermatitis, have been reported post-marketing [see Adverse Reactions (  6.2  )]  .",Hypersensitivity Reactions Hypersensitivity is not a named entity
"5.2 Hypersensitivity Reactions      Hypersensitivity reactions, including anaphylaxis and allergic contact dermatitis, have been reported post-marketing [see Adverse Reactions (  6.2  )]  .",6.2 ) ] is not a named entity
"5.2 Hypersensitivity Reactions      Hypersensitivity reactions, including anaphylaxis and allergic contact dermatitis, have been reported post-marketing [see Adverse Reactions (  6.2  )]  .",allergic contact dermatitis is an adverse reaction entity
"5.2 Hypersensitivity Reactions      Hypersensitivity reactions, including anaphylaxis and allergic contact dermatitis, have been reported post-marketing [see Adverse Reactions (  6.2  )]  .",Adverse is not a named entity
"5.2 Hypersensitivity Reactions      Hypersensitivity reactions, including anaphylaxis and allergic contact dermatitis, have been reported post-marketing [see Adverse Reactions (  6.2  )]  .",anaphylaxis is an adverse reaction entity
"5.2 Hypersensitivity Reactions      Hypersensitivity reactions, including anaphylaxis and allergic contact dermatitis, have been reported post-marketing [see Adverse Reactions (  6.2  )]  .",Hypersensitivity reactions is an adverse reaction entity
"5.3 Local Skin Reactions      Severe skin reactions in the treated area, including erythema, crusting, swelling, vesiculation/postulation, and erosion/ulceration, can occur after topical application of Picato  (r)  gel [see Adverse Reactions (  6     )]  .",application is not a named entity
"5.3 Local Skin Reactions      Severe skin reactions in the treated area, including erythema, crusting, swelling, vesiculation/postulation, and erosion/ulceration, can occur after topical application of Picato  (r)  gel [see Adverse Reactions (  6     )]  .",", can occur is not a named entity"
"5.3 Local Skin Reactions      Severe skin reactions in the treated area, including erythema, crusting, swelling, vesiculation/postulation, and erosion/ulceration, can occur after topical application of Picato  (r)  gel [see Adverse Reactions (  6     )]  .",gel [ see is not a named entity
"5.3 Local Skin Reactions      Severe skin reactions in the treated area, including erythema, crusting, swelling, vesiculation/postulation, and erosion/ulceration, can occur after topical application of Picato  (r)  gel [see Adverse Reactions (  6     )]  .",in the treated is not a named entity
"5.3 Local Skin Reactions      Severe skin reactions in the treated area, including erythema, crusting, swelling, vesiculation/postulation, and erosion/ulceration, can occur after topical application of Picato  (r)  gel [see Adverse Reactions (  6     )]  .","erosion/ulceration , is not a named entity"
"5.3 Local Skin Reactions      Severe skin reactions in the treated area, including erythema, crusting, swelling, vesiculation/postulation, and erosion/ulceration, can occur after topical application of Picato  (r)  gel [see Adverse Reactions (  6     )]  .",skin reactions in the treated area crusting is an adverse reaction entity
"5.3 Local Skin Reactions      Severe skin reactions in the treated area, including erythema, crusting, swelling, vesiculation/postulation, and erosion/ulceration, can occur after topical application of Picato  (r)  gel [see Adverse Reactions (  6     )]  .",skin reactions in the treated area postulation is an adverse reaction entity
"5.3 Local Skin Reactions      Severe skin reactions in the treated area, including erythema, crusting, swelling, vesiculation/postulation, and erosion/ulceration, can occur after topical application of Picato  (r)  gel [see Adverse Reactions (  6     )]  .",skin reactions in the treated area is an adverse reaction entity
"5.3 Local Skin Reactions      Severe skin reactions in the treated area, including erythema, crusting, swelling, vesiculation/postulation, and erosion/ulceration, can occur after topical application of Picato  (r)  gel [see Adverse Reactions (  6     )]  .",Picato ( is not a named entity
"5.3 Local Skin Reactions      Severe skin reactions in the treated area, including erythema, crusting, swelling, vesiculation/postulation, and erosion/ulceration, can occur after topical application of Picato  (r)  gel [see Adverse Reactions (  6     )]  .",skin reactions in the treated area ulceration is an adverse reaction entity
"5.3 Local Skin Reactions      Severe skin reactions in the treated area, including erythema, crusting, swelling, vesiculation/postulation, and erosion/ulceration, can occur after topical application of Picato  (r)  gel [see Adverse Reactions (  6     )]  .",skin reactions in the treated area erosion is an adverse reaction entity
"5.3 Local Skin Reactions      Severe skin reactions in the treated area, including erythema, crusting, swelling, vesiculation/postulation, and erosion/ulceration, can occur after topical application of Picato  (r)  gel [see Adverse Reactions (  6     )]  .",", swelling , is not a named entity"
"5.3 Local Skin Reactions      Severe skin reactions in the treated area, including erythema, crusting, swelling, vesiculation/postulation, and erosion/ulceration, can occur after topical application of Picato  (r)  gel [see Adverse Reactions (  6     )]  .",skin reactions in the treated area vesiculation is an adverse reaction entity
"5.3 Local Skin Reactions      Severe skin reactions in the treated area, including erythema, crusting, swelling, vesiculation/postulation, and erosion/ulceration, can occur after topical application of Picato  (r)  gel [see Adverse Reactions (  6     )]  .",skin reactions in the treated area erythema is an adverse reaction entity
"5.3 Local Skin Reactions      Severe skin reactions in the treated area, including erythema, crusting, swelling, vesiculation/postulation, and erosion/ulceration, can occur after topical application of Picato  (r)  gel [see Adverse Reactions (  6     )]  .",see is not a named entity
"5.3 Local Skin Reactions      Severe skin reactions in the treated area, including erythema, crusting, swelling, vesiculation/postulation, and erosion/ulceration, can occur after topical application of Picato  (r)  gel [see Adverse Reactions (  6     )]  .",skin reactions in the treated area swelling is an adverse reaction entity
"Local skin reactions, including erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration were assessed within the selected treatment area and graded by the investigator on a scale of 0 to 4.",Local skin reactions is an adverse reaction entity
"Local skin reactions, including erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration were assessed within the selected treatment area and graded by the investigator on a scale of 0 to 4.",the is not a named entity
"Local skin reactions, including erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration were assessed within the selected treatment area and graded by the investigator on a scale of 0 to 4.",Local skin flaking is an adverse reaction entity
"Local skin reactions, including erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration were assessed within the selected treatment area and graded by the investigator on a scale of 0 to 4.","swelling , is not a named entity"
"Local skin reactions, including erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration were assessed within the selected treatment area and graded by the investigator on a scale of 0 to 4.",Local skin vesiculation is an adverse reaction entity
"Local skin reactions, including erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration were assessed within the selected treatment area and graded by the investigator on a scale of 0 to 4.",including is not a named entity
"Local skin reactions, including erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration were assessed within the selected treatment area and graded by the investigator on a scale of 0 to 4.",Local skin pustulation is an adverse reaction entity
"Local skin reactions, including erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration were assessed within the selected treatment area and graded by the investigator on a scale of 0 to 4.",Local skin swelling is an adverse reaction entity
"Local skin reactions, including erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration were assessed within the selected treatment area and graded by the investigator on a scale of 0 to 4.",Local skin ulceration is an adverse reaction entity
"Local skin reactions, including erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration were assessed within the selected treatment area and graded by the investigator on a scale of 0 to 4.","swelling , vesiculation/pustulation is not a named entity"
"Local skin reactions, including erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration were assessed within the selected treatment area and graded by the investigator on a scale of 0 to 4.",Local skin crusting is an adverse reaction entity
"Local skin reactions, including erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration were assessed within the selected treatment area and graded by the investigator on a scale of 0 to 4.",", including is not a named entity"
"Local skin reactions, including erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration were assessed within the selected treatment area and graded by the investigator on a scale of 0 to 4.",by the investigator is not a named entity
"Local skin reactions, including erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration were assessed within the selected treatment area and graded by the investigator on a scale of 0 to 4.",the selected is not a named entity
"Local skin reactions, including erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration were assessed within the selected treatment area and graded by the investigator on a scale of 0 to 4.",Local skin erythema is an adverse reaction entity
"Local skin reactions, including erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration were assessed within the selected treatment area and graded by the investigator on a scale of 0 to 4.","vesiculation/pustulation , is not a named entity"
"Local skin reactions, including erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration were assessed within the selected treatment area and graded by the investigator on a scale of 0 to 4.",Local skin erosion is an adverse reaction entity
"Local skin reactions, including erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration were assessed within the selected treatment area and graded by the investigator on a scale of 0 to 4.",", is not a named entity"
"Local skin reactions, including erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration were assessed within the selected treatment area and graded by the investigator on a scale of 0 to 4.",of 0 to is not a named entity
"Local skin reactions, including erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration were assessed within the selected treatment area and graded by the investigator on a scale of 0 to 4.",Local skin scaling is an adverse reaction entity
"(  5.1  )          Local skin reactions can occur including severe reactions (e.g., vesiculation/pustulation, erosion/ulceration).",Local skin erosion is an adverse reaction entity
"(  5.1  )          Local skin reactions can occur including severe reactions (e.g., vesiculation/pustulation, erosion/ulceration).","e.g. , vesiculation/pustulation is not a named entity"
"(  5.1  )          Local skin reactions can occur including severe reactions (e.g., vesiculation/pustulation, erosion/ulceration).",", erosion/ulceration is not a named entity"
"(  5.1  )          Local skin reactions can occur including severe reactions (e.g., vesiculation/pustulation, erosion/ulceration).",( 5.1 ) is not a named entity
"(  5.1  )          Local skin reactions can occur including severe reactions (e.g., vesiculation/pustulation, erosion/ulceration).",Local skin vesiculation is an adverse reaction entity
"(  5.1  )          Local skin reactions can occur including severe reactions (e.g., vesiculation/pustulation, erosion/ulceration).",5.1 is not a named entity
"(  5.1  )          Local skin reactions can occur including severe reactions (e.g., vesiculation/pustulation, erosion/ulceration).",Local skin reactions is an adverse reaction entity
"(  5.1  )          Local skin reactions can occur including severe reactions (e.g., vesiculation/pustulation, erosion/ulceration).",Local skin pustulation is an adverse reaction entity
"(  5.1  )          Local skin reactions can occur including severe reactions (e.g., vesiculation/pustulation, erosion/ulceration).",) Local is not a named entity
"(  5.1  )          Local skin reactions can occur including severe reactions (e.g., vesiculation/pustulation, erosion/ulceration).",Local skin ulceration is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in the  Warnings and Precautions (5)  section of the labeling:     *  Endophthalmitis and retinal detachments   *  Increased intraocular pressure   *  Thromboembolic events        EXCERPT:   The most common adverse reactions (>=5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous floaters, intraocular pressure increased, and vitreous detachment.",Increased intraocular pressure is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in the  Warnings and Precautions (5)  section of the labeling:     *  Endophthalmitis and retinal detachments   *  Increased intraocular pressure   *  Thromboembolic events        EXCERPT:   The most common adverse reactions (>=5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous floaters, intraocular pressure increased, and vitreous detachment.",conjunctival hemorrhage is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in the  Warnings and Precautions (5)  section of the labeling:     *  Endophthalmitis and retinal detachments   *  Increased intraocular pressure   *  Thromboembolic events        EXCERPT:   The most common adverse reactions (>=5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous floaters, intraocular pressure increased, and vitreous detachment.",cataract is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in the  Warnings and Precautions (5)  section of the labeling:     *  Endophthalmitis and retinal detachments   *  Increased intraocular pressure   *  Thromboembolic events        EXCERPT:   The most common adverse reactions (>=5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous floaters, intraocular pressure increased, and vitreous detachment.",vitreous floaters is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in the  Warnings and Precautions (5)  section of the labeling:     *  Endophthalmitis and retinal detachments   *  Increased intraocular pressure   *  Thromboembolic events        EXCERPT:   The most common adverse reactions (>=5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous floaters, intraocular pressure increased, and vitreous detachment.",eye pain is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in the  Warnings and Precautions (5)  section of the labeling:     *  Endophthalmitis and retinal detachments   *  Increased intraocular pressure   *  Thromboembolic events        EXCERPT:   The most common adverse reactions (>=5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous floaters, intraocular pressure increased, and vitreous detachment.",Endophthalmitis is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in the  Warnings and Precautions (5)  section of the labeling:     *  Endophthalmitis and retinal detachments   *  Increased intraocular pressure   *  Thromboembolic events        EXCERPT:   The most common adverse reactions (>=5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous floaters, intraocular pressure increased, and vitreous detachment.",) reported is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in the  Warnings and Precautions (5)  section of the labeling:     *  Endophthalmitis and retinal detachments   *  Increased intraocular pressure   *  Thromboembolic events        EXCERPT:   The most common adverse reactions (>=5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous floaters, intraocular pressure increased, and vitreous detachment.",", and is not a named entity"
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in the  Warnings and Precautions (5)  section of the labeling:     *  Endophthalmitis and retinal detachments   *  Increased intraocular pressure   *  Thromboembolic events        EXCERPT:   The most common adverse reactions (>=5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous floaters, intraocular pressure increased, and vitreous detachment.","floaters , intraocular is not a named entity"
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in the  Warnings and Precautions (5)  section of the labeling:     *  Endophthalmitis and retinal detachments   *  Increased intraocular pressure   *  Thromboembolic events        EXCERPT:   The most common adverse reactions (>=5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous floaters, intraocular pressure increased, and vitreous detachment.",intraocular pressure increased is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in the  Warnings and Precautions (5)  section of the labeling:     *  Endophthalmitis and retinal detachments   *  Increased intraocular pressure   *  Thromboembolic events        EXCERPT:   The most common adverse reactions (>=5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous floaters, intraocular pressure increased, and vitreous detachment.",events EXCERPT : is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in the  Warnings and Precautions (5)  section of the labeling:     *  Endophthalmitis and retinal detachments   *  Increased intraocular pressure   *  Thromboembolic events        EXCERPT:   The most common adverse reactions (>=5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous floaters, intraocular pressure increased, and vitreous detachment.",* Increased is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in the  Warnings and Precautions (5)  section of the labeling:     *  Endophthalmitis and retinal detachments   *  Increased intraocular pressure   *  Thromboembolic events        EXCERPT:   The most common adverse reactions (>=5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous floaters, intraocular pressure increased, and vitreous detachment.",vitreous detachment is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in the  Warnings and Precautions (5)  section of the labeling:     *  Endophthalmitis and retinal detachments   *  Increased intraocular pressure   *  Thromboembolic events        EXCERPT:   The most common adverse reactions (>=5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous floaters, intraocular pressure increased, and vitreous detachment.",", intraocular pressure is not a named entity"
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in the  Warnings and Precautions (5)  section of the labeling:     *  Endophthalmitis and retinal detachments   *  Increased intraocular pressure   *  Thromboembolic events        EXCERPT:   The most common adverse reactions (>=5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous floaters, intraocular pressure increased, and vitreous detachment.",adverse reactions is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in the  Warnings and Precautions (5)  section of the labeling:     *  Endophthalmitis and retinal detachments   *  Increased intraocular pressure   *  Thromboembolic events        EXCERPT:   The most common adverse reactions (>=5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous floaters, intraocular pressure increased, and vitreous detachment.",Precautions ( 5 is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in the  Warnings and Precautions (5)  section of the labeling:     *  Endophthalmitis and retinal detachments   *  Increased intraocular pressure   *  Thromboembolic events        EXCERPT:   The most common adverse reactions (>=5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous floaters, intraocular pressure increased, and vitreous detachment.",greater detail in is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in the  Warnings and Precautions (5)  section of the labeling:     *  Endophthalmitis and retinal detachments   *  Increased intraocular pressure   *  Thromboembolic events        EXCERPT:   The most common adverse reactions (>=5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous floaters, intraocular pressure increased, and vitreous detachment.",retinal detachments is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in the  Warnings and Precautions (5)  section of the labeling:     *  Endophthalmitis and retinal detachments   *  Increased intraocular pressure   *  Thromboembolic events        EXCERPT:   The most common adverse reactions (>=5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous floaters, intraocular pressure increased, and vitreous detachment.",Thromboembolic events is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in the  Warnings and Precautions (5)  section of the labeling:     *  Endophthalmitis and retinal detachments   *  Increased intraocular pressure   *  Thromboembolic events        EXCERPT:   The most common adverse reactions (>=5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous floaters, intraocular pressure increased, and vitreous detachment.",5 ) is not a named entity
"5.2 Increase in Intraocular Pressure    Acute increases in intraocular pressure have been seen within 60 minutes of intravitreal injection, including with EYLEA [  seeAdverse Reactions (6.1)  ].",been seen is not a named entity
"5.2 Increase in Intraocular Pressure    Acute increases in intraocular pressure have been seen within 60 minutes of intravitreal injection, including with EYLEA [  seeAdverse Reactions (6.1)  ].",Acute increases in intraocular pressure is an adverse reaction entity
"Among those, 2110 patients were treated with the recommended dose of 2 mg. Serious adverse reactions related to the injection procedure have occurred in <0.1% of intravitreal injections with EYLEA including endophthalmitis and retinal detachment.",related to is not a named entity
"Among those, 2110 patients were treated with the recommended dose of 2 mg. Serious adverse reactions related to the injection procedure have occurred in <0.1% of intravitreal injections with EYLEA including endophthalmitis and retinal detachment.",retinal detachment is an adverse reaction entity
"Among those, 2110 patients were treated with the recommended dose of 2 mg. Serious adverse reactions related to the injection procedure have occurred in <0.1% of intravitreal injections with EYLEA including endophthalmitis and retinal detachment.",2 mg. Serious is not a named entity
"Among those, 2110 patients were treated with the recommended dose of 2 mg. Serious adverse reactions related to the injection procedure have occurred in <0.1% of intravitreal injections with EYLEA including endophthalmitis and retinal detachment.",endophthalmitis is an adverse reaction entity
"5.3 Thromboembolic Events      There is a potential risk of arterial thromboembolic events (ATEs) following intravitreal use of VEGF inhibitors, including EYLEA.",ATEs is an adverse reaction entity
"5.3 Thromboembolic Events      There is a potential risk of arterial thromboembolic events (ATEs) following intravitreal use of VEGF inhibitors, including EYLEA.",EYLEA is not a named entity
"5.3 Thromboembolic Events      There is a potential risk of arterial thromboembolic events (ATEs) following intravitreal use of VEGF inhibitors, including EYLEA.",of VEGF is not a named entity
"5.3 Thromboembolic Events      There is a potential risk of arterial thromboembolic events (ATEs) following intravitreal use of VEGF inhibitors, including EYLEA.",arterial thromboembolic events is an adverse reaction entity
(5.2)   *  There is a potential risk of arterial thromboembolic events following intravitreal use of VEGF inhibitors.,* is not a named entity
(5.2)   *  There is a potential risk of arterial thromboembolic events following intravitreal use of VEGF inhibitors.,arterial thromboembolic events is an adverse reaction entity
(5.1)   *  Increases in intraocular pressure have been seen within 60 minutes of an intravitreal injection.,Increases in intraocular pressure is an adverse reaction entity
(5.1)   *  Increases in intraocular pressure have been seen within 60 minutes of an intravitreal injection.,have is not a named entity
Sustained increases in intraocular pressure have also been reported after repeated intravitreal dosing with vascular endothelial growth factor (VEGF) inhibitors.,growth is not a named entity
Sustained increases in intraocular pressure have also been reported after repeated intravitreal dosing with vascular endothelial growth factor (VEGF) inhibitors.,Sustained increases in intraocular pressure is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS     EXCERPT:    *  Endophthalmitis and retinal detachments may occur following intravitreal injections.,Endophthalmitis is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS     EXCERPT:    *  Endophthalmitis and retinal detachments may occur following intravitreal injections.,5 WARNINGS AND is not a named entity
5 WARNINGS AND PRECAUTIONS     EXCERPT:    *  Endophthalmitis and retinal detachments may occur following intravitreal injections.,retinal detachments is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS     EXCERPT:    *  Endophthalmitis and retinal detachments may occur following intravitreal injections.,occur following intravitreal is not a named entity
"Ovarian Cancer       In some epidemiological studies, the use of estrogen-only products, in particular for 5 or more years, has been associated with an increased risk of ovarian cancer.",ovarian cancer is an adverse reaction entity
"Ovarian Cancer       In some epidemiological studies, the use of estrogen-only products, in particular for 5 or more years, has been associated with an increased risk of ovarian cancer.",or more years is not a named entity
An increased risk of stroke and DVT has been reported with estrogen-alone therapy.,DVT has been is not a named entity
An increased risk of stroke and DVT has been reported with estrogen-alone therapy.,stroke is an adverse reaction entity
An increased risk of stroke and DVT has been reported with estrogen-alone therapy.,DVT is an adverse reaction entity
An increased risk of stroke and DVT has been reported with estrogen-alone therapy.,estrogen-alone is not a named entity
"Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin).",increased angiotensinogen is an adverse reaction entity
"Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin).",", alpha-1-antitrypsin , is not a named entity"
"Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin).",ceruloplasmin ) is not a named entity
"Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin).","angiotensinogen/renin substrate , is not a named entity"
"Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin).",increased renin substrate is an adverse reaction entity
"Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin).",increased ( angiotensinogen/renin is not a named entity
"Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin).",Other plasma is not a named entity
"Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin).",plasma proteins increased is an adverse reaction entity
"Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin).",increased alpha-1-antitrypsin is an adverse reaction entity
"Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin).",increased ceruloplasmin is an adverse reaction entity
"BOXED WARNING: WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA       WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA         *  Women taking DUAVEE should not take additional estrogens [see Warnings and Precautions (5.1)]   *  There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens.",woman with a is not a named entity
"BOXED WARNING: WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA       WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA         *  Women taking DUAVEE should not take additional estrogens [see Warnings and Precautions (5.1)]   *  There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens.",BOXED is not a named entity
"BOXED WARNING: WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA       WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA         *  Women taking DUAVEE should not take additional estrogens [see Warnings and Precautions (5.1)]   *  There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens.",Women taking DUAVEE is not a named entity
"BOXED WARNING: WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA       WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA         *  Women taking DUAVEE should not take additional estrogens [see Warnings and Precautions (5.1)]   *  There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens.",CARDIOVASCULAR DISORDERS is an adverse reaction entity
"BOXED WARNING: WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA       WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA         *  Women taking DUAVEE should not take additional estrogens [see Warnings and Precautions (5.1)]   *  There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens.",CARDIOVASCULAR DISORDERS is an adverse reaction entity
"BOXED WARNING: WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA       WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA         *  Women taking DUAVEE should not take additional estrogens [see Warnings and Precautions (5.1)]   *  There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens.",ENDOMETRIAL CANCER is an adverse reaction entity
"BOXED WARNING: WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA       WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA         *  Women taking DUAVEE should not take additional estrogens [see Warnings and Precautions (5.1)]   *  There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens.",DEMENTIA is an adverse reaction entity
"BOXED WARNING: WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA       WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA         *  Women taking DUAVEE should not take additional estrogens [see Warnings and Precautions (5.1)]   *  There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens.",take additional estrogens is not a named entity
"BOXED WARNING: WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA       WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA         *  Women taking DUAVEE should not take additional estrogens [see Warnings and Precautions (5.1)]   *  There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens.",see Warnings is not a named entity
"BOXED WARNING: WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA       WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA         *  Women taking DUAVEE should not take additional estrogens [see Warnings and Precautions (5.1)]   *  There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens.",DEMENTIA is an adverse reaction entity
"BOXED WARNING: WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA       WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA         *  Women taking DUAVEE should not take additional estrogens [see Warnings and Precautions (5.1)]   *  There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens.",DEMENTIA * is not a named entity
"BOXED WARNING: WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA       WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA         *  Women taking DUAVEE should not take additional estrogens [see Warnings and Precautions (5.1)]   *  There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens.","ENDOMETRIAL CANCER , is not a named entity"
"BOXED WARNING: WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA       WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA         *  Women taking DUAVEE should not take additional estrogens [see Warnings and Precautions (5.1)]   *  There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens.",ENDOMETRIAL CANCER is an adverse reaction entity
"BOXED WARNING: WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA       WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA         *  Women taking DUAVEE should not take additional estrogens [see Warnings and Precautions (5.1)]   *  There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens.",endometrial cancer is an adverse reaction entity
"5.7 Elevated Blood Pressure      In a small number of case reports in women receiving estrogens, substantial increases in blood pressure have been attributed to idiosyncratic reactions to estrogens.",have been attributed is not a named entity
"5.7 Elevated Blood Pressure      In a small number of case reports in women receiving estrogens, substantial increases in blood pressure have been attributed to idiosyncratic reactions to estrogens.",increases in blood pressure is an adverse reaction entity
"Stroke       In the WHI estrogen-alone substudy, a statistically significant increased risk of stroke was reported in women 50 to 79 years of age receiving daily conjugated estrogens (CE) (0.625 mg)-alone compared to women in the same age group receiving placebo (45 versus 33 per 10,000 women-years).",stroke is an adverse reaction entity
"Stroke       In the WHI estrogen-alone substudy, a statistically significant increased risk of stroke was reported in women 50 to 79 years of age receiving daily conjugated estrogens (CE) (0.625 mg)-alone compared to women in the same age group receiving placebo (45 versus 33 per 10,000 women-years).",women 50 to is not a named entity
5.6 Visual Abnormalities      Retinal vascular thrombosis has been reported in patients receiving estrogens.,Retinal vascular thrombosis is an adverse reaction entity
5.6 Visual Abnormalities      Retinal vascular thrombosis has been reported in patients receiving estrogens.,has been is not a named entity
"In the WHI estrogen-alone substudy, after an average follow-up of 7.1 years, daily conjugated estrogen (0.625 mg)-alone was not associated with an increased risk of invasive breast cancer (relative risk [RR] 0.80).",invasive breast cancer is an adverse reaction entity
"In the WHI estrogen-alone substudy, after an average follow-up of 7.1 years, daily conjugated estrogen (0.625 mg)-alone was not associated with an increased risk of invasive breast cancer (relative risk [RR] 0.80).",daily is not a named entity
"Venous Thromboembolism (VTE)       In the WHI estrogen-alone substudy, the risk of VTE [DVT and pulmonary embolism (PE)] was increased for women receiving daily conjugated estrogens (0.625 mg)-alone compared to placebo (30 versus 22 per 10,000 women-years), although only the increased risk of DVT reached statistical significance (23 versus 15 per 10,000 women-years).",PE is an adverse reaction entity
"Venous Thromboembolism (VTE)       In the WHI estrogen-alone substudy, the risk of VTE [DVT and pulmonary embolism (PE)] was increased for women receiving daily conjugated estrogens (0.625 mg)-alone compared to placebo (30 versus 22 per 10,000 women-years), although only the increased risk of DVT reached statistical significance (23 versus 15 per 10,000 women-years).",pulmonary embolism is an adverse reaction entity
"Venous Thromboembolism (VTE)       In the WHI estrogen-alone substudy, the risk of VTE [DVT and pulmonary embolism (PE)] was increased for women receiving daily conjugated estrogens (0.625 mg)-alone compared to placebo (30 versus 22 per 10,000 women-years), although only the increased risk of DVT reached statistical significance (23 versus 15 per 10,000 women-years).",for women is not a named entity
"Venous Thromboembolism (VTE)       In the WHI estrogen-alone substudy, the risk of VTE [DVT and pulmonary embolism (PE)] was increased for women receiving daily conjugated estrogens (0.625 mg)-alone compared to placebo (30 versus 22 per 10,000 women-years), although only the increased risk of DVT reached statistical significance (23 versus 15 per 10,000 women-years).",placebo ( is not a named entity
"Venous Thromboembolism (VTE)       In the WHI estrogen-alone substudy, the risk of VTE [DVT and pulmonary embolism (PE)] was increased for women receiving daily conjugated estrogens (0.625 mg)-alone compared to placebo (30 versus 22 per 10,000 women-years), although only the increased risk of DVT reached statistical significance (23 versus 15 per 10,000 women-years).",VTE is an adverse reaction entity
"Venous Thromboembolism (VTE)       In the WHI estrogen-alone substudy, the risk of VTE [DVT and pulmonary embolism (PE)] was increased for women receiving daily conjugated estrogens (0.625 mg)-alone compared to placebo (30 versus 22 per 10,000 women-years), although only the increased risk of DVT reached statistical significance (23 versus 15 per 10,000 women-years).",) ] was is not a named entity
"Venous Thromboembolism (VTE)       In the WHI estrogen-alone substudy, the risk of VTE [DVT and pulmonary embolism (PE)] was increased for women receiving daily conjugated estrogens (0.625 mg)-alone compared to placebo (30 versus 22 per 10,000 women-years), although only the increased risk of DVT reached statistical significance (23 versus 15 per 10,000 women-years).",DVT is an adverse reaction entity
"Venous Thromboembolism (VTE)       In the WHI estrogen-alone substudy, the risk of VTE [DVT and pulmonary embolism (PE)] was increased for women receiving daily conjugated estrogens (0.625 mg)-alone compared to placebo (30 versus 22 per 10,000 women-years), although only the increased risk of DVT reached statistical significance (23 versus 15 per 10,000 women-years).",women receiving daily is not a named entity
"Venous Thromboembolism (VTE)       In the WHI estrogen-alone substudy, the risk of VTE [DVT and pulmonary embolism (PE)] was increased for women receiving daily conjugated estrogens (0.625 mg)-alone compared to placebo (30 versus 22 per 10,000 women-years), although only the increased risk of DVT reached statistical significance (23 versus 15 per 10,000 women-years).",the WHI is not a named entity
"Venous Thromboembolism (VTE)       In the WHI estrogen-alone substudy, the risk of VTE [DVT and pulmonary embolism (PE)] was increased for women receiving daily conjugated estrogens (0.625 mg)-alone compared to placebo (30 versus 22 per 10,000 women-years), although only the increased risk of DVT reached statistical significance (23 versus 15 per 10,000 women-years).",DVT is an adverse reaction entity
5.5 Gallbladder Disease      A 2- to 4-fold increase in the risk of gallbladder disease requiring surgery in postmenopausal women receiving estrogens has been reported.,5.5 Gallbladder is not a named entity
5.5 Gallbladder Disease      A 2- to 4-fold increase in the risk of gallbladder disease requiring surgery in postmenopausal women receiving estrogens has been reported.,gallbladder disease is an adverse reaction entity
5.3 Malignant Neoplasms       Endometrial Cancer       An increased risk of endometrial cancer has been reported with the use of unopposed estrogen therapy in women with a uterus.,uterus is not a named entity
5.3 Malignant Neoplasms       Endometrial Cancer       An increased risk of endometrial cancer has been reported with the use of unopposed estrogen therapy in women with a uterus.,endometrial cancer is an adverse reaction entity
"5.17 Drug-Laboratory Test Interactions      Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.",increased factors VII antigen is an adverse reaction entity
"5.17 Drug-Laboratory Test Interactions      Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.","VIII antigen , is not a named entity"
"5.17 Drug-Laboratory Test Interactions      Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.",increased factors II-VII-X complex is an adverse reaction entity
"5.17 Drug-Laboratory Test Interactions      Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.",increased factors IX is an adverse reaction entity
"5.17 Drug-Laboratory Test Interactions      Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.",increased factors VIII coagulant activity is an adverse reaction entity
"5.17 Drug-Laboratory Test Interactions      Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.","antigen , VIII is not a named entity"
"5.17 Drug-Laboratory Test Interactions      Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.",and platelet aggregation is not a named entity
"5.17 Drug-Laboratory Test Interactions      Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.",Test Interactions Accelerated is not a named entity
"5.17 Drug-Laboratory Test Interactions      Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.","activity , IX is not a named entity"
"5.17 Drug-Laboratory Test Interactions      Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.",increased plasminogen antigen is an adverse reaction entity
"5.17 Drug-Laboratory Test Interactions      Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.",increased factors VII-X complex is an adverse reaction entity
"5.17 Drug-Laboratory Test Interactions      Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.",increased beta-thromboglobulin is an adverse reaction entity
"5.17 Drug-Laboratory Test Interactions      Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.",Accelerated platelet aggregation time is an adverse reaction entity
"5.17 Drug-Laboratory Test Interactions      Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.",fibrinogen and fibrinogen is not a named entity
"5.17 Drug-Laboratory Test Interactions      Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.",Accelerated partial thromboplastin time is an adverse reaction entity
"5.17 Drug-Laboratory Test Interactions      Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.",decreased antithrombin III activity is an adverse reaction entity
"5.17 Drug-Laboratory Test Interactions      Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.",; decreased is not a named entity
"5.17 Drug-Laboratory Test Interactions      Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.",time ; is not a named entity
"5.17 Drug-Laboratory Test Interactions      Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.",complex is not a named entity
"5.17 Drug-Laboratory Test Interactions      Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.",increased plasminogen activity is an adverse reaction entity
"5.17 Drug-Laboratory Test Interactions      Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.",and antithrombin is not a named entity
"5.17 Drug-Laboratory Test Interactions      Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.",increased factors VIII antigen is an adverse reaction entity
"5.17 Drug-Laboratory Test Interactions      Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.",", is not a named entity"
"5.17 Drug-Laboratory Test Interactions      Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.",Accelerated prothrombin time is an adverse reaction entity
"5.17 Drug-Laboratory Test Interactions      Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.",", is not a named entity"
"5.17 Drug-Laboratory Test Interactions      Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.",decreased levels of antifactor Xa is an adverse reaction entity
"5.17 Drug-Laboratory Test Interactions      Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.",increased levels of fibrinogen is an adverse reaction entity
"5.17 Drug-Laboratory Test Interactions      Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.",increased factors II is an adverse reaction entity
"5.17 Drug-Laboratory Test Interactions      Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.",complex is not a named entity
"5.17 Drug-Laboratory Test Interactions      Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.",increased factors XII is an adverse reaction entity
"5.17 Drug-Laboratory Test Interactions      Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.",VIII coagulant activity is not a named entity
"5.17 Drug-Laboratory Test Interactions      Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.",decreased levels of antithrombin III is an adverse reaction entity
"5.17 Drug-Laboratory Test Interactions      Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.",increased factors X is an adverse reaction entity
"5.17 Drug-Laboratory Test Interactions      Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.",", is not a named entity"
"5.17 Drug-Laboratory Test Interactions      Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.",; increased is not a named entity
"5.17 Drug-Laboratory Test Interactions      Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.","VIII antigen , is not a named entity"
"5.17 Drug-Laboratory Test Interactions      Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.",increased platelet count is an adverse reaction entity
"5.17 Drug-Laboratory Test Interactions      Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.",increased levels of fibrinogen activity is an adverse reaction entity
"5.17 Drug-Laboratory Test Interactions      Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.",", is not a named entity"
"5.17 Drug-Laboratory Test Interactions      Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.",", II-VII-X complex is not a named entity"
"5.17 Drug-Laboratory Test Interactions      Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.",fibrinogen is not a named entity
"5.17 Drug-Laboratory Test Interactions      Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.",partial is not a named entity
Adverse reactions of venous thromboembolism were reported in 0.0% of patients treated with DUAVEE and 0.1% of patients treated with placebo.,were is not a named entity
Adverse reactions of venous thromboembolism were reported in 0.0% of patients treated with DUAVEE and 0.1% of patients treated with placebo.,venous thromboembolism is an adverse reaction entity
"5.8 Hypertriglyceridemia      In women with pre-existing hypertriglyceridemia, treatment with estrogens may be associated with elevations of plasma triglycerides leading to pancreatitis.",elevations of plasma triglycerides is an adverse reaction entity
"5.8 Hypertriglyceridemia      In women with pre-existing hypertriglyceridemia, treatment with estrogens may be associated with elevations of plasma triglycerides leading to pancreatitis.",triglycerides leading to is not a named entity
"5.8 Hypertriglyceridemia      In women with pre-existing hypertriglyceridemia, treatment with estrogens may be associated with elevations of plasma triglycerides leading to pancreatitis.",may be associated is not a named entity
"5.8 Hypertriglyceridemia      In women with pre-existing hypertriglyceridemia, treatment with estrogens may be associated with elevations of plasma triglycerides leading to pancreatitis.",pancreatitis is an adverse reaction entity
"Women with normal thyroid function can compensate for the increased TBG by making more thyroid hormone, thus maintaining free T4 and T3 serum concentrations in the normal range.",function is not a named entity
"Women with normal thyroid function can compensate for the increased TBG by making more thyroid hormone, thus maintaining free T4 and T3 serum concentrations in the normal range.",increased TBG is an adverse reaction entity
"Due to the low rate of events in both groups, it is not possible to conclude that the risk of venous thromboembolism with DUAVEE is different from that seen with other estrogen therapies  [see  Warnings and Precautions (5.2)  ]  .",venous thromboembolism is an adverse reaction entity
"Due to the low rate of events in both groups, it is not possible to conclude that the risk of venous thromboembolism with DUAVEE is different from that seen with other estrogen therapies  [see  Warnings and Precautions (5.2)  ]  .",risk of is not a named entity
The incidence of all-cause mortality was 0.0% in the DUAVEE group and 0.2% in the placebo group.,mortality is an adverse reaction entity
The incidence of all-cause mortality was 0.0% in the DUAVEE group and 0.2% in the placebo group.,% in the is not a named entity
"The absolute risk of probable dementia for CE-alone versus placebo was 37 versus 25 cases per 10,000 women-years [see  Use in Specific Populations (8.5)  and  Clinical Studies (14.6)  ]  .",dementia is an adverse reaction entity
"The absolute risk of probable dementia for CE-alone versus placebo was 37 versus 25 cases per 10,000 women-years [see  Use in Specific Populations (8.5)  and  Clinical Studies (14.6)  ]  .",versus 25 cases is not a named entity
The increase in VTE risk was demonstrated during the first 2 years [see  Clinical Studies (14.5)  ]  .,VTE is an adverse reaction entity
The increase in VTE risk was demonstrated during the first 2 years [see  Clinical Studies (14.5)  ]  .,in is not a named entity
"The relative risk of probable dementia for CE-alone versus placebo was 1.49 (95 percent CI, 0.83-2.66).",dementia is an adverse reaction entity
"The relative risk of probable dementia for CE-alone versus placebo was 1.49 (95 percent CI, 0.83-2.66).",for CE-alone is not a named entity
5.10 Hypothyroidism      Estrogen administration leads to increased thyroid-binding globulin (TBG) levels.,increased thyroid-binding globulin levels is an adverse reaction entity
5.10 Hypothyroidism      Estrogen administration leads to increased thyroid-binding globulin (TBG) levels.,increased TBG levels is an adverse reaction entity
5.10 Hypothyroidism      Estrogen administration leads to increased thyroid-binding globulin (TBG) levels.,Estrogen administration leads is not a named entity
5.10 Hypothyroidism      Estrogen administration leads to increased thyroid-binding globulin (TBG) levels.,TBG is not a named entity
"Increased thyroid-binding globulin (TBG) leading to increased circulating total thyroid hormone, as measured by protein-bound iodine (PBI), T4 levels (by column or by radioimmunoassay), or T3 levels by radioimmunoassay.",") , T4 is not a named entity"
"Increased thyroid-binding globulin (TBG) leading to increased circulating total thyroid hormone, as measured by protein-bound iodine (PBI), T4 levels (by column or by radioimmunoassay), or T3 levels by radioimmunoassay.",increased circulating total thyroid hormone is an adverse reaction entity
"Increased thyroid-binding globulin (TBG) leading to increased circulating total thyroid hormone, as measured by protein-bound iodine (PBI), T4 levels (by column or by radioimmunoassay), or T3 levels by radioimmunoassay.",increased T3 levels is an adverse reaction entity
"Increased thyroid-binding globulin (TBG) leading to increased circulating total thyroid hormone, as measured by protein-bound iodine (PBI), T4 levels (by column or by radioimmunoassay), or T3 levels by radioimmunoassay.",leading to increased is not a named entity
"Increased thyroid-binding globulin (TBG) leading to increased circulating total thyroid hormone, as measured by protein-bound iodine (PBI), T4 levels (by column or by radioimmunoassay), or T3 levels by radioimmunoassay.",Increased TBG is an adverse reaction entity
"Increased thyroid-binding globulin (TBG) leading to increased circulating total thyroid hormone, as measured by protein-bound iodine (PBI), T4 levels (by column or by radioimmunoassay), or T3 levels by radioimmunoassay.",or T3 is not a named entity
"Increased thyroid-binding globulin (TBG) leading to increased circulating total thyroid hormone, as measured by protein-bound iodine (PBI), T4 levels (by column or by radioimmunoassay), or T3 levels by radioimmunoassay.",( by is not a named entity
"Increased thyroid-binding globulin (TBG) leading to increased circulating total thyroid hormone, as measured by protein-bound iodine (PBI), T4 levels (by column or by radioimmunoassay), or T3 levels by radioimmunoassay.",Increased thyroid-binding globulin is an adverse reaction entity
"Increased thyroid-binding globulin (TBG) leading to increased circulating total thyroid hormone, as measured by protein-bound iodine (PBI), T4 levels (by column or by radioimmunoassay), or T3 levels by radioimmunoassay.",as measured by is not a named entity
"Increased thyroid-binding globulin (TBG) leading to increased circulating total thyroid hormone, as measured by protein-bound iodine (PBI), T4 levels (by column or by radioimmunoassay), or T3 levels by radioimmunoassay.",increased T4 levels is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the label:     *  Cardiovascular Disorders [see  Warnings and Precautions (5.2)  ]    *  Malignant Neoplasms [see  Warnings and Precautions (5.3)  ]    *  Gallbladder Disease [see  Warnings and Precautions (5.5)  ]    *  Hypertriglyceridemia [see  Warnings and Precautions (5.8)  ]         EXCERPT:   In four prospective, randomized, placebo-controlled trials the common adverse reactions (incidence >= 5%) were muscle spasms, nausea, diarrhea, dyspepsia, abdominal pain upper, oropharyngeal pain, dizziness, and neck pain (  6.1  )       To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.",and is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the label:     *  Cardiovascular Disorders [see  Warnings and Precautions (5.2)  ]    *  Malignant Neoplasms [see  Warnings and Precautions (5.3)  ]    *  Gallbladder Disease [see  Warnings and Precautions (5.5)  ]    *  Hypertriglyceridemia [see  Warnings and Precautions (5.8)  ]         EXCERPT:   In four prospective, randomized, placebo-controlled trials the common adverse reactions (incidence >= 5%) were muscle spasms, nausea, diarrhea, dyspepsia, abdominal pain upper, oropharyngeal pain, dizziness, and neck pain (  6.1  )       To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.",trials is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the label:     *  Cardiovascular Disorders [see  Warnings and Precautions (5.2)  ]    *  Malignant Neoplasms [see  Warnings and Precautions (5.3)  ]    *  Gallbladder Disease [see  Warnings and Precautions (5.5)  ]    *  Hypertriglyceridemia [see  Warnings and Precautions (5.8)  ]         EXCERPT:   In four prospective, randomized, placebo-controlled trials the common adverse reactions (incidence >= 5%) were muscle spasms, nausea, diarrhea, dyspepsia, abdominal pain upper, oropharyngeal pain, dizziness, and neck pain (  6.1  )       To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.",dizziness is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the label:     *  Cardiovascular Disorders [see  Warnings and Precautions (5.2)  ]    *  Malignant Neoplasms [see  Warnings and Precautions (5.3)  ]    *  Gallbladder Disease [see  Warnings and Precautions (5.5)  ]    *  Hypertriglyceridemia [see  Warnings and Precautions (5.8)  ]         EXCERPT:   In four prospective, randomized, placebo-controlled trials the common adverse reactions (incidence >= 5%) were muscle spasms, nausea, diarrhea, dyspepsia, abdominal pain upper, oropharyngeal pain, dizziness, and neck pain (  6.1  )       To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.",( is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the label:     *  Cardiovascular Disorders [see  Warnings and Precautions (5.2)  ]    *  Malignant Neoplasms [see  Warnings and Precautions (5.3)  ]    *  Gallbladder Disease [see  Warnings and Precautions (5.5)  ]    *  Hypertriglyceridemia [see  Warnings and Precautions (5.8)  ]         EXCERPT:   In four prospective, randomized, placebo-controlled trials the common adverse reactions (incidence >= 5%) were muscle spasms, nausea, diarrhea, dyspepsia, abdominal pain upper, oropharyngeal pain, dizziness, and neck pain (  6.1  )       To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.",muscle spasms is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the label:     *  Cardiovascular Disorders [see  Warnings and Precautions (5.2)  ]    *  Malignant Neoplasms [see  Warnings and Precautions (5.3)  ]    *  Gallbladder Disease [see  Warnings and Precautions (5.5)  ]    *  Hypertriglyceridemia [see  Warnings and Precautions (5.8)  ]         EXCERPT:   In four prospective, randomized, placebo-controlled trials the common adverse reactions (incidence >= 5%) were muscle spasms, nausea, diarrhea, dyspepsia, abdominal pain upper, oropharyngeal pain, dizziness, and neck pain (  6.1  )       To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.",contact Pfizer Inc. is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the label:     *  Cardiovascular Disorders [see  Warnings and Precautions (5.2)  ]    *  Malignant Neoplasms [see  Warnings and Precautions (5.3)  ]    *  Gallbladder Disease [see  Warnings and Precautions (5.5)  ]    *  Hypertriglyceridemia [see  Warnings and Precautions (5.8)  ]         EXCERPT:   In four prospective, randomized, placebo-controlled trials the common adverse reactions (incidence >= 5%) were muscle spasms, nausea, diarrhea, dyspepsia, abdominal pain upper, oropharyngeal pain, dizziness, and neck pain (  6.1  )       To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.",Gallbladder Disease is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the label:     *  Cardiovascular Disorders [see  Warnings and Precautions (5.2)  ]    *  Malignant Neoplasms [see  Warnings and Precautions (5.3)  ]    *  Gallbladder Disease [see  Warnings and Precautions (5.5)  ]    *  Hypertriglyceridemia [see  Warnings and Precautions (5.8)  ]         EXCERPT:   In four prospective, randomized, placebo-controlled trials the common adverse reactions (incidence >= 5%) were muscle spasms, nausea, diarrhea, dyspepsia, abdominal pain upper, oropharyngeal pain, dizziness, and neck pain (  6.1  )       To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.",Cardiovascular Disorders is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the label:     *  Cardiovascular Disorders [see  Warnings and Precautions (5.2)  ]    *  Malignant Neoplasms [see  Warnings and Precautions (5.3)  ]    *  Gallbladder Disease [see  Warnings and Precautions (5.5)  ]    *  Hypertriglyceridemia [see  Warnings and Precautions (5.8)  ]         EXCERPT:   In four prospective, randomized, placebo-controlled trials the common adverse reactions (incidence >= 5%) were muscle spasms, nausea, diarrhea, dyspepsia, abdominal pain upper, oropharyngeal pain, dizziness, and neck pain (  6.1  )       To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.",nausea is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the label:     *  Cardiovascular Disorders [see  Warnings and Precautions (5.2)  ]    *  Malignant Neoplasms [see  Warnings and Precautions (5.3)  ]    *  Gallbladder Disease [see  Warnings and Precautions (5.5)  ]    *  Hypertriglyceridemia [see  Warnings and Precautions (5.8)  ]         EXCERPT:   In four prospective, randomized, placebo-controlled trials the common adverse reactions (incidence >= 5%) were muscle spasms, nausea, diarrhea, dyspepsia, abdominal pain upper, oropharyngeal pain, dizziness, and neck pain (  6.1  )       To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.",Hypertriglyceridemia is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the label:     *  Cardiovascular Disorders [see  Warnings and Precautions (5.2)  ]    *  Malignant Neoplasms [see  Warnings and Precautions (5.3)  ]    *  Gallbladder Disease [see  Warnings and Precautions (5.5)  ]    *  Hypertriglyceridemia [see  Warnings and Precautions (5.8)  ]         EXCERPT:   In four prospective, randomized, placebo-controlled trials the common adverse reactions (incidence >= 5%) were muscle spasms, nausea, diarrhea, dyspepsia, abdominal pain upper, oropharyngeal pain, dizziness, and neck pain (  6.1  )       To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.",the is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the label:     *  Cardiovascular Disorders [see  Warnings and Precautions (5.2)  ]    *  Malignant Neoplasms [see  Warnings and Precautions (5.3)  ]    *  Gallbladder Disease [see  Warnings and Precautions (5.5)  ]    *  Hypertriglyceridemia [see  Warnings and Precautions (5.8)  ]         EXCERPT:   In four prospective, randomized, placebo-controlled trials the common adverse reactions (incidence >= 5%) were muscle spasms, nausea, diarrhea, dyspepsia, abdominal pain upper, oropharyngeal pain, dizziness, and neck pain (  6.1  )       To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.",diarrhea is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the label:     *  Cardiovascular Disorders [see  Warnings and Precautions (5.2)  ]    *  Malignant Neoplasms [see  Warnings and Precautions (5.3)  ]    *  Gallbladder Disease [see  Warnings and Precautions (5.5)  ]    *  Hypertriglyceridemia [see  Warnings and Precautions (5.8)  ]         EXCERPT:   In four prospective, randomized, placebo-controlled trials the common adverse reactions (incidence >= 5%) were muscle spasms, nausea, diarrhea, dyspepsia, abdominal pain upper, oropharyngeal pain, dizziness, and neck pain (  6.1  )       To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.",[ see is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the label:     *  Cardiovascular Disorders [see  Warnings and Precautions (5.2)  ]    *  Malignant Neoplasms [see  Warnings and Precautions (5.3)  ]    *  Gallbladder Disease [see  Warnings and Precautions (5.5)  ]    *  Hypertriglyceridemia [see  Warnings and Precautions (5.8)  ]         EXCERPT:   In four prospective, randomized, placebo-controlled trials the common adverse reactions (incidence >= 5%) were muscle spasms, nausea, diarrhea, dyspepsia, abdominal pain upper, oropharyngeal pain, dizziness, and neck pain (  6.1  )       To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.","nausea , diarrhea is not a named entity"
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the label:     *  Cardiovascular Disorders [see  Warnings and Precautions (5.2)  ]    *  Malignant Neoplasms [see  Warnings and Precautions (5.3)  ]    *  Gallbladder Disease [see  Warnings and Precautions (5.5)  ]    *  Hypertriglyceridemia [see  Warnings and Precautions (5.8)  ]         EXCERPT:   In four prospective, randomized, placebo-controlled trials the common adverse reactions (incidence >= 5%) were muscle spasms, nausea, diarrhea, dyspepsia, abdominal pain upper, oropharyngeal pain, dizziness, and neck pain (  6.1  )       To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.",% is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the label:     *  Cardiovascular Disorders [see  Warnings and Precautions (5.2)  ]    *  Malignant Neoplasms [see  Warnings and Precautions (5.3)  ]    *  Gallbladder Disease [see  Warnings and Precautions (5.5)  ]    *  Hypertriglyceridemia [see  Warnings and Precautions (5.8)  ]         EXCERPT:   In four prospective, randomized, placebo-controlled trials the common adverse reactions (incidence >= 5%) were muscle spasms, nausea, diarrhea, dyspepsia, abdominal pain upper, oropharyngeal pain, dizziness, and neck pain (  6.1  )       To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.","diarrhea , is not a named entity"
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the label:     *  Cardiovascular Disorders [see  Warnings and Precautions (5.2)  ]    *  Malignant Neoplasms [see  Warnings and Precautions (5.3)  ]    *  Gallbladder Disease [see  Warnings and Precautions (5.5)  ]    *  Hypertriglyceridemia [see  Warnings and Precautions (5.8)  ]         EXCERPT:   In four prospective, randomized, placebo-controlled trials the common adverse reactions (incidence >= 5%) were muscle spasms, nausea, diarrhea, dyspepsia, abdominal pain upper, oropharyngeal pain, dizziness, and neck pain (  6.1  )       To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.",neck pain is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the label:     *  Cardiovascular Disorders [see  Warnings and Precautions (5.2)  ]    *  Malignant Neoplasms [see  Warnings and Precautions (5.3)  ]    *  Gallbladder Disease [see  Warnings and Precautions (5.5)  ]    *  Hypertriglyceridemia [see  Warnings and Precautions (5.8)  ]         EXCERPT:   In four prospective, randomized, placebo-controlled trials the common adverse reactions (incidence >= 5%) were muscle spasms, nausea, diarrhea, dyspepsia, abdominal pain upper, oropharyngeal pain, dizziness, and neck pain (  6.1  )       To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.",dyspepsia is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the label:     *  Cardiovascular Disorders [see  Warnings and Precautions (5.2)  ]    *  Malignant Neoplasms [see  Warnings and Precautions (5.3)  ]    *  Gallbladder Disease [see  Warnings and Precautions (5.5)  ]    *  Hypertriglyceridemia [see  Warnings and Precautions (5.8)  ]         EXCERPT:   In four prospective, randomized, placebo-controlled trials the common adverse reactions (incidence >= 5%) were muscle spasms, nausea, diarrhea, dyspepsia, abdominal pain upper, oropharyngeal pain, dizziness, and neck pain (  6.1  )       To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.",) is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the label:     *  Cardiovascular Disorders [see  Warnings and Precautions (5.2)  ]    *  Malignant Neoplasms [see  Warnings and Precautions (5.3)  ]    *  Gallbladder Disease [see  Warnings and Precautions (5.5)  ]    *  Hypertriglyceridemia [see  Warnings and Precautions (5.8)  ]         EXCERPT:   In four prospective, randomized, placebo-controlled trials the common adverse reactions (incidence >= 5%) were muscle spasms, nausea, diarrhea, dyspepsia, abdominal pain upper, oropharyngeal pain, dizziness, and neck pain (  6.1  )       To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.",Malignant Neoplasms is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the label:     *  Cardiovascular Disorders [see  Warnings and Precautions (5.2)  ]    *  Malignant Neoplasms [see  Warnings and Precautions (5.3)  ]    *  Gallbladder Disease [see  Warnings and Precautions (5.5)  ]    *  Hypertriglyceridemia [see  Warnings and Precautions (5.8)  ]         EXCERPT:   In four prospective, randomized, placebo-controlled trials the common adverse reactions (incidence >= 5%) were muscle spasms, nausea, diarrhea, dyspepsia, abdominal pain upper, oropharyngeal pain, dizziness, and neck pain (  6.1  )       To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.",oropharyngeal pain is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the label:     *  Cardiovascular Disorders [see  Warnings and Precautions (5.2)  ]    *  Malignant Neoplasms [see  Warnings and Precautions (5.3)  ]    *  Gallbladder Disease [see  Warnings and Precautions (5.5)  ]    *  Hypertriglyceridemia [see  Warnings and Precautions (5.8)  ]         EXCERPT:   In four prospective, randomized, placebo-controlled trials the common adverse reactions (incidence >= 5%) were muscle spasms, nausea, diarrhea, dyspepsia, abdominal pain upper, oropharyngeal pain, dizziness, and neck pain (  6.1  )       To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.",* Hypertriglyceridemia is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the label:     *  Cardiovascular Disorders [see  Warnings and Precautions (5.2)  ]    *  Malignant Neoplasms [see  Warnings and Precautions (5.3)  ]    *  Gallbladder Disease [see  Warnings and Precautions (5.5)  ]    *  Hypertriglyceridemia [see  Warnings and Precautions (5.8)  ]         EXCERPT:   In four prospective, randomized, placebo-controlled trials the common adverse reactions (incidence >= 5%) were muscle spasms, nausea, diarrhea, dyspepsia, abdominal pain upper, oropharyngeal pain, dizziness, and neck pain (  6.1  )       To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.",other sections is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the label:     *  Cardiovascular Disorders [see  Warnings and Precautions (5.2)  ]    *  Malignant Neoplasms [see  Warnings and Precautions (5.3)  ]    *  Gallbladder Disease [see  Warnings and Precautions (5.5)  ]    *  Hypertriglyceridemia [see  Warnings and Precautions (5.8)  ]         EXCERPT:   In four prospective, randomized, placebo-controlled trials the common adverse reactions (incidence >= 5%) were muscle spasms, nausea, diarrhea, dyspepsia, abdominal pain upper, oropharyngeal pain, dizziness, and neck pain (  6.1  )       To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.",abdominal pain upper is an adverse reaction entity
"In a large, randomized, placebo-controlled clinical study, a generalized effect of estrogens on blood pressure was not seen.",pressure is not a named entity
"In a large, randomized, placebo-controlled clinical study, a generalized effect of estrogens on blood pressure was not seen.",effect on blood pressure is an adverse reaction entity
"EXCERPT:     WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA         See full prescribing information for complete Boxed Warning.","ENDOMETRIAL CANCER , is not a named entity"
"EXCERPT:     WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA         See full prescribing information for complete Boxed Warning.",DEMENTIA See full is not a named entity
"EXCERPT:     WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA         See full prescribing information for complete Boxed Warning.",ENDOMETRIAL CANCER is an adverse reaction entity
"EXCERPT:     WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA         See full prescribing information for complete Boxed Warning.",CARDIOVASCULAR DISORDERS is an adverse reaction entity
"EXCERPT:     WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA         See full prescribing information for complete Boxed Warning.",EXCERPT : is not a named entity
"EXCERPT:     WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, AND PROBABLE DEMENTIA         See full prescribing information for complete Boxed Warning.",DEMENTIA is an adverse reaction entity
"[                      see Contraindications                           (4)  , Warnings and Precautions                           (5.1)  ,  and Adverse Reactions                           (6)    ]                          EXCERPT:     WARNING: ANAPHYLAXIS         See full prescribing  information for complete boxed warning                           Anaphylaxis  has been reported after administration of KALBITOR                          (r)  .",ANAPHYLAXIS is an adverse reaction entity
"[                      see Contraindications                           (4)  , Warnings and Precautions                           (5.1)  ,  and Adverse Reactions                           (6)    ]                          EXCERPT:     WARNING: ANAPHYLAXIS         See full prescribing  information for complete boxed warning                           Anaphylaxis  has been reported after administration of KALBITOR                          (r)  .",has is not a named entity
"[                      see Contraindications                           (4)  , Warnings and Precautions                           (5.1)  ,  and Adverse Reactions                           (6)    ]                          EXCERPT:     WARNING: ANAPHYLAXIS         See full prescribing  information for complete boxed warning                           Anaphylaxis  has been reported after administration of KALBITOR                          (r)  .",Anaphylaxis is an adverse reaction entity
"[                      see Contraindications                           (4)  , Warnings and Precautions                           (5.1)  ,  and Adverse Reactions                           (6)    ]                          EXCERPT:     WARNING: ANAPHYLAXIS         See full prescribing  information for complete boxed warning                           Anaphylaxis  has been reported after administration of KALBITOR                          (r)  .",) is not a named entity
"5.1  Hypersensitivity Reactions, Including Anaphylaxis      Potentially serious hypersensitivity reactions, including anaphylaxis, have occurred in patients treated with KALBITOR.",serious hypersensitivity is not a named entity
"5.1  Hypersensitivity Reactions, Including Anaphylaxis      Potentially serious hypersensitivity reactions, including anaphylaxis, have occurred in patients treated with KALBITOR.",anaphylaxis is an adverse reaction entity
"5.1  Hypersensitivity Reactions, Including Anaphylaxis      Potentially serious hypersensitivity reactions, including anaphylaxis, have occurred in patients treated with KALBITOR.","Reactions , Including is not a named entity"
"5.1  Hypersensitivity Reactions, Including Anaphylaxis      Potentially serious hypersensitivity reactions, including anaphylaxis, have occurred in patients treated with KALBITOR.",hypersensitivity is an adverse reaction entity
BOXED WARNING: WARNING: ANAPHYLAXIS    WARNING: ANAPHYLAXIS      Anaphylaxis has been reported  after administration of KALBITOR.,of KALBITOR is not a named entity
BOXED WARNING: WARNING: ANAPHYLAXIS    WARNING: ANAPHYLAXIS      Anaphylaxis has been reported  after administration of KALBITOR.,ANAPHYLAXIS WARNING : is not a named entity
BOXED WARNING: WARNING: ANAPHYLAXIS    WARNING: ANAPHYLAXIS      Anaphylaxis has been reported  after administration of KALBITOR.,ANAPHYLAXIS is an adverse reaction entity
BOXED WARNING: WARNING: ANAPHYLAXIS    WARNING: ANAPHYLAXIS      Anaphylaxis has been reported  after administration of KALBITOR.,ANAPHYLAXIS is an adverse reaction entity
BOXED WARNING: WARNING: ANAPHYLAXIS    WARNING: ANAPHYLAXIS      Anaphylaxis has been reported  after administration of KALBITOR.,been is not a named entity
BOXED WARNING: WARNING: ANAPHYLAXIS    WARNING: ANAPHYLAXIS      Anaphylaxis has been reported  after administration of KALBITOR.,Anaphylaxis is an adverse reaction entity
"Other adverse reactions indicative of hypersensitivity reactions included the following: pruritus (5%), rash (3%), and urticaria (2%).",rash is an adverse reaction entity
"Other adverse reactions indicative of hypersensitivity reactions included the following: pruritus (5%), rash (3%), and urticaria (2%).",the following : is not a named entity
"Other adverse reactions indicative of hypersensitivity reactions included the following: pruritus (5%), rash (3%), and urticaria (2%).",( 5 is not a named entity
"Other adverse reactions indicative of hypersensitivity reactions included the following: pruritus (5%), rash (3%), and urticaria (2%).",urticaria is an adverse reaction entity
"Other adverse reactions indicative of hypersensitivity reactions included the following: pruritus (5%), rash (3%), and urticaria (2%).",pruritus is an adverse reaction entity
"Other adverse reactions indicative of hypersensitivity reactions included the following: pruritus (5%), rash (3%), and urticaria (2%).",% is not a named entity
"Other adverse reactions indicative of hypersensitivity reactions included the following: pruritus (5%), rash (3%), and urticaria (2%).",of hypersensitivity is not a named entity
"Other adverse reactions indicative of hypersensitivity reactions included the following: pruritus (5%), rash (3%), and urticaria (2%).",hypersensitivity is an adverse reaction entity
"Injection site reactions were characterized by local pruritus, erythema, pain, irritation, urticaria, and/or bruising.",Injection site pruritus is an adverse reaction entity
"Injection site reactions were characterized by local pruritus, erythema, pain, irritation, urticaria, and/or bruising.",Injection site erythema is an adverse reaction entity
"Injection site reactions were characterized by local pruritus, erythema, pain, irritation, urticaria, and/or bruising.",Injection site bruising is an adverse reaction entity
"Injection site reactions were characterized by local pruritus, erythema, pain, irritation, urticaria, and/or bruising.","local pruritus , is not a named entity"
"Injection site reactions were characterized by local pruritus, erythema, pain, irritation, urticaria, and/or bruising.",", and/or bruising is not a named entity"
"Injection site reactions were characterized by local pruritus, erythema, pain, irritation, urticaria, and/or bruising.",Injection site urticaria is an adverse reaction entity
"Injection site reactions were characterized by local pruritus, erythema, pain, irritation, urticaria, and/or bruising.","local pruritus , is not a named entity"
"Injection site reactions were characterized by local pruritus, erythema, pain, irritation, urticaria, and/or bruising.",Injection site pain is an adverse reaction entity
"Injection site reactions were characterized by local pruritus, erythema, pain, irritation, urticaria, and/or bruising.",", is not a named entity"
"Injection site reactions were characterized by local pruritus, erythema, pain, irritation, urticaria, and/or bruising.","erythema , pain is not a named entity"
"Injection site reactions were characterized by local pruritus, erythema, pain, irritation, urticaria, and/or bruising.",Injection site reactions is an adverse reaction entity
"Injection site reactions were characterized by local pruritus, erythema, pain, irritation, urticaria, and/or bruising.",", erythema is not a named entity"
"Injection site reactions were characterized by local pruritus, erythema, pain, irritation, urticaria, and/or bruising.",", is not a named entity"
"Injection site reactions were characterized by local pruritus, erythema, pain, irritation, urticaria, and/or bruising.",Injection site irritation is an adverse reaction entity
5  WARNINGS AND PRECAUTIONS       EXCERPT:    *  Hypersensitivity Reactions Including Anaphylaxis: Anaphylaxis has occurred in 4% of treated patients.,Hypersensitivity Reactions is an adverse reaction entity
5  WARNINGS AND PRECAUTIONS       EXCERPT:    *  Hypersensitivity Reactions Including Anaphylaxis: Anaphylaxis has occurred in 4% of treated patients.,of is not a named entity
5  WARNINGS AND PRECAUTIONS       EXCERPT:    *  Hypersensitivity Reactions Including Anaphylaxis: Anaphylaxis has occurred in 4% of treated patients.,AND is not a named entity
5  WARNINGS AND PRECAUTIONS       EXCERPT:    *  Hypersensitivity Reactions Including Anaphylaxis: Anaphylaxis has occurred in 4% of treated patients.,Anaphylaxis is an adverse reaction entity
5  WARNINGS AND PRECAUTIONS       EXCERPT:    *  Hypersensitivity Reactions Including Anaphylaxis: Anaphylaxis has occurred in 4% of treated patients.,Anaphylaxis : is not a named entity
5  WARNINGS AND PRECAUTIONS       EXCERPT:    *  Hypersensitivity Reactions Including Anaphylaxis: Anaphylaxis has occurred in 4% of treated patients.,Anaphylaxis is an adverse reaction entity
"6  ADVERSE REACTIONS    Hypersensitivity reactions, including anaphylaxis, have occurred in patients treated with KALBITOR [  see Contraindications  (4)      and Warnings and Precautions  (5.1)    ].",5.1 is not a named entity
"6  ADVERSE REACTIONS    Hypersensitivity reactions, including anaphylaxis, have occurred in patients treated with KALBITOR [  see Contraindications  (4)      and Warnings and Precautions  (5.1)    ].",Contraindications ( 4 is not a named entity
"6  ADVERSE REACTIONS    Hypersensitivity reactions, including anaphylaxis, have occurred in patients treated with KALBITOR [  see Contraindications  (4)      and Warnings and Precautions  (5.1)    ].",anaphylaxis is an adverse reaction entity
"6  ADVERSE REACTIONS    Hypersensitivity reactions, including anaphylaxis, have occurred in patients treated with KALBITOR [  see Contraindications  (4)      and Warnings and Precautions  (5.1)    ].",Hypersensitivity is an adverse reaction entity
"Symptoms associated with these reactions have included chest discomfort, flushing, pharyngeal edema, pruritus, rhinorrhea, sneezing, nasal congestion, throat irritation, urticaria, wheezing, and hypotension.",sneezing is an adverse reaction entity
"Symptoms associated with these reactions have included chest discomfort, flushing, pharyngeal edema, pruritus, rhinorrhea, sneezing, nasal congestion, throat irritation, urticaria, wheezing, and hypotension.",", is not a named entity"
"Symptoms associated with these reactions have included chest discomfort, flushing, pharyngeal edema, pruritus, rhinorrhea, sneezing, nasal congestion, throat irritation, urticaria, wheezing, and hypotension.",hypotension is an adverse reaction entity
"Symptoms associated with these reactions have included chest discomfort, flushing, pharyngeal edema, pruritus, rhinorrhea, sneezing, nasal congestion, throat irritation, urticaria, wheezing, and hypotension.",pharyngeal edema is an adverse reaction entity
"Symptoms associated with these reactions have included chest discomfort, flushing, pharyngeal edema, pruritus, rhinorrhea, sneezing, nasal congestion, throat irritation, urticaria, wheezing, and hypotension.",", rhinorrhea is not a named entity"
"Symptoms associated with these reactions have included chest discomfort, flushing, pharyngeal edema, pruritus, rhinorrhea, sneezing, nasal congestion, throat irritation, urticaria, wheezing, and hypotension.",chest discomfort is an adverse reaction entity
"Symptoms associated with these reactions have included chest discomfort, flushing, pharyngeal edema, pruritus, rhinorrhea, sneezing, nasal congestion, throat irritation, urticaria, wheezing, and hypotension.",", is not a named entity"
"Symptoms associated with these reactions have included chest discomfort, flushing, pharyngeal edema, pruritus, rhinorrhea, sneezing, nasal congestion, throat irritation, urticaria, wheezing, and hypotension.",have included chest is not a named entity
"Symptoms associated with these reactions have included chest discomfort, flushing, pharyngeal edema, pruritus, rhinorrhea, sneezing, nasal congestion, throat irritation, urticaria, wheezing, and hypotension.",rhinorrhea is an adverse reaction entity
"Symptoms associated with these reactions have included chest discomfort, flushing, pharyngeal edema, pruritus, rhinorrhea, sneezing, nasal congestion, throat irritation, urticaria, wheezing, and hypotension.",reactions have included is not a named entity
"Symptoms associated with these reactions have included chest discomfort, flushing, pharyngeal edema, pruritus, rhinorrhea, sneezing, nasal congestion, throat irritation, urticaria, wheezing, and hypotension.",throat irritation is an adverse reaction entity
"Symptoms associated with these reactions have included chest discomfort, flushing, pharyngeal edema, pruritus, rhinorrhea, sneezing, nasal congestion, throat irritation, urticaria, wheezing, and hypotension.",flushing is an adverse reaction entity
"Symptoms associated with these reactions have included chest discomfort, flushing, pharyngeal edema, pruritus, rhinorrhea, sneezing, nasal congestion, throat irritation, urticaria, wheezing, and hypotension.",edema is not a named entity
"Symptoms associated with these reactions have included chest discomfort, flushing, pharyngeal edema, pruritus, rhinorrhea, sneezing, nasal congestion, throat irritation, urticaria, wheezing, and hypotension.",included is not a named entity
"Symptoms associated with these reactions have included chest discomfort, flushing, pharyngeal edema, pruritus, rhinorrhea, sneezing, nasal congestion, throat irritation, urticaria, wheezing, and hypotension.",have is not a named entity
"Symptoms associated with these reactions have included chest discomfort, flushing, pharyngeal edema, pruritus, rhinorrhea, sneezing, nasal congestion, throat irritation, urticaria, wheezing, and hypotension.","urticaria , wheezing is not a named entity"
"Symptoms associated with these reactions have included chest discomfort, flushing, pharyngeal edema, pruritus, rhinorrhea, sneezing, nasal congestion, throat irritation, urticaria, wheezing, and hypotension.",wheezing is an adverse reaction entity
"Symptoms associated with these reactions have included chest discomfort, flushing, pharyngeal edema, pruritus, rhinorrhea, sneezing, nasal congestion, throat irritation, urticaria, wheezing, and hypotension.","throat irritation , is not a named entity"
"Symptoms associated with these reactions have included chest discomfort, flushing, pharyngeal edema, pruritus, rhinorrhea, sneezing, nasal congestion, throat irritation, urticaria, wheezing, and hypotension.",urticaria is an adverse reaction entity
"Symptoms associated with these reactions have included chest discomfort, flushing, pharyngeal edema, pruritus, rhinorrhea, sneezing, nasal congestion, throat irritation, urticaria, wheezing, and hypotension.",have included chest is not a named entity
"Symptoms associated with these reactions have included chest discomfort, flushing, pharyngeal edema, pruritus, rhinorrhea, sneezing, nasal congestion, throat irritation, urticaria, wheezing, and hypotension.",nasal congestion is an adverse reaction entity
"Symptoms associated with these reactions have included chest discomfort, flushing, pharyngeal edema, pruritus, rhinorrhea, sneezing, nasal congestion, throat irritation, urticaria, wheezing, and hypotension.",pruritus is an adverse reaction entity
"EXCERPT:   Most common adverse reactions (incidence >= 3%) are upper respiratory tract infection, bronchitis, cough, flatulence and increased bilirubin.",incidence > is not a named entity
"EXCERPT:   Most common adverse reactions (incidence >= 3%) are upper respiratory tract infection, bronchitis, cough, flatulence and increased bilirubin.",flatulence is an adverse reaction entity
"EXCERPT:   Most common adverse reactions (incidence >= 3%) are upper respiratory tract infection, bronchitis, cough, flatulence and increased bilirubin.",cough is an adverse reaction entity
"EXCERPT:   Most common adverse reactions (incidence >= 3%) are upper respiratory tract infection, bronchitis, cough, flatulence and increased bilirubin.",upper respiratory tract infection is an adverse reaction entity
"EXCERPT:   Most common adverse reactions (incidence >= 3%) are upper respiratory tract infection, bronchitis, cough, flatulence and increased bilirubin.",common adverse is not a named entity
"EXCERPT:   Most common adverse reactions (incidence >= 3%) are upper respiratory tract infection, bronchitis, cough, flatulence and increased bilirubin.",) are upper is not a named entity
"EXCERPT:   Most common adverse reactions (incidence >= 3%) are upper respiratory tract infection, bronchitis, cough, flatulence and increased bilirubin.",bronchitis is an adverse reaction entity
"EXCERPT:   Most common adverse reactions (incidence >= 3%) are upper respiratory tract infection, bronchitis, cough, flatulence and increased bilirubin.",= 3 % is not a named entity
"EXCERPT:   Most common adverse reactions (incidence >= 3%) are upper respiratory tract infection, bronchitis, cough, flatulence and increased bilirubin.",% ) are is not a named entity
"EXCERPT:   Most common adverse reactions (incidence >= 3%) are upper respiratory tract infection, bronchitis, cough, flatulence and increased bilirubin.",increased bilirubin is an adverse reaction entity
Table 4: Clinical Cure Rates in a Phase 3 Trial of cIAI by Baseline Renal Function (MITT Population)   Baseline Renal Function             ZERBAXA plus metronidazolen/N (%)          Meropenemn/N (%)                 Normal/mild impairment(CrCl >=50 mL/min)           312/366 (85.2)                     355/404 (87.9)               Moderate impairment(CrCl 30 to <=50 mL/min)            11/23 (47.8)                        9/13 (69.2)                           5.2 Hypersensitivity Reactions      Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving beta-lactam antibacterial drugs.,Moderate impairment ( is not a named entity
Table 4: Clinical Cure Rates in a Phase 3 Trial of cIAI by Baseline Renal Function (MITT Population)   Baseline Renal Function             ZERBAXA plus metronidazolen/N (%)          Meropenemn/N (%)                 Normal/mild impairment(CrCl >=50 mL/min)           312/366 (85.2)                     355/404 (87.9)               Moderate impairment(CrCl 30 to <=50 mL/min)            11/23 (47.8)                        9/13 (69.2)                           5.2 Hypersensitivity Reactions      Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving beta-lactam antibacterial drugs.,Phase is not a named entity
Table 4: Clinical Cure Rates in a Phase 3 Trial of cIAI by Baseline Renal Function (MITT Population)   Baseline Renal Function             ZERBAXA plus metronidazolen/N (%)          Meropenemn/N (%)                 Normal/mild impairment(CrCl >=50 mL/min)           312/366 (85.2)                     355/404 (87.9)               Moderate impairment(CrCl 30 to <=50 mL/min)            11/23 (47.8)                        9/13 (69.2)                           5.2 Hypersensitivity Reactions      Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving beta-lactam antibacterial drugs.,anaphylactic reactions is an adverse reaction entity
Table 4: Clinical Cure Rates in a Phase 3 Trial of cIAI by Baseline Renal Function (MITT Population)   Baseline Renal Function             ZERBAXA plus metronidazolen/N (%)          Meropenemn/N (%)                 Normal/mild impairment(CrCl >=50 mL/min)           312/366 (85.2)                     355/404 (87.9)               Moderate impairment(CrCl 30 to <=50 mL/min)            11/23 (47.8)                        9/13 (69.2)                           5.2 Hypersensitivity Reactions      Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving beta-lactam antibacterial drugs.,occasionally fatal is not a named entity
Table 4: Clinical Cure Rates in a Phase 3 Trial of cIAI by Baseline Renal Function (MITT Population)   Baseline Renal Function             ZERBAXA plus metronidazolen/N (%)          Meropenemn/N (%)                 Normal/mild impairment(CrCl >=50 mL/min)           312/366 (85.2)                     355/404 (87.9)               Moderate impairment(CrCl 30 to <=50 mL/min)            11/23 (47.8)                        9/13 (69.2)                           5.2 Hypersensitivity Reactions      Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving beta-lactam antibacterial drugs.,anaphylactic reactions is an adverse reaction entity
Table 4: Clinical Cure Rates in a Phase 3 Trial of cIAI by Baseline Renal Function (MITT Population)   Baseline Renal Function             ZERBAXA plus metronidazolen/N (%)          Meropenemn/N (%)                 Normal/mild impairment(CrCl >=50 mL/min)           312/366 (85.2)                     355/404 (87.9)               Moderate impairment(CrCl 30 to <=50 mL/min)            11/23 (47.8)                        9/13 (69.2)                           5.2 Hypersensitivity Reactions      Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving beta-lactam antibacterial drugs.,( 87.9 is not a named entity
Table 4: Clinical Cure Rates in a Phase 3 Trial of cIAI by Baseline Renal Function (MITT Population)   Baseline Renal Function             ZERBAXA plus metronidazolen/N (%)          Meropenemn/N (%)                 Normal/mild impairment(CrCl >=50 mL/min)           312/366 (85.2)                     355/404 (87.9)               Moderate impairment(CrCl 30 to <=50 mL/min)            11/23 (47.8)                        9/13 (69.2)                           5.2 Hypersensitivity Reactions      Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving beta-lactam antibacterial drugs.,87.9 ) Moderate is not a named entity
Table 4: Clinical Cure Rates in a Phase 3 Trial of cIAI by Baseline Renal Function (MITT Population)   Baseline Renal Function             ZERBAXA plus metronidazolen/N (%)          Meropenemn/N (%)                 Normal/mild impairment(CrCl >=50 mL/min)           312/366 (85.2)                     355/404 (87.9)               Moderate impairment(CrCl 30 to <=50 mL/min)            11/23 (47.8)                        9/13 (69.2)                           5.2 Hypersensitivity Reactions      Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving beta-lactam antibacterial drugs.,hypersensitivity reactions is an adverse reaction entity
Table 4: Clinical Cure Rates in a Phase 3 Trial of cIAI by Baseline Renal Function (MITT Population)   Baseline Renal Function             ZERBAXA plus metronidazolen/N (%)          Meropenemn/N (%)                 Normal/mild impairment(CrCl >=50 mL/min)           312/366 (85.2)                     355/404 (87.9)               Moderate impairment(CrCl 30 to <=50 mL/min)            11/23 (47.8)                        9/13 (69.2)                           5.2 Hypersensitivity Reactions      Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving beta-lactam antibacterial drugs.,fatal is an adverse reaction entity
Table 4: Clinical Cure Rates in a Phase 3 Trial of cIAI by Baseline Renal Function (MITT Population)   Baseline Renal Function             ZERBAXA plus metronidazolen/N (%)          Meropenemn/N (%)                 Normal/mild impairment(CrCl >=50 mL/min)           312/366 (85.2)                     355/404 (87.9)               Moderate impairment(CrCl 30 to <=50 mL/min)            11/23 (47.8)                        9/13 (69.2)                           5.2 Hypersensitivity Reactions      Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving beta-lactam antibacterial drugs.,hypersensitivity reactions is an adverse reaction entity
"The causes of death varied and included worsening and/or complications of infection, surgery and underlying conditions.",and included is not a named entity
"The causes of death varied and included worsening and/or complications of infection, surgery and underlying conditions.",complications of infection is an adverse reaction entity
"The causes of death varied and included worsening and/or complications of infection, surgery and underlying conditions.",and underlying is not a named entity
"The causes of death varied and included worsening and/or complications of infection, surgery and underlying conditions.",causes is not a named entity
"The causes of death varied and included worsening and/or complications of infection, surgery and underlying conditions.",death is an adverse reaction entity
"The causes of death varied and included worsening and/or complications of infection, surgery and underlying conditions.",worsening infection is an adverse reaction entity
"Renal impairment (including the terms renal impairment, renal failure, and renal failure acute) led to discontinuation of treatment in 5/1015 (0.5%) subjects receiving ZERBAXA and none in the comparator arms.",treatment is not a named entity
"Renal impairment (including the terms renal impairment, renal failure, and renal failure acute) led to discontinuation of treatment in 5/1015 (0.5%) subjects receiving ZERBAXA and none in the comparator arms.",renal failure is an adverse reaction entity
"Renal impairment (including the terms renal impairment, renal failure, and renal failure acute) led to discontinuation of treatment in 5/1015 (0.5%) subjects receiving ZERBAXA and none in the comparator arms.",) led to is not a named entity
"Renal impairment (including the terms renal impairment, renal failure, and renal failure acute) led to discontinuation of treatment in 5/1015 (0.5%) subjects receiving ZERBAXA and none in the comparator arms.",renal impairment is an adverse reaction entity
"Renal impairment (including the terms renal impairment, renal failure, and renal failure acute) led to discontinuation of treatment in 5/1015 (0.5%) subjects receiving ZERBAXA and none in the comparator arms.",subjects receiving ZERBAXA is not a named entity
"Renal impairment (including the terms renal impairment, renal failure, and renal failure acute) led to discontinuation of treatment in 5/1015 (0.5%) subjects receiving ZERBAXA and none in the comparator arms.",subjects receiving ZERBAXA is not a named entity
"Renal impairment (including the terms renal impairment, renal failure, and renal failure acute) led to discontinuation of treatment in 5/1015 (0.5%) subjects receiving ZERBAXA and none in the comparator arms.",Renal impairment is an adverse reaction entity
"Renal impairment (including the terms renal impairment, renal failure, and renal failure acute) led to discontinuation of treatment in 5/1015 (0.5%) subjects receiving ZERBAXA and none in the comparator arms.",renal failure acute is an adverse reaction entity
"Increased Mortality       In the cIAI trials (Phase 2 and 3), death occurred in 2.5% (14/564) of patients receiving ZERBAXA and in 1.5% (8/536) of patients receiving meropenem.",death is an adverse reaction entity
"Increased Mortality       In the cIAI trials (Phase 2 and 3), death occurred in 2.5% (14/564) of patients receiving ZERBAXA and in 1.5% (8/536) of patients receiving meropenem.",Phase is not a named entity
(  5.1  )   *  Serious hypersensitivity (anaphylactic) reactions have been reported with beta-lactam antibacterial drugs.,anaphylactic reactions is an adverse reaction entity
(  5.1  )   *  Serious hypersensitivity (anaphylactic) reactions have been reported with beta-lactam antibacterial drugs.,reactions have is not a named entity
(  5.1  )   *  Serious hypersensitivity (anaphylactic) reactions have been reported with beta-lactam antibacterial drugs.,hypersensitivity reactions is an adverse reaction entity
(  5.1  )   *  Serious hypersensitivity (anaphylactic) reactions have been reported with beta-lactam antibacterial drugs.,* Serious hypersensitivity is not a named entity
"(  5.2  )   *   Clostridium difficile -associated diarrhea (CDAD) has been reported with nearly all systemic antibacterial agents, including ZERBAXA.",nearly all systemic is not a named entity
"(  5.2  )   *   Clostridium difficile -associated diarrhea (CDAD) has been reported with nearly all systemic antibacterial agents, including ZERBAXA.",Clostridium difficile -associated diarrhea is an adverse reaction entity
"(  5.2  )   *   Clostridium difficile -associated diarrhea (CDAD) has been reported with nearly all systemic antibacterial agents, including ZERBAXA.",CDAD is an adverse reaction entity
"(  5.2  )   *   Clostridium difficile -associated diarrhea (CDAD) has been reported with nearly all systemic antibacterial agents, including ZERBAXA.",been reported with is not a named entity
5.2 Acute Respiratory Distress Syndrome (ARDS)      Acute respiratory distress syndrome (ARDS) can occur in patients receiving human granulocyte colony-stimulating factors.,ARDS ) can is not a named entity
5.2 Acute Respiratory Distress Syndrome (ARDS)      Acute respiratory distress syndrome (ARDS) can occur in patients receiving human granulocyte colony-stimulating factors.,Acute respiratory distress syndrome is an adverse reaction entity
5.2 Acute Respiratory Distress Syndrome (ARDS)      Acute respiratory distress syndrome (ARDS) can occur in patients receiving human granulocyte colony-stimulating factors.,) is not a named entity
5.2 Acute Respiratory Distress Syndrome (ARDS)      Acute respiratory distress syndrome (ARDS) can occur in patients receiving human granulocyte colony-stimulating factors.,ARDS is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *    Splenic Rupture: Discontinue GRANIX if suspected (  5.1  )   *    Acute Respiratory Distress Syndrome (ARDS): Monitor for and manage immediately.,: Monitor for is not a named entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *    Splenic Rupture: Discontinue GRANIX if suspected (  5.1  )   *    Acute Respiratory Distress Syndrome (ARDS): Monitor for and manage immediately.,Splenic Rupture is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *    Splenic Rupture: Discontinue GRANIX if suspected (  5.1  )   *    Acute Respiratory Distress Syndrome (ARDS): Monitor for and manage immediately.,: Monitor is not a named entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *    Splenic Rupture: Discontinue GRANIX if suspected (  5.1  )   *    Acute Respiratory Distress Syndrome (ARDS): Monitor for and manage immediately.,Distress Syndrome ( is not a named entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *    Splenic Rupture: Discontinue GRANIX if suspected (  5.1  )   *    Acute Respiratory Distress Syndrome (ARDS): Monitor for and manage immediately.,ARDS is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *    Splenic Rupture: Discontinue GRANIX if suspected (  5.1  )   *    Acute Respiratory Distress Syndrome (ARDS): Monitor for and manage immediately.,Acute Respiratory Distress Syndrome is an adverse reaction entity
"Additional Adverse Reactions     Other adverse reactions known to occur following administration of human granulocyte colony-stimulating factors include myalgia, headache, vomiting, Sweet's syndrome (acute febrile neutrophilic dermatosis), cutaneous vasculitis and thrombocytopenia.",Sweet's syndrome is an adverse reaction entity
"Additional Adverse Reactions     Other adverse reactions known to occur following administration of human granulocyte colony-stimulating factors include myalgia, headache, vomiting, Sweet's syndrome (acute febrile neutrophilic dermatosis), cutaneous vasculitis and thrombocytopenia.",cutaneous vasculitis is an adverse reaction entity
"Additional Adverse Reactions     Other adverse reactions known to occur following administration of human granulocyte colony-stimulating factors include myalgia, headache, vomiting, Sweet's syndrome (acute febrile neutrophilic dermatosis), cutaneous vasculitis and thrombocytopenia.",and thrombocytopenia is not a named entity
"Additional Adverse Reactions     Other adverse reactions known to occur following administration of human granulocyte colony-stimulating factors include myalgia, headache, vomiting, Sweet's syndrome (acute febrile neutrophilic dermatosis), cutaneous vasculitis and thrombocytopenia.",Reactions Other adverse is not a named entity
"Additional Adverse Reactions     Other adverse reactions known to occur following administration of human granulocyte colony-stimulating factors include myalgia, headache, vomiting, Sweet's syndrome (acute febrile neutrophilic dermatosis), cutaneous vasculitis and thrombocytopenia.",vomiting is an adverse reaction entity
"Additional Adverse Reactions     Other adverse reactions known to occur following administration of human granulocyte colony-stimulating factors include myalgia, headache, vomiting, Sweet's syndrome (acute febrile neutrophilic dermatosis), cutaneous vasculitis and thrombocytopenia.",thrombocytopenia is an adverse reaction entity
"Additional Adverse Reactions     Other adverse reactions known to occur following administration of human granulocyte colony-stimulating factors include myalgia, headache, vomiting, Sweet's syndrome (acute febrile neutrophilic dermatosis), cutaneous vasculitis and thrombocytopenia.",headache is an adverse reaction entity
"Additional Adverse Reactions     Other adverse reactions known to occur following administration of human granulocyte colony-stimulating factors include myalgia, headache, vomiting, Sweet's syndrome (acute febrile neutrophilic dermatosis), cutaneous vasculitis and thrombocytopenia.",granulocyte colony-stimulating is not a named entity
"Additional Adverse Reactions     Other adverse reactions known to occur following administration of human granulocyte colony-stimulating factors include myalgia, headache, vomiting, Sweet's syndrome (acute febrile neutrophilic dermatosis), cutaneous vasculitis and thrombocytopenia.",myalgia is an adverse reaction entity
"Additional Adverse Reactions     Other adverse reactions known to occur following administration of human granulocyte colony-stimulating factors include myalgia, headache, vomiting, Sweet's syndrome (acute febrile neutrophilic dermatosis), cutaneous vasculitis and thrombocytopenia.",to is not a named entity
"Additional Adverse Reactions     Other adverse reactions known to occur following administration of human granulocyte colony-stimulating factors include myalgia, headache, vomiting, Sweet's syndrome (acute febrile neutrophilic dermatosis), cutaneous vasculitis and thrombocytopenia.",reactions known is not a named entity
"Additional Adverse Reactions     Other adverse reactions known to occur following administration of human granulocyte colony-stimulating factors include myalgia, headache, vomiting, Sweet's syndrome (acute febrile neutrophilic dermatosis), cutaneous vasculitis and thrombocytopenia.",Adverse Reactions is not a named entity
"Additional Adverse Reactions     Other adverse reactions known to occur following administration of human granulocyte colony-stimulating factors include myalgia, headache, vomiting, Sweet's syndrome (acute febrile neutrophilic dermatosis), cutaneous vasculitis and thrombocytopenia.",acute febrile neutrophilic dermatosis is an adverse reaction entity
"Additional Adverse Reactions     Other adverse reactions known to occur following administration of human granulocyte colony-stimulating factors include myalgia, headache, vomiting, Sweet's syndrome (acute febrile neutrophilic dermatosis), cutaneous vasculitis and thrombocytopenia.",known to is not a named entity
5.3 Allergic Reactions      Serious allergic reactions including anaphylaxis can occur in patients receiving human granulocyte colony-stimulating factors.,anaphylaxis is an adverse reaction entity
5.3 Allergic Reactions      Serious allergic reactions including anaphylaxis can occur in patients receiving human granulocyte colony-stimulating factors.,can occur in is not a named entity
5.3 Allergic Reactions      Serious allergic reactions including anaphylaxis can occur in patients receiving human granulocyte colony-stimulating factors.,allergic reactions is an adverse reaction entity
5.3 Allergic Reactions      Serious allergic reactions including anaphylaxis can occur in patients receiving human granulocyte colony-stimulating factors.,can occur is not a named entity
5.4 Use in Patients with Sickle Cell Disease      Severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disease receiving human granulocyte colony-stimulating factors.,human granulocyte colony-stimulating is not a named entity
5.4 Use in Patients with Sickle Cell Disease      Severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disease receiving human granulocyte colony-stimulating factors.,can occur in is not a named entity
5.4 Use in Patients with Sickle Cell Disease      Severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disease receiving human granulocyte colony-stimulating factors.,fatal is an adverse reaction entity
5.4 Use in Patients with Sickle Cell Disease      Severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disease receiving human granulocyte colony-stimulating factors.,sickle cell crises is an adverse reaction entity
Bone pain was the most frequent treatment-emergent adverse reaction that occurred in at least 1% or greater in patients treated with GRANIX at the recommended dose and was numerically two times more frequent than in the placebo group.,Bone pain is an adverse reaction entity
Bone pain was the most frequent treatment-emergent adverse reaction that occurred in at least 1% or greater in patients treated with GRANIX at the recommended dose and was numerically two times more frequent than in the placebo group.,two times more is not a named entity
No complications attributable to leukocytosis were reported in clinical studies.,leukocytosis is an adverse reaction entity
No complications attributable to leukocytosis were reported in clinical studies.,leukocytosis were is not a named entity
"5.5 Capillary Leak Syndrome      Capillary leak syndrome (CLS) can occur in patients receiving human granulocyte colony-stimulating factors and is characterized by hypotension, hypoalbuminemia, edema and hemoconcentration.",CLS is an adverse reaction entity
"5.5 Capillary Leak Syndrome      Capillary leak syndrome (CLS) can occur in patients receiving human granulocyte colony-stimulating factors and is characterized by hypotension, hypoalbuminemia, edema and hemoconcentration.",hypotension is an adverse reaction entity
"5.5 Capillary Leak Syndrome      Capillary leak syndrome (CLS) can occur in patients receiving human granulocyte colony-stimulating factors and is characterized by hypotension, hypoalbuminemia, edema and hemoconcentration.",edema and hemoconcentration is not a named entity
"5.5 Capillary Leak Syndrome      Capillary leak syndrome (CLS) can occur in patients receiving human granulocyte colony-stimulating factors and is characterized by hypotension, hypoalbuminemia, edema and hemoconcentration.",edema is an adverse reaction entity
"5.5 Capillary Leak Syndrome      Capillary leak syndrome (CLS) can occur in patients receiving human granulocyte colony-stimulating factors and is characterized by hypotension, hypoalbuminemia, edema and hemoconcentration.",syndrome is not a named entity
"5.5 Capillary Leak Syndrome      Capillary leak syndrome (CLS) can occur in patients receiving human granulocyte colony-stimulating factors and is characterized by hypotension, hypoalbuminemia, edema and hemoconcentration.",Capillary is not a named entity
"5.5 Capillary Leak Syndrome      Capillary leak syndrome (CLS) can occur in patients receiving human granulocyte colony-stimulating factors and is characterized by hypotension, hypoalbuminemia, edema and hemoconcentration.",factors is not a named entity
"5.5 Capillary Leak Syndrome      Capillary leak syndrome (CLS) can occur in patients receiving human granulocyte colony-stimulating factors and is characterized by hypotension, hypoalbuminemia, edema and hemoconcentration.",hemoconcentration is an adverse reaction entity
"5.5 Capillary Leak Syndrome      Capillary leak syndrome (CLS) can occur in patients receiving human granulocyte colony-stimulating factors and is characterized by hypotension, hypoalbuminemia, edema and hemoconcentration.",hypoalbuminemia is an adverse reaction entity
"5.5 Capillary Leak Syndrome      Capillary leak syndrome (CLS) can occur in patients receiving human granulocyte colony-stimulating factors and is characterized by hypotension, hypoalbuminemia, edema and hemoconcentration.",Capillary leak syndrome is an adverse reaction entity
"5.5 Capillary Leak Syndrome      Capillary leak syndrome (CLS) can occur in patients receiving human granulocyte colony-stimulating factors and is characterized by hypotension, hypoalbuminemia, edema and hemoconcentration.",in patients receiving is not a named entity
"5.5 Capillary Leak Syndrome      Capillary leak syndrome (CLS) can occur in patients receiving human granulocyte colony-stimulating factors and is characterized by hypotension, hypoalbuminemia, edema and hemoconcentration.",human granulocyte is not a named entity
"The    overall incidence of bone pain in Cycle 1 of treatment was 3.4% (3.4% GRANIX, 1.4% placebo, 7.5% non-US-approved filgrastim product).",incidence of bone is not a named entity
"The    overall incidence of bone pain in Cycle 1 of treatment was 3.4% (3.4% GRANIX, 1.4% placebo, 7.5% non-US-approved filgrastim product).",bone pain is an adverse reaction entity
"Discontinue GRANIX if suspected (  5.4  )   *    Capillary Leak Syndrome: Monitor if symptoms develop and administer standard symptomatic treatment (5.5)             5.1 Splenic Rupture      Splenic rupture, including fatal cases, can occur following administration of human granulocyte colony-stimulating factors.",rupture is not a named entity
"Discontinue GRANIX if suspected (  5.4  )   *    Capillary Leak Syndrome: Monitor if symptoms develop and administer standard symptomatic treatment (5.5)             5.1 Splenic Rupture      Splenic rupture, including fatal cases, can occur following administration of human granulocyte colony-stimulating factors.",standard symptomatic is not a named entity
"Discontinue GRANIX if suspected (  5.4  )   *    Capillary Leak Syndrome: Monitor if symptoms develop and administer standard symptomatic treatment (5.5)             5.1 Splenic Rupture      Splenic rupture, including fatal cases, can occur following administration of human granulocyte colony-stimulating factors.",Capillary Leak Syndrome is an adverse reaction entity
"Discontinue GRANIX if suspected (  5.4  )   *    Capillary Leak Syndrome: Monitor if symptoms develop and administer standard symptomatic treatment (5.5)             5.1 Splenic Rupture      Splenic rupture, including fatal cases, can occur following administration of human granulocyte colony-stimulating factors.","rupture , including is not a named entity"
"Discontinue GRANIX if suspected (  5.4  )   *    Capillary Leak Syndrome: Monitor if symptoms develop and administer standard symptomatic treatment (5.5)             5.1 Splenic Rupture      Splenic rupture, including fatal cases, can occur following administration of human granulocyte colony-stimulating factors.",Splenic rupture is an adverse reaction entity
"Discontinue GRANIX if suspected (  5.4  )   *    Capillary Leak Syndrome: Monitor if symptoms develop and administer standard symptomatic treatment (5.5)             5.1 Splenic Rupture      Splenic rupture, including fatal cases, can occur following administration of human granulocyte colony-stimulating factors.",fatal is an adverse reaction entity
"All 5 patients had maximum ALT or AST levels >8 * ULN, which returned to baseline levels following interruption of KALYDECO dosing.",AST levels >8 * ULN is an adverse reaction entity
"All 5 patients had maximum ALT or AST levels >8 * ULN, which returned to baseline levels following interruption of KALYDECO dosing.",5 patients had is not a named entity
"All 5 patients had maximum ALT or AST levels >8 * ULN, which returned to baseline levels following interruption of KALYDECO dosing.",levels is not a named entity
"All 5 patients had maximum ALT or AST levels >8 * ULN, which returned to baseline levels following interruption of KALYDECO dosing.",ALT levels >8 * ULN is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Elevated transaminases (ALT or AST): Transaminases (ALT and AST) should be assessed prior to initiating KALYDECO, every 3 months during the first year of treatment, and annually thereafter.",ALT and is not a named entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Elevated transaminases (ALT or AST): Transaminases (ALT and AST) should be assessed prior to initiating KALYDECO, every 3 months during the first year of treatment, and annually thereafter.",3 months during is not a named entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Elevated transaminases (ALT or AST): Transaminases (ALT and AST) should be assessed prior to initiating KALYDECO, every 3 months during the first year of treatment, and annually thereafter.",Elevated AST is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Elevated transaminases (ALT or AST): Transaminases (ALT and AST) should be assessed prior to initiating KALYDECO, every 3 months during the first year of treatment, and annually thereafter.",5 WARNINGS is not a named entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Elevated transaminases (ALT or AST): Transaminases (ALT and AST) should be assessed prior to initiating KALYDECO, every 3 months during the first year of treatment, and annually thereafter.",Elevated transaminases is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Elevated transaminases (ALT or AST): Transaminases (ALT and AST) should be assessed prior to initiating KALYDECO, every 3 months during the first year of treatment, and annually thereafter.",Elevated ALT is an adverse reaction entity
"Laboratory Abnormalities         Transaminase Elevations:  In Trials 1, 2, and 3 the incidence of maximum transaminase (ALT or AST) >8, >5, or >3 * ULN was 2%, 2%, and 6% in KALYDECO-treated patients and 2%, 2%, and 8% in placebo-treated patients, respectively.",% in placebo-treated is not a named entity
"Laboratory Abnormalities         Transaminase Elevations:  In Trials 1, 2, and 3 the incidence of maximum transaminase (ALT or AST) >8, >5, or >3 * ULN was 2%, 2%, and 6% in KALYDECO-treated patients and 2%, 2%, and 8% in placebo-treated patients, respectively.",AST >3 * ULN is an adverse reaction entity
"Laboratory Abnormalities         Transaminase Elevations:  In Trials 1, 2, and 3 the incidence of maximum transaminase (ALT or AST) >8, >5, or >3 * ULN was 2%, 2%, and 6% in KALYDECO-treated patients and 2%, 2%, and 8% in placebo-treated patients, respectively.",2 is not a named entity
"Laboratory Abnormalities         Transaminase Elevations:  In Trials 1, 2, and 3 the incidence of maximum transaminase (ALT or AST) >8, >5, or >3 * ULN was 2%, 2%, and 6% in KALYDECO-treated patients and 2%, 2%, and 8% in placebo-treated patients, respectively.",", or > is not a named entity"
"Laboratory Abnormalities         Transaminase Elevations:  In Trials 1, 2, and 3 the incidence of maximum transaminase (ALT or AST) >8, >5, or >3 * ULN was 2%, 2%, and 6% in KALYDECO-treated patients and 2%, 2%, and 8% in placebo-treated patients, respectively.",ALT >5 * ULN is an adverse reaction entity
"Laboratory Abnormalities         Transaminase Elevations:  In Trials 1, 2, and 3 the incidence of maximum transaminase (ALT or AST) >8, >5, or >3 * ULN was 2%, 2%, and 6% in KALYDECO-treated patients and 2%, 2%, and 8% in placebo-treated patients, respectively.",transaminase >8 * ULN is an adverse reaction entity
"Laboratory Abnormalities         Transaminase Elevations:  In Trials 1, 2, and 3 the incidence of maximum transaminase (ALT or AST) >8, >5, or >3 * ULN was 2%, 2%, and 6% in KALYDECO-treated patients and 2%, 2%, and 8% in placebo-treated patients, respectively.",or AST is not a named entity
"Laboratory Abnormalities         Transaminase Elevations:  In Trials 1, 2, and 3 the incidence of maximum transaminase (ALT or AST) >8, >5, or >3 * ULN was 2%, 2%, and 6% in KALYDECO-treated patients and 2%, 2%, and 8% in placebo-treated patients, respectively.",2 is not a named entity
"Laboratory Abnormalities         Transaminase Elevations:  In Trials 1, 2, and 3 the incidence of maximum transaminase (ALT or AST) >8, >5, or >3 * ULN was 2%, 2%, and 6% in KALYDECO-treated patients and 2%, 2%, and 8% in placebo-treated patients, respectively.",AST >8 * ULN is an adverse reaction entity
"Laboratory Abnormalities         Transaminase Elevations:  In Trials 1, 2, and 3 the incidence of maximum transaminase (ALT or AST) >8, >5, or >3 * ULN was 2%, 2%, and 6% in KALYDECO-treated patients and 2%, 2%, and 8% in placebo-treated patients, respectively.",transaminase >3 * ULN is an adverse reaction entity
"Laboratory Abnormalities         Transaminase Elevations:  In Trials 1, 2, and 3 the incidence of maximum transaminase (ALT or AST) >8, >5, or >3 * ULN was 2%, 2%, and 6% in KALYDECO-treated patients and 2%, 2%, and 8% in placebo-treated patients, respectively.",of maximum transaminase is not a named entity
"Laboratory Abnormalities         Transaminase Elevations:  In Trials 1, 2, and 3 the incidence of maximum transaminase (ALT or AST) >8, >5, or >3 * ULN was 2%, 2%, and 6% in KALYDECO-treated patients and 2%, 2%, and 8% in placebo-treated patients, respectively.",AST ) > is not a named entity
"Laboratory Abnormalities         Transaminase Elevations:  In Trials 1, 2, and 3 the incidence of maximum transaminase (ALT or AST) >8, >5, or >3 * ULN was 2%, 2%, and 6% in KALYDECO-treated patients and 2%, 2%, and 8% in placebo-treated patients, respectively.",ALT >8 * ULN is an adverse reaction entity
"Laboratory Abnormalities         Transaminase Elevations:  In Trials 1, 2, and 3 the incidence of maximum transaminase (ALT or AST) >8, >5, or >3 * ULN was 2%, 2%, and 6% in KALYDECO-treated patients and 2%, 2%, and 8% in placebo-treated patients, respectively.",ALT >3 * ULN is an adverse reaction entity
"Laboratory Abnormalities         Transaminase Elevations:  In Trials 1, 2, and 3 the incidence of maximum transaminase (ALT or AST) >8, >5, or >3 * ULN was 2%, 2%, and 6% in KALYDECO-treated patients and 2%, 2%, and 8% in placebo-treated patients, respectively.",AST >5 * ULN is an adverse reaction entity
"Laboratory Abnormalities         Transaminase Elevations:  In Trials 1, 2, and 3 the incidence of maximum transaminase (ALT or AST) >8, >5, or >3 * ULN was 2%, 2%, and 6% in KALYDECO-treated patients and 2%, 2%, and 8% in placebo-treated patients, respectively.",8 % is not a named entity
"Laboratory Abnormalities         Transaminase Elevations:  In Trials 1, 2, and 3 the incidence of maximum transaminase (ALT or AST) >8, >5, or >3 * ULN was 2%, 2%, and 6% in KALYDECO-treated patients and 2%, 2%, and 8% in placebo-treated patients, respectively.",3 the incidence is not a named entity
"Laboratory Abnormalities         Transaminase Elevations:  In Trials 1, 2, and 3 the incidence of maximum transaminase (ALT or AST) >8, >5, or >3 * ULN was 2%, 2%, and 6% in KALYDECO-treated patients and 2%, 2%, and 8% in placebo-treated patients, respectively.",transaminase >5 * ULN is an adverse reaction entity
"During the 24-week, open-label, clinical trial in 34 patients ages 2 to less than 6 years (Trial 6), where patients received either 50 mg (less than 14 kg) or 75 mg (14 kg or greater) ivacaftor granules twice daily, the incidence of patients experiencing transaminase elevations (ALT or AST) >3 * ULN was 14.7% (5/34).",( 5/34 ) is not a named entity
"During the 24-week, open-label, clinical trial in 34 patients ages 2 to less than 6 years (Trial 6), where patients received either 50 mg (less than 14 kg) or 75 mg (14 kg or greater) ivacaftor granules twice daily, the incidence of patients experiencing transaminase elevations (ALT or AST) >3 * ULN was 14.7% (5/34).",daily is not a named entity
"During the 24-week, open-label, clinical trial in 34 patients ages 2 to less than 6 years (Trial 6), where patients received either 50 mg (less than 14 kg) or 75 mg (14 kg or greater) ivacaftor granules twice daily, the incidence of patients experiencing transaminase elevations (ALT or AST) >3 * ULN was 14.7% (5/34).",( 14 is not a named entity
"During the 24-week, open-label, clinical trial in 34 patients ages 2 to less than 6 years (Trial 6), where patients received either 50 mg (less than 14 kg) or 75 mg (14 kg or greater) ivacaftor granules twice daily, the incidence of patients experiencing transaminase elevations (ALT or AST) >3 * ULN was 14.7% (5/34).",transaminase elevations is an adverse reaction entity
"During the 24-week, open-label, clinical trial in 34 patients ages 2 to less than 6 years (Trial 6), where patients received either 50 mg (less than 14 kg) or 75 mg (14 kg or greater) ivacaftor granules twice daily, the incidence of patients experiencing transaminase elevations (ALT or AST) >3 * ULN was 14.7% (5/34).",ALT >3 * ULN is an adverse reaction entity
"During the 24-week, open-label, clinical trial in 34 patients ages 2 to less than 6 years (Trial 6), where patients received either 50 mg (less than 14 kg) or 75 mg (14 kg or greater) ivacaftor granules twice daily, the incidence of patients experiencing transaminase elevations (ALT or AST) >3 * ULN was 14.7% (5/34).",AST >3 * ULN is an adverse reaction entity
"Two patients (2%) on placebo and 1 patient (0.5%) on KALYDECO permanently discontinued treatment for elevated transaminases, all >8 * ULN.",treatment for elevated is not a named entity
"Two patients (2%) on placebo and 1 patient (0.5%) on KALYDECO permanently discontinued treatment for elevated transaminases, all >8 * ULN.",elevated transaminases is an adverse reaction entity
Two patients treated with KALYDECO were reported to have serious adverse reactions of elevated liver transaminases compared to none on placebo.,elevated liver transaminases is an adverse reaction entity
Two patients treated with KALYDECO were reported to have serious adverse reactions of elevated liver transaminases compared to none on placebo.,reactions of elevated is not a named entity
"The most common adverse reactions in the 221 patients treated with KALYDECO were headache (17%), upper respiratory tract infection (16%), nasal congestion (16%), nausea (10%), rash (10%), rhinitis (6%), dizziness (5%), arthralgia (5%), and bacteria in sputum (5%).",nausea is an adverse reaction entity
"The most common adverse reactions in the 221 patients treated with KALYDECO were headache (17%), upper respiratory tract infection (16%), nasal congestion (16%), nausea (10%), rash (10%), rhinitis (6%), dizziness (5%), arthralgia (5%), and bacteria in sputum (5%).",headache ( is not a named entity
"The most common adverse reactions in the 221 patients treated with KALYDECO were headache (17%), upper respiratory tract infection (16%), nasal congestion (16%), nausea (10%), rash (10%), rhinitis (6%), dizziness (5%), arthralgia (5%), and bacteria in sputum (5%).",% is not a named entity
"The most common adverse reactions in the 221 patients treated with KALYDECO were headache (17%), upper respiratory tract infection (16%), nasal congestion (16%), nausea (10%), rash (10%), rhinitis (6%), dizziness (5%), arthralgia (5%), and bacteria in sputum (5%).",upper respiratory tract infection is an adverse reaction entity
"The most common adverse reactions in the 221 patients treated with KALYDECO were headache (17%), upper respiratory tract infection (16%), nasal congestion (16%), nausea (10%), rash (10%), rhinitis (6%), dizziness (5%), arthralgia (5%), and bacteria in sputum (5%).",( 17 % is not a named entity
"The most common adverse reactions in the 221 patients treated with KALYDECO were headache (17%), upper respiratory tract infection (16%), nasal congestion (16%), nausea (10%), rash (10%), rhinitis (6%), dizziness (5%), arthralgia (5%), and bacteria in sputum (5%).",bacteria in sputum is an adverse reaction entity
"The most common adverse reactions in the 221 patients treated with KALYDECO were headache (17%), upper respiratory tract infection (16%), nasal congestion (16%), nausea (10%), rash (10%), rhinitis (6%), dizziness (5%), arthralgia (5%), and bacteria in sputum (5%).",16 is not a named entity
"The most common adverse reactions in the 221 patients treated with KALYDECO were headache (17%), upper respiratory tract infection (16%), nasal congestion (16%), nausea (10%), rash (10%), rhinitis (6%), dizziness (5%), arthralgia (5%), and bacteria in sputum (5%).",rhinitis is an adverse reaction entity
"The most common adverse reactions in the 221 patients treated with KALYDECO were headache (17%), upper respiratory tract infection (16%), nasal congestion (16%), nausea (10%), rash (10%), rhinitis (6%), dizziness (5%), arthralgia (5%), and bacteria in sputum (5%).",% is not a named entity
"The most common adverse reactions in the 221 patients treated with KALYDECO were headache (17%), upper respiratory tract infection (16%), nasal congestion (16%), nausea (10%), rash (10%), rhinitis (6%), dizziness (5%), arthralgia (5%), and bacteria in sputum (5%).",rash is an adverse reaction entity
"The most common adverse reactions in the 221 patients treated with KALYDECO were headache (17%), upper respiratory tract infection (16%), nasal congestion (16%), nausea (10%), rash (10%), rhinitis (6%), dizziness (5%), arthralgia (5%), and bacteria in sputum (5%).",nasal congestion is an adverse reaction entity
"The most common adverse reactions in the 221 patients treated with KALYDECO were headache (17%), upper respiratory tract infection (16%), nasal congestion (16%), nausea (10%), rash (10%), rhinitis (6%), dizziness (5%), arthralgia (5%), and bacteria in sputum (5%).",( 5 is not a named entity
"The most common adverse reactions in the 221 patients treated with KALYDECO were headache (17%), upper respiratory tract infection (16%), nasal congestion (16%), nausea (10%), rash (10%), rhinitis (6%), dizziness (5%), arthralgia (5%), and bacteria in sputum (5%).",arthralgia is an adverse reaction entity
"The most common adverse reactions in the 221 patients treated with KALYDECO were headache (17%), upper respiratory tract infection (16%), nasal congestion (16%), nausea (10%), rash (10%), rhinitis (6%), dizziness (5%), arthralgia (5%), and bacteria in sputum (5%).",congestion is not a named entity
"The most common adverse reactions in the 221 patients treated with KALYDECO were headache (17%), upper respiratory tract infection (16%), nasal congestion (16%), nausea (10%), rash (10%), rhinitis (6%), dizziness (5%), arthralgia (5%), and bacteria in sputum (5%).",most common is not a named entity
"The most common adverse reactions in the 221 patients treated with KALYDECO were headache (17%), upper respiratory tract infection (16%), nasal congestion (16%), nausea (10%), rash (10%), rhinitis (6%), dizziness (5%), arthralgia (5%), and bacteria in sputum (5%).",headache is an adverse reaction entity
"The most common adverse reactions in the 221 patients treated with KALYDECO were headache (17%), upper respiratory tract infection (16%), nasal congestion (16%), nausea (10%), rash (10%), rhinitis (6%), dizziness (5%), arthralgia (5%), and bacteria in sputum (5%).",dizziness is an adverse reaction entity
"The most common adverse reactions in the 221 patients treated with KALYDECO were headache (17%), upper respiratory tract infection (16%), nasal congestion (16%), nausea (10%), rash (10%), rhinitis (6%), dizziness (5%), arthralgia (5%), and bacteria in sputum (5%).",the 221 patients is not a named entity
"6 ADVERSE REACTIONS    The following adverse reaction is discussed in greater detail in other sections of the label:     *  Transaminase Elevations [ see    Warnings and Precautions (5.1)   ]        EXCERPT:   The most common adverse drug reactions to KALYDECO (occurring in >=8% of patients with CF who have a  G551D  mutation in the  CFTR  gene) were headache, oropharyngeal pain, upper respiratory tract infection, nasal congestion, abdominal pain, nasopharyngitis, diarrhea, rash, nausea, and dizziness.",", oropharyngeal is not a named entity"
"6 ADVERSE REACTIONS    The following adverse reaction is discussed in greater detail in other sections of the label:     *  Transaminase Elevations [ see    Warnings and Precautions (5.1)   ]        EXCERPT:   The most common adverse drug reactions to KALYDECO (occurring in >=8% of patients with CF who have a  G551D  mutation in the  CFTR  gene) were headache, oropharyngeal pain, upper respiratory tract infection, nasal congestion, abdominal pain, nasopharyngitis, diarrhea, rash, nausea, and dizziness.",nausea is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reaction is discussed in greater detail in other sections of the label:     *  Transaminase Elevations [ see    Warnings and Precautions (5.1)   ]        EXCERPT:   The most common adverse drug reactions to KALYDECO (occurring in >=8% of patients with CF who have a  G551D  mutation in the  CFTR  gene) were headache, oropharyngeal pain, upper respiratory tract infection, nasal congestion, abdominal pain, nasopharyngitis, diarrhea, rash, nausea, and dizziness.",and is not a named entity
"6 ADVERSE REACTIONS    The following adverse reaction is discussed in greater detail in other sections of the label:     *  Transaminase Elevations [ see    Warnings and Precautions (5.1)   ]        EXCERPT:   The most common adverse drug reactions to KALYDECO (occurring in >=8% of patients with CF who have a  G551D  mutation in the  CFTR  gene) were headache, oropharyngeal pain, upper respiratory tract infection, nasal congestion, abdominal pain, nasopharyngitis, diarrhea, rash, nausea, and dizziness.",abdominal pain is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reaction is discussed in greater detail in other sections of the label:     *  Transaminase Elevations [ see    Warnings and Precautions (5.1)   ]        EXCERPT:   The most common adverse drug reactions to KALYDECO (occurring in >=8% of patients with CF who have a  G551D  mutation in the  CFTR  gene) were headache, oropharyngeal pain, upper respiratory tract infection, nasal congestion, abdominal pain, nasopharyngitis, diarrhea, rash, nausea, and dizziness.",dizziness is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reaction is discussed in greater detail in other sections of the label:     *  Transaminase Elevations [ see    Warnings and Precautions (5.1)   ]        EXCERPT:   The most common adverse drug reactions to KALYDECO (occurring in >=8% of patients with CF who have a  G551D  mutation in the  CFTR  gene) were headache, oropharyngeal pain, upper respiratory tract infection, nasal congestion, abdominal pain, nasopharyngitis, diarrhea, rash, nausea, and dizziness.",oropharyngeal pain is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reaction is discussed in greater detail in other sections of the label:     *  Transaminase Elevations [ see    Warnings and Precautions (5.1)   ]        EXCERPT:   The most common adverse drug reactions to KALYDECO (occurring in >=8% of patients with CF who have a  G551D  mutation in the  CFTR  gene) were headache, oropharyngeal pain, upper respiratory tract infection, nasal congestion, abdominal pain, nasopharyngitis, diarrhea, rash, nausea, and dizziness.",rash is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reaction is discussed in greater detail in other sections of the label:     *  Transaminase Elevations [ see    Warnings and Precautions (5.1)   ]        EXCERPT:   The most common adverse drug reactions to KALYDECO (occurring in >=8% of patients with CF who have a  G551D  mutation in the  CFTR  gene) were headache, oropharyngeal pain, upper respiratory tract infection, nasal congestion, abdominal pain, nasopharyngitis, diarrhea, rash, nausea, and dizziness.",nasal congestion is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reaction is discussed in greater detail in other sections of the label:     *  Transaminase Elevations [ see    Warnings and Precautions (5.1)   ]        EXCERPT:   The most common adverse drug reactions to KALYDECO (occurring in >=8% of patients with CF who have a  G551D  mutation in the  CFTR  gene) were headache, oropharyngeal pain, upper respiratory tract infection, nasal congestion, abdominal pain, nasopharyngitis, diarrhea, rash, nausea, and dizziness.",: The is not a named entity
"6 ADVERSE REACTIONS    The following adverse reaction is discussed in greater detail in other sections of the label:     *  Transaminase Elevations [ see    Warnings and Precautions (5.1)   ]        EXCERPT:   The most common adverse drug reactions to KALYDECO (occurring in >=8% of patients with CF who have a  G551D  mutation in the  CFTR  gene) were headache, oropharyngeal pain, upper respiratory tract infection, nasal congestion, abdominal pain, nasopharyngitis, diarrhea, rash, nausea, and dizziness.",) were is not a named entity
"6 ADVERSE REACTIONS    The following adverse reaction is discussed in greater detail in other sections of the label:     *  Transaminase Elevations [ see    Warnings and Precautions (5.1)   ]        EXCERPT:   The most common adverse drug reactions to KALYDECO (occurring in >=8% of patients with CF who have a  G551D  mutation in the  CFTR  gene) were headache, oropharyngeal pain, upper respiratory tract infection, nasal congestion, abdominal pain, nasopharyngitis, diarrhea, rash, nausea, and dizziness.",to KALYDECO ( is not a named entity
"6 ADVERSE REACTIONS    The following adverse reaction is discussed in greater detail in other sections of the label:     *  Transaminase Elevations [ see    Warnings and Precautions (5.1)   ]        EXCERPT:   The most common adverse drug reactions to KALYDECO (occurring in >=8% of patients with CF who have a  G551D  mutation in the  CFTR  gene) were headache, oropharyngeal pain, upper respiratory tract infection, nasal congestion, abdominal pain, nasopharyngitis, diarrhea, rash, nausea, and dizziness.",nasopharyngitis is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reaction is discussed in greater detail in other sections of the label:     *  Transaminase Elevations [ see    Warnings and Precautions (5.1)   ]        EXCERPT:   The most common adverse drug reactions to KALYDECO (occurring in >=8% of patients with CF who have a  G551D  mutation in the  CFTR  gene) were headache, oropharyngeal pain, upper respiratory tract infection, nasal congestion, abdominal pain, nasopharyngitis, diarrhea, rash, nausea, and dizziness.",Transaminase Elevations is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reaction is discussed in greater detail in other sections of the label:     *  Transaminase Elevations [ see    Warnings and Precautions (5.1)   ]        EXCERPT:   The most common adverse drug reactions to KALYDECO (occurring in >=8% of patients with CF who have a  G551D  mutation in the  CFTR  gene) were headache, oropharyngeal pain, upper respiratory tract infection, nasal congestion, abdominal pain, nasopharyngitis, diarrhea, rash, nausea, and dizziness.",", oropharyngeal pain is not a named entity"
"6 ADVERSE REACTIONS    The following adverse reaction is discussed in greater detail in other sections of the label:     *  Transaminase Elevations [ see    Warnings and Precautions (5.1)   ]        EXCERPT:   The most common adverse drug reactions to KALYDECO (occurring in >=8% of patients with CF who have a  G551D  mutation in the  CFTR  gene) were headache, oropharyngeal pain, upper respiratory tract infection, nasal congestion, abdominal pain, nasopharyngitis, diarrhea, rash, nausea, and dizziness.",diarrhea is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reaction is discussed in greater detail in other sections of the label:     *  Transaminase Elevations [ see    Warnings and Precautions (5.1)   ]        EXCERPT:   The most common adverse drug reactions to KALYDECO (occurring in >=8% of patients with CF who have a  G551D  mutation in the  CFTR  gene) were headache, oropharyngeal pain, upper respiratory tract infection, nasal congestion, abdominal pain, nasopharyngitis, diarrhea, rash, nausea, and dizziness.",upper respiratory tract infection is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reaction is discussed in greater detail in other sections of the label:     *  Transaminase Elevations [ see    Warnings and Precautions (5.1)   ]        EXCERPT:   The most common adverse drug reactions to KALYDECO (occurring in >=8% of patients with CF who have a  G551D  mutation in the  CFTR  gene) were headache, oropharyngeal pain, upper respiratory tract infection, nasal congestion, abdominal pain, nasopharyngitis, diarrhea, rash, nausea, and dizziness.",in is not a named entity
"6 ADVERSE REACTIONS    The following adverse reaction is discussed in greater detail in other sections of the label:     *  Transaminase Elevations [ see    Warnings and Precautions (5.1)   ]        EXCERPT:   The most common adverse drug reactions to KALYDECO (occurring in >=8% of patients with CF who have a  G551D  mutation in the  CFTR  gene) were headache, oropharyngeal pain, upper respiratory tract infection, nasal congestion, abdominal pain, nasopharyngitis, diarrhea, rash, nausea, and dizziness.",", and is not a named entity"
"6 ADVERSE REACTIONS    The following adverse reaction is discussed in greater detail in other sections of the label:     *  Transaminase Elevations [ see    Warnings and Precautions (5.1)   ]        EXCERPT:   The most common adverse drug reactions to KALYDECO (occurring in >=8% of patients with CF who have a  G551D  mutation in the  CFTR  gene) were headache, oropharyngeal pain, upper respiratory tract infection, nasal congestion, abdominal pain, nasopharyngitis, diarrhea, rash, nausea, and dizziness.",gene ) were is not a named entity
"6 ADVERSE REACTIONS    The following adverse reaction is discussed in greater detail in other sections of the label:     *  Transaminase Elevations [ see    Warnings and Precautions (5.1)   ]        EXCERPT:   The most common adverse drug reactions to KALYDECO (occurring in >=8% of patients with CF who have a  G551D  mutation in the  CFTR  gene) were headache, oropharyngeal pain, upper respiratory tract infection, nasal congestion, abdominal pain, nasopharyngitis, diarrhea, rash, nausea, and dizziness.",headache is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reaction is discussed in greater detail in other sections of the label:     *  Transaminase Elevations [ see    Warnings and Precautions (5.1)   ]        EXCERPT:   The most common adverse drug reactions to KALYDECO (occurring in >=8% of patients with CF who have a  G551D  mutation in the  CFTR  gene) were headache, oropharyngeal pain, upper respiratory tract infection, nasal congestion, abdominal pain, nasopharyngitis, diarrhea, rash, nausea, and dizziness.",] EXCERPT : is not a named entity
"6 ADVERSE REACTIONS    The following adverse reaction is discussed in greater detail in other sections of the label:     *  Transaminase Elevations [ see    Warnings and Precautions (5.1)   ]        EXCERPT:   The most common adverse drug reactions to KALYDECO (occurring in >=8% of patients with CF who have a  G551D  mutation in the  CFTR  gene) were headache, oropharyngeal pain, upper respiratory tract infection, nasal congestion, abdominal pain, nasopharyngitis, diarrhea, rash, nausea, and dizziness.","pain , is not a named entity"
"*  The risk for NSF appears highest among patients with:Chronic, severe kidney disease (GFR < 30 mL/min/1.73 m2), orAcute kidney injury.",< 30 mL/min/1.73 is not a named entity
"*  The risk for NSF appears highest among patients with:Chronic, severe kidney disease (GFR < 30 mL/min/1.73 m2), orAcute kidney injury.",NSF is an adverse reaction entity
"*  The risk for NSF appears highest among patients with:Chronic, severe kidney disease (GFR < 30 mL/min/1.73 m2), orAcute kidney injury.",kidney disease ( is not a named entity
"*  The risk for NSF appears highest among patients with:Chronic, severe kidney disease (GFR < 30 mL/min/1.73 m2), orAcute kidney injury.",NSF is an adverse reaction entity
Extravasation into tissues during DOTAREM administration may result in tissue irritation [see Nonclinical Toxicology (  13.2  )]  .,] is not a named entity
Extravasation into tissues during DOTAREM administration may result in tissue irritation [see Nonclinical Toxicology (  13.2  )]  .,administration tissue irritation is an adverse reaction entity
NSF has not been reported in patients with a clear history of exposure to DOTAREM alone.,NSF is an adverse reaction entity
NSF has not been reported in patients with a clear history of exposure to DOTAREM alone.,exposure to is not a named entity
Hypersensitivity reactions and acute kidney injury are described in other sections of the labeling  [see Warnings and Precautions (  5.2  ) and (  5.3  )]  .,Hypersensitivity reactions is an adverse reaction entity
Hypersensitivity reactions and acute kidney injury are described in other sections of the labeling  [see Warnings and Precautions (  5.2  ) and (  5.3  )]  .,acute kidney injury is an adverse reaction entity
Hypersensitivity reactions and acute kidney injury are described in other sections of the labeling  [see Warnings and Precautions (  5.2  ) and (  5.3  )]  .,) and ( is not a named entity
Hypersensitivity reactions and acute kidney injury are described in other sections of the labeling  [see Warnings and Precautions (  5.2  ) and (  5.3  )]  .,reactions and is not a named entity
6 ADVERSE REACTIONS    GBCAs have been associated with a risk for NSF  [see Warnings and Precautions (  5.1  )]  .,have is not a named entity
6 ADVERSE REACTIONS    GBCAs have been associated with a risk for NSF  [see Warnings and Precautions (  5.1  )]  .,NSF is an adverse reaction entity
"(  5.1  )   *  Hypersensitivity: Anaphylactoid/anaphylactic reactions with cardiovascular, respiratory or cutaneous manifestations, ranging from mild to severe, including death, have uncommonly occurred.",ranging from mild is not a named entity
"(  5.1  )   *  Hypersensitivity: Anaphylactoid/anaphylactic reactions with cardiovascular, respiratory or cutaneous manifestations, ranging from mild to severe, including death, have uncommonly occurred.",* Hypersensitivity is not a named entity
"(  5.1  )   *  Hypersensitivity: Anaphylactoid/anaphylactic reactions with cardiovascular, respiratory or cutaneous manifestations, ranging from mild to severe, including death, have uncommonly occurred.",or cutaneous manifestations is not a named entity
"(  5.1  )   *  Hypersensitivity: Anaphylactoid/anaphylactic reactions with cardiovascular, respiratory or cutaneous manifestations, ranging from mild to severe, including death, have uncommonly occurred.",Hypersensitivity is an adverse reaction entity
"(  5.1  )   *  Hypersensitivity: Anaphylactoid/anaphylactic reactions with cardiovascular, respiratory or cutaneous manifestations, ranging from mild to severe, including death, have uncommonly occurred.",respiratory manifestations is an adverse reaction entity
"(  5.1  )   *  Hypersensitivity: Anaphylactoid/anaphylactic reactions with cardiovascular, respiratory or cutaneous manifestations, ranging from mild to severe, including death, have uncommonly occurred.","to severe , is not a named entity"
"(  5.1  )   *  Hypersensitivity: Anaphylactoid/anaphylactic reactions with cardiovascular, respiratory or cutaneous manifestations, ranging from mild to severe, including death, have uncommonly occurred.",from mild is not a named entity
"(  5.1  )   *  Hypersensitivity: Anaphylactoid/anaphylactic reactions with cardiovascular, respiratory or cutaneous manifestations, ranging from mild to severe, including death, have uncommonly occurred.","death , is not a named entity"
"(  5.1  )   *  Hypersensitivity: Anaphylactoid/anaphylactic reactions with cardiovascular, respiratory or cutaneous manifestations, ranging from mild to severe, including death, have uncommonly occurred.",cardiovascular manifestations is an adverse reaction entity
"(  5.1  )   *  Hypersensitivity: Anaphylactoid/anaphylactic reactions with cardiovascular, respiratory or cutaneous manifestations, ranging from mild to severe, including death, have uncommonly occurred.",death is an adverse reaction entity
"(  5.1  )   *  Hypersensitivity: Anaphylactoid/anaphylactic reactions with cardiovascular, respiratory or cutaneous manifestations, ranging from mild to severe, including death, have uncommonly occurred.",Anaphylactoid reactions is an adverse reaction entity
"(  5.1  )   *  Hypersensitivity: Anaphylactoid/anaphylactic reactions with cardiovascular, respiratory or cutaneous manifestations, ranging from mild to severe, including death, have uncommonly occurred.",anaphylactic reactions is an adverse reaction entity
"(  5.1  )   *  Hypersensitivity: Anaphylactoid/anaphylactic reactions with cardiovascular, respiratory or cutaneous manifestations, ranging from mild to severe, including death, have uncommonly occurred.",cutaneous manifestations is an adverse reaction entity
"(  5.1  )   *  Hypersensitivity: Anaphylactoid/anaphylactic reactions with cardiovascular, respiratory or cutaneous manifestations, ranging from mild to severe, including death, have uncommonly occurred.",: is not a named entity
"EXCERPT:   The most frequent (>= 0.2%) adverse reactions in clinical studies were nausea, headache, injection site pain, injection site coldness, and burning sensation.",injection site coldness is an adverse reaction entity
"EXCERPT:   The most frequent (>= 0.2%) adverse reactions in clinical studies were nausea, headache, injection site pain, injection site coldness, and burning sensation.",and burning sensation is not a named entity
"EXCERPT:   The most frequent (>= 0.2%) adverse reactions in clinical studies were nausea, headache, injection site pain, injection site coldness, and burning sensation.",", is not a named entity"
"EXCERPT:   The most frequent (>= 0.2%) adverse reactions in clinical studies were nausea, headache, injection site pain, injection site coldness, and burning sensation.",injection site pain is an adverse reaction entity
"EXCERPT:   The most frequent (>= 0.2%) adverse reactions in clinical studies were nausea, headache, injection site pain, injection site coldness, and burning sensation.",burning sensation is an adverse reaction entity
"EXCERPT:   The most frequent (>= 0.2%) adverse reactions in clinical studies were nausea, headache, injection site pain, injection site coldness, and burning sensation.",sensation is not a named entity
"EXCERPT:   The most frequent (>= 0.2%) adverse reactions in clinical studies were nausea, headache, injection site pain, injection site coldness, and burning sensation.",were nausea is not a named entity
"EXCERPT:   The most frequent (>= 0.2%) adverse reactions in clinical studies were nausea, headache, injection site pain, injection site coldness, and burning sensation.",nausea is an adverse reaction entity
"EXCERPT:   The most frequent (>= 0.2%) adverse reactions in clinical studies were nausea, headache, injection site pain, injection site coldness, and burning sensation.",", injection site is not a named entity"
"EXCERPT:   The most frequent (>= 0.2%) adverse reactions in clinical studies were nausea, headache, injection site pain, injection site coldness, and burning sensation.",headache is an adverse reaction entity
"5.2 Hypersensitivity Reactions      Anaphylactic and anaphylactoid reactions have been reported with DOTAREM, involving cardiovascular, respiratory, and/or cutaneous manifestations.",Anaphylactic reactions is an adverse reaction entity
"5.2 Hypersensitivity Reactions      Anaphylactic and anaphylactoid reactions have been reported with DOTAREM, involving cardiovascular, respiratory, and/or cutaneous manifestations.",Hypersensitivity Reactions Anaphylactic is not a named entity
"5.2 Hypersensitivity Reactions      Anaphylactic and anaphylactoid reactions have been reported with DOTAREM, involving cardiovascular, respiratory, and/or cutaneous manifestations.","respiratory , is not a named entity"
"5.2 Hypersensitivity Reactions      Anaphylactic and anaphylactoid reactions have been reported with DOTAREM, involving cardiovascular, respiratory, and/or cutaneous manifestations.",anaphylactoid reactions is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS         EXCERPT:    *  Nephrogenic Systemic Fibrosis has occurred in patients with impaired elimination of GBCAs.,WARNINGS AND PRECAUTIONS is not a named entity
5 WARNINGS AND PRECAUTIONS         EXCERPT:    *  Nephrogenic Systemic Fibrosis has occurred in patients with impaired elimination of GBCAs.,Nephrogenic Systemic Fibrosis is an adverse reaction entity
EXCERPT:     WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)           See full prescribing information for complete boxed warning           Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs.,FIBROSIS ( is not a named entity
EXCERPT:     WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)           See full prescribing information for complete boxed warning           Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs.,boxed is not a named entity
EXCERPT:     WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)           See full prescribing information for complete boxed warning           Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs.,WARNING is not a named entity
EXCERPT:     WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)           See full prescribing information for complete boxed warning           Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs.,NEPHROGENIC SYSTEMIC FIBROSIS is an adverse reaction entity
EXCERPT:     WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)           See full prescribing information for complete boxed warning           Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs.,NSF is an adverse reaction entity
EXCERPT:     WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)           See full prescribing information for complete boxed warning           Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs.,NSF is an adverse reaction entity
These patients may have an increased risk for a hypersensitivity reaction to DOTAREM.,an increased is not a named entity
These patients may have an increased risk for a hypersensitivity reaction to DOTAREM.,hypersensitivity reaction is an adverse reaction entity
"Overall, the rate of PTLD in 949 patients treated with any of the NULOJIX regimens was 9-fold higher in those who were EBV seronegative or EBV serostatus unknown (8/139) compared to those who were EBV seropositive (5/810 patients).",PTLD is an adverse reaction entity
"Overall, the rate of PTLD in 949 patients treated with any of the NULOJIX regimens was 9-fold higher in those who were EBV seronegative or EBV serostatus unknown (8/139) compared to those who were EBV seropositive (5/810 patients).",EBV seropositive is not a named entity
"Of the patients treated with the NULOJIX recommended regimen, 5% (14/304) developed NODAT by the end of one year compared to 10% (27/280) of patients on the cyclosporine control regimen.",end is not a named entity
"Of the patients treated with the NULOJIX recommended regimen, 5% (14/304) developed NODAT by the end of one year compared to 10% (27/280) of patients on the cyclosporine control regimen.",NODAT is an adverse reaction entity
"However, by the end of the third year, the cumulative incidence of NODAT was 8% (24/304) in patients treated with the NULOJIX recommended regimen and 10% (29/280) in patients treated with the cyclosporine regimen.",the is not a named entity
"However, by the end of the third year, the cumulative incidence of NODAT was 8% (24/304) in patients treated with the NULOJIX recommended regimen and 10% (29/280) in patients treated with the cyclosporine regimen.",NODAT is an adverse reaction entity
"Progressive Multifocal Leukoencephalopathy    Two fatal cases of progressive multifocal leukoencephalopathy (PML) have been reported among 1096 patients treated with a NULOJIX-containing regimen: one patient in clinical trials of kidney transplant (Studies 1, 2, and 3 described above) and one patient in a trial of liver transplant (trial of 250 patients).",PML is an adverse reaction entity
"Progressive Multifocal Leukoencephalopathy    Two fatal cases of progressive multifocal leukoencephalopathy (PML) have been reported among 1096 patients treated with a NULOJIX-containing regimen: one patient in clinical trials of kidney transplant (Studies 1, 2, and 3 described above) and one patient in a trial of liver transplant (trial of 250 patients).",have been is not a named entity
"Progressive Multifocal Leukoencephalopathy    Two fatal cases of progressive multifocal leukoencephalopathy (PML) have been reported among 1096 patients treated with a NULOJIX-containing regimen: one patient in clinical trials of kidney transplant (Studies 1, 2, and 3 described above) and one patient in a trial of liver transplant (trial of 250 patients).",progressive multifocal leukoencephalopathy is an adverse reaction entity
"Progressive Multifocal Leukoencephalopathy    Two fatal cases of progressive multifocal leukoencephalopathy (PML) have been reported among 1096 patients treated with a NULOJIX-containing regimen: one patient in clinical trials of kidney transplant (Studies 1, 2, and 3 described above) and one patient in a trial of liver transplant (trial of 250 patients).",have been reported is not a named entity
"Progressive Multifocal Leukoencephalopathy    Two fatal cases of progressive multifocal leukoencephalopathy (PML) have been reported among 1096 patients treated with a NULOJIX-containing regimen: one patient in clinical trials of kidney transplant (Studies 1, 2, and 3 described above) and one patient in a trial of liver transplant (trial of 250 patients).",multifocal leukoencephalopathy is not a named entity
"Progressive Multifocal Leukoencephalopathy    Two fatal cases of progressive multifocal leukoencephalopathy (PML) have been reported among 1096 patients treated with a NULOJIX-containing regimen: one patient in clinical trials of kidney transplant (Studies 1, 2, and 3 described above) and one patient in a trial of liver transplant (trial of 250 patients).",fatal is an adverse reaction entity
"Among the 477 patients in Studies 1, 2, and 3 treated with the NULOJIX regimen of higher cumulative dose and more frequent dosing than recommended, there were 8 cases of PTLD: 2 in EBV seropositive patients and 6 in EBV seronegative or serostatus unknown patients.",PTLD is an adverse reaction entity
"Among the 477 patients in Studies 1, 2, and 3 treated with the NULOJIX regimen of higher cumulative dose and more frequent dosing than recommended, there were 8 cases of PTLD: 2 in EBV seropositive patients and 6 in EBV seronegative or serostatus unknown patients.",2 in is not a named entity
"(5.3)     *     Progressive Multifocal Leukoencephalopathy (PML) : increased risk; consider in the diagnosis of patients reporting new or worsening neurological, cognitive, or behavioral signs and symptoms.",PML is an adverse reaction entity
"(5.3)     *     Progressive Multifocal Leukoencephalopathy (PML) : increased risk; consider in the diagnosis of patients reporting new or worsening neurological, cognitive, or behavioral signs and symptoms.",Leukoencephalopathy is not a named entity
"(5.3)     *     Progressive Multifocal Leukoencephalopathy (PML) : increased risk; consider in the diagnosis of patients reporting new or worsening neurological, cognitive, or behavioral signs and symptoms.",Progressive Multifocal Leukoencephalopathy is an adverse reaction entity
"(5.3)     *     Progressive Multifocal Leukoencephalopathy (PML) : increased risk; consider in the diagnosis of patients reporting new or worsening neurological, cognitive, or behavioral signs and symptoms.","neurological , cognitive is not a named entity"
Hypertension was reported as an adverse reaction in 32% of NULOJIX-treated patients and 37% of cyclosporine-treated patients (see Table 4).,Hypertension is an adverse reaction entity
Hypertension was reported as an adverse reaction in 32% of NULOJIX-treated patients and 37% of cyclosporine-treated patients (see Table 4).,NULOJIX-treated patients and is not a named entity
BK virus-associated nephropathy was reported in 6 NULOJIX patients (4 of which resulted in graft loss) and 6 cyclosporine patients (none of which resulted in graft loss) by Year 3.,BK virus-associated nephropathy is an adverse reaction entity
BK virus-associated nephropathy was reported in 6 NULOJIX patients (4 of which resulted in graft loss) and 6 cyclosporine patients (none of which resulted in graft loss) by Year 3.,and 6 is not a named entity
"*  Increased risk for developing post-transplant lymphoproliferative disorder (PTLD), predominantly involving the central nervous system (CNS).",PTLD is an adverse reaction entity
"*  Increased risk for developing post-transplant lymphoproliferative disorder (PTLD), predominantly involving the central nervous system (CNS).",involving the is not a named entity
"*  Increased risk for developing post-transplant lymphoproliferative disorder (PTLD), predominantly involving the central nervous system (CNS).",post-transplant lymphoproliferative disorder is an adverse reaction entity
"*  Increased risk for developing post-transplant lymphoproliferative disorder (PTLD), predominantly involving the central nervous system (CNS).",) is not a named entity
"Of the patients who developed tuberculosis through 3 years, all but one NULOJIX patient lived in countries with a high prevalence of tuberculosis [see    Warnings and Precautions (5.5)    ].",tuberculosis is an adverse reaction entity
"Of the patients who developed tuberculosis through 3 years, all but one NULOJIX patient lived in countries with a high prevalence of tuberculosis [see    Warnings and Precautions (5.5)    ].",NULOJIX patient lived is not a named entity
"Fungal infections were reported in 18% of patients receiving NULOJIX compared to 22% receiving cyclosporine, primarily due to skin and mucocutaneous fungal infections.",mucocutaneous fungal infections is an adverse reaction entity
"Fungal infections were reported in 18% of patients receiving NULOJIX compared to 22% receiving cyclosporine, primarily due to skin and mucocutaneous fungal infections.",skin fungal infections is an adverse reaction entity
"Fungal infections were reported in 18% of patients receiving NULOJIX compared to 22% receiving cyclosporine, primarily due to skin and mucocutaneous fungal infections.","cyclosporine , is not a named entity"
"Fungal infections were reported in 18% of patients receiving NULOJIX compared to 22% receiving cyclosporine, primarily due to skin and mucocutaneous fungal infections.",primarily due is not a named entity
"Fungal infections were reported in 18% of patients receiving NULOJIX compared to 22% receiving cyclosporine, primarily due to skin and mucocutaneous fungal infections.",Fungal infections is an adverse reaction entity
"Fungal infections were reported in 18% of patients receiving NULOJIX compared to 22% receiving cyclosporine, primarily due to skin and mucocutaneous fungal infections.",reported in 18 is not a named entity
"For infectious adverse reactions, the causative organism is reported if specified by the physician in the clinical trials.",infectious adverse reactions is an adverse reaction entity
"For infectious adverse reactions, the causative organism is reported if specified by the physician in the clinical trials.",trials is not a named entity
"There were no differences in the occurrence of 3+ proteinuria (<4% in both studies) at any time point, and no patients experienced 4+ proteinuria.",4 % is not a named entity
"There were no differences in the occurrence of 3+ proteinuria (<4% in both studies) at any time point, and no patients experienced 4+ proteinuria.",proteinuria is an adverse reaction entity
"There were no differences in the occurrence of 3+ proteinuria (<4% in both studies) at any time point, and no patients experienced 4+ proteinuria.",proteinuria ( < is not a named entity
"There were no differences in the occurrence of 3+ proteinuria (<4% in both studies) at any time point, and no patients experienced 4+ proteinuria.",proteinuria is an adverse reaction entity
"In addition, two cases of PTLD involving the liver allograft (one fatal) and one fatal case of PML were observed among the 147 patients randomized to NULOJIX.",fatal is an adverse reaction entity
"In addition, two cases of PTLD involving the liver allograft (one fatal) and one fatal case of PML were observed among the 147 patients randomized to NULOJIX.",PTLD is an adverse reaction entity
"In addition, two cases of PTLD involving the liver allograft (one fatal) and one fatal case of PML were observed among the 147 patients randomized to NULOJIX.",PML is an adverse reaction entity
"In addition, two cases of PTLD involving the liver allograft (one fatal) and one fatal case of PML were observed among the 147 patients randomized to NULOJIX.",the liver allograft is not a named entity
"In addition, two cases of PTLD involving the liver allograft (one fatal) and one fatal case of PML were observed among the 147 patients randomized to NULOJIX.",one fatal ) is not a named entity
"In addition, two cases of PTLD involving the liver allograft (one fatal) and one fatal case of PML were observed among the 147 patients randomized to NULOJIX.",fatal is an adverse reaction entity
"In addition, two cases of PTLD involving the liver allograft (one fatal) and one fatal case of PML were observed among the 147 patients randomized to NULOJIX.",one fatal is not a named entity
"In addition, two cases of PTLD involving the liver allograft (one fatal) and one fatal case of PML were observed among the 147 patients randomized to NULOJIX.",the is not a named entity
All cases of PTLD reported up to 36 months post transplant in NULOJIX- or cyclosporine-treated patients presented within 18 months of transplantation.,PTLD is an adverse reaction entity
All cases of PTLD reported up to 36 months post transplant in NULOJIX- or cyclosporine-treated patients presented within 18 months of transplantation.,of transplantation is not a named entity
"CNS PTLD, PML, and other CNS infections were more frequently observed in association with a NULOJIX regimen of higher cumulative dose and more frequent dosing compared to the recommended regimen; therefore, administration of higher than the recommended doses and/or more frequent dosing of NULOJIX is not recommended [see    Dosage and Administration (2.1)    ].",", is not a named entity"
"CNS PTLD, PML, and other CNS infections were more frequently observed in association with a NULOJIX regimen of higher cumulative dose and more frequent dosing compared to the recommended regimen; therefore, administration of higher than the recommended doses and/or more frequent dosing of NULOJIX is not recommended [see    Dosage and Administration (2.1)    ].",PML is an adverse reaction entity
"CNS PTLD, PML, and other CNS infections were more frequently observed in association with a NULOJIX regimen of higher cumulative dose and more frequent dosing compared to the recommended regimen; therefore, administration of higher than the recommended doses and/or more frequent dosing of NULOJIX is not recommended [see    Dosage and Administration (2.1)    ].",CNS PTLD is an adverse reaction entity
"CNS PTLD, PML, and other CNS infections were more frequently observed in association with a NULOJIX regimen of higher cumulative dose and more frequent dosing compared to the recommended regimen; therefore, administration of higher than the recommended doses and/or more frequent dosing of NULOJIX is not recommended [see    Dosage and Administration (2.1)    ].",] is not a named entity
"CNS PTLD, PML, and other CNS infections were more frequently observed in association with a NULOJIX regimen of higher cumulative dose and more frequent dosing compared to the recommended regimen; therefore, administration of higher than the recommended doses and/or more frequent dosing of NULOJIX is not recommended [see    Dosage and Administration (2.1)    ].",", is not a named entity"
"CNS PTLD, PML, and other CNS infections were more frequently observed in association with a NULOJIX regimen of higher cumulative dose and more frequent dosing compared to the recommended regimen; therefore, administration of higher than the recommended doses and/or more frequent dosing of NULOJIX is not recommended [see    Dosage and Administration (2.1)    ].",CNS infections is an adverse reaction entity
The most common adverse reactions leading to discontinuation in NULOJIX-treated patients were cytomegalovirus infection (1.5%) and complications of transplanted kidney (1.5%).,complications of transplanted kidney is an adverse reaction entity
The most common adverse reactions leading to discontinuation in NULOJIX-treated patients were cytomegalovirus infection (1.5%) and complications of transplanted kidney (1.5%).,of transplanted kidney is not a named entity
The most common adverse reactions leading to discontinuation in NULOJIX-treated patients were cytomegalovirus infection (1.5%) and complications of transplanted kidney (1.5%).,cytomegalovirus infection is an adverse reaction entity
The most common adverse reactions leading to discontinuation in NULOJIX-treated patients were cytomegalovirus infection (1.5%) and complications of transplanted kidney (1.5%).,NULOJIX-treated is not a named entity
"Increased susceptibility to infection and the possible development of malignancies may result from immunosuppression [see     Warnings and Precautions (5.1  ,   5.3  ,   5.4  ,   5.5)    ].",Increased susceptibility to infection is an adverse reaction entity
"Increased susceptibility to infection and the possible development of malignancies may result from immunosuppression [see     Warnings and Precautions (5.1  ,   5.3  ,   5.4  ,   5.5)    ].",malignancies is an adverse reaction entity
"Increased susceptibility to infection and the possible development of malignancies may result from immunosuppression [see     Warnings and Precautions (5.1  ,   5.3  ,   5.4  ,   5.5)    ].",", 5.3 , is not a named entity"
"Increased susceptibility to infection and the possible development of malignancies may result from immunosuppression [see     Warnings and Precautions (5.1  ,   5.3  ,   5.4  ,   5.5)    ].",", is not a named entity"
The frequency of 2+ proteinuria was similar between the two treatment groups between one and three years after transplantation (<10% in both studies).,proteinuria is an adverse reaction entity
The frequency of 2+ proteinuria was similar between the two treatment groups between one and three years after transplantation (<10% in both studies).,frequency is not a named entity
(5.2)   *  Increased susceptibility to infection and the possible development of malignancies may result from immunosuppression.,immunosuppression is not a named entity
(5.2)   *  Increased susceptibility to infection and the possible development of malignancies may result from immunosuppression.,Increased susceptibility to infection is an adverse reaction entity
(5.2)   *  Increased susceptibility to infection and the possible development of malignancies may result from immunosuppression.,may result from is not a named entity
(5.2)   *  Increased susceptibility to infection and the possible development of malignancies may result from immunosuppression.,malignancies is an adverse reaction entity
"Six patients out of the 403 who were treated with the NULOJIX regimen of higher cumulative dose and more frequent dosing than recommended in Studies 1 and 2 (1.5%) were reported to have developed CNS infections, including 2 cases of cryptococcal meningitis, one case of Chagas encephalitis with cryptococcal meningitis, one case of cerebral aspergillosis, one case of West Nile encephalitis, and one case of PML (discussed above).",Chagas encephalitis is an adverse reaction entity
"Six patients out of the 403 who were treated with the NULOJIX regimen of higher cumulative dose and more frequent dosing than recommended in Studies 1 and 2 (1.5%) were reported to have developed CNS infections, including 2 cases of cryptococcal meningitis, one case of Chagas encephalitis with cryptococcal meningitis, one case of cerebral aspergillosis, one case of West Nile encephalitis, and one case of PML (discussed above).",case is not a named entity
"Six patients out of the 403 who were treated with the NULOJIX regimen of higher cumulative dose and more frequent dosing than recommended in Studies 1 and 2 (1.5%) were reported to have developed CNS infections, including 2 cases of cryptococcal meningitis, one case of Chagas encephalitis with cryptococcal meningitis, one case of cerebral aspergillosis, one case of West Nile encephalitis, and one case of PML (discussed above).",of is not a named entity
"Six patients out of the 403 who were treated with the NULOJIX regimen of higher cumulative dose and more frequent dosing than recommended in Studies 1 and 2 (1.5%) were reported to have developed CNS infections, including 2 cases of cryptococcal meningitis, one case of Chagas encephalitis with cryptococcal meningitis, one case of cerebral aspergillosis, one case of West Nile encephalitis, and one case of PML (discussed above).",cerebral aspergillosis is an adverse reaction entity
"Six patients out of the 403 who were treated with the NULOJIX regimen of higher cumulative dose and more frequent dosing than recommended in Studies 1 and 2 (1.5%) were reported to have developed CNS infections, including 2 cases of cryptococcal meningitis, one case of Chagas encephalitis with cryptococcal meningitis, one case of cerebral aspergillosis, one case of West Nile encephalitis, and one case of PML (discussed above).",with the NULOJIX is not a named entity
"Six patients out of the 403 who were treated with the NULOJIX regimen of higher cumulative dose and more frequent dosing than recommended in Studies 1 and 2 (1.5%) were reported to have developed CNS infections, including 2 cases of cryptococcal meningitis, one case of Chagas encephalitis with cryptococcal meningitis, one case of cerebral aspergillosis, one case of West Nile encephalitis, and one case of PML (discussed above).",have developed CNS is not a named entity
"Six patients out of the 403 who were treated with the NULOJIX regimen of higher cumulative dose and more frequent dosing than recommended in Studies 1 and 2 (1.5%) were reported to have developed CNS infections, including 2 cases of cryptococcal meningitis, one case of Chagas encephalitis with cryptococcal meningitis, one case of cerebral aspergillosis, one case of West Nile encephalitis, and one case of PML (discussed above).",cryptococcal meningitis is an adverse reaction entity
"Six patients out of the 403 who were treated with the NULOJIX regimen of higher cumulative dose and more frequent dosing than recommended in Studies 1 and 2 (1.5%) were reported to have developed CNS infections, including 2 cases of cryptococcal meningitis, one case of Chagas encephalitis with cryptococcal meningitis, one case of cerebral aspergillosis, one case of West Nile encephalitis, and one case of PML (discussed above).",cryptococcal meningitis is an adverse reaction entity
"Six patients out of the 403 who were treated with the NULOJIX regimen of higher cumulative dose and more frequent dosing than recommended in Studies 1 and 2 (1.5%) were reported to have developed CNS infections, including 2 cases of cryptococcal meningitis, one case of Chagas encephalitis with cryptococcal meningitis, one case of cerebral aspergillosis, one case of West Nile encephalitis, and one case of PML (discussed above).",PML is an adverse reaction entity
"Six patients out of the 403 who were treated with the NULOJIX regimen of higher cumulative dose and more frequent dosing than recommended in Studies 1 and 2 (1.5%) were reported to have developed CNS infections, including 2 cases of cryptococcal meningitis, one case of Chagas encephalitis with cryptococcal meningitis, one case of cerebral aspergillosis, one case of West Nile encephalitis, and one case of PML (discussed above).",case of West is not a named entity
"Six patients out of the 403 who were treated with the NULOJIX regimen of higher cumulative dose and more frequent dosing than recommended in Studies 1 and 2 (1.5%) were reported to have developed CNS infections, including 2 cases of cryptococcal meningitis, one case of Chagas encephalitis with cryptococcal meningitis, one case of cerebral aspergillosis, one case of West Nile encephalitis, and one case of PML (discussed above).",West Nile encephalitis is an adverse reaction entity
"Six patients out of the 403 who were treated with the NULOJIX regimen of higher cumulative dose and more frequent dosing than recommended in Studies 1 and 2 (1.5%) were reported to have developed CNS infections, including 2 cases of cryptococcal meningitis, one case of Chagas encephalitis with cryptococcal meningitis, one case of cerebral aspergillosis, one case of West Nile encephalitis, and one case of PML (discussed above).",CNS infections is an adverse reaction entity
"Six patients out of the 403 who were treated with the NULOJIX regimen of higher cumulative dose and more frequent dosing than recommended in Studies 1 and 2 (1.5%) were reported to have developed CNS infections, including 2 cases of cryptococcal meningitis, one case of Chagas encephalitis with cryptococcal meningitis, one case of cerebral aspergillosis, one case of West Nile encephalitis, and one case of PML (discussed above).",case of Chagas is not a named entity
"Six patients out of the 403 who were treated with the NULOJIX regimen of higher cumulative dose and more frequent dosing than recommended in Studies 1 and 2 (1.5%) were reported to have developed CNS infections, including 2 cases of cryptococcal meningitis, one case of Chagas encephalitis with cryptococcal meningitis, one case of cerebral aspergillosis, one case of West Nile encephalitis, and one case of PML (discussed above).",regimen of is not a named entity
"Table 2: Summary of PTLD Reported in Studies 1, 2, and 3 Through Three Years of Treatment                      NULOJIX    Non-Recommended    Regimen*    (N=477)      NULOJIX    Recommended    Regimen        (N=472)      Cyclosporine    (N=476)         Trial            EBV    Positive    (n=406)      EBV    Negative    (n=43)      EBV    Unknown    (n=28)      EBV    Positive    (n=404)      EBV    Negative    (n=48)      EBV    Unknown    (n=20)      EBV    Positive    (n=399)      EBV    Negative    (n=57)      EBV    Unknown    (n=20)          *  Regimen with higher cumulative dose and more frequent dosing than the recommended NULOJIX regimen.",Negative is not a named entity
"Table 2: Summary of PTLD Reported in Studies 1, 2, and 3 Through Three Years of Treatment                      NULOJIX    Non-Recommended    Regimen*    (N=477)      NULOJIX    Recommended    Regimen        (N=472)      Cyclosporine    (N=476)         Trial            EBV    Positive    (n=406)      EBV    Negative    (n=43)      EBV    Unknown    (n=28)      EBV    Positive    (n=404)      EBV    Negative    (n=48)      EBV    Unknown    (n=20)      EBV    Positive    (n=399)      EBV    Negative    (n=57)      EBV    Unknown    (n=20)          *  Regimen with higher cumulative dose and more frequent dosing than the recommended NULOJIX regimen.",PTLD is an adverse reaction entity
No cases of PML were reported in patients treated with the recommended NULOJIX regimen or the control regimen in these trials.,PML is an adverse reaction entity
No cases of PML were reported in patients treated with the recommended NULOJIX regimen or the control regimen in these trials.,regimen is not a named entity
"Polyoma Virus Nephropathy      In addition to cases of JC virus-associated PML [see   Warnings and Precautions (5.4)    ], cases of polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, have been reported.",and Precautions is not a named entity
"Polyoma Virus Nephropathy      In addition to cases of JC virus-associated PML [see   Warnings and Precautions (5.4)    ], cases of polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, have been reported.",to cases is not a named entity
"Polyoma Virus Nephropathy      In addition to cases of JC virus-associated PML [see   Warnings and Precautions (5.4)    ], cases of polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, have been reported.",) is not a named entity
"Polyoma Virus Nephropathy      In addition to cases of JC virus-associated PML [see   Warnings and Precautions (5.4)    ], cases of polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, have been reported.",PML is an adverse reaction entity
"Polyoma Virus Nephropathy      In addition to cases of JC virus-associated PML [see   Warnings and Precautions (5.4)    ], cases of polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, have been reported.",virus-associated PML is not a named entity
"Polyoma Virus Nephropathy      In addition to cases of JC virus-associated PML [see   Warnings and Precautions (5.4)    ], cases of polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, have been reported.",polyoma virus-associated nephropathy is an adverse reaction entity
"Polyoma Virus Nephropathy      In addition to cases of JC virus-associated PML [see   Warnings and Precautions (5.4)    ], cases of polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, have been reported.",JC virus is an adverse reaction entity
"Polyoma Virus Nephropathy      In addition to cases of JC virus-associated PML [see   Warnings and Precautions (5.4)    ], cases of polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, have been reported.",PVAN is an adverse reaction entity
"Polyoma Virus Nephropathy      In addition to cases of JC virus-associated PML [see   Warnings and Precautions (5.4)    ], cases of polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, have been reported.",addition to cases is not a named entity
"Polyoma Virus Nephropathy      In addition to cases of JC virus-associated PML [see   Warnings and Precautions (5.4)    ], cases of polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, have been reported.",BK virus infection is an adverse reaction entity
"(5.4)     *     Other serious infections : increased risk of bacterial, viral, fungal, and protozoal infections, including opportunistic infections and tuberculosis.",opportunistic infections is an adverse reaction entity
"(5.4)     *     Other serious infections : increased risk of bacterial, viral, fungal, and protozoal infections, including opportunistic infections and tuberculosis.","of bacterial , is not a named entity"
"(5.4)     *     Other serious infections : increased risk of bacterial, viral, fungal, and protozoal infections, including opportunistic infections and tuberculosis.",* is not a named entity
"(5.4)     *     Other serious infections : increased risk of bacterial, viral, fungal, and protozoal infections, including opportunistic infections and tuberculosis.",protozoal infections is an adverse reaction entity
"(5.4)     *     Other serious infections : increased risk of bacterial, viral, fungal, and protozoal infections, including opportunistic infections and tuberculosis.",infections is an adverse reaction entity
"(5.4)     *     Other serious infections : increased risk of bacterial, viral, fungal, and protozoal infections, including opportunistic infections and tuberculosis.",fungal infections is an adverse reaction entity
"(5.4)     *     Other serious infections : increased risk of bacterial, viral, fungal, and protozoal infections, including opportunistic infections and tuberculosis.",of bacterial is not a named entity
"(5.4)     *     Other serious infections : increased risk of bacterial, viral, fungal, and protozoal infections, including opportunistic infections and tuberculosis.",viral infections is an adverse reaction entity
"(5.4)     *     Other serious infections : increased risk of bacterial, viral, fungal, and protozoal infections, including opportunistic infections and tuberculosis.","viral , fungal is not a named entity"
"(5.4)     *     Other serious infections : increased risk of bacterial, viral, fungal, and protozoal infections, including opportunistic infections and tuberculosis.",bacterial infections is an adverse reaction entity
"(5.4)     *     Other serious infections : increased risk of bacterial, viral, fungal, and protozoal infections, including opportunistic infections and tuberculosis.",) is not a named entity
"(5.4)     *     Other serious infections : increased risk of bacterial, viral, fungal, and protozoal infections, including opportunistic infections and tuberculosis.",and protozoal is not a named entity
"(5.4)     *     Other serious infections : increased risk of bacterial, viral, fungal, and protozoal infections, including opportunistic infections and tuberculosis.","infections , is not a named entity"
"(5.4)     *     Other serious infections : increased risk of bacterial, viral, fungal, and protozoal infections, including opportunistic infections and tuberculosis.",tuberculosis is an adverse reaction entity
"EXCERPT:   WARNING: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER, OTHER MALIGNANCIES, AND SERIOUS INFECTIONS         See full prescribing information for complete boxed warning.",MALIGNANCIES is an adverse reaction entity
"EXCERPT:   WARNING: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER, OTHER MALIGNANCIES, AND SERIOUS INFECTIONS         See full prescribing information for complete boxed warning.",POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER is an adverse reaction entity
"EXCERPT:   WARNING: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER, OTHER MALIGNANCIES, AND SERIOUS INFECTIONS         See full prescribing information for complete boxed warning.",OTHER MALIGNANCIES is not a named entity
"EXCERPT:   WARNING: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER, OTHER MALIGNANCIES, AND SERIOUS INFECTIONS         See full prescribing information for complete boxed warning.",INFECTIONS is an adverse reaction entity
"EXCERPT:   WARNING: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER, OTHER MALIGNANCIES, AND SERIOUS INFECTIONS         See full prescribing information for complete boxed warning.","MALIGNANCIES , is not a named entity"
"EXCERPT:   WARNING: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER, OTHER MALIGNANCIES, AND SERIOUS INFECTIONS         See full prescribing information for complete boxed warning.",", AND SERIOUS is not a named entity"
#    Most herpes infections were non-serious and 1 led to treatment discontinuation.,# Most is not a named entity
#    Most herpes infections were non-serious and 1 led to treatment discontinuation.,herpes infections is an adverse reaction entity
#    Most herpes infections were non-serious and 1 led to treatment discontinuation.,# Most herpes is not a named entity
#    Most herpes infections were non-serious and 1 led to treatment discontinuation.,herpes infections is an adverse reaction entity
"One of the 476 patients treated with cyclosporine developed PTLD, without CNS involvement.","developed PTLD , is not a named entity"
"One of the 476 patients treated with cyclosporine developed PTLD, without CNS involvement.",PTLD is an adverse reaction entity
"Infusion-related reactions within one hour of infusion were reported in 5% of patients treated with the recommended dose of NULOJIX, similar to the placebo rate.",reported in 5 is not a named entity
"Infusion-related reactions within one hour of infusion were reported in 5% of patients treated with the recommended dose of NULOJIX, similar to the placebo rate.",Infusion-related reactions is an adverse reaction entity
"(Boxed Warning  ,  4  ,  5.1  ,  5.6)     *     Other malignancies : increased risk with all immunosuppressants; appears related to intensity and duration of use.","5.1 , is not a named entity"
"(Boxed Warning  ,  4  ,  5.1  ,  5.6)     *     Other malignancies : increased risk with all immunosuppressants; appears related to intensity and duration of use.",malignancies is an adverse reaction entity
"The clinical significance of CMV serology as a risk factor for PTLD remains to be determined; however, these findings should be considered when prescribing NULOJIX [see    Warnings and Precautions (5.1)    ].",remains is not a named entity
"The clinical significance of CMV serology as a risk factor for PTLD remains to be determined; however, these findings should be considered when prescribing NULOJIX [see    Warnings and Precautions (5.1)    ].",PTLD is an adverse reaction entity
"6 ADVERSE REACTIONS    The most serious adverse reactions reported with NULOJIX are:     *    PTLD, predominantly CNS PTLD, and other malignancies [see   Boxed Warning   and   Warnings and Precautions (5.1  ,  5.3)   ]   *    Serious infections, including JC virus-associated PML and polyoma virus nephropathy [see   Warnings and Precautions (5.4  ,  5.5  ,  5.6)   ]        EXCERPT:   Most common adverse reactions (>=20% on NULOJIX treatment) are anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",vomiting is an adverse reaction entity
"6 ADVERSE REACTIONS    The most serious adverse reactions reported with NULOJIX are:     *    PTLD, predominantly CNS PTLD, and other malignancies [see   Boxed Warning   and   Warnings and Precautions (5.1  ,  5.3)   ]   *    Serious infections, including JC virus-associated PML and polyoma virus nephropathy [see   Warnings and Precautions (5.4  ,  5.5  ,  5.6)   ]        EXCERPT:   Most common adverse reactions (>=20% on NULOJIX treatment) are anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",* Serious infections is not a named entity
"6 ADVERSE REACTIONS    The most serious adverse reactions reported with NULOJIX are:     *    PTLD, predominantly CNS PTLD, and other malignancies [see   Boxed Warning   and   Warnings and Precautions (5.1  ,  5.3)   ]   *    Serious infections, including JC virus-associated PML and polyoma virus nephropathy [see   Warnings and Precautions (5.4  ,  5.5  ,  5.6)   ]        EXCERPT:   Most common adverse reactions (>=20% on NULOJIX treatment) are anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",graft dysfunction is an adverse reaction entity
"6 ADVERSE REACTIONS    The most serious adverse reactions reported with NULOJIX are:     *    PTLD, predominantly CNS PTLD, and other malignancies [see   Boxed Warning   and   Warnings and Precautions (5.1  ,  5.3)   ]   *    Serious infections, including JC virus-associated PML and polyoma virus nephropathy [see   Warnings and Precautions (5.4  ,  5.5  ,  5.6)   ]        EXCERPT:   Most common adverse reactions (>=20% on NULOJIX treatment) are anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",hypertension is an adverse reaction entity
"6 ADVERSE REACTIONS    The most serious adverse reactions reported with NULOJIX are:     *    PTLD, predominantly CNS PTLD, and other malignancies [see   Boxed Warning   and   Warnings and Precautions (5.1  ,  5.3)   ]   *    Serious infections, including JC virus-associated PML and polyoma virus nephropathy [see   Warnings and Precautions (5.4  ,  5.5  ,  5.6)   ]        EXCERPT:   Most common adverse reactions (>=20% on NULOJIX treatment) are anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",", pyrexia is not a named entity"
"6 ADVERSE REACTIONS    The most serious adverse reactions reported with NULOJIX are:     *    PTLD, predominantly CNS PTLD, and other malignancies [see   Boxed Warning   and   Warnings and Precautions (5.1  ,  5.3)   ]   *    Serious infections, including JC virus-associated PML and polyoma virus nephropathy [see   Warnings and Precautions (5.4  ,  5.5  ,  5.6)   ]        EXCERPT:   Most common adverse reactions (>=20% on NULOJIX treatment) are anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",6 is not a named entity
"6 ADVERSE REACTIONS    The most serious adverse reactions reported with NULOJIX are:     *    PTLD, predominantly CNS PTLD, and other malignancies [see   Boxed Warning   and   Warnings and Precautions (5.1  ,  5.3)   ]   *    Serious infections, including JC virus-associated PML and polyoma virus nephropathy [see   Warnings and Precautions (5.4  ,  5.5  ,  5.6)   ]        EXCERPT:   Most common adverse reactions (>=20% on NULOJIX treatment) are anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",Warnings and is not a named entity
"6 ADVERSE REACTIONS    The most serious adverse reactions reported with NULOJIX are:     *    PTLD, predominantly CNS PTLD, and other malignancies [see   Boxed Warning   and   Warnings and Precautions (5.1  ,  5.3)   ]   *    Serious infections, including JC virus-associated PML and polyoma virus nephropathy [see   Warnings and Precautions (5.4  ,  5.5  ,  5.6)   ]        EXCERPT:   Most common adverse reactions (>=20% on NULOJIX treatment) are anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",", including JC is not a named entity"
"6 ADVERSE REACTIONS    The most serious adverse reactions reported with NULOJIX are:     *    PTLD, predominantly CNS PTLD, and other malignancies [see   Boxed Warning   and   Warnings and Precautions (5.1  ,  5.3)   ]   *    Serious infections, including JC virus-associated PML and polyoma virus nephropathy [see   Warnings and Precautions (5.4  ,  5.5  ,  5.6)   ]        EXCERPT:   Most common adverse reactions (>=20% on NULOJIX treatment) are anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",6 is not a named entity
"6 ADVERSE REACTIONS    The most serious adverse reactions reported with NULOJIX are:     *    PTLD, predominantly CNS PTLD, and other malignancies [see   Boxed Warning   and   Warnings and Precautions (5.1  ,  5.3)   ]   *    Serious infections, including JC virus-associated PML and polyoma virus nephropathy [see   Warnings and Precautions (5.4  ,  5.5  ,  5.6)   ]        EXCERPT:   Most common adverse reactions (>=20% on NULOJIX treatment) are anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",peripheral edema is an adverse reaction entity
"6 ADVERSE REACTIONS    The most serious adverse reactions reported with NULOJIX are:     *    PTLD, predominantly CNS PTLD, and other malignancies [see   Boxed Warning   and   Warnings and Precautions (5.1  ,  5.3)   ]   *    Serious infections, including JC virus-associated PML and polyoma virus nephropathy [see   Warnings and Precautions (5.4  ,  5.5  ,  5.6)   ]        EXCERPT:   Most common adverse reactions (>=20% on NULOJIX treatment) are anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",JC virus is an adverse reaction entity
"6 ADVERSE REACTIONS    The most serious adverse reactions reported with NULOJIX are:     *    PTLD, predominantly CNS PTLD, and other malignancies [see   Boxed Warning   and   Warnings and Precautions (5.1  ,  5.3)   ]   *    Serious infections, including JC virus-associated PML and polyoma virus nephropathy [see   Warnings and Precautions (5.4  ,  5.5  ,  5.6)   ]        EXCERPT:   Most common adverse reactions (>=20% on NULOJIX treatment) are anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",", is not a named entity"
"6 ADVERSE REACTIONS    The most serious adverse reactions reported with NULOJIX are:     *    PTLD, predominantly CNS PTLD, and other malignancies [see   Boxed Warning   and   Warnings and Precautions (5.1  ,  5.3)   ]   *    Serious infections, including JC virus-associated PML and polyoma virus nephropathy [see   Warnings and Precautions (5.4  ,  5.5  ,  5.6)   ]        EXCERPT:   Most common adverse reactions (>=20% on NULOJIX treatment) are anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.","pyrexia , is not a named entity"
"6 ADVERSE REACTIONS    The most serious adverse reactions reported with NULOJIX are:     *    PTLD, predominantly CNS PTLD, and other malignancies [see   Boxed Warning   and   Warnings and Precautions (5.1  ,  5.3)   ]   *    Serious infections, including JC virus-associated PML and polyoma virus nephropathy [see   Warnings and Precautions (5.4  ,  5.5  ,  5.6)   ]        EXCERPT:   Most common adverse reactions (>=20% on NULOJIX treatment) are anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",5.4 is not a named entity
"6 ADVERSE REACTIONS    The most serious adverse reactions reported with NULOJIX are:     *    PTLD, predominantly CNS PTLD, and other malignancies [see   Boxed Warning   and   Warnings and Precautions (5.1  ,  5.3)   ]   *    Serious infections, including JC virus-associated PML and polyoma virus nephropathy [see   Warnings and Precautions (5.4  ,  5.5  ,  5.6)   ]        EXCERPT:   Most common adverse reactions (>=20% on NULOJIX treatment) are anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",Most is not a named entity
"6 ADVERSE REACTIONS    The most serious adverse reactions reported with NULOJIX are:     *    PTLD, predominantly CNS PTLD, and other malignancies [see   Boxed Warning   and   Warnings and Precautions (5.1  ,  5.3)   ]   *    Serious infections, including JC virus-associated PML and polyoma virus nephropathy [see   Warnings and Precautions (5.4  ,  5.5  ,  5.6)   ]        EXCERPT:   Most common adverse reactions (>=20% on NULOJIX treatment) are anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",hypokalemia is an adverse reaction entity
"6 ADVERSE REACTIONS    The most serious adverse reactions reported with NULOJIX are:     *    PTLD, predominantly CNS PTLD, and other malignancies [see   Boxed Warning   and   Warnings and Precautions (5.1  ,  5.3)   ]   *    Serious infections, including JC virus-associated PML and polyoma virus nephropathy [see   Warnings and Precautions (5.4  ,  5.5  ,  5.6)   ]        EXCERPT:   Most common adverse reactions (>=20% on NULOJIX treatment) are anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",", is not a named entity"
"6 ADVERSE REACTIONS    The most serious adverse reactions reported with NULOJIX are:     *    PTLD, predominantly CNS PTLD, and other malignancies [see   Boxed Warning   and   Warnings and Precautions (5.1  ,  5.3)   ]   *    Serious infections, including JC virus-associated PML and polyoma virus nephropathy [see   Warnings and Precautions (5.4  ,  5.5  ,  5.6)   ]        EXCERPT:   Most common adverse reactions (>=20% on NULOJIX treatment) are anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",nausea is an adverse reaction entity
"6 ADVERSE REACTIONS    The most serious adverse reactions reported with NULOJIX are:     *    PTLD, predominantly CNS PTLD, and other malignancies [see   Boxed Warning   and   Warnings and Precautions (5.1  ,  5.3)   ]   *    Serious infections, including JC virus-associated PML and polyoma virus nephropathy [see   Warnings and Precautions (5.4  ,  5.5  ,  5.6)   ]        EXCERPT:   Most common adverse reactions (>=20% on NULOJIX treatment) are anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",urinary tract infection is an adverse reaction entity
"6 ADVERSE REACTIONS    The most serious adverse reactions reported with NULOJIX are:     *    PTLD, predominantly CNS PTLD, and other malignancies [see   Boxed Warning   and   Warnings and Precautions (5.1  ,  5.3)   ]   *    Serious infections, including JC virus-associated PML and polyoma virus nephropathy [see   Warnings and Precautions (5.4  ,  5.5  ,  5.6)   ]        EXCERPT:   Most common adverse reactions (>=20% on NULOJIX treatment) are anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",JC virus-associated PML is not a named entity
"6 ADVERSE REACTIONS    The most serious adverse reactions reported with NULOJIX are:     *    PTLD, predominantly CNS PTLD, and other malignancies [see   Boxed Warning   and   Warnings and Precautions (5.1  ,  5.3)   ]   *    Serious infections, including JC virus-associated PML and polyoma virus nephropathy [see   Warnings and Precautions (5.4  ,  5.5  ,  5.6)   ]        EXCERPT:   Most common adverse reactions (>=20% on NULOJIX treatment) are anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",CNS PTLD is an adverse reaction entity
"6 ADVERSE REACTIONS    The most serious adverse reactions reported with NULOJIX are:     *    PTLD, predominantly CNS PTLD, and other malignancies [see   Boxed Warning   and   Warnings and Precautions (5.1  ,  5.3)   ]   *    Serious infections, including JC virus-associated PML and polyoma virus nephropathy [see   Warnings and Precautions (5.4  ,  5.5  ,  5.6)   ]        EXCERPT:   Most common adverse reactions (>=20% on NULOJIX treatment) are anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",infections is an adverse reaction entity
"6 ADVERSE REACTIONS    The most serious adverse reactions reported with NULOJIX are:     *    PTLD, predominantly CNS PTLD, and other malignancies [see   Boxed Warning   and   Warnings and Precautions (5.1  ,  5.3)   ]   *    Serious infections, including JC virus-associated PML and polyoma virus nephropathy [see   Warnings and Precautions (5.4  ,  5.5  ,  5.6)   ]        EXCERPT:   Most common adverse reactions (>=20% on NULOJIX treatment) are anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",leukopenia is an adverse reaction entity
"6 ADVERSE REACTIONS    The most serious adverse reactions reported with NULOJIX are:     *    PTLD, predominantly CNS PTLD, and other malignancies [see   Boxed Warning   and   Warnings and Precautions (5.1  ,  5.3)   ]   *    Serious infections, including JC virus-associated PML and polyoma virus nephropathy [see   Warnings and Precautions (5.4  ,  5.5  ,  5.6)   ]        EXCERPT:   Most common adverse reactions (>=20% on NULOJIX treatment) are anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",", peripheral is not a named entity"
"6 ADVERSE REACTIONS    The most serious adverse reactions reported with NULOJIX are:     *    PTLD, predominantly CNS PTLD, and other malignancies [see   Boxed Warning   and   Warnings and Precautions (5.1  ,  5.3)   ]   *    Serious infections, including JC virus-associated PML and polyoma virus nephropathy [see   Warnings and Precautions (5.4  ,  5.5  ,  5.6)   ]        EXCERPT:   Most common adverse reactions (>=20% on NULOJIX treatment) are anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",diarrhea is an adverse reaction entity
"6 ADVERSE REACTIONS    The most serious adverse reactions reported with NULOJIX are:     *    PTLD, predominantly CNS PTLD, and other malignancies [see   Boxed Warning   and   Warnings and Precautions (5.1  ,  5.3)   ]   *    Serious infections, including JC virus-associated PML and polyoma virus nephropathy [see   Warnings and Precautions (5.4  ,  5.5  ,  5.6)   ]        EXCERPT:   Most common adverse reactions (>=20% on NULOJIX treatment) are anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",", is not a named entity"
"6 ADVERSE REACTIONS    The most serious adverse reactions reported with NULOJIX are:     *    PTLD, predominantly CNS PTLD, and other malignancies [see   Boxed Warning   and   Warnings and Precautions (5.1  ,  5.3)   ]   *    Serious infections, including JC virus-associated PML and polyoma virus nephropathy [see   Warnings and Precautions (5.4  ,  5.5  ,  5.6)   ]        EXCERPT:   Most common adverse reactions (>=20% on NULOJIX treatment) are anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",( is not a named entity
"6 ADVERSE REACTIONS    The most serious adverse reactions reported with NULOJIX are:     *    PTLD, predominantly CNS PTLD, and other malignancies [see   Boxed Warning   and   Warnings and Precautions (5.1  ,  5.3)   ]   *    Serious infections, including JC virus-associated PML and polyoma virus nephropathy [see   Warnings and Precautions (5.4  ,  5.5  ,  5.6)   ]        EXCERPT:   Most common adverse reactions (>=20% on NULOJIX treatment) are anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",cough is an adverse reaction entity
"6 ADVERSE REACTIONS    The most serious adverse reactions reported with NULOJIX are:     *    PTLD, predominantly CNS PTLD, and other malignancies [see   Boxed Warning   and   Warnings and Precautions (5.1  ,  5.3)   ]   *    Serious infections, including JC virus-associated PML and polyoma virus nephropathy [see   Warnings and Precautions (5.4  ,  5.5  ,  5.6)   ]        EXCERPT:   Most common adverse reactions (>=20% on NULOJIX treatment) are anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",constipation is an adverse reaction entity
"6 ADVERSE REACTIONS    The most serious adverse reactions reported with NULOJIX are:     *    PTLD, predominantly CNS PTLD, and other malignancies [see   Boxed Warning   and   Warnings and Precautions (5.1  ,  5.3)   ]   *    Serious infections, including JC virus-associated PML and polyoma virus nephropathy [see   Warnings and Precautions (5.4  ,  5.5  ,  5.6)   ]        EXCERPT:   Most common adverse reactions (>=20% on NULOJIX treatment) are anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",", is not a named entity"
"6 ADVERSE REACTIONS    The most serious adverse reactions reported with NULOJIX are:     *    PTLD, predominantly CNS PTLD, and other malignancies [see   Boxed Warning   and   Warnings and Precautions (5.1  ,  5.3)   ]   *    Serious infections, including JC virus-associated PML and polyoma virus nephropathy [see   Warnings and Precautions (5.4  ,  5.5  ,  5.6)   ]        EXCERPT:   Most common adverse reactions (>=20% on NULOJIX treatment) are anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",headache is an adverse reaction entity
"6 ADVERSE REACTIONS    The most serious adverse reactions reported with NULOJIX are:     *    PTLD, predominantly CNS PTLD, and other malignancies [see   Boxed Warning   and   Warnings and Precautions (5.1  ,  5.3)   ]   *    Serious infections, including JC virus-associated PML and polyoma virus nephropathy [see   Warnings and Precautions (5.4  ,  5.5  ,  5.6)   ]        EXCERPT:   Most common adverse reactions (>=20% on NULOJIX treatment) are anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",anemia is an adverse reaction entity
"6 ADVERSE REACTIONS    The most serious adverse reactions reported with NULOJIX are:     *    PTLD, predominantly CNS PTLD, and other malignancies [see   Boxed Warning   and   Warnings and Precautions (5.1  ,  5.3)   ]   *    Serious infections, including JC virus-associated PML and polyoma virus nephropathy [see   Warnings and Precautions (5.4  ,  5.5  ,  5.6)   ]        EXCERPT:   Most common adverse reactions (>=20% on NULOJIX treatment) are anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",pyrexia is an adverse reaction entity
"6 ADVERSE REACTIONS    The most serious adverse reactions reported with NULOJIX are:     *    PTLD, predominantly CNS PTLD, and other malignancies [see   Boxed Warning   and   Warnings and Precautions (5.1  ,  5.3)   ]   *    Serious infections, including JC virus-associated PML and polyoma virus nephropathy [see   Warnings and Precautions (5.4  ,  5.5  ,  5.6)   ]        EXCERPT:   Most common adverse reactions (>=20% on NULOJIX treatment) are anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",polyoma virus nephropathy is an adverse reaction entity
"6 ADVERSE REACTIONS    The most serious adverse reactions reported with NULOJIX are:     *    PTLD, predominantly CNS PTLD, and other malignancies [see   Boxed Warning   and   Warnings and Precautions (5.1  ,  5.3)   ]   *    Serious infections, including JC virus-associated PML and polyoma virus nephropathy [see   Warnings and Precautions (5.4  ,  5.5  ,  5.6)   ]        EXCERPT:   Most common adverse reactions (>=20% on NULOJIX treatment) are anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",are : is not a named entity
"6 ADVERSE REACTIONS    The most serious adverse reactions reported with NULOJIX are:     *    PTLD, predominantly CNS PTLD, and other malignancies [see   Boxed Warning   and   Warnings and Precautions (5.1  ,  5.3)   ]   *    Serious infections, including JC virus-associated PML and polyoma virus nephropathy [see   Warnings and Precautions (5.4  ,  5.5  ,  5.6)   ]        EXCERPT:   Most common adverse reactions (>=20% on NULOJIX treatment) are anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",: is not a named entity
"6 ADVERSE REACTIONS    The most serious adverse reactions reported with NULOJIX are:     *    PTLD, predominantly CNS PTLD, and other malignancies [see   Boxed Warning   and   Warnings and Precautions (5.1  ,  5.3)   ]   *    Serious infections, including JC virus-associated PML and polyoma virus nephropathy [see   Warnings and Precautions (5.4  ,  5.5  ,  5.6)   ]        EXCERPT:   Most common adverse reactions (>=20% on NULOJIX treatment) are anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",common is not a named entity
"6 ADVERSE REACTIONS    The most serious adverse reactions reported with NULOJIX are:     *    PTLD, predominantly CNS PTLD, and other malignancies [see   Boxed Warning   and   Warnings and Precautions (5.1  ,  5.3)   ]   *    Serious infections, including JC virus-associated PML and polyoma virus nephropathy [see   Warnings and Precautions (5.4  ,  5.5  ,  5.6)   ]        EXCERPT:   Most common adverse reactions (>=20% on NULOJIX treatment) are anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",PTLD is an adverse reaction entity
"6 ADVERSE REACTIONS    The most serious adverse reactions reported with NULOJIX are:     *    PTLD, predominantly CNS PTLD, and other malignancies [see   Boxed Warning   and   Warnings and Precautions (5.1  ,  5.3)   ]   *    Serious infections, including JC virus-associated PML and polyoma virus nephropathy [see   Warnings and Precautions (5.4  ,  5.5  ,  5.6)   ]        EXCERPT:   Most common adverse reactions (>=20% on NULOJIX treatment) are anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",are anemia is not a named entity
"6 ADVERSE REACTIONS    The most serious adverse reactions reported with NULOJIX are:     *    PTLD, predominantly CNS PTLD, and other malignancies [see   Boxed Warning   and   Warnings and Precautions (5.1  ,  5.3)   ]   *    Serious infections, including JC virus-associated PML and polyoma virus nephropathy [see   Warnings and Precautions (5.4  ,  5.5  ,  5.6)   ]        EXCERPT:   Most common adverse reactions (>=20% on NULOJIX treatment) are anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",PML is an adverse reaction entity
"6 ADVERSE REACTIONS    The most serious adverse reactions reported with NULOJIX are:     *    PTLD, predominantly CNS PTLD, and other malignancies [see   Boxed Warning   and   Warnings and Precautions (5.1  ,  5.3)   ]   *    Serious infections, including JC virus-associated PML and polyoma virus nephropathy [see   Warnings and Precautions (5.4  ,  5.5  ,  5.6)   ]        EXCERPT:   Most common adverse reactions (>=20% on NULOJIX treatment) are anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",hyperkalemia is an adverse reaction entity
"6 ADVERSE REACTIONS    The most serious adverse reactions reported with NULOJIX are:     *    PTLD, predominantly CNS PTLD, and other malignancies [see   Boxed Warning   and   Warnings and Precautions (5.1  ,  5.3)   ]   *    Serious infections, including JC virus-associated PML and polyoma virus nephropathy [see   Warnings and Precautions (5.4  ,  5.5  ,  5.6)   ]        EXCERPT:   Most common adverse reactions (>=20% on NULOJIX treatment) are anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",malignancies is an adverse reaction entity
"6 ADVERSE REACTIONS    The most serious adverse reactions reported with NULOJIX are:     *    PTLD, predominantly CNS PTLD, and other malignancies [see   Boxed Warning   and   Warnings and Precautions (5.1  ,  5.3)   ]   *    Serious infections, including JC virus-associated PML and polyoma virus nephropathy [see   Warnings and Precautions (5.4  ,  5.5  ,  5.6)   ]        EXCERPT:   Most common adverse reactions (>=20% on NULOJIX treatment) are anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.","infections , including is not a named entity"
"6 ADVERSE REACTIONS    The most serious adverse reactions reported with NULOJIX are:     *    PTLD, predominantly CNS PTLD, and other malignancies [see   Boxed Warning   and   Warnings and Precautions (5.1  ,  5.3)   ]   *    Serious infections, including JC virus-associated PML and polyoma virus nephropathy [see   Warnings and Precautions (5.4  ,  5.5  ,  5.6)   ]        EXCERPT:   Most common adverse reactions (>=20% on NULOJIX treatment) are anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",EXCERPT is not a named entity
Polyoma virus-associated nephropathy can lead to kidney graft loss; consider reduction in immunosuppression.,can lead to is not a named entity
Polyoma virus-associated nephropathy can lead to kidney graft loss; consider reduction in immunosuppression.,Polyoma virus-associated nephropathy is an adverse reaction entity
Polyoma virus-associated nephropathy can lead to kidney graft loss; consider reduction in immunosuppression.,kidney graft loss is an adverse reaction entity
Polyoma virus-associated nephropathy can lead to kidney graft loss; consider reduction in immunosuppression.,; consider reduction is not a named entity
"Among 401 patients in Studies 1 and 2 treated with the recommended regimen of NULOJIX and the 71 patients in Study 3 treated with a very similar (but non-identical) NULOJIX regimen, there were 5 cases of PTLD: 3 in EBV seropositive patients and 2 in EBV seronegative patients.",PTLD is an adverse reaction entity
"Among 401 patients in Studies 1 and 2 treated with the recommended regimen of NULOJIX and the 71 patients in Study 3 treated with a very similar (but non-identical) NULOJIX regimen, there were 5 cases of PTLD: 3 in EBV seropositive patients and 2 in EBV seronegative patients.",recommended is not a named entity
Tuberculosis      Tuberculosis was more frequently observed in patients receiving NULOJIX than cyclosporine in clinical trials [see   Adverse Reactions (6.1)    ].,receiving NULOJIX than is not a named entity
Tuberculosis      Tuberculosis was more frequently observed in patients receiving NULOJIX than cyclosporine in clinical trials [see   Adverse Reactions (6.1)    ].,Tuberculosis is an adverse reaction entity
Infusion Reactions    There were no reports of anaphylaxis or drug hypersensitivity in patients treated with NULOJIX in Studies 1 and 2 through three years.,anaphylaxis is an adverse reaction entity
Infusion Reactions    There were no reports of anaphylaxis or drug hypersensitivity in patients treated with NULOJIX in Studies 1 and 2 through three years.,patients treated is not a named entity
Infusion Reactions    There were no reports of anaphylaxis or drug hypersensitivity in patients treated with NULOJIX in Studies 1 and 2 through three years.,Reactions is not a named entity
Infusion Reactions    There were no reports of anaphylaxis or drug hypersensitivity in patients treated with NULOJIX in Studies 1 and 2 through three years.,drug hypersensitivity is an adverse reaction entity
New-Onset Diabetes After Transplantation    The incidence of new-onset diabetes after transplantation (NODAT) was defined in Studies 1 and 2 as use of an antidiabetic agent for >=30 days or >=2 fasting plasma glucose values >=126 mg/dL (7.0 mmol/L) post-transplantation.,( NODAT ) is not a named entity
New-Onset Diabetes After Transplantation    The incidence of new-onset diabetes after transplantation (NODAT) was defined in Studies 1 and 2 as use of an antidiabetic agent for >=30 days or >=2 fasting plasma glucose values >=126 mg/dL (7.0 mmol/L) post-transplantation.,agent for is not a named entity
New-Onset Diabetes After Transplantation    The incidence of new-onset diabetes after transplantation (NODAT) was defined in Studies 1 and 2 as use of an antidiabetic agent for >=30 days or >=2 fasting plasma glucose values >=126 mg/dL (7.0 mmol/L) post-transplantation.,new-onset diabetes after transplantation is an adverse reaction entity
New-Onset Diabetes After Transplantation    The incidence of new-onset diabetes after transplantation (NODAT) was defined in Studies 1 and 2 as use of an antidiabetic agent for >=30 days or >=2 fasting plasma glucose values >=126 mg/dL (7.0 mmol/L) post-transplantation.,NODAT is an adverse reaction entity
"5.5 Other Serious Infections      Patients receiving immunosuppressants, including NULOJIX, are at increased risk of developing bacterial, viral (cytomegalovirus [CMV] and herpes), fungal, and protozoal infections, including opportunistic infections.",and herpes is not a named entity
"5.5 Other Serious Infections      Patients receiving immunosuppressants, including NULOJIX, are at increased risk of developing bacterial, viral (cytomegalovirus [CMV] and herpes), fungal, and protozoal infections, including opportunistic infections.",viral infections is an adverse reaction entity
"5.5 Other Serious Infections      Patients receiving immunosuppressants, including NULOJIX, are at increased risk of developing bacterial, viral (cytomegalovirus [CMV] and herpes), fungal, and protozoal infections, including opportunistic infections.",CMV infections is an adverse reaction entity
"5.5 Other Serious Infections      Patients receiving immunosuppressants, including NULOJIX, are at increased risk of developing bacterial, viral (cytomegalovirus [CMV] and herpes), fungal, and protozoal infections, including opportunistic infections.",herpes infections is an adverse reaction entity
"5.5 Other Serious Infections      Patients receiving immunosuppressants, including NULOJIX, are at increased risk of developing bacterial, viral (cytomegalovirus [CMV] and herpes), fungal, and protozoal infections, including opportunistic infections.",fungal infections is an adverse reaction entity
"5.5 Other Serious Infections      Patients receiving immunosuppressants, including NULOJIX, are at increased risk of developing bacterial, viral (cytomegalovirus [CMV] and herpes), fungal, and protozoal infections, including opportunistic infections.",Patients receiving is not a named entity
"5.5 Other Serious Infections      Patients receiving immunosuppressants, including NULOJIX, are at increased risk of developing bacterial, viral (cytomegalovirus [CMV] and herpes), fungal, and protozoal infections, including opportunistic infections.",", fungal , is not a named entity"
"5.5 Other Serious Infections      Patients receiving immunosuppressants, including NULOJIX, are at increased risk of developing bacterial, viral (cytomegalovirus [CMV] and herpes), fungal, and protozoal infections, including opportunistic infections.",cytomegalovirus infections is an adverse reaction entity
"5.5 Other Serious Infections      Patients receiving immunosuppressants, including NULOJIX, are at increased risk of developing bacterial, viral (cytomegalovirus [CMV] and herpes), fungal, and protozoal infections, including opportunistic infections.",", is not a named entity"
"5.5 Other Serious Infections      Patients receiving immunosuppressants, including NULOJIX, are at increased risk of developing bacterial, viral (cytomegalovirus [CMV] and herpes), fungal, and protozoal infections, including opportunistic infections.",", fungal is not a named entity"
"5.5 Other Serious Infections      Patients receiving immunosuppressants, including NULOJIX, are at increased risk of developing bacterial, viral (cytomegalovirus [CMV] and herpes), fungal, and protozoal infections, including opportunistic infections.",bacterial infections is an adverse reaction entity
"5.5 Other Serious Infections      Patients receiving immunosuppressants, including NULOJIX, are at increased risk of developing bacterial, viral (cytomegalovirus [CMV] and herpes), fungal, and protozoal infections, including opportunistic infections.",", viral is not a named entity"
"5.5 Other Serious Infections      Patients receiving immunosuppressants, including NULOJIX, are at increased risk of developing bacterial, viral (cytomegalovirus [CMV] and herpes), fungal, and protozoal infections, including opportunistic infections.",are is not a named entity
"5.5 Other Serious Infections      Patients receiving immunosuppressants, including NULOJIX, are at increased risk of developing bacterial, viral (cytomegalovirus [CMV] and herpes), fungal, and protozoal infections, including opportunistic infections.",NULOJIX is not a named entity
"5.5 Other Serious Infections      Patients receiving immunosuppressants, including NULOJIX, are at increased risk of developing bacterial, viral (cytomegalovirus [CMV] and herpes), fungal, and protozoal infections, including opportunistic infections.",protozoal infections is an adverse reaction entity
"5.5 Other Serious Infections      Patients receiving immunosuppressants, including NULOJIX, are at increased risk of developing bacterial, viral (cytomegalovirus [CMV] and herpes), fungal, and protozoal infections, including opportunistic infections.",opportunistic infections is an adverse reaction entity
"The overall number of infections, serious infections, and select infections with identified etiology reported in patients treated with the NULOJIX recommended regimen or the cyclosporine control in Studies 1 and 2 are shown in Table 3.",NULOJIX recommended is not a named entity
"The overall number of infections, serious infections, and select infections with identified etiology reported in patients treated with the NULOJIX recommended regimen or the cyclosporine control in Studies 1 and 2 are shown in Table 3.",infections is an adverse reaction entity
"The overall number of infections, serious infections, and select infections with identified etiology reported in patients treated with the NULOJIX recommended regimen or the cyclosporine control in Studies 1 and 2 are shown in Table 3.",overall number of is not a named entity
"The overall number of infections, serious infections, and select infections with identified etiology reported in patients treated with the NULOJIX recommended regimen or the cyclosporine control in Studies 1 and 2 are shown in Table 3.",1 is not a named entity
"The overall number of infections, serious infections, and select infections with identified etiology reported in patients treated with the NULOJIX recommended regimen or the cyclosporine control in Studies 1 and 2 are shown in Table 3.",infections is an adverse reaction entity
"The overall number of infections, serious infections, and select infections with identified etiology reported in patients treated with the NULOJIX recommended regimen or the cyclosporine control in Studies 1 and 2 are shown in Table 3.",infections is an adverse reaction entity
"In a clinical trial of liver transplant patients, use of NULOJIX regimens with more frequent administration of belatacept than any of those studied in kidney transplant, along with mycophenolate mofetil (MMF) and corticosteroids, was associated with a higher rate of graft loss and death compared to the tacrolimus control arms.",", along is not a named entity"
"In a clinical trial of liver transplant patients, use of NULOJIX regimens with more frequent administration of belatacept than any of those studied in kidney transplant, along with mycophenolate mofetil (MMF) and corticosteroids, was associated with a higher rate of graft loss and death compared to the tacrolimus control arms.","transplant , is not a named entity"
"In a clinical trial of liver transplant patients, use of NULOJIX regimens with more frequent administration of belatacept than any of those studied in kidney transplant, along with mycophenolate mofetil (MMF) and corticosteroids, was associated with a higher rate of graft loss and death compared to the tacrolimus control arms.",graft loss is an adverse reaction entity
"In a clinical trial of liver transplant patients, use of NULOJIX regimens with more frequent administration of belatacept than any of those studied in kidney transplant, along with mycophenolate mofetil (MMF) and corticosteroids, was associated with a higher rate of graft loss and death compared to the tacrolimus control arms.",death is an adverse reaction entity
"5.7 Acute Rejection and Graft Loss with Corticosteroid Minimization      In postmarketing experience, use of NULOJIX in conjunction with basiliximab induction, MMF, and corticosteroid minimization to 5 mg per day between Day 3 and Week 6 post-transplant was associated with an increased rate and grade of acute rejection, particularly Grade III rejection.",post-transplant acute rejection is an adverse reaction entity
"5.7 Acute Rejection and Graft Loss with Corticosteroid Minimization      In postmarketing experience, use of NULOJIX in conjunction with basiliximab induction, MMF, and corticosteroid minimization to 5 mg per day between Day 3 and Week 6 post-transplant was associated with an increased rate and grade of acute rejection, particularly Grade III rejection.",corticosteroid minimization to is not a named entity
"5.7 Acute Rejection and Graft Loss with Corticosteroid Minimization      In postmarketing experience, use of NULOJIX in conjunction with basiliximab induction, MMF, and corticosteroid minimization to 5 mg per day between Day 3 and Week 6 post-transplant was associated with an increased rate and grade of acute rejection, particularly Grade III rejection.",post-transplant acute rejection is an adverse reaction entity
"5.7 Acute Rejection and Graft Loss with Corticosteroid Minimization      In postmarketing experience, use of NULOJIX in conjunction with basiliximab induction, MMF, and corticosteroid minimization to 5 mg per day between Day 3 and Week 6 post-transplant was associated with an increased rate and grade of acute rejection, particularly Grade III rejection.",grade of acute is not a named entity
"5.3 Other Malignancies      Patients receiving immunosuppressants, including NULOJIX, are at increased risk of developing malignancies, in addition to PTLD, including the skin [see   Boxed Warning    and   Warnings and Precautions (5.1)    ].",malignancies is an adverse reaction entity
"5.3 Other Malignancies      Patients receiving immunosuppressants, including NULOJIX, are at increased risk of developing malignancies, in addition to PTLD, including the skin [see   Boxed Warning    and   Warnings and Precautions (5.1)    ].",skin [ see is not a named entity
"5.3 Other Malignancies      Patients receiving immunosuppressants, including NULOJIX, are at increased risk of developing malignancies, in addition to PTLD, including the skin [see   Boxed Warning    and   Warnings and Precautions (5.1)    ].",PTLD is an adverse reaction entity
"5.3 Other Malignancies      Patients receiving immunosuppressants, including NULOJIX, are at increased risk of developing malignancies, in addition to PTLD, including the skin [see   Boxed Warning    and   Warnings and Precautions (5.1)    ].",malignancies skin is an adverse reaction entity
"5.3 Other Malignancies      Patients receiving immunosuppressants, including NULOJIX, are at increased risk of developing malignancies, in addition to PTLD, including the skin [see   Boxed Warning    and   Warnings and Precautions (5.1)    ].",", is not a named entity"
"5.3 Other Malignancies      Patients receiving immunosuppressants, including NULOJIX, are at increased risk of developing malignancies, in addition to PTLD, including the skin [see   Boxed Warning    and   Warnings and Precautions (5.1)    ].",", including NULOJIX is not a named entity"
"In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of suicidal behavior or ideation among 27,863 AED treated patients was 0.43%, compared to 0.24% among 16,029 placebo treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated.",estimated is not a named entity
"In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of suicidal behavior or ideation among 27,863 AED treated patients was 0.43%, compared to 0.24% among 16,029 placebo treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated.",of suicidal is not a named entity
"In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of suicidal behavior or ideation among 27,863 AED treated patients was 0.43%, compared to 0.24% among 16,029 placebo treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated.",suicidal behavior is an adverse reaction entity
"In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of suicidal behavior or ideation among 27,863 AED treated patients was 0.43%, compared to 0.24% among 16,029 placebo treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated.",suicidal ideation is an adverse reaction entity
"In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of suicidal behavior or ideation among 27,863 AED treated patients was 0.43%, compared to 0.24% among 16,029 placebo treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated.",", compared is not a named entity"
"In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of suicidal behavior or ideation among 27,863 AED treated patients was 0.43%, compared to 0.24% among 16,029 placebo treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated.",suicidal thinking is an adverse reaction entity
"In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of suicidal behavior or ideation among 27,863 AED treated patients was 0.43%, compared to 0.24% among 16,029 placebo treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated.",behavior for every is not a named entity
"In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of suicidal behavior or ideation among 27,863 AED treated patients was 0.43%, compared to 0.24% among 16,029 placebo treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated.",suicidal behavior is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS         EXCERPT:    *  Somnolence or Sedation: Monitor for central nervous system (CNS) depression.,Somnolence is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS         EXCERPT:    *  Somnolence or Sedation: Monitor for central nervous system (CNS) depression.,Sedation is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS         EXCERPT:    *  Somnolence or Sedation: Monitor for central nervous system (CNS) depression.,nervous system is not a named entity
5 WARNINGS AND PRECAUTIONS         EXCERPT:    *  Somnolence or Sedation: Monitor for central nervous system (CNS) depression.,Sedation : is not a named entity
"Adverse Reactions Leading to Discontinuation in an LGS Placebo Controlled Clinical Trial (Study 1)  The adverse reactions associated with ONFI treatment discontinuation in >=1% of patients in decreasing order of frequency included lethargy, somnolence, ataxia, aggression, fatigue, and insomnia.",patients is not a named entity
"Adverse Reactions Leading to Discontinuation in an LGS Placebo Controlled Clinical Trial (Study 1)  The adverse reactions associated with ONFI treatment discontinuation in >=1% of patients in decreasing order of frequency included lethargy, somnolence, ataxia, aggression, fatigue, and insomnia.",( Study 1 is not a named entity
"Adverse Reactions Leading to Discontinuation in an LGS Placebo Controlled Clinical Trial (Study 1)  The adverse reactions associated with ONFI treatment discontinuation in >=1% of patients in decreasing order of frequency included lethargy, somnolence, ataxia, aggression, fatigue, and insomnia.",aggression is an adverse reaction entity
"Adverse Reactions Leading to Discontinuation in an LGS Placebo Controlled Clinical Trial (Study 1)  The adverse reactions associated with ONFI treatment discontinuation in >=1% of patients in decreasing order of frequency included lethargy, somnolence, ataxia, aggression, fatigue, and insomnia.",Discontinuation in an is not a named entity
"Adverse Reactions Leading to Discontinuation in an LGS Placebo Controlled Clinical Trial (Study 1)  The adverse reactions associated with ONFI treatment discontinuation in >=1% of patients in decreasing order of frequency included lethargy, somnolence, ataxia, aggression, fatigue, and insomnia.",Adverse is not a named entity
"Adverse Reactions Leading to Discontinuation in an LGS Placebo Controlled Clinical Trial (Study 1)  The adverse reactions associated with ONFI treatment discontinuation in >=1% of patients in decreasing order of frequency included lethargy, somnolence, ataxia, aggression, fatigue, and insomnia.",lethargy is an adverse reaction entity
"Adverse Reactions Leading to Discontinuation in an LGS Placebo Controlled Clinical Trial (Study 1)  The adverse reactions associated with ONFI treatment discontinuation in >=1% of patients in decreasing order of frequency included lethargy, somnolence, ataxia, aggression, fatigue, and insomnia.",Clinical is not a named entity
"Adverse Reactions Leading to Discontinuation in an LGS Placebo Controlled Clinical Trial (Study 1)  The adverse reactions associated with ONFI treatment discontinuation in >=1% of patients in decreasing order of frequency included lethargy, somnolence, ataxia, aggression, fatigue, and insomnia.",insomnia is an adverse reaction entity
"Adverse Reactions Leading to Discontinuation in an LGS Placebo Controlled Clinical Trial (Study 1)  The adverse reactions associated with ONFI treatment discontinuation in >=1% of patients in decreasing order of frequency included lethargy, somnolence, ataxia, aggression, fatigue, and insomnia.",1 ) The is not a named entity
"Adverse Reactions Leading to Discontinuation in an LGS Placebo Controlled Clinical Trial (Study 1)  The adverse reactions associated with ONFI treatment discontinuation in >=1% of patients in decreasing order of frequency included lethargy, somnolence, ataxia, aggression, fatigue, and insomnia.",fatigue is an adverse reaction entity
"Adverse Reactions Leading to Discontinuation in an LGS Placebo Controlled Clinical Trial (Study 1)  The adverse reactions associated with ONFI treatment discontinuation in >=1% of patients in decreasing order of frequency included lethargy, somnolence, ataxia, aggression, fatigue, and insomnia.",ataxia is an adverse reaction entity
"Adverse Reactions Leading to Discontinuation in an LGS Placebo Controlled Clinical Trial (Study 1)  The adverse reactions associated with ONFI treatment discontinuation in >=1% of patients in decreasing order of frequency included lethargy, somnolence, ataxia, aggression, fatigue, and insomnia.",somnolence is an adverse reaction entity
"There were four suicides in drug treated patients in the trials and none in placebo treated patients, but the number is too small to allow any conclusion about drug effect on suicide.",suicide is an adverse reaction entity
"There were four suicides in drug treated patients in the trials and none in placebo treated patients, but the number is too small to allow any conclusion about drug effect on suicide.",treated is not a named entity
"There were four suicides in drug treated patients in the trials and none in placebo treated patients, but the number is too small to allow any conclusion about drug effect on suicide.",suicides is an adverse reaction entity
"There were four suicides in drug treated patients in the trials and none in placebo treated patients, but the number is too small to allow any conclusion about drug effect on suicide.",and none in is not a named entity
"In clinical trials, somnolence or sedation was reported at all effective doses and was dose-related.",all effective doses is not a named entity
"In clinical trials, somnolence or sedation was reported at all effective doses and was dose-related.",sedation is an adverse reaction entity
"In clinical trials, somnolence or sedation was reported at all effective doses and was dose-related.",somnolence is an adverse reaction entity
"In clinical trials, somnolence or sedation was reported at all effective doses and was dose-related.",sedation was is not a named entity
The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed.,among is not a named entity
The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed.,drugs in the is not a named entity
The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed.,suicidal thoughts is an adverse reaction entity
The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed.,suicidal behavior is an adverse reaction entity
"(  5.4  )   *  Physical and Psychological Dependence: Monitor patients with a history of substance abuse for signs of habituation and dependence (  5.5  ,  9  )   *  Suicidal Behavior and Ideation: Monitor for suicidal thoughts or behaviors (  5.6  )              5.1 Somnolence or Sedation        ONFI causes somnolence and sedation.",somnolence is an adverse reaction entity
"(  5.4  )   *  Physical and Psychological Dependence: Monitor patients with a history of substance abuse for signs of habituation and dependence (  5.5  ,  9  )   *  Suicidal Behavior and Ideation: Monitor for suicidal thoughts or behaviors (  5.6  )              5.1 Somnolence or Sedation        ONFI causes somnolence and sedation.",( is not a named entity
"(  5.4  )   *  Physical and Psychological Dependence: Monitor patients with a history of substance abuse for signs of habituation and dependence (  5.5  ,  9  )   *  Suicidal Behavior and Ideation: Monitor for suicidal thoughts or behaviors (  5.6  )              5.1 Somnolence or Sedation        ONFI causes somnolence and sedation.",Psychological Dependence is an adverse reaction entity
"(  5.4  )   *  Physical and Psychological Dependence: Monitor patients with a history of substance abuse for signs of habituation and dependence (  5.5  ,  9  )   *  Suicidal Behavior and Ideation: Monitor for suicidal thoughts or behaviors (  5.6  )              5.1 Somnolence or Sedation        ONFI causes somnolence and sedation.",patients with a is not a named entity
"(  5.4  )   *  Physical and Psychological Dependence: Monitor patients with a history of substance abuse for signs of habituation and dependence (  5.5  ,  9  )   *  Suicidal Behavior and Ideation: Monitor for suicidal thoughts or behaviors (  5.6  )              5.1 Somnolence or Sedation        ONFI causes somnolence and sedation.",and is not a named entity
"(  5.4  )   *  Physical and Psychological Dependence: Monitor patients with a history of substance abuse for signs of habituation and dependence (  5.5  ,  9  )   *  Suicidal Behavior and Ideation: Monitor for suicidal thoughts or behaviors (  5.6  )              5.1 Somnolence or Sedation        ONFI causes somnolence and sedation.",somnolence and sedation is not a named entity
"(  5.4  )   *  Physical and Psychological Dependence: Monitor patients with a history of substance abuse for signs of habituation and dependence (  5.5  ,  9  )   *  Suicidal Behavior and Ideation: Monitor for suicidal thoughts or behaviors (  5.6  )              5.1 Somnolence or Sedation        ONFI causes somnolence and sedation.",Suicidal Behavior is an adverse reaction entity
"(  5.4  )   *  Physical and Psychological Dependence: Monitor patients with a history of substance abuse for signs of habituation and dependence (  5.5  ,  9  )   *  Suicidal Behavior and Ideation: Monitor for suicidal thoughts or behaviors (  5.6  )              5.1 Somnolence or Sedation        ONFI causes somnolence and sedation.",sedation is an adverse reaction entity
"(  5.4  )   *  Physical and Psychological Dependence: Monitor patients with a history of substance abuse for signs of habituation and dependence (  5.5  ,  9  )   *  Suicidal Behavior and Ideation: Monitor for suicidal thoughts or behaviors (  5.6  )              5.1 Somnolence or Sedation        ONFI causes somnolence and sedation.",Suicidal Ideation is an adverse reaction entity
"(  5.4  )   *  Physical and Psychological Dependence: Monitor patients with a history of substance abuse for signs of habituation and dependence (  5.5  ,  9  )   *  Suicidal Behavior and Ideation: Monitor for suicidal thoughts or behaviors (  5.6  )              5.1 Somnolence or Sedation        ONFI causes somnolence and sedation.",Physical Dependence is an adverse reaction entity
"(  5.4  )   *  Physical and Psychological Dependence: Monitor patients with a history of substance abuse for signs of habituation and dependence (  5.5  ,  9  )   *  Suicidal Behavior and Ideation: Monitor for suicidal thoughts or behaviors (  5.6  )              5.1 Somnolence or Sedation        ONFI causes somnolence and sedation.",habituation is not a named entity
"(  5.4  )   *  Physical and Psychological Dependence: Monitor patients with a history of substance abuse for signs of habituation and dependence (  5.5  ,  9  )   *  Suicidal Behavior and Ideation: Monitor for suicidal thoughts or behaviors (  5.6  )              5.1 Somnolence or Sedation        ONFI causes somnolence and sedation.",patients with a is not a named entity
"In general, somnolence and sedation begin within the first month of treatment and may diminish with continued treatment.",somnolence is an adverse reaction entity
"In general, somnolence and sedation begin within the first month of treatment and may diminish with continued treatment.",the first month is not a named entity
"In general, somnolence and sedation begin within the first month of treatment and may diminish with continued treatment.",sedation is an adverse reaction entity
"In general, somnolence and sedation begin within the first month of treatment and may diminish with continued treatment.",the first month is not a named entity
"5.4 Serious Dermatological Reactions        Serious skin reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported with ONFI in both children and adults during the post-marketing period.",Stevens-Johnson syndrome is an adverse reaction entity
"5.4 Serious Dermatological Reactions        Serious skin reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported with ONFI in both children and adults during the post-marketing period.",children and adults is not a named entity
"5.4 Serious Dermatological Reactions        Serious skin reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported with ONFI in both children and adults during the post-marketing period.",skin reactions is an adverse reaction entity
"5.4 Serious Dermatological Reactions        Serious skin reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported with ONFI in both children and adults during the post-marketing period.",TEN is an adverse reaction entity
"5.4 Serious Dermatological Reactions        Serious skin reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported with ONFI in both children and adults during the post-marketing period.",post-marketing period is not a named entity
"5.4 Serious Dermatological Reactions        Serious skin reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported with ONFI in both children and adults during the post-marketing period.",SJS is an adverse reaction entity
"5.4 Serious Dermatological Reactions        Serious skin reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported with ONFI in both children and adults during the post-marketing period.",toxic epidermal necrolysis is an adverse reaction entity
"5.4 Serious Dermatological Reactions        Serious skin reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported with ONFI in both children and adults during the post-marketing period.",with ONFI is not a named entity
"5.4 Serious Dermatological Reactions        Serious skin reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported with ONFI in both children and adults during the post-marketing period.",necrolysis is not a named entity
"5.4 Serious Dermatological Reactions        Serious skin reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported with ONFI in both children and adults during the post-marketing period.",and adults is not a named entity
(  5.3  )   *  Serious Dermatological Reactions(including Stevens-Johnson syndrome and toxic epidermal necrolysis):Discontinue ONFI at first sign of rash unless the rash is clearly not drug-related.,sign is not a named entity
(  5.3  )   *  Serious Dermatological Reactions(including Stevens-Johnson syndrome and toxic epidermal necrolysis):Discontinue ONFI at first sign of rash unless the rash is clearly not drug-related.,syndrome and toxic is not a named entity
(  5.3  )   *  Serious Dermatological Reactions(including Stevens-Johnson syndrome and toxic epidermal necrolysis):Discontinue ONFI at first sign of rash unless the rash is clearly not drug-related.,toxic epidermal necrolysis is an adverse reaction entity
(  5.3  )   *  Serious Dermatological Reactions(including Stevens-Johnson syndrome and toxic epidermal necrolysis):Discontinue ONFI at first sign of rash unless the rash is clearly not drug-related.,first is not a named entity
(  5.3  )   *  Serious Dermatological Reactions(including Stevens-Johnson syndrome and toxic epidermal necrolysis):Discontinue ONFI at first sign of rash unless the rash is clearly not drug-related.,Stevens-Johnson syndrome is an adverse reaction entity
(  5.3  )   *  Serious Dermatological Reactions(including Stevens-Johnson syndrome and toxic epidermal necrolysis):Discontinue ONFI at first sign of rash unless the rash is clearly not drug-related.,Dermatological Reactions is an adverse reaction entity
"In double-blind placebo-controlled short-term studies, where the dose was increased slowly, as recommended above, syncope was reported in 0.4% (5/1344) of patients treated with FANAPT, compared with 0.2% (1/587) on placebo.",syncope is an adverse reaction entity
"In double-blind placebo-controlled short-term studies, where the dose was increased slowly, as recommended above, syncope was reported in 0.4% (5/1344) of patients treated with FANAPT, compared with 0.2% (1/587) on placebo.",FANAPT is not a named entity
"In short-term, placebo-controlled trials, somnolence (including sedation) was reported in 11.9% (104/874) of adult patients treated with FANAPT     at doses of 10 mg/day or greater versus 5.3% (31/587) treated with placebo.",% ( is not a named entity
"In short-term, placebo-controlled trials, somnolence (including sedation) was reported in 11.9% (104/874) of adult patients treated with FANAPT     at doses of 10 mg/day or greater versus 5.3% (31/587) treated with placebo.",doses is not a named entity
"In short-term, placebo-controlled trials, somnolence (including sedation) was reported in 11.9% (104/874) of adult patients treated with FANAPT     at doses of 10 mg/day or greater versus 5.3% (31/587) treated with placebo.",somnolence is an adverse reaction entity
"In short-term, placebo-controlled trials, somnolence (including sedation) was reported in 11.9% (104/874) of adult patients treated with FANAPT     at doses of 10 mg/day or greater versus 5.3% (31/587) treated with placebo.",sedation is an adverse reaction entity
"Dose-Related Adverse Reactions in Clinical Trials       Based on the pooled data from 4 placebo-controlled, 4- or 6-week, fixed- or flexible-dose studies, adverse reactions that occurred with a greater than 2% incidence in the patients treated with FANAPT, and for which the incidence in patients treated with FANAPT     20 to 24 mg/day were twice than the incidence in patients treated with FANAPT 10 to 16 mg/day were: abdominal discomfort, dizziness, hypotension, musculoskeletal stiffness, tachycardia, and weight increased.",weight increased is an adverse reaction entity
"Dose-Related Adverse Reactions in Clinical Trials       Based on the pooled data from 4 placebo-controlled, 4- or 6-week, fixed- or flexible-dose studies, adverse reactions that occurred with a greater than 2% incidence in the patients treated with FANAPT, and for which the incidence in patients treated with FANAPT     20 to 24 mg/day were twice than the incidence in patients treated with FANAPT 10 to 16 mg/day were: abdominal discomfort, dizziness, hypotension, musculoskeletal stiffness, tachycardia, and weight increased.",hypotension is an adverse reaction entity
"Dose-Related Adverse Reactions in Clinical Trials       Based on the pooled data from 4 placebo-controlled, 4- or 6-week, fixed- or flexible-dose studies, adverse reactions that occurred with a greater than 2% incidence in the patients treated with FANAPT, and for which the incidence in patients treated with FANAPT     20 to 24 mg/day were twice than the incidence in patients treated with FANAPT 10 to 16 mg/day were: abdominal discomfort, dizziness, hypotension, musculoskeletal stiffness, tachycardia, and weight increased.",tachycardia is an adverse reaction entity
"Dose-Related Adverse Reactions in Clinical Trials       Based on the pooled data from 4 placebo-controlled, 4- or 6-week, fixed- or flexible-dose studies, adverse reactions that occurred with a greater than 2% incidence in the patients treated with FANAPT, and for which the incidence in patients treated with FANAPT     20 to 24 mg/day were twice than the incidence in patients treated with FANAPT 10 to 16 mg/day were: abdominal discomfort, dizziness, hypotension, musculoskeletal stiffness, tachycardia, and weight increased.",Dose-Related Adverse is not a named entity
"Dose-Related Adverse Reactions in Clinical Trials       Based on the pooled data from 4 placebo-controlled, 4- or 6-week, fixed- or flexible-dose studies, adverse reactions that occurred with a greater than 2% incidence in the patients treated with FANAPT, and for which the incidence in patients treated with FANAPT     20 to 24 mg/day were twice than the incidence in patients treated with FANAPT 10 to 16 mg/day were: abdominal discomfort, dizziness, hypotension, musculoskeletal stiffness, tachycardia, and weight increased.",with is not a named entity
"Dose-Related Adverse Reactions in Clinical Trials       Based on the pooled data from 4 placebo-controlled, 4- or 6-week, fixed- or flexible-dose studies, adverse reactions that occurred with a greater than 2% incidence in the patients treated with FANAPT, and for which the incidence in patients treated with FANAPT     20 to 24 mg/day were twice than the incidence in patients treated with FANAPT 10 to 16 mg/day were: abdominal discomfort, dizziness, hypotension, musculoskeletal stiffness, tachycardia, and weight increased.",musculoskeletal stiffness is an adverse reaction entity
"Dose-Related Adverse Reactions in Clinical Trials       Based on the pooled data from 4 placebo-controlled, 4- or 6-week, fixed- or flexible-dose studies, adverse reactions that occurred with a greater than 2% incidence in the patients treated with FANAPT, and for which the incidence in patients treated with FANAPT     20 to 24 mg/day were twice than the incidence in patients treated with FANAPT 10 to 16 mg/day were: abdominal discomfort, dizziness, hypotension, musculoskeletal stiffness, tachycardia, and weight increased.",", adverse is not a named entity"
"Dose-Related Adverse Reactions in Clinical Trials       Based on the pooled data from 4 placebo-controlled, 4- or 6-week, fixed- or flexible-dose studies, adverse reactions that occurred with a greater than 2% incidence in the patients treated with FANAPT, and for which the incidence in patients treated with FANAPT     20 to 24 mg/day were twice than the incidence in patients treated with FANAPT 10 to 16 mg/day were: abdominal discomfort, dizziness, hypotension, musculoskeletal stiffness, tachycardia, and weight increased.",dizziness is an adverse reaction entity
"Dose-Related Adverse Reactions in Clinical Trials       Based on the pooled data from 4 placebo-controlled, 4- or 6-week, fixed- or flexible-dose studies, adverse reactions that occurred with a greater than 2% incidence in the patients treated with FANAPT, and for which the incidence in patients treated with FANAPT     20 to 24 mg/day were twice than the incidence in patients treated with FANAPT 10 to 16 mg/day were: abdominal discomfort, dizziness, hypotension, musculoskeletal stiffness, tachycardia, and weight increased.",with a greater is not a named entity
"Dose-Related Adverse Reactions in Clinical Trials       Based on the pooled data from 4 placebo-controlled, 4- or 6-week, fixed- or flexible-dose studies, adverse reactions that occurred with a greater than 2% incidence in the patients treated with FANAPT, and for which the incidence in patients treated with FANAPT     20 to 24 mg/day were twice than the incidence in patients treated with FANAPT 10 to 16 mg/day were: abdominal discomfort, dizziness, hypotension, musculoskeletal stiffness, tachycardia, and weight increased.","studies , is not a named entity"
"Dose-Related Adverse Reactions in Clinical Trials       Based on the pooled data from 4 placebo-controlled, 4- or 6-week, fixed- or flexible-dose studies, adverse reactions that occurred with a greater than 2% incidence in the patients treated with FANAPT, and for which the incidence in patients treated with FANAPT     20 to 24 mg/day were twice than the incidence in patients treated with FANAPT 10 to 16 mg/day were: abdominal discomfort, dizziness, hypotension, musculoskeletal stiffness, tachycardia, and weight increased.",mg/day is not a named entity
"Dose-Related Adverse Reactions in Clinical Trials       Based on the pooled data from 4 placebo-controlled, 4- or 6-week, fixed- or flexible-dose studies, adverse reactions that occurred with a greater than 2% incidence in the patients treated with FANAPT, and for which the incidence in patients treated with FANAPT     20 to 24 mg/day were twice than the incidence in patients treated with FANAPT 10 to 16 mg/day were: abdominal discomfort, dizziness, hypotension, musculoskeletal stiffness, tachycardia, and weight increased.",abdominal discomfort is an adverse reaction entity
"5.2     QT Prolongation      In an open-label QTc study in patients with schizophrenia or schizoaffective disorder (n=160), FANAPT was associated with QTc prolongation of 9 msec at an iloperidone dose of 12 mg twice daily.","n=160 ) , is not a named entity"
"5.2     QT Prolongation      In an open-label QTc study in patients with schizophrenia or schizoaffective disorder (n=160), FANAPT was associated with QTc prolongation of 9 msec at an iloperidone dose of 12 mg twice daily.",QTc prolongation is an adverse reaction entity
Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.,bone density in is not a named entity
Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.,decreased bone density is an adverse reaction entity
Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.,both is not a named entity
Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.,hypogonadism is an adverse reaction entity
Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.,Long-standing hyperprolactinemia is an adverse reaction entity
Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male patients.,hypogonadism may is not a named entity
"5.7     Orthostatic Hypotension and Syncope      FANAPT can induce orthostatic hypotension associated with dizziness, tachycardia, and syncope.",hypotension associated is not a named entity
"5.7     Orthostatic Hypotension and Syncope      FANAPT can induce orthostatic hypotension associated with dizziness, tachycardia, and syncope.",orthostatic hypotension is an adverse reaction entity
"5.7     Orthostatic Hypotension and Syncope      FANAPT can induce orthostatic hypotension associated with dizziness, tachycardia, and syncope.",tachycardia is an adverse reaction entity
"5.7     Orthostatic Hypotension and Syncope      FANAPT can induce orthostatic hypotension associated with dizziness, tachycardia, and syncope.","tachycardia , and is not a named entity"
"5.7     Orthostatic Hypotension and Syncope      FANAPT can induce orthostatic hypotension associated with dizziness, tachycardia, and syncope.",FANAPT can induce is not a named entity
"5.7     Orthostatic Hypotension and Syncope      FANAPT can induce orthostatic hypotension associated with dizziness, tachycardia, and syncope.",and is not a named entity
"5.7     Orthostatic Hypotension and Syncope      FANAPT can induce orthostatic hypotension associated with dizziness, tachycardia, and syncope.",syncope is an adverse reaction entity
"5.7     Orthostatic Hypotension and Syncope      FANAPT can induce orthostatic hypotension associated with dizziness, tachycardia, and syncope.",dizziness is an adverse reaction entity
"Analysis of seventeen placebo-controlled trials (modal duration 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in the drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients.",death is an adverse reaction entity
"Analysis of seventeen placebo-controlled trials (modal duration 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in the drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients.","weeks ) , is not a named entity"
Drugs with alpha-adrenergic blocking effects have been reported to induce priapism.,have been reported is not a named entity
Drugs with alpha-adrenergic blocking effects have been reported to induce priapism.,priapism is an adverse reaction entity
"Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group.",% in is not a named entity
"Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group.",death is an adverse reaction entity
"Dizziness, tachycardia, and weight increased were at least twice as common on 20 to 24 mg/day as on 10 to 16 mg/day.",weight increased is an adverse reaction entity
"Dizziness, tachycardia, and weight increased were at least twice as common on 20 to 24 mg/day as on 10 to 16 mg/day.",and is not a named entity
"Dizziness, tachycardia, and weight increased were at least twice as common on 20 to 24 mg/day as on 10 to 16 mg/day.",Dizziness is an adverse reaction entity
"Dizziness, tachycardia, and weight increased were at least twice as common on 20 to 24 mg/day as on 10 to 16 mg/day.",to 16 is not a named entity
"Dizziness, tachycardia, and weight increased were at least twice as common on 20 to 24 mg/day as on 10 to 16 mg/day.",common is not a named entity
"Dizziness, tachycardia, and weight increased were at least twice as common on 20 to 24 mg/day as on 10 to 16 mg/day.",tachycardia is an adverse reaction entity
"(  5.6  )   *   Orthostatic hypotension: Dizziness, tachycardia, and syncope can occur with standing.",5.6 ) is not a named entity
"(  5.6  )   *   Orthostatic hypotension: Dizziness, tachycardia, and syncope can occur with standing.",with is not a named entity
"(  5.6  )   *   Orthostatic hypotension: Dizziness, tachycardia, and syncope can occur with standing.",and is not a named entity
"(  5.6  )   *   Orthostatic hypotension: Dizziness, tachycardia, and syncope can occur with standing.",Dizziness is an adverse reaction entity
"(  5.6  )   *   Orthostatic hypotension: Dizziness, tachycardia, and syncope can occur with standing.",tachycardia is an adverse reaction entity
"(  5.6  )   *   Orthostatic hypotension: Dizziness, tachycardia, and syncope can occur with standing.",hypotension : Dizziness is not a named entity
"(  5.6  )   *   Orthostatic hypotension: Dizziness, tachycardia, and syncope can occur with standing.",Orthostatic hypotension is an adverse reaction entity
"(  5.6  )   *   Orthostatic hypotension: Dizziness, tachycardia, and syncope can occur with standing.",syncope is an adverse reaction entity
"Common and Drug-Related Adverse Reactions in Clinical Trials       Based on the pooled data from 4 placebo-controlled, 4- or 6-week, fixed- or flexible-dose studies, the following adverse reactions occurred in >=5% incidence in the patients treated with FANAPT and at least twice the placebo rate for at least 1 dose: dizziness, dry mouth, fatigue, nasal congestion, somnolence, tachycardia, orthostatic hypotension, and weight increased.",nasal congestion is an adverse reaction entity
"Common and Drug-Related Adverse Reactions in Clinical Trials       Based on the pooled data from 4 placebo-controlled, 4- or 6-week, fixed- or flexible-dose studies, the following adverse reactions occurred in >=5% incidence in the patients treated with FANAPT and at least twice the placebo rate for at least 1 dose: dizziness, dry mouth, fatigue, nasal congestion, somnolence, tachycardia, orthostatic hypotension, and weight increased.",", orthostatic hypotension is not a named entity"
"Common and Drug-Related Adverse Reactions in Clinical Trials       Based on the pooled data from 4 placebo-controlled, 4- or 6-week, fixed- or flexible-dose studies, the following adverse reactions occurred in >=5% incidence in the patients treated with FANAPT and at least twice the placebo rate for at least 1 dose: dizziness, dry mouth, fatigue, nasal congestion, somnolence, tachycardia, orthostatic hypotension, and weight increased.",", fixed- or is not a named entity"
"Common and Drug-Related Adverse Reactions in Clinical Trials       Based on the pooled data from 4 placebo-controlled, 4- or 6-week, fixed- or flexible-dose studies, the following adverse reactions occurred in >=5% incidence in the patients treated with FANAPT and at least twice the placebo rate for at least 1 dose: dizziness, dry mouth, fatigue, nasal congestion, somnolence, tachycardia, orthostatic hypotension, and weight increased.",orthostatic hypotension is an adverse reaction entity
"Common and Drug-Related Adverse Reactions in Clinical Trials       Based on the pooled data from 4 placebo-controlled, 4- or 6-week, fixed- or flexible-dose studies, the following adverse reactions occurred in >=5% incidence in the patients treated with FANAPT and at least twice the placebo rate for at least 1 dose: dizziness, dry mouth, fatigue, nasal congestion, somnolence, tachycardia, orthostatic hypotension, and weight increased.",somnolence is an adverse reaction entity
"Common and Drug-Related Adverse Reactions in Clinical Trials       Based on the pooled data from 4 placebo-controlled, 4- or 6-week, fixed- or flexible-dose studies, the following adverse reactions occurred in >=5% incidence in the patients treated with FANAPT and at least twice the placebo rate for at least 1 dose: dizziness, dry mouth, fatigue, nasal congestion, somnolence, tachycardia, orthostatic hypotension, and weight increased.",tachycardia is an adverse reaction entity
"Common and Drug-Related Adverse Reactions in Clinical Trials       Based on the pooled data from 4 placebo-controlled, 4- or 6-week, fixed- or flexible-dose studies, the following adverse reactions occurred in >=5% incidence in the patients treated with FANAPT and at least twice the placebo rate for at least 1 dose: dizziness, dry mouth, fatigue, nasal congestion, somnolence, tachycardia, orthostatic hypotension, and weight increased.",twice is not a named entity
"Common and Drug-Related Adverse Reactions in Clinical Trials       Based on the pooled data from 4 placebo-controlled, 4- or 6-week, fixed- or flexible-dose studies, the following adverse reactions occurred in >=5% incidence in the patients treated with FANAPT and at least twice the placebo rate for at least 1 dose: dizziness, dry mouth, fatigue, nasal congestion, somnolence, tachycardia, orthostatic hypotension, and weight increased.",> =5 % is not a named entity
"Common and Drug-Related Adverse Reactions in Clinical Trials       Based on the pooled data from 4 placebo-controlled, 4- or 6-week, fixed- or flexible-dose studies, the following adverse reactions occurred in >=5% incidence in the patients treated with FANAPT and at least twice the placebo rate for at least 1 dose: dizziness, dry mouth, fatigue, nasal congestion, somnolence, tachycardia, orthostatic hypotension, and weight increased.",increased is not a named entity
"Common and Drug-Related Adverse Reactions in Clinical Trials       Based on the pooled data from 4 placebo-controlled, 4- or 6-week, fixed- or flexible-dose studies, the following adverse reactions occurred in >=5% incidence in the patients treated with FANAPT and at least twice the placebo rate for at least 1 dose: dizziness, dry mouth, fatigue, nasal congestion, somnolence, tachycardia, orthostatic hypotension, and weight increased.",weight increased is an adverse reaction entity
"Common and Drug-Related Adverse Reactions in Clinical Trials       Based on the pooled data from 4 placebo-controlled, 4- or 6-week, fixed- or flexible-dose studies, the following adverse reactions occurred in >=5% incidence in the patients treated with FANAPT and at least twice the placebo rate for at least 1 dose: dizziness, dry mouth, fatigue, nasal congestion, somnolence, tachycardia, orthostatic hypotension, and weight increased.",dizziness is an adverse reaction entity
"Common and Drug-Related Adverse Reactions in Clinical Trials       Based on the pooled data from 4 placebo-controlled, 4- or 6-week, fixed- or flexible-dose studies, the following adverse reactions occurred in >=5% incidence in the patients treated with FANAPT and at least twice the placebo rate for at least 1 dose: dizziness, dry mouth, fatigue, nasal congestion, somnolence, tachycardia, orthostatic hypotension, and weight increased.",dry mouth is an adverse reaction entity
"Common and Drug-Related Adverse Reactions in Clinical Trials       Based on the pooled data from 4 placebo-controlled, 4- or 6-week, fixed- or flexible-dose studies, the following adverse reactions occurred in >=5% incidence in the patients treated with FANAPT and at least twice the placebo rate for at least 1 dose: dizziness, dry mouth, fatigue, nasal congestion, somnolence, tachycardia, orthostatic hypotension, and weight increased.",least twice the is not a named entity
"Common and Drug-Related Adverse Reactions in Clinical Trials       Based on the pooled data from 4 placebo-controlled, 4- or 6-week, fixed- or flexible-dose studies, the following adverse reactions occurred in >=5% incidence in the patients treated with FANAPT and at least twice the placebo rate for at least 1 dose: dizziness, dry mouth, fatigue, nasal congestion, somnolence, tachycardia, orthostatic hypotension, and weight increased.",Clinical is not a named entity
"Common and Drug-Related Adverse Reactions in Clinical Trials       Based on the pooled data from 4 placebo-controlled, 4- or 6-week, fixed- or flexible-dose studies, the following adverse reactions occurred in >=5% incidence in the patients treated with FANAPT and at least twice the placebo rate for at least 1 dose: dizziness, dry mouth, fatigue, nasal congestion, somnolence, tachycardia, orthostatic hypotension, and weight increased.",Reactions is not a named entity
"Common and Drug-Related Adverse Reactions in Clinical Trials       Based on the pooled data from 4 placebo-controlled, 4- or 6-week, fixed- or flexible-dose studies, the following adverse reactions occurred in >=5% incidence in the patients treated with FANAPT and at least twice the placebo rate for at least 1 dose: dizziness, dry mouth, fatigue, nasal congestion, somnolence, tachycardia, orthostatic hypotension, and weight increased.",fatigue is an adverse reaction entity
5.13     Priapism      Three cases of priapism were reported in the premarketing FANAPT program.,FANAPT program is not a named entity
5.13     Priapism      Three cases of priapism were reported in the premarketing FANAPT program.,priapism is an adverse reaction entity
5.10     Body Temperature Regulation      Disruption of the body's ability to reduce core body temperature has been attributed to antipsychotic agents.,Disruption of the body's ability to reduce core body temperature is an adverse reaction entity
5.10     Body Temperature Regulation      Disruption of the body's ability to reduce core body temperature has been attributed to antipsychotic agents.,5.10 Body is not a named entity
5.5     Metabolic Changes      Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk.,increase cardiovascular risk is an adverse reaction entity
5.5     Metabolic Changes      Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk.,increase cerebrovascular risk is an adverse reaction entity
5.5     Metabolic Changes      Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk.,that is not a named entity
5.5     Metabolic Changes      Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk.,have been associated is not a named entity
(  5.1  )   *   QT prolongation: Prolongs QT interval and may be associated with arrhythmia and sudden death-consider using other antipsychotics first.,be associated with is not a named entity
(  5.1  )   *   QT prolongation: Prolongs QT interval and may be associated with arrhythmia and sudden death-consider using other antipsychotics first.,and may is not a named entity
(  5.1  )   *   QT prolongation: Prolongs QT interval and may be associated with arrhythmia and sudden death-consider using other antipsychotics first.,QT prolongation is an adverse reaction entity
(  5.1  )   *   QT prolongation: Prolongs QT interval and may be associated with arrhythmia and sudden death-consider using other antipsychotics first.,Prolongs QT interval is an adverse reaction entity
(  5.1  )   *   QT prolongation: Prolongs QT interval and may be associated with arrhythmia and sudden death-consider using other antipsychotics first.,arrhythmia is an adverse reaction entity
(  5.1  )   *   QT prolongation: Prolongs QT interval and may be associated with arrhythmia and sudden death-consider using other antipsychotics first.,death-consider is not a named entity
(  5.1  )   *   QT prolongation: Prolongs QT interval and may be associated with arrhythmia and sudden death-consider using other antipsychotics first.,sudden death is an adverse reaction entity
(  5.1  )   *   QT prolongation: Prolongs QT interval and may be associated with arrhythmia and sudden death-consider using other antipsychotics first.,( 5.1 is not a named entity
"In this trial, elevated plasma prolactin levels were observed in 26% of adults treated with FANAPT compared to 12% in the placebo-group.",elevated plasma prolactin levels is an adverse reaction entity
"In this trial, elevated plasma prolactin levels were observed in 26% of adults treated with FANAPT compared to 12% in the placebo-group.",In this is not a named entity
5.11     Dysphagia      Esophageal dysmotility and aspiration have been associated with antipsychotic drug use.,with is not a named entity
5.11     Dysphagia      Esophageal dysmotility and aspiration have been associated with antipsychotic drug use.,aspiration is an adverse reaction entity
5.11     Dysphagia      Esophageal dysmotility and aspiration have been associated with antipsychotic drug use.,Esophageal dysmotility is an adverse reaction entity
5.11     Dysphagia      Esophageal dysmotility and aspiration have been associated with antipsychotic drug use.,5.11 Dysphagia Esophageal is not a named entity
(  5.12  )   *   Priapism: Cases have been reported in association with FANAPT treatment.,Priapism is an adverse reaction entity
(  5.12  )   *   Priapism: Cases have been reported in association with FANAPT treatment.,) is not a named entity
"These metabolic changes include hyperglycemia, dyslipidemia, and body weight gain [see Patient Counseling Information (17.3)]  .","hyperglycemia , dyslipidemia is not a named entity"
"These metabolic changes include hyperglycemia, dyslipidemia, and body weight gain [see Patient Counseling Information (17.3)]  .",hyperglycemia is an adverse reaction entity
"These metabolic changes include hyperglycemia, dyslipidemia, and body weight gain [see Patient Counseling Information (17.3)]  .",Counseling Information ( is not a named entity
"These metabolic changes include hyperglycemia, dyslipidemia, and body weight gain [see Patient Counseling Information (17.3)]  .",dyslipidemia is an adverse reaction entity
"These metabolic changes include hyperglycemia, dyslipidemia, and body weight gain [see Patient Counseling Information (17.3)]  .",gain [ is not a named entity
"These metabolic changes include hyperglycemia, dyslipidemia, and body weight gain [see Patient Counseling Information (17.3)]  .",body weight gain is an adverse reaction entity
"5.9     Hyperprolactinemia      As with other drugs that antagonize dopamine D2 receptors, FANAPT elevates prolactin levels.","receptors , FANAPT is not a named entity"
"5.9     Hyperprolactinemia      As with other drugs that antagonize dopamine D2 receptors, FANAPT elevates prolactin levels.",elevates prolactin levels is an adverse reaction entity
BOXED WARNING: WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS      WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS        Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.,increased is not a named entity
BOXED WARNING: WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS      WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS        Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.,MORTALITY is an adverse reaction entity
BOXED WARNING: WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS      WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS        Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.,MORTALITY is an adverse reaction entity
BOXED WARNING: WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS      WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS        Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.,MORTALITY IN is not a named entity
BOXED WARNING: WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS      WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS        Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.,IN ELDERLY PATIENTS is not a named entity
BOXED WARNING: WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS      WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS        Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.,death is an adverse reaction entity
"Orthostatic hypotension was reported in 5% of patients given 20 to 24 mg/day, 3% of patients given 10 to 16 mg/day, and 1% of patients given placebo.","mg/day , and is not a named entity"
"Orthostatic hypotension was reported in 5% of patients given 20 to 24 mg/day, 3% of patients given 10 to 16 mg/day, and 1% of patients given placebo.",Orthostatic hypotension is an adverse reaction entity
(  5.5  )   *   Dyslipidemia: Undesirable alterations have been observed in patients treated with atypical antipsychotics.,Dyslipidemia is an adverse reaction entity
(  5.5  )   *   Dyslipidemia: Undesirable alterations have been observed in patients treated with atypical antipsychotics.,alterations have been is not a named entity
(  5.13  )   *   Potential for cognitive and motor impairment: Use caution when operating machinery.,( is not a named entity
(  5.13  )   *   Potential for cognitive and motor impairment: Use caution when operating machinery.,5.13 is not a named entity
(  5.13  )   *   Potential for cognitive and motor impairment: Use caution when operating machinery.,motor impairment is an adverse reaction entity
(  5.13  )   *   Potential for cognitive and motor impairment: Use caution when operating machinery.,cognitive impairment is an adverse reaction entity
"Changes in body weight (kg) and the proportion of subjects with >=7% gain in body weight from 4 placebo-controlled, 4- or 6-week, fixed- or flexible-dose studies in adult subjects are presented in Table 6.",gain in body weight is an adverse reaction entity
"Changes in body weight (kg) and the proportion of subjects with >=7% gain in body weight from 4 placebo-controlled, 4- or 6-week, fixed- or flexible-dose studies in adult subjects are presented in Table 6.","4 placebo-controlled , is not a named entity"
[See Warnings and Precautions (5.1)]         EXCERPT:     WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS              See full prescribing information for complete boxed warning.,MORTALITY is an adverse reaction entity
[See Warnings and Precautions (5.1)]         EXCERPT:     WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS              See full prescribing information for complete boxed warning.,prescribing is not a named entity
Mammary gland proliferative changes and increases in serum prolactin were seen in mice and rats treated with FANAPT  [see Nonclinical Toxicology (13.1)]  .,gland is not a named entity
Mammary gland proliferative changes and increases in serum prolactin were seen in mice and rats treated with FANAPT  [see Nonclinical Toxicology (13.1)]  .,] is not a named entity
Mammary gland proliferative changes and increases in serum prolactin were seen in mice and rats treated with FANAPT  [see Nonclinical Toxicology (13.1)]  .,increases in serum prolactin is an adverse reaction entity
Mammary gland proliferative changes and increases in serum prolactin were seen in mice and rats treated with FANAPT  [see Nonclinical Toxicology (13.1)]  .,Mammary gland proliferative changes is an adverse reaction entity
"In the short-term trials, FANAPT was associated with modest levels of prolactin elevation compared to greater prolactin elevations observed with some other antipsychotic agents.",some other is not a named entity
"In the short-term trials, FANAPT was associated with modest levels of prolactin elevation compared to greater prolactin elevations observed with some other antipsychotic agents.",prolactin elevation is an adverse reaction entity
"In the short-term trials, FANAPT was associated with modest levels of prolactin elevation compared to greater prolactin elevations observed with some other antipsychotic agents.",FANAPT is not a named entity
"In the short-term trials, FANAPT was associated with modest levels of prolactin elevation compared to greater prolactin elevations observed with some other antipsychotic agents.",prolactin elevations is an adverse reaction entity
"In pooled analysis from clinical studies including longer term trials, in 3210 adults treated with iloperidone, gynecomastia was reported in 2 male subjects (0.1%) compared to 0% in placebo-treated patients, and galactorrhea was reported in 8 female subjects (0.2%) compared to 3 female subjects (0.5%) in placebo-treated patients.",3 female is not a named entity
"In pooled analysis from clinical studies including longer term trials, in 3210 adults treated with iloperidone, gynecomastia was reported in 2 male subjects (0.1%) compared to 0% in placebo-treated patients, and galactorrhea was reported in 8 female subjects (0.2%) compared to 3 female subjects (0.5%) in placebo-treated patients.",gynecomastia is an adverse reaction entity
"In pooled analysis from clinical studies including longer term trials, in 3210 adults treated with iloperidone, gynecomastia was reported in 2 male subjects (0.1%) compared to 0% in placebo-treated patients, and galactorrhea was reported in 8 female subjects (0.2%) compared to 3 female subjects (0.5%) in placebo-treated patients.",galactorrhea is an adverse reaction entity
"In pooled analysis from clinical studies including longer term trials, in 3210 adults treated with iloperidone, gynecomastia was reported in 2 male subjects (0.1%) compared to 0% in placebo-treated patients, and galactorrhea was reported in 8 female subjects (0.2%) compared to 3 female subjects (0.5%) in placebo-treated patients.",longer is not a named entity
"Under conditions of metabolic inhibition for both 2D6 and 3A4, FANAPT 12 mg twice daily was associated with a mean QTcF increase from baseline of about 19 msec.",QTcF increase is an adverse reaction entity
"Under conditions of metabolic inhibition for both 2D6 and 3A4, FANAPT 12 mg twice daily was associated with a mean QTcF increase from baseline of about 19 msec.",FANAPT is not a named entity
No cases of torsade de pointes or other severe cardiac arrhythmias were observed during the pre-marketing clinical program.,during the pre-marketing is not a named entity
No cases of torsade de pointes or other severe cardiac arrhythmias were observed during the pre-marketing clinical program.,torsade de pointes is an adverse reaction entity
No cases of torsade de pointes or other severe cardiac arrhythmias were observed during the pre-marketing clinical program.,pre-marketing is not a named entity
No cases of torsade de pointes or other severe cardiac arrhythmias were observed during the pre-marketing clinical program.,cardiac arrhythmias is an adverse reaction entity
"This, in turn, may inhibit reproductive function by impairing gonadalsteroidogenesis in both female and male patients.",impairing gonadalsteroidogenesis is an adverse reaction entity
"This, in turn, may inhibit reproductive function by impairing gonadalsteroidogenesis in both female and male patients.",inhibit reproductive function is an adverse reaction entity
"This, in turn, may inhibit reproductive function by impairing gonadalsteroidogenesis in both female and male patients.",male patients is not a named entity
"This, in turn, may inhibit reproductive function by impairing gonadalsteroidogenesis in both female and male patients.",female and male is not a named entity
"Table 6: Change in Body Weight                                      FANAPT           FANAPT                               Placebo          10-16 mg/day     20-24 mg/day                        n=576            n=481            n=391                Weight (kg)                                                            Change from Baseline    -0.1             2.0              2.7                  Weight Gain                                                            >=7% increase from Baseline    4%               12%              18%                             5.6     Seizures      In short-term placebo-controlled trials (4- to 6-weeks), seizures occurred in 0.1% (1/1344) of patients treated with FANAPT compared to 0.3% (2/587) on placebo.",) Change is not a named entity
"Table 6: Change in Body Weight                                      FANAPT           FANAPT                               Placebo          10-16 mg/day     20-24 mg/day                        n=576            n=481            n=391                Weight (kg)                                                            Change from Baseline    -0.1             2.0              2.7                  Weight Gain                                                            >=7% increase from Baseline    4%               12%              18%                             5.6     Seizures      In short-term placebo-controlled trials (4- to 6-weeks), seizures occurred in 0.1% (1/1344) of patients treated with FANAPT compared to 0.3% (2/587) on placebo.",seizures is an adverse reaction entity
"5.8     Leukopenia, Neutropenia and Agranulocytosis      In clinical trial and postmarketing experience, events of leukopenia/neutropenia have been reported temporally related to antipsychotic agents.",neutropenia is an adverse reaction entity
"5.8     Leukopenia, Neutropenia and Agranulocytosis      In clinical trial and postmarketing experience, events of leukopenia/neutropenia have been reported temporally related to antipsychotic agents.",leukopenia is an adverse reaction entity
"5.8     Leukopenia, Neutropenia and Agranulocytosis      In clinical trial and postmarketing experience, events of leukopenia/neutropenia have been reported temporally related to antipsychotic agents.",been is not a named entity
"5.8     Leukopenia, Neutropenia and Agranulocytosis      In clinical trial and postmarketing experience, events of leukopenia/neutropenia have been reported temporally related to antipsychotic agents.",related is not a named entity
"Hyperprolactinemia may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotropin secretion.",Hyperprolactinemia is an adverse reaction entity
"Hyperprolactinemia may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotropin secretion.",Hyperprolactinemia may suppress is not a named entity
"Hyperprolactinemia may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotropin secretion.",", resulting in is not a named entity"
"Hyperprolactinemia may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotropin secretion.",reduced pituitary gonadotropin secretion is an adverse reaction entity
"Hyperprolactinemia may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotropin secretion.",suppress hypothalamic GnRH is an adverse reaction entity
"Hyperprolactinemia may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotropin secretion.",", resulting in is not a named entity"
"5.14     Potential for Cognitive and Motor Impairment      FANAPT, like other antipsychotics, has the potential to impair judgment, thinking or motor skills.",other is not a named entity
"5.14     Potential for Cognitive and Motor Impairment      FANAPT, like other antipsychotics, has the potential to impair judgment, thinking or motor skills.",impair thinking is an adverse reaction entity
"5.14     Potential for Cognitive and Motor Impairment      FANAPT, like other antipsychotics, has the potential to impair judgment, thinking or motor skills.",or is not a named entity
"5.14     Potential for Cognitive and Motor Impairment      FANAPT, like other antipsychotics, has the potential to impair judgment, thinking or motor skills.",impair motor skills is an adverse reaction entity
"5.14     Potential for Cognitive and Motor Impairment      FANAPT, like other antipsychotics, has the potential to impair judgment, thinking or motor skills.",Cognitive is not a named entity
"5.14     Potential for Cognitive and Motor Impairment      FANAPT, like other antipsychotics, has the potential to impair judgment, thinking or motor skills.",impair judgment is an adverse reaction entity
"In a short-term placebo-controlled trial (4-weeks), the mean change from baseline to endpoint in plasma prolactin levels for the FANAPT 24 mg/day-treated group was an increase of 2.6 ng/mL compared to a decrease of 6.3 ng/mL in the placebo-group.",prolactin levels is not a named entity
"In a short-term placebo-controlled trial (4-weeks), the mean change from baseline to endpoint in plasma prolactin levels for the FANAPT 24 mg/day-treated group was an increase of 2.6 ng/mL compared to a decrease of 6.3 ng/mL in the placebo-group.",plasma prolactin levels increase is an adverse reaction entity
"Respiratory, Thoracic and Mediastinal Disorders: Infrequent  - epistaxis, asthma, rhinorrhea, sinus congestion, nasal dryness;  Rare  - dry throat, sleep apnea syndrome, dyspnea exertional       6.2     Postmarketing Experience    The following adverse reactions have been identified during post-approval use of FANAPT: retrograde ejaculation.",of FANAPT : is not a named entity
"Respiratory, Thoracic and Mediastinal Disorders: Infrequent  - epistaxis, asthma, rhinorrhea, sinus congestion, nasal dryness;  Rare  - dry throat, sleep apnea syndrome, dyspnea exertional       6.2     Postmarketing Experience    The following adverse reactions have been identified during post-approval use of FANAPT: retrograde ejaculation.",identified during post-approval is not a named entity
"Respiratory, Thoracic and Mediastinal Disorders: Infrequent  - epistaxis, asthma, rhinorrhea, sinus congestion, nasal dryness;  Rare  - dry throat, sleep apnea syndrome, dyspnea exertional       6.2     Postmarketing Experience    The following adverse reactions have been identified during post-approval use of FANAPT: retrograde ejaculation.",The following adverse is not a named entity
"Respiratory, Thoracic and Mediastinal Disorders: Infrequent  - epistaxis, asthma, rhinorrhea, sinus congestion, nasal dryness;  Rare  - dry throat, sleep apnea syndrome, dyspnea exertional       6.2     Postmarketing Experience    The following adverse reactions have been identified during post-approval use of FANAPT: retrograde ejaculation.",rhinorrhea is an adverse reaction entity
"Respiratory, Thoracic and Mediastinal Disorders: Infrequent  - epistaxis, asthma, rhinorrhea, sinus congestion, nasal dryness;  Rare  - dry throat, sleep apnea syndrome, dyspnea exertional       6.2     Postmarketing Experience    The following adverse reactions have been identified during post-approval use of FANAPT: retrograde ejaculation.",adverse reactions have is not a named entity
"Respiratory, Thoracic and Mediastinal Disorders: Infrequent  - epistaxis, asthma, rhinorrhea, sinus congestion, nasal dryness;  Rare  - dry throat, sleep apnea syndrome, dyspnea exertional       6.2     Postmarketing Experience    The following adverse reactions have been identified during post-approval use of FANAPT: retrograde ejaculation.",sleep apnea syndrome is an adverse reaction entity
"Respiratory, Thoracic and Mediastinal Disorders: Infrequent  - epistaxis, asthma, rhinorrhea, sinus congestion, nasal dryness;  Rare  - dry throat, sleep apnea syndrome, dyspnea exertional       6.2     Postmarketing Experience    The following adverse reactions have been identified during post-approval use of FANAPT: retrograde ejaculation.",sinus congestion is an adverse reaction entity
"Respiratory, Thoracic and Mediastinal Disorders: Infrequent  - epistaxis, asthma, rhinorrhea, sinus congestion, nasal dryness;  Rare  - dry throat, sleep apnea syndrome, dyspnea exertional       6.2     Postmarketing Experience    The following adverse reactions have been identified during post-approval use of FANAPT: retrograde ejaculation.",dyspnea exertional is an adverse reaction entity
"Respiratory, Thoracic and Mediastinal Disorders: Infrequent  - epistaxis, asthma, rhinorrhea, sinus congestion, nasal dryness;  Rare  - dry throat, sleep apnea syndrome, dyspnea exertional       6.2     Postmarketing Experience    The following adverse reactions have been identified during post-approval use of FANAPT: retrograde ejaculation.",Rare is not a named entity
"Respiratory, Thoracic and Mediastinal Disorders: Infrequent  - epistaxis, asthma, rhinorrhea, sinus congestion, nasal dryness;  Rare  - dry throat, sleep apnea syndrome, dyspnea exertional       6.2     Postmarketing Experience    The following adverse reactions have been identified during post-approval use of FANAPT: retrograde ejaculation.",", nasal dryness is not a named entity"
"Respiratory, Thoracic and Mediastinal Disorders: Infrequent  - epistaxis, asthma, rhinorrhea, sinus congestion, nasal dryness;  Rare  - dry throat, sleep apnea syndrome, dyspnea exertional       6.2     Postmarketing Experience    The following adverse reactions have been identified during post-approval use of FANAPT: retrograde ejaculation.",nasal dryness is an adverse reaction entity
"Respiratory, Thoracic and Mediastinal Disorders: Infrequent  - epistaxis, asthma, rhinorrhea, sinus congestion, nasal dryness;  Rare  - dry throat, sleep apnea syndrome, dyspnea exertional       6.2     Postmarketing Experience    The following adverse reactions have been identified during post-approval use of FANAPT: retrograde ejaculation.",retrograde ejaculation is an adverse reaction entity
"Respiratory, Thoracic and Mediastinal Disorders: Infrequent  - epistaxis, asthma, rhinorrhea, sinus congestion, nasal dryness;  Rare  - dry throat, sleep apnea syndrome, dyspnea exertional       6.2     Postmarketing Experience    The following adverse reactions have been identified during post-approval use of FANAPT: retrograde ejaculation.",dry throat is an adverse reaction entity
"Respiratory, Thoracic and Mediastinal Disorders: Infrequent  - epistaxis, asthma, rhinorrhea, sinus congestion, nasal dryness;  Rare  - dry throat, sleep apnea syndrome, dyspnea exertional       6.2     Postmarketing Experience    The following adverse reactions have been identified during post-approval use of FANAPT: retrograde ejaculation.",epistaxis is an adverse reaction entity
"Respiratory, Thoracic and Mediastinal Disorders: Infrequent  - epistaxis, asthma, rhinorrhea, sinus congestion, nasal dryness;  Rare  - dry throat, sleep apnea syndrome, dyspnea exertional       6.2     Postmarketing Experience    The following adverse reactions have been identified during post-approval use of FANAPT: retrograde ejaculation.",have been is not a named entity
"Respiratory, Thoracic and Mediastinal Disorders: Infrequent  - epistaxis, asthma, rhinorrhea, sinus congestion, nasal dryness;  Rare  - dry throat, sleep apnea syndrome, dyspnea exertional       6.2     Postmarketing Experience    The following adverse reactions have been identified during post-approval use of FANAPT: retrograde ejaculation.","congestion , nasal is not a named entity"
"Respiratory, Thoracic and Mediastinal Disorders: Infrequent  - epistaxis, asthma, rhinorrhea, sinus congestion, nasal dryness;  Rare  - dry throat, sleep apnea syndrome, dyspnea exertional       6.2     Postmarketing Experience    The following adverse reactions have been identified during post-approval use of FANAPT: retrograde ejaculation.",use is not a named entity
"Respiratory, Thoracic and Mediastinal Disorders: Infrequent  - epistaxis, asthma, rhinorrhea, sinus congestion, nasal dryness;  Rare  - dry throat, sleep apnea syndrome, dyspnea exertional       6.2     Postmarketing Experience    The following adverse reactions have been identified during post-approval use of FANAPT: retrograde ejaculation.",asthma is an adverse reaction entity
Possible risk factors for leukopenia/neutropenia include preexisting low white blood cell count (WBC) and history of drug induced leukopenia/neutropenia.,induced is not a named entity
Possible risk factors for leukopenia/neutropenia include preexisting low white blood cell count (WBC) and history of drug induced leukopenia/neutropenia.,WBC ) and is not a named entity
Possible risk factors for leukopenia/neutropenia include preexisting low white blood cell count (WBC) and history of drug induced leukopenia/neutropenia.,leukopenia is an adverse reaction entity
Possible risk factors for leukopenia/neutropenia include preexisting low white blood cell count (WBC) and history of drug induced leukopenia/neutropenia.,neutropenia is an adverse reaction entity
Adverse event data collected from those trials showed the following rates of EPS-related adverse events as shown in Table 8.,EPS-related adverse events is an adverse reaction entity
Adverse event data collected from those trials showed the following rates of EPS-related adverse events as shown in Table 8.,shown is not a named entity
"(  1  ,  5.2  ,  7.1  ,  7.3  ,  12.3  )   *   Neuroleptic Malignant Syndrome: Manage with immediate discontinuation of drug and close monitoring.",Neuroleptic Malignant Syndrome is an adverse reaction entity
"(  1  ,  5.2  ,  7.1  ,  7.3  ,  12.3  )   *   Neuroleptic Malignant Syndrome: Manage with immediate discontinuation of drug and close monitoring.",Malignant Syndrome : is not a named entity
"(  5.7  )   *   Leukopenia, Neutropenia, and Agranulocytosis have been reported with antipsychotics.",with antipsychotics is not a named entity
"(  5.7  )   *   Leukopenia, Neutropenia, and Agranulocytosis have been reported with antipsychotics.",", and is not a named entity"
"(  5.7  )   *   Leukopenia, Neutropenia, and Agranulocytosis have been reported with antipsychotics.",) is not a named entity
"(  5.7  )   *   Leukopenia, Neutropenia, and Agranulocytosis have been reported with antipsychotics.",Neutropenia is an adverse reaction entity
"(  5.7  )   *   Leukopenia, Neutropenia, and Agranulocytosis have been reported with antipsychotics.",Agranulocytosis is an adverse reaction entity
"(  5.7  )   *   Leukopenia, Neutropenia, and Agranulocytosis have been reported with antipsychotics.",Leukopenia is an adverse reaction entity
"5.3 Thrombotic Events      COMETRIQ treatment results in an increased incidence of thrombotic events (venous thromboembolism: 6% vs. 3% and arterial thromboembolism: 2% vs. 0% in COMETRIQ-treated and placebo-treated patients, respectively).",venous thromboembolism is an adverse reaction entity
"5.3 Thrombotic Events      COMETRIQ treatment results in an increased incidence of thrombotic events (venous thromboembolism: 6% vs. 3% and arterial thromboembolism: 2% vs. 0% in COMETRIQ-treated and placebo-treated patients, respectively).",thromboembolism : 2 is not a named entity
"5.3 Thrombotic Events      COMETRIQ treatment results in an increased incidence of thrombotic events (venous thromboembolism: 6% vs. 3% and arterial thromboembolism: 2% vs. 0% in COMETRIQ-treated and placebo-treated patients, respectively).",3 % is not a named entity
"5.3 Thrombotic Events      COMETRIQ treatment results in an increased incidence of thrombotic events (venous thromboembolism: 6% vs. 3% and arterial thromboembolism: 2% vs. 0% in COMETRIQ-treated and placebo-treated patients, respectively).",thrombotic events is an adverse reaction entity
"5.3 Thrombotic Events      COMETRIQ treatment results in an increased incidence of thrombotic events (venous thromboembolism: 6% vs. 3% and arterial thromboembolism: 2% vs. 0% in COMETRIQ-treated and placebo-treated patients, respectively).",Thrombotic Events is not a named entity
"5.3 Thrombotic Events      COMETRIQ treatment results in an increased incidence of thrombotic events (venous thromboembolism: 6% vs. 3% and arterial thromboembolism: 2% vs. 0% in COMETRIQ-treated and placebo-treated patients, respectively).",arterial thromboembolism is an adverse reaction entity
"Grade 3-4 adverse reactions and laboratory abnormalities which occurred in >= 5% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 2% included, in order of decreasing frequency; diarrhea, PPES, lymphopenia, hypocalcemia, fatigue, hypertension, asthenia, increased ALT, decreased weight, stomatitis, and decreased appetite (see  Table 1  ,  Table 2  ).","included , in is not a named entity"
"Grade 3-4 adverse reactions and laboratory abnormalities which occurred in >= 5% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 2% included, in order of decreasing frequency; diarrhea, PPES, lymphopenia, hypocalcemia, fatigue, hypertension, asthenia, increased ALT, decreased weight, stomatitis, and decreased appetite (see  Table 1  ,  Table 2  ).",laboratory abnormalities is not a named entity
"Grade 3-4 adverse reactions and laboratory abnormalities which occurred in >= 5% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 2% included, in order of decreasing frequency; diarrhea, PPES, lymphopenia, hypocalcemia, fatigue, hypertension, asthenia, increased ALT, decreased weight, stomatitis, and decreased appetite (see  Table 1  ,  Table 2  ).",Table 2 is not a named entity
"Grade 3-4 adverse reactions and laboratory abnormalities which occurred in >= 5% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 2% included, in order of decreasing frequency; diarrhea, PPES, lymphopenia, hypocalcemia, fatigue, hypertension, asthenia, increased ALT, decreased weight, stomatitis, and decreased appetite (see  Table 1  ,  Table 2  ).",lymphopenia is an adverse reaction entity
"Grade 3-4 adverse reactions and laboratory abnormalities which occurred in >= 5% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 2% included, in order of decreasing frequency; diarrhea, PPES, lymphopenia, hypocalcemia, fatigue, hypertension, asthenia, increased ALT, decreased weight, stomatitis, and decreased appetite (see  Table 1  ,  Table 2  ).",PPES is an adverse reaction entity
"Grade 3-4 adverse reactions and laboratory abnormalities which occurred in >= 5% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 2% included, in order of decreasing frequency; diarrhea, PPES, lymphopenia, hypocalcemia, fatigue, hypertension, asthenia, increased ALT, decreased weight, stomatitis, and decreased appetite (see  Table 1  ,  Table 2  ).",diarrhea is an adverse reaction entity
"Grade 3-4 adverse reactions and laboratory abnormalities which occurred in >= 5% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 2% included, in order of decreasing frequency; diarrhea, PPES, lymphopenia, hypocalcemia, fatigue, hypertension, asthenia, increased ALT, decreased weight, stomatitis, and decreased appetite (see  Table 1  ,  Table 2  ).",asthenia is an adverse reaction entity
"Grade 3-4 adverse reactions and laboratory abnormalities which occurred in >= 5% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 2% included, in order of decreasing frequency; diarrhea, PPES, lymphopenia, hypocalcemia, fatigue, hypertension, asthenia, increased ALT, decreased weight, stomatitis, and decreased appetite (see  Table 1  ,  Table 2  ).",increased ALT is an adverse reaction entity
"Grade 3-4 adverse reactions and laboratory abnormalities which occurred in >= 5% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 2% included, in order of decreasing frequency; diarrhea, PPES, lymphopenia, hypocalcemia, fatigue, hypertension, asthenia, increased ALT, decreased weight, stomatitis, and decreased appetite (see  Table 1  ,  Table 2  ).",3-4 is not a named entity
"Grade 3-4 adverse reactions and laboratory abnormalities which occurred in >= 5% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 2% included, in order of decreasing frequency; diarrhea, PPES, lymphopenia, hypocalcemia, fatigue, hypertension, asthenia, increased ALT, decreased weight, stomatitis, and decreased appetite (see  Table 1  ,  Table 2  ).",and is not a named entity
"Grade 3-4 adverse reactions and laboratory abnormalities which occurred in >= 5% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 2% included, in order of decreasing frequency; diarrhea, PPES, lymphopenia, hypocalcemia, fatigue, hypertension, asthenia, increased ALT, decreased weight, stomatitis, and decreased appetite (see  Table 1  ,  Table 2  ).",of > is not a named entity
"Grade 3-4 adverse reactions and laboratory abnormalities which occurred in >= 5% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 2% included, in order of decreasing frequency; diarrhea, PPES, lymphopenia, hypocalcemia, fatigue, hypertension, asthenia, increased ALT, decreased weight, stomatitis, and decreased appetite (see  Table 1  ,  Table 2  ).",= is not a named entity
"Grade 3-4 adverse reactions and laboratory abnormalities which occurred in >= 5% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 2% included, in order of decreasing frequency; diarrhea, PPES, lymphopenia, hypocalcemia, fatigue, hypertension, asthenia, increased ALT, decreased weight, stomatitis, and decreased appetite (see  Table 1  ,  Table 2  ).",decreased appetite is an adverse reaction entity
"Grade 3-4 adverse reactions and laboratory abnormalities which occurred in >= 5% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 2% included, in order of decreasing frequency; diarrhea, PPES, lymphopenia, hypocalcemia, fatigue, hypertension, asthenia, increased ALT, decreased weight, stomatitis, and decreased appetite (see  Table 1  ,  Table 2  ).",fatigue is an adverse reaction entity
"Grade 3-4 adverse reactions and laboratory abnormalities which occurred in >= 5% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 2% included, in order of decreasing frequency; diarrhea, PPES, lymphopenia, hypocalcemia, fatigue, hypertension, asthenia, increased ALT, decreased weight, stomatitis, and decreased appetite (see  Table 1  ,  Table 2  ).",% included is not a named entity
"Grade 3-4 adverse reactions and laboratory abnormalities which occurred in >= 5% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 2% included, in order of decreasing frequency; diarrhea, PPES, lymphopenia, hypocalcemia, fatigue, hypertension, asthenia, increased ALT, decreased weight, stomatitis, and decreased appetite (see  Table 1  ,  Table 2  ).",stomatitis is an adverse reaction entity
"Grade 3-4 adverse reactions and laboratory abnormalities which occurred in >= 5% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 2% included, in order of decreasing frequency; diarrhea, PPES, lymphopenia, hypocalcemia, fatigue, hypertension, asthenia, increased ALT, decreased weight, stomatitis, and decreased appetite (see  Table 1  ,  Table 2  ).",decreased weight is an adverse reaction entity
"Grade 3-4 adverse reactions and laboratory abnormalities which occurred in >= 5% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 2% included, in order of decreasing frequency; diarrhea, PPES, lymphopenia, hypocalcemia, fatigue, hypertension, asthenia, increased ALT, decreased weight, stomatitis, and decreased appetite (see  Table 1  ,  Table 2  ).",hypertension is an adverse reaction entity
"Grade 3-4 adverse reactions and laboratory abnormalities which occurred in >= 5% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 2% included, in order of decreasing frequency; diarrhea, PPES, lymphopenia, hypocalcemia, fatigue, hypertension, asthenia, increased ALT, decreased weight, stomatitis, and decreased appetite (see  Table 1  ,  Table 2  ).",hypocalcemia is an adverse reaction entity
"Grade 3-4 adverse reactions and laboratory abnormalities which occurred in >= 5% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 2% included, in order of decreasing frequency; diarrhea, PPES, lymphopenia, hypocalcemia, fatigue, hypertension, asthenia, increased ALT, decreased weight, stomatitis, and decreased appetite (see  Table 1  ,  Table 2  ).",of is not a named entity
"Grade 3-4 adverse reactions and laboratory abnormalities which occurred in >= 5% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 2% included, in order of decreasing frequency; diarrhea, PPES, lymphopenia, hypocalcemia, fatigue, hypertension, asthenia, increased ALT, decreased weight, stomatitis, and decreased appetite (see  Table 1  ,  Table 2  ).",> is not a named entity
"Grade 3-4 adverse reactions and laboratory abnormalities which occurred in >= 5% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 2% included, in order of decreasing frequency; diarrhea, PPES, lymphopenia, hypocalcemia, fatigue, hypertension, asthenia, increased ALT, decreased weight, stomatitis, and decreased appetite (see  Table 1  ,  Table 2  ).","stomatitis , and is not a named entity"
5.7 Palmar-Plantar Erythrodysesthesia Syndrome      Palmar-plantar erythrodysesthesia syndrome (PPES) occurred in 50% of patients treated with COMETRIQ and was severe (>= Grade 3) in 13% of patients.,Palmar-plantar erythrodysesthesia syndrome is an adverse reaction entity
5.7 Palmar-Plantar Erythrodysesthesia Syndrome      Palmar-plantar erythrodysesthesia syndrome (PPES) occurred in 50% of patients treated with COMETRIQ and was severe (>= Grade 3) in 13% of patients.,3 is not a named entity
5.7 Palmar-Plantar Erythrodysesthesia Syndrome      Palmar-plantar erythrodysesthesia syndrome (PPES) occurred in 50% of patients treated with COMETRIQ and was severe (>= Grade 3) in 13% of patients.,was severe ( is not a named entity
5.7 Palmar-Plantar Erythrodysesthesia Syndrome      Palmar-plantar erythrodysesthesia syndrome (PPES) occurred in 50% of patients treated with COMETRIQ and was severe (>= Grade 3) in 13% of patients.,Erythrodysesthesia Syndrome is not a named entity
5.7 Palmar-Plantar Erythrodysesthesia Syndrome      Palmar-plantar erythrodysesthesia syndrome (PPES) occurred in 50% of patients treated with COMETRIQ and was severe (>= Grade 3) in 13% of patients.,Palmar-plantar erythrodysesthesia syndrome is an adverse reaction entity
5.7 Palmar-Plantar Erythrodysesthesia Syndrome      Palmar-plantar erythrodysesthesia syndrome (PPES) occurred in 50% of patients treated with COMETRIQ and was severe (>= Grade 3) in 13% of patients.,PPES is an adverse reaction entity
5.7 Palmar-Plantar Erythrodysesthesia Syndrome      Palmar-plantar erythrodysesthesia syndrome (PPES) occurred in 50% of patients treated with COMETRIQ and was severe (>= Grade 3) in 13% of patients.,PPES is an adverse reaction entity
5.7 Palmar-Plantar Erythrodysesthesia Syndrome      Palmar-plantar erythrodysesthesia syndrome (PPES) occurred in 50% of patients treated with COMETRIQ and was severe (>= Grade 3) in 13% of patients.,PPES ) occurred is not a named entity
5.2 Hemorrhage      Serious and sometimes fatal hemorrhage occurred with COMETRIQ.,hemorrhage is an adverse reaction entity
5.2 Hemorrhage      Serious and sometimes fatal hemorrhage occurred with COMETRIQ.,fatal is an adverse reaction entity
5.2 Hemorrhage      Serious and sometimes fatal hemorrhage occurred with COMETRIQ.,with COMETRIQ is not a named entity
5.2 Hemorrhage      Serious and sometimes fatal hemorrhage occurred with COMETRIQ.,hemorrhage is an adverse reaction entity
5.2 Hemorrhage      Serious and sometimes fatal hemorrhage occurred with COMETRIQ.,occurred with COMETRIQ is not a named entity
5.2 Hemorrhage      Serious and sometimes fatal hemorrhage occurred with COMETRIQ.,5.2 Hemorrhage is not a named entity
"Fatal adverse reactions occurred in 6% of patients receiving COMETRIQ and resulted from hemorrhage, pneumonia, septicemia, fistulas, cardiac arrest, respiratory failure, and unspecified death.",death is an adverse reaction entity
"Fatal adverse reactions occurred in 6% of patients receiving COMETRIQ and resulted from hemorrhage, pneumonia, septicemia, fistulas, cardiac arrest, respiratory failure, and unspecified death.",hemorrhage is an adverse reaction entity
"Fatal adverse reactions occurred in 6% of patients receiving COMETRIQ and resulted from hemorrhage, pneumonia, septicemia, fistulas, cardiac arrest, respiratory failure, and unspecified death.",and is not a named entity
"Fatal adverse reactions occurred in 6% of patients receiving COMETRIQ and resulted from hemorrhage, pneumonia, septicemia, fistulas, cardiac arrest, respiratory failure, and unspecified death.",", is not a named entity"
"Fatal adverse reactions occurred in 6% of patients receiving COMETRIQ and resulted from hemorrhage, pneumonia, septicemia, fistulas, cardiac arrest, respiratory failure, and unspecified death.",respiratory failure is an adverse reaction entity
"Fatal adverse reactions occurred in 6% of patients receiving COMETRIQ and resulted from hemorrhage, pneumonia, septicemia, fistulas, cardiac arrest, respiratory failure, and unspecified death.",and is not a named entity
"Fatal adverse reactions occurred in 6% of patients receiving COMETRIQ and resulted from hemorrhage, pneumonia, septicemia, fistulas, cardiac arrest, respiratory failure, and unspecified death.",fistulas is an adverse reaction entity
"Fatal adverse reactions occurred in 6% of patients receiving COMETRIQ and resulted from hemorrhage, pneumonia, septicemia, fistulas, cardiac arrest, respiratory failure, and unspecified death.","arrest , respiratory is not a named entity"
"Fatal adverse reactions occurred in 6% of patients receiving COMETRIQ and resulted from hemorrhage, pneumonia, septicemia, fistulas, cardiac arrest, respiratory failure, and unspecified death.","fistulas , is not a named entity"
"Fatal adverse reactions occurred in 6% of patients receiving COMETRIQ and resulted from hemorrhage, pneumonia, septicemia, fistulas, cardiac arrest, respiratory failure, and unspecified death.",of patients receiving is not a named entity
"Fatal adverse reactions occurred in 6% of patients receiving COMETRIQ and resulted from hemorrhage, pneumonia, septicemia, fistulas, cardiac arrest, respiratory failure, and unspecified death.",from hemorrhage is not a named entity
"Fatal adverse reactions occurred in 6% of patients receiving COMETRIQ and resulted from hemorrhage, pneumonia, septicemia, fistulas, cardiac arrest, respiratory failure, and unspecified death.",", fistulas is not a named entity"
"Fatal adverse reactions occurred in 6% of patients receiving COMETRIQ and resulted from hemorrhage, pneumonia, septicemia, fistulas, cardiac arrest, respiratory failure, and unspecified death.",Fatal is an adverse reaction entity
"Fatal adverse reactions occurred in 6% of patients receiving COMETRIQ and resulted from hemorrhage, pneumonia, septicemia, fistulas, cardiac arrest, respiratory failure, and unspecified death.",cardiac arrest is an adverse reaction entity
"Fatal adverse reactions occurred in 6% of patients receiving COMETRIQ and resulted from hemorrhage, pneumonia, septicemia, fistulas, cardiac arrest, respiratory failure, and unspecified death.",septicemia is an adverse reaction entity
"Fatal adverse reactions occurred in 6% of patients receiving COMETRIQ and resulted from hemorrhage, pneumonia, septicemia, fistulas, cardiac arrest, respiratory failure, and unspecified death.",pneumonia is an adverse reaction entity
"(5.1)   *  Hemorrhage: Severe, sometimes fatal, hemorrhage including hemoptysis and gastrointestinal hemorrhage occurred in 3% of COMETRIQ-treated patients.",", hemorrhage is not a named entity"
"(5.1)   *  Hemorrhage: Severe, sometimes fatal, hemorrhage including hemoptysis and gastrointestinal hemorrhage occurred in 3% of COMETRIQ-treated patients.",% of COMETRIQ-treated is not a named entity
"(5.1)   *  Hemorrhage: Severe, sometimes fatal, hemorrhage including hemoptysis and gastrointestinal hemorrhage occurred in 3% of COMETRIQ-treated patients.",fatal is an adverse reaction entity
"(5.1)   *  Hemorrhage: Severe, sometimes fatal, hemorrhage including hemoptysis and gastrointestinal hemorrhage occurred in 3% of COMETRIQ-treated patients.",hemorrhage is an adverse reaction entity
"(5.1)   *  Hemorrhage: Severe, sometimes fatal, hemorrhage including hemoptysis and gastrointestinal hemorrhage occurred in 3% of COMETRIQ-treated patients.",including is not a named entity
"(5.1)   *  Hemorrhage: Severe, sometimes fatal, hemorrhage including hemoptysis and gastrointestinal hemorrhage occurred in 3% of COMETRIQ-treated patients.",hemoptysis is an adverse reaction entity
"(5.1)   *  Hemorrhage: Severe, sometimes fatal, hemorrhage including hemoptysis and gastrointestinal hemorrhage occurred in 3% of COMETRIQ-treated patients.",5.1 is not a named entity
"(5.1)   *  Hemorrhage: Severe, sometimes fatal, hemorrhage including hemoptysis and gastrointestinal hemorrhage occurred in 3% of COMETRIQ-treated patients.",hemorrhage is an adverse reaction entity
"(5.1)   *  Hemorrhage: Severe, sometimes fatal, hemorrhage including hemoptysis and gastrointestinal hemorrhage occurred in 3% of COMETRIQ-treated patients.",and is not a named entity
"(5.1)   *  Hemorrhage: Severe, sometimes fatal, hemorrhage including hemoptysis and gastrointestinal hemorrhage occurred in 3% of COMETRIQ-treated patients.",gastrointestinal hemorrhage is an adverse reaction entity
"(5.1)   *  Hemorrhage: Severe, sometimes fatal, hemorrhage including hemoptysis and gastrointestinal hemorrhage occurred in 3% of COMETRIQ-treated patients.",( is not a named entity
"(5.1)   *  Hemorrhage: Severe, sometimes fatal, hemorrhage including hemoptysis and gastrointestinal hemorrhage occurred in 3% of COMETRIQ-treated patients.",Hemorrhage is an adverse reaction entity
(  5.3  )   *  Wound Complications: Withhold COMETRIQ for dehiscence or complications requiring medical intervention.,Withhold COMETRIQ is not a named entity
(  5.3  )   *  Wound Complications: Withhold COMETRIQ for dehiscence or complications requiring medical intervention.,Wound Complications is an adverse reaction entity
Increased levels of thyroid stimulating hormone (TSH) were observed in 57% of patients receiving COMETRIQ after the first dose compared to 19% of patients receiving placebo (regardless of baseline value).,thyroid stimulating hormone is not a named entity
Increased levels of thyroid stimulating hormone (TSH) were observed in 57% of patients receiving COMETRIQ after the first dose compared to 19% of patients receiving placebo (regardless of baseline value).,Increased levels of thyroid stimulating hormone is an adverse reaction entity
5.6 Osteonecrosis of the Jaw      Osteonecrosis of the jaw (ONJ) occurred in 1% of COMETRIQ-treated patients.,Osteonecrosis of the jaw is an adverse reaction entity
5.6 Osteonecrosis of the Jaw      Osteonecrosis of the jaw (ONJ) occurred in 1% of COMETRIQ-treated patients.,of COMETRIQ-treated patients is not a named entity
5.6 Osteonecrosis of the Jaw      Osteonecrosis of the jaw (ONJ) occurred in 1% of COMETRIQ-treated patients.,ONJ is an adverse reaction entity
5.6 Osteonecrosis of the Jaw      Osteonecrosis of the jaw (ONJ) occurred in 1% of COMETRIQ-treated patients.,Jaw Osteonecrosis is not a named entity
"BOXED WARNING: WARNING: PERFORATIONS AND FISTULAS, and HEMORRHAGE    WARNING: PERFORATIONS AND FISTULAS, and HEMORRHAGE      Perforations and fistulas: Gastrointestinal perforations occurred in 3% and fistula formation in 1% of COMETRIQTM-treated patients.",% and is not a named entity
"BOXED WARNING: WARNING: PERFORATIONS AND FISTULAS, and HEMORRHAGE    WARNING: PERFORATIONS AND FISTULAS, and HEMORRHAGE      Perforations and fistulas: Gastrointestinal perforations occurred in 3% and fistula formation in 1% of COMETRIQTM-treated patients.",PERFORATIONS is an adverse reaction entity
"BOXED WARNING: WARNING: PERFORATIONS AND FISTULAS, and HEMORRHAGE    WARNING: PERFORATIONS AND FISTULAS, and HEMORRHAGE      Perforations and fistulas: Gastrointestinal perforations occurred in 3% and fistula formation in 1% of COMETRIQTM-treated patients.","FISTULAS , is not a named entity"
"BOXED WARNING: WARNING: PERFORATIONS AND FISTULAS, and HEMORRHAGE    WARNING: PERFORATIONS AND FISTULAS, and HEMORRHAGE      Perforations and fistulas: Gastrointestinal perforations occurred in 3% and fistula formation in 1% of COMETRIQTM-treated patients.",HEMORRHAGE is an adverse reaction entity
"BOXED WARNING: WARNING: PERFORATIONS AND FISTULAS, and HEMORRHAGE    WARNING: PERFORATIONS AND FISTULAS, and HEMORRHAGE      Perforations and fistulas: Gastrointestinal perforations occurred in 3% and fistula formation in 1% of COMETRIQTM-treated patients.",and is not a named entity
"BOXED WARNING: WARNING: PERFORATIONS AND FISTULAS, and HEMORRHAGE    WARNING: PERFORATIONS AND FISTULAS, and HEMORRHAGE      Perforations and fistulas: Gastrointestinal perforations occurred in 3% and fistula formation in 1% of COMETRIQTM-treated patients.",: Gastrointestinal is not a named entity
"BOXED WARNING: WARNING: PERFORATIONS AND FISTULAS, and HEMORRHAGE    WARNING: PERFORATIONS AND FISTULAS, and HEMORRHAGE      Perforations and fistulas: Gastrointestinal perforations occurred in 3% and fistula formation in 1% of COMETRIQTM-treated patients.",: is not a named entity
"BOXED WARNING: WARNING: PERFORATIONS AND FISTULAS, and HEMORRHAGE    WARNING: PERFORATIONS AND FISTULAS, and HEMORRHAGE      Perforations and fistulas: Gastrointestinal perforations occurred in 3% and fistula formation in 1% of COMETRIQTM-treated patients.",fistulas is an adverse reaction entity
"BOXED WARNING: WARNING: PERFORATIONS AND FISTULAS, and HEMORRHAGE    WARNING: PERFORATIONS AND FISTULAS, and HEMORRHAGE      Perforations and fistulas: Gastrointestinal perforations occurred in 3% and fistula formation in 1% of COMETRIQTM-treated patients.",Perforations is an adverse reaction entity
"BOXED WARNING: WARNING: PERFORATIONS AND FISTULAS, and HEMORRHAGE    WARNING: PERFORATIONS AND FISTULAS, and HEMORRHAGE      Perforations and fistulas: Gastrointestinal perforations occurred in 3% and fistula formation in 1% of COMETRIQTM-treated patients.",FISTULAS is an adverse reaction entity
"BOXED WARNING: WARNING: PERFORATIONS AND FISTULAS, and HEMORRHAGE    WARNING: PERFORATIONS AND FISTULAS, and HEMORRHAGE      Perforations and fistulas: Gastrointestinal perforations occurred in 3% and fistula formation in 1% of COMETRIQTM-treated patients.",and HEMORRHAGE WARNING is not a named entity
"BOXED WARNING: WARNING: PERFORATIONS AND FISTULAS, and HEMORRHAGE    WARNING: PERFORATIONS AND FISTULAS, and HEMORRHAGE      Perforations and fistulas: Gastrointestinal perforations occurred in 3% and fistula formation in 1% of COMETRIQTM-treated patients.",FISTULAS is an adverse reaction entity
"BOXED WARNING: WARNING: PERFORATIONS AND FISTULAS, and HEMORRHAGE    WARNING: PERFORATIONS AND FISTULAS, and HEMORRHAGE      Perforations and fistulas: Gastrointestinal perforations occurred in 3% and fistula formation in 1% of COMETRIQTM-treated patients.",PERFORATIONS is an adverse reaction entity
"BOXED WARNING: WARNING: PERFORATIONS AND FISTULAS, and HEMORRHAGE    WARNING: PERFORATIONS AND FISTULAS, and HEMORRHAGE      Perforations and fistulas: Gastrointestinal perforations occurred in 3% and fistula formation in 1% of COMETRIQTM-treated patients.",fistula formation is an adverse reaction entity
"BOXED WARNING: WARNING: PERFORATIONS AND FISTULAS, and HEMORRHAGE    WARNING: PERFORATIONS AND FISTULAS, and HEMORRHAGE      Perforations and fistulas: Gastrointestinal perforations occurred in 3% and fistula formation in 1% of COMETRIQTM-treated patients.",HEMORRHAGE is an adverse reaction entity
"BOXED WARNING: WARNING: PERFORATIONS AND FISTULAS, and HEMORRHAGE    WARNING: PERFORATIONS AND FISTULAS, and HEMORRHAGE      Perforations and fistulas: Gastrointestinal perforations occurred in 3% and fistula formation in 1% of COMETRIQTM-treated patients.",Gastrointestinal perforations is an adverse reaction entity
"BOXED WARNING: WARNING: PERFORATIONS AND FISTULAS, and HEMORRHAGE    WARNING: PERFORATIONS AND FISTULAS, and HEMORRHAGE      Perforations and fistulas: Gastrointestinal perforations occurred in 3% and fistula formation in 1% of COMETRIQTM-treated patients.",1 % is not a named entity
"BOXED WARNING: WARNING: PERFORATIONS AND FISTULAS, and HEMORRHAGE    WARNING: PERFORATIONS AND FISTULAS, and HEMORRHAGE      Perforations and fistulas: Gastrointestinal perforations occurred in 3% and fistula formation in 1% of COMETRIQTM-treated patients.",HEMORRHAGE Perforations and is not a named entity
"BOXED WARNING: WARNING: PERFORATIONS AND FISTULAS, and HEMORRHAGE    WARNING: PERFORATIONS AND FISTULAS, and HEMORRHAGE      Perforations and fistulas: Gastrointestinal perforations occurred in 3% and fistula formation in 1% of COMETRIQTM-treated patients.",in 3 is not a named entity
"BOXED WARNING: WARNING: PERFORATIONS AND FISTULAS, and HEMORRHAGE    WARNING: PERFORATIONS AND FISTULAS, and HEMORRHAGE      Perforations and fistulas: Gastrointestinal perforations occurred in 3% and fistula formation in 1% of COMETRIQTM-treated patients.",perforations occurred is not a named entity
"5.9 Reversible Posterior Leukoencephalopathy Syndrome      Reversible Posterior Leukoencephalopathy Syndrome (RPLS), a syndrome of subcortical vasogenic edema diagnosed by characteristic finding on MRI, occurred in one (<1%) patient.",by characteristic is not a named entity
"5.9 Reversible Posterior Leukoencephalopathy Syndrome      Reversible Posterior Leukoencephalopathy Syndrome (RPLS), a syndrome of subcortical vasogenic edema diagnosed by characteristic finding on MRI, occurred in one (<1%) patient.",RPLS is an adverse reaction entity
"5.9 Reversible Posterior Leukoencephalopathy Syndrome      Reversible Posterior Leukoencephalopathy Syndrome (RPLS), a syndrome of subcortical vasogenic edema diagnosed by characteristic finding on MRI, occurred in one (<1%) patient.",subcortical vasogenic edema is an adverse reaction entity
"5.9 Reversible Posterior Leukoencephalopathy Syndrome      Reversible Posterior Leukoencephalopathy Syndrome (RPLS), a syndrome of subcortical vasogenic edema diagnosed by characteristic finding on MRI, occurred in one (<1%) patient.",Leukoencephalopathy Syndrome ( is not a named entity
"5.9 Reversible Posterior Leukoencephalopathy Syndrome      Reversible Posterior Leukoencephalopathy Syndrome (RPLS), a syndrome of subcortical vasogenic edema diagnosed by characteristic finding on MRI, occurred in one (<1%) patient.",Reversible Posterior Leukoencephalopathy Syndrome is an adverse reaction entity
"5.9 Reversible Posterior Leukoencephalopathy Syndrome      Reversible Posterior Leukoencephalopathy Syndrome (RPLS), a syndrome of subcortical vasogenic edema diagnosed by characteristic finding on MRI, occurred in one (<1%) patient.",( RPLS is not a named entity
The incidence of Grade >=3 hemorrhagic events was higher in COMETRIQ-treated patients compared with placebo (3% vs. 1%).,hemorrhagic events is an adverse reaction entity
The incidence of Grade >=3 hemorrhagic events was higher in COMETRIQ-treated patients compared with placebo (3% vs. 1%).,incidence is not a named entity
"Table 3 Per-Patient Incidence of Hypertension in Protocol XL184-301      Hypertension, JNCStage                                                    COMETRIQN=211(%)  PlaceboN=107(%)        Normal: Grade 0: Systolic < 120 mmHg and Diastolic < 80 mmHg                   4             15             Pre-hypertension: Systolic >= 120 mmHg or Diastolic >= 80 mmHg                 34            54             Stage 1: Systolic >= 140 mmHg or Diastolic >= 90 mmHg                          46            25             Stage 2: Systolic >= 160 mmHg or Diastolic >= 100 mmHg                         15            5              Malignant: Diastolic >= 120 mmHg                                               0             0",< 120 mmHg is not a named entity
"Table 3 Per-Patient Incidence of Hypertension in Protocol XL184-301      Hypertension, JNCStage                                                    COMETRIQN=211(%)  PlaceboN=107(%)        Normal: Grade 0: Systolic < 120 mmHg and Diastolic < 80 mmHg                   4             15             Pre-hypertension: Systolic >= 120 mmHg or Diastolic >= 80 mmHg                 34            54             Stage 1: Systolic >= 140 mmHg or Diastolic >= 90 mmHg                          46            25             Stage 2: Systolic >= 160 mmHg or Diastolic >= 100 mmHg                         15            5              Malignant: Diastolic >= 120 mmHg                                               0             0",> = is not a named entity
"Table 3 Per-Patient Incidence of Hypertension in Protocol XL184-301      Hypertension, JNCStage                                                    COMETRIQN=211(%)  PlaceboN=107(%)        Normal: Grade 0: Systolic < 120 mmHg and Diastolic < 80 mmHg                   4             15             Pre-hypertension: Systolic >= 120 mmHg or Diastolic >= 80 mmHg                 34            54             Stage 1: Systolic >= 140 mmHg or Diastolic >= 90 mmHg                          46            25             Stage 2: Systolic >= 160 mmHg or Diastolic >= 100 mmHg                         15            5              Malignant: Diastolic >= 120 mmHg                                               0             0",Hypertension is an adverse reaction entity
"Table 3 Per-Patient Incidence of Hypertension in Protocol XL184-301      Hypertension, JNCStage                                                    COMETRIQN=211(%)  PlaceboN=107(%)        Normal: Grade 0: Systolic < 120 mmHg and Diastolic < 80 mmHg                   4             15             Pre-hypertension: Systolic >= 120 mmHg or Diastolic >= 80 mmHg                 34            54             Stage 1: Systolic >= 140 mmHg or Diastolic >= 90 mmHg                          46            25             Stage 2: Systolic >= 160 mmHg or Diastolic >= 100 mmHg                         15            5              Malignant: Diastolic >= 120 mmHg                                               0             0",Pre-hypertension is an adverse reaction entity
"Table 3 Per-Patient Incidence of Hypertension in Protocol XL184-301      Hypertension, JNCStage                                                    COMETRIQN=211(%)  PlaceboN=107(%)        Normal: Grade 0: Systolic < 120 mmHg and Diastolic < 80 mmHg                   4             15             Pre-hypertension: Systolic >= 120 mmHg or Diastolic >= 80 mmHg                 34            54             Stage 1: Systolic >= 140 mmHg or Diastolic >= 90 mmHg                          46            25             Stage 2: Systolic >= 160 mmHg or Diastolic >= 100 mmHg                         15            5              Malignant: Diastolic >= 120 mmHg                                               0             0",15 5 is not a named entity
"Table 3 Per-Patient Incidence of Hypertension in Protocol XL184-301      Hypertension, JNCStage                                                    COMETRIQN=211(%)  PlaceboN=107(%)        Normal: Grade 0: Systolic < 120 mmHg and Diastolic < 80 mmHg                   4             15             Pre-hypertension: Systolic >= 120 mmHg or Diastolic >= 80 mmHg                 34            54             Stage 1: Systolic >= 140 mmHg or Diastolic >= 90 mmHg                          46            25             Stage 2: Systolic >= 160 mmHg or Diastolic >= 100 mmHg                         15            5              Malignant: Diastolic >= 120 mmHg                                               0             0",Hypertension is an adverse reaction entity
*  Perforations and Fistulas: Gastrointestinal perforations occurred in 3% and fistula formation in 1% of COMETRIQ-treated patients.,fistula formation in is not a named entity
*  Perforations and Fistulas: Gastrointestinal perforations occurred in 3% and fistula formation in 1% of COMETRIQ-treated patients.,in 3 is not a named entity
*  Perforations and Fistulas: Gastrointestinal perforations occurred in 3% and fistula formation in 1% of COMETRIQ-treated patients.,Gastrointestinal perforations is an adverse reaction entity
*  Perforations and Fistulas: Gastrointestinal perforations occurred in 3% and fistula formation in 1% of COMETRIQ-treated patients.,fistula formation is an adverse reaction entity
*  Perforations and Fistulas: Gastrointestinal perforations occurred in 3% and fistula formation in 1% of COMETRIQ-treated patients.,Fistulas is an adverse reaction entity
*  Perforations and Fistulas: Gastrointestinal perforations occurred in 3% and fistula formation in 1% of COMETRIQ-treated patients.,% and fistula is not a named entity
*  Perforations and Fistulas: Gastrointestinal perforations occurred in 3% and fistula formation in 1% of COMETRIQ-treated patients.,Perforations is an adverse reaction entity
*  Perforations and Fistulas: Gastrointestinal perforations occurred in 3% and fistula formation in 1% of COMETRIQ-treated patients.,% of is not a named entity
"5.5 Hypertension      COMETRIQ treatment results in an increased incidence of treatment-emergent hypertension with Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (modified JNC criteria) stage 1 or 2 hypertension identified in 61% in COMETRIQ-treated patients compared with 30% of placebo-treated patients in the randomized trial.",hypertension is an adverse reaction entity
"5.5 Hypertension      COMETRIQ treatment results in an increased incidence of treatment-emergent hypertension with Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (modified JNC criteria) stage 1 or 2 hypertension identified in 61% in COMETRIQ-treated patients compared with 30% of placebo-treated patients in the randomized trial.",hypertension is an adverse reaction entity
"5.5 Hypertension      COMETRIQ treatment results in an increased incidence of treatment-emergent hypertension with Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (modified JNC criteria) stage 1 or 2 hypertension identified in 61% in COMETRIQ-treated patients compared with 30% of placebo-treated patients in the randomized trial.",with Joint National is not a named entity
"5.5 Hypertension      COMETRIQ treatment results in an increased incidence of treatment-emergent hypertension with Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (modified JNC criteria) stage 1 or 2 hypertension identified in 61% in COMETRIQ-treated patients compared with 30% of placebo-treated patients in the randomized trial.",High is not a named entity
"The most common laboratory abnormalities (>25%) were increased AST, increased ALT, lymphopenia, increased ALP, hypocalcemia, neutropenia, thrombocytopenia, hypophosphatemia, and hyperbilirubinemia.",lymphopenia is an adverse reaction entity
"The most common laboratory abnormalities (>25%) were increased AST, increased ALT, lymphopenia, increased ALP, hypocalcemia, neutropenia, thrombocytopenia, hypophosphatemia, and hyperbilirubinemia.",hyperbilirubinemia is an adverse reaction entity
"The most common laboratory abnormalities (>25%) were increased AST, increased ALT, lymphopenia, increased ALP, hypocalcemia, neutropenia, thrombocytopenia, hypophosphatemia, and hyperbilirubinemia.",", increased ALP is not a named entity"
"The most common laboratory abnormalities (>25%) were increased AST, increased ALT, lymphopenia, increased ALP, hypocalcemia, neutropenia, thrombocytopenia, hypophosphatemia, and hyperbilirubinemia.",thrombocytopenia is an adverse reaction entity
"The most common laboratory abnormalities (>25%) were increased AST, increased ALT, lymphopenia, increased ALP, hypocalcemia, neutropenia, thrombocytopenia, hypophosphatemia, and hyperbilirubinemia.",", is not a named entity"
"The most common laboratory abnormalities (>25%) were increased AST, increased ALT, lymphopenia, increased ALP, hypocalcemia, neutropenia, thrombocytopenia, hypophosphatemia, and hyperbilirubinemia.",", increased is not a named entity"
"The most common laboratory abnormalities (>25%) were increased AST, increased ALT, lymphopenia, increased ALP, hypocalcemia, neutropenia, thrombocytopenia, hypophosphatemia, and hyperbilirubinemia.",hypocalcemia is an adverse reaction entity
"The most common laboratory abnormalities (>25%) were increased AST, increased ALT, lymphopenia, increased ALP, hypocalcemia, neutropenia, thrombocytopenia, hypophosphatemia, and hyperbilirubinemia.",The is not a named entity
"The most common laboratory abnormalities (>25%) were increased AST, increased ALT, lymphopenia, increased ALP, hypocalcemia, neutropenia, thrombocytopenia, hypophosphatemia, and hyperbilirubinemia.",increased ALP is an adverse reaction entity
"The most common laboratory abnormalities (>25%) were increased AST, increased ALT, lymphopenia, increased ALP, hypocalcemia, neutropenia, thrombocytopenia, hypophosphatemia, and hyperbilirubinemia.",were increased AST is not a named entity
"The most common laboratory abnormalities (>25%) were increased AST, increased ALT, lymphopenia, increased ALP, hypocalcemia, neutropenia, thrombocytopenia, hypophosphatemia, and hyperbilirubinemia.",neutropenia is an adverse reaction entity
"The most common laboratory abnormalities (>25%) were increased AST, increased ALT, lymphopenia, increased ALP, hypocalcemia, neutropenia, thrombocytopenia, hypophosphatemia, and hyperbilirubinemia.",The most common is not a named entity
"The most common laboratory abnormalities (>25%) were increased AST, increased ALT, lymphopenia, increased ALP, hypocalcemia, neutropenia, thrombocytopenia, hypophosphatemia, and hyperbilirubinemia.",most common laboratory is not a named entity
"The most common laboratory abnormalities (>25%) were increased AST, increased ALT, lymphopenia, increased ALP, hypocalcemia, neutropenia, thrombocytopenia, hypophosphatemia, and hyperbilirubinemia.",hypophosphatemia is an adverse reaction entity
"The most common laboratory abnormalities (>25%) were increased AST, increased ALT, lymphopenia, increased ALP, hypocalcemia, neutropenia, thrombocytopenia, hypophosphatemia, and hyperbilirubinemia.",increased AST is an adverse reaction entity
"The most common laboratory abnormalities (>25%) were increased AST, increased ALT, lymphopenia, increased ALP, hypocalcemia, neutropenia, thrombocytopenia, hypophosphatemia, and hyperbilirubinemia.",increased ALT is an adverse reaction entity
"The most common laboratory abnormalities (>25%) were increased AST, increased ALT, lymphopenia, increased ALP, hypocalcemia, neutropenia, thrombocytopenia, hypophosphatemia, and hyperbilirubinemia.",were is not a named entity
"The most common laboratory abnormalities (>25%) were increased AST, increased ALT, lymphopenia, increased ALP, hypocalcemia, neutropenia, thrombocytopenia, hypophosphatemia, and hyperbilirubinemia.",25 % ) is not a named entity
"EXCERPT:     WARNING: PERFORATIONS AND FISTULAS, andHEMORRHAGE         See full prescribing information for complete boxed warning.",FISTULAS is an adverse reaction entity
"EXCERPT:     WARNING: PERFORATIONS AND FISTULAS, andHEMORRHAGE         See full prescribing information for complete boxed warning.",See full prescribing is not a named entity
"EXCERPT:     WARNING: PERFORATIONS AND FISTULAS, andHEMORRHAGE         See full prescribing information for complete boxed warning.",warning is not a named entity
"EXCERPT:     WARNING: PERFORATIONS AND FISTULAS, andHEMORRHAGE         See full prescribing information for complete boxed warning.",PERFORATIONS is an adverse reaction entity
"EXCERPT:     WARNING: PERFORATIONS AND FISTULAS, andHEMORRHAGE         See full prescribing information for complete boxed warning.",HEMORRHAGE is an adverse reaction entity
"EXCERPT:     WARNING: PERFORATIONS AND FISTULAS, andHEMORRHAGE         See full prescribing information for complete boxed warning.",full prescribing information is not a named entity
"*  Palmar-plantar Erythrodysesthesia syndrome (PPES): Interrupt COMETRIQ, decrease dose.",Interrupt COMETRIQ is not a named entity
"*  Palmar-plantar Erythrodysesthesia syndrome (PPES): Interrupt COMETRIQ, decrease dose.",PPES is an adverse reaction entity
"*  Palmar-plantar Erythrodysesthesia syndrome (PPES): Interrupt COMETRIQ, decrease dose.",* is not a named entity
"*  Palmar-plantar Erythrodysesthesia syndrome (PPES): Interrupt COMETRIQ, decrease dose.",Palmar-plantar Erythrodysesthesia syndrome is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Thrombotic Events: Discontinue COMETRIQ for myocardial infarction, cerebral infarction, or other serious arterial thromboembolic events.",Thrombotic Events is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Thrombotic Events: Discontinue COMETRIQ for myocardial infarction, cerebral infarction, or other serious arterial thromboembolic events.",: is not a named entity
"Adverse reactions which occurred in >= 25% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 5% included, in order of decreasing frequency: diarrhea, stomatitis, palmar-plantar erythrodysesthesia syndrome (PPES), decreased weight, decreased appetite, nausea, fatigue, oral pain, hair color changes, dysgeusia, hypertension, abdominal pain, and constipation.",= 25 is not a named entity
"Adverse reactions which occurred in >= 25% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 5% included, in order of decreasing frequency: diarrhea, stomatitis, palmar-plantar erythrodysesthesia syndrome (PPES), decreased weight, decreased appetite, nausea, fatigue, oral pain, hair color changes, dysgeusia, hypertension, abdominal pain, and constipation.",abdominal pain is an adverse reaction entity
"Adverse reactions which occurred in >= 25% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 5% included, in order of decreasing frequency: diarrhea, stomatitis, palmar-plantar erythrodysesthesia syndrome (PPES), decreased weight, decreased appetite, nausea, fatigue, oral pain, hair color changes, dysgeusia, hypertension, abdominal pain, and constipation.",a is not a named entity
"Adverse reactions which occurred in >= 25% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 5% included, in order of decreasing frequency: diarrhea, stomatitis, palmar-plantar erythrodysesthesia syndrome (PPES), decreased weight, decreased appetite, nausea, fatigue, oral pain, hair color changes, dysgeusia, hypertension, abdominal pain, and constipation.","included , is not a named entity"
"Adverse reactions which occurred in >= 25% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 5% included, in order of decreasing frequency: diarrhea, stomatitis, palmar-plantar erythrodysesthesia syndrome (PPES), decreased weight, decreased appetite, nausea, fatigue, oral pain, hair color changes, dysgeusia, hypertension, abdominal pain, and constipation.",PPES is an adverse reaction entity
"Adverse reactions which occurred in >= 25% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 5% included, in order of decreasing frequency: diarrhea, stomatitis, palmar-plantar erythrodysesthesia syndrome (PPES), decreased weight, decreased appetite, nausea, fatigue, oral pain, hair color changes, dysgeusia, hypertension, abdominal pain, and constipation.",erythrodysesthesia syndrome ( is not a named entity
"Adverse reactions which occurred in >= 25% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 5% included, in order of decreasing frequency: diarrhea, stomatitis, palmar-plantar erythrodysesthesia syndrome (PPES), decreased weight, decreased appetite, nausea, fatigue, oral pain, hair color changes, dysgeusia, hypertension, abdominal pain, and constipation.",syndrome ( is not a named entity
"Adverse reactions which occurred in >= 25% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 5% included, in order of decreasing frequency: diarrhea, stomatitis, palmar-plantar erythrodysesthesia syndrome (PPES), decreased weight, decreased appetite, nausea, fatigue, oral pain, hair color changes, dysgeusia, hypertension, abdominal pain, and constipation.",hypertension is an adverse reaction entity
"Adverse reactions which occurred in >= 25% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 5% included, in order of decreasing frequency: diarrhea, stomatitis, palmar-plantar erythrodysesthesia syndrome (PPES), decreased weight, decreased appetite, nausea, fatigue, oral pain, hair color changes, dysgeusia, hypertension, abdominal pain, and constipation.",: diarrhea is not a named entity
"Adverse reactions which occurred in >= 25% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 5% included, in order of decreasing frequency: diarrhea, stomatitis, palmar-plantar erythrodysesthesia syndrome (PPES), decreased weight, decreased appetite, nausea, fatigue, oral pain, hair color changes, dysgeusia, hypertension, abdominal pain, and constipation.",included is not a named entity
"Adverse reactions which occurred in >= 25% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 5% included, in order of decreasing frequency: diarrhea, stomatitis, palmar-plantar erythrodysesthesia syndrome (PPES), decreased weight, decreased appetite, nausea, fatigue, oral pain, hair color changes, dysgeusia, hypertension, abdominal pain, and constipation.",> = is not a named entity
"Adverse reactions which occurred in >= 25% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 5% included, in order of decreasing frequency: diarrhea, stomatitis, palmar-plantar erythrodysesthesia syndrome (PPES), decreased weight, decreased appetite, nausea, fatigue, oral pain, hair color changes, dysgeusia, hypertension, abdominal pain, and constipation.",diarrhea is an adverse reaction entity
"Adverse reactions which occurred in >= 25% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 5% included, in order of decreasing frequency: diarrhea, stomatitis, palmar-plantar erythrodysesthesia syndrome (PPES), decreased weight, decreased appetite, nausea, fatigue, oral pain, hair color changes, dysgeusia, hypertension, abdominal pain, and constipation.",oral pain is an adverse reaction entity
"Adverse reactions which occurred in >= 25% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 5% included, in order of decreasing frequency: diarrhea, stomatitis, palmar-plantar erythrodysesthesia syndrome (PPES), decreased weight, decreased appetite, nausea, fatigue, oral pain, hair color changes, dysgeusia, hypertension, abdominal pain, and constipation.",decreased appetite is an adverse reaction entity
"Adverse reactions which occurred in >= 25% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 5% included, in order of decreasing frequency: diarrhea, stomatitis, palmar-plantar erythrodysesthesia syndrome (PPES), decreased weight, decreased appetite, nausea, fatigue, oral pain, hair color changes, dysgeusia, hypertension, abdominal pain, and constipation.","appetite , is not a named entity"
"Adverse reactions which occurred in >= 25% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 5% included, in order of decreasing frequency: diarrhea, stomatitis, palmar-plantar erythrodysesthesia syndrome (PPES), decreased weight, decreased appetite, nausea, fatigue, oral pain, hair color changes, dysgeusia, hypertension, abdominal pain, and constipation.",", abdominal pain is not a named entity"
"Adverse reactions which occurred in >= 25% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 5% included, in order of decreasing frequency: diarrhea, stomatitis, palmar-plantar erythrodysesthesia syndrome (PPES), decreased weight, decreased appetite, nausea, fatigue, oral pain, hair color changes, dysgeusia, hypertension, abdominal pain, and constipation.",dysgeusia is an adverse reaction entity
"Adverse reactions which occurred in >= 25% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 5% included, in order of decreasing frequency: diarrhea, stomatitis, palmar-plantar erythrodysesthesia syndrome (PPES), decreased weight, decreased appetite, nausea, fatigue, oral pain, hair color changes, dysgeusia, hypertension, abdominal pain, and constipation.",fatigue is an adverse reaction entity
"Adverse reactions which occurred in >= 25% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 5% included, in order of decreasing frequency: diarrhea, stomatitis, palmar-plantar erythrodysesthesia syndrome (PPES), decreased weight, decreased appetite, nausea, fatigue, oral pain, hair color changes, dysgeusia, hypertension, abdominal pain, and constipation.",in is not a named entity
"Adverse reactions which occurred in >= 25% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 5% included, in order of decreasing frequency: diarrhea, stomatitis, palmar-plantar erythrodysesthesia syndrome (PPES), decreased weight, decreased appetite, nausea, fatigue, oral pain, hair color changes, dysgeusia, hypertension, abdominal pain, and constipation.",decreased weight is an adverse reaction entity
"Adverse reactions which occurred in >= 25% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 5% included, in order of decreasing frequency: diarrhea, stomatitis, palmar-plantar erythrodysesthesia syndrome (PPES), decreased weight, decreased appetite, nausea, fatigue, oral pain, hair color changes, dysgeusia, hypertension, abdominal pain, and constipation.",nausea is an adverse reaction entity
"Adverse reactions which occurred in >= 25% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 5% included, in order of decreasing frequency: diarrhea, stomatitis, palmar-plantar erythrodysesthesia syndrome (PPES), decreased weight, decreased appetite, nausea, fatigue, oral pain, hair color changes, dysgeusia, hypertension, abdominal pain, and constipation.",stomatitis is an adverse reaction entity
"Adverse reactions which occurred in >= 25% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 5% included, in order of decreasing frequency: diarrhea, stomatitis, palmar-plantar erythrodysesthesia syndrome (PPES), decreased weight, decreased appetite, nausea, fatigue, oral pain, hair color changes, dysgeusia, hypertension, abdominal pain, and constipation.",constipation is an adverse reaction entity
"Adverse reactions which occurred in >= 25% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 5% included, in order of decreasing frequency: diarrhea, stomatitis, palmar-plantar erythrodysesthesia syndrome (PPES), decreased weight, decreased appetite, nausea, fatigue, oral pain, hair color changes, dysgeusia, hypertension, abdominal pain, and constipation.","diarrhea , stomatitis is not a named entity"
"Adverse reactions which occurred in >= 25% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 5% included, in order of decreasing frequency: diarrhea, stomatitis, palmar-plantar erythrodysesthesia syndrome (PPES), decreased weight, decreased appetite, nausea, fatigue, oral pain, hair color changes, dysgeusia, hypertension, abdominal pain, and constipation.",in the is not a named entity
"Adverse reactions which occurred in >= 25% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 5% included, in order of decreasing frequency: diarrhea, stomatitis, palmar-plantar erythrodysesthesia syndrome (PPES), decreased weight, decreased appetite, nausea, fatigue, oral pain, hair color changes, dysgeusia, hypertension, abdominal pain, and constipation.",palmar-plantar erythrodysesthesia syndrome is an adverse reaction entity
"Adverse reactions which occurred in >= 25% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 5% included, in order of decreasing frequency: diarrhea, stomatitis, palmar-plantar erythrodysesthesia syndrome (PPES), decreased weight, decreased appetite, nausea, fatigue, oral pain, hair color changes, dysgeusia, hypertension, abdominal pain, and constipation.",hair color changes is an adverse reaction entity
"Adverse reactions which occurred in >= 25% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of >= 5% included, in order of decreasing frequency: diarrhea, stomatitis, palmar-plantar erythrodysesthesia syndrome (PPES), decreased weight, decreased appetite, nausea, fatigue, oral pain, hair color changes, dysgeusia, hypertension, abdominal pain, and constipation.",", dysgeusia , is not a named entity"
"The most common laboratory abnormalities (>=25%) are increased AST, increased ALT, lymphopenia, increased alkaline phosphatase, hypocalcemia, neutropenia, thrombocytopenia, hypophosphatemia, and hyperbilirubinemia.",", is not a named entity"
"The most common laboratory abnormalities (>=25%) are increased AST, increased ALT, lymphopenia, increased alkaline phosphatase, hypocalcemia, neutropenia, thrombocytopenia, hypophosphatemia, and hyperbilirubinemia.","phosphatase , is not a named entity"
"The most common laboratory abnormalities (>=25%) are increased AST, increased ALT, lymphopenia, increased alkaline phosphatase, hypocalcemia, neutropenia, thrombocytopenia, hypophosphatemia, and hyperbilirubinemia.",hyperbilirubinemia is an adverse reaction entity
"The most common laboratory abnormalities (>=25%) are increased AST, increased ALT, lymphopenia, increased alkaline phosphatase, hypocalcemia, neutropenia, thrombocytopenia, hypophosphatemia, and hyperbilirubinemia.",thrombocytopenia is an adverse reaction entity
"The most common laboratory abnormalities (>=25%) are increased AST, increased ALT, lymphopenia, increased alkaline phosphatase, hypocalcemia, neutropenia, thrombocytopenia, hypophosphatemia, and hyperbilirubinemia.",hypophosphatemia is an adverse reaction entity
"The most common laboratory abnormalities (>=25%) are increased AST, increased ALT, lymphopenia, increased alkaline phosphatase, hypocalcemia, neutropenia, thrombocytopenia, hypophosphatemia, and hyperbilirubinemia.",hypocalcemia is an adverse reaction entity
"The most common laboratory abnormalities (>=25%) are increased AST, increased ALT, lymphopenia, increased alkaline phosphatase, hypocalcemia, neutropenia, thrombocytopenia, hypophosphatemia, and hyperbilirubinemia.","thrombocytopenia , hypophosphatemia is not a named entity"
"The most common laboratory abnormalities (>=25%) are increased AST, increased ALT, lymphopenia, increased alkaline phosphatase, hypocalcemia, neutropenia, thrombocytopenia, hypophosphatemia, and hyperbilirubinemia.",are increased is not a named entity
"The most common laboratory abnormalities (>=25%) are increased AST, increased ALT, lymphopenia, increased alkaline phosphatase, hypocalcemia, neutropenia, thrombocytopenia, hypophosphatemia, and hyperbilirubinemia.",lymphopenia is an adverse reaction entity
"The most common laboratory abnormalities (>=25%) are increased AST, increased ALT, lymphopenia, increased alkaline phosphatase, hypocalcemia, neutropenia, thrombocytopenia, hypophosphatemia, and hyperbilirubinemia.",increased alkaline phosphatase is an adverse reaction entity
"The most common laboratory abnormalities (>=25%) are increased AST, increased ALT, lymphopenia, increased alkaline phosphatase, hypocalcemia, neutropenia, thrombocytopenia, hypophosphatemia, and hyperbilirubinemia.",are increased is not a named entity
"The most common laboratory abnormalities (>=25%) are increased AST, increased ALT, lymphopenia, increased alkaline phosphatase, hypocalcemia, neutropenia, thrombocytopenia, hypophosphatemia, and hyperbilirubinemia.",increased AST is an adverse reaction entity
"The most common laboratory abnormalities (>=25%) are increased AST, increased ALT, lymphopenia, increased alkaline phosphatase, hypocalcemia, neutropenia, thrombocytopenia, hypophosphatemia, and hyperbilirubinemia.",( > =25 is not a named entity
"The most common laboratory abnormalities (>=25%) are increased AST, increased ALT, lymphopenia, increased alkaline phosphatase, hypocalcemia, neutropenia, thrombocytopenia, hypophosphatemia, and hyperbilirubinemia.",neutropenia is an adverse reaction entity
"The most common laboratory abnormalities (>=25%) are increased AST, increased ALT, lymphopenia, increased alkaline phosphatase, hypocalcemia, neutropenia, thrombocytopenia, hypophosphatemia, and hyperbilirubinemia.",", is not a named entity"
"The most common laboratory abnormalities (>=25%) are increased AST, increased ALT, lymphopenia, increased alkaline phosphatase, hypocalcemia, neutropenia, thrombocytopenia, hypophosphatemia, and hyperbilirubinemia.",and is not a named entity
"The most common laboratory abnormalities (>=25%) are increased AST, increased ALT, lymphopenia, increased alkaline phosphatase, hypocalcemia, neutropenia, thrombocytopenia, hypophosphatemia, and hyperbilirubinemia.","hypophosphatemia , is not a named entity"
"The most common laboratory abnormalities (>=25%) are increased AST, increased ALT, lymphopenia, increased alkaline phosphatase, hypocalcemia, neutropenia, thrombocytopenia, hypophosphatemia, and hyperbilirubinemia.",increased ALT is an adverse reaction entity
"Cabozantinib was embryolethal in rats at exposures below the recommended human dose, with increased incidences of skeletal variations in rats and visceral variations and malformations in rabbits.",human dose is not a named entity
"Cabozantinib was embryolethal in rats at exposures below the recommended human dose, with increased incidences of skeletal variations in rats and visceral variations and malformations in rabbits.",was embryolethal is not a named entity
"Cabozantinib was embryolethal in rats at exposures below the recommended human dose, with increased incidences of skeletal variations in rats and visceral variations and malformations in rabbits.",rats at exposures is not a named entity
"Cabozantinib was embryolethal in rats at exposures below the recommended human dose, with increased incidences of skeletal variations in rats and visceral variations and malformations in rabbits.",visceral variations is an adverse reaction entity
"Cabozantinib was embryolethal in rats at exposures below the recommended human dose, with increased incidences of skeletal variations in rats and visceral variations and malformations in rabbits.",visceral malformations is an adverse reaction entity
"Cabozantinib was embryolethal in rats at exposures below the recommended human dose, with increased incidences of skeletal variations in rats and visceral variations and malformations in rabbits.",skeletal variations is an adverse reaction entity
"Cabozantinib was embryolethal in rats at exposures below the recommended human dose, with increased incidences of skeletal variations in rats and visceral variations and malformations in rabbits.",embryolethal is an adverse reaction entity
"Cabozantinib was embryolethal in rats at exposures below the recommended human dose, with increased incidences of skeletal variations in rats and visceral variations and malformations in rabbits.",variations and malformations is not a named entity
"There was considerable variation in risk of suicidality among drugs, but a tendency toward an increase in the younger patients for almost all drugs studied.",a tendency toward is not a named entity
"There was considerable variation in risk of suicidality among drugs, but a tendency toward an increase in the younger patients for almost all drugs studied.",suicidality is an adverse reaction entity
"*     Serotonin Syndrome: Serotonin syndrome has been reported with SSRIs and SNRIs, including with PRISTIQ, both when taken alone, but especially when co-administered with other serotonergic agents (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's Wort).",other serotonergic agents is not a named entity
"*     Serotonin Syndrome: Serotonin syndrome has been reported with SSRIs and SNRIs, including with PRISTIQ, both when taken alone, but especially when co-administered with other serotonergic agents (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's Wort).",agents ( including is not a named entity
"*     Serotonin Syndrome: Serotonin syndrome has been reported with SSRIs and SNRIs, including with PRISTIQ, both when taken alone, but especially when co-administered with other serotonergic agents (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's Wort).",Serotonin Syndrome is an adverse reaction entity
"*     Serotonin Syndrome: Serotonin syndrome has been reported with SSRIs and SNRIs, including with PRISTIQ, both when taken alone, but especially when co-administered with other serotonergic agents (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's Wort).",Serotonin syndrome is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *     Clinical Worsening/Suicide Risk: Monitor for clinical worsening and suicide risk (  5.1  ).,Suicide Risk is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *     Clinical Worsening/Suicide Risk: Monitor for clinical worsening and suicide risk (  5.1  ).,suicide is not a named entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *     Clinical Worsening/Suicide Risk: Monitor for clinical worsening and suicide risk (  5.1  ).,Clinical Worsening is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *     Clinical Worsening/Suicide Risk: Monitor for clinical worsening and suicide risk (  5.1  ).,5 WARNINGS is not a named entity
*     Elevated Blood Pressure: Control hypertension before initiating treatment.,: Control is not a named entity
*     Elevated Blood Pressure: Control hypertension before initiating treatment.,Elevated Blood Pressure is an adverse reaction entity
"Lipids         Elevations in fasting serum total cholesterol, LDL (low density lipoproteins) cholesterol, and triglycerides occurred in the controlled studies.",Elevations in fasting serum LDL is an adverse reaction entity
"Lipids         Elevations in fasting serum total cholesterol, LDL (low density lipoproteins) cholesterol, and triglycerides occurred in the controlled studies.",LDL is not a named entity
"Lipids         Elevations in fasting serum total cholesterol, LDL (low density lipoproteins) cholesterol, and triglycerides occurred in the controlled studies.",Elevations in fasting serum low density lipoproteins is an adverse reaction entity
"Lipids         Elevations in fasting serum total cholesterol, LDL (low density lipoproteins) cholesterol, and triglycerides occurred in the controlled studies.",controlled is not a named entity
"Lipids         Elevations in fasting serum total cholesterol, LDL (low density lipoproteins) cholesterol, and triglycerides occurred in the controlled studies.","cholesterol , LDL is not a named entity"
"Lipids         Elevations in fasting serum total cholesterol, LDL (low density lipoproteins) cholesterol, and triglycerides occurred in the controlled studies.",Elevations in fasting serum triglycerides is an adverse reaction entity
"Lipids         Elevations in fasting serum total cholesterol, LDL (low density lipoproteins) cholesterol, and triglycerides occurred in the controlled studies.",controlled studies is not a named entity
"Lipids         Elevations in fasting serum total cholesterol, LDL (low density lipoproteins) cholesterol, and triglycerides occurred in the controlled studies.",Elevations in fasting serum total cholesterol is an adverse reaction entity
"Lipids         Elevations in fasting serum total cholesterol, LDL (low density lipoproteins) cholesterol, and triglycerides occurred in the controlled studies.",", is not a named entity"
"Lipids         Elevations in fasting serum total cholesterol, LDL (low density lipoproteins) cholesterol, and triglycerides occurred in the controlled studies.",Elevations in fasting serum cholesterol is an adverse reaction entity
"There were suicides in the adult studies, but the number was not sufficient to reach any conclusion about drug effect on suicide.",suicides is an adverse reaction entity
"There were suicides in the adult studies, but the number was not sufficient to reach any conclusion about drug effect on suicide.",the adult studies is not a named entity
5.10 Interstitial Lung Disease and Eosinophilic Pneumonia      Interstitial lung disease and eosinophilic pneumonia associated with venlafaxine (the parent drug of PRISTIQ) therapy have been rarely reported.,the parent is not a named entity
5.10 Interstitial Lung Disease and Eosinophilic Pneumonia      Interstitial lung disease and eosinophilic pneumonia associated with venlafaxine (the parent drug of PRISTIQ) therapy have been rarely reported.,eosinophilic pneumonia is an adverse reaction entity
5.10 Interstitial Lung Disease and Eosinophilic Pneumonia      Interstitial lung disease and eosinophilic pneumonia associated with venlafaxine (the parent drug of PRISTIQ) therapy have been rarely reported.,Interstitial lung disease is an adverse reaction entity
5.10 Interstitial Lung Disease and Eosinophilic Pneumonia      Interstitial lung disease and eosinophilic pneumonia associated with venlafaxine (the parent drug of PRISTIQ) therapy have been rarely reported.,pneumonia is not a named entity
"Common adverse reactions in placebo-controlled MDD studies       The most commonly observed adverse reactions in PRISTIQ treated MDD patients in pre-marketing pooled 8-week, placebo-controlled, fixed-dose studies (incidence >= 5% and at least twice the rate of placebo in the 50 or 100 mg dose groups) were: nausea, dizziness, insomnia, hyperhidrosis, constipation, somnolence, decreased appetite, anxiety, and specific male sexual function disorders.",dizziness is an adverse reaction entity
"Common adverse reactions in placebo-controlled MDD studies       The most commonly observed adverse reactions in PRISTIQ treated MDD patients in pre-marketing pooled 8-week, placebo-controlled, fixed-dose studies (incidence >= 5% and at least twice the rate of placebo in the 50 or 100 mg dose groups) were: nausea, dizziness, insomnia, hyperhidrosis, constipation, somnolence, decreased appetite, anxiety, and specific male sexual function disorders.",decreased appetite is an adverse reaction entity
"Common adverse reactions in placebo-controlled MDD studies       The most commonly observed adverse reactions in PRISTIQ treated MDD patients in pre-marketing pooled 8-week, placebo-controlled, fixed-dose studies (incidence >= 5% and at least twice the rate of placebo in the 50 or 100 mg dose groups) were: nausea, dizziness, insomnia, hyperhidrosis, constipation, somnolence, decreased appetite, anxiety, and specific male sexual function disorders.",placebo in the is not a named entity
"Common adverse reactions in placebo-controlled MDD studies       The most commonly observed adverse reactions in PRISTIQ treated MDD patients in pre-marketing pooled 8-week, placebo-controlled, fixed-dose studies (incidence >= 5% and at least twice the rate of placebo in the 50 or 100 mg dose groups) were: nausea, dizziness, insomnia, hyperhidrosis, constipation, somnolence, decreased appetite, anxiety, and specific male sexual function disorders.",sexual is not a named entity
"Common adverse reactions in placebo-controlled MDD studies       The most commonly observed adverse reactions in PRISTIQ treated MDD patients in pre-marketing pooled 8-week, placebo-controlled, fixed-dose studies (incidence >= 5% and at least twice the rate of placebo in the 50 or 100 mg dose groups) were: nausea, dizziness, insomnia, hyperhidrosis, constipation, somnolence, decreased appetite, anxiety, and specific male sexual function disorders.",anxiety is an adverse reaction entity
"Common adverse reactions in placebo-controlled MDD studies       The most commonly observed adverse reactions in PRISTIQ treated MDD patients in pre-marketing pooled 8-week, placebo-controlled, fixed-dose studies (incidence >= 5% and at least twice the rate of placebo in the 50 or 100 mg dose groups) were: nausea, dizziness, insomnia, hyperhidrosis, constipation, somnolence, decreased appetite, anxiety, and specific male sexual function disorders.",", constipation is not a named entity"
"Common adverse reactions in placebo-controlled MDD studies       The most commonly observed adverse reactions in PRISTIQ treated MDD patients in pre-marketing pooled 8-week, placebo-controlled, fixed-dose studies (incidence >= 5% and at least twice the rate of placebo in the 50 or 100 mg dose groups) were: nausea, dizziness, insomnia, hyperhidrosis, constipation, somnolence, decreased appetite, anxiety, and specific male sexual function disorders.",Common adverse is not a named entity
"Common adverse reactions in placebo-controlled MDD studies       The most commonly observed adverse reactions in PRISTIQ treated MDD patients in pre-marketing pooled 8-week, placebo-controlled, fixed-dose studies (incidence >= 5% and at least twice the rate of placebo in the 50 or 100 mg dose groups) were: nausea, dizziness, insomnia, hyperhidrosis, constipation, somnolence, decreased appetite, anxiety, and specific male sexual function disorders.",constipation is an adverse reaction entity
"Common adverse reactions in placebo-controlled MDD studies       The most commonly observed adverse reactions in PRISTIQ treated MDD patients in pre-marketing pooled 8-week, placebo-controlled, fixed-dose studies (incidence >= 5% and at least twice the rate of placebo in the 50 or 100 mg dose groups) were: nausea, dizziness, insomnia, hyperhidrosis, constipation, somnolence, decreased appetite, anxiety, and specific male sexual function disorders.",treated MDD is not a named entity
"Common adverse reactions in placebo-controlled MDD studies       The most commonly observed adverse reactions in PRISTIQ treated MDD patients in pre-marketing pooled 8-week, placebo-controlled, fixed-dose studies (incidence >= 5% and at least twice the rate of placebo in the 50 or 100 mg dose groups) were: nausea, dizziness, insomnia, hyperhidrosis, constipation, somnolence, decreased appetite, anxiety, and specific male sexual function disorders.",were : is not a named entity
"Common adverse reactions in placebo-controlled MDD studies       The most commonly observed adverse reactions in PRISTIQ treated MDD patients in pre-marketing pooled 8-week, placebo-controlled, fixed-dose studies (incidence >= 5% and at least twice the rate of placebo in the 50 or 100 mg dose groups) were: nausea, dizziness, insomnia, hyperhidrosis, constipation, somnolence, decreased appetite, anxiety, and specific male sexual function disorders.","dizziness , is not a named entity"
"Common adverse reactions in placebo-controlled MDD studies       The most commonly observed adverse reactions in PRISTIQ treated MDD patients in pre-marketing pooled 8-week, placebo-controlled, fixed-dose studies (incidence >= 5% and at least twice the rate of placebo in the 50 or 100 mg dose groups) were: nausea, dizziness, insomnia, hyperhidrosis, constipation, somnolence, decreased appetite, anxiety, and specific male sexual function disorders.",least twice the is not a named entity
"Common adverse reactions in placebo-controlled MDD studies       The most commonly observed adverse reactions in PRISTIQ treated MDD patients in pre-marketing pooled 8-week, placebo-controlled, fixed-dose studies (incidence >= 5% and at least twice the rate of placebo in the 50 or 100 mg dose groups) were: nausea, dizziness, insomnia, hyperhidrosis, constipation, somnolence, decreased appetite, anxiety, and specific male sexual function disorders.",insomnia is an adverse reaction entity
"Common adverse reactions in placebo-controlled MDD studies       The most commonly observed adverse reactions in PRISTIQ treated MDD patients in pre-marketing pooled 8-week, placebo-controlled, fixed-dose studies (incidence >= 5% and at least twice the rate of placebo in the 50 or 100 mg dose groups) were: nausea, dizziness, insomnia, hyperhidrosis, constipation, somnolence, decreased appetite, anxiety, and specific male sexual function disorders.",= 5 % is not a named entity
"Common adverse reactions in placebo-controlled MDD studies       The most commonly observed adverse reactions in PRISTIQ treated MDD patients in pre-marketing pooled 8-week, placebo-controlled, fixed-dose studies (incidence >= 5% and at least twice the rate of placebo in the 50 or 100 mg dose groups) were: nausea, dizziness, insomnia, hyperhidrosis, constipation, somnolence, decreased appetite, anxiety, and specific male sexual function disorders.",nausea is an adverse reaction entity
"Common adverse reactions in placebo-controlled MDD studies       The most commonly observed adverse reactions in PRISTIQ treated MDD patients in pre-marketing pooled 8-week, placebo-controlled, fixed-dose studies (incidence >= 5% and at least twice the rate of placebo in the 50 or 100 mg dose groups) were: nausea, dizziness, insomnia, hyperhidrosis, constipation, somnolence, decreased appetite, anxiety, and specific male sexual function disorders.",somnolence is an adverse reaction entity
"Common adverse reactions in placebo-controlled MDD studies       The most commonly observed adverse reactions in PRISTIQ treated MDD patients in pre-marketing pooled 8-week, placebo-controlled, fixed-dose studies (incidence >= 5% and at least twice the rate of placebo in the 50 or 100 mg dose groups) were: nausea, dizziness, insomnia, hyperhidrosis, constipation, somnolence, decreased appetite, anxiety, and specific male sexual function disorders.",male sexual function disorders is an adverse reaction entity
"Common adverse reactions in placebo-controlled MDD studies       The most commonly observed adverse reactions in PRISTIQ treated MDD patients in pre-marketing pooled 8-week, placebo-controlled, fixed-dose studies (incidence >= 5% and at least twice the rate of placebo in the 50 or 100 mg dose groups) were: nausea, dizziness, insomnia, hyperhidrosis, constipation, somnolence, decreased appetite, anxiety, and specific male sexual function disorders.",hyperhidrosis is an adverse reaction entity
Analyses of patients in PRISTIQ pre-marketing short-term controlled studies who met criteria for sustained hypertension revealed a consistent increase in the proportion of patients who developed sustained hypertension.,Analyses of patients is not a named entity
Analyses of patients in PRISTIQ pre-marketing short-term controlled studies who met criteria for sustained hypertension revealed a consistent increase in the proportion of patients who developed sustained hypertension.,hypertension is an adverse reaction entity
Analyses of patients in PRISTIQ pre-marketing short-term controlled studies who met criteria for sustained hypertension revealed a consistent increase in the proportion of patients who developed sustained hypertension.,hypertension is an adverse reaction entity
Analyses of patients in PRISTIQ pre-marketing short-term controlled studies who met criteria for sustained hypertension revealed a consistent increase in the proportion of patients who developed sustained hypertension.,Analyses of is not a named entity
"Investigations -    Weight increased, liver function test abnormal, blood prolactin increased.",prolactin is not a named entity
"Investigations -    Weight increased, liver function test abnormal, blood prolactin increased.",liver function test abnormal is an adverse reaction entity
"Investigations -    Weight increased, liver function test abnormal, blood prolactin increased.",prolactin is not a named entity
"Investigations -    Weight increased, liver function test abnormal, blood prolactin increased.",blood prolactin increased is an adverse reaction entity
"Investigations -    Weight increased, liver function test abnormal, blood prolactin increased.",Weight increased is an adverse reaction entity
"Investigations -    Weight increased, liver function test abnormal, blood prolactin increased.",function test abnormal is not a named entity
5.3 Elevated Blood Pressure      Patients receiving PRISTIQ should have regular monitoring of blood pressure since increases in blood pressure were observed in clinical studies [see  Adverse Reactions (6.1)  ]  .,Adverse is not a named entity
5.3 Elevated Blood Pressure      Patients receiving PRISTIQ should have regular monitoring of blood pressure since increases in blood pressure were observed in clinical studies [see  Adverse Reactions (6.1)  ]  .,increases in blood pressure is an adverse reaction entity
"Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which can lead to falls.",hyponatremia is an adverse reaction entity
"Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which can lead to falls.",which can is not a named entity
"Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which can lead to falls.",of hyponatremia include is not a named entity
"Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which can lead to falls.",memory impairment is an adverse reaction entity
"Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which can lead to falls.",weakness is an adverse reaction entity
"Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which can lead to falls.",symptoms of is not a named entity
"Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which can lead to falls.",falls is an adverse reaction entity
"Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which can lead to falls.",of hyponatremia include is not a named entity
"Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which can lead to falls.",", difficulty is not a named entity"
"Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which can lead to falls.","headache , difficulty is not a named entity"
"Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which can lead to falls.",unsteadiness is an adverse reaction entity
"Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which can lead to falls.",headache is an adverse reaction entity
"Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which can lead to falls.",which is not a named entity
"Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which can lead to falls.",difficulty concentrating is an adverse reaction entity
"Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which can lead to falls.",confusion is an adverse reaction entity
"Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which can lead to falls.","concentrating , memory is not a named entity"
*     Discontinuation Syndrome: Taper dose when possible and monitor for discontinuation symptoms (  5.7  ).,Discontinuation Syndrome is an adverse reaction entity
*     Discontinuation Syndrome: Taper dose when possible and monitor for discontinuation symptoms (  5.7  ).,for discontinuation symptoms is not a named entity
"Signs and symptoms associated with more severe and/or acute cases have included hallucination, syncope, seizure, coma, respiratory arrest, and death.",more severe and/or is not a named entity
"Signs and symptoms associated with more severe and/or acute cases have included hallucination, syncope, seizure, coma, respiratory arrest, and death.",respiratory arrest is an adverse reaction entity
"Signs and symptoms associated with more severe and/or acute cases have included hallucination, syncope, seizure, coma, respiratory arrest, and death.",syncope is an adverse reaction entity
"Signs and symptoms associated with more severe and/or acute cases have included hallucination, syncope, seizure, coma, respiratory arrest, and death.",coma is an adverse reaction entity
"Signs and symptoms associated with more severe and/or acute cases have included hallucination, syncope, seizure, coma, respiratory arrest, and death.",death is an adverse reaction entity
"Signs and symptoms associated with more severe and/or acute cases have included hallucination, syncope, seizure, coma, respiratory arrest, and death.",hallucination is an adverse reaction entity
"Signs and symptoms associated with more severe and/or acute cases have included hallucination, syncope, seizure, coma, respiratory arrest, and death.",", respiratory is not a named entity"
"Signs and symptoms associated with more severe and/or acute cases have included hallucination, syncope, seizure, coma, respiratory arrest, and death.",severe and/or acute is not a named entity
"Signs and symptoms associated with more severe and/or acute cases have included hallucination, syncope, seizure, coma, respiratory arrest, and death.",seizure is an adverse reaction entity
"Signs and symptoms associated with more severe and/or acute cases have included hallucination, syncope, seizure, coma, respiratory arrest, and death.",Signs and symptoms is not a named entity
"Signs and symptoms associated with more severe and/or acute cases have included hallucination, syncope, seizure, coma, respiratory arrest, and death.",severe and/or is not a named entity
"Signs and symptoms associated with more severe and/or acute cases have included hallucination, syncope, seizure, coma, respiratory arrest, and death.","respiratory arrest , is not a named entity"
"5.6 Activation of Mania/Hypomania      During all MDD phase 2 and phase 3 studies, mania was reported for approximately 0.02% of patients treated with PRISTIQ.",% of patients is not a named entity
"5.6 Activation of Mania/Hypomania      During all MDD phase 2 and phase 3 studies, mania was reported for approximately 0.02% of patients treated with PRISTIQ.",mania is an adverse reaction entity
"The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric.",major depressive disorder is not a named entity
"The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric.","agitation , panic is not a named entity"
"The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric.",pediatric is not a named entity
"The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric.",irritability is an adverse reaction entity
"The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric.",", and mania is not a named entity"
"The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric.",akathisia is an adverse reaction entity
"The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric.",adult is not a named entity
"The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric.",psychomotor restlessness is an adverse reaction entity
"The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric.",hostility is an adverse reaction entity
"The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric.",being is not a named entity
"The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric.",disorder as well is not a named entity
"The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric.",") , hypomania is not a named entity"
"The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric.",mania is an adverse reaction entity
"The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric.","and mania , is not a named entity"
"The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric.",insomnia is an adverse reaction entity
"The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric.","hypomania , and is not a named entity"
"The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric.",panic attacks is an adverse reaction entity
"The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric.",anxiety is an adverse reaction entity
"The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric.",impulsivity is an adverse reaction entity
"The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric.",aggressiveness is an adverse reaction entity
"The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric.",", is not a named entity"
"The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric.",", is not a named entity"
"The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric.",agitation is an adverse reaction entity
"The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric.",hypomania is an adverse reaction entity
EXCERPT:   WARNING: SUICIDAL THOUGHTS AND BEHAVIORS         See full prescribing information for complete boxed warning.,See full is not a named entity
EXCERPT:   WARNING: SUICIDAL THOUGHTS AND BEHAVIORS         See full prescribing information for complete boxed warning.,SUICIDAL THOUGHTS is an adverse reaction entity
EXCERPT:   WARNING: SUICIDAL THOUGHTS AND BEHAVIORS         See full prescribing information for complete boxed warning.,SUICIDAL BEHAVIORS is an adverse reaction entity
EXCERPT:   WARNING: SUICIDAL THOUGHTS AND BEHAVIORS         See full prescribing information for complete boxed warning.,for complete is not a named entity
"These risk differences (drug-placebo difference in the number of cases of suicidality per 1,000 patients treated) are provided in Table 1.",suicidality is an adverse reaction entity
"These risk differences (drug-placebo difference in the number of cases of suicidality per 1,000 patients treated) are provided in Table 1.",suicidality per is not a named entity
"Table 5: Incidence (%) of Patients with Proteinuria in the Fixed-dose Clinical Studies                                           PRISTIQ                                  Placebo          50 mg            100 mg           200 mg           400 mg                Proteinuria          4                6                8                5                7                                   Vital sign changes         Table 6 summarizes the changes that were observed in placebo-controlled, short-term, pre-marketing studies with PRISTIQ in patients with MDD (doses 50 to 400 mg).",Proteinuria is an adverse reaction entity
"Table 5: Incidence (%) of Patients with Proteinuria in the Fixed-dose Clinical Studies                                           PRISTIQ                                  Placebo          50 mg            100 mg           200 mg           400 mg                Proteinuria          4                6                8                5                7                                   Vital sign changes         Table 6 summarizes the changes that were observed in placebo-controlled, short-term, pre-marketing studies with PRISTIQ in patients with MDD (doses 50 to 400 mg).",Proteinuria is an adverse reaction entity
"Table 5: Incidence (%) of Patients with Proteinuria in the Fixed-dose Clinical Studies                                           PRISTIQ                                  Placebo          50 mg            100 mg           200 mg           400 mg                Proteinuria          4                6                8                5                7                                   Vital sign changes         Table 6 summarizes the changes that were observed in placebo-controlled, short-term, pre-marketing studies with PRISTIQ in patients with MDD (doses 50 to 400 mg).",6 summarizes the is not a named entity
"Table 5: Incidence (%) of Patients with Proteinuria in the Fixed-dose Clinical Studies                                           PRISTIQ                                  Placebo          50 mg            100 mg           200 mg           400 mg                Proteinuria          4                6                8                5                7                                   Vital sign changes         Table 6 summarizes the changes that were observed in placebo-controlled, short-term, pre-marketing studies with PRISTIQ in patients with MDD (doses 50 to 400 mg).",with PRISTIQ in is not a named entity
Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction with antidepressants compared to placebo in adults aged 65 and older.,suicidality is an adverse reaction entity
Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction with antidepressants compared to placebo in adults aged 65 and older.,65 and is not a named entity
This proteinuria was not associated with increases in BUN or creatinine and was generally transient.,This proteinuria was is not a named entity
This proteinuria was not associated with increases in BUN or creatinine and was generally transient.,This proteinuria is not a named entity
This proteinuria was not associated with increases in BUN or creatinine and was generally transient.,increases in BUN is an adverse reaction entity
This proteinuria was not associated with increases in BUN or creatinine and was generally transient.,proteinuria is an adverse reaction entity
This proteinuria was not associated with increases in BUN or creatinine and was generally transient.,increases creatinine is an adverse reaction entity
This proteinuria was not associated with increases in BUN or creatinine and was generally transient.,proteinuria was not is not a named entity
These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older [  see   Warnings and Precautions (5.1)    ].,was is not a named entity
These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older [  see   Warnings and Precautions (5.1)    ].,suicidal behavior is an adverse reaction entity
These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older [  see   Warnings and Precautions (5.1)    ].,in risk with is not a named entity
These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older [  see   Warnings and Precautions (5.1)    ].,suicidal thoughts is an adverse reaction entity
Case reports and epidemiological studies (case-control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of gastrointestinal bleeding.,gastrointestinal bleeding is an adverse reaction entity
Case reports and epidemiological studies (case-control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of gastrointestinal bleeding.,with serotonin is not a named entity
*     Angle Closure Glaucoma: Angle closure glaucoma has occurred in patients with untreated anatomically narrow angles treated with antidepressants.,* Angle Closure is not a named entity
*     Angle Closure Glaucoma: Angle closure glaucoma has occurred in patients with untreated anatomically narrow angles treated with antidepressants.,Angle Closure Glaucoma is an adverse reaction entity
*     Angle Closure Glaucoma: Angle closure glaucoma has occurred in patients with untreated anatomically narrow angles treated with antidepressants.,Angle closure glaucoma is an adverse reaction entity
*     Angle Closure Glaucoma: Angle closure glaucoma has occurred in patients with untreated anatomically narrow angles treated with antidepressants.,: Angle is not a named entity
Activation of mania/hypomania has also been reported in a small proportion of patients with major affective disorder who were treated with other marketed antidepressants.,mania/hypomania has is not a named entity
Activation of mania/hypomania has also been reported in a small proportion of patients with major affective disorder who were treated with other marketed antidepressants.,Activation of hypomania is an adverse reaction entity
Activation of mania/hypomania has also been reported in a small proportion of patients with major affective disorder who were treated with other marketed antidepressants.,Activation of mania is an adverse reaction entity
Activation of mania/hypomania has also been reported in a small proportion of patients with major affective disorder who were treated with other marketed antidepressants.,in is not a named entity
Elderly patients may be at greater risk of developing hyponatremia with SSRIs and SNRIs.,developing hyponatremia is not a named entity
Elderly patients may be at greater risk of developing hyponatremia with SSRIs and SNRIs.,hyponatremia is an adverse reaction entity
"There were differences in absolute risk of suicidality across the different indications, with the highest incidence in MDD.",the is not a named entity
"There were differences in absolute risk of suicidality across the different indications, with the highest incidence in MDD.",suicidality is an adverse reaction entity
5.8 Seizure      Cases of seizure have been reported in pre-marketing clinical studies with PRISTIQ.,seizure is an adverse reaction entity
5.8 Seizure      Cases of seizure have been reported in pre-marketing clinical studies with PRISTIQ.,Cases of seizure is not a named entity
"BOXED WARNING: WARNING: SUICIDAL THOUGHTS AND BEHAVIORS      WARNING: SUICIDAL THOUGHTS AND BEHAVIORS        Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies.",studies is not a named entity
"BOXED WARNING: WARNING: SUICIDAL THOUGHTS AND BEHAVIORS      WARNING: SUICIDAL THOUGHTS AND BEHAVIORS        Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies.",young adults is not a named entity
"BOXED WARNING: WARNING: SUICIDAL THOUGHTS AND BEHAVIORS      WARNING: SUICIDAL THOUGHTS AND BEHAVIORS        Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies.",suicidal behavior is an adverse reaction entity
"BOXED WARNING: WARNING: SUICIDAL THOUGHTS AND BEHAVIORS      WARNING: SUICIDAL THOUGHTS AND BEHAVIORS        Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies.",SUICIDAL THOUGHTS is an adverse reaction entity
"BOXED WARNING: WARNING: SUICIDAL THOUGHTS AND BEHAVIORS      WARNING: SUICIDAL THOUGHTS AND BEHAVIORS        Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies.",SUICIDAL BEHAVIORS is an adverse reaction entity
"BOXED WARNING: WARNING: SUICIDAL THOUGHTS AND BEHAVIORS      WARNING: SUICIDAL THOUGHTS AND BEHAVIORS        Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies.",: is not a named entity
"BOXED WARNING: WARNING: SUICIDAL THOUGHTS AND BEHAVIORS      WARNING: SUICIDAL THOUGHTS AND BEHAVIORS        Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies.",SUICIDAL THOUGHTS is an adverse reaction entity
"BOXED WARNING: WARNING: SUICIDAL THOUGHTS AND BEHAVIORS      WARNING: SUICIDAL THOUGHTS AND BEHAVIORS        Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies.",and behavior in is not a named entity
"BOXED WARNING: WARNING: SUICIDAL THOUGHTS AND BEHAVIORS      WARNING: SUICIDAL THOUGHTS AND BEHAVIORS        Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies.",suicidal thoughts is an adverse reaction entity
"BOXED WARNING: WARNING: SUICIDAL THOUGHTS AND BEHAVIORS      WARNING: SUICIDAL THOUGHTS AND BEHAVIORS        Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies.",adults in short-term is not a named entity
"BOXED WARNING: WARNING: SUICIDAL THOUGHTS AND BEHAVIORS      WARNING: SUICIDAL THOUGHTS AND BEHAVIORS        Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies.",SUICIDAL BEHAVIORS is an adverse reaction entity
"BOXED WARNING: WARNING: SUICIDAL THOUGHTS AND BEHAVIORS      WARNING: SUICIDAL THOUGHTS AND BEHAVIORS        Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies.",BOXED WARNING : is not a named entity
"The most common adverse reactions leading to discontinuation in at least 2% and at a rate greater than placebo of the PRISTIQ treated patients in the short-term studies, up to 8 weeks, were: nausea (4%); dizziness, headache and vomiting (2% each).",nausea is an adverse reaction entity
"The most common adverse reactions leading to discontinuation in at least 2% and at a rate greater than placebo of the PRISTIQ treated patients in the short-term studies, up to 8 weeks, were: nausea (4%); dizziness, headache and vomiting (2% each).",vomiting is an adverse reaction entity
"The most common adverse reactions leading to discontinuation in at least 2% and at a rate greater than placebo of the PRISTIQ treated patients in the short-term studies, up to 8 weeks, were: nausea (4%); dizziness, headache and vomiting (2% each).","; dizziness , is not a named entity"
"The most common adverse reactions leading to discontinuation in at least 2% and at a rate greater than placebo of the PRISTIQ treated patients in the short-term studies, up to 8 weeks, were: nausea (4%); dizziness, headache and vomiting (2% each).",in at is not a named entity
"The most common adverse reactions leading to discontinuation in at least 2% and at a rate greater than placebo of the PRISTIQ treated patients in the short-term studies, up to 8 weeks, were: nausea (4%); dizziness, headache and vomiting (2% each).",discontinuation in is not a named entity
"The most common adverse reactions leading to discontinuation in at least 2% and at a rate greater than placebo of the PRISTIQ treated patients in the short-term studies, up to 8 weeks, were: nausea (4%); dizziness, headache and vomiting (2% each).",at a is not a named entity
"The most common adverse reactions leading to discontinuation in at least 2% and at a rate greater than placebo of the PRISTIQ treated patients in the short-term studies, up to 8 weeks, were: nausea (4%); dizziness, headache and vomiting (2% each).",headache is an adverse reaction entity
"The most common adverse reactions leading to discontinuation in at least 2% and at a rate greater than placebo of the PRISTIQ treated patients in the short-term studies, up to 8 weeks, were: nausea (4%); dizziness, headache and vomiting (2% each).",dizziness is an adverse reaction entity
"There has been a long-standing concern, however, that antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients during the early phases of treatment.",suicidality is an adverse reaction entity
"There has been a long-standing concern, however, that antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients during the early phases of treatment.",worsening of depression is an adverse reaction entity
"There has been a long-standing concern, however, that antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients during the early phases of treatment.","however , that is not a named entity"
"There has been a long-standing concern, however, that antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients during the early phases of treatment.",patients during the is not a named entity
"5.4 Abnormal Bleeding      SSRIs and SNRIs, including PRISTIQ, may increase the risk of bleeding events.",including PRISTIQ is not a named entity
"5.4 Abnormal Bleeding      SSRIs and SNRIs, including PRISTIQ, may increase the risk of bleeding events.",bleeding is an adverse reaction entity
(  5.5  )   *     Activation of Mania/Hypomania: Use cautiously in patients with Bipolar Disorder.,Activation of Mania is an adverse reaction entity
(  5.5  )   *     Activation of Mania/Hypomania: Use cautiously in patients with Bipolar Disorder.,in patients with is not a named entity
(  5.5  )   *     Activation of Mania/Hypomania: Use cautiously in patients with Bipolar Disorder.,5.5 ) is not a named entity
(  5.5  )   *     Activation of Mania/Hypomania: Use cautiously in patients with Bipolar Disorder.,Activation of Hypomania is an adverse reaction entity
"Bleeding events related to SSRIs and SNRIs have ranged from ecchymosis, hematoma, epistaxis, and petechiae to life-threatening hemorrhages.",", hematoma , is not a named entity"
"Bleeding events related to SSRIs and SNRIs have ranged from ecchymosis, hematoma, epistaxis, and petechiae to life-threatening hemorrhages.",hematoma is an adverse reaction entity
"Bleeding events related to SSRIs and SNRIs have ranged from ecchymosis, hematoma, epistaxis, and petechiae to life-threatening hemorrhages.",life-threatening is not a named entity
"Bleeding events related to SSRIs and SNRIs have ranged from ecchymosis, hematoma, epistaxis, and petechiae to life-threatening hemorrhages.",petechiae is an adverse reaction entity
"Bleeding events related to SSRIs and SNRIs have ranged from ecchymosis, hematoma, epistaxis, and petechiae to life-threatening hemorrhages.",", is not a named entity"
"Bleeding events related to SSRIs and SNRIs have ranged from ecchymosis, hematoma, epistaxis, and petechiae to life-threatening hemorrhages.",ecchymosis is an adverse reaction entity
"Bleeding events related to SSRIs and SNRIs have ranged from ecchymosis, hematoma, epistaxis, and petechiae to life-threatening hemorrhages.",hemorrhages is an adverse reaction entity
"Bleeding events related to SSRIs and SNRIs have ranged from ecchymosis, hematoma, epistaxis, and petechiae to life-threatening hemorrhages.",epistaxis is an adverse reaction entity
"Bleeding events related to SSRIs and SNRIs have ranged from ecchymosis, hematoma, epistaxis, and petechiae to life-threatening hemorrhages.",Bleeding is an adverse reaction entity
"Bleeding events related to SSRIs and SNRIs have ranged from ecchymosis, hematoma, epistaxis, and petechiae to life-threatening hemorrhages.",have ranged is not a named entity
"Bleeding events related to SSRIs and SNRIs have ranged from ecchymosis, hematoma, epistaxis, and petechiae to life-threatening hemorrhages.",petechiae to life-threatening is not a named entity
"Bleeding events related to SSRIs and SNRIs have ranged from ecchymosis, hematoma, epistaxis, and petechiae to life-threatening hemorrhages.",SSRIs is not a named entity
(  5.5  )             5.1 Embryofetal Toxicity (Use with Ribavirin and Peginterferon Alfa)      Ribavirin may cause birth defects and/or death of the exposed fetus.,fetus is not a named entity
(  5.5  )             5.1 Embryofetal Toxicity (Use with Ribavirin and Peginterferon Alfa)      Ribavirin may cause birth defects and/or death of the exposed fetus.,fetus is not a named entity
(  5.5  )             5.1 Embryofetal Toxicity (Use with Ribavirin and Peginterferon Alfa)      Ribavirin may cause birth defects and/or death of the exposed fetus.,birth defects is an adverse reaction entity
(  5.5  )             5.1 Embryofetal Toxicity (Use with Ribavirin and Peginterferon Alfa)      Ribavirin may cause birth defects and/or death of the exposed fetus.,death of the exposed fetus is an adverse reaction entity
"In clinical trials with VICTRELIS, dose modifications (generally of PegIntron/REBETOL) due to anemia occurred twice as often in subjects treated with the combination of VICTRELIS with PegIntron/REBETOL (26%) compared to PegIntron/REBETOL (13%).",clinical trials is not a named entity
"In clinical trials with VICTRELIS, dose modifications (generally of PegIntron/REBETOL) due to anemia occurred twice as often in subjects treated with the combination of VICTRELIS with PegIntron/REBETOL (26%) compared to PegIntron/REBETOL (13%).",anemia is an adverse reaction entity
"(  5.3  )   *  Hypersensitivity - Serious acute hypersensitivity reactions (e.g., urticaria, angioedema) have been observed during combination therapy with VICTRELIS, peginterferon alfa and ribavirin.",been is not a named entity
"(  5.3  )   *  Hypersensitivity - Serious acute hypersensitivity reactions (e.g., urticaria, angioedema) have been observed during combination therapy with VICTRELIS, peginterferon alfa and ribavirin.",Hypersensitivity is an adverse reaction entity
"(  5.3  )   *  Hypersensitivity - Serious acute hypersensitivity reactions (e.g., urticaria, angioedema) have been observed during combination therapy with VICTRELIS, peginterferon alfa and ribavirin.",alfa and ribavirin is not a named entity
"(  5.3  )   *  Hypersensitivity - Serious acute hypersensitivity reactions (e.g., urticaria, angioedema) have been observed during combination therapy with VICTRELIS, peginterferon alfa and ribavirin.",peginterferon is not a named entity
"(  5.3  )   *  Hypersensitivity - Serious acute hypersensitivity reactions (e.g., urticaria, angioedema) have been observed during combination therapy with VICTRELIS, peginterferon alfa and ribavirin.",angioedema is an adverse reaction entity
"(  5.3  )   *  Hypersensitivity - Serious acute hypersensitivity reactions (e.g., urticaria, angioedema) have been observed during combination therapy with VICTRELIS, peginterferon alfa and ribavirin.",urticaria is an adverse reaction entity
"(  5.3  )   *  Hypersensitivity - Serious acute hypersensitivity reactions (e.g., urticaria, angioedema) have been observed during combination therapy with VICTRELIS, peginterferon alfa and ribavirin.",( is not a named entity
"(  5.3  )   *  Hypersensitivity - Serious acute hypersensitivity reactions (e.g., urticaria, angioedema) have been observed during combination therapy with VICTRELIS, peginterferon alfa and ribavirin.",acute hypersensitivity reactions is an adverse reaction entity
"5.5 Hypersensitivity      Serious acute hypersensitivity reactions (e.g., urticaria, angioedema) have been observed during combination therapy with VICTRELIS, peginterferon alfa and ribavirin.",acute hypersensitivity reactions is an adverse reaction entity
"5.5 Hypersensitivity      Serious acute hypersensitivity reactions (e.g., urticaria, angioedema) have been observed during combination therapy with VICTRELIS, peginterferon alfa and ribavirin.",", peginterferon alfa is not a named entity"
"5.5 Hypersensitivity      Serious acute hypersensitivity reactions (e.g., urticaria, angioedema) have been observed during combination therapy with VICTRELIS, peginterferon alfa and ribavirin.",angioedema is an adverse reaction entity
"5.5 Hypersensitivity      Serious acute hypersensitivity reactions (e.g., urticaria, angioedema) have been observed during combination therapy with VICTRELIS, peginterferon alfa and ribavirin.",hypersensitivity reactions is not a named entity
"5.5 Hypersensitivity      Serious acute hypersensitivity reactions (e.g., urticaria, angioedema) have been observed during combination therapy with VICTRELIS, peginterferon alfa and ribavirin.",hypersensitivity reactions ( is not a named entity
"5.5 Hypersensitivity      Serious acute hypersensitivity reactions (e.g., urticaria, angioedema) have been observed during combination therapy with VICTRELIS, peginterferon alfa and ribavirin.",urticaria is an adverse reaction entity
Only anemia and fatigue were reported as events that led to discontinuation in more than 1% of subjects in any arm.,were reported as is not a named entity
Only anemia and fatigue were reported as events that led to discontinuation in more than 1% of subjects in any arm.,fatigue is an adverse reaction entity
Only anemia and fatigue were reported as events that led to discontinuation in more than 1% of subjects in any arm.,anemia is an adverse reaction entity
Only anemia and fatigue were reported as events that led to discontinuation in more than 1% of subjects in any arm.,that led is not a named entity
"Certain adverse reactions consistent with symptoms of anemia, such as dyspnea, exertional dyspnea, dizziness and syncope were reported more frequently in subjects who received the combination of VICTRELIS with PegIntron/REBETOL than in those treated with PegIntron/REBETOL alone [see  Adverse Reactions (6.1)  ].",dyspnea is an adverse reaction entity
"Certain adverse reactions consistent with symptoms of anemia, such as dyspnea, exertional dyspnea, dizziness and syncope were reported more frequently in subjects who received the combination of VICTRELIS with PegIntron/REBETOL than in those treated with PegIntron/REBETOL alone [see  Adverse Reactions (6.1)  ].",syncope is an adverse reaction entity
"Certain adverse reactions consistent with symptoms of anemia, such as dyspnea, exertional dyspnea, dizziness and syncope were reported more frequently in subjects who received the combination of VICTRELIS with PegIntron/REBETOL than in those treated with PegIntron/REBETOL alone [see  Adverse Reactions (6.1)  ].",dizziness is an adverse reaction entity
"Certain adverse reactions consistent with symptoms of anemia, such as dyspnea, exertional dyspnea, dizziness and syncope were reported more frequently in subjects who received the combination of VICTRELIS with PegIntron/REBETOL than in those treated with PegIntron/REBETOL alone [see  Adverse Reactions (6.1)  ].",exertional dyspnea is an adverse reaction entity
"Certain adverse reactions consistent with symptoms of anemia, such as dyspnea, exertional dyspnea, dizziness and syncope were reported more frequently in subjects who received the combination of VICTRELIS with PegIntron/REBETOL than in those treated with PegIntron/REBETOL alone [see  Adverse Reactions (6.1)  ].",Reactions ( is not a named entity
"Certain adverse reactions consistent with symptoms of anemia, such as dyspnea, exertional dyspnea, dizziness and syncope were reported more frequently in subjects who received the combination of VICTRELIS with PegIntron/REBETOL than in those treated with PegIntron/REBETOL alone [see  Adverse Reactions (6.1)  ].",who received the is not a named entity
"Certain adverse reactions consistent with symptoms of anemia, such as dyspnea, exertional dyspnea, dizziness and syncope were reported more frequently in subjects who received the combination of VICTRELIS with PegIntron/REBETOL than in those treated with PegIntron/REBETOL alone [see  Adverse Reactions (6.1)  ].",see Adverse is not a named entity
"Certain adverse reactions consistent with symptoms of anemia, such as dyspnea, exertional dyspnea, dizziness and syncope were reported more frequently in subjects who received the combination of VICTRELIS with PegIntron/REBETOL than in those treated with PegIntron/REBETOL alone [see  Adverse Reactions (6.1)  ].",alone is not a named entity
"Certain adverse reactions consistent with symptoms of anemia, such as dyspnea, exertional dyspnea, dizziness and syncope were reported more frequently in subjects who received the combination of VICTRELIS with PegIntron/REBETOL than in those treated with PegIntron/REBETOL alone [see  Adverse Reactions (6.1)  ].",anemia is an adverse reaction entity
"Certain adverse reactions consistent with symptoms of anemia, such as dyspnea, exertional dyspnea, dizziness and syncope were reported more frequently in subjects who received the combination of VICTRELIS with PegIntron/REBETOL than in those treated with PegIntron/REBETOL alone [see  Adverse Reactions (6.1)  ].",( is not a named entity
"The following serious and otherwise important adverse drug reactions (ADRs) are discussed in detail in another section of the labeling:     *  Anemia [see  Warnings and Precautions (5.2)  ]    *  Neutropenia [see  Warnings and Precautions (5.3)  ]    *  Pancytopenia [see  Warnings and Precautions (5.4)  ]    *  Hypersensitivity [see  Contraindications (4)  and  Warnings and Precautions (5.5)  ]       The most commonly reported adverse reactions (more than 35% of subjects regardless of investigator's causality assessment) in adult subjects were fatigue, anemia, nausea, headache, and dysgeusia when VICTRELIS was used in combination with PegIntron and REBETOL.",fatigue is an adverse reaction entity
"The following serious and otherwise important adverse drug reactions (ADRs) are discussed in detail in another section of the labeling:     *  Anemia [see  Warnings and Precautions (5.2)  ]    *  Neutropenia [see  Warnings and Precautions (5.3)  ]    *  Pancytopenia [see  Warnings and Precautions (5.4)  ]    *  Hypersensitivity [see  Contraindications (4)  and  Warnings and Precautions (5.5)  ]       The most commonly reported adverse reactions (more than 35% of subjects regardless of investigator's causality assessment) in adult subjects were fatigue, anemia, nausea, headache, and dysgeusia when VICTRELIS was used in combination with PegIntron and REBETOL.",[ see is not a named entity
"The following serious and otherwise important adverse drug reactions (ADRs) are discussed in detail in another section of the labeling:     *  Anemia [see  Warnings and Precautions (5.2)  ]    *  Neutropenia [see  Warnings and Precautions (5.3)  ]    *  Pancytopenia [see  Warnings and Precautions (5.4)  ]    *  Hypersensitivity [see  Contraindications (4)  and  Warnings and Precautions (5.5)  ]       The most commonly reported adverse reactions (more than 35% of subjects regardless of investigator's causality assessment) in adult subjects were fatigue, anemia, nausea, headache, and dysgeusia when VICTRELIS was used in combination with PegIntron and REBETOL.",Neutropenia is an adverse reaction entity
"The following serious and otherwise important adverse drug reactions (ADRs) are discussed in detail in another section of the labeling:     *  Anemia [see  Warnings and Precautions (5.2)  ]    *  Neutropenia [see  Warnings and Precautions (5.3)  ]    *  Pancytopenia [see  Warnings and Precautions (5.4)  ]    *  Hypersensitivity [see  Contraindications (4)  and  Warnings and Precautions (5.5)  ]       The most commonly reported adverse reactions (more than 35% of subjects regardless of investigator's causality assessment) in adult subjects were fatigue, anemia, nausea, headache, and dysgeusia when VICTRELIS was used in combination with PegIntron and REBETOL.",Anemia is an adverse reaction entity
"The following serious and otherwise important adverse drug reactions (ADRs) are discussed in detail in another section of the labeling:     *  Anemia [see  Warnings and Precautions (5.2)  ]    *  Neutropenia [see  Warnings and Precautions (5.3)  ]    *  Pancytopenia [see  Warnings and Precautions (5.4)  ]    *  Hypersensitivity [see  Contraindications (4)  and  Warnings and Precautions (5.5)  ]       The most commonly reported adverse reactions (more than 35% of subjects regardless of investigator's causality assessment) in adult subjects were fatigue, anemia, nausea, headache, and dysgeusia when VICTRELIS was used in combination with PegIntron and REBETOL.",dysgeusia is an adverse reaction entity
"The following serious and otherwise important adverse drug reactions (ADRs) are discussed in detail in another section of the labeling:     *  Anemia [see  Warnings and Precautions (5.2)  ]    *  Neutropenia [see  Warnings and Precautions (5.3)  ]    *  Pancytopenia [see  Warnings and Precautions (5.4)  ]    *  Hypersensitivity [see  Contraindications (4)  and  Warnings and Precautions (5.5)  ]       The most commonly reported adverse reactions (more than 35% of subjects regardless of investigator's causality assessment) in adult subjects were fatigue, anemia, nausea, headache, and dysgeusia when VICTRELIS was used in combination with PegIntron and REBETOL.",anemia is an adverse reaction entity
"The following serious and otherwise important adverse drug reactions (ADRs) are discussed in detail in another section of the labeling:     *  Anemia [see  Warnings and Precautions (5.2)  ]    *  Neutropenia [see  Warnings and Precautions (5.3)  ]    *  Pancytopenia [see  Warnings and Precautions (5.4)  ]    *  Hypersensitivity [see  Contraindications (4)  and  Warnings and Precautions (5.5)  ]       The most commonly reported adverse reactions (more than 35% of subjects regardless of investigator's causality assessment) in adult subjects were fatigue, anemia, nausea, headache, and dysgeusia when VICTRELIS was used in combination with PegIntron and REBETOL.",otherwise is not a named entity
"The following serious and otherwise important adverse drug reactions (ADRs) are discussed in detail in another section of the labeling:     *  Anemia [see  Warnings and Precautions (5.2)  ]    *  Neutropenia [see  Warnings and Precautions (5.3)  ]    *  Pancytopenia [see  Warnings and Precautions (5.4)  ]    *  Hypersensitivity [see  Contraindications (4)  and  Warnings and Precautions (5.5)  ]       The most commonly reported adverse reactions (more than 35% of subjects regardless of investigator's causality assessment) in adult subjects were fatigue, anemia, nausea, headache, and dysgeusia when VICTRELIS was used in combination with PegIntron and REBETOL.",Neutropenia [ see is not a named entity
"The following serious and otherwise important adverse drug reactions (ADRs) are discussed in detail in another section of the labeling:     *  Anemia [see  Warnings and Precautions (5.2)  ]    *  Neutropenia [see  Warnings and Precautions (5.3)  ]    *  Pancytopenia [see  Warnings and Precautions (5.4)  ]    *  Hypersensitivity [see  Contraindications (4)  and  Warnings and Precautions (5.5)  ]       The most commonly reported adverse reactions (more than 35% of subjects regardless of investigator's causality assessment) in adult subjects were fatigue, anemia, nausea, headache, and dysgeusia when VICTRELIS was used in combination with PegIntron and REBETOL.",Hypersensitivity is an adverse reaction entity
"The following serious and otherwise important adverse drug reactions (ADRs) are discussed in detail in another section of the labeling:     *  Anemia [see  Warnings and Precautions (5.2)  ]    *  Neutropenia [see  Warnings and Precautions (5.3)  ]    *  Pancytopenia [see  Warnings and Precautions (5.4)  ]    *  Hypersensitivity [see  Contraindications (4)  and  Warnings and Precautions (5.5)  ]       The most commonly reported adverse reactions (more than 35% of subjects regardless of investigator's causality assessment) in adult subjects were fatigue, anemia, nausea, headache, and dysgeusia when VICTRELIS was used in combination with PegIntron and REBETOL.",detail is not a named entity
"The following serious and otherwise important adverse drug reactions (ADRs) are discussed in detail in another section of the labeling:     *  Anemia [see  Warnings and Precautions (5.2)  ]    *  Neutropenia [see  Warnings and Precautions (5.3)  ]    *  Pancytopenia [see  Warnings and Precautions (5.4)  ]    *  Hypersensitivity [see  Contraindications (4)  and  Warnings and Precautions (5.5)  ]       The most commonly reported adverse reactions (more than 35% of subjects regardless of investigator's causality assessment) in adult subjects were fatigue, anemia, nausea, headache, and dysgeusia when VICTRELIS was used in combination with PegIntron and REBETOL.",reported adverse reactions is not a named entity
"The following serious and otherwise important adverse drug reactions (ADRs) are discussed in detail in another section of the labeling:     *  Anemia [see  Warnings and Precautions (5.2)  ]    *  Neutropenia [see  Warnings and Precautions (5.3)  ]    *  Pancytopenia [see  Warnings and Precautions (5.4)  ]    *  Hypersensitivity [see  Contraindications (4)  and  Warnings and Precautions (5.5)  ]       The most commonly reported adverse reactions (more than 35% of subjects regardless of investigator's causality assessment) in adult subjects were fatigue, anemia, nausea, headache, and dysgeusia when VICTRELIS was used in combination with PegIntron and REBETOL.",see Warnings is not a named entity
"The following serious and otherwise important adverse drug reactions (ADRs) are discussed in detail in another section of the labeling:     *  Anemia [see  Warnings and Precautions (5.2)  ]    *  Neutropenia [see  Warnings and Precautions (5.3)  ]    *  Pancytopenia [see  Warnings and Precautions (5.4)  ]    *  Hypersensitivity [see  Contraindications (4)  and  Warnings and Precautions (5.5)  ]       The most commonly reported adverse reactions (more than 35% of subjects regardless of investigator's causality assessment) in adult subjects were fatigue, anemia, nausea, headache, and dysgeusia when VICTRELIS was used in combination with PegIntron and REBETOL.",headache is an adverse reaction entity
"The following serious and otherwise important adverse drug reactions (ADRs) are discussed in detail in another section of the labeling:     *  Anemia [see  Warnings and Precautions (5.2)  ]    *  Neutropenia [see  Warnings and Precautions (5.3)  ]    *  Pancytopenia [see  Warnings and Precautions (5.4)  ]    *  Hypersensitivity [see  Contraindications (4)  and  Warnings and Precautions (5.5)  ]       The most commonly reported adverse reactions (more than 35% of subjects regardless of investigator's causality assessment) in adult subjects were fatigue, anemia, nausea, headache, and dysgeusia when VICTRELIS was used in combination with PegIntron and REBETOL.",* Hypersensitivity [ is not a named entity
"The following serious and otherwise important adverse drug reactions (ADRs) are discussed in detail in another section of the labeling:     *  Anemia [see  Warnings and Precautions (5.2)  ]    *  Neutropenia [see  Warnings and Precautions (5.3)  ]    *  Pancytopenia [see  Warnings and Precautions (5.4)  ]    *  Hypersensitivity [see  Contraindications (4)  and  Warnings and Precautions (5.5)  ]       The most commonly reported adverse reactions (more than 35% of subjects regardless of investigator's causality assessment) in adult subjects were fatigue, anemia, nausea, headache, and dysgeusia when VICTRELIS was used in combination with PegIntron and REBETOL.",nausea is an adverse reaction entity
"The following serious and otherwise important adverse drug reactions (ADRs) are discussed in detail in another section of the labeling:     *  Anemia [see  Warnings and Precautions (5.2)  ]    *  Neutropenia [see  Warnings and Precautions (5.3)  ]    *  Pancytopenia [see  Warnings and Precautions (5.4)  ]    *  Hypersensitivity [see  Contraindications (4)  and  Warnings and Precautions (5.5)  ]       The most commonly reported adverse reactions (more than 35% of subjects regardless of investigator's causality assessment) in adult subjects were fatigue, anemia, nausea, headache, and dysgeusia when VICTRELIS was used in combination with PegIntron and REBETOL.",: * is not a named entity
"The following serious and otherwise important adverse drug reactions (ADRs) are discussed in detail in another section of the labeling:     *  Anemia [see  Warnings and Precautions (5.2)  ]    *  Neutropenia [see  Warnings and Precautions (5.3)  ]    *  Pancytopenia [see  Warnings and Precautions (5.4)  ]    *  Hypersensitivity [see  Contraindications (4)  and  Warnings and Precautions (5.5)  ]       The most commonly reported adverse reactions (more than 35% of subjects regardless of investigator's causality assessment) in adult subjects were fatigue, anemia, nausea, headache, and dysgeusia when VICTRELIS was used in combination with PegIntron and REBETOL.",Warnings is not a named entity
"The following serious and otherwise important adverse drug reactions (ADRs) are discussed in detail in another section of the labeling:     *  Anemia [see  Warnings and Precautions (5.2)  ]    *  Neutropenia [see  Warnings and Precautions (5.3)  ]    *  Pancytopenia [see  Warnings and Precautions (5.4)  ]    *  Hypersensitivity [see  Contraindications (4)  and  Warnings and Precautions (5.5)  ]       The most commonly reported adverse reactions (more than 35% of subjects regardless of investigator's causality assessment) in adult subjects were fatigue, anemia, nausea, headache, and dysgeusia when VICTRELIS was used in combination with PegIntron and REBETOL.",Pancytopenia is an adverse reaction entity
5.2 Anemia (Use with Ribavirin and Peginterferon Alfa)      Anemia has been reported with peginterferon alfa and ribavirin therapy.,and Peginterferon Alfa is not a named entity
5.2 Anemia (Use with Ribavirin and Peginterferon Alfa)      Anemia has been reported with peginterferon alfa and ribavirin therapy.,Anemia is an adverse reaction entity
"Three subjects experienced severe or life-threatening infections associated with neutropenia, and two subjects experienced life-threatening neutropenia while receiving the combination of VICTRELIS with PegIntron/REBETOL.",neutropenia is an adverse reaction entity
"Three subjects experienced severe or life-threatening infections associated with neutropenia, and two subjects experienced life-threatening neutropenia while receiving the combination of VICTRELIS with PegIntron/REBETOL.",neutropenia is an adverse reaction entity
"Three subjects experienced severe or life-threatening infections associated with neutropenia, and two subjects experienced life-threatening neutropenia while receiving the combination of VICTRELIS with PegIntron/REBETOL.",receiving the combination is not a named entity
"Three subjects experienced severe or life-threatening infections associated with neutropenia, and two subjects experienced life-threatening neutropenia while receiving the combination of VICTRELIS with PegIntron/REBETOL.",infections is an adverse reaction entity
"Three subjects experienced severe or life-threatening infections associated with neutropenia, and two subjects experienced life-threatening neutropenia while receiving the combination of VICTRELIS with PegIntron/REBETOL.",subjects is not a named entity
"Three subjects experienced severe or life-threatening infections associated with neutropenia, and two subjects experienced life-threatening neutropenia while receiving the combination of VICTRELIS with PegIntron/REBETOL.",Three is not a named entity
The addition of VICTRELIS to peginterferon alfa and ribavirin is associated with an additional decrease in hemoglobin concentrations.,additional decrease in hemoglobin concentrations is an adverse reaction entity
The addition of VICTRELIS to peginterferon alfa and ribavirin is associated with an additional decrease in hemoglobin concentrations.,VICTRELIS to is not a named entity
Gastrointestinal Disorders       Dysgeusia (alteration of taste) was an adverse event reported at an increased frequency in subjects receiving VICTRELIS in combination with peginterferon alfa and ribavirin compared with subjects receiving peginterferon alfa and ribavirin alone (  Table 3  ).,Dysgeusia is an adverse reaction entity
Gastrointestinal Disorders       Dysgeusia (alteration of taste) was an adverse event reported at an increased frequency in subjects receiving VICTRELIS in combination with peginterferon alfa and ribavirin compared with subjects receiving peginterferon alfa and ribavirin alone (  Table 3  ).,alteration of taste is an adverse reaction entity
Gastrointestinal Disorders       Dysgeusia (alteration of taste) was an adverse event reported at an increased frequency in subjects receiving VICTRELIS in combination with peginterferon alfa and ribavirin compared with subjects receiving peginterferon alfa and ribavirin alone (  Table 3  ).,alone is not a named entity
Gastrointestinal Disorders       Dysgeusia (alteration of taste) was an adverse event reported at an increased frequency in subjects receiving VICTRELIS in combination with peginterferon alfa and ribavirin compared with subjects receiving peginterferon alfa and ribavirin alone (  Table 3  ).,ribavirin compared is not a named entity
"EXCERPT:   The most commonly reported adverse reactions (greater than 35% of subjects) in clinical trials in adult subjects receiving the combination of VICTRELIS with PegIntron and REBETOL were fatigue, anemia, nausea, headache and dysgeusia.",headache is an adverse reaction entity
"EXCERPT:   The most commonly reported adverse reactions (greater than 35% of subjects) in clinical trials in adult subjects receiving the combination of VICTRELIS with PegIntron and REBETOL were fatigue, anemia, nausea, headache and dysgeusia.",greater than is not a named entity
"EXCERPT:   The most commonly reported adverse reactions (greater than 35% of subjects) in clinical trials in adult subjects receiving the combination of VICTRELIS with PegIntron and REBETOL were fatigue, anemia, nausea, headache and dysgeusia.",the combination is not a named entity
"EXCERPT:   The most commonly reported adverse reactions (greater than 35% of subjects) in clinical trials in adult subjects receiving the combination of VICTRELIS with PegIntron and REBETOL were fatigue, anemia, nausea, headache and dysgeusia.",than 35 is not a named entity
"EXCERPT:   The most commonly reported adverse reactions (greater than 35% of subjects) in clinical trials in adult subjects receiving the combination of VICTRELIS with PegIntron and REBETOL were fatigue, anemia, nausea, headache and dysgeusia.",anemia is an adverse reaction entity
"EXCERPT:   The most commonly reported adverse reactions (greater than 35% of subjects) in clinical trials in adult subjects receiving the combination of VICTRELIS with PegIntron and REBETOL were fatigue, anemia, nausea, headache and dysgeusia.","anemia , is not a named entity"
"EXCERPT:   The most commonly reported adverse reactions (greater than 35% of subjects) in clinical trials in adult subjects receiving the combination of VICTRELIS with PegIntron and REBETOL were fatigue, anemia, nausea, headache and dysgeusia.",fatigue is an adverse reaction entity
"EXCERPT:   The most commonly reported adverse reactions (greater than 35% of subjects) in clinical trials in adult subjects receiving the combination of VICTRELIS with PegIntron and REBETOL were fatigue, anemia, nausea, headache and dysgeusia.",dysgeusia is an adverse reaction entity
"EXCERPT:   The most commonly reported adverse reactions (greater than 35% of subjects) in clinical trials in adult subjects receiving the combination of VICTRELIS with PegIntron and REBETOL were fatigue, anemia, nausea, headache and dysgeusia.",nausea is an adverse reaction entity
"EXCERPT:   The most commonly reported adverse reactions (greater than 35% of subjects) in clinical trials in adult subjects receiving the combination of VICTRELIS with PegIntron and REBETOL were fatigue, anemia, nausea, headache and dysgeusia.",PegIntron and REBETOL is not a named entity
"In clinical trials, the median time to onset of hemoglobin less than 10 g per dL from the initiation of therapy was similar among subjects treated with the combination of VICTRELIS and PegIntron/REBETOL (71 days with a range of 15-337 days), compared to those who received PegIntron/REBETOL (71 days with a range of 8-337 days).",hemoglobin less than 10 g per dL is an adverse reaction entity
"In clinical trials, the median time to onset of hemoglobin less than 10 g per dL from the initiation of therapy was similar among subjects treated with the combination of VICTRELIS and PegIntron/REBETOL (71 days with a range of 15-337 days), compared to those who received PegIntron/REBETOL (71 days with a range of 8-337 days).",combination of is not a named entity
"The most common reason for dose reduction was anemia, which occurred more frequently in subjects receiving the combination of VICTRELIS with PegIntron/REBETOL than in subjects receiving PegIntron/REBETOL alone.",reason is not a named entity
"The most common reason for dose reduction was anemia, which occurred more frequently in subjects receiving the combination of VICTRELIS with PegIntron/REBETOL than in subjects receiving PegIntron/REBETOL alone.",anemia is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS      EXCERPT:    Use of VICTRELIS with Ribavirin and Peginterferon alfa:       *   Embryofetal Toxicity (Use with Ribavirin and Peginterferon Alfa): Ribavirin may cause birth defects and fetal death; avoid pregnancy in female patients and female partners of male patients.,may cause is not a named entity
5 WARNINGS AND PRECAUTIONS      EXCERPT:    Use of VICTRELIS with Ribavirin and Peginterferon alfa:       *   Embryofetal Toxicity (Use with Ribavirin and Peginterferon Alfa): Ribavirin may cause birth defects and fetal death; avoid pregnancy in female patients and female partners of male patients.,fetal death is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS      EXCERPT:    Use of VICTRELIS with Ribavirin and Peginterferon alfa:       *   Embryofetal Toxicity (Use with Ribavirin and Peginterferon Alfa): Ribavirin may cause birth defects and fetal death; avoid pregnancy in female patients and female partners of male patients.,Embryofetal Toxicity is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS      EXCERPT:    Use of VICTRELIS with Ribavirin and Peginterferon alfa:       *   Embryofetal Toxicity (Use with Ribavirin and Peginterferon Alfa): Ribavirin may cause birth defects and fetal death; avoid pregnancy in female patients and female partners of male patients.,birth defects is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS      EXCERPT:    Use of VICTRELIS with Ribavirin and Peginterferon alfa:       *   Embryofetal Toxicity (Use with Ribavirin and Peginterferon Alfa): Ribavirin may cause birth defects and fetal death; avoid pregnancy in female patients and female partners of male patients.,female patients and is not a named entity
5 WARNINGS AND PRECAUTIONS      EXCERPT:    Use of VICTRELIS with Ribavirin and Peginterferon alfa:       *   Embryofetal Toxicity (Use with Ribavirin and Peginterferon Alfa): Ribavirin may cause birth defects and fetal death; avoid pregnancy in female patients and female partners of male patients.,pregnancy in female is not a named entity
5.4 Pancytopenia (Use with Ribavirin and Peginterferon Alfa)       Serious cases of pancytopenia have been reported postmarketing in patients receiving VICTRELIS in combination with peginterferon alfa and ribavirin.,pancytopenia is an adverse reaction entity
5.4 Pancytopenia (Use with Ribavirin and Peginterferon Alfa)       Serious cases of pancytopenia have been reported postmarketing in patients receiving VICTRELIS in combination with peginterferon alfa and ribavirin.,5.4 Pancytopenia is not a named entity
"Adverse events such as dry mouth, nausea, vomiting and diarrhea were also reported at an increased frequency in subjects receiving VICTRELIS in combination with peginterferon alfa and ribavirin.",reported at is not a named entity
"Adverse events such as dry mouth, nausea, vomiting and diarrhea were also reported at an increased frequency in subjects receiving VICTRELIS in combination with peginterferon alfa and ribavirin.",diarrhea were is not a named entity
"Adverse events such as dry mouth, nausea, vomiting and diarrhea were also reported at an increased frequency in subjects receiving VICTRELIS in combination with peginterferon alfa and ribavirin.",diarrhea is an adverse reaction entity
"Adverse events such as dry mouth, nausea, vomiting and diarrhea were also reported at an increased frequency in subjects receiving VICTRELIS in combination with peginterferon alfa and ribavirin.",nausea is an adverse reaction entity
"Adverse events such as dry mouth, nausea, vomiting and diarrhea were also reported at an increased frequency in subjects receiving VICTRELIS in combination with peginterferon alfa and ribavirin.",dry mouth is an adverse reaction entity
"Adverse events such as dry mouth, nausea, vomiting and diarrhea were also reported at an increased frequency in subjects receiving VICTRELIS in combination with peginterferon alfa and ribavirin.",vomiting is an adverse reaction entity
"Adverse events such as dry mouth, nausea, vomiting and diarrhea were also reported at an increased frequency in subjects receiving VICTRELIS in combination with peginterferon alfa and ribavirin.",as dry is not a named entity
"Adverse events such as dry mouth, nausea, vomiting and diarrhea were also reported at an increased frequency in subjects receiving VICTRELIS in combination with peginterferon alfa and ribavirin.",in is not a named entity
(  5.1  )   *  Anemia - The addition of VICTRELIS to peginterferon alfa and ribavirin is associated with an additional decrease in hemoglobin concentrations compared with peginterferon alfa and ribavirin alone.,decrease in hemoglobin concentrations is an adverse reaction entity
(  5.1  )   *  Anemia - The addition of VICTRELIS to peginterferon alfa and ribavirin is associated with an additional decrease in hemoglobin concentrations compared with peginterferon alfa and ribavirin alone.,Anemia is an adverse reaction entity
(  5.1  )   *  Anemia - The addition of VICTRELIS to peginterferon alfa and ribavirin is associated with an additional decrease in hemoglobin concentrations compared with peginterferon alfa and ribavirin alone.,- The is not a named entity
(  5.1  )   *  Anemia - The addition of VICTRELIS to peginterferon alfa and ribavirin is associated with an additional decrease in hemoglobin concentrations compared with peginterferon alfa and ribavirin alone.,to peginterferon alfa is not a named entity
Patients who demonstrate hemodynamic instability on alpha-blocker therapy alone are at increased risk of symptomatic hypotension with concomitant use of PDE5 inhibitors.,symptomatic hypotension is an adverse reaction entity
Patients who demonstrate hemodynamic instability on alpha-blocker therapy alone are at increased risk of symptomatic hypotension with concomitant use of PDE5 inhibitors.,with concomitant is not a named entity
"In some patients, concomitant use of these two drug classes can lower blood pressure significantly leading to symptomatic hypotension (e.g., dizziness, lightheadedness, fainting).",hypotension is not a named entity
"In some patients, concomitant use of these two drug classes can lower blood pressure significantly leading to symptomatic hypotension (e.g., dizziness, lightheadedness, fainting).",dizziness is an adverse reaction entity
"In some patients, concomitant use of these two drug classes can lower blood pressure significantly leading to symptomatic hypotension (e.g., dizziness, lightheadedness, fainting).",lower is not a named entity
"In some patients, concomitant use of these two drug classes can lower blood pressure significantly leading to symptomatic hypotension (e.g., dizziness, lightheadedness, fainting).",symptomatic hypotension is an adverse reaction entity
"In some patients, concomitant use of these two drug classes can lower blood pressure significantly leading to symptomatic hypotension (e.g., dizziness, lightheadedness, fainting).",fainting is an adverse reaction entity
"In some patients, concomitant use of these two drug classes can lower blood pressure significantly leading to symptomatic hypotension (e.g., dizziness, lightheadedness, fainting).",blood pressure is not a named entity
"In some patients, concomitant use of these two drug classes can lower blood pressure significantly leading to symptomatic hypotension (e.g., dizziness, lightheadedness, fainting).","e.g. , dizziness is not a named entity"
"In some patients, concomitant use of these two drug classes can lower blood pressure significantly leading to symptomatic hypotension (e.g., dizziness, lightheadedness, fainting).",lightheadedness is an adverse reaction entity
"Table 4: Adverse Reactions Reported by >= 2% of Patients Treated with STENDRA in a Placebo-Controlled Clinical Trial Lasting 2 Months to Determine the Time to Onset of Effect (Study 3)   Adverse Reaction                              Placebon=143      STENDRA 100 mgn=146   STENDRA 200 mgn=146         Headache                                          0.7%                  1.4%                  8.9%             Nasal congestion                                  0.0%                  0.7%                  4.1%             Gastroenteritis viral                             0.0%                  0.0%                  2.1%                      Across all trials with any STENDRA dose, 1 subject reported a change in color vision.",% of is not a named entity
"Table 4: Adverse Reactions Reported by >= 2% of Patients Treated with STENDRA in a Placebo-Controlled Clinical Trial Lasting 2 Months to Determine the Time to Onset of Effect (Study 3)   Adverse Reaction                              Placebon=143      STENDRA 100 mgn=146   STENDRA 200 mgn=146         Headache                                          0.7%                  1.4%                  8.9%             Nasal congestion                                  0.0%                  0.7%                  4.1%             Gastroenteritis viral                             0.0%                  0.0%                  2.1%                      Across all trials with any STENDRA dose, 1 subject reported a change in color vision.",Nasal congestion is an adverse reaction entity
"Table 4: Adverse Reactions Reported by >= 2% of Patients Treated with STENDRA in a Placebo-Controlled Clinical Trial Lasting 2 Months to Determine the Time to Onset of Effect (Study 3)   Adverse Reaction                              Placebon=143      STENDRA 100 mgn=146   STENDRA 200 mgn=146         Headache                                          0.7%                  1.4%                  8.9%             Nasal congestion                                  0.0%                  0.7%                  4.1%             Gastroenteritis viral                             0.0%                  0.0%                  2.1%                      Across all trials with any STENDRA dose, 1 subject reported a change in color vision.",a Placebo-Controlled Clinical is not a named entity
"Table 4: Adverse Reactions Reported by >= 2% of Patients Treated with STENDRA in a Placebo-Controlled Clinical Trial Lasting 2 Months to Determine the Time to Onset of Effect (Study 3)   Adverse Reaction                              Placebon=143      STENDRA 100 mgn=146   STENDRA 200 mgn=146         Headache                                          0.7%                  1.4%                  8.9%             Nasal congestion                                  0.0%                  0.7%                  4.1%             Gastroenteritis viral                             0.0%                  0.0%                  2.1%                      Across all trials with any STENDRA dose, 1 subject reported a change in color vision.",Treated with STENDRA is not a named entity
"Table 4: Adverse Reactions Reported by >= 2% of Patients Treated with STENDRA in a Placebo-Controlled Clinical Trial Lasting 2 Months to Determine the Time to Onset of Effect (Study 3)   Adverse Reaction                              Placebon=143      STENDRA 100 mgn=146   STENDRA 200 mgn=146         Headache                                          0.7%                  1.4%                  8.9%             Nasal congestion                                  0.0%                  0.7%                  4.1%             Gastroenteritis viral                             0.0%                  0.0%                  2.1%                      Across all trials with any STENDRA dose, 1 subject reported a change in color vision.",Headache is an adverse reaction entity
"Table 4: Adverse Reactions Reported by >= 2% of Patients Treated with STENDRA in a Placebo-Controlled Clinical Trial Lasting 2 Months to Determine the Time to Onset of Effect (Study 3)   Adverse Reaction                              Placebon=143      STENDRA 100 mgn=146   STENDRA 200 mgn=146         Headache                                          0.7%                  1.4%                  8.9%             Nasal congestion                                  0.0%                  0.7%                  4.1%             Gastroenteritis viral                             0.0%                  0.0%                  2.1%                      Across all trials with any STENDRA dose, 1 subject reported a change in color vision.",Gastroenteritis viral is an adverse reaction entity
"Table 4: Adverse Reactions Reported by >= 2% of Patients Treated with STENDRA in a Placebo-Controlled Clinical Trial Lasting 2 Months to Determine the Time to Onset of Effect (Study 3)   Adverse Reaction                              Placebon=143      STENDRA 100 mgn=146   STENDRA 200 mgn=146         Headache                                          0.7%                  1.4%                  8.9%             Nasal congestion                                  0.0%                  0.7%                  4.1%             Gastroenteritis viral                             0.0%                  0.0%                  2.1%                      Across all trials with any STENDRA dose, 1 subject reported a change in color vision.",% is not a named entity
"Table 4: Adverse Reactions Reported by >= 2% of Patients Treated with STENDRA in a Placebo-Controlled Clinical Trial Lasting 2 Months to Determine the Time to Onset of Effect (Study 3)   Adverse Reaction                              Placebon=143      STENDRA 100 mgn=146   STENDRA 200 mgn=146         Headache                                          0.7%                  1.4%                  8.9%             Nasal congestion                                  0.0%                  0.7%                  4.1%             Gastroenteritis viral                             0.0%                  0.0%                  2.1%                      Across all trials with any STENDRA dose, 1 subject reported a change in color vision.",change in color vision is an adverse reaction entity
5.3 Prolonged Erection    Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours in duration) have been reported with other PDE5 inhibitors.,painful erections is an adverse reaction entity
5.3 Prolonged Erection    Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours in duration) have been reported with other PDE5 inhibitors.,Prolonged erection is an adverse reaction entity
5.3 Prolonged Erection    Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours in duration) have been reported with other PDE5 inhibitors.,priapism is an adverse reaction entity
5.3 Prolonged Erection    Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours in duration) have been reported with other PDE5 inhibitors.,greater than is not a named entity
5.3 Prolonged Erection    Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours in duration) have been reported with other PDE5 inhibitors.,than 4 is not a named entity
5.3 Prolonged Erection    Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours in duration) have been reported with other PDE5 inhibitors.,greater than 4 is not a named entity
"5.5 Sudden Hearing Loss    Use of PDE5 inhibitors has been associated with sudden decrease or loss of hearing, which may be accompanied by tinnitus or dizziness.",5.5 Sudden is not a named entity
"5.5 Sudden Hearing Loss    Use of PDE5 inhibitors has been associated with sudden decrease or loss of hearing, which may be accompanied by tinnitus or dizziness.",which may is not a named entity
"5.5 Sudden Hearing Loss    Use of PDE5 inhibitors has been associated with sudden decrease or loss of hearing, which may be accompanied by tinnitus or dizziness.",Sudden Hearing is not a named entity
"5.5 Sudden Hearing Loss    Use of PDE5 inhibitors has been associated with sudden decrease or loss of hearing, which may be accompanied by tinnitus or dizziness.",sudden decrease of hearing is an adverse reaction entity
"5.5 Sudden Hearing Loss    Use of PDE5 inhibitors has been associated with sudden decrease or loss of hearing, which may be accompanied by tinnitus or dizziness.",tinnitus is an adverse reaction entity
"5.5 Sudden Hearing Loss    Use of PDE5 inhibitors has been associated with sudden decrease or loss of hearing, which may be accompanied by tinnitus or dizziness.",loss of hearing is an adverse reaction entity
"5.5 Sudden Hearing Loss    Use of PDE5 inhibitors has been associated with sudden decrease or loss of hearing, which may be accompanied by tinnitus or dizziness.",tinnitus or is not a named entity
"5.5 Sudden Hearing Loss    Use of PDE5 inhibitors has been associated with sudden decrease or loss of hearing, which may be accompanied by tinnitus or dizziness.",dizziness is an adverse reaction entity
"Such an event may be a sign of non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition and a cause of decreased vision including permanent loss of vision that has been reported rarely postmarketing in temporal association with the use of all PDE5 inhibitors.",non-arteritic anterior ischemic optic neuropathy is an adverse reaction entity
"Such an event may be a sign of non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition and a cause of decreased vision including permanent loss of vision that has been reported rarely postmarketing in temporal association with the use of all PDE5 inhibitors.",event is not a named entity
"Such an event may be a sign of non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition and a cause of decreased vision including permanent loss of vision that has been reported rarely postmarketing in temporal association with the use of all PDE5 inhibitors.",NAION is an adverse reaction entity
"Such an event may be a sign of non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition and a cause of decreased vision including permanent loss of vision that has been reported rarely postmarketing in temporal association with the use of all PDE5 inhibitors.",anterior ischemic is not a named entity
"Such an event may be a sign of non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition and a cause of decreased vision including permanent loss of vision that has been reported rarely postmarketing in temporal association with the use of all PDE5 inhibitors.",", a rare is not a named entity"
"Such an event may be a sign of non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition and a cause of decreased vision including permanent loss of vision that has been reported rarely postmarketing in temporal association with the use of all PDE5 inhibitors.",all PDE5 is not a named entity
"Such an event may be a sign of non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition and a cause of decreased vision including permanent loss of vision that has been reported rarely postmarketing in temporal association with the use of all PDE5 inhibitors.",permanent loss of vision is an adverse reaction entity
"Such an event may be a sign of non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition and a cause of decreased vision including permanent loss of vision that has been reported rarely postmarketing in temporal association with the use of all PDE5 inhibitors.",decreased vision is an adverse reaction entity
"Patients with a ""crowded"" optic disc may also be at an increased risk of NAION (5.4,6.2)   *  Patients should stop taking STENDRA and seek prompt medical attention in the event of sudden decrease or loss of hearing (5.5)          5.1 Cardiovascular Risks    There is a potential for cardiac risk during sexual activity in patients with pre-existing cardiovascular disease.",attention is not a named entity
"Patients with a ""crowded"" optic disc may also be at an increased risk of NAION (5.4,6.2)   *  Patients should stop taking STENDRA and seek prompt medical attention in the event of sudden decrease or loss of hearing (5.5)          5.1 Cardiovascular Risks    There is a potential for cardiac risk during sexual activity in patients with pre-existing cardiovascular disease.",cardiac risk is an adverse reaction entity
"6 ADVERSE REACTIONS    EXCERPT:   Most common adverse reactions (greater than or equal to 2%) include headache, flushing, nasal congestion, nasopharyngitis, and back pain (6.1)       To report SUSPECTED ADVERSE REACTIONS, contact 1-877-663-0412 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",nasopharyngitis is an adverse reaction entity
"6 ADVERSE REACTIONS    EXCERPT:   Most common adverse reactions (greater than or equal to 2%) include headache, flushing, nasal congestion, nasopharyngitis, and back pain (6.1)       To report SUSPECTED ADVERSE REACTIONS, contact 1-877-663-0412 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",back pain is an adverse reaction entity
"6 ADVERSE REACTIONS    EXCERPT:   Most common adverse reactions (greater than or equal to 2%) include headache, flushing, nasal congestion, nasopharyngitis, and back pain (6.1)       To report SUSPECTED ADVERSE REACTIONS, contact 1-877-663-0412 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",", nasal is not a named entity"
"6 ADVERSE REACTIONS    EXCERPT:   Most common adverse reactions (greater than or equal to 2%) include headache, flushing, nasal congestion, nasopharyngitis, and back pain (6.1)       To report SUSPECTED ADVERSE REACTIONS, contact 1-877-663-0412 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",nasal congestion is an adverse reaction entity
"6 ADVERSE REACTIONS    EXCERPT:   Most common adverse reactions (greater than or equal to 2%) include headache, flushing, nasal congestion, nasopharyngitis, and back pain (6.1)       To report SUSPECTED ADVERSE REACTIONS, contact 1-877-663-0412 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",) To is not a named entity
"6 ADVERSE REACTIONS    EXCERPT:   Most common adverse reactions (greater than or equal to 2%) include headache, flushing, nasal congestion, nasopharyngitis, and back pain (6.1)       To report SUSPECTED ADVERSE REACTIONS, contact 1-877-663-0412 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",1-800-FDA-1088 or is not a named entity
"6 ADVERSE REACTIONS    EXCERPT:   Most common adverse reactions (greater than or equal to 2%) include headache, flushing, nasal congestion, nasopharyngitis, and back pain (6.1)       To report SUSPECTED ADVERSE REACTIONS, contact 1-877-663-0412 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",or FDA at is not a named entity
"6 ADVERSE REACTIONS    EXCERPT:   Most common adverse reactions (greater than or equal to 2%) include headache, flushing, nasal congestion, nasopharyngitis, and back pain (6.1)       To report SUSPECTED ADVERSE REACTIONS, contact 1-877-663-0412 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",", and is not a named entity"
"6 ADVERSE REACTIONS    EXCERPT:   Most common adverse reactions (greater than or equal to 2%) include headache, flushing, nasal congestion, nasopharyngitis, and back pain (6.1)       To report SUSPECTED ADVERSE REACTIONS, contact 1-877-663-0412 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",headache is an adverse reaction entity
"6 ADVERSE REACTIONS    EXCERPT:   Most common adverse reactions (greater than or equal to 2%) include headache, flushing, nasal congestion, nasopharyngitis, and back pain (6.1)       To report SUSPECTED ADVERSE REACTIONS, contact 1-877-663-0412 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.",flushing is an adverse reaction entity
"6.2 Postmarketing Experience    Ophthalmologic:     Non-arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision including permanent loss of vision, has been reported rarely post-marketing in temporal association with the use of phosphodiesterase type 5 (PDE5) inhibitors.",NAION is an adverse reaction entity
"6.2 Postmarketing Experience    Ophthalmologic:     Non-arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision including permanent loss of vision, has been reported rarely post-marketing in temporal association with the use of phosphodiesterase type 5 (PDE5) inhibitors.",permanent loss of vision is an adverse reaction entity
"6.2 Postmarketing Experience    Ophthalmologic:     Non-arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision including permanent loss of vision, has been reported rarely post-marketing in temporal association with the use of phosphodiesterase type 5 (PDE5) inhibitors.",including is not a named entity
"6.2 Postmarketing Experience    Ophthalmologic:     Non-arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision including permanent loss of vision, has been reported rarely post-marketing in temporal association with the use of phosphodiesterase type 5 (PDE5) inhibitors.",the is not a named entity
"6.2 Postmarketing Experience    Ophthalmologic:     Non-arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision including permanent loss of vision, has been reported rarely post-marketing in temporal association with the use of phosphodiesterase type 5 (PDE5) inhibitors.",a cause is not a named entity
"6.2 Postmarketing Experience    Ophthalmologic:     Non-arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision including permanent loss of vision, has been reported rarely post-marketing in temporal association with the use of phosphodiesterase type 5 (PDE5) inhibitors.",anterior ischemic is not a named entity
"6.2 Postmarketing Experience    Ophthalmologic:     Non-arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision including permanent loss of vision, has been reported rarely post-marketing in temporal association with the use of phosphodiesterase type 5 (PDE5) inhibitors.",decreased vision is an adverse reaction entity
"6.2 Postmarketing Experience    Ophthalmologic:     Non-arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision including permanent loss of vision, has been reported rarely post-marketing in temporal association with the use of phosphodiesterase type 5 (PDE5) inhibitors.",Non-arteritic anterior ischemic optic neuropathy is an adverse reaction entity
"STENDRA 200 mg resulted in transient decreases in sitting blood pressure in healthy volunteers of 8.0 mmHg systolic and 3.3 mmHg diastolic  [seeClinical Pharmacology (12.2)]  , with the maximum decrease observed at 1 hour after dosing.",volunteers of 8.0 is not a named entity
"STENDRA 200 mg resulted in transient decreases in sitting blood pressure in healthy volunteers of 8.0 mmHg systolic and 3.3 mmHg diastolic  [seeClinical Pharmacology (12.2)]  , with the maximum decrease observed at 1 hour after dosing.",transient decreases in sitting blood pressure is an adverse reaction entity
"(2.3,5.1)   *  Bullous and Exfoliative Skin Disorders: Severe bullous, blistering, and exfoliating lesions occurred in 0.15% of patients.","2.3,5.1 ) is not a named entity"
"(2.3,5.1)   *  Bullous and Exfoliative Skin Disorders: Severe bullous, blistering, and exfoliating lesions occurred in 0.15% of patients.",of patients is not a named entity
"(2.3,5.1)   *  Bullous and Exfoliative Skin Disorders: Severe bullous, blistering, and exfoliating lesions occurred in 0.15% of patients.",Skin bullous lesions is an adverse reaction entity
"(2.3,5.1)   *  Bullous and Exfoliative Skin Disorders: Severe bullous, blistering, and exfoliating lesions occurred in 0.15% of patients.",Skin exfoliating lesions is an adverse reaction entity
"(2.3,5.1)   *  Bullous and Exfoliative Skin Disorders: Severe bullous, blistering, and exfoliating lesions occurred in 0.15% of patients.",Bullous and Exfoliative is not a named entity
"(2.3,5.1)   *  Bullous and Exfoliative Skin Disorders: Severe bullous, blistering, and exfoliating lesions occurred in 0.15% of patients.",Skin blistering lesions is an adverse reaction entity
The incidence of ILD appeared to be higher in patients of Asian ethnicity (2.1%) as compared to non-Asians (1.2%).,ILD is an adverse reaction entity
The incidence of ILD appeared to be higher in patients of Asian ethnicity (2.1%) as compared to non-Asians (1.2%).,patients of is not a named entity
"5.4 Hepatic Toxicity    In 3865 patients who received GILOTRIF across clinical trials, 10.1% had liver test abnormalities, of which 7 (0.18%) were fatal.",7 ( is not a named entity
"5.4 Hepatic Toxicity    In 3865 patients who received GILOTRIF across clinical trials, 10.1% had liver test abnormalities, of which 7 (0.18%) were fatal.",across clinical is not a named entity
"5.4 Hepatic Toxicity    In 3865 patients who received GILOTRIF across clinical trials, 10.1% had liver test abnormalities, of which 7 (0.18%) were fatal.",fatal is an adverse reaction entity
"5.4 Hepatic Toxicity    In 3865 patients who received GILOTRIF across clinical trials, 10.1% had liver test abnormalities, of which 7 (0.18%) were fatal.",liver test abnormalities is an adverse reaction entity
"The most frequent serious adverse reactions reported in patients treated with GILOTRIF were diarrhea (6.6%); vomiting (4.8%); and dyspnea, fatigue, and hypokalemia (1.7% each).",and is not a named entity
"The most frequent serious adverse reactions reported in patients treated with GILOTRIF were diarrhea (6.6%); vomiting (4.8%); and dyspnea, fatigue, and hypokalemia (1.7% each).",4.8 % is not a named entity
"The most frequent serious adverse reactions reported in patients treated with GILOTRIF were diarrhea (6.6%); vomiting (4.8%); and dyspnea, fatigue, and hypokalemia (1.7% each).",most frequent serious is not a named entity
"The most frequent serious adverse reactions reported in patients treated with GILOTRIF were diarrhea (6.6%); vomiting (4.8%); and dyspnea, fatigue, and hypokalemia (1.7% each).",dyspnea is an adverse reaction entity
"The most frequent serious adverse reactions reported in patients treated with GILOTRIF were diarrhea (6.6%); vomiting (4.8%); and dyspnea, fatigue, and hypokalemia (1.7% each).","dyspnea , fatigue is not a named entity"
"The most frequent serious adverse reactions reported in patients treated with GILOTRIF were diarrhea (6.6%); vomiting (4.8%); and dyspnea, fatigue, and hypokalemia (1.7% each).",hypokalemia is an adverse reaction entity
"The most frequent serious adverse reactions reported in patients treated with GILOTRIF were diarrhea (6.6%); vomiting (4.8%); and dyspnea, fatigue, and hypokalemia (1.7% each).",vomiting is an adverse reaction entity
"The most frequent serious adverse reactions reported in patients treated with GILOTRIF were diarrhea (6.6%); vomiting (4.8%); and dyspnea, fatigue, and hypokalemia (1.7% each).",diarrhea is an adverse reaction entity
"The most frequent serious adverse reactions reported in patients treated with GILOTRIF were diarrhea (6.6%); vomiting (4.8%); and dyspnea, fatigue, and hypokalemia (1.7% each).","fatigue , and is not a named entity"
"The most frequent serious adverse reactions reported in patients treated with GILOTRIF were diarrhea (6.6%); vomiting (4.8%); and dyspnea, fatigue, and hypokalemia (1.7% each).",fatigue is an adverse reaction entity
"In Study 1, liver test abnormalities of any grade occurred in 17.5% of the patients treated with GILOTRIF.",liver test abnormalities is an adverse reaction entity
"In Study 1, liver test abnormalities of any grade occurred in 17.5% of the patients treated with GILOTRIF.",occurred is not a named entity
"Afatinib was embryotoxic and, in animals with maternal toxicity, led to abortions at late gestational stages in rabbits at doses of 5 mg/kg (approximately 0.2 times the human exposure at the recommended dose of 40 mg daily) or greater.","toxicity , is not a named entity"
"Afatinib was embryotoxic and, in animals with maternal toxicity, led to abortions at late gestational stages in rabbits at doses of 5 mg/kg (approximately 0.2 times the human exposure at the recommended dose of 40 mg daily) or greater.",0.2 is not a named entity
"Afatinib was embryotoxic and, in animals with maternal toxicity, led to abortions at late gestational stages in rabbits at doses of 5 mg/kg (approximately 0.2 times the human exposure at the recommended dose of 40 mg daily) or greater.",abortions at late gestational stages is an adverse reaction entity
"Afatinib was embryotoxic and, in animals with maternal toxicity, led to abortions at late gestational stages in rabbits at doses of 5 mg/kg (approximately 0.2 times the human exposure at the recommended dose of 40 mg daily) or greater.",embryotoxic is an adverse reaction entity
"In addition, the incidence of Grade 1-3 palmar-plantar erythrodysesthesia syndrome was 7%.",palmar-plantar erythrodysesthesia syndrome is an adverse reaction entity
"In addition, the incidence of Grade 1-3 palmar-plantar erythrodysesthesia syndrome was 7%.",Grade 1-3 is not a named entity
5  WARNINGS AND PRECAUTIONS     EXCERPT:    *  Diarrhea: Diarrhea may result in dehydration and renal failure.,dehydration is an adverse reaction entity
5  WARNINGS AND PRECAUTIONS     EXCERPT:    *  Diarrhea: Diarrhea may result in dehydration and renal failure.,dehydration and renal is not a named entity
5  WARNINGS AND PRECAUTIONS     EXCERPT:    *  Diarrhea: Diarrhea may result in dehydration and renal failure.,renal failure is an adverse reaction entity
5  WARNINGS AND PRECAUTIONS     EXCERPT:    *  Diarrhea: Diarrhea may result in dehydration and renal failure.,Diarrhea is an adverse reaction entity
5  WARNINGS AND PRECAUTIONS     EXCERPT:    *  Diarrhea: Diarrhea may result in dehydration and renal failure.,PRECAUTIONS EXCERPT is not a named entity
5  WARNINGS AND PRECAUTIONS     EXCERPT:    *  Diarrhea: Diarrhea may result in dehydration and renal failure.,Diarrhea may result is not a named entity
"5.2 Bullous and Exfoliative Skin Disorders    Grade 3 cutaneous reactions characterized by bullous, blistering, and exfoliating lesions occurred in 6 (0.15%) of the 3865 patients who received GILOTRIF across clinical trials  [see Adverse Reactions (6.1)].",clinical trials is not a named entity
"5.2 Bullous and Exfoliative Skin Disorders    Grade 3 cutaneous reactions characterized by bullous, blistering, and exfoliating lesions occurred in 6 (0.15%) of the 3865 patients who received GILOTRIF across clinical trials  [see Adverse Reactions (6.1)].",bullous lesions is an adverse reaction entity
"5.2 Bullous and Exfoliative Skin Disorders    Grade 3 cutaneous reactions characterized by bullous, blistering, and exfoliating lesions occurred in 6 (0.15%) of the 3865 patients who received GILOTRIF across clinical trials  [see Adverse Reactions (6.1)].",cutaneous reactions is an adverse reaction entity
"5.2 Bullous and Exfoliative Skin Disorders    Grade 3 cutaneous reactions characterized by bullous, blistering, and exfoliating lesions occurred in 6 (0.15%) of the 3865 patients who received GILOTRIF across clinical trials  [see Adverse Reactions (6.1)].",see is not a named entity
"5.2 Bullous and Exfoliative Skin Disorders    Grade 3 cutaneous reactions characterized by bullous, blistering, and exfoliating lesions occurred in 6 (0.15%) of the 3865 patients who received GILOTRIF across clinical trials  [see Adverse Reactions (6.1)].",Adverse Reactions ( is not a named entity
"5.2 Bullous and Exfoliative Skin Disorders    Grade 3 cutaneous reactions characterized by bullous, blistering, and exfoliating lesions occurred in 6 (0.15%) of the 3865 patients who received GILOTRIF across clinical trials  [see Adverse Reactions (6.1)].",blistering lesions is an adverse reaction entity
"5.2 Bullous and Exfoliative Skin Disorders    Grade 3 cutaneous reactions characterized by bullous, blistering, and exfoliating lesions occurred in 6 (0.15%) of the 3865 patients who received GILOTRIF across clinical trials  [see Adverse Reactions (6.1)].",6 ( 0.15 is not a named entity
"5.2 Bullous and Exfoliative Skin Disorders    Grade 3 cutaneous reactions characterized by bullous, blistering, and exfoliating lesions occurred in 6 (0.15%) of the 3865 patients who received GILOTRIF across clinical trials  [see Adverse Reactions (6.1)].",exfoliating lesions is an adverse reaction entity
(5.6)          5.1 Diarrhea    Diarrhea has resulted in dehydration with or without renal impairment; some of these cases were fatal.,fatal is an adverse reaction entity
(5.6)          5.1 Diarrhea    Diarrhea has resulted in dehydration with or without renal impairment; some of these cases were fatal.,impairment is not a named entity
(5.6)          5.1 Diarrhea    Diarrhea has resulted in dehydration with or without renal impairment; some of these cases were fatal.,dehydration with is not a named entity
(5.6)          5.1 Diarrhea    Diarrhea has resulted in dehydration with or without renal impairment; some of these cases were fatal.,renal impairment is an adverse reaction entity
(5.6)          5.1 Diarrhea    Diarrhea has resulted in dehydration with or without renal impairment; some of these cases were fatal.,) 5.1 Diarrhea is not a named entity
(5.6)          5.1 Diarrhea    Diarrhea has resulted in dehydration with or without renal impairment; some of these cases were fatal.,resulted in dehydration is not a named entity
(5.6)          5.1 Diarrhea    Diarrhea has resulted in dehydration with or without renal impairment; some of these cases were fatal.,Diarrhea is an adverse reaction entity
(5.6)          5.1 Diarrhea    Diarrhea has resulted in dehydration with or without renal impairment; some of these cases were fatal.,dehydration is an adverse reaction entity
"Renal impairment as a consequence of diarrhea occurred in 6.1% of patients treated with GILOTRIF, out of which 3 (1.3%) were Grade 3.",", out of is not a named entity"
"Renal impairment as a consequence of diarrhea occurred in 6.1% of patients treated with GILOTRIF, out of which 3 (1.3%) were Grade 3.",diarrhea is an adverse reaction entity
"Renal impairment as a consequence of diarrhea occurred in 6.1% of patients treated with GILOTRIF, out of which 3 (1.3%) were Grade 3.",Renal impairment is an adverse reaction entity
"Renal impairment as a consequence of diarrhea occurred in 6.1% of patients treated with GILOTRIF, out of which 3 (1.3%) were Grade 3.",Renal impairment is an adverse reaction entity
"Renal impairment as a consequence of diarrhea occurred in 6.1% of patients treated with GILOTRIF, out of which 3 (1.3%) were Grade 3.",Grade is not a named entity
"Renal impairment as a consequence of diarrhea occurred in 6.1% of patients treated with GILOTRIF, out of which 3 (1.3%) were Grade 3.",which 3 ( is not a named entity
"(2.3,5.3)   *  Hepatic toxicity: Fatal hepatic impairment occurs in 0.18% of patients.",hepatic impairment is an adverse reaction entity
"(2.3,5.3)   *  Hepatic toxicity: Fatal hepatic impairment occurs in 0.18% of patients.",Hepatic toxicity is an adverse reaction entity
"(2.3,5.3)   *  Hepatic toxicity: Fatal hepatic impairment occurs in 0.18% of patients.",impairment occurs is not a named entity
"(2.3,5.3)   *  Hepatic toxicity: Fatal hepatic impairment occurs in 0.18% of patients.",Fatal is an adverse reaction entity
"(2.3,5.3)   *  Hepatic toxicity: Fatal hepatic impairment occurs in 0.18% of patients.",occurs is not a named entity
"(2.3,5.3)   *  Hepatic toxicity: Fatal hepatic impairment occurs in 0.18% of patients.",occurs in is not a named entity
"In Study 1, diarrhea occurred in 96% of patients treated with GILOTRIF (n=229), of which 15% was Grade 3 in severity and occurred within the first 6 weeks  [see Adverse Reactions (6.1)].",diarrhea is an adverse reaction entity
"In Study 1, diarrhea occurred in 96% of patients treated with GILOTRIF (n=229), of which 15% was Grade 3 in severity and occurred within the first 6 weeks  [see Adverse Reactions (6.1)].",GILOTRIF is not a named entity
"In Study 1, diarrhea occurred in 96% of patients treated with GILOTRIF (n=229), of which 15% was Grade 3 in severity and occurred within the first 6 weeks  [see Adverse Reactions (6.1)].",diarrhea is an adverse reaction entity
"In Study 1, diarrhea occurred in 96% of patients treated with GILOTRIF (n=229), of which 15% was Grade 3 in severity and occurred within the first 6 weeks  [see Adverse Reactions (6.1)].",treated is not a named entity
"The most frequent adverse reactions that led to dose reduction in the patients treated with GILOTRIF were diarrhea (20%), rash/acne (19%), paronychia (14%), and stomatitis (10%).",20 is not a named entity
"The most frequent adverse reactions that led to dose reduction in the patients treated with GILOTRIF were diarrhea (20%), rash/acne (19%), paronychia (14%), and stomatitis (10%).",and stomatitis ( is not a named entity
"The most frequent adverse reactions that led to dose reduction in the patients treated with GILOTRIF were diarrhea (20%), rash/acne (19%), paronychia (14%), and stomatitis (10%).",20 % ) is not a named entity
"The most frequent adverse reactions that led to dose reduction in the patients treated with GILOTRIF were diarrhea (20%), rash/acne (19%), paronychia (14%), and stomatitis (10%).",) is not a named entity
"The most frequent adverse reactions that led to dose reduction in the patients treated with GILOTRIF were diarrhea (20%), rash/acne (19%), paronychia (14%), and stomatitis (10%).",rash is an adverse reaction entity
"The most frequent adverse reactions that led to dose reduction in the patients treated with GILOTRIF were diarrhea (20%), rash/acne (19%), paronychia (14%), and stomatitis (10%).",( is not a named entity
"The most frequent adverse reactions that led to dose reduction in the patients treated with GILOTRIF were diarrhea (20%), rash/acne (19%), paronychia (14%), and stomatitis (10%).",paronychia is an adverse reaction entity
"The most frequent adverse reactions that led to dose reduction in the patients treated with GILOTRIF were diarrhea (20%), rash/acne (19%), paronychia (14%), and stomatitis (10%).",acne is an adverse reaction entity
"The most frequent adverse reactions that led to dose reduction in the patients treated with GILOTRIF were diarrhea (20%), rash/acne (19%), paronychia (14%), and stomatitis (10%).",diarrhea is an adverse reaction entity
"The most frequent adverse reactions that led to dose reduction in the patients treated with GILOTRIF were diarrhea (20%), rash/acne (19%), paronychia (14%), and stomatitis (10%).",stomatitis is an adverse reaction entity
"5.3 Interstitial Lung Disease (ILD)    ILD or ILD-like adverse reactions (e.g., lung infiltration, pneumonitis, acute respiratory distress syndrome, or alveolitis allergic) occurred in 1.5% of the 3865 patients who received GILOTRIF across clinical trials; of these, 0.4% were fatal.",lung infiltration is an adverse reaction entity
"5.3 Interstitial Lung Disease (ILD)    ILD or ILD-like adverse reactions (e.g., lung infiltration, pneumonitis, acute respiratory distress syndrome, or alveolitis allergic) occurred in 1.5% of the 3865 patients who received GILOTRIF across clinical trials; of these, 0.4% were fatal.",patients who received is not a named entity
"5.3 Interstitial Lung Disease (ILD)    ILD or ILD-like adverse reactions (e.g., lung infiltration, pneumonitis, acute respiratory distress syndrome, or alveolitis allergic) occurred in 1.5% of the 3865 patients who received GILOTRIF across clinical trials; of these, 0.4% were fatal.",ILD-like adverse reactions is an adverse reaction entity
"5.3 Interstitial Lung Disease (ILD)    ILD or ILD-like adverse reactions (e.g., lung infiltration, pneumonitis, acute respiratory distress syndrome, or alveolitis allergic) occurred in 1.5% of the 3865 patients who received GILOTRIF across clinical trials; of these, 0.4% were fatal.","lung infiltration , is not a named entity"
"5.3 Interstitial Lung Disease (ILD)    ILD or ILD-like adverse reactions (e.g., lung infiltration, pneumonitis, acute respiratory distress syndrome, or alveolitis allergic) occurred in 1.5% of the 3865 patients who received GILOTRIF across clinical trials; of these, 0.4% were fatal.","syndrome , is not a named entity"
"5.3 Interstitial Lung Disease (ILD)    ILD or ILD-like adverse reactions (e.g., lung infiltration, pneumonitis, acute respiratory distress syndrome, or alveolitis allergic) occurred in 1.5% of the 3865 patients who received GILOTRIF across clinical trials; of these, 0.4% were fatal.",acute respiratory distress syndrome is an adverse reaction entity
"5.3 Interstitial Lung Disease (ILD)    ILD or ILD-like adverse reactions (e.g., lung infiltration, pneumonitis, acute respiratory distress syndrome, or alveolitis allergic) occurred in 1.5% of the 3865 patients who received GILOTRIF across clinical trials; of these, 0.4% were fatal.",pneumonitis is an adverse reaction entity
"5.3 Interstitial Lung Disease (ILD)    ILD or ILD-like adverse reactions (e.g., lung infiltration, pneumonitis, acute respiratory distress syndrome, or alveolitis allergic) occurred in 1.5% of the 3865 patients who received GILOTRIF across clinical trials; of these, 0.4% were fatal.",", pneumonitis is not a named entity"
"5.3 Interstitial Lung Disease (ILD)    ILD or ILD-like adverse reactions (e.g., lung infiltration, pneumonitis, acute respiratory distress syndrome, or alveolitis allergic) occurred in 1.5% of the 3865 patients who received GILOTRIF across clinical trials; of these, 0.4% were fatal.",fatal is an adverse reaction entity
"5.3 Interstitial Lung Disease (ILD)    ILD or ILD-like adverse reactions (e.g., lung infiltration, pneumonitis, acute respiratory distress syndrome, or alveolitis allergic) occurred in 1.5% of the 3865 patients who received GILOTRIF across clinical trials; of these, 0.4% were fatal.",) ILD is not a named entity
"5.3 Interstitial Lung Disease (ILD)    ILD or ILD-like adverse reactions (e.g., lung infiltration, pneumonitis, acute respiratory distress syndrome, or alveolitis allergic) occurred in 1.5% of the 3865 patients who received GILOTRIF across clinical trials; of these, 0.4% were fatal.",GILOTRIF is not a named entity
"5.3 Interstitial Lung Disease (ILD)    ILD or ILD-like adverse reactions (e.g., lung infiltration, pneumonitis, acute respiratory distress syndrome, or alveolitis allergic) occurred in 1.5% of the 3865 patients who received GILOTRIF across clinical trials; of these, 0.4% were fatal.",ILD is an adverse reaction entity
"5.3 Interstitial Lung Disease (ILD)    ILD or ILD-like adverse reactions (e.g., lung infiltration, pneumonitis, acute respiratory distress syndrome, or alveolitis allergic) occurred in 1.5% of the 3865 patients who received GILOTRIF across clinical trials; of these, 0.4% were fatal.",who received GILOTRIF is not a named entity
"5.3 Interstitial Lung Disease (ILD)    ILD or ILD-like adverse reactions (e.g., lung infiltration, pneumonitis, acute respiratory distress syndrome, or alveolitis allergic) occurred in 1.5% of the 3865 patients who received GILOTRIF across clinical trials; of these, 0.4% were fatal.",alveolitis allergic is an adverse reaction entity
"In Study 1, the incidence of Grade >=3 ILD was 1.3% and resulted in death in 1% of GILOTRIF-treated patients.",and is not a named entity
"In Study 1, the incidence of Grade >=3 ILD was 1.3% and resulted in death in 1% of GILOTRIF-treated patients.",ILD is an adverse reaction entity
"In Study 1, the incidence of Grade >=3 ILD was 1.3% and resulted in death in 1% of GILOTRIF-treated patients.",death is an adverse reaction entity
"In Study 1, the incidence of Grade >=3 ILD was 1.3% and resulted in death in 1% of GILOTRIF-treated patients.",In Study is not a named entity
"The adverse events observed during long-term, open-label studies were similar to those observed in the 12-week, placebo-controlled studies, and included dry mouth, constipation, dry eyes, dyspepsia, and abdominal pain.",in the 12-week is not a named entity
"The adverse events observed during long-term, open-label studies were similar to those observed in the 12-week, placebo-controlled studies, and included dry mouth, constipation, dry eyes, dyspepsia, and abdominal pain.","long-term , is not a named entity"
"The adverse events observed during long-term, open-label studies were similar to those observed in the 12-week, placebo-controlled studies, and included dry mouth, constipation, dry eyes, dyspepsia, and abdominal pain.",dry eyes is an adverse reaction entity
"The adverse events observed during long-term, open-label studies were similar to those observed in the 12-week, placebo-controlled studies, and included dry mouth, constipation, dry eyes, dyspepsia, and abdominal pain.",constipation is an adverse reaction entity
"The adverse events observed during long-term, open-label studies were similar to those observed in the 12-week, placebo-controlled studies, and included dry mouth, constipation, dry eyes, dyspepsia, and abdominal pain.",The adverse is not a named entity
"The adverse events observed during long-term, open-label studies were similar to those observed in the 12-week, placebo-controlled studies, and included dry mouth, constipation, dry eyes, dyspepsia, and abdominal pain.",abdominal pain is an adverse reaction entity
"The adverse events observed during long-term, open-label studies were similar to those observed in the 12-week, placebo-controlled studies, and included dry mouth, constipation, dry eyes, dyspepsia, and abdominal pain.",open-label is not a named entity
"The adverse events observed during long-term, open-label studies were similar to those observed in the 12-week, placebo-controlled studies, and included dry mouth, constipation, dry eyes, dyspepsia, and abdominal pain.",in the is not a named entity
"The adverse events observed during long-term, open-label studies were similar to those observed in the 12-week, placebo-controlled studies, and included dry mouth, constipation, dry eyes, dyspepsia, and abdominal pain.",dyspepsia is an adverse reaction entity
"The adverse events observed during long-term, open-label studies were similar to those observed in the 12-week, placebo-controlled studies, and included dry mouth, constipation, dry eyes, dyspepsia, and abdominal pain.",dry mouth is an adverse reaction entity
"Dry mouth led to discontinuation in 0.4%, 0.4%, and 0.8% of patients receiving placebo, Toviaz 4 mg, and Toviaz 8 mg, respectively.",to discontinuation is not a named entity
"Dry mouth led to discontinuation in 0.4%, 0.4%, and 0.8% of patients receiving placebo, Toviaz 4 mg, and Toviaz 8 mg, respectively.",Dry mouth is an adverse reaction entity
"(  5.9  )             5.1 Angioedema      Angioedema of the face, lips, tongue, and/or larynx has been reported with fesoterodine.",) is not a named entity
"(  5.9  )             5.1 Angioedema      Angioedema of the face, lips, tongue, and/or larynx has been reported with fesoterodine.",Angioedema of the face is an adverse reaction entity
"(  5.9  )             5.1 Angioedema      Angioedema of the face, lips, tongue, and/or larynx has been reported with fesoterodine.",larynx has been is not a named entity
"(  5.9  )             5.1 Angioedema      Angioedema of the face, lips, tongue, and/or larynx has been reported with fesoterodine.",Angioedema of the tongue is an adverse reaction entity
"(  5.9  )             5.1 Angioedema      Angioedema of the face, lips, tongue, and/or larynx has been reported with fesoterodine.",larynx is not a named entity
"(  5.9  )             5.1 Angioedema      Angioedema of the face, lips, tongue, and/or larynx has been reported with fesoterodine.",Angioedema of the lips is an adverse reaction entity
"(  5.9  )             5.1 Angioedema      Angioedema of the face, lips, tongue, and/or larynx has been reported with fesoterodine.",Angioedema of the larynx is an adverse reaction entity
"(  5.9  )             5.1 Angioedema      Angioedema of the face, lips, tongue, and/or larynx has been reported with fesoterodine.",5.9 ) is not a named entity
"The incidence of constipation was 2% in those taking placebo, 4% in those taking 4 mg/day, and 6% in those taking 8 mg/day.",% in those is not a named entity
"The incidence of constipation was 2% in those taking placebo, 4% in those taking 4 mg/day, and 6% in those taking 8 mg/day.",constipation is an adverse reaction entity
"All serious adverse events were judged to be not related or unlikely to be related to study medication by the investigator, except for four patients receiving Toviaz who reported one serious adverse event each: angina, chest pain, gastroenteritis, and QT prolongation on ECG.",chest pain is an adverse reaction entity
"All serious adverse events were judged to be not related or unlikely to be related to study medication by the investigator, except for four patients receiving Toviaz who reported one serious adverse event each: angina, chest pain, gastroenteritis, and QT prolongation on ECG.",gastroenteritis is an adverse reaction entity
"All serious adverse events were judged to be not related or unlikely to be related to study medication by the investigator, except for four patients receiving Toviaz who reported one serious adverse event each: angina, chest pain, gastroenteritis, and QT prolongation on ECG.",QT prolongation is an adverse reaction entity
"All serious adverse events were judged to be not related or unlikely to be related to study medication by the investigator, except for four patients receiving Toviaz who reported one serious adverse event each: angina, chest pain, gastroenteritis, and QT prolongation on ECG.",event each : is not a named entity
"All serious adverse events were judged to be not related or unlikely to be related to study medication by the investigator, except for four patients receiving Toviaz who reported one serious adverse event each: angina, chest pain, gastroenteritis, and QT prolongation on ECG.",on is not a named entity
"All serious adverse events were judged to be not related or unlikely to be related to study medication by the investigator, except for four patients receiving Toviaz who reported one serious adverse event each: angina, chest pain, gastroenteritis, and QT prolongation on ECG.","pain , gastroenteritis is not a named entity"
"All serious adverse events were judged to be not related or unlikely to be related to study medication by the investigator, except for four patients receiving Toviaz who reported one serious adverse event each: angina, chest pain, gastroenteritis, and QT prolongation on ECG.",angina is an adverse reaction entity
"All serious adverse events were judged to be not related or unlikely to be related to study medication by the investigator, except for four patients receiving Toviaz who reported one serious adverse event each: angina, chest pain, gastroenteritis, and QT prolongation on ECG.",", chest pain is not a named entity"
"Serious adverse events, judged to be at least possibly related to study medication by the investigator and reported more than once during the open-label treatment period of up to 3 years, included urinary retention (3 cases), diverticulitis (3 cases), constipation (2 cases), irritable bowel syndrome (2 cases), and electrocardiogram QT corrected interval prolongation (2 cases).",", irritable bowel is not a named entity"
"Serious adverse events, judged to be at least possibly related to study medication by the investigator and reported more than once during the open-label treatment period of up to 3 years, included urinary retention (3 cases), diverticulitis (3 cases), constipation (2 cases), irritable bowel syndrome (2 cases), and electrocardiogram QT corrected interval prolongation (2 cases).",QT corrected interval prolongation is an adverse reaction entity
"Serious adverse events, judged to be at least possibly related to study medication by the investigator and reported more than once during the open-label treatment period of up to 3 years, included urinary retention (3 cases), diverticulitis (3 cases), constipation (2 cases), irritable bowel syndrome (2 cases), and electrocardiogram QT corrected interval prolongation (2 cases).","cases ) , is not a named entity"
"Serious adverse events, judged to be at least possibly related to study medication by the investigator and reported more than once during the open-label treatment period of up to 3 years, included urinary retention (3 cases), diverticulitis (3 cases), constipation (2 cases), irritable bowel syndrome (2 cases), and electrocardiogram QT corrected interval prolongation (2 cases).",irritable bowel syndrome is an adverse reaction entity
"Serious adverse events, judged to be at least possibly related to study medication by the investigator and reported more than once during the open-label treatment period of up to 3 years, included urinary retention (3 cases), diverticulitis (3 cases), constipation (2 cases), irritable bowel syndrome (2 cases), and electrocardiogram QT corrected interval prolongation (2 cases).",constipation ( 2 is not a named entity
"Serious adverse events, judged to be at least possibly related to study medication by the investigator and reported more than once during the open-label treatment period of up to 3 years, included urinary retention (3 cases), diverticulitis (3 cases), constipation (2 cases), irritable bowel syndrome (2 cases), and electrocardiogram QT corrected interval prolongation (2 cases).",of up is not a named entity
"Serious adverse events, judged to be at least possibly related to study medication by the investigator and reported more than once during the open-label treatment period of up to 3 years, included urinary retention (3 cases), diverticulitis (3 cases), constipation (2 cases), irritable bowel syndrome (2 cases), and electrocardiogram QT corrected interval prolongation (2 cases).",constipation is an adverse reaction entity
"Serious adverse events, judged to be at least possibly related to study medication by the investigator and reported more than once during the open-label treatment period of up to 3 years, included urinary retention (3 cases), diverticulitis (3 cases), constipation (2 cases), irritable bowel syndrome (2 cases), and electrocardiogram QT corrected interval prolongation (2 cases).",diverticulitis is an adverse reaction entity
"Serious adverse events, judged to be at least possibly related to study medication by the investigator and reported more than once during the open-label treatment period of up to 3 years, included urinary retention (3 cases), diverticulitis (3 cases), constipation (2 cases), irritable bowel syndrome (2 cases), and electrocardiogram QT corrected interval prolongation (2 cases).",urinary retention is an adverse reaction entity
"Serious adverse events, judged to be at least possibly related to study medication by the investigator and reported more than once during the open-label treatment period of up to 3 years, included urinary retention (3 cases), diverticulitis (3 cases), constipation (2 cases), irritable bowel syndrome (2 cases), and electrocardiogram QT corrected interval prolongation (2 cases).",to 3 is not a named entity
"The incidence of dry mouth was higher in those taking 8 mg/day (35%) and in those taking 4 mg/day (19%), as compared to placebo (7%).",( is not a named entity
"The incidence of dry mouth was higher in those taking 8 mg/day (35%) and in those taking 4 mg/day (19%), as compared to placebo (7%).",dry mouth is an adverse reaction entity
"For those patients who reported dry mouth, most had their first occurrence of the event within the first month of treatment.",dry mouth is an adverse reaction entity
"For those patients who reported dry mouth, most had their first occurrence of the event within the first month of treatment.",of treatment is not a named entity
"Similar to the controlled studies, most adverse events of dry mouth and constipation were mild to moderate in intensity.",of dry is not a named entity
"Similar to the controlled studies, most adverse events of dry mouth and constipation were mild to moderate in intensity.",dry mouth is an adverse reaction entity
"Similar to the controlled studies, most adverse events of dry mouth and constipation were mild to moderate in intensity.",of dry mouth is not a named entity
"Similar to the controlled studies, most adverse events of dry mouth and constipation were mild to moderate in intensity.",constipation is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *    Angioedema of the face, lips, tongue, and/or larynx has been reported with fesoterodine.",Angioedema of the tongue is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *    Angioedema of the face, lips, tongue, and/or larynx has been reported with fesoterodine.","tongue , is not a named entity"
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *    Angioedema of the face, lips, tongue, and/or larynx has been reported with fesoterodine.",Angioedema of the lips is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *    Angioedema of the face, lips, tongue, and/or larynx has been reported with fesoterodine.",Angioedema of the larynx is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *    Angioedema of the face, lips, tongue, and/or larynx has been reported with fesoterodine.",: * is not a named entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *    Angioedema of the face, lips, tongue, and/or larynx has been reported with fesoterodine.",Angioedema of the face is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *    Angioedema of the face, lips, tongue, and/or larynx has been reported with fesoterodine.",PRECAUTIONS is not a named entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *    Angioedema of the face, lips, tongue, and/or larynx has been reported with fesoterodine.",* Angioedema is not a named entity
6 ADVERSE REACTIONS    EXCERPT:   Hypersensitivity and injection site reactions have been reported following DaTscan administration.,injection site reactions is an adverse reaction entity
6 ADVERSE REACTIONS    EXCERPT:   Hypersensitivity and injection site reactions have been reported following DaTscan administration.,REACTIONS EXCERPT : is not a named entity
6 ADVERSE REACTIONS    EXCERPT:   Hypersensitivity and injection site reactions have been reported following DaTscan administration.,Hypersensitivity is an adverse reaction entity
6 ADVERSE REACTIONS    EXCERPT:   Hypersensitivity and injection site reactions have been reported following DaTscan administration.,have been is not a named entity
The reactions generally related to rash and pruritis within minutes of DaTscan administration.,The reactions generally is not a named entity
The reactions generally related to rash and pruritis within minutes of DaTscan administration.,rash is an adverse reaction entity
The reactions generally related to rash and pruritis within minutes of DaTscan administration.,pruritis within is not a named entity
The reactions generally related to rash and pruritis within minutes of DaTscan administration.,pruritis is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Hypersensitivity reactions have been reported following DaTscan administration.,5 WARNINGS is not a named entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Hypersensitivity reactions have been reported following DaTscan administration.,Hypersensitivity reactions is an adverse reaction entity
The reactions have generally consisted of skin erythema and pruritis and have either resolved spontaneously or following the administration of corticosteroids and anti-histamines.,pruritis is an adverse reaction entity
The reactions have generally consisted of skin erythema and pruritis and have either resolved spontaneously or following the administration of corticosteroids and anti-histamines.,following the administration is not a named entity
The reactions have generally consisted of skin erythema and pruritis and have either resolved spontaneously or following the administration of corticosteroids and anti-histamines.,erythema is not a named entity
The reactions have generally consisted of skin erythema and pruritis and have either resolved spontaneously or following the administration of corticosteroids and anti-histamines.,skin erythema is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS     EXCERPT:    *  Mineralocorticoid excess: Use ZYTIGA with caution in patients with a history of cardiovascular disease.,Mineralocorticoid excess is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS     EXCERPT:    *  Mineralocorticoid excess: Use ZYTIGA with caution in patients with a history of cardiovascular disease.,with is not a named entity
(5.1)   *  Adrenocortical insufficiency: Monitor for symptoms and signs of adrenocortical insufficiency.,Adrenocortical insufficiency is an adverse reaction entity
(5.1)   *  Adrenocortical insufficiency: Monitor for symptoms and signs of adrenocortical insufficiency.,5.1 ) * is not a named entity
"The most common adverse drug reactions (>=10%) reported in the two randomized clinical trials that occurred more commonly (>2%) in the abiraterone acetate arm were fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.",the is not a named entity
"The most common adverse drug reactions (>=10%) reported in the two randomized clinical trials that occurred more commonly (>2%) in the abiraterone acetate arm were fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.",adverse drug is not a named entity
"The most common adverse drug reactions (>=10%) reported in the two randomized clinical trials that occurred more commonly (>2%) in the abiraterone acetate arm were fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.",joint swelling is an adverse reaction entity
"The most common adverse drug reactions (>=10%) reported in the two randomized clinical trials that occurred more commonly (>2%) in the abiraterone acetate arm were fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.",) reported in is not a named entity
"The most common adverse drug reactions (>=10%) reported in the two randomized clinical trials that occurred more commonly (>2%) in the abiraterone acetate arm were fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.",diarrhea is an adverse reaction entity
"The most common adverse drug reactions (>=10%) reported in the two randomized clinical trials that occurred more commonly (>2%) in the abiraterone acetate arm were fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.",hypertension is an adverse reaction entity
"The most common adverse drug reactions (>=10%) reported in the two randomized clinical trials that occurred more commonly (>2%) in the abiraterone acetate arm were fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.",abiraterone is not a named entity
"The most common adverse drug reactions (>=10%) reported in the two randomized clinical trials that occurred more commonly (>2%) in the abiraterone acetate arm were fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.",drug reactions is not a named entity
"The most common adverse drug reactions (>=10%) reported in the two randomized clinical trials that occurred more commonly (>2%) in the abiraterone acetate arm were fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.",abiraterone acetate arm is not a named entity
"The most common adverse drug reactions (>=10%) reported in the two randomized clinical trials that occurred more commonly (>2%) in the abiraterone acetate arm were fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.",common adverse drug is not a named entity
"The most common adverse drug reactions (>=10%) reported in the two randomized clinical trials that occurred more commonly (>2%) in the abiraterone acetate arm were fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.",The most common is not a named entity
"The most common adverse drug reactions (>=10%) reported in the two randomized clinical trials that occurred more commonly (>2%) in the abiraterone acetate arm were fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.",occurred more is not a named entity
"The most common adverse drug reactions (>=10%) reported in the two randomized clinical trials that occurred more commonly (>2%) in the abiraterone acetate arm were fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.",hot flush is an adverse reaction entity
"The most common adverse drug reactions (>=10%) reported in the two randomized clinical trials that occurred more commonly (>2%) in the abiraterone acetate arm were fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.",2 % is not a named entity
"The most common adverse drug reactions (>=10%) reported in the two randomized clinical trials that occurred more commonly (>2%) in the abiraterone acetate arm were fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.",", hypertension , is not a named entity"
"The most common adverse drug reactions (>=10%) reported in the two randomized clinical trials that occurred more commonly (>2%) in the abiraterone acetate arm were fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.",dyspnea is an adverse reaction entity
"The most common adverse drug reactions (>=10%) reported in the two randomized clinical trials that occurred more commonly (>2%) in the abiraterone acetate arm were fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.","hypertension , is not a named entity"
"The most common adverse drug reactions (>=10%) reported in the two randomized clinical trials that occurred more commonly (>2%) in the abiraterone acetate arm were fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.",contusion is an adverse reaction entity
"The most common adverse drug reactions (>=10%) reported in the two randomized clinical trials that occurred more commonly (>2%) in the abiraterone acetate arm were fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.",joint discomfort is an adverse reaction entity
"The most common adverse drug reactions (>=10%) reported in the two randomized clinical trials that occurred more commonly (>2%) in the abiraterone acetate arm were fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.",urinary tract infection is an adverse reaction entity
"The most common adverse drug reactions (>=10%) reported in the two randomized clinical trials that occurred more commonly (>2%) in the abiraterone acetate arm were fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.",edema is an adverse reaction entity
"The most common adverse drug reactions (>=10%) reported in the two randomized clinical trials that occurred more commonly (>2%) in the abiraterone acetate arm were fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.",fatigue is an adverse reaction entity
"The most common adverse drug reactions (>=10%) reported in the two randomized clinical trials that occurred more commonly (>2%) in the abiraterone acetate arm were fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.",vomiting is an adverse reaction entity
"The most common adverse drug reactions (>=10%) reported in the two randomized clinical trials that occurred more commonly (>2%) in the abiraterone acetate arm were fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.",cough is an adverse reaction entity
There were no treatment discontinuations and one death due to cardiac failure in the placebo group.,failure in the is not a named entity
There were no treatment discontinuations and one death due to cardiac failure in the placebo group.,cardiac failure is an adverse reaction entity
There were no treatment discontinuations and one death due to cardiac failure in the placebo group.,death is an adverse reaction entity
There were no treatment discontinuations and one death due to cardiac failure in the placebo group.,due to cardiac is not a named entity
Myocardial ischemia or myocardial infarction led to death in 3 patients in the placebo arms and 2 deaths in the ZYTIGA arms.,ischemia or is not a named entity
Myocardial ischemia or myocardial infarction led to death in 3 patients in the placebo arms and 2 deaths in the ZYTIGA arms.,deaths is an adverse reaction entity
Myocardial ischemia or myocardial infarction led to death in 3 patients in the placebo arms and 2 deaths in the ZYTIGA arms.,in the is not a named entity
Myocardial ischemia or myocardial infarction led to death in 3 patients in the placebo arms and 2 deaths in the ZYTIGA arms.,Myocardial ischemia is an adverse reaction entity
Myocardial ischemia or myocardial infarction led to death in 3 patients in the placebo arms and 2 deaths in the ZYTIGA arms.,myocardial infarction is an adverse reaction entity
Myocardial ischemia or myocardial infarction led to death in 3 patients in the placebo arms and 2 deaths in the ZYTIGA arms.,death is an adverse reaction entity
Myocardial ischemia or myocardial infarction led to death in 3 patients in the placebo arms and 2 deaths in the ZYTIGA arms.,placebo arms and is not a named entity
Myocardial ischemia or myocardial infarction led to death in 3 patients in the placebo arms and 2 deaths in the ZYTIGA arms.,2 deaths in is not a named entity
Treatment discontinuation due to liver enzyme increases occurred in 1% of patients taking ZYTIGA.,due to liver is not a named entity
Treatment discontinuation due to liver enzyme increases occurred in 1% of patients taking ZYTIGA.,liver enzyme increases is an adverse reaction entity
Grade 3-4 low serum phosphorus (7%) and low potassium (5%) occurred at a greater than or equal to 5% rate in the ZYTIGA arm.,low serum phosphorus is an adverse reaction entity
Grade 3-4 low serum phosphorus (7%) and low potassium (5%) occurred at a greater than or equal to 5% rate in the ZYTIGA arm.,5 is not a named entity
Grade 3-4 low serum phosphorus (7%) and low potassium (5%) occurred at a greater than or equal to 5% rate in the ZYTIGA arm.,low potassium is an adverse reaction entity
Grade 3-4 low serum phosphorus (7%) and low potassium (5%) occurred at a greater than or equal to 5% rate in the ZYTIGA arm.,at is not a named entity
"Musculoskeletal and Connective Tissue Disorders  : myopathy, including rhabdomyolysis.",", including rhabdomyolysis is not a named entity"
"Musculoskeletal and Connective Tissue Disorders  : myopathy, including rhabdomyolysis.",: is not a named entity
"Musculoskeletal and Connective Tissue Disorders  : myopathy, including rhabdomyolysis.",rhabdomyolysis is an adverse reaction entity
"Musculoskeletal and Connective Tissue Disorders  : myopathy, including rhabdomyolysis.",myopathy is an adverse reaction entity
"In the two randomized clinical trials, grade 3 to 4 hypertension occurred in 2% of patients, grade 3 to 4 hypokalemia in 4% of patients, and grade 3 to 4 edema in 1% of patients treated with ZYTIGA  [seeAdverse Reactions (6)]  .",hypertension is an adverse reaction entity
"In the two randomized clinical trials, grade 3 to 4 hypertension occurred in 2% of patients, grade 3 to 4 hypokalemia in 4% of patients, and grade 3 to 4 edema in 1% of patients treated with ZYTIGA  [seeAdverse Reactions (6)]  .","clinical trials , is not a named entity"
"In the two randomized clinical trials, grade 3 to 4 hypertension occurred in 2% of patients, grade 3 to 4 hypokalemia in 4% of patients, and grade 3 to 4 edema in 1% of patients treated with ZYTIGA  [seeAdverse Reactions (6)]  .",hypokalemia is an adverse reaction entity
"In the two randomized clinical trials, grade 3 to 4 hypertension occurred in 2% of patients, grade 3 to 4 hypokalemia in 4% of patients, and grade 3 to 4 edema in 1% of patients treated with ZYTIGA  [seeAdverse Reactions (6)]  .",grade 3 to is not a named entity
"In the two randomized clinical trials, grade 3 to 4 hypertension occurred in 2% of patients, grade 3 to 4 hypokalemia in 4% of patients, and grade 3 to 4 edema in 1% of patients treated with ZYTIGA  [seeAdverse Reactions (6)]  .",edema is an adverse reaction entity
"In the two randomized clinical trials, grade 3 to 4 hypertension occurred in 2% of patients, grade 3 to 4 hypokalemia in 4% of patients, and grade 3 to 4 edema in 1% of patients treated with ZYTIGA  [seeAdverse Reactions (6)]  .",treated is not a named entity
There was one death associated with arrhythmia and one patient with sudden death in the ZYTIGA arms and no deaths in the placebo arms.,sudden death is an adverse reaction entity
There was one death associated with arrhythmia and one patient with sudden death in the ZYTIGA arms and no deaths in the placebo arms.,one is not a named entity
There was one death associated with arrhythmia and one patient with sudden death in the ZYTIGA arms and no deaths in the placebo arms.,patient with is not a named entity
There was one death associated with arrhythmia and one patient with sudden death in the ZYTIGA arms and no deaths in the placebo arms.,sudden death in is not a named entity
There was one death associated with arrhythmia and one patient with sudden death in the ZYTIGA arms and no deaths in the placebo arms.,the is not a named entity
There was one death associated with arrhythmia and one patient with sudden death in the ZYTIGA arms and no deaths in the placebo arms.,deaths is an adverse reaction entity
There was one death associated with arrhythmia and one patient with sudden death in the ZYTIGA arms and no deaths in the placebo arms.,arrhythmia is an adverse reaction entity
There was one death associated with arrhythmia and one patient with sudden death in the ZYTIGA arms and no deaths in the placebo arms.,death is an adverse reaction entity
"EXCERPT:   The most common adverse reactions (>=10%) are fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.",are is not a named entity
"EXCERPT:   The most common adverse reactions (>=10%) are fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.",vomiting is an adverse reaction entity
"EXCERPT:   The most common adverse reactions (>=10%) are fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.",urinary tract infection is an adverse reaction entity
"EXCERPT:   The most common adverse reactions (>=10%) are fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.",dyspnea is an adverse reaction entity
"EXCERPT:   The most common adverse reactions (>=10%) are fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.",diarrhea is an adverse reaction entity
"EXCERPT:   The most common adverse reactions (>=10%) are fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.",", hot is not a named entity"
"EXCERPT:   The most common adverse reactions (>=10%) are fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.",cough is an adverse reaction entity
"EXCERPT:   The most common adverse reactions (>=10%) are fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.",( > is not a named entity
"EXCERPT:   The most common adverse reactions (>=10%) are fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.",% ) is not a named entity
"EXCERPT:   The most common adverse reactions (>=10%) are fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.","vomiting , cough is not a named entity"
"EXCERPT:   The most common adverse reactions (>=10%) are fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.",", urinary is not a named entity"
"EXCERPT:   The most common adverse reactions (>=10%) are fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.",", diarrhea , is not a named entity"
"EXCERPT:   The most common adverse reactions (>=10%) are fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.",", urinary tract is not a named entity"
"EXCERPT:   The most common adverse reactions (>=10%) are fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.",joint discomfort is an adverse reaction entity
"EXCERPT:   The most common adverse reactions (>=10%) are fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.",hot flush is an adverse reaction entity
"EXCERPT:   The most common adverse reactions (>=10%) are fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.",edema is an adverse reaction entity
"EXCERPT:   The most common adverse reactions (>=10%) are fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.",", joint is not a named entity"
"EXCERPT:   The most common adverse reactions (>=10%) are fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.","flush , diarrhea is not a named entity"
"EXCERPT:   The most common adverse reactions (>=10%) are fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.",( > =10 is not a named entity
"EXCERPT:   The most common adverse reactions (>=10%) are fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.",fatigue is an adverse reaction entity
"EXCERPT:   The most common adverse reactions (>=10%) are fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.",contusion is an adverse reaction entity
"EXCERPT:   The most common adverse reactions (>=10%) are fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.",reactions ( is not a named entity
"EXCERPT:   The most common adverse reactions (>=10%) are fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.",joint swelling is an adverse reaction entity
"EXCERPT:   The most common adverse reactions (>=10%) are fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection and contusion.",hypertension is an adverse reaction entity
5.2 Adrenocortical Insufficiency    Adrenal insufficiency occurred in the two randomized clinical studies in 0.5% of patients taking ZYTIGA and in 0.2% of patients taking placebo.,Adrenal insufficiency is an adverse reaction entity
5.2 Adrenocortical Insufficiency    Adrenal insufficiency occurred in the two randomized clinical studies in 0.5% of patients taking ZYTIGA and in 0.2% of patients taking placebo.,two randomized is not a named entity
Patients whose baseline ALT or AST were elevated were more likely to experience liver test elevation than those beginning with normal values.,liver test elevation is an adverse reaction entity
Patients whose baseline ALT or AST were elevated were more likely to experience liver test elevation than those beginning with normal values.,baseline ALT or is not a named entity
"5.3 Hepatotoxicity    In the two randomized clinical trials, grade 3 or 4 ALT or AST increases (at least 5* ULN) were reported in 4% of patients who received ZYTIGA, typically during the first 3 months after starting treatment.",AST increases is an adverse reaction entity
"5.3 Hepatotoxicity    In the two randomized clinical trials, grade 3 or 4 ALT or AST increases (at least 5* ULN) were reported in 4% of patients who received ZYTIGA, typically during the first 3 months after starting treatment.",randomized clinical trials is not a named entity
"5.3 Hepatotoxicity    In the two randomized clinical trials, grade 3 or 4 ALT or AST increases (at least 5* ULN) were reported in 4% of patients who received ZYTIGA, typically during the first 3 months after starting treatment.",ALT increases is an adverse reaction entity
"5.3 Hepatotoxicity    In the two randomized clinical trials, grade 3 or 4 ALT or AST increases (at least 5* ULN) were reported in 4% of patients who received ZYTIGA, typically during the first 3 months after starting treatment.",4 % is not a named entity
"(5.2)   *  Hepatotoxicity: Increases in liver enzymes have led to drug interruption, dose modification and/or discontinuation.",Increases in liver enzymes is an adverse reaction entity
"(5.2)   *  Hepatotoxicity: Increases in liver enzymes have led to drug interruption, dose modification and/or discontinuation.",) * is not a named entity
"(5.2)   *  Hepatotoxicity: Increases in liver enzymes have led to drug interruption, dose modification and/or discontinuation.",", dose modification is not a named entity"
"(5.2)   *  Hepatotoxicity: Increases in liver enzymes have led to drug interruption, dose modification and/or discontinuation.",Hepatotoxicity is an adverse reaction entity
Grade 3-4 cardiac failure occurred in 1.6% of patients taking ZYTIGA and led to 5 treatment discontinuations and 2 deaths.,deaths is an adverse reaction entity
Grade 3-4 cardiac failure occurred in 1.6% of patients taking ZYTIGA and led to 5 treatment discontinuations and 2 deaths.,failure is not a named entity
Grade 3-4 cardiac failure occurred in 1.6% of patients taking ZYTIGA and led to 5 treatment discontinuations and 2 deaths.,2 deaths is not a named entity
Grade 3-4 cardiac failure occurred in 1.6% of patients taking ZYTIGA and led to 5 treatment discontinuations and 2 deaths.,cardiac failure is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS     EXCERPT:    *  Hypertension including hypertensive crisis has been observed.,crisis is not a named entity
5 WARNINGS AND PRECAUTIONS     EXCERPT:    *  Hypertension including hypertensive crisis has been observed.,been observed is not a named entity
5 WARNINGS AND PRECAUTIONS     EXCERPT:    *  Hypertension including hypertensive crisis has been observed.,hypertensive crisis is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS     EXCERPT:    *  Hypertension including hypertensive crisis has been observed.,Hypertension is an adverse reaction entity
The median onset time for hypertension (systolic blood pressure >150 mmHg or diastolic blood pressure >100 mmHg) was within the first month of the start of INLYTA treatment and blood pressure increases have been observed as early as 4 days after starting INLYTA.,hypertension is an adverse reaction entity
The median onset time for hypertension (systolic blood pressure >150 mmHg or diastolic blood pressure >100 mmHg) was within the first month of the start of INLYTA treatment and blood pressure increases have been observed as early as 4 days after starting INLYTA.,blood pressure increases is an adverse reaction entity
The median onset time for hypertension (systolic blood pressure >150 mmHg or diastolic blood pressure >100 mmHg) was within the first month of the start of INLYTA treatment and blood pressure increases have been observed as early as 4 days after starting INLYTA.,start is not a named entity
The median onset time for hypertension (systolic blood pressure >150 mmHg or diastolic blood pressure >100 mmHg) was within the first month of the start of INLYTA treatment and blood pressure increases have been observed as early as 4 days after starting INLYTA.,( is not a named entity
The median onset time for hypertension (systolic blood pressure >150 mmHg or diastolic blood pressure >100 mmHg) was within the first month of the start of INLYTA treatment and blood pressure increases have been observed as early as 4 days after starting INLYTA.,of is not a named entity
The median onset time for hypertension (systolic blood pressure >150 mmHg or diastolic blood pressure >100 mmHg) was within the first month of the start of INLYTA treatment and blood pressure increases have been observed as early as 4 days after starting INLYTA.,systolic blood pressure >150 mmHg is an adverse reaction entity
The median onset time for hypertension (systolic blood pressure >150 mmHg or diastolic blood pressure >100 mmHg) was within the first month of the start of INLYTA treatment and blood pressure increases have been observed as early as 4 days after starting INLYTA.,diastolic blood pressure >100 mmHg is an adverse reaction entity
The median onset time for hypertension (systolic blood pressure >150 mmHg or diastolic blood pressure >100 mmHg) was within the first month of the start of INLYTA treatment and blood pressure increases have been observed as early as 4 days after starting INLYTA.,the first is not a named entity
"5.7 Thyroid Dysfunction    In a controlled clinical study with INLYTA for the treatment of patients with RCC, hypothyroidism was reported in 69/359 patients (19%) receiving INLYTA and 29/355 patients (8%) receiving sorafenib.",sorafenib is not a named entity
"5.7 Thyroid Dysfunction    In a controlled clinical study with INLYTA for the treatment of patients with RCC, hypothyroidism was reported in 69/359 patients (19%) receiving INLYTA and 29/355 patients (8%) receiving sorafenib.",hypothyroidism is an adverse reaction entity
(5.8)   *  Reversible Posterior Leukoencephalopathy Syndrome (RPLS) has been observed.,( is not a named entity
(5.8)   *  Reversible Posterior Leukoencephalopathy Syndrome (RPLS) has been observed.,RPLS is an adverse reaction entity
(5.8)   *  Reversible Posterior Leukoencephalopathy Syndrome (RPLS) has been observed.,has been observed is not a named entity
(5.8)   *  Reversible Posterior Leukoencephalopathy Syndrome (RPLS) has been observed.,Reversible Posterior Leukoencephalopathy Syndrome is an adverse reaction entity
"5.3 Venous Thromboembolic Events    In clinical trials, venous thromboembolic events have been reported, including deaths.",reported is not a named entity
"5.3 Venous Thromboembolic Events    In clinical trials, venous thromboembolic events have been reported, including deaths.",venous thromboembolic events is an adverse reaction entity
"5.3 Venous Thromboembolic Events    In clinical trials, venous thromboembolic events have been reported, including deaths.",", is not a named entity"
"5.3 Venous Thromboembolic Events    In clinical trials, venous thromboembolic events have been reported, including deaths.",deaths is an adverse reaction entity
(5.6)   *  Hypothyroidism requiring thyroid hormone replacement has been reported.,Hypothyroidism is an adverse reaction entity
(5.6)   *  Hypothyroidism requiring thyroid hormone replacement has been reported.,hormone replacement is not a named entity
"Grade 3/4 venous thromboembolic events were reported in 9/359 patients (3%) receiving INLYTA (including pulmonary embolism, deep vein thrombosis, retinal vein occlusion and retinal vein thrombosis) and 2/355 patients (1%) receiving sorafenib.",venous thromboembolic events is an adverse reaction entity
"Grade 3/4 venous thromboembolic events were reported in 9/359 patients (3%) receiving INLYTA (including pulmonary embolism, deep vein thrombosis, retinal vein occlusion and retinal vein thrombosis) and 2/355 patients (1%) receiving sorafenib.",pulmonary embolism is an adverse reaction entity
"Grade 3/4 venous thromboembolic events were reported in 9/359 patients (3%) receiving INLYTA (including pulmonary embolism, deep vein thrombosis, retinal vein occlusion and retinal vein thrombosis) and 2/355 patients (1%) receiving sorafenib.",deep vein thrombosis is an adverse reaction entity
"Grade 3/4 venous thromboembolic events were reported in 9/359 patients (3%) receiving INLYTA (including pulmonary embolism, deep vein thrombosis, retinal vein occlusion and retinal vein thrombosis) and 2/355 patients (1%) receiving sorafenib.",9/359 patients ( is not a named entity
"Grade 3/4 venous thromboembolic events were reported in 9/359 patients (3%) receiving INLYTA (including pulmonary embolism, deep vein thrombosis, retinal vein occlusion and retinal vein thrombosis) and 2/355 patients (1%) receiving sorafenib.",( is not a named entity
"Grade 3/4 venous thromboembolic events were reported in 9/359 patients (3%) receiving INLYTA (including pulmonary embolism, deep vein thrombosis, retinal vein occlusion and retinal vein thrombosis) and 2/355 patients (1%) receiving sorafenib.",vein is not a named entity
"Grade 3/4 venous thromboembolic events were reported in 9/359 patients (3%) receiving INLYTA (including pulmonary embolism, deep vein thrombosis, retinal vein occlusion and retinal vein thrombosis) and 2/355 patients (1%) receiving sorafenib.",( including is not a named entity
"Grade 3/4 venous thromboembolic events were reported in 9/359 patients (3%) receiving INLYTA (including pulmonary embolism, deep vein thrombosis, retinal vein occlusion and retinal vein thrombosis) and 2/355 patients (1%) receiving sorafenib.",retinal vein thrombosis is an adverse reaction entity
"Grade 3/4 venous thromboembolic events were reported in 9/359 patients (3%) receiving INLYTA (including pulmonary embolism, deep vein thrombosis, retinal vein occlusion and retinal vein thrombosis) and 2/355 patients (1%) receiving sorafenib.",retinal vein occlusion is an adverse reaction entity
"Grade 3/4 venous thromboembolic events were reported in 9/359 patients (3%) receiving INLYTA (including pulmonary embolism, deep vein thrombosis, retinal vein occlusion and retinal vein thrombosis) and 2/355 patients (1%) receiving sorafenib.",and retinal vein is not a named entity
"5.11 Elevation of Liver Enzymes    In a controlled clinical study with INLYTA for the treatment of patients with RCC, alanine aminotransferase (ALT) elevations of all grades occurred in 22% of patients on both arms, with Grade 3/4 events in <1% of patients on the INLYTA arm and 2% of patients on the sorafenib arm.",2 % is not a named entity
"5.11 Elevation of Liver Enzymes    In a controlled clinical study with INLYTA for the treatment of patients with RCC, alanine aminotransferase (ALT) elevations of all grades occurred in 22% of patients on both arms, with Grade 3/4 events in <1% of patients on the INLYTA arm and 2% of patients on the sorafenib arm.",", is not a named entity"
"5.11 Elevation of Liver Enzymes    In a controlled clinical study with INLYTA for the treatment of patients with RCC, alanine aminotransferase (ALT) elevations of all grades occurred in 22% of patients on both arms, with Grade 3/4 events in <1% of patients on the INLYTA arm and 2% of patients on the sorafenib arm.",alanine aminotransferase elevations is an adverse reaction entity
"5.11 Elevation of Liver Enzymes    In a controlled clinical study with INLYTA for the treatment of patients with RCC, alanine aminotransferase (ALT) elevations of all grades occurred in 22% of patients on both arms, with Grade 3/4 events in <1% of patients on the INLYTA arm and 2% of patients on the sorafenib arm.",ALT elevations is an adverse reaction entity
"5.11 Elevation of Liver Enzymes    In a controlled clinical study with INLYTA for the treatment of patients with RCC, alanine aminotransferase (ALT) elevations of all grades occurred in 22% of patients on both arms, with Grade 3/4 events in <1% of patients on the INLYTA arm and 2% of patients on the sorafenib arm.",ALT ) elevations is not a named entity
"5.11 Elevation of Liver Enzymes    In a controlled clinical study with INLYTA for the treatment of patients with RCC, alanine aminotransferase (ALT) elevations of all grades occurred in 22% of patients on both arms, with Grade 3/4 events in <1% of patients on the INLYTA arm and 2% of patients on the sorafenib arm.",ALT elevations is an adverse reaction entity
"5.11 Elevation of Liver Enzymes    In a controlled clinical study with INLYTA for the treatment of patients with RCC, alanine aminotransferase (ALT) elevations of all grades occurred in 22% of patients on both arms, with Grade 3/4 events in <1% of patients on the INLYTA arm and 2% of patients on the sorafenib arm.","both arms , is not a named entity"
"5.11 Elevation of Liver Enzymes    In a controlled clinical study with INLYTA for the treatment of patients with RCC, alanine aminotransferase (ALT) elevations of all grades occurred in 22% of patients on both arms, with Grade 3/4 events in <1% of patients on the INLYTA arm and 2% of patients on the sorafenib arm.",alanine aminotransferase elevations is an adverse reaction entity
"In patients who had thyroid stimulating hormone (TSH) <5 muU/mL before treatment, elevations of TSH to >=10 muU/mL occurred in 79/245 patients (32%) receiving INLYTA and 25/232 patients (11%) receiving sorafenib  [seeAdverse Reactions (6.1)].",> is not a named entity
"In patients who had thyroid stimulating hormone (TSH) <5 muU/mL before treatment, elevations of TSH to >=10 muU/mL occurred in 79/245 patients (32%) receiving INLYTA and 25/232 patients (11%) receiving sorafenib  [seeAdverse Reactions (6.1)].",elevations of TSH is an adverse reaction entity
"5.4 Hemorrhage    In a controlled clinical study with INLYTA for the treatment of patients with RCC, hemorrhagic events were reported in 58/359 patients (16%) receiving INLYTA and 64/355 patients (18%) receiving sorafenib.",hemorrhagic events is an adverse reaction entity
"5.4 Hemorrhage    In a controlled clinical study with INLYTA for the treatment of patients with RCC, hemorrhagic events were reported in 58/359 patients (16%) receiving INLYTA and 64/355 patients (18%) receiving sorafenib.",a controlled is not a named entity
Hypertensive crisis was reported in 2/359 patients (<1%) receiving INLYTA and none of the patients receiving sorafenib.,Hypertensive crisis is an adverse reaction entity
Hypertensive crisis was reported in 2/359 patients (<1%) receiving INLYTA and none of the patients receiving sorafenib.,2/359 is not a named entity
"5.9 Reversible Posterior Leukoencephalopathy Syndrome    In a controlled clinical study with INLYTA for the treatment of patients with RCC, reversible posterior leukoencephalopathy syndrome (RPLS) was reported in 1/359 patients (<1%) receiving INLYTA and none of the patients receiving sorafenib  [seeAdverse Reactions (6.1)]  .",RPLS is an adverse reaction entity
"5.9 Reversible Posterior Leukoencephalopathy Syndrome    In a controlled clinical study with INLYTA for the treatment of patients with RCC, reversible posterior leukoencephalopathy syndrome (RPLS) was reported in 1/359 patients (<1%) receiving INLYTA and none of the patients receiving sorafenib  [seeAdverse Reactions (6.1)]  .",reversible posterior leukoencephalopathy syndrome is an adverse reaction entity
"5.9 Reversible Posterior Leukoencephalopathy Syndrome    In a controlled clinical study with INLYTA for the treatment of patients with RCC, reversible posterior leukoencephalopathy syndrome (RPLS) was reported in 1/359 patients (<1%) receiving INLYTA and none of the patients receiving sorafenib  [seeAdverse Reactions (6.1)]  .",receiving INLYTA and is not a named entity
"5.9 Reversible Posterior Leukoencephalopathy Syndrome    In a controlled clinical study with INLYTA for the treatment of patients with RCC, reversible posterior leukoencephalopathy syndrome (RPLS) was reported in 1/359 patients (<1%) receiving INLYTA and none of the patients receiving sorafenib  [seeAdverse Reactions (6.1)]  .",patients with is not a named entity
"5.2 Arterial Thromboembolic Events    In clinical trials, arterial thromboembolic events have been reported, including deaths.",arterial thromboembolic events is an adverse reaction entity
"5.2 Arterial Thromboembolic Events    In clinical trials, arterial thromboembolic events have been reported, including deaths.",events is not a named entity
"5.2 Arterial Thromboembolic Events    In clinical trials, arterial thromboembolic events have been reported, including deaths.",deaths is an adverse reaction entity
"5.2 Arterial Thromboembolic Events    In clinical trials, arterial thromboembolic events have been reported, including deaths.",", including is not a named entity"
Hyperthyroidism was reported in 4/359 patients (1%) receiving INLYTA and 4/355 patients (1%) receiving sorafenib.,Hyperthyroidism is an adverse reaction entity
Hyperthyroidism was reported in 4/359 patients (1%) receiving INLYTA and 4/355 patients (1%) receiving sorafenib.,receiving is not a named entity
Fatal cardiac failure was reported in 2/359 patients (1%) receiving INLYTA and 1/355 patients (<1%) receiving sorafenib.,cardiac failure is an adverse reaction entity
Fatal cardiac failure was reported in 2/359 patients (1%) receiving INLYTA and 1/355 patients (<1%) receiving sorafenib.,reported in is not a named entity
Fatal cardiac failure was reported in 2/359 patients (1%) receiving INLYTA and 1/355 patients (<1%) receiving sorafenib.,Fatal is an adverse reaction entity
Fatal cardiac failure was reported in 2/359 patients (1%) receiving INLYTA and 1/355 patients (<1%) receiving sorafenib.,receiving INLYTA is not a named entity
Fatal hemorrhage was reported in 1/359 patients (<1%) receiving INLYTA (gastric hemorrhage) and 3/355 patients (1%) receiving sorafenib.,receiving is not a named entity
Fatal hemorrhage was reported in 1/359 patients (<1%) receiving INLYTA (gastric hemorrhage) and 3/355 patients (1%) receiving sorafenib.,1 % is not a named entity
Fatal hemorrhage was reported in 1/359 patients (<1%) receiving INLYTA (gastric hemorrhage) and 3/355 patients (1%) receiving sorafenib.,Fatal is an adverse reaction entity
Fatal hemorrhage was reported in 1/359 patients (<1%) receiving INLYTA (gastric hemorrhage) and 3/355 patients (1%) receiving sorafenib.,hemorrhage is an adverse reaction entity
Fatal hemorrhage was reported in 1/359 patients (<1%) receiving INLYTA (gastric hemorrhage) and 3/355 patients (1%) receiving sorafenib.,) receiving is not a named entity
Fatal hemorrhage was reported in 1/359 patients (<1%) receiving INLYTA (gastric hemorrhage) and 3/355 patients (1%) receiving sorafenib.,gastric hemorrhage is an adverse reaction entity
Discontinuation of INLYTA treatment due to hypertension occurred in 1/359 patients (<1%) receiving INLYTA and none of the patients receiving sorafenib  [seeAdverse Reactions (6.1)].,receiving sorafenib [ is not a named entity
Discontinuation of INLYTA treatment due to hypertension occurred in 1/359 patients (<1%) receiving INLYTA and none of the patients receiving sorafenib  [seeAdverse Reactions (6.1)].,hypertension is an adverse reaction entity
(5.10)   *  Liver enzyme elevation has been observed during treatment with INLYTA.,Liver enzyme elevation is an adverse reaction entity
(5.10)   *  Liver enzyme elevation has been observed during treatment with INLYTA.,has is not a named entity
Grade 3/4 hypertension was observed in 56/359 patients (16%) receiving INLYTA and 39/355 patients (11%) receiving sorafenib.,sorafenib is not a named entity
Grade 3/4 hypertension was observed in 56/359 patients (16%) receiving INLYTA and 39/355 patients (11%) receiving sorafenib.,hypertension is an adverse reaction entity
"In a controlled clinical study with INLYTA for the treatment of patients with RCC, Grade 3/4 arterial thromboembolic events were reported in 4/359 patients (1%) receiving INLYTA and 4/355 patients (1%) receiving sorafenib.",arterial thromboembolic events is an adverse reaction entity
"In a controlled clinical study with INLYTA for the treatment of patients with RCC, Grade 3/4 arterial thromboembolic events were reported in 4/359 patients (1%) receiving INLYTA and 4/355 patients (1%) receiving sorafenib.",receiving is not a named entity
Fatal pulmonary embolism was reported in 1/359 patients (<1%) receiving INLYTA and none of the patients receiving sorafenib.,pulmonary embolism is an adverse reaction entity
Fatal pulmonary embolism was reported in 1/359 patients (<1%) receiving INLYTA and none of the patients receiving sorafenib.,Fatal is an adverse reaction entity
Fatal pulmonary embolism was reported in 1/359 patients (<1%) receiving INLYTA and none of the patients receiving sorafenib.,) receiving is not a named entity
Fatal pulmonary embolism was reported in 1/359 patients (<1%) receiving INLYTA and none of the patients receiving sorafenib.,reported is not a named entity
"(5.13,8.1)          5.1 Hypertension and Hypertensive Crisis    In a controlled clinical study with INLYTA for the treatment of patients with RCC, hypertension was reported in 145/359 patients (40%) receiving INLYTA and 103/355 patients (29%) receiving sorafenib.",hypertension is an adverse reaction entity
"(5.13,8.1)          5.1 Hypertension and Hypertensive Crisis    In a controlled clinical study with INLYTA for the treatment of patients with RCC, hypertension was reported in 145/359 patients (40%) receiving INLYTA and 103/355 patients (29%) receiving sorafenib.",( is not a named entity
"5.10 Proteinuria    In a controlled clinical study with INLYTA for the treatment of patients with RCC, proteinuria was reported in 39/359 patients (11%) receiving INLYTA and 26/355 patients (7%) receiving sorafenib.",26/355 patients is not a named entity
"5.10 Proteinuria    In a controlled clinical study with INLYTA for the treatment of patients with RCC, proteinuria was reported in 39/359 patients (11%) receiving INLYTA and 26/355 patients (7%) receiving sorafenib.",proteinuria is an adverse reaction entity
"In developmental toxicity studies in mice, axitinib was teratogenic, embryotoxic and fetotoxic at maternal exposures that were lower than human exposures at the recommended clinical dose.",", embryotoxic is not a named entity"
"In developmental toxicity studies in mice, axitinib was teratogenic, embryotoxic and fetotoxic at maternal exposures that were lower than human exposures at the recommended clinical dose.",fetotoxic is an adverse reaction entity
"In developmental toxicity studies in mice, axitinib was teratogenic, embryotoxic and fetotoxic at maternal exposures that were lower than human exposures at the recommended clinical dose.",that were is not a named entity
"In developmental toxicity studies in mice, axitinib was teratogenic, embryotoxic and fetotoxic at maternal exposures that were lower than human exposures at the recommended clinical dose.",embryotoxic is an adverse reaction entity
"In developmental toxicity studies in mice, axitinib was teratogenic, embryotoxic and fetotoxic at maternal exposures that were lower than human exposures at the recommended clinical dose.",human is not a named entity
"In developmental toxicity studies in mice, axitinib was teratogenic, embryotoxic and fetotoxic at maternal exposures that were lower than human exposures at the recommended clinical dose.",teratogenic is an adverse reaction entity
5.13 Pregnancy    INLYTA can cause fetal harm when administered to a pregnant woman based on its mechanism of action.,of is not a named entity
5.13 Pregnancy    INLYTA can cause fetal harm when administered to a pregnant woman based on its mechanism of action.,fetal harm is an adverse reaction entity
"EXCERPT:   The most common (>=20%) adverse reactions are diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, palmar-plantar erythrodysesthesia (hand-foot) syndrome, weight decreased, vomiting, asthenia, and constipation.",hypertension is an adverse reaction entity
"EXCERPT:   The most common (>=20%) adverse reactions are diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, palmar-plantar erythrodysesthesia (hand-foot) syndrome, weight decreased, vomiting, asthenia, and constipation.","vomiting , asthenia is not a named entity"
"EXCERPT:   The most common (>=20%) adverse reactions are diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, palmar-plantar erythrodysesthesia (hand-foot) syndrome, weight decreased, vomiting, asthenia, and constipation.",) syndrome is not a named entity
"EXCERPT:   The most common (>=20%) adverse reactions are diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, palmar-plantar erythrodysesthesia (hand-foot) syndrome, weight decreased, vomiting, asthenia, and constipation.",dysphonia is an adverse reaction entity
"EXCERPT:   The most common (>=20%) adverse reactions are diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, palmar-plantar erythrodysesthesia (hand-foot) syndrome, weight decreased, vomiting, asthenia, and constipation.",weight decreased is an adverse reaction entity
"EXCERPT:   The most common (>=20%) adverse reactions are diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, palmar-plantar erythrodysesthesia (hand-foot) syndrome, weight decreased, vomiting, asthenia, and constipation.",constipation is an adverse reaction entity
"EXCERPT:   The most common (>=20%) adverse reactions are diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, palmar-plantar erythrodysesthesia (hand-foot) syndrome, weight decreased, vomiting, asthenia, and constipation.",fatigue is an adverse reaction entity
"EXCERPT:   The most common (>=20%) adverse reactions are diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, palmar-plantar erythrodysesthesia (hand-foot) syndrome, weight decreased, vomiting, asthenia, and constipation.",", fatigue , is not a named entity"
"EXCERPT:   The most common (>=20%) adverse reactions are diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, palmar-plantar erythrodysesthesia (hand-foot) syndrome, weight decreased, vomiting, asthenia, and constipation.","decreased , vomiting is not a named entity"
"EXCERPT:   The most common (>=20%) adverse reactions are diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, palmar-plantar erythrodysesthesia (hand-foot) syndrome, weight decreased, vomiting, asthenia, and constipation.",nausea is an adverse reaction entity
"EXCERPT:   The most common (>=20%) adverse reactions are diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, palmar-plantar erythrodysesthesia (hand-foot) syndrome, weight decreased, vomiting, asthenia, and constipation.",", fatigue , is not a named entity"
"EXCERPT:   The most common (>=20%) adverse reactions are diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, palmar-plantar erythrodysesthesia (hand-foot) syndrome, weight decreased, vomiting, asthenia, and constipation.",decreased appetite is an adverse reaction entity
"EXCERPT:   The most common (>=20%) adverse reactions are diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, palmar-plantar erythrodysesthesia (hand-foot) syndrome, weight decreased, vomiting, asthenia, and constipation.",appetite is not a named entity
"EXCERPT:   The most common (>=20%) adverse reactions are diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, palmar-plantar erythrodysesthesia (hand-foot) syndrome, weight decreased, vomiting, asthenia, and constipation.",palmar-plantar erythrodysesthesia syndrome is an adverse reaction entity
"EXCERPT:   The most common (>=20%) adverse reactions are diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, palmar-plantar erythrodysesthesia (hand-foot) syndrome, weight decreased, vomiting, asthenia, and constipation.",( hand-foot ) is not a named entity
"EXCERPT:   The most common (>=20%) adverse reactions are diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, palmar-plantar erythrodysesthesia (hand-foot) syndrome, weight decreased, vomiting, asthenia, and constipation.","vomiting , is not a named entity"
"EXCERPT:   The most common (>=20%) adverse reactions are diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, palmar-plantar erythrodysesthesia (hand-foot) syndrome, weight decreased, vomiting, asthenia, and constipation.",> =20 % is not a named entity
"EXCERPT:   The most common (>=20%) adverse reactions are diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, palmar-plantar erythrodysesthesia (hand-foot) syndrome, weight decreased, vomiting, asthenia, and constipation.",asthenia is an adverse reaction entity
"EXCERPT:   The most common (>=20%) adverse reactions are diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, palmar-plantar erythrodysesthesia (hand-foot) syndrome, weight decreased, vomiting, asthenia, and constipation.",diarrhea is an adverse reaction entity
"EXCERPT:   The most common (>=20%) adverse reactions are diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, palmar-plantar erythrodysesthesia (hand-foot) syndrome, weight decreased, vomiting, asthenia, and constipation.",hand-foot syndrome is an adverse reaction entity
"EXCERPT:   The most common (>=20%) adverse reactions are diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, palmar-plantar erythrodysesthesia (hand-foot) syndrome, weight decreased, vomiting, asthenia, and constipation.",", asthenia is not a named entity"
"EXCERPT:   The most common (>=20%) adverse reactions are diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, palmar-plantar erythrodysesthesia (hand-foot) syndrome, weight decreased, vomiting, asthenia, and constipation.",common ( is not a named entity
"EXCERPT:   The most common (>=20%) adverse reactions are diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, palmar-plantar erythrodysesthesia (hand-foot) syndrome, weight decreased, vomiting, asthenia, and constipation.",vomiting is an adverse reaction entity
"EXCERPT:   The most common (>=20%) adverse reactions are diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, palmar-plantar erythrodysesthesia (hand-foot) syndrome, weight decreased, vomiting, asthenia, and constipation.","decreased , vomiting is not a named entity"
"In clinical trials with INLYTA, venous thromboembolic events were reported in 22/715 patients (3%), with two deaths secondary to pulmonary embolism.",were is not a named entity
"In clinical trials with INLYTA, venous thromboembolic events were reported in 22/715 patients (3%), with two deaths secondary to pulmonary embolism.",deaths is an adverse reaction entity
"In clinical trials with INLYTA, venous thromboembolic events were reported in 22/715 patients (3%), with two deaths secondary to pulmonary embolism.",pulmonary embolism is an adverse reaction entity
"In clinical trials with INLYTA, venous thromboembolic events were reported in 22/715 patients (3%), with two deaths secondary to pulmonary embolism.",two is not a named entity
"In clinical trials with INLYTA, venous thromboembolic events were reported in 22/715 patients (3%), with two deaths secondary to pulmonary embolism.","INLYTA , venous is not a named entity"
"In clinical trials with INLYTA, venous thromboembolic events were reported in 22/715 patients (3%), with two deaths secondary to pulmonary embolism.",venous thromboembolic events is an adverse reaction entity
"In addition to cases of gastrointestinal perforation, fistulas were reported in 4/715 patients (1%).","perforation , is not a named entity"
"In addition to cases of gastrointestinal perforation, fistulas were reported in 4/715 patients (1%).",gastrointestinal perforation is an adverse reaction entity
"In addition to cases of gastrointestinal perforation, fistulas were reported in 4/715 patients (1%).",gastrointestinal fistulas is an adverse reaction entity
"In addition to cases of gastrointestinal perforation, fistulas were reported in 4/715 patients (1%).",) is not a named entity
"In clinical trials with INLYTA, arterial thromboembolic events (including transient ischemic attack, cerebrovascular accident, myocardial infarction, and retinal artery occlusion) were reported in 17/715 patients (2%), with two deaths secondary to cerebrovascular accident.",transient ischemic attack is an adverse reaction entity
"In clinical trials with INLYTA, arterial thromboembolic events (including transient ischemic attack, cerebrovascular accident, myocardial infarction, and retinal artery occlusion) were reported in 17/715 patients (2%), with two deaths secondary to cerebrovascular accident.",to cerebrovascular is not a named entity
"In clinical trials with INLYTA, arterial thromboembolic events (including transient ischemic attack, cerebrovascular accident, myocardial infarction, and retinal artery occlusion) were reported in 17/715 patients (2%), with two deaths secondary to cerebrovascular accident.",cerebrovascular accident is an adverse reaction entity
"In clinical trials with INLYTA, arterial thromboembolic events (including transient ischemic attack, cerebrovascular accident, myocardial infarction, and retinal artery occlusion) were reported in 17/715 patients (2%), with two deaths secondary to cerebrovascular accident.",% is not a named entity
"In clinical trials with INLYTA, arterial thromboembolic events (including transient ischemic attack, cerebrovascular accident, myocardial infarction, and retinal artery occlusion) were reported in 17/715 patients (2%), with two deaths secondary to cerebrovascular accident.",with two is not a named entity
"In clinical trials with INLYTA, arterial thromboembolic events (including transient ischemic attack, cerebrovascular accident, myocardial infarction, and retinal artery occlusion) were reported in 17/715 patients (2%), with two deaths secondary to cerebrovascular accident.",myocardial infarction is an adverse reaction entity
"In clinical trials with INLYTA, arterial thromboembolic events (including transient ischemic attack, cerebrovascular accident, myocardial infarction, and retinal artery occlusion) were reported in 17/715 patients (2%), with two deaths secondary to cerebrovascular accident.",retinal artery occlusion is an adverse reaction entity
"In clinical trials with INLYTA, arterial thromboembolic events (including transient ischemic attack, cerebrovascular accident, myocardial infarction, and retinal artery occlusion) were reported in 17/715 patients (2%), with two deaths secondary to cerebrovascular accident.",", is not a named entity"
"In clinical trials with INLYTA, arterial thromboembolic events (including transient ischemic attack, cerebrovascular accident, myocardial infarction, and retinal artery occlusion) were reported in 17/715 patients (2%), with two deaths secondary to cerebrovascular accident.",In is not a named entity
"In clinical trials with INLYTA, arterial thromboembolic events (including transient ischemic attack, cerebrovascular accident, myocardial infarction, and retinal artery occlusion) were reported in 17/715 patients (2%), with two deaths secondary to cerebrovascular accident.",arterial thromboembolic events is an adverse reaction entity
"In clinical trials with INLYTA, arterial thromboembolic events (including transient ischemic attack, cerebrovascular accident, myocardial infarction, and retinal artery occlusion) were reported in 17/715 patients (2%), with two deaths secondary to cerebrovascular accident.",were is not a named entity
"In clinical trials with INLYTA, arterial thromboembolic events (including transient ischemic attack, cerebrovascular accident, myocardial infarction, and retinal artery occlusion) were reported in 17/715 patients (2%), with two deaths secondary to cerebrovascular accident.",including transient is not a named entity
"In clinical trials with INLYTA, arterial thromboembolic events (including transient ischemic attack, cerebrovascular accident, myocardial infarction, and retinal artery occlusion) were reported in 17/715 patients (2%), with two deaths secondary to cerebrovascular accident.",deaths is an adverse reaction entity
"In clinical trials with INLYTA, arterial thromboembolic events (including transient ischemic attack, cerebrovascular accident, myocardial infarction, and retinal artery occlusion) were reported in 17/715 patients (2%), with two deaths secondary to cerebrovascular accident.",cerebrovascular accident is an adverse reaction entity
Patients with a history of genital mycotic infections were more likely to develop genital mycotic infections [see  Adverse Reactions (6.1)  ]  .,) is not a named entity
Patients with a history of genital mycotic infections were more likely to develop genital mycotic infections [see  Adverse Reactions (6.1)  ]  .,genital mycotic infections is an adverse reaction entity
"By Week 24, hematocrit values >55% were reported in 0.4% of placebo-treated patients and 1.3% of FARXIGA 10 mg-treated patients.",hematocrit values >55% is an adverse reaction entity
"By Week 24, hematocrit values >55% were reported in 0.4% of placebo-treated patients and 1.3% of FARXIGA 10 mg-treated patients.",in 0.4 % is not a named entity
"(5.2)     *     Hypoglycemia: In patients taking insulin or an insulin secretagogue with FARXIGA, consider a lower dose of insulin or the insulin secretagogue to reduce the risk of hypoglycemia.",hypoglycemia is not a named entity
"(5.2)     *     Hypoglycemia: In patients taking insulin or an insulin secretagogue with FARXIGA, consider a lower dose of insulin or the insulin secretagogue to reduce the risk of hypoglycemia.",Hypoglycemia is an adverse reaction entity
"Volume Depletion      FARXIGA causes an osmotic diuresis, which may lead to reductions in intravascular volume.",Volume Depletion is not a named entity
"Volume Depletion      FARXIGA causes an osmotic diuresis, which may lead to reductions in intravascular volume.",reductions in intravascular volume is an adverse reaction entity
"Volume Depletion      FARXIGA causes an osmotic diuresis, which may lead to reductions in intravascular volume.",osmotic diuresis is an adverse reaction entity
"Volume Depletion      FARXIGA causes an osmotic diuresis, which may lead to reductions in intravascular volume.",an osmotic is not a named entity
"Mean percent changes from baseline at Week 24, were 0.0% versus 2.5% for total cholesterol and -1.0% versus 2.9% for LDL cholesterol, in the placebo and FARXIGA 10 mg groups, respectively.",changes for total cholesterol is an adverse reaction entity
"Mean percent changes from baseline at Week 24, were 0.0% versus 2.5% for total cholesterol and -1.0% versus 2.9% for LDL cholesterol, in the placebo and FARXIGA 10 mg groups, respectively.",for total cholesterol is not a named entity
"Mean percent changes from baseline at Week 24, were 0.0% versus 2.5% for total cholesterol and -1.0% versus 2.9% for LDL cholesterol, in the placebo and FARXIGA 10 mg groups, respectively.",changes for LDL cholesterol is an adverse reaction entity
"Mean percent changes from baseline at Week 24, were 0.0% versus 2.5% for total cholesterol and -1.0% versus 2.9% for LDL cholesterol, in the placebo and FARXIGA 10 mg groups, respectively.",versus is not a named entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *     Hypotension: Before initiating FARXIGA, assess volume status and correct hypovolemia in the elderly, in patients with renal impairment or low systolic blood pressure, and in patients on diuretics.",Hypotension is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *     Hypotension: Before initiating FARXIGA, assess volume status and correct hypovolemia in the elderly, in patients with renal impairment or low systolic blood pressure, and in patients on diuretics.",", and is not a named entity"
"Renal-related adverse reactions, including renal failure and blood creatinine increase, were more frequent in patients treated with FARXIGA (see Table 4).",blood creatinine increase is an adverse reaction entity
"Renal-related adverse reactions, including renal failure and blood creatinine increase, were more frequent in patients treated with FARXIGA (see Table 4).",Renal-related adverse reactions is an adverse reaction entity
"Renal-related adverse reactions, including renal failure and blood creatinine increase, were more frequent in patients treated with FARXIGA (see Table 4).",with is not a named entity
"Renal-related adverse reactions, including renal failure and blood creatinine increase, were more frequent in patients treated with FARXIGA (see Table 4).",renal failure is an adverse reaction entity
"Renal-related adverse reactions, including renal failure and blood creatinine increase, were more frequent in patients treated with FARXIGA (see Table 4).",treated is not a named entity
"Renal-related adverse reactions, including renal failure and blood creatinine increase, were more frequent in patients treated with FARXIGA (see Table 4).",see Table is not a named entity
(5.5)     *     Bladder Cancer: An imbalance in bladder cancers was observed in clinical trials.,) is not a named entity
(5.5)     *     Bladder Cancer: An imbalance in bladder cancers was observed in clinical trials.,Bladder Cancer is an adverse reaction entity
(5.5)     *     Bladder Cancer: An imbalance in bladder cancers was observed in clinical trials.,cancers was observed is not a named entity
(5.5)     *     Bladder Cancer: An imbalance in bladder cancers was observed in clinical trials.,bladder cancers is an adverse reaction entity
"Higher proportions of patients with marked laboratory abnormalities of hyperphosphatemia (>=5.6 mg/dL for age 17-65 years or >=5.1 mg/dL for age >=66 years) were reported on FARXIGA at Week 24 (0.9% versus 1.7% for placebo and FARXIGA 10 mg, respectively).",% for placebo is not a named entity
"Higher proportions of patients with marked laboratory abnormalities of hyperphosphatemia (>=5.6 mg/dL for age 17-65 years or >=5.1 mg/dL for age >=66 years) were reported on FARXIGA at Week 24 (0.9% versus 1.7% for placebo and FARXIGA 10 mg, respectively).",hyperphosphatemia is an adverse reaction entity
"1.7           2.9                     3.8                          Male genital mycotic infectionsGenital mycotic infections include the following adverse reactions, listed in order of frequency reported for males: balanitis, fungal genital infection, balanitis candida, genital candidiasis, genital infection male, penile infection, balanoposthitis, balanoposthitis infective, genital infection, posthitis.",genital candidiasis is an adverse reaction entity
"1.7           2.9                     3.8                          Male genital mycotic infectionsGenital mycotic infections include the following adverse reactions, listed in order of frequency reported for males: balanitis, fungal genital infection, balanitis candida, genital candidiasis, genital infection male, penile infection, balanoposthitis, balanoposthitis infective, genital infection, posthitis.",posthitis is an adverse reaction entity
"1.7           2.9                     3.8                          Male genital mycotic infectionsGenital mycotic infections include the following adverse reactions, listed in order of frequency reported for males: balanitis, fungal genital infection, balanitis candida, genital candidiasis, genital infection male, penile infection, balanoposthitis, balanoposthitis infective, genital infection, posthitis.",fungal genital infection is an adverse reaction entity
"1.7           2.9                     3.8                          Male genital mycotic infectionsGenital mycotic infections include the following adverse reactions, listed in order of frequency reported for males: balanitis, fungal genital infection, balanitis candida, genital candidiasis, genital infection male, penile infection, balanoposthitis, balanoposthitis infective, genital infection, posthitis.",adverse reactions is not a named entity
"1.7           2.9                     3.8                          Male genital mycotic infectionsGenital mycotic infections include the following adverse reactions, listed in order of frequency reported for males: balanitis, fungal genital infection, balanitis candida, genital candidiasis, genital infection male, penile infection, balanoposthitis, balanoposthitis infective, genital infection, posthitis.",balanoposthitis is an adverse reaction entity
"1.7           2.9                     3.8                          Male genital mycotic infectionsGenital mycotic infections include the following adverse reactions, listed in order of frequency reported for males: balanitis, fungal genital infection, balanitis candida, genital candidiasis, genital infection male, penile infection, balanoposthitis, balanoposthitis infective, genital infection, posthitis.","male , is not a named entity"
"1.7           2.9                     3.8                          Male genital mycotic infectionsGenital mycotic infections include the following adverse reactions, listed in order of frequency reported for males: balanitis, fungal genital infection, balanitis candida, genital candidiasis, genital infection male, penile infection, balanoposthitis, balanoposthitis infective, genital infection, posthitis.",", is not a named entity"
"1.7           2.9                     3.8                          Male genital mycotic infectionsGenital mycotic infections include the following adverse reactions, listed in order of frequency reported for males: balanitis, fungal genital infection, balanitis candida, genital candidiasis, genital infection male, penile infection, balanoposthitis, balanoposthitis infective, genital infection, posthitis.",genital infection male is an adverse reaction entity
"1.7           2.9                     3.8                          Male genital mycotic infectionsGenital mycotic infections include the following adverse reactions, listed in order of frequency reported for males: balanitis, fungal genital infection, balanitis candida, genital candidiasis, genital infection male, penile infection, balanoposthitis, balanoposthitis infective, genital infection, posthitis.",2.9 is not a named entity
"1.7           2.9                     3.8                          Male genital mycotic infectionsGenital mycotic infections include the following adverse reactions, listed in order of frequency reported for males: balanitis, fungal genital infection, balanitis candida, genital candidiasis, genital infection male, penile infection, balanoposthitis, balanoposthitis infective, genital infection, posthitis.",balanoposthitis infective is an adverse reaction entity
"1.7           2.9                     3.8                          Male genital mycotic infectionsGenital mycotic infections include the following adverse reactions, listed in order of frequency reported for males: balanitis, fungal genital infection, balanitis candida, genital candidiasis, genital infection male, penile infection, balanoposthitis, balanoposthitis infective, genital infection, posthitis.",genital infection is an adverse reaction entity
"1.7           2.9                     3.8                          Male genital mycotic infectionsGenital mycotic infections include the following adverse reactions, listed in order of frequency reported for males: balanitis, fungal genital infection, balanitis candida, genital candidiasis, genital infection male, penile infection, balanoposthitis, balanoposthitis infective, genital infection, posthitis.","penile infection , is not a named entity"
"1.7           2.9                     3.8                          Male genital mycotic infectionsGenital mycotic infections include the following adverse reactions, listed in order of frequency reported for males: balanitis, fungal genital infection, balanitis candida, genital candidiasis, genital infection male, penile infection, balanoposthitis, balanoposthitis infective, genital infection, posthitis.",Genital mycotic infections males is an adverse reaction entity
"1.7           2.9                     3.8                          Male genital mycotic infectionsGenital mycotic infections include the following adverse reactions, listed in order of frequency reported for males: balanitis, fungal genital infection, balanitis candida, genital candidiasis, genital infection male, penile infection, balanoposthitis, balanoposthitis infective, genital infection, posthitis.","candida , is not a named entity"
"1.7           2.9                     3.8                          Male genital mycotic infectionsGenital mycotic infections include the following adverse reactions, listed in order of frequency reported for males: balanitis, fungal genital infection, balanitis candida, genital candidiasis, genital infection male, penile infection, balanoposthitis, balanoposthitis infective, genital infection, posthitis.","infection , balanoposthitis is not a named entity"
"1.7           2.9                     3.8                          Male genital mycotic infectionsGenital mycotic infections include the following adverse reactions, listed in order of frequency reported for males: balanitis, fungal genital infection, balanitis candida, genital candidiasis, genital infection male, penile infection, balanoposthitis, balanoposthitis infective, genital infection, posthitis.",adverse is not a named entity
"1.7           2.9                     3.8                          Male genital mycotic infectionsGenital mycotic infections include the following adverse reactions, listed in order of frequency reported for males: balanitis, fungal genital infection, balanitis candida, genital candidiasis, genital infection male, penile infection, balanoposthitis, balanoposthitis infective, genital infection, posthitis.","balanoposthitis , is not a named entity"
"1.7           2.9                     3.8                          Male genital mycotic infectionsGenital mycotic infections include the following adverse reactions, listed in order of frequency reported for males: balanitis, fungal genital infection, balanitis candida, genital candidiasis, genital infection male, penile infection, balanoposthitis, balanoposthitis infective, genital infection, posthitis.",balanitis is an adverse reaction entity
"1.7           2.9                     3.8                          Male genital mycotic infectionsGenital mycotic infections include the following adverse reactions, listed in order of frequency reported for males: balanitis, fungal genital infection, balanitis candida, genital candidiasis, genital infection male, penile infection, balanoposthitis, balanoposthitis infective, genital infection, posthitis.",balanitis candida is an adverse reaction entity
"1.7           2.9                     3.8                          Male genital mycotic infectionsGenital mycotic infections include the following adverse reactions, listed in order of frequency reported for males: balanitis, fungal genital infection, balanitis candida, genital candidiasis, genital infection male, penile infection, balanoposthitis, balanoposthitis infective, genital infection, posthitis.","balanitis , is not a named entity"
"1.7           2.9                     3.8                          Male genital mycotic infectionsGenital mycotic infections include the following adverse reactions, listed in order of frequency reported for males: balanitis, fungal genital infection, balanitis candida, genital candidiasis, genital infection male, penile infection, balanoposthitis, balanoposthitis infective, genital infection, posthitis.",penile infection is an adverse reaction entity
"1.7           2.9                     3.8                          Male genital mycotic infectionsGenital mycotic infections include the following adverse reactions, listed in order of frequency reported for males: balanitis, fungal genital infection, balanitis candida, genital candidiasis, genital infection male, penile infection, balanoposthitis, balanoposthitis infective, genital infection, posthitis.",1.7 is not a named entity
"Symptomatic hypotension can occur after initiating FARXIGA [see  Adverse Reactions (6.1)  ]  particularly in patients with impaired renal function (eGFR less than 60 mL/min/1.73 m  2  ), elderly patients, or patients on loop diuretics.",eGFR is not a named entity
"Symptomatic hypotension can occur after initiating FARXIGA [see  Adverse Reactions (6.1)  ]  particularly in patients with impaired renal function (eGFR less than 60 mL/min/1.73 m  2  ), elderly patients, or patients on loop diuretics.",Symptomatic hypotension is an adverse reaction entity
"3.7           5.7                     4.3                          Back pain                                   3.2           3.1                     4.2                          Increased urinationIncreased urination includes the following adverse reactions, listed in order of frequency reported: pollakiuria, polyuria, and urine output increased.",polyuria is an adverse reaction entity
"3.7           5.7                     4.3                          Back pain                                   3.2           3.1                     4.2                          Increased urinationIncreased urination includes the following adverse reactions, listed in order of frequency reported: pollakiuria, polyuria, and urine output increased.",Back pain is an adverse reaction entity
"3.7           5.7                     4.3                          Back pain                                   3.2           3.1                     4.2                          Increased urinationIncreased urination includes the following adverse reactions, listed in order of frequency reported: pollakiuria, polyuria, and urine output increased.","adverse reactions , is not a named entity"
"3.7           5.7                     4.3                          Back pain                                   3.2           3.1                     4.2                          Increased urinationIncreased urination includes the following adverse reactions, listed in order of frequency reported: pollakiuria, polyuria, and urine output increased.",urine output increased is an adverse reaction entity
"3.7           5.7                     4.3                          Back pain                                   3.2           3.1                     4.2                          Increased urinationIncreased urination includes the following adverse reactions, listed in order of frequency reported: pollakiuria, polyuria, and urine output increased.",3.1 4.2 is not a named entity
"3.7           5.7                     4.3                          Back pain                                   3.2           3.1                     4.2                          Increased urinationIncreased urination includes the following adverse reactions, listed in order of frequency reported: pollakiuria, polyuria, and urine output increased.",: pollakiuria is not a named entity
"3.7           5.7                     4.3                          Back pain                                   3.2           3.1                     4.2                          Increased urinationIncreased urination includes the following adverse reactions, listed in order of frequency reported: pollakiuria, polyuria, and urine output increased.",Increased urination is an adverse reaction entity
"3.7           5.7                     4.3                          Back pain                                   3.2           3.1                     4.2                          Increased urinationIncreased urination includes the following adverse reactions, listed in order of frequency reported: pollakiuria, polyuria, and urine output increased.",includes the is not a named entity
"3.7           5.7                     4.3                          Back pain                                   3.2           3.1                     4.2                          Increased urinationIncreased urination includes the following adverse reactions, listed in order of frequency reported: pollakiuria, polyuria, and urine output increased.",in is not a named entity
"3.7           5.7                     4.3                          Back pain                                   3.2           3.1                     4.2                          Increased urinationIncreased urination includes the following adverse reactions, listed in order of frequency reported: pollakiuria, polyuria, and urine output increased.",pollakiuria is an adverse reaction entity
"(5.1  ,  6.1)     *     Impairment in renal function: Monitor renal function during therapy.",Impairment in renal function is an adverse reaction entity
"(5.1  ,  6.1)     *     Impairment in renal function: Monitor renal function during therapy.",) is not a named entity
The most frequently reported genital mycotic infections were vulvovaginal mycotic infections in females and balanitis in males.,balanitis is an adverse reaction entity
The most frequently reported genital mycotic infections were vulvovaginal mycotic infections in females and balanitis in males.,mycotic is not a named entity
The most frequently reported genital mycotic infections were vulvovaginal mycotic infections in females and balanitis in males.,infections in is not a named entity
The most frequently reported genital mycotic infections were vulvovaginal mycotic infections in females and balanitis in males.,vulvovaginal mycotic infections is an adverse reaction entity
The most frequently reported genital mycotic infections were vulvovaginal mycotic infections in females and balanitis in males.,genital mycotic infections is an adverse reaction entity
The most frequently reported genital mycotic infections were vulvovaginal mycotic infections in females and balanitis in males.,and balanitis in is not a named entity
Infections were more frequently reported in females than in males (see Table 1).,Infections is an adverse reaction entity
Infections were more frequently reported in females than in males (see Table 1).,Table is not a named entity
5.2 Impairment in Renal Function      FARXIGA increases serum creatinine and decreases eGFR.,Function is not a named entity
5.2 Impairment in Renal Function      FARXIGA increases serum creatinine and decreases eGFR.,eGFR is not a named entity
5.2 Impairment in Renal Function      FARXIGA increases serum creatinine and decreases eGFR.,increases serum creatinine is an adverse reaction entity
5.2 Impairment in Renal Function      FARXIGA increases serum creatinine and decreases eGFR.,decreases eGFR is an adverse reaction entity
In this study 13 patients experienced bone fractures for treatment durations up to 104 weeks.,bone fractures is an adverse reaction entity
In this study 13 patients experienced bone fractures for treatment durations up to 104 weeks.,In this is not a named entity
"No fractures occurred in the placebo group, 5 occurred in the FARXIGA 5 mg group, and 8 occurred in the FARXIGA 10 mg group.",fractures occurred in is not a named entity
"No fractures occurred in the placebo group, 5 occurred in the FARXIGA 5 mg group, and 8 occurred in the FARXIGA 10 mg group.",fractures is an adverse reaction entity
"Table 2: Adverse Reactions of Volume DepletionVolume depletion includes reports of dehydration, hypovolemia, orthostatic hypotension, or hypotension.",Volume Depletion is an adverse reaction entity
"Table 2: Adverse Reactions of Volume DepletionVolume depletion includes reports of dehydration, hypovolemia, orthostatic hypotension, or hypotension.",", orthostatic is not a named entity"
"Table 2: Adverse Reactions of Volume DepletionVolume depletion includes reports of dehydration, hypovolemia, orthostatic hypotension, or hypotension.",Volume depletion is an adverse reaction entity
"Table 2: Adverse Reactions of Volume DepletionVolume depletion includes reports of dehydration, hypovolemia, orthostatic hypotension, or hypotension.",", hypovolemia , is not a named entity"
"Table 2: Adverse Reactions of Volume DepletionVolume depletion includes reports of dehydration, hypovolemia, orthostatic hypotension, or hypotension.",Reactions of is not a named entity
"Table 2: Adverse Reactions of Volume DepletionVolume depletion includes reports of dehydration, hypovolemia, orthostatic hypotension, or hypotension.",dehydration is an adverse reaction entity
"Table 2: Adverse Reactions of Volume DepletionVolume depletion includes reports of dehydration, hypovolemia, orthostatic hypotension, or hypotension.",Reactions is not a named entity
"Table 2: Adverse Reactions of Volume DepletionVolume depletion includes reports of dehydration, hypovolemia, orthostatic hypotension, or hypotension.",of is not a named entity
"Table 2: Adverse Reactions of Volume DepletionVolume depletion includes reports of dehydration, hypovolemia, orthostatic hypotension, or hypotension.",orthostatic hypotension is an adverse reaction entity
"Table 2: Adverse Reactions of Volume DepletionVolume depletion includes reports of dehydration, hypovolemia, orthostatic hypotension, or hypotension.",", is not a named entity"
"Table 2: Adverse Reactions of Volume DepletionVolume depletion includes reports of dehydration, hypovolemia, orthostatic hypotension, or hypotension.",hypovolemia is an adverse reaction entity
"Table 2: Adverse Reactions of Volume DepletionVolume depletion includes reports of dehydration, hypovolemia, orthostatic hypotension, or hypotension.",hypotension is an adverse reaction entity
5.5 Increases in Low-Density Lipoprotein Cholesterol (LDL-C)      Increases in LDL-C occur with FARXIGA [see  Adverse Reactions (6.1)  ]  .,LDL-C occur with is not a named entity
5.5 Increases in Low-Density Lipoprotein Cholesterol (LDL-C)      Increases in LDL-C occur with FARXIGA [see  Adverse Reactions (6.1)  ]  .,Increases in LDL-C is an adverse reaction entity
"After excluding patients in whom exposure to study drug was less than one year at the time of diagnosis of bladder cancer, there were 4 cases with FARXIGA and no cases with placebo/comparator.",bladder cancer is an adverse reaction entity
"After excluding patients in whom exposure to study drug was less than one year at the time of diagnosis of bladder cancer, there were 4 cases with FARXIGA and no cases with placebo/comparator.",4 cases with is not a named entity
"Genital mycotic infections were reported in 0.9% of patients on placebo, 5.7% on FARXIGA 5 mg, and 4.8% on FARXIGA 10 mg, in the 12-study placebo-controlled pool.",Genital mycotic infections is an adverse reaction entity
"Genital mycotic infections were reported in 0.9% of patients on placebo, 5.7% on FARXIGA 5 mg, and 4.8% on FARXIGA 10 mg, in the 12-study placebo-controlled pool.","mg , is not a named entity"
"5.6 Bladder Cancer      Across 22 clinical studies, newly diagnosed cases of bladder cancer were reported in 10/6045 patients (0.17%) treated with FARXIGA and 1/3512 patient (0.03%) treated with placebo/comparator.",bladder cancer is an adverse reaction entity
"5.6 Bladder Cancer      Across 22 clinical studies, newly diagnosed cases of bladder cancer were reported in 10/6045 patients (0.17%) treated with FARXIGA and 1/3512 patient (0.03%) treated with placebo/comparator.",reported in 10/6045 is not a named entity
5.4 Genital Mycotic Infections      FARXIGA increases the risk of genital mycotic infections.,of is not a named entity
5.4 Genital Mycotic Infections      FARXIGA increases the risk of genital mycotic infections.,genital mycotic infections is an adverse reaction entity
"Hypersensitivity Reactions      Hypersensitivity reactions (e.g., angioedema, urticaria, hypersensitivity) were reported with FARXIGA treatment.",( e.g. is not a named entity
"Hypersensitivity Reactions      Hypersensitivity reactions (e.g., angioedema, urticaria, hypersensitivity) were reported with FARXIGA treatment.",angioedema is an adverse reaction entity
"Hypersensitivity Reactions      Hypersensitivity reactions (e.g., angioedema, urticaria, hypersensitivity) were reported with FARXIGA treatment.",Hypersensitivity Reactions Hypersensitivity is not a named entity
"Hypersensitivity Reactions      Hypersensitivity reactions (e.g., angioedema, urticaria, hypersensitivity) were reported with FARXIGA treatment.",hypersensitivity is an adverse reaction entity
"Hypersensitivity Reactions      Hypersensitivity reactions (e.g., angioedema, urticaria, hypersensitivity) were reported with FARXIGA treatment.",urticaria is an adverse reaction entity
"Hypersensitivity Reactions      Hypersensitivity reactions (e.g., angioedema, urticaria, hypersensitivity) were reported with FARXIGA treatment.",FARXIGA treatment is not a named entity
"Hypersensitivity Reactions      Hypersensitivity reactions (e.g., angioedema, urticaria, hypersensitivity) were reported with FARXIGA treatment.",Hypersensitivity reactions is an adverse reaction entity
"Hypersensitivity Reactions      Hypersensitivity reactions (e.g., angioedema, urticaria, hypersensitivity) were reported with FARXIGA treatment.",reported with FARXIGA is not a named entity
Hypoglycemia      The frequency of hypoglycemia by study  [see  Clinical Studies (14)  ]  is shown in Table 5.,14 ) is not a named entity
Hypoglycemia      The frequency of hypoglycemia by study  [see  Clinical Studies (14)  ]  is shown in Table 5.,hypoglycemia is an adverse reaction entity
"Laboratory Tests        Increase in Hematocrit      In the pool of 13 placebo-controlled studies, increases from baseline in mean hematocrit values were observed in FARXIGA-treated patients starting at Week 1 and continuing up to Week 16, when the maximum mean difference from baseline was observed.",", when is not a named entity"
"Laboratory Tests        Increase in Hematocrit      In the pool of 13 placebo-controlled studies, increases from baseline in mean hematocrit values were observed in FARXIGA-treated patients starting at Week 1 and continuing up to Week 16, when the maximum mean difference from baseline was observed.",increases in mean hematocrit values is an adverse reaction entity
"At Week 24, the mean changes from baseline in hematocrit were -0.33% in the placebo group and 2.30% in the FARXIGA 10 mg group.",changes in hematocrit is an adverse reaction entity
"At Week 24, the mean changes from baseline in hematocrit were -0.33% in the placebo group and 2.30% in the FARXIGA 10 mg group.",", the mean is not a named entity"
(24 weeks)    N=197                 N=212            N=196                  Major [n (%)]                                    1 (0.5)               1 (0.5)          1 (0.5)                Minor [n (%)]                                    67 (34.0)             92 (43.4)        79 (40.3)                        Genital Mycotic Infections      Genital mycotic infections were more frequent with FARXIGA treatment.,N=197 N=212 N=196 is not a named entity
(24 weeks)    N=197                 N=212            N=196                  Major [n (%)]                                    1 (0.5)               1 (0.5)          1 (0.5)                Minor [n (%)]                                    67 (34.0)             92 (43.4)        79 (40.3)                        Genital Mycotic Infections      Genital mycotic infections were more frequent with FARXIGA treatment.,Genital mycotic infections is an adverse reaction entity
"Liver chemistry elevations consistent with immune reconstitution syndrome were observed in some subjects with hepatitis B and/or C at the start of therapy with TIVICAY, particularly in the setting where anti-hepatitis therapy was withdrawn  [see Warnings and Precautions (5.2)]  .",( 5.2 ) is not a named entity
"Liver chemistry elevations consistent with immune reconstitution syndrome were observed in some subjects with hepatitis B and/or C at the start of therapy with TIVICAY, particularly in the setting where anti-hepatitis therapy was withdrawn  [see Warnings and Precautions (5.2)]  .",Liver chemistry elevations is an adverse reaction entity
"Liver chemistry elevations consistent with immune reconstitution syndrome were observed in some subjects with hepatitis B and/or C at the start of therapy with TIVICAY, particularly in the setting where anti-hepatitis therapy was withdrawn  [see Warnings and Precautions (5.2)]  .",TIVICAY is not a named entity
"Liver chemistry elevations consistent with immune reconstitution syndrome were observed in some subjects with hepatitis B and/or C at the start of therapy with TIVICAY, particularly in the setting where anti-hepatitis therapy was withdrawn  [see Warnings and Precautions (5.2)]  .",immune reconstitution syndrome is an adverse reaction entity
"Gastrointestinal Disorders:  Abdominal pain, abdominal discomfort, flatulence, upper abdominal pain, vomiting.",discomfort is not a named entity
"Gastrointestinal Disorders:  Abdominal pain, abdominal discomfort, flatulence, upper abdominal pain, vomiting.","abdominal discomfort , is not a named entity"
"Gastrointestinal Disorders:  Abdominal pain, abdominal discomfort, flatulence, upper abdominal pain, vomiting.",Abdominal pain is an adverse reaction entity
"Gastrointestinal Disorders:  Abdominal pain, abdominal discomfort, flatulence, upper abdominal pain, vomiting.","pain , abdominal is not a named entity"
"Gastrointestinal Disorders:  Abdominal pain, abdominal discomfort, flatulence, upper abdominal pain, vomiting.","pain , is not a named entity"
"Gastrointestinal Disorders:  Abdominal pain, abdominal discomfort, flatulence, upper abdominal pain, vomiting.",flatulence is an adverse reaction entity
"Gastrointestinal Disorders:  Abdominal pain, abdominal discomfort, flatulence, upper abdominal pain, vomiting.",: Abdominal is not a named entity
"Gastrointestinal Disorders:  Abdominal pain, abdominal discomfort, flatulence, upper abdominal pain, vomiting.",vomiting is an adverse reaction entity
"Gastrointestinal Disorders:  Abdominal pain, abdominal discomfort, flatulence, upper abdominal pain, vomiting.",abdominal discomfort is an adverse reaction entity
"Gastrointestinal Disorders:  Abdominal pain, abdominal discomfort, flatulence, upper abdominal pain, vomiting.",upper abdominal pain is an adverse reaction entity
Increases in serum creatinine occurred within the first 4 weeks of treatment and remained stable through 48 to 96 weeks.,Increases in serum creatinine is an adverse reaction entity
Increases in serum creatinine occurred within the first 4 weeks of treatment and remained stable through 48 to 96 weeks.,within the first is not a named entity
Changes in Serum Creatinine       Dolutegravir has been shown to increase serum creatinine due to inhibition of tubular secretion of creatinine without affecting renal glomerular function  [see Clinical Pharmacology (12.2)]  .,tubular secretion is not a named entity
Changes in Serum Creatinine       Dolutegravir has been shown to increase serum creatinine due to inhibition of tubular secretion of creatinine without affecting renal glomerular function  [see Clinical Pharmacology (12.2)]  .,increase serum creatinine is an adverse reaction entity
"The only treatment-emergent ADR of moderate to severe intensity with at least 2% frequency in either treatment group was diarrhea, 2% (6 of 354) in subjects receiving TIVICAY 50 mg once daily + background regimen and 1% (5 of 361) in subjects receiving raltegravir 400 mg twice daily + background regimen.",diarrhea is an adverse reaction entity
"The only treatment-emergent ADR of moderate to severe intensity with at least 2% frequency in either treatment group was diarrhea, 2% (6 of 354) in subjects receiving TIVICAY 50 mg once daily + background regimen and 1% (5 of 361) in subjects receiving raltegravir 400 mg twice daily + background regimen.",and 1 % is not a named entity
"5.4 Immune Reconstitution Syndrome      Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy, including TIVICAY.",Immune reconstitution syndrome is an adverse reaction entity
"5.4 Immune Reconstitution Syndrome      Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy, including TIVICAY.","antiretroviral therapy , is not a named entity"
Grades 2 to 4 ALT abnormalities in hepatitis B and/or C co-infected compared with HIV mono-infected subjects receiving TIVICAY were observed in 18% vs. 3% with the 50-mg once-daily dose and 13% vs. 8% with the 50-mg twice-daily dose.,B and/or is not a named entity
Grades 2 to 4 ALT abnormalities in hepatitis B and/or C co-infected compared with HIV mono-infected subjects receiving TIVICAY were observed in 18% vs. 3% with the 50-mg once-daily dose and 13% vs. 8% with the 50-mg twice-daily dose.,ALT abnormalities is an adverse reaction entity
(  5.1  )   *    Patients with underlying hepatitis B or C may be at increased risk for worsening or development of transaminase elevations with use of TIVICAY.,at increased risk is not a named entity
(  5.1  )   *    Patients with underlying hepatitis B or C may be at increased risk for worsening or development of transaminase elevations with use of TIVICAY.,transaminase elevations is an adverse reaction entity
"Two percent (4 of 183) of subjects had a Grade 3 to 4 treatment-emergent hematology laboratory abnormality, with neutropenia (2% [3 of 183]) being the most frequently reported.",neutropenia is an adverse reaction entity
"Two percent (4 of 183) of subjects had a Grade 3 to 4 treatment-emergent hematology laboratory abnormality, with neutropenia (2% [3 of 183]) being the most frequently reported.",a is not a named entity
"Grade 2 ADRs reported in at least 1 subject were rash (n = 1), abdominal pain (n = 1), and diarrhea (n = 1).",rash ( is not a named entity
"Grade 2 ADRs reported in at least 1 subject were rash (n = 1), abdominal pain (n = 1), and diarrhea (n = 1).",abdominal pain ( is not a named entity
"Grade 2 ADRs reported in at least 1 subject were rash (n = 1), abdominal pain (n = 1), and diarrhea (n = 1).",abdominal pain is an adverse reaction entity
"Grade 2 ADRs reported in at least 1 subject were rash (n = 1), abdominal pain (n = 1), and diarrhea (n = 1).",", and is not a named entity"
"Grade 2 ADRs reported in at least 1 subject were rash (n = 1), abdominal pain (n = 1), and diarrhea (n = 1).",rash is an adverse reaction entity
"Grade 2 ADRs reported in at least 1 subject were rash (n = 1), abdominal pain (n = 1), and diarrhea (n = 1).",diarrhea is an adverse reaction entity
"During the initial phase of combination antiretroviral treatment, patients whose immune systems respond may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium  infection, cytomegalovirus, Pneumocystis jirovecii  pneumonia [PCP], or tuberculosis), which may necessitate further evaluation and treatment.",Pneumocystis jirovecii pneumonia is an adverse reaction entity
"During the initial phase of combination antiretroviral treatment, patients whose immune systems respond may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium  infection, cytomegalovirus, Pneumocystis jirovecii  pneumonia [PCP], or tuberculosis), which may necessitate further evaluation and treatment.",such as Mycobacterium is not a named entity
"During the initial phase of combination antiretroviral treatment, patients whose immune systems respond may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium  infection, cytomegalovirus, Pneumocystis jirovecii  pneumonia [PCP], or tuberculosis), which may necessitate further evaluation and treatment.",whose is not a named entity
"During the initial phase of combination antiretroviral treatment, patients whose immune systems respond may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium  infection, cytomegalovirus, Pneumocystis jirovecii  pneumonia [PCP], or tuberculosis), which may necessitate further evaluation and treatment.",further evaluation is not a named entity
"During the initial phase of combination antiretroviral treatment, patients whose immune systems respond may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium  infection, cytomegalovirus, Pneumocystis jirovecii  pneumonia [PCP], or tuberculosis), which may necessitate further evaluation and treatment.",tuberculosis is an adverse reaction entity
"During the initial phase of combination antiretroviral treatment, patients whose immune systems respond may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium  infection, cytomegalovirus, Pneumocystis jirovecii  pneumonia [PCP], or tuberculosis), which may necessitate further evaluation and treatment.",an inflammatory is not a named entity
"During the initial phase of combination antiretroviral treatment, patients whose immune systems respond may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium  infection, cytomegalovirus, Pneumocystis jirovecii  pneumonia [PCP], or tuberculosis), which may necessitate further evaluation and treatment.",cytomegalovirus is an adverse reaction entity
"During the initial phase of combination antiretroviral treatment, patients whose immune systems respond may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium  infection, cytomegalovirus, Pneumocystis jirovecii  pneumonia [PCP], or tuberculosis), which may necessitate further evaluation and treatment.",inflammatory response is an adverse reaction entity
"During the initial phase of combination antiretroviral treatment, patients whose immune systems respond may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium  infection, cytomegalovirus, Pneumocystis jirovecii  pneumonia [PCP], or tuberculosis), which may necessitate further evaluation and treatment.",which may is not a named entity
"During the initial phase of combination antiretroviral treatment, patients whose immune systems respond may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium  infection, cytomegalovirus, Pneumocystis jirovecii  pneumonia [PCP], or tuberculosis), which may necessitate further evaluation and treatment.",PCP is an adverse reaction entity
"During the initial phase of combination antiretroviral treatment, patients whose immune systems respond may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium  infection, cytomegalovirus, Pneumocystis jirovecii  pneumonia [PCP], or tuberculosis), which may necessitate further evaluation and treatment.",Mycobacterium avium infection is an adverse reaction entity
"During the initial phase of combination antiretroviral treatment, patients whose immune systems respond may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium  infection, cytomegalovirus, Pneumocystis jirovecii  pneumonia [PCP], or tuberculosis), which may necessitate further evaluation and treatment.","cytomegalovirus , Pneumocystis is not a named entity"
"During the initial phase of combination antiretroviral treatment, patients whose immune systems respond may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium  infection, cytomegalovirus, Pneumocystis jirovecii  pneumonia [PCP], or tuberculosis), which may necessitate further evaluation and treatment.",residual opportunistic infections is an adverse reaction entity
"During the initial phase of combination antiretroviral treatment, patients whose immune systems respond may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium  infection, cytomegalovirus, Pneumocystis jirovecii  pneumonia [PCP], or tuberculosis), which may necessitate further evaluation and treatment.",", is not a named entity"
Appropriate laboratory testing prior to initiating therapy and monitoring for hepatotoxicity during therapy with TIVICAY is recommended in patients with underlying hepatic disease such as hepatitis B or C. (  5.2  )   *    Redistribution/accumulation of body fat and immune reconstitution syndrome have been reported in patients treated with combination antiretroviral therapy.,Redistribution of body fat is an adverse reaction entity
Appropriate laboratory testing prior to initiating therapy and monitoring for hepatotoxicity during therapy with TIVICAY is recommended in patients with underlying hepatic disease such as hepatitis B or C. (  5.2  )   *    Redistribution/accumulation of body fat and immune reconstitution syndrome have been reported in patients treated with combination antiretroviral therapy.,immune reconstitution syndrome is an adverse reaction entity
Appropriate laboratory testing prior to initiating therapy and monitoring for hepatotoxicity during therapy with TIVICAY is recommended in patients with underlying hepatic disease such as hepatitis B or C. (  5.2  )   *    Redistribution/accumulation of body fat and immune reconstitution syndrome have been reported in patients treated with combination antiretroviral therapy.,accumulation of body fat is an adverse reaction entity
Appropriate laboratory testing prior to initiating therapy and monitoring for hepatotoxicity during therapy with TIVICAY is recommended in patients with underlying hepatic disease such as hepatitis B or C. (  5.2  )   *    Redistribution/accumulation of body fat and immune reconstitution syndrome have been reported in patients treated with combination antiretroviral therapy.,such as is not a named entity
Appropriate laboratory testing prior to initiating therapy and monitoring for hepatotoxicity during therapy with TIVICAY is recommended in patients with underlying hepatic disease such as hepatitis B or C. (  5.2  )   *    Redistribution/accumulation of body fat and immune reconstitution syndrome have been reported in patients treated with combination antiretroviral therapy.,with combination antiretroviral is not a named entity
Appropriate laboratory testing prior to initiating therapy and monitoring for hepatotoxicity during therapy with TIVICAY is recommended in patients with underlying hepatic disease such as hepatitis B or C. (  5.2  )   *    Redistribution/accumulation of body fat and immune reconstitution syndrome have been reported in patients treated with combination antiretroviral therapy.,recommended in is not a named entity
5.2 Effects on Serum Liver Biochemistries in Patients with Hepatitis B or C Co-infection      Patients with underlying hepatitis B or C may be at increased risk for worsening or development of transaminase elevations with use of TIVICAY [see Adverse Reactions (6.1)]  .,B is not a named entity
5.2 Effects on Serum Liver Biochemistries in Patients with Hepatitis B or C Co-infection      Patients with underlying hepatitis B or C may be at increased risk for worsening or development of transaminase elevations with use of TIVICAY [see Adverse Reactions (6.1)]  .,transaminase elevations is an adverse reaction entity
"Overall, the safety profile in subjects with hepatitis B and/or C virus co-infection was similar to that observed in subjects without hepatitis B or C co-infection, although the rates of AST and ALT abnormalities were higher in the subgroup with hepatitis B and/or C virus co-infection for all treatment groups.",ALT abnormalities is an adverse reaction entity
"Overall, the safety profile in subjects with hepatitis B and/or C virus co-infection was similar to that observed in subjects without hepatitis B or C co-infection, although the rates of AST and ALT abnormalities were higher in the subgroup with hepatitis B and/or C virus co-infection for all treatment groups.",AST abnormalities is an adverse reaction entity
"Overall, the safety profile in subjects with hepatitis B and/or C virus co-infection was similar to that observed in subjects without hepatitis B or C co-infection, although the rates of AST and ALT abnormalities were higher in the subgroup with hepatitis B and/or C virus co-infection for all treatment groups.",rates of is not a named entity
"Overall, the safety profile in subjects with hepatitis B and/or C virus co-infection was similar to that observed in subjects without hepatitis B or C co-infection, although the rates of AST and ALT abnormalities were higher in the subgroup with hepatitis B and/or C virus co-infection for all treatment groups.",and ALT abnormalities is not a named entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *    Hypersensitivity reactions characterized by rash, constitutional findings, and sometimes organ dysfunction, including liver injury, have been reported.",PRECAUTIONS EXCERPT : is not a named entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *    Hypersensitivity reactions characterized by rash, constitutional findings, and sometimes organ dysfunction, including liver injury, have been reported.",rash is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *    Hypersensitivity reactions characterized by rash, constitutional findings, and sometimes organ dysfunction, including liver injury, have been reported.",have been is not a named entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *    Hypersensitivity reactions characterized by rash, constitutional findings, and sometimes organ dysfunction, including liver injury, have been reported.",", constitutional is not a named entity"
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *    Hypersensitivity reactions characterized by rash, constitutional findings, and sometimes organ dysfunction, including liver injury, have been reported.",Hypersensitivity reactions is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *    Hypersensitivity reactions characterized by rash, constitutional findings, and sometimes organ dysfunction, including liver injury, have been reported.",organ dysfunction is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *    Hypersensitivity reactions characterized by rash, constitutional findings, and sometimes organ dysfunction, including liver injury, have been reported.",including liver injury is not a named entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *    Hypersensitivity reactions characterized by rash, constitutional findings, and sometimes organ dysfunction, including liver injury, have been reported.",liver injury is an adverse reaction entity
"Treatment-experienced, Integrase Strand Transfer Inhibitor-experienced Subjects  : The most common treatment-emergent laboratory abnormalities (greater than 5% for Grades 2 to 4 combined) observed in VIKING-3 at Week 48 were elevated ALT (9%), AST (8%), cholesterol (10%), creatine kinase (6%), hyperglycemia (14%), and lipase (10%).",elevated lipase is an adverse reaction entity
"Treatment-experienced, Integrase Strand Transfer Inhibitor-experienced Subjects  : The most common treatment-emergent laboratory abnormalities (greater than 5% for Grades 2 to 4 combined) observed in VIKING-3 at Week 48 were elevated ALT (9%), AST (8%), cholesterol (10%), creatine kinase (6%), hyperglycemia (14%), and lipase (10%).","Treatment-experienced , is not a named entity"
"Treatment-experienced, Integrase Strand Transfer Inhibitor-experienced Subjects  : The most common treatment-emergent laboratory abnormalities (greater than 5% for Grades 2 to 4 combined) observed in VIKING-3 at Week 48 were elevated ALT (9%), AST (8%), cholesterol (10%), creatine kinase (6%), hyperglycemia (14%), and lipase (10%).",", creatine kinase is not a named entity"
"Treatment-experienced, Integrase Strand Transfer Inhibitor-experienced Subjects  : The most common treatment-emergent laboratory abnormalities (greater than 5% for Grades 2 to 4 combined) observed in VIKING-3 at Week 48 were elevated ALT (9%), AST (8%), cholesterol (10%), creatine kinase (6%), hyperglycemia (14%), and lipase (10%).",elevated creatine kinase is an adverse reaction entity
"Treatment-experienced, Integrase Strand Transfer Inhibitor-experienced Subjects  : The most common treatment-emergent laboratory abnormalities (greater than 5% for Grades 2 to 4 combined) observed in VIKING-3 at Week 48 were elevated ALT (9%), AST (8%), cholesterol (10%), creatine kinase (6%), hyperglycemia (14%), and lipase (10%).",hyperglycemia is an adverse reaction entity
"Treatment-experienced, Integrase Strand Transfer Inhibitor-experienced Subjects  : The most common treatment-emergent laboratory abnormalities (greater than 5% for Grades 2 to 4 combined) observed in VIKING-3 at Week 48 were elevated ALT (9%), AST (8%), cholesterol (10%), creatine kinase (6%), hyperglycemia (14%), and lipase (10%).",: is not a named entity
"Treatment-experienced, Integrase Strand Transfer Inhibitor-experienced Subjects  : The most common treatment-emergent laboratory abnormalities (greater than 5% for Grades 2 to 4 combined) observed in VIKING-3 at Week 48 were elevated ALT (9%), AST (8%), cholesterol (10%), creatine kinase (6%), hyperglycemia (14%), and lipase (10%).",elevated cholesterol is an adverse reaction entity
"Treatment-experienced, Integrase Strand Transfer Inhibitor-experienced Subjects  : The most common treatment-emergent laboratory abnormalities (greater than 5% for Grades 2 to 4 combined) observed in VIKING-3 at Week 48 were elevated ALT (9%), AST (8%), cholesterol (10%), creatine kinase (6%), hyperglycemia (14%), and lipase (10%).",elevated ALT is an adverse reaction entity
"Treatment-experienced, Integrase Strand Transfer Inhibitor-experienced Subjects  : The most common treatment-emergent laboratory abnormalities (greater than 5% for Grades 2 to 4 combined) observed in VIKING-3 at Week 48 were elevated ALT (9%), AST (8%), cholesterol (10%), creatine kinase (6%), hyperglycemia (14%), and lipase (10%).",in VIKING-3 is not a named entity
"Treatment-experienced, Integrase Strand Transfer Inhibitor-experienced Subjects  : The most common treatment-emergent laboratory abnormalities (greater than 5% for Grades 2 to 4 combined) observed in VIKING-3 at Week 48 were elevated ALT (9%), AST (8%), cholesterol (10%), creatine kinase (6%), hyperglycemia (14%), and lipase (10%).",treatment-emergent laboratory abnormalities is not a named entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *    Cardiac toxicities include cardiac failure and myocardial infarction with fatal outcome, and myocardial ischemia.",myocardial infarction is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *    Cardiac toxicities include cardiac failure and myocardial infarction with fatal outcome, and myocardial ischemia.",fatal is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *    Cardiac toxicities include cardiac failure and myocardial infarction with fatal outcome, and myocardial ischemia.",", is not a named entity"
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *    Cardiac toxicities include cardiac failure and myocardial infarction with fatal outcome, and myocardial ischemia.",WARNINGS is not a named entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *    Cardiac toxicities include cardiac failure and myocardial infarction with fatal outcome, and myocardial ischemia.",Cardiac toxicities is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *    Cardiac toxicities include cardiac failure and myocardial infarction with fatal outcome, and myocardial ischemia.",* Cardiac toxicities is not a named entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *    Cardiac toxicities include cardiac failure and myocardial infarction with fatal outcome, and myocardial ischemia.",cardiac failure is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *    Cardiac toxicities include cardiac failure and myocardial infarction with fatal outcome, and myocardial ischemia.",WARNINGS AND PRECAUTIONS is not a named entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *    Cardiac toxicities include cardiac failure and myocardial infarction with fatal outcome, and myocardial ischemia.",: is not a named entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *    Cardiac toxicities include cardiac failure and myocardial infarction with fatal outcome, and myocardial ischemia.",myocardial ischemia is an adverse reaction entity
"(  5.14  ,  8.1  )              5.1 Cardiac Toxicities         New onset or worsening of pre-existing cardiac failure (e.g., congestive heart failure, pulmonary edema, decreased ejection fraction), restrictive cardiomyopathy, myocardial ischemia, and myocardial infarction including fatalities have occurred following administration of Kyprolis.",restrictive cardiomyopathy is an adverse reaction entity
"(  5.14  ,  8.1  )              5.1 Cardiac Toxicities         New onset or worsening of pre-existing cardiac failure (e.g., congestive heart failure, pulmonary edema, decreased ejection fraction), restrictive cardiomyopathy, myocardial ischemia, and myocardial infarction including fatalities have occurred following administration of Kyprolis.",", is not a named entity"
"(  5.14  ,  8.1  )              5.1 Cardiac Toxicities         New onset or worsening of pre-existing cardiac failure (e.g., congestive heart failure, pulmonary edema, decreased ejection fraction), restrictive cardiomyopathy, myocardial ischemia, and myocardial infarction including fatalities have occurred following administration of Kyprolis.",worsening of pre-existing cardiac failure is an adverse reaction entity
"(  5.14  ,  8.1  )              5.1 Cardiac Toxicities         New onset or worsening of pre-existing cardiac failure (e.g., congestive heart failure, pulmonary edema, decreased ejection fraction), restrictive cardiomyopathy, myocardial ischemia, and myocardial infarction including fatalities have occurred following administration of Kyprolis.",myocardial ischemia is an adverse reaction entity
"(  5.14  ,  8.1  )              5.1 Cardiac Toxicities         New onset or worsening of pre-existing cardiac failure (e.g., congestive heart failure, pulmonary edema, decreased ejection fraction), restrictive cardiomyopathy, myocardial ischemia, and myocardial infarction including fatalities have occurred following administration of Kyprolis.",", restrictive cardiomyopathy is not a named entity"
"(  5.14  ,  8.1  )              5.1 Cardiac Toxicities         New onset or worsening of pre-existing cardiac failure (e.g., congestive heart failure, pulmonary edema, decreased ejection fraction), restrictive cardiomyopathy, myocardial ischemia, and myocardial infarction including fatalities have occurred following administration of Kyprolis.",New onset or is not a named entity
"(  5.14  ,  8.1  )              5.1 Cardiac Toxicities         New onset or worsening of pre-existing cardiac failure (e.g., congestive heart failure, pulmonary edema, decreased ejection fraction), restrictive cardiomyopathy, myocardial ischemia, and myocardial infarction including fatalities have occurred following administration of Kyprolis.",occurred following administration is not a named entity
"(  5.14  ,  8.1  )              5.1 Cardiac Toxicities         New onset or worsening of pre-existing cardiac failure (e.g., congestive heart failure, pulmonary edema, decreased ejection fraction), restrictive cardiomyopathy, myocardial ischemia, and myocardial infarction including fatalities have occurred following administration of Kyprolis.",fatalities is an adverse reaction entity
"(  5.14  ,  8.1  )              5.1 Cardiac Toxicities         New onset or worsening of pre-existing cardiac failure (e.g., congestive heart failure, pulmonary edema, decreased ejection fraction), restrictive cardiomyopathy, myocardial ischemia, and myocardial infarction including fatalities have occurred following administration of Kyprolis.",pulmonary edema is an adverse reaction entity
"(  5.14  ,  8.1  )              5.1 Cardiac Toxicities         New onset or worsening of pre-existing cardiac failure (e.g., congestive heart failure, pulmonary edema, decreased ejection fraction), restrictive cardiomyopathy, myocardial ischemia, and myocardial infarction including fatalities have occurred following administration of Kyprolis.",New onset cardiac failure is an adverse reaction entity
"(  5.14  ,  8.1  )              5.1 Cardiac Toxicities         New onset or worsening of pre-existing cardiac failure (e.g., congestive heart failure, pulmonary edema, decreased ejection fraction), restrictive cardiomyopathy, myocardial ischemia, and myocardial infarction including fatalities have occurred following administration of Kyprolis.","e.g. , congestive is not a named entity"
"(  5.14  ,  8.1  )              5.1 Cardiac Toxicities         New onset or worsening of pre-existing cardiac failure (e.g., congestive heart failure, pulmonary edema, decreased ejection fraction), restrictive cardiomyopathy, myocardial ischemia, and myocardial infarction including fatalities have occurred following administration of Kyprolis.",myocardial infarction is an adverse reaction entity
"(  5.14  ,  8.1  )              5.1 Cardiac Toxicities         New onset or worsening of pre-existing cardiac failure (e.g., congestive heart failure, pulmonary edema, decreased ejection fraction), restrictive cardiomyopathy, myocardial ischemia, and myocardial infarction including fatalities have occurred following administration of Kyprolis.",congestive heart failure is an adverse reaction entity
"(  5.14  ,  8.1  )              5.1 Cardiac Toxicities         New onset or worsening of pre-existing cardiac failure (e.g., congestive heart failure, pulmonary edema, decreased ejection fraction), restrictive cardiomyopathy, myocardial ischemia, and myocardial infarction including fatalities have occurred following administration of Kyprolis.",decreased ejection fraction is an adverse reaction entity
"(  5.14  ,  8.1  )              5.1 Cardiac Toxicities         New onset or worsening of pre-existing cardiac failure (e.g., congestive heart failure, pulmonary edema, decreased ejection fraction), restrictive cardiomyopathy, myocardial ischemia, and myocardial infarction including fatalities have occurred following administration of Kyprolis.",onset is not a named entity
"(  5.14  ,  8.1  )              5.1 Cardiac Toxicities         New onset or worsening of pre-existing cardiac failure (e.g., congestive heart failure, pulmonary edema, decreased ejection fraction), restrictive cardiomyopathy, myocardial ischemia, and myocardial infarction including fatalities have occurred following administration of Kyprolis.","failure , is not a named entity"
"(  5.14  ,  8.1  )              5.1 Cardiac Toxicities         New onset or worsening of pre-existing cardiac failure (e.g., congestive heart failure, pulmonary edema, decreased ejection fraction), restrictive cardiomyopathy, myocardial ischemia, and myocardial infarction including fatalities have occurred following administration of Kyprolis.",following is not a named entity
"(  5.14  ,  8.1  )              5.1 Cardiac Toxicities         New onset or worsening of pre-existing cardiac failure (e.g., congestive heart failure, pulmonary edema, decreased ejection fraction), restrictive cardiomyopathy, myocardial ischemia, and myocardial infarction including fatalities have occurred following administration of Kyprolis.",", and is not a named entity"
"5.9 Infusion Reactions         Infusion reactions, including life-threatening reactions, have occurred in patients receiving Kyprolis.",including is not a named entity
"5.9 Infusion Reactions         Infusion reactions, including life-threatening reactions, have occurred in patients receiving Kyprolis.",in patients receiving is not a named entity
"5.9 Infusion Reactions         Infusion reactions, including life-threatening reactions, have occurred in patients receiving Kyprolis.",Infusion reactions is an adverse reaction entity
"5.9 Infusion Reactions         Infusion reactions, including life-threatening reactions, have occurred in patients receiving Kyprolis.",Infusion reactions is an adverse reaction entity
"5.7 Hypertension         Hypertension, including hypertensive crisis and hypertensive emergency, has been observed with Kyprolis.",emergency is not a named entity
"5.7 Hypertension         Hypertension, including hypertensive crisis and hypertensive emergency, has been observed with Kyprolis.","Hypertension , including is not a named entity"
"5.7 Hypertension         Hypertension, including hypertensive crisis and hypertensive emergency, has been observed with Kyprolis.",and hypertensive emergency is not a named entity
"5.7 Hypertension         Hypertension, including hypertensive crisis and hypertensive emergency, has been observed with Kyprolis.",Hypertension is an adverse reaction entity
"5.7 Hypertension         Hypertension, including hypertensive crisis and hypertensive emergency, has been observed with Kyprolis.",hypertensive emergency is an adverse reaction entity
"5.7 Hypertension         Hypertension, including hypertensive crisis and hypertensive emergency, has been observed with Kyprolis.",hypertensive crisis is an adverse reaction entity
(  5.11  )   *    Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS).,hemolytic uremic syndrome is an adverse reaction entity
(  5.11  )   *    Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS).,syndrome ( is not a named entity
(  5.11  )   *    Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS).,purpura/hemolytic uremic is not a named entity
(  5.11  )   *    Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS).,5.11 ) is not a named entity
(  5.11  )   *    Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS).,TTP is an adverse reaction entity
(  5.11  )   *    Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS).,HUS is an adverse reaction entity
(  5.11  )   *    Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS).,uremic syndrome ( is not a named entity
(  5.11  )   *    Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS).,Thrombotic thrombocytopenic purpura is an adverse reaction entity
"In a randomized trial comparing Kyprolis as a single agent versus corticosteroids with optional oral cyclophosphamide for patients with relapsed and refractory multiple myeloma, mortality was higher in the patients treated with Kyprolis in comparison to the control arm in the subgroup of 48 patients >=75 years of age.",48 patients is not a named entity
"In a randomized trial comparing Kyprolis as a single agent versus corticosteroids with optional oral cyclophosphamide for patients with relapsed and refractory multiple myeloma, mortality was higher in the patients treated with Kyprolis in comparison to the control arm in the subgroup of 48 patients >=75 years of age.",mortality is an adverse reaction entity
Acute renal failure was reported more frequently in patients with advanced relapsed and refractory multiple myeloma who received Kyprolis monotherapy.,Acute renal failure is an adverse reaction entity
Acute renal failure was reported more frequently in patients with advanced relapsed and refractory multiple myeloma who received Kyprolis monotherapy.,received is not a named entity
Thrombocytopenia was reported in approximately 40% of patients in clinical trials with Kyprolis.,% of is not a named entity
Thrombocytopenia was reported in approximately 40% of patients in clinical trials with Kyprolis.,Thrombocytopenia is an adverse reaction entity
5.5 Pulmonary Hypertension         Pulmonary arterial hypertension (PAH) was reported in approximately 1% of patients treated with Kyprolis and was Grade 3 or greater in less than 1% of patients.,Pulmonary arterial hypertension is an adverse reaction entity
5.5 Pulmonary Hypertension         Pulmonary arterial hypertension (PAH) was reported in approximately 1% of patients treated with Kyprolis and was Grade 3 or greater in less than 1% of patients.,Pulmonary arterial hypertension is an adverse reaction entity
5.5 Pulmonary Hypertension         Pulmonary arterial hypertension (PAH) was reported in approximately 1% of patients treated with Kyprolis and was Grade 3 or greater in less than 1% of patients.,Hypertension is not a named entity
5.5 Pulmonary Hypertension         Pulmonary arterial hypertension (PAH) was reported in approximately 1% of patients treated with Kyprolis and was Grade 3 or greater in less than 1% of patients.,5.5 is not a named entity
5.5 Pulmonary Hypertension         Pulmonary arterial hypertension (PAH) was reported in approximately 1% of patients treated with Kyprolis and was Grade 3 or greater in less than 1% of patients.,PAH is an adverse reaction entity
5.5 Pulmonary Hypertension         Pulmonary arterial hypertension (PAH) was reported in approximately 1% of patients treated with Kyprolis and was Grade 3 or greater in less than 1% of patients.,patients is not a named entity
5.5 Pulmonary Hypertension         Pulmonary arterial hypertension (PAH) was reported in approximately 1% of patients treated with Kyprolis and was Grade 3 or greater in less than 1% of patients.,Hypertension Pulmonary arterial is not a named entity
5.5 Pulmonary Hypertension         Pulmonary arterial hypertension (PAH) was reported in approximately 1% of patients treated with Kyprolis and was Grade 3 or greater in less than 1% of patients.,PAH is an adverse reaction entity
"Renal insufficiency adverse events (renal impairment, acute renal failure, renal failure) have occurred with an incidence of approximately 8% in a randomized controlled trial.",Renal insufficiency adverse events is an adverse reaction entity
"Renal insufficiency adverse events (renal impairment, acute renal failure, renal failure) have occurred with an incidence of approximately 8% in a randomized controlled trial.",renal failure is an adverse reaction entity
"Renal insufficiency adverse events (renal impairment, acute renal failure, renal failure) have occurred with an incidence of approximately 8% in a randomized controlled trial.",adverse events ( is not a named entity
"Renal insufficiency adverse events (renal impairment, acute renal failure, renal failure) have occurred with an incidence of approximately 8% in a randomized controlled trial.",with an incidence is not a named entity
"Renal insufficiency adverse events (renal impairment, acute renal failure, renal failure) have occurred with an incidence of approximately 8% in a randomized controlled trial.",acute renal failure is an adverse reaction entity
"Renal insufficiency adverse events (renal impairment, acute renal failure, renal failure) have occurred with an incidence of approximately 8% in a randomized controlled trial.",randomized is not a named entity
"Renal insufficiency adverse events (renal impairment, acute renal failure, renal failure) have occurred with an incidence of approximately 8% in a randomized controlled trial.",) have is not a named entity
"Renal insufficiency adverse events (renal impairment, acute renal failure, renal failure) have occurred with an incidence of approximately 8% in a randomized controlled trial.",renal impairment is an adverse reaction entity
"5.11 Hepatic Toxicity and Hepatic Failure         Cases of hepatic failure, including fatal cases, have been reported (< 1%) during treatment with Kyprolis.",fatal is an adverse reaction entity
"5.11 Hepatic Toxicity and Hepatic Failure         Cases of hepatic failure, including fatal cases, have been reported (< 1%) during treatment with Kyprolis.",including is not a named entity
"5.11 Hepatic Toxicity and Hepatic Failure         Cases of hepatic failure, including fatal cases, have been reported (< 1%) during treatment with Kyprolis.",hepatic failure is an adverse reaction entity
"5.11 Hepatic Toxicity and Hepatic Failure         Cases of hepatic failure, including fatal cases, have been reported (< 1%) during treatment with Kyprolis.",Toxicity and Hepatic is not a named entity
The most common cause of discontinuation due to an adverse event was acute renal failure (2%).,renal failure is not a named entity
The most common cause of discontinuation due to an adverse event was acute renal failure (2%).,acute renal failure is an adverse reaction entity
Death due to cardiac arrest has occurred within a day of Kyprolis administration.,Death is an adverse reaction entity
Death due to cardiac arrest has occurred within a day of Kyprolis administration.,cardiac arrest is an adverse reaction entity
Death due to cardiac arrest has occurred within a day of Kyprolis administration.,day of Kyprolis is not a named entity
Death due to cardiac arrest has occurred within a day of Kyprolis administration.,Kyprolis administration is not a named entity
Deaths due to adverse events within 30 days of the last dose of any therapy in the KRd arm occurred in 27/392 (7%) patients compared with 27/389 (7%) patients who died due to adverse events within 30 days of the last dose of any Rd therapy.,due to is not a named entity
Deaths due to adverse events within 30 days of the last dose of any therapy in the KRd arm occurred in 27/392 (7%) patients compared with 27/389 (7%) patients who died due to adverse events within 30 days of the last dose of any Rd therapy.,Deaths is an adverse reaction entity
Deaths due to adverse events within 30 days of the last dose of any therapy in the KRd arm occurred in 27/392 (7%) patients compared with 27/389 (7%) patients who died due to adverse events within 30 days of the last dose of any Rd therapy.,died is an adverse reaction entity
Deaths due to adverse events within 30 days of the last dose of any therapy in the KRd arm occurred in 27/392 (7%) patients compared with 27/389 (7%) patients who died due to adverse events within 30 days of the last dose of any Rd therapy.,7 % is not a named entity
"The most common serious adverse events were: pneumonia (8%), acute renal failure (5%), disease progression (4%), pyrexia (3%), hypercalcemia (3%), congestive heart failure (3%), multiple myeloma (3%), anemia (2%), and dyspnea (2%).",congestive heart failure is an adverse reaction entity
"The most common serious adverse events were: pneumonia (8%), acute renal failure (5%), disease progression (4%), pyrexia (3%), hypercalcemia (3%), congestive heart failure (3%), multiple myeloma (3%), anemia (2%), and dyspnea (2%).",% ) is not a named entity
"The most common serious adverse events were: pneumonia (8%), acute renal failure (5%), disease progression (4%), pyrexia (3%), hypercalcemia (3%), congestive heart failure (3%), multiple myeloma (3%), anemia (2%), and dyspnea (2%).",multiple myeloma is an adverse reaction entity
"The most common serious adverse events were: pneumonia (8%), acute renal failure (5%), disease progression (4%), pyrexia (3%), hypercalcemia (3%), congestive heart failure (3%), multiple myeloma (3%), anemia (2%), and dyspnea (2%).",( 8 % is not a named entity
"The most common serious adverse events were: pneumonia (8%), acute renal failure (5%), disease progression (4%), pyrexia (3%), hypercalcemia (3%), congestive heart failure (3%), multiple myeloma (3%), anemia (2%), and dyspnea (2%).",dyspnea is an adverse reaction entity
"The most common serious adverse events were: pneumonia (8%), acute renal failure (5%), disease progression (4%), pyrexia (3%), hypercalcemia (3%), congestive heart failure (3%), multiple myeloma (3%), anemia (2%), and dyspnea (2%).",hypercalcemia is an adverse reaction entity
"The most common serious adverse events were: pneumonia (8%), acute renal failure (5%), disease progression (4%), pyrexia (3%), hypercalcemia (3%), congestive heart failure (3%), multiple myeloma (3%), anemia (2%), and dyspnea (2%).",pneumonia is an adverse reaction entity
"The most common serious adverse events were: pneumonia (8%), acute renal failure (5%), disease progression (4%), pyrexia (3%), hypercalcemia (3%), congestive heart failure (3%), multiple myeloma (3%), anemia (2%), and dyspnea (2%).",( 5 % is not a named entity
"The most common serious adverse events were: pneumonia (8%), acute renal failure (5%), disease progression (4%), pyrexia (3%), hypercalcemia (3%), congestive heart failure (3%), multiple myeloma (3%), anemia (2%), and dyspnea (2%).",acute renal failure is an adverse reaction entity
"The most common serious adverse events were: pneumonia (8%), acute renal failure (5%), disease progression (4%), pyrexia (3%), hypercalcemia (3%), congestive heart failure (3%), multiple myeloma (3%), anemia (2%), and dyspnea (2%).",most common is not a named entity
"The most common serious adverse events were: pneumonia (8%), acute renal failure (5%), disease progression (4%), pyrexia (3%), hypercalcemia (3%), congestive heart failure (3%), multiple myeloma (3%), anemia (2%), and dyspnea (2%).",disease progression is an adverse reaction entity
"The most common serious adverse events were: pneumonia (8%), acute renal failure (5%), disease progression (4%), pyrexia (3%), hypercalcemia (3%), congestive heart failure (3%), multiple myeloma (3%), anemia (2%), and dyspnea (2%).",anemia is an adverse reaction entity
"The most common serious adverse events were: pneumonia (8%), acute renal failure (5%), disease progression (4%), pyrexia (3%), hypercalcemia (3%), congestive heart failure (3%), multiple myeloma (3%), anemia (2%), and dyspnea (2%).",pyrexia is an adverse reaction entity
"The most common serious adverse events were: pneumonia (8%), acute renal failure (5%), disease progression (4%), pyrexia (3%), hypercalcemia (3%), congestive heart failure (3%), multiple myeloma (3%), anemia (2%), and dyspnea (2%).",adverse events is not a named entity
"The most common serious adverse events were: pneumonia (8%), acute renal failure (5%), disease progression (4%), pyrexia (3%), hypercalcemia (3%), congestive heart failure (3%), multiple myeloma (3%), anemia (2%), and dyspnea (2%).",serious adverse events is not a named entity
"The most common serious adverse events were: pneumonia (8%), acute renal failure (5%), disease progression (4%), pyrexia (3%), hypercalcemia (3%), congestive heart failure (3%), multiple myeloma (3%), anemia (2%), and dyspnea (2%).",heart is not a named entity
"The most common serious adverse events were: pneumonia (8%), acute renal failure (5%), disease progression (4%), pyrexia (3%), hypercalcemia (3%), congestive heart failure (3%), multiple myeloma (3%), anemia (2%), and dyspnea (2%).",% ) is not a named entity
"The most common serious adverse events were: pneumonia (8%), acute renal failure (5%), disease progression (4%), pyrexia (3%), hypercalcemia (3%), congestive heart failure (3%), multiple myeloma (3%), anemia (2%), and dyspnea (2%).",most is not a named entity
"5.4 Pulmonary Toxicity         Acute Respiratory Distress Syndrome (ARDS), acute respiratory failure, and acute diffuse infiltrative pulmonary disease such as pneumonitis and interstitial lung disease have occurred in less than 1% of patients receiving Kyprolis.",", acute respiratory is not a named entity"
"5.4 Pulmonary Toxicity         Acute Respiratory Distress Syndrome (ARDS), acute respiratory failure, and acute diffuse infiltrative pulmonary disease such as pneumonitis and interstitial lung disease have occurred in less than 1% of patients receiving Kyprolis.",interstitial lung disease is an adverse reaction entity
"5.4 Pulmonary Toxicity         Acute Respiratory Distress Syndrome (ARDS), acute respiratory failure, and acute diffuse infiltrative pulmonary disease such as pneumonitis and interstitial lung disease have occurred in less than 1% of patients receiving Kyprolis.",acute respiratory failure is an adverse reaction entity
"5.4 Pulmonary Toxicity         Acute Respiratory Distress Syndrome (ARDS), acute respiratory failure, and acute diffuse infiltrative pulmonary disease such as pneumonitis and interstitial lung disease have occurred in less than 1% of patients receiving Kyprolis.",acute diffuse infiltrative pulmonary disease is an adverse reaction entity
"5.4 Pulmonary Toxicity         Acute Respiratory Distress Syndrome (ARDS), acute respiratory failure, and acute diffuse infiltrative pulmonary disease such as pneumonitis and interstitial lung disease have occurred in less than 1% of patients receiving Kyprolis.",respiratory failure is not a named entity
"5.4 Pulmonary Toxicity         Acute Respiratory Distress Syndrome (ARDS), acute respiratory failure, and acute diffuse infiltrative pulmonary disease such as pneumonitis and interstitial lung disease have occurred in less than 1% of patients receiving Kyprolis.",patients receiving is not a named entity
"5.4 Pulmonary Toxicity         Acute Respiratory Distress Syndrome (ARDS), acute respiratory failure, and acute diffuse infiltrative pulmonary disease such as pneumonitis and interstitial lung disease have occurred in less than 1% of patients receiving Kyprolis.",receiving is not a named entity
"5.4 Pulmonary Toxicity         Acute Respiratory Distress Syndrome (ARDS), acute respiratory failure, and acute diffuse infiltrative pulmonary disease such as pneumonitis and interstitial lung disease have occurred in less than 1% of patients receiving Kyprolis.",Acute Respiratory Distress Syndrome is an adverse reaction entity
"5.4 Pulmonary Toxicity         Acute Respiratory Distress Syndrome (ARDS), acute respiratory failure, and acute diffuse infiltrative pulmonary disease such as pneumonitis and interstitial lung disease have occurred in less than 1% of patients receiving Kyprolis.",ARDS is an adverse reaction entity
"5.4 Pulmonary Toxicity         Acute Respiratory Distress Syndrome (ARDS), acute respiratory failure, and acute diffuse infiltrative pulmonary disease such as pneumonitis and interstitial lung disease have occurred in less than 1% of patients receiving Kyprolis.",pneumonitis is an adverse reaction entity
"5.4 Pulmonary Toxicity         Acute Respiratory Distress Syndrome (ARDS), acute respiratory failure, and acute diffuse infiltrative pulmonary disease such as pneumonitis and interstitial lung disease have occurred in less than 1% of patients receiving Kyprolis.",pulmonary disease is not a named entity
"5.4 Pulmonary Toxicity         Acute Respiratory Distress Syndrome (ARDS), acute respiratory failure, and acute diffuse infiltrative pulmonary disease such as pneumonitis and interstitial lung disease have occurred in less than 1% of patients receiving Kyprolis.",less is not a named entity
"The most common cause of deaths occurring in patients (%) in the two arms (KRd versus Rd) included cardiac 10 (3%) versus 7 (2%), infection 9 (2%) versus 10 (3%), renal 0 (0%) versus 1 (< 1%), and other adverse events 9 (2%) versus 10 (3%).",renal adverse events is an adverse reaction entity
"The most common cause of deaths occurring in patients (%) in the two arms (KRd versus Rd) included cardiac 10 (3%) versus 7 (2%), infection 9 (2%) versus 10 (3%), renal 0 (0%) versus 1 (< 1%), and other adverse events 9 (2%) versus 10 (3%).",3 % ) is not a named entity
"The most common cause of deaths occurring in patients (%) in the two arms (KRd versus Rd) included cardiac 10 (3%) versus 7 (2%), infection 9 (2%) versus 10 (3%), renal 0 (0%) versus 1 (< 1%), and other adverse events 9 (2%) versus 10 (3%).",infection adverse events is an adverse reaction entity
"The most common cause of deaths occurring in patients (%) in the two arms (KRd versus Rd) included cardiac 10 (3%) versus 7 (2%), infection 9 (2%) versus 10 (3%), renal 0 (0%) versus 1 (< 1%), and other adverse events 9 (2%) versus 10 (3%).",% ) is not a named entity
"The most common cause of deaths occurring in patients (%) in the two arms (KRd versus Rd) included cardiac 10 (3%) versus 7 (2%), infection 9 (2%) versus 10 (3%), renal 0 (0%) versus 1 (< 1%), and other adverse events 9 (2%) versus 10 (3%).",) versus is not a named entity
"The most common cause of deaths occurring in patients (%) in the two arms (KRd versus Rd) included cardiac 10 (3%) versus 7 (2%), infection 9 (2%) versus 10 (3%), renal 0 (0%) versus 1 (< 1%), and other adverse events 9 (2%) versus 10 (3%).",deaths is an adverse reaction entity
"The most common cause of deaths occurring in patients (%) in the two arms (KRd versus Rd) included cardiac 10 (3%) versus 7 (2%), infection 9 (2%) versus 10 (3%), renal 0 (0%) versus 1 (< 1%), and other adverse events 9 (2%) versus 10 (3%).",cardiac adverse events is an adverse reaction entity
"The most common cause of deaths occurring in patients (%) in the two arms (KRd versus Rd) included cardiac 10 (3%) versus 7 (2%), infection 9 (2%) versus 10 (3%), renal 0 (0%) versus 1 (< 1%), and other adverse events 9 (2%) versus 10 (3%).",% is not a named entity
"With Kyprolis monotherapy, the incidence of venous thromboembolic events was 2%.",Kyprolis is not a named entity
"With Kyprolis monotherapy, the incidence of venous thromboembolic events was 2%.",venous thromboembolic events is an adverse reaction entity
"5.3 Tumor Lysis Syndrome         Cases of tumor lysis syndrome (TLS), including fatal outcomes, have been reported in patients who received Kyprolis.",been is not a named entity
"5.3 Tumor Lysis Syndrome         Cases of tumor lysis syndrome (TLS), including fatal outcomes, have been reported in patients who received Kyprolis.",who received Kyprolis is not a named entity
"5.3 Tumor Lysis Syndrome         Cases of tumor lysis syndrome (TLS), including fatal outcomes, have been reported in patients who received Kyprolis.",been reported in is not a named entity
"5.3 Tumor Lysis Syndrome         Cases of tumor lysis syndrome (TLS), including fatal outcomes, have been reported in patients who received Kyprolis.",tumor lysis syndrome is an adverse reaction entity
"5.3 Tumor Lysis Syndrome         Cases of tumor lysis syndrome (TLS), including fatal outcomes, have been reported in patients who received Kyprolis.",TLS is an adverse reaction entity
"5.3 Tumor Lysis Syndrome         Cases of tumor lysis syndrome (TLS), including fatal outcomes, have been reported in patients who received Kyprolis.",fatal is an adverse reaction entity
"(  2.4  ,  5.10  )   *    Hepatic Toxicity and Hepatic Failure: Monitor liver enzymes.",Hepatic Failure is an adverse reaction entity
"(  2.4  ,  5.10  )   *    Hepatic Toxicity and Hepatic Failure: Monitor liver enzymes.",: Monitor liver is not a named entity
"(  2.4  ,  5.10  )   *    Hepatic Toxicity and Hepatic Failure: Monitor liver enzymes.",: is not a named entity
"(  2.4  ,  5.10  )   *    Hepatic Toxicity and Hepatic Failure: Monitor liver enzymes.",Hepatic Toxicity is an adverse reaction entity
5.8 Venous Thrombosis         Venous thromboembolic events (including deep venous thrombosis and pulmonary embolism) have been observed with Kyprolis.,) have is not a named entity
5.8 Venous Thrombosis         Venous thromboembolic events (including deep venous thrombosis and pulmonary embolism) have been observed with Kyprolis.,) have is not a named entity
5.8 Venous Thrombosis         Venous thromboembolic events (including deep venous thrombosis and pulmonary embolism) have been observed with Kyprolis.,Venous thromboembolic events is an adverse reaction entity
5.8 Venous Thrombosis         Venous thromboembolic events (including deep venous thrombosis and pulmonary embolism) have been observed with Kyprolis.,deep venous thrombosis is an adverse reaction entity
5.8 Venous Thrombosis         Venous thromboembolic events (including deep venous thrombosis and pulmonary embolism) have been observed with Kyprolis.,pulmonary embolism is an adverse reaction entity
5.8 Venous Thrombosis         Venous thromboembolic events (including deep venous thrombosis and pulmonary embolism) have been observed with Kyprolis.,embolism is not a named entity
5.12 Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome         Cases of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) including fatal outcome have been reported in patients who received Kyprolis.,HUS is an adverse reaction entity
5.12 Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome         Cases of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) including fatal outcome have been reported in patients who received Kyprolis.,hemolytic uremic syndrome is an adverse reaction entity
5.12 Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome         Cases of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) including fatal outcome have been reported in patients who received Kyprolis.,fatal is an adverse reaction entity
5.12 Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome         Cases of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) including fatal outcome have been reported in patients who received Kyprolis.,purpura/hemolytic uremic syndrome is not a named entity
5.12 Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome         Cases of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) including fatal outcome have been reported in patients who received Kyprolis.,reported in is not a named entity
5.12 Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome         Cases of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) including fatal outcome have been reported in patients who received Kyprolis.,Syndrome Cases is not a named entity
5.12 Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome         Cases of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) including fatal outcome have been reported in patients who received Kyprolis.,who is not a named entity
5.12 Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome         Cases of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) including fatal outcome have been reported in patients who received Kyprolis.,thrombotic thrombocytopenic purpura is an adverse reaction entity
5.12 Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome         Cases of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) including fatal outcome have been reported in patients who received Kyprolis.,TTP is an adverse reaction entity
5.12 Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome         Cases of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) including fatal outcome have been reported in patients who received Kyprolis.,Kyprolis is not a named entity
"In the combination study, the incidence of venous thromboembolic events in the first 12 cycles was 13% in the Kyprolis combination arm versus 6% in the control arm.",13 is not a named entity
"In the combination study, the incidence of venous thromboembolic events in the first 12 cycles was 13% in the Kyprolis combination arm versus 6% in the control arm.",venous thromboembolic events is an adverse reaction entity
"(  5.3  )   *    Pulmonary Toxicity: including Acute Respiratory Distress Syndrome, acute respiratory failure, and acute diffuse infiltrative pulmonary disease: Withhold Kyprolis and evaluate promptly (  5.4  )   *    Pulmonary Hypertension: Withhold Kyprolis and evaluate (  5.5  )   *    Dyspnea: For severe or life threatening dyspnea, withhold Kyprolis and evaluate.",Dyspnea is an adverse reaction entity
"(  5.3  )   *    Pulmonary Toxicity: including Acute Respiratory Distress Syndrome, acute respiratory failure, and acute diffuse infiltrative pulmonary disease: Withhold Kyprolis and evaluate promptly (  5.4  )   *    Pulmonary Hypertension: Withhold Kyprolis and evaluate (  5.5  )   *    Dyspnea: For severe or life threatening dyspnea, withhold Kyprolis and evaluate.",life threatening is not a named entity
"(  5.3  )   *    Pulmonary Toxicity: including Acute Respiratory Distress Syndrome, acute respiratory failure, and acute diffuse infiltrative pulmonary disease: Withhold Kyprolis and evaluate promptly (  5.4  )   *    Pulmonary Hypertension: Withhold Kyprolis and evaluate (  5.5  )   *    Dyspnea: For severe or life threatening dyspnea, withhold Kyprolis and evaluate.",diffuse infiltrative is not a named entity
"(  5.3  )   *    Pulmonary Toxicity: including Acute Respiratory Distress Syndrome, acute respiratory failure, and acute diffuse infiltrative pulmonary disease: Withhold Kyprolis and evaluate promptly (  5.4  )   *    Pulmonary Hypertension: Withhold Kyprolis and evaluate (  5.5  )   *    Dyspnea: For severe or life threatening dyspnea, withhold Kyprolis and evaluate.",Acute Respiratory Distress Syndrome is an adverse reaction entity
"(  5.3  )   *    Pulmonary Toxicity: including Acute Respiratory Distress Syndrome, acute respiratory failure, and acute diffuse infiltrative pulmonary disease: Withhold Kyprolis and evaluate promptly (  5.4  )   *    Pulmonary Hypertension: Withhold Kyprolis and evaluate (  5.5  )   *    Dyspnea: For severe or life threatening dyspnea, withhold Kyprolis and evaluate.",Pulmonary Toxicity is an adverse reaction entity
"(  5.3  )   *    Pulmonary Toxicity: including Acute Respiratory Distress Syndrome, acute respiratory failure, and acute diffuse infiltrative pulmonary disease: Withhold Kyprolis and evaluate promptly (  5.4  )   *    Pulmonary Hypertension: Withhold Kyprolis and evaluate (  5.5  )   *    Dyspnea: For severe or life threatening dyspnea, withhold Kyprolis and evaluate.",acute diffuse infiltrative pulmonary disease is an adverse reaction entity
"(  5.3  )   *    Pulmonary Toxicity: including Acute Respiratory Distress Syndrome, acute respiratory failure, and acute diffuse infiltrative pulmonary disease: Withhold Kyprolis and evaluate promptly (  5.4  )   *    Pulmonary Hypertension: Withhold Kyprolis and evaluate (  5.5  )   *    Dyspnea: For severe or life threatening dyspnea, withhold Kyprolis and evaluate.",promptly ( 5.4 is not a named entity
"(  5.3  )   *    Pulmonary Toxicity: including Acute Respiratory Distress Syndrome, acute respiratory failure, and acute diffuse infiltrative pulmonary disease: Withhold Kyprolis and evaluate promptly (  5.4  )   *    Pulmonary Hypertension: Withhold Kyprolis and evaluate (  5.5  )   *    Dyspnea: For severe or life threatening dyspnea, withhold Kyprolis and evaluate.",and is not a named entity
"(  5.3  )   *    Pulmonary Toxicity: including Acute Respiratory Distress Syndrome, acute respiratory failure, and acute diffuse infiltrative pulmonary disease: Withhold Kyprolis and evaluate promptly (  5.4  )   *    Pulmonary Hypertension: Withhold Kyprolis and evaluate (  5.5  )   *    Dyspnea: For severe or life threatening dyspnea, withhold Kyprolis and evaluate.",and evaluate promptly is not a named entity
"(  5.3  )   *    Pulmonary Toxicity: including Acute Respiratory Distress Syndrome, acute respiratory failure, and acute diffuse infiltrative pulmonary disease: Withhold Kyprolis and evaluate promptly (  5.4  )   *    Pulmonary Hypertension: Withhold Kyprolis and evaluate (  5.5  )   *    Dyspnea: For severe or life threatening dyspnea, withhold Kyprolis and evaluate.","dyspnea , is not a named entity"
"(  5.3  )   *    Pulmonary Toxicity: including Acute Respiratory Distress Syndrome, acute respiratory failure, and acute diffuse infiltrative pulmonary disease: Withhold Kyprolis and evaluate promptly (  5.4  )   *    Pulmonary Hypertension: Withhold Kyprolis and evaluate (  5.5  )   *    Dyspnea: For severe or life threatening dyspnea, withhold Kyprolis and evaluate.",acute respiratory failure is an adverse reaction entity
"(  5.3  )   *    Pulmonary Toxicity: including Acute Respiratory Distress Syndrome, acute respiratory failure, and acute diffuse infiltrative pulmonary disease: Withhold Kyprolis and evaluate promptly (  5.4  )   *    Pulmonary Hypertension: Withhold Kyprolis and evaluate (  5.5  )   *    Dyspnea: For severe or life threatening dyspnea, withhold Kyprolis and evaluate.",Pulmonary Hypertension is an adverse reaction entity
"d    Hypertension includes the preferred terms of hypertension, hypertensive crisis, and hypertensive emergency.",preferred is not a named entity
"d    Hypertension includes the preferred terms of hypertension, hypertensive crisis, and hypertensive emergency.",crisis is not a named entity
"d    Hypertension includes the preferred terms of hypertension, hypertensive crisis, and hypertensive emergency.",hypertensive emergency is an adverse reaction entity
"d    Hypertension includes the preferred terms of hypertension, hypertensive crisis, and hypertensive emergency.",hypertensive crisis is an adverse reaction entity
"d    Hypertension includes the preferred terms of hypertension, hypertensive crisis, and hypertensive emergency.",d is not a named entity
"d    Hypertension includes the preferred terms of hypertension, hypertensive crisis, and hypertensive emergency.",Hypertension is an adverse reaction entity
"d    Hypertension includes the preferred terms of hypertension, hypertensive crisis, and hypertensive emergency.",hypertension is an adverse reaction entity
"d    Hypertension includes the preferred terms of hypertension, hypertensive crisis, and hypertensive emergency.",d is not a named entity
"The most common serious adverse events reported in the KRd arm as compared with the Rd arm were pneumonia (14% versus 11%), respiratory tract infection (4% versus 1.5%), pyrexia (4% versus 2%), and pulmonary embolism (3% versus 2%).",KRd is not a named entity
"The most common serious adverse events reported in the KRd arm as compared with the Rd arm were pneumonia (14% versus 11%), respiratory tract infection (4% versus 1.5%), pyrexia (4% versus 2%), and pulmonary embolism (3% versus 2%).",infection is not a named entity
"The most common serious adverse events reported in the KRd arm as compared with the Rd arm were pneumonia (14% versus 11%), respiratory tract infection (4% versus 1.5%), pyrexia (4% versus 2%), and pulmonary embolism (3% versus 2%).",pulmonary embolism is an adverse reaction entity
"The most common serious adverse events reported in the KRd arm as compared with the Rd arm were pneumonia (14% versus 11%), respiratory tract infection (4% versus 1.5%), pyrexia (4% versus 2%), and pulmonary embolism (3% versus 2%).",were pneumonia ( is not a named entity
"The most common serious adverse events reported in the KRd arm as compared with the Rd arm were pneumonia (14% versus 11%), respiratory tract infection (4% versus 1.5%), pyrexia (4% versus 2%), and pulmonary embolism (3% versus 2%).","% ) , is not a named entity"
"The most common serious adverse events reported in the KRd arm as compared with the Rd arm were pneumonia (14% versus 11%), respiratory tract infection (4% versus 1.5%), pyrexia (4% versus 2%), and pulmonary embolism (3% versus 2%).",respiratory tract infection is an adverse reaction entity
"The most common serious adverse events reported in the KRd arm as compared with the Rd arm were pneumonia (14% versus 11%), respiratory tract infection (4% versus 1.5%), pyrexia (4% versus 2%), and pulmonary embolism (3% versus 2%).",pneumonia is an adverse reaction entity
"The most common serious adverse events reported in the KRd arm as compared with the Rd arm were pneumonia (14% versus 11%), respiratory tract infection (4% versus 1.5%), pyrexia (4% versus 2%), and pulmonary embolism (3% versus 2%).",pyrexia is an adverse reaction entity
Carfilzomib caused embryo-fetal toxicity in pregnant rabbits at doses that were lower than in patients receiving the recommended dose.,in pregnant is not a named entity
Carfilzomib caused embryo-fetal toxicity in pregnant rabbits at doses that were lower than in patients receiving the recommended dose.,embryo-fetal toxicity is an adverse reaction entity
5.10 Thrombocytopenia         Kyprolis causes thrombocytopenia with platelet nadirs observed between Day 8 and Day 15 of each 28-day cycle with recovery to baseline platelet count usually by the start of the next cycle [ see Adverse Reactions (  6  )  ].,platelet nadirs is an adverse reaction entity
5.10 Thrombocytopenia         Kyprolis causes thrombocytopenia with platelet nadirs observed between Day 8 and Day 15 of each 28-day cycle with recovery to baseline platelet count usually by the start of the next cycle [ see Adverse Reactions (  6  )  ].,each 28-day cycle is not a named entity
5.10 Thrombocytopenia         Kyprolis causes thrombocytopenia with platelet nadirs observed between Day 8 and Day 15 of each 28-day cycle with recovery to baseline platelet count usually by the start of the next cycle [ see Adverse Reactions (  6  )  ].,thrombocytopenia is an adverse reaction entity
5.10 Thrombocytopenia         Kyprolis causes thrombocytopenia with platelet nadirs observed between Day 8 and Day 15 of each 28-day cycle with recovery to baseline platelet count usually by the start of the next cycle [ see Adverse Reactions (  6  )  ].,6 is not a named entity
5.2 Acute Renal Failure         Cases of acute renal failure have occurred in patients receiving Kyprolis.,acute renal failure is an adverse reaction entity
5.2 Acute Renal Failure         Cases of acute renal failure have occurred in patients receiving Kyprolis.,occurred in is not a named entity
Deaths due to adverse events within 30 days of the last dose of Kyprolis occurred in 30/598 (5%) patients receiving Kyprolis monotherapy.,Deaths is an adverse reaction entity
Deaths due to adverse events within 30 days of the last dose of Kyprolis occurred in 30/598 (5%) patients receiving Kyprolis monotherapy.,patients receiving is not a named entity
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, or parasitic organisms including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, and tuberculosis have been reported with TNF-blockers.",listeriosis is an adverse reaction entity
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, or parasitic organisms including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, and tuberculosis have been reported with TNF-blockers.",Opportunistic infections invasive fungal is an adverse reaction entity
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, or parasitic organisms including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, and tuberculosis have been reported with TNF-blockers.","to bacterial , is not a named entity"
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, or parasitic organisms including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, and tuberculosis have been reported with TNF-blockers.",histoplasmosis is an adverse reaction entity
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, or parasitic organisms including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, and tuberculosis have been reported with TNF-blockers.","blastomycosis , is not a named entity"
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, or parasitic organisms including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, and tuberculosis have been reported with TNF-blockers.",candidiasis is an adverse reaction entity
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, or parasitic organisms including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, and tuberculosis have been reported with TNF-blockers.",tuberculosis is an adverse reaction entity
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, or parasitic organisms including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, and tuberculosis have been reported with TNF-blockers.","invasive fungal , is not a named entity"
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, or parasitic organisms including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, and tuberculosis have been reported with TNF-blockers.",pneumocystosis is an adverse reaction entity
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, or parasitic organisms including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, and tuberculosis have been reported with TNF-blockers.","fungal , viral is not a named entity"
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, or parasitic organisms including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, and tuberculosis have been reported with TNF-blockers.",Opportunistic infections mycobacterial is an adverse reaction entity
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, or parasitic organisms including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, and tuberculosis have been reported with TNF-blockers.",", listeriosis is not a named entity"
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, or parasitic organisms including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, and tuberculosis have been reported with TNF-blockers.",Opportunistic infections bacterial is an adverse reaction entity
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, or parasitic organisms including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, and tuberculosis have been reported with TNF-blockers.",been reported is not a named entity
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, or parasitic organisms including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, and tuberculosis have been reported with TNF-blockers.","fungal , viral is not a named entity"
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, or parasitic organisms including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, and tuberculosis have been reported with TNF-blockers.",Opportunistic infections parasitic is an adverse reaction entity
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, or parasitic organisms including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, and tuberculosis have been reported with TNF-blockers.",", is not a named entity"
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, or parasitic organisms including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, and tuberculosis have been reported with TNF-blockers.",been is not a named entity
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, or parasitic organisms including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, and tuberculosis have been reported with TNF-blockers.","bacterial , mycobacterial is not a named entity"
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, or parasitic organisms including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, and tuberculosis have been reported with TNF-blockers.",parasitic is not a named entity
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, or parasitic organisms including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, and tuberculosis have been reported with TNF-blockers.",invasive is not a named entity
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, or parasitic organisms including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, and tuberculosis have been reported with TNF-blockers.",legionellosis is an adverse reaction entity
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, or parasitic organisms including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, and tuberculosis have been reported with TNF-blockers.",coccidioidomycosis is an adverse reaction entity
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, or parasitic organisms including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, and tuberculosis have been reported with TNF-blockers.",or parasitic organisms is not a named entity
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, or parasitic organisms including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, and tuberculosis have been reported with TNF-blockers.",Opportunistic infections viral is an adverse reaction entity
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, or parasitic organisms including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, and tuberculosis have been reported with TNF-blockers.","bacterial , mycobacterial is not a named entity"
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, or parasitic organisms including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, and tuberculosis have been reported with TNF-blockers.",blastomycosis is an adverse reaction entity
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, or parasitic organisms including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, and tuberculosis have been reported with TNF-blockers.",Opportunistic infections is an adverse reaction entity
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, or parasitic organisms including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, and tuberculosis have been reported with TNF-blockers.",aspergillosis is an adverse reaction entity
"Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, or parasitic organisms including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, and tuberculosis have been reported with TNF-blockers.",", is not a named entity"
Malignancies       One case of malignancy other than lymphoma and NMSC with SIMPONI ARIA was reported through Week 24 during the controlled phase of Trial 1.,Malignancies One is not a named entity
Malignancies       One case of malignancy other than lymphoma and NMSC with SIMPONI ARIA was reported through Week 24 during the controlled phase of Trial 1.,NMSC is an adverse reaction entity
Malignancies       One case of malignancy other than lymphoma and NMSC with SIMPONI ARIA was reported through Week 24 during the controlled phase of Trial 1.,with is not a named entity
Malignancies       One case of malignancy other than lymphoma and NMSC with SIMPONI ARIA was reported through Week 24 during the controlled phase of Trial 1.,lymphoma is an adverse reaction entity
Malignancies       One case of malignancy other than lymphoma and NMSC with SIMPONI ARIA was reported through Week 24 during the controlled phase of Trial 1.,malignancy is an adverse reaction entity
Malignancies       One case of malignancy other than lymphoma and NMSC with SIMPONI ARIA was reported through Week 24 during the controlled phase of Trial 1.,malignancy other than is not a named entity
SERIOUS INFECTIONS         Patients treated with SIMPONI ARIA are at increased risk for developing serious infections that may lead to hospitalization or death   [see   Warnings and Precautions (5.1)  ]  .,infections that may is not a named entity
SERIOUS INFECTIONS         Patients treated with SIMPONI ARIA are at increased risk for developing serious infections that may lead to hospitalization or death   [see   Warnings and Precautions (5.1)  ]  .,lead to is not a named entity
SERIOUS INFECTIONS         Patients treated with SIMPONI ARIA are at increased risk for developing serious infections that may lead to hospitalization or death   [see   Warnings and Precautions (5.1)  ]  .,death is an adverse reaction entity
SERIOUS INFECTIONS         Patients treated with SIMPONI ARIA are at increased risk for developing serious infections that may lead to hospitalization or death   [see   Warnings and Precautions (5.1)  ]  .,infections is an adverse reaction entity
"In the controlled and uncontrolled portions through approximately 92 weeks, the incidence of malignancies per 100 patient-years, other than lymphoma and NMSC, in SIMPONI ARIA-treated patients was 0.31 (CI: 0.06, 0.92) and the incidence of NMSC was 0.1 (95% CI: 0.00, 0.58).",lymphoma is an adverse reaction entity
"In the controlled and uncontrolled portions through approximately 92 weeks, the incidence of malignancies per 100 patient-years, other than lymphoma and NMSC, in SIMPONI ARIA-treated patients was 0.31 (CI: 0.06, 0.92) and the incidence of NMSC was 0.1 (95% CI: 0.00, 0.58).",malignancies is an adverse reaction entity
"In the controlled and uncontrolled portions through approximately 92 weeks, the incidence of malignancies per 100 patient-years, other than lymphoma and NMSC, in SIMPONI ARIA-treated patients was 0.31 (CI: 0.06, 0.92) and the incidence of NMSC was 0.1 (95% CI: 0.00, 0.58).",through is not a named entity
"In the controlled and uncontrolled portions through approximately 92 weeks, the incidence of malignancies per 100 patient-years, other than lymphoma and NMSC, in SIMPONI ARIA-treated patients was 0.31 (CI: 0.06, 0.92) and the incidence of NMSC was 0.1 (95% CI: 0.00, 0.58).",lymphoma and is not a named entity
"In the controlled and uncontrolled portions through approximately 92 weeks, the incidence of malignancies per 100 patient-years, other than lymphoma and NMSC, in SIMPONI ARIA-treated patients was 0.31 (CI: 0.06, 0.92) and the incidence of NMSC was 0.1 (95% CI: 0.00, 0.58).",malignancies per is not a named entity
"In the controlled and uncontrolled portions through approximately 92 weeks, the incidence of malignancies per 100 patient-years, other than lymphoma and NMSC, in SIMPONI ARIA-treated patients was 0.31 (CI: 0.06, 0.92) and the incidence of NMSC was 0.1 (95% CI: 0.00, 0.58).",0.58 is not a named entity
"In the controlled and uncontrolled portions through approximately 92 weeks, the incidence of malignancies per 100 patient-years, other than lymphoma and NMSC, in SIMPONI ARIA-treated patients was 0.31 (CI: 0.06, 0.92) and the incidence of NMSC was 0.1 (95% CI: 0.00, 0.58).",NMSC is an adverse reaction entity
"In the controlled and uncontrolled portions through approximately 92 weeks, the incidence of malignancies per 100 patient-years, other than lymphoma and NMSC, in SIMPONI ARIA-treated patients was 0.31 (CI: 0.06, 0.92) and the incidence of NMSC was 0.1 (95% CI: 0.00, 0.58).",NMSC is an adverse reaction entity
The majority of the TB cases occurred in countries with a high incidence rate of TB  [see  Warnings and Precautions (5.1)  ]  .,Precautions ( 5.1 is not a named entity
The majority of the TB cases occurred in countries with a high incidence rate of TB  [see  Warnings and Precautions (5.1)  ]  .,TB is an adverse reaction entity
"5.8 Hematologic Cytopenias      There have been post-marketing reports of pancytopenia, leukopenia, neutropenia, aplastic anemia, and thrombocytopenia in patients receiving TNF-blockers.","pancytopenia , is not a named entity"
"5.8 Hematologic Cytopenias      There have been post-marketing reports of pancytopenia, leukopenia, neutropenia, aplastic anemia, and thrombocytopenia in patients receiving TNF-blockers.",and is not a named entity
"5.8 Hematologic Cytopenias      There have been post-marketing reports of pancytopenia, leukopenia, neutropenia, aplastic anemia, and thrombocytopenia in patients receiving TNF-blockers.",5.8 is not a named entity
"5.8 Hematologic Cytopenias      There have been post-marketing reports of pancytopenia, leukopenia, neutropenia, aplastic anemia, and thrombocytopenia in patients receiving TNF-blockers.",aplastic anemia is an adverse reaction entity
"5.8 Hematologic Cytopenias      There have been post-marketing reports of pancytopenia, leukopenia, neutropenia, aplastic anemia, and thrombocytopenia in patients receiving TNF-blockers.",leukopenia is an adverse reaction entity
"5.8 Hematologic Cytopenias      There have been post-marketing reports of pancytopenia, leukopenia, neutropenia, aplastic anemia, and thrombocytopenia in patients receiving TNF-blockers.",Hematologic Cytopenias is not a named entity
"5.8 Hematologic Cytopenias      There have been post-marketing reports of pancytopenia, leukopenia, neutropenia, aplastic anemia, and thrombocytopenia in patients receiving TNF-blockers.",neutropenia is an adverse reaction entity
"5.8 Hematologic Cytopenias      There have been post-marketing reports of pancytopenia, leukopenia, neutropenia, aplastic anemia, and thrombocytopenia in patients receiving TNF-blockers.",pancytopenia is an adverse reaction entity
"5.8 Hematologic Cytopenias      There have been post-marketing reports of pancytopenia, leukopenia, neutropenia, aplastic anemia, and thrombocytopenia in patients receiving TNF-blockers.",thrombocytopenia is an adverse reaction entity
"5.8 Hematologic Cytopenias      There have been post-marketing reports of pancytopenia, leukopenia, neutropenia, aplastic anemia, and thrombocytopenia in patients receiving TNF-blockers.",and thrombocytopenia is not a named entity
"In the controlled phase of Trial 1, through Week 24, ALT elevations >= 5 * ULN occurred in 0.8% of SIMPONI ARIA-treated patients and 0% of control-treated patients and ALT elevations >= 3 * ULN occurred in 2.3% of SIMPONI ARIA-treated patients and 2.5% of control-treated patients.",ALT elevations is an adverse reaction entity
"In the controlled phase of Trial 1, through Week 24, ALT elevations >= 5 * ULN occurred in 0.8% of SIMPONI ARIA-treated patients and 0% of control-treated patients and ALT elevations >= 3 * ULN occurred in 2.3% of SIMPONI ARIA-treated patients and 2.5% of control-treated patients.",and is not a named entity
"In the controlled phase of Trial 1, through Week 24, ALT elevations >= 5 * ULN occurred in 0.8% of SIMPONI ARIA-treated patients and 0% of control-treated patients and ALT elevations >= 3 * ULN occurred in 2.3% of SIMPONI ARIA-treated patients and 2.5% of control-treated patients.",ALT elevations is an adverse reaction entity
"In the controlled phase of Trial 1, through Week 24, ALT elevations >= 5 * ULN occurred in 0.8% of SIMPONI ARIA-treated patients and 0% of control-treated patients and ALT elevations >= 3 * ULN occurred in 2.3% of SIMPONI ARIA-treated patients and 2.5% of control-treated patients.",controlled phase is not a named entity
"5.2 Malignancies       Malignancies in Pediatric Patients       Malignancies, some fatal, have been reported among children, adolescents, and young adults who received treatment with TNF-blocking agents (initiation of therapy <= 18 years of age), of which SIMPONI ARIA is a member.",fatal is an adverse reaction entity
"5.2 Malignancies       Malignancies in Pediatric Patients       Malignancies, some fatal, have been reported among children, adolescents, and young adults who received treatment with TNF-blocking agents (initiation of therapy <= 18 years of age), of which SIMPONI ARIA is a member.",adults is not a named entity
"5.2 Malignancies       Malignancies in Pediatric Patients       Malignancies, some fatal, have been reported among children, adolescents, and young adults who received treatment with TNF-blocking agents (initiation of therapy <= 18 years of age), of which SIMPONI ARIA is a member.",Malignancies is an adverse reaction entity
"5.2 Malignancies       Malignancies in Pediatric Patients       Malignancies, some fatal, have been reported among children, adolescents, and young adults who received treatment with TNF-blocking agents (initiation of therapy <= 18 years of age), of which SIMPONI ARIA is a member.",therapy < = is not a named entity
"Infections       Serious infections observed in SIMPONI ARIA-treated patients included sepsis, pneumonia, cellulitis, abscess, opportunistic infections, tuberculosis (TB), and invasive fungal infections.","TB ) , is not a named entity"
"Infections       Serious infections observed in SIMPONI ARIA-treated patients included sepsis, pneumonia, cellulitis, abscess, opportunistic infections, tuberculosis (TB), and invasive fungal infections.",Serious infections observed is not a named entity
"Infections       Serious infections observed in SIMPONI ARIA-treated patients included sepsis, pneumonia, cellulitis, abscess, opportunistic infections, tuberculosis (TB), and invasive fungal infections.",and invasive is not a named entity
"Infections       Serious infections observed in SIMPONI ARIA-treated patients included sepsis, pneumonia, cellulitis, abscess, opportunistic infections, tuberculosis (TB), and invasive fungal infections.",opportunistic infections is an adverse reaction entity
"Infections       Serious infections observed in SIMPONI ARIA-treated patients included sepsis, pneumonia, cellulitis, abscess, opportunistic infections, tuberculosis (TB), and invasive fungal infections.",", tuberculosis is not a named entity"
"Infections       Serious infections observed in SIMPONI ARIA-treated patients included sepsis, pneumonia, cellulitis, abscess, opportunistic infections, tuberculosis (TB), and invasive fungal infections.",sepsis is an adverse reaction entity
"Infections       Serious infections observed in SIMPONI ARIA-treated patients included sepsis, pneumonia, cellulitis, abscess, opportunistic infections, tuberculosis (TB), and invasive fungal infections.",( TB ) is not a named entity
"Infections       Serious infections observed in SIMPONI ARIA-treated patients included sepsis, pneumonia, cellulitis, abscess, opportunistic infections, tuberculosis (TB), and invasive fungal infections.",cellulitis is an adverse reaction entity
"Infections       Serious infections observed in SIMPONI ARIA-treated patients included sepsis, pneumonia, cellulitis, abscess, opportunistic infections, tuberculosis (TB), and invasive fungal infections.",tuberculosis ( is not a named entity
"Infections       Serious infections observed in SIMPONI ARIA-treated patients included sepsis, pneumonia, cellulitis, abscess, opportunistic infections, tuberculosis (TB), and invasive fungal infections.",tuberculosis is an adverse reaction entity
"Infections       Serious infections observed in SIMPONI ARIA-treated patients included sepsis, pneumonia, cellulitis, abscess, opportunistic infections, tuberculosis (TB), and invasive fungal infections.",abscess is an adverse reaction entity
"Infections       Serious infections observed in SIMPONI ARIA-treated patients included sepsis, pneumonia, cellulitis, abscess, opportunistic infections, tuberculosis (TB), and invasive fungal infections.",", pneumonia , is not a named entity"
"Infections       Serious infections observed in SIMPONI ARIA-treated patients included sepsis, pneumonia, cellulitis, abscess, opportunistic infections, tuberculosis (TB), and invasive fungal infections.",TB is an adverse reaction entity
"Infections       Serious infections observed in SIMPONI ARIA-treated patients included sepsis, pneumonia, cellulitis, abscess, opportunistic infections, tuberculosis (TB), and invasive fungal infections.",Infections Serious infections is not a named entity
"Infections       Serious infections observed in SIMPONI ARIA-treated patients included sepsis, pneumonia, cellulitis, abscess, opportunistic infections, tuberculosis (TB), and invasive fungal infections.",infections is an adverse reaction entity
"Infections       Serious infections observed in SIMPONI ARIA-treated patients included sepsis, pneumonia, cellulitis, abscess, opportunistic infections, tuberculosis (TB), and invasive fungal infections.",invasive fungal infections is an adverse reaction entity
"Infections       Serious infections observed in SIMPONI ARIA-treated patients included sepsis, pneumonia, cellulitis, abscess, opportunistic infections, tuberculosis (TB), and invasive fungal infections.",and invasive is not a named entity
"Infections       Serious infections observed in SIMPONI ARIA-treated patients included sepsis, pneumonia, cellulitis, abscess, opportunistic infections, tuberculosis (TB), and invasive fungal infections.",pneumonia is an adverse reaction entity
"Hepatitis B Virus Reactivation       The use of TNF-blockers, of which SIMPONI ARIA is a member, has been associated with reactivation of hepatitis B virus (HBV) in patients who are chronic hepatitis B carriers (i.e., surface antigen positive).",( HBV ) is not a named entity
"Hepatitis B Virus Reactivation       The use of TNF-blockers, of which SIMPONI ARIA is a member, has been associated with reactivation of hepatitis B virus (HBV) in patients who are chronic hepatitis B carriers (i.e., surface antigen positive).",reactivation of HBV is an adverse reaction entity
"Hepatitis B Virus Reactivation       The use of TNF-blockers, of which SIMPONI ARIA is a member, has been associated with reactivation of hepatitis B virus (HBV) in patients who are chronic hepatitis B carriers (i.e., surface antigen positive).",reactivation of hepatitis B virus is an adverse reaction entity
"Hepatitis B Virus Reactivation       The use of TNF-blockers, of which SIMPONI ARIA is a member, has been associated with reactivation of hepatitis B virus (HBV) in patients who are chronic hepatitis B carriers (i.e., surface antigen positive).",virus ( is not a named entity
"In controlled trials of other TNF-blockers in patients at higher risk for malignancies (e.g., patients with COPD, patients with Wegener's granulomatosis treated with concomitant cyclophosphamide) a greater portion of malignancies occurred in the TNF-blocker group compared to the controlled group.","e.g. , patients is not a named entity"
"In controlled trials of other TNF-blockers in patients at higher risk for malignancies (e.g., patients with COPD, patients with Wegener's granulomatosis treated with concomitant cyclophosphamide) a greater portion of malignancies occurred in the TNF-blocker group compared to the controlled group.",malignancies is an adverse reaction entity
BOXED WARNING: WARNING: SERIOUS INFECTIONS AND MALIGNANCY      WARNING: SERIOUS INFECTIONS AND MALIGNANCY      EXCERPT:   WARNING:  SERIOUS INFECTIONS AND MALIGNANCY       See full prescribing information for complete boxed warning.,AND is not a named entity
BOXED WARNING: WARNING: SERIOUS INFECTIONS AND MALIGNANCY      WARNING: SERIOUS INFECTIONS AND MALIGNANCY      EXCERPT:   WARNING:  SERIOUS INFECTIONS AND MALIGNANCY       See full prescribing information for complete boxed warning.,INFECTIONS is an adverse reaction entity
BOXED WARNING: WARNING: SERIOUS INFECTIONS AND MALIGNANCY      WARNING: SERIOUS INFECTIONS AND MALIGNANCY      EXCERPT:   WARNING:  SERIOUS INFECTIONS AND MALIGNANCY       See full prescribing information for complete boxed warning.,INFECTIONS is an adverse reaction entity
BOXED WARNING: WARNING: SERIOUS INFECTIONS AND MALIGNANCY      WARNING: SERIOUS INFECTIONS AND MALIGNANCY      EXCERPT:   WARNING:  SERIOUS INFECTIONS AND MALIGNANCY       See full prescribing information for complete boxed warning.,BOXED WARNING is not a named entity
BOXED WARNING: WARNING: SERIOUS INFECTIONS AND MALIGNANCY      WARNING: SERIOUS INFECTIONS AND MALIGNANCY      EXCERPT:   WARNING:  SERIOUS INFECTIONS AND MALIGNANCY       See full prescribing information for complete boxed warning.,MALIGNANCY is an adverse reaction entity
BOXED WARNING: WARNING: SERIOUS INFECTIONS AND MALIGNANCY      WARNING: SERIOUS INFECTIONS AND MALIGNANCY      EXCERPT:   WARNING:  SERIOUS INFECTIONS AND MALIGNANCY       See full prescribing information for complete boxed warning.,INFECTIONS AND is not a named entity
BOXED WARNING: WARNING: SERIOUS INFECTIONS AND MALIGNANCY      WARNING: SERIOUS INFECTIONS AND MALIGNANCY      EXCERPT:   WARNING:  SERIOUS INFECTIONS AND MALIGNANCY       See full prescribing information for complete boxed warning.,MALIGNANCY is an adverse reaction entity
BOXED WARNING: WARNING: SERIOUS INFECTIONS AND MALIGNANCY      WARNING: SERIOUS INFECTIONS AND MALIGNANCY      EXCERPT:   WARNING:  SERIOUS INFECTIONS AND MALIGNANCY       See full prescribing information for complete boxed warning.,WARNING : is not a named entity
BOXED WARNING: WARNING: SERIOUS INFECTIONS AND MALIGNANCY      WARNING: SERIOUS INFECTIONS AND MALIGNANCY      EXCERPT:   WARNING:  SERIOUS INFECTIONS AND MALIGNANCY       See full prescribing information for complete boxed warning.,MALIGNANCY is an adverse reaction entity
BOXED WARNING: WARNING: SERIOUS INFECTIONS AND MALIGNANCY      WARNING: SERIOUS INFECTIONS AND MALIGNANCY      EXCERPT:   WARNING:  SERIOUS INFECTIONS AND MALIGNANCY       See full prescribing information for complete boxed warning.,SERIOUS INFECTIONS AND is not a named entity
BOXED WARNING: WARNING: SERIOUS INFECTIONS AND MALIGNANCY      WARNING: SERIOUS INFECTIONS AND MALIGNANCY      EXCERPT:   WARNING:  SERIOUS INFECTIONS AND MALIGNANCY       See full prescribing information for complete boxed warning.,complete is not a named entity
BOXED WARNING: WARNING: SERIOUS INFECTIONS AND MALIGNANCY      WARNING: SERIOUS INFECTIONS AND MALIGNANCY      EXCERPT:   WARNING:  SERIOUS INFECTIONS AND MALIGNANCY       See full prescribing information for complete boxed warning.,INFECTIONS is an adverse reaction entity
*  Malignancies - More cases of lymphoma have been observed among patients receiving TNF-blockers compared with patients in the control groups.,Malignancies is an adverse reaction entity
*  Malignancies - More cases of lymphoma have been observed among patients receiving TNF-blockers compared with patients in the control groups.,lymphoma is an adverse reaction entity
*  Malignancies - More cases of lymphoma have been observed among patients receiving TNF-blockers compared with patients in the control groups.,the is not a named entity
*  Malignancies - More cases of lymphoma have been observed among patients receiving TNF-blockers compared with patients in the control groups.,More is not a named entity
Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.,as methotrexate or is not a named entity
Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.,infections is an adverse reaction entity
"Upper respiratory tract infection was the most common adverse reaction reported in the trial through Week 24 occurring in 6.5% of SIMPONI ARIA-treated patients as compared with 7.6% of control-treated patients, respectively.",Upper respiratory tract infection is an adverse reaction entity
"Upper respiratory tract infection was the most common adverse reaction reported in the trial through Week 24 occurring in 6.5% of SIMPONI ARIA-treated patients as compared with 7.6% of control-treated patients, respectively.",ARIA-treated patients as is not a named entity
"Neoplasm Benign and Malignant  : Melanoma  [see  Warnings and Precautions (5.2)  ]         Immune System Disorders  : Serious systemic hypersensitivity reactions (including anaphylactic reaction)  [see  Warnings and Precautions (5.10)  ]  , sarcoidosis       Respiratory, thoracic and mediastinal disorders  : Interstitial lung disease       Skin and subcutaneous tissue disorders  : Skin exfoliation, bullous skin reactions",Respiratory is not a named entity
"Neoplasm Benign and Malignant  : Melanoma  [see  Warnings and Precautions (5.2)  ]         Immune System Disorders  : Serious systemic hypersensitivity reactions (including anaphylactic reaction)  [see  Warnings and Precautions (5.10)  ]  , sarcoidosis       Respiratory, thoracic and mediastinal disorders  : Interstitial lung disease       Skin and subcutaneous tissue disorders  : Skin exfoliation, bullous skin reactions",systemic hypersensitivity reactions is an adverse reaction entity
"Neoplasm Benign and Malignant  : Melanoma  [see  Warnings and Precautions (5.2)  ]         Immune System Disorders  : Serious systemic hypersensitivity reactions (including anaphylactic reaction)  [see  Warnings and Precautions (5.10)  ]  , sarcoidosis       Respiratory, thoracic and mediastinal disorders  : Interstitial lung disease       Skin and subcutaneous tissue disorders  : Skin exfoliation, bullous skin reactions",sarcoidosis is an adverse reaction entity
"Neoplasm Benign and Malignant  : Melanoma  [see  Warnings and Precautions (5.2)  ]         Immune System Disorders  : Serious systemic hypersensitivity reactions (including anaphylactic reaction)  [see  Warnings and Precautions (5.10)  ]  , sarcoidosis       Respiratory, thoracic and mediastinal disorders  : Interstitial lung disease       Skin and subcutaneous tissue disorders  : Skin exfoliation, bullous skin reactions",( including anaphylactic is not a named entity
"Neoplasm Benign and Malignant  : Melanoma  [see  Warnings and Precautions (5.2)  ]         Immune System Disorders  : Serious systemic hypersensitivity reactions (including anaphylactic reaction)  [see  Warnings and Precautions (5.10)  ]  , sarcoidosis       Respiratory, thoracic and mediastinal disorders  : Interstitial lung disease       Skin and subcutaneous tissue disorders  : Skin exfoliation, bullous skin reactions",[ see Warnings is not a named entity
"Neoplasm Benign and Malignant  : Melanoma  [see  Warnings and Precautions (5.2)  ]         Immune System Disorders  : Serious systemic hypersensitivity reactions (including anaphylactic reaction)  [see  Warnings and Precautions (5.10)  ]  , sarcoidosis       Respiratory, thoracic and mediastinal disorders  : Interstitial lung disease       Skin and subcutaneous tissue disorders  : Skin exfoliation, bullous skin reactions",] is not a named entity
"Neoplasm Benign and Malignant  : Melanoma  [see  Warnings and Precautions (5.2)  ]         Immune System Disorders  : Serious systemic hypersensitivity reactions (including anaphylactic reaction)  [see  Warnings and Precautions (5.10)  ]  , sarcoidosis       Respiratory, thoracic and mediastinal disorders  : Interstitial lung disease       Skin and subcutaneous tissue disorders  : Skin exfoliation, bullous skin reactions",Precautions ( is not a named entity
"Neoplasm Benign and Malignant  : Melanoma  [see  Warnings and Precautions (5.2)  ]         Immune System Disorders  : Serious systemic hypersensitivity reactions (including anaphylactic reaction)  [see  Warnings and Precautions (5.10)  ]  , sarcoidosis       Respiratory, thoracic and mediastinal disorders  : Interstitial lung disease       Skin and subcutaneous tissue disorders  : Skin exfoliation, bullous skin reactions",bullous skin reactions is an adverse reaction entity
"Neoplasm Benign and Malignant  : Melanoma  [see  Warnings and Precautions (5.2)  ]         Immune System Disorders  : Serious systemic hypersensitivity reactions (including anaphylactic reaction)  [see  Warnings and Precautions (5.10)  ]  , sarcoidosis       Respiratory, thoracic and mediastinal disorders  : Interstitial lung disease       Skin and subcutaneous tissue disorders  : Skin exfoliation, bullous skin reactions",disorders : Interstitial is not a named entity
"Neoplasm Benign and Malignant  : Melanoma  [see  Warnings and Precautions (5.2)  ]         Immune System Disorders  : Serious systemic hypersensitivity reactions (including anaphylactic reaction)  [see  Warnings and Precautions (5.10)  ]  , sarcoidosis       Respiratory, thoracic and mediastinal disorders  : Interstitial lung disease       Skin and subcutaneous tissue disorders  : Skin exfoliation, bullous skin reactions","exfoliation , is not a named entity"
"Neoplasm Benign and Malignant  : Melanoma  [see  Warnings and Precautions (5.2)  ]         Immune System Disorders  : Serious systemic hypersensitivity reactions (including anaphylactic reaction)  [see  Warnings and Precautions (5.10)  ]  , sarcoidosis       Respiratory, thoracic and mediastinal disorders  : Interstitial lung disease       Skin and subcutaneous tissue disorders  : Skin exfoliation, bullous skin reactions",Interstitial lung disease is an adverse reaction entity
"Neoplasm Benign and Malignant  : Melanoma  [see  Warnings and Precautions (5.2)  ]         Immune System Disorders  : Serious systemic hypersensitivity reactions (including anaphylactic reaction)  [see  Warnings and Precautions (5.10)  ]  , sarcoidosis       Respiratory, thoracic and mediastinal disorders  : Interstitial lung disease       Skin and subcutaneous tissue disorders  : Skin exfoliation, bullous skin reactions",Skin exfoliation is an adverse reaction entity
"Neoplasm Benign and Malignant  : Melanoma  [see  Warnings and Precautions (5.2)  ]         Immune System Disorders  : Serious systemic hypersensitivity reactions (including anaphylactic reaction)  [see  Warnings and Precautions (5.10)  ]  , sarcoidosis       Respiratory, thoracic and mediastinal disorders  : Interstitial lung disease       Skin and subcutaneous tissue disorders  : Skin exfoliation, bullous skin reactions",anaphylactic reaction is an adverse reaction entity
"Neoplasm Benign and Malignant  : Melanoma  [see  Warnings and Precautions (5.2)  ]         Immune System Disorders  : Serious systemic hypersensitivity reactions (including anaphylactic reaction)  [see  Warnings and Precautions (5.10)  ]  , sarcoidosis       Respiratory, thoracic and mediastinal disorders  : Interstitial lung disease       Skin and subcutaneous tissue disorders  : Skin exfoliation, bullous skin reactions",Melanoma is an adverse reaction entity
"*  Serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal (such as histoplasmosis), and other opportunistic infections have occurred in patients receiving SIMPONI ARIA (5.1).",infections is an adverse reaction entity
"*  Serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal (such as histoplasmosis), and other opportunistic infections have occurred in patients receiving SIMPONI ARIA (5.1).",in is not a named entity
"*  Serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal (such as histoplasmosis), and other opportunistic infections have occurred in patients receiving SIMPONI ARIA (5.1).",as is not a named entity
"*  Serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal (such as histoplasmosis), and other opportunistic infections have occurred in patients receiving SIMPONI ARIA (5.1).",or death is not a named entity
"*  Serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal (such as histoplasmosis), and other opportunistic infections have occurred in patients receiving SIMPONI ARIA (5.1).",tuberculosis is an adverse reaction entity
"*  Serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal (such as histoplasmosis), and other opportunistic infections have occurred in patients receiving SIMPONI ARIA (5.1).",invasive fungal infections is an adverse reaction entity
"*  Serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal (such as histoplasmosis), and other opportunistic infections have occurred in patients receiving SIMPONI ARIA (5.1).",TB is an adverse reaction entity
"*  Serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal (such as histoplasmosis), and other opportunistic infections have occurred in patients receiving SIMPONI ARIA (5.1).",or death is not a named entity
"*  Serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal (such as histoplasmosis), and other opportunistic infections have occurred in patients receiving SIMPONI ARIA (5.1).",opportunistic infections is an adverse reaction entity
"*  Serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal (such as histoplasmosis), and other opportunistic infections have occurred in patients receiving SIMPONI ARIA (5.1).",SIMPONI ARIA ( is not a named entity
"*  Serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal (such as histoplasmosis), and other opportunistic infections have occurred in patients receiving SIMPONI ARIA (5.1).",bacterial sepsis is an adverse reaction entity
"*  Serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal (such as histoplasmosis), and other opportunistic infections have occurred in patients receiving SIMPONI ARIA (5.1).",death is an adverse reaction entity
"*  Serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal (such as histoplasmosis), and other opportunistic infections have occurred in patients receiving SIMPONI ARIA (5.1).",") , bacterial is not a named entity"
"*  Serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal (such as histoplasmosis), and other opportunistic infections have occurred in patients receiving SIMPONI ARIA (5.1).",5.1 is not a named entity
"*  Serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal (such as histoplasmosis), and other opportunistic infections have occurred in patients receiving SIMPONI ARIA (5.1).",infections leading is not a named entity
"*  Serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal (such as histoplasmosis), and other opportunistic infections have occurred in patients receiving SIMPONI ARIA (5.1).",histoplasmosis is an adverse reaction entity
"Patients with RA and other chronic inflammatory diseases, particularly patients with highly active disease and/or chronic exposure to immunosuppressant therapies, may be at higher risk (up to several fold) than the general population for the development of lymphoma, even in the absence of TNF-blocking therapy.",lymphoma is an adverse reaction entity
"Patients with RA and other chronic inflammatory diseases, particularly patients with highly active disease and/or chronic exposure to immunosuppressant therapies, may be at higher risk (up to several fold) than the general population for the development of lymphoma, even in the absence of TNF-blocking therapy.",risk ( is not a named entity
Cases of other malignancies have been observed among patients receiving TNF-blockers (  5.2  ).,( is not a named entity
Cases of other malignancies have been observed among patients receiving TNF-blockers (  5.2  ).,malignancies is an adverse reaction entity
*  Hepatitis B reactivation - Monitor HBV carriers during and several months after therapy.,Hepatitis B reactivation is an adverse reaction entity
*  Hepatitis B reactivation - Monitor HBV carriers during and several months after therapy.,* Hepatitis is not a named entity
Rare post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL) have been reported in patients treated with TNF-blocking agents.,hepatosplenic T-cell lymphoma is an adverse reaction entity
Rare post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL) have been reported in patients treated with TNF-blocking agents.,treated with is not a named entity
Rare post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL) have been reported in patients treated with TNF-blocking agents.,post-marketing cases is not a named entity
Rare post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL) have been reported in patients treated with TNF-blocking agents.,HSTCL is an adverse reaction entity
"*  Invasive fungal infections - For patients who develop a systemic illness on SIMPONI ARIA, consider empiric antifungal therapy for those who reside in or travel to regions where mycoses are endemic (  5.1  ).",Invasive fungal infections is an adverse reaction entity
"*  Invasive fungal infections - For patients who develop a systemic illness on SIMPONI ARIA, consider empiric antifungal therapy for those who reside in or travel to regions where mycoses are endemic (  5.1  ).",", consider is not a named entity"
Cases of acute and chronic leukemia have been reported with post-marketing TNF-blocker use in rheumatoid arthritis and other indications.,have been reported is not a named entity
Cases of acute and chronic leukemia have been reported with post-marketing TNF-blocker use in rheumatoid arthritis and other indications.,acute leukemia is an adverse reaction entity
Cases of acute and chronic leukemia have been reported with post-marketing TNF-blocker use in rheumatoid arthritis and other indications.,chronic leukemia is an adverse reaction entity
Cases of acute and chronic leukemia have been reported with post-marketing TNF-blocker use in rheumatoid arthritis and other indications.,of acute is not a named entity
"In the controlled and uncontrolled portions of Trial 1, in SIMPONI ARIA treated patients, the incidence of active TB per 100 patient-years was 0.31 (95% CI: 0.06; 0.92) and the incidence of other opportunistic infections per 100 patient-years was 0.42 (95% CI: 0.11, 1.07).",0.06 ; 0.92 is not a named entity
"In the controlled and uncontrolled portions of Trial 1, in SIMPONI ARIA treated patients, the incidence of active TB per 100 patient-years was 0.31 (95% CI: 0.06; 0.92) and the incidence of other opportunistic infections per 100 patient-years was 0.42 (95% CI: 0.11, 1.07).",active TB is an adverse reaction entity
"In the controlled and uncontrolled portions of Trial 1, in SIMPONI ARIA treated patients, the incidence of active TB per 100 patient-years was 0.31 (95% CI: 0.06; 0.92) and the incidence of other opportunistic infections per 100 patient-years was 0.42 (95% CI: 0.11, 1.07).","Trial 1 , is not a named entity"
"In the controlled and uncontrolled portions of Trial 1, in SIMPONI ARIA treated patients, the incidence of active TB per 100 patient-years was 0.31 (95% CI: 0.06; 0.92) and the incidence of other opportunistic infections per 100 patient-years was 0.42 (95% CI: 0.11, 1.07).",opportunistic infections is an adverse reaction entity
This rare type of T-cell lymphoma has a very aggressive disease course and is usually fatal.,T-cell lymphoma has is not a named entity
This rare type of T-cell lymphoma has a very aggressive disease course and is usually fatal.,rare type of T-cell lymphoma is an adverse reaction entity
This rare type of T-cell lymphoma has a very aggressive disease course and is usually fatal.,and is not a named entity
This rare type of T-cell lymphoma has a very aggressive disease course and is usually fatal.,fatal is an adverse reaction entity
Merkel cell carcinoma has been reported in patients treated with TNF-blocking agents.,Merkel cell carcinoma is an adverse reaction entity
Merkel cell carcinoma has been reported in patients treated with TNF-blocking agents.,cell carcinoma has is not a named entity
"During the controlled portion of the Phase 3 trial in RA for SIMPONI ARIA, the incidence of malignancies other than lymphoma and NMSC per 100-patient-years of follow-up was 0.56 (95% CI: 0.01, 3.11) in the SIMPONI ARIA group compared with an incidence of 0 (95% CI: 0.00, 3.79) in the placebo group.",malignancies is an adverse reaction entity
"During the controlled portion of the Phase 3 trial in RA for SIMPONI ARIA, the incidence of malignancies other than lymphoma and NMSC per 100-patient-years of follow-up was 0.56 (95% CI: 0.01, 3.11) in the SIMPONI ARIA group compared with an incidence of 0 (95% CI: 0.00, 3.79) in the placebo group.",ARIA group compared is not a named entity
"Reported infections with TNF-blockers, of which SIMPONI ARIA is a member, include:       *  Active tuberculosis, including reactivation of latent tuberculosis.",reactivation of latent tuberculosis is an adverse reaction entity
"Reported infections with TNF-blockers, of which SIMPONI ARIA is a member, include:       *  Active tuberculosis, including reactivation of latent tuberculosis.",including is not a named entity
"Reported infections with TNF-blockers, of which SIMPONI ARIA is a member, include:       *  Active tuberculosis, including reactivation of latent tuberculosis.",Active tuberculosis is an adverse reaction entity
"Reported infections with TNF-blockers, of which SIMPONI ARIA is a member, include:       *  Active tuberculosis, including reactivation of latent tuberculosis.",* Active is not a named entity
"In the controlled phase of Trial 1 through Week 24, infections were observed in 27% of SIMPONI ARIA-treated patients compared with 24% of control-treated patients, and serious infections were observed in 0.9% of SIMPONI ARIA-treated patients and 0.0% of control-treated patients.",infections is an adverse reaction entity
"In the controlled phase of Trial 1 through Week 24, infections were observed in 27% of SIMPONI ARIA-treated patients compared with 24% of control-treated patients, and serious infections were observed in 0.9% of SIMPONI ARIA-treated patients and 0.0% of control-treated patients.",of SIMPONI ARIA-treated is not a named entity
"In the controlled phase of Trial 1 through Week 24, infections were observed in 27% of SIMPONI ARIA-treated patients compared with 24% of control-treated patients, and serious infections were observed in 0.9% of SIMPONI ARIA-treated patients and 0.0% of control-treated patients.",infections is an adverse reaction entity
"In the controlled phase of Trial 1 through Week 24, infections were observed in 27% of SIMPONI ARIA-treated patients compared with 24% of control-treated patients, and serious infections were observed in 0.9% of SIMPONI ARIA-treated patients and 0.0% of control-treated patients.","patients , and is not a named entity"
"At Week 20 in Trial 1, 17% of SIMPONI ARIA-treated patients and 13% of control patients were newly ANA-positive (at titers of 1:160 or greater).",newly ANA-positive is an adverse reaction entity
"At Week 20 in Trial 1, 17% of SIMPONI ARIA-treated patients and 13% of control patients were newly ANA-positive (at titers of 1:160 or greater).",were newly is not a named entity
"In some instances, HBV reactivation occurring in conjunction with TNF-blocker therapy has been fatal.",HBV reactivation is an adverse reaction entity
"In some instances, HBV reactivation occurring in conjunction with TNF-blocker therapy has been fatal.",fatal is an adverse reaction entity
"In some instances, HBV reactivation occurring in conjunction with TNF-blocker therapy has been fatal.",", HBV is not a named entity"
"In some instances, HBV reactivation occurring in conjunction with TNF-blocker therapy has been fatal.",with is not a named entity
"Melanoma has been reported in patients treated with TNF-blocking agents, including the subcutaneous formulation of golimumab.",of is not a named entity
"Melanoma has been reported in patients treated with TNF-blocking agents, including the subcutaneous formulation of golimumab.",Melanoma is an adverse reaction entity
5.1 Serious Infections      Patients treated with SIMPONI ARIA are at increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death.,to hospitalization or is not a named entity
5.1 Serious Infections      Patients treated with SIMPONI ARIA are at increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death.,hospitalization or death is not a named entity
5.1 Serious Infections      Patients treated with SIMPONI ARIA are at increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death.,death is an adverse reaction entity
5.1 Serious Infections      Patients treated with SIMPONI ARIA are at increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death.,infections is an adverse reaction entity
"Of these patients, one SIMPONI ARIA-treated patient and no control-treated patients had newly positive anti-dsDNA antibodies.",newly positive anti-dsDNA antibodies is an adverse reaction entity
"Of these patients, one SIMPONI ARIA-treated patient and no control-treated patients had newly positive anti-dsDNA antibodies.",anti-dsDNA antibodies is not a named entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Serious infections - Do not start SIMPONI ARIA during an active infection.,SIMPONI ARIA is not a named entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Serious infections - Do not start SIMPONI ARIA during an active infection.,infections is an adverse reaction entity
"5.3 Congestive Heart Failure      Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF-blockers, including SIMPONI ARIA.",5.3 Congestive is not a named entity
"5.3 Congestive Heart Failure      Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF-blockers, including SIMPONI ARIA.",have is not a named entity
"5.3 Congestive Heart Failure      Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF-blockers, including SIMPONI ARIA.",new onset CHF is an adverse reaction entity
"5.3 Congestive Heart Failure      Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF-blockers, including SIMPONI ARIA.",worsening congestive heart failure is an adverse reaction entity
"5.3 Congestive Heart Failure      Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF-blockers, including SIMPONI ARIA.",Failure Cases of is not a named entity
"5.3 Congestive Heart Failure      Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF-blockers, including SIMPONI ARIA.",worsening CHF is an adverse reaction entity
"5.4 Demyelinating Disorders      Use of TNF-blockers, of which SIMPONI ARIA is a member, has been associated with rare cases of new onset or exacerbation of central nervous system (CNS) demyelinating disorders, including multiple sclerosis (MS) and peripheral demyelinating disorders, including Guillain-Barre syndrome.",disorders is not a named entity
"5.4 Demyelinating Disorders      Use of TNF-blockers, of which SIMPONI ARIA is a member, has been associated with rare cases of new onset or exacerbation of central nervous system (CNS) demyelinating disorders, including multiple sclerosis (MS) and peripheral demyelinating disorders, including Guillain-Barre syndrome.",is a is not a named entity
"5.4 Demyelinating Disorders      Use of TNF-blockers, of which SIMPONI ARIA is a member, has been associated with rare cases of new onset or exacerbation of central nervous system (CNS) demyelinating disorders, including multiple sclerosis (MS) and peripheral demyelinating disorders, including Guillain-Barre syndrome.",Guillain-Barre syndrome is an adverse reaction entity
"5.4 Demyelinating Disorders      Use of TNF-blockers, of which SIMPONI ARIA is a member, has been associated with rare cases of new onset or exacerbation of central nervous system (CNS) demyelinating disorders, including multiple sclerosis (MS) and peripheral demyelinating disorders, including Guillain-Barre syndrome.",multiple sclerosis is an adverse reaction entity
"5.4 Demyelinating Disorders      Use of TNF-blockers, of which SIMPONI ARIA is a member, has been associated with rare cases of new onset or exacerbation of central nervous system (CNS) demyelinating disorders, including multiple sclerosis (MS) and peripheral demyelinating disorders, including Guillain-Barre syndrome.",exacerbation of central nervous system demyelinating disorders is an adverse reaction entity
"5.4 Demyelinating Disorders      Use of TNF-blockers, of which SIMPONI ARIA is a member, has been associated with rare cases of new onset or exacerbation of central nervous system (CNS) demyelinating disorders, including multiple sclerosis (MS) and peripheral demyelinating disorders, including Guillain-Barre syndrome.",peripheral demyelinating disorders is an adverse reaction entity
"5.4 Demyelinating Disorders      Use of TNF-blockers, of which SIMPONI ARIA is a member, has been associated with rare cases of new onset or exacerbation of central nervous system (CNS) demyelinating disorders, including multiple sclerosis (MS) and peripheral demyelinating disorders, including Guillain-Barre syndrome.",exacerbation of CNS demyelinating disorders is an adverse reaction entity
"5.4 Demyelinating Disorders      Use of TNF-blockers, of which SIMPONI ARIA is a member, has been associated with rare cases of new onset or exacerbation of central nervous system (CNS) demyelinating disorders, including multiple sclerosis (MS) and peripheral demyelinating disorders, including Guillain-Barre syndrome.",new onset central nervous system demyelinating disorders is an adverse reaction entity
"5.4 Demyelinating Disorders      Use of TNF-blockers, of which SIMPONI ARIA is a member, has been associated with rare cases of new onset or exacerbation of central nervous system (CNS) demyelinating disorders, including multiple sclerosis (MS) and peripheral demyelinating disorders, including Guillain-Barre syndrome.","demyelinating disorders , is not a named entity"
"5.4 Demyelinating Disorders      Use of TNF-blockers, of which SIMPONI ARIA is a member, has been associated with rare cases of new onset or exacerbation of central nervous system (CNS) demyelinating disorders, including multiple sclerosis (MS) and peripheral demyelinating disorders, including Guillain-Barre syndrome.",MS is an adverse reaction entity
"5.4 Demyelinating Disorders      Use of TNF-blockers, of which SIMPONI ARIA is a member, has been associated with rare cases of new onset or exacerbation of central nervous system (CNS) demyelinating disorders, including multiple sclerosis (MS) and peripheral demyelinating disorders, including Guillain-Barre syndrome.",new onset CNS demyelinating disorders is an adverse reaction entity
"5.4 Demyelinating Disorders      Use of TNF-blockers, of which SIMPONI ARIA is a member, has been associated with rare cases of new onset or exacerbation of central nervous system (CNS) demyelinating disorders, including multiple sclerosis (MS) and peripheral demyelinating disorders, including Guillain-Barre syndrome.",( is not a named entity
"5.4 Demyelinating Disorders      Use of TNF-blockers, of which SIMPONI ARIA is a member, has been associated with rare cases of new onset or exacerbation of central nervous system (CNS) demyelinating disorders, including multiple sclerosis (MS) and peripheral demyelinating disorders, including Guillain-Barre syndrome.","disorders , including is not a named entity"
"5.4 Demyelinating Disorders      Use of TNF-blockers, of which SIMPONI ARIA is a member, has been associated with rare cases of new onset or exacerbation of central nervous system (CNS) demyelinating disorders, including multiple sclerosis (MS) and peripheral demyelinating disorders, including Guillain-Barre syndrome.",including multiple is not a named entity
"5.4 Demyelinating Disorders      Use of TNF-blockers, of which SIMPONI ARIA is a member, has been associated with rare cases of new onset or exacerbation of central nervous system (CNS) demyelinating disorders, including multiple sclerosis (MS) and peripheral demyelinating disorders, including Guillain-Barre syndrome.",associated with is not a named entity
"5.4 Demyelinating Disorders      Use of TNF-blockers, of which SIMPONI ARIA is a member, has been associated with rare cases of new onset or exacerbation of central nervous system (CNS) demyelinating disorders, including multiple sclerosis (MS) and peripheral demyelinating disorders, including Guillain-Barre syndrome.",or exacerbation is not a named entity
"5.10 Hypersensitivity Reactions      In post-marketing experience, serious systemic hypersensitivity reactions (including anaphylactic reaction) have been reported following administration of the subcutaneous formulation of golimumab.",including anaphylactic is not a named entity
"5.10 Hypersensitivity Reactions      In post-marketing experience, serious systemic hypersensitivity reactions (including anaphylactic reaction) have been reported following administration of the subcutaneous formulation of golimumab.",anaphylactic reaction is an adverse reaction entity
"5.10 Hypersensitivity Reactions      In post-marketing experience, serious systemic hypersensitivity reactions (including anaphylactic reaction) have been reported following administration of the subcutaneous formulation of golimumab.",reported following is not a named entity
"5.10 Hypersensitivity Reactions      In post-marketing experience, serious systemic hypersensitivity reactions (including anaphylactic reaction) have been reported following administration of the subcutaneous formulation of golimumab.",hypersensitivity reactions is an adverse reaction entity
"In several exploratory trials of other TNF-blockers in the treatment of CHF, there were greater proportions of TNF-blocker treated patients who had CHF exacerbations requiring hospitalization or increased mortality.",other is not a named entity
"In several exploratory trials of other TNF-blockers in the treatment of CHF, there were greater proportions of TNF-blocker treated patients who had CHF exacerbations requiring hospitalization or increased mortality.",CHF exacerbations is an adverse reaction entity
"In several exploratory trials of other TNF-blockers in the treatment of CHF, there were greater proportions of TNF-blocker treated patients who had CHF exacerbations requiring hospitalization or increased mortality.",increased mortality is an adverse reaction entity
"In several exploratory trials of other TNF-blockers in the treatment of CHF, there were greater proportions of TNF-blocker treated patients who had CHF exacerbations requiring hospitalization or increased mortality.",of is not a named entity
"Serious Adverse Reactions:  myocardial infarction (2 cases), ruptured ovarian cyst (2 cases), deep vein thrombosis, focal nodular hyperplasia of the liver, uterine leiomyoma, acute cholecystitis, and chronic acalculous cholecystitis.",focal nodular hyperplasia of the liver is an adverse reaction entity
"Serious Adverse Reactions:  myocardial infarction (2 cases), ruptured ovarian cyst (2 cases), deep vein thrombosis, focal nodular hyperplasia of the liver, uterine leiomyoma, acute cholecystitis, and chronic acalculous cholecystitis.",deep vein thrombosis is an adverse reaction entity
"Serious Adverse Reactions:  myocardial infarction (2 cases), ruptured ovarian cyst (2 cases), deep vein thrombosis, focal nodular hyperplasia of the liver, uterine leiomyoma, acute cholecystitis, and chronic acalculous cholecystitis.",acute cholecystitis is an adverse reaction entity
"Serious Adverse Reactions:  myocardial infarction (2 cases), ruptured ovarian cyst (2 cases), deep vein thrombosis, focal nodular hyperplasia of the liver, uterine leiomyoma, acute cholecystitis, and chronic acalculous cholecystitis.",uterine leiomyoma is an adverse reaction entity
"Serious Adverse Reactions:  myocardial infarction (2 cases), ruptured ovarian cyst (2 cases), deep vein thrombosis, focal nodular hyperplasia of the liver, uterine leiomyoma, acute cholecystitis, and chronic acalculous cholecystitis.",: is not a named entity
"Serious Adverse Reactions:  myocardial infarction (2 cases), ruptured ovarian cyst (2 cases), deep vein thrombosis, focal nodular hyperplasia of the liver, uterine leiomyoma, acute cholecystitis, and chronic acalculous cholecystitis.",myocardial infarction is an adverse reaction entity
"Serious Adverse Reactions:  myocardial infarction (2 cases), ruptured ovarian cyst (2 cases), deep vein thrombosis, focal nodular hyperplasia of the liver, uterine leiomyoma, acute cholecystitis, and chronic acalculous cholecystitis.",ruptured ovarian cyst is an adverse reaction entity
"Serious Adverse Reactions:  myocardial infarction (2 cases), ruptured ovarian cyst (2 cases), deep vein thrombosis, focal nodular hyperplasia of the liver, uterine leiomyoma, acute cholecystitis, and chronic acalculous cholecystitis.","cases ) , is not a named entity"
"Serious Adverse Reactions:  myocardial infarction (2 cases), ruptured ovarian cyst (2 cases), deep vein thrombosis, focal nodular hyperplasia of the liver, uterine leiomyoma, acute cholecystitis, and chronic acalculous cholecystitis.",chronic acalculous cholecystitis is an adverse reaction entity
"Serious Adverse Reactions:  myocardial infarction (2 cases), ruptured ovarian cyst (2 cases), deep vein thrombosis, focal nodular hyperplasia of the liver, uterine leiomyoma, acute cholecystitis, and chronic acalculous cholecystitis.",leiomyoma is not a named entity
"Serious Adverse Reactions:  myocardial infarction (2 cases), ruptured ovarian cyst (2 cases), deep vein thrombosis, focal nodular hyperplasia of the liver, uterine leiomyoma, acute cholecystitis, and chronic acalculous cholecystitis.",Reactions : myocardial is not a named entity
"Serious Adverse Reactions:  myocardial infarction (2 cases), ruptured ovarian cyst (2 cases), deep vein thrombosis, focal nodular hyperplasia of the liver, uterine leiomyoma, acute cholecystitis, and chronic acalculous cholecystitis.",( is not a named entity
"Serious Adverse Reactions:  myocardial infarction (2 cases), ruptured ovarian cyst (2 cases), deep vein thrombosis, focal nodular hyperplasia of the liver, uterine leiomyoma, acute cholecystitis, and chronic acalculous cholecystitis.",", deep is not a named entity"
"Serious Adverse Reactions:  myocardial infarction (2 cases), ruptured ovarian cyst (2 cases), deep vein thrombosis, focal nodular hyperplasia of the liver, uterine leiomyoma, acute cholecystitis, and chronic acalculous cholecystitis.","cholecystitis , and is not a named entity"
(  5.6  )   *     Headache : Evaluate significant change in headaches and discontinue Natazia if indicated.,) is not a named entity
(  5.6  )   *     Headache : Evaluate significant change in headaches and discontinue Natazia if indicated.,Headache is an adverse reaction entity
"Women with hypertriglyceridemia, or a family history thereof, may be at an increased risk of pancreatitis when using COCs.",risk of is not a named entity
"Women with hypertriglyceridemia, or a family history thereof, may be at an increased risk of pancreatitis when using COCs.",pancreatitis is an adverse reaction entity
"Use of COCs also increases the risk of arterial thromboses such as strokes and myocardial infarctions, especially in women with other risk factors for these events.",arterial thromboses is an adverse reaction entity
"Use of COCs also increases the risk of arterial thromboses such as strokes and myocardial infarctions, especially in women with other risk factors for these events.",of is not a named entity
"Use of COCs also increases the risk of arterial thromboses such as strokes and myocardial infarctions, especially in women with other risk factors for these events.",myocardial infarctions is an adverse reaction entity
"Use of COCs also increases the risk of arterial thromboses such as strokes and myocardial infarctions, especially in women with other risk factors for these events.","infarctions , especially is not a named entity"
"Use of COCs also increases the risk of arterial thromboses such as strokes and myocardial infarctions, especially in women with other risk factors for these events.",these events is not a named entity
"Use of COCs also increases the risk of arterial thromboses such as strokes and myocardial infarctions, especially in women with other risk factors for these events.",strokes is an adverse reaction entity
COCs also increase the risk for stroke in women with other underlying risk factors.,stroke is an adverse reaction entity
COCs also increase the risk for stroke in women with other underlying risk factors.,in women with is not a named entity
EXCERPT:   WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS       See full prescribing information for complete boxed warning.,See full is not a named entity
EXCERPT:   WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS       See full prescribing information for complete boxed warning.,CARDIOVASCULAR EVENTS is an adverse reaction entity
(  5.3  )   *     High blood pressure : Do not prescribe Natazia for women with uncontrolled hypertension or hypertension with vascular disease.,High blood pressure is an adverse reaction entity
(  5.3  )   *     High blood pressure : Do not prescribe Natazia for women with uncontrolled hypertension or hypertension with vascular disease.,vascular is not a named entity
The incidence of hypertension increases with increasing concentration of progestin.,hypertension is an adverse reaction entity
The incidence of hypertension increases with increasing concentration of progestin.,increasing is not a named entity
Data from this safety study indicate that the greatest risk of VTE is present after initially starting a COC or restarting (following a 4 week or greater pill-free interval) the same or a different COC.,interval ) the is not a named entity
Data from this safety study indicate that the greatest risk of VTE is present after initially starting a COC or restarting (following a 4 week or greater pill-free interval) the same or a different COC.,VTE is an adverse reaction entity
Women on thyroid hormone replacement therapy may need increased doses of thyroid hormone because serum concentrations of thyroid-binding globulin increase with use of COCs [see Clinical Pharmacology (  12.3  )]  .,[ is not a named entity
Women on thyroid hormone replacement therapy may need increased doses of thyroid hormone because serum concentrations of thyroid-binding globulin increase with use of COCs [see Clinical Pharmacology (  12.3  )]  .,thyroid-binding globulin increase is an adverse reaction entity
"COCs have been shown to increase both the relative and attributable risks of cerebrovascular events (thrombotic and hemorrhagic strokes), although, in general, the risk is greatest among older (>35 years of age), hypertensive women who also smoke.",and attributable is not a named entity
"COCs have been shown to increase both the relative and attributable risks of cerebrovascular events (thrombotic and hemorrhagic strokes), although, in general, the risk is greatest among older (>35 years of age), hypertensive women who also smoke.",years of is not a named entity
"COCs have been shown to increase both the relative and attributable risks of cerebrovascular events (thrombotic and hemorrhagic strokes), although, in general, the risk is greatest among older (>35 years of age), hypertensive women who also smoke.",hemorrhagic strokes is an adverse reaction entity
"COCs have been shown to increase both the relative and attributable risks of cerebrovascular events (thrombotic and hemorrhagic strokes), although, in general, the risk is greatest among older (>35 years of age), hypertensive women who also smoke.",thrombotic strokes is an adverse reaction entity
"COCs have been shown to increase both the relative and attributable risks of cerebrovascular events (thrombotic and hemorrhagic strokes), although, in general, the risk is greatest among older (>35 years of age), hypertensive women who also smoke.",to increase both is not a named entity
"COCs have been shown to increase both the relative and attributable risks of cerebrovascular events (thrombotic and hemorrhagic strokes), although, in general, the risk is greatest among older (>35 years of age), hypertensive women who also smoke.",cerebrovascular events is an adverse reaction entity
"Based on patient diaries from three clinical trials evaluating the safety and efficacy of Natazia for contraception, 10-23% of women experienced intracyclic bleeding per cycle.",intracyclic bleeding is an adverse reaction entity
"Based on patient diaries from three clinical trials evaluating the safety and efficacy of Natazia for contraception, 10-23% of women experienced intracyclic bleeding per cycle.",clinical is not a named entity
The risk of thromboembolic disease due to oral contraceptives gradually disappears after COC use is discontinued.,thromboembolic disease is an adverse reaction entity
The risk of thromboembolic disease due to oral contraceptives gradually disappears after COC use is discontinued.,use is discontinued is not a named entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *     Vascular risks : Stop Natazia if a thrombotic event occurs.,Vascular risks thrombotic is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *     Vascular risks : Stop Natazia if a thrombotic event occurs.,: Stop Natazia is not a named entity
(4)   *  Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use.,( is not a named entity
(4)   *  Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use.,cardiovascular events is an adverse reaction entity
"An increase in blood pressure has been reported in women taking COCs, and this increase is more likely in older women and with extended duration of use.",use is not a named entity
"An increase in blood pressure has been reported in women taking COCs, and this increase is more likely in older women and with extended duration of use.",increase in blood pressure is an adverse reaction entity
5.5 Gallbladder Disease      Studies suggest a small increased relative risk of developing gallbladder disease among COC users.,gallbladder disease is an adverse reaction entity
5.5 Gallbladder Disease      Studies suggest a small increased relative risk of developing gallbladder disease among COC users.,relative is not a named entity
"However, pregnancy increases the risk of venous thromboembolism as much or more than the use of COCs.",venous thromboembolism is an adverse reaction entity
"However, pregnancy increases the risk of venous thromboembolism as much or more than the use of COCs.","However , pregnancy is not a named entity"
5.9 COC Use Before or During Early Pregnancy      Extensive epidemiological studies have revealed no increased risk of birth defects in women who have used oral contraceptives prior to pregnancy.,defects in is not a named entity
5.9 COC Use Before or During Early Pregnancy      Extensive epidemiological studies have revealed no increased risk of birth defects in women who have used oral contraceptives prior to pregnancy.,birth defects is an adverse reaction entity
"Vascular disorders: Venous and arterial thromboembolic events (including pulmonary emboli, deep vein thrombosis, cerebral thrombosis, myocardial infarction and stroke), hypertension     Hepatobiliary disorders: Gallbladder disease, hepatitis     Immune system disorders: Hypersensitivity     Metabolism and nutrition disorders: Fluid retention, hypertriglyceridemia     Nervous system disorders: Dizziness     Skin and subcutaneous tissue disorders: Chloasma, angioedema, erythema nodosum, erythema multiforme     Gastrointestinal disorders: Gastrointestinal symptoms (for example, abdominal pain)     Infections and infestations: Vulvovaginal candidiasis",Gastrointestinal symptoms ( is not a named entity
"Vascular disorders: Venous and arterial thromboembolic events (including pulmonary emboli, deep vein thrombosis, cerebral thrombosis, myocardial infarction and stroke), hypertension     Hepatobiliary disorders: Gallbladder disease, hepatitis     Immune system disorders: Hypersensitivity     Metabolism and nutrition disorders: Fluid retention, hypertriglyceridemia     Nervous system disorders: Dizziness     Skin and subcutaneous tissue disorders: Chloasma, angioedema, erythema nodosum, erythema multiforme     Gastrointestinal disorders: Gastrointestinal symptoms (for example, abdominal pain)     Infections and infestations: Vulvovaginal candidiasis",( is not a named entity
"Vascular disorders: Venous and arterial thromboembolic events (including pulmonary emboli, deep vein thrombosis, cerebral thrombosis, myocardial infarction and stroke), hypertension     Hepatobiliary disorders: Gallbladder disease, hepatitis     Immune system disorders: Hypersensitivity     Metabolism and nutrition disorders: Fluid retention, hypertriglyceridemia     Nervous system disorders: Dizziness     Skin and subcutaneous tissue disorders: Chloasma, angioedema, erythema nodosum, erythema multiforme     Gastrointestinal disorders: Gastrointestinal symptoms (for example, abdominal pain)     Infections and infestations: Vulvovaginal candidiasis","pulmonary emboli , is not a named entity"
"Vascular disorders: Venous and arterial thromboembolic events (including pulmonary emboli, deep vein thrombosis, cerebral thrombosis, myocardial infarction and stroke), hypertension     Hepatobiliary disorders: Gallbladder disease, hepatitis     Immune system disorders: Hypersensitivity     Metabolism and nutrition disorders: Fluid retention, hypertriglyceridemia     Nervous system disorders: Dizziness     Skin and subcutaneous tissue disorders: Chloasma, angioedema, erythema nodosum, erythema multiforme     Gastrointestinal disorders: Gastrointestinal symptoms (for example, abdominal pain)     Infections and infestations: Vulvovaginal candidiasis",hypertriglyceridemia is an adverse reaction entity
"Vascular disorders: Venous and arterial thromboembolic events (including pulmonary emboli, deep vein thrombosis, cerebral thrombosis, myocardial infarction and stroke), hypertension     Hepatobiliary disorders: Gallbladder disease, hepatitis     Immune system disorders: Hypersensitivity     Metabolism and nutrition disorders: Fluid retention, hypertriglyceridemia     Nervous system disorders: Dizziness     Skin and subcutaneous tissue disorders: Chloasma, angioedema, erythema nodosum, erythema multiforme     Gastrointestinal disorders: Gastrointestinal symptoms (for example, abdominal pain)     Infections and infestations: Vulvovaginal candidiasis",Nervous system is not a named entity
"Vascular disorders: Venous and arterial thromboembolic events (including pulmonary emboli, deep vein thrombosis, cerebral thrombosis, myocardial infarction and stroke), hypertension     Hepatobiliary disorders: Gallbladder disease, hepatitis     Immune system disorders: Hypersensitivity     Metabolism and nutrition disorders: Fluid retention, hypertriglyceridemia     Nervous system disorders: Dizziness     Skin and subcutaneous tissue disorders: Chloasma, angioedema, erythema nodosum, erythema multiforme     Gastrointestinal disorders: Gastrointestinal symptoms (for example, abdominal pain)     Infections and infestations: Vulvovaginal candidiasis",events ( including is not a named entity
"Vascular disorders: Venous and arterial thromboembolic events (including pulmonary emboli, deep vein thrombosis, cerebral thrombosis, myocardial infarction and stroke), hypertension     Hepatobiliary disorders: Gallbladder disease, hepatitis     Immune system disorders: Hypersensitivity     Metabolism and nutrition disorders: Fluid retention, hypertriglyceridemia     Nervous system disorders: Dizziness     Skin and subcutaneous tissue disorders: Chloasma, angioedema, erythema nodosum, erythema multiforme     Gastrointestinal disorders: Gastrointestinal symptoms (for example, abdominal pain)     Infections and infestations: Vulvovaginal candidiasis",Gastrointestinal disorders is not a named entity
"Vascular disorders: Venous and arterial thromboembolic events (including pulmonary emboli, deep vein thrombosis, cerebral thrombosis, myocardial infarction and stroke), hypertension     Hepatobiliary disorders: Gallbladder disease, hepatitis     Immune system disorders: Hypersensitivity     Metabolism and nutrition disorders: Fluid retention, hypertriglyceridemia     Nervous system disorders: Dizziness     Skin and subcutaneous tissue disorders: Chloasma, angioedema, erythema nodosum, erythema multiforme     Gastrointestinal disorders: Gastrointestinal symptoms (for example, abdominal pain)     Infections and infestations: Vulvovaginal candidiasis",Metabolism is not a named entity
"Vascular disorders: Venous and arterial thromboembolic events (including pulmonary emboli, deep vein thrombosis, cerebral thrombosis, myocardial infarction and stroke), hypertension     Hepatobiliary disorders: Gallbladder disease, hepatitis     Immune system disorders: Hypersensitivity     Metabolism and nutrition disorders: Fluid retention, hypertriglyceridemia     Nervous system disorders: Dizziness     Skin and subcutaneous tissue disorders: Chloasma, angioedema, erythema nodosum, erythema multiforme     Gastrointestinal disorders: Gastrointestinal symptoms (for example, abdominal pain)     Infections and infestations: Vulvovaginal candidiasis",for example is not a named entity
"Vascular disorders: Venous and arterial thromboembolic events (including pulmonary emboli, deep vein thrombosis, cerebral thrombosis, myocardial infarction and stroke), hypertension     Hepatobiliary disorders: Gallbladder disease, hepatitis     Immune system disorders: Hypersensitivity     Metabolism and nutrition disorders: Fluid retention, hypertriglyceridemia     Nervous system disorders: Dizziness     Skin and subcutaneous tissue disorders: Chloasma, angioedema, erythema nodosum, erythema multiforme     Gastrointestinal disorders: Gastrointestinal symptoms (for example, abdominal pain)     Infections and infestations: Vulvovaginal candidiasis",Gastrointestinal symptoms is an adverse reaction entity
"Vascular disorders: Venous and arterial thromboembolic events (including pulmonary emboli, deep vein thrombosis, cerebral thrombosis, myocardial infarction and stroke), hypertension     Hepatobiliary disorders: Gallbladder disease, hepatitis     Immune system disorders: Hypersensitivity     Metabolism and nutrition disorders: Fluid retention, hypertriglyceridemia     Nervous system disorders: Dizziness     Skin and subcutaneous tissue disorders: Chloasma, angioedema, erythema nodosum, erythema multiforme     Gastrointestinal disorders: Gastrointestinal symptoms (for example, abdominal pain)     Infections and infestations: Vulvovaginal candidiasis",erythema multiforme is an adverse reaction entity
"Vascular disorders: Venous and arterial thromboembolic events (including pulmonary emboli, deep vein thrombosis, cerebral thrombosis, myocardial infarction and stroke), hypertension     Hepatobiliary disorders: Gallbladder disease, hepatitis     Immune system disorders: Hypersensitivity     Metabolism and nutrition disorders: Fluid retention, hypertriglyceridemia     Nervous system disorders: Dizziness     Skin and subcutaneous tissue disorders: Chloasma, angioedema, erythema nodosum, erythema multiforme     Gastrointestinal disorders: Gastrointestinal symptoms (for example, abdominal pain)     Infections and infestations: Vulvovaginal candidiasis",Vulvovaginal candidiasis is an adverse reaction entity
"Vascular disorders: Venous and arterial thromboembolic events (including pulmonary emboli, deep vein thrombosis, cerebral thrombosis, myocardial infarction and stroke), hypertension     Hepatobiliary disorders: Gallbladder disease, hepatitis     Immune system disorders: Hypersensitivity     Metabolism and nutrition disorders: Fluid retention, hypertriglyceridemia     Nervous system disorders: Dizziness     Skin and subcutaneous tissue disorders: Chloasma, angioedema, erythema nodosum, erythema multiforme     Gastrointestinal disorders: Gastrointestinal symptoms (for example, abdominal pain)     Infections and infestations: Vulvovaginal candidiasis",hypertension is an adverse reaction entity
"Vascular disorders: Venous and arterial thromboembolic events (including pulmonary emboli, deep vein thrombosis, cerebral thrombosis, myocardial infarction and stroke), hypertension     Hepatobiliary disorders: Gallbladder disease, hepatitis     Immune system disorders: Hypersensitivity     Metabolism and nutrition disorders: Fluid retention, hypertriglyceridemia     Nervous system disorders: Dizziness     Skin and subcutaneous tissue disorders: Chloasma, angioedema, erythema nodosum, erythema multiforme     Gastrointestinal disorders: Gastrointestinal symptoms (for example, abdominal pain)     Infections and infestations: Vulvovaginal candidiasis",system is not a named entity
"Vascular disorders: Venous and arterial thromboembolic events (including pulmonary emboli, deep vein thrombosis, cerebral thrombosis, myocardial infarction and stroke), hypertension     Hepatobiliary disorders: Gallbladder disease, hepatitis     Immune system disorders: Hypersensitivity     Metabolism and nutrition disorders: Fluid retention, hypertriglyceridemia     Nervous system disorders: Dizziness     Skin and subcutaneous tissue disorders: Chloasma, angioedema, erythema nodosum, erythema multiforme     Gastrointestinal disorders: Gastrointestinal symptoms (for example, abdominal pain)     Infections and infestations: Vulvovaginal candidiasis",Venous thromboembolic events is an adverse reaction entity
"Vascular disorders: Venous and arterial thromboembolic events (including pulmonary emboli, deep vein thrombosis, cerebral thrombosis, myocardial infarction and stroke), hypertension     Hepatobiliary disorders: Gallbladder disease, hepatitis     Immune system disorders: Hypersensitivity     Metabolism and nutrition disorders: Fluid retention, hypertriglyceridemia     Nervous system disorders: Dizziness     Skin and subcutaneous tissue disorders: Chloasma, angioedema, erythema nodosum, erythema multiforme     Gastrointestinal disorders: Gastrointestinal symptoms (for example, abdominal pain)     Infections and infestations: Vulvovaginal candidiasis",", is not a named entity"
"Vascular disorders: Venous and arterial thromboembolic events (including pulmonary emboli, deep vein thrombosis, cerebral thrombosis, myocardial infarction and stroke), hypertension     Hepatobiliary disorders: Gallbladder disease, hepatitis     Immune system disorders: Hypersensitivity     Metabolism and nutrition disorders: Fluid retention, hypertriglyceridemia     Nervous system disorders: Dizziness     Skin and subcutaneous tissue disorders: Chloasma, angioedema, erythema nodosum, erythema multiforme     Gastrointestinal disorders: Gastrointestinal symptoms (for example, abdominal pain)     Infections and infestations: Vulvovaginal candidiasis",Skin and is not a named entity
"Vascular disorders: Venous and arterial thromboembolic events (including pulmonary emboli, deep vein thrombosis, cerebral thrombosis, myocardial infarction and stroke), hypertension     Hepatobiliary disorders: Gallbladder disease, hepatitis     Immune system disorders: Hypersensitivity     Metabolism and nutrition disorders: Fluid retention, hypertriglyceridemia     Nervous system disorders: Dizziness     Skin and subcutaneous tissue disorders: Chloasma, angioedema, erythema nodosum, erythema multiforme     Gastrointestinal disorders: Gastrointestinal symptoms (for example, abdominal pain)     Infections and infestations: Vulvovaginal candidiasis",myocardial infarction is an adverse reaction entity
"Vascular disorders: Venous and arterial thromboembolic events (including pulmonary emboli, deep vein thrombosis, cerebral thrombosis, myocardial infarction and stroke), hypertension     Hepatobiliary disorders: Gallbladder disease, hepatitis     Immune system disorders: Hypersensitivity     Metabolism and nutrition disorders: Fluid retention, hypertriglyceridemia     Nervous system disorders: Dizziness     Skin and subcutaneous tissue disorders: Chloasma, angioedema, erythema nodosum, erythema multiforme     Gastrointestinal disorders: Gastrointestinal symptoms (for example, abdominal pain)     Infections and infestations: Vulvovaginal candidiasis",thrombosis is not a named entity
"Vascular disorders: Venous and arterial thromboembolic events (including pulmonary emboli, deep vein thrombosis, cerebral thrombosis, myocardial infarction and stroke), hypertension     Hepatobiliary disorders: Gallbladder disease, hepatitis     Immune system disorders: Hypersensitivity     Metabolism and nutrition disorders: Fluid retention, hypertriglyceridemia     Nervous system disorders: Dizziness     Skin and subcutaneous tissue disorders: Chloasma, angioedema, erythema nodosum, erythema multiforme     Gastrointestinal disorders: Gastrointestinal symptoms (for example, abdominal pain)     Infections and infestations: Vulvovaginal candidiasis",and infestations : is not a named entity
"Vascular disorders: Venous and arterial thromboembolic events (including pulmonary emboli, deep vein thrombosis, cerebral thrombosis, myocardial infarction and stroke), hypertension     Hepatobiliary disorders: Gallbladder disease, hepatitis     Immune system disorders: Hypersensitivity     Metabolism and nutrition disorders: Fluid retention, hypertriglyceridemia     Nervous system disorders: Dizziness     Skin and subcutaneous tissue disorders: Chloasma, angioedema, erythema nodosum, erythema multiforme     Gastrointestinal disorders: Gastrointestinal symptoms (for example, abdominal pain)     Infections and infestations: Vulvovaginal candidiasis",pulmonary emboli is an adverse reaction entity
"Vascular disorders: Venous and arterial thromboembolic events (including pulmonary emboli, deep vein thrombosis, cerebral thrombosis, myocardial infarction and stroke), hypertension     Hepatobiliary disorders: Gallbladder disease, hepatitis     Immune system disorders: Hypersensitivity     Metabolism and nutrition disorders: Fluid retention, hypertriglyceridemia     Nervous system disorders: Dizziness     Skin and subcutaneous tissue disorders: Chloasma, angioedema, erythema nodosum, erythema multiforme     Gastrointestinal disorders: Gastrointestinal symptoms (for example, abdominal pain)     Infections and infestations: Vulvovaginal candidiasis",tissue is not a named entity
"Vascular disorders: Venous and arterial thromboembolic events (including pulmonary emboli, deep vein thrombosis, cerebral thrombosis, myocardial infarction and stroke), hypertension     Hepatobiliary disorders: Gallbladder disease, hepatitis     Immune system disorders: Hypersensitivity     Metabolism and nutrition disorders: Fluid retention, hypertriglyceridemia     Nervous system disorders: Dizziness     Skin and subcutaneous tissue disorders: Chloasma, angioedema, erythema nodosum, erythema multiforme     Gastrointestinal disorders: Gastrointestinal symptoms (for example, abdominal pain)     Infections and infestations: Vulvovaginal candidiasis",Dizziness is an adverse reaction entity
"Vascular disorders: Venous and arterial thromboembolic events (including pulmonary emboli, deep vein thrombosis, cerebral thrombosis, myocardial infarction and stroke), hypertension     Hepatobiliary disorders: Gallbladder disease, hepatitis     Immune system disorders: Hypersensitivity     Metabolism and nutrition disorders: Fluid retention, hypertriglyceridemia     Nervous system disorders: Dizziness     Skin and subcutaneous tissue disorders: Chloasma, angioedema, erythema nodosum, erythema multiforme     Gastrointestinal disorders: Gastrointestinal symptoms (for example, abdominal pain)     Infections and infestations: Vulvovaginal candidiasis",hepatitis is an adverse reaction entity
"Vascular disorders: Venous and arterial thromboembolic events (including pulmonary emboli, deep vein thrombosis, cerebral thrombosis, myocardial infarction and stroke), hypertension     Hepatobiliary disorders: Gallbladder disease, hepatitis     Immune system disorders: Hypersensitivity     Metabolism and nutrition disorders: Fluid retention, hypertriglyceridemia     Nervous system disorders: Dizziness     Skin and subcutaneous tissue disorders: Chloasma, angioedema, erythema nodosum, erythema multiforme     Gastrointestinal disorders: Gastrointestinal symptoms (for example, abdominal pain)     Infections and infestations: Vulvovaginal candidiasis",disorders : is not a named entity
"Vascular disorders: Venous and arterial thromboembolic events (including pulmonary emboli, deep vein thrombosis, cerebral thrombosis, myocardial infarction and stroke), hypertension     Hepatobiliary disorders: Gallbladder disease, hepatitis     Immune system disorders: Hypersensitivity     Metabolism and nutrition disorders: Fluid retention, hypertriglyceridemia     Nervous system disorders: Dizziness     Skin and subcutaneous tissue disorders: Chloasma, angioedema, erythema nodosum, erythema multiforme     Gastrointestinal disorders: Gastrointestinal symptoms (for example, abdominal pain)     Infections and infestations: Vulvovaginal candidiasis",Chloasma is an adverse reaction entity
"Vascular disorders: Venous and arterial thromboembolic events (including pulmonary emboli, deep vein thrombosis, cerebral thrombosis, myocardial infarction and stroke), hypertension     Hepatobiliary disorders: Gallbladder disease, hepatitis     Immune system disorders: Hypersensitivity     Metabolism and nutrition disorders: Fluid retention, hypertriglyceridemia     Nervous system disorders: Dizziness     Skin and subcutaneous tissue disorders: Chloasma, angioedema, erythema nodosum, erythema multiforme     Gastrointestinal disorders: Gastrointestinal symptoms (for example, abdominal pain)     Infections and infestations: Vulvovaginal candidiasis",arterial thromboembolic events is an adverse reaction entity
"Vascular disorders: Venous and arterial thromboembolic events (including pulmonary emboli, deep vein thrombosis, cerebral thrombosis, myocardial infarction and stroke), hypertension     Hepatobiliary disorders: Gallbladder disease, hepatitis     Immune system disorders: Hypersensitivity     Metabolism and nutrition disorders: Fluid retention, hypertriglyceridemia     Nervous system disorders: Dizziness     Skin and subcutaneous tissue disorders: Chloasma, angioedema, erythema nodosum, erythema multiforme     Gastrointestinal disorders: Gastrointestinal symptoms (for example, abdominal pain)     Infections and infestations: Vulvovaginal candidiasis",Nervous system disorders is not a named entity
"Vascular disorders: Venous and arterial thromboembolic events (including pulmonary emboli, deep vein thrombosis, cerebral thrombosis, myocardial infarction and stroke), hypertension     Hepatobiliary disorders: Gallbladder disease, hepatitis     Immune system disorders: Hypersensitivity     Metabolism and nutrition disorders: Fluid retention, hypertriglyceridemia     Nervous system disorders: Dizziness     Skin and subcutaneous tissue disorders: Chloasma, angioedema, erythema nodosum, erythema multiforme     Gastrointestinal disorders: Gastrointestinal symptoms (for example, abdominal pain)     Infections and infestations: Vulvovaginal candidiasis",cerebral thrombosis is an adverse reaction entity
"Vascular disorders: Venous and arterial thromboembolic events (including pulmonary emboli, deep vein thrombosis, cerebral thrombosis, myocardial infarction and stroke), hypertension     Hepatobiliary disorders: Gallbladder disease, hepatitis     Immune system disorders: Hypersensitivity     Metabolism and nutrition disorders: Fluid retention, hypertriglyceridemia     Nervous system disorders: Dizziness     Skin and subcutaneous tissue disorders: Chloasma, angioedema, erythema nodosum, erythema multiforme     Gastrointestinal disorders: Gastrointestinal symptoms (for example, abdominal pain)     Infections and infestations: Vulvovaginal candidiasis",stroke is an adverse reaction entity
"Vascular disorders: Venous and arterial thromboembolic events (including pulmonary emboli, deep vein thrombosis, cerebral thrombosis, myocardial infarction and stroke), hypertension     Hepatobiliary disorders: Gallbladder disease, hepatitis     Immune system disorders: Hypersensitivity     Metabolism and nutrition disorders: Fluid retention, hypertriglyceridemia     Nervous system disorders: Dizziness     Skin and subcutaneous tissue disorders: Chloasma, angioedema, erythema nodosum, erythema multiforme     Gastrointestinal disorders: Gastrointestinal symptoms (for example, abdominal pain)     Infections and infestations: Vulvovaginal candidiasis",erythema nodosum is an adverse reaction entity
"Vascular disorders: Venous and arterial thromboembolic events (including pulmonary emboli, deep vein thrombosis, cerebral thrombosis, myocardial infarction and stroke), hypertension     Hepatobiliary disorders: Gallbladder disease, hepatitis     Immune system disorders: Hypersensitivity     Metabolism and nutrition disorders: Fluid retention, hypertriglyceridemia     Nervous system disorders: Dizziness     Skin and subcutaneous tissue disorders: Chloasma, angioedema, erythema nodosum, erythema multiforme     Gastrointestinal disorders: Gastrointestinal symptoms (for example, abdominal pain)     Infections and infestations: Vulvovaginal candidiasis",thrombosis is not a named entity
"Vascular disorders: Venous and arterial thromboembolic events (including pulmonary emboli, deep vein thrombosis, cerebral thrombosis, myocardial infarction and stroke), hypertension     Hepatobiliary disorders: Gallbladder disease, hepatitis     Immune system disorders: Hypersensitivity     Metabolism and nutrition disorders: Fluid retention, hypertriglyceridemia     Nervous system disorders: Dizziness     Skin and subcutaneous tissue disorders: Chloasma, angioedema, erythema nodosum, erythema multiforme     Gastrointestinal disorders: Gastrointestinal symptoms (for example, abdominal pain)     Infections and infestations: Vulvovaginal candidiasis","emboli , deep is not a named entity"
"Vascular disorders: Venous and arterial thromboembolic events (including pulmonary emboli, deep vein thrombosis, cerebral thrombosis, myocardial infarction and stroke), hypertension     Hepatobiliary disorders: Gallbladder disease, hepatitis     Immune system disorders: Hypersensitivity     Metabolism and nutrition disorders: Fluid retention, hypertriglyceridemia     Nervous system disorders: Dizziness     Skin and subcutaneous tissue disorders: Chloasma, angioedema, erythema nodosum, erythema multiforme     Gastrointestinal disorders: Gastrointestinal symptoms (for example, abdominal pain)     Infections and infestations: Vulvovaginal candidiasis",Fluid retention is an adverse reaction entity
"Vascular disorders: Venous and arterial thromboembolic events (including pulmonary emboli, deep vein thrombosis, cerebral thrombosis, myocardial infarction and stroke), hypertension     Hepatobiliary disorders: Gallbladder disease, hepatitis     Immune system disorders: Hypersensitivity     Metabolism and nutrition disorders: Fluid retention, hypertriglyceridemia     Nervous system disorders: Dizziness     Skin and subcutaneous tissue disorders: Chloasma, angioedema, erythema nodosum, erythema multiforme     Gastrointestinal disorders: Gastrointestinal symptoms (for example, abdominal pain)     Infections and infestations: Vulvovaginal candidiasis",Gallbladder disease is an adverse reaction entity
"Vascular disorders: Venous and arterial thromboembolic events (including pulmonary emboli, deep vein thrombosis, cerebral thrombosis, myocardial infarction and stroke), hypertension     Hepatobiliary disorders: Gallbladder disease, hepatitis     Immune system disorders: Hypersensitivity     Metabolism and nutrition disorders: Fluid retention, hypertriglyceridemia     Nervous system disorders: Dizziness     Skin and subcutaneous tissue disorders: Chloasma, angioedema, erythema nodosum, erythema multiforme     Gastrointestinal disorders: Gastrointestinal symptoms (for example, abdominal pain)     Infections and infestations: Vulvovaginal candidiasis",Dizziness Skin and is not a named entity
"Vascular disorders: Venous and arterial thromboembolic events (including pulmonary emboli, deep vein thrombosis, cerebral thrombosis, myocardial infarction and stroke), hypertension     Hepatobiliary disorders: Gallbladder disease, hepatitis     Immune system disorders: Hypersensitivity     Metabolism and nutrition disorders: Fluid retention, hypertriglyceridemia     Nervous system disorders: Dizziness     Skin and subcutaneous tissue disorders: Chloasma, angioedema, erythema nodosum, erythema multiforme     Gastrointestinal disorders: Gastrointestinal symptoms (for example, abdominal pain)     Infections and infestations: Vulvovaginal candidiasis",) is not a named entity
"Vascular disorders: Venous and arterial thromboembolic events (including pulmonary emboli, deep vein thrombosis, cerebral thrombosis, myocardial infarction and stroke), hypertension     Hepatobiliary disorders: Gallbladder disease, hepatitis     Immune system disorders: Hypersensitivity     Metabolism and nutrition disorders: Fluid retention, hypertriglyceridemia     Nervous system disorders: Dizziness     Skin and subcutaneous tissue disorders: Chloasma, angioedema, erythema nodosum, erythema multiforme     Gastrointestinal disorders: Gastrointestinal symptoms (for example, abdominal pain)     Infections and infestations: Vulvovaginal candidiasis",Hypersensitivity is an adverse reaction entity
"Vascular disorders: Venous and arterial thromboembolic events (including pulmonary emboli, deep vein thrombosis, cerebral thrombosis, myocardial infarction and stroke), hypertension     Hepatobiliary disorders: Gallbladder disease, hepatitis     Immune system disorders: Hypersensitivity     Metabolism and nutrition disorders: Fluid retention, hypertriglyceridemia     Nervous system disorders: Dizziness     Skin and subcutaneous tissue disorders: Chloasma, angioedema, erythema nodosum, erythema multiforme     Gastrointestinal disorders: Gastrointestinal symptoms (for example, abdominal pain)     Infections and infestations: Vulvovaginal candidiasis",angioedema is an adverse reaction entity
"Vascular disorders: Venous and arterial thromboembolic events (including pulmonary emboli, deep vein thrombosis, cerebral thrombosis, myocardial infarction and stroke), hypertension     Hepatobiliary disorders: Gallbladder disease, hepatitis     Immune system disorders: Hypersensitivity     Metabolism and nutrition disorders: Fluid retention, hypertriglyceridemia     Nervous system disorders: Dizziness     Skin and subcutaneous tissue disorders: Chloasma, angioedema, erythema nodosum, erythema multiforme     Gastrointestinal disorders: Gastrointestinal symptoms (for example, abdominal pain)     Infections and infestations: Vulvovaginal candidiasis",abdominal pain is an adverse reaction entity
"Vascular disorders: Venous and arterial thromboembolic events (including pulmonary emboli, deep vein thrombosis, cerebral thrombosis, myocardial infarction and stroke), hypertension     Hepatobiliary disorders: Gallbladder disease, hepatitis     Immune system disorders: Hypersensitivity     Metabolism and nutrition disorders: Fluid retention, hypertriglyceridemia     Nervous system disorders: Dizziness     Skin and subcutaneous tissue disorders: Chloasma, angioedema, erythema nodosum, erythema multiforme     Gastrointestinal disorders: Gastrointestinal symptoms (for example, abdominal pain)     Infections and infestations: Vulvovaginal candidiasis",disorders is not a named entity
"Vascular disorders: Venous and arterial thromboembolic events (including pulmonary emboli, deep vein thrombosis, cerebral thrombosis, myocardial infarction and stroke), hypertension     Hepatobiliary disorders: Gallbladder disease, hepatitis     Immune system disorders: Hypersensitivity     Metabolism and nutrition disorders: Fluid retention, hypertriglyceridemia     Nervous system disorders: Dizziness     Skin and subcutaneous tissue disorders: Chloasma, angioedema, erythema nodosum, erythema multiforme     Gastrointestinal disorders: Gastrointestinal symptoms (for example, abdominal pain)     Infections and infestations: Vulvovaginal candidiasis",deep vein thrombosis is an adverse reaction entity
Some studies suggest that COCs are associated with an increase in the risk of cervical cancer or intraepithelial neoplasia.,risk of is not a named entity
Some studies suggest that COCs are associated with an increase in the risk of cervical cancer or intraepithelial neoplasia.,cervical cancer is an adverse reaction entity
Some studies suggest that COCs are associated with an increase in the risk of cervical cancer or intraepithelial neoplasia.,the risk of is not a named entity
Some studies suggest that COCs are associated with an increase in the risk of cervical cancer or intraepithelial neoplasia.,cervical intraepithelial neoplasia is an adverse reaction entity
An increase in frequency or severity of migraine during COC use (which may be prodromal of a cerebrovascular event) may be a reason for immediate discontinuation of the COC.,migraine is an adverse reaction entity
An increase in frequency or severity of migraine during COC use (which may be prodromal of a cerebrovascular event) may be a reason for immediate discontinuation of the COC.,for is not a named entity
An increase in frequency or severity of migraine during COC use (which may be prodromal of a cerebrovascular event) may be a reason for immediate discontinuation of the COC.,frequency or severity is not a named entity
An increase in frequency or severity of migraine during COC use (which may be prodromal of a cerebrovascular event) may be a reason for immediate discontinuation of the COC.,cerebrovascular event is an adverse reaction entity
Oral contraceptive-related cholestasis may occur in women with a history of pregnancy-related cholestasis.,Oral is not a named entity
Oral contraceptive-related cholestasis may occur in women with a history of pregnancy-related cholestasis.,cholestasis is an adverse reaction entity
"Although some past studies have suggested that COCs might increase the incidence of breast cancer, more recent studies have not confirmed such findings.",breast cancer is an adverse reaction entity
"Although some past studies have suggested that COCs might increase the incidence of breast cancer, more recent studies have not confirmed such findings.",studies have is not a named entity
There is substantial evidence that COCs do not increase the incidence of breast cancer.,breast cancer is an adverse reaction entity
There is substantial evidence that COCs do not increase the incidence of breast cancer.,that COCs do is not a named entity
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).",nausea is an adverse reaction entity
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).",( 3.0 % is not a named entity
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).",dysthymic disorder is an adverse reaction entity
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).",vomiting is an adverse reaction entity
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).",affect lability is an adverse reaction entity
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).",breast tenderness is an adverse reaction entity
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).",disorders ( metrorrhagia is not a named entity
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).","% ) , is not a named entity"
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).",vaginal hemorrhage is an adverse reaction entity
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).","irregular , menorrhagia is not a named entity"
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).",mood altered is an adverse reaction entity
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).",abnormal withdrawal bleeding is an adverse reaction entity
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).",) ( is not a named entity
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).",uterine hemorrhage is an adverse reaction entity
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).",mood swings is an adverse reaction entity
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).",( is not a named entity
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).","withdrawal bleeding , is not a named entity"
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).",: headache is not a named entity
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).",", is not a named entity"
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).",2.9 is not a named entity
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).",increased weight is an adverse reaction entity
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).","pain , discomfort is not a named entity"
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).",depressed mood is an adverse reaction entity
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).",( is not a named entity
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).",menstrual disorders is an adverse reaction entity
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).","mood , is not a named entity"
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).",( is not a named entity
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).",or tenderness is not a named entity
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).",and increased is not a named entity
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).",breast discomfort is an adverse reaction entity
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).",depression is an adverse reaction entity
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).",mood changes is an adverse reaction entity
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).","dysthymic disorder , is not a named entity"
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).",menstruation irregular is an adverse reaction entity
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).",genital hemorrhage is an adverse reaction entity
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).","% ) , is not a named entity"
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).",", discomfort is not a named entity"
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).",) : headache is not a named entity
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).",dysfunctional uterine bleeding is an adverse reaction entity
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).",migraines is an adverse reaction entity
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).","menorrhagia , vaginal is not a named entity"
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).","% ) , is not a named entity"
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).",acne is an adverse reaction entity
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).",metrorrhagia is an adverse reaction entity
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).",menorrhagia is an adverse reaction entity
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).",breast pain is an adverse reaction entity
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).",crying is an adverse reaction entity
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).",or is not a named entity
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).",headache is an adverse reaction entity
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).",( 3.0 % is not a named entity
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).","affect lability , is not a named entity"
"Common Adverse Reactions (>= 2%):  headache (including migraines) (12.7%), breast pain, discomfort or tenderness (7.0%), menstrual disorders (metrorrhagia, menstruation irregular, menorrhagia, vaginal hemorrhage, dysfunctional uterine bleeding, genital hemorrhage, abnormal withdrawal bleeding, uterine hemorrhage) (6.9%), nausea or vomiting (6.0%), acne (3.9%), mood changes (depression, mood swings, depressed mood, mood altered, affect lability, dysthymic disorder, crying) (3.0%) and increased weight (2.9%).","dysthymic disorder , is not a named entity"
The underlying pathology was not ascertained in all patients but in some instances included immune-mediated hepatitis.,but in some is not a named entity
The underlying pathology was not ascertained in all patients but in some instances included immune-mediated hepatitis.,immune-mediated hepatitis is an adverse reaction entity
EXCERPT:   WARNING: IMMUNE-MEDIATED ADVERSE REACTIONS       See full prescribing information for complete boxed warning.,prescribing information is not a named entity
EXCERPT:   WARNING: IMMUNE-MEDIATED ADVERSE REACTIONS       See full prescribing information for complete boxed warning.,IMMUNE-MEDIATED ADVERSE REACTIONS is an adverse reaction entity
Immune-mediated endocrinopathies: Monitor thyroid function tests and clinical chemistries prior to each dose.,clinical chemistries prior is not a named entity
Immune-mediated endocrinopathies: Monitor thyroid function tests and clinical chemistries prior to each dose.,Immune-mediated endocrinopathies is an adverse reaction entity
"5.6   Other Immune-mediated Adverse Reactions, Including Ocular Manifestations      The following clinically significant immune-mediated adverse reactions were seen in less than 1% of YERVOY-treated patients in Study 1: nephritis, pneumonitis, meningitis, pericarditis, uveitis, iritis, and hemolytic anemia.",pneumonitis is an adverse reaction entity
"5.6   Other Immune-mediated Adverse Reactions, Including Ocular Manifestations      The following clinically significant immune-mediated adverse reactions were seen in less than 1% of YERVOY-treated patients in Study 1: nephritis, pneumonitis, meningitis, pericarditis, uveitis, iritis, and hemolytic anemia.",hemolytic anemia is an adverse reaction entity
"5.6   Other Immune-mediated Adverse Reactions, Including Ocular Manifestations      The following clinically significant immune-mediated adverse reactions were seen in less than 1% of YERVOY-treated patients in Study 1: nephritis, pneumonitis, meningitis, pericarditis, uveitis, iritis, and hemolytic anemia.",nephritis is an adverse reaction entity
"5.6   Other Immune-mediated Adverse Reactions, Including Ocular Manifestations      The following clinically significant immune-mediated adverse reactions were seen in less than 1% of YERVOY-treated patients in Study 1: nephritis, pneumonitis, meningitis, pericarditis, uveitis, iritis, and hemolytic anemia.",than 1 % is not a named entity
"5.6   Other Immune-mediated Adverse Reactions, Including Ocular Manifestations      The following clinically significant immune-mediated adverse reactions were seen in less than 1% of YERVOY-treated patients in Study 1: nephritis, pneumonitis, meningitis, pericarditis, uveitis, iritis, and hemolytic anemia.",iritis is an adverse reaction entity
"5.6   Other Immune-mediated Adverse Reactions, Including Ocular Manifestations      The following clinically significant immune-mediated adverse reactions were seen in less than 1% of YERVOY-treated patients in Study 1: nephritis, pneumonitis, meningitis, pericarditis, uveitis, iritis, and hemolytic anemia.",clinically significant immune-mediated is not a named entity
"5.6   Other Immune-mediated Adverse Reactions, Including Ocular Manifestations      The following clinically significant immune-mediated adverse reactions were seen in less than 1% of YERVOY-treated patients in Study 1: nephritis, pneumonitis, meningitis, pericarditis, uveitis, iritis, and hemolytic anemia.",clinically significant immune-mediated is not a named entity
"5.6   Other Immune-mediated Adverse Reactions, Including Ocular Manifestations      The following clinically significant immune-mediated adverse reactions were seen in less than 1% of YERVOY-treated patients in Study 1: nephritis, pneumonitis, meningitis, pericarditis, uveitis, iritis, and hemolytic anemia.",than 1 % is not a named entity
"5.6   Other Immune-mediated Adverse Reactions, Including Ocular Manifestations      The following clinically significant immune-mediated adverse reactions were seen in less than 1% of YERVOY-treated patients in Study 1: nephritis, pneumonitis, meningitis, pericarditis, uveitis, iritis, and hemolytic anemia.","uveitis , is not a named entity"
"5.6   Other Immune-mediated Adverse Reactions, Including Ocular Manifestations      The following clinically significant immune-mediated adverse reactions were seen in less than 1% of YERVOY-treated patients in Study 1: nephritis, pneumonitis, meningitis, pericarditis, uveitis, iritis, and hemolytic anemia.",uveitis is an adverse reaction entity
"5.6   Other Immune-mediated Adverse Reactions, Including Ocular Manifestations      The following clinically significant immune-mediated adverse reactions were seen in less than 1% of YERVOY-treated patients in Study 1: nephritis, pneumonitis, meningitis, pericarditis, uveitis, iritis, and hemolytic anemia.",immune-mediated adverse reactions is an adverse reaction entity
"5.6   Other Immune-mediated Adverse Reactions, Including Ocular Manifestations      The following clinically significant immune-mediated adverse reactions were seen in less than 1% of YERVOY-treated patients in Study 1: nephritis, pneumonitis, meningitis, pericarditis, uveitis, iritis, and hemolytic anemia.",pericarditis is an adverse reaction entity
"5.6   Other Immune-mediated Adverse Reactions, Including Ocular Manifestations      The following clinically significant immune-mediated adverse reactions were seen in less than 1% of YERVOY-treated patients in Study 1: nephritis, pneumonitis, meningitis, pericarditis, uveitis, iritis, and hemolytic anemia.","meningitis , pericarditis is not a named entity"
"5.6   Other Immune-mediated Adverse Reactions, Including Ocular Manifestations      The following clinically significant immune-mediated adverse reactions were seen in less than 1% of YERVOY-treated patients in Study 1: nephritis, pneumonitis, meningitis, pericarditis, uveitis, iritis, and hemolytic anemia.","nephritis , is not a named entity"
"5.6   Other Immune-mediated Adverse Reactions, Including Ocular Manifestations      The following clinically significant immune-mediated adverse reactions were seen in less than 1% of YERVOY-treated patients in Study 1: nephritis, pneumonitis, meningitis, pericarditis, uveitis, iritis, and hemolytic anemia.",significant immune-mediated is not a named entity
"5.6   Other Immune-mediated Adverse Reactions, Including Ocular Manifestations      The following clinically significant immune-mediated adverse reactions were seen in less than 1% of YERVOY-treated patients in Study 1: nephritis, pneumonitis, meningitis, pericarditis, uveitis, iritis, and hemolytic anemia.",meningitis is an adverse reaction entity
"All 9 patients had hypopituitarism and some had additional concomitant endocrinopathies such as adrenal insufficiency, hypogonadism, and hypothyroidism.",endocrinopathies is an adverse reaction entity
"All 9 patients had hypopituitarism and some had additional concomitant endocrinopathies such as adrenal insufficiency, hypogonadism, and hypothyroidism.",some had additional is not a named entity
"All 9 patients had hypopituitarism and some had additional concomitant endocrinopathies such as adrenal insufficiency, hypogonadism, and hypothyroidism.",as adrenal insufficiency is not a named entity
"All 9 patients had hypopituitarism and some had additional concomitant endocrinopathies such as adrenal insufficiency, hypogonadism, and hypothyroidism.",hypothyroidism is an adverse reaction entity
"All 9 patients had hypopituitarism and some had additional concomitant endocrinopathies such as adrenal insufficiency, hypogonadism, and hypothyroidism.",All 9 is not a named entity
"All 9 patients had hypopituitarism and some had additional concomitant endocrinopathies such as adrenal insufficiency, hypogonadism, and hypothyroidism.",hypopituitarism is an adverse reaction entity
"All 9 patients had hypopituitarism and some had additional concomitant endocrinopathies such as adrenal insufficiency, hypogonadism, and hypothyroidism.","hypogonadism , and is not a named entity"
"All 9 patients had hypopituitarism and some had additional concomitant endocrinopathies such as adrenal insufficiency, hypogonadism, and hypothyroidism.",additional concomitant is not a named entity
"All 9 patients had hypopituitarism and some had additional concomitant endocrinopathies such as adrenal insufficiency, hypogonadism, and hypothyroidism.",adrenal insufficiency is an adverse reaction entity
"All 9 patients had hypopituitarism and some had additional concomitant endocrinopathies such as adrenal insufficiency, hypogonadism, and hypothyroidism.",hypogonadism is an adverse reaction entity
"The majority of these immune-mediated reactions initially manifested during treatment; however, a minority occurred weeks to months after discontinuation of YERVOY.",to months is not a named entity
"The majority of these immune-mediated reactions initially manifested during treatment; however, a minority occurred weeks to months after discontinuation of YERVOY.",immune-mediated reactions is an adverse reaction entity
5    WARNINGS AND PRECAUTIONS      YERVOY can result in severe and fatal immune-mediated reactions due to T-cell activation and proliferation.,immune-mediated reactions is an adverse reaction entity
5    WARNINGS AND PRECAUTIONS      YERVOY can result in severe and fatal immune-mediated reactions due to T-cell activation and proliferation.,AND PRECAUTIONS is not a named entity
5    WARNINGS AND PRECAUTIONS      YERVOY can result in severe and fatal immune-mediated reactions due to T-cell activation and proliferation.,T-cell activation is not a named entity
5    WARNINGS AND PRECAUTIONS      YERVOY can result in severe and fatal immune-mediated reactions due to T-cell activation and proliferation.,fatal is an adverse reaction entity
"Of the 63 patients with moderate dermatitis, 25 (40%) were treated with systemic corticosteroids (median of 60 mg/day of prednisone or equivalent) for a median of 2.1 weeks, 7 (11%) were treated with only topical corticosteroids, and 31 (49%) did not receive systemic or topical corticosteroids.",dermatitis is an adverse reaction entity
"Of the 63 patients with moderate dermatitis, 25 (40%) were treated with systemic corticosteroids (median of 60 mg/day of prednisone or equivalent) for a median of 2.1 weeks, 7 (11%) were treated with only topical corticosteroids, and 31 (49%) did not receive systemic or topical corticosteroids.",) were is not a named entity
YERVOY can result in severe and fatal immune-mediated adverse reactions due to T-cell activation and proliferation.,fatal is an adverse reaction entity
YERVOY can result in severe and fatal immune-mediated adverse reactions due to T-cell activation and proliferation.,severe and fatal is not a named entity
YERVOY can result in severe and fatal immune-mediated adverse reactions due to T-cell activation and proliferation.,immune-mediated adverse reactions is an adverse reaction entity
YERVOY can result in severe and fatal immune-mediated adverse reactions due to T-cell activation and proliferation.,adverse is not a named entity
"Based on the experience in the entire clinical program for melanoma, the incidence and severity of enterocolitis and hepatitis appear to be dose dependent.",enterocolitis and is not a named entity
"Based on the experience in the entire clinical program for melanoma, the incidence and severity of enterocolitis and hepatitis appear to be dose dependent.",appear to is not a named entity
"Based on the experience in the entire clinical program for melanoma, the incidence and severity of enterocolitis and hepatitis appear to be dose dependent.",hepatitis is an adverse reaction entity
"Based on the experience in the entire clinical program for melanoma, the incidence and severity of enterocolitis and hepatitis appear to be dose dependent.",enterocolitis is an adverse reaction entity
"5.4   Immune-mediated Neuropathies      In Study 1, 1 case of fatal Guillain-Barre syndrome and 1 case of severe (Grade 3) peripheral motor neuropathy were reported.",of severe ( is not a named entity
"5.4   Immune-mediated Neuropathies      In Study 1, 1 case of fatal Guillain-Barre syndrome and 1 case of severe (Grade 3) peripheral motor neuropathy were reported.",5.4 Immune-mediated is not a named entity
"5.4   Immune-mediated Neuropathies      In Study 1, 1 case of fatal Guillain-Barre syndrome and 1 case of severe (Grade 3) peripheral motor neuropathy were reported.",peripheral motor neuropathy is an adverse reaction entity
"5.4   Immune-mediated Neuropathies      In Study 1, 1 case of fatal Guillain-Barre syndrome and 1 case of severe (Grade 3) peripheral motor neuropathy were reported.",fatal is an adverse reaction entity
"5.4   Immune-mediated Neuropathies      In Study 1, 1 case of fatal Guillain-Barre syndrome and 1 case of severe (Grade 3) peripheral motor neuropathy were reported.",Guillain-Barre syndrome is an adverse reaction entity
"5.4   Immune-mediated Neuropathies      In Study 1, 1 case of fatal Guillain-Barre syndrome and 1 case of severe (Grade 3) peripheral motor neuropathy were reported.",( Grade 3 is not a named entity
"These immune-mediated reactions may involve any organ system; however, the most common severe immune-mediated adverse reactions are enterocolitis, hepatitis, dermatitis (including toxic epidermal necrolysis), neuropathy, and endocrinopathy.",reactions is not a named entity
"These immune-mediated reactions may involve any organ system; however, the most common severe immune-mediated adverse reactions are enterocolitis, hepatitis, dermatitis (including toxic epidermal necrolysis), neuropathy, and endocrinopathy.","however , the is not a named entity"
"These immune-mediated reactions may involve any organ system; however, the most common severe immune-mediated adverse reactions are enterocolitis, hepatitis, dermatitis (including toxic epidermal necrolysis), neuropathy, and endocrinopathy.",epidermal necrolysis ) is not a named entity
"These immune-mediated reactions may involve any organ system; however, the most common severe immune-mediated adverse reactions are enterocolitis, hepatitis, dermatitis (including toxic epidermal necrolysis), neuropathy, and endocrinopathy.",dermatitis is an adverse reaction entity
"These immune-mediated reactions may involve any organ system; however, the most common severe immune-mediated adverse reactions are enterocolitis, hepatitis, dermatitis (including toxic epidermal necrolysis), neuropathy, and endocrinopathy.",", hepatitis is not a named entity"
"These immune-mediated reactions may involve any organ system; however, the most common severe immune-mediated adverse reactions are enterocolitis, hepatitis, dermatitis (including toxic epidermal necrolysis), neuropathy, and endocrinopathy.",most is not a named entity
"These immune-mediated reactions may involve any organ system; however, the most common severe immune-mediated adverse reactions are enterocolitis, hepatitis, dermatitis (including toxic epidermal necrolysis), neuropathy, and endocrinopathy.",immune-mediated reactions is an adverse reaction entity
"These immune-mediated reactions may involve any organ system; however, the most common severe immune-mediated adverse reactions are enterocolitis, hepatitis, dermatitis (including toxic epidermal necrolysis), neuropathy, and endocrinopathy.",neuropathy is an adverse reaction entity
"These immune-mediated reactions may involve any organ system; however, the most common severe immune-mediated adverse reactions are enterocolitis, hepatitis, dermatitis (including toxic epidermal necrolysis), neuropathy, and endocrinopathy.",immune-mediated adverse reactions is an adverse reaction entity
"These immune-mediated reactions may involve any organ system; however, the most common severe immune-mediated adverse reactions are enterocolitis, hepatitis, dermatitis (including toxic epidermal necrolysis), neuropathy, and endocrinopathy.",; however is not a named entity
"These immune-mediated reactions may involve any organ system; however, the most common severe immune-mediated adverse reactions are enterocolitis, hepatitis, dermatitis (including toxic epidermal necrolysis), neuropathy, and endocrinopathy.",endocrinopathy is an adverse reaction entity
"These immune-mediated reactions may involve any organ system; however, the most common severe immune-mediated adverse reactions are enterocolitis, hepatitis, dermatitis (including toxic epidermal necrolysis), neuropathy, and endocrinopathy.",hepatitis is an adverse reaction entity
"These immune-mediated reactions may involve any organ system; however, the most common severe immune-mediated adverse reactions are enterocolitis, hepatitis, dermatitis (including toxic epidermal necrolysis), neuropathy, and endocrinopathy.",enterocolitis is an adverse reaction entity
"These immune-mediated reactions may involve any organ system; however, the most common severe immune-mediated adverse reactions are enterocolitis, hepatitis, dermatitis (including toxic epidermal necrolysis), neuropathy, and endocrinopathy.",toxic epidermal necrolysis is an adverse reaction entity
"These immune-mediated reactions may involve any organ system; however, the most common severe immune-mediated adverse reactions are enterocolitis, hepatitis, dermatitis (including toxic epidermal necrolysis), neuropathy, and endocrinopathy.",adverse reactions is not a named entity
"These immune-mediated reactions may involve any organ system; however, the most common severe immune-mediated adverse reactions are enterocolitis, hepatitis, dermatitis (including toxic epidermal necrolysis), neuropathy, and endocrinopathy.",These immune-mediated is not a named entity
"Across the clinical development program for YERVOY, the following likely immune-mediated adverse reactions were also reported with less than 1% incidence: myocarditis, angiopathy, temporal arteritis, vasculitis, polymyalgia rheumatica, conjunctivitis, blepharitis, episcleritis, scleritis, leukocytoclastic vasculitis, erythema multiforme, psoriasis, pancreatitis, arthritis, autoimmune thyroiditis, sarcoidosis, neurosensory hypoacusis, autoimmune central neuropathy (encephalitis), myositis, polymyositis, and ocular myositis.",than 1 % is not a named entity
"Across the clinical development program for YERVOY, the following likely immune-mediated adverse reactions were also reported with less than 1% incidence: myocarditis, angiopathy, temporal arteritis, vasculitis, polymyalgia rheumatica, conjunctivitis, blepharitis, episcleritis, scleritis, leukocytoclastic vasculitis, erythema multiforme, psoriasis, pancreatitis, arthritis, autoimmune thyroiditis, sarcoidosis, neurosensory hypoacusis, autoimmune central neuropathy (encephalitis), myositis, polymyositis, and ocular myositis.",polymyositis is an adverse reaction entity
"Across the clinical development program for YERVOY, the following likely immune-mediated adverse reactions were also reported with less than 1% incidence: myocarditis, angiopathy, temporal arteritis, vasculitis, polymyalgia rheumatica, conjunctivitis, blepharitis, episcleritis, scleritis, leukocytoclastic vasculitis, erythema multiforme, psoriasis, pancreatitis, arthritis, autoimmune thyroiditis, sarcoidosis, neurosensory hypoacusis, autoimmune central neuropathy (encephalitis), myositis, polymyositis, and ocular myositis.",Across the is not a named entity
"Across the clinical development program for YERVOY, the following likely immune-mediated adverse reactions were also reported with less than 1% incidence: myocarditis, angiopathy, temporal arteritis, vasculitis, polymyalgia rheumatica, conjunctivitis, blepharitis, episcleritis, scleritis, leukocytoclastic vasculitis, erythema multiforme, psoriasis, pancreatitis, arthritis, autoimmune thyroiditis, sarcoidosis, neurosensory hypoacusis, autoimmune central neuropathy (encephalitis), myositis, polymyositis, and ocular myositis.",") , myositis is not a named entity"
"Across the clinical development program for YERVOY, the following likely immune-mediated adverse reactions were also reported with less than 1% incidence: myocarditis, angiopathy, temporal arteritis, vasculitis, polymyalgia rheumatica, conjunctivitis, blepharitis, episcleritis, scleritis, leukocytoclastic vasculitis, erythema multiforme, psoriasis, pancreatitis, arthritis, autoimmune thyroiditis, sarcoidosis, neurosensory hypoacusis, autoimmune central neuropathy (encephalitis), myositis, polymyositis, and ocular myositis.",myositis is an adverse reaction entity
"Across the clinical development program for YERVOY, the following likely immune-mediated adverse reactions were also reported with less than 1% incidence: myocarditis, angiopathy, temporal arteritis, vasculitis, polymyalgia rheumatica, conjunctivitis, blepharitis, episcleritis, scleritis, leukocytoclastic vasculitis, erythema multiforme, psoriasis, pancreatitis, arthritis, autoimmune thyroiditis, sarcoidosis, neurosensory hypoacusis, autoimmune central neuropathy (encephalitis), myositis, polymyositis, and ocular myositis.",immune-mediated adverse reactions is an adverse reaction entity
"Across the clinical development program for YERVOY, the following likely immune-mediated adverse reactions were also reported with less than 1% incidence: myocarditis, angiopathy, temporal arteritis, vasculitis, polymyalgia rheumatica, conjunctivitis, blepharitis, episcleritis, scleritis, leukocytoclastic vasculitis, erythema multiforme, psoriasis, pancreatitis, arthritis, autoimmune thyroiditis, sarcoidosis, neurosensory hypoacusis, autoimmune central neuropathy (encephalitis), myositis, polymyositis, and ocular myositis.","hypoacusis , autoimmune is not a named entity"
"Across the clinical development program for YERVOY, the following likely immune-mediated adverse reactions were also reported with less than 1% incidence: myocarditis, angiopathy, temporal arteritis, vasculitis, polymyalgia rheumatica, conjunctivitis, blepharitis, episcleritis, scleritis, leukocytoclastic vasculitis, erythema multiforme, psoriasis, pancreatitis, arthritis, autoimmune thyroiditis, sarcoidosis, neurosensory hypoacusis, autoimmune central neuropathy (encephalitis), myositis, polymyositis, and ocular myositis.",likely immune-mediated is not a named entity
"Across the clinical development program for YERVOY, the following likely immune-mediated adverse reactions were also reported with less than 1% incidence: myocarditis, angiopathy, temporal arteritis, vasculitis, polymyalgia rheumatica, conjunctivitis, blepharitis, episcleritis, scleritis, leukocytoclastic vasculitis, erythema multiforme, psoriasis, pancreatitis, arthritis, autoimmune thyroiditis, sarcoidosis, neurosensory hypoacusis, autoimmune central neuropathy (encephalitis), myositis, polymyositis, and ocular myositis.",autoimmune thyroiditis is an adverse reaction entity
"Across the clinical development program for YERVOY, the following likely immune-mediated adverse reactions were also reported with less than 1% incidence: myocarditis, angiopathy, temporal arteritis, vasculitis, polymyalgia rheumatica, conjunctivitis, blepharitis, episcleritis, scleritis, leukocytoclastic vasculitis, erythema multiforme, psoriasis, pancreatitis, arthritis, autoimmune thyroiditis, sarcoidosis, neurosensory hypoacusis, autoimmune central neuropathy (encephalitis), myositis, polymyositis, and ocular myositis.",sarcoidosis is an adverse reaction entity
"Across the clinical development program for YERVOY, the following likely immune-mediated adverse reactions were also reported with less than 1% incidence: myocarditis, angiopathy, temporal arteritis, vasculitis, polymyalgia rheumatica, conjunctivitis, blepharitis, episcleritis, scleritis, leukocytoclastic vasculitis, erythema multiforme, psoriasis, pancreatitis, arthritis, autoimmune thyroiditis, sarcoidosis, neurosensory hypoacusis, autoimmune central neuropathy (encephalitis), myositis, polymyositis, and ocular myositis.",arthritis is an adverse reaction entity
"Across the clinical development program for YERVOY, the following likely immune-mediated adverse reactions were also reported with less than 1% incidence: myocarditis, angiopathy, temporal arteritis, vasculitis, polymyalgia rheumatica, conjunctivitis, blepharitis, episcleritis, scleritis, leukocytoclastic vasculitis, erythema multiforme, psoriasis, pancreatitis, arthritis, autoimmune thyroiditis, sarcoidosis, neurosensory hypoacusis, autoimmune central neuropathy (encephalitis), myositis, polymyositis, and ocular myositis.",blepharitis is an adverse reaction entity
"Across the clinical development program for YERVOY, the following likely immune-mediated adverse reactions were also reported with less than 1% incidence: myocarditis, angiopathy, temporal arteritis, vasculitis, polymyalgia rheumatica, conjunctivitis, blepharitis, episcleritis, scleritis, leukocytoclastic vasculitis, erythema multiforme, psoriasis, pancreatitis, arthritis, autoimmune thyroiditis, sarcoidosis, neurosensory hypoacusis, autoimmune central neuropathy (encephalitis), myositis, polymyositis, and ocular myositis.",vasculitis is an adverse reaction entity
"Across the clinical development program for YERVOY, the following likely immune-mediated adverse reactions were also reported with less than 1% incidence: myocarditis, angiopathy, temporal arteritis, vasculitis, polymyalgia rheumatica, conjunctivitis, blepharitis, episcleritis, scleritis, leukocytoclastic vasculitis, erythema multiforme, psoriasis, pancreatitis, arthritis, autoimmune thyroiditis, sarcoidosis, neurosensory hypoacusis, autoimmune central neuropathy (encephalitis), myositis, polymyositis, and ocular myositis.",", is not a named entity"
"Across the clinical development program for YERVOY, the following likely immune-mediated adverse reactions were also reported with less than 1% incidence: myocarditis, angiopathy, temporal arteritis, vasculitis, polymyalgia rheumatica, conjunctivitis, blepharitis, episcleritis, scleritis, leukocytoclastic vasculitis, erythema multiforme, psoriasis, pancreatitis, arthritis, autoimmune thyroiditis, sarcoidosis, neurosensory hypoacusis, autoimmune central neuropathy (encephalitis), myositis, polymyositis, and ocular myositis.",", autoimmune central is not a named entity"
"Across the clinical development program for YERVOY, the following likely immune-mediated adverse reactions were also reported with less than 1% incidence: myocarditis, angiopathy, temporal arteritis, vasculitis, polymyalgia rheumatica, conjunctivitis, blepharitis, episcleritis, scleritis, leukocytoclastic vasculitis, erythema multiforme, psoriasis, pancreatitis, arthritis, autoimmune thyroiditis, sarcoidosis, neurosensory hypoacusis, autoimmune central neuropathy (encephalitis), myositis, polymyositis, and ocular myositis.",pancreatitis is an adverse reaction entity
"Across the clinical development program for YERVOY, the following likely immune-mediated adverse reactions were also reported with less than 1% incidence: myocarditis, angiopathy, temporal arteritis, vasculitis, polymyalgia rheumatica, conjunctivitis, blepharitis, episcleritis, scleritis, leukocytoclastic vasculitis, erythema multiforme, psoriasis, pancreatitis, arthritis, autoimmune thyroiditis, sarcoidosis, neurosensory hypoacusis, autoimmune central neuropathy (encephalitis), myositis, polymyositis, and ocular myositis.",angiopathy is an adverse reaction entity
"Across the clinical development program for YERVOY, the following likely immune-mediated adverse reactions were also reported with less than 1% incidence: myocarditis, angiopathy, temporal arteritis, vasculitis, polymyalgia rheumatica, conjunctivitis, blepharitis, episcleritis, scleritis, leukocytoclastic vasculitis, erythema multiforme, psoriasis, pancreatitis, arthritis, autoimmune thyroiditis, sarcoidosis, neurosensory hypoacusis, autoimmune central neuropathy (encephalitis), myositis, polymyositis, and ocular myositis.",with is not a named entity
"Across the clinical development program for YERVOY, the following likely immune-mediated adverse reactions were also reported with less than 1% incidence: myocarditis, angiopathy, temporal arteritis, vasculitis, polymyalgia rheumatica, conjunctivitis, blepharitis, episcleritis, scleritis, leukocytoclastic vasculitis, erythema multiforme, psoriasis, pancreatitis, arthritis, autoimmune thyroiditis, sarcoidosis, neurosensory hypoacusis, autoimmune central neuropathy (encephalitis), myositis, polymyositis, and ocular myositis.",erythema multiforme is an adverse reaction entity
"Across the clinical development program for YERVOY, the following likely immune-mediated adverse reactions were also reported with less than 1% incidence: myocarditis, angiopathy, temporal arteritis, vasculitis, polymyalgia rheumatica, conjunctivitis, blepharitis, episcleritis, scleritis, leukocytoclastic vasculitis, erythema multiforme, psoriasis, pancreatitis, arthritis, autoimmune thyroiditis, sarcoidosis, neurosensory hypoacusis, autoimmune central neuropathy (encephalitis), myositis, polymyositis, and ocular myositis.",psoriasis is an adverse reaction entity
"Across the clinical development program for YERVOY, the following likely immune-mediated adverse reactions were also reported with less than 1% incidence: myocarditis, angiopathy, temporal arteritis, vasculitis, polymyalgia rheumatica, conjunctivitis, blepharitis, episcleritis, scleritis, leukocytoclastic vasculitis, erythema multiforme, psoriasis, pancreatitis, arthritis, autoimmune thyroiditis, sarcoidosis, neurosensory hypoacusis, autoimmune central neuropathy (encephalitis), myositis, polymyositis, and ocular myositis.",encephalitis ) is not a named entity
"Across the clinical development program for YERVOY, the following likely immune-mediated adverse reactions were also reported with less than 1% incidence: myocarditis, angiopathy, temporal arteritis, vasculitis, polymyalgia rheumatica, conjunctivitis, blepharitis, episcleritis, scleritis, leukocytoclastic vasculitis, erythema multiforme, psoriasis, pancreatitis, arthritis, autoimmune thyroiditis, sarcoidosis, neurosensory hypoacusis, autoimmune central neuropathy (encephalitis), myositis, polymyositis, and ocular myositis.",autoimmune central neuropathy is an adverse reaction entity
"Across the clinical development program for YERVOY, the following likely immune-mediated adverse reactions were also reported with less than 1% incidence: myocarditis, angiopathy, temporal arteritis, vasculitis, polymyalgia rheumatica, conjunctivitis, blepharitis, episcleritis, scleritis, leukocytoclastic vasculitis, erythema multiforme, psoriasis, pancreatitis, arthritis, autoimmune thyroiditis, sarcoidosis, neurosensory hypoacusis, autoimmune central neuropathy (encephalitis), myositis, polymyositis, and ocular myositis.",) is not a named entity
"Across the clinical development program for YERVOY, the following likely immune-mediated adverse reactions were also reported with less than 1% incidence: myocarditis, angiopathy, temporal arteritis, vasculitis, polymyalgia rheumatica, conjunctivitis, blepharitis, episcleritis, scleritis, leukocytoclastic vasculitis, erythema multiforme, psoriasis, pancreatitis, arthritis, autoimmune thyroiditis, sarcoidosis, neurosensory hypoacusis, autoimmune central neuropathy (encephalitis), myositis, polymyositis, and ocular myositis.",% is not a named entity
"Across the clinical development program for YERVOY, the following likely immune-mediated adverse reactions were also reported with less than 1% incidence: myocarditis, angiopathy, temporal arteritis, vasculitis, polymyalgia rheumatica, conjunctivitis, blepharitis, episcleritis, scleritis, leukocytoclastic vasculitis, erythema multiforme, psoriasis, pancreatitis, arthritis, autoimmune thyroiditis, sarcoidosis, neurosensory hypoacusis, autoimmune central neuropathy (encephalitis), myositis, polymyositis, and ocular myositis.",adverse reactions is not a named entity
"Across the clinical development program for YERVOY, the following likely immune-mediated adverse reactions were also reported with less than 1% incidence: myocarditis, angiopathy, temporal arteritis, vasculitis, polymyalgia rheumatica, conjunctivitis, blepharitis, episcleritis, scleritis, leukocytoclastic vasculitis, erythema multiforme, psoriasis, pancreatitis, arthritis, autoimmune thyroiditis, sarcoidosis, neurosensory hypoacusis, autoimmune central neuropathy (encephalitis), myositis, polymyositis, and ocular myositis.","polymyositis , is not a named entity"
"Across the clinical development program for YERVOY, the following likely immune-mediated adverse reactions were also reported with less than 1% incidence: myocarditis, angiopathy, temporal arteritis, vasculitis, polymyalgia rheumatica, conjunctivitis, blepharitis, episcleritis, scleritis, leukocytoclastic vasculitis, erythema multiforme, psoriasis, pancreatitis, arthritis, autoimmune thyroiditis, sarcoidosis, neurosensory hypoacusis, autoimmune central neuropathy (encephalitis), myositis, polymyositis, and ocular myositis.","arteritis , is not a named entity"
"Across the clinical development program for YERVOY, the following likely immune-mediated adverse reactions were also reported with less than 1% incidence: myocarditis, angiopathy, temporal arteritis, vasculitis, polymyalgia rheumatica, conjunctivitis, blepharitis, episcleritis, scleritis, leukocytoclastic vasculitis, erythema multiforme, psoriasis, pancreatitis, arthritis, autoimmune thyroiditis, sarcoidosis, neurosensory hypoacusis, autoimmune central neuropathy (encephalitis), myositis, polymyositis, and ocular myositis.",clinical is not a named entity
"Across the clinical development program for YERVOY, the following likely immune-mediated adverse reactions were also reported with less than 1% incidence: myocarditis, angiopathy, temporal arteritis, vasculitis, polymyalgia rheumatica, conjunctivitis, blepharitis, episcleritis, scleritis, leukocytoclastic vasculitis, erythema multiforme, psoriasis, pancreatitis, arthritis, autoimmune thyroiditis, sarcoidosis, neurosensory hypoacusis, autoimmune central neuropathy (encephalitis), myositis, polymyositis, and ocular myositis.",temporal arteritis is an adverse reaction entity
"Across the clinical development program for YERVOY, the following likely immune-mediated adverse reactions were also reported with less than 1% incidence: myocarditis, angiopathy, temporal arteritis, vasculitis, polymyalgia rheumatica, conjunctivitis, blepharitis, episcleritis, scleritis, leukocytoclastic vasculitis, erythema multiforme, psoriasis, pancreatitis, arthritis, autoimmune thyroiditis, sarcoidosis, neurosensory hypoacusis, autoimmune central neuropathy (encephalitis), myositis, polymyositis, and ocular myositis.","vasculitis , is not a named entity"
"Across the clinical development program for YERVOY, the following likely immune-mediated adverse reactions were also reported with less than 1% incidence: myocarditis, angiopathy, temporal arteritis, vasculitis, polymyalgia rheumatica, conjunctivitis, blepharitis, episcleritis, scleritis, leukocytoclastic vasculitis, erythema multiforme, psoriasis, pancreatitis, arthritis, autoimmune thyroiditis, sarcoidosis, neurosensory hypoacusis, autoimmune central neuropathy (encephalitis), myositis, polymyositis, and ocular myositis.",episcleritis is an adverse reaction entity
"Across the clinical development program for YERVOY, the following likely immune-mediated adverse reactions were also reported with less than 1% incidence: myocarditis, angiopathy, temporal arteritis, vasculitis, polymyalgia rheumatica, conjunctivitis, blepharitis, episcleritis, scleritis, leukocytoclastic vasculitis, erythema multiforme, psoriasis, pancreatitis, arthritis, autoimmune thyroiditis, sarcoidosis, neurosensory hypoacusis, autoimmune central neuropathy (encephalitis), myositis, polymyositis, and ocular myositis.",% incidence is not a named entity
"Across the clinical development program for YERVOY, the following likely immune-mediated adverse reactions were also reported with less than 1% incidence: myocarditis, angiopathy, temporal arteritis, vasculitis, polymyalgia rheumatica, conjunctivitis, blepharitis, episcleritis, scleritis, leukocytoclastic vasculitis, erythema multiforme, psoriasis, pancreatitis, arthritis, autoimmune thyroiditis, sarcoidosis, neurosensory hypoacusis, autoimmune central neuropathy (encephalitis), myositis, polymyositis, and ocular myositis.",", the following is not a named entity"
"Across the clinical development program for YERVOY, the following likely immune-mediated adverse reactions were also reported with less than 1% incidence: myocarditis, angiopathy, temporal arteritis, vasculitis, polymyalgia rheumatica, conjunctivitis, blepharitis, episcleritis, scleritis, leukocytoclastic vasculitis, erythema multiforme, psoriasis, pancreatitis, arthritis, autoimmune thyroiditis, sarcoidosis, neurosensory hypoacusis, autoimmune central neuropathy (encephalitis), myositis, polymyositis, and ocular myositis.","vasculitis , erythema is not a named entity"
"Across the clinical development program for YERVOY, the following likely immune-mediated adverse reactions were also reported with less than 1% incidence: myocarditis, angiopathy, temporal arteritis, vasculitis, polymyalgia rheumatica, conjunctivitis, blepharitis, episcleritis, scleritis, leukocytoclastic vasculitis, erythema multiforme, psoriasis, pancreatitis, arthritis, autoimmune thyroiditis, sarcoidosis, neurosensory hypoacusis, autoimmune central neuropathy (encephalitis), myositis, polymyositis, and ocular myositis.","encephalitis ) , is not a named entity"
"Across the clinical development program for YERVOY, the following likely immune-mediated adverse reactions were also reported with less than 1% incidence: myocarditis, angiopathy, temporal arteritis, vasculitis, polymyalgia rheumatica, conjunctivitis, blepharitis, episcleritis, scleritis, leukocytoclastic vasculitis, erythema multiforme, psoriasis, pancreatitis, arthritis, autoimmune thyroiditis, sarcoidosis, neurosensory hypoacusis, autoimmune central neuropathy (encephalitis), myositis, polymyositis, and ocular myositis.",polymyalgia rheumatica is an adverse reaction entity
"Across the clinical development program for YERVOY, the following likely immune-mediated adverse reactions were also reported with less than 1% incidence: myocarditis, angiopathy, temporal arteritis, vasculitis, polymyalgia rheumatica, conjunctivitis, blepharitis, episcleritis, scleritis, leukocytoclastic vasculitis, erythema multiforme, psoriasis, pancreatitis, arthritis, autoimmune thyroiditis, sarcoidosis, neurosensory hypoacusis, autoimmune central neuropathy (encephalitis), myositis, polymyositis, and ocular myositis.",", conjunctivitis is not a named entity"
"Across the clinical development program for YERVOY, the following likely immune-mediated adverse reactions were also reported with less than 1% incidence: myocarditis, angiopathy, temporal arteritis, vasculitis, polymyalgia rheumatica, conjunctivitis, blepharitis, episcleritis, scleritis, leukocytoclastic vasculitis, erythema multiforme, psoriasis, pancreatitis, arthritis, autoimmune thyroiditis, sarcoidosis, neurosensory hypoacusis, autoimmune central neuropathy (encephalitis), myositis, polymyositis, and ocular myositis.",neurosensory hypoacusis is an adverse reaction entity
"Across the clinical development program for YERVOY, the following likely immune-mediated adverse reactions were also reported with less than 1% incidence: myocarditis, angiopathy, temporal arteritis, vasculitis, polymyalgia rheumatica, conjunctivitis, blepharitis, episcleritis, scleritis, leukocytoclastic vasculitis, erythema multiforme, psoriasis, pancreatitis, arthritis, autoimmune thyroiditis, sarcoidosis, neurosensory hypoacusis, autoimmune central neuropathy (encephalitis), myositis, polymyositis, and ocular myositis.",scleritis is an adverse reaction entity
"Across the clinical development program for YERVOY, the following likely immune-mediated adverse reactions were also reported with less than 1% incidence: myocarditis, angiopathy, temporal arteritis, vasculitis, polymyalgia rheumatica, conjunctivitis, blepharitis, episcleritis, scleritis, leukocytoclastic vasculitis, erythema multiforme, psoriasis, pancreatitis, arthritis, autoimmune thyroiditis, sarcoidosis, neurosensory hypoacusis, autoimmune central neuropathy (encephalitis), myositis, polymyositis, and ocular myositis.","arthritis , autoimmune is not a named entity"
"Across the clinical development program for YERVOY, the following likely immune-mediated adverse reactions were also reported with less than 1% incidence: myocarditis, angiopathy, temporal arteritis, vasculitis, polymyalgia rheumatica, conjunctivitis, blepharitis, episcleritis, scleritis, leukocytoclastic vasculitis, erythema multiforme, psoriasis, pancreatitis, arthritis, autoimmune thyroiditis, sarcoidosis, neurosensory hypoacusis, autoimmune central neuropathy (encephalitis), myositis, polymyositis, and ocular myositis.",myocarditis is an adverse reaction entity
"Across the clinical development program for YERVOY, the following likely immune-mediated adverse reactions were also reported with less than 1% incidence: myocarditis, angiopathy, temporal arteritis, vasculitis, polymyalgia rheumatica, conjunctivitis, blepharitis, episcleritis, scleritis, leukocytoclastic vasculitis, erythema multiforme, psoriasis, pancreatitis, arthritis, autoimmune thyroiditis, sarcoidosis, neurosensory hypoacusis, autoimmune central neuropathy (encephalitis), myositis, polymyositis, and ocular myositis.",1 is not a named entity
"Across the clinical development program for YERVOY, the following likely immune-mediated adverse reactions were also reported with less than 1% incidence: myocarditis, angiopathy, temporal arteritis, vasculitis, polymyalgia rheumatica, conjunctivitis, blepharitis, episcleritis, scleritis, leukocytoclastic vasculitis, erythema multiforme, psoriasis, pancreatitis, arthritis, autoimmune thyroiditis, sarcoidosis, neurosensory hypoacusis, autoimmune central neuropathy (encephalitis), myositis, polymyositis, and ocular myositis.",leukocytoclastic vasculitis is an adverse reaction entity
"Across the clinical development program for YERVOY, the following likely immune-mediated adverse reactions were also reported with less than 1% incidence: myocarditis, angiopathy, temporal arteritis, vasculitis, polymyalgia rheumatica, conjunctivitis, blepharitis, episcleritis, scleritis, leukocytoclastic vasculitis, erythema multiforme, psoriasis, pancreatitis, arthritis, autoimmune thyroiditis, sarcoidosis, neurosensory hypoacusis, autoimmune central neuropathy (encephalitis), myositis, polymyositis, and ocular myositis.",ocular myositis is an adverse reaction entity
"Across the clinical development program for YERVOY, the following likely immune-mediated adverse reactions were also reported with less than 1% incidence: myocarditis, angiopathy, temporal arteritis, vasculitis, polymyalgia rheumatica, conjunctivitis, blepharitis, episcleritis, scleritis, leukocytoclastic vasculitis, erythema multiforme, psoriasis, pancreatitis, arthritis, autoimmune thyroiditis, sarcoidosis, neurosensory hypoacusis, autoimmune central neuropathy (encephalitis), myositis, polymyositis, and ocular myositis.",encephalitis is an adverse reaction entity
"Across the clinical development program for YERVOY, the following likely immune-mediated adverse reactions were also reported with less than 1% incidence: myocarditis, angiopathy, temporal arteritis, vasculitis, polymyalgia rheumatica, conjunctivitis, blepharitis, episcleritis, scleritis, leukocytoclastic vasculitis, erythema multiforme, psoriasis, pancreatitis, arthritis, autoimmune thyroiditis, sarcoidosis, neurosensory hypoacusis, autoimmune central neuropathy (encephalitis), myositis, polymyositis, and ocular myositis.",conjunctivitis is an adverse reaction entity
"Forty-four (70%) patients with moderate dermatitis were reported to have complete resolution, 7 (11%) improved to mild (Grade 1) severity, and 12 (19%) had no reported improvement.",dermatitis is an adverse reaction entity
"Forty-four (70%) patients with moderate dermatitis were reported to have complete resolution, 7 (11%) improved to mild (Grade 1) severity, and 12 (19%) had no reported improvement.",) is not a named entity
An additional 13 (2.5%) patients experienced moderate hepatotoxicity manifested by liver function test abnormalities (AST or ALT elevations of more than 2.5 times but not more than 5 times the upper limit of normal or total bilirubin elevation of more than 1.5 times but not more than 3 times the upper limit of normal; Grade 2).,times the is not a named entity
An additional 13 (2.5%) patients experienced moderate hepatotoxicity manifested by liver function test abnormalities (AST or ALT elevations of more than 2.5 times but not more than 5 times the upper limit of normal or total bilirubin elevation of more than 1.5 times but not more than 3 times the upper limit of normal; Grade 2).,AST elevations is an adverse reaction entity
An additional 13 (2.5%) patients experienced moderate hepatotoxicity manifested by liver function test abnormalities (AST or ALT elevations of more than 2.5 times but not more than 5 times the upper limit of normal or total bilirubin elevation of more than 1.5 times but not more than 3 times the upper limit of normal; Grade 2).,; Grade 2 is not a named entity
An additional 13 (2.5%) patients experienced moderate hepatotoxicity manifested by liver function test abnormalities (AST or ALT elevations of more than 2.5 times but not more than 5 times the upper limit of normal or total bilirubin elevation of more than 1.5 times but not more than 3 times the upper limit of normal; Grade 2).,) is not a named entity
An additional 13 (2.5%) patients experienced moderate hepatotoxicity manifested by liver function test abnormalities (AST or ALT elevations of more than 2.5 times but not more than 5 times the upper limit of normal or total bilirubin elevation of more than 1.5 times but not more than 3 times the upper limit of normal; Grade 2).,the is not a named entity
An additional 13 (2.5%) patients experienced moderate hepatotoxicity manifested by liver function test abnormalities (AST or ALT elevations of more than 2.5 times but not more than 5 times the upper limit of normal or total bilirubin elevation of more than 1.5 times but not more than 3 times the upper limit of normal; Grade 2).,liver function test abnormalities is an adverse reaction entity
An additional 13 (2.5%) patients experienced moderate hepatotoxicity manifested by liver function test abnormalities (AST or ALT elevations of more than 2.5 times but not more than 5 times the upper limit of normal or total bilirubin elevation of more than 1.5 times but not more than 3 times the upper limit of normal; Grade 2).,not is not a named entity
An additional 13 (2.5%) patients experienced moderate hepatotoxicity manifested by liver function test abnormalities (AST or ALT elevations of more than 2.5 times but not more than 5 times the upper limit of normal or total bilirubin elevation of more than 1.5 times but not more than 3 times the upper limit of normal; Grade 2).,total bilirubin elevation is an adverse reaction entity
An additional 13 (2.5%) patients experienced moderate hepatotoxicity manifested by liver function test abnormalities (AST or ALT elevations of more than 2.5 times but not more than 5 times the upper limit of normal or total bilirubin elevation of more than 1.5 times but not more than 3 times the upper limit of normal; Grade 2).,hepatotoxicity is an adverse reaction entity
An additional 13 (2.5%) patients experienced moderate hepatotoxicity manifested by liver function test abnormalities (AST or ALT elevations of more than 2.5 times but not more than 5 times the upper limit of normal or total bilirubin elevation of more than 1.5 times but not more than 3 times the upper limit of normal; Grade 2).,ALT elevations is an adverse reaction entity
"Of the 34 patients with Grade 3-5 enterocolitis, 74% experienced complete resolution, 3% experienced improvement to Grade 2 severity, and 24% did not improve.",resolution is not a named entity
"Of the 34 patients with Grade 3-5 enterocolitis, 74% experienced complete resolution, 3% experienced improvement to Grade 2 severity, and 24% did not improve.",enterocolitis is an adverse reaction entity
"5.5   Immune-mediated Endocrinopathies      In Study 1, severe to life-threatening immune-mediated endocrinopathies (requiring hospitalization, urgent medical intervention, or interfering with activities of daily living; Grade 3-4) occurred in 9 (1.8%) YERVOY-treated patients.",immune-mediated endocrinopathies is an adverse reaction entity
"5.5   Immune-mediated Endocrinopathies      In Study 1, severe to life-threatening immune-mediated endocrinopathies (requiring hospitalization, urgent medical intervention, or interfering with activities of daily living; Grade 3-4) occurred in 9 (1.8%) YERVOY-treated patients.",9 ( 1.8 is not a named entity
"Infliximab was administered to 5 of the 62 patients (8%) with moderate, severe, or life-threatening immune-mediated enterocolitis following inadequate response to corticosteroids.",immune-mediated enterocolitis is an adverse reaction entity
"Infliximab was administered to 5 of the 62 patients (8%) with moderate, severe, or life-threatening immune-mediated enterocolitis following inadequate response to corticosteroids.",following inadequate response is not a named entity
Immune-mediated hepatitis: Evaluate liver function tests before each dose of YERVOY.,Immune-mediated hepatitis is an adverse reaction entity
Immune-mediated hepatitis: Evaluate liver function tests before each dose of YERVOY.,of YERVOY is not a named entity
"Among the 28 patients with Grade 2 enterocolitis, 79% experienced complete resolution, 11% improved, and 11% did not improve.",enterocolitis is an adverse reaction entity
"Among the 28 patients with Grade 2 enterocolitis, 79% experienced complete resolution, 11% improved, and 11% did not improve.",11 is not a named entity
"Across the clinical development program of YERVOY, myasthenia gravis and additional cases of Guillain-Barre syndrome have been reported.",myasthenia gravis is an adverse reaction entity
"Across the clinical development program of YERVOY, myasthenia gravis and additional cases of Guillain-Barre syndrome have been reported.",Guillain-Barre syndrome is an adverse reaction entity
"Across the clinical development program of YERVOY, myasthenia gravis and additional cases of Guillain-Barre syndrome have been reported.",clinical development is not a named entity
"Across the clinical development program of YERVOY, myasthenia gravis and additional cases of Guillain-Barre syndrome have been reported.","of YERVOY , is not a named entity"
"Skin and Subcutaneous Tissue Disorders:  Drug reaction with eosinophilia and systemic symptoms (DRESS syndrome)       6.3   Immunogenicity    In clinical studies, 1.1% of 1024 evaluable patients tested positive for binding antibodies against ipilimumab in an electrochemiluminescent (ECL) based assay.",with eosinophilia and is not a named entity
"Skin and Subcutaneous Tissue Disorders:  Drug reaction with eosinophilia and systemic symptoms (DRESS syndrome)       6.3   Immunogenicity    In clinical studies, 1.1% of 1024 evaluable patients tested positive for binding antibodies against ipilimumab in an electrochemiluminescent (ECL) based assay.",Drug reaction with eosinophilia and systemic symptoms is an adverse reaction entity
"Skin and Subcutaneous Tissue Disorders:  Drug reaction with eosinophilia and systemic symptoms (DRESS syndrome)       6.3   Immunogenicity    In clinical studies, 1.1% of 1024 evaluable patients tested positive for binding antibodies against ipilimumab in an electrochemiluminescent (ECL) based assay.",DRESS syndrome is an adverse reaction entity
"Skin and Subcutaneous Tissue Disorders:  Drug reaction with eosinophilia and systemic symptoms (DRESS syndrome)       6.3   Immunogenicity    In clinical studies, 1.1% of 1024 evaluable patients tested positive for binding antibodies against ipilimumab in an electrochemiluminescent (ECL) based assay.",of 1024 evaluable is not a named entity
"Of the 28 patients with moderate enterocolitis, 46% were not treated with systemic corticosteroids, 29% were treated with <40 mg prednisone or equivalent per day for a median duration of 5.1 weeks, and 25% were treated with high-dose corticosteroids for a median duration of 10 days prior to corticosteroid taper.",enterocolitis is an adverse reaction entity
"Of the 28 patients with moderate enterocolitis, 46% were not treated with systemic corticosteroids, 29% were treated with <40 mg prednisone or equivalent per day for a median duration of 5.1 weeks, and 25% were treated with high-dose corticosteroids for a median duration of 10 days prior to corticosteroid taper.",days prior is not a named entity
"The median time to onset of moderate, severe, or life-threatening immune-mediated dermatitis was 3.1 weeks and ranged up to 17.3 weeks from the initiation of YERVOY.",immune-mediated dermatitis is an adverse reaction entity
"The median time to onset of moderate, severe, or life-threatening immune-mediated dermatitis was 3.1 weeks and ranged up to 17.3 weeks from the initiation of YERVOY.",dermatitis was is not a named entity
"Other immune-mediated adverse reactions, including ocular manifestations [see  Warnings and Precautions (5.6)  ] .",immune-mediated adverse reactions is an adverse reaction entity
"Other immune-mediated adverse reactions, including ocular manifestations [see  Warnings and Precautions (5.6)  ] .",ocular manifestations is an adverse reaction entity
"Other immune-mediated adverse reactions, including ocular manifestations [see  Warnings and Precautions (5.6)  ] .",( is not a named entity
"Other immune-mediated adverse reactions, including ocular manifestations [see  Warnings and Precautions (5.6)  ] .",manifestations [ see is not a named entity
"The most common adverse reactions (>=5%) in patients who received YERVOY at 3 mg/kg were fatigue, diarrhea, pruritus, rash, and colitis.",diarrhea is an adverse reaction entity
"The most common adverse reactions (>=5%) in patients who received YERVOY at 3 mg/kg were fatigue, diarrhea, pruritus, rash, and colitis.",rash is an adverse reaction entity
"The most common adverse reactions (>=5%) in patients who received YERVOY at 3 mg/kg were fatigue, diarrhea, pruritus, rash, and colitis.",pruritus is an adverse reaction entity
"The most common adverse reactions (>=5%) in patients who received YERVOY at 3 mg/kg were fatigue, diarrhea, pruritus, rash, and colitis.",colitis is an adverse reaction entity
"The most common adverse reactions (>=5%) in patients who received YERVOY at 3 mg/kg were fatigue, diarrhea, pruritus, rash, and colitis.",mg/kg were is not a named entity
"The most common adverse reactions (>=5%) in patients who received YERVOY at 3 mg/kg were fatigue, diarrhea, pruritus, rash, and colitis.",3 mg/kg were is not a named entity
"The most common adverse reactions (>=5%) in patients who received YERVOY at 3 mg/kg were fatigue, diarrhea, pruritus, rash, and colitis.",> is not a named entity
"The most common adverse reactions (>=5%) in patients who received YERVOY at 3 mg/kg were fatigue, diarrhea, pruritus, rash, and colitis.",", pruritus , is not a named entity"
"The most common adverse reactions (>=5%) in patients who received YERVOY at 3 mg/kg were fatigue, diarrhea, pruritus, rash, and colitis.",and is not a named entity
"The most common adverse reactions (>=5%) in patients who received YERVOY at 3 mg/kg were fatigue, diarrhea, pruritus, rash, and colitis.",fatigue is an adverse reaction entity
Infusion-related or peri-infusional reactions consistent with hypersensitivity or anaphylaxis were not reported in these 11 patients nor were neutralizing antibodies against ipilimumab detected.,anaphylaxis is an adverse reaction entity
Infusion-related or peri-infusional reactions consistent with hypersensitivity or anaphylaxis were not reported in these 11 patients nor were neutralizing antibodies against ipilimumab detected.,hypersensitivity is an adverse reaction entity
Infusion-related or peri-infusional reactions consistent with hypersensitivity or anaphylaxis were not reported in these 11 patients nor were neutralizing antibodies against ipilimumab detected.,or anaphylaxis is not a named entity
Infusion-related or peri-infusional reactions consistent with hypersensitivity or anaphylaxis were not reported in these 11 patients nor were neutralizing antibodies against ipilimumab detected.,Infusion-related reactions is an adverse reaction entity
Infusion-related or peri-infusional reactions consistent with hypersensitivity or anaphylaxis were not reported in these 11 patients nor were neutralizing antibodies against ipilimumab detected.,consistent is not a named entity
Infusion-related or peri-infusional reactions consistent with hypersensitivity or anaphylaxis were not reported in these 11 patients nor were neutralizing antibodies against ipilimumab detected.,or peri-infusional is not a named entity
Infusion-related or peri-infusional reactions consistent with hypersensitivity or anaphylaxis were not reported in these 11 patients nor were neutralizing antibodies against ipilimumab detected.,in these 11 is not a named entity
Infusion-related or peri-infusional reactions consistent with hypersensitivity or anaphylaxis were not reported in these 11 patients nor were neutralizing antibodies against ipilimumab detected.,peri-infusional reactions is an adverse reaction entity
"The median time to onset was 7.4 weeks (range: 1.6-13.4) and 6.3 weeks (range: 0.3-18.9) after the initiation of YERVOY for patients with Grade 3-5 enterocolitis and with Grade 2 enterocolitis, respectively.",enterocolitis is an adverse reaction entity
"The median time to onset was 7.4 weeks (range: 1.6-13.4) and 6.3 weeks (range: 0.3-18.9) after the initiation of YERVOY for patients with Grade 3-5 enterocolitis and with Grade 2 enterocolitis, respectively.",enterocolitis is an adverse reaction entity
"The median time to onset was 7.4 weeks (range: 1.6-13.4) and 6.3 weeks (range: 0.3-18.9) after the initiation of YERVOY for patients with Grade 3-5 enterocolitis and with Grade 2 enterocolitis, respectively.",weeks ( range is not a named entity
"The median time to onset was 7.4 weeks (range: 1.6-13.4) and 6.3 weeks (range: 0.3-18.9) after the initiation of YERVOY for patients with Grade 3-5 enterocolitis and with Grade 2 enterocolitis, respectively.",onset was is not a named entity
"EXCERPT:   Most common adverse reactions (>=5%) are fatigue, diarrhea, pruritus, rash, and colitis.",colitis is an adverse reaction entity
"EXCERPT:   Most common adverse reactions (>=5%) are fatigue, diarrhea, pruritus, rash, and colitis.",diarrhea is an adverse reaction entity
"EXCERPT:   Most common adverse reactions (>=5%) are fatigue, diarrhea, pruritus, rash, and colitis.",) are fatigue is not a named entity
"EXCERPT:   Most common adverse reactions (>=5%) are fatigue, diarrhea, pruritus, rash, and colitis.",", is not a named entity"
"EXCERPT:   Most common adverse reactions (>=5%) are fatigue, diarrhea, pruritus, rash, and colitis.",pruritus is an adverse reaction entity
"EXCERPT:   Most common adverse reactions (>=5%) are fatigue, diarrhea, pruritus, rash, and colitis.",fatigue is an adverse reaction entity
"EXCERPT:   Most common adverse reactions (>=5%) are fatigue, diarrhea, pruritus, rash, and colitis.",> is not a named entity
"EXCERPT:   Most common adverse reactions (>=5%) are fatigue, diarrhea, pruritus, rash, and colitis.",rash is an adverse reaction entity
"EXCERPT:   Most common adverse reactions (>=5%) are fatigue, diarrhea, pruritus, rash, and colitis.","diarrhea , is not a named entity"
"EXCERPT:   Most common adverse reactions (>=5%) are fatigue, diarrhea, pruritus, rash, and colitis.",) are fatigue is not a named entity
"5.2   Immune-mediated Hepatitis      In Study 1, severe, life-threatening, or fatal hepatotoxicity (AST or ALT elevations of more than 5 times the upper limit of normal or total bilirubin elevations more than 3 times the upper limit of normal; Grade 3-5) occurred in 8 (2%) YERVOY-treated patients, with fatal hepatic failure in 0.2% and hospitalization in 0.4% of YERVOY-treated patients.",failure in 0.2 is not a named entity
"5.2   Immune-mediated Hepatitis      In Study 1, severe, life-threatening, or fatal hepatotoxicity (AST or ALT elevations of more than 5 times the upper limit of normal or total bilirubin elevations more than 3 times the upper limit of normal; Grade 3-5) occurred in 8 (2%) YERVOY-treated patients, with fatal hepatic failure in 0.2% and hospitalization in 0.4% of YERVOY-treated patients.",AST elevations is an adverse reaction entity
"5.2   Immune-mediated Hepatitis      In Study 1, severe, life-threatening, or fatal hepatotoxicity (AST or ALT elevations of more than 5 times the upper limit of normal or total bilirubin elevations more than 3 times the upper limit of normal; Grade 3-5) occurred in 8 (2%) YERVOY-treated patients, with fatal hepatic failure in 0.2% and hospitalization in 0.4% of YERVOY-treated patients.",fatal is an adverse reaction entity
"5.2   Immune-mediated Hepatitis      In Study 1, severe, life-threatening, or fatal hepatotoxicity (AST or ALT elevations of more than 5 times the upper limit of normal or total bilirubin elevations more than 3 times the upper limit of normal; Grade 3-5) occurred in 8 (2%) YERVOY-treated patients, with fatal hepatic failure in 0.2% and hospitalization in 0.4% of YERVOY-treated patients.",of more is not a named entity
"5.2   Immune-mediated Hepatitis      In Study 1, severe, life-threatening, or fatal hepatotoxicity (AST or ALT elevations of more than 5 times the upper limit of normal or total bilirubin elevations more than 3 times the upper limit of normal; Grade 3-5) occurred in 8 (2%) YERVOY-treated patients, with fatal hepatic failure in 0.2% and hospitalization in 0.4% of YERVOY-treated patients.",ALT elevations is an adverse reaction entity
"5.2   Immune-mediated Hepatitis      In Study 1, severe, life-threatening, or fatal hepatotoxicity (AST or ALT elevations of more than 5 times the upper limit of normal or total bilirubin elevations more than 3 times the upper limit of normal; Grade 3-5) occurred in 8 (2%) YERVOY-treated patients, with fatal hepatic failure in 0.2% and hospitalization in 0.4% of YERVOY-treated patients.",limit is not a named entity
"5.2   Immune-mediated Hepatitis      In Study 1, severe, life-threatening, or fatal hepatotoxicity (AST or ALT elevations of more than 5 times the upper limit of normal or total bilirubin elevations more than 3 times the upper limit of normal; Grade 3-5) occurred in 8 (2%) YERVOY-treated patients, with fatal hepatic failure in 0.2% and hospitalization in 0.4% of YERVOY-treated patients.",hepatotoxicity is an adverse reaction entity
"5.2   Immune-mediated Hepatitis      In Study 1, severe, life-threatening, or fatal hepatotoxicity (AST or ALT elevations of more than 5 times the upper limit of normal or total bilirubin elevations more than 3 times the upper limit of normal; Grade 3-5) occurred in 8 (2%) YERVOY-treated patients, with fatal hepatic failure in 0.2% and hospitalization in 0.4% of YERVOY-treated patients.",% is not a named entity
"5.2   Immune-mediated Hepatitis      In Study 1, severe, life-threatening, or fatal hepatotoxicity (AST or ALT elevations of more than 5 times the upper limit of normal or total bilirubin elevations more than 3 times the upper limit of normal; Grade 3-5) occurred in 8 (2%) YERVOY-treated patients, with fatal hepatic failure in 0.2% and hospitalization in 0.4% of YERVOY-treated patients.",in 8 ( is not a named entity
"5.2   Immune-mediated Hepatitis      In Study 1, severe, life-threatening, or fatal hepatotoxicity (AST or ALT elevations of more than 5 times the upper limit of normal or total bilirubin elevations more than 3 times the upper limit of normal; Grade 3-5) occurred in 8 (2%) YERVOY-treated patients, with fatal hepatic failure in 0.2% and hospitalization in 0.4% of YERVOY-treated patients.",total bilirubin elevations is an adverse reaction entity
"5.2   Immune-mediated Hepatitis      In Study 1, severe, life-threatening, or fatal hepatotoxicity (AST or ALT elevations of more than 5 times the upper limit of normal or total bilirubin elevations more than 3 times the upper limit of normal; Grade 3-5) occurred in 8 (2%) YERVOY-treated patients, with fatal hepatic failure in 0.2% and hospitalization in 0.4% of YERVOY-treated patients.",hepatic failure is an adverse reaction entity
"5.2   Immune-mediated Hepatitis      In Study 1, severe, life-threatening, or fatal hepatotoxicity (AST or ALT elevations of more than 5 times the upper limit of normal or total bilirubin elevations more than 3 times the upper limit of normal; Grade 3-5) occurred in 8 (2%) YERVOY-treated patients, with fatal hepatic failure in 0.2% and hospitalization in 0.4% of YERVOY-treated patients.",fatal is an adverse reaction entity
"5.2   Immune-mediated Hepatitis      In Study 1, severe, life-threatening, or fatal hepatotoxicity (AST or ALT elevations of more than 5 times the upper limit of normal or total bilirubin elevations more than 3 times the upper limit of normal; Grade 3-5) occurred in 8 (2%) YERVOY-treated patients, with fatal hepatic failure in 0.2% and hospitalization in 0.4% of YERVOY-treated patients.",or is not a named entity
"5.2   Immune-mediated Hepatitis      In Study 1, severe, life-threatening, or fatal hepatotoxicity (AST or ALT elevations of more than 5 times the upper limit of normal or total bilirubin elevations more than 3 times the upper limit of normal; Grade 3-5) occurred in 8 (2%) YERVOY-treated patients, with fatal hepatic failure in 0.2% and hospitalization in 0.4% of YERVOY-treated patients.",more than is not a named entity
In these trials 6% of patients on POTIGA and 1.2% on placebo discontinued treatment because of dizziness; 3% of patients on POTIGA and <1.0% on placebo discontinued because of somnolence.,patients on is not a named entity
In these trials 6% of patients on POTIGA and 1.2% on placebo discontinued treatment because of dizziness; 3% of patients on POTIGA and <1.0% on placebo discontinued because of somnolence.,dizziness ; is not a named entity
In these trials 6% of patients on POTIGA and 1.2% on placebo discontinued treatment because of dizziness; 3% of patients on POTIGA and <1.0% on placebo discontinued because of somnolence.,somnolence is an adverse reaction entity
In these trials 6% of patients on POTIGA and 1.2% on placebo discontinued treatment because of dizziness; 3% of patients on POTIGA and <1.0% on placebo discontinued because of somnolence.,dizziness is an adverse reaction entity
"In placebo-controlled trials in patients with epilepsy, dizziness was reported in 23% of patients treated with POTIGA and 9% of patients treated with placebo.",", dizziness was is not a named entity"
"In placebo-controlled trials in patients with epilepsy, dizziness was reported in 23% of patients treated with POTIGA and 9% of patients treated with placebo.",dizziness is an adverse reaction entity
"In the placebo-controlled epilepsy trials, ""urinary retention,"" ""urinary hesitation,"" and ""dysuria"" were reported in 0.9%, 2.2%, and 2.3% of patients on POTIGA, respectively, and in 0.5%, 0.9%, and 0.7% of patients on placebo, respectively.",respectively is not a named entity
"In the placebo-controlled epilepsy trials, ""urinary retention,"" ""urinary hesitation,"" and ""dysuria"" were reported in 0.9%, 2.2%, and 2.3% of patients on POTIGA, respectively, and in 0.5%, 0.9%, and 0.7% of patients on placebo, respectively.",urinary retention is an adverse reaction entity
"In the placebo-controlled epilepsy trials, ""urinary retention,"" ""urinary hesitation,"" and ""dysuria"" were reported in 0.9%, 2.2%, and 2.3% of patients on POTIGA, respectively, and in 0.5%, 0.9%, and 0.7% of patients on placebo, respectively.",`` is not a named entity
"In the placebo-controlled epilepsy trials, ""urinary retention,"" ""urinary hesitation,"" and ""dysuria"" were reported in 0.9%, 2.2%, and 2.3% of patients on POTIGA, respectively, and in 0.5%, 0.9%, and 0.7% of patients on placebo, respectively.",urinary hesitation is an adverse reaction entity
"In the placebo-controlled epilepsy trials, ""urinary retention,"" ""urinary hesitation,"" and ""dysuria"" were reported in 0.9%, 2.2%, and 2.3% of patients on POTIGA, respectively, and in 0.5%, 0.9%, and 0.7% of patients on placebo, respectively.",dysuria is an adverse reaction entity
"In the placebo-controlled epilepsy trials, ""urinary retention,"" ""urinary hesitation,"" and ""dysuria"" were reported in 0.9%, 2.2%, and 2.3% of patients on POTIGA, respectively, and in 0.5%, 0.9%, and 0.7% of patients on placebo, respectively.",were reported in is not a named entity
The rate of progression of retinal abnormalities and their reversibility are unknown.,retinal abnormalities is an adverse reaction entity
The rate of progression of retinal abnormalities and their reversibility are unknown.,retinal abnormalities and is not a named entity
The abnormalities seen in patients treated with POTIGA have funduscopic features similar to those seen in retinal pigment dystrophies that are known to result in damage to photoreceptors and vision loss.,The abnormalities seen is not a named entity
The abnormalities seen in patients treated with POTIGA have funduscopic features similar to those seen in retinal pigment dystrophies that are known to result in damage to photoreceptors and vision loss.,funduscopic features similar to retinal pigment dystrophies is an adverse reaction entity
The abnormalities seen in patients treated with POTIGA have funduscopic features similar to those seen in retinal pigment dystrophies that are known to result in damage to photoreceptors and vision loss.,damage to photoreceptors is an adverse reaction entity
The abnormalities seen in patients treated with POTIGA have funduscopic features similar to those seen in retinal pigment dystrophies that are known to result in damage to photoreceptors and vision loss.,that is not a named entity
The abnormalities seen in patients treated with POTIGA have funduscopic features similar to those seen in retinal pigment dystrophies that are known to result in damage to photoreceptors and vision loss.,vision loss is an adverse reaction entity
The abnormalities seen in patients treated with POTIGA have funduscopic features similar to those seen in retinal pigment dystrophies that are known to result in damage to photoreceptors and vision loss.,The abnormalities seen is not a named entity
Funduscopic abnormalities have most commonly been described as perivascular pigmentation (bone spicule pattern) in the retinal periphery and/or as areas of focal retinal pigment epithelium clumping.,perivascular pigmentation bone spicule pattern in the retinal periphery is an adverse reaction entity
Funduscopic abnormalities have most commonly been described as perivascular pigmentation (bone spicule pattern) in the retinal periphery and/or as areas of focal retinal pigment epithelium clumping.,perivascular pigmentation in the retinal periphery is an adverse reaction entity
Funduscopic abnormalities have most commonly been described as perivascular pigmentation (bone spicule pattern) in the retinal periphery and/or as areas of focal retinal pigment epithelium clumping.,focal retinal pigment epithelium clumping is an adverse reaction entity
Funduscopic abnormalities have most commonly been described as perivascular pigmentation (bone spicule pattern) in the retinal periphery and/or as areas of focal retinal pigment epithelium clumping.,pigmentation is not a named entity
Funduscopic abnormalities have most commonly been described as perivascular pigmentation (bone spicule pattern) in the retinal periphery and/or as areas of focal retinal pigment epithelium clumping.,( bone is not a named entity
Funduscopic abnormalities have most commonly been described as perivascular pigmentation (bone spicule pattern) in the retinal periphery and/or as areas of focal retinal pigment epithelium clumping.,as is not a named entity
Funduscopic abnormalities have most commonly been described as perivascular pigmentation (bone spicule pattern) in the retinal periphery and/or as areas of focal retinal pigment epithelium clumping.,in the retinal is not a named entity
Funduscopic abnormalities have most commonly been described as perivascular pigmentation (bone spicule pattern) in the retinal periphery and/or as areas of focal retinal pigment epithelium clumping.,Funduscopic abnormalities is an adverse reaction entity
The retinal abnormalities observed with POTIGA have been reported in patients who were originally enrolled in clinical trials with POTIGA and who have generally taken the drug for a long period of time in 2 ongoing extension trials.,who were originally is not a named entity
The retinal abnormalities observed with POTIGA have been reported in patients who were originally enrolled in clinical trials with POTIGA and who have generally taken the drug for a long period of time in 2 ongoing extension trials.,retinal abnormalities is an adverse reaction entity
"Most of the adverse reactions appear to be dose related (especially those classified as psychiatric and nervous system symptoms), including dizziness, somnolence, confusional state, tremor, abnormal coordination, memory impairment, blurred vision, gait disturbance, aphasia, balance disorder, constipation, dysuria, and chromaturia.",as is not a named entity
"Most of the adverse reactions appear to be dose related (especially those classified as psychiatric and nervous system symptoms), including dizziness, somnolence, confusional state, tremor, abnormal coordination, memory impairment, blurred vision, gait disturbance, aphasia, balance disorder, constipation, dysuria, and chromaturia.",abnormal coordination is an adverse reaction entity
"Most of the adverse reactions appear to be dose related (especially those classified as psychiatric and nervous system symptoms), including dizziness, somnolence, confusional state, tremor, abnormal coordination, memory impairment, blurred vision, gait disturbance, aphasia, balance disorder, constipation, dysuria, and chromaturia.","dizziness , somnolence is not a named entity"
"Most of the adverse reactions appear to be dose related (especially those classified as psychiatric and nervous system symptoms), including dizziness, somnolence, confusional state, tremor, abnormal coordination, memory impairment, blurred vision, gait disturbance, aphasia, balance disorder, constipation, dysuria, and chromaturia.",", dysuria is not a named entity"
"Most of the adverse reactions appear to be dose related (especially those classified as psychiatric and nervous system symptoms), including dizziness, somnolence, confusional state, tremor, abnormal coordination, memory impairment, blurred vision, gait disturbance, aphasia, balance disorder, constipation, dysuria, and chromaturia.",dizziness is an adverse reaction entity
"Most of the adverse reactions appear to be dose related (especially those classified as psychiatric and nervous system symptoms), including dizziness, somnolence, confusional state, tremor, abnormal coordination, memory impairment, blurred vision, gait disturbance, aphasia, balance disorder, constipation, dysuria, and chromaturia.","balance disorder , is not a named entity"
"Most of the adverse reactions appear to be dose related (especially those classified as psychiatric and nervous system symptoms), including dizziness, somnolence, confusional state, tremor, abnormal coordination, memory impairment, blurred vision, gait disturbance, aphasia, balance disorder, constipation, dysuria, and chromaturia.",blurred vision is an adverse reaction entity
"Most of the adverse reactions appear to be dose related (especially those classified as psychiatric and nervous system symptoms), including dizziness, somnolence, confusional state, tremor, abnormal coordination, memory impairment, blurred vision, gait disturbance, aphasia, balance disorder, constipation, dysuria, and chromaturia.",reactions appear to is not a named entity
"Most of the adverse reactions appear to be dose related (especially those classified as psychiatric and nervous system symptoms), including dizziness, somnolence, confusional state, tremor, abnormal coordination, memory impairment, blurred vision, gait disturbance, aphasia, balance disorder, constipation, dysuria, and chromaturia.",aphasia is an adverse reaction entity
"Most of the adverse reactions appear to be dose related (especially those classified as psychiatric and nervous system symptoms), including dizziness, somnolence, confusional state, tremor, abnormal coordination, memory impairment, blurred vision, gait disturbance, aphasia, balance disorder, constipation, dysuria, and chromaturia.",confusional state is an adverse reaction entity
"Most of the adverse reactions appear to be dose related (especially those classified as psychiatric and nervous system symptoms), including dizziness, somnolence, confusional state, tremor, abnormal coordination, memory impairment, blurred vision, gait disturbance, aphasia, balance disorder, constipation, dysuria, and chromaturia.",dysuria is an adverse reaction entity
"Most of the adverse reactions appear to be dose related (especially those classified as psychiatric and nervous system symptoms), including dizziness, somnolence, confusional state, tremor, abnormal coordination, memory impairment, blurred vision, gait disturbance, aphasia, balance disorder, constipation, dysuria, and chromaturia.",reactions appear is not a named entity
"Most of the adverse reactions appear to be dose related (especially those classified as psychiatric and nervous system symptoms), including dizziness, somnolence, confusional state, tremor, abnormal coordination, memory impairment, blurred vision, gait disturbance, aphasia, balance disorder, constipation, dysuria, and chromaturia.",constipation is an adverse reaction entity
"Most of the adverse reactions appear to be dose related (especially those classified as psychiatric and nervous system symptoms), including dizziness, somnolence, confusional state, tremor, abnormal coordination, memory impairment, blurred vision, gait disturbance, aphasia, balance disorder, constipation, dysuria, and chromaturia.",balance disorder is an adverse reaction entity
"Most of the adverse reactions appear to be dose related (especially those classified as psychiatric and nervous system symptoms), including dizziness, somnolence, confusional state, tremor, abnormal coordination, memory impairment, blurred vision, gait disturbance, aphasia, balance disorder, constipation, dysuria, and chromaturia.",including dizziness is not a named entity
"Most of the adverse reactions appear to be dose related (especially those classified as psychiatric and nervous system symptoms), including dizziness, somnolence, confusional state, tremor, abnormal coordination, memory impairment, blurred vision, gait disturbance, aphasia, balance disorder, constipation, dysuria, and chromaturia.","somnolence , confusional is not a named entity"
"Most of the adverse reactions appear to be dose related (especially those classified as psychiatric and nervous system symptoms), including dizziness, somnolence, confusional state, tremor, abnormal coordination, memory impairment, blurred vision, gait disturbance, aphasia, balance disorder, constipation, dysuria, and chromaturia.",classified as psychiatric is not a named entity
"Most of the adverse reactions appear to be dose related (especially those classified as psychiatric and nervous system symptoms), including dizziness, somnolence, confusional state, tremor, abnormal coordination, memory impairment, blurred vision, gait disturbance, aphasia, balance disorder, constipation, dysuria, and chromaturia.",somnolence is an adverse reaction entity
"Most of the adverse reactions appear to be dose related (especially those classified as psychiatric and nervous system symptoms), including dizziness, somnolence, confusional state, tremor, abnormal coordination, memory impairment, blurred vision, gait disturbance, aphasia, balance disorder, constipation, dysuria, and chromaturia.",nervous is not a named entity
"Most of the adverse reactions appear to be dose related (especially those classified as psychiatric and nervous system symptoms), including dizziness, somnolence, confusional state, tremor, abnormal coordination, memory impairment, blurred vision, gait disturbance, aphasia, balance disorder, constipation, dysuria, and chromaturia.","vision , is not a named entity"
"Most of the adverse reactions appear to be dose related (especially those classified as psychiatric and nervous system symptoms), including dizziness, somnolence, confusional state, tremor, abnormal coordination, memory impairment, blurred vision, gait disturbance, aphasia, balance disorder, constipation, dysuria, and chromaturia.",related ( especially is not a named entity
"Most of the adverse reactions appear to be dose related (especially those classified as psychiatric and nervous system symptoms), including dizziness, somnolence, confusional state, tremor, abnormal coordination, memory impairment, blurred vision, gait disturbance, aphasia, balance disorder, constipation, dysuria, and chromaturia.",tremor is an adverse reaction entity
"Most of the adverse reactions appear to be dose related (especially those classified as psychiatric and nervous system symptoms), including dizziness, somnolence, confusional state, tremor, abnormal coordination, memory impairment, blurred vision, gait disturbance, aphasia, balance disorder, constipation, dysuria, and chromaturia.",gait disturbance is an adverse reaction entity
"Most of the adverse reactions appear to be dose related (especially those classified as psychiatric and nervous system symptoms), including dizziness, somnolence, confusional state, tremor, abnormal coordination, memory impairment, blurred vision, gait disturbance, aphasia, balance disorder, constipation, dysuria, and chromaturia.",chromaturia is an adverse reaction entity
"Most of the adverse reactions appear to be dose related (especially those classified as psychiatric and nervous system symptoms), including dizziness, somnolence, confusional state, tremor, abnormal coordination, memory impairment, blurred vision, gait disturbance, aphasia, balance disorder, constipation, dysuria, and chromaturia.",") , including is not a named entity"
"Most of the adverse reactions appear to be dose related (especially those classified as psychiatric and nervous system symptoms), including dizziness, somnolence, confusional state, tremor, abnormal coordination, memory impairment, blurred vision, gait disturbance, aphasia, balance disorder, constipation, dysuria, and chromaturia.",memory impairment is an adverse reaction entity
"In these trials, which had a median treatment duration of 12 weeks, the estimated incidence of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43% compared with 0.24% among 16,029 placebo-treated patients, representing an increase of approximately 1 case of suicidal thinking or behavior for every 530 patients treated.",1 case is not a named entity
"In these trials, which had a median treatment duration of 12 weeks, the estimated incidence of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43% compared with 0.24% among 16,029 placebo-treated patients, representing an increase of approximately 1 case of suicidal thinking or behavior for every 530 patients treated.",suicidal behavior is an adverse reaction entity
"In these trials, which had a median treatment duration of 12 weeks, the estimated incidence of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43% compared with 0.24% among 16,029 placebo-treated patients, representing an increase of approximately 1 case of suicidal thinking or behavior for every 530 patients treated.","16,029 placebo-treated patients is not a named entity"
"In these trials, which had a median treatment duration of 12 weeks, the estimated incidence of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43% compared with 0.24% among 16,029 placebo-treated patients, representing an increase of approximately 1 case of suicidal thinking or behavior for every 530 patients treated.",duration of 12 is not a named entity
"In these trials, which had a median treatment duration of 12 weeks, the estimated incidence of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43% compared with 0.24% among 16,029 placebo-treated patients, representing an increase of approximately 1 case of suicidal thinking or behavior for every 530 patients treated.",suicidal thinking is an adverse reaction entity
"In these trials, which had a median treatment duration of 12 weeks, the estimated incidence of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43% compared with 0.24% among 16,029 placebo-treated patients, representing an increase of approximately 1 case of suicidal thinking or behavior for every 530 patients treated.",suicidal ideation is an adverse reaction entity
"In these trials, which had a median treatment duration of 12 weeks, the estimated incidence of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43% compared with 0.24% among 16,029 placebo-treated patients, representing an increase of approximately 1 case of suicidal thinking or behavior for every 530 patients treated.",which is not a named entity
"In these trials, which had a median treatment duration of 12 weeks, the estimated incidence of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43% compared with 0.24% among 16,029 placebo-treated patients, representing an increase of approximately 1 case of suicidal thinking or behavior for every 530 patients treated.",suicidal behavior is an adverse reaction entity
Some patients with retinal abnormalities have been found to have abnormal visual acuity.,abnormalities have been is not a named entity
Some patients with retinal abnormalities have been found to have abnormal visual acuity.,retinal abnormalities is an adverse reaction entity
Some patients with retinal abnormalities have been found to have abnormal visual acuity.,abnormal visual acuity is an adverse reaction entity
Some patients with retinal abnormalities have been found to have abnormal visual acuity.,patients with retinal is not a named entity
(  5.5  )   *    QT prolongation: QT interval should be monitored in patients taking concomitant medications known to increase the QT interval or with certain heart conditions.,the is not a named entity
(  5.5  )   *    QT prolongation: QT interval should be monitored in patients taking concomitant medications known to increase the QT interval or with certain heart conditions.,QT prolongation is an adverse reaction entity
"The results of these evaluations were consistent with a retinal dystrophy, including abnormalities in the electroretinogram and electrooculogram of both patients, with abnormal fluorescein angiography and diminished sensitivity on visual field testing in one patient.",angiography and is not a named entity
"The results of these evaluations were consistent with a retinal dystrophy, including abnormalities in the electroretinogram and electrooculogram of both patients, with abnormal fluorescein angiography and diminished sensitivity on visual field testing in one patient.",evaluations is not a named entity
"The results of these evaluations were consistent with a retinal dystrophy, including abnormalities in the electroretinogram and electrooculogram of both patients, with abnormal fluorescein angiography and diminished sensitivity on visual field testing in one patient.",abnormalities in electrooculogram is an adverse reaction entity
"The results of these evaluations were consistent with a retinal dystrophy, including abnormalities in the electroretinogram and electrooculogram of both patients, with abnormal fluorescein angiography and diminished sensitivity on visual field testing in one patient.",abnormalities in the electroretinogram is an adverse reaction entity
"The results of these evaluations were consistent with a retinal dystrophy, including abnormalities in the electroretinogram and electrooculogram of both patients, with abnormal fluorescein angiography and diminished sensitivity on visual field testing in one patient.",retinal dystrophy is an adverse reaction entity
"The results of these evaluations were consistent with a retinal dystrophy, including abnormalities in the electroretinogram and electrooculogram of both patients, with abnormal fluorescein angiography and diminished sensitivity on visual field testing in one patient.",in is not a named entity
"The results of these evaluations were consistent with a retinal dystrophy, including abnormalities in the electroretinogram and electrooculogram of both patients, with abnormal fluorescein angiography and diminished sensitivity on visual field testing in one patient.",diminished sensitivity on visual field is an adverse reaction entity
"The results of these evaluations were consistent with a retinal dystrophy, including abnormalities in the electroretinogram and electrooculogram of both patients, with abnormal fluorescein angiography and diminished sensitivity on visual field testing in one patient.",abnormal fluorescein angiography is an adverse reaction entity
"The results of these evaluations were consistent with a retinal dystrophy, including abnormalities in the electroretinogram and electrooculogram of both patients, with abnormal fluorescein angiography and diminished sensitivity on visual field testing in one patient.",electroretinogram and is not a named entity
"The results of these evaluations were consistent with a retinal dystrophy, including abnormalities in the electroretinogram and electrooculogram of both patients, with abnormal fluorescein angiography and diminished sensitivity on visual field testing in one patient.",and diminished is not a named entity
The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed.,generally consistent is not a named entity
The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed.,suicidal behavior is an adverse reaction entity
The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed.,in the data is not a named entity
The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed.,suicidal thoughts is an adverse reaction entity
"The most common adverse reactions leading to withdrawal in patients receiving POTIGA were dizziness (6%), confusional state (4%), fatigue (3%), and somnolence (3%).",to is not a named entity
"The most common adverse reactions leading to withdrawal in patients receiving POTIGA were dizziness (6%), confusional state (4%), fatigue (3%), and somnolence (3%).",6 % is not a named entity
"The most common adverse reactions leading to withdrawal in patients receiving POTIGA were dizziness (6%), confusional state (4%), fatigue (3%), and somnolence (3%).",receiving POTIGA were is not a named entity
"The most common adverse reactions leading to withdrawal in patients receiving POTIGA were dizziness (6%), confusional state (4%), fatigue (3%), and somnolence (3%).",somnolence is an adverse reaction entity
"The most common adverse reactions leading to withdrawal in patients receiving POTIGA were dizziness (6%), confusional state (4%), fatigue (3%), and somnolence (3%).",fatigue is an adverse reaction entity
"The most common adverse reactions leading to withdrawal in patients receiving POTIGA were dizziness (6%), confusional state (4%), fatigue (3%), and somnolence (3%).",dizziness is an adverse reaction entity
"The most common adverse reactions leading to withdrawal in patients receiving POTIGA were dizziness (6%), confusional state (4%), fatigue (3%), and somnolence (3%).",% ) is not a named entity
"The most common adverse reactions leading to withdrawal in patients receiving POTIGA were dizziness (6%), confusional state (4%), fatigue (3%), and somnolence (3%).",confusional state is an adverse reaction entity
"Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive-therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted relative risk 1.8, 95% confidence interval [CI]: 1.2, 2.7) of suicidal thinking or behavior compared with patients randomized to placebo.",suicidal thinking is an adverse reaction entity
"Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive-therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted relative risk 1.8, 95% confidence interval [CI]: 1.2, 2.7) of suicidal thinking or behavior compared with patients randomized to placebo.",suicidal behavior is an adverse reaction entity
"Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive-therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted relative risk 1.8, 95% confidence interval [CI]: 1.2, 2.7) of suicidal thinking or behavior compared with patients randomized to placebo.",AEDs is not a named entity
"Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive-therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted relative risk 1.8, 95% confidence interval [CI]: 1.2, 2.7) of suicidal thinking or behavior compared with patients randomized to placebo.",adjusted is not a named entity
The rate of progression of retinal abnormalities and the reversibility after drug discontinuation are unknown.,progression is not a named entity
The rate of progression of retinal abnormalities and the reversibility after drug discontinuation are unknown.,retinal abnormalities is an adverse reaction entity
"It is not possible to determine whether POTIGA caused this decreased visual acuity, as baseline assessments are not available for these patients.",decreased visual acuity is an adverse reaction entity
"It is not possible to determine whether POTIGA caused this decreased visual acuity, as baseline assessments are not available for these patients.",assessments is not a named entity
"Urinary retention was reported as an adverse event in 29 of 1,365 (approximately 2%) patients treated with POTIGA in the open-label and placebo-controlled epilepsy database [see Clinical Studies (14)]  .",Urinary retention is an adverse reaction entity
"Urinary retention was reported as an adverse event in 29 of 1,365 (approximately 2%) patients treated with POTIGA in the open-label and placebo-controlled epilepsy database [see Clinical Studies (14)]  .",( approximately 2 is not a named entity
Half of the patients in the controlled trials who discontinued POTIGA due to hallucinations or psychosis required hospitalization.,psychosis is an adverse reaction entity
Half of the patients in the controlled trials who discontinued POTIGA due to hallucinations or psychosis required hospitalization.,hallucinations is an adverse reaction entity
Half of the patients in the controlled trials who discontinued POTIGA due to hallucinations or psychosis required hospitalization.,to hallucinations or is not a named entity
Half of the patients in the controlled trials who discontinued POTIGA due to hallucinations or psychosis required hospitalization.,hallucinations or psychosis is not a named entity
(  5.7  )             5.1 Retinal Abnormalities and Potential Vision Loss      POTIGA can cause abnormalities of the retina.,Retinal is not a named entity
(  5.7  )             5.1 Retinal Abnormalities and Potential Vision Loss      POTIGA can cause abnormalities of the retina.,abnormalities of the retina is an adverse reaction entity
"5.7 Suicidal Behavior and Ideation      Antiepileptic drugs (AEDs), including POTIGA, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication.",5.7 Suicidal is not a named entity
"5.7 Suicidal Behavior and Ideation      Antiepileptic drugs (AEDs), including POTIGA, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication.",suicidal behavior is an adverse reaction entity
"5.7 Suicidal Behavior and Ideation      Antiepileptic drugs (AEDs), including POTIGA, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication.",thoughts or behavior is not a named entity
"5.7 Suicidal Behavior and Ideation      Antiepileptic drugs (AEDs), including POTIGA, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication.",suicidal thoughts is an adverse reaction entity
"An earlier onset cannot be ruled out, and it is possible that retinal abnormalities were present earlier in the course of exposure to POTIGA.","out , is not a named entity"
"An earlier onset cannot be ruled out, and it is possible that retinal abnormalities were present earlier in the course of exposure to POTIGA.",retinal abnormalities is an adverse reaction entity
"Major Neuropsychiatric Symptoms in Placebo-Controlled Epilepsy Trials         Adverse Reaction      Number (%) with Adverse Reaction    Number (%) Discontinuing       POTIGA  (n = 813)     Placebo  (n = 427)    POTIGA  (n = 813)    Placebo  (n = 427)       Confusional state     75 (9%)              11 (3%)              32 (4%)          4 (<1%)            Psychosis             9 (1%)               0                    6 (<1%)          0                  Hallucinationsa       14 (2%)              2 (<1%)              6 (<1%)          0                             a  Hallucinations includes visual, auditory, and mixed hallucinations.",Confusional state is an adverse reaction entity
"Major Neuropsychiatric Symptoms in Placebo-Controlled Epilepsy Trials         Adverse Reaction      Number (%) with Adverse Reaction    Number (%) Discontinuing       POTIGA  (n = 813)     Placebo  (n = 427)    POTIGA  (n = 813)    Placebo  (n = 427)       Confusional state     75 (9%)              11 (3%)              32 (4%)          4 (<1%)            Psychosis             9 (1%)               0                    6 (<1%)          0                  Hallucinationsa       14 (2%)              2 (<1%)              6 (<1%)          0                             a  Hallucinations includes visual, auditory, and mixed hallucinations.",% ) is not a named entity
"Major Neuropsychiatric Symptoms in Placebo-Controlled Epilepsy Trials         Adverse Reaction      Number (%) with Adverse Reaction    Number (%) Discontinuing       POTIGA  (n = 813)     Placebo  (n = 427)    POTIGA  (n = 813)    Placebo  (n = 427)       Confusional state     75 (9%)              11 (3%)              32 (4%)          4 (<1%)            Psychosis             9 (1%)               0                    6 (<1%)          0                  Hallucinationsa       14 (2%)              2 (<1%)              6 (<1%)          0                             a  Hallucinations includes visual, auditory, and mixed hallucinations.",( is not a named entity
"Major Neuropsychiatric Symptoms in Placebo-Controlled Epilepsy Trials         Adverse Reaction      Number (%) with Adverse Reaction    Number (%) Discontinuing       POTIGA  (n = 813)     Placebo  (n = 427)    POTIGA  (n = 813)    Placebo  (n = 427)       Confusional state     75 (9%)              11 (3%)              32 (4%)          4 (<1%)            Psychosis             9 (1%)               0                    6 (<1%)          0                  Hallucinationsa       14 (2%)              2 (<1%)              6 (<1%)          0                             a  Hallucinations includes visual, auditory, and mixed hallucinations.",visual hallucinations is an adverse reaction entity
"Major Neuropsychiatric Symptoms in Placebo-Controlled Epilepsy Trials         Adverse Reaction      Number (%) with Adverse Reaction    Number (%) Discontinuing       POTIGA  (n = 813)     Placebo  (n = 427)    POTIGA  (n = 813)    Placebo  (n = 427)       Confusional state     75 (9%)              11 (3%)              32 (4%)          4 (<1%)            Psychosis             9 (1%)               0                    6 (<1%)          0                  Hallucinationsa       14 (2%)              2 (<1%)              6 (<1%)          0                             a  Hallucinations includes visual, auditory, and mixed hallucinations.",Psychosis is an adverse reaction entity
"Major Neuropsychiatric Symptoms in Placebo-Controlled Epilepsy Trials         Adverse Reaction      Number (%) with Adverse Reaction    Number (%) Discontinuing       POTIGA  (n = 813)     Placebo  (n = 427)    POTIGA  (n = 813)    Placebo  (n = 427)       Confusional state     75 (9%)              11 (3%)              32 (4%)          4 (<1%)            Psychosis             9 (1%)               0                    6 (<1%)          0                  Hallucinationsa       14 (2%)              2 (<1%)              6 (<1%)          0                             a  Hallucinations includes visual, auditory, and mixed hallucinations.",mixed hallucinations is an adverse reaction entity
"Major Neuropsychiatric Symptoms in Placebo-Controlled Epilepsy Trials         Adverse Reaction      Number (%) with Adverse Reaction    Number (%) Discontinuing       POTIGA  (n = 813)     Placebo  (n = 427)    POTIGA  (n = 813)    Placebo  (n = 427)       Confusional state     75 (9%)              11 (3%)              32 (4%)          4 (<1%)            Psychosis             9 (1%)               0                    6 (<1%)          0                  Hallucinationsa       14 (2%)              2 (<1%)              6 (<1%)          0                             a  Hallucinations includes visual, auditory, and mixed hallucinations.",Hallucinations is an adverse reaction entity
"Major Neuropsychiatric Symptoms in Placebo-Controlled Epilepsy Trials         Adverse Reaction      Number (%) with Adverse Reaction    Number (%) Discontinuing       POTIGA  (n = 813)     Placebo  (n = 427)    POTIGA  (n = 813)    Placebo  (n = 427)       Confusional state     75 (9%)              11 (3%)              32 (4%)          4 (<1%)            Psychosis             9 (1%)               0                    6 (<1%)          0                  Hallucinationsa       14 (2%)              2 (<1%)              6 (<1%)          0                             a  Hallucinations includes visual, auditory, and mixed hallucinations.",auditory hallucinations is an adverse reaction entity
"Major Neuropsychiatric Symptoms in Placebo-Controlled Epilepsy Trials         Adverse Reaction      Number (%) with Adverse Reaction    Number (%) Discontinuing       POTIGA  (n = 813)     Placebo  (n = 427)    POTIGA  (n = 813)    Placebo  (n = 427)       Confusional state     75 (9%)              11 (3%)              32 (4%)          4 (<1%)            Psychosis             9 (1%)               0                    6 (<1%)          0                  Hallucinationsa       14 (2%)              2 (<1%)              6 (<1%)          0                             a  Hallucinations includes visual, auditory, and mixed hallucinations.",( is not a named entity
"Major Neuropsychiatric Symptoms in Placebo-Controlled Epilepsy Trials         Adverse Reaction      Number (%) with Adverse Reaction    Number (%) Discontinuing       POTIGA  (n = 813)     Placebo  (n = 427)    POTIGA  (n = 813)    Placebo  (n = 427)       Confusional state     75 (9%)              11 (3%)              32 (4%)          4 (<1%)            Psychosis             9 (1%)               0                    6 (<1%)          0                  Hallucinationsa       14 (2%)              2 (<1%)              6 (<1%)          0                             a  Hallucinations includes visual, auditory, and mixed hallucinations.",Neuropsychiatric Symptoms is an adverse reaction entity
"Major Neuropsychiatric Symptoms in Placebo-Controlled Epilepsy Trials         Adverse Reaction      Number (%) with Adverse Reaction    Number (%) Discontinuing       POTIGA  (n = 813)     Placebo  (n = 427)    POTIGA  (n = 813)    Placebo  (n = 427)       Confusional state     75 (9%)              11 (3%)              32 (4%)          4 (<1%)            Psychosis             9 (1%)               0                    6 (<1%)          0                  Hallucinationsa       14 (2%)              2 (<1%)              6 (<1%)          0                             a  Hallucinations includes visual, auditory, and mixed hallucinations.",Placebo is not a named entity
"Major Neuropsychiatric Symptoms in Placebo-Controlled Epilepsy Trials         Adverse Reaction      Number (%) with Adverse Reaction    Number (%) Discontinuing       POTIGA  (n = 813)     Placebo  (n = 427)    POTIGA  (n = 813)    Placebo  (n = 427)       Confusional state     75 (9%)              11 (3%)              32 (4%)          4 (<1%)            Psychosis             9 (1%)               0                    6 (<1%)          0                  Hallucinationsa       14 (2%)              2 (<1%)              6 (<1%)          0                             a  Hallucinations includes visual, auditory, and mixed hallucinations.",0 is not a named entity
"Major Neuropsychiatric Symptoms in Placebo-Controlled Epilepsy Trials         Adverse Reaction      Number (%) with Adverse Reaction    Number (%) Discontinuing       POTIGA  (n = 813)     Placebo  (n = 427)    POTIGA  (n = 813)    Placebo  (n = 427)       Confusional state     75 (9%)              11 (3%)              32 (4%)          4 (<1%)            Psychosis             9 (1%)               0                    6 (<1%)          0                  Hallucinationsa       14 (2%)              2 (<1%)              6 (<1%)          0                             a  Hallucinations includes visual, auditory, and mixed hallucinations.",) Discontinuing is not a named entity
"Major Neuropsychiatric Symptoms in Placebo-Controlled Epilepsy Trials         Adverse Reaction      Number (%) with Adverse Reaction    Number (%) Discontinuing       POTIGA  (n = 813)     Placebo  (n = 427)    POTIGA  (n = 813)    Placebo  (n = 427)       Confusional state     75 (9%)              11 (3%)              32 (4%)          4 (<1%)            Psychosis             9 (1%)               0                    6 (<1%)          0                  Hallucinationsa       14 (2%)              2 (<1%)              6 (<1%)          0                             a  Hallucinations includes visual, auditory, and mixed hallucinations.",32 is not a named entity
"Major Neuropsychiatric Symptoms in Placebo-Controlled Epilepsy Trials         Adverse Reaction      Number (%) with Adverse Reaction    Number (%) Discontinuing       POTIGA  (n = 813)     Placebo  (n = 427)    POTIGA  (n = 813)    Placebo  (n = 427)       Confusional state     75 (9%)              11 (3%)              32 (4%)          4 (<1%)            Psychosis             9 (1%)               0                    6 (<1%)          0                  Hallucinationsa       14 (2%)              2 (<1%)              6 (<1%)          0                             a  Hallucinations includes visual, auditory, and mixed hallucinations.",Reaction Number is not a named entity
"Major Neuropsychiatric Symptoms in Placebo-Controlled Epilepsy Trials         Adverse Reaction      Number (%) with Adverse Reaction    Number (%) Discontinuing       POTIGA  (n = 813)     Placebo  (n = 427)    POTIGA  (n = 813)    Placebo  (n = 427)       Confusional state     75 (9%)              11 (3%)              32 (4%)          4 (<1%)            Psychosis             9 (1%)               0                    6 (<1%)          0                  Hallucinationsa       14 (2%)              2 (<1%)              6 (<1%)          0                             a  Hallucinations includes visual, auditory, and mixed hallucinations.",Hallucinations is an adverse reaction entity
"Additional Adverse Reactions Observed during All Phase 2 and 3 Clinical Trials       Following is a list of adverse reactions reported by patients treated with POTIGA during all clinical trials: rash, nystagmus, dyspnea, leukopenia, muscle spasms, alopecia, nephrolithiasis, syncope, neutropenia, thrombocytopenia, euphoric mood, renal colic, coma, encephalopathy.",Adverse is not a named entity
"Additional Adverse Reactions Observed during All Phase 2 and 3 Clinical Trials       Following is a list of adverse reactions reported by patients treated with POTIGA during all clinical trials: rash, nystagmus, dyspnea, leukopenia, muscle spasms, alopecia, nephrolithiasis, syncope, neutropenia, thrombocytopenia, euphoric mood, renal colic, coma, encephalopathy.",Reactions Observed is not a named entity
"Additional Adverse Reactions Observed during All Phase 2 and 3 Clinical Trials       Following is a list of adverse reactions reported by patients treated with POTIGA during all clinical trials: rash, nystagmus, dyspnea, leukopenia, muscle spasms, alopecia, nephrolithiasis, syncope, neutropenia, thrombocytopenia, euphoric mood, renal colic, coma, encephalopathy.",neutropenia is an adverse reaction entity
"Additional Adverse Reactions Observed during All Phase 2 and 3 Clinical Trials       Following is a list of adverse reactions reported by patients treated with POTIGA during all clinical trials: rash, nystagmus, dyspnea, leukopenia, muscle spasms, alopecia, nephrolithiasis, syncope, neutropenia, thrombocytopenia, euphoric mood, renal colic, coma, encephalopathy.",of adverse is not a named entity
"Additional Adverse Reactions Observed during All Phase 2 and 3 Clinical Trials       Following is a list of adverse reactions reported by patients treated with POTIGA during all clinical trials: rash, nystagmus, dyspnea, leukopenia, muscle spasms, alopecia, nephrolithiasis, syncope, neutropenia, thrombocytopenia, euphoric mood, renal colic, coma, encephalopathy.",nephrolithiasis is an adverse reaction entity
"Additional Adverse Reactions Observed during All Phase 2 and 3 Clinical Trials       Following is a list of adverse reactions reported by patients treated with POTIGA during all clinical trials: rash, nystagmus, dyspnea, leukopenia, muscle spasms, alopecia, nephrolithiasis, syncope, neutropenia, thrombocytopenia, euphoric mood, renal colic, coma, encephalopathy.",trials is not a named entity
"Additional Adverse Reactions Observed during All Phase 2 and 3 Clinical Trials       Following is a list of adverse reactions reported by patients treated with POTIGA during all clinical trials: rash, nystagmus, dyspnea, leukopenia, muscle spasms, alopecia, nephrolithiasis, syncope, neutropenia, thrombocytopenia, euphoric mood, renal colic, coma, encephalopathy.",alopecia is an adverse reaction entity
"Additional Adverse Reactions Observed during All Phase 2 and 3 Clinical Trials       Following is a list of adverse reactions reported by patients treated with POTIGA during all clinical trials: rash, nystagmus, dyspnea, leukopenia, muscle spasms, alopecia, nephrolithiasis, syncope, neutropenia, thrombocytopenia, euphoric mood, renal colic, coma, encephalopathy.",Adverse is not a named entity
"Additional Adverse Reactions Observed during All Phase 2 and 3 Clinical Trials       Following is a list of adverse reactions reported by patients treated with POTIGA during all clinical trials: rash, nystagmus, dyspnea, leukopenia, muscle spasms, alopecia, nephrolithiasis, syncope, neutropenia, thrombocytopenia, euphoric mood, renal colic, coma, encephalopathy.",dyspnea is an adverse reaction entity
"Additional Adverse Reactions Observed during All Phase 2 and 3 Clinical Trials       Following is a list of adverse reactions reported by patients treated with POTIGA during all clinical trials: rash, nystagmus, dyspnea, leukopenia, muscle spasms, alopecia, nephrolithiasis, syncope, neutropenia, thrombocytopenia, euphoric mood, renal colic, coma, encephalopathy.",renal colic is an adverse reaction entity
"Additional Adverse Reactions Observed during All Phase 2 and 3 Clinical Trials       Following is a list of adverse reactions reported by patients treated with POTIGA during all clinical trials: rash, nystagmus, dyspnea, leukopenia, muscle spasms, alopecia, nephrolithiasis, syncope, neutropenia, thrombocytopenia, euphoric mood, renal colic, coma, encephalopathy.",euphoric mood is an adverse reaction entity
"Additional Adverse Reactions Observed during All Phase 2 and 3 Clinical Trials       Following is a list of adverse reactions reported by patients treated with POTIGA during all clinical trials: rash, nystagmus, dyspnea, leukopenia, muscle spasms, alopecia, nephrolithiasis, syncope, neutropenia, thrombocytopenia, euphoric mood, renal colic, coma, encephalopathy.",rash is an adverse reaction entity
"Additional Adverse Reactions Observed during All Phase 2 and 3 Clinical Trials       Following is a list of adverse reactions reported by patients treated with POTIGA during all clinical trials: rash, nystagmus, dyspnea, leukopenia, muscle spasms, alopecia, nephrolithiasis, syncope, neutropenia, thrombocytopenia, euphoric mood, renal colic, coma, encephalopathy.",during all clinical is not a named entity
"Additional Adverse Reactions Observed during All Phase 2 and 3 Clinical Trials       Following is a list of adverse reactions reported by patients treated with POTIGA during all clinical trials: rash, nystagmus, dyspnea, leukopenia, muscle spasms, alopecia, nephrolithiasis, syncope, neutropenia, thrombocytopenia, euphoric mood, renal colic, coma, encephalopathy.","neutropenia , thrombocytopenia is not a named entity"
"Additional Adverse Reactions Observed during All Phase 2 and 3 Clinical Trials       Following is a list of adverse reactions reported by patients treated with POTIGA during all clinical trials: rash, nystagmus, dyspnea, leukopenia, muscle spasms, alopecia, nephrolithiasis, syncope, neutropenia, thrombocytopenia, euphoric mood, renal colic, coma, encephalopathy.",muscle spasms is an adverse reaction entity
"Additional Adverse Reactions Observed during All Phase 2 and 3 Clinical Trials       Following is a list of adverse reactions reported by patients treated with POTIGA during all clinical trials: rash, nystagmus, dyspnea, leukopenia, muscle spasms, alopecia, nephrolithiasis, syncope, neutropenia, thrombocytopenia, euphoric mood, renal colic, coma, encephalopathy.","syncope , neutropenia is not a named entity"
"Additional Adverse Reactions Observed during All Phase 2 and 3 Clinical Trials       Following is a list of adverse reactions reported by patients treated with POTIGA during all clinical trials: rash, nystagmus, dyspnea, leukopenia, muscle spasms, alopecia, nephrolithiasis, syncope, neutropenia, thrombocytopenia, euphoric mood, renal colic, coma, encephalopathy.","nystagmus , is not a named entity"
"Additional Adverse Reactions Observed during All Phase 2 and 3 Clinical Trials       Following is a list of adverse reactions reported by patients treated with POTIGA during all clinical trials: rash, nystagmus, dyspnea, leukopenia, muscle spasms, alopecia, nephrolithiasis, syncope, neutropenia, thrombocytopenia, euphoric mood, renal colic, coma, encephalopathy.",nystagmus is an adverse reaction entity
"Additional Adverse Reactions Observed during All Phase 2 and 3 Clinical Trials       Following is a list of adverse reactions reported by patients treated with POTIGA during all clinical trials: rash, nystagmus, dyspnea, leukopenia, muscle spasms, alopecia, nephrolithiasis, syncope, neutropenia, thrombocytopenia, euphoric mood, renal colic, coma, encephalopathy.",syncope is an adverse reaction entity
"Additional Adverse Reactions Observed during All Phase 2 and 3 Clinical Trials       Following is a list of adverse reactions reported by patients treated with POTIGA during all clinical trials: rash, nystagmus, dyspnea, leukopenia, muscle spasms, alopecia, nephrolithiasis, syncope, neutropenia, thrombocytopenia, euphoric mood, renal colic, coma, encephalopathy.",", encephalopathy is not a named entity"
"Additional Adverse Reactions Observed during All Phase 2 and 3 Clinical Trials       Following is a list of adverse reactions reported by patients treated with POTIGA during all clinical trials: rash, nystagmus, dyspnea, leukopenia, muscle spasms, alopecia, nephrolithiasis, syncope, neutropenia, thrombocytopenia, euphoric mood, renal colic, coma, encephalopathy.",thrombocytopenia is an adverse reaction entity
"Additional Adverse Reactions Observed during All Phase 2 and 3 Clinical Trials       Following is a list of adverse reactions reported by patients treated with POTIGA during all clinical trials: rash, nystagmus, dyspnea, leukopenia, muscle spasms, alopecia, nephrolithiasis, syncope, neutropenia, thrombocytopenia, euphoric mood, renal colic, coma, encephalopathy.",coma is an adverse reaction entity
"Additional Adverse Reactions Observed during All Phase 2 and 3 Clinical Trials       Following is a list of adverse reactions reported by patients treated with POTIGA during all clinical trials: rash, nystagmus, dyspnea, leukopenia, muscle spasms, alopecia, nephrolithiasis, syncope, neutropenia, thrombocytopenia, euphoric mood, renal colic, coma, encephalopathy.","dyspnea , is not a named entity"
"Additional Adverse Reactions Observed during All Phase 2 and 3 Clinical Trials       Following is a list of adverse reactions reported by patients treated with POTIGA during all clinical trials: rash, nystagmus, dyspnea, leukopenia, muscle spasms, alopecia, nephrolithiasis, syncope, neutropenia, thrombocytopenia, euphoric mood, renal colic, coma, encephalopathy.",", nystagmus is not a named entity"
"Additional Adverse Reactions Observed during All Phase 2 and 3 Clinical Trials       Following is a list of adverse reactions reported by patients treated with POTIGA during all clinical trials: rash, nystagmus, dyspnea, leukopenia, muscle spasms, alopecia, nephrolithiasis, syncope, neutropenia, thrombocytopenia, euphoric mood, renal colic, coma, encephalopathy.","nephrolithiasis , syncope is not a named entity"
"Additional Adverse Reactions Observed during All Phase 2 and 3 Clinical Trials       Following is a list of adverse reactions reported by patients treated with POTIGA during all clinical trials: rash, nystagmus, dyspnea, leukopenia, muscle spasms, alopecia, nephrolithiasis, syncope, neutropenia, thrombocytopenia, euphoric mood, renal colic, coma, encephalopathy.",", alopecia , is not a named entity"
"Additional Adverse Reactions Observed during All Phase 2 and 3 Clinical Trials       Following is a list of adverse reactions reported by patients treated with POTIGA during all clinical trials: rash, nystagmus, dyspnea, leukopenia, muscle spasms, alopecia, nephrolithiasis, syncope, neutropenia, thrombocytopenia, euphoric mood, renal colic, coma, encephalopathy.",leukopenia is an adverse reaction entity
"Additional Adverse Reactions Observed during All Phase 2 and 3 Clinical Trials       Following is a list of adverse reactions reported by patients treated with POTIGA during all clinical trials: rash, nystagmus, dyspnea, leukopenia, muscle spasms, alopecia, nephrolithiasis, syncope, neutropenia, thrombocytopenia, euphoric mood, renal colic, coma, encephalopathy.",encephalopathy is an adverse reaction entity
It is not possible to determine whether POTIGA caused this decreased visual acuity.,decreased visual acuity is an adverse reaction entity
It is not possible to determine whether POTIGA caused this decreased visual acuity.,possible to is not a named entity
Approximately one third of the patients who had eye examinations performed after approximately 4 years of treatment were found to have retinal pigmentary abnormalities.,have retinal pigmentary is not a named entity
Approximately one third of the patients who had eye examinations performed after approximately 4 years of treatment were found to have retinal pigmentary abnormalities.,retinal pigmentary abnormalities is an adverse reaction entity
Approximately two-thirds of patients with psychosis in controlled trials had no prior psychiatric history.,prior psychiatric history is not a named entity
Approximately two-thirds of patients with psychosis in controlled trials had no prior psychiatric history.,psychosis is an adverse reaction entity
5.6 QT Interval Effect      A study of cardiac conduction showed that POTIGA produced a mean 7.7-msec QT prolongation in healthy volunteers titrated to 400 mg 3 times daily.,QT prolongation is an adverse reaction entity
5.6 QT Interval Effect      A study of cardiac conduction showed that POTIGA produced a mean 7.7-msec QT prolongation in healthy volunteers titrated to 400 mg 3 times daily.,QT Interval is not a named entity
5.5 Dizziness and Somnolence      POTIGA causes dose-related increases in dizziness and somnolence [see Adverse Reactions (6.1)]  .,somnolence is an adverse reaction entity
5.5 Dizziness and Somnolence      POTIGA causes dose-related increases in dizziness and somnolence [see Adverse Reactions (6.1)]  .,6.1 ) ] is not a named entity
5.5 Dizziness and Somnolence      POTIGA causes dose-related increases in dizziness and somnolence [see Adverse Reactions (6.1)]  .,Dizziness and is not a named entity
5.5 Dizziness and Somnolence      POTIGA causes dose-related increases in dizziness and somnolence [see Adverse Reactions (6.1)]  .,dizziness is an adverse reaction entity
Approximately 15% of patients with retinal pigmentary abnormalities had no such discoloration.,discoloration is an adverse reaction entity
Approximately 15% of patients with retinal pigmentary abnormalities had no such discoloration.,pigmentary is not a named entity
Approximately 15% of patients with retinal pigmentary abnormalities had no such discoloration.,patients with is not a named entity
Approximately 15% of patients with retinal pigmentary abnormalities had no such discoloration.,retinal pigmentary abnormalities is an adverse reaction entity
The increased risk of suicidal thoughts or behavior with AEDs was observed as early as 1 week after starting treatment with AEDs and persisted for the duration of treatment assessed.,suicidal behavior is an adverse reaction entity
The increased risk of suicidal thoughts or behavior with AEDs was observed as early as 1 week after starting treatment with AEDs and persisted for the duration of treatment assessed.,of is not a named entity
The increased risk of suicidal thoughts or behavior with AEDs was observed as early as 1 week after starting treatment with AEDs and persisted for the duration of treatment assessed.,suicidal thoughts is an adverse reaction entity
The increased risk of suicidal thoughts or behavior with AEDs was observed as early as 1 week after starting treatment with AEDs and persisted for the duration of treatment assessed.,of is not a named entity
"However, an earlier onset cannot be ruled out, and it is possible that retinal abnormalities were present earlier in the course of exposure to POTIGA.",were present earlier is not a named entity
"However, an earlier onset cannot be ruled out, and it is possible that retinal abnormalities were present earlier in the course of exposure to POTIGA.",retinal abnormalities is an adverse reaction entity
"The skin discoloration is generally described as blue, but has also been described as grey-blue or brown.",skin discoloration is an adverse reaction entity
"The skin discoloration is generally described as blue, but has also been described as grey-blue or brown.",described is not a named entity
"POTIGA causes skin, scleral, nail, and mucous membrane discoloration and it is not clear whether this discoloration is related to retinal abnormalities [see Warnings and Precautions (5.3)]  .",POTIGA causes skin is not a named entity
"POTIGA causes skin, scleral, nail, and mucous membrane discoloration and it is not clear whether this discoloration is related to retinal abnormalities [see Warnings and Precautions (5.3)]  .",and it is not a named entity
"POTIGA causes skin, scleral, nail, and mucous membrane discoloration and it is not clear whether this discoloration is related to retinal abnormalities [see Warnings and Precautions (5.3)]  .",discoloration is an adverse reaction entity
"POTIGA causes skin, scleral, nail, and mucous membrane discoloration and it is not clear whether this discoloration is related to retinal abnormalities [see Warnings and Precautions (5.3)]  .",to retinal abnormalities is not a named entity
"POTIGA causes skin, scleral, nail, and mucous membrane discoloration and it is not clear whether this discoloration is related to retinal abnormalities [see Warnings and Precautions (5.3)]  .",mucous membrane discoloration is an adverse reaction entity
"POTIGA causes skin, scleral, nail, and mucous membrane discoloration and it is not clear whether this discoloration is related to retinal abnormalities [see Warnings and Precautions (5.3)]  .",nail discoloration is an adverse reaction entity
"POTIGA causes skin, scleral, nail, and mucous membrane discoloration and it is not clear whether this discoloration is related to retinal abnormalities [see Warnings and Precautions (5.3)]  .",and it is is not a named entity
"POTIGA causes skin, scleral, nail, and mucous membrane discoloration and it is not clear whether this discoloration is related to retinal abnormalities [see Warnings and Precautions (5.3)]  .",this discoloration is is not a named entity
"POTIGA causes skin, scleral, nail, and mucous membrane discoloration and it is not clear whether this discoloration is related to retinal abnormalities [see Warnings and Precautions (5.3)]  .",retinal abnormalities is an adverse reaction entity
"POTIGA causes skin, scleral, nail, and mucous membrane discoloration and it is not clear whether this discoloration is related to retinal abnormalities [see Warnings and Precautions (5.3)]  .",skin discoloration is an adverse reaction entity
"POTIGA causes skin, scleral, nail, and mucous membrane discoloration and it is not clear whether this discoloration is related to retinal abnormalities [see Warnings and Precautions (5.3)]  .",Warnings and is not a named entity
"POTIGA causes skin, scleral, nail, and mucous membrane discoloration and it is not clear whether this discoloration is related to retinal abnormalities [see Warnings and Precautions (5.3)]  .",scleral discoloration is an adverse reaction entity
Rapid titration at greater than the recommended doses appeared to increase the risk of psychosis and hallucinations.,psychosis is an adverse reaction entity
Rapid titration at greater than the recommended doses appeared to increase the risk of psychosis and hallucinations.,titration at greater is not a named entity
Rapid titration at greater than the recommended doses appeared to increase the risk of psychosis and hallucinations.,hallucinations is an adverse reaction entity
Rapid titration at greater than the recommended doses appeared to increase the risk of psychosis and hallucinations.,risk of psychosis is not a named entity
"Information on the consequences, reversibility, time to onset, and pathophysiology of the skin abnormalities remains incomplete.",skin abnormalities is an adverse reaction entity
"Information on the consequences, reversibility, time to onset, and pathophysiology of the skin abnormalities remains incomplete.",", time to is not a named entity"
Two patients with retinal abnormalities have had more extensive diagnostic retinal evaluations.,abnormalities is not a named entity
Two patients with retinal abnormalities have had more extensive diagnostic retinal evaluations.,retinal abnormalities is an adverse reaction entity
"POTIGA was associated with dose-related weight gain, with mean weight increasing by 0.2 kg, 1.2 kg, 1.6 kg, and 2.7 kg in the placebo, 600 mg per day, 900 mg per day, and 1,200 mg per day groups, respectively.",mg per is not a named entity
"POTIGA was associated with dose-related weight gain, with mean weight increasing by 0.2 kg, 1.2 kg, 1.6 kg, and 2.7 kg in the placebo, 600 mg per day, 900 mg per day, and 1,200 mg per day groups, respectively.",weight gain is an adverse reaction entity
"POTIGA was associated with dose-related weight gain, with mean weight increasing by 0.2 kg, 1.2 kg, 1.6 kg, and 2.7 kg in the placebo, 600 mg per day, 900 mg per day, and 1,200 mg per day groups, respectively.",weight increasing is an adverse reaction entity
"POTIGA was associated with dose-related weight gain, with mean weight increasing by 0.2 kg, 1.2 kg, 1.6 kg, and 2.7 kg in the placebo, 600 mg per day, 900 mg per day, and 1,200 mg per day groups, respectively.","kg , is not a named entity"
The range of time to diagnosis of cuSCC was 136 to197 days in the combination arm and was 9 to 197 days in the arm receiving TAFINLAR as a single agent.,cuSCC is an adverse reaction entity
The range of time to diagnosis of cuSCC was 136 to197 days in the combination arm and was 9 to 197 days in the arm receiving TAFINLAR as a single agent.,as a single is not a named entity
"In patients receiving TAFINLAR in combination with trametinib four cases of non-cutaneous malignancies were identified: KRAS mutation-positive pancreatic adenocarcinoma (n = 1), recurrent NRAS mutation-positive colorectal carcinoma (n = 1), head and neck carcinoma (n = 1), and glioblastoma (n = 1).",= 1 ) is not a named entity
"In patients receiving TAFINLAR in combination with trametinib four cases of non-cutaneous malignancies were identified: KRAS mutation-positive pancreatic adenocarcinoma (n = 1), recurrent NRAS mutation-positive colorectal carcinoma (n = 1), head and neck carcinoma (n = 1), and glioblastoma (n = 1).",KRAS mutation-positive pancreatic adenocarcinoma is an adverse reaction entity
"In patients receiving TAFINLAR in combination with trametinib four cases of non-cutaneous malignancies were identified: KRAS mutation-positive pancreatic adenocarcinoma (n = 1), recurrent NRAS mutation-positive colorectal carcinoma (n = 1), head and neck carcinoma (n = 1), and glioblastoma (n = 1).",trametinib four is not a named entity
"In patients receiving TAFINLAR in combination with trametinib four cases of non-cutaneous malignancies were identified: KRAS mutation-positive pancreatic adenocarcinoma (n = 1), recurrent NRAS mutation-positive colorectal carcinoma (n = 1), head and neck carcinoma (n = 1), and glioblastoma (n = 1).",( n is not a named entity
"In patients receiving TAFINLAR in combination with trametinib four cases of non-cutaneous malignancies were identified: KRAS mutation-positive pancreatic adenocarcinoma (n = 1), recurrent NRAS mutation-positive colorectal carcinoma (n = 1), head and neck carcinoma (n = 1), and glioblastoma (n = 1).",glioblastoma is an adverse reaction entity
"In patients receiving TAFINLAR in combination with trametinib four cases of non-cutaneous malignancies were identified: KRAS mutation-positive pancreatic adenocarcinoma (n = 1), recurrent NRAS mutation-positive colorectal carcinoma (n = 1), head and neck carcinoma (n = 1), and glioblastoma (n = 1).",receiving TAFINLAR in is not a named entity
"In patients receiving TAFINLAR in combination with trametinib four cases of non-cutaneous malignancies were identified: KRAS mutation-positive pancreatic adenocarcinoma (n = 1), recurrent NRAS mutation-positive colorectal carcinoma (n = 1), head and neck carcinoma (n = 1), and glioblastoma (n = 1).",head and neck carcinoma is an adverse reaction entity
"In patients receiving TAFINLAR in combination with trametinib four cases of non-cutaneous malignancies were identified: KRAS mutation-positive pancreatic adenocarcinoma (n = 1), recurrent NRAS mutation-positive colorectal carcinoma (n = 1), head and neck carcinoma (n = 1), and glioblastoma (n = 1).",recurrent NRAS mutation-positive colorectal carcinoma is an adverse reaction entity
"In patients receiving TAFINLAR in combination with trametinib four cases of non-cutaneous malignancies were identified: KRAS mutation-positive pancreatic adenocarcinoma (n = 1), recurrent NRAS mutation-positive colorectal carcinoma (n = 1), head and neck carcinoma (n = 1), and glioblastoma (n = 1).",adenocarcinoma ( is not a named entity
"In patients receiving TAFINLAR in combination with trametinib four cases of non-cutaneous malignancies were identified: KRAS mutation-positive pancreatic adenocarcinoma (n = 1), recurrent NRAS mutation-positive colorectal carcinoma (n = 1), head and neck carcinoma (n = 1), and glioblastoma (n = 1).",non-cutaneous malignancies is an adverse reaction entity
"5.3 Hemorrhage         Hemorrhages, including major hemorrhages defined as symptomatic bleeding in a critical area or organ, can occur when TAFINLAR is used in combination with trametinib.",with is not a named entity
"5.3 Hemorrhage         Hemorrhages, including major hemorrhages defined as symptomatic bleeding in a critical area or organ, can occur when TAFINLAR is used in combination with trametinib.",hemorrhages is an adverse reaction entity
"5.3 Hemorrhage         Hemorrhages, including major hemorrhages defined as symptomatic bleeding in a critical area or organ, can occur when TAFINLAR is used in combination with trametinib.",symptomatic bleeding is an adverse reaction entity
"5.3 Hemorrhage         Hemorrhages, including major hemorrhages defined as symptomatic bleeding in a critical area or organ, can occur when TAFINLAR is used in combination with trametinib.",hemorrhages defined is not a named entity
"5.3 Hemorrhage         Hemorrhages, including major hemorrhages defined as symptomatic bleeding in a critical area or organ, can occur when TAFINLAR is used in combination with trametinib.",Hemorrhages is an adverse reaction entity
"5.3 Hemorrhage         Hemorrhages, including major hemorrhages defined as symptomatic bleeding in a critical area or organ, can occur when TAFINLAR is used in combination with trametinib.",a is not a named entity
"In Trial 1, the incidence of fever (serious and non-serious) was 28% in patients treated with TAFINLAR and 10% in patients treated with dacarbazine.",) is not a named entity
"In Trial 1, the incidence of fever (serious and non-serious) was 28% in patients treated with TAFINLAR and 10% in patients treated with dacarbazine.",28 % is not a named entity
"In Trial 1, the incidence of fever (serious and non-serious) was 28% in patients treated with TAFINLAR and 10% in patients treated with dacarbazine.",fever is an adverse reaction entity
"In Trial 1, the incidence of fever (serious and non-serious) was 28% in patients treated with TAFINLAR and 10% in patients treated with dacarbazine.",fever is an adverse reaction entity
"Serious febrile reactions and fever of any severity complicated by hypotension, rigors or chills occurred in 25% (14/55) of patients treated with TAFINLAR in combination with trametinib compared with 2% (1/53) of patients treated with TAFINLAR as a single agent.",rigors or chills is not a named entity
"Serious febrile reactions and fever of any severity complicated by hypotension, rigors or chills occurred in 25% (14/55) of patients treated with TAFINLAR in combination with trametinib compared with 2% (1/53) of patients treated with TAFINLAR as a single agent.",TAFINLAR as is not a named entity
"Serious febrile reactions and fever of any severity complicated by hypotension, rigors or chills occurred in 25% (14/55) of patients treated with TAFINLAR in combination with trametinib compared with 2% (1/53) of patients treated with TAFINLAR as a single agent.",chills is an adverse reaction entity
"Serious febrile reactions and fever of any severity complicated by hypotension, rigors or chills occurred in 25% (14/55) of patients treated with TAFINLAR in combination with trametinib compared with 2% (1/53) of patients treated with TAFINLAR as a single agent.",hypotension is an adverse reaction entity
"Serious febrile reactions and fever of any severity complicated by hypotension, rigors or chills occurred in 25% (14/55) of patients treated with TAFINLAR in combination with trametinib compared with 2% (1/53) of patients treated with TAFINLAR as a single agent.",febrile reactions is an adverse reaction entity
"Serious febrile reactions and fever of any severity complicated by hypotension, rigors or chills occurred in 25% (14/55) of patients treated with TAFINLAR in combination with trametinib compared with 2% (1/53) of patients treated with TAFINLAR as a single agent.",of patients is not a named entity
"Serious febrile reactions and fever of any severity complicated by hypotension, rigors or chills occurred in 25% (14/55) of patients treated with TAFINLAR in combination with trametinib compared with 2% (1/53) of patients treated with TAFINLAR as a single agent.",rigors is an adverse reaction entity
"Serious febrile reactions and fever of any severity complicated by hypotension, rigors or chills occurred in 25% (14/55) of patients treated with TAFINLAR in combination with trametinib compared with 2% (1/53) of patients treated with TAFINLAR as a single agent.",fever is an adverse reaction entity
"Serious febrile reactions and fever of any severity complicated by hypotension, rigors or chills occurred in 25% (14/55) of patients treated with TAFINLAR in combination with trametinib compared with 2% (1/53) of patients treated with TAFINLAR as a single agent.",( 1/53 is not a named entity
"Serious febrile reactions and fever of any severity complicated by hypotension, rigors or chills occurred in 25% (14/55) of patients treated with TAFINLAR in combination with trametinib compared with 2% (1/53) of patients treated with TAFINLAR as a single agent.",compared is not a named entity
"Serious febrile reactions and fever of any severity complicated by hypotension, rigors or chills occurred in 3.7% (7/187) of patients treated with TAFINLAR and in none of the 59 patients treated with dacarbazine.",chills is an adverse reaction entity
"Serious febrile reactions and fever of any severity complicated by hypotension, rigors or chills occurred in 3.7% (7/187) of patients treated with TAFINLAR and in none of the 59 patients treated with dacarbazine.",febrile reactions is an adverse reaction entity
"Serious febrile reactions and fever of any severity complicated by hypotension, rigors or chills occurred in 3.7% (7/187) of patients treated with TAFINLAR and in none of the 59 patients treated with dacarbazine.",hypotension is an adverse reaction entity
"Serious febrile reactions and fever of any severity complicated by hypotension, rigors or chills occurred in 3.7% (7/187) of patients treated with TAFINLAR and in none of the 59 patients treated with dacarbazine.",rigors is an adverse reaction entity
"Serious febrile reactions and fever of any severity complicated by hypotension, rigors or chills occurred in 3.7% (7/187) of patients treated with TAFINLAR and in none of the 59 patients treated with dacarbazine.",treated is not a named entity
"Serious febrile reactions and fever of any severity complicated by hypotension, rigors or chills occurred in 3.7% (7/187) of patients treated with TAFINLAR and in none of the 59 patients treated with dacarbazine.","hypotension , rigors is not a named entity"
"Serious febrile reactions and fever of any severity complicated by hypotension, rigors or chills occurred in 3.7% (7/187) of patients treated with TAFINLAR and in none of the 59 patients treated with dacarbazine.",any severity is not a named entity
"Serious febrile reactions and fever of any severity complicated by hypotension, rigors or chills occurred in 3.7% (7/187) of patients treated with TAFINLAR and in none of the 59 patients treated with dacarbazine.",fever is an adverse reaction entity
"Serious febrile reactions and fever of any severity complicated by hypotension, rigors or chills occurred in 3.7% (7/187) of patients treated with TAFINLAR and in none of the 59 patients treated with dacarbazine.",by hypotension is not a named entity
"Serious febrile reactions and fever of any severity complicated by hypotension, rigors or chills occurred in 3.7% (7/187) of patients treated with TAFINLAR and in none of the 59 patients treated with dacarbazine.",occurred in 3.7 is not a named entity
5.6 Ocular Toxicities          Retinal Pigment Epithelial Detachment (RPED):          Retinal pigment epithelial detachments (RPED) can occur when TAFINLAR is used in combination with trametinib and with trametinib as a single agent [refer to Full Prescribing Information for trametinib]  .,and with is not a named entity
5.6 Ocular Toxicities          Retinal Pigment Epithelial Detachment (RPED):          Retinal pigment epithelial detachments (RPED) can occur when TAFINLAR is used in combination with trametinib and with trametinib as a single agent [refer to Full Prescribing Information for trametinib]  .,Retinal pigment epithelial detachments is an adverse reaction entity
5.6 Ocular Toxicities          Retinal Pigment Epithelial Detachment (RPED):          Retinal pigment epithelial detachments (RPED) can occur when TAFINLAR is used in combination with trametinib and with trametinib as a single agent [refer to Full Prescribing Information for trametinib]  .,RPED is an adverse reaction entity
5.6 Ocular Toxicities          Retinal Pigment Epithelial Detachment (RPED):          Retinal pigment epithelial detachments (RPED) can occur when TAFINLAR is used in combination with trametinib and with trametinib as a single agent [refer to Full Prescribing Information for trametinib]  .,] is not a named entity
The median time to onset of skin toxicity in patients treated with TAFINLAR in combination with trametinib was 37 days (range: 1 to 225 days) and median time to resolution of skin toxicity was 33 days (range: 3 to 421 days).,skin toxicity is an adverse reaction entity
The median time to onset of skin toxicity in patients treated with TAFINLAR in combination with trametinib was 37 days (range: 1 to 225 days) and median time to resolution of skin toxicity was 33 days (range: 3 to 421 days).,skin toxicity is an adverse reaction entity
The median time to onset of skin toxicity in patients treated with TAFINLAR in combination with trametinib was 37 days (range: 1 to 225 days) and median time to resolution of skin toxicity was 33 days (range: 3 to 421 days).,to is not a named entity
The median time to onset of skin toxicity in patients treated with TAFINLAR in combination with trametinib was 37 days (range: 1 to 225 days) and median time to resolution of skin toxicity was 33 days (range: 3 to 421 days).,median is not a named entity
"(  5.7  ,  2.3  )   *    Serious Skin Toxicity: Monitor for skin toxicities and for secondary infections.",Skin Toxicity is an adverse reaction entity
"(  5.7  ,  2.3  )   *    Serious Skin Toxicity: Monitor for skin toxicities and for secondary infections.",toxicities is not a named entity
RPED occurred in 2% (1/55) of patients receiving TAFINLAR in combination with trametinib.,) of patients is not a named entity
RPED occurred in 2% (1/55) of patients receiving TAFINLAR in combination with trametinib.,RPED is an adverse reaction entity
New primary melanoma occurred in 2% (1/53) of patients receiving TAFINLAR as a single agent and in none of the 55 patients receiving TAFINLAR in combination with trametinib.,primary melanoma is an adverse reaction entity
New primary melanoma occurred in 2% (1/53) of patients receiving TAFINLAR as a single agent and in none of the 55 patients receiving TAFINLAR in combination with trametinib.,New primary melanoma is not a named entity
5.5 Cardiomyopathy         Cardiomyopathy can occur when TAFINLAR is used in combination with trametinib and with trametinib as a single agent [refer to Full Prescribing Information for trametinib]  .,trametinib as is not a named entity
5.5 Cardiomyopathy         Cardiomyopathy can occur when TAFINLAR is used in combination with trametinib and with trametinib as a single agent [refer to Full Prescribing Information for trametinib]  .,Cardiomyopathy is an adverse reaction entity
The incidence and severity of pyrexia are increased when TAFINLAR is used in combination with trametinib compared with TAFINLAR as a single agent [see Adverse Reactions (6.1)].,pyrexia is an adverse reaction entity
The incidence and severity of pyrexia are increased when TAFINLAR is used in combination with trametinib compared with TAFINLAR as a single agent [see Adverse Reactions (6.1)].,pyrexia are increased is not a named entity
"The most commonly occurring adverse reactions (>=20%) in patients treated with TAFINLAR were, in order of decreasing frequency: hyperkeratosis, headache, pyrexia, arthralgia, papilloma, alopecia, and palmar-plantar erythrodysesthesia syndrome (PPES).",pyrexia is an adverse reaction entity
"The most commonly occurring adverse reactions (>=20%) in patients treated with TAFINLAR were, in order of decreasing frequency: hyperkeratosis, headache, pyrexia, arthralgia, papilloma, alopecia, and palmar-plantar erythrodysesthesia syndrome (PPES).",", papilloma , is not a named entity"
"The most commonly occurring adverse reactions (>=20%) in patients treated with TAFINLAR were, in order of decreasing frequency: hyperkeratosis, headache, pyrexia, arthralgia, papilloma, alopecia, and palmar-plantar erythrodysesthesia syndrome (PPES).",palmar-plantar erythrodysesthesia syndrome is an adverse reaction entity
"The most commonly occurring adverse reactions (>=20%) in patients treated with TAFINLAR were, in order of decreasing frequency: hyperkeratosis, headache, pyrexia, arthralgia, papilloma, alopecia, and palmar-plantar erythrodysesthesia syndrome (PPES).",arthralgia is an adverse reaction entity
"The most commonly occurring adverse reactions (>=20%) in patients treated with TAFINLAR were, in order of decreasing frequency: hyperkeratosis, headache, pyrexia, arthralgia, papilloma, alopecia, and palmar-plantar erythrodysesthesia syndrome (PPES).",most commonly occurring is not a named entity
"The most commonly occurring adverse reactions (>=20%) in patients treated with TAFINLAR were, in order of decreasing frequency: hyperkeratosis, headache, pyrexia, arthralgia, papilloma, alopecia, and palmar-plantar erythrodysesthesia syndrome (PPES).",PPES is an adverse reaction entity
"The most commonly occurring adverse reactions (>=20%) in patients treated with TAFINLAR were, in order of decreasing frequency: hyperkeratosis, headache, pyrexia, arthralgia, papilloma, alopecia, and palmar-plantar erythrodysesthesia syndrome (PPES).",PPES ) is not a named entity
"The most commonly occurring adverse reactions (>=20%) in patients treated with TAFINLAR were, in order of decreasing frequency: hyperkeratosis, headache, pyrexia, arthralgia, papilloma, alopecia, and palmar-plantar erythrodysesthesia syndrome (PPES).",hyperkeratosis is an adverse reaction entity
"The most commonly occurring adverse reactions (>=20%) in patients treated with TAFINLAR were, in order of decreasing frequency: hyperkeratosis, headache, pyrexia, arthralgia, papilloma, alopecia, and palmar-plantar erythrodysesthesia syndrome (PPES).",", alopecia is not a named entity"
"The most commonly occurring adverse reactions (>=20%) in patients treated with TAFINLAR were, in order of decreasing frequency: hyperkeratosis, headache, pyrexia, arthralgia, papilloma, alopecia, and palmar-plantar erythrodysesthesia syndrome (PPES).",headache is an adverse reaction entity
"The most commonly occurring adverse reactions (>=20%) in patients treated with TAFINLAR were, in order of decreasing frequency: hyperkeratosis, headache, pyrexia, arthralgia, papilloma, alopecia, and palmar-plantar erythrodysesthesia syndrome (PPES).",papilloma is an adverse reaction entity
"The most commonly occurring adverse reactions (>=20%) in patients treated with TAFINLAR were, in order of decreasing frequency: hyperkeratosis, headache, pyrexia, arthralgia, papilloma, alopecia, and palmar-plantar erythrodysesthesia syndrome (PPES).",patients treated is not a named entity
"The most commonly occurring adverse reactions (>=20%) in patients treated with TAFINLAR were, in order of decreasing frequency: hyperkeratosis, headache, pyrexia, arthralgia, papilloma, alopecia, and palmar-plantar erythrodysesthesia syndrome (PPES).",alopecia is an adverse reaction entity
"The most commonly occurring adverse reactions (>=20%) in patients treated with TAFINLAR were, in order of decreasing frequency: hyperkeratosis, headache, pyrexia, arthralgia, papilloma, alopecia, and palmar-plantar erythrodysesthesia syndrome (PPES).","TAFINLAR were , is not a named entity"
"The most commonly occurring adverse reactions (>=20%) in patients treated with TAFINLAR were, in order of decreasing frequency: hyperkeratosis, headache, pyrexia, arthralgia, papilloma, alopecia, and palmar-plantar erythrodysesthesia syndrome (PPES).",", pyrexia , is not a named entity"
"The most commonly occurring adverse reactions (>=20%) in patients treated with TAFINLAR were, in order of decreasing frequency: hyperkeratosis, headache, pyrexia, arthralgia, papilloma, alopecia, and palmar-plantar erythrodysesthesia syndrome (PPES).",> is not a named entity
Uveitis and Iritis:          Uveitis and iritis can occur when TAFINLAR is administered as a single agent or when used in combination with trametinib.,Uveitis and is not a named entity
Uveitis and Iritis:          Uveitis and iritis can occur when TAFINLAR is administered as a single agent or when used in combination with trametinib.,with is not a named entity
Uveitis and Iritis:          Uveitis and iritis can occur when TAFINLAR is administered as a single agent or when used in combination with trametinib.,iritis is an adverse reaction entity
Uveitis and Iritis:          Uveitis and iritis can occur when TAFINLAR is administered as a single agent or when used in combination with trametinib.,Uveitis is an adverse reaction entity
"Neoplasms Benign, Malignant, and Unspecified (including cysts and polyps):  Skin papilloma.",Skin papilloma is an adverse reaction entity
"Neoplasms Benign, Malignant, and Unspecified (including cysts and polyps):  Skin papilloma.","Malignant , is not a named entity"
"5.7 Serious Febrile Reactions       Serious febrile reactions and fever of any severity complicated by hypotension, rigors or chills, dehydration, or renal failure, can occur when TAFINLAR is administered as a single agent or when used in combination with trametinib.",Serious Febrile is not a named entity
"5.7 Serious Febrile Reactions       Serious febrile reactions and fever of any severity complicated by hypotension, rigors or chills, dehydration, or renal failure, can occur when TAFINLAR is administered as a single agent or when used in combination with trametinib.",Serious febrile is not a named entity
"5.7 Serious Febrile Reactions       Serious febrile reactions and fever of any severity complicated by hypotension, rigors or chills, dehydration, or renal failure, can occur when TAFINLAR is administered as a single agent or when used in combination with trametinib.",used is not a named entity
"5.7 Serious Febrile Reactions       Serious febrile reactions and fever of any severity complicated by hypotension, rigors or chills, dehydration, or renal failure, can occur when TAFINLAR is administered as a single agent or when used in combination with trametinib.",or when is not a named entity
"5.7 Serious Febrile Reactions       Serious febrile reactions and fever of any severity complicated by hypotension, rigors or chills, dehydration, or renal failure, can occur when TAFINLAR is administered as a single agent or when used in combination with trametinib.",chills is an adverse reaction entity
"5.7 Serious Febrile Reactions       Serious febrile reactions and fever of any severity complicated by hypotension, rigors or chills, dehydration, or renal failure, can occur when TAFINLAR is administered as a single agent or when used in combination with trametinib.",febrile reactions is an adverse reaction entity
"5.7 Serious Febrile Reactions       Serious febrile reactions and fever of any severity complicated by hypotension, rigors or chills, dehydration, or renal failure, can occur when TAFINLAR is administered as a single agent or when used in combination with trametinib.",is is not a named entity
"5.7 Serious Febrile Reactions       Serious febrile reactions and fever of any severity complicated by hypotension, rigors or chills, dehydration, or renal failure, can occur when TAFINLAR is administered as a single agent or when used in combination with trametinib.",hypotension is an adverse reaction entity
"5.7 Serious Febrile Reactions       Serious febrile reactions and fever of any severity complicated by hypotension, rigors or chills, dehydration, or renal failure, can occur when TAFINLAR is administered as a single agent or when used in combination with trametinib.",rigors is an adverse reaction entity
"5.7 Serious Febrile Reactions       Serious febrile reactions and fever of any severity complicated by hypotension, rigors or chills, dehydration, or renal failure, can occur when TAFINLAR is administered as a single agent or when used in combination with trametinib.",fever is an adverse reaction entity
"5.7 Serious Febrile Reactions       Serious febrile reactions and fever of any severity complicated by hypotension, rigors or chills, dehydration, or renal failure, can occur when TAFINLAR is administered as a single agent or when used in combination with trametinib.",dehydration is an adverse reaction entity
"5.7 Serious Febrile Reactions       Serious febrile reactions and fever of any severity complicated by hypotension, rigors or chills, dehydration, or renal failure, can occur when TAFINLAR is administered as a single agent or when used in combination with trametinib.",renal failure is an adverse reaction entity
"5.7 Serious Febrile Reactions       Serious febrile reactions and fever of any severity complicated by hypotension, rigors or chills, dehydration, or renal failure, can occur when TAFINLAR is administered as a single agent or when used in combination with trametinib.",used is not a named entity
"5.7 Serious Febrile Reactions       Serious febrile reactions and fever of any severity complicated by hypotension, rigors or chills, dehydration, or renal failure, can occur when TAFINLAR is administered as a single agent or when used in combination with trametinib.",used in is not a named entity
5.9 Hyperglycemia       Hyperglycemia can occur when TAFINLAR is administered as a single agent or when used in combination with trametinib  .,combination with is not a named entity
5.9 Hyperglycemia       Hyperglycemia can occur when TAFINLAR is administered as a single agent or when used in combination with trametinib  .,Hyperglycemia is an adverse reaction entity
Two percent demonstrated a decrease in LVEF below institutional lower limits of normal with an absolute decrease in LVEF of >=20% below baseline.,=20 is not a named entity
Two percent demonstrated a decrease in LVEF below institutional lower limits of normal with an absolute decrease in LVEF of >=20% below baseline.,absolute decrease in LVEF is an adverse reaction entity
Two percent demonstrated a decrease in LVEF below institutional lower limits of normal with an absolute decrease in LVEF of >=20% below baseline.,decrease in LVEF is an adverse reaction entity
Two percent demonstrated a decrease in LVEF below institutional lower limits of normal with an absolute decrease in LVEF of >=20% below baseline.,% is not a named entity
The major hemorrhagic events of intracranial or gastric hemorrhage occurred in 5% (3/55) of patients treated with TAFINLAR in combination with trametinib compared with none of the 53 patients treated with TAFINLAR as a single agent.,hemorrhagic events is an adverse reaction entity
The major hemorrhagic events of intracranial or gastric hemorrhage occurred in 5% (3/55) of patients treated with TAFINLAR in combination with trametinib compared with none of the 53 patients treated with TAFINLAR as a single agent.,with is not a named entity
The major hemorrhagic events of intracranial or gastric hemorrhage occurred in 5% (3/55) of patients treated with TAFINLAR in combination with trametinib compared with none of the 53 patients treated with TAFINLAR as a single agent.,% ( is not a named entity
The major hemorrhagic events of intracranial or gastric hemorrhage occurred in 5% (3/55) of patients treated with TAFINLAR in combination with trametinib compared with none of the 53 patients treated with TAFINLAR as a single agent.,gastric hemorrhage is an adverse reaction entity
The major hemorrhagic events of intracranial or gastric hemorrhage occurred in 5% (3/55) of patients treated with TAFINLAR in combination with trametinib compared with none of the 53 patients treated with TAFINLAR as a single agent.,treated with TAFINLAR is not a named entity
The major hemorrhagic events of intracranial or gastric hemorrhage occurred in 5% (3/55) of patients treated with TAFINLAR in combination with trametinib compared with none of the 53 patients treated with TAFINLAR as a single agent.,intracranial hemorrhage is an adverse reaction entity
"In Trial 2, the incidence of fever (serious and non-serious) was 71% (39/55) in patients treated with TAFINLAR in combination with trametinib and 26% (14/53) in patients treated with TAFINLAR as a single agent.",fever is an adverse reaction entity
"In Trial 2, the incidence of fever (serious and non-serious) was 71% (39/55) in patients treated with TAFINLAR in combination with trametinib and 26% (14/53) in patients treated with TAFINLAR as a single agent.",was is not a named entity
"In Trial 2, the incidence of fever (serious and non-serious) was 71% (39/55) in patients treated with TAFINLAR in combination with trametinib and 26% (14/53) in patients treated with TAFINLAR as a single agent.",fever ( serious is not a named entity
"In Trial 2, the incidence of fever (serious and non-serious) was 71% (39/55) in patients treated with TAFINLAR in combination with trametinib and 26% (14/53) in patients treated with TAFINLAR as a single agent.",fever is an adverse reaction entity
"Of those patients who developed new cuSCC, approximately 33% developed one or more cuSCC with continued administration of TAFINLAR.",cuSCC is an adverse reaction entity
"Of those patients who developed new cuSCC, approximately 33% developed one or more cuSCC with continued administration of TAFINLAR.",developed is not a named entity
"Of those patients who developed new cuSCC, approximately 33% developed one or more cuSCC with continued administration of TAFINLAR.",more cuSCC is not a named entity
"Of those patients who developed new cuSCC, approximately 33% developed one or more cuSCC with continued administration of TAFINLAR.",cuSCC is an adverse reaction entity
"Cutaneous Malignancies:       TAFINLAR results in an increased incidence of cutaneous squamous cell carcinoma, keratoacanthoma, and melanoma.",keratoacanthoma is an adverse reaction entity
"Cutaneous Malignancies:       TAFINLAR results in an increased incidence of cutaneous squamous cell carcinoma, keratoacanthoma, and melanoma.",an increased is not a named entity
"Cutaneous Malignancies:       TAFINLAR results in an increased incidence of cutaneous squamous cell carcinoma, keratoacanthoma, and melanoma.",cutaneous squamous cell carcinoma is an adverse reaction entity
"Cutaneous Malignancies:       TAFINLAR results in an increased incidence of cutaneous squamous cell carcinoma, keratoacanthoma, and melanoma.",", and is not a named entity"
"Cutaneous Malignancies:       TAFINLAR results in an increased incidence of cutaneous squamous cell carcinoma, keratoacanthoma, and melanoma.",melanoma is an adverse reaction entity
"Cutaneous Malignancies:       TAFINLAR results in an increased incidence of cutaneous squamous cell carcinoma, keratoacanthoma, and melanoma.","keratoacanthoma , and is not a named entity"
"In Trial 1, the incidence of new primary malignant melanomas was 2% (3/187) for patients receiving TAFINLAR while no dacarbazine-treated patient was diagnosed with new primary malignant melanoma.",for patients is not a named entity
"In Trial 1, the incidence of new primary malignant melanomas was 2% (3/187) for patients receiving TAFINLAR while no dacarbazine-treated patient was diagnosed with new primary malignant melanoma.",primary malignant melanomas is an adverse reaction entity
"In Trial 2, the incidence of any skin toxicity was similar for patients receiving TAFINLAR in combination with trametinib (65% [36/55]) compared with patients receiving TAFINLAR as a single agent (68% [36/53]).",receiving TAFINLAR is not a named entity
"In Trial 2, the incidence of any skin toxicity was similar for patients receiving TAFINLAR in combination with trametinib (65% [36/55]) compared with patients receiving TAFINLAR as a single agent (68% [36/53]).",skin toxicity is an adverse reaction entity
"The following serious adverse reactions of trametinib as a single agent, which may occur when TAFINLAR is used in combination with trametinib, are not described in the Full Prescribing Information for TAFINLAR:       *     Retinal vein occlusion    *     Interstitial lung disease      *    New primary malignancies, cutaneous and non-cutaneous, can occur when TAFINLAR is administered as a single agent or in combination with trametinib.","primary malignancies, cutaneous is an adverse reaction entity"
"The following serious adverse reactions of trametinib as a single agent, which may occur when TAFINLAR is used in combination with trametinib, are not described in the Full Prescribing Information for TAFINLAR:       *     Retinal vein occlusion    *     Interstitial lung disease      *    New primary malignancies, cutaneous and non-cutaneous, can occur when TAFINLAR is administered as a single agent or in combination with trametinib.",: * is not a named entity
"The following serious adverse reactions of trametinib as a single agent, which may occur when TAFINLAR is used in combination with trametinib, are not described in the Full Prescribing Information for TAFINLAR:       *     Retinal vein occlusion    *     Interstitial lung disease      *    New primary malignancies, cutaneous and non-cutaneous, can occur when TAFINLAR is administered as a single agent or in combination with trametinib.",primary malignancies non-cutaneous is an adverse reaction entity
"The following serious adverse reactions of trametinib as a single agent, which may occur when TAFINLAR is used in combination with trametinib, are not described in the Full Prescribing Information for TAFINLAR:       *     Retinal vein occlusion    *     Interstitial lung disease      *    New primary malignancies, cutaneous and non-cutaneous, can occur when TAFINLAR is administered as a single agent or in combination with trametinib.",in combination is not a named entity
"The following serious adverse reactions of trametinib as a single agent, which may occur when TAFINLAR is used in combination with trametinib, are not described in the Full Prescribing Information for TAFINLAR:       *     Retinal vein occlusion    *     Interstitial lung disease      *    New primary malignancies, cutaneous and non-cutaneous, can occur when TAFINLAR is administered as a single agent or in combination with trametinib.",Interstitial lung disease is an adverse reaction entity
"The following serious adverse reactions of trametinib as a single agent, which may occur when TAFINLAR is used in combination with trametinib, are not described in the Full Prescribing Information for TAFINLAR:       *     Retinal vein occlusion    *     Interstitial lung disease      *    New primary malignancies, cutaneous and non-cutaneous, can occur when TAFINLAR is administered as a single agent or in combination with trametinib.",Retinal vein occlusion is an adverse reaction entity
"The following serious adverse reactions of trametinib as a single agent, which may occur when TAFINLAR is used in combination with trametinib, are not described in the Full Prescribing Information for TAFINLAR:       *     Retinal vein occlusion    *     Interstitial lung disease      *    New primary malignancies, cutaneous and non-cutaneous, can occur when TAFINLAR is administered as a single agent or in combination with trametinib.",: * Retinal is not a named entity
"The following serious adverse reactions of trametinib as a single agent, which may occur when TAFINLAR is used in combination with trametinib, are not described in the Full Prescribing Information for TAFINLAR:       *     Retinal vein occlusion    *     Interstitial lung disease      *    New primary malignancies, cutaneous and non-cutaneous, can occur when TAFINLAR is administered as a single agent or in combination with trametinib.","non-cutaneous , is not a named entity"
"Across clinical trials of TAFINLAR administered in combination with trametinib (N = 202), 8% of patients developed evidence of cardiomyopathy (decrease in LVEF below institutional lower limits of normal with an absolute decrease in LVEF >=10% below baseline).",decrease in LVEF is an adverse reaction entity
"Across clinical trials of TAFINLAR administered in combination with trametinib (N = 202), 8% of patients developed evidence of cardiomyopathy (decrease in LVEF below institutional lower limits of normal with an absolute decrease in LVEF >=10% below baseline).",% is not a named entity
"Across clinical trials of TAFINLAR administered in combination with trametinib (N = 202), 8% of patients developed evidence of cardiomyopathy (decrease in LVEF below institutional lower limits of normal with an absolute decrease in LVEF >=10% below baseline).",absolute decrease in LVEF is an adverse reaction entity
"Across clinical trials of TAFINLAR administered in combination with trametinib (N = 202), 8% of patients developed evidence of cardiomyopathy (decrease in LVEF below institutional lower limits of normal with an absolute decrease in LVEF >=10% below baseline).",lower limits is not a named entity
"Across clinical trials of TAFINLAR administered in combination with trametinib (N = 202), 8% of patients developed evidence of cardiomyopathy (decrease in LVEF below institutional lower limits of normal with an absolute decrease in LVEF >=10% below baseline).",trametinib is not a named entity
"Across clinical trials of TAFINLAR administered in combination with trametinib (N = 202), 8% of patients developed evidence of cardiomyopathy (decrease in LVEF below institutional lower limits of normal with an absolute decrease in LVEF >=10% below baseline).",cardiomyopathy is an adverse reaction entity
"Other clinically important adverse reactions (N = 202) observed in <10% of patients treated with TAFINLAR in combination with trametinib were:       Eye Disorders:  Vision blurred, transient blindness.",Vision blurred is an adverse reaction entity
"Other clinically important adverse reactions (N = 202) observed in <10% of patients treated with TAFINLAR in combination with trametinib were:       Eye Disorders:  Vision blurred, transient blindness.",in combination is not a named entity
"Other clinically important adverse reactions (N = 202) observed in <10% of patients treated with TAFINLAR in combination with trametinib were:       Eye Disorders:  Vision blurred, transient blindness.",( N is not a named entity
"Other clinically important adverse reactions (N = 202) observed in <10% of patients treated with TAFINLAR in combination with trametinib were:       Eye Disorders:  Vision blurred, transient blindness.",transient blindness is an adverse reaction entity
(  5.3  )   *    Venous Thromboembolism: Deep vein thrombosis and pulmonary embolism can occur in patients receiving TAFINLAR in combination with trametinib.,Venous Thromboembolism is an adverse reaction entity
(  5.3  )   *    Venous Thromboembolism: Deep vein thrombosis and pulmonary embolism can occur in patients receiving TAFINLAR in combination with trametinib.,Deep vein thrombosis is an adverse reaction entity
(  5.3  )   *    Venous Thromboembolism: Deep vein thrombosis and pulmonary embolism can occur in patients receiving TAFINLAR in combination with trametinib.,vein thrombosis and is not a named entity
(  5.3  )   *    Venous Thromboembolism: Deep vein thrombosis and pulmonary embolism can occur in patients receiving TAFINLAR in combination with trametinib.,trametinib is not a named entity
(  5.3  )   *    Venous Thromboembolism: Deep vein thrombosis and pulmonary embolism can occur in patients receiving TAFINLAR in combination with trametinib.,and is not a named entity
(  5.3  )   *    Venous Thromboembolism: Deep vein thrombosis and pulmonary embolism can occur in patients receiving TAFINLAR in combination with trametinib.,pulmonary embolism is an adverse reaction entity
Dabrafenib was teratogenic and embryotoxic in rats at doses three times greater than the human exposure at the recommended clinical dose.,embryotoxic is an adverse reaction entity
Dabrafenib was teratogenic and embryotoxic in rats at doses three times greater than the human exposure at the recommended clinical dose.,teratogenic is an adverse reaction entity
Dabrafenib was teratogenic and embryotoxic in rats at doses three times greater than the human exposure at the recommended clinical dose.,doses is not a named entity
Dabrafenib was teratogenic and embryotoxic in rats at doses three times greater than the human exposure at the recommended clinical dose.,recommended is not a named entity
"In Trial 2, treatment with TAFINLAR in combination with trametinib resulted in an increased incidence and severity of any hemorrhagic event: 16% (9/55) of patients treated with TAFINLAR in combination with trametinib compared with 2% (1/53) of patients treated with TAFINLAR as a single agent.",hemorrhagic event is an adverse reaction entity
"In Trial 2, treatment with TAFINLAR in combination with trametinib resulted in an increased incidence and severity of any hemorrhagic event: 16% (9/55) of patients treated with TAFINLAR in combination with trametinib compared with 2% (1/53) of patients treated with TAFINLAR as a single agent.",trametinib resulted is not a named entity
"(  5.6  ,  2.3  )   *    Serious Febrile Reactions: Incidence and severity of pyrexia are increased with TAFINLAR in combination with trametinib.",* Serious is not a named entity
"(  5.6  ,  2.3  )   *    Serious Febrile Reactions: Incidence and severity of pyrexia are increased with TAFINLAR in combination with trametinib.",pyrexia is an adverse reaction entity
"(  5.6  ,  2.3  )   *    Serious Febrile Reactions: Incidence and severity of pyrexia are increased with TAFINLAR in combination with trametinib.",Febrile Reactions is an adverse reaction entity
"(  5.6  ,  2.3  )   *    Serious Febrile Reactions: Incidence and severity of pyrexia are increased with TAFINLAR in combination with trametinib.",are is not a named entity
"Fever was complicated with chills/rigors in 51% (28/55), dehydration in 9% (5/55), renal failure in 4% (2/55), and syncope in 4% (2/55) of patients in Trial 2.",( 2/55 is not a named entity
"Fever was complicated with chills/rigors in 51% (28/55), dehydration in 9% (5/55), renal failure in 4% (2/55), and syncope in 4% (2/55) of patients in Trial 2.",dehydration is an adverse reaction entity
"Fever was complicated with chills/rigors in 51% (28/55), dehydration in 9% (5/55), renal failure in 4% (2/55), and syncope in 4% (2/55) of patients in Trial 2.",was complicated with is not a named entity
"Fever was complicated with chills/rigors in 51% (28/55), dehydration in 9% (5/55), renal failure in 4% (2/55), and syncope in 4% (2/55) of patients in Trial 2.",51 % is not a named entity
"Fever was complicated with chills/rigors in 51% (28/55), dehydration in 9% (5/55), renal failure in 4% (2/55), and syncope in 4% (2/55) of patients in Trial 2.",Fever is an adverse reaction entity
"Fever was complicated with chills/rigors in 51% (28/55), dehydration in 9% (5/55), renal failure in 4% (2/55), and syncope in 4% (2/55) of patients in Trial 2.",of patients in is not a named entity
"Fever was complicated with chills/rigors in 51% (28/55), dehydration in 9% (5/55), renal failure in 4% (2/55), and syncope in 4% (2/55) of patients in Trial 2.",rigors is an adverse reaction entity
"Fever was complicated with chills/rigors in 51% (28/55), dehydration in 9% (5/55), renal failure in 4% (2/55), and syncope in 4% (2/55) of patients in Trial 2.",chills is an adverse reaction entity
"Fever was complicated with chills/rigors in 51% (28/55), dehydration in 9% (5/55), renal failure in 4% (2/55), and syncope in 4% (2/55) of patients in Trial 2.",renal failure is an adverse reaction entity
"Fever was complicated with chills/rigors in 51% (28/55), dehydration in 9% (5/55), renal failure in 4% (2/55), and syncope in 4% (2/55) of patients in Trial 2.",syncope is an adverse reaction entity
"Fever was complicated with chills/rigors in 51% (28/55), dehydration in 9% (5/55), renal failure in 4% (2/55), and syncope in 4% (2/55) of patients in Trial 2.",chills/rigors in is not a named entity
"Fever was complicated with chills/rigors in 51% (28/55), dehydration in 9% (5/55), renal failure in 4% (2/55), and syncope in 4% (2/55) of patients in Trial 2.","5/55 ) , is not a named entity"
"Retinal detachments resulting from trametinib are often bilateral and multifocal, occurring in the macular region of the retina.",the is not a named entity
"Retinal detachments resulting from trametinib are often bilateral and multifocal, occurring in the macular region of the retina.",Retinal detachments is an adverse reaction entity
"d  Includes the following terms: abdominal pain, abdominal pain upper, abdominal pain lower, and abdominal discomfort.",", abdominal is not a named entity"
"d  Includes the following terms: abdominal pain, abdominal pain upper, abdominal pain lower, and abdominal discomfort.",d Includes the is not a named entity
"d  Includes the following terms: abdominal pain, abdominal pain upper, abdominal pain lower, and abdominal discomfort.",", is not a named entity"
"d  Includes the following terms: abdominal pain, abdominal pain upper, abdominal pain lower, and abdominal discomfort.",pain lower is not a named entity
"d  Includes the following terms: abdominal pain, abdominal pain upper, abdominal pain lower, and abdominal discomfort.",abdominal discomfort is an adverse reaction entity
"d  Includes the following terms: abdominal pain, abdominal pain upper, abdominal pain lower, and abdominal discomfort.",abdominal pain upper is an adverse reaction entity
"d  Includes the following terms: abdominal pain, abdominal pain upper, abdominal pain lower, and abdominal discomfort.",abdominal pain lower is an adverse reaction entity
"d  Includes the following terms: abdominal pain, abdominal pain upper, abdominal pain lower, and abdominal discomfort.",abdominal pain is an adverse reaction entity
"Across clinical trials of TAFINLAR administered in combination with trametinib (N = 202), the incidence of RPED was 1% (2/202).",% ( 2/202 is not a named entity
"Across clinical trials of TAFINLAR administered in combination with trametinib (N = 202), the incidence of RPED was 1% (2/202).",RPED is an adverse reaction entity
The median time between diagnosis of the first cuSCC and the second cuSCC was 6 weeks.,cuSCC is an adverse reaction entity
The median time between diagnosis of the first cuSCC and the second cuSCC was 6 weeks.,was 6 weeks is not a named entity
The median time between diagnosis of the first cuSCC and the second cuSCC was 6 weeks.,cuSCC is an adverse reaction entity
The median time between diagnosis of the first cuSCC and the second cuSCC was 6 weeks.,the first cuSCC is not a named entity
Development of cardiomyopathy resolved in all five patients following dose reduction (4/55) and/or dose interruption (1/55).,( 1/55 is not a named entity
Development of cardiomyopathy resolved in all five patients following dose reduction (4/55) and/or dose interruption (1/55).,cardiomyopathy is an adverse reaction entity
5.8 Serious Skin Toxicity         Serious skin toxicity can occur when TAFINLAR is used in combination with trametinib and with trametinib as a single agent [refer to Full Prescribing Information for trametinib]  .,[ refer is not a named entity
5.8 Serious Skin Toxicity         Serious skin toxicity can occur when TAFINLAR is used in combination with trametinib and with trametinib as a single agent [refer to Full Prescribing Information for trametinib]  .,skin toxicity is an adverse reaction entity
Cardiomyopathy was identified within the first month of treatment with TAFINLAR in combination with trametinib in two of five patients.,Cardiomyopathy is an adverse reaction entity
Cardiomyopathy was identified within the first month of treatment with TAFINLAR in combination with trametinib in two of five patients.,month of treatment is not a named entity
The median time to onset of cardiomyopathy in patients treated with TAFINLAR in combination with trametinib was 86 days (range: 27 to 253 days).,cardiomyopathy is an adverse reaction entity
The median time to onset of cardiomyopathy in patients treated with TAFINLAR in combination with trametinib was 86 days (range: 27 to 253 days).,in patients is not a named entity
Other clinically important adverse reactions observed in <10% of patients (N = 586) treated with TAFINLAR were:       Gastrointestinal Disorders:  Pancreatitis.,in is not a named entity
Other clinically important adverse reactions observed in <10% of patients (N = 586) treated with TAFINLAR were:       Gastrointestinal Disorders:  Pancreatitis.,Pancreatitis is an adverse reaction entity
"Non-cutaneous Malignancies:          Based on its mechanism of action, TAFINLAR may promote the growth and development of malignancies with activation of RAS through mutation or other mechanisms [see Warnings and Precautions (5.2)]  .",malignancies is an adverse reaction entity
"Non-cutaneous Malignancies:          Based on its mechanism of action, TAFINLAR may promote the growth and development of malignancies with activation of RAS through mutation or other mechanisms [see Warnings and Precautions (5.2)]  .",Malignancies is not a named entity
5.4 Venous Thromboembolism         Venous thromboembolism can occur when TAFINLAR is used in combination with trametinib.,Venous thromboembolism is an adverse reaction entity
5.4 Venous Thromboembolism         Venous thromboembolism can occur when TAFINLAR is used in combination with trametinib.,is is not a named entity
b  Grade 4 adverse reactions limited to hyperkeratosis (n = 1) and constipation (n = 1).,hyperkeratosis is an adverse reaction entity
b  Grade 4 adverse reactions limited to hyperkeratosis (n = 1) and constipation (n = 1).,1 is not a named entity
b  Grade 4 adverse reactions limited to hyperkeratosis (n = 1) and constipation (n = 1).,adverse reactions is not a named entity
b  Grade 4 adverse reactions limited to hyperkeratosis (n = 1) and constipation (n = 1).,constipation is an adverse reaction entity
TAFINLAR when used in combination with trametinib results in an increased incidence of basal cell carcinoma.,incidence of basal is not a named entity
TAFINLAR when used in combination with trametinib results in an increased incidence of basal cell carcinoma.,basal cell carcinoma is an adverse reaction entity
"In Trial 2, the incidence of Grade 3 hyperglycemia based on laboratory values was 5% (3/55) in patients treated with TAFINLAR in combination with trametinib compared with 2% (1/53) in patients treated with TAFINLAR as a single agent.",hyperglycemia is an adverse reaction entity
"In Trial 2, the incidence of Grade 3 hyperglycemia based on laboratory values was 5% (3/55) in patients treated with TAFINLAR in combination with trametinib compared with 2% (1/53) in patients treated with TAFINLAR as a single agent.",the incidence is not a named entity
"In Trial 2, treatment with TAFINLAR in combination with trametinib resulted in an increased incidence of deep venous thrombosis (DVT) and pulmonary embolism (PE): 7% (4/55) of patients treated with TAFINLAR in combination with trametinib compared with none of the 53 patients treated with TAFINLAR as a single agent.",TAFINLAR is not a named entity
"In Trial 2, treatment with TAFINLAR in combination with trametinib resulted in an increased incidence of deep venous thrombosis (DVT) and pulmonary embolism (PE): 7% (4/55) of patients treated with TAFINLAR in combination with trametinib compared with none of the 53 patients treated with TAFINLAR as a single agent.",DVT is an adverse reaction entity
"In Trial 2, treatment with TAFINLAR in combination with trametinib resulted in an increased incidence of deep venous thrombosis (DVT) and pulmonary embolism (PE): 7% (4/55) of patients treated with TAFINLAR in combination with trametinib compared with none of the 53 patients treated with TAFINLAR as a single agent.",PE is an adverse reaction entity
"In Trial 2, treatment with TAFINLAR in combination with trametinib resulted in an increased incidence of deep venous thrombosis (DVT) and pulmonary embolism (PE): 7% (4/55) of patients treated with TAFINLAR in combination with trametinib compared with none of the 53 patients treated with TAFINLAR as a single agent.",pulmonary embolism is an adverse reaction entity
"In Trial 2, treatment with TAFINLAR in combination with trametinib resulted in an increased incidence of deep venous thrombosis (DVT) and pulmonary embolism (PE): 7% (4/55) of patients treated with TAFINLAR in combination with trametinib compared with none of the 53 patients treated with TAFINLAR as a single agent.",TAFINLAR as a is not a named entity
"In Trial 2, treatment with TAFINLAR in combination with trametinib resulted in an increased incidence of deep venous thrombosis (DVT) and pulmonary embolism (PE): 7% (4/55) of patients treated with TAFINLAR in combination with trametinib compared with none of the 53 patients treated with TAFINLAR as a single agent.",deep venous thrombosis is an adverse reaction entity
"In Trial 2, treatment with TAFINLAR in combination with trametinib resulted in an increased incidence of deep venous thrombosis (DVT) and pulmonary embolism (PE): 7% (4/55) of patients treated with TAFINLAR in combination with trametinib compared with none of the 53 patients treated with TAFINLAR as a single agent.",of patients treated is not a named entity
"In Trial 2, treatment with TAFINLAR in combination with trametinib resulted in an increased incidence of deep venous thrombosis (DVT) and pulmonary embolism (PE): 7% (4/55) of patients treated with TAFINLAR in combination with trametinib compared with none of the 53 patients treated with TAFINLAR as a single agent.",( 4/55 ) is not a named entity
"(  6.1  )   *    Most common adverse reactions (>=20%) for TAFINLAR in combination with trametinib are pyrexia, chills, fatigue, rash, nausea, vomiting, diarrhea, abdominal pain, peripheral edema, cough, headache, arthralgia, night sweats, decreased appetite, constipation, and myalgia.",vomiting is an adverse reaction entity
"(  6.1  )   *    Most common adverse reactions (>=20%) for TAFINLAR in combination with trametinib are pyrexia, chills, fatigue, rash, nausea, vomiting, diarrhea, abdominal pain, peripheral edema, cough, headache, arthralgia, night sweats, decreased appetite, constipation, and myalgia.",", peripheral is not a named entity"
"(  6.1  )   *    Most common adverse reactions (>=20%) for TAFINLAR in combination with trametinib are pyrexia, chills, fatigue, rash, nausea, vomiting, diarrhea, abdominal pain, peripheral edema, cough, headache, arthralgia, night sweats, decreased appetite, constipation, and myalgia.",abdominal pain is an adverse reaction entity
"(  6.1  )   *    Most common adverse reactions (>=20%) for TAFINLAR in combination with trametinib are pyrexia, chills, fatigue, rash, nausea, vomiting, diarrhea, abdominal pain, peripheral edema, cough, headache, arthralgia, night sweats, decreased appetite, constipation, and myalgia.",diarrhea is an adverse reaction entity
"(  6.1  )   *    Most common adverse reactions (>=20%) for TAFINLAR in combination with trametinib are pyrexia, chills, fatigue, rash, nausea, vomiting, diarrhea, abdominal pain, peripheral edema, cough, headache, arthralgia, night sweats, decreased appetite, constipation, and myalgia.",peripheral edema is an adverse reaction entity
"(  6.1  )   *    Most common adverse reactions (>=20%) for TAFINLAR in combination with trametinib are pyrexia, chills, fatigue, rash, nausea, vomiting, diarrhea, abdominal pain, peripheral edema, cough, headache, arthralgia, night sweats, decreased appetite, constipation, and myalgia.",", is not a named entity"
"(  6.1  )   *    Most common adverse reactions (>=20%) for TAFINLAR in combination with trametinib are pyrexia, chills, fatigue, rash, nausea, vomiting, diarrhea, abdominal pain, peripheral edema, cough, headache, arthralgia, night sweats, decreased appetite, constipation, and myalgia.",* is not a named entity
"(  6.1  )   *    Most common adverse reactions (>=20%) for TAFINLAR in combination with trametinib are pyrexia, chills, fatigue, rash, nausea, vomiting, diarrhea, abdominal pain, peripheral edema, cough, headache, arthralgia, night sweats, decreased appetite, constipation, and myalgia.",", is not a named entity"
"(  6.1  )   *    Most common adverse reactions (>=20%) for TAFINLAR in combination with trametinib are pyrexia, chills, fatigue, rash, nausea, vomiting, diarrhea, abdominal pain, peripheral edema, cough, headache, arthralgia, night sweats, decreased appetite, constipation, and myalgia.",", decreased appetite is not a named entity"
"(  6.1  )   *    Most common adverse reactions (>=20%) for TAFINLAR in combination with trametinib are pyrexia, chills, fatigue, rash, nausea, vomiting, diarrhea, abdominal pain, peripheral edema, cough, headache, arthralgia, night sweats, decreased appetite, constipation, and myalgia.",constipation is an adverse reaction entity
"(  6.1  )   *    Most common adverse reactions (>=20%) for TAFINLAR in combination with trametinib are pyrexia, chills, fatigue, rash, nausea, vomiting, diarrhea, abdominal pain, peripheral edema, cough, headache, arthralgia, night sweats, decreased appetite, constipation, and myalgia.",", cough is not a named entity"
"(  6.1  )   *    Most common adverse reactions (>=20%) for TAFINLAR in combination with trametinib are pyrexia, chills, fatigue, rash, nausea, vomiting, diarrhea, abdominal pain, peripheral edema, cough, headache, arthralgia, night sweats, decreased appetite, constipation, and myalgia.",pyrexia is an adverse reaction entity
"(  6.1  )   *    Most common adverse reactions (>=20%) for TAFINLAR in combination with trametinib are pyrexia, chills, fatigue, rash, nausea, vomiting, diarrhea, abdominal pain, peripheral edema, cough, headache, arthralgia, night sweats, decreased appetite, constipation, and myalgia.",arthralgia is an adverse reaction entity
"(  6.1  )   *    Most common adverse reactions (>=20%) for TAFINLAR in combination with trametinib are pyrexia, chills, fatigue, rash, nausea, vomiting, diarrhea, abdominal pain, peripheral edema, cough, headache, arthralgia, night sweats, decreased appetite, constipation, and myalgia.",chills is an adverse reaction entity
"(  6.1  )   *    Most common adverse reactions (>=20%) for TAFINLAR in combination with trametinib are pyrexia, chills, fatigue, rash, nausea, vomiting, diarrhea, abdominal pain, peripheral edema, cough, headache, arthralgia, night sweats, decreased appetite, constipation, and myalgia.",in combination with is not a named entity
"(  6.1  )   *    Most common adverse reactions (>=20%) for TAFINLAR in combination with trametinib are pyrexia, chills, fatigue, rash, nausea, vomiting, diarrhea, abdominal pain, peripheral edema, cough, headache, arthralgia, night sweats, decreased appetite, constipation, and myalgia.",pain is not a named entity
"(  6.1  )   *    Most common adverse reactions (>=20%) for TAFINLAR in combination with trametinib are pyrexia, chills, fatigue, rash, nausea, vomiting, diarrhea, abdominal pain, peripheral edema, cough, headache, arthralgia, night sweats, decreased appetite, constipation, and myalgia.","arthralgia , night is not a named entity"
"(  6.1  )   *    Most common adverse reactions (>=20%) for TAFINLAR in combination with trametinib are pyrexia, chills, fatigue, rash, nausea, vomiting, diarrhea, abdominal pain, peripheral edema, cough, headache, arthralgia, night sweats, decreased appetite, constipation, and myalgia.",headache is an adverse reaction entity
"(  6.1  )   *    Most common adverse reactions (>=20%) for TAFINLAR in combination with trametinib are pyrexia, chills, fatigue, rash, nausea, vomiting, diarrhea, abdominal pain, peripheral edema, cough, headache, arthralgia, night sweats, decreased appetite, constipation, and myalgia.",Most common adverse is not a named entity
"(  6.1  )   *    Most common adverse reactions (>=20%) for TAFINLAR in combination with trametinib are pyrexia, chills, fatigue, rash, nausea, vomiting, diarrhea, abdominal pain, peripheral edema, cough, headache, arthralgia, night sweats, decreased appetite, constipation, and myalgia.",cough is an adverse reaction entity
"(  6.1  )   *    Most common adverse reactions (>=20%) for TAFINLAR in combination with trametinib are pyrexia, chills, fatigue, rash, nausea, vomiting, diarrhea, abdominal pain, peripheral edema, cough, headache, arthralgia, night sweats, decreased appetite, constipation, and myalgia.","headache , is not a named entity"
"(  6.1  )   *    Most common adverse reactions (>=20%) for TAFINLAR in combination with trametinib are pyrexia, chills, fatigue, rash, nausea, vomiting, diarrhea, abdominal pain, peripheral edema, cough, headache, arthralgia, night sweats, decreased appetite, constipation, and myalgia.",myalgia is an adverse reaction entity
"(  6.1  )   *    Most common adverse reactions (>=20%) for TAFINLAR in combination with trametinib are pyrexia, chills, fatigue, rash, nausea, vomiting, diarrhea, abdominal pain, peripheral edema, cough, headache, arthralgia, night sweats, decreased appetite, constipation, and myalgia.",decreased appetite is an adverse reaction entity
"(  6.1  )   *    Most common adverse reactions (>=20%) for TAFINLAR in combination with trametinib are pyrexia, chills, fatigue, rash, nausea, vomiting, diarrhea, abdominal pain, peripheral edema, cough, headache, arthralgia, night sweats, decreased appetite, constipation, and myalgia.",night sweats is an adverse reaction entity
"(  6.1  )   *    Most common adverse reactions (>=20%) for TAFINLAR in combination with trametinib are pyrexia, chills, fatigue, rash, nausea, vomiting, diarrhea, abdominal pain, peripheral edema, cough, headache, arthralgia, night sweats, decreased appetite, constipation, and myalgia.",fatigue is an adverse reaction entity
"(  6.1  )   *    Most common adverse reactions (>=20%) for TAFINLAR in combination with trametinib are pyrexia, chills, fatigue, rash, nausea, vomiting, diarrhea, abdominal pain, peripheral edema, cough, headache, arthralgia, night sweats, decreased appetite, constipation, and myalgia.",rash is an adverse reaction entity
"(  6.1  )   *    Most common adverse reactions (>=20%) for TAFINLAR in combination with trametinib are pyrexia, chills, fatigue, rash, nausea, vomiting, diarrhea, abdominal pain, peripheral edema, cough, headache, arthralgia, night sweats, decreased appetite, constipation, and myalgia.",nausea is an adverse reaction entity
"(  6.1  )   *    Most common adverse reactions (>=20%) for TAFINLAR in combination with trametinib are pyrexia, chills, fatigue, rash, nausea, vomiting, diarrhea, abdominal pain, peripheral edema, cough, headache, arthralgia, night sweats, decreased appetite, constipation, and myalgia.",) is not a named entity
"(  6.1  )   *    Most common adverse reactions (>=20%) for TAFINLAR in combination with trametinib are pyrexia, chills, fatigue, rash, nausea, vomiting, diarrhea, abdominal pain, peripheral edema, cough, headache, arthralgia, night sweats, decreased appetite, constipation, and myalgia.",with trametinib are is not a named entity
"(  6.1  )   *    Most common adverse reactions (>=20%) for TAFINLAR in combination with trametinib are pyrexia, chills, fatigue, rash, nausea, vomiting, diarrhea, abdominal pain, peripheral edema, cough, headache, arthralgia, night sweats, decreased appetite, constipation, and myalgia.",=20 % ) is not a named entity
"(  6.1  )   *    Most common adverse reactions (>=20%) for TAFINLAR in combination with trametinib are pyrexia, chills, fatigue, rash, nausea, vomiting, diarrhea, abdominal pain, peripheral edema, cough, headache, arthralgia, night sweats, decreased appetite, constipation, and myalgia.",Most common is not a named entity
"(  6.1  )   *    Most common adverse reactions (>=20%) for TAFINLAR in combination with trametinib are pyrexia, chills, fatigue, rash, nausea, vomiting, diarrhea, abdominal pain, peripheral edema, cough, headache, arthralgia, night sweats, decreased appetite, constipation, and myalgia.","fatigue , rash is not a named entity"
Uveitis (including iritis) occurred in 1% (6/586) of patients treated with TAFINLAR as a single agent and uveitis occurred in 1% (2/202) of patients treated with TAFINLAR in combination with trametinib.,patients is not a named entity
Uveitis (including iritis) occurred in 1% (6/586) of patients treated with TAFINLAR as a single agent and uveitis occurred in 1% (2/202) of patients treated with TAFINLAR in combination with trametinib.,Uveitis is an adverse reaction entity
Uveitis (including iritis) occurred in 1% (6/586) of patients treated with TAFINLAR as a single agent and uveitis occurred in 1% (2/202) of patients treated with TAFINLAR in combination with trametinib.,iritis is an adverse reaction entity
Uveitis (including iritis) occurred in 1% (6/586) of patients treated with TAFINLAR as a single agent and uveitis occurred in 1% (2/202) of patients treated with TAFINLAR in combination with trametinib.,uveitis is an adverse reaction entity
Uveitis (including iritis) occurred in 1% (6/586) of patients treated with TAFINLAR as a single agent and uveitis occurred in 1% (2/202) of patients treated with TAFINLAR in combination with trametinib.,Uveitis ( is not a named entity
Uveitis (including iritis) occurred in 1% (6/586) of patients treated with TAFINLAR as a single agent and uveitis occurred in 1% (2/202) of patients treated with TAFINLAR in combination with trametinib.,Uveitis ( including is not a named entity
"The most frequent (>=2%) adverse reactions leading to dose reduction of TAFINLAR were pyrexia (9%), PPES (3%), chills (3%), fatigue (2%), and headache (2%).",dose reduction of is not a named entity
"The most frequent (>=2%) adverse reactions leading to dose reduction of TAFINLAR were pyrexia (9%), PPES (3%), chills (3%), fatigue (2%), and headache (2%).",chills is an adverse reaction entity
"The most frequent (>=2%) adverse reactions leading to dose reduction of TAFINLAR were pyrexia (9%), PPES (3%), chills (3%), fatigue (2%), and headache (2%).",reduction of TAFINLAR is not a named entity
"The most frequent (>=2%) adverse reactions leading to dose reduction of TAFINLAR were pyrexia (9%), PPES (3%), chills (3%), fatigue (2%), and headache (2%).",dose reduction of is not a named entity
"The most frequent (>=2%) adverse reactions leading to dose reduction of TAFINLAR were pyrexia (9%), PPES (3%), chills (3%), fatigue (2%), and headache (2%).",headache is an adverse reaction entity
"The most frequent (>=2%) adverse reactions leading to dose reduction of TAFINLAR were pyrexia (9%), PPES (3%), chills (3%), fatigue (2%), and headache (2%).",fatigue ( is not a named entity
"The most frequent (>=2%) adverse reactions leading to dose reduction of TAFINLAR were pyrexia (9%), PPES (3%), chills (3%), fatigue (2%), and headache (2%).",PPES is an adverse reaction entity
"The most frequent (>=2%) adverse reactions leading to dose reduction of TAFINLAR were pyrexia (9%), PPES (3%), chills (3%), fatigue (2%), and headache (2%).",pyrexia is an adverse reaction entity
"The most frequent (>=2%) adverse reactions leading to dose reduction of TAFINLAR were pyrexia (9%), PPES (3%), chills (3%), fatigue (2%), and headache (2%).",fatigue is an adverse reaction entity
"The most frequent (>=2%) adverse reactions leading to dose reduction of TAFINLAR were pyrexia (9%), PPES (3%), chills (3%), fatigue (2%), and headache (2%).",frequent is not a named entity
"Skin and Subcutaneous Tissue Disorders:  Palmar-plantar erythrodysesthesia syndrome, hyperkeratosis, hyperhidrosis.","hyperkeratosis , hyperhidrosis is not a named entity"
"Skin and Subcutaneous Tissue Disorders:  Palmar-plantar erythrodysesthesia syndrome, hyperkeratosis, hyperhidrosis.",Skin is not a named entity
"Skin and Subcutaneous Tissue Disorders:  Palmar-plantar erythrodysesthesia syndrome, hyperkeratosis, hyperhidrosis.",hyperhidrosis is an adverse reaction entity
"Skin and Subcutaneous Tissue Disorders:  Palmar-plantar erythrodysesthesia syndrome, hyperkeratosis, hyperhidrosis.",Palmar-plantar erythrodysesthesia syndrome is an adverse reaction entity
"Skin and Subcutaneous Tissue Disorders:  Palmar-plantar erythrodysesthesia syndrome, hyperkeratosis, hyperhidrosis.",hyperkeratosis is an adverse reaction entity
"Skin and Subcutaneous Tissue Disorders:  Palmar-plantar erythrodysesthesia syndrome, hyperkeratosis, hyperhidrosis.",Disorders : is not a named entity
"5.10 Glucose-6-Phosphate Dehydrogenase Deficiency      TAFINLAR, which contains a sulfonamide moiety, confers a potential risk of hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency.",hemolytic anemia is an adverse reaction entity
"5.10 Glucose-6-Phosphate Dehydrogenase Deficiency      TAFINLAR, which contains a sulfonamide moiety, confers a potential risk of hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency.",potential risk of is not a named entity
"(  5.11  ,  8.1  )        EXCERPT:          5.1 New Primary Malignancies      New primary malignancies, cutaneous and non-cutaneous, can occur when TAFINLAR is administered as a single agent or when used in combination with trametinib.",in combination with is not a named entity
"(  5.11  ,  8.1  )        EXCERPT:          5.1 New Primary Malignancies      New primary malignancies, cutaneous and non-cutaneous, can occur when TAFINLAR is administered as a single agent or when used in combination with trametinib.",primary malignancies non-cutaneous is an adverse reaction entity
"(  5.11  ,  8.1  )        EXCERPT:          5.1 New Primary Malignancies      New primary malignancies, cutaneous and non-cutaneous, can occur when TAFINLAR is administered as a single agent or when used in combination with trametinib.","primary malignancies, cutaneous is an adverse reaction entity"
"(  5.11  ,  8.1  )        EXCERPT:          5.1 New Primary Malignancies      New primary malignancies, cutaneous and non-cutaneous, can occur when TAFINLAR is administered as a single agent or when used in combination with trametinib.",) EXCERPT is not a named entity
"In Trial 1, cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC) occurred in 7% (14/187) of patients treated with TAFINLAR and in none of the patients treated with dacarbazine.",keratoacanthomas is an adverse reaction entity
"In Trial 1, cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC) occurred in 7% (14/187) of patients treated with TAFINLAR and in none of the patients treated with dacarbazine.",( is not a named entity
"In Trial 1, cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC) occurred in 7% (14/187) of patients treated with TAFINLAR and in none of the patients treated with dacarbazine.",none is not a named entity
"In Trial 1, cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC) occurred in 7% (14/187) of patients treated with TAFINLAR and in none of the patients treated with dacarbazine.",) occurred in is not a named entity
"In Trial 1, cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC) occurred in 7% (14/187) of patients treated with TAFINLAR and in none of the patients treated with dacarbazine.",cutaneous squamous cell carcinomas is an adverse reaction entity
"In Trial 1, cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC) occurred in 7% (14/187) of patients treated with TAFINLAR and in none of the patients treated with dacarbazine.",cuSCC is an adverse reaction entity
"(  5.1  ,  2.3  )   *    Tumor Promotion in BRAF Wild-Type Melanoma: Increased cell proliferation can occur with BRAF inhibitors.",Increased cell proliferation is an adverse reaction entity
"(  5.1  ,  2.3  )   *    Tumor Promotion in BRAF Wild-Type Melanoma: Increased cell proliferation can occur with BRAF inhibitors.",Tumor Promotion in BRAF Wild-Type Melanoma is an adverse reaction entity
"(  5.1  ,  2.3  )   *    Tumor Promotion in BRAF Wild-Type Melanoma: Increased cell proliferation can occur with BRAF inhibitors.",Promotion is not a named entity
"(  5.1  ,  2.3  )   *    Tumor Promotion in BRAF Wild-Type Melanoma: Increased cell proliferation can occur with BRAF inhibitors.",proliferation can occur is not a named entity
Increases in blood pressure were unrelated to the pretreatment blood pressure but were related to treatment-related increases in pain.,increases in pain is an adverse reaction entity
Increases in blood pressure were unrelated to the pretreatment blood pressure but were related to treatment-related increases in pain.,Increases in blood pressure is an adverse reaction entity
Increases in blood pressure were unrelated to the pretreatment blood pressure but were related to treatment-related increases in pain.,blood pressure were is not a named entity
Increases in blood pressure were unrelated to the pretreatment blood pressure but were related to treatment-related increases in pain.,but is not a named entity
"5.4 Application Associated Pain      Even following use of a local anesthetic prior to administration of Qutenza, patients may experience substantial procedural pain.",following use is not a named entity
"5.4 Application Associated Pain      Even following use of a local anesthetic prior to administration of Qutenza, patients may experience substantial procedural pain.",procedural pain is an adverse reaction entity
"Patients with unstable or poorly controlled hypertension, a recent history of cardiovascular or cerebrovascular events may be at an increased risk of adverse cardiovascular effects.",adverse cardiovascular effects is an adverse reaction entity
"Patients with unstable or poorly controlled hypertension, a recent history of cardiovascular or cerebrovascular events may be at an increased risk of adverse cardiovascular effects.",cardiovascular effects is not a named entity
"(  5.2  ,  5.3  )   *  Transient increases in blood pressure may occur in patients during and shortly after the Qutenza treatment.",increases in blood pressure is an adverse reaction entity
"(  5.2  ,  5.3  )   *  Transient increases in blood pressure may occur in patients during and shortly after the Qutenza treatment.",shortly after the is not a named entity
"5.5 Increase in Blood Pressure      In clinical trials, increases in blood pressure occurred during or shortly after exposure to Qutenza.",increases in blood pressure is an adverse reaction entity
"5.5 Increase in Blood Pressure      In clinical trials, increases in blood pressure occurred during or shortly after exposure to Qutenza.",trials is not a named entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed elsewhere in the labeling:     Application-Associated Pain [  see  Warnings and Precautions (5.4  )]       Increase in Blood Pressure [  see  Warnings and Precautions (5.5  )]         EXCERPT:   The most common adverse reactions (>= 5% and greater than control) are application site erythema, application site pain, application site pruritus and application site papules.",Application-Associated Pain is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed elsewhere in the labeling:     Application-Associated Pain [  see  Warnings and Precautions (5.4  )]       Increase in Blood Pressure [  see  Warnings and Precautions (5.5  )]         EXCERPT:   The most common adverse reactions (>= 5% and greater than control) are application site erythema, application site pain, application site pruritus and application site papules.",= 5 % is not a named entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed elsewhere in the labeling:     Application-Associated Pain [  see  Warnings and Precautions (5.4  )]       Increase in Blood Pressure [  see  Warnings and Precautions (5.5  )]         EXCERPT:   The most common adverse reactions (>= 5% and greater than control) are application site erythema, application site pain, application site pruritus and application site papules.",site pruritus is not a named entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed elsewhere in the labeling:     Application-Associated Pain [  see  Warnings and Precautions (5.4  )]       Increase in Blood Pressure [  see  Warnings and Precautions (5.5  )]         EXCERPT:   The most common adverse reactions (>= 5% and greater than control) are application site erythema, application site pain, application site pruritus and application site papules.",control is not a named entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed elsewhere in the labeling:     Application-Associated Pain [  see  Warnings and Precautions (5.4  )]       Increase in Blood Pressure [  see  Warnings and Precautions (5.5  )]         EXCERPT:   The most common adverse reactions (>= 5% and greater than control) are application site erythema, application site pain, application site pruritus and application site papules.",site pruritus is not a named entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed elsewhere in the labeling:     Application-Associated Pain [  see  Warnings and Precautions (5.4  )]       Increase in Blood Pressure [  see  Warnings and Precautions (5.5  )]         EXCERPT:   The most common adverse reactions (>= 5% and greater than control) are application site erythema, application site pain, application site pruritus and application site papules.",5.4 ) ] is not a named entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed elsewhere in the labeling:     Application-Associated Pain [  see  Warnings and Precautions (5.4  )]       Increase in Blood Pressure [  see  Warnings and Precautions (5.5  )]         EXCERPT:   The most common adverse reactions (>= 5% and greater than control) are application site erythema, application site pain, application site pruritus and application site papules.",application site pain is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed elsewhere in the labeling:     Application-Associated Pain [  see  Warnings and Precautions (5.4  )]       Increase in Blood Pressure [  see  Warnings and Precautions (5.5  )]         EXCERPT:   The most common adverse reactions (>= 5% and greater than control) are application site erythema, application site pain, application site pruritus and application site papules.",application site pruritus is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed elsewhere in the labeling:     Application-Associated Pain [  see  Warnings and Precautions (5.4  )]       Increase in Blood Pressure [  see  Warnings and Precautions (5.5  )]         EXCERPT:   The most common adverse reactions (>= 5% and greater than control) are application site erythema, application site pain, application site pruritus and application site papules.",following serious adverse is not a named entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed elsewhere in the labeling:     Application-Associated Pain [  see  Warnings and Precautions (5.4  )]       Increase in Blood Pressure [  see  Warnings and Precautions (5.5  )]         EXCERPT:   The most common adverse reactions (>= 5% and greater than control) are application site erythema, application site pain, application site pruritus and application site papules.",application site papules is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed elsewhere in the labeling:     Application-Associated Pain [  see  Warnings and Precautions (5.4  )]       Increase in Blood Pressure [  see  Warnings and Precautions (5.5  )]         EXCERPT:   The most common adverse reactions (>= 5% and greater than control) are application site erythema, application site pain, application site pruritus and application site papules.",Increase in Blood Pressure is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed elsewhere in the labeling:     Application-Associated Pain [  see  Warnings and Precautions (5.4  )]       Increase in Blood Pressure [  see  Warnings and Precautions (5.5  )]         EXCERPT:   The most common adverse reactions (>= 5% and greater than control) are application site erythema, application site pain, application site pruritus and application site papules.",application site erythema is an adverse reaction entity
(  5.1  )   *  Inhalation of airborne capsaicin can result in coughing or sneezing.,coughing is an adverse reaction entity
(  5.1  )   *  Inhalation of airborne capsaicin can result in coughing or sneezing.,) * Inhalation is not a named entity
(  5.1  )   *  Inhalation of airborne capsaicin can result in coughing or sneezing.,sneezing is an adverse reaction entity
(  5.1  )   *  Inhalation of airborne capsaicin can result in coughing or sneezing.,result in is not a named entity
EXCERPT:    Hyperammonemia  : Monitor plasma ammonia levels during treatment.,Hyperammonemia : Monitor is not a named entity
EXCERPT:    Hyperammonemia  : Monitor plasma ammonia levels during treatment.,Hyperammonemia is an adverse reaction entity
"6 ADVERSE REACTIONS      6.1    Retrospective Case Series Experience                  The most common adverse reactions (occurring in >= 13% of patients), regardless of causality, are: Infections, vomiting, abdominal pain, pyrexia, tonsilitis, anemia, ear infection, diarrhea, nasopharyngitis, and headache.",adverse reactions ( is not a named entity
"6 ADVERSE REACTIONS      6.1    Retrospective Case Series Experience                  The most common adverse reactions (occurring in >= 13% of patients), regardless of causality, are: Infections, vomiting, abdominal pain, pyrexia, tonsilitis, anemia, ear infection, diarrhea, nasopharyngitis, and headache.",headache is an adverse reaction entity
"6 ADVERSE REACTIONS      6.1    Retrospective Case Series Experience                  The most common adverse reactions (occurring in >= 13% of patients), regardless of causality, are: Infections, vomiting, abdominal pain, pyrexia, tonsilitis, anemia, ear infection, diarrhea, nasopharyngitis, and headache.",vomiting is an adverse reaction entity
"6 ADVERSE REACTIONS      6.1    Retrospective Case Series Experience                  The most common adverse reactions (occurring in >= 13% of patients), regardless of causality, are: Infections, vomiting, abdominal pain, pyrexia, tonsilitis, anemia, ear infection, diarrhea, nasopharyngitis, and headache.","vomiting , is not a named entity"
"6 ADVERSE REACTIONS      6.1    Retrospective Case Series Experience                  The most common adverse reactions (occurring in >= 13% of patients), regardless of causality, are: Infections, vomiting, abdominal pain, pyrexia, tonsilitis, anemia, ear infection, diarrhea, nasopharyngitis, and headache.",tonsilitis is an adverse reaction entity
"6 ADVERSE REACTIONS      6.1    Retrospective Case Series Experience                  The most common adverse reactions (occurring in >= 13% of patients), regardless of causality, are: Infections, vomiting, abdominal pain, pyrexia, tonsilitis, anemia, ear infection, diarrhea, nasopharyngitis, and headache.",", ear is not a named entity"
"6 ADVERSE REACTIONS      6.1    Retrospective Case Series Experience                  The most common adverse reactions (occurring in >= 13% of patients), regardless of causality, are: Infections, vomiting, abdominal pain, pyrexia, tonsilitis, anemia, ear infection, diarrhea, nasopharyngitis, and headache.",ADVERSE REACTIONS is not a named entity
"6 ADVERSE REACTIONS      6.1    Retrospective Case Series Experience                  The most common adverse reactions (occurring in >= 13% of patients), regardless of causality, are: Infections, vomiting, abdominal pain, pyrexia, tonsilitis, anemia, ear infection, diarrhea, nasopharyngitis, and headache.",are : Infections is not a named entity
"6 ADVERSE REACTIONS      6.1    Retrospective Case Series Experience                  The most common adverse reactions (occurring in >= 13% of patients), regardless of causality, are: Infections, vomiting, abdominal pain, pyrexia, tonsilitis, anemia, ear infection, diarrhea, nasopharyngitis, and headache.",ear infection is an adverse reaction entity
"6 ADVERSE REACTIONS      6.1    Retrospective Case Series Experience                  The most common adverse reactions (occurring in >= 13% of patients), regardless of causality, are: Infections, vomiting, abdominal pain, pyrexia, tonsilitis, anemia, ear infection, diarrhea, nasopharyngitis, and headache.",pyrexia is an adverse reaction entity
"6 ADVERSE REACTIONS      6.1    Retrospective Case Series Experience                  The most common adverse reactions (occurring in >= 13% of patients), regardless of causality, are: Infections, vomiting, abdominal pain, pyrexia, tonsilitis, anemia, ear infection, diarrhea, nasopharyngitis, and headache.",", pyrexia , is not a named entity"
"6 ADVERSE REACTIONS      6.1    Retrospective Case Series Experience                  The most common adverse reactions (occurring in >= 13% of patients), regardless of causality, are: Infections, vomiting, abdominal pain, pyrexia, tonsilitis, anemia, ear infection, diarrhea, nasopharyngitis, and headache.",anemia is an adverse reaction entity
"6 ADVERSE REACTIONS      6.1    Retrospective Case Series Experience                  The most common adverse reactions (occurring in >= 13% of patients), regardless of causality, are: Infections, vomiting, abdominal pain, pyrexia, tonsilitis, anemia, ear infection, diarrhea, nasopharyngitis, and headache.",reactions is not a named entity
"6 ADVERSE REACTIONS      6.1    Retrospective Case Series Experience                  The most common adverse reactions (occurring in >= 13% of patients), regardless of causality, are: Infections, vomiting, abdominal pain, pyrexia, tonsilitis, anemia, ear infection, diarrhea, nasopharyngitis, and headache.",Infections is an adverse reaction entity
"6 ADVERSE REACTIONS      6.1    Retrospective Case Series Experience                  The most common adverse reactions (occurring in >= 13% of patients), regardless of causality, are: Infections, vomiting, abdominal pain, pyrexia, tonsilitis, anemia, ear infection, diarrhea, nasopharyngitis, and headache.","tonsilitis , anemia is not a named entity"
"6 ADVERSE REACTIONS      6.1    Retrospective Case Series Experience                  The most common adverse reactions (occurring in >= 13% of patients), regardless of causality, are: Infections, vomiting, abdominal pain, pyrexia, tonsilitis, anemia, ear infection, diarrhea, nasopharyngitis, and headache.",and is not a named entity
"6 ADVERSE REACTIONS      6.1    Retrospective Case Series Experience                  The most common adverse reactions (occurring in >= 13% of patients), regardless of causality, are: Infections, vomiting, abdominal pain, pyrexia, tonsilitis, anemia, ear infection, diarrhea, nasopharyngitis, and headache.",", anemia is not a named entity"
"6 ADVERSE REACTIONS      6.1    Retrospective Case Series Experience                  The most common adverse reactions (occurring in >= 13% of patients), regardless of causality, are: Infections, vomiting, abdominal pain, pyrexia, tonsilitis, anemia, ear infection, diarrhea, nasopharyngitis, and headache.",diarrhea is an adverse reaction entity
"6 ADVERSE REACTIONS      6.1    Retrospective Case Series Experience                  The most common adverse reactions (occurring in >= 13% of patients), regardless of causality, are: Infections, vomiting, abdominal pain, pyrexia, tonsilitis, anemia, ear infection, diarrhea, nasopharyngitis, and headache.",abdominal pain is an adverse reaction entity
"6 ADVERSE REACTIONS      6.1    Retrospective Case Series Experience                  The most common adverse reactions (occurring in >= 13% of patients), regardless of causality, are: Infections, vomiting, abdominal pain, pyrexia, tonsilitis, anemia, ear infection, diarrhea, nasopharyngitis, and headache.",nasopharyngitis is an adverse reaction entity
5.2     Hepatotoxicity       Drug-induced hepatotoxicity occurred in patients treated with ZYKADIA.,hepatotoxicity is an adverse reaction entity
5.2     Hepatotoxicity       Drug-induced hepatotoxicity occurred in patients treated with ZYKADIA.,Hepatotoxicity is not a named entity
One percent (1%) of patients discontinued ZYKADIA in Study 1 due to ILD/pneumonitis.,ILD is an adverse reaction entity
One percent (1%) of patients discontinued ZYKADIA in Study 1 due to ILD/pneumonitis.,pneumonitis is an adverse reaction entity
One percent (1%) of patients discontinued ZYKADIA in Study 1 due to ILD/pneumonitis.,due is not a named entity
One percent (1%) of patients discontinued ZYKADIA in Study 1 due to ILD/pneumonitis.,discontinued ZYKADIA in is not a named entity
"5.7     Pancreatitis       Pancreatitis, including one fatality, has been reported in less than 1% of patients receiving ZYKADIA in clinical trials.",Pancreatitis is an adverse reaction entity
"5.7     Pancreatitis       Pancreatitis, including one fatality, has been reported in less than 1% of patients receiving ZYKADIA in clinical trials.",% of patients is not a named entity
"5.7     Pancreatitis       Pancreatitis, including one fatality, has been reported in less than 1% of patients receiving ZYKADIA in clinical trials.",fatality is an adverse reaction entity
"5.7     Pancreatitis       Pancreatitis, including one fatality, has been reported in less than 1% of patients receiving ZYKADIA in clinical trials.",of patients receiving is not a named entity
5.5     Hyperglycemia      Hyperglycemia can occur in patients receiving ZYKADIA.,Hyperglycemia Hyperglycemia is not a named entity
5.5     Hyperglycemia      Hyperglycemia can occur in patients receiving ZYKADIA.,Hyperglycemia is an adverse reaction entity
"The most frequent adverse drug reactions that led to discontinuation in 1% or more of patients in Study 1 were pneumonia, ILD/pneumonitis, and decreased appetite.",pneumonitis is an adverse reaction entity
"The most frequent adverse drug reactions that led to discontinuation in 1% or more of patients in Study 1 were pneumonia, ILD/pneumonitis, and decreased appetite.",pneumonia is an adverse reaction entity
"The most frequent adverse drug reactions that led to discontinuation in 1% or more of patients in Study 1 were pneumonia, ILD/pneumonitis, and decreased appetite.",drug reactions that is not a named entity
"The most frequent adverse drug reactions that led to discontinuation in 1% or more of patients in Study 1 were pneumonia, ILD/pneumonitis, and decreased appetite.",ILD is an adverse reaction entity
"The most frequent adverse drug reactions that led to discontinuation in 1% or more of patients in Study 1 were pneumonia, ILD/pneumonitis, and decreased appetite.",", ILD/pneumonitis , is not a named entity"
"The most frequent adverse drug reactions that led to discontinuation in 1% or more of patients in Study 1 were pneumonia, ILD/pneumonitis, and decreased appetite.",to is not a named entity
"The most frequent adverse drug reactions that led to discontinuation in 1% or more of patients in Study 1 were pneumonia, ILD/pneumonitis, and decreased appetite.",decreased appetite is an adverse reaction entity
"The most frequent adverse drug reactions that led to discontinuation in 1% or more of patients in Study 1 were pneumonia, ILD/pneumonitis, and decreased appetite.",adverse is not a named entity
"In Study 1, sinus bradycardia, defined as a heart rate of less than 50 beats per minute, was noted as a new finding in 1% of 255 patients.",50 beats is not a named entity
"In Study 1, sinus bradycardia, defined as a heart rate of less than 50 beats per minute, was noted as a new finding in 1% of 255 patients.",sinus bradycardia is an adverse reaction entity
"In Study 1, sinus bradycardia, defined as a heart rate of less than 50 beats per minute, was noted as a new finding in 1% of 255 patients.",of less is not a named entity
"In Study 1, sinus bradycardia, defined as a heart rate of less than 50 beats per minute, was noted as a new finding in 1% of 255 patients.",heart rate of less than 50 beats per minute is an adverse reaction entity
"CTCAE Grade 3 or 4 ILD/pneumonitis was reported in 3% of patients, and fatal ILD/pneumonitis was reported in 1 patient (0.4%) in Study 1.",pneumonitis is an adverse reaction entity
"CTCAE Grade 3 or 4 ILD/pneumonitis was reported in 3% of patients, and fatal ILD/pneumonitis was reported in 1 patient (0.4%) in Study 1.",fatal is an adverse reaction entity
"CTCAE Grade 3 or 4 ILD/pneumonitis was reported in 3% of patients, and fatal ILD/pneumonitis was reported in 1 patient (0.4%) in Study 1.",ILD is an adverse reaction entity
"CTCAE Grade 3 or 4 ILD/pneumonitis was reported in 3% of patients, and fatal ILD/pneumonitis was reported in 1 patient (0.4%) in Study 1.",", and fatal is not a named entity"
"CTCAE Grade 3 or 4 ILD/pneumonitis was reported in 3% of patients, and fatal ILD/pneumonitis was reported in 1 patient (0.4%) in Study 1.",pneumonitis is an adverse reaction entity
"CTCAE Grade 3 or 4 ILD/pneumonitis was reported in 3% of patients, and fatal ILD/pneumonitis was reported in 1 patient (0.4%) in Study 1.","of patients , is not a named entity"
"CTCAE Grade 3 or 4 ILD/pneumonitis was reported in 3% of patients, and fatal ILD/pneumonitis was reported in 1 patient (0.4%) in Study 1.",and fatal ILD/pneumonitis is not a named entity
"CTCAE Grade 3 or 4 ILD/pneumonitis was reported in 3% of patients, and fatal ILD/pneumonitis was reported in 1 patient (0.4%) in Study 1.",) in Study is not a named entity
"CTCAE Grade 3 or 4 ILD/pneumonitis was reported in 3% of patients, and fatal ILD/pneumonitis was reported in 1 patient (0.4%) in Study 1.",ILD is an adverse reaction entity
"CTCAE Grade 3 or 4 ILD/pneumonitis was reported in 3% of patients, and fatal ILD/pneumonitis was reported in 1 patient (0.4%) in Study 1.",4 ILD/pneumonitis is not a named entity
There was a 6-fold increase in the risk of CTCAE Grade 3-4 hyperglycemia in patients with diabetes or glucose intolerance and a 2-fold increase in patients taking corticosteroids.,in patients is not a named entity
There was a 6-fold increase in the risk of CTCAE Grade 3-4 hyperglycemia in patients with diabetes or glucose intolerance and a 2-fold increase in patients taking corticosteroids.,hyperglycemia is an adverse reaction entity
"The most frequent adverse reactions, reported in at least 10% of patients, that led to dose reductions or interruptions were: increased ALT (29%), nausea (20%), increased AST (16%), diarrhea (16%), and vomiting (16%).",that is not a named entity
"The most frequent adverse reactions, reported in at least 10% of patients, that led to dose reductions or interruptions were: increased ALT (29%), nausea (20%), increased AST (16%), diarrhea (16%), and vomiting (16%).",diarrhea is an adverse reaction entity
"The most frequent adverse reactions, reported in at least 10% of patients, that led to dose reductions or interruptions were: increased ALT (29%), nausea (20%), increased AST (16%), diarrhea (16%), and vomiting (16%).",", and is not a named entity"
"The most frequent adverse reactions, reported in at least 10% of patients, that led to dose reductions or interruptions were: increased ALT (29%), nausea (20%), increased AST (16%), diarrhea (16%), and vomiting (16%).",% ) is not a named entity
"The most frequent adverse reactions, reported in at least 10% of patients, that led to dose reductions or interruptions were: increased ALT (29%), nausea (20%), increased AST (16%), diarrhea (16%), and vomiting (16%).",", increased is not a named entity"
"The most frequent adverse reactions, reported in at least 10% of patients, that led to dose reductions or interruptions were: increased ALT (29%), nausea (20%), increased AST (16%), diarrhea (16%), and vomiting (16%).",increased AST is an adverse reaction entity
"The most frequent adverse reactions, reported in at least 10% of patients, that led to dose reductions or interruptions were: increased ALT (29%), nausea (20%), increased AST (16%), diarrhea (16%), and vomiting (16%).",vomiting is an adverse reaction entity
"The most frequent adverse reactions, reported in at least 10% of patients, that led to dose reductions or interruptions were: increased ALT (29%), nausea (20%), increased AST (16%), diarrhea (16%), and vomiting (16%).",increased ALT is an adverse reaction entity
"The most frequent adverse reactions, reported in at least 10% of patients, that led to dose reductions or interruptions were: increased ALT (29%), nausea (20%), increased AST (16%), diarrhea (16%), and vomiting (16%).",most frequent is not a named entity
"The most frequent adverse reactions, reported in at least 10% of patients, that led to dose reductions or interruptions were: increased ALT (29%), nausea (20%), increased AST (16%), diarrhea (16%), and vomiting (16%).",nausea is an adverse reaction entity
"(  2.2  ,  5.2  )   *   Interstitial Lung Disease (ILD)/Pneumonitis : Occurred in 4% of patients.",) * is not a named entity
"(  2.2  ,  5.2  )   *   Interstitial Lung Disease (ILD)/Pneumonitis : Occurred in 4% of patients.",Interstitial Lung Disease is an adverse reaction entity
"(  2.2  ,  5.2  )   *   Interstitial Lung Disease (ILD)/Pneumonitis : Occurred in 4% of patients.",Pneumonitis is an adverse reaction entity
"(  2.2  ,  5.2  )   *   Interstitial Lung Disease (ILD)/Pneumonitis : Occurred in 4% of patients.",) /Pneumonitis is not a named entity
"(  2.2  ,  5.2  )   *   Interstitial Lung Disease (ILD)/Pneumonitis : Occurred in 4% of patients.",of is not a named entity
"(  2.2  ,  5.2  )   *   Interstitial Lung Disease (ILD)/Pneumonitis : Occurred in 4% of patients.",ILD is an adverse reaction entity
"Serious adverse drug reactions reported in 2% or more of patients in Study 1 were convulsion, pneumonia, ILD/pneumonitis, dyspnea, dehydration, hyperglycemia, and nausea.","ILD/pneumonitis , dyspnea is not a named entity"
"Serious adverse drug reactions reported in 2% or more of patients in Study 1 were convulsion, pneumonia, ILD/pneumonitis, dyspnea, dehydration, hyperglycemia, and nausea.",reported is not a named entity
"Serious adverse drug reactions reported in 2% or more of patients in Study 1 were convulsion, pneumonia, ILD/pneumonitis, dyspnea, dehydration, hyperglycemia, and nausea.",of patients in is not a named entity
"Serious adverse drug reactions reported in 2% or more of patients in Study 1 were convulsion, pneumonia, ILD/pneumonitis, dyspnea, dehydration, hyperglycemia, and nausea.",in 2 is not a named entity
"Serious adverse drug reactions reported in 2% or more of patients in Study 1 were convulsion, pneumonia, ILD/pneumonitis, dyspnea, dehydration, hyperglycemia, and nausea.",reactions reported is not a named entity
"Serious adverse drug reactions reported in 2% or more of patients in Study 1 were convulsion, pneumonia, ILD/pneumonitis, dyspnea, dehydration, hyperglycemia, and nausea.",dyspnea is an adverse reaction entity
"Serious adverse drug reactions reported in 2% or more of patients in Study 1 were convulsion, pneumonia, ILD/pneumonitis, dyspnea, dehydration, hyperglycemia, and nausea.",dehydration is an adverse reaction entity
"Serious adverse drug reactions reported in 2% or more of patients in Study 1 were convulsion, pneumonia, ILD/pneumonitis, dyspnea, dehydration, hyperglycemia, and nausea.",pneumonia is an adverse reaction entity
"Serious adverse drug reactions reported in 2% or more of patients in Study 1 were convulsion, pneumonia, ILD/pneumonitis, dyspnea, dehydration, hyperglycemia, and nausea.",drug reactions is not a named entity
"Serious adverse drug reactions reported in 2% or more of patients in Study 1 were convulsion, pneumonia, ILD/pneumonitis, dyspnea, dehydration, hyperglycemia, and nausea.",more of is not a named entity
"Serious adverse drug reactions reported in 2% or more of patients in Study 1 were convulsion, pneumonia, ILD/pneumonitis, dyspnea, dehydration, hyperglycemia, and nausea.",hyperglycemia is an adverse reaction entity
"Serious adverse drug reactions reported in 2% or more of patients in Study 1 were convulsion, pneumonia, ILD/pneumonitis, dyspnea, dehydration, hyperglycemia, and nausea.",more of patients is not a named entity
"Serious adverse drug reactions reported in 2% or more of patients in Study 1 were convulsion, pneumonia, ILD/pneumonitis, dyspnea, dehydration, hyperglycemia, and nausea.",pneumonitis is an adverse reaction entity
"Serious adverse drug reactions reported in 2% or more of patients in Study 1 were convulsion, pneumonia, ILD/pneumonitis, dyspnea, dehydration, hyperglycemia, and nausea.",convulsion is an adverse reaction entity
"Serious adverse drug reactions reported in 2% or more of patients in Study 1 were convulsion, pneumonia, ILD/pneumonitis, dyspnea, dehydration, hyperglycemia, and nausea.",nausea is an adverse reaction entity
"Serious adverse drug reactions reported in 2% or more of patients in Study 1 were convulsion, pneumonia, ILD/pneumonitis, dyspnea, dehydration, hyperglycemia, and nausea.",ILD is an adverse reaction entity
"(  2.2  ,  5.6  )   *   Pancreatitis : Elevations of lipase and/or amylase and pancreatitis can occur.",pancreatitis is an adverse reaction entity
"(  2.2  ,  5.6  )   *   Pancreatitis : Elevations of lipase and/or amylase and pancreatitis can occur.",amylase and is not a named entity
"(  2.2  ,  5.6  )   *   Pancreatitis : Elevations of lipase and/or amylase and pancreatitis can occur.",Pancreatitis is an adverse reaction entity
"(  2.2  ,  5.6  )   *   Pancreatitis : Elevations of lipase and/or amylase and pancreatitis can occur.",Elevations of amylase is an adverse reaction entity
"(  2.2  ,  5.6  )   *   Pancreatitis : Elevations of lipase and/or amylase and pancreatitis can occur.",) * Pancreatitis is not a named entity
"(  2.2  ,  5.6  )   *   Pancreatitis : Elevations of lipase and/or amylase and pancreatitis can occur.",: Elevations of is not a named entity
"(  2.2  ,  5.6  )   *   Pancreatitis : Elevations of lipase and/or amylase and pancreatitis can occur.",Elevations of lipase is an adverse reaction entity
"(  2.2  ,  5.6  )   *   Pancreatitis : Elevations of lipase and/or amylase and pancreatitis can occur.",of is not a named entity
"Fatal adverse reactions in patients treated with ZYKADIA occurred in 5% of patients, consisting of: pneumonia (4 patients), respiratory failure, ILD/pneumonitis, pneumothorax, gastric hemorrhage, general physical health deterioration, pulmonary tuberculosis, cardiac tamponade, and sepsis (1 patient each).",: pneumonia ( is not a named entity
"Fatal adverse reactions in patients treated with ZYKADIA occurred in 5% of patients, consisting of: pneumonia (4 patients), respiratory failure, ILD/pneumonitis, pneumothorax, gastric hemorrhage, general physical health deterioration, pulmonary tuberculosis, cardiac tamponade, and sepsis (1 patient each).",4 is not a named entity
"Fatal adverse reactions in patients treated with ZYKADIA occurred in 5% of patients, consisting of: pneumonia (4 patients), respiratory failure, ILD/pneumonitis, pneumothorax, gastric hemorrhage, general physical health deterioration, pulmonary tuberculosis, cardiac tamponade, and sepsis (1 patient each).",", is not a named entity"
"Fatal adverse reactions in patients treated with ZYKADIA occurred in 5% of patients, consisting of: pneumonia (4 patients), respiratory failure, ILD/pneumonitis, pneumothorax, gastric hemorrhage, general physical health deterioration, pulmonary tuberculosis, cardiac tamponade, and sepsis (1 patient each).",4 patients is not a named entity
"Fatal adverse reactions in patients treated with ZYKADIA occurred in 5% of patients, consisting of: pneumonia (4 patients), respiratory failure, ILD/pneumonitis, pneumothorax, gastric hemorrhage, general physical health deterioration, pulmonary tuberculosis, cardiac tamponade, and sepsis (1 patient each).",physical health deterioration is not a named entity
"Fatal adverse reactions in patients treated with ZYKADIA occurred in 5% of patients, consisting of: pneumonia (4 patients), respiratory failure, ILD/pneumonitis, pneumothorax, gastric hemorrhage, general physical health deterioration, pulmonary tuberculosis, cardiac tamponade, and sepsis (1 patient each).",ILD is an adverse reaction entity
"Fatal adverse reactions in patients treated with ZYKADIA occurred in 5% of patients, consisting of: pneumonia (4 patients), respiratory failure, ILD/pneumonitis, pneumothorax, gastric hemorrhage, general physical health deterioration, pulmonary tuberculosis, cardiac tamponade, and sepsis (1 patient each).",pneumothorax is an adverse reaction entity
"Fatal adverse reactions in patients treated with ZYKADIA occurred in 5% of patients, consisting of: pneumonia (4 patients), respiratory failure, ILD/pneumonitis, pneumothorax, gastric hemorrhage, general physical health deterioration, pulmonary tuberculosis, cardiac tamponade, and sepsis (1 patient each).",occurred in is not a named entity
"Fatal adverse reactions in patients treated with ZYKADIA occurred in 5% of patients, consisting of: pneumonia (4 patients), respiratory failure, ILD/pneumonitis, pneumothorax, gastric hemorrhage, general physical health deterioration, pulmonary tuberculosis, cardiac tamponade, and sepsis (1 patient each).",Fatal is an adverse reaction entity
"Fatal adverse reactions in patients treated with ZYKADIA occurred in 5% of patients, consisting of: pneumonia (4 patients), respiratory failure, ILD/pneumonitis, pneumothorax, gastric hemorrhage, general physical health deterioration, pulmonary tuberculosis, cardiac tamponade, and sepsis (1 patient each).",respiratory failure is an adverse reaction entity
"Fatal adverse reactions in patients treated with ZYKADIA occurred in 5% of patients, consisting of: pneumonia (4 patients), respiratory failure, ILD/pneumonitis, pneumothorax, gastric hemorrhage, general physical health deterioration, pulmonary tuberculosis, cardiac tamponade, and sepsis (1 patient each).",pneumonia is an adverse reaction entity
"Fatal adverse reactions in patients treated with ZYKADIA occurred in 5% of patients, consisting of: pneumonia (4 patients), respiratory failure, ILD/pneumonitis, pneumothorax, gastric hemorrhage, general physical health deterioration, pulmonary tuberculosis, cardiac tamponade, and sepsis (1 patient each).",physical health deterioration is not a named entity
"Fatal adverse reactions in patients treated with ZYKADIA occurred in 5% of patients, consisting of: pneumonia (4 patients), respiratory failure, ILD/pneumonitis, pneumothorax, gastric hemorrhage, general physical health deterioration, pulmonary tuberculosis, cardiac tamponade, and sepsis (1 patient each).",patients is not a named entity
"Fatal adverse reactions in patients treated with ZYKADIA occurred in 5% of patients, consisting of: pneumonia (4 patients), respiratory failure, ILD/pneumonitis, pneumothorax, gastric hemorrhage, general physical health deterioration, pulmonary tuberculosis, cardiac tamponade, and sepsis (1 patient each).",cardiac tamponade is an adverse reaction entity
"Fatal adverse reactions in patients treated with ZYKADIA occurred in 5% of patients, consisting of: pneumonia (4 patients), respiratory failure, ILD/pneumonitis, pneumothorax, gastric hemorrhage, general physical health deterioration, pulmonary tuberculosis, cardiac tamponade, and sepsis (1 patient each).",gastric hemorrhage is an adverse reaction entity
"Fatal adverse reactions in patients treated with ZYKADIA occurred in 5% of patients, consisting of: pneumonia (4 patients), respiratory failure, ILD/pneumonitis, pneumothorax, gastric hemorrhage, general physical health deterioration, pulmonary tuberculosis, cardiac tamponade, and sepsis (1 patient each).",pneumonitis is an adverse reaction entity
"Fatal adverse reactions in patients treated with ZYKADIA occurred in 5% of patients, consisting of: pneumonia (4 patients), respiratory failure, ILD/pneumonitis, pneumothorax, gastric hemorrhage, general physical health deterioration, pulmonary tuberculosis, cardiac tamponade, and sepsis (1 patient each).",each is not a named entity
"Fatal adverse reactions in patients treated with ZYKADIA occurred in 5% of patients, consisting of: pneumonia (4 patients), respiratory failure, ILD/pneumonitis, pneumothorax, gastric hemorrhage, general physical health deterioration, pulmonary tuberculosis, cardiac tamponade, and sepsis (1 patient each).",sepsis is an adverse reaction entity
"Fatal adverse reactions in patients treated with ZYKADIA occurred in 5% of patients, consisting of: pneumonia (4 patients), respiratory failure, ILD/pneumonitis, pneumothorax, gastric hemorrhage, general physical health deterioration, pulmonary tuberculosis, cardiac tamponade, and sepsis (1 patient each).",general physical health deterioration is an adverse reaction entity
"Fatal adverse reactions in patients treated with ZYKADIA occurred in 5% of patients, consisting of: pneumonia (4 patients), respiratory failure, ILD/pneumonitis, pneumothorax, gastric hemorrhage, general physical health deterioration, pulmonary tuberculosis, cardiac tamponade, and sepsis (1 patient each).","pneumothorax , is not a named entity"
"Fatal adverse reactions in patients treated with ZYKADIA occurred in 5% of patients, consisting of: pneumonia (4 patients), respiratory failure, ILD/pneumonitis, pneumothorax, gastric hemorrhage, general physical health deterioration, pulmonary tuberculosis, cardiac tamponade, and sepsis (1 patient each).",pulmonary tuberculosis is an adverse reaction entity
"Fatal adverse reactions in patients treated with ZYKADIA occurred in 5% of patients, consisting of: pneumonia (4 patients), respiratory failure, ILD/pneumonitis, pneumothorax, gastric hemorrhage, general physical health deterioration, pulmonary tuberculosis, cardiac tamponade, and sepsis (1 patient each).",ZYKADIA occurred is not a named entity
"(  2.2  ,  5.3  )   *   QT Interval Prolongation : ZYKADIA can cause QTc interval prolongation.",ZYKADIA is not a named entity
"(  2.2  ,  5.3  )   *   QT Interval Prolongation : ZYKADIA can cause QTc interval prolongation.",QTc interval prolongation is an adverse reaction entity
"(  2.2  ,  5.3  )   *   QT Interval Prolongation : ZYKADIA can cause QTc interval prolongation.",Interval Prolongation : is not a named entity
"(  2.2  ,  5.3  )   *   QT Interval Prolongation : ZYKADIA can cause QTc interval prolongation.",QT Interval Prolongation is an adverse reaction entity
"Concurrent elevations in ALT greater than 3 times the ULN and total bilirubin greater than 2 times the ULN, with normal alkaline phosphatase, occurred in less than 1% of patients in clinical studies.",elevations in ALT is an adverse reaction entity
"Concurrent elevations in ALT greater than 3 times the ULN and total bilirubin greater than 2 times the ULN, with normal alkaline phosphatase, occurred in less than 1% of patients in clinical studies.",total bilirubin 2 times the ULN is an adverse reaction entity
"Concurrent elevations in ALT greater than 3 times the ULN and total bilirubin greater than 2 times the ULN, with normal alkaline phosphatase, occurred in less than 1% of patients in clinical studies.","the ULN , is not a named entity"
"Concurrent elevations in ALT greater than 3 times the ULN and total bilirubin greater than 2 times the ULN, with normal alkaline phosphatase, occurred in less than 1% of patients in clinical studies.",normal is not a named entity
"Across the development program of ZYKADIA, one of 304 patients (less than 1%) treated with ZYKADIA doses ranging from 50 to 750 mg was found to have a QTc greater than 500 msec and 3% of patients had an increase from baseline QTc greater than 60 msec.",QTc greater than 500 msec is an adverse reaction entity
"Across the development program of ZYKADIA, one of 304 patients (less than 1%) treated with ZYKADIA doses ranging from 50 to 750 mg was found to have a QTc greater than 500 msec and 3% of patients had an increase from baseline QTc greater than 60 msec.",increase from baseline QTc is an adverse reaction entity
"Across the development program of ZYKADIA, one of 304 patients (less than 1%) treated with ZYKADIA doses ranging from 50 to 750 mg was found to have a QTc greater than 500 msec and 3% of patients had an increase from baseline QTc greater than 60 msec.",to is not a named entity
"Across the development program of ZYKADIA, one of 304 patients (less than 1%) treated with ZYKADIA doses ranging from 50 to 750 mg was found to have a QTc greater than 500 msec and 3% of patients had an increase from baseline QTc greater than 60 msec.",less is not a named entity
"(  5.8  ,  8.1  ,  8.7  )             5.1     Severe or Persistent Gastrointestinal Toxicity      Diarrhea, nausea, vomiting, or abdominal pain occurred in 96% of 255 patients including severe cases in 14% of patients treated with ZYKADIA in Study 1.",nausea is an adverse reaction entity
"(  5.8  ,  8.1  ,  8.7  )             5.1     Severe or Persistent Gastrointestinal Toxicity      Diarrhea, nausea, vomiting, or abdominal pain occurred in 96% of 255 patients including severe cases in 14% of patients treated with ZYKADIA in Study 1.",% is not a named entity
"(  5.8  ,  8.1  ,  8.7  )             5.1     Severe or Persistent Gastrointestinal Toxicity      Diarrhea, nausea, vomiting, or abdominal pain occurred in 96% of 255 patients including severe cases in 14% of patients treated with ZYKADIA in Study 1.",patients treated is not a named entity
"(  5.8  ,  8.1  ,  8.7  )             5.1     Severe or Persistent Gastrointestinal Toxicity      Diarrhea, nausea, vomiting, or abdominal pain occurred in 96% of 255 patients including severe cases in 14% of patients treated with ZYKADIA in Study 1.",or abdominal is not a named entity
"(  5.8  ,  8.1  ,  8.7  )             5.1     Severe or Persistent Gastrointestinal Toxicity      Diarrhea, nausea, vomiting, or abdominal pain occurred in 96% of 255 patients including severe cases in 14% of patients treated with ZYKADIA in Study 1.",Diarrhea is an adverse reaction entity
"(  5.8  ,  8.1  ,  8.7  )             5.1     Severe or Persistent Gastrointestinal Toxicity      Diarrhea, nausea, vomiting, or abdominal pain occurred in 96% of 255 patients including severe cases in 14% of patients treated with ZYKADIA in Study 1.",Diarrhea is an adverse reaction entity
"(  5.8  ,  8.1  ,  8.7  )             5.1     Severe or Persistent Gastrointestinal Toxicity      Diarrhea, nausea, vomiting, or abdominal pain occurred in 96% of 255 patients including severe cases in 14% of patients treated with ZYKADIA in Study 1.",8.1 is not a named entity
"(  5.8  ,  8.1  ,  8.7  )             5.1     Severe or Persistent Gastrointestinal Toxicity      Diarrhea, nausea, vomiting, or abdominal pain occurred in 96% of 255 patients including severe cases in 14% of patients treated with ZYKADIA in Study 1.",nausea is an adverse reaction entity
"(  5.8  ,  8.1  ,  8.7  )             5.1     Severe or Persistent Gastrointestinal Toxicity      Diarrhea, nausea, vomiting, or abdominal pain occurred in 96% of 255 patients including severe cases in 14% of patients treated with ZYKADIA in Study 1.",patients is not a named entity
"(  5.8  ,  8.1  ,  8.7  )             5.1     Severe or Persistent Gastrointestinal Toxicity      Diarrhea, nausea, vomiting, or abdominal pain occurred in 96% of 255 patients including severe cases in 14% of patients treated with ZYKADIA in Study 1.",", 8.7 is not a named entity"
"(  5.8  ,  8.1  ,  8.7  )             5.1     Severe or Persistent Gastrointestinal Toxicity      Diarrhea, nausea, vomiting, or abdominal pain occurred in 96% of 255 patients including severe cases in 14% of patients treated with ZYKADIA in Study 1.",abdominal pain is an adverse reaction entity
"(  5.8  ,  8.1  ,  8.7  )             5.1     Severe or Persistent Gastrointestinal Toxicity      Diarrhea, nausea, vomiting, or abdominal pain occurred in 96% of 255 patients including severe cases in 14% of patients treated with ZYKADIA in Study 1.",vomiting is an adverse reaction entity
"(  5.8  ,  8.1  ,  8.7  )             5.1     Severe or Persistent Gastrointestinal Toxicity      Diarrhea, nausea, vomiting, or abdominal pain occurred in 96% of 255 patients including severe cases in 14% of patients treated with ZYKADIA in Study 1.",patients is not a named entity
"(  5.8  ,  8.1  ,  8.7  )             5.1     Severe or Persistent Gastrointestinal Toxicity      Diarrhea, nausea, vomiting, or abdominal pain occurred in 96% of 255 patients including severe cases in 14% of patients treated with ZYKADIA in Study 1.",vomiting is an adverse reaction entity
"(  5.8  ,  8.1  ,  8.7  )             5.1     Severe or Persistent Gastrointestinal Toxicity      Diarrhea, nausea, vomiting, or abdominal pain occurred in 96% of 255 patients including severe cases in 14% of patients treated with ZYKADIA in Study 1.",96 % is not a named entity
"(  5.8  ,  8.1  ,  8.7  )             5.1     Severe or Persistent Gastrointestinal Toxicity      Diarrhea, nausea, vomiting, or abdominal pain occurred in 96% of 255 patients including severe cases in 14% of patients treated with ZYKADIA in Study 1.",abdominal pain is an adverse reaction entity
Elevations in alanine aminotransferase (ALT) greater than 5 times the upper limit of normal (ULN) occurred in 27% of 255 patients in Study 1.,normal ( is not a named entity
Elevations in alanine aminotransferase (ALT) greater than 5 times the upper limit of normal (ULN) occurred in 27% of 255 patients in Study 1.,Elevations in alanine aminotransferase is an adverse reaction entity
"5.3     Interstitial Lung Disease (ILD)/Pneumonitis      Severe, life-threatening, or fatal ILD/pneumonitis can occur in patients treated with ZYKADIA.",ILD ) /Pneumonitis is not a named entity
"5.3     Interstitial Lung Disease (ILD)/Pneumonitis      Severe, life-threatening, or fatal ILD/pneumonitis can occur in patients treated with ZYKADIA.",5.3 Interstitial Lung is not a named entity
"5.3     Interstitial Lung Disease (ILD)/Pneumonitis      Severe, life-threatening, or fatal ILD/pneumonitis can occur in patients treated with ZYKADIA.",can occur in is not a named entity
"5.3     Interstitial Lung Disease (ILD)/Pneumonitis      Severe, life-threatening, or fatal ILD/pneumonitis can occur in patients treated with ZYKADIA.",( ILD is not a named entity
"5.3     Interstitial Lung Disease (ILD)/Pneumonitis      Severe, life-threatening, or fatal ILD/pneumonitis can occur in patients treated with ZYKADIA.",pneumonitis is an adverse reaction entity
"5.3     Interstitial Lung Disease (ILD)/Pneumonitis      Severe, life-threatening, or fatal ILD/pneumonitis can occur in patients treated with ZYKADIA.",ILD is an adverse reaction entity
"5.3     Interstitial Lung Disease (ILD)/Pneumonitis      Severe, life-threatening, or fatal ILD/pneumonitis can occur in patients treated with ZYKADIA.",fatal is an adverse reaction entity
"5.3     Interstitial Lung Disease (ILD)/Pneumonitis      Severe, life-threatening, or fatal ILD/pneumonitis can occur in patients treated with ZYKADIA.",ILD ) /Pneumonitis is not a named entity
"5.3     Interstitial Lung Disease (ILD)/Pneumonitis      Severe, life-threatening, or fatal ILD/pneumonitis can occur in patients treated with ZYKADIA.",pneumonitis is an adverse reaction entity
"5.3     Interstitial Lung Disease (ILD)/Pneumonitis      Severe, life-threatening, or fatal ILD/pneumonitis can occur in patients treated with ZYKADIA.",ILD is an adverse reaction entity
Three percent (3%) of 255 patients experienced a QTc interval increase over baseline greater than 60 msec in Study 1.,QTc interval increase is an adverse reaction entity
Three percent (3%) of 255 patients experienced a QTc interval increase over baseline greater than 60 msec in Study 1.,patients experienced a is not a named entity
Bradycardia was reported as an adverse drug reaction in 3% of patients in Study 1.,was reported as is not a named entity
Bradycardia was reported as an adverse drug reaction in 3% of patients in Study 1.,Bradycardia is an adverse reaction entity
The onset of vision disorder generally was within the first week of drug administration.,generally was within is not a named entity
The onset of vision disorder generally was within the first week of drug administration.,vision disorder is an adverse reaction entity
Renal cysts occurred in 8 (5%) patients treated with XALKORI and 1 (1%) patient treated with chemotherapy in Study 1.,treated with chemotherapy is not a named entity
Renal cysts occurred in 8 (5%) patients treated with XALKORI and 1 (1%) patient treated with chemotherapy in Study 1.,Renal cysts is an adverse reaction entity
5.4 Bradycardia       Symptomatic bradycardia can occur in patients receiving XALKORI.,can is not a named entity
5.4 Bradycardia       Symptomatic bradycardia can occur in patients receiving XALKORI.,Symptomatic bradycardia is an adverse reaction entity
"Based on the Visual Symptom Assessment Questionnaire (VSAQ-ALK), patients treated with XALKORI in Studies 1 and 2 reported a higher incidence of visual disturbances compared to patients treated with chemotherapy.",with XALKORI is not a named entity
"Based on the Visual Symptom Assessment Questionnaire (VSAQ-ALK), patients treated with XALKORI in Studies 1 and 2 reported a higher incidence of visual disturbances compared to patients treated with chemotherapy.",visual disturbances is an adverse reaction entity
The most frequent adverse reactions that led to dose reduction in these patients were nausea (1.8%) and elevated transaminases (1.8%).,elevated transaminases is an adverse reaction entity
The most frequent adverse reactions that led to dose reduction in these patients were nausea (1.8%) and elevated transaminases (1.8%).,led to is not a named entity
The most frequent adverse reactions that led to dose reduction in these patients were nausea (1.8%) and elevated transaminases (1.8%).,adverse is not a named entity
The most frequent adverse reactions that led to dose reduction in these patients were nausea (1.8%) and elevated transaminases (1.8%).,nausea is an adverse reaction entity
There were 13 (0.8%) patients with Grade 3 and 4 (0.2%) patients with Grade 4 visual impairment.,visual impairment is an adverse reaction entity
There were 13 (0.8%) patients with Grade 3 and 4 (0.2%) patients with Grade 4 visual impairment.,13 is not a named entity
There were 13 (0.8%) patients with Grade 3 and 4 (0.2%) patients with Grade 4 visual impairment.,visual impairment is an adverse reaction entity
There were 13 (0.8%) patients with Grade 3 and 4 (0.2%) patients with Grade 4 visual impairment.,There were 13 is not a named entity
"Additionally, elevations in ALT or AST greater than five times the ULN occurred in 184 (11%) and 93 (5.7%) patients, respectively.",elevations in ALT is an adverse reaction entity
"Additionally, elevations in ALT or AST greater than five times the ULN occurred in 184 (11%) and 93 (5.7%) patients, respectively.",Additionally is not a named entity
"Additionally, elevations in ALT or AST greater than five times the ULN occurred in 184 (11%) and 93 (5.7%) patients, respectively.",elevations in AST is an adverse reaction entity
"Additionally, elevations in ALT or AST greater than five times the ULN occurred in 184 (11%) and 93 (5.7%) patients, respectively.",93 is not a named entity
"Fatal adverse events in XALKORI-treated patients occurred in 2.3% patients, consisting of septic shock, acute respiratory failure, and diabetic ketoacidosis.",diabetic ketoacidosis is an adverse reaction entity
"Fatal adverse events in XALKORI-treated patients occurred in 2.3% patients, consisting of septic shock, acute respiratory failure, and diabetic ketoacidosis.",XALKORI-treated patients occurred is not a named entity
"Fatal adverse events in XALKORI-treated patients occurred in 2.3% patients, consisting of septic shock, acute respiratory failure, and diabetic ketoacidosis.",events in XALKORI-treated is not a named entity
"Fatal adverse events in XALKORI-treated patients occurred in 2.3% patients, consisting of septic shock, acute respiratory failure, and diabetic ketoacidosis.",Fatal adverse is not a named entity
"Fatal adverse events in XALKORI-treated patients occurred in 2.3% patients, consisting of septic shock, acute respiratory failure, and diabetic ketoacidosis.",acute respiratory failure is an adverse reaction entity
"Fatal adverse events in XALKORI-treated patients occurred in 2.3% patients, consisting of septic shock, acute respiratory failure, and diabetic ketoacidosis.",Fatal is an adverse reaction entity
"Fatal adverse events in XALKORI-treated patients occurred in 2.3% patients, consisting of septic shock, acute respiratory failure, and diabetic ketoacidosis.",septic shock is an adverse reaction entity
"Fatal adverse events in XALKORI-treated patients occurred in 2.3% patients, consisting of septic shock, acute respiratory failure, and diabetic ketoacidosis.",in XALKORI-treated is not a named entity
"The most frequent serious adverse reactions reported in patients treated with XALKORI were pneumonia (4.1%), pulmonary embolism (3.5%), dyspnea (2.3%), and ILD (2.9%).",reported is not a named entity
"The most frequent serious adverse reactions reported in patients treated with XALKORI were pneumonia (4.1%), pulmonary embolism (3.5%), dyspnea (2.3%), and ILD (2.9%).",pneumonia is an adverse reaction entity
"The most frequent serious adverse reactions reported in patients treated with XALKORI were pneumonia (4.1%), pulmonary embolism (3.5%), dyspnea (2.3%), and ILD (2.9%).",pulmonary embolism is an adverse reaction entity
"The most frequent serious adverse reactions reported in patients treated with XALKORI were pneumonia (4.1%), pulmonary embolism (3.5%), dyspnea (2.3%), and ILD (2.9%).",( is not a named entity
"The most frequent serious adverse reactions reported in patients treated with XALKORI were pneumonia (4.1%), pulmonary embolism (3.5%), dyspnea (2.3%), and ILD (2.9%).",", is not a named entity"
"The most frequent serious adverse reactions reported in patients treated with XALKORI were pneumonia (4.1%), pulmonary embolism (3.5%), dyspnea (2.3%), and ILD (2.9%).",ILD ( is not a named entity
"The most frequent serious adverse reactions reported in patients treated with XALKORI were pneumonia (4.1%), pulmonary embolism (3.5%), dyspnea (2.3%), and ILD (2.9%).",dyspnea is an adverse reaction entity
"The most frequent serious adverse reactions reported in patients treated with XALKORI were pneumonia (4.1%), pulmonary embolism (3.5%), dyspnea (2.3%), and ILD (2.9%).",ILD is an adverse reaction entity
Optic atrophy and optic nerve disorder have been reported as potential causes of vision loss.,of vision is not a named entity
Optic atrophy and optic nerve disorder have been reported as potential causes of vision loss.,have is not a named entity
Optic atrophy and optic nerve disorder have been reported as potential causes of vision loss.,vision loss is an adverse reaction entity
Optic atrophy and optic nerve disorder have been reported as potential causes of vision loss.,Optic atrophy is an adverse reaction entity
Optic atrophy and optic nerve disorder have been reported as potential causes of vision loss.,as is not a named entity
Optic atrophy and optic nerve disorder have been reported as potential causes of vision loss.,optic nerve disorder is an adverse reaction entity
"However, across clinical trials no renal abscesses were confirmed by microbiology tests.",renal abscesses is an adverse reaction entity
"However, across clinical trials no renal abscesses were confirmed by microbiology tests.",", is not a named entity"
(  5.1  )   *  Interstitial Lung Disease (ILD)/Pneumonitis: Occurred in 2.9% of patients.,2.9 is not a named entity
(  5.1  )   *  Interstitial Lung Disease (ILD)/Pneumonitis: Occurred in 2.9% of patients.,patients is not a named entity
(  5.1  )   *  Interstitial Lung Disease (ILD)/Pneumonitis: Occurred in 2.9% of patients.,Pneumonitis is an adverse reaction entity
(  5.1  )   *  Interstitial Lung Disease (ILD)/Pneumonitis: Occurred in 2.9% of patients.,ILD is an adverse reaction entity
(  5.1  )   *  Interstitial Lung Disease (ILD)/Pneumonitis: Occurred in 2.9% of patients.,% of patients is not a named entity
(  5.1  )   *  Interstitial Lung Disease (ILD)/Pneumonitis: Occurred in 2.9% of patients.,Interstitial Lung Disease is an adverse reaction entity
"5.2 Interstitial Lung Disease (Pneumonitis)       Severe, life-threatening, or fatal interstitial lung disease (ILD)/pneumonitis can occur in patients treated with XALKORI.",lung is not a named entity
"5.2 Interstitial Lung Disease (Pneumonitis)       Severe, life-threatening, or fatal interstitial lung disease (ILD)/pneumonitis can occur in patients treated with XALKORI.",interstitial lung disease is an adverse reaction entity
"5.2 Interstitial Lung Disease (Pneumonitis)       Severe, life-threatening, or fatal interstitial lung disease (ILD)/pneumonitis can occur in patients treated with XALKORI.",ILD is an adverse reaction entity
"5.2 Interstitial Lung Disease (Pneumonitis)       Severe, life-threatening, or fatal interstitial lung disease (ILD)/pneumonitis can occur in patients treated with XALKORI.",fatal is an adverse reaction entity
"5.2 Interstitial Lung Disease (Pneumonitis)       Severe, life-threatening, or fatal interstitial lung disease (ILD)/pneumonitis can occur in patients treated with XALKORI.",treated with XALKORI is not a named entity
"5.2 Interstitial Lung Disease (Pneumonitis)       Severe, life-threatening, or fatal interstitial lung disease (ILD)/pneumonitis can occur in patients treated with XALKORI.",ILD is an adverse reaction entity
"5.2 Interstitial Lung Disease (Pneumonitis)       Severe, life-threatening, or fatal interstitial lung disease (ILD)/pneumonitis can occur in patients treated with XALKORI.",pneumonitis is an adverse reaction entity
"5.2 Interstitial Lung Disease (Pneumonitis)       Severe, life-threatening, or fatal interstitial lung disease (ILD)/pneumonitis can occur in patients treated with XALKORI.",pneumonitis is an adverse reaction entity
"5.2 Interstitial Lung Disease (Pneumonitis)       Severe, life-threatening, or fatal interstitial lung disease (ILD)/pneumonitis can occur in patients treated with XALKORI.",) Severe is not a named entity
"5.2 Interstitial Lung Disease (Pneumonitis)       Severe, life-threatening, or fatal interstitial lung disease (ILD)/pneumonitis can occur in patients treated with XALKORI.",in patients is not a named entity
"5.2 Interstitial Lung Disease (Pneumonitis)       Severe, life-threatening, or fatal interstitial lung disease (ILD)/pneumonitis can occur in patients treated with XALKORI.",interstitial lung disease is an adverse reaction entity
"5.2 Interstitial Lung Disease (Pneumonitis)       Severe, life-threatening, or fatal interstitial lung disease (ILD)/pneumonitis can occur in patients treated with XALKORI.",", is not a named entity"
"5.2 Interstitial Lung Disease (Pneumonitis)       Severe, life-threatening, or fatal interstitial lung disease (ILD)/pneumonitis can occur in patients treated with XALKORI.",treated with is not a named entity
"5.2 Interstitial Lung Disease (Pneumonitis)       Severe, life-threatening, or fatal interstitial lung disease (ILD)/pneumonitis can occur in patients treated with XALKORI.",can occur in is not a named entity
Renal cysts occurred in 8 (5%) patients treated with XALKORI and 1 (1%) patient treated with chemotherapy in Study 2.,Renal cysts is an adverse reaction entity
Renal cysts occurred in 8 (5%) patients treated with XALKORI and 1 (1%) patient treated with chemotherapy in Study 2.,chemotherapy is not a named entity
5.3 QT Interval Prolongation       QTc prolongation can occur in patients treated with XALKORI.,Prolongation QTc is not a named entity
5.3 QT Interval Prolongation       QTc prolongation can occur in patients treated with XALKORI.,QTc prolongation is an adverse reaction entity
"5.6 Embryofetal Toxicity       Based on its mechanism of action, XALKORI can cause fetal harm when administered to a pregnant woman.",XALKORI can cause is not a named entity
"5.6 Embryofetal Toxicity       Based on its mechanism of action, XALKORI can cause fetal harm when administered to a pregnant woman.",fetal harm is an adverse reaction entity
"In animal reproduction studies, oral administration of crizotinib in pregnant rats during organogenesis at exposures similar to those observed with the maximum recommended human dose resulted in embryotoxicity and fetotoxicity.",of crizotinib is not a named entity
"In animal reproduction studies, oral administration of crizotinib in pregnant rats during organogenesis at exposures similar to those observed with the maximum recommended human dose resulted in embryotoxicity and fetotoxicity.",fetotoxicity is an adverse reaction entity
"In animal reproduction studies, oral administration of crizotinib in pregnant rats during organogenesis at exposures similar to those observed with the maximum recommended human dose resulted in embryotoxicity and fetotoxicity.",embryotoxicity is an adverse reaction entity
"In animal reproduction studies, oral administration of crizotinib in pregnant rats during organogenesis at exposures similar to those observed with the maximum recommended human dose resulted in embryotoxicity and fetotoxicity.",observed with the is not a named entity
"Across clinical trials, 32 of 1560 patients (2.1%) had QTcF (corrected QT by the Fridericia method) greater than or equal to 500 ms and 76 of 1520 patients (5.0%) had an increase from baseline QTcF greater than or equal to 60 ms by automated machine-read evaluation of ECG.",QTcF greater than or equal to 500 ms is an adverse reaction entity
"Across clinical trials, 32 of 1560 patients (2.1%) had QTcF (corrected QT by the Fridericia method) greater than or equal to 500 ms and 76 of 1520 patients (5.0%) had an increase from baseline QTcF greater than or equal to 60 ms by automated machine-read evaluation of ECG.",) had is not a named entity
"Across clinical trials, 32 of 1560 patients (2.1%) had QTcF (corrected QT by the Fridericia method) greater than or equal to 500 ms and 76 of 1520 patients (5.0%) had an increase from baseline QTcF greater than or equal to 60 ms by automated machine-read evaluation of ECG.",increase QTcF is an adverse reaction entity
"Across clinical trials, 32 of 1560 patients (2.1%) had QTcF (corrected QT by the Fridericia method) greater than or equal to 500 ms and 76 of 1520 patients (5.0%) had an increase from baseline QTcF greater than or equal to 60 ms by automated machine-read evaluation of ECG.",equal is not a named entity
"Across clinical trials, bradycardia occurred in 205 (12.3%) of 1669 patients treated with XALKORI.",of 1669 patients is not a named entity
"Across clinical trials, bradycardia occurred in 205 (12.3%) of 1669 patients treated with XALKORI.",bradycardia is an adverse reaction entity
"Fatal adverse reactions in XALKORI-treated patients in Study 2 occurred in 9 (5%) patients, consisting of: acute respiratory distress syndrome, arrhythmia, dyspnea, pneumonia, pneumonitis, pulmonary embolism, ILD, respiratory failure and sepsis.",in Study 2 is not a named entity
"Fatal adverse reactions in XALKORI-treated patients in Study 2 occurred in 9 (5%) patients, consisting of: acute respiratory distress syndrome, arrhythmia, dyspnea, pneumonia, pneumonitis, pulmonary embolism, ILD, respiratory failure and sepsis.",dyspnea is an adverse reaction entity
"Fatal adverse reactions in XALKORI-treated patients in Study 2 occurred in 9 (5%) patients, consisting of: acute respiratory distress syndrome, arrhythmia, dyspnea, pneumonia, pneumonitis, pulmonary embolism, ILD, respiratory failure and sepsis.",patients in Study is not a named entity
"Fatal adverse reactions in XALKORI-treated patients in Study 2 occurred in 9 (5%) patients, consisting of: acute respiratory distress syndrome, arrhythmia, dyspnea, pneumonia, pneumonitis, pulmonary embolism, ILD, respiratory failure and sepsis.","ILD , is not a named entity"
"Fatal adverse reactions in XALKORI-treated patients in Study 2 occurred in 9 (5%) patients, consisting of: acute respiratory distress syndrome, arrhythmia, dyspnea, pneumonia, pneumonitis, pulmonary embolism, ILD, respiratory failure and sepsis.","embolism , is not a named entity"
"Fatal adverse reactions in XALKORI-treated patients in Study 2 occurred in 9 (5%) patients, consisting of: acute respiratory distress syndrome, arrhythmia, dyspnea, pneumonia, pneumonitis, pulmonary embolism, ILD, respiratory failure and sepsis.",Fatal is an adverse reaction entity
"Fatal adverse reactions in XALKORI-treated patients in Study 2 occurred in 9 (5%) patients, consisting of: acute respiratory distress syndrome, arrhythmia, dyspnea, pneumonia, pneumonitis, pulmonary embolism, ILD, respiratory failure and sepsis.",sepsis is an adverse reaction entity
"Fatal adverse reactions in XALKORI-treated patients in Study 2 occurred in 9 (5%) patients, consisting of: acute respiratory distress syndrome, arrhythmia, dyspnea, pneumonia, pneumonitis, pulmonary embolism, ILD, respiratory failure and sepsis.",pneumonitis is an adverse reaction entity
"Fatal adverse reactions in XALKORI-treated patients in Study 2 occurred in 9 (5%) patients, consisting of: acute respiratory distress syndrome, arrhythmia, dyspnea, pneumonia, pneumonitis, pulmonary embolism, ILD, respiratory failure and sepsis.",pneumonia is an adverse reaction entity
"Fatal adverse reactions in XALKORI-treated patients in Study 2 occurred in 9 (5%) patients, consisting of: acute respiratory distress syndrome, arrhythmia, dyspnea, pneumonia, pneumonitis, pulmonary embolism, ILD, respiratory failure and sepsis.",ILD is an adverse reaction entity
"Fatal adverse reactions in XALKORI-treated patients in Study 2 occurred in 9 (5%) patients, consisting of: acute respiratory distress syndrome, arrhythmia, dyspnea, pneumonia, pneumonitis, pulmonary embolism, ILD, respiratory failure and sepsis.",respiratory failure is an adverse reaction entity
"Fatal adverse reactions in XALKORI-treated patients in Study 2 occurred in 9 (5%) patients, consisting of: acute respiratory distress syndrome, arrhythmia, dyspnea, pneumonia, pneumonitis, pulmonary embolism, ILD, respiratory failure and sepsis.",Study is not a named entity
"Fatal adverse reactions in XALKORI-treated patients in Study 2 occurred in 9 (5%) patients, consisting of: acute respiratory distress syndrome, arrhythmia, dyspnea, pneumonia, pneumonitis, pulmonary embolism, ILD, respiratory failure and sepsis.",in is not a named entity
"Fatal adverse reactions in XALKORI-treated patients in Study 2 occurred in 9 (5%) patients, consisting of: acute respiratory distress syndrome, arrhythmia, dyspnea, pneumonia, pneumonitis, pulmonary embolism, ILD, respiratory failure and sepsis.",arrhythmia is an adverse reaction entity
"Fatal adverse reactions in XALKORI-treated patients in Study 2 occurred in 9 (5%) patients, consisting of: acute respiratory distress syndrome, arrhythmia, dyspnea, pneumonia, pneumonitis, pulmonary embolism, ILD, respiratory failure and sepsis.",pulmonary embolism is an adverse reaction entity
"Fatal adverse reactions in XALKORI-treated patients in Study 2 occurred in 9 (5%) patients, consisting of: acute respiratory distress syndrome, arrhythmia, dyspnea, pneumonia, pneumonitis, pulmonary embolism, ILD, respiratory failure and sepsis.",in is not a named entity
"Fatal adverse reactions in XALKORI-treated patients in Study 2 occurred in 9 (5%) patients, consisting of: acute respiratory distress syndrome, arrhythmia, dyspnea, pneumonia, pneumonitis, pulmonary embolism, ILD, respiratory failure and sepsis.",acute respiratory distress syndrome is an adverse reaction entity
"Fatal adverse reactions in XALKORI-treated patients in Study 2 occurred in 9 (5%) patients, consisting of: acute respiratory distress syndrome, arrhythmia, dyspnea, pneumonia, pneumonitis, pulmonary embolism, ILD, respiratory failure and sepsis.",failure and sepsis is not a named entity
"Fatal adverse reactions in XALKORI-treated patients in Study 2 occurred in 9 (5%) patients, consisting of: acute respiratory distress syndrome, arrhythmia, dyspnea, pneumonia, pneumonitis, pulmonary embolism, ILD, respiratory failure and sepsis.",adverse is not a named entity
"Fatal adverse reactions in XALKORI-treated patients in Study 2 occurred in 9 (5%) patients, consisting of: acute respiratory distress syndrome, arrhythmia, dyspnea, pneumonia, pneumonitis, pulmonary embolism, ILD, respiratory failure and sepsis.",9 is not a named entity
"In Studies 1 and 2, Grade 3 syncope occurred in 2.0% of XALKORI-treated patients and in 0.6% of the chemotherapy-treated patients.",syncope is an adverse reaction entity
"In Studies 1 and 2, Grade 3 syncope occurred in 2.0% of XALKORI-treated patients and in 0.6% of the chemotherapy-treated patients.",patients is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the labeling:     *  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Interstitial Lung Disease/Pneumonitis [see  Warnings and Precautions (5.2)  ]    *  QT Interval Prolongation [see  Warnings and Precautions (5.3)  ]    *  Bradycardia [see  Warnings and Precautions (5.4)  ]    *  Severe Visual Loss [see  Warnings and Precautions (5.5)  ]         EXCERPT:   The most common adverse reactions (>=25%) are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.",Hepatotoxicity is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the labeling:     *  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Interstitial Lung Disease/Pneumonitis [see  Warnings and Precautions (5.2)  ]    *  QT Interval Prolongation [see  Warnings and Precautions (5.3)  ]    *  Bradycardia [see  Warnings and Precautions (5.4)  ]    *  Severe Visual Loss [see  Warnings and Precautions (5.5)  ]         EXCERPT:   The most common adverse reactions (>=25%) are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.",QT Interval Prolongation is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the labeling:     *  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Interstitial Lung Disease/Pneumonitis [see  Warnings and Precautions (5.2)  ]    *  QT Interval Prolongation [see  Warnings and Precautions (5.3)  ]    *  Bradycardia [see  Warnings and Precautions (5.4)  ]    *  Severe Visual Loss [see  Warnings and Precautions (5.5)  ]         EXCERPT:   The most common adverse reactions (>=25%) are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.",vomiting is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the labeling:     *  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Interstitial Lung Disease/Pneumonitis [see  Warnings and Precautions (5.2)  ]    *  QT Interval Prolongation [see  Warnings and Precautions (5.3)  ]    *  Bradycardia [see  Warnings and Precautions (5.4)  ]    *  Severe Visual Loss [see  Warnings and Precautions (5.5)  ]         EXCERPT:   The most common adverse reactions (>=25%) are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.",[ see is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the labeling:     *  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Interstitial Lung Disease/Pneumonitis [see  Warnings and Precautions (5.2)  ]    *  QT Interval Prolongation [see  Warnings and Precautions (5.3)  ]    *  Bradycardia [see  Warnings and Precautions (5.4)  ]    *  Severe Visual Loss [see  Warnings and Precautions (5.5)  ]         EXCERPT:   The most common adverse reactions (>=25%) are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.",Pneumonitis is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the labeling:     *  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Interstitial Lung Disease/Pneumonitis [see  Warnings and Precautions (5.2)  ]    *  QT Interval Prolongation [see  Warnings and Precautions (5.3)  ]    *  Bradycardia [see  Warnings and Precautions (5.4)  ]    *  Severe Visual Loss [see  Warnings and Precautions (5.5)  ]         EXCERPT:   The most common adverse reactions (>=25%) are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.",decreased appetite is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the labeling:     *  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Interstitial Lung Disease/Pneumonitis [see  Warnings and Precautions (5.2)  ]    *  QT Interval Prolongation [see  Warnings and Precautions (5.3)  ]    *  Bradycardia [see  Warnings and Precautions (5.4)  ]    *  Severe Visual Loss [see  Warnings and Precautions (5.5)  ]         EXCERPT:   The most common adverse reactions (>=25%) are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.",constipation is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the labeling:     *  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Interstitial Lung Disease/Pneumonitis [see  Warnings and Precautions (5.2)  ]    *  QT Interval Prolongation [see  Warnings and Precautions (5.3)  ]    *  Bradycardia [see  Warnings and Precautions (5.4)  ]    *  Severe Visual Loss [see  Warnings and Precautions (5.5)  ]         EXCERPT:   The most common adverse reactions (>=25%) are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.",upper respiratory infection is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the labeling:     *  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Interstitial Lung Disease/Pneumonitis [see  Warnings and Precautions (5.2)  ]    *  QT Interval Prolongation [see  Warnings and Precautions (5.3)  ]    *  Bradycardia [see  Warnings and Precautions (5.4)  ]    *  Severe Visual Loss [see  Warnings and Precautions (5.5)  ]         EXCERPT:   The most common adverse reactions (>=25%) are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.",Interstitial Lung Disease is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the labeling:     *  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Interstitial Lung Disease/Pneumonitis [see  Warnings and Precautions (5.2)  ]    *  QT Interval Prolongation [see  Warnings and Precautions (5.3)  ]    *  Bradycardia [see  Warnings and Precautions (5.4)  ]    *  Severe Visual Loss [see  Warnings and Precautions (5.5)  ]         EXCERPT:   The most common adverse reactions (>=25%) are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.",nausea is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the labeling:     *  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Interstitial Lung Disease/Pneumonitis [see  Warnings and Precautions (5.2)  ]    *  QT Interval Prolongation [see  Warnings and Precautions (5.3)  ]    *  Bradycardia [see  Warnings and Precautions (5.4)  ]    *  Severe Visual Loss [see  Warnings and Precautions (5.5)  ]         EXCERPT:   The most common adverse reactions (>=25%) are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.",vision disorders is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the labeling:     *  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Interstitial Lung Disease/Pneumonitis [see  Warnings and Precautions (5.2)  ]    *  QT Interval Prolongation [see  Warnings and Precautions (5.3)  ]    *  Bradycardia [see  Warnings and Precautions (5.4)  ]    *  Severe Visual Loss [see  Warnings and Precautions (5.5)  ]         EXCERPT:   The most common adverse reactions (>=25%) are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.",and Precautions is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the labeling:     *  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Interstitial Lung Disease/Pneumonitis [see  Warnings and Precautions (5.2)  ]    *  QT Interval Prolongation [see  Warnings and Precautions (5.3)  ]    *  Bradycardia [see  Warnings and Precautions (5.4)  ]    *  Severe Visual Loss [see  Warnings and Precautions (5.5)  ]         EXCERPT:   The most common adverse reactions (>=25%) are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.",5.3 is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the labeling:     *  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Interstitial Lung Disease/Pneumonitis [see  Warnings and Precautions (5.2)  ]    *  QT Interval Prolongation [see  Warnings and Precautions (5.3)  ]    *  Bradycardia [see  Warnings and Precautions (5.4)  ]    *  Severe Visual Loss [see  Warnings and Precautions (5.5)  ]         EXCERPT:   The most common adverse reactions (>=25%) are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.","elevated transaminases , is not a named entity"
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the labeling:     *  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Interstitial Lung Disease/Pneumonitis [see  Warnings and Precautions (5.2)  ]    *  QT Interval Prolongation [see  Warnings and Precautions (5.3)  ]    *  Bradycardia [see  Warnings and Precautions (5.4)  ]    *  Severe Visual Loss [see  Warnings and Precautions (5.5)  ]         EXCERPT:   The most common adverse reactions (>=25%) are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.",diarrhea is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the labeling:     *  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Interstitial Lung Disease/Pneumonitis [see  Warnings and Precautions (5.2)  ]    *  QT Interval Prolongation [see  Warnings and Precautions (5.3)  ]    *  Bradycardia [see  Warnings and Precautions (5.4)  ]    *  Severe Visual Loss [see  Warnings and Precautions (5.5)  ]         EXCERPT:   The most common adverse reactions (>=25%) are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.",Visual Loss is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the labeling:     *  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Interstitial Lung Disease/Pneumonitis [see  Warnings and Precautions (5.2)  ]    *  QT Interval Prolongation [see  Warnings and Precautions (5.3)  ]    *  Bradycardia [see  Warnings and Precautions (5.4)  ]    *  Severe Visual Loss [see  Warnings and Precautions (5.5)  ]         EXCERPT:   The most common adverse reactions (>=25%) are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.",and Precautions is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the labeling:     *  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Interstitial Lung Disease/Pneumonitis [see  Warnings and Precautions (5.2)  ]    *  QT Interval Prolongation [see  Warnings and Precautions (5.3)  ]    *  Bradycardia [see  Warnings and Precautions (5.4)  ]    *  Severe Visual Loss [see  Warnings and Precautions (5.5)  ]         EXCERPT:   The most common adverse reactions (>=25%) are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.",elevated transaminases is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the labeling:     *  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Interstitial Lung Disease/Pneumonitis [see  Warnings and Precautions (5.2)  ]    *  QT Interval Prolongation [see  Warnings and Precautions (5.3)  ]    *  Bradycardia [see  Warnings and Precautions (5.4)  ]    *  Severe Visual Loss [see  Warnings and Precautions (5.5)  ]         EXCERPT:   The most common adverse reactions (>=25%) are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.",EXCERPT : is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the labeling:     *  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Interstitial Lung Disease/Pneumonitis [see  Warnings and Precautions (5.2)  ]    *  QT Interval Prolongation [see  Warnings and Precautions (5.3)  ]    *  Bradycardia [see  Warnings and Precautions (5.4)  ]    *  Severe Visual Loss [see  Warnings and Precautions (5.5)  ]         EXCERPT:   The most common adverse reactions (>=25%) are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.","transaminases , upper is not a named entity"
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the labeling:     *  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Interstitial Lung Disease/Pneumonitis [see  Warnings and Precautions (5.2)  ]    *  QT Interval Prolongation [see  Warnings and Precautions (5.3)  ]    *  Bradycardia [see  Warnings and Precautions (5.4)  ]    *  Severe Visual Loss [see  Warnings and Precautions (5.5)  ]         EXCERPT:   The most common adverse reactions (>=25%) are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.","vision disorders , is not a named entity"
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the labeling:     *  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Interstitial Lung Disease/Pneumonitis [see  Warnings and Precautions (5.2)  ]    *  QT Interval Prolongation [see  Warnings and Precautions (5.3)  ]    *  Bradycardia [see  Warnings and Precautions (5.4)  ]    *  Severe Visual Loss [see  Warnings and Precautions (5.5)  ]         EXCERPT:   The most common adverse reactions (>=25%) are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.",Bradycardia is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the labeling:     *  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Interstitial Lung Disease/Pneumonitis [see  Warnings and Precautions (5.2)  ]    *  QT Interval Prolongation [see  Warnings and Precautions (5.3)  ]    *  Bradycardia [see  Warnings and Precautions (5.4)  ]    *  Severe Visual Loss [see  Warnings and Precautions (5.5)  ]         EXCERPT:   The most common adverse reactions (>=25%) are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.",discussed in greater is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the labeling:     *  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Interstitial Lung Disease/Pneumonitis [see  Warnings and Precautions (5.2)  ]    *  QT Interval Prolongation [see  Warnings and Precautions (5.3)  ]    *  Bradycardia [see  Warnings and Precautions (5.4)  ]    *  Severe Visual Loss [see  Warnings and Precautions (5.5)  ]         EXCERPT:   The most common adverse reactions (>=25%) are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.",labeling : * is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the labeling:     *  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Interstitial Lung Disease/Pneumonitis [see  Warnings and Precautions (5.2)  ]    *  QT Interval Prolongation [see  Warnings and Precautions (5.3)  ]    *  Bradycardia [see  Warnings and Precautions (5.4)  ]    *  Severe Visual Loss [see  Warnings and Precautions (5.5)  ]         EXCERPT:   The most common adverse reactions (>=25%) are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.",( 5.4 is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the labeling:     *  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Interstitial Lung Disease/Pneumonitis [see  Warnings and Precautions (5.2)  ]    *  QT Interval Prolongation [see  Warnings and Precautions (5.3)  ]    *  Bradycardia [see  Warnings and Precautions (5.4)  ]    *  Severe Visual Loss [see  Warnings and Precautions (5.5)  ]         EXCERPT:   The most common adverse reactions (>=25%) are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.",] EXCERPT : is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the labeling:     *  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Interstitial Lung Disease/Pneumonitis [see  Warnings and Precautions (5.2)  ]    *  QT Interval Prolongation [see  Warnings and Precautions (5.3)  ]    *  Bradycardia [see  Warnings and Precautions (5.4)  ]    *  Severe Visual Loss [see  Warnings and Precautions (5.5)  ]         EXCERPT:   The most common adverse reactions (>=25%) are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.",( 5.2 ) is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the labeling:     *  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Interstitial Lung Disease/Pneumonitis [see  Warnings and Precautions (5.2)  ]    *  QT Interval Prolongation [see  Warnings and Precautions (5.3)  ]    *  Bradycardia [see  Warnings and Precautions (5.4)  ]    *  Severe Visual Loss [see  Warnings and Precautions (5.5)  ]         EXCERPT:   The most common adverse reactions (>=25%) are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.",edema is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the labeling:     *  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Interstitial Lung Disease/Pneumonitis [see  Warnings and Precautions (5.2)  ]    *  QT Interval Prolongation [see  Warnings and Precautions (5.3)  ]    *  Bradycardia [see  Warnings and Precautions (5.4)  ]    *  Severe Visual Loss [see  Warnings and Precautions (5.5)  ]         EXCERPT:   The most common adverse reactions (>=25%) are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.",Lung Disease/Pneumonitis [ is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the labeling:     *  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Interstitial Lung Disease/Pneumonitis [see  Warnings and Precautions (5.2)  ]    *  QT Interval Prolongation [see  Warnings and Precautions (5.3)  ]    *  Bradycardia [see  Warnings and Precautions (5.4)  ]    *  Severe Visual Loss [see  Warnings and Precautions (5.5)  ]         EXCERPT:   The most common adverse reactions (>=25%) are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.","infection , is not a named entity"
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the labeling:     *  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Interstitial Lung Disease/Pneumonitis [see  Warnings and Precautions (5.2)  ]    *  QT Interval Prolongation [see  Warnings and Precautions (5.3)  ]    *  Bradycardia [see  Warnings and Precautions (5.4)  ]    *  Severe Visual Loss [see  Warnings and Precautions (5.5)  ]         EXCERPT:   The most common adverse reactions (>=25%) are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.","diarrhea , nausea is not a named entity"
"6 ADVERSE REACTIONS    The following adverse reactions are discussed in greater detail in other sections of the labeling:     *  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Interstitial Lung Disease/Pneumonitis [see  Warnings and Precautions (5.2)  ]    *  QT Interval Prolongation [see  Warnings and Precautions (5.3)  ]    *  Bradycardia [see  Warnings and Precautions (5.4)  ]    *  Severe Visual Loss [see  Warnings and Precautions (5.5)  ]         EXCERPT:   The most common adverse reactions (>=25%) are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.",dysgeusia is an adverse reaction entity
"The most frequent adverse reactions that led to discontinuation of XALKORI were ILD (1.7%), ALT and AST elevation (1.2%), dyspnea (1.2%), and pulmonary embolism (1.2%).",of is not a named entity
"The most frequent adverse reactions that led to discontinuation of XALKORI were ILD (1.7%), ALT and AST elevation (1.2%), dyspnea (1.2%), and pulmonary embolism (1.2%).",pulmonary embolism is an adverse reaction entity
"The most frequent adverse reactions that led to discontinuation of XALKORI were ILD (1.7%), ALT and AST elevation (1.2%), dyspnea (1.2%), and pulmonary embolism (1.2%).",ALT elevation is an adverse reaction entity
"The most frequent adverse reactions that led to discontinuation of XALKORI were ILD (1.7%), ALT and AST elevation (1.2%), dyspnea (1.2%), and pulmonary embolism (1.2%).",ILD is an adverse reaction entity
"The most frequent adverse reactions that led to discontinuation of XALKORI were ILD (1.7%), ALT and AST elevation (1.2%), dyspnea (1.2%), and pulmonary embolism (1.2%).",The most frequent is not a named entity
"The most frequent adverse reactions that led to discontinuation of XALKORI were ILD (1.7%), ALT and AST elevation (1.2%), dyspnea (1.2%), and pulmonary embolism (1.2%).",dyspnea is an adverse reaction entity
"The most frequent adverse reactions that led to discontinuation of XALKORI were ILD (1.7%), ALT and AST elevation (1.2%), dyspnea (1.2%), and pulmonary embolism (1.2%).",that led is not a named entity
"The most frequent adverse reactions that led to discontinuation of XALKORI were ILD (1.7%), ALT and AST elevation (1.2%), dyspnea (1.2%), and pulmonary embolism (1.2%).",( 1.2 % is not a named entity
"The most frequent adverse reactions that led to discontinuation of XALKORI were ILD (1.7%), ALT and AST elevation (1.2%), dyspnea (1.2%), and pulmonary embolism (1.2%).",1.7 % is not a named entity
"The most frequent adverse reactions that led to discontinuation of XALKORI were ILD (1.7%), ALT and AST elevation (1.2%), dyspnea (1.2%), and pulmonary embolism (1.2%).",AST elevation is an adverse reaction entity
"The most common adverse reactions (>=25%) of XALKORI in Studies 1 and 2 are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.",vision disorders is an adverse reaction entity
"The most common adverse reactions (>=25%) of XALKORI in Studies 1 and 2 are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.",diarrhea is an adverse reaction entity
"The most common adverse reactions (>=25%) of XALKORI in Studies 1 and 2 are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.",) of is not a named entity
"The most common adverse reactions (>=25%) of XALKORI in Studies 1 and 2 are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.",decreased appetite is an adverse reaction entity
"The most common adverse reactions (>=25%) of XALKORI in Studies 1 and 2 are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.",and is not a named entity
"The most common adverse reactions (>=25%) of XALKORI in Studies 1 and 2 are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.",", edema , is not a named entity"
"The most common adverse reactions (>=25%) of XALKORI in Studies 1 and 2 are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.",", constipation is not a named entity"
"The most common adverse reactions (>=25%) of XALKORI in Studies 1 and 2 are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.",1 and 2 is not a named entity
"The most common adverse reactions (>=25%) of XALKORI in Studies 1 and 2 are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.",nausea is an adverse reaction entity
"The most common adverse reactions (>=25%) of XALKORI in Studies 1 and 2 are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.",vomiting is an adverse reaction entity
"The most common adverse reactions (>=25%) of XALKORI in Studies 1 and 2 are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.",edema is an adverse reaction entity
"The most common adverse reactions (>=25%) of XALKORI in Studies 1 and 2 are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.",elevated transaminases is an adverse reaction entity
"The most common adverse reactions (>=25%) of XALKORI in Studies 1 and 2 are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.","disorders , is not a named entity"
"The most common adverse reactions (>=25%) of XALKORI in Studies 1 and 2 are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.",constipation is an adverse reaction entity
"The most common adverse reactions (>=25%) of XALKORI in Studies 1 and 2 are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.",are vision disorders is not a named entity
"The most common adverse reactions (>=25%) of XALKORI in Studies 1 and 2 are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.",upper respiratory infection is an adverse reaction entity
"The most common adverse reactions (>=25%) of XALKORI in Studies 1 and 2 are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.",dysgeusia is an adverse reaction entity
"The most common adverse reactions (>=25%) of XALKORI in Studies 1 and 2 are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.",2 is not a named entity
"The most common adverse reactions (>=25%) of XALKORI in Studies 1 and 2 are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.",", is not a named entity"
"The most common adverse reactions (>=25%) of XALKORI in Studies 1 and 2 are vision disorders, diarrhea, nausea, vomiting, constipation, edema, elevated transaminases, upper respiratory infection, decreased appetite, and dysgeusia.",and is not a named entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Hepatotoxicity: Fatal hepatotoxicity occurred in 0.1% of patients.,: * is not a named entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Hepatotoxicity: Fatal hepatotoxicity occurred in 0.1% of patients.,Hepatotoxicity is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Hepatotoxicity: Fatal hepatotoxicity occurred in 0.1% of patients.,hepatotoxicity is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Hepatotoxicity: Fatal hepatotoxicity occurred in 0.1% of patients.,Fatal is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Hepatotoxicity: Fatal hepatotoxicity occurred in 0.1% of patients.,0.1 is not a named entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Hepatotoxicity: Fatal hepatotoxicity occurred in 0.1% of patients.,AND PRECAUTIONS is not a named entity
Swallowing and breathing difficulties can be life threatening and there have been reports of death.,death is an adverse reaction entity
Swallowing and breathing difficulties can be life threatening and there have been reports of death.,and there is not a named entity
Swallowing and breathing difficulties can be life threatening and there have been reports of death.,and is not a named entity
Swallowing and breathing difficulties can be life threatening and there have been reports of death.,breathing difficulties is an adverse reaction entity
Swallowing and breathing difficulties can be life threatening and there have been reports of death.,Swallowing difficulties is an adverse reaction entity
Swallowing and breathing difficulties can be life threatening and there have been reports of death.,and is not a named entity
No cases of transmission of viral diseases or CJD have ever been reported for albumin.,ever been is not a named entity
No cases of transmission of viral diseases or CJD have ever been reported for albumin.,diseases or CJD is not a named entity
No cases of transmission of viral diseases or CJD have ever been reported for albumin.,CJD is an adverse reaction entity
No cases of transmission of viral diseases or CJD have ever been reported for albumin.,viral diseases is an adverse reaction entity
"Other than injection site reactions, most adverse reactions became noticeable about one week after treatment and lasted several weeks.",most adverse is not a named entity
"Other than injection site reactions, most adverse reactions became noticeable about one week after treatment and lasted several weeks.",injection site reactions is an adverse reaction entity
"Common Adverse Reactions       The most commonly reported adverse reactions (occurring in more than 5% of patients who received 500 Units of DYSPORT    (r)    in the placebo controlled clinical trials) in cervical dystonia patients were: muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, neck pain, musculoskeletal pain, dysphonia, injection site pain, and eye disorders (consisting of blurred vision, diplopia, and reduced visual acuity and accommodation).",: is not a named entity
"Common Adverse Reactions       The most commonly reported adverse reactions (occurring in more than 5% of patients who received 500 Units of DYSPORT    (r)    in the placebo controlled clinical trials) in cervical dystonia patients were: muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, neck pain, musculoskeletal pain, dysphonia, injection site pain, and eye disorders (consisting of blurred vision, diplopia, and reduced visual acuity and accommodation).",: muscular is not a named entity
"Common Adverse Reactions       The most commonly reported adverse reactions (occurring in more than 5% of patients who received 500 Units of DYSPORT    (r)    in the placebo controlled clinical trials) in cervical dystonia patients were: muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, neck pain, musculoskeletal pain, dysphonia, injection site pain, and eye disorders (consisting of blurred vision, diplopia, and reduced visual acuity and accommodation).",dysphagia is an adverse reaction entity
"Common Adverse Reactions       The most commonly reported adverse reactions (occurring in more than 5% of patients who received 500 Units of DYSPORT    (r)    in the placebo controlled clinical trials) in cervical dystonia patients were: muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, neck pain, musculoskeletal pain, dysphonia, injection site pain, and eye disorders (consisting of blurred vision, diplopia, and reduced visual acuity and accommodation).",", and is not a named entity"
"Common Adverse Reactions       The most commonly reported adverse reactions (occurring in more than 5% of patients who received 500 Units of DYSPORT    (r)    in the placebo controlled clinical trials) in cervical dystonia patients were: muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, neck pain, musculoskeletal pain, dysphonia, injection site pain, and eye disorders (consisting of blurred vision, diplopia, and reduced visual acuity and accommodation).",weakness is not a named entity
"Common Adverse Reactions       The most commonly reported adverse reactions (occurring in more than 5% of patients who received 500 Units of DYSPORT    (r)    in the placebo controlled clinical trials) in cervical dystonia patients were: muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, neck pain, musculoskeletal pain, dysphonia, injection site pain, and eye disorders (consisting of blurred vision, diplopia, and reduced visual acuity and accommodation).",acuity and accommodation is not a named entity
"Common Adverse Reactions       The most commonly reported adverse reactions (occurring in more than 5% of patients who received 500 Units of DYSPORT    (r)    in the placebo controlled clinical trials) in cervical dystonia patients were: muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, neck pain, musculoskeletal pain, dysphonia, injection site pain, and eye disorders (consisting of blurred vision, diplopia, and reduced visual acuity and accommodation).",Reactions The is not a named entity
"Common Adverse Reactions       The most commonly reported adverse reactions (occurring in more than 5% of patients who received 500 Units of DYSPORT    (r)    in the placebo controlled clinical trials) in cervical dystonia patients were: muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, neck pain, musculoskeletal pain, dysphonia, injection site pain, and eye disorders (consisting of blurred vision, diplopia, and reduced visual acuity and accommodation).",of blurred is not a named entity
"Common Adverse Reactions       The most commonly reported adverse reactions (occurring in more than 5% of patients who received 500 Units of DYSPORT    (r)    in the placebo controlled clinical trials) in cervical dystonia patients were: muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, neck pain, musculoskeletal pain, dysphonia, injection site pain, and eye disorders (consisting of blurred vision, diplopia, and reduced visual acuity and accommodation).",dysphonia is an adverse reaction entity
"Common Adverse Reactions       The most commonly reported adverse reactions (occurring in more than 5% of patients who received 500 Units of DYSPORT    (r)    in the placebo controlled clinical trials) in cervical dystonia patients were: muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, neck pain, musculoskeletal pain, dysphonia, injection site pain, and eye disorders (consisting of blurred vision, diplopia, and reduced visual acuity and accommodation).",neck pain is an adverse reaction entity
"Common Adverse Reactions       The most commonly reported adverse reactions (occurring in more than 5% of patients who received 500 Units of DYSPORT    (r)    in the placebo controlled clinical trials) in cervical dystonia patients were: muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, neck pain, musculoskeletal pain, dysphonia, injection site pain, and eye disorders (consisting of blurred vision, diplopia, and reduced visual acuity and accommodation).",eye disorders is an adverse reaction entity
"Common Adverse Reactions       The most commonly reported adverse reactions (occurring in more than 5% of patients who received 500 Units of DYSPORT    (r)    in the placebo controlled clinical trials) in cervical dystonia patients were: muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, neck pain, musculoskeletal pain, dysphonia, injection site pain, and eye disorders (consisting of blurred vision, diplopia, and reduced visual acuity and accommodation).",fatigue is an adverse reaction entity
"Common Adverse Reactions       The most commonly reported adverse reactions (occurring in more than 5% of patients who received 500 Units of DYSPORT    (r)    in the placebo controlled clinical trials) in cervical dystonia patients were: muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, neck pain, musculoskeletal pain, dysphonia, injection site pain, and eye disorders (consisting of blurred vision, diplopia, and reduced visual acuity and accommodation).",consisting is not a named entity
"Common Adverse Reactions       The most commonly reported adverse reactions (occurring in more than 5% of patients who received 500 Units of DYSPORT    (r)    in the placebo controlled clinical trials) in cervical dystonia patients were: muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, neck pain, musculoskeletal pain, dysphonia, injection site pain, and eye disorders (consisting of blurred vision, diplopia, and reduced visual acuity and accommodation).","dysphagia , dry is not a named entity"
"Common Adverse Reactions       The most commonly reported adverse reactions (occurring in more than 5% of patients who received 500 Units of DYSPORT    (r)    in the placebo controlled clinical trials) in cervical dystonia patients were: muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, neck pain, musculoskeletal pain, dysphonia, injection site pain, and eye disorders (consisting of blurred vision, diplopia, and reduced visual acuity and accommodation).",in is not a named entity
"Common Adverse Reactions       The most commonly reported adverse reactions (occurring in more than 5% of patients who received 500 Units of DYSPORT    (r)    in the placebo controlled clinical trials) in cervical dystonia patients were: muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, neck pain, musculoskeletal pain, dysphonia, injection site pain, and eye disorders (consisting of blurred vision, diplopia, and reduced visual acuity and accommodation).",", dry mouth is not a named entity"
"Common Adverse Reactions       The most commonly reported adverse reactions (occurring in more than 5% of patients who received 500 Units of DYSPORT    (r)    in the placebo controlled clinical trials) in cervical dystonia patients were: muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, neck pain, musculoskeletal pain, dysphonia, injection site pain, and eye disorders (consisting of blurred vision, diplopia, and reduced visual acuity and accommodation).",cervical dystonia is not a named entity
"Common Adverse Reactions       The most commonly reported adverse reactions (occurring in more than 5% of patients who received 500 Units of DYSPORT    (r)    in the placebo controlled clinical trials) in cervical dystonia patients were: muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, neck pain, musculoskeletal pain, dysphonia, injection site pain, and eye disorders (consisting of blurred vision, diplopia, and reduced visual acuity and accommodation).",musculoskeletal pain is an adverse reaction entity
"Common Adverse Reactions       The most commonly reported adverse reactions (occurring in more than 5% of patients who received 500 Units of DYSPORT    (r)    in the placebo controlled clinical trials) in cervical dystonia patients were: muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, neck pain, musculoskeletal pain, dysphonia, injection site pain, and eye disorders (consisting of blurred vision, diplopia, and reduced visual acuity and accommodation).",diplopia is an adverse reaction entity
"Common Adverse Reactions       The most commonly reported adverse reactions (occurring in more than 5% of patients who received 500 Units of DYSPORT    (r)    in the placebo controlled clinical trials) in cervical dystonia patients were: muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, neck pain, musculoskeletal pain, dysphonia, injection site pain, and eye disorders (consisting of blurred vision, diplopia, and reduced visual acuity and accommodation).",blurred vision is an adverse reaction entity
"Common Adverse Reactions       The most commonly reported adverse reactions (occurring in more than 5% of patients who received 500 Units of DYSPORT    (r)    in the placebo controlled clinical trials) in cervical dystonia patients were: muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, neck pain, musculoskeletal pain, dysphonia, injection site pain, and eye disorders (consisting of blurred vision, diplopia, and reduced visual acuity and accommodation).",injection site discomfort is an adverse reaction entity
"Common Adverse Reactions       The most commonly reported adverse reactions (occurring in more than 5% of patients who received 500 Units of DYSPORT    (r)    in the placebo controlled clinical trials) in cervical dystonia patients were: muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, neck pain, musculoskeletal pain, dysphonia, injection site pain, and eye disorders (consisting of blurred vision, diplopia, and reduced visual acuity and accommodation).",dry mouth is an adverse reaction entity
"Common Adverse Reactions       The most commonly reported adverse reactions (occurring in more than 5% of patients who received 500 Units of DYSPORT    (r)    in the placebo controlled clinical trials) in cervical dystonia patients were: muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, neck pain, musculoskeletal pain, dysphonia, injection site pain, and eye disorders (consisting of blurred vision, diplopia, and reduced visual acuity and accommodation).",reduced visual acuity is an adverse reaction entity
"Common Adverse Reactions       The most commonly reported adverse reactions (occurring in more than 5% of patients who received 500 Units of DYSPORT    (r)    in the placebo controlled clinical trials) in cervical dystonia patients were: muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, neck pain, musculoskeletal pain, dysphonia, injection site pain, and eye disorders (consisting of blurred vision, diplopia, and reduced visual acuity and accommodation).",headache is an adverse reaction entity
"Common Adverse Reactions       The most commonly reported adverse reactions (occurring in more than 5% of patients who received 500 Units of DYSPORT    (r)    in the placebo controlled clinical trials) in cervical dystonia patients were: muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, neck pain, musculoskeletal pain, dysphonia, injection site pain, and eye disorders (consisting of blurred vision, diplopia, and reduced visual acuity and accommodation).",muscular weakness is an adverse reaction entity
"Common Adverse Reactions       The most commonly reported adverse reactions (occurring in more than 5% of patients who received 500 Units of DYSPORT    (r)    in the placebo controlled clinical trials) in cervical dystonia patients were: muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, neck pain, musculoskeletal pain, dysphonia, injection site pain, and eye disorders (consisting of blurred vision, diplopia, and reduced visual acuity and accommodation).",and accommodation ) is not a named entity
"Common Adverse Reactions       The most commonly reported adverse reactions (occurring in more than 5% of patients who received 500 Units of DYSPORT    (r)    in the placebo controlled clinical trials) in cervical dystonia patients were: muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, neck pain, musculoskeletal pain, dysphonia, injection site pain, and eye disorders (consisting of blurred vision, diplopia, and reduced visual acuity and accommodation).",acuity is not a named entity
"Common Adverse Reactions       The most commonly reported adverse reactions (occurring in more than 5% of patients who received 500 Units of DYSPORT    (r)    in the placebo controlled clinical trials) in cervical dystonia patients were: muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, neck pain, musculoskeletal pain, dysphonia, injection site pain, and eye disorders (consisting of blurred vision, diplopia, and reduced visual acuity and accommodation).",) is not a named entity
"Common Adverse Reactions       The most commonly reported adverse reactions (occurring in more than 5% of patients who received 500 Units of DYSPORT    (r)    in the placebo controlled clinical trials) in cervical dystonia patients were: muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, neck pain, musculoskeletal pain, dysphonia, injection site pain, and eye disorders (consisting of blurred vision, diplopia, and reduced visual acuity and accommodation).",reduced visual accommodation is an adverse reaction entity
"Common Adverse Reactions       The most commonly reported adverse reactions (occurring in more than 5% of patients who received 500 Units of DYSPORT    (r)    in the placebo controlled clinical trials) in cervical dystonia patients were: muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, neck pain, musculoskeletal pain, dysphonia, injection site pain, and eye disorders (consisting of blurred vision, diplopia, and reduced visual acuity and accommodation).",injection site pain is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS     EXCERPT:    *  The potency Units of DYSPORT  (r)  are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of DYSPORT  (r)  cannot be compared to or converted into units of any other botulinum toxin products (5.1)    *  Recommended dose and frequency of administration should not be exceeded (5.4)   *  Immediate medical attention may be required in cases of respiratory, speech or swallowing difficulties (5.3)   *  Concomitant neuromuscular disorder may exacerbate clinical effects of treatment (5.5)   *  DYSPORT   (r)   contains human albumin.",speech difficulties is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS     EXCERPT:    *  The potency Units of DYSPORT  (r)  are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of DYSPORT  (r)  cannot be compared to or converted into units of any other botulinum toxin products (5.1)    *  Recommended dose and frequency of administration should not be exceeded (5.4)   *  Immediate medical attention may be required in cases of respiratory, speech or swallowing difficulties (5.3)   *  Concomitant neuromuscular disorder may exacerbate clinical effects of treatment (5.5)   *  DYSPORT   (r)   contains human albumin.",swallowing difficulties is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS     EXCERPT:    *  The potency Units of DYSPORT  (r)  are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of DYSPORT  (r)  cannot be compared to or converted into units of any other botulinum toxin products (5.1)    *  Recommended dose and frequency of administration should not be exceeded (5.4)   *  Immediate medical attention may be required in cases of respiratory, speech or swallowing difficulties (5.3)   *  Concomitant neuromuscular disorder may exacerbate clinical effects of treatment (5.5)   *  DYSPORT   (r)   contains human albumin.",of is not a named entity
"5 WARNINGS AND PRECAUTIONS     EXCERPT:    *  The potency Units of DYSPORT  (r)  are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of DYSPORT  (r)  cannot be compared to or converted into units of any other botulinum toxin products (5.1)    *  Recommended dose and frequency of administration should not be exceeded (5.4)   *  Immediate medical attention may be required in cases of respiratory, speech or swallowing difficulties (5.3)   *  Concomitant neuromuscular disorder may exacerbate clinical effects of treatment (5.5)   *  DYSPORT   (r)   contains human albumin.",contains human is not a named entity
"5 WARNINGS AND PRECAUTIONS     EXCERPT:    *  The potency Units of DYSPORT  (r)  are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of DYSPORT  (r)  cannot be compared to or converted into units of any other botulinum toxin products (5.1)    *  Recommended dose and frequency of administration should not be exceeded (5.4)   *  Immediate medical attention may be required in cases of respiratory, speech or swallowing difficulties (5.3)   *  Concomitant neuromuscular disorder may exacerbate clinical effects of treatment (5.5)   *  DYSPORT   (r)   contains human albumin.",respiratory difficulties is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS     EXCERPT:    *  The potency Units of DYSPORT  (r)  are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of DYSPORT  (r)  cannot be compared to or converted into units of any other botulinum toxin products (5.1)    *  Recommended dose and frequency of administration should not be exceeded (5.4)   *  Immediate medical attention may be required in cases of respiratory, speech or swallowing difficulties (5.3)   *  Concomitant neuromuscular disorder may exacerbate clinical effects of treatment (5.5)   *  DYSPORT   (r)   contains human albumin.",products and is not a named entity
A theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD) is also considered extremely remote.,considered is not a named entity
A theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD) is also considered extremely remote.,CJD is an adverse reaction entity
A theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD) is also considered extremely remote.,extremely remote is not a named entity
A theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD) is also considered extremely remote.,Creutzfeldt-Jakob disease is an adverse reaction entity
Treatment of cervical dystonia with botulinum toxins may weaken neck muscles that serve as accessory muscles of ventilation.,may weaken neck is not a named entity
Treatment of cervical dystonia with botulinum toxins may weaken neck muscles that serve as accessory muscles of ventilation.,weaken neck muscles is an adverse reaction entity
"In clinical trials, subjects who received a higher dose of DYSPORT    (r)    had an increased incidence of eyelid ptosis.",eyelid ptosis is an adverse reaction entity
"In clinical trials, subjects who received a higher dose of DYSPORT    (r)    had an increased incidence of eyelid ptosis.",had is not a named entity
Patients with neuromuscular disorders may be at increased risk of clinically significant effects including severe dysphagia and respiratory compromise from typical doses of DYSPORT    (r)    [  seeAdverse Reactions (6.1)  ].,respiratory compromise is an adverse reaction entity
Patients with neuromuscular disorders may be at increased risk of clinically significant effects including severe dysphagia and respiratory compromise from typical doses of DYSPORT    (r)    [  seeAdverse Reactions (6.1)  ].,r is not a named entity
Patients with neuromuscular disorders may be at increased risk of clinically significant effects including severe dysphagia and respiratory compromise from typical doses of DYSPORT    (r)    [  seeAdverse Reactions (6.1)  ].,at is not a named entity
Patients with neuromuscular disorders may be at increased risk of clinically significant effects including severe dysphagia and respiratory compromise from typical doses of DYSPORT    (r)    [  seeAdverse Reactions (6.1)  ].,dysphagia is an adverse reaction entity
"(6.1)       Upper Limb Spasticity       The most frequently reported adverse reactions (>=2%) are: urinary tract infection, nasopharyngitis, muscular weakness, musculoskeletal pain, dizziness, fall and depression.",nasopharyngitis is an adverse reaction entity
"(6.1)       Upper Limb Spasticity       The most frequently reported adverse reactions (>=2%) are: urinary tract infection, nasopharyngitis, muscular weakness, musculoskeletal pain, dizziness, fall and depression.",musculoskeletal pain is an adverse reaction entity
"(6.1)       Upper Limb Spasticity       The most frequently reported adverse reactions (>=2%) are: urinary tract infection, nasopharyngitis, muscular weakness, musculoskeletal pain, dizziness, fall and depression.",dizziness is an adverse reaction entity
"(6.1)       Upper Limb Spasticity       The most frequently reported adverse reactions (>=2%) are: urinary tract infection, nasopharyngitis, muscular weakness, musculoskeletal pain, dizziness, fall and depression.",> =2 % is not a named entity
"(6.1)       Upper Limb Spasticity       The most frequently reported adverse reactions (>=2%) are: urinary tract infection, nasopharyngitis, muscular weakness, musculoskeletal pain, dizziness, fall and depression.",The most is not a named entity
"(6.1)       Upper Limb Spasticity       The most frequently reported adverse reactions (>=2%) are: urinary tract infection, nasopharyngitis, muscular weakness, musculoskeletal pain, dizziness, fall and depression.",muscular weakness is an adverse reaction entity
"(6.1)       Upper Limb Spasticity       The most frequently reported adverse reactions (>=2%) are: urinary tract infection, nasopharyngitis, muscular weakness, musculoskeletal pain, dizziness, fall and depression.",adverse is not a named entity
"(6.1)       Upper Limb Spasticity       The most frequently reported adverse reactions (>=2%) are: urinary tract infection, nasopharyngitis, muscular weakness, musculoskeletal pain, dizziness, fall and depression.",urinary tract infection is an adverse reaction entity
"(6.1)       Upper Limb Spasticity       The most frequently reported adverse reactions (>=2%) are: urinary tract infection, nasopharyngitis, muscular weakness, musculoskeletal pain, dizziness, fall and depression.",and depression is not a named entity
"(6.1)       Upper Limb Spasticity       The most frequently reported adverse reactions (>=2%) are: urinary tract infection, nasopharyngitis, muscular weakness, musculoskeletal pain, dizziness, fall and depression.",depression is an adverse reaction entity
"(6.1)       Upper Limb Spasticity       The most frequently reported adverse reactions (>=2%) are: urinary tract infection, nasopharyngitis, muscular weakness, musculoskeletal pain, dizziness, fall and depression.",fall is an adverse reaction entity
"(6.1)       Upper Limb Spasticity       The most frequently reported adverse reactions (>=2%) are: urinary tract infection, nasopharyngitis, muscular weakness, musculoskeletal pain, dizziness, fall and depression.",> is not a named entity
"(6.1)       Upper Limb Spasticity       The most frequently reported adverse reactions (>=2%) are: urinary tract infection, nasopharyngitis, muscular weakness, musculoskeletal pain, dizziness, fall and depression.",=2 % ) is not a named entity
"(6.1)       Upper Limb Spasticity       The most frequently reported adverse reactions (>=2%) are: urinary tract infection, nasopharyngitis, muscular weakness, musculoskeletal pain, dizziness, fall and depression.",infection is not a named entity
BOXED WARNING: WARNING: DISTANT SPREAD OF TOXIN EFFECT    WARNING: DISTANT SPREAD OF TOXIN EFFECT      Postmarketing reports indicate that the effects of DYSPORT(r) and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects.,OF TOXIN EFFECT is not a named entity
BOXED WARNING: WARNING: DISTANT SPREAD OF TOXIN EFFECT    WARNING: DISTANT SPREAD OF TOXIN EFFECT      Postmarketing reports indicate that the effects of DYSPORT(r) and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects.,DISTANT SPREAD OF TOXIN EFFECT is an adverse reaction entity
BOXED WARNING: WARNING: DISTANT SPREAD OF TOXIN EFFECT    WARNING: DISTANT SPREAD OF TOXIN EFFECT      Postmarketing reports indicate that the effects of DYSPORT(r) and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects.,WARNING : is not a named entity
BOXED WARNING: WARNING: DISTANT SPREAD OF TOXIN EFFECT    WARNING: DISTANT SPREAD OF TOXIN EFFECT      Postmarketing reports indicate that the effects of DYSPORT(r) and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects.,spread toxin effects is an adverse reaction entity
BOXED WARNING: WARNING: DISTANT SPREAD OF TOXIN EFFECT    WARNING: DISTANT SPREAD OF TOXIN EFFECT      Postmarketing reports indicate that the effects of DYSPORT(r) and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects.,TOXIN EFFECT WARNING is not a named entity
BOXED WARNING: WARNING: DISTANT SPREAD OF TOXIN EFFECT    WARNING: DISTANT SPREAD OF TOXIN EFFECT      Postmarketing reports indicate that the effects of DYSPORT(r) and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects.,DISTANT SPREAD OF TOXIN EFFECT is an adverse reaction entity
"Less Common Adverse Reactions       In a pooled analysis of clinical studies, adverse reactions with an incidence of less than 2% reported in DYSPORT    (r)    treatment groups included dysphagia 0.5%, gait disturbance 0.5%, hypertonia 0.5%, and sensation of heaviness 0.3%.",gait disturbance is an adverse reaction entity
"Less Common Adverse Reactions       In a pooled analysis of clinical studies, adverse reactions with an incidence of less than 2% reported in DYSPORT    (r)    treatment groups included dysphagia 0.5%, gait disturbance 0.5%, hypertonia 0.5%, and sensation of heaviness 0.3%.",sensation of heaviness is an adverse reaction entity
"Less Common Adverse Reactions       In a pooled analysis of clinical studies, adverse reactions with an incidence of less than 2% reported in DYSPORT    (r)    treatment groups included dysphagia 0.5%, gait disturbance 0.5%, hypertonia 0.5%, and sensation of heaviness 0.3%.",clinical studies is not a named entity
"Less Common Adverse Reactions       In a pooled analysis of clinical studies, adverse reactions with an incidence of less than 2% reported in DYSPORT    (r)    treatment groups included dysphagia 0.5%, gait disturbance 0.5%, hypertonia 0.5%, and sensation of heaviness 0.3%.",dysphagia is an adverse reaction entity
"Less Common Adverse Reactions       In a pooled analysis of clinical studies, adverse reactions with an incidence of less than 2% reported in DYSPORT    (r)    treatment groups included dysphagia 0.5%, gait disturbance 0.5%, hypertonia 0.5%, and sensation of heaviness 0.3%.",hypertonia is an adverse reaction entity
"Less Common Adverse Reactions       In a pooled analysis of clinical studies, adverse reactions with an incidence of less than 2% reported in DYSPORT    (r)    treatment groups included dysphagia 0.5%, gait disturbance 0.5%, hypertonia 0.5%, and sensation of heaviness 0.3%.",Less Common Adverse is not a named entity
"Less Common Adverse Reactions       In a pooled analysis of clinical studies, adverse reactions with an incidence of less than 2% reported in DYSPORT    (r)    treatment groups included dysphagia 0.5%, gait disturbance 0.5%, hypertonia 0.5%, and sensation of heaviness 0.3%.",analysis is not a named entity
"Less Common Adverse Reactions       In a pooled analysis of clinical studies, adverse reactions with an incidence of less than 2% reported in DYSPORT    (r)    treatment groups included dysphagia 0.5%, gait disturbance 0.5%, hypertonia 0.5%, and sensation of heaviness 0.3%.",adverse reactions with is not a named entity
"Adverse reactions that occurred after repeated injections in 2-3% of the population included bronchitis, influenza, pharyngolaryngeal pain, cough, contact dermatitis, injection site swelling, and injection site discomfort.","site swelling , is not a named entity"
"Adverse reactions that occurred after repeated injections in 2-3% of the population included bronchitis, influenza, pharyngolaryngeal pain, cough, contact dermatitis, injection site swelling, and injection site discomfort.",2-3 % of is not a named entity
"Adverse reactions that occurred after repeated injections in 2-3% of the population included bronchitis, influenza, pharyngolaryngeal pain, cough, contact dermatitis, injection site swelling, and injection site discomfort.",bronchitis is an adverse reaction entity
"Adverse reactions that occurred after repeated injections in 2-3% of the population included bronchitis, influenza, pharyngolaryngeal pain, cough, contact dermatitis, injection site swelling, and injection site discomfort.",contact dermatitis is an adverse reaction entity
"Adverse reactions that occurred after repeated injections in 2-3% of the population included bronchitis, influenza, pharyngolaryngeal pain, cough, contact dermatitis, injection site swelling, and injection site discomfort.",reactions that is not a named entity
"Adverse reactions that occurred after repeated injections in 2-3% of the population included bronchitis, influenza, pharyngolaryngeal pain, cough, contact dermatitis, injection site swelling, and injection site discomfort.",injection site swelling is an adverse reaction entity
"Adverse reactions that occurred after repeated injections in 2-3% of the population included bronchitis, influenza, pharyngolaryngeal pain, cough, contact dermatitis, injection site swelling, and injection site discomfort.","cough , contact is not a named entity"
"Adverse reactions that occurred after repeated injections in 2-3% of the population included bronchitis, influenza, pharyngolaryngeal pain, cough, contact dermatitis, injection site swelling, and injection site discomfort.",the population included is not a named entity
"Adverse reactions that occurred after repeated injections in 2-3% of the population included bronchitis, influenza, pharyngolaryngeal pain, cough, contact dermatitis, injection site swelling, and injection site discomfort.",injection site discomfort is an adverse reaction entity
"Adverse reactions that occurred after repeated injections in 2-3% of the population included bronchitis, influenza, pharyngolaryngeal pain, cough, contact dermatitis, injection site swelling, and injection site discomfort.",cough is an adverse reaction entity
"Adverse reactions that occurred after repeated injections in 2-3% of the population included bronchitis, influenza, pharyngolaryngeal pain, cough, contact dermatitis, injection site swelling, and injection site discomfort.",occurred is not a named entity
"Adverse reactions that occurred after repeated injections in 2-3% of the population included bronchitis, influenza, pharyngolaryngeal pain, cough, contact dermatitis, injection site swelling, and injection site discomfort.",pharyngolaryngeal pain is an adverse reaction entity
"Adverse reactions that occurred after repeated injections in 2-3% of the population included bronchitis, influenza, pharyngolaryngeal pain, cough, contact dermatitis, injection site swelling, and injection site discomfort.",influenza is an adverse reaction entity
"Adverse reactions that occurred after repeated injections in 2-3% of the population included bronchitis, influenza, pharyngolaryngeal pain, cough, contact dermatitis, injection site swelling, and injection site discomfort.",", pharyngolaryngeal is not a named entity"
This may result in a critical loss of breathing capacity in patients with respiratory disorders who may have become dependent upon these accessory muscles.,loss of breathing capacity is an adverse reaction entity
This may result in a critical loss of breathing capacity in patients with respiratory disorders who may have become dependent upon these accessory muscles.,with respiratory disorders is not a named entity
Aspiration may result from severe dysphagia and is a particular risk when treating patients in whom swallowing or respiratory function is already compromised.,already compromised is not a named entity
Aspiration may result from severe dysphagia and is a particular risk when treating patients in whom swallowing or respiratory function is already compromised.,Aspiration is an adverse reaction entity
Aspiration may result from severe dysphagia and is a particular risk when treating patients in whom swallowing or respiratory function is already compromised.,dysphagia is an adverse reaction entity
Aspiration may result from severe dysphagia and is a particular risk when treating patients in whom swallowing or respiratory function is already compromised.,is already is not a named entity
"Dysphagia may persist for several weeks, and require use of a feeding tube to maintain adequate nutrition and hydration.",Dysphagia is an adverse reaction entity
"Dysphagia may persist for several weeks, and require use of a feeding tube to maintain adequate nutrition and hydration.",and hydration is not a named entity
Swallowing and breathing difficulties can be life threatening and there have been reports of death.,death is an adverse reaction entity
Swallowing and breathing difficulties can be life threatening and there have been reports of death.,Swallowing difficulties is an adverse reaction entity
Swallowing and breathing difficulties can be life threatening and there have been reports of death.,can is not a named entity
Swallowing and breathing difficulties can be life threatening and there have been reports of death.,have is not a named entity
Swallowing and breathing difficulties can be life threatening and there have been reports of death.,breathing difficulties is an adverse reaction entity
Swallowing and breathing difficulties can be life threatening and there have been reports of death.,and is not a named entity
The majority of the reports of eyelid ptosis were mild to moderate in severity and resolved over several weeks.,were mild is not a named entity
The majority of the reports of eyelid ptosis were mild to moderate in severity and resolved over several weeks.,eyelid ptosis is an adverse reaction entity
The majority of the reports of eyelid ptosis were mild to moderate in severity and resolved over several weeks.,majority of the is not a named entity
The majority of the reports of eyelid ptosis were mild to moderate in severity and resolved over several weeks.,eyelid ptosis is an adverse reaction entity
Laboratory Findings       Patients treated with DYSPORT    (r)    exhibited a small increase from baseline (0.23 mol/L) in mean blood glucose relative to placebo- treated patients.,increase in mean blood glucose is an adverse reaction entity
Laboratory Findings       Patients treated with DYSPORT    (r)    exhibited a small increase from baseline (0.23 mol/L) in mean blood glucose relative to placebo- treated patients.,in is not a named entity
"The following adverse reactions have been identified during post-approval use of DYSPORT  (r)  : vertigo, photophobia, influenza-like illness, amyotrophy, burning sensation, facial paresis, hypoesthesia, erythema, and excessive granulation tissue.",have been is not a named entity
"The following adverse reactions have been identified during post-approval use of DYSPORT  (r)  : vertigo, photophobia, influenza-like illness, amyotrophy, burning sensation, facial paresis, hypoesthesia, erythema, and excessive granulation tissue.",burning sensation is an adverse reaction entity
"The following adverse reactions have been identified during post-approval use of DYSPORT  (r)  : vertigo, photophobia, influenza-like illness, amyotrophy, burning sensation, facial paresis, hypoesthesia, erythema, and excessive granulation tissue.",excessive granulation tissue is an adverse reaction entity
"The following adverse reactions have been identified during post-approval use of DYSPORT  (r)  : vertigo, photophobia, influenza-like illness, amyotrophy, burning sensation, facial paresis, hypoesthesia, erythema, and excessive granulation tissue.",photophobia is an adverse reaction entity
"The following adverse reactions have been identified during post-approval use of DYSPORT  (r)  : vertigo, photophobia, influenza-like illness, amyotrophy, burning sensation, facial paresis, hypoesthesia, erythema, and excessive granulation tissue.","paresis , is not a named entity"
"The following adverse reactions have been identified during post-approval use of DYSPORT  (r)  : vertigo, photophobia, influenza-like illness, amyotrophy, burning sensation, facial paresis, hypoesthesia, erythema, and excessive granulation tissue.","erythema , and is not a named entity"
"The following adverse reactions have been identified during post-approval use of DYSPORT  (r)  : vertigo, photophobia, influenza-like illness, amyotrophy, burning sensation, facial paresis, hypoesthesia, erythema, and excessive granulation tissue.",r ) is not a named entity
"The following adverse reactions have been identified during post-approval use of DYSPORT  (r)  : vertigo, photophobia, influenza-like illness, amyotrophy, burning sensation, facial paresis, hypoesthesia, erythema, and excessive granulation tissue.",adverse reactions is not a named entity
"The following adverse reactions have been identified during post-approval use of DYSPORT  (r)  : vertigo, photophobia, influenza-like illness, amyotrophy, burning sensation, facial paresis, hypoesthesia, erythema, and excessive granulation tissue.",erythema is an adverse reaction entity
"The following adverse reactions have been identified during post-approval use of DYSPORT  (r)  : vertigo, photophobia, influenza-like illness, amyotrophy, burning sensation, facial paresis, hypoesthesia, erythema, and excessive granulation tissue.",) is not a named entity
"The following adverse reactions have been identified during post-approval use of DYSPORT  (r)  : vertigo, photophobia, influenza-like illness, amyotrophy, burning sensation, facial paresis, hypoesthesia, erythema, and excessive granulation tissue.",post-approval is not a named entity
"The following adverse reactions have been identified during post-approval use of DYSPORT  (r)  : vertigo, photophobia, influenza-like illness, amyotrophy, burning sensation, facial paresis, hypoesthesia, erythema, and excessive granulation tissue.",hypoesthesia is an adverse reaction entity
"The following adverse reactions have been identified during post-approval use of DYSPORT  (r)  : vertigo, photophobia, influenza-like illness, amyotrophy, burning sensation, facial paresis, hypoesthesia, erythema, and excessive granulation tissue.","erythema , is not a named entity"
"The following adverse reactions have been identified during post-approval use of DYSPORT  (r)  : vertigo, photophobia, influenza-like illness, amyotrophy, burning sensation, facial paresis, hypoesthesia, erythema, and excessive granulation tissue.",adverse reactions is not a named entity
"The following adverse reactions have been identified during post-approval use of DYSPORT  (r)  : vertigo, photophobia, influenza-like illness, amyotrophy, burning sensation, facial paresis, hypoesthesia, erythema, and excessive granulation tissue.",amyotrophy is an adverse reaction entity
"The following adverse reactions have been identified during post-approval use of DYSPORT  (r)  : vertigo, photophobia, influenza-like illness, amyotrophy, burning sensation, facial paresis, hypoesthesia, erythema, and excessive granulation tissue.",influenza-like illness is an adverse reaction entity
"The following adverse reactions have been identified during post-approval use of DYSPORT  (r)  : vertigo, photophobia, influenza-like illness, amyotrophy, burning sensation, facial paresis, hypoesthesia, erythema, and excessive granulation tissue.",vertigo is an adverse reaction entity
"The following adverse reactions have been identified during post-approval use of DYSPORT  (r)  : vertigo, photophobia, influenza-like illness, amyotrophy, burning sensation, facial paresis, hypoesthesia, erythema, and excessive granulation tissue.",facial paresis is an adverse reaction entity
"Other adverse reactions with incidences of less than 5% in the DYSPORT    (r)    500 Units group in the double-blind phase of clinical trials included dizziness in 3.5% of DYSPORT    (r)    -treated patients and 1% of placebo-treated patients, and muscle atrophy in 1% of DYSPORT    (r)    -treated patients and in none of the placebo-treated patients.",in is not a named entity
"Other adverse reactions with incidences of less than 5% in the DYSPORT    (r)    500 Units group in the double-blind phase of clinical trials included dizziness in 3.5% of DYSPORT    (r)    -treated patients and 1% of placebo-treated patients, and muscle atrophy in 1% of DYSPORT    (r)    -treated patients and in none of the placebo-treated patients.",dizziness is an adverse reaction entity
"Other adverse reactions with incidences of less than 5% in the DYSPORT    (r)    500 Units group in the double-blind phase of clinical trials included dizziness in 3.5% of DYSPORT    (r)    -treated patients and 1% of placebo-treated patients, and muscle atrophy in 1% of DYSPORT    (r)    -treated patients and in none of the placebo-treated patients.",muscle atrophy is an adverse reaction entity
"Other adverse reactions with incidences of less than 5% in the DYSPORT    (r)    500 Units group in the double-blind phase of clinical trials included dizziness in 3.5% of DYSPORT    (r)    -treated patients and 1% of placebo-treated patients, and muscle atrophy in 1% of DYSPORT    (r)    -treated patients and in none of the placebo-treated patients.",5 % in is not a named entity
The incidence of eyelid ptosis did not increase in the long-term safety studies with multiple re-treatments at intervals >= three months.,eyelid ptosis did is not a named entity
The incidence of eyelid ptosis did not increase in the long-term safety studies with multiple re-treatments at intervals >= three months.,eyelid ptosis is an adverse reaction entity
Breathing Difficulty       Breathing difficulties were reported by approximately 3% of patients following DYSPORT    (r)    administration and in 1% of placebo patients in clinical trials during the double-blind phase.,Breathing difficulties were is not a named entity
Breathing Difficulty       Breathing difficulties were reported by approximately 3% of patients following DYSPORT    (r)    administration and in 1% of placebo patients in clinical trials during the double-blind phase.,Breathing difficulties is an adverse reaction entity
"Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases.",viral diseases is an adverse reaction entity
"Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases.",transmission of is not a named entity
"(6.1)       Glabellar Lines       The most frequently reported adverse reactions (>=2%) are: nasopharyngitis, headache, injection site pain, injection site reaction, upper respiratory tract infection, eyelid edema, eyelid ptosis, sinusitis, and nausea.",6.1 ) Glabellar is not a named entity
"(6.1)       Glabellar Lines       The most frequently reported adverse reactions (>=2%) are: nasopharyngitis, headache, injection site pain, injection site reaction, upper respiratory tract infection, eyelid edema, eyelid ptosis, sinusitis, and nausea.",sinusitis is an adverse reaction entity
"(6.1)       Glabellar Lines       The most frequently reported adverse reactions (>=2%) are: nasopharyngitis, headache, injection site pain, injection site reaction, upper respiratory tract infection, eyelid edema, eyelid ptosis, sinusitis, and nausea.",", eyelid edema is not a named entity"
"(6.1)       Glabellar Lines       The most frequently reported adverse reactions (>=2%) are: nasopharyngitis, headache, injection site pain, injection site reaction, upper respiratory tract infection, eyelid edema, eyelid ptosis, sinusitis, and nausea.",headache is an adverse reaction entity
"(6.1)       Glabellar Lines       The most frequently reported adverse reactions (>=2%) are: nasopharyngitis, headache, injection site pain, injection site reaction, upper respiratory tract infection, eyelid edema, eyelid ptosis, sinusitis, and nausea.",nausea is an adverse reaction entity
"(6.1)       Glabellar Lines       The most frequently reported adverse reactions (>=2%) are: nasopharyngitis, headache, injection site pain, injection site reaction, upper respiratory tract infection, eyelid edema, eyelid ptosis, sinusitis, and nausea.",injection site reaction is an adverse reaction entity
"(6.1)       Glabellar Lines       The most frequently reported adverse reactions (>=2%) are: nasopharyngitis, headache, injection site pain, injection site reaction, upper respiratory tract infection, eyelid edema, eyelid ptosis, sinusitis, and nausea.",adverse reactions is not a named entity
"(6.1)       Glabellar Lines       The most frequently reported adverse reactions (>=2%) are: nasopharyngitis, headache, injection site pain, injection site reaction, upper respiratory tract infection, eyelid edema, eyelid ptosis, sinusitis, and nausea.",: nasopharyngitis is not a named entity
"(6.1)       Glabellar Lines       The most frequently reported adverse reactions (>=2%) are: nasopharyngitis, headache, injection site pain, injection site reaction, upper respiratory tract infection, eyelid edema, eyelid ptosis, sinusitis, and nausea.",eyelid ptosis is an adverse reaction entity
"(6.1)       Glabellar Lines       The most frequently reported adverse reactions (>=2%) are: nasopharyngitis, headache, injection site pain, injection site reaction, upper respiratory tract infection, eyelid edema, eyelid ptosis, sinusitis, and nausea.",and is not a named entity
"(6.1)       Glabellar Lines       The most frequently reported adverse reactions (>=2%) are: nasopharyngitis, headache, injection site pain, injection site reaction, upper respiratory tract infection, eyelid edema, eyelid ptosis, sinusitis, and nausea.",ptosis is not a named entity
"(6.1)       Glabellar Lines       The most frequently reported adverse reactions (>=2%) are: nasopharyngitis, headache, injection site pain, injection site reaction, upper respiratory tract infection, eyelid edema, eyelid ptosis, sinusitis, and nausea.",eyelid edema is an adverse reaction entity
"(6.1)       Glabellar Lines       The most frequently reported adverse reactions (>=2%) are: nasopharyngitis, headache, injection site pain, injection site reaction, upper respiratory tract infection, eyelid edema, eyelid ptosis, sinusitis, and nausea.",upper respiratory tract infection is an adverse reaction entity
"(6.1)       Glabellar Lines       The most frequently reported adverse reactions (>=2%) are: nasopharyngitis, headache, injection site pain, injection site reaction, upper respiratory tract infection, eyelid edema, eyelid ptosis, sinusitis, and nausea.",respiratory is not a named entity
"(6.1)       Glabellar Lines       The most frequently reported adverse reactions (>=2%) are: nasopharyngitis, headache, injection site pain, injection site reaction, upper respiratory tract infection, eyelid edema, eyelid ptosis, sinusitis, and nausea.",nasopharyngitis is an adverse reaction entity
"(6.1)       Glabellar Lines       The most frequently reported adverse reactions (>=2%) are: nasopharyngitis, headache, injection site pain, injection site reaction, upper respiratory tract infection, eyelid edema, eyelid ptosis, sinusitis, and nausea.",site is not a named entity
"(6.1)       Glabellar Lines       The most frequently reported adverse reactions (>=2%) are: nasopharyngitis, headache, injection site pain, injection site reaction, upper respiratory tract infection, eyelid edema, eyelid ptosis, sinusitis, and nausea.",The most is not a named entity
"(6.1)       Glabellar Lines       The most frequently reported adverse reactions (>=2%) are: nasopharyngitis, headache, injection site pain, injection site reaction, upper respiratory tract infection, eyelid edema, eyelid ptosis, sinusitis, and nausea.",injection site pain is an adverse reaction entity
"The most frequently reported of these adverse reactions were headache, nasopharyngitis, injection site pain, sinusitis, URI, injection site bruising, and injection site reaction (numbness, discomfort, erythema, tenderness, tingling, itching, stinging, warmth, irritation, tightness, swelling).",", is not a named entity"
"The most frequently reported of these adverse reactions were headache, nasopharyngitis, injection site pain, sinusitis, URI, injection site bruising, and injection site reaction (numbness, discomfort, erythema, tenderness, tingling, itching, stinging, warmth, irritation, tightness, swelling).",injection site warmth is an adverse reaction entity
"The most frequently reported of these adverse reactions were headache, nasopharyngitis, injection site pain, sinusitis, URI, injection site bruising, and injection site reaction (numbness, discomfort, erythema, tenderness, tingling, itching, stinging, warmth, irritation, tightness, swelling).",", is not a named entity"
"The most frequently reported of these adverse reactions were headache, nasopharyngitis, injection site pain, sinusitis, URI, injection site bruising, and injection site reaction (numbness, discomfort, erythema, tenderness, tingling, itching, stinging, warmth, irritation, tightness, swelling).",injection site stinging is an adverse reaction entity
"The most frequently reported of these adverse reactions were headache, nasopharyngitis, injection site pain, sinusitis, URI, injection site bruising, and injection site reaction (numbness, discomfort, erythema, tenderness, tingling, itching, stinging, warmth, irritation, tightness, swelling).",injection site irritation is an adverse reaction entity
"The most frequently reported of these adverse reactions were headache, nasopharyngitis, injection site pain, sinusitis, URI, injection site bruising, and injection site reaction (numbness, discomfort, erythema, tenderness, tingling, itching, stinging, warmth, irritation, tightness, swelling).",injection site reaction is an adverse reaction entity
"The most frequently reported of these adverse reactions were headache, nasopharyngitis, injection site pain, sinusitis, URI, injection site bruising, and injection site reaction (numbness, discomfort, erythema, tenderness, tingling, itching, stinging, warmth, irritation, tightness, swelling).",sinusitis is an adverse reaction entity
"The most frequently reported of these adverse reactions were headache, nasopharyngitis, injection site pain, sinusitis, URI, injection site bruising, and injection site reaction (numbness, discomfort, erythema, tenderness, tingling, itching, stinging, warmth, irritation, tightness, swelling).",URI is an adverse reaction entity
"The most frequently reported of these adverse reactions were headache, nasopharyngitis, injection site pain, sinusitis, URI, injection site bruising, and injection site reaction (numbness, discomfort, erythema, tenderness, tingling, itching, stinging, warmth, irritation, tightness, swelling).","warmth , is not a named entity"
"The most frequently reported of these adverse reactions were headache, nasopharyngitis, injection site pain, sinusitis, URI, injection site bruising, and injection site reaction (numbness, discomfort, erythema, tenderness, tingling, itching, stinging, warmth, irritation, tightness, swelling).",injection site swelling is an adverse reaction entity
"The most frequently reported of these adverse reactions were headache, nasopharyngitis, injection site pain, sinusitis, URI, injection site bruising, and injection site reaction (numbness, discomfort, erythema, tenderness, tingling, itching, stinging, warmth, irritation, tightness, swelling).","nasopharyngitis , is not a named entity"
"The most frequently reported of these adverse reactions were headache, nasopharyngitis, injection site pain, sinusitis, URI, injection site bruising, and injection site reaction (numbness, discomfort, erythema, tenderness, tingling, itching, stinging, warmth, irritation, tightness, swelling).",injection site numbness is an adverse reaction entity
"The most frequently reported of these adverse reactions were headache, nasopharyngitis, injection site pain, sinusitis, URI, injection site bruising, and injection site reaction (numbness, discomfort, erythema, tenderness, tingling, itching, stinging, warmth, irritation, tightness, swelling).",injection site tenderness is an adverse reaction entity
"The most frequently reported of these adverse reactions were headache, nasopharyngitis, injection site pain, sinusitis, URI, injection site bruising, and injection site reaction (numbness, discomfort, erythema, tenderness, tingling, itching, stinging, warmth, irritation, tightness, swelling).",injection site erythema is an adverse reaction entity
"The most frequently reported of these adverse reactions were headache, nasopharyngitis, injection site pain, sinusitis, URI, injection site bruising, and injection site reaction (numbness, discomfort, erythema, tenderness, tingling, itching, stinging, warmth, irritation, tightness, swelling).",", discomfort is not a named entity"
"The most frequently reported of these adverse reactions were headache, nasopharyngitis, injection site pain, sinusitis, URI, injection site bruising, and injection site reaction (numbness, discomfort, erythema, tenderness, tingling, itching, stinging, warmth, irritation, tightness, swelling).",headache is an adverse reaction entity
"The most frequently reported of these adverse reactions were headache, nasopharyngitis, injection site pain, sinusitis, URI, injection site bruising, and injection site reaction (numbness, discomfort, erythema, tenderness, tingling, itching, stinging, warmth, irritation, tightness, swelling).",", injection is not a named entity"
"The most frequently reported of these adverse reactions were headache, nasopharyngitis, injection site pain, sinusitis, URI, injection site bruising, and injection site reaction (numbness, discomfort, erythema, tenderness, tingling, itching, stinging, warmth, irritation, tightness, swelling).",most frequently reported is not a named entity
"The most frequently reported of these adverse reactions were headache, nasopharyngitis, injection site pain, sinusitis, URI, injection site bruising, and injection site reaction (numbness, discomfort, erythema, tenderness, tingling, itching, stinging, warmth, irritation, tightness, swelling).",nasopharyngitis is an adverse reaction entity
"The most frequently reported of these adverse reactions were headache, nasopharyngitis, injection site pain, sinusitis, URI, injection site bruising, and injection site reaction (numbness, discomfort, erythema, tenderness, tingling, itching, stinging, warmth, irritation, tightness, swelling).","tenderness , tingling is not a named entity"
"The most frequently reported of these adverse reactions were headache, nasopharyngitis, injection site pain, sinusitis, URI, injection site bruising, and injection site reaction (numbness, discomfort, erythema, tenderness, tingling, itching, stinging, warmth, irritation, tightness, swelling).",injection site pain is an adverse reaction entity
"The most frequently reported of these adverse reactions were headache, nasopharyngitis, injection site pain, sinusitis, URI, injection site bruising, and injection site reaction (numbness, discomfort, erythema, tenderness, tingling, itching, stinging, warmth, irritation, tightness, swelling).",adverse is not a named entity
"The most frequently reported of these adverse reactions were headache, nasopharyngitis, injection site pain, sinusitis, URI, injection site bruising, and injection site reaction (numbness, discomfort, erythema, tenderness, tingling, itching, stinging, warmth, irritation, tightness, swelling).",tightness is not a named entity
"The most frequently reported of these adverse reactions were headache, nasopharyngitis, injection site pain, sinusitis, URI, injection site bruising, and injection site reaction (numbness, discomfort, erythema, tenderness, tingling, itching, stinging, warmth, irritation, tightness, swelling).",injection site discomfort is an adverse reaction entity
"The most frequently reported of these adverse reactions were headache, nasopharyngitis, injection site pain, sinusitis, URI, injection site bruising, and injection site reaction (numbness, discomfort, erythema, tenderness, tingling, itching, stinging, warmth, irritation, tightness, swelling).",these adverse is not a named entity
"The most frequently reported of these adverse reactions were headache, nasopharyngitis, injection site pain, sinusitis, URI, injection site bruising, and injection site reaction (numbness, discomfort, erythema, tenderness, tingling, itching, stinging, warmth, irritation, tightness, swelling).","site pain , is not a named entity"
"The most frequently reported of these adverse reactions were headache, nasopharyngitis, injection site pain, sinusitis, URI, injection site bruising, and injection site reaction (numbness, discomfort, erythema, tenderness, tingling, itching, stinging, warmth, irritation, tightness, swelling).",injection site tingling is an adverse reaction entity
"The most frequently reported of these adverse reactions were headache, nasopharyngitis, injection site pain, sinusitis, URI, injection site bruising, and injection site reaction (numbness, discomfort, erythema, tenderness, tingling, itching, stinging, warmth, irritation, tightness, swelling).",injection site tightness is an adverse reaction entity
"The most frequently reported of these adverse reactions were headache, nasopharyngitis, injection site pain, sinusitis, URI, injection site bruising, and injection site reaction (numbness, discomfort, erythema, tenderness, tingling, itching, stinging, warmth, irritation, tightness, swelling).",", nasopharyngitis is not a named entity"
"The most frequently reported of these adverse reactions were headache, nasopharyngitis, injection site pain, sinusitis, URI, injection site bruising, and injection site reaction (numbness, discomfort, erythema, tenderness, tingling, itching, stinging, warmth, irritation, tightness, swelling).",", warmth is not a named entity"
"The most frequently reported of these adverse reactions were headache, nasopharyngitis, injection site pain, sinusitis, URI, injection site bruising, and injection site reaction (numbness, discomfort, erythema, tenderness, tingling, itching, stinging, warmth, irritation, tightness, swelling).",", warmth , is not a named entity"
"The most frequently reported of these adverse reactions were headache, nasopharyngitis, injection site pain, sinusitis, URI, injection site bruising, and injection site reaction (numbness, discomfort, erythema, tenderness, tingling, itching, stinging, warmth, irritation, tightness, swelling).",", is not a named entity"
"The most frequently reported of these adverse reactions were headache, nasopharyngitis, injection site pain, sinusitis, URI, injection site bruising, and injection site reaction (numbness, discomfort, erythema, tenderness, tingling, itching, stinging, warmth, irritation, tightness, swelling).",injection site bruising is an adverse reaction entity
"The most frequently reported of these adverse reactions were headache, nasopharyngitis, injection site pain, sinusitis, URI, injection site bruising, and injection site reaction (numbness, discomfort, erythema, tenderness, tingling, itching, stinging, warmth, irritation, tightness, swelling).",", irritation is not a named entity"
"The most frequently reported of these adverse reactions were headache, nasopharyngitis, injection site pain, sinusitis, URI, injection site bruising, and injection site reaction (numbness, discomfort, erythema, tenderness, tingling, itching, stinging, warmth, irritation, tightness, swelling).",swelling ) is not a named entity
"The most frequently reported of these adverse reactions were headache, nasopharyngitis, injection site pain, sinusitis, URI, injection site bruising, and injection site reaction (numbness, discomfort, erythema, tenderness, tingling, itching, stinging, warmth, irritation, tightness, swelling).",injection site itching is an adverse reaction entity
"In unapproved uses, including spasticity in children and in approved indications, symptoms consistent with spread of toxin effect have been reported at doses comparable to or lower than the maximum recommended total dose.","indications , is not a named entity"
"In unapproved uses, including spasticity in children and in approved indications, symptoms consistent with spread of toxin effect have been reported at doses comparable to or lower than the maximum recommended total dose.",spread of toxin effect is an adverse reaction entity
"5.2 Spread of Toxin Effect    Post-marketing safety data from DYSPORT    (r)    and other approved botulinum toxins suggest that botulinum toxin effects may, in some cases, be observed beyond the site of local injection.","cases , be is not a named entity"
"5.2 Spread of Toxin Effect    Post-marketing safety data from DYSPORT    (r)    and other approved botulinum toxins suggest that botulinum toxin effects may, in some cases, be observed beyond the site of local injection.",toxin effects beyond the site of local injection is an adverse reaction entity
(5.2)             5.1 Agranulocytosis/Neutropenia      Fatal agranulocytosis can occur with Ferriprox use.,Agranulocytosis/Neutropenia Fatal is not a named entity
(5.2)             5.1 Agranulocytosis/Neutropenia      Fatal agranulocytosis can occur with Ferriprox use.,agranulocytosis is an adverse reaction entity
(5.2)             5.1 Agranulocytosis/Neutropenia      Fatal agranulocytosis can occur with Ferriprox use.,occur is not a named entity
(5.2)             5.1 Agranulocytosis/Neutropenia      Fatal agranulocytosis can occur with Ferriprox use.,Fatal is an adverse reaction entity
"5.3 Laboratory Tests       Serum Liver Enzyme Activities          In clinical studies, 7.5% of 642 subjects treated with Ferriprox developed increased ALT values.",Tests Serum Liver is not a named entity
"5.3 Laboratory Tests       Serum Liver Enzyme Activities          In clinical studies, 7.5% of 642 subjects treated with Ferriprox developed increased ALT values.",increased ALT values is an adverse reaction entity
"Agranulocytosis and neutropenia usually resolve upon discontinuation of Ferriprox, but there have been reports of agranulocytosis leading to death.","Ferriprox , is not a named entity"
"Agranulocytosis and neutropenia usually resolve upon discontinuation of Ferriprox, but there have been reports of agranulocytosis leading to death.",neutropenia is an adverse reaction entity
"Agranulocytosis and neutropenia usually resolve upon discontinuation of Ferriprox, but there have been reports of agranulocytosis leading to death.",discontinuation of Ferriprox is not a named entity
"Agranulocytosis and neutropenia usually resolve upon discontinuation of Ferriprox, but there have been reports of agranulocytosis leading to death.",Agranulocytosis is an adverse reaction entity
"Agranulocytosis and neutropenia usually resolve upon discontinuation of Ferriprox, but there have been reports of agranulocytosis leading to death.",death is an adverse reaction entity
"Agranulocytosis and neutropenia usually resolve upon discontinuation of Ferriprox, but there have been reports of agranulocytosis leading to death.",Ferriprox is not a named entity
"Agranulocytosis and neutropenia usually resolve upon discontinuation of Ferriprox, but there have been reports of agranulocytosis leading to death.",reports of agranulocytosis is not a named entity
"Agranulocytosis and neutropenia usually resolve upon discontinuation of Ferriprox, but there have been reports of agranulocytosis leading to death.",agranulocytosis is an adverse reaction entity
Four (0.62%) Ferriprox-treated subjects discontinued the drug due to increased serum ALT levels and 1 (0.16%) due to an increase in both ALT and AST.,drug due to is not a named entity
Four (0.62%) Ferriprox-treated subjects discontinued the drug due to increased serum ALT levels and 1 (0.16%) due to an increase in both ALT and AST.,increase in AST is an adverse reaction entity
Four (0.62%) Ferriprox-treated subjects discontinued the drug due to increased serum ALT levels and 1 (0.16%) due to an increase in both ALT and AST.,( 0.16 is not a named entity
Four (0.62%) Ferriprox-treated subjects discontinued the drug due to increased serum ALT levels and 1 (0.16%) due to an increase in both ALT and AST.,increased serum ALT is an adverse reaction entity
Four (0.62%) Ferriprox-treated subjects discontinued the drug due to increased serum ALT levels and 1 (0.16%) due to an increase in both ALT and AST.,% ) is not a named entity
Four (0.62%) Ferriprox-treated subjects discontinued the drug due to increased serum ALT levels and 1 (0.16%) due to an increase in both ALT and AST.,increase in ALT is an adverse reaction entity
"Nervous system disorders  : cerebellar syndrome, cerebral hemorrhage, convulsion, gait disturbance, intracranial pressure increased, psychomotor skills impaired, pyramidal tract syndrome, somnolence.",somnolence is an adverse reaction entity
"Nervous system disorders  : cerebellar syndrome, cerebral hemorrhage, convulsion, gait disturbance, intracranial pressure increased, psychomotor skills impaired, pyramidal tract syndrome, somnolence.",", cerebral hemorrhage is not a named entity"
"Nervous system disorders  : cerebellar syndrome, cerebral hemorrhage, convulsion, gait disturbance, intracranial pressure increased, psychomotor skills impaired, pyramidal tract syndrome, somnolence.",cerebral hemorrhage is an adverse reaction entity
"Nervous system disorders  : cerebellar syndrome, cerebral hemorrhage, convulsion, gait disturbance, intracranial pressure increased, psychomotor skills impaired, pyramidal tract syndrome, somnolence.",", cerebral hemorrhage is not a named entity"
"Nervous system disorders  : cerebellar syndrome, cerebral hemorrhage, convulsion, gait disturbance, intracranial pressure increased, psychomotor skills impaired, pyramidal tract syndrome, somnolence.",pyramidal tract syndrome is an adverse reaction entity
"Nervous system disorders  : cerebellar syndrome, cerebral hemorrhage, convulsion, gait disturbance, intracranial pressure increased, psychomotor skills impaired, pyramidal tract syndrome, somnolence.",cerebellar syndrome is an adverse reaction entity
"Nervous system disorders  : cerebellar syndrome, cerebral hemorrhage, convulsion, gait disturbance, intracranial pressure increased, psychomotor skills impaired, pyramidal tract syndrome, somnolence.",: is not a named entity
"Nervous system disorders  : cerebellar syndrome, cerebral hemorrhage, convulsion, gait disturbance, intracranial pressure increased, psychomotor skills impaired, pyramidal tract syndrome, somnolence.",convulsion is an adverse reaction entity
"Nervous system disorders  : cerebellar syndrome, cerebral hemorrhage, convulsion, gait disturbance, intracranial pressure increased, psychomotor skills impaired, pyramidal tract syndrome, somnolence.",gait disturbance is an adverse reaction entity
"Nervous system disorders  : cerebellar syndrome, cerebral hemorrhage, convulsion, gait disturbance, intracranial pressure increased, psychomotor skills impaired, pyramidal tract syndrome, somnolence.",hemorrhage is not a named entity
"Nervous system disorders  : cerebellar syndrome, cerebral hemorrhage, convulsion, gait disturbance, intracranial pressure increased, psychomotor skills impaired, pyramidal tract syndrome, somnolence.",intracranial pressure increased is an adverse reaction entity
"Nervous system disorders  : cerebellar syndrome, cerebral hemorrhage, convulsion, gait disturbance, intracranial pressure increased, psychomotor skills impaired, pyramidal tract syndrome, somnolence.","hemorrhage , is not a named entity"
"Nervous system disorders  : cerebellar syndrome, cerebral hemorrhage, convulsion, gait disturbance, intracranial pressure increased, psychomotor skills impaired, pyramidal tract syndrome, somnolence.",psychomotor skills impaired is an adverse reaction entity
"Nervous system disorders  : cerebellar syndrome, cerebral hemorrhage, convulsion, gait disturbance, intracranial pressure increased, psychomotor skills impaired, pyramidal tract syndrome, somnolence.",skills is not a named entity
"Nervous system disorders  : cerebellar syndrome, cerebral hemorrhage, convulsion, gait disturbance, intracranial pressure increased, psychomotor skills impaired, pyramidal tract syndrome, somnolence.","gait disturbance , is not a named entity"
"Nervous system disorders  : cerebellar syndrome, cerebral hemorrhage, convulsion, gait disturbance, intracranial pressure increased, psychomotor skills impaired, pyramidal tract syndrome, somnolence.",", is not a named entity"
"The most common adverse reactions reported during clinical trials were chromaturia, nausea, vomiting, abdominal pain, alanine aminotransferase increased, arthralgia and neutropenia.",reactions reported during is not a named entity
"The most common adverse reactions reported during clinical trials were chromaturia, nausea, vomiting, abdominal pain, alanine aminotransferase increased, arthralgia and neutropenia.",vomiting is an adverse reaction entity
"The most common adverse reactions reported during clinical trials were chromaturia, nausea, vomiting, abdominal pain, alanine aminotransferase increased, arthralgia and neutropenia.","vomiting , is not a named entity"
"The most common adverse reactions reported during clinical trials were chromaturia, nausea, vomiting, abdominal pain, alanine aminotransferase increased, arthralgia and neutropenia.",alanine aminotransferase increased is an adverse reaction entity
"The most common adverse reactions reported during clinical trials were chromaturia, nausea, vomiting, abdominal pain, alanine aminotransferase increased, arthralgia and neutropenia.",arthralgia and neutropenia is not a named entity
"The most common adverse reactions reported during clinical trials were chromaturia, nausea, vomiting, abdominal pain, alanine aminotransferase increased, arthralgia and neutropenia.",", arthralgia and is not a named entity"
"The most common adverse reactions reported during clinical trials were chromaturia, nausea, vomiting, abdominal pain, alanine aminotransferase increased, arthralgia and neutropenia.",most is not a named entity
"The most common adverse reactions reported during clinical trials were chromaturia, nausea, vomiting, abdominal pain, alanine aminotransferase increased, arthralgia and neutropenia.",arthralgia is an adverse reaction entity
"The most common adverse reactions reported during clinical trials were chromaturia, nausea, vomiting, abdominal pain, alanine aminotransferase increased, arthralgia and neutropenia.",", is not a named entity"
"The most common adverse reactions reported during clinical trials were chromaturia, nausea, vomiting, abdominal pain, alanine aminotransferase increased, arthralgia and neutropenia.",nausea is an adverse reaction entity
"The most common adverse reactions reported during clinical trials were chromaturia, nausea, vomiting, abdominal pain, alanine aminotransferase increased, arthralgia and neutropenia.",abdominal pain is an adverse reaction entity
"The most common adverse reactions reported during clinical trials were chromaturia, nausea, vomiting, abdominal pain, alanine aminotransferase increased, arthralgia and neutropenia.",chromaturia is an adverse reaction entity
"The most common adverse reactions reported during clinical trials were chromaturia, nausea, vomiting, abdominal pain, alanine aminotransferase increased, arthralgia and neutropenia.",neutropenia is an adverse reaction entity
"The most common adverse reactions reported during clinical trials were chromaturia, nausea, vomiting, abdominal pain, alanine aminotransferase increased, arthralgia and neutropenia.",The most common is not a named entity
"General disorders and administration site conditions  : chills, pyrexia, edema peripheral, multi-organ failure.",administration site is not a named entity
"General disorders and administration site conditions  : chills, pyrexia, edema peripheral, multi-organ failure.",administration is not a named entity
"General disorders and administration site conditions  : chills, pyrexia, edema peripheral, multi-organ failure.",disorders is not a named entity
"General disorders and administration site conditions  : chills, pyrexia, edema peripheral, multi-organ failure.",pyrexia is an adverse reaction entity
"General disorders and administration site conditions  : chills, pyrexia, edema peripheral, multi-organ failure.",multi-organ failure is an adverse reaction entity
"General disorders and administration site conditions  : chills, pyrexia, edema peripheral, multi-organ failure.",chills is an adverse reaction entity
"General disorders and administration site conditions  : chills, pyrexia, edema peripheral, multi-organ failure.",edema peripheral is an adverse reaction entity
"General disorders and administration site conditions  : chills, pyrexia, edema peripheral, multi-organ failure.",and administration site is not a named entity
"Gastrointestinal disorders  : enterocolitis, rectal hemorrhage, gastric ulcer, pancreatitis, parotid gland enlargement.",parotid gland enlargement is an adverse reaction entity
"Gastrointestinal disorders  : enterocolitis, rectal hemorrhage, gastric ulcer, pancreatitis, parotid gland enlargement.",pancreatitis is an adverse reaction entity
"Gastrointestinal disorders  : enterocolitis, rectal hemorrhage, gastric ulcer, pancreatitis, parotid gland enlargement.",disorders : enterocolitis is not a named entity
"Gastrointestinal disorders  : enterocolitis, rectal hemorrhage, gastric ulcer, pancreatitis, parotid gland enlargement.",hemorrhage is not a named entity
"Gastrointestinal disorders  : enterocolitis, rectal hemorrhage, gastric ulcer, pancreatitis, parotid gland enlargement.",", pancreatitis is not a named entity"
"Gastrointestinal disorders  : enterocolitis, rectal hemorrhage, gastric ulcer, pancreatitis, parotid gland enlargement.",gastric ulcer is an adverse reaction entity
"Gastrointestinal disorders  : enterocolitis, rectal hemorrhage, gastric ulcer, pancreatitis, parotid gland enlargement.",enterocolitis is an adverse reaction entity
"Gastrointestinal disorders  : enterocolitis, rectal hemorrhage, gastric ulcer, pancreatitis, parotid gland enlargement.",rectal hemorrhage is an adverse reaction entity
"Gastrointestinal disorders  : enterocolitis, rectal hemorrhage, gastric ulcer, pancreatitis, parotid gland enlargement.",gland is not a named entity
"Gastrointestinal disorders  : enterocolitis, rectal hemorrhage, gastric ulcer, pancreatitis, parotid gland enlargement.",", gastric is not a named entity"
The most serious adverse reaction reported in clinical trials with Ferriprox was agranulocytosis  [see  Warnings and Precautions (5.1)  ]  .,agranulocytosis is an adverse reaction entity
The most serious adverse reaction reported in clinical trials with Ferriprox was agranulocytosis  [see  Warnings and Precautions (5.1)  ]  .,[ is not a named entity
BOXED WARNING: WARNING: AGRANULOCYTOSIS/NEUTROPENIA    WARNING: AGRANULOCYTOSIS/NEUTROPENIA      *  Ferriprox can cause agranulocytosis that can lead to serious infections and death.,agranulocytosis is an adverse reaction entity
BOXED WARNING: WARNING: AGRANULOCYTOSIS/NEUTROPENIA    WARNING: AGRANULOCYTOSIS/NEUTROPENIA      *  Ferriprox can cause agranulocytosis that can lead to serious infections and death.,WARNING : is not a named entity
BOXED WARNING: WARNING: AGRANULOCYTOSIS/NEUTROPENIA    WARNING: AGRANULOCYTOSIS/NEUTROPENIA      *  Ferriprox can cause agranulocytosis that can lead to serious infections and death.,serious infections is not a named entity
BOXED WARNING: WARNING: AGRANULOCYTOSIS/NEUTROPENIA    WARNING: AGRANULOCYTOSIS/NEUTROPENIA      *  Ferriprox can cause agranulocytosis that can lead to serious infections and death.,AGRANULOCYTOSIS is an adverse reaction entity
BOXED WARNING: WARNING: AGRANULOCYTOSIS/NEUTROPENIA    WARNING: AGRANULOCYTOSIS/NEUTROPENIA      *  Ferriprox can cause agranulocytosis that can lead to serious infections and death.,: is not a named entity
BOXED WARNING: WARNING: AGRANULOCYTOSIS/NEUTROPENIA    WARNING: AGRANULOCYTOSIS/NEUTROPENIA      *  Ferriprox can cause agranulocytosis that can lead to serious infections and death.,AGRANULOCYTOSIS is an adverse reaction entity
BOXED WARNING: WARNING: AGRANULOCYTOSIS/NEUTROPENIA    WARNING: AGRANULOCYTOSIS/NEUTROPENIA      *  Ferriprox can cause agranulocytosis that can lead to serious infections and death.,NEUTROPENIA is an adverse reaction entity
BOXED WARNING: WARNING: AGRANULOCYTOSIS/NEUTROPENIA    WARNING: AGRANULOCYTOSIS/NEUTROPENIA      *  Ferriprox can cause agranulocytosis that can lead to serious infections and death.,WARNING : WARNING is not a named entity
BOXED WARNING: WARNING: AGRANULOCYTOSIS/NEUTROPENIA    WARNING: AGRANULOCYTOSIS/NEUTROPENIA      *  Ferriprox can cause agranulocytosis that can lead to serious infections and death.,NEUTROPENIA is an adverse reaction entity
BOXED WARNING: WARNING: AGRANULOCYTOSIS/NEUTROPENIA    WARNING: AGRANULOCYTOSIS/NEUTROPENIA      *  Ferriprox can cause agranulocytosis that can lead to serious infections and death.,WARNING is not a named entity
BOXED WARNING: WARNING: AGRANULOCYTOSIS/NEUTROPENIA    WARNING: AGRANULOCYTOSIS/NEUTROPENIA      *  Ferriprox can cause agranulocytosis that can lead to serious infections and death.,: AGRANULOCYTOSIS/NEUTROPENIA * is not a named entity
BOXED WARNING: WARNING: AGRANULOCYTOSIS/NEUTROPENIA    WARNING: AGRANULOCYTOSIS/NEUTROPENIA      *  Ferriprox can cause agranulocytosis that can lead to serious infections and death.,infections is an adverse reaction entity
BOXED WARNING: WARNING: AGRANULOCYTOSIS/NEUTROPENIA    WARNING: AGRANULOCYTOSIS/NEUTROPENIA      *  Ferriprox can cause agranulocytosis that can lead to serious infections and death.,death is an adverse reaction entity
BOXED WARNING: WARNING: AGRANULOCYTOSIS/NEUTROPENIA    WARNING: AGRANULOCYTOSIS/NEUTROPENIA      *  Ferriprox can cause agranulocytosis that can lead to serious infections and death.,WARNING : WARNING is not a named entity
"Investigations  : blood bilirubin increased, blood creatinine phosphokinase increased.",blood creatinine phosphokinase increased is an adverse reaction entity
"Investigations  : blood bilirubin increased, blood creatinine phosphokinase increased.",: is not a named entity
"Investigations  : blood bilirubin increased, blood creatinine phosphokinase increased.",blood bilirubin increased is an adverse reaction entity
"Investigations  : blood bilirubin increased, blood creatinine phosphokinase increased.",bilirubin is not a named entity
"5.2 Embryofetal Toxicity      Based on evidence of genotoxicity and developmental toxicity in animal studies, Ferriprox can cause fetal harm when administered to a pregnant woman.",on is not a named entity
"5.2 Embryofetal Toxicity      Based on evidence of genotoxicity and developmental toxicity in animal studies, Ferriprox can cause fetal harm when administered to a pregnant woman.",fetal harm is an adverse reaction entity
"5.2 Embryofetal Toxicity      Based on evidence of genotoxicity and developmental toxicity in animal studies, Ferriprox can cause fetal harm when administered to a pregnant woman.",Ferriprox can cause is not a named entity
"5.2 Embryofetal Toxicity      Based on evidence of genotoxicity and developmental toxicity in animal studies, Ferriprox can cause fetal harm when administered to a pregnant woman.",of genotoxicity and is not a named entity
"5.2 Embryofetal Toxicity      Based on evidence of genotoxicity and developmental toxicity in animal studies, Ferriprox can cause fetal harm when administered to a pregnant woman.",genotoxicity is an adverse reaction entity
"5.2 Embryofetal Toxicity      Based on evidence of genotoxicity and developmental toxicity in animal studies, Ferriprox can cause fetal harm when administered to a pregnant woman.",Embryofetal developmental toxicity is an adverse reaction entity
*  Ferriprox can cause agranulocytosis that can lead to serious infections and death.,agranulocytosis is an adverse reaction entity
*  Ferriprox can cause agranulocytosis that can lead to serious infections and death.,infections is an adverse reaction entity
*  Ferriprox can cause agranulocytosis that can lead to serious infections and death.,* Ferriprox can is not a named entity
*  Ferriprox can cause agranulocytosis that can lead to serious infections and death.,agranulocytosis that can is not a named entity
*  Ferriprox can cause agranulocytosis that can lead to serious infections and death.,and death is not a named entity
*  Ferriprox can cause agranulocytosis that can lead to serious infections and death.,death is an adverse reaction entity
"6 ADVERSE REACTIONS       EXCERPT:    *  The most common adverse reactions are (incidence >= 5%) chromaturia, nausea, vomiting and abdominal pain, alanine aminotransferase increased, arthralgia and neutropenia.",chromaturia is an adverse reaction entity
"6 ADVERSE REACTIONS       EXCERPT:    *  The most common adverse reactions are (incidence >= 5%) chromaturia, nausea, vomiting and abdominal pain, alanine aminotransferase increased, arthralgia and neutropenia.",neutropenia is an adverse reaction entity
"6 ADVERSE REACTIONS       EXCERPT:    *  The most common adverse reactions are (incidence >= 5%) chromaturia, nausea, vomiting and abdominal pain, alanine aminotransferase increased, arthralgia and neutropenia.",are ( is not a named entity
"6 ADVERSE REACTIONS       EXCERPT:    *  The most common adverse reactions are (incidence >= 5%) chromaturia, nausea, vomiting and abdominal pain, alanine aminotransferase increased, arthralgia and neutropenia.",nausea is an adverse reaction entity
"6 ADVERSE REACTIONS       EXCERPT:    *  The most common adverse reactions are (incidence >= 5%) chromaturia, nausea, vomiting and abdominal pain, alanine aminotransferase increased, arthralgia and neutropenia.",EXCERPT : * is not a named entity
"6 ADVERSE REACTIONS       EXCERPT:    *  The most common adverse reactions are (incidence >= 5%) chromaturia, nausea, vomiting and abdominal pain, alanine aminotransferase increased, arthralgia and neutropenia.",vomiting is an adverse reaction entity
"6 ADVERSE REACTIONS       EXCERPT:    *  The most common adverse reactions are (incidence >= 5%) chromaturia, nausea, vomiting and abdominal pain, alanine aminotransferase increased, arthralgia and neutropenia.",adverse reactions is not a named entity
"6 ADVERSE REACTIONS       EXCERPT:    *  The most common adverse reactions are (incidence >= 5%) chromaturia, nausea, vomiting and abdominal pain, alanine aminotransferase increased, arthralgia and neutropenia.",arthralgia is an adverse reaction entity
"6 ADVERSE REACTIONS       EXCERPT:    *  The most common adverse reactions are (incidence >= 5%) chromaturia, nausea, vomiting and abdominal pain, alanine aminotransferase increased, arthralgia and neutropenia.",incidence > is not a named entity
"6 ADVERSE REACTIONS       EXCERPT:    *  The most common adverse reactions are (incidence >= 5%) chromaturia, nausea, vomiting and abdominal pain, alanine aminotransferase increased, arthralgia and neutropenia.",alanine aminotransferase increased is an adverse reaction entity
"6 ADVERSE REACTIONS       EXCERPT:    *  The most common adverse reactions are (incidence >= 5%) chromaturia, nausea, vomiting and abdominal pain, alanine aminotransferase increased, arthralgia and neutropenia.",% ) is not a named entity
"6 ADVERSE REACTIONS       EXCERPT:    *  The most common adverse reactions are (incidence >= 5%) chromaturia, nausea, vomiting and abdominal pain, alanine aminotransferase increased, arthralgia and neutropenia.",pain is not a named entity
"6 ADVERSE REACTIONS       EXCERPT:    *  The most common adverse reactions are (incidence >= 5%) chromaturia, nausea, vomiting and abdominal pain, alanine aminotransferase increased, arthralgia and neutropenia.",abdominal pain is an adverse reaction entity
"6 ADVERSE REACTIONS       EXCERPT:    *  The most common adverse reactions are (incidence >= 5%) chromaturia, nausea, vomiting and abdominal pain, alanine aminotransferase increased, arthralgia and neutropenia.",ADVERSE REACTIONS EXCERPT is not a named entity
"(  5.1  ,  6  )            To report SUSPECTED ADVERSE REACTIONS, contact ApoPharma Inc. at:  Telephone: 1-866-949-0995       Email:    medicalsafety@apopharma.com    or FDA at 1-800-FDA-1088 or        www.fda.gov/medwatch       }}     6.1 Clinical Trial Experience    The following adverse reactions are also discussed in other sections of the labeling: Agranulocytosis/Neutropenia  [see  Warnings and Precautions (5.1)  ]  .",Agranulocytosis is an adverse reaction entity
"(  5.1  ,  6  )            To report SUSPECTED ADVERSE REACTIONS, contact ApoPharma Inc. at:  Telephone: 1-866-949-0995       Email:    medicalsafety@apopharma.com    or FDA at 1-800-FDA-1088 or        www.fda.gov/medwatch       }}     6.1 Clinical Trial Experience    The following adverse reactions are also discussed in other sections of the labeling: Agranulocytosis/Neutropenia  [see  Warnings and Precautions (5.1)  ]  .",Neutropenia is an adverse reaction entity
"(  5.1  ,  6  )            To report SUSPECTED ADVERSE REACTIONS, contact ApoPharma Inc. at:  Telephone: 1-866-949-0995       Email:    medicalsafety@apopharma.com    or FDA at 1-800-FDA-1088 or        www.fda.gov/medwatch       }}     6.1 Clinical Trial Experience    The following adverse reactions are also discussed in other sections of the labeling: Agranulocytosis/Neutropenia  [see  Warnings and Precautions (5.1)  ]  .",at is not a named entity
"(  5.1  ,  6  )            To report SUSPECTED ADVERSE REACTIONS, contact ApoPharma Inc. at:  Telephone: 1-866-949-0995       Email:    medicalsafety@apopharma.com    or FDA at 1-800-FDA-1088 or        www.fda.gov/medwatch       }}     6.1 Clinical Trial Experience    The following adverse reactions are also discussed in other sections of the labeling: Agranulocytosis/Neutropenia  [see  Warnings and Precautions (5.1)  ]  .",ApoPharma Inc. is not a named entity
"In animal studies, administration of deferiprone during the period of organogenesis resulted in embryofetal death and malformations at doses lower than equivalent human clinical doses.",embryofetal malformations is an adverse reaction entity
"In animal studies, administration of deferiprone during the period of organogenesis resulted in embryofetal death and malformations at doses lower than equivalent human clinical doses.",embryofetal death is an adverse reaction entity
"In animal studies, administration of deferiprone during the period of organogenesis resulted in embryofetal death and malformations at doses lower than equivalent human clinical doses.",malformations at is not a named entity
"In animal studies, administration of deferiprone during the period of organogenesis resulted in embryofetal death and malformations at doses lower than equivalent human clinical doses.",administration is not a named entity
"In these patients, the majority of lymphocyte counts remained <0.5x10  9  /L with continued therapy.",", the is not a named entity"
"In these patients, the majority of lymphocyte counts remained <0.5x10  9  /L with continued therapy.",lymphocyte counts <0.5x10 9 /L is an adverse reaction entity
"During the clinical trial, the patient experienced prolonged lymphopenia (lymphocyte counts predominantly <0.5x10  9  /L for 3.5 years) while taking TECFIDERA [see Warnings and Precautions (  5.3  )]  .",", the patient is not a named entity"
"During the clinical trial, the patient experienced prolonged lymphopenia (lymphocyte counts predominantly <0.5x10  9  /L for 3.5 years) while taking TECFIDERA [see Warnings and Precautions (  5.3  )]  .",lymphopenia is an adverse reaction entity
*  Progressive multifocal leukoencephalopathy [see Warnings and Precautions (  5.2  )].,Warnings and is not a named entity
*  Progressive multifocal leukoencephalopathy [see Warnings and Precautions (  5.2  )].,Progressive multifocal leukoencephalopathy is an adverse reaction entity
Discontinuations due to elevated hepatic transaminases were < 1% and were similar in patients treated with TECFIDERA or placebo.,hepatic is not a named entity
Discontinuations due to elevated hepatic transaminases were < 1% and were similar in patients treated with TECFIDERA or placebo.,elevated hepatic transaminases is an adverse reaction entity
"5.4 Flushing         TECFIDERA may cause flushing (e.g., warmth, redness, itching, and/or burning sensation).",", is not a named entity"
"5.4 Flushing         TECFIDERA may cause flushing (e.g., warmth, redness, itching, and/or burning sensation).",", warmth is not a named entity"
"5.4 Flushing         TECFIDERA may cause flushing (e.g., warmth, redness, itching, and/or burning sensation).",burning sensation is an adverse reaction entity
"5.4 Flushing         TECFIDERA may cause flushing (e.g., warmth, redness, itching, and/or burning sensation).",", warmth is not a named entity"
"5.4 Flushing         TECFIDERA may cause flushing (e.g., warmth, redness, itching, and/or burning sensation).",warmth is an adverse reaction entity
"5.4 Flushing         TECFIDERA may cause flushing (e.g., warmth, redness, itching, and/or burning sensation).",itching is an adverse reaction entity
"5.4 Flushing         TECFIDERA may cause flushing (e.g., warmth, redness, itching, and/or burning sensation).",", redness , is not a named entity"
"5.4 Flushing         TECFIDERA may cause flushing (e.g., warmth, redness, itching, and/or burning sensation).",flushing is an adverse reaction entity
"5.4 Flushing         TECFIDERA may cause flushing (e.g., warmth, redness, itching, and/or burning sensation).",burning sensation ) is not a named entity
"5.4 Flushing         TECFIDERA may cause flushing (e.g., warmth, redness, itching, and/or burning sensation).",redness is an adverse reaction entity
"The incidence of infections (60% vs 58%) and serious infections (2% vs 2%) was similar in patients treated with TECFIDERA or placebo, respectively.",infections is an adverse reaction entity
"The incidence of infections (60% vs 58%) and serious infections (2% vs 2%) was similar in patients treated with TECFIDERA or placebo, respectively.",infections is an adverse reaction entity
"The incidence of infections (60% vs 58%) and serious infections (2% vs 2%) was similar in patients treated with TECFIDERA or placebo, respectively.",was similar in is not a named entity
"The incidence of infections (60% vs 58%) and serious infections (2% vs 2%) was similar in patients treated with TECFIDERA or placebo, respectively.","placebo , is not a named entity"
"In the majority of patients who experienced flushing, it was mild or moderate in severity.",flushing is an adverse reaction entity
"In the majority of patients who experienced flushing, it was mild or moderate in severity.",in is not a named entity
There were no elevations in transaminases >= 3 times the ULN with concomitant elevations in total bilirubin > 2 times the ULN.,in transaminases > is not a named entity
There were no elevations in transaminases >= 3 times the ULN with concomitant elevations in total bilirubin > 2 times the ULN.,times is not a named entity
There were no elevations in transaminases >= 3 times the ULN with concomitant elevations in total bilirubin > 2 times the ULN.,elevations in transaminases is an adverse reaction entity
There were no elevations in transaminases >= 3 times the ULN with concomitant elevations in total bilirubin > 2 times the ULN.,elevations in total bilirubin is an adverse reaction entity
Eosinophilia       A transient increase in mean eosinophil counts was seen during the first 2 months of therapy.,increase in mean eosinophil counts is an adverse reaction entity
Eosinophilia       A transient increase in mean eosinophil counts was seen during the first 2 months of therapy.,the first is not a named entity
Four percent (4%) of patients treated with TECFIDERA and less than 1% of placebo patients discontinued due to gastrointestinal events.,gastrointestinal events is an adverse reaction entity
Four percent (4%) of patients treated with TECFIDERA and less than 1% of placebo patients discontinued due to gastrointestinal events.,patients is not a named entity
Elevations of alanine aminotransferase and aspartate aminotransferase to >= 3 times the ULN occurred in a small number of patients treated with both TECFIDERA and placebo and were balanced between groups.,TECFIDERA and is not a named entity
Elevations of alanine aminotransferase and aspartate aminotransferase to >= 3 times the ULN occurred in a small number of patients treated with both TECFIDERA and placebo and were balanced between groups.,Elevations of alanine aminotransferase is an adverse reaction entity
Elevations of alanine aminotransferase and aspartate aminotransferase to >= 3 times the ULN occurred in a small number of patients treated with both TECFIDERA and placebo and were balanced between groups.,Elevations of aspartate aminotransferase is an adverse reaction entity
Elevations of alanine aminotransferase and aspartate aminotransferase to >= 3 times the ULN occurred in a small number of patients treated with both TECFIDERA and placebo and were balanced between groups.,and were is not a named entity
"Hepatic Transaminases       An increased incidence of elevations of hepatic transaminases in patients treated with TECFIDERA was seen primarily during the first six months of treatment, and most patients with elevations had levels < 3 times the upper limit of normal (ULN).",times the is not a named entity
"Hepatic Transaminases       An increased incidence of elevations of hepatic transaminases in patients treated with TECFIDERA was seen primarily during the first six months of treatment, and most patients with elevations had levels < 3 times the upper limit of normal (ULN).",elevations of hepatic transaminases is an adverse reaction entity
"EXCERPT:   Most common adverse reactions (incidence >=10% and >=2% placebo) were flushing, abdominal pain, diarrhea, and nausea.",diarrhea is an adverse reaction entity
"EXCERPT:   Most common adverse reactions (incidence >=10% and >=2% placebo) were flushing, abdominal pain, diarrhea, and nausea.",nausea is an adverse reaction entity
"EXCERPT:   Most common adverse reactions (incidence >=10% and >=2% placebo) were flushing, abdominal pain, diarrhea, and nausea.",placebo ) were is not a named entity
"EXCERPT:   Most common adverse reactions (incidence >=10% and >=2% placebo) were flushing, abdominal pain, diarrhea, and nausea.",abdominal pain is an adverse reaction entity
"EXCERPT:   Most common adverse reactions (incidence >=10% and >=2% placebo) were flushing, abdominal pain, diarrhea, and nausea.",placebo is not a named entity
"EXCERPT:   Most common adverse reactions (incidence >=10% and >=2% placebo) were flushing, abdominal pain, diarrhea, and nausea.",adverse reactions ( is not a named entity
"EXCERPT:   Most common adverse reactions (incidence >=10% and >=2% placebo) were flushing, abdominal pain, diarrhea, and nausea.","pain , is not a named entity"
"EXCERPT:   Most common adverse reactions (incidence >=10% and >=2% placebo) were flushing, abdominal pain, diarrhea, and nausea.",flushing is an adverse reaction entity
"In the MS placebo controlled trials, mean lymphocyte counts decreased by approximately 30% during the first year of treatment with TECFIDERA and then remained stable.",lymphocyte counts decreased is an adverse reaction entity
"In the MS placebo controlled trials, mean lymphocyte counts decreased by approximately 30% during the first year of treatment with TECFIDERA and then remained stable.",TECFIDERA and is not a named entity
6 ADVERSE REACTIONS    The following important adverse reactions are described elsewhere in labeling:     *  Anaphylaxis and Angioedema [see Warnings and Precautions (  5.1  )].,are described is not a named entity
6 ADVERSE REACTIONS    The following important adverse reactions are described elsewhere in labeling:     *  Anaphylaxis and Angioedema [see Warnings and Precautions (  5.1  )].,and is not a named entity
6 ADVERSE REACTIONS    The following important adverse reactions are described elsewhere in labeling:     *  Anaphylaxis and Angioedema [see Warnings and Precautions (  5.1  )].,Angioedema is an adverse reaction entity
6 ADVERSE REACTIONS    The following important adverse reactions are described elsewhere in labeling:     *  Anaphylaxis and Angioedema [see Warnings and Precautions (  5.1  )].,Anaphylaxis is an adverse reaction entity
"There was no increased incidence of serious infections observed in patients with lymphocyte counts <0.8x10  9  /L or 0.5x10  9  /L in controlled trials, although one patient in an extension study developed PML in the setting of prolonged lymphopenia (lymphocyte counts predominantly <0.5x10  9  /L for 3.5 years) [see Warnings and Precautions (  5.2  )]  .",increased infections is an adverse reaction entity
"There was no increased incidence of serious infections observed in patients with lymphocyte counts <0.8x10  9  /L or 0.5x10  9  /L in controlled trials, although one patient in an extension study developed PML in the setting of prolonged lymphopenia (lymphocyte counts predominantly <0.5x10  9  /L for 3.5 years) [see Warnings and Precautions (  5.2  )]  .",PML is an adverse reaction entity
"There was no increased incidence of serious infections observed in patients with lymphocyte counts <0.8x10  9  /L or 0.5x10  9  /L in controlled trials, although one patient in an extension study developed PML in the setting of prolonged lymphopenia (lymphocyte counts predominantly <0.5x10  9  /L for 3.5 years) [see Warnings and Precautions (  5.2  )]  .",patient is not a named entity
"There was no increased incidence of serious infections observed in patients with lymphocyte counts <0.8x10  9  /L or 0.5x10  9  /L in controlled trials, although one patient in an extension study developed PML in the setting of prolonged lymphopenia (lymphocyte counts predominantly <0.5x10  9  /L for 3.5 years) [see Warnings and Precautions (  5.2  )]  .",prolonged lymphopenia is an adverse reaction entity
"There was no increased incidence of serious infections observed in patients with lymphocyte counts <0.8x10  9  /L or 0.5x10  9  /L in controlled trials, although one patient in an extension study developed PML in the setting of prolonged lymphopenia (lymphocyte counts predominantly <0.5x10  9  /L for 3.5 years) [see Warnings and Precautions (  5.2  )]  .",9 /L is not a named entity
"There was no increased incidence of serious infections observed in patients with lymphocyte counts <0.8x10  9  /L or 0.5x10  9  /L in controlled trials, although one patient in an extension study developed PML in the setting of prolonged lymphopenia (lymphocyte counts predominantly <0.5x10  9  /L for 3.5 years) [see Warnings and Precautions (  5.2  )]  .",counts predominantly is not a named entity
"(  5.2  )   *  Lymphopenia: Obtain a CBC including lymphocyte count before initiating TECFIDERA, after 6 months, and every 6 to 12 months thereafter.",5.2 ) is not a named entity
"(  5.2  )   *  Lymphopenia: Obtain a CBC including lymphocyte count before initiating TECFIDERA, after 6 months, and every 6 to 12 months thereafter.",Lymphopenia is an adverse reaction entity
(  5.3  )                5.1 Anaphylaxis and Angioedema         TECFIDERA can cause anaphylaxis and angioedema after the first dose or at any time during treatment.,5.3 is not a named entity
(  5.3  )                5.1 Anaphylaxis and Angioedema         TECFIDERA can cause anaphylaxis and angioedema after the first dose or at any time during treatment.,angioedema is an adverse reaction entity
(  5.3  )                5.1 Anaphylaxis and Angioedema         TECFIDERA can cause anaphylaxis and angioedema after the first dose or at any time during treatment.,anaphylaxis is an adverse reaction entity
(  5.3  )                5.1 Anaphylaxis and Angioedema         TECFIDERA can cause anaphylaxis and angioedema after the first dose or at any time during treatment.,angioedema after the is not a named entity
"The most common adverse reactions (incidence >=10% and >=2% more than placebo) for TECFIDERA were flushing, abdominal pain, diarrhea, and nausea.",adverse is not a named entity
"The most common adverse reactions (incidence >=10% and >=2% more than placebo) for TECFIDERA were flushing, abdominal pain, diarrhea, and nausea.",TECFIDERA were flushing is not a named entity
"The most common adverse reactions (incidence >=10% and >=2% more than placebo) for TECFIDERA were flushing, abdominal pain, diarrhea, and nausea.",abdominal pain is an adverse reaction entity
"The most common adverse reactions (incidence >=10% and >=2% more than placebo) for TECFIDERA were flushing, abdominal pain, diarrhea, and nausea.",most common is not a named entity
"The most common adverse reactions (incidence >=10% and >=2% more than placebo) for TECFIDERA were flushing, abdominal pain, diarrhea, and nausea.",flushing is an adverse reaction entity
"The most common adverse reactions (incidence >=10% and >=2% more than placebo) for TECFIDERA were flushing, abdominal pain, diarrhea, and nausea.",diarrhea is an adverse reaction entity
"The most common adverse reactions (incidence >=10% and >=2% more than placebo) for TECFIDERA were flushing, abdominal pain, diarrhea, and nausea.","diarrhea , is not a named entity"
"The most common adverse reactions (incidence >=10% and >=2% more than placebo) for TECFIDERA were flushing, abdominal pain, diarrhea, and nausea.",nausea is an adverse reaction entity
Flushing symptoms generally began soon after initiating TECFIDERA and usually improved or resolved over time.,Flushing is an adverse reaction entity
Flushing symptoms generally began soon after initiating TECFIDERA and usually improved or resolved over time.,TECFIDERA and is not a named entity
"In both Studies 1 and 2, aminotransferase elevations of at least 3 times the upper limit of normal developed more frequently in the SIRTURO treatment group (11/102 [10.8%] vs 6/105 [5.7%]) than in the placebo treatment group.",than is not a named entity
"In both Studies 1 and 2, aminotransferase elevations of at least 3 times the upper limit of normal developed more frequently in the SIRTURO treatment group (11/102 [10.8%] vs 6/105 [5.7%]) than in the placebo treatment group.",aminotransferase elevations is an adverse reaction entity
"Increased Mortality       In Study 1, there was a statistically significant increased mortality risk by Week 120 in the SIRTURO treatment group compared to the placebo treatment group (9/79 (11.4%) versus 2/81 (2.5%), p-value=0.03, an exact 95% confidence interval of the difference [1.1%, 18.2%]).",risk by is not a named entity
"Increased Mortality       In Study 1, there was a statistically significant increased mortality risk by Week 120 in the SIRTURO treatment group compared to the placebo treatment group (9/79 (11.4%) versus 2/81 (2.5%), p-value=0.03, an exact 95% confidence interval of the difference [1.1%, 18.2%]).",increased mortality is an adverse reaction entity
Five of the 9 SIRTURO deaths and the 2 placebo deaths were tuberculosis-related.,the 9 SIRTURO is not a named entity
Five of the 9 SIRTURO deaths and the 2 placebo deaths were tuberculosis-related.,deaths is an adverse reaction entity
Five of the 9 SIRTURO deaths and the 2 placebo deaths were tuberculosis-related.,deaths is an adverse reaction entity
Five of the 9 SIRTURO deaths and the 2 placebo deaths were tuberculosis-related.,Five of the is not a named entity
BOXED WARNING: WARNINGS: INCREASED MORTALITY; QT PROLONGATION    WARNINGS: INCREASED MORTALITY; QT PROLONGATION    EXCERPT:   WARNINGS: INCREASED MORTALITY; QT PROLONGATION       See full prescribing information for complete boxed warning.,PROLONGATION EXCERPT is not a named entity
BOXED WARNING: WARNINGS: INCREASED MORTALITY; QT PROLONGATION    WARNINGS: INCREASED MORTALITY; QT PROLONGATION    EXCERPT:   WARNINGS: INCREASED MORTALITY; QT PROLONGATION       See full prescribing information for complete boxed warning.,EXCERPT is not a named entity
BOXED WARNING: WARNINGS: INCREASED MORTALITY; QT PROLONGATION    WARNINGS: INCREASED MORTALITY; QT PROLONGATION    EXCERPT:   WARNINGS: INCREASED MORTALITY; QT PROLONGATION       See full prescribing information for complete boxed warning.,INCREASED MORTALITY is an adverse reaction entity
BOXED WARNING: WARNINGS: INCREASED MORTALITY; QT PROLONGATION    WARNINGS: INCREASED MORTALITY; QT PROLONGATION    EXCERPT:   WARNINGS: INCREASED MORTALITY; QT PROLONGATION       See full prescribing information for complete boxed warning.,INCREASED MORTALITY is an adverse reaction entity
BOXED WARNING: WARNINGS: INCREASED MORTALITY; QT PROLONGATION    WARNINGS: INCREASED MORTALITY; QT PROLONGATION    EXCERPT:   WARNINGS: INCREASED MORTALITY; QT PROLONGATION       See full prescribing information for complete boxed warning.,QT PROLONGATION is an adverse reaction entity
BOXED WARNING: WARNINGS: INCREASED MORTALITY; QT PROLONGATION    WARNINGS: INCREASED MORTALITY; QT PROLONGATION    EXCERPT:   WARNINGS: INCREASED MORTALITY; QT PROLONGATION       See full prescribing information for complete boxed warning.,MORTALITY ; QT is not a named entity
BOXED WARNING: WARNINGS: INCREASED MORTALITY; QT PROLONGATION    WARNINGS: INCREASED MORTALITY; QT PROLONGATION    EXCERPT:   WARNINGS: INCREASED MORTALITY; QT PROLONGATION       See full prescribing information for complete boxed warning.,: is not a named entity
BOXED WARNING: WARNINGS: INCREASED MORTALITY; QT PROLONGATION    WARNINGS: INCREASED MORTALITY; QT PROLONGATION    EXCERPT:   WARNINGS: INCREASED MORTALITY; QT PROLONGATION       See full prescribing information for complete boxed warning.,See full prescribing is not a named entity
BOXED WARNING: WARNINGS: INCREASED MORTALITY; QT PROLONGATION    WARNINGS: INCREASED MORTALITY; QT PROLONGATION    EXCERPT:   WARNINGS: INCREASED MORTALITY; QT PROLONGATION       See full prescribing information for complete boxed warning.,QT PROLONGATION is an adverse reaction entity
BOXED WARNING: WARNINGS: INCREASED MORTALITY; QT PROLONGATION    WARNINGS: INCREASED MORTALITY; QT PROLONGATION    EXCERPT:   WARNINGS: INCREASED MORTALITY; QT PROLONGATION       See full prescribing information for complete boxed warning.,prescribing is not a named entity
BOXED WARNING: WARNINGS: INCREASED MORTALITY; QT PROLONGATION    WARNINGS: INCREASED MORTALITY; QT PROLONGATION    EXCERPT:   WARNINGS: INCREASED MORTALITY; QT PROLONGATION       See full prescribing information for complete boxed warning.,QT PROLONGATION is an adverse reaction entity
BOXED WARNING: WARNINGS: INCREASED MORTALITY; QT PROLONGATION    WARNINGS: INCREASED MORTALITY; QT PROLONGATION    EXCERPT:   WARNINGS: INCREASED MORTALITY; QT PROLONGATION       See full prescribing information for complete boxed warning.,INCREASED MORTALITY is an adverse reaction entity
"The imbalance in deaths is unexplained; no discernible pattern between death and sputum conversion, relapse, sensitivity to other drugs used to treat tuberculosis, HIV status, and severity of disease was observed.",unexplained ; is not a named entity
"The imbalance in deaths is unexplained; no discernible pattern between death and sputum conversion, relapse, sensitivity to other drugs used to treat tuberculosis, HIV status, and severity of disease was observed.",deaths is an adverse reaction entity
"The imbalance in deaths is unexplained; no discernible pattern between death and sputum conversion, relapse, sensitivity to other drugs used to treat tuberculosis, HIV status, and severity of disease was observed.",deaths is is not a named entity
"The imbalance in deaths is unexplained; no discernible pattern between death and sputum conversion, relapse, sensitivity to other drugs used to treat tuberculosis, HIV status, and severity of disease was observed.",death is an adverse reaction entity
"The following may increase the risk for QT prolongation when patients are receiving SIRTURO:     *  use with other QT prolonging drugs including fluoroquinolones and macrolide antibacterial drugs and the antimycobacterial drug, clofazimine   *  a history of Torsade de Pointes   *  a history of congenital long QT syndrome   *  a history of or ongoing hypothyroidism   *  a history of or ongoing bradyarrhythmias   *  a history of uncompensated heart failure   *  serum calcium, magnesium, or potassium levels below the lower limits of normal      If necessary, bedaquiline treatment initiation could be considered in these patients after a favorable benefit risk assessment and with frequent ECG monitoring.",QT prolongation is an adverse reaction entity
"The following may increase the risk for QT prolongation when patients are receiving SIRTURO:     *  use with other QT prolonging drugs including fluoroquinolones and macrolide antibacterial drugs and the antimycobacterial drug, clofazimine   *  a history of Torsade de Pointes   *  a history of congenital long QT syndrome   *  a history of or ongoing hypothyroidism   *  a history of or ongoing bradyarrhythmias   *  a history of uncompensated heart failure   *  serum calcium, magnesium, or potassium levels below the lower limits of normal      If necessary, bedaquiline treatment initiation could be considered in these patients after a favorable benefit risk assessment and with frequent ECG monitoring.",long QT is not a named entity
"Increased Mortality       *  An increased risk of death was seen in the SIRTURO treatment group (9/79, 11.4%) compared to the placebo treatment group (2/81, 2.5%) in one placebo-controlled trial.",group ( is not a named entity
"Increased Mortality       *  An increased risk of death was seen in the SIRTURO treatment group (9/79, 11.4%) compared to the placebo treatment group (2/81, 2.5%) in one placebo-controlled trial.",death is an adverse reaction entity
"No discernible pattern between death and sputum culture conversion, relapse, sensitivity to other drugs used to treat tuberculosis, HIV status, or severity of disease could be observed.",death is an adverse reaction entity
"No discernible pattern between death and sputum culture conversion, relapse, sensitivity to other drugs used to treat tuberculosis, HIV status, or severity of disease could be observed.",drugs is not a named entity
The most common cause of death as reported by the investigator was TB (9 subjects).,as is not a named entity
The most common cause of death as reported by the investigator was TB (9 subjects).,death is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  QT prolongation can occur with SIRTURO.,WARNINGS is not a named entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  QT prolongation can occur with SIRTURO.,QT prolongation is an adverse reaction entity
"(  5.3  )    *   Suicidal thoughts or behaviors: HORIZANT is a prodrug of gabapentin, an antiepileptic drug (AED).",Suicidal thoughts is an adverse reaction entity
"(  5.3  )    *   Suicidal thoughts or behaviors: HORIZANT is a prodrug of gabapentin, an antiepileptic drug (AED).",Suicidal behaviors is an adverse reaction entity
"(  5.3  )    *   Suicidal thoughts or behaviors: HORIZANT is a prodrug of gabapentin, an antiepileptic drug (AED).",( is not a named entity
"(  5.3  )    *   Suicidal thoughts or behaviors: HORIZANT is a prodrug of gabapentin, an antiepileptic drug (AED).",an antiepileptic is not a named entity
The increased risk of suicidal thoughts or behavior with AEDs was observed as early as 1 week after starting drug treatment with AEDs and persisted for the duration of treatment assessed.,suicidal thoughts or is not a named entity
The increased risk of suicidal thoughts or behavior with AEDs was observed as early as 1 week after starting drug treatment with AEDs and persisted for the duration of treatment assessed.,suicidal behavior is an adverse reaction entity
The increased risk of suicidal thoughts or behavior with AEDs was observed as early as 1 week after starting drug treatment with AEDs and persisted for the duration of treatment assessed.,as 1 is not a named entity
The increased risk of suicidal thoughts or behavior with AEDs was observed as early as 1 week after starting drug treatment with AEDs and persisted for the duration of treatment assessed.,suicidal thoughts is an adverse reaction entity
"The most commonly observed adverse reactions (>=10% and greater than placebo) in this trial for the 1,200 mg dose of HORIZANT were dizziness, somnolence, and headache (see  Table 5  ).",dizziness is an adverse reaction entity
"The most commonly observed adverse reactions (>=10% and greater than placebo) in this trial for the 1,200 mg dose of HORIZANT were dizziness, somnolence, and headache (see  Table 5  ).",than placebo ) is not a named entity
"The most commonly observed adverse reactions (>=10% and greater than placebo) in this trial for the 1,200 mg dose of HORIZANT were dizziness, somnolence, and headache (see  Table 5  ).",somnolence is an adverse reaction entity
"The most commonly observed adverse reactions (>=10% and greater than placebo) in this trial for the 1,200 mg dose of HORIZANT were dizziness, somnolence, and headache (see  Table 5  ).",greater than is not a named entity
"The most commonly observed adverse reactions (>=10% and greater than placebo) in this trial for the 1,200 mg dose of HORIZANT were dizziness, somnolence, and headache (see  Table 5  ).",=10 % and is not a named entity
"The most commonly observed adverse reactions (>=10% and greater than placebo) in this trial for the 1,200 mg dose of HORIZANT were dizziness, somnolence, and headache (see  Table 5  ).",headache is an adverse reaction entity
"Pooled analyses of 199 placebo-controlled clinical trials (monotherapy and adjunctive therapy) of 11 different AEDs showed that patients randomized to 1 of the AEDs had approximately twice the risk [adjusted relative risk 1.8, 95% confidence interval (CI): 1.2, 2.7] of suicidal thinking or behavior compared with patients randomized to placebo.",( monotherapy and is not a named entity
"Pooled analyses of 199 placebo-controlled clinical trials (monotherapy and adjunctive therapy) of 11 different AEDs showed that patients randomized to 1 of the AEDs had approximately twice the risk [adjusted relative risk 1.8, 95% confidence interval (CI): 1.2, 2.7] of suicidal thinking or behavior compared with patients randomized to placebo.",suicidal thinking is an adverse reaction entity
"Pooled analyses of 199 placebo-controlled clinical trials (monotherapy and adjunctive therapy) of 11 different AEDs showed that patients randomized to 1 of the AEDs had approximately twice the risk [adjusted relative risk 1.8, 95% confidence interval (CI): 1.2, 2.7] of suicidal thinking or behavior compared with patients randomized to placebo.",confidence is not a named entity
"Pooled analyses of 199 placebo-controlled clinical trials (monotherapy and adjunctive therapy) of 11 different AEDs showed that patients randomized to 1 of the AEDs had approximately twice the risk [adjusted relative risk 1.8, 95% confidence interval (CI): 1.2, 2.7] of suicidal thinking or behavior compared with patients randomized to placebo.",suicidal behavior is an adverse reaction entity
"Dizziness led to withdrawal in 2% of patients receiving 1,200 mg of HORIZANT per day compared with 3% of patients receiving placebo.",Dizziness is an adverse reaction entity
"Dizziness led to withdrawal in 2% of patients receiving 1,200 mg of HORIZANT per day compared with 3% of patients receiving placebo.",withdrawal is not a named entity
The most commonly observed adverse reactions (>=5% and at least 2 times the rate of placebo) in these trials for the 600 mg dose of HORIZANT were somnolence/sedation and dizziness (see  Table 4  ).,mg dose is not a named entity
The most commonly observed adverse reactions (>=5% and at least 2 times the rate of placebo) in these trials for the 600 mg dose of HORIZANT were somnolence/sedation and dizziness (see  Table 4  ).,dizziness is an adverse reaction entity
The most commonly observed adverse reactions (>=5% and at least 2 times the rate of placebo) in these trials for the 600 mg dose of HORIZANT were somnolence/sedation and dizziness (see  Table 4  ).,sedation is an adverse reaction entity
The most commonly observed adverse reactions (>=5% and at least 2 times the rate of placebo) in these trials for the 600 mg dose of HORIZANT were somnolence/sedation and dizziness (see  Table 4  ).,somnolence is an adverse reaction entity
The most commonly observed adverse reactions (>=5% and at least 2 times the rate of placebo) in these trials for the 600 mg dose of HORIZANT were somnolence/sedation and dizziness (see  Table 4  ).,somnolence/sedation and is not a named entity
The most commonly observed adverse reactions (>=5% and at least 2 times the rate of placebo) in these trials for the 600 mg dose of HORIZANT were somnolence/sedation and dizziness (see  Table 4  ).,rate is not a named entity
Whether the impairment is related to somnolence [see Warnings and Precautions (  5.2  )]  or other effects of HORIZANT is unknown.,somnolence [ is not a named entity
Whether the impairment is related to somnolence [see Warnings and Precautions (  5.2  )]  or other effects of HORIZANT is unknown.,somnolence is an adverse reaction entity
Dizziness led to withdrawal in 1% of patients receiving 600 mg of HORIZANT per day.,Dizziness is an adverse reaction entity
Dizziness led to withdrawal in 1% of patients receiving 600 mg of HORIZANT per day.,mg of HORIZANT is not a named entity
"During the 12-week, controlled study in patients with PHN, somnolence was reported in 10% of patients treated with 1,200 mg of HORIZANT per day compared with 8% of patients receiving placebo.",somnolence is an adverse reaction entity
"During the 12-week, controlled study in patients with PHN, somnolence was reported in 10% of patients treated with 1,200 mg of HORIZANT per day compared with 8% of patients receiving placebo.",% of is not a named entity
"5.7 Tumorigenic Potential      In an oral carcinogenicity study, gabapentin enacarbil increased the incidence of pancreatic acinar cell adenoma and carcinoma in male and female rats [see Nonclinical Toxicology (  13.1  )]  .",pancreatic acinar cell adenoma is an adverse reaction entity
"5.7 Tumorigenic Potential      In an oral carcinogenicity study, gabapentin enacarbil increased the incidence of pancreatic acinar cell adenoma and carcinoma in male and female rats [see Nonclinical Toxicology (  13.1  )]  .",and female rats is not a named entity
"5.7 Tumorigenic Potential      In an oral carcinogenicity study, gabapentin enacarbil increased the incidence of pancreatic acinar cell adenoma and carcinoma in male and female rats [see Nonclinical Toxicology (  13.1  )]  .",pancreatic acinar cell carcinoma is an adverse reaction entity
"5.7 Tumorigenic Potential      In an oral carcinogenicity study, gabapentin enacarbil increased the incidence of pancreatic acinar cell adenoma and carcinoma in male and female rats [see Nonclinical Toxicology (  13.1  )]  .",incidence of pancreatic is not a named entity
"(  6.1  )    *   PHN: Most common adverse reactions (>=10% and greater than placebo) were dizziness, somnolence, and headache.",headache is an adverse reaction entity
"(  6.1  )    *   PHN: Most common adverse reactions (>=10% and greater than placebo) were dizziness, somnolence, and headache.",than is not a named entity
"(  6.1  )    *   PHN: Most common adverse reactions (>=10% and greater than placebo) were dizziness, somnolence, and headache.",somnolence is an adverse reaction entity
"(  6.1  )    *   PHN: Most common adverse reactions (>=10% and greater than placebo) were dizziness, somnolence, and headache.",dizziness is an adverse reaction entity
"(  6.1  )    *   PHN: Most common adverse reactions (>=10% and greater than placebo) were dizziness, somnolence, and headache.",greater than is not a named entity
"(  6.1  )    *   PHN: Most common adverse reactions (>=10% and greater than placebo) were dizziness, somnolence, and headache.",than placebo is not a named entity
Somnolence/sedation led to withdrawal in 2% of patients receiving 600 mg of HORIZANT per day.,receiving 600 mg is not a named entity
Somnolence/sedation led to withdrawal in 2% of patients receiving 600 mg of HORIZANT per day.,Somnolence is an adverse reaction entity
Somnolence/sedation led to withdrawal in 2% of patients receiving 600 mg of HORIZANT per day.,sedation is an adverse reaction entity
Somnolence/sedation led to withdrawal in 2% of patients receiving 600 mg of HORIZANT per day.,HORIZANT per day is not a named entity
(  5.4  )              5.1 Effects on Driving       HORIZANT may cause significant driving impairment [see Clinical Studies (  14.3  )]  .,driving impairment is an adverse reaction entity
(  5.4  )              5.1 Effects on Driving       HORIZANT may cause significant driving impairment [see Clinical Studies (  14.3  )]  .,HORIZANT may cause is not a named entity
"Dizziness, somnolence, fatigue, and insomnia appeared to show a dose relationship.",", somnolence , is not a named entity"
"Dizziness, somnolence, fatigue, and insomnia appeared to show a dose relationship.",fatigue is an adverse reaction entity
"Dizziness, somnolence, fatigue, and insomnia appeared to show a dose relationship.",show is not a named entity
"Dizziness, somnolence, fatigue, and insomnia appeared to show a dose relationship.",insomnia is an adverse reaction entity
"Dizziness, somnolence, fatigue, and insomnia appeared to show a dose relationship.",appeared is not a named entity
"Dizziness, somnolence, fatigue, and insomnia appeared to show a dose relationship.",somnolence is an adverse reaction entity
"Dizziness, somnolence, fatigue, and insomnia appeared to show a dose relationship.",Dizziness is an adverse reaction entity
"Dizziness, somnolence, fatigue, and insomnia appeared to show a dose relationship.",", is not a named entity"
"Dizziness was reported in 17% of patients receiving 1,200 mg of HORIZANT per day compared with 15% of patients receiving placebo.",17 % of is not a named entity
"Dizziness was reported in 17% of patients receiving 1,200 mg of HORIZANT per day compared with 15% of patients receiving placebo.",Dizziness is an adverse reaction entity
"In clinical studies of gabapentin as adjunctive therapy in epilepsy comprising 2,085 patient-years of exposure in patients >12 years of age, new tumors were reported in 10 patients (2 breast, 3 brain, 2 lung, 1 adrenal, 1 non-Hodgkin's lymphoma, 1 endometrial carcinoma in situ), and preexisting tumors worsened in 11 patients (9 brain, 1 breast, 1 prostate) during or up to 2 years following discontinuation of gabapentin.",11 patients is not a named entity
"In clinical studies of gabapentin as adjunctive therapy in epilepsy comprising 2,085 patient-years of exposure in patients >12 years of age, new tumors were reported in 10 patients (2 breast, 3 brain, 2 lung, 1 adrenal, 1 non-Hodgkin's lymphoma, 1 endometrial carcinoma in situ), and preexisting tumors worsened in 11 patients (9 brain, 1 breast, 1 prostate) during or up to 2 years following discontinuation of gabapentin.",tumors worsened prostate is an adverse reaction entity
"In clinical studies of gabapentin as adjunctive therapy in epilepsy comprising 2,085 patient-years of exposure in patients >12 years of age, new tumors were reported in 10 patients (2 breast, 3 brain, 2 lung, 1 adrenal, 1 non-Hodgkin's lymphoma, 1 endometrial carcinoma in situ), and preexisting tumors worsened in 11 patients (9 brain, 1 breast, 1 prostate) during or up to 2 years following discontinuation of gabapentin.",during is not a named entity
"In clinical studies of gabapentin as adjunctive therapy in epilepsy comprising 2,085 patient-years of exposure in patients >12 years of age, new tumors were reported in 10 patients (2 breast, 3 brain, 2 lung, 1 adrenal, 1 non-Hodgkin's lymphoma, 1 endometrial carcinoma in situ), and preexisting tumors worsened in 11 patients (9 brain, 1 breast, 1 prostate) during or up to 2 years following discontinuation of gabapentin.",tumors adrenal is an adverse reaction entity
"In clinical studies of gabapentin as adjunctive therapy in epilepsy comprising 2,085 patient-years of exposure in patients >12 years of age, new tumors were reported in 10 patients (2 breast, 3 brain, 2 lung, 1 adrenal, 1 non-Hodgkin's lymphoma, 1 endometrial carcinoma in situ), and preexisting tumors worsened in 11 patients (9 brain, 1 breast, 1 prostate) during or up to 2 years following discontinuation of gabapentin.",tumors worsened brain is an adverse reaction entity
"In clinical studies of gabapentin as adjunctive therapy in epilepsy comprising 2,085 patient-years of exposure in patients >12 years of age, new tumors were reported in 10 patients (2 breast, 3 brain, 2 lung, 1 adrenal, 1 non-Hodgkin's lymphoma, 1 endometrial carcinoma in situ), and preexisting tumors worsened in 11 patients (9 brain, 1 breast, 1 prostate) during or up to 2 years following discontinuation of gabapentin.",", 1 is not a named entity"
"In clinical studies of gabapentin as adjunctive therapy in epilepsy comprising 2,085 patient-years of exposure in patients >12 years of age, new tumors were reported in 10 patients (2 breast, 3 brain, 2 lung, 1 adrenal, 1 non-Hodgkin's lymphoma, 1 endometrial carcinoma in situ), and preexisting tumors worsened in 11 patients (9 brain, 1 breast, 1 prostate) during or up to 2 years following discontinuation of gabapentin.",in is not a named entity
"In clinical studies of gabapentin as adjunctive therapy in epilepsy comprising 2,085 patient-years of exposure in patients >12 years of age, new tumors were reported in 10 patients (2 breast, 3 brain, 2 lung, 1 adrenal, 1 non-Hodgkin's lymphoma, 1 endometrial carcinoma in situ), and preexisting tumors worsened in 11 patients (9 brain, 1 breast, 1 prostate) during or up to 2 years following discontinuation of gabapentin.",tumors worsened breast is an adverse reaction entity
"In clinical studies of gabapentin as adjunctive therapy in epilepsy comprising 2,085 patient-years of exposure in patients >12 years of age, new tumors were reported in 10 patients (2 breast, 3 brain, 2 lung, 1 adrenal, 1 non-Hodgkin's lymphoma, 1 endometrial carcinoma in situ), and preexisting tumors worsened in 11 patients (9 brain, 1 breast, 1 prostate) during or up to 2 years following discontinuation of gabapentin.",non-Hodgkin's lymphoma is an adverse reaction entity
"In clinical studies of gabapentin as adjunctive therapy in epilepsy comprising 2,085 patient-years of exposure in patients >12 years of age, new tumors were reported in 10 patients (2 breast, 3 brain, 2 lung, 1 adrenal, 1 non-Hodgkin's lymphoma, 1 endometrial carcinoma in situ), and preexisting tumors worsened in 11 patients (9 brain, 1 breast, 1 prostate) during or up to 2 years following discontinuation of gabapentin.",tumors lung is an adverse reaction entity
"In clinical studies of gabapentin as adjunctive therapy in epilepsy comprising 2,085 patient-years of exposure in patients >12 years of age, new tumors were reported in 10 patients (2 breast, 3 brain, 2 lung, 1 adrenal, 1 non-Hodgkin's lymphoma, 1 endometrial carcinoma in situ), and preexisting tumors worsened in 11 patients (9 brain, 1 breast, 1 prostate) during or up to 2 years following discontinuation of gabapentin.",tumors is an adverse reaction entity
"In clinical studies of gabapentin as adjunctive therapy in epilepsy comprising 2,085 patient-years of exposure in patients >12 years of age, new tumors were reported in 10 patients (2 breast, 3 brain, 2 lung, 1 adrenal, 1 non-Hodgkin's lymphoma, 1 endometrial carcinoma in situ), and preexisting tumors worsened in 11 patients (9 brain, 1 breast, 1 prostate) during or up to 2 years following discontinuation of gabapentin.",endometrial carcinoma in situ is an adverse reaction entity
"In clinical studies of gabapentin as adjunctive therapy in epilepsy comprising 2,085 patient-years of exposure in patients >12 years of age, new tumors were reported in 10 patients (2 breast, 3 brain, 2 lung, 1 adrenal, 1 non-Hodgkin's lymphoma, 1 endometrial carcinoma in situ), and preexisting tumors worsened in 11 patients (9 brain, 1 breast, 1 prostate) during or up to 2 years following discontinuation of gabapentin.",were is not a named entity
"In clinical studies of gabapentin as adjunctive therapy in epilepsy comprising 2,085 patient-years of exposure in patients >12 years of age, new tumors were reported in 10 patients (2 breast, 3 brain, 2 lung, 1 adrenal, 1 non-Hodgkin's lymphoma, 1 endometrial carcinoma in situ), and preexisting tumors worsened in 11 patients (9 brain, 1 breast, 1 prostate) during or up to 2 years following discontinuation of gabapentin.",tumors breast is an adverse reaction entity
"In clinical studies of gabapentin as adjunctive therapy in epilepsy comprising 2,085 patient-years of exposure in patients >12 years of age, new tumors were reported in 10 patients (2 breast, 3 brain, 2 lung, 1 adrenal, 1 non-Hodgkin's lymphoma, 1 endometrial carcinoma in situ), and preexisting tumors worsened in 11 patients (9 brain, 1 breast, 1 prostate) during or up to 2 years following discontinuation of gabapentin.",tumors brain is an adverse reaction entity
"In clinical studies of gabapentin as adjunctive therapy in epilepsy comprising 2,085 patient-years of exposure in patients >12 years of age, new tumors were reported in 10 patients (2 breast, 3 brain, 2 lung, 1 adrenal, 1 non-Hodgkin's lymphoma, 1 endometrial carcinoma in situ), and preexisting tumors worsened in 11 patients (9 brain, 1 breast, 1 prostate) during or up to 2 years following discontinuation of gabapentin.",") , is not a named entity"
"In clinical studies of gabapentin as adjunctive therapy in epilepsy comprising 2,085 patient-years of exposure in patients >12 years of age, new tumors were reported in 10 patients (2 breast, 3 brain, 2 lung, 1 adrenal, 1 non-Hodgkin's lymphoma, 1 endometrial carcinoma in situ), and preexisting tumors worsened in 11 patients (9 brain, 1 breast, 1 prostate) during or up to 2 years following discontinuation of gabapentin.","2,085 patient-years of is not a named entity"
"In clinical studies of gabapentin as adjunctive therapy in epilepsy comprising 2,085 patient-years of exposure in patients >12 years of age, new tumors were reported in 10 patients (2 breast, 3 brain, 2 lung, 1 adrenal, 1 non-Hodgkin's lymphoma, 1 endometrial carcinoma in situ), and preexisting tumors worsened in 11 patients (9 brain, 1 breast, 1 prostate) during or up to 2 years following discontinuation of gabapentin.",2 lung is not a named entity
"In clinical studies of gabapentin as adjunctive therapy in epilepsy comprising 2,085 patient-years of exposure in patients >12 years of age, new tumors were reported in 10 patients (2 breast, 3 brain, 2 lung, 1 adrenal, 1 non-Hodgkin's lymphoma, 1 endometrial carcinoma in situ), and preexisting tumors worsened in 11 patients (9 brain, 1 breast, 1 prostate) during or up to 2 years following discontinuation of gabapentin.",", and is not a named entity"
"In clinical studies of gabapentin as adjunctive therapy in epilepsy comprising 2,085 patient-years of exposure in patients >12 years of age, new tumors were reported in 10 patients (2 breast, 3 brain, 2 lung, 1 adrenal, 1 non-Hodgkin's lymphoma, 1 endometrial carcinoma in situ), and preexisting tumors worsened in 11 patients (9 brain, 1 breast, 1 prostate) during or up to 2 years following discontinuation of gabapentin.",) is not a named entity
"In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared with 0.24% among 16,029 placebo-treated patients, representing an increase of approximately 1 case of suicidal thinking or behavior for every 530 patients treated.",suicidal ideation is an adverse reaction entity
"In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared with 0.24% among 16,029 placebo-treated patients, representing an increase of approximately 1 case of suicidal thinking or behavior for every 530 patients treated.",suicidal behavior is an adverse reaction entity
"In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared with 0.24% among 16,029 placebo-treated patients, representing an increase of approximately 1 case of suicidal thinking or behavior for every 530 patients treated.","% , compared is not a named entity"
"In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared with 0.24% among 16,029 placebo-treated patients, representing an increase of approximately 1 case of suicidal thinking or behavior for every 530 patients treated.",or is not a named entity
"In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared with 0.24% among 16,029 placebo-treated patients, representing an increase of approximately 1 case of suicidal thinking or behavior for every 530 patients treated.",suicidal thinking is an adverse reaction entity
"In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared with 0.24% among 16,029 placebo-treated patients, representing an increase of approximately 1 case of suicidal thinking or behavior for every 530 patients treated.",", the is not a named entity"
"In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared with 0.24% among 16,029 placebo-treated patients, representing an increase of approximately 1 case of suicidal thinking or behavior for every 530 patients treated.",suicidal behavior is an adverse reaction entity
"In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared with 0.24% among 16,029 placebo-treated patients, representing an increase of approximately 1 case of suicidal thinking or behavior for every 530 patients treated.",with is not a named entity
"In those patients treated with HORIZANT who reported somnolence, the somnolence persisted during treatment in about 30%.",in is not a named entity
"In those patients treated with HORIZANT who reported somnolence, the somnolence persisted during treatment in about 30%.",the somnolence is not a named entity
"In those patients treated with HORIZANT who reported somnolence, the somnolence persisted during treatment in about 30%.",somnolence is an adverse reaction entity
"In those patients treated with HORIZANT who reported somnolence, the somnolence persisted during treatment in about 30%.",somnolence is an adverse reaction entity
"6.2 Adverse Events Associated With Gabapentin    The following adverse events have been reported in patients receiving gabapentin, either in clinical trials or postmarketing: breast enlargement, gynecomastia, and elevated creatine kinase.",gynecomastia is an adverse reaction entity
"6.2 Adverse Events Associated With Gabapentin    The following adverse events have been reported in patients receiving gabapentin, either in clinical trials or postmarketing: breast enlargement, gynecomastia, and elevated creatine kinase.",receiving is not a named entity
"6.2 Adverse Events Associated With Gabapentin    The following adverse events have been reported in patients receiving gabapentin, either in clinical trials or postmarketing: breast enlargement, gynecomastia, and elevated creatine kinase.",Associated is not a named entity
"6.2 Adverse Events Associated With Gabapentin    The following adverse events have been reported in patients receiving gabapentin, either in clinical trials or postmarketing: breast enlargement, gynecomastia, and elevated creatine kinase.",breast enlargement is an adverse reaction entity
"6.2 Adverse Events Associated With Gabapentin    The following adverse events have been reported in patients receiving gabapentin, either in clinical trials or postmarketing: breast enlargement, gynecomastia, and elevated creatine kinase.",elevated creatine kinase is an adverse reaction entity
"6.2 Adverse Events Associated With Gabapentin    The following adverse events have been reported in patients receiving gabapentin, either in clinical trials or postmarketing: breast enlargement, gynecomastia, and elevated creatine kinase.",or postmarketing is not a named entity
"Somnolence led to withdrawal in <1% of patients receiving 1,200 mg of HORIZANT per day compared with 2% of patients receiving placebo.",day compared with is not a named entity
"Somnolence led to withdrawal in <1% of patients receiving 1,200 mg of HORIZANT per day compared with 2% of patients receiving placebo.",Somnolence is an adverse reaction entity
"In those patients treated with 1,200 mg of HORIZANT per day who reported somnolence (10%), the somnolence persisted during treatment in about 27%.",patients treated is not a named entity
"In those patients treated with 1,200 mg of HORIZANT per day who reported somnolence (10%), the somnolence persisted during treatment in about 27%.","with 1,200 mg is not a named entity"
"In those patients treated with 1,200 mg of HORIZANT per day who reported somnolence (10%), the somnolence persisted during treatment in about 27%.",somnolence is an adverse reaction entity
"In those patients treated with 1,200 mg of HORIZANT per day who reported somnolence (10%), the somnolence persisted during treatment in about 27%.",somnolence is an adverse reaction entity
"In those patients treated with HORIZANT who reported dizziness, symptoms persisted during treatment in about 20%.",20 is not a named entity
"In those patients treated with HORIZANT who reported dizziness, symptoms persisted during treatment in about 20%.",dizziness is an adverse reaction entity
"5.5 Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity      Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), also known as multiorgan hypersensitivity, has been reported in patients taking antiepileptic drugs, including gabapentin.",Drug Reaction with Eosinophilia and Systemic Symptoms is an adverse reaction entity
"5.5 Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity      Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), also known as multiorgan hypersensitivity, has been reported in patients taking antiepileptic drugs, including gabapentin.",/Multiorgan Hypersensitivity is not a named entity
"5.5 Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity      Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), also known as multiorgan hypersensitivity, has been reported in patients taking antiepileptic drugs, including gabapentin.",DRESS is an adverse reaction entity
"5.5 Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity      Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), also known as multiorgan hypersensitivity, has been reported in patients taking antiepileptic drugs, including gabapentin.",antiepileptic drugs is not a named entity
"5.5 Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity      Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), also known as multiorgan hypersensitivity, has been reported in patients taking antiepileptic drugs, including gabapentin.",reported in is not a named entity
"5.5 Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity      Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), also known as multiorgan hypersensitivity, has been reported in patients taking antiepileptic drugs, including gabapentin.",multiorgan hypersensitivity is an adverse reaction entity
5.2 Somnolence/Sedation and Dizziness      HORIZANT causes somnolence/sedation and dizziness (see  Tables 4  and  5  ).,and is not a named entity
5.2 Somnolence/Sedation and Dizziness      HORIZANT causes somnolence/sedation and dizziness (see  Tables 4  and  5  ).,causes somnolence/sedation is not a named entity
5.2 Somnolence/Sedation and Dizziness      HORIZANT causes somnolence/sedation and dizziness (see  Tables 4  and  5  ).,5.2 Somnolence/Sedation and is not a named entity
5.2 Somnolence/Sedation and Dizziness      HORIZANT causes somnolence/sedation and dizziness (see  Tables 4  and  5  ).,sedation is an adverse reaction entity
5.2 Somnolence/Sedation and Dizziness      HORIZANT causes somnolence/sedation and dizziness (see  Tables 4  and  5  ).,somnolence is an adverse reaction entity
5.2 Somnolence/Sedation and Dizziness      HORIZANT causes somnolence/sedation and dizziness (see  Tables 4  and  5  ).,dizziness is an adverse reaction entity
(  5.1  )    *   Somnolence/sedation and dizziness: May impair the patient's ability to operate complex machinery.,dizziness is an adverse reaction entity
(  5.1  )    *   Somnolence/sedation and dizziness: May impair the patient's ability to operate complex machinery.,: is not a named entity
(  5.1  )    *   Somnolence/sedation and dizziness: May impair the patient's ability to operate complex machinery.,sedation is an adverse reaction entity
(  5.1  )    *   Somnolence/sedation and dizziness: May impair the patient's ability to operate complex machinery.,Somnolence is an adverse reaction entity
(  5.1  )    *   Somnolence/sedation and dizziness: May impair the patient's ability to operate complex machinery.,( is not a named entity
(  5.1  )    *   Somnolence/sedation and dizziness: May impair the patient's ability to operate complex machinery.,impair the patient is not a named entity
(  5.1  )    *   Somnolence/sedation and dizziness: May impair the patient's ability to operate complex machinery.,impair ability to operate complex machinery is an adverse reaction entity
(  5.1  )    *   Somnolence/sedation and dizziness: May impair the patient's ability to operate complex machinery.,to is not a named entity
The duration of driving impairment after starting therapy with HORIZANT is unknown.,driving impairment is an adverse reaction entity
The duration of driving impairment after starting therapy with HORIZANT is unknown.,with HORIZANT is not a named entity
"Benzyl alcohol has been associated with a fatal ""Gasping Syndrome"" in premature infants and infants of low birth weight.",birth weight is not a named entity
"Benzyl alcohol has been associated with a fatal ""Gasping Syndrome"" in premature infants and infants of low birth weight.",fatal is an adverse reaction entity
"Benzyl alcohol has been associated with a fatal ""Gasping Syndrome"" in premature infants and infants of low birth weight.",Gasping Syndrome is an adverse reaction entity
"Benzyl alcohol has been associated with a fatal ""Gasping Syndrome"" in premature infants and infants of low birth weight.",premature is not a named entity
"AdreView may increase release of norepinephrine from chromaffin granules and produce a transient episode of hypertension, although this was not observed in the clinical studies.",transient episode of hypertension is an adverse reaction entity
"AdreView may increase release of norepinephrine from chromaffin granules and produce a transient episode of hypertension, although this was not observed in the clinical studies.",produce a is not a named entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Hypersensitivity reactions have followed AdreView administration.,Hypersensitivity reactions is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Hypersensitivity reactions have followed AdreView administration.,: * is not a named entity
(  5.6  )             5.1 Hypersensitivity Reactions      Hypersensitivity reactions have been reported following AdreView administration.,reactions have is not a named entity
(  5.6  )             5.1 Hypersensitivity Reactions      Hypersensitivity reactions have been reported following AdreView administration.,Hypersensitivity reactions is an adverse reaction entity
"Adverse reactions that occurred with a frequency > 1% were associated with the injection site (1.3%), problems such as hematoma and bruising.",problems such as is not a named entity
"Adverse reactions that occurred with a frequency > 1% were associated with the injection site (1.3%), problems such as hematoma and bruising.",injection site problems is an adverse reaction entity
"Adverse reactions that occurred with a frequency > 1% were associated with the injection site (1.3%), problems such as hematoma and bruising.",that is not a named entity
"Adverse reactions that occurred with a frequency > 1% were associated with the injection site (1.3%), problems such as hematoma and bruising.",injection site bruising is an adverse reaction entity
"Adverse reactions that occurred with a frequency > 1% were associated with the injection site (1.3%), problems such as hematoma and bruising.",", problems such is not a named entity"
"Adverse reactions that occurred with a frequency > 1% were associated with the injection site (1.3%), problems such as hematoma and bruising.",injection site hematoma is an adverse reaction entity
"The most common adverse reactions, dizziness, rash, pruritis, flushing, headache, and injection site hemorrhage occurred in < 1.3% of patients.",headache is an adverse reaction entity
"The most common adverse reactions, dizziness, rash, pruritis, flushing, headache, and injection site hemorrhage occurred in < 1.3% of patients.",common adverse reactions is not a named entity
"The most common adverse reactions, dizziness, rash, pruritis, flushing, headache, and injection site hemorrhage occurred in < 1.3% of patients.",flushing is an adverse reaction entity
"The most common adverse reactions, dizziness, rash, pruritis, flushing, headache, and injection site hemorrhage occurred in < 1.3% of patients.",", dizziness , is not a named entity"
"The most common adverse reactions, dizziness, rash, pruritis, flushing, headache, and injection site hemorrhage occurred in < 1.3% of patients.",dizziness is an adverse reaction entity
"The most common adverse reactions, dizziness, rash, pruritis, flushing, headache, and injection site hemorrhage occurred in < 1.3% of patients.",adverse is not a named entity
"The most common adverse reactions, dizziness, rash, pruritis, flushing, headache, and injection site hemorrhage occurred in < 1.3% of patients.",pruritis is an adverse reaction entity
"The most common adverse reactions, dizziness, rash, pruritis, flushing, headache, and injection site hemorrhage occurred in < 1.3% of patients.",rash is an adverse reaction entity
"The most common adverse reactions, dizziness, rash, pruritis, flushing, headache, and injection site hemorrhage occurred in < 1.3% of patients.",", pruritis , is not a named entity"
"The most common adverse reactions, dizziness, rash, pruritis, flushing, headache, and injection site hemorrhage occurred in < 1.3% of patients.","reactions , is not a named entity"
"The most common adverse reactions, dizziness, rash, pruritis, flushing, headache, and injection site hemorrhage occurred in < 1.3% of patients.",injection site hemorrhage is an adverse reaction entity
"The most common adverse reactions, dizziness, rash, pruritis, flushing, headache, and injection site hemorrhage occurred in < 1.3% of patients.",", is not a named entity"
"Laboratory and Imaging Tests           Increases in Serum Potassium       In a pooled population of patients (N=723) with moderate renal impairment (eGFR 45 to less than 60 mL/min/1.73 m  2  ), increases in serum potassium to greater than 5.4 mEq/L and 15% above baseline occurred in 5.3%, 5.0%, and 8.8% of patients treated with placebo, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.",increases in serum potassium is an adverse reaction entity
"Laboratory and Imaging Tests           Increases in Serum Potassium       In a pooled population of patients (N=723) with moderate renal impairment (eGFR 45 to less than 60 mL/min/1.73 m  2  ), increases in serum potassium to greater than 5.4 mEq/L and 15% above baseline occurred in 5.3%, 5.0%, and 8.8% of patients treated with placebo, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.",of is not a named entity
"Laboratory and Imaging Tests           Increases in Serum Potassium       In a pooled population of patients (N=723) with moderate renal impairment (eGFR 45 to less than 60 mL/min/1.73 m  2  ), increases in serum potassium to greater than 5.4 mEq/L and 15% above baseline occurred in 5.3%, 5.0%, and 8.8% of patients treated with placebo, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.",increases in serum potassium is an adverse reaction entity
"Laboratory and Imaging Tests           Increases in Serum Potassium       In a pooled population of patients (N=723) with moderate renal impairment (eGFR 45 to less than 60 mL/min/1.73 m  2  ), increases in serum potassium to greater than 5.4 mEq/L and 15% above baseline occurred in 5.3%, 5.0%, and 8.8% of patients treated with placebo, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.",serum potassium to is not a named entity
"Symptomatic hypotension can occur after initiating INVOKANA [see  Adverse Reactions (6.1  )]  particularly in patients with impaired renal function (eGFR less than 60 mL/min/1.73 m  2  ), elderly patients, patients on either diuretics or medications that interfere with the renin-angiotensin-aldosterone system (e.g., angiotensin-converting-enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs]), or patients with low systolic blood pressure.",] particularly is not a named entity
"Symptomatic hypotension can occur after initiating INVOKANA [see  Adverse Reactions (6.1  )]  particularly in patients with impaired renal function (eGFR less than 60 mL/min/1.73 m  2  ), elderly patients, patients on either diuretics or medications that interfere with the renin-angiotensin-aldosterone system (e.g., angiotensin-converting-enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs]), or patients with low systolic blood pressure.",Symptomatic hypotension is an adverse reaction entity
"In the pool of four placebo-controlled clinical trials, male genital mycotic infections (e.g., candidal balanitis, balanoposthitis) occurred in 0.6%, 4.2%, and 3.7% of males treated with placebo, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.",balanoposthitis is an adverse reaction entity
"In the pool of four placebo-controlled clinical trials, male genital mycotic infections (e.g., candidal balanitis, balanoposthitis) occurred in 0.6%, 4.2%, and 3.7% of males treated with placebo, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.",male genital mycotic infections is an adverse reaction entity
"In the pool of four placebo-controlled clinical trials, male genital mycotic infections (e.g., candidal balanitis, balanoposthitis) occurred in 0.6%, 4.2%, and 3.7% of males treated with placebo, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.",candidal balanitis is an adverse reaction entity
"In the pool of four placebo-controlled clinical trials, male genital mycotic infections (e.g., candidal balanitis, balanoposthitis) occurred in 0.6%, 4.2%, and 3.7% of males treated with placebo, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.",and 3.7 % is not a named entity
"In the pool of four placebo-controlled clinical trials, male genital mycotic infections (e.g., candidal balanitis, balanoposthitis) occurred in 0.6%, 4.2%, and 3.7% of males treated with placebo, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.",mg is not a named entity
"In the pool of four placebo-controlled clinical trials, male genital mycotic infections (e.g., candidal balanitis, balanoposthitis) occurred in 0.6%, 4.2%, and 3.7% of males treated with placebo, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.","balanitis , is not a named entity"
"Increases in Hemoglobin       In the pool of four placebo-controlled trials, mean changes (percent changes) from baseline in hemoglobin were -0.18 g/dL (-1.1%) with placebo, 0.47 g/dL (3.5%) with INVOKANA 100 mg, and 0.51 g/dL (3.8%) with INVOKANA 300 mg.",placebo-controlled is not a named entity
"Increases in Hemoglobin       In the pool of four placebo-controlled trials, mean changes (percent changes) from baseline in hemoglobin were -0.18 g/dL (-1.1%) with placebo, 0.47 g/dL (3.5%) with INVOKANA 100 mg, and 0.51 g/dL (3.8%) with INVOKANA 300 mg.",changes in hemoglobin is an adverse reaction entity
"In the pool of four placebo-controlled trials, the mean percent change in serum magnesium levels was 8.1% and 9.3% with INVOKANA 100 mg and INVOKANA 300 mg, respectively, compared to -0.6% with placebo.",change in serum magnesium levels is an adverse reaction entity
"In the pool of four placebo-controlled trials, the mean percent change in serum magnesium levels was 8.1% and 9.3% with INVOKANA 100 mg and INVOKANA 300 mg, respectively, compared to -0.6% with placebo.",the is not a named entity
"In a pooled population of patients with moderate renal impairment (N=1085) with baseline eGFR of 30 to less than 60 mL/min/1.73 m  2  (mean baseline eGFR 48 mL/min/1.73 m  2  ), the overall incidence of these events was lower than in the dedicated trial but a dose-dependent increase in incident episodes of significant renal function decline compared to placebo was still observed.",in is not a named entity
"In a pooled population of patients with moderate renal impairment (N=1085) with baseline eGFR of 30 to less than 60 mL/min/1.73 m  2  (mean baseline eGFR 48 mL/min/1.73 m  2  ), the overall incidence of these events was lower than in the dedicated trial but a dose-dependent increase in incident episodes of significant renal function decline compared to placebo was still observed.",renal function decline is an adverse reaction entity
"Mean changes (percent changes) from baseline in non-HDL-C relative to placebo were 2.1 mg/dL (1.5%) and 5.1 mg/dL (3.6%) with INVOKANA 100 mg and 300 mg, respectively.",changes is not a named entity
"Mean changes (percent changes) from baseline in non-HDL-C relative to placebo were 2.1 mg/dL (1.5%) and 5.1 mg/dL (3.6%) with INVOKANA 100 mg and 300 mg, respectively.",changes in non-HDL-C is an adverse reaction entity
Patients with a history of genital mycotic infections and uncircumcised males were more likely to develop genital mycotic infections [see  Adverse Reactions (6.1)  ]  .,genital mycotic infections is an adverse reaction entity
Patients with a history of genital mycotic infections and uncircumcised males were more likely to develop genital mycotic infections [see  Adverse Reactions (6.1)  ]  .,were more likely is not a named entity
Increases in Serum Magnesium       Dose-related increases in serum magnesium were observed early after initiation of INVOKANA (within 6 weeks) and remained elevated throughout treatment.,Magnesium is not a named entity
Increases in Serum Magnesium       Dose-related increases in serum magnesium were observed early after initiation of INVOKANA (within 6 weeks) and remained elevated throughout treatment.,increases in serum magnesium is an adverse reaction entity
"In a trial of patients with moderate renal impairment  [see  Clinical Studies (14.3)  ]  , the mean serum phosphate levels increased by 1.2%, 5.0%, and 9.3% with placebo, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.",14.3 ) is not a named entity
"In a trial of patients with moderate renal impairment  [see  Clinical Studies (14.3)  ]  , the mean serum phosphate levels increased by 1.2%, 5.0%, and 9.3% with placebo, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.",serum phosphate levels increased is an adverse reaction entity
"The incidence rates of adjudicated bone fractures were 1.1, 1.4, and 1.5 per 100 patient-years of exposure in the comparator, INVOKANA 100 mg, and INVOKANA 300 mg groups, respectively.",adjudicated bone is not a named entity
"The incidence rates of adjudicated bone fractures were 1.1, 1.4, and 1.5 per 100 patient-years of exposure in the comparator, INVOKANA 100 mg, and INVOKANA 300 mg groups, respectively.",bone fractures is an adverse reaction entity
"In a trial of patients with moderate renal impairment  [see  Clinical Studies (14.3)  ]  , serum magnesium levels increased by 0.2%, 9.2%, and 14.8% with placebo, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.",of is not a named entity
"In a trial of patients with moderate renal impairment  [see  Clinical Studies (14.3)  ]  , serum magnesium levels increased by 0.2%, 9.2%, and 14.8% with placebo, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.",serum magnesium levels increased is an adverse reaction entity
"In the pool of eight clinical trials, hypersensitivity-related adverse reactions (including erythema, rash, pruritus, urticaria, and angioedema) occurred in 3.0%, 3.8%, and 4.2% of patients receiving comparator, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.",3.0 % is not a named entity
"In the pool of eight clinical trials, hypersensitivity-related adverse reactions (including erythema, rash, pruritus, urticaria, and angioedema) occurred in 3.0%, 3.8%, and 4.2% of patients receiving comparator, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.",angioedema is an adverse reaction entity
"In the pool of eight clinical trials, hypersensitivity-related adverse reactions (including erythema, rash, pruritus, urticaria, and angioedema) occurred in 3.0%, 3.8%, and 4.2% of patients receiving comparator, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.",", and is not a named entity"
"In the pool of eight clinical trials, hypersensitivity-related adverse reactions (including erythema, rash, pruritus, urticaria, and angioedema) occurred in 3.0%, 3.8%, and 4.2% of patients receiving comparator, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.",INVOKANA is not a named entity
"In the pool of eight clinical trials, hypersensitivity-related adverse reactions (including erythema, rash, pruritus, urticaria, and angioedema) occurred in 3.0%, 3.8%, and 4.2% of patients receiving comparator, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.",pruritus is an adverse reaction entity
"In the pool of eight clinical trials, hypersensitivity-related adverse reactions (including erythema, rash, pruritus, urticaria, and angioedema) occurred in 3.0%, 3.8%, and 4.2% of patients receiving comparator, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.",", pruritus is not a named entity"
"In the pool of eight clinical trials, hypersensitivity-related adverse reactions (including erythema, rash, pruritus, urticaria, and angioedema) occurred in 3.0%, 3.8%, and 4.2% of patients receiving comparator, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.",hypersensitivity-related adverse reactions is an adverse reaction entity
"In the pool of eight clinical trials, hypersensitivity-related adverse reactions (including erythema, rash, pruritus, urticaria, and angioedema) occurred in 3.0%, 3.8%, and 4.2% of patients receiving comparator, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.",rash is an adverse reaction entity
"In the pool of eight clinical trials, hypersensitivity-related adverse reactions (including erythema, rash, pruritus, urticaria, and angioedema) occurred in 3.0%, 3.8%, and 4.2% of patients receiving comparator, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.",erythema is an adverse reaction entity
"In the pool of eight clinical trials, hypersensitivity-related adverse reactions (including erythema, rash, pruritus, urticaria, and angioedema) occurred in 3.0%, 3.8%, and 4.2% of patients receiving comparator, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.",occurred in is not a named entity
"In the pool of eight clinical trials, hypersensitivity-related adverse reactions (including erythema, rash, pruritus, urticaria, and angioedema) occurred in 3.0%, 3.8%, and 4.2% of patients receiving comparator, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.",adverse reactions is not a named entity
"In the pool of eight clinical trials, hypersensitivity-related adverse reactions (including erythema, rash, pruritus, urticaria, and angioedema) occurred in 3.0%, 3.8%, and 4.2% of patients receiving comparator, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.",urticaria is an adverse reaction entity
"Fractures were observed as early as 12 weeks after treatment initiation and were more likely to be low trauma (e.g., fall from no more than standing height), and affect the upper extremities  [see  Warnings and Precautions (5.7)  ]  .",Fractures upper extremities is an adverse reaction entity
"Fractures were observed as early as 12 weeks after treatment initiation and were more likely to be low trauma (e.g., fall from no more than standing height), and affect the upper extremities  [see  Warnings and Precautions (5.7)  ]  .",early is not a named entity
"Fractures were observed as early as 12 weeks after treatment initiation and were more likely to be low trauma (e.g., fall from no more than standing height), and affect the upper extremities  [see  Warnings and Precautions (5.7)  ]  .",Fractures is an adverse reaction entity
"Fractures were observed as early as 12 weeks after treatment initiation and were more likely to be low trauma (e.g., fall from no more than standing height), and affect the upper extremities  [see  Warnings and Precautions (5.7)  ]  .",to be is not a named entity
"Fractures were observed as early as 12 weeks after treatment initiation and were more likely to be low trauma (e.g., fall from no more than standing height), and affect the upper extremities  [see  Warnings and Precautions (5.7)  ]  .",be low is not a named entity
"Fractures were observed as early as 12 weeks after treatment initiation and were more likely to be low trauma (e.g., fall from no more than standing height), and affect the upper extremities  [see  Warnings and Precautions (5.7)  ]  .",Fractures is an adverse reaction entity
"In females, discontinuation due to genital mycotic infections occurred in 0% and 0.7% of patients treated with placebo and INVOKANA, respectively  [see  Warnings and Precautions (5.5)  ]  .",mycotic infections occurred is not a named entity
"In females, discontinuation due to genital mycotic infections occurred in 0% and 0.7% of patients treated with placebo and INVOKANA, respectively  [see  Warnings and Precautions (5.5)  ]  .",females genital mycotic infections is an adverse reaction entity
"Photosensitivity-related adverse reactions (including photosensitivity reaction, polymorphic light eruption, and sunburn) occurred in 0.1%, 0.2%, and 0.2% of patients receiving comparator, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.",0.1 is not a named entity
"Photosensitivity-related adverse reactions (including photosensitivity reaction, polymorphic light eruption, and sunburn) occurred in 0.1%, 0.2%, and 0.2% of patients receiving comparator, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.",of patients receiving is not a named entity
"Photosensitivity-related adverse reactions (including photosensitivity reaction, polymorphic light eruption, and sunburn) occurred in 0.1%, 0.2%, and 0.2% of patients receiving comparator, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.",) occurred in is not a named entity
"Photosensitivity-related adverse reactions (including photosensitivity reaction, polymorphic light eruption, and sunburn) occurred in 0.1%, 0.2%, and 0.2% of patients receiving comparator, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.",Photosensitivity-related adverse reactions is an adverse reaction entity
"Photosensitivity-related adverse reactions (including photosensitivity reaction, polymorphic light eruption, and sunburn) occurred in 0.1%, 0.2%, and 0.2% of patients receiving comparator, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.",sunburn is an adverse reaction entity
"Photosensitivity-related adverse reactions (including photosensitivity reaction, polymorphic light eruption, and sunburn) occurred in 0.1%, 0.2%, and 0.2% of patients receiving comparator, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.",photosensitivity reaction is an adverse reaction entity
"Photosensitivity-related adverse reactions (including photosensitivity reaction, polymorphic light eruption, and sunburn) occurred in 0.1%, 0.2%, and 0.2% of patients receiving comparator, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.","eruption , and is not a named entity"
"Photosensitivity-related adverse reactions (including photosensitivity reaction, polymorphic light eruption, and sunburn) occurred in 0.1%, 0.2%, and 0.2% of patients receiving comparator, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.",polymorphic light eruption is an adverse reaction entity
"In the pool of four placebo controlled trials, the mean percent change in serum phosphate levels were 3.6% and 5.1% with INVOKANA 100 mg and INVOKANA 300 mg, respectively, compared to 1.5% with placebo.",and INVOKANA is not a named entity
"In the pool of four placebo controlled trials, the mean percent change in serum phosphate levels were 3.6% and 5.1% with INVOKANA 100 mg and INVOKANA 300 mg, respectively, compared to 1.5% with placebo.",change in serum phosphate levels is an adverse reaction entity
"At 2 years, patients randomized to INVOKANA 100 mg and INVOKANA 300 mg had placebo-corrected declines in BMD at the total hip of 0.9% and 1.2%, respectively, and at the lumbar spine of 0.3% and 0.7%, respectively.",declines in BMD at the total hip is an adverse reaction entity
"At 2 years, patients randomized to INVOKANA 100 mg and INVOKANA 300 mg had placebo-corrected declines in BMD at the total hip of 0.9% and 1.2%, respectively, and at the lumbar spine of 0.3% and 0.7%, respectively.",the total is not a named entity
"At 2 years, patients randomized to INVOKANA 100 mg and INVOKANA 300 mg had placebo-corrected declines in BMD at the total hip of 0.9% and 1.2%, respectively, and at the lumbar spine of 0.3% and 0.7%, respectively.",1.2 is not a named entity
"At 2 years, patients randomized to INVOKANA 100 mg and INVOKANA 300 mg had placebo-corrected declines in BMD at the total hip of 0.9% and 1.2%, respectively, and at the lumbar spine of 0.3% and 0.7%, respectively.",declines in BMD at the lumbar spine is an adverse reaction entity
Male genital mycotic infections occurred more commonly in uncircumcised males and in males with a prior history of balanitis or balanoposthitis.,Male genital mycotic infections is an adverse reaction entity
Male genital mycotic infections occurred more commonly in uncircumcised males and in males with a prior history of balanitis or balanoposthitis.,males and in is not a named entity
"Mean changes (percent changes) from baseline in LDL-C relative to placebo were 4.4 mg/dL (4.5%) and 8.2 mg/dL (8.0%) with INVOKANA 100 mg and INVOKANA 300 mg, respectively.",changes in LDL-C is an adverse reaction entity
"Mean changes (percent changes) from baseline in LDL-C relative to placebo were 4.4 mg/dL (4.5%) and 8.2 mg/dL (8.0%) with INVOKANA 100 mg and INVOKANA 300 mg, respectively.","mg , is not a named entity"
"Other adverse reactions occurring more frequently on INVOKANA than on comparator were:         Volume Depletion-Related Adverse Reactions       INVOKANA results in an osmotic diuresis, which may lead to reductions in intravascular volume.",Volume Depletion-Related Adverse is not a named entity
"Other adverse reactions occurring more frequently on INVOKANA than on comparator were:         Volume Depletion-Related Adverse Reactions       INVOKANA results in an osmotic diuresis, which may lead to reductions in intravascular volume.",Adverse is not a named entity
"Other adverse reactions occurring more frequently on INVOKANA than on comparator were:         Volume Depletion-Related Adverse Reactions       INVOKANA results in an osmotic diuresis, which may lead to reductions in intravascular volume.",osmotic diuresis is an adverse reaction entity
"Other adverse reactions occurring more frequently on INVOKANA than on comparator were:         Volume Depletion-Related Adverse Reactions       INVOKANA results in an osmotic diuresis, which may lead to reductions in intravascular volume.",reductions in intravascular volume is an adverse reaction entity
"In these patients, increases in potassium were more commonly seen in those with elevated potassium at baseline.",increases in potassium is an adverse reaction entity
"In these patients, increases in potassium were more commonly seen in those with elevated potassium at baseline.",seen is not a named entity
Monitor for signs and symptoms during therapy (  5.1  )   *  Impairment in Renal Function: Monitor renal function during therapy.,function is not a named entity
Monitor for signs and symptoms during therapy (  5.1  )   *  Impairment in Renal Function: Monitor renal function during therapy.,Impairment in Renal Function is an adverse reaction entity
"In clinical studies, treatment with INVOKANA was associated with a dose-dependent increase in the incidence of volume depletion-related adverse reactions (e.g., hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration).",volume depletion-related adverse reactions is an adverse reaction entity
"In clinical studies, treatment with INVOKANA was associated with a dose-dependent increase in the incidence of volume depletion-related adverse reactions (e.g., hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration).",syncope is an adverse reaction entity
"In clinical studies, treatment with INVOKANA was associated with a dose-dependent increase in the incidence of volume depletion-related adverse reactions (e.g., hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration).",postural dizziness is an adverse reaction entity
"In clinical studies, treatment with INVOKANA was associated with a dose-dependent increase in the incidence of volume depletion-related adverse reactions (e.g., hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration).",e.g. is not a named entity
"In clinical studies, treatment with INVOKANA was associated with a dose-dependent increase in the incidence of volume depletion-related adverse reactions (e.g., hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration).","e.g. , is not a named entity"
"In clinical studies, treatment with INVOKANA was associated with a dose-dependent increase in the incidence of volume depletion-related adverse reactions (e.g., hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration).",hypotension is an adverse reaction entity
"In clinical studies, treatment with INVOKANA was associated with a dose-dependent increase in the incidence of volume depletion-related adverse reactions (e.g., hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration).",in the is not a named entity
"In clinical studies, treatment with INVOKANA was associated with a dose-dependent increase in the incidence of volume depletion-related adverse reactions (e.g., hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration).",", syncope is not a named entity"
"In clinical studies, treatment with INVOKANA was associated with a dose-dependent increase in the incidence of volume depletion-related adverse reactions (e.g., hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration).",orthostatic hypotension is an adverse reaction entity
"In clinical studies, treatment with INVOKANA was associated with a dose-dependent increase in the incidence of volume depletion-related adverse reactions (e.g., hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration).",hypotension is not a named entity
"In clinical studies, treatment with INVOKANA was associated with a dose-dependent increase in the incidence of volume depletion-related adverse reactions (e.g., hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration).",dehydration is an adverse reaction entity
"In clinical studies, treatment with INVOKANA was associated with a dose-dependent increase in the incidence of volume depletion-related adverse reactions (e.g., hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration).",incidence of volume is not a named entity
"In the pooled analysis of 8 controlled trials, phimosis was reported in 0.3% of uncircumcised male patients treated with INVOKANA and 0.2% required circumcision to treat the phimosis  [see  Warnings and Precautions (5.5)  ]  .",phimosis is an adverse reaction entity
"In the pooled analysis of 8 controlled trials, phimosis was reported in 0.3% of uncircumcised male patients treated with INVOKANA and 0.2% required circumcision to treat the phimosis  [see  Warnings and Precautions (5.5)  ]  .",Warnings is not a named entity
"In the pooled analysis of 8 controlled trials, phimosis was reported in 0.3% of uncircumcised male patients treated with INVOKANA and 0.2% required circumcision to treat the phimosis  [see  Warnings and Precautions (5.5)  ]  .",see is not a named entity
"In the pooled analysis of 8 controlled trials, phimosis was reported in 0.3% of uncircumcised male patients treated with INVOKANA and 0.2% required circumcision to treat the phimosis  [see  Warnings and Precautions (5.5)  ]  .",phimosis is an adverse reaction entity
"The three factors associated with the largest increase in volume depletion-related adverse reactions were the use of loop diuretics, moderate renal impairment (eGFR 30 to less than 60 mL/min/1.73 m  2  ), and age 75 years and older (Table 2)  [see  Dosage and Administration (2.2)  ,  Warnings and Precautions (5.1)  , and  Use in Specific Populations (8.5  and  8.6)  ]  .",volume depletion-related adverse reactions is an adverse reaction entity
"The three factors associated with the largest increase in volume depletion-related adverse reactions were the use of loop diuretics, moderate renal impairment (eGFR 30 to less than 60 mL/min/1.73 m  2  ), and age 75 years and older (Table 2)  [see  Dosage and Administration (2.2)  ,  Warnings and Precautions (5.1)  , and  Use in Specific Populations (8.5  and  8.6)  ]  .",( 8.5 is not a named entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Hypotension: Before initiating INVOKANA, assess volume status and correct hypovolemia in patients with renal impairment, the elderly, in patients with low systolic blood pressure, or if on diuretics, ACEi, or ARB.",Hypotension is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Hypotension: Before initiating INVOKANA, assess volume status and correct hypovolemia in patients with renal impairment, the elderly, in patients with low systolic blood pressure, or if on diuretics, ACEi, or ARB.",with low is not a named entity
"In males, discontinuations due to genital mycotic infections occurred in 0% and 0.5% of patients treated with placebo and INVOKANA, respectively.",of is not a named entity
"In males, discontinuations due to genital mycotic infections occurred in 0% and 0.5% of patients treated with placebo and INVOKANA, respectively.",males genital mycotic infections is an adverse reaction entity
5.2 Impairment in Renal Function      INVOKANA increases serum creatinine and decreases eGFR.,increases serum creatinine is an adverse reaction entity
5.2 Impairment in Renal Function      INVOKANA increases serum creatinine and decreases eGFR.,INVOKANA is not a named entity
5.2 Impairment in Renal Function      INVOKANA increases serum creatinine and decreases eGFR.,in Renal is not a named entity
5.2 Impairment in Renal Function      INVOKANA increases serum creatinine and decreases eGFR.,decreases eGFR is an adverse reaction entity
"Five patients experienced serious adverse reactions of hypersensitivity with INVOKANA, which included 4 patients with urticaria and 1 patient with a diffuse rash and urticaria occurring within hours of exposure to INVOKANA.",which is not a named entity
"Five patients experienced serious adverse reactions of hypersensitivity with INVOKANA, which included 4 patients with urticaria and 1 patient with a diffuse rash and urticaria occurring within hours of exposure to INVOKANA.",occurring within hours is not a named entity
"Five patients experienced serious adverse reactions of hypersensitivity with INVOKANA, which included 4 patients with urticaria and 1 patient with a diffuse rash and urticaria occurring within hours of exposure to INVOKANA.",urticaria is an adverse reaction entity
"Five patients experienced serious adverse reactions of hypersensitivity with INVOKANA, which included 4 patients with urticaria and 1 patient with a diffuse rash and urticaria occurring within hours of exposure to INVOKANA.",experienced is not a named entity
"Five patients experienced serious adverse reactions of hypersensitivity with INVOKANA, which included 4 patients with urticaria and 1 patient with a diffuse rash and urticaria occurring within hours of exposure to INVOKANA.",reactions is not a named entity
"Five patients experienced serious adverse reactions of hypersensitivity with INVOKANA, which included 4 patients with urticaria and 1 patient with a diffuse rash and urticaria occurring within hours of exposure to INVOKANA.",diffuse rash is an adverse reaction entity
"Five patients experienced serious adverse reactions of hypersensitivity with INVOKANA, which included 4 patients with urticaria and 1 patient with a diffuse rash and urticaria occurring within hours of exposure to INVOKANA.",urticaria is an adverse reaction entity
"Five patients experienced serious adverse reactions of hypersensitivity with INVOKANA, which included 4 patients with urticaria and 1 patient with a diffuse rash and urticaria occurring within hours of exposure to INVOKANA.",hypersensitivity is an adverse reaction entity
Increases in Serum Phosphate       Dose-related increases in serum phosphate levels were observed with INVOKANA.,increases in serum phosphate is an adverse reaction entity
Increases in Serum Phosphate       Dose-related increases in serum phosphate levels were observed with INVOKANA.,were observed with is not a named entity
"Genital Mycotic Infections       In the pool of four placebo-controlled clinical trials, female genital mycotic infections (e.g., vulvovaginal mycotic infection, vulvovaginal candidiasis, and vulvovaginitis) occurred in 3.2%, 10.4%, and 11.4% of females treated with placebo, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.",vulvovaginitis is an adverse reaction entity
"Genital Mycotic Infections       In the pool of four placebo-controlled clinical trials, female genital mycotic infections (e.g., vulvovaginal mycotic infection, vulvovaginal candidiasis, and vulvovaginitis) occurred in 3.2%, 10.4%, and 11.4% of females treated with placebo, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.",vulvovaginal candidiasis is an adverse reaction entity
"Genital Mycotic Infections       In the pool of four placebo-controlled clinical trials, female genital mycotic infections (e.g., vulvovaginal mycotic infection, vulvovaginal candidiasis, and vulvovaginitis) occurred in 3.2%, 10.4%, and 11.4% of females treated with placebo, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.",) is not a named entity
"Genital Mycotic Infections       In the pool of four placebo-controlled clinical trials, female genital mycotic infections (e.g., vulvovaginal mycotic infection, vulvovaginal candidiasis, and vulvovaginitis) occurred in 3.2%, 10.4%, and 11.4% of females treated with placebo, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.","3.2 % , is not a named entity"
"Genital Mycotic Infections       In the pool of four placebo-controlled clinical trials, female genital mycotic infections (e.g., vulvovaginal mycotic infection, vulvovaginal candidiasis, and vulvovaginitis) occurred in 3.2%, 10.4%, and 11.4% of females treated with placebo, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.",female genital mycotic infections is an adverse reaction entity
"Genital Mycotic Infections       In the pool of four placebo-controlled clinical trials, female genital mycotic infections (e.g., vulvovaginal mycotic infection, vulvovaginal candidiasis, and vulvovaginitis) occurred in 3.2%, 10.4%, and 11.4% of females treated with placebo, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.",", female genital is not a named entity"
"Genital Mycotic Infections       In the pool of four placebo-controlled clinical trials, female genital mycotic infections (e.g., vulvovaginal mycotic infection, vulvovaginal candidiasis, and vulvovaginitis) occurred in 3.2%, 10.4%, and 11.4% of females treated with placebo, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.",vulvovaginal mycotic infection is an adverse reaction entity
"Genital Mycotic Infections       In the pool of four placebo-controlled clinical trials, female genital mycotic infections (e.g., vulvovaginal mycotic infection, vulvovaginal candidiasis, and vulvovaginitis) occurred in 3.2%, 10.4%, and 11.4% of females treated with placebo, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.",occurred is not a named entity
Impairment in Renal Function       INVOKANA is associated with a dose-dependent increase in serum creatinine and a concomitant fall in estimated GFR (Table 3).,fall in estimated GFR is an adverse reaction entity
Impairment in Renal Function       INVOKANA is associated with a dose-dependent increase in serum creatinine and a concomitant fall in estimated GFR (Table 3).,increase in serum creatinine is an adverse reaction entity
Impairment in Renal Function       INVOKANA is associated with a dose-dependent increase in serum creatinine and a concomitant fall in estimated GFR (Table 3).,Impairment in is not a named entity
Impairment in Renal Function       INVOKANA is associated with a dose-dependent increase in serum creatinine and a concomitant fall in estimated GFR (Table 3).,dose-dependent increase is not a named entity
"At the end of treatment, 0.8%, 4.0%, and 2.7% of patients treated with placebo, INVOKANA 100 mg, and INVOKANA 300 mg, respectively, had hemoglobin above the upper limit of normal.",hemoglobin above the upper limit of normal is an adverse reaction entity
"At the end of treatment, 0.8%, 4.0%, and 2.7% of patients treated with placebo, INVOKANA 100 mg, and INVOKANA 300 mg, respectively, had hemoglobin above the upper limit of normal.",the end of is not a named entity
The higher risk of falls for patients treated with INVOKANA was observed within the first few weeks of treatment.,observed is not a named entity
The higher risk of falls for patients treated with INVOKANA was observed within the first few weeks of treatment.,falls is an adverse reaction entity
Patients with a history of genital mycotic infections were more likely to develop genital mycotic infections on INVOKANA.,genital mycotic infections is an adverse reaction entity
Patients with a history of genital mycotic infections were more likely to develop genital mycotic infections on INVOKANA.,with a is not a named entity
"5.2 Radiation Risk      Amyvid, similar to other radiopharmaceuticals, contributes to a patient's overall long-term cumulative radiation exposure.",", contributes to is not a named entity"
"5.2 Radiation Risk      Amyvid, similar to other radiopharmaceuticals, contributes to a patient's overall long-term cumulative radiation exposure.",long-term cumulative radiation exposure is an adverse reaction entity
Long-term cumulative radiation exposure is associated with an increased risk of cancer.,increased is not a named entity
Long-term cumulative radiation exposure is associated with an increased risk of cancer.,exposure is not a named entity
Long-term cumulative radiation exposure is associated with an increased risk of cancer.,cancer is an adverse reaction entity
Long-term cumulative radiation exposure is associated with an increased risk of cancer.,Long-term cumulative radiation exposure is an adverse reaction entity
"6 ADVERSE REACTIONS    EXCERPT:   The most common reported adverse reaction was headache, occurring in 2% of patients, followed by musculoskeletal pain, blood pressure increased, fatigue, nausea, and injection site reaction, all occurring in <1% of patients (  6  ).",", fatigue , is not a named entity"
"6 ADVERSE REACTIONS    EXCERPT:   The most common reported adverse reaction was headache, occurring in 2% of patients, followed by musculoskeletal pain, blood pressure increased, fatigue, nausea, and injection site reaction, all occurring in <1% of patients (  6  ).",", followed is not a named entity"
"6 ADVERSE REACTIONS    EXCERPT:   The most common reported adverse reaction was headache, occurring in 2% of patients, followed by musculoskeletal pain, blood pressure increased, fatigue, nausea, and injection site reaction, all occurring in <1% of patients (  6  ).",by musculoskeletal is not a named entity
"6 ADVERSE REACTIONS    EXCERPT:   The most common reported adverse reaction was headache, occurring in 2% of patients, followed by musculoskeletal pain, blood pressure increased, fatigue, nausea, and injection site reaction, all occurring in <1% of patients (  6  ).",in is not a named entity
"6 ADVERSE REACTIONS    EXCERPT:   The most common reported adverse reaction was headache, occurring in 2% of patients, followed by musculoskeletal pain, blood pressure increased, fatigue, nausea, and injection site reaction, all occurring in <1% of patients (  6  ).",fatigue is an adverse reaction entity
"6 ADVERSE REACTIONS    EXCERPT:   The most common reported adverse reaction was headache, occurring in 2% of patients, followed by musculoskeletal pain, blood pressure increased, fatigue, nausea, and injection site reaction, all occurring in <1% of patients (  6  ).",blood pressure increased is an adverse reaction entity
"6 ADVERSE REACTIONS    EXCERPT:   The most common reported adverse reaction was headache, occurring in 2% of patients, followed by musculoskeletal pain, blood pressure increased, fatigue, nausea, and injection site reaction, all occurring in <1% of patients (  6  ).",nausea is an adverse reaction entity
"6 ADVERSE REACTIONS    EXCERPT:   The most common reported adverse reaction was headache, occurring in 2% of patients, followed by musculoskeletal pain, blood pressure increased, fatigue, nausea, and injection site reaction, all occurring in <1% of patients (  6  ).",musculoskeletal pain is an adverse reaction entity
"6 ADVERSE REACTIONS    EXCERPT:   The most common reported adverse reaction was headache, occurring in 2% of patients, followed by musculoskeletal pain, blood pressure increased, fatigue, nausea, and injection site reaction, all occurring in <1% of patients (  6  ).",injection site reaction is an adverse reaction entity
"6 ADVERSE REACTIONS    EXCERPT:   The most common reported adverse reaction was headache, occurring in 2% of patients, followed by musculoskeletal pain, blood pressure increased, fatigue, nausea, and injection site reaction, all occurring in <1% of patients (  6  ).",headache is an adverse reaction entity
"6 ADVERSE REACTIONS    EXCERPT:   The most common reported adverse reaction was headache, occurring in 2% of patients, followed by musculoskeletal pain, blood pressure increased, fatigue, nausea, and injection site reaction, all occurring in <1% of patients (  6  ).","was headache , is not a named entity"
"6 ADVERSE REACTIONS    EXCERPT:   The most common reported adverse reaction was headache, occurring in 2% of patients, followed by musculoskeletal pain, blood pressure increased, fatigue, nausea, and injection site reaction, all occurring in <1% of patients (  6  ).",", is not a named entity"
Table 2: Adverse Reactions Reported in Clinical Trials (N=555 patients)    a Includes the terms blood pressure increased and hypertension.,hypertension is an adverse reaction entity
Table 2: Adverse Reactions Reported in Clinical Trials (N=555 patients)    a Includes the terms blood pressure increased and hypertension.,Adverse Reactions Reported is not a named entity
Table 2: Adverse Reactions Reported in Clinical Trials (N=555 patients)    a Includes the terms blood pressure increased and hypertension.,blood pressure increased is an adverse reaction entity
Table 2: Adverse Reactions Reported in Clinical Trials (N=555 patients)    a Includes the terms blood pressure increased and hypertension.,increased and is not a named entity
5 WARNINGS AND PRECAUTIONS     EXCERPT:    *   Anaphylaxis and Hypersensitivity Reactions: Life-threatening anaphylaxis and hypersensitivity reactions have been observed in some patients during and after treatment with alglucosidase alfa.,: is not a named entity
5 WARNINGS AND PRECAUTIONS     EXCERPT:    *   Anaphylaxis and Hypersensitivity Reactions: Life-threatening anaphylaxis and hypersensitivity reactions have been observed in some patients during and after treatment with alglucosidase alfa.,Anaphylaxis is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS     EXCERPT:    *   Anaphylaxis and Hypersensitivity Reactions: Life-threatening anaphylaxis and hypersensitivity reactions have been observed in some patients during and after treatment with alglucosidase alfa.,reactions is not a named entity
5 WARNINGS AND PRECAUTIONS     EXCERPT:    *   Anaphylaxis and Hypersensitivity Reactions: Life-threatening anaphylaxis and hypersensitivity reactions have been observed in some patients during and after treatment with alglucosidase alfa.,Hypersensitivity Reactions is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS     EXCERPT:    *   Anaphylaxis and Hypersensitivity Reactions: Life-threatening anaphylaxis and hypersensitivity reactions have been observed in some patients during and after treatment with alglucosidase alfa.,with alglucosidase is not a named entity
5 WARNINGS AND PRECAUTIONS     EXCERPT:    *   Anaphylaxis and Hypersensitivity Reactions: Life-threatening anaphylaxis and hypersensitivity reactions have been observed in some patients during and after treatment with alglucosidase alfa.,* Anaphylaxis and is not a named entity
5 WARNINGS AND PRECAUTIONS     EXCERPT:    *   Anaphylaxis and Hypersensitivity Reactions: Life-threatening anaphylaxis and hypersensitivity reactions have been observed in some patients during and after treatment with alglucosidase alfa.,anaphylaxis is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS     EXCERPT:    *   Anaphylaxis and Hypersensitivity Reactions: Life-threatening anaphylaxis and hypersensitivity reactions have been observed in some patients during and after treatment with alglucosidase alfa.,hypersensitivity reactions is an adverse reaction entity
Another patient developed severe inflammatory arthropathy in association with pyrexia and elevated erythrocyte sedimentation rate.,erythrocyte sedimentation rate is not a named entity
Another patient developed severe inflammatory arthropathy in association with pyrexia and elevated erythrocyte sedimentation rate.,elevated erythrocyte sedimentation rate is an adverse reaction entity
Another patient developed severe inflammatory arthropathy in association with pyrexia and elevated erythrocyte sedimentation rate.,inflammatory arthropathy in is not a named entity
Another patient developed severe inflammatory arthropathy in association with pyrexia and elevated erythrocyte sedimentation rate.,with pyrexia and is not a named entity
Another patient developed severe inflammatory arthropathy in association with pyrexia and elevated erythrocyte sedimentation rate.,inflammatory arthropathy is an adverse reaction entity
Another patient developed severe inflammatory arthropathy in association with pyrexia and elevated erythrocyte sedimentation rate.,pyrexia is an adverse reaction entity
Some of the patients who tested positive for alglucosidase alfa-specific IgE antibodies experienced anaphylactic reactions  [seeBoxed WarningandWarnings and Precautions (5.1)].,( is not a named entity
Some of the patients who tested positive for alglucosidase alfa-specific IgE antibodies experienced anaphylactic reactions  [seeBoxed WarningandWarnings and Precautions (5.1)].,anaphylactic reactions is an adverse reaction entity
"Some patients who were pre-treated with antihistamines, antipyretics and/or corticosteroids still experienced hypersensitivity reactions.",hypersensitivity reactions is an adverse reaction entity
"Some patients who were pre-treated with antihistamines, antipyretics and/or corticosteroids still experienced hypersensitivity reactions.",experienced hypersensitivity reactions is not a named entity
"Systemic immune-mediated reactions, including possible type III immune-mediated reactions have been observed with alglucosidase alfa.",type III immune-mediated reactions is an adverse reaction entity
"Systemic immune-mediated reactions, including possible type III immune-mediated reactions have been observed with alglucosidase alfa.",Systemic immune-mediated reactions is an adverse reaction entity
"Systemic immune-mediated reactions, including possible type III immune-mediated reactions have been observed with alglucosidase alfa.",with alglucosidase is not a named entity
"Systemic immune-mediated reactions, including possible type III immune-mediated reactions have been observed with alglucosidase alfa.",observed is not a named entity
*   Risk of Acute Cardiorespiratory Failure: Patients with compromised cardiac or respiratory function may be at risk of acute cardiorespiratory failure.,acute cardiorespiratory failure is an adverse reaction entity
*   Risk of Acute Cardiorespiratory Failure: Patients with compromised cardiac or respiratory function may be at risk of acute cardiorespiratory failure.,Failure is not a named entity
*   Risk of Acute Cardiorespiratory Failure: Patients with compromised cardiac or respiratory function may be at risk of acute cardiorespiratory failure.,Acute Cardiorespiratory Failure is an adverse reaction entity
*   Risk of Acute Cardiorespiratory Failure: Patients with compromised cardiac or respiratory function may be at risk of acute cardiorespiratory failure.,Cardiorespiratory Failure is not a named entity
"Delayed-onset reactions, defined as adverse reactions occurring 2 - 48 hours after completion of alglucosidase alfa infusion, that were observed in >= 3% more patients in the alglucosidase alfa-treated group compared to patients in the placebo-treated group in the controlled trial, included hyperhidrosis.",patients in is not a named entity
"Delayed-onset reactions, defined as adverse reactions occurring 2 - 48 hours after completion of alglucosidase alfa infusion, that were observed in >= 3% more patients in the alglucosidase alfa-treated group compared to patients in the placebo-treated group in the controlled trial, included hyperhidrosis.",hyperhidrosis is an adverse reaction entity
5.3 Risk of Acute Cardiorespiratory Failure    Patients with acute underlying respiratory illness or compromised cardiac and/or respiratory function may be at risk of serious exacerbation of their cardiac or respiratory compromise during infusions.,respiratory illness or is not a named entity
5.3 Risk of Acute Cardiorespiratory Failure    Patients with acute underlying respiratory illness or compromised cardiac and/or respiratory function may be at risk of serious exacerbation of their cardiac or respiratory compromise during infusions.,exacerbation of respiratory compromise is an adverse reaction entity
5.3 Risk of Acute Cardiorespiratory Failure    Patients with acute underlying respiratory illness or compromised cardiac and/or respiratory function may be at risk of serious exacerbation of their cardiac or respiratory compromise during infusions.,exacerbation of cardiac compromise is an adverse reaction entity
5.3 Risk of Acute Cardiorespiratory Failure    Patients with acute underlying respiratory illness or compromised cardiac and/or respiratory function may be at risk of serious exacerbation of their cardiac or respiratory compromise during infusions.,respiratory function is not a named entity
"Systemic and cutaneous immune-mediated reactions, including proteinuria and nephrotic syndrome secondary to membranous glomerulonephritis, and necrotizing skin lesions have been reported in postmarketing safety experience with alglucosidase alfa  [seeWarnings and Precautions (5.2)]  .",Systemic immune-mediated reactions is an adverse reaction entity
"Systemic and cutaneous immune-mediated reactions, including proteinuria and nephrotic syndrome secondary to membranous glomerulonephritis, and necrotizing skin lesions have been reported in postmarketing safety experience with alglucosidase alfa  [seeWarnings and Precautions (5.2)]  .",membranous glomerulonephritis is an adverse reaction entity
"Systemic and cutaneous immune-mediated reactions, including proteinuria and nephrotic syndrome secondary to membranous glomerulonephritis, and necrotizing skin lesions have been reported in postmarketing safety experience with alglucosidase alfa  [seeWarnings and Precautions (5.2)]  .",nephrotic syndrome is an adverse reaction entity
"Systemic and cutaneous immune-mediated reactions, including proteinuria and nephrotic syndrome secondary to membranous glomerulonephritis, and necrotizing skin lesions have been reported in postmarketing safety experience with alglucosidase alfa  [seeWarnings and Precautions (5.2)]  .",reported in postmarketing is not a named entity
"Systemic and cutaneous immune-mediated reactions, including proteinuria and nephrotic syndrome secondary to membranous glomerulonephritis, and necrotizing skin lesions have been reported in postmarketing safety experience with alglucosidase alfa  [seeWarnings and Precautions (5.2)]  .",and Precautions is not a named entity
"Systemic and cutaneous immune-mediated reactions, including proteinuria and nephrotic syndrome secondary to membranous glomerulonephritis, and necrotizing skin lesions have been reported in postmarketing safety experience with alglucosidase alfa  [seeWarnings and Precautions (5.2)]  .","reactions , is not a named entity"
"Systemic and cutaneous immune-mediated reactions, including proteinuria and nephrotic syndrome secondary to membranous glomerulonephritis, and necrotizing skin lesions have been reported in postmarketing safety experience with alglucosidase alfa  [seeWarnings and Precautions (5.2)]  .",necrotizing skin lesions is an adverse reaction entity
"Systemic and cutaneous immune-mediated reactions, including proteinuria and nephrotic syndrome secondary to membranous glomerulonephritis, and necrotizing skin lesions have been reported in postmarketing safety experience with alglucosidase alfa  [seeWarnings and Precautions (5.2)]  .",cutaneous immune-mediated reactions is an adverse reaction entity
"Systemic and cutaneous immune-mediated reactions, including proteinuria and nephrotic syndrome secondary to membranous glomerulonephritis, and necrotizing skin lesions have been reported in postmarketing safety experience with alglucosidase alfa  [seeWarnings and Precautions (5.2)]  .",( 5.2 is not a named entity
"Systemic and cutaneous immune-mediated reactions, including proteinuria and nephrotic syndrome secondary to membranous glomerulonephritis, and necrotizing skin lesions have been reported in postmarketing safety experience with alglucosidase alfa  [seeWarnings and Precautions (5.2)]  .",experience with alglucosidase is not a named entity
"Systemic and cutaneous immune-mediated reactions, including proteinuria and nephrotic syndrome secondary to membranous glomerulonephritis, and necrotizing skin lesions have been reported in postmarketing safety experience with alglucosidase alfa  [seeWarnings and Precautions (5.2)]  .",with alglucosidase is not a named entity
"Systemic and cutaneous immune-mediated reactions, including proteinuria and nephrotic syndrome secondary to membranous glomerulonephritis, and necrotizing skin lesions have been reported in postmarketing safety experience with alglucosidase alfa  [seeWarnings and Precautions (5.2)]  .",proteinuria is an adverse reaction entity
"Additional hypersensitivity reactions observed in infantile-onset Pompe disease patients treated in other clinical trials and expanded access programs with alglucosidase alfa included livedo reticularis, irritability, retching, increased lacrimation, ventricular extrasystoles, nodal rhythm, rales, respiratory tract irritation, and cold sweat.",", is not a named entity"
"Additional hypersensitivity reactions observed in infantile-onset Pompe disease patients treated in other clinical trials and expanded access programs with alglucosidase alfa included livedo reticularis, irritability, retching, increased lacrimation, ventricular extrasystoles, nodal rhythm, rales, respiratory tract irritation, and cold sweat.",alfa included is not a named entity
"Additional hypersensitivity reactions observed in infantile-onset Pompe disease patients treated in other clinical trials and expanded access programs with alglucosidase alfa included livedo reticularis, irritability, retching, increased lacrimation, ventricular extrasystoles, nodal rhythm, rales, respiratory tract irritation, and cold sweat.",", rales is not a named entity"
"Additional hypersensitivity reactions observed in infantile-onset Pompe disease patients treated in other clinical trials and expanded access programs with alglucosidase alfa included livedo reticularis, irritability, retching, increased lacrimation, ventricular extrasystoles, nodal rhythm, rales, respiratory tract irritation, and cold sweat.",cold sweat is an adverse reaction entity
"Additional hypersensitivity reactions observed in infantile-onset Pompe disease patients treated in other clinical trials and expanded access programs with alglucosidase alfa included livedo reticularis, irritability, retching, increased lacrimation, ventricular extrasystoles, nodal rhythm, rales, respiratory tract irritation, and cold sweat.",irritability is an adverse reaction entity
"Additional hypersensitivity reactions observed in infantile-onset Pompe disease patients treated in other clinical trials and expanded access programs with alglucosidase alfa included livedo reticularis, irritability, retching, increased lacrimation, ventricular extrasystoles, nodal rhythm, rales, respiratory tract irritation, and cold sweat.",increased lacrimation is an adverse reaction entity
"Additional hypersensitivity reactions observed in infantile-onset Pompe disease patients treated in other clinical trials and expanded access programs with alglucosidase alfa included livedo reticularis, irritability, retching, increased lacrimation, ventricular extrasystoles, nodal rhythm, rales, respiratory tract irritation, and cold sweat.",disease patients is not a named entity
"Additional hypersensitivity reactions observed in infantile-onset Pompe disease patients treated in other clinical trials and expanded access programs with alglucosidase alfa included livedo reticularis, irritability, retching, increased lacrimation, ventricular extrasystoles, nodal rhythm, rales, respiratory tract irritation, and cold sweat.",nodal rhythm is an adverse reaction entity
"Additional hypersensitivity reactions observed in infantile-onset Pompe disease patients treated in other clinical trials and expanded access programs with alglucosidase alfa included livedo reticularis, irritability, retching, increased lacrimation, ventricular extrasystoles, nodal rhythm, rales, respiratory tract irritation, and cold sweat.",", respiratory is not a named entity"
"Additional hypersensitivity reactions observed in infantile-onset Pompe disease patients treated in other clinical trials and expanded access programs with alglucosidase alfa included livedo reticularis, irritability, retching, increased lacrimation, ventricular extrasystoles, nodal rhythm, rales, respiratory tract irritation, and cold sweat.",observed in infantile-onset is not a named entity
"Additional hypersensitivity reactions observed in infantile-onset Pompe disease patients treated in other clinical trials and expanded access programs with alglucosidase alfa included livedo reticularis, irritability, retching, increased lacrimation, ventricular extrasystoles, nodal rhythm, rales, respiratory tract irritation, and cold sweat.",rales is an adverse reaction entity
"Additional hypersensitivity reactions observed in infantile-onset Pompe disease patients treated in other clinical trials and expanded access programs with alglucosidase alfa included livedo reticularis, irritability, retching, increased lacrimation, ventricular extrasystoles, nodal rhythm, rales, respiratory tract irritation, and cold sweat.",alglucosidase alfa included is not a named entity
"Additional hypersensitivity reactions observed in infantile-onset Pompe disease patients treated in other clinical trials and expanded access programs with alglucosidase alfa included livedo reticularis, irritability, retching, increased lacrimation, ventricular extrasystoles, nodal rhythm, rales, respiratory tract irritation, and cold sweat.",other is not a named entity
"Additional hypersensitivity reactions observed in infantile-onset Pompe disease patients treated in other clinical trials and expanded access programs with alglucosidase alfa included livedo reticularis, irritability, retching, increased lacrimation, ventricular extrasystoles, nodal rhythm, rales, respiratory tract irritation, and cold sweat.",livedo reticularis is an adverse reaction entity
"Additional hypersensitivity reactions observed in infantile-onset Pompe disease patients treated in other clinical trials and expanded access programs with alglucosidase alfa included livedo reticularis, irritability, retching, increased lacrimation, ventricular extrasystoles, nodal rhythm, rales, respiratory tract irritation, and cold sweat.",in infantile-onset Pompe is not a named entity
"Additional hypersensitivity reactions observed in infantile-onset Pompe disease patients treated in other clinical trials and expanded access programs with alglucosidase alfa included livedo reticularis, irritability, retching, increased lacrimation, ventricular extrasystoles, nodal rhythm, rales, respiratory tract irritation, and cold sweat.",ventricular extrasystoles is an adverse reaction entity
"Additional hypersensitivity reactions observed in infantile-onset Pompe disease patients treated in other clinical trials and expanded access programs with alglucosidase alfa included livedo reticularis, irritability, retching, increased lacrimation, ventricular extrasystoles, nodal rhythm, rales, respiratory tract irritation, and cold sweat.",hypersensitivity reactions is an adverse reaction entity
"Additional hypersensitivity reactions observed in infantile-onset Pompe disease patients treated in other clinical trials and expanded access programs with alglucosidase alfa included livedo reticularis, irritability, retching, increased lacrimation, ventricular extrasystoles, nodal rhythm, rales, respiratory tract irritation, and cold sweat.",respiratory tract irritation is an adverse reaction entity
"Additional hypersensitivity reactions observed in infantile-onset Pompe disease patients treated in other clinical trials and expanded access programs with alglucosidase alfa included livedo reticularis, irritability, retching, increased lacrimation, ventricular extrasystoles, nodal rhythm, rales, respiratory tract irritation, and cold sweat.",retching is an adverse reaction entity
"Additional hypersensitivity reactions observed in infantile-onset Pompe disease patients treated in other clinical trials and expanded access programs with alglucosidase alfa included livedo reticularis, irritability, retching, increased lacrimation, ventricular extrasystoles, nodal rhythm, rales, respiratory tract irritation, and cold sweat.",treated in is not a named entity
One patient with a history of Wolff-Parkinson-White syndrome experienced a serious adverse reaction of supraventricular tachycardia.,supraventricular tachycardia is an adverse reaction entity
One patient with a history of Wolff-Parkinson-White syndrome experienced a serious adverse reaction of supraventricular tachycardia.,patient is not a named entity
"Additional delayed-onset reactions occurring in alglucosidase alfa-treated patients included fatigue, myalgia, and nausea.",myalgia is an adverse reaction entity
"Additional delayed-onset reactions occurring in alglucosidase alfa-treated patients included fatigue, myalgia, and nausea.",fatigue is an adverse reaction entity
"Additional delayed-onset reactions occurring in alglucosidase alfa-treated patients included fatigue, myalgia, and nausea.",patients included is not a named entity
"Additional delayed-onset reactions occurring in alglucosidase alfa-treated patients included fatigue, myalgia, and nausea.",included fatigue is not a named entity
"Additional delayed-onset reactions occurring in alglucosidase alfa-treated patients included fatigue, myalgia, and nausea.",", and nausea is not a named entity"
"Additional delayed-onset reactions occurring in alglucosidase alfa-treated patients included fatigue, myalgia, and nausea.",nausea is an adverse reaction entity
"There is evidence to suggest that some patients who develop high and sustained IgG antibody titers may experience reduced clinical efficacy to alglucosidase alfa treatment, such as loss of motor function, ventilator dependence, or death.",efficacy to alglucosidase is not a named entity
"There is evidence to suggest that some patients who develop high and sustained IgG antibody titers may experience reduced clinical efficacy to alglucosidase alfa treatment, such as loss of motor function, ventilator dependence, or death.",loss of motor function is an adverse reaction entity
"There is evidence to suggest that some patients who develop high and sustained IgG antibody titers may experience reduced clinical efficacy to alglucosidase alfa treatment, such as loss of motor function, ventilator dependence, or death.",death is an adverse reaction entity
"There is evidence to suggest that some patients who develop high and sustained IgG antibody titers may experience reduced clinical efficacy to alglucosidase alfa treatment, such as loss of motor function, ventilator dependence, or death.",that some is not a named entity
"There is evidence to suggest that some patients who develop high and sustained IgG antibody titers may experience reduced clinical efficacy to alglucosidase alfa treatment, such as loss of motor function, ventilator dependence, or death.",reduced clinical efficacy is an adverse reaction entity
"There is evidence to suggest that some patients who develop high and sustained IgG antibody titers may experience reduced clinical efficacy to alglucosidase alfa treatment, such as loss of motor function, ventilator dependence, or death.","treatment , is not a named entity"
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.",pressure is not a named entity
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.",wheezing is an adverse reaction entity
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.",", wheezing is not a named entity"
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.","pain , is not a named entity"
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.","dizziness , hypertension/increased is not a named entity"
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.","pruritus , rash is not a named entity"
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.",", rash is not a named entity"
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.",oxygen saturation is not a named entity
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.",hyperhidrosis is an adverse reaction entity
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.",chest pain is an adverse reaction entity
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.",nervousness is an adverse reaction entity
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.",rash is an adverse reaction entity
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.",erythema is an adverse reaction entity
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.","nausea , dizziness is not a named entity"
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.",back pain is an adverse reaction entity
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.",", is not a named entity"
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.",increased blood pressure is an adverse reaction entity
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.",pruritus is an adverse reaction entity
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.","pallor , is not a named entity"
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.",dizziness is an adverse reaction entity
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.",", is not a named entity"
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.","cyanosis , is not a named entity"
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.",paresthesia is an adverse reaction entity
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.","discomfort/pain , wheezing is not a named entity"
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.",", is not a named entity"
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.",decreased oxygen saturation is an adverse reaction entity
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.",peripheral coldness is an adverse reaction entity
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.",", is not a named entity"
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.",chest discomfort is an adverse reaction entity
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.",tachypnea is an adverse reaction entity
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.",restlessness is an adverse reaction entity
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.",cyanosis is an adverse reaction entity
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.",", is not a named entity"
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.",feeling hot is an adverse reaction entity
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.",nausea is an adverse reaction entity
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.",", tachypnea , is not a named entity"
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.","headache , back is not a named entity"
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.",", pallor is not a named entity"
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.",included chest discomfort/pain is not a named entity
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.",pressure is not a named entity
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.",flushing is an adverse reaction entity
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.",", wheezing , is not a named entity"
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.","nausea , is not a named entity"
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.",hypertension is an adverse reaction entity
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.",convulsions is an adverse reaction entity
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.","headache , is not a named entity"
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.",", peripheral coldness is not a named entity"
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.",pyrexia is an adverse reaction entity
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.",headache is an adverse reaction entity
"Other accompanying reactions included chest discomfort/pain, wheezing, tachypnea, cyanosis, decreased oxygen saturation, convulsions, pruritus, rash, hyperhidrosis, nausea, dizziness, hypertension/increased blood pressure, flushing/feeling hot, erythema, pyrexia, pallor, peripheral coldness, restlessness, nervousness, headache, back pain, and paresthesia.",pallor is an adverse reaction entity
"WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, and RISK OF CARDIORESPIRATORY FAILURE       See full prescribing information for complete boxed warning.",prescribing is not a named entity
"WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, and RISK OF CARDIORESPIRATORY FAILURE       See full prescribing information for complete boxed warning.",IMMUNE-MEDIATED REACTIONS is an adverse reaction entity
"WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, and RISK OF CARDIORESPIRATORY FAILURE       See full prescribing information for complete boxed warning.","REACTIONS , and is not a named entity"
"WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, and RISK OF CARDIORESPIRATORY FAILURE       See full prescribing information for complete boxed warning.",and RISK OF is not a named entity
"WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, and RISK OF CARDIORESPIRATORY FAILURE       See full prescribing information for complete boxed warning.",HYPERSENSITIVITY is an adverse reaction entity
"WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, and RISK OF CARDIORESPIRATORY FAILURE       See full prescribing information for complete boxed warning.",FAILURE See is not a named entity
"WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, and RISK OF CARDIORESPIRATORY FAILURE       See full prescribing information for complete boxed warning.",CARDIORESPIRATORY FAILURE is an adverse reaction entity
"WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, and RISK OF CARDIORESPIRATORY FAILURE       See full prescribing information for complete boxed warning.",ANAPHYLAXIS is an adverse reaction entity
*  Life-threatening anaphylactic reactions and severe hypersensitivity reactions have occurred in some patients during and after alglucosidase alfa infusions.,alfa is not a named entity
*  Life-threatening anaphylactic reactions and severe hypersensitivity reactions have occurred in some patients during and after alglucosidase alfa infusions.,anaphylactic reactions is an adverse reaction entity
*  Life-threatening anaphylactic reactions and severe hypersensitivity reactions have occurred in some patients during and after alglucosidase alfa infusions.,have occurred is not a named entity
*  Life-threatening anaphylactic reactions and severe hypersensitivity reactions have occurred in some patients during and after alglucosidase alfa infusions.,hypersensitivity reactions is an adverse reaction entity
"The most common adverse reactions requiring intervention in clinical trials were hypersensitivity reactions, occurring in 20 of 39 (51%) patients treated with alglucosidase alfa, and included rash, pyrexia, urticaria, flushing, decreased oxygen saturation, cough, tachypnea, tachycardia, hypertension/increased blood pressure, pallor, rigors, vomiting, cyanosis, agitation, and tremor.",", cough , is not a named entity"
"The most common adverse reactions requiring intervention in clinical trials were hypersensitivity reactions, occurring in 20 of 39 (51%) patients treated with alglucosidase alfa, and included rash, pyrexia, urticaria, flushing, decreased oxygen saturation, cough, tachypnea, tachycardia, hypertension/increased blood pressure, pallor, rigors, vomiting, cyanosis, agitation, and tremor.",hypertension is an adverse reaction entity
"The most common adverse reactions requiring intervention in clinical trials were hypersensitivity reactions, occurring in 20 of 39 (51%) patients treated with alglucosidase alfa, and included rash, pyrexia, urticaria, flushing, decreased oxygen saturation, cough, tachypnea, tachycardia, hypertension/increased blood pressure, pallor, rigors, vomiting, cyanosis, agitation, and tremor.","hypersensitivity reactions , is not a named entity"
"The most common adverse reactions requiring intervention in clinical trials were hypersensitivity reactions, occurring in 20 of 39 (51%) patients treated with alglucosidase alfa, and included rash, pyrexia, urticaria, flushing, decreased oxygen saturation, cough, tachypnea, tachycardia, hypertension/increased blood pressure, pallor, rigors, vomiting, cyanosis, agitation, and tremor.",cyanosis is an adverse reaction entity
"The most common adverse reactions requiring intervention in clinical trials were hypersensitivity reactions, occurring in 20 of 39 (51%) patients treated with alglucosidase alfa, and included rash, pyrexia, urticaria, flushing, decreased oxygen saturation, cough, tachypnea, tachycardia, hypertension/increased blood pressure, pallor, rigors, vomiting, cyanosis, agitation, and tremor.",tremor is an adverse reaction entity
"The most common adverse reactions requiring intervention in clinical trials were hypersensitivity reactions, occurring in 20 of 39 (51%) patients treated with alglucosidase alfa, and included rash, pyrexia, urticaria, flushing, decreased oxygen saturation, cough, tachypnea, tachycardia, hypertension/increased blood pressure, pallor, rigors, vomiting, cyanosis, agitation, and tremor.",patients is not a named entity
"The most common adverse reactions requiring intervention in clinical trials were hypersensitivity reactions, occurring in 20 of 39 (51%) patients treated with alglucosidase alfa, and included rash, pyrexia, urticaria, flushing, decreased oxygen saturation, cough, tachypnea, tachycardia, hypertension/increased blood pressure, pallor, rigors, vomiting, cyanosis, agitation, and tremor.",flushing is an adverse reaction entity
"The most common adverse reactions requiring intervention in clinical trials were hypersensitivity reactions, occurring in 20 of 39 (51%) patients treated with alglucosidase alfa, and included rash, pyrexia, urticaria, flushing, decreased oxygen saturation, cough, tachypnea, tachycardia, hypertension/increased blood pressure, pallor, rigors, vomiting, cyanosis, agitation, and tremor.","rigors , is not a named entity"
"The most common adverse reactions requiring intervention in clinical trials were hypersensitivity reactions, occurring in 20 of 39 (51%) patients treated with alglucosidase alfa, and included rash, pyrexia, urticaria, flushing, decreased oxygen saturation, cough, tachypnea, tachycardia, hypertension/increased blood pressure, pallor, rigors, vomiting, cyanosis, agitation, and tremor.",increased blood pressure is an adverse reaction entity
"The most common adverse reactions requiring intervention in clinical trials were hypersensitivity reactions, occurring in 20 of 39 (51%) patients treated with alglucosidase alfa, and included rash, pyrexia, urticaria, flushing, decreased oxygen saturation, cough, tachypnea, tachycardia, hypertension/increased blood pressure, pallor, rigors, vomiting, cyanosis, agitation, and tremor.",cough is an adverse reaction entity
"The most common adverse reactions requiring intervention in clinical trials were hypersensitivity reactions, occurring in 20 of 39 (51%) patients treated with alglucosidase alfa, and included rash, pyrexia, urticaria, flushing, decreased oxygen saturation, cough, tachypnea, tachycardia, hypertension/increased blood pressure, pallor, rigors, vomiting, cyanosis, agitation, and tremor.",", is not a named entity"
"The most common adverse reactions requiring intervention in clinical trials were hypersensitivity reactions, occurring in 20 of 39 (51%) patients treated with alglucosidase alfa, and included rash, pyrexia, urticaria, flushing, decreased oxygen saturation, cough, tachypnea, tachycardia, hypertension/increased blood pressure, pallor, rigors, vomiting, cyanosis, agitation, and tremor.",tachycardia is an adverse reaction entity
"The most common adverse reactions requiring intervention in clinical trials were hypersensitivity reactions, occurring in 20 of 39 (51%) patients treated with alglucosidase alfa, and included rash, pyrexia, urticaria, flushing, decreased oxygen saturation, cough, tachypnea, tachycardia, hypertension/increased blood pressure, pallor, rigors, vomiting, cyanosis, agitation, and tremor.","agitation , is not a named entity"
"The most common adverse reactions requiring intervention in clinical trials were hypersensitivity reactions, occurring in 20 of 39 (51%) patients treated with alglucosidase alfa, and included rash, pyrexia, urticaria, flushing, decreased oxygen saturation, cough, tachypnea, tachycardia, hypertension/increased blood pressure, pallor, rigors, vomiting, cyanosis, agitation, and tremor.",trials were hypersensitivity is not a named entity
"The most common adverse reactions requiring intervention in clinical trials were hypersensitivity reactions, occurring in 20 of 39 (51%) patients treated with alglucosidase alfa, and included rash, pyrexia, urticaria, flushing, decreased oxygen saturation, cough, tachypnea, tachycardia, hypertension/increased blood pressure, pallor, rigors, vomiting, cyanosis, agitation, and tremor.",", pyrexia , is not a named entity"
"The most common adverse reactions requiring intervention in clinical trials were hypersensitivity reactions, occurring in 20 of 39 (51%) patients treated with alglucosidase alfa, and included rash, pyrexia, urticaria, flushing, decreased oxygen saturation, cough, tachypnea, tachycardia, hypertension/increased blood pressure, pallor, rigors, vomiting, cyanosis, agitation, and tremor.",rigors is an adverse reaction entity
"The most common adverse reactions requiring intervention in clinical trials were hypersensitivity reactions, occurring in 20 of 39 (51%) patients treated with alglucosidase alfa, and included rash, pyrexia, urticaria, flushing, decreased oxygen saturation, cough, tachypnea, tachycardia, hypertension/increased blood pressure, pallor, rigors, vomiting, cyanosis, agitation, and tremor.","urticaria , is not a named entity"
"The most common adverse reactions requiring intervention in clinical trials were hypersensitivity reactions, occurring in 20 of 39 (51%) patients treated with alglucosidase alfa, and included rash, pyrexia, urticaria, flushing, decreased oxygen saturation, cough, tachypnea, tachycardia, hypertension/increased blood pressure, pallor, rigors, vomiting, cyanosis, agitation, and tremor.",decreased oxygen saturation is an adverse reaction entity
"The most common adverse reactions requiring intervention in clinical trials were hypersensitivity reactions, occurring in 20 of 39 (51%) patients treated with alglucosidase alfa, and included rash, pyrexia, urticaria, flushing, decreased oxygen saturation, cough, tachypnea, tachycardia, hypertension/increased blood pressure, pallor, rigors, vomiting, cyanosis, agitation, and tremor.",pallor is an adverse reaction entity
"The most common adverse reactions requiring intervention in clinical trials were hypersensitivity reactions, occurring in 20 of 39 (51%) patients treated with alglucosidase alfa, and included rash, pyrexia, urticaria, flushing, decreased oxygen saturation, cough, tachypnea, tachycardia, hypertension/increased blood pressure, pallor, rigors, vomiting, cyanosis, agitation, and tremor.",", is not a named entity"
"The most common adverse reactions requiring intervention in clinical trials were hypersensitivity reactions, occurring in 20 of 39 (51%) patients treated with alglucosidase alfa, and included rash, pyrexia, urticaria, flushing, decreased oxygen saturation, cough, tachypnea, tachycardia, hypertension/increased blood pressure, pallor, rigors, vomiting, cyanosis, agitation, and tremor.",( 51 % is not a named entity
"The most common adverse reactions requiring intervention in clinical trials were hypersensitivity reactions, occurring in 20 of 39 (51%) patients treated with alglucosidase alfa, and included rash, pyrexia, urticaria, flushing, decreased oxygen saturation, cough, tachypnea, tachycardia, hypertension/increased blood pressure, pallor, rigors, vomiting, cyanosis, agitation, and tremor.",reactions is not a named entity
"The most common adverse reactions requiring intervention in clinical trials were hypersensitivity reactions, occurring in 20 of 39 (51%) patients treated with alglucosidase alfa, and included rash, pyrexia, urticaria, flushing, decreased oxygen saturation, cough, tachypnea, tachycardia, hypertension/increased blood pressure, pallor, rigors, vomiting, cyanosis, agitation, and tremor.","pyrexia , is not a named entity"
"The most common adverse reactions requiring intervention in clinical trials were hypersensitivity reactions, occurring in 20 of 39 (51%) patients treated with alglucosidase alfa, and included rash, pyrexia, urticaria, flushing, decreased oxygen saturation, cough, tachypnea, tachycardia, hypertension/increased blood pressure, pallor, rigors, vomiting, cyanosis, agitation, and tremor.",", rigors , is not a named entity"
"The most common adverse reactions requiring intervention in clinical trials were hypersensitivity reactions, occurring in 20 of 39 (51%) patients treated with alglucosidase alfa, and included rash, pyrexia, urticaria, flushing, decreased oxygen saturation, cough, tachypnea, tachycardia, hypertension/increased blood pressure, pallor, rigors, vomiting, cyanosis, agitation, and tremor.",urticaria is an adverse reaction entity
"The most common adverse reactions requiring intervention in clinical trials were hypersensitivity reactions, occurring in 20 of 39 (51%) patients treated with alglucosidase alfa, and included rash, pyrexia, urticaria, flushing, decreased oxygen saturation, cough, tachypnea, tachycardia, hypertension/increased blood pressure, pallor, rigors, vomiting, cyanosis, agitation, and tremor.",tachypnea is an adverse reaction entity
"The most common adverse reactions requiring intervention in clinical trials were hypersensitivity reactions, occurring in 20 of 39 (51%) patients treated with alglucosidase alfa, and included rash, pyrexia, urticaria, flushing, decreased oxygen saturation, cough, tachypnea, tachycardia, hypertension/increased blood pressure, pallor, rigors, vomiting, cyanosis, agitation, and tremor.",51 is not a named entity
"The most common adverse reactions requiring intervention in clinical trials were hypersensitivity reactions, occurring in 20 of 39 (51%) patients treated with alglucosidase alfa, and included rash, pyrexia, urticaria, flushing, decreased oxygen saturation, cough, tachypnea, tachycardia, hypertension/increased blood pressure, pallor, rigors, vomiting, cyanosis, agitation, and tremor.",vomiting is an adverse reaction entity
"The most common adverse reactions requiring intervention in clinical trials were hypersensitivity reactions, occurring in 20 of 39 (51%) patients treated with alglucosidase alfa, and included rash, pyrexia, urticaria, flushing, decreased oxygen saturation, cough, tachypnea, tachycardia, hypertension/increased blood pressure, pallor, rigors, vomiting, cyanosis, agitation, and tremor.",agitation is an adverse reaction entity
"The most common adverse reactions requiring intervention in clinical trials were hypersensitivity reactions, occurring in 20 of 39 (51%) patients treated with alglucosidase alfa, and included rash, pyrexia, urticaria, flushing, decreased oxygen saturation, cough, tachypnea, tachycardia, hypertension/increased blood pressure, pallor, rigors, vomiting, cyanosis, agitation, and tremor.",blood pressure is not a named entity
"The most common adverse reactions requiring intervention in clinical trials were hypersensitivity reactions, occurring in 20 of 39 (51%) patients treated with alglucosidase alfa, and included rash, pyrexia, urticaria, flushing, decreased oxygen saturation, cough, tachypnea, tachycardia, hypertension/increased blood pressure, pallor, rigors, vomiting, cyanosis, agitation, and tremor.",pyrexia is an adverse reaction entity
"The most common adverse reactions requiring intervention in clinical trials were hypersensitivity reactions, occurring in 20 of 39 (51%) patients treated with alglucosidase alfa, and included rash, pyrexia, urticaria, flushing, decreased oxygen saturation, cough, tachypnea, tachycardia, hypertension/increased blood pressure, pallor, rigors, vomiting, cyanosis, agitation, and tremor.",requiring is not a named entity
"The most common adverse reactions requiring intervention in clinical trials were hypersensitivity reactions, occurring in 20 of 39 (51%) patients treated with alglucosidase alfa, and included rash, pyrexia, urticaria, flushing, decreased oxygen saturation, cough, tachypnea, tachycardia, hypertension/increased blood pressure, pallor, rigors, vomiting, cyanosis, agitation, and tremor.",hypersensitivity reactions is an adverse reaction entity
"The most common adverse reactions requiring intervention in clinical trials were hypersensitivity reactions, occurring in 20 of 39 (51%) patients treated with alglucosidase alfa, and included rash, pyrexia, urticaria, flushing, decreased oxygen saturation, cough, tachypnea, tachycardia, hypertension/increased blood pressure, pallor, rigors, vomiting, cyanosis, agitation, and tremor.",rash is an adverse reaction entity
"In postmarketing experience with alglucosidase alfa, serious adverse reactions have been reported, including anaphylaxis  [seeBoxed WarningandWarnings and Precautions (5.1)]  .",anaphylaxis is an adverse reaction entity
"In postmarketing experience with alglucosidase alfa, serious adverse reactions have been reported, including anaphylaxis  [seeBoxed WarningandWarnings and Precautions (5.1)]  .",( is not a named entity
*   Immune-Mediated Reactions: Monitor patients for the development of systemic immune-mediated reactions involving skin and other organs (5.2).,* Immune-Mediated is not a named entity
*   Immune-Mediated Reactions: Monitor patients for the development of systemic immune-mediated reactions involving skin and other organs (5.2).,Immune-Mediated Reactions is an adverse reaction entity
"Immune-mediated reactions presenting as proteinuria, nephrotic syndrome, and necrotizing skin lesions have occurred in some patients following alglucosidase alfa treatment.",nephrotic syndrome is an adverse reaction entity
"Immune-mediated reactions presenting as proteinuria, nephrotic syndrome, and necrotizing skin lesions have occurred in some patients following alglucosidase alfa treatment.",and is not a named entity
"Immune-mediated reactions presenting as proteinuria, nephrotic syndrome, and necrotizing skin lesions have occurred in some patients following alglucosidase alfa treatment.",and necrotizing skin is not a named entity
"Immune-mediated reactions presenting as proteinuria, nephrotic syndrome, and necrotizing skin lesions have occurred in some patients following alglucosidase alfa treatment.",in is not a named entity
"Immune-mediated reactions presenting as proteinuria, nephrotic syndrome, and necrotizing skin lesions have occurred in some patients following alglucosidase alfa treatment.",presenting as is not a named entity
"Immune-mediated reactions presenting as proteinuria, nephrotic syndrome, and necrotizing skin lesions have occurred in some patients following alglucosidase alfa treatment.",necrotizing skin lesions is an adverse reaction entity
"Immune-mediated reactions presenting as proteinuria, nephrotic syndrome, and necrotizing skin lesions have occurred in some patients following alglucosidase alfa treatment.",Immune-mediated reactions is an adverse reaction entity
"Immune-mediated reactions presenting as proteinuria, nephrotic syndrome, and necrotizing skin lesions have occurred in some patients following alglucosidase alfa treatment.",proteinuria is an adverse reaction entity
"Acute cardiorespiratory failure has been observed in infantile-onset Pompe disease patients with underlying cardiac hypertrophy, possibly associated with fluid overload with intravenous administration of alglucosidase alfa  [seeDosage and Administration (2.2)]  .",Acute cardiorespiratory failure is an adverse reaction entity
"Acute cardiorespiratory failure has been observed in infantile-onset Pompe disease patients with underlying cardiac hypertrophy, possibly associated with fluid overload with intravenous administration of alglucosidase alfa  [seeDosage and Administration (2.2)]  .",failure is not a named entity
"Acute cardiorespiratory failure has been observed in infantile-onset Pompe disease patients with underlying cardiac hypertrophy, possibly associated with fluid overload with intravenous administration of alglucosidase alfa  [seeDosage and Administration (2.2)]  .",failure is not a named entity
"Acute cardiorespiratory failure has been observed in infantile-onset Pompe disease patients with underlying cardiac hypertrophy, possibly associated with fluid overload with intravenous administration of alglucosidase alfa  [seeDosage and Administration (2.2)]  .",fluid overload is an adverse reaction entity
Skin biopsy in one patient demonstrated deposition of anti-rhGAA antibodies in the lesion.,deposition of anti-rhGAA antibodies is an adverse reaction entity
Skin biopsy in one patient demonstrated deposition of anti-rhGAA antibodies in the lesion.,demonstrated deposition is not a named entity
"Recurrent reactions consisting of flu-like illness or a combination of events such as pyrexia, chills, myalgia, arthralgia, pain, or fatigue occurring after completion of infusions and lasting usually for 1 - 3 days have been observed in some patients treated with alglucosidase alfa.",of infusions and is not a named entity
"Recurrent reactions consisting of flu-like illness or a combination of events such as pyrexia, chills, myalgia, arthralgia, pain, or fatigue occurring after completion of infusions and lasting usually for 1 - 3 days have been observed in some patients treated with alglucosidase alfa.",myalgia is an adverse reaction entity
"Recurrent reactions consisting of flu-like illness or a combination of events such as pyrexia, chills, myalgia, arthralgia, pain, or fatigue occurring after completion of infusions and lasting usually for 1 - 3 days have been observed in some patients treated with alglucosidase alfa.",alfa is not a named entity
"Recurrent reactions consisting of flu-like illness or a combination of events such as pyrexia, chills, myalgia, arthralgia, pain, or fatigue occurring after completion of infusions and lasting usually for 1 - 3 days have been observed in some patients treated with alglucosidase alfa.",patients treated is not a named entity
"Recurrent reactions consisting of flu-like illness or a combination of events such as pyrexia, chills, myalgia, arthralgia, pain, or fatigue occurring after completion of infusions and lasting usually for 1 - 3 days have been observed in some patients treated with alglucosidase alfa.",chills is an adverse reaction entity
"Recurrent reactions consisting of flu-like illness or a combination of events such as pyrexia, chills, myalgia, arthralgia, pain, or fatigue occurring after completion of infusions and lasting usually for 1 - 3 days have been observed in some patients treated with alglucosidase alfa.",lasting is not a named entity
"Recurrent reactions consisting of flu-like illness or a combination of events such as pyrexia, chills, myalgia, arthralgia, pain, or fatigue occurring after completion of infusions and lasting usually for 1 - 3 days have been observed in some patients treated with alglucosidase alfa.",pyrexia is an adverse reaction entity
"Recurrent reactions consisting of flu-like illness or a combination of events such as pyrexia, chills, myalgia, arthralgia, pain, or fatigue occurring after completion of infusions and lasting usually for 1 - 3 days have been observed in some patients treated with alglucosidase alfa.",of is not a named entity
"Recurrent reactions consisting of flu-like illness or a combination of events such as pyrexia, chills, myalgia, arthralgia, pain, or fatigue occurring after completion of infusions and lasting usually for 1 - 3 days have been observed in some patients treated with alglucosidase alfa.",pain is an adverse reaction entity
"Recurrent reactions consisting of flu-like illness or a combination of events such as pyrexia, chills, myalgia, arthralgia, pain, or fatigue occurring after completion of infusions and lasting usually for 1 - 3 days have been observed in some patients treated with alglucosidase alfa.",lasting usually is not a named entity
"Recurrent reactions consisting of flu-like illness or a combination of events such as pyrexia, chills, myalgia, arthralgia, pain, or fatigue occurring after completion of infusions and lasting usually for 1 - 3 days have been observed in some patients treated with alglucosidase alfa.",arthralgia is an adverse reaction entity
"Recurrent reactions consisting of flu-like illness or a combination of events such as pyrexia, chills, myalgia, arthralgia, pain, or fatigue occurring after completion of infusions and lasting usually for 1 - 3 days have been observed in some patients treated with alglucosidase alfa.",fatigue is an adverse reaction entity
"Recurrent reactions consisting of flu-like illness or a combination of events such as pyrexia, chills, myalgia, arthralgia, pain, or fatigue occurring after completion of infusions and lasting usually for 1 - 3 days have been observed in some patients treated with alglucosidase alfa.",flu-like illness is an adverse reaction entity
"Recurrent reactions consisting of flu-like illness or a combination of events such as pyrexia, chills, myalgia, arthralgia, pain, or fatigue occurring after completion of infusions and lasting usually for 1 - 3 days have been observed in some patients treated with alglucosidase alfa.",patients treated with is not a named entity
"Infantile-onset Pompe disease patients with compromised cardiac or respiratory function may be at risk of serious acute exacerbation of their cardiac or respiratory compromise due to fluid overload, and require additional monitoring   [see Warnings and Precautions (5.3)]  .",Pompe disease is not a named entity
"Infantile-onset Pompe disease patients with compromised cardiac or respiratory function may be at risk of serious acute exacerbation of their cardiac or respiratory compromise due to fluid overload, and require additional monitoring   [see Warnings and Precautions (5.3)]  .",fluid overload is an adverse reaction entity
"Infantile-onset Pompe disease patients with compromised cardiac or respiratory function may be at risk of serious acute exacerbation of their cardiac or respiratory compromise due to fluid overload, and require additional monitoring   [see Warnings and Precautions (5.3)]  .",or respiratory function is not a named entity
"Infantile-onset Pompe disease patients with compromised cardiac or respiratory function may be at risk of serious acute exacerbation of their cardiac or respiratory compromise due to fluid overload, and require additional monitoring   [see Warnings and Precautions (5.3)]  .",function may is not a named entity
"Infantile-onset Pompe disease patients with compromised cardiac or respiratory function may be at risk of serious acute exacerbation of their cardiac or respiratory compromise due to fluid overload, and require additional monitoring   [see Warnings and Precautions (5.3)]  .",acute exacerbation of cardiac compromise is an adverse reaction entity
"Infantile-onset Pompe disease patients with compromised cardiac or respiratory function may be at risk of serious acute exacerbation of their cardiac or respiratory compromise due to fluid overload, and require additional monitoring   [see Warnings and Precautions (5.3)]  .",acute exacerbation of respiratory compromise is an adverse reaction entity
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",increased blood pressure is an adverse reaction entity
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",in clinical is not a named entity
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",", pallor is not a named entity"
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",reactions is not a named entity
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",clinical trials were is not a named entity
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",", decreased is not a named entity"
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",cough is an adverse reaction entity
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).","headache , is not a named entity"
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).","urticaria , is not a named entity"
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",pallor is an adverse reaction entity
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",headache is an adverse reaction entity
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",hypersensitivity reactions is an adverse reaction entity
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",: is not a named entity
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",tachypnea is an adverse reaction entity
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",pyrexia is an adverse reaction entity
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",", rigors , is not a named entity"
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",hypertension is an adverse reaction entity
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).","erythema , is not a named entity"
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",% ) is not a named entity
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",hyperhidrosis is an adverse reaction entity
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",myalgia is an adverse reaction entity
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",erythema is an adverse reaction entity
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",", is not a named entity"
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",", decreased is not a named entity"
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",frequently reported adverse is not a named entity
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",ADVERSE is not a named entity
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",> = 5 is not a named entity
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",decreased oxygen saturation is an adverse reaction entity
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",feeling hot is an adverse reaction entity
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",tremor is an adverse reaction entity
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",", is not a named entity"
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",flushing is an adverse reaction entity
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).","hot , is not a named entity"
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",* The is not a named entity
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",agitation is an adverse reaction entity
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",nausea is an adverse reaction entity
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",cyanosis is an adverse reaction entity
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",: anaphylaxis is not a named entity
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",tachycardia is an adverse reaction entity
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",muscle twitching is an adverse reaction entity
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",EXCERPT : is not a named entity
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",fatigue is an adverse reaction entity
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).","chest discomfort , is not a named entity"
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",: is not a named entity
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",= is not a named entity
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).","oxygen saturation , is not a named entity"
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",urticaria is an adverse reaction entity
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",dizziness is an adverse reaction entity
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).","muscle twitching , is not a named entity"
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",chest discomfort is an adverse reaction entity
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",", tremor is not a named entity"
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",rash is an adverse reaction entity
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",rigors is an adverse reaction entity
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",vomiting is an adverse reaction entity
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",myalgia ( 6.1 is not a named entity
"6 ADVERSE REACTIONS     EXCERPT:    *  The most frequently reported adverse reactions (>= 5%) in clinical trials were hypersensitivity reactions and included: anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia (6.1).",anaphylaxis is an adverse reaction entity
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",hypersensitivity reactions is an adverse reaction entity
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",increased blood pressure is an adverse reaction entity
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",", agitation , is not a named entity"
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",", is not a named entity"
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",pyrexia is an adverse reaction entity
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",", decreased is not a named entity"
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",erythema is an adverse reaction entity
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",reactions is not a named entity
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",clinical trials is not a named entity
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",", is not a named entity"
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.","cough , decreased is not a named entity"
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.","nausea , cough is not a named entity"
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",blood pressure is not a named entity
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",tachycardia is an adverse reaction entity
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",nausea is an adverse reaction entity
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",hyperhidrosis is an adverse reaction entity
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",myalgia is an adverse reaction entity
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.","agitation , cyanosis is not a named entity"
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",", vomiting is not a named entity"
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.","muscle twitching , is not a named entity"
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",adverse reactions ( is not a named entity
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",", cough , is not a named entity"
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",urticaria is an adverse reaction entity
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",cough is an adverse reaction entity
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",tremor is an adverse reaction entity
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",", is not a named entity"
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",chest discomfort is an adverse reaction entity
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",decreased oxygen saturation is an adverse reaction entity
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",the most is not a named entity
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",muscle twitching is an adverse reaction entity
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",hypertension is an adverse reaction entity
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",reactions is not a named entity
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",cyanosis is an adverse reaction entity
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",rash is an adverse reaction entity
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",rigors is an adverse reaction entity
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",tachypnea is an adverse reaction entity
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",", pyrexia , is not a named entity"
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",fatigue is an adverse reaction entity
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",vomiting is an adverse reaction entity
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",) following alglucosidase is not a named entity
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",agitation is an adverse reaction entity
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",", tachycardia , is not a named entity"
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",= is not a named entity
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",", tachycardia , is not a named entity"
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",flushing is an adverse reaction entity
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.","urticaria , is not a named entity"
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",headache is an adverse reaction entity
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",feeling hot is an adverse reaction entity
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",anaphylaxis is an adverse reaction entity
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",In clinical trials is not a named entity
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",", is not a named entity"
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",pallor is an adverse reaction entity
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.","hyperhidrosis , is not a named entity"
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.","headache , is not a named entity"
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",dizziness is an adverse reaction entity
"In clinical trials, the most common adverse reactions (>= 5%) following alglucosidase alfa treatment were hypersensitivity reactions, and included anaphylaxis, rash, pyrexia, flushing/feeling hot, urticaria, headache, hyperhidrosis, nausea, cough, decreased oxygen saturation, tachycardia, tachypnea, chest discomfort, dizziness, muscle twitching, agitation, cyanosis, erythema, hypertension/increased blood pressure, pallor, rigors, tremor, vomiting, fatigue, and myalgia.",and included is not a named entity
"The most common adverse reactions (>= 3%; 2 or more patients) observed in alglucosidase alfa-treated patients were hypersensitivity reactions and included anaphylaxis, headache, nausea, urticaria, dizziness, chest discomfort, vomiting, hyperhidrosis, flushing/feeling hot, increased blood pressure, paresthesia, pyrexia, local swelling, diarrhea, pruritus, rash, and throat tightness.","rash , and is not a named entity"
"The most common adverse reactions (>= 3%; 2 or more patients) observed in alglucosidase alfa-treated patients were hypersensitivity reactions and included anaphylaxis, headache, nausea, urticaria, dizziness, chest discomfort, vomiting, hyperhidrosis, flushing/feeling hot, increased blood pressure, paresthesia, pyrexia, local swelling, diarrhea, pruritus, rash, and throat tightness.","hot , increased is not a named entity"
"The most common adverse reactions (>= 3%; 2 or more patients) observed in alglucosidase alfa-treated patients were hypersensitivity reactions and included anaphylaxis, headache, nausea, urticaria, dizziness, chest discomfort, vomiting, hyperhidrosis, flushing/feeling hot, increased blood pressure, paresthesia, pyrexia, local swelling, diarrhea, pruritus, rash, and throat tightness.",", flushing/feeling hot is not a named entity"
"The most common adverse reactions (>= 3%; 2 or more patients) observed in alglucosidase alfa-treated patients were hypersensitivity reactions and included anaphylaxis, headache, nausea, urticaria, dizziness, chest discomfort, vomiting, hyperhidrosis, flushing/feeling hot, increased blood pressure, paresthesia, pyrexia, local swelling, diarrhea, pruritus, rash, and throat tightness.",hypersensitivity reactions is an adverse reaction entity
"The most common adverse reactions (>= 3%; 2 or more patients) observed in alglucosidase alfa-treated patients were hypersensitivity reactions and included anaphylaxis, headache, nausea, urticaria, dizziness, chest discomfort, vomiting, hyperhidrosis, flushing/feeling hot, increased blood pressure, paresthesia, pyrexia, local swelling, diarrhea, pruritus, rash, and throat tightness.",pruritus is an adverse reaction entity
"The most common adverse reactions (>= 3%; 2 or more patients) observed in alglucosidase alfa-treated patients were hypersensitivity reactions and included anaphylaxis, headache, nausea, urticaria, dizziness, chest discomfort, vomiting, hyperhidrosis, flushing/feeling hot, increased blood pressure, paresthesia, pyrexia, local swelling, diarrhea, pruritus, rash, and throat tightness.",more patients ) is not a named entity
"The most common adverse reactions (>= 3%; 2 or more patients) observed in alglucosidase alfa-treated patients were hypersensitivity reactions and included anaphylaxis, headache, nausea, urticaria, dizziness, chest discomfort, vomiting, hyperhidrosis, flushing/feeling hot, increased blood pressure, paresthesia, pyrexia, local swelling, diarrhea, pruritus, rash, and throat tightness.",feeling hot is an adverse reaction entity
"The most common adverse reactions (>= 3%; 2 or more patients) observed in alglucosidase alfa-treated patients were hypersensitivity reactions and included anaphylaxis, headache, nausea, urticaria, dizziness, chest discomfort, vomiting, hyperhidrosis, flushing/feeling hot, increased blood pressure, paresthesia, pyrexia, local swelling, diarrhea, pruritus, rash, and throat tightness.",pyrexia is an adverse reaction entity
"The most common adverse reactions (>= 3%; 2 or more patients) observed in alglucosidase alfa-treated patients were hypersensitivity reactions and included anaphylaxis, headache, nausea, urticaria, dizziness, chest discomfort, vomiting, hyperhidrosis, flushing/feeling hot, increased blood pressure, paresthesia, pyrexia, local swelling, diarrhea, pruritus, rash, and throat tightness.",hyperhidrosis is an adverse reaction entity
"The most common adverse reactions (>= 3%; 2 or more patients) observed in alglucosidase alfa-treated patients were hypersensitivity reactions and included anaphylaxis, headache, nausea, urticaria, dizziness, chest discomfort, vomiting, hyperhidrosis, flushing/feeling hot, increased blood pressure, paresthesia, pyrexia, local swelling, diarrhea, pruritus, rash, and throat tightness.",throat tightness is an adverse reaction entity
"The most common adverse reactions (>= 3%; 2 or more patients) observed in alglucosidase alfa-treated patients were hypersensitivity reactions and included anaphylaxis, headache, nausea, urticaria, dizziness, chest discomfort, vomiting, hyperhidrosis, flushing/feeling hot, increased blood pressure, paresthesia, pyrexia, local swelling, diarrhea, pruritus, rash, and throat tightness.",in is not a named entity
"The most common adverse reactions (>= 3%; 2 or more patients) observed in alglucosidase alfa-treated patients were hypersensitivity reactions and included anaphylaxis, headache, nausea, urticaria, dizziness, chest discomfort, vomiting, hyperhidrosis, flushing/feeling hot, increased blood pressure, paresthesia, pyrexia, local swelling, diarrhea, pruritus, rash, and throat tightness.",headache is an adverse reaction entity
"The most common adverse reactions (>= 3%; 2 or more patients) observed in alglucosidase alfa-treated patients were hypersensitivity reactions and included anaphylaxis, headache, nausea, urticaria, dizziness, chest discomfort, vomiting, hyperhidrosis, flushing/feeling hot, increased blood pressure, paresthesia, pyrexia, local swelling, diarrhea, pruritus, rash, and throat tightness.",swelling is not a named entity
"The most common adverse reactions (>= 3%; 2 or more patients) observed in alglucosidase alfa-treated patients were hypersensitivity reactions and included anaphylaxis, headache, nausea, urticaria, dizziness, chest discomfort, vomiting, hyperhidrosis, flushing/feeling hot, increased blood pressure, paresthesia, pyrexia, local swelling, diarrhea, pruritus, rash, and throat tightness.",urticaria is an adverse reaction entity
"The most common adverse reactions (>= 3%; 2 or more patients) observed in alglucosidase alfa-treated patients were hypersensitivity reactions and included anaphylaxis, headache, nausea, urticaria, dizziness, chest discomfort, vomiting, hyperhidrosis, flushing/feeling hot, increased blood pressure, paresthesia, pyrexia, local swelling, diarrhea, pruritus, rash, and throat tightness.",", rash , is not a named entity"
"The most common adverse reactions (>= 3%; 2 or more patients) observed in alglucosidase alfa-treated patients were hypersensitivity reactions and included anaphylaxis, headache, nausea, urticaria, dizziness, chest discomfort, vomiting, hyperhidrosis, flushing/feeling hot, increased blood pressure, paresthesia, pyrexia, local swelling, diarrhea, pruritus, rash, and throat tightness.",local swelling is an adverse reaction entity
"The most common adverse reactions (>= 3%; 2 or more patients) observed in alglucosidase alfa-treated patients were hypersensitivity reactions and included anaphylaxis, headache, nausea, urticaria, dizziness, chest discomfort, vomiting, hyperhidrosis, flushing/feeling hot, increased blood pressure, paresthesia, pyrexia, local swelling, diarrhea, pruritus, rash, and throat tightness.",or more is not a named entity
"The most common adverse reactions (>= 3%; 2 or more patients) observed in alglucosidase alfa-treated patients were hypersensitivity reactions and included anaphylaxis, headache, nausea, urticaria, dizziness, chest discomfort, vomiting, hyperhidrosis, flushing/feeling hot, increased blood pressure, paresthesia, pyrexia, local swelling, diarrhea, pruritus, rash, and throat tightness.",nausea is an adverse reaction entity
"The most common adverse reactions (>= 3%; 2 or more patients) observed in alglucosidase alfa-treated patients were hypersensitivity reactions and included anaphylaxis, headache, nausea, urticaria, dizziness, chest discomfort, vomiting, hyperhidrosis, flushing/feeling hot, increased blood pressure, paresthesia, pyrexia, local swelling, diarrhea, pruritus, rash, and throat tightness.",observed is not a named entity
"The most common adverse reactions (>= 3%; 2 or more patients) observed in alglucosidase alfa-treated patients were hypersensitivity reactions and included anaphylaxis, headache, nausea, urticaria, dizziness, chest discomfort, vomiting, hyperhidrosis, flushing/feeling hot, increased blood pressure, paresthesia, pyrexia, local swelling, diarrhea, pruritus, rash, and throat tightness.",chest discomfort is an adverse reaction entity
"The most common adverse reactions (>= 3%; 2 or more patients) observed in alglucosidase alfa-treated patients were hypersensitivity reactions and included anaphylaxis, headache, nausea, urticaria, dizziness, chest discomfort, vomiting, hyperhidrosis, flushing/feeling hot, increased blood pressure, paresthesia, pyrexia, local swelling, diarrhea, pruritus, rash, and throat tightness.",", pyrexia , is not a named entity"
"The most common adverse reactions (>= 3%; 2 or more patients) observed in alglucosidase alfa-treated patients were hypersensitivity reactions and included anaphylaxis, headache, nausea, urticaria, dizziness, chest discomfort, vomiting, hyperhidrosis, flushing/feeling hot, increased blood pressure, paresthesia, pyrexia, local swelling, diarrhea, pruritus, rash, and throat tightness.",% ; is not a named entity
"The most common adverse reactions (>= 3%; 2 or more patients) observed in alglucosidase alfa-treated patients were hypersensitivity reactions and included anaphylaxis, headache, nausea, urticaria, dizziness, chest discomfort, vomiting, hyperhidrosis, flushing/feeling hot, increased blood pressure, paresthesia, pyrexia, local swelling, diarrhea, pruritus, rash, and throat tightness.",flushing is an adverse reaction entity
"The most common adverse reactions (>= 3%; 2 or more patients) observed in alglucosidase alfa-treated patients were hypersensitivity reactions and included anaphylaxis, headache, nausea, urticaria, dizziness, chest discomfort, vomiting, hyperhidrosis, flushing/feeling hot, increased blood pressure, paresthesia, pyrexia, local swelling, diarrhea, pruritus, rash, and throat tightness.",", diarrhea , is not a named entity"
"The most common adverse reactions (>= 3%; 2 or more patients) observed in alglucosidase alfa-treated patients were hypersensitivity reactions and included anaphylaxis, headache, nausea, urticaria, dizziness, chest discomfort, vomiting, hyperhidrosis, flushing/feeling hot, increased blood pressure, paresthesia, pyrexia, local swelling, diarrhea, pruritus, rash, and throat tightness.",vomiting is an adverse reaction entity
"The most common adverse reactions (>= 3%; 2 or more patients) observed in alglucosidase alfa-treated patients were hypersensitivity reactions and included anaphylaxis, headache, nausea, urticaria, dizziness, chest discomfort, vomiting, hyperhidrosis, flushing/feeling hot, increased blood pressure, paresthesia, pyrexia, local swelling, diarrhea, pruritus, rash, and throat tightness.","included anaphylaxis , is not a named entity"
"The most common adverse reactions (>= 3%; 2 or more patients) observed in alglucosidase alfa-treated patients were hypersensitivity reactions and included anaphylaxis, headache, nausea, urticaria, dizziness, chest discomfort, vomiting, hyperhidrosis, flushing/feeling hot, increased blood pressure, paresthesia, pyrexia, local swelling, diarrhea, pruritus, rash, and throat tightness.",dizziness is an adverse reaction entity
"The most common adverse reactions (>= 3%; 2 or more patients) observed in alglucosidase alfa-treated patients were hypersensitivity reactions and included anaphylaxis, headache, nausea, urticaria, dizziness, chest discomfort, vomiting, hyperhidrosis, flushing/feeling hot, increased blood pressure, paresthesia, pyrexia, local swelling, diarrhea, pruritus, rash, and throat tightness.",anaphylaxis is an adverse reaction entity
"The most common adverse reactions (>= 3%; 2 or more patients) observed in alglucosidase alfa-treated patients were hypersensitivity reactions and included anaphylaxis, headache, nausea, urticaria, dizziness, chest discomfort, vomiting, hyperhidrosis, flushing/feeling hot, increased blood pressure, paresthesia, pyrexia, local swelling, diarrhea, pruritus, rash, and throat tightness.",", is not a named entity"
"The most common adverse reactions (>= 3%; 2 or more patients) observed in alglucosidase alfa-treated patients were hypersensitivity reactions and included anaphylaxis, headache, nausea, urticaria, dizziness, chest discomfort, vomiting, hyperhidrosis, flushing/feeling hot, increased blood pressure, paresthesia, pyrexia, local swelling, diarrhea, pruritus, rash, and throat tightness.",diarrhea is an adverse reaction entity
"The most common adverse reactions (>= 3%; 2 or more patients) observed in alglucosidase alfa-treated patients were hypersensitivity reactions and included anaphylaxis, headache, nausea, urticaria, dizziness, chest discomfort, vomiting, hyperhidrosis, flushing/feeling hot, increased blood pressure, paresthesia, pyrexia, local swelling, diarrhea, pruritus, rash, and throat tightness.",rash is an adverse reaction entity
"The most common adverse reactions (>= 3%; 2 or more patients) observed in alglucosidase alfa-treated patients were hypersensitivity reactions and included anaphylaxis, headache, nausea, urticaria, dizziness, chest discomfort, vomiting, hyperhidrosis, flushing/feeling hot, increased blood pressure, paresthesia, pyrexia, local swelling, diarrhea, pruritus, rash, and throat tightness.",increased blood pressure is an adverse reaction entity
"The most common adverse reactions (>= 3%; 2 or more patients) observed in alglucosidase alfa-treated patients were hypersensitivity reactions and included anaphylaxis, headache, nausea, urticaria, dizziness, chest discomfort, vomiting, hyperhidrosis, flushing/feeling hot, increased blood pressure, paresthesia, pyrexia, local swelling, diarrhea, pruritus, rash, and throat tightness.",reactions is not a named entity
"The most common adverse reactions (>= 3%; 2 or more patients) observed in alglucosidase alfa-treated patients were hypersensitivity reactions and included anaphylaxis, headache, nausea, urticaria, dizziness, chest discomfort, vomiting, hyperhidrosis, flushing/feeling hot, increased blood pressure, paresthesia, pyrexia, local swelling, diarrhea, pruritus, rash, and throat tightness.",paresthesia is an adverse reaction entity
"The most common adverse reactions (>= 3%; 2 or more patients) observed in alglucosidase alfa-treated patients were hypersensitivity reactions and included anaphylaxis, headache, nausea, urticaria, dizziness, chest discomfort, vomiting, hyperhidrosis, flushing/feeling hot, increased blood pressure, paresthesia, pyrexia, local swelling, diarrhea, pruritus, rash, and throat tightness.",more patients ) is not a named entity
"The most common adverse reactions (>= 3%; 2 or more patients) observed in alglucosidase alfa-treated patients were hypersensitivity reactions and included anaphylaxis, headache, nausea, urticaria, dizziness, chest discomfort, vomiting, hyperhidrosis, flushing/feeling hot, increased blood pressure, paresthesia, pyrexia, local swelling, diarrhea, pruritus, rash, and throat tightness.",adverse reactions is not a named entity
"The most common adverse reactions (>= 3%; 2 or more patients) observed in alglucosidase alfa-treated patients were hypersensitivity reactions and included anaphylaxis, headache, nausea, urticaria, dizziness, chest discomfort, vomiting, hyperhidrosis, flushing/feeling hot, increased blood pressure, paresthesia, pyrexia, local swelling, diarrhea, pruritus, rash, and throat tightness.",", pyrexia is not a named entity"
"The most common adverse reactions (>= 3%; 2 or more patients) observed in alglucosidase alfa-treated patients were hypersensitivity reactions and included anaphylaxis, headache, nausea, urticaria, dizziness, chest discomfort, vomiting, hyperhidrosis, flushing/feeling hot, increased blood pressure, paresthesia, pyrexia, local swelling, diarrhea, pruritus, rash, and throat tightness.","local swelling , is not a named entity"
"Acute cardiorespiratory failure, possibly associated with fluid overload, has been reported in infantile-onset Pompe disease patients with pre-existing hypertrophic cardiomyopathy  [seeBoxed WarningandWarning and Precautions (5.3)].",fluid overload is an adverse reaction entity
"Acute cardiorespiratory failure, possibly associated with fluid overload, has been reported in infantile-onset Pompe disease patients with pre-existing hypertrophic cardiomyopathy  [seeBoxed WarningandWarning and Precautions (5.3)].",Acute cardiorespiratory failure is an adverse reaction entity
"Acute cardiorespiratory failure, possibly associated with fluid overload, has been reported in infantile-onset Pompe disease patients with pre-existing hypertrophic cardiomyopathy  [seeBoxed WarningandWarning and Precautions (5.3)].",Pompe is not a named entity
"Acute cardiorespiratory failure, possibly associated with fluid overload, has been reported in infantile-onset Pompe disease patients with pre-existing hypertrophic cardiomyopathy  [seeBoxed WarningandWarning and Precautions (5.3)].",] is not a named entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",bronchospasm is an adverse reaction entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.","hypotension , is not a named entity"
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",cardiac arrest is an adverse reaction entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",respiratory arrest is an adverse reaction entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",( including is not a named entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",face edema is an adverse reaction entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",hypoxia is an adverse reaction entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",of is not a named entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",angioedema is an adverse reaction entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",", cardiac is not a named entity"
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",edema is not a named entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",were life-threatening and is not a named entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",cardiac arrest is an adverse reaction entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.","arrest , respiratory is not a named entity"
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",", angioedema ( is not a named entity"
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",hypotension is an adverse reaction entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",Some of is not a named entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",urticaria is an adverse reaction entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",", is not a named entity"
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",", dyspnea is not a named entity"
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",face edema is an adverse reaction entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",dyspnea is an adverse reaction entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.","bronchospasm , throat is not a named entity"
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",hypotension is an adverse reaction entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.","swelling , periorbital is not a named entity"
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",respiratory arrest is an adverse reaction entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.","lip swelling , is not a named entity"
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",", respiratory is not a named entity"
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",apnea is an adverse reaction entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.","cardiac arrest , is not a named entity"
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",periorbital edema is an adverse reaction entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",dyspnea is an adverse reaction entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",", periorbital is not a named entity"
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",", respiratory is not a named entity"
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",tachycardia is an adverse reaction entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",angioedema ( including is not a named entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",respiratory distress is an adverse reaction entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.","distress , hypoxia is not a named entity"
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",tachycardia is an adverse reaction entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",were life-threatening and is not a named entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",", respiratory is not a named entity"
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",tongue swelling is an adverse reaction entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.","distress , hypoxia is not a named entity"
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",periorbital edema is an adverse reaction entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",and included anaphylactic is not a named entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",angioedema ( is not a named entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",angioedema is an adverse reaction entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.","dyspnea , is not a named entity"
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",respiratory distress is an adverse reaction entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",lip swelling is an adverse reaction entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",bradycardia is an adverse reaction entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",", throat is not a named entity"
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",throat tightness is an adverse reaction entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",throat tightness is an adverse reaction entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",lip swelling is an adverse reaction entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",hypoxia is an adverse reaction entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.","swelling , periorbital is not a named entity"
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",tongue swelling is an adverse reaction entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",anaphylactic shock is an adverse reaction entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",bronchospasm is an adverse reaction entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",", and face is not a named entity"
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",apnea is an adverse reaction entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",bradycardia is an adverse reaction entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",", tachycardia , is not a named entity"
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",", bronchospasm is not a named entity"
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",anaphylactic shock is an adverse reaction entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.","apnea , dyspnea is not a named entity"
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",urticaria is an adverse reaction entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",including tongue or is not a named entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",life-threatening and included is not a named entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",life-threatening and is not a named entity
"Some of the reactions were life-threatening and included anaphylactic shock, cardiac arrest, respiratory arrest, respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria.",reactions were life-threatening is not a named entity
Nephrotic syndrome secondary to membranous glomerulonephritis was observed in some Pompe disease patients treated with alglucosidase alfa who had persistently positive anti-rhGAA IgG antibody titers.,membranous glomerulonephritis is an adverse reaction entity
Nephrotic syndrome secondary to membranous glomerulonephritis was observed in some Pompe disease patients treated with alglucosidase alfa who had persistently positive anti-rhGAA IgG antibody titers.,patients treated with is not a named entity
Nephrotic syndrome secondary to membranous glomerulonephritis was observed in some Pompe disease patients treated with alglucosidase alfa who had persistently positive anti-rhGAA IgG antibody titers.,Pompe disease patients is not a named entity
Nephrotic syndrome secondary to membranous glomerulonephritis was observed in some Pompe disease patients treated with alglucosidase alfa who had persistently positive anti-rhGAA IgG antibody titers.,disease patients treated is not a named entity
Nephrotic syndrome secondary to membranous glomerulonephritis was observed in some Pompe disease patients treated with alglucosidase alfa who had persistently positive anti-rhGAA IgG antibody titers.,positive anti-rhGAA IgG antibody titers is an adverse reaction entity
Nephrotic syndrome secondary to membranous glomerulonephritis was observed in some Pompe disease patients treated with alglucosidase alfa who had persistently positive anti-rhGAA IgG antibody titers.,Nephrotic syndrome is an adverse reaction entity
"Among the 290 patients included in the safety evaluation of VORAXAZE, there were 8 deaths within 30 days of VORAXAZE exposure that were not related to progressive disease.",deaths is an adverse reaction entity
"Among the 290 patients included in the safety evaluation of VORAXAZE, there were 8 deaths within 30 days of VORAXAZE exposure that were not related to progressive disease.",were 8 is not a named entity
"EXCERPT:   In clinical trials, the most common related adverse events (occurring in >1% of patients) were paraesthesia, flushing, nausea and/or vomiting, hypotension and headache.",1 is not a named entity
"EXCERPT:   In clinical trials, the most common related adverse events (occurring in >1% of patients) were paraesthesia, flushing, nausea and/or vomiting, hypotension and headache.",: In clinical is not a named entity
"EXCERPT:   In clinical trials, the most common related adverse events (occurring in >1% of patients) were paraesthesia, flushing, nausea and/or vomiting, hypotension and headache.",vomiting is an adverse reaction entity
"EXCERPT:   In clinical trials, the most common related adverse events (occurring in >1% of patients) were paraesthesia, flushing, nausea and/or vomiting, hypotension and headache.",hypotension is an adverse reaction entity
"EXCERPT:   In clinical trials, the most common related adverse events (occurring in >1% of patients) were paraesthesia, flushing, nausea and/or vomiting, hypotension and headache.","flushing , nausea is not a named entity"
"EXCERPT:   In clinical trials, the most common related adverse events (occurring in >1% of patients) were paraesthesia, flushing, nausea and/or vomiting, hypotension and headache.",paraesthesia is an adverse reaction entity
"EXCERPT:   In clinical trials, the most common related adverse events (occurring in >1% of patients) were paraesthesia, flushing, nausea and/or vomiting, hypotension and headache.",In clinical trials is not a named entity
"EXCERPT:   In clinical trials, the most common related adverse events (occurring in >1% of patients) were paraesthesia, flushing, nausea and/or vomiting, hypotension and headache.",headache is an adverse reaction entity
"EXCERPT:   In clinical trials, the most common related adverse events (occurring in >1% of patients) were paraesthesia, flushing, nausea and/or vomiting, hypotension and headache.","were paraesthesia , is not a named entity"
"EXCERPT:   In clinical trials, the most common related adverse events (occurring in >1% of patients) were paraesthesia, flushing, nausea and/or vomiting, hypotension and headache.",nausea is an adverse reaction entity
"EXCERPT:   In clinical trials, the most common related adverse events (occurring in >1% of patients) were paraesthesia, flushing, nausea and/or vomiting, hypotension and headache.",flushing is an adverse reaction entity
"EXCERPT:   In clinical trials, the most common related adverse events (occurring in >1% of patients) were paraesthesia, flushing, nausea and/or vomiting, hypotension and headache.",: In is not a named entity
"5        WARNINGS AND PRECAUTIONS       EXCERPT:    *  Serious allergic reactions, including anaphylactic reactions, may occur.",: * Serious is not a named entity
"5        WARNINGS AND PRECAUTIONS       EXCERPT:    *  Serious allergic reactions, including anaphylactic reactions, may occur.",AND PRECAUTIONS is not a named entity
"5        WARNINGS AND PRECAUTIONS       EXCERPT:    *  Serious allergic reactions, including anaphylactic reactions, may occur.",anaphylactic reactions is an adverse reaction entity
"5        WARNINGS AND PRECAUTIONS       EXCERPT:    *  Serious allergic reactions, including anaphylactic reactions, may occur.",allergic reactions is an adverse reaction entity
"The most common adverse reactions (incidence >1%) with VORAXAZE are paraesthesias, flushing, nausea and/or vomiting, hypotension, and headache.",flushing is an adverse reaction entity
"The most common adverse reactions (incidence >1%) with VORAXAZE are paraesthesias, flushing, nausea and/or vomiting, hypotension, and headache.","paraesthesias , flushing is not a named entity"
"The most common adverse reactions (incidence >1%) with VORAXAZE are paraesthesias, flushing, nausea and/or vomiting, hypotension, and headache.",", is not a named entity"
"The most common adverse reactions (incidence >1%) with VORAXAZE are paraesthesias, flushing, nausea and/or vomiting, hypotension, and headache.",adverse is not a named entity
"The most common adverse reactions (incidence >1%) with VORAXAZE are paraesthesias, flushing, nausea and/or vomiting, hypotension, and headache.",hypotension is an adverse reaction entity
"The most common adverse reactions (incidence >1%) with VORAXAZE are paraesthesias, flushing, nausea and/or vomiting, hypotension, and headache.",vomiting is an adverse reaction entity
"The most common adverse reactions (incidence >1%) with VORAXAZE are paraesthesias, flushing, nausea and/or vomiting, hypotension, and headache.",headache is an adverse reaction entity
"The most common adverse reactions (incidence >1%) with VORAXAZE are paraesthesias, flushing, nausea and/or vomiting, hypotension, and headache.","flushing , is not a named entity"
"The most common adverse reactions (incidence >1%) with VORAXAZE are paraesthesias, flushing, nausea and/or vomiting, hypotension, and headache.",nausea is an adverse reaction entity
"The most common adverse reactions (incidence >1%) with VORAXAZE are paraesthesias, flushing, nausea and/or vomiting, hypotension, and headache.","vomiting , is not a named entity"
"The most common adverse reactions (incidence >1%) with VORAXAZE are paraesthesias, flushing, nausea and/or vomiting, hypotension, and headache.",paraesthesias is an adverse reaction entity
"The most common adverse reactions (incidence >1%) with VORAXAZE are paraesthesias, flushing, nausea and/or vomiting, hypotension, and headache.",) is not a named entity
(  5.3  )             5.1     Serious Allergic Reactions      Serious allergic reactions occurred in less than 1% of patients [ see Adverse Reactions (  6.1  )  ].,5.1 Serious is not a named entity
(  5.3  )             5.1     Serious Allergic Reactions      Serious allergic reactions occurred in less than 1% of patients [ see Adverse Reactions (  6.1  )  ].,allergic reactions is an adverse reaction entity
Discontinuation from study due to genital infection occurred in 0% of placebo-treated patients and 0.2% of patients treated with either JARDIANCE 10 or 25 mg.,placebo-treated is not a named entity
Discontinuation from study due to genital infection occurred in 0% of placebo-treated patients and 0.2% of patients treated with either JARDIANCE 10 or 25 mg.,genital infection is an adverse reaction entity
"In the pool of five placebo-controlled clinical trials, adverse reactions related to volume depletion (e.g., blood pressure (ambulatory) decreased, blood pressure systolic decreased, dehydration, hypotension, hypovolemia, orthostatic hypotension, and syncope) were reported by 0.3%, 0.5%, and 0.3% of patients treated with placebo, JARDIANCE 10 mg, and JARDIANCE 25 mg respectively.","mg , and is not a named entity"
"In the pool of five placebo-controlled clinical trials, adverse reactions related to volume depletion (e.g., blood pressure (ambulatory) decreased, blood pressure systolic decreased, dehydration, hypotension, hypovolemia, orthostatic hypotension, and syncope) were reported by 0.3%, 0.5%, and 0.3% of patients treated with placebo, JARDIANCE 10 mg, and JARDIANCE 25 mg respectively.",to is not a named entity
"In the pool of five placebo-controlled clinical trials, adverse reactions related to volume depletion (e.g., blood pressure (ambulatory) decreased, blood pressure systolic decreased, dehydration, hypotension, hypovolemia, orthostatic hypotension, and syncope) were reported by 0.3%, 0.5%, and 0.3% of patients treated with placebo, JARDIANCE 10 mg, and JARDIANCE 25 mg respectively.",patients treated is not a named entity
"In the pool of five placebo-controlled clinical trials, adverse reactions related to volume depletion (e.g., blood pressure (ambulatory) decreased, blood pressure systolic decreased, dehydration, hypotension, hypovolemia, orthostatic hypotension, and syncope) were reported by 0.3%, 0.5%, and 0.3% of patients treated with placebo, JARDIANCE 10 mg, and JARDIANCE 25 mg respectively.",", hypovolemia , is not a named entity"
"In the pool of five placebo-controlled clinical trials, adverse reactions related to volume depletion (e.g., blood pressure (ambulatory) decreased, blood pressure systolic decreased, dehydration, hypotension, hypovolemia, orthostatic hypotension, and syncope) were reported by 0.3%, 0.5%, and 0.3% of patients treated with placebo, JARDIANCE 10 mg, and JARDIANCE 25 mg respectively.",dehydration is an adverse reaction entity
"In the pool of five placebo-controlled clinical trials, adverse reactions related to volume depletion (e.g., blood pressure (ambulatory) decreased, blood pressure systolic decreased, dehydration, hypotension, hypovolemia, orthostatic hypotension, and syncope) were reported by 0.3%, 0.5%, and 0.3% of patients treated with placebo, JARDIANCE 10 mg, and JARDIANCE 25 mg respectively.",systolic is not a named entity
"In the pool of five placebo-controlled clinical trials, adverse reactions related to volume depletion (e.g., blood pressure (ambulatory) decreased, blood pressure systolic decreased, dehydration, hypotension, hypovolemia, orthostatic hypotension, and syncope) were reported by 0.3%, 0.5%, and 0.3% of patients treated with placebo, JARDIANCE 10 mg, and JARDIANCE 25 mg respectively.",syncope ) is not a named entity
"In the pool of five placebo-controlled clinical trials, adverse reactions related to volume depletion (e.g., blood pressure (ambulatory) decreased, blood pressure systolic decreased, dehydration, hypotension, hypovolemia, orthostatic hypotension, and syncope) were reported by 0.3%, 0.5%, and 0.3% of patients treated with placebo, JARDIANCE 10 mg, and JARDIANCE 25 mg respectively.",blood pressure systolic decreased is an adverse reaction entity
"In the pool of five placebo-controlled clinical trials, adverse reactions related to volume depletion (e.g., blood pressure (ambulatory) decreased, blood pressure systolic decreased, dehydration, hypotension, hypovolemia, orthostatic hypotension, and syncope) were reported by 0.3%, 0.5%, and 0.3% of patients treated with placebo, JARDIANCE 10 mg, and JARDIANCE 25 mg respectively.",blood pressure decreased is an adverse reaction entity
"In the pool of five placebo-controlled clinical trials, adverse reactions related to volume depletion (e.g., blood pressure (ambulatory) decreased, blood pressure systolic decreased, dehydration, hypotension, hypovolemia, orthostatic hypotension, and syncope) were reported by 0.3%, 0.5%, and 0.3% of patients treated with placebo, JARDIANCE 10 mg, and JARDIANCE 25 mg respectively.",hypovolemia is an adverse reaction entity
"In the pool of five placebo-controlled clinical trials, adverse reactions related to volume depletion (e.g., blood pressure (ambulatory) decreased, blood pressure systolic decreased, dehydration, hypotension, hypovolemia, orthostatic hypotension, and syncope) were reported by 0.3%, 0.5%, and 0.3% of patients treated with placebo, JARDIANCE 10 mg, and JARDIANCE 25 mg respectively.",orthostatic hypotension is an adverse reaction entity
"In the pool of five placebo-controlled clinical trials, adverse reactions related to volume depletion (e.g., blood pressure (ambulatory) decreased, blood pressure systolic decreased, dehydration, hypotension, hypovolemia, orthostatic hypotension, and syncope) were reported by 0.3%, 0.5%, and 0.3% of patients treated with placebo, JARDIANCE 10 mg, and JARDIANCE 25 mg respectively.",volume depletion is an adverse reaction entity
"In the pool of five placebo-controlled clinical trials, adverse reactions related to volume depletion (e.g., blood pressure (ambulatory) decreased, blood pressure systolic decreased, dehydration, hypotension, hypovolemia, orthostatic hypotension, and syncope) were reported by 0.3%, 0.5%, and 0.3% of patients treated with placebo, JARDIANCE 10 mg, and JARDIANCE 25 mg respectively.",of patients treated is not a named entity
"In the pool of five placebo-controlled clinical trials, adverse reactions related to volume depletion (e.g., blood pressure (ambulatory) decreased, blood pressure systolic decreased, dehydration, hypotension, hypovolemia, orthostatic hypotension, and syncope) were reported by 0.3%, 0.5%, and 0.3% of patients treated with placebo, JARDIANCE 10 mg, and JARDIANCE 25 mg respectively.",hypotension is an adverse reaction entity
"In the pool of five placebo-controlled clinical trials, adverse reactions related to volume depletion (e.g., blood pressure (ambulatory) decreased, blood pressure systolic decreased, dehydration, hypotension, hypovolemia, orthostatic hypotension, and syncope) were reported by 0.3%, 0.5%, and 0.3% of patients treated with placebo, JARDIANCE 10 mg, and JARDIANCE 25 mg respectively.",syncope is an adverse reaction entity
"In the pool of five placebo-controlled clinical trials, adverse reactions related to volume depletion (e.g., blood pressure (ambulatory) decreased, blood pressure systolic decreased, dehydration, hypotension, hypovolemia, orthostatic hypotension, and syncope) were reported by 0.3%, 0.5%, and 0.3% of patients treated with placebo, JARDIANCE 10 mg, and JARDIANCE 25 mg respectively.",", is not a named entity"
"Specifically, nocturia was reported by 0.4%, 0.3%, and 0.8% of patients treated with placebo, JARDIANCE 10 mg, and JARDIANCE 25 mg, respectively.",nocturia is an adverse reaction entity
"Specifically, nocturia was reported by 0.4%, 0.3%, and 0.8% of patients treated with placebo, JARDIANCE 10 mg, and JARDIANCE 25 mg, respectively.",Specifically is not a named entity
Impairment in Renal Function  Use of JARDIANCE was associated with increases in serum creatinine and decreases in eGFR (see Table 2).,associated with increases is not a named entity
Impairment in Renal Function  Use of JARDIANCE was associated with increases in serum creatinine and decreases in eGFR (see Table 2).,decreases in eGFR is an adverse reaction entity
Impairment in Renal Function  Use of JARDIANCE was associated with increases in serum creatinine and decreases in eGFR (see Table 2).,Use of is not a named entity
Impairment in Renal Function  Use of JARDIANCE was associated with increases in serum creatinine and decreases in eGFR (see Table 2).,in is not a named entity
Impairment in Renal Function  Use of JARDIANCE was associated with increases in serum creatinine and decreases in eGFR (see Table 2).,Impairment in Renal Function is an adverse reaction entity
Impairment in Renal Function  Use of JARDIANCE was associated with increases in serum creatinine and decreases in eGFR (see Table 2).,increases in serum creatinine is an adverse reaction entity
The risk of impaired renal function with JARDIANCE is increased in elderly patients and patients with moderate renal impairment.,moderate renal is not a named entity
The risk of impaired renal function with JARDIANCE is increased in elderly patients and patients with moderate renal impairment.,impaired renal function is an adverse reaction entity
Genital mycotic infections occurred more frequently in female than male patients (see Table 1).,frequently in female is not a named entity
Genital mycotic infections occurred more frequently in female than male patients (see Table 1).,Genital mycotic infections is an adverse reaction entity
(  5.1  )   *   Impairment in renal function: Monitor renal function during therapy.,Impairment in renal function is an adverse reaction entity
(  5.1  )   *   Impairment in renal function: Monitor renal function during therapy.,renal function is not a named entity
"c  Predefined adverse event grouping, including, but not limited to, polyuria, pollakiuria, and nocturia       d  Male genital mycotic infections include the following adverse reactions: balanoposthitis, balanitis, genital infections fungal, genitourinary tract infection, balanitis candida, scrotal abscess, penile infection.",scrotal abscess is an adverse reaction entity
"c  Predefined adverse event grouping, including, but not limited to, polyuria, pollakiuria, and nocturia       d  Male genital mycotic infections include the following adverse reactions: balanoposthitis, balanitis, genital infections fungal, genitourinary tract infection, balanitis candida, scrotal abscess, penile infection.",nocturia is an adverse reaction entity
"c  Predefined adverse event grouping, including, but not limited to, polyuria, pollakiuria, and nocturia       d  Male genital mycotic infections include the following adverse reactions: balanoposthitis, balanitis, genital infections fungal, genitourinary tract infection, balanitis candida, scrotal abscess, penile infection.",limited to is not a named entity
"c  Predefined adverse event grouping, including, but not limited to, polyuria, pollakiuria, and nocturia       d  Male genital mycotic infections include the following adverse reactions: balanoposthitis, balanitis, genital infections fungal, genitourinary tract infection, balanitis candida, scrotal abscess, penile infection.",balanoposthitis is an adverse reaction entity
"c  Predefined adverse event grouping, including, but not limited to, polyuria, pollakiuria, and nocturia       d  Male genital mycotic infections include the following adverse reactions: balanoposthitis, balanitis, genital infections fungal, genitourinary tract infection, balanitis candida, scrotal abscess, penile infection.",polyuria is an adverse reaction entity
"c  Predefined adverse event grouping, including, but not limited to, polyuria, pollakiuria, and nocturia       d  Male genital mycotic infections include the following adverse reactions: balanoposthitis, balanitis, genital infections fungal, genitourinary tract infection, balanitis candida, scrotal abscess, penile infection.",", penile is not a named entity"
"c  Predefined adverse event grouping, including, but not limited to, polyuria, pollakiuria, and nocturia       d  Male genital mycotic infections include the following adverse reactions: balanoposthitis, balanitis, genital infections fungal, genitourinary tract infection, balanitis candida, scrotal abscess, penile infection.","including , but is not a named entity"
"c  Predefined adverse event grouping, including, but not limited to, polyuria, pollakiuria, and nocturia       d  Male genital mycotic infections include the following adverse reactions: balanoposthitis, balanitis, genital infections fungal, genitourinary tract infection, balanitis candida, scrotal abscess, penile infection.",genital infections fungal is an adverse reaction entity
"c  Predefined adverse event grouping, including, but not limited to, polyuria, pollakiuria, and nocturia       d  Male genital mycotic infections include the following adverse reactions: balanoposthitis, balanitis, genital infections fungal, genitourinary tract infection, balanitis candida, scrotal abscess, penile infection.",Predefined is not a named entity
"c  Predefined adverse event grouping, including, but not limited to, polyuria, pollakiuria, and nocturia       d  Male genital mycotic infections include the following adverse reactions: balanoposthitis, balanitis, genital infections fungal, genitourinary tract infection, balanitis candida, scrotal abscess, penile infection.",to is not a named entity
"c  Predefined adverse event grouping, including, but not limited to, polyuria, pollakiuria, and nocturia       d  Male genital mycotic infections include the following adverse reactions: balanoposthitis, balanitis, genital infections fungal, genitourinary tract infection, balanitis candida, scrotal abscess, penile infection.",", and is not a named entity"
"c  Predefined adverse event grouping, including, but not limited to, polyuria, pollakiuria, and nocturia       d  Male genital mycotic infections include the following adverse reactions: balanoposthitis, balanitis, genital infections fungal, genitourinary tract infection, balanitis candida, scrotal abscess, penile infection.",pollakiuria is an adverse reaction entity
"c  Predefined adverse event grouping, including, but not limited to, polyuria, pollakiuria, and nocturia       d  Male genital mycotic infections include the following adverse reactions: balanoposthitis, balanitis, genital infections fungal, genitourinary tract infection, balanitis candida, scrotal abscess, penile infection.",genitourinary tract infection is an adverse reaction entity
"c  Predefined adverse event grouping, including, but not limited to, polyuria, pollakiuria, and nocturia       d  Male genital mycotic infections include the following adverse reactions: balanoposthitis, balanitis, genital infections fungal, genitourinary tract infection, balanitis candida, scrotal abscess, penile infection.",genital mycotic infections is not a named entity
"c  Predefined adverse event grouping, including, but not limited to, polyuria, pollakiuria, and nocturia       d  Male genital mycotic infections include the following adverse reactions: balanoposthitis, balanitis, genital infections fungal, genitourinary tract infection, balanitis candida, scrotal abscess, penile infection.",penile infection is an adverse reaction entity
"c  Predefined adverse event grouping, including, but not limited to, polyuria, pollakiuria, and nocturia       d  Male genital mycotic infections include the following adverse reactions: balanoposthitis, balanitis, genital infections fungal, genitourinary tract infection, balanitis candida, scrotal abscess, penile infection.",balanitis candida is an adverse reaction entity
"c  Predefined adverse event grouping, including, but not limited to, polyuria, pollakiuria, and nocturia       d  Male genital mycotic infections include the following adverse reactions: balanoposthitis, balanitis, genital infections fungal, genitourinary tract infection, balanitis candida, scrotal abscess, penile infection.",balanitis is an adverse reaction entity
"c  Predefined adverse event grouping, including, but not limited to, polyuria, pollakiuria, and nocturia       d  Male genital mycotic infections include the following adverse reactions: balanoposthitis, balanitis, genital infections fungal, genitourinary tract infection, balanitis candida, scrotal abscess, penile infection.",infection is not a named entity
"c  Predefined adverse event grouping, including, but not limited to, polyuria, pollakiuria, and nocturia       d  Male genital mycotic infections include the following adverse reactions: balanoposthitis, balanitis, genital infections fungal, genitourinary tract infection, balanitis candida, scrotal abscess, penile infection.",Male is not a named entity
"c  Predefined adverse event grouping, including, but not limited to, polyuria, pollakiuria, and nocturia       d  Male genital mycotic infections include the following adverse reactions: balanoposthitis, balanitis, genital infections fungal, genitourinary tract infection, balanitis candida, scrotal abscess, penile infection.",: balanoposthitis is not a named entity
Patients with a history of chronic or recurrent urinary tract infections were more likely to experience a urinary tract infection.,chronic or is not a named entity
Patients with a history of chronic or recurrent urinary tract infections were more likely to experience a urinary tract infection.,urinary tract infection is an adverse reaction entity
5.2 Impairment in Renal Function      JARDIANCE increases serum creatinine and decreases eGFR [see Adverse Reactions (  6.1  )]  .,decreases eGFR is an adverse reaction entity
5.2 Impairment in Renal Function      JARDIANCE increases serum creatinine and decreases eGFR [see Adverse Reactions (  6.1  )]  .,increases serum creatinine is an adverse reaction entity
5.2 Impairment in Renal Function      JARDIANCE increases serum creatinine and decreases eGFR [see Adverse Reactions (  6.1  )]  .,creatinine and is not a named entity
5.2 Impairment in Renal Function      JARDIANCE increases serum creatinine and decreases eGFR [see Adverse Reactions (  6.1  )]  .,Impairment in Renal is not a named entity
"The rate of treatment discontinuation due to urinary tract infections was 0.1%, 0.2%, and 0.1% for placebo, JARDIANCE 10 mg, and JARDIANCE 25 mg, respectively.",% for is not a named entity
"The rate of treatment discontinuation due to urinary tract infections was 0.1%, 0.2%, and 0.1% for placebo, JARDIANCE 10 mg, and JARDIANCE 25 mg, respectively.",urinary tract infections is an adverse reaction entity
"Urinary Tract Infections  In the pool of five placebo-controlled clinical trials, the incidence of urinary tract infections (e.g., urinary tract infection, asymptomatic bacteriuria, and cystitis) was increased in patients treated with JARDIANCE compared to placebo (see Table 1).",asymptomatic bacteriuria is an adverse reaction entity
"Urinary Tract Infections  In the pool of five placebo-controlled clinical trials, the incidence of urinary tract infections (e.g., urinary tract infection, asymptomatic bacteriuria, and cystitis) was increased in patients treated with JARDIANCE compared to placebo (see Table 1).",and is not a named entity
"Urinary Tract Infections  In the pool of five placebo-controlled clinical trials, the incidence of urinary tract infections (e.g., urinary tract infection, asymptomatic bacteriuria, and cystitis) was increased in patients treated with JARDIANCE compared to placebo (see Table 1).",urinary tract infection is an adverse reaction entity
"Urinary Tract Infections  In the pool of five placebo-controlled clinical trials, the incidence of urinary tract infections (e.g., urinary tract infection, asymptomatic bacteriuria, and cystitis) was increased in patients treated with JARDIANCE compared to placebo (see Table 1).",Infections In the is not a named entity
"Urinary Tract Infections  In the pool of five placebo-controlled clinical trials, the incidence of urinary tract infections (e.g., urinary tract infection, asymptomatic bacteriuria, and cystitis) was increased in patients treated with JARDIANCE compared to placebo (see Table 1).",", and is not a named entity"
"Urinary Tract Infections  In the pool of five placebo-controlled clinical trials, the incidence of urinary tract infections (e.g., urinary tract infection, asymptomatic bacteriuria, and cystitis) was increased in patients treated with JARDIANCE compared to placebo (see Table 1).",placebo-controlled is not a named entity
"Urinary Tract Infections  In the pool of five placebo-controlled clinical trials, the incidence of urinary tract infections (e.g., urinary tract infection, asymptomatic bacteriuria, and cystitis) was increased in patients treated with JARDIANCE compared to placebo (see Table 1).",urinary tract infections is an adverse reaction entity
"Urinary Tract Infections  In the pool of five placebo-controlled clinical trials, the incidence of urinary tract infections (e.g., urinary tract infection, asymptomatic bacteriuria, and cystitis) was increased in patients treated with JARDIANCE compared to placebo (see Table 1).",cystitis is an adverse reaction entity
"Urinary Tract Infections  In the pool of five placebo-controlled clinical trials, the incidence of urinary tract infections (e.g., urinary tract infection, asymptomatic bacteriuria, and cystitis) was increased in patients treated with JARDIANCE compared to placebo (see Table 1).",Urinary Tract Infections is an adverse reaction entity
"Urinary Tract Infections  In the pool of five placebo-controlled clinical trials, the incidence of urinary tract infections (e.g., urinary tract infection, asymptomatic bacteriuria, and cystitis) was increased in patients treated with JARDIANCE compared to placebo (see Table 1).",e.g. is not a named entity
Patients with a history of chronic or recurrent genital mycotic infections were more likely to develop mycotic genital infections.,of chronic or is not a named entity
Patients with a history of chronic or recurrent genital mycotic infections were more likely to develop mycotic genital infections.,mycotic genital infections is an adverse reaction entity
"The incidence of urinary tract infections in female patients randomized to placebo, JARDIANCE 10 mg, and JARDIANCE 25 mg was 16.6%, 18.4%, and 17.0%, respectively.",urinary tract infections is an adverse reaction entity
"The incidence of urinary tract infections in female patients randomized to placebo, JARDIANCE 10 mg, and JARDIANCE 25 mg was 16.6%, 18.4%, and 17.0%, respectively.",", respectively is not a named entity"
"The incidence of urinary tract infections in male patients randomized to placebo, JARDIANCE 10 mg, and JARDIANCE 25 mg was 3.2%, 3.6%, and 4.1%, respectively  [see Warnings and Precautions (  5.5  ) and Use in Specific Populations (  8.5  )]  .",was 3.2 is not a named entity
"The incidence of urinary tract infections in male patients randomized to placebo, JARDIANCE 10 mg, and JARDIANCE 25 mg was 3.2%, 3.6%, and 4.1%, respectively  [see Warnings and Precautions (  5.5  ) and Use in Specific Populations (  8.5  )]  .",urinary tract infections is an adverse reaction entity
"Symptomatic hypotension may occur after initiating JARDIANCE [see Adverse Reactions (  6.1  )]  particularly in patients with renal impairment, the elderly, in patients with low systolic blood pressure, and in patients on diuretics.",Symptomatic hypotension is an adverse reaction entity
"Symptomatic hypotension may occur after initiating JARDIANCE [see Adverse Reactions (  6.1  )]  particularly in patients with renal impairment, the elderly, in patients with low systolic blood pressure, and in patients on diuretics.",impairment is not a named entity
Table 1 shows common adverse reactions (excluding hypoglycemia) associated with the use of JARDIANCE.,hypoglycemia is an adverse reaction entity
Table 1 shows common adverse reactions (excluding hypoglycemia) associated with the use of JARDIANCE.,with the is not a named entity
"Increased Urination  In the pool of five placebo-controlled clinical trials, adverse reactions of increased urination (e.g., polyuria, pollakiuria, and nocturia) occurred more frequently on JARDIANCE than on placebo (see Table 1).",see Table 1 is not a named entity
"Increased Urination  In the pool of five placebo-controlled clinical trials, adverse reactions of increased urination (e.g., polyuria, pollakiuria, and nocturia) occurred more frequently on JARDIANCE than on placebo (see Table 1).",five is not a named entity
"Increased Urination  In the pool of five placebo-controlled clinical trials, adverse reactions of increased urination (e.g., polyuria, pollakiuria, and nocturia) occurred more frequently on JARDIANCE than on placebo (see Table 1).",see Table is not a named entity
"Increased Urination  In the pool of five placebo-controlled clinical trials, adverse reactions of increased urination (e.g., polyuria, pollakiuria, and nocturia) occurred more frequently on JARDIANCE than on placebo (see Table 1).",nocturia is an adverse reaction entity
"Increased Urination  In the pool of five placebo-controlled clinical trials, adverse reactions of increased urination (e.g., polyuria, pollakiuria, and nocturia) occurred more frequently on JARDIANCE than on placebo (see Table 1).",) is not a named entity
"Increased Urination  In the pool of five placebo-controlled clinical trials, adverse reactions of increased urination (e.g., polyuria, pollakiuria, and nocturia) occurred more frequently on JARDIANCE than on placebo (see Table 1).","e.g. , is not a named entity"
"Increased Urination  In the pool of five placebo-controlled clinical trials, adverse reactions of increased urination (e.g., polyuria, pollakiuria, and nocturia) occurred more frequently on JARDIANCE than on placebo (see Table 1).",increased urination is an adverse reaction entity
"Increased Urination  In the pool of five placebo-controlled clinical trials, adverse reactions of increased urination (e.g., polyuria, pollakiuria, and nocturia) occurred more frequently on JARDIANCE than on placebo (see Table 1).",polyuria is an adverse reaction entity
"Increased Urination  In the pool of five placebo-controlled clinical trials, adverse reactions of increased urination (e.g., polyuria, pollakiuria, and nocturia) occurred more frequently on JARDIANCE than on placebo (see Table 1).",Increased Urination is an adverse reaction entity
"Increased Urination  In the pool of five placebo-controlled clinical trials, adverse reactions of increased urination (e.g., polyuria, pollakiuria, and nocturia) occurred more frequently on JARDIANCE than on placebo (see Table 1).",pollakiuria is an adverse reaction entity
Phimosis occurred more frequently in male patients treated with JARDIANCE 10 mg (less than 0.1%) and JARDIANCE 25 mg (0.1%) than placebo (0%).,0.1 % is not a named entity
Phimosis occurred more frequently in male patients treated with JARDIANCE 10 mg (less than 0.1%) and JARDIANCE 25 mg (0.1%) than placebo (0%).,Phimosis is an adverse reaction entity
"Increase in Hematocrit  In a pool of four placebo-controlled studies, median hematocrit decreased by 1.3% in placebo and increased by 2.8% in JARDIANCE 10 mg and 2.8% in JARDIANCE 25 mg treated patients.",hematocrit increased is an adverse reaction entity
"Increase in Hematocrit  In a pool of four placebo-controlled studies, median hematocrit decreased by 1.3% in placebo and increased by 2.8% in JARDIANCE 10 mg and 2.8% in JARDIANCE 25 mg treated patients.",mg treated patients is not a named entity
"Increase in Hematocrit  In a pool of four placebo-controlled studies, median hematocrit decreased by 1.3% in placebo and increased by 2.8% in JARDIANCE 10 mg and 2.8% in JARDIANCE 25 mg treated patients.",hematocrit decreased is an adverse reaction entity
"Increase in Hematocrit  In a pool of four placebo-controlled studies, median hematocrit decreased by 1.3% in placebo and increased by 2.8% in JARDIANCE 10 mg and 2.8% in JARDIANCE 25 mg treated patients.",a pool of is not a named entity
"Increase in Hematocrit  In a pool of four placebo-controlled studies, median hematocrit decreased by 1.3% in placebo and increased by 2.8% in JARDIANCE 10 mg and 2.8% in JARDIANCE 25 mg treated patients.",Increase in Hematocrit is an adverse reaction entity
"Increase in Hematocrit  In a pool of four placebo-controlled studies, median hematocrit decreased by 1.3% in placebo and increased by 2.8% in JARDIANCE 10 mg and 2.8% in JARDIANCE 25 mg treated patients.",in JARDIANCE 25 is not a named entity
"LDL-C increased by 2.3%, 4.6%, and 6.5% in patients treated with placebo, JARDIANCE 10 mg, and JARDIANCE 25 mg, respectively  [see Warnings and Precautions (  5.6  )]  .",", and is not a named entity"
"LDL-C increased by 2.3%, 4.6%, and 6.5% in patients treated with placebo, JARDIANCE 10 mg, and JARDIANCE 25 mg, respectively  [see Warnings and Precautions (  5.6  )]  .",LDL-C increased is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS     EXCERPT:    *    Acute pancreatitis: There have been postmarketing reports of acute pancreatitis.,of acute is not a named entity
5 WARNINGS AND PRECAUTIONS     EXCERPT:    *    Acute pancreatitis: There have been postmarketing reports of acute pancreatitis.,acute pancreatitis is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS     EXCERPT:    *    Acute pancreatitis: There have been postmarketing reports of acute pancreatitis.,AND PRECAUTIONS EXCERPT is not a named entity
5 WARNINGS AND PRECAUTIONS     EXCERPT:    *    Acute pancreatitis: There have been postmarketing reports of acute pancreatitis.,Acute pancreatitis is an adverse reaction entity
The use of NESINA as add-on therapy to glyburide or insulin did not increase the incidence of hypoglycemia compared to placebo.,of hypoglycemia compared is not a named entity
The use of NESINA as add-on therapy to glyburide or insulin did not increase the incidence of hypoglycemia compared to placebo.,hypoglycemia is an adverse reaction entity
"In randomized controlled studies, serum alanine aminotransferase (ALT) elevations greater than three times the upper limit of normal (ULN) were observed: 1.3% in alogliptin-treated patients and 1.5% in all comparator-treated patients.",serum alanine aminotransferase elevations is an adverse reaction entity
"In randomized controlled studies, serum alanine aminotransferase (ALT) elevations greater than three times the upper limit of normal (ULN) were observed: 1.3% in alogliptin-treated patients and 1.5% in all comparator-treated patients.",patients and 1.5 is not a named entity
"In randomized controlled studies, serum alanine aminotransferase (ALT) elevations greater than three times the upper limit of normal (ULN) were observed: 1.3% in alogliptin-treated patients and 1.5% in all comparator-treated patients.",alanine is not a named entity
"In randomized controlled studies, serum alanine aminotransferase (ALT) elevations greater than three times the upper limit of normal (ULN) were observed: 1.3% in alogliptin-treated patients and 1.5% in all comparator-treated patients.",ALT elevations is an adverse reaction entity
(5.4)   *    Arthralgia: Severe and disabling arthralgia has been reported in patients taking DPP-4 inhibitors.,arthralgia has is not a named entity
(5.4)   *    Arthralgia: Severe and disabling arthralgia has been reported in patients taking DPP-4 inhibitors.,arthralgia is an adverse reaction entity
(5.4)   *    Arthralgia: Severe and disabling arthralgia has been reported in patients taking DPP-4 inhibitors.,: is not a named entity
(5.4)   *    Arthralgia: Severe and disabling arthralgia has been reported in patients taking DPP-4 inhibitors.,Arthralgia is an adverse reaction entity
"Hypersensitivity Reactions       In a pooled analysis, the overall incidence of hypersensitivity reactions was 0.6% with NESINA 25 mg compared to 0.8% with all comparators.",hypersensitivity reactions is an adverse reaction entity
"Hypersensitivity Reactions       In a pooled analysis, the overall incidence of hypersensitivity reactions was 0.6% with NESINA 25 mg compared to 0.8% with all comparators.",% is not a named entity
"5.3 Hepatic Effects    There have been postmarketing reports of fatal and nonfatal hepatic failure in patients taking NESINA, although some of the reports contain insufficient information necessary to establish the probable cause  [seeAdverse Reactions (6.2)]  .",hepatic failure is an adverse reaction entity
"5.3 Hepatic Effects    There have been postmarketing reports of fatal and nonfatal hepatic failure in patients taking NESINA, although some of the reports contain insufficient information necessary to establish the probable cause  [seeAdverse Reactions (6.2)]  .",5.3 Hepatic Effects is not a named entity
"5.3 Hepatic Effects    There have been postmarketing reports of fatal and nonfatal hepatic failure in patients taking NESINA, although some of the reports contain insufficient information necessary to establish the probable cause  [seeAdverse Reactions (6.2)]  .",hepatic failure is an adverse reaction entity
"5.3 Hepatic Effects    There have been postmarketing reports of fatal and nonfatal hepatic failure in patients taking NESINA, although some of the reports contain insufficient information necessary to establish the probable cause  [seeAdverse Reactions (6.2)]  .",probable cause is not a named entity
"5.3 Hepatic Effects    There have been postmarketing reports of fatal and nonfatal hepatic failure in patients taking NESINA, although some of the reports contain insufficient information necessary to establish the probable cause  [seeAdverse Reactions (6.2)]  .",fatal is an adverse reaction entity
"5.3 Hepatic Effects    There have been postmarketing reports of fatal and nonfatal hepatic failure in patients taking NESINA, although some of the reports contain insufficient information necessary to establish the probable cause  [seeAdverse Reactions (6.2)]  .",information necessary to is not a named entity
"In a monotherapy study comparing NESINA to a sulfonylurea in elderly patients, the incidence of hypoglycemia was 5.4% with NESINA compared to 26% with glipizide  (Table 2)  .",hypoglycemia is an adverse reaction entity
"In a monotherapy study comparing NESINA to a sulfonylurea in elderly patients, the incidence of hypoglycemia was 5.4% with NESINA compared to 26% with glipizide  (Table 2)  .",5.4 is not a named entity
"These reactions include anaphylaxis, angioedema and severe cutaneous adverse reactions, including Stevens-Johnson syndrome.",cutaneous adverse reactions is an adverse reaction entity
"These reactions include anaphylaxis, angioedema and severe cutaneous adverse reactions, including Stevens-Johnson syndrome.","reactions , is not a named entity"
"These reactions include anaphylaxis, angioedema and severe cutaneous adverse reactions, including Stevens-Johnson syndrome.",", angioedema is not a named entity"
"These reactions include anaphylaxis, angioedema and severe cutaneous adverse reactions, including Stevens-Johnson syndrome.",Stevens-Johnson syndrome is an adverse reaction entity
"These reactions include anaphylaxis, angioedema and severe cutaneous adverse reactions, including Stevens-Johnson syndrome.","anaphylaxis , angioedema is not a named entity"
"These reactions include anaphylaxis, angioedema and severe cutaneous adverse reactions, including Stevens-Johnson syndrome.",angioedema is an adverse reaction entity
"These reactions include anaphylaxis, angioedema and severe cutaneous adverse reactions, including Stevens-Johnson syndrome.",anaphylaxis is an adverse reaction entity
"These reactions include anaphylaxis, angioedema and severe cutaneous adverse reactions, including Stevens-Johnson syndrome.",reactions is not a named entity
"6 ADVERSE REACTIONS    EXCERPT:   Common adverse reactions (reported in >=4% of patients treated with NESINA 25 mg and more frequently than in patients who received placebo) are: nasopharyngitis, headache and upper respiratory tract infection.",in is not a named entity
"6 ADVERSE REACTIONS    EXCERPT:   Common adverse reactions (reported in >=4% of patients treated with NESINA 25 mg and more frequently than in patients who received placebo) are: nasopharyngitis, headache and upper respiratory tract infection.",headache is an adverse reaction entity
"6 ADVERSE REACTIONS    EXCERPT:   Common adverse reactions (reported in >=4% of patients treated with NESINA 25 mg and more frequently than in patients who received placebo) are: nasopharyngitis, headache and upper respiratory tract infection.",received placebo is not a named entity
"6 ADVERSE REACTIONS    EXCERPT:   Common adverse reactions (reported in >=4% of patients treated with NESINA 25 mg and more frequently than in patients who received placebo) are: nasopharyngitis, headache and upper respiratory tract infection.",in > =4 is not a named entity
"6 ADVERSE REACTIONS    EXCERPT:   Common adverse reactions (reported in >=4% of patients treated with NESINA 25 mg and more frequently than in patients who received placebo) are: nasopharyngitis, headache and upper respiratory tract infection.",upper respiratory tract infection is an adverse reaction entity
"6 ADVERSE REACTIONS    EXCERPT:   Common adverse reactions (reported in >=4% of patients treated with NESINA 25 mg and more frequently than in patients who received placebo) are: nasopharyngitis, headache and upper respiratory tract infection.",nasopharyngitis is an adverse reaction entity
"Hypersensitivity reactions including anaphylaxis, angioedema, rash, urticaria and severe cutaneous adverse reactions, including Stevens-Johnson syndrome, hepatic enzyme elevations, fulminant hepatic failure, severe and disabling arthralgia and acute pancreatitis  [see Warnings and Precautions (5.1,5.2,5.3,5.5)]  .",Hypersensitivity reactions including is not a named entity
"Hypersensitivity reactions including anaphylaxis, angioedema, rash, urticaria and severe cutaneous adverse reactions, including Stevens-Johnson syndrome, hepatic enzyme elevations, fulminant hepatic failure, severe and disabling arthralgia and acute pancreatitis  [see Warnings and Precautions (5.1,5.2,5.3,5.5)]  .",reactions is not a named entity
"Hypersensitivity reactions including anaphylaxis, angioedema, rash, urticaria and severe cutaneous adverse reactions, including Stevens-Johnson syndrome, hepatic enzyme elevations, fulminant hepatic failure, severe and disabling arthralgia and acute pancreatitis  [see Warnings and Precautions (5.1,5.2,5.3,5.5)]  .",rash is an adverse reaction entity
"Hypersensitivity reactions including anaphylaxis, angioedema, rash, urticaria and severe cutaneous adverse reactions, including Stevens-Johnson syndrome, hepatic enzyme elevations, fulminant hepatic failure, severe and disabling arthralgia and acute pancreatitis  [see Warnings and Precautions (5.1,5.2,5.3,5.5)]  .",angioedema is an adverse reaction entity
"Hypersensitivity reactions including anaphylaxis, angioedema, rash, urticaria and severe cutaneous adverse reactions, including Stevens-Johnson syndrome, hepatic enzyme elevations, fulminant hepatic failure, severe and disabling arthralgia and acute pancreatitis  [see Warnings and Precautions (5.1,5.2,5.3,5.5)]  .","hepatic failure , is not a named entity"
"Hypersensitivity reactions including anaphylaxis, angioedema, rash, urticaria and severe cutaneous adverse reactions, including Stevens-Johnson syndrome, hepatic enzyme elevations, fulminant hepatic failure, severe and disabling arthralgia and acute pancreatitis  [see Warnings and Precautions (5.1,5.2,5.3,5.5)]  .",", urticaria is not a named entity"
"Hypersensitivity reactions including anaphylaxis, angioedema, rash, urticaria and severe cutaneous adverse reactions, including Stevens-Johnson syndrome, hepatic enzyme elevations, fulminant hepatic failure, severe and disabling arthralgia and acute pancreatitis  [see Warnings and Precautions (5.1,5.2,5.3,5.5)]  .",arthralgia is an adverse reaction entity
"Hypersensitivity reactions including anaphylaxis, angioedema, rash, urticaria and severe cutaneous adverse reactions, including Stevens-Johnson syndrome, hepatic enzyme elevations, fulminant hepatic failure, severe and disabling arthralgia and acute pancreatitis  [see Warnings and Precautions (5.1,5.2,5.3,5.5)]  .",Hypersensitivity reactions is an adverse reaction entity
"Hypersensitivity reactions including anaphylaxis, angioedema, rash, urticaria and severe cutaneous adverse reactions, including Stevens-Johnson syndrome, hepatic enzyme elevations, fulminant hepatic failure, severe and disabling arthralgia and acute pancreatitis  [see Warnings and Precautions (5.1,5.2,5.3,5.5)]  .",anaphylaxis is an adverse reaction entity
"Hypersensitivity reactions including anaphylaxis, angioedema, rash, urticaria and severe cutaneous adverse reactions, including Stevens-Johnson syndrome, hepatic enzyme elevations, fulminant hepatic failure, severe and disabling arthralgia and acute pancreatitis  [see Warnings and Precautions (5.1,5.2,5.3,5.5)]  .",severe and is not a named entity
"Hypersensitivity reactions including anaphylaxis, angioedema, rash, urticaria and severe cutaneous adverse reactions, including Stevens-Johnson syndrome, hepatic enzyme elevations, fulminant hepatic failure, severe and disabling arthralgia and acute pancreatitis  [see Warnings and Precautions (5.1,5.2,5.3,5.5)]  .",fulminant hepatic failure is an adverse reaction entity
"Hypersensitivity reactions including anaphylaxis, angioedema, rash, urticaria and severe cutaneous adverse reactions, including Stevens-Johnson syndrome, hepatic enzyme elevations, fulminant hepatic failure, severe and disabling arthralgia and acute pancreatitis  [see Warnings and Precautions (5.1,5.2,5.3,5.5)]  .",pancreatitis is not a named entity
"Hypersensitivity reactions including anaphylaxis, angioedema, rash, urticaria and severe cutaneous adverse reactions, including Stevens-Johnson syndrome, hepatic enzyme elevations, fulminant hepatic failure, severe and disabling arthralgia and acute pancreatitis  [see Warnings and Precautions (5.1,5.2,5.3,5.5)]  .",Stevens-Johnson syndrome is an adverse reaction entity
"Hypersensitivity reactions including anaphylaxis, angioedema, rash, urticaria and severe cutaneous adverse reactions, including Stevens-Johnson syndrome, hepatic enzyme elevations, fulminant hepatic failure, severe and disabling arthralgia and acute pancreatitis  [see Warnings and Precautions (5.1,5.2,5.3,5.5)]  .",] is not a named entity
"Hypersensitivity reactions including anaphylaxis, angioedema, rash, urticaria and severe cutaneous adverse reactions, including Stevens-Johnson syndrome, hepatic enzyme elevations, fulminant hepatic failure, severe and disabling arthralgia and acute pancreatitis  [see Warnings and Precautions (5.1,5.2,5.3,5.5)]  .",acute pancreatitis is an adverse reaction entity
"Hypersensitivity reactions including anaphylaxis, angioedema, rash, urticaria and severe cutaneous adverse reactions, including Stevens-Johnson syndrome, hepatic enzyme elevations, fulminant hepatic failure, severe and disabling arthralgia and acute pancreatitis  [see Warnings and Precautions (5.1,5.2,5.3,5.5)]  .",urticaria is an adverse reaction entity
"Hypersensitivity reactions including anaphylaxis, angioedema, rash, urticaria and severe cutaneous adverse reactions, including Stevens-Johnson syndrome, hepatic enzyme elevations, fulminant hepatic failure, severe and disabling arthralgia and acute pancreatitis  [see Warnings and Precautions (5.1,5.2,5.3,5.5)]  .",reactions including anaphylaxis is not a named entity
"Hypersensitivity reactions including anaphylaxis, angioedema, rash, urticaria and severe cutaneous adverse reactions, including Stevens-Johnson syndrome, hepatic enzyme elevations, fulminant hepatic failure, severe and disabling arthralgia and acute pancreatitis  [see Warnings and Precautions (5.1,5.2,5.3,5.5)]  .",Warnings and Precautions is not a named entity
"Hypersensitivity reactions including anaphylaxis, angioedema, rash, urticaria and severe cutaneous adverse reactions, including Stevens-Johnson syndrome, hepatic enzyme elevations, fulminant hepatic failure, severe and disabling arthralgia and acute pancreatitis  [see Warnings and Precautions (5.1,5.2,5.3,5.5)]  .",cutaneous adverse reactions is an adverse reaction entity
"Hypersensitivity reactions including anaphylaxis, angioedema, rash, urticaria and severe cutaneous adverse reactions, including Stevens-Johnson syndrome, hepatic enzyme elevations, fulminant hepatic failure, severe and disabling arthralgia and acute pancreatitis  [see Warnings and Precautions (5.1,5.2,5.3,5.5)]  .",Warnings and Precautions is not a named entity
"Hypersensitivity reactions including anaphylaxis, angioedema, rash, urticaria and severe cutaneous adverse reactions, including Stevens-Johnson syndrome, hepatic enzyme elevations, fulminant hepatic failure, severe and disabling arthralgia and acute pancreatitis  [see Warnings and Precautions (5.1,5.2,5.3,5.5)]  .",", is not a named entity"
"Hypersensitivity reactions including anaphylaxis, angioedema, rash, urticaria and severe cutaneous adverse reactions, including Stevens-Johnson syndrome, hepatic enzyme elevations, fulminant hepatic failure, severe and disabling arthralgia and acute pancreatitis  [see Warnings and Precautions (5.1,5.2,5.3,5.5)]  .",hepatic enzyme elevations is an adverse reaction entity
"In the monotherapy study, the incidence of hypoglycemia was 1.5% in patients treated with NESINA compared to 1.6% with placebo.",hypoglycemia is an adverse reaction entity
"In the monotherapy study, the incidence of hypoglycemia was 1.5% in patients treated with NESINA compared to 1.6% with placebo.",the is not a named entity
"in Placebo and Active-Controlled Studies when NESINA Was Used as Add-On Therapy to Glyburide, Insulin, Metformin, Pioglitazone or Compared to Glipizide       Add-On to Glyburide(26 Weeks)                NESINA 25 mg+ Glyburide    Placebo+ Glyburide                                                               N=198                      N=99                                  Overall (%)                                19 (9.6)                   11 (11.1)                             Severe (%)Severe events of hypoglycemia were defined as those events requiring medical assistance or exhibiting depressed level or loss of consciousness or seizure.",events of is not a named entity
"in Placebo and Active-Controlled Studies when NESINA Was Used as Add-On Therapy to Glyburide, Insulin, Metformin, Pioglitazone or Compared to Glipizide       Add-On to Glyburide(26 Weeks)                NESINA 25 mg+ Glyburide    Placebo+ Glyburide                                                               N=198                      N=99                                  Overall (%)                                19 (9.6)                   11 (11.1)                             Severe (%)Severe events of hypoglycemia were defined as those events requiring medical assistance or exhibiting depressed level or loss of consciousness or seizure.",hypoglycemia is an adverse reaction entity
A single event of serum sickness was reported in a patient treated with NESINA 25 mg.         Hypoglycemia       Hypoglycemic events were documented based upon a blood glucose value and/or clinical signs and symptoms of hypoglycemia.,hypoglycemia is an adverse reaction entity
A single event of serum sickness was reported in a patient treated with NESINA 25 mg.         Hypoglycemia       Hypoglycemic events were documented based upon a blood glucose value and/or clinical signs and symptoms of hypoglycemia.,Hypoglycemic events is an adverse reaction entity
A single event of serum sickness was reported in a patient treated with NESINA 25 mg.         Hypoglycemia       Hypoglycemic events were documented based upon a blood glucose value and/or clinical signs and symptoms of hypoglycemia.,clinical signs is not a named entity
A single event of serum sickness was reported in a patient treated with NESINA 25 mg.         Hypoglycemia       Hypoglycemic events were documented based upon a blood glucose value and/or clinical signs and symptoms of hypoglycemia.,sickness was is not a named entity
A single event of serum sickness was reported in a patient treated with NESINA 25 mg.         Hypoglycemia       Hypoglycemic events were documented based upon a blood glucose value and/or clinical signs and symptoms of hypoglycemia.,were documented is not a named entity
A single event of serum sickness was reported in a patient treated with NESINA 25 mg.         Hypoglycemia       Hypoglycemic events were documented based upon a blood glucose value and/or clinical signs and symptoms of hypoglycemia.,serum sickness is an adverse reaction entity
"(5.3)   *    Hypoglycemia: When an insulin secretagogue (e.g., sulfonylurea) or insulin is used in combination with NESINA, a lower dose of the insulin secretagogue or insulin may be required to minimize the risk of hypoglycemia.",Hypoglycemia is an adverse reaction entity
"(5.3)   *    Hypoglycemia: When an insulin secretagogue (e.g., sulfonylurea) or insulin is used in combination with NESINA, a lower dose of the insulin secretagogue or insulin may be required to minimize the risk of hypoglycemia.",or is not a named entity
5.5 Severe Cutaneous Reactions      One case of toxic epidermal necrolysis (TEN) occurred in a study of Zydelig in combination with rituximab and bendamustine.,TEN is an adverse reaction entity
5.5 Severe Cutaneous Reactions      One case of toxic epidermal necrolysis (TEN) occurred in a study of Zydelig in combination with rituximab and bendamustine.,Zydelig in is not a named entity
5.5 Severe Cutaneous Reactions      One case of toxic epidermal necrolysis (TEN) occurred in a study of Zydelig in combination with rituximab and bendamustine.,occurred in is not a named entity
5.5 Severe Cutaneous Reactions      One case of toxic epidermal necrolysis (TEN) occurred in a study of Zydelig in combination with rituximab and bendamustine.,toxic epidermal necrolysis is an adverse reaction entity
Serum chemistry abnormalities                                                                                    ALT increased                                    73 (50)            20 (14)            7 (5)                   AST increased                                    60 (41)            12 (8)             6 (4)                 Hematology abnormalities                                neutrophils decreased                            78 (53)            20 (14)            16 (11)                 hemoglobin decreased                             41 (28)            3 (2)              0                       platelets decreased                              38 (26)            4 (3)              5 (3),4 ) Hematology is not a named entity
Serum chemistry abnormalities                                                                                    ALT increased                                    73 (50)            20 (14)            7 (5)                   AST increased                                    60 (41)            12 (8)             6 (4)                 Hematology abnormalities                                neutrophils decreased                            78 (53)            20 (14)            16 (11)                 hemoglobin decreased                             41 (28)            3 (2)              0                       platelets decreased                              38 (26)            4 (3)              5 (3),( 3 is not a named entity
Serum chemistry abnormalities                                                                                    ALT increased                                    73 (50)            20 (14)            7 (5)                   AST increased                                    60 (41)            12 (8)             6 (4)                 Hematology abnormalities                                neutrophils decreased                            78 (53)            20 (14)            16 (11)                 hemoglobin decreased                             41 (28)            3 (2)              0                       platelets decreased                              38 (26)            4 (3)              5 (3),AST increased is an adverse reaction entity
Serum chemistry abnormalities                                                                                    ALT increased                                    73 (50)            20 (14)            7 (5)                   AST increased                                    60 (41)            12 (8)             6 (4)                 Hematology abnormalities                                neutrophils decreased                            78 (53)            20 (14)            16 (11)                 hemoglobin decreased                             41 (28)            3 (2)              0                       platelets decreased                              38 (26)            4 (3)              5 (3),platelets decreased is an adverse reaction entity
Serum chemistry abnormalities                                                                                    ALT increased                                    73 (50)            20 (14)            7 (5)                   AST increased                                    60 (41)            12 (8)             6 (4)                 Hematology abnormalities                                neutrophils decreased                            78 (53)            20 (14)            16 (11)                 hemoglobin decreased                             41 (28)            3 (2)              0                       platelets decreased                              38 (26)            4 (3)              5 (3),ALT increased is an adverse reaction entity
Serum chemistry abnormalities                                                                                    ALT increased                                    73 (50)            20 (14)            7 (5)                   AST increased                                    60 (41)            12 (8)             6 (4)                 Hematology abnormalities                                neutrophils decreased                            78 (53)            20 (14)            16 (11)                 hemoglobin decreased                             41 (28)            3 (2)              0                       platelets decreased                              38 (26)            4 (3)              5 (3),hemoglobin decreased is an adverse reaction entity
Serum chemistry abnormalities                                                                                    ALT increased                                    73 (50)            20 (14)            7 (5)                   AST increased                                    60 (41)            12 (8)             6 (4)                 Hematology abnormalities                                neutrophils decreased                            78 (53)            20 (14)            16 (11)                 hemoglobin decreased                             41 (28)            3 (2)              0                       platelets decreased                              38 (26)            4 (3)              5 (3),increased 73 ( is not a named entity
Serum chemistry abnormalities                                                                                    ALT increased                                    73 (50)            20 (14)            7 (5)                   AST increased                                    60 (41)            12 (8)             6 (4)                 Hematology abnormalities                                neutrophils decreased                            78 (53)            20 (14)            16 (11)                 hemoglobin decreased                             41 (28)            3 (2)              0                       platelets decreased                              38 (26)            4 (3)              5 (3),11 ) is not a named entity
Serum chemistry abnormalities                                                                                    ALT increased                                    73 (50)            20 (14)            7 (5)                   AST increased                                    60 (41)            12 (8)             6 (4)                 Hematology abnormalities                                neutrophils decreased                            78 (53)            20 (14)            16 (11)                 hemoglobin decreased                             41 (28)            3 (2)              0                       platelets decreased                              38 (26)            4 (3)              5 (3),38 is not a named entity
Serum chemistry abnormalities                                                                                    ALT increased                                    73 (50)            20 (14)            7 (5)                   AST increased                                    60 (41)            12 (8)             6 (4)                 Hematology abnormalities                                neutrophils decreased                            78 (53)            20 (14)            16 (11)                 hemoglobin decreased                             41 (28)            3 (2)              0                       platelets decreased                              38 (26)            4 (3)              5 (3),neutrophils decreased is an adverse reaction entity
"5.6 Anaphylaxis      Serious allergic reactions, including anaphylaxis, have been reported in patients on Zydelig.",allergic reactions is an adverse reaction entity
"5.6 Anaphylaxis      Serious allergic reactions, including anaphylaxis, have been reported in patients on Zydelig.",", have is not a named entity"
"5.6 Anaphylaxis      Serious allergic reactions, including anaphylaxis, have been reported in patients on Zydelig.",Serious allergic reactions is not a named entity
"5.6 Anaphylaxis      Serious allergic reactions, including anaphylaxis, have been reported in patients on Zydelig.",anaphylaxis is an adverse reaction entity
"5.8 Embryo-fetal Toxicity      Based on findings in animals, Zydelig may cause fetal harm when administered to a pregnant woman.",Toxicity Based on is not a named entity
"5.8 Embryo-fetal Toxicity      Based on findings in animals, Zydelig may cause fetal harm when administered to a pregnant woman.",fetal harm is an adverse reaction entity
The most common adverse reactions that led to treatment discontinuations were hepatotoxicity and diarrhea/colitis.,colitis is an adverse reaction entity
The most common adverse reactions that led to treatment discontinuations were hepatotoxicity and diarrhea/colitis.,diarrhea is an adverse reaction entity
The most common adverse reactions that led to treatment discontinuations were hepatotoxicity and diarrhea/colitis.,adverse reactions that is not a named entity
The most common adverse reactions that led to treatment discontinuations were hepatotoxicity and diarrhea/colitis.,hepatotoxicity is an adverse reaction entity
The most common adverse reactions that led to treatment discontinuations were hepatotoxicity and diarrhea/colitis.,were hepatotoxicity is not a named entity
The most common adverse reactions that led to treatment discontinuations were hepatotoxicity and diarrhea/colitis.,common adverse reactions is not a named entity
"The most common reasons for interruption or discontinuations were diarrhea (11%), pneumonia (11%), and elevated transaminases (10%).",most common is not a named entity
"The most common reasons for interruption or discontinuations were diarrhea (11%), pneumonia (11%), and elevated transaminases (10%).",The is not a named entity
"The most common reasons for interruption or discontinuations were diarrhea (11%), pneumonia (11%), and elevated transaminases (10%).",10 is not a named entity
"The most common reasons for interruption or discontinuations were diarrhea (11%), pneumonia (11%), and elevated transaminases (10%).",elevated transaminases is an adverse reaction entity
"The most common reasons for interruption or discontinuations were diarrhea (11%), pneumonia (11%), and elevated transaminases (10%).",diarrhea is an adverse reaction entity
"The most common reasons for interruption or discontinuations were diarrhea (11%), pneumonia (11%), and elevated transaminases (10%).",pneumonia is an adverse reaction entity
( 5.1)   *  Fatal and/or serious and severe diarrhea or colitis occurred in 14% of Zydelig-treated patients.,colitis is an adverse reaction entity
( 5.1)   *  Fatal and/or serious and severe diarrhea or colitis occurred in 14% of Zydelig-treated patients.,Fatal is an adverse reaction entity
( 5.1)   *  Fatal and/or serious and severe diarrhea or colitis occurred in 14% of Zydelig-treated patients.,) * Fatal is not a named entity
( 5.1)   *  Fatal and/or serious and severe diarrhea or colitis occurred in 14% of Zydelig-treated patients.,diarrhea is an adverse reaction entity
( 5.1)   *  Fatal and/or serious and severe diarrhea or colitis occurred in 14% of Zydelig-treated patients.,5.1 is not a named entity
( 5.1)   *  Fatal and/or serious and severe diarrhea or colitis occurred in 14% of Zydelig-treated patients.,) * is not a named entity
"*  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Severe Diarrhea or Colitis [see  Warnings and Precautions (5.2)  ]    *  Pneumonitis [see  Warnings and Precautions (5.3)  ]    *  Intestinal Perforation [see  Warnings and Precautions (5.4)  ]    *  Severe Cutaneous Reactions [see  Warnings and Precautions (5.5)  ]    *  Anaphylaxis [see  Warnings and Precautions (5.6)  ]    *  Neutropenia [see  Warnings and Precautions (5.7)  ]         EXCERPT:   The most common adverse reactions (incidence >=20%) are diarrhea, pyrexia, fatigue, nausea, cough, pneumonia, abdominal pain, chills, and rash (  6.1  ).",) is not a named entity
"*  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Severe Diarrhea or Colitis [see  Warnings and Precautions (5.2)  ]    *  Pneumonitis [see  Warnings and Precautions (5.3)  ]    *  Intestinal Perforation [see  Warnings and Precautions (5.4)  ]    *  Severe Cutaneous Reactions [see  Warnings and Precautions (5.5)  ]    *  Anaphylaxis [see  Warnings and Precautions (5.6)  ]    *  Neutropenia [see  Warnings and Precautions (5.7)  ]         EXCERPT:   The most common adverse reactions (incidence >=20%) are diarrhea, pyrexia, fatigue, nausea, cough, pneumonia, abdominal pain, chills, and rash (  6.1  ).",Intestinal Perforation is an adverse reaction entity
"*  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Severe Diarrhea or Colitis [see  Warnings and Precautions (5.2)  ]    *  Pneumonitis [see  Warnings and Precautions (5.3)  ]    *  Intestinal Perforation [see  Warnings and Precautions (5.4)  ]    *  Severe Cutaneous Reactions [see  Warnings and Precautions (5.5)  ]    *  Anaphylaxis [see  Warnings and Precautions (5.6)  ]    *  Neutropenia [see  Warnings and Precautions (5.7)  ]         EXCERPT:   The most common adverse reactions (incidence >=20%) are diarrhea, pyrexia, fatigue, nausea, cough, pneumonia, abdominal pain, chills, and rash (  6.1  ).",) ] is not a named entity
"*  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Severe Diarrhea or Colitis [see  Warnings and Precautions (5.2)  ]    *  Pneumonitis [see  Warnings and Precautions (5.3)  ]    *  Intestinal Perforation [see  Warnings and Precautions (5.4)  ]    *  Severe Cutaneous Reactions [see  Warnings and Precautions (5.5)  ]    *  Anaphylaxis [see  Warnings and Precautions (5.6)  ]    *  Neutropenia [see  Warnings and Precautions (5.7)  ]         EXCERPT:   The most common adverse reactions (incidence >=20%) are diarrhea, pyrexia, fatigue, nausea, cough, pneumonia, abdominal pain, chills, and rash (  6.1  ).",fatigue is an adverse reaction entity
"*  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Severe Diarrhea or Colitis [see  Warnings and Precautions (5.2)  ]    *  Pneumonitis [see  Warnings and Precautions (5.3)  ]    *  Intestinal Perforation [see  Warnings and Precautions (5.4)  ]    *  Severe Cutaneous Reactions [see  Warnings and Precautions (5.5)  ]    *  Anaphylaxis [see  Warnings and Precautions (5.6)  ]    *  Neutropenia [see  Warnings and Precautions (5.7)  ]         EXCERPT:   The most common adverse reactions (incidence >=20%) are diarrhea, pyrexia, fatigue, nausea, cough, pneumonia, abdominal pain, chills, and rash (  6.1  ).",EXCERPT : is not a named entity
"*  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Severe Diarrhea or Colitis [see  Warnings and Precautions (5.2)  ]    *  Pneumonitis [see  Warnings and Precautions (5.3)  ]    *  Intestinal Perforation [see  Warnings and Precautions (5.4)  ]    *  Severe Cutaneous Reactions [see  Warnings and Precautions (5.5)  ]    *  Anaphylaxis [see  Warnings and Precautions (5.6)  ]    *  Neutropenia [see  Warnings and Precautions (5.7)  ]         EXCERPT:   The most common adverse reactions (incidence >=20%) are diarrhea, pyrexia, fatigue, nausea, cough, pneumonia, abdominal pain, chills, and rash (  6.1  ).",Anaphylaxis [ is not a named entity
"*  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Severe Diarrhea or Colitis [see  Warnings and Precautions (5.2)  ]    *  Pneumonitis [see  Warnings and Precautions (5.3)  ]    *  Intestinal Perforation [see  Warnings and Precautions (5.4)  ]    *  Severe Cutaneous Reactions [see  Warnings and Precautions (5.5)  ]    *  Anaphylaxis [see  Warnings and Precautions (5.6)  ]    *  Neutropenia [see  Warnings and Precautions (5.7)  ]         EXCERPT:   The most common adverse reactions (incidence >=20%) are diarrhea, pyrexia, fatigue, nausea, cough, pneumonia, abdominal pain, chills, and rash (  6.1  ).",Severe Cutaneous Reactions is not a named entity
"*  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Severe Diarrhea or Colitis [see  Warnings and Precautions (5.2)  ]    *  Pneumonitis [see  Warnings and Precautions (5.3)  ]    *  Intestinal Perforation [see  Warnings and Precautions (5.4)  ]    *  Severe Cutaneous Reactions [see  Warnings and Precautions (5.5)  ]    *  Anaphylaxis [see  Warnings and Precautions (5.6)  ]    *  Neutropenia [see  Warnings and Precautions (5.7)  ]         EXCERPT:   The most common adverse reactions (incidence >=20%) are diarrhea, pyrexia, fatigue, nausea, cough, pneumonia, abdominal pain, chills, and rash (  6.1  ).",nausea is an adverse reaction entity
"*  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Severe Diarrhea or Colitis [see  Warnings and Precautions (5.2)  ]    *  Pneumonitis [see  Warnings and Precautions (5.3)  ]    *  Intestinal Perforation [see  Warnings and Precautions (5.4)  ]    *  Severe Cutaneous Reactions [see  Warnings and Precautions (5.5)  ]    *  Anaphylaxis [see  Warnings and Precautions (5.6)  ]    *  Neutropenia [see  Warnings and Precautions (5.7)  ]         EXCERPT:   The most common adverse reactions (incidence >=20%) are diarrhea, pyrexia, fatigue, nausea, cough, pneumonia, abdominal pain, chills, and rash (  6.1  ).",pneumonia is an adverse reaction entity
"*  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Severe Diarrhea or Colitis [see  Warnings and Precautions (5.2)  ]    *  Pneumonitis [see  Warnings and Precautions (5.3)  ]    *  Intestinal Perforation [see  Warnings and Precautions (5.4)  ]    *  Severe Cutaneous Reactions [see  Warnings and Precautions (5.5)  ]    *  Anaphylaxis [see  Warnings and Precautions (5.6)  ]    *  Neutropenia [see  Warnings and Precautions (5.7)  ]         EXCERPT:   The most common adverse reactions (incidence >=20%) are diarrhea, pyrexia, fatigue, nausea, cough, pneumonia, abdominal pain, chills, and rash (  6.1  ).",) ] * is not a named entity
"*  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Severe Diarrhea or Colitis [see  Warnings and Precautions (5.2)  ]    *  Pneumonitis [see  Warnings and Precautions (5.3)  ]    *  Intestinal Perforation [see  Warnings and Precautions (5.4)  ]    *  Severe Cutaneous Reactions [see  Warnings and Precautions (5.5)  ]    *  Anaphylaxis [see  Warnings and Precautions (5.6)  ]    *  Neutropenia [see  Warnings and Precautions (5.7)  ]         EXCERPT:   The most common adverse reactions (incidence >=20%) are diarrhea, pyrexia, fatigue, nausea, cough, pneumonia, abdominal pain, chills, and rash (  6.1  ).",] * Pneumonitis is not a named entity
"*  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Severe Diarrhea or Colitis [see  Warnings and Precautions (5.2)  ]    *  Pneumonitis [see  Warnings and Precautions (5.3)  ]    *  Intestinal Perforation [see  Warnings and Precautions (5.4)  ]    *  Severe Cutaneous Reactions [see  Warnings and Precautions (5.5)  ]    *  Anaphylaxis [see  Warnings and Precautions (5.6)  ]    *  Neutropenia [see  Warnings and Precautions (5.7)  ]         EXCERPT:   The most common adverse reactions (incidence >=20%) are diarrhea, pyrexia, fatigue, nausea, cough, pneumonia, abdominal pain, chills, and rash (  6.1  ).",[ see Warnings is not a named entity
"*  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Severe Diarrhea or Colitis [see  Warnings and Precautions (5.2)  ]    *  Pneumonitis [see  Warnings and Precautions (5.3)  ]    *  Intestinal Perforation [see  Warnings and Precautions (5.4)  ]    *  Severe Cutaneous Reactions [see  Warnings and Precautions (5.5)  ]    *  Anaphylaxis [see  Warnings and Precautions (5.6)  ]    *  Neutropenia [see  Warnings and Precautions (5.7)  ]         EXCERPT:   The most common adverse reactions (incidence >=20%) are diarrhea, pyrexia, fatigue, nausea, cough, pneumonia, abdominal pain, chills, and rash (  6.1  ).",adverse reactions is not a named entity
"*  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Severe Diarrhea or Colitis [see  Warnings and Precautions (5.2)  ]    *  Pneumonitis [see  Warnings and Precautions (5.3)  ]    *  Intestinal Perforation [see  Warnings and Precautions (5.4)  ]    *  Severe Cutaneous Reactions [see  Warnings and Precautions (5.5)  ]    *  Anaphylaxis [see  Warnings and Precautions (5.6)  ]    *  Neutropenia [see  Warnings and Precautions (5.7)  ]         EXCERPT:   The most common adverse reactions (incidence >=20%) are diarrhea, pyrexia, fatigue, nausea, cough, pneumonia, abdominal pain, chills, and rash (  6.1  ).",Diarrhea is an adverse reaction entity
"*  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Severe Diarrhea or Colitis [see  Warnings and Precautions (5.2)  ]    *  Pneumonitis [see  Warnings and Precautions (5.3)  ]    *  Intestinal Perforation [see  Warnings and Precautions (5.4)  ]    *  Severe Cutaneous Reactions [see  Warnings and Precautions (5.5)  ]    *  Anaphylaxis [see  Warnings and Precautions (5.6)  ]    *  Neutropenia [see  Warnings and Precautions (5.7)  ]         EXCERPT:   The most common adverse reactions (incidence >=20%) are diarrhea, pyrexia, fatigue, nausea, cough, pneumonia, abdominal pain, chills, and rash (  6.1  ).",abdominal pain is an adverse reaction entity
"*  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Severe Diarrhea or Colitis [see  Warnings and Precautions (5.2)  ]    *  Pneumonitis [see  Warnings and Precautions (5.3)  ]    *  Intestinal Perforation [see  Warnings and Precautions (5.4)  ]    *  Severe Cutaneous Reactions [see  Warnings and Precautions (5.5)  ]    *  Anaphylaxis [see  Warnings and Precautions (5.6)  ]    *  Neutropenia [see  Warnings and Precautions (5.7)  ]         EXCERPT:   The most common adverse reactions (incidence >=20%) are diarrhea, pyrexia, fatigue, nausea, cough, pneumonia, abdominal pain, chills, and rash (  6.1  ).",[ see is not a named entity
"*  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Severe Diarrhea or Colitis [see  Warnings and Precautions (5.2)  ]    *  Pneumonitis [see  Warnings and Precautions (5.3)  ]    *  Intestinal Perforation [see  Warnings and Precautions (5.4)  ]    *  Severe Cutaneous Reactions [see  Warnings and Precautions (5.5)  ]    *  Anaphylaxis [see  Warnings and Precautions (5.6)  ]    *  Neutropenia [see  Warnings and Precautions (5.7)  ]         EXCERPT:   The most common adverse reactions (incidence >=20%) are diarrhea, pyrexia, fatigue, nausea, cough, pneumonia, abdominal pain, chills, and rash (  6.1  ).",chills is an adverse reaction entity
"*  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Severe Diarrhea or Colitis [see  Warnings and Precautions (5.2)  ]    *  Pneumonitis [see  Warnings and Precautions (5.3)  ]    *  Intestinal Perforation [see  Warnings and Precautions (5.4)  ]    *  Severe Cutaneous Reactions [see  Warnings and Precautions (5.5)  ]    *  Anaphylaxis [see  Warnings and Precautions (5.6)  ]    *  Neutropenia [see  Warnings and Precautions (5.7)  ]         EXCERPT:   The most common adverse reactions (incidence >=20%) are diarrhea, pyrexia, fatigue, nausea, cough, pneumonia, abdominal pain, chills, and rash (  6.1  ).",Neutropenia is an adverse reaction entity
"*  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Severe Diarrhea or Colitis [see  Warnings and Precautions (5.2)  ]    *  Pneumonitis [see  Warnings and Precautions (5.3)  ]    *  Intestinal Perforation [see  Warnings and Precautions (5.4)  ]    *  Severe Cutaneous Reactions [see  Warnings and Precautions (5.5)  ]    *  Anaphylaxis [see  Warnings and Precautions (5.6)  ]    *  Neutropenia [see  Warnings and Precautions (5.7)  ]         EXCERPT:   The most common adverse reactions (incidence >=20%) are diarrhea, pyrexia, fatigue, nausea, cough, pneumonia, abdominal pain, chills, and rash (  6.1  ).",Hepatotoxicity is an adverse reaction entity
"*  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Severe Diarrhea or Colitis [see  Warnings and Precautions (5.2)  ]    *  Pneumonitis [see  Warnings and Precautions (5.3)  ]    *  Intestinal Perforation [see  Warnings and Precautions (5.4)  ]    *  Severe Cutaneous Reactions [see  Warnings and Precautions (5.5)  ]    *  Anaphylaxis [see  Warnings and Precautions (5.6)  ]    *  Neutropenia [see  Warnings and Precautions (5.7)  ]         EXCERPT:   The most common adverse reactions (incidence >=20%) are diarrhea, pyrexia, fatigue, nausea, cough, pneumonia, abdominal pain, chills, and rash (  6.1  ).",Pneumonitis is an adverse reaction entity
"*  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Severe Diarrhea or Colitis [see  Warnings and Precautions (5.2)  ]    *  Pneumonitis [see  Warnings and Precautions (5.3)  ]    *  Intestinal Perforation [see  Warnings and Precautions (5.4)  ]    *  Severe Cutaneous Reactions [see  Warnings and Precautions (5.5)  ]    *  Anaphylaxis [see  Warnings and Precautions (5.6)  ]    *  Neutropenia [see  Warnings and Precautions (5.7)  ]         EXCERPT:   The most common adverse reactions (incidence >=20%) are diarrhea, pyrexia, fatigue, nausea, cough, pneumonia, abdominal pain, chills, and rash (  6.1  ).",Colitis is an adverse reaction entity
"*  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Severe Diarrhea or Colitis [see  Warnings and Precautions (5.2)  ]    *  Pneumonitis [see  Warnings and Precautions (5.3)  ]    *  Intestinal Perforation [see  Warnings and Precautions (5.4)  ]    *  Severe Cutaneous Reactions [see  Warnings and Precautions (5.5)  ]    *  Anaphylaxis [see  Warnings and Precautions (5.6)  ]    *  Neutropenia [see  Warnings and Precautions (5.7)  ]         EXCERPT:   The most common adverse reactions (incidence >=20%) are diarrhea, pyrexia, fatigue, nausea, cough, pneumonia, abdominal pain, chills, and rash (  6.1  ).",rash is an adverse reaction entity
"*  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Severe Diarrhea or Colitis [see  Warnings and Precautions (5.2)  ]    *  Pneumonitis [see  Warnings and Precautions (5.3)  ]    *  Intestinal Perforation [see  Warnings and Precautions (5.4)  ]    *  Severe Cutaneous Reactions [see  Warnings and Precautions (5.5)  ]    *  Anaphylaxis [see  Warnings and Precautions (5.6)  ]    *  Neutropenia [see  Warnings and Precautions (5.7)  ]         EXCERPT:   The most common adverse reactions (incidence >=20%) are diarrhea, pyrexia, fatigue, nausea, cough, pneumonia, abdominal pain, chills, and rash (  6.1  ).",and is not a named entity
"*  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Severe Diarrhea or Colitis [see  Warnings and Precautions (5.2)  ]    *  Pneumonitis [see  Warnings and Precautions (5.3)  ]    *  Intestinal Perforation [see  Warnings and Precautions (5.4)  ]    *  Severe Cutaneous Reactions [see  Warnings and Precautions (5.5)  ]    *  Anaphylaxis [see  Warnings and Precautions (5.6)  ]    *  Neutropenia [see  Warnings and Precautions (5.7)  ]         EXCERPT:   The most common adverse reactions (incidence >=20%) are diarrhea, pyrexia, fatigue, nausea, cough, pneumonia, abdominal pain, chills, and rash (  6.1  ).","cough , is not a named entity"
"*  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Severe Diarrhea or Colitis [see  Warnings and Precautions (5.2)  ]    *  Pneumonitis [see  Warnings and Precautions (5.3)  ]    *  Intestinal Perforation [see  Warnings and Precautions (5.4)  ]    *  Severe Cutaneous Reactions [see  Warnings and Precautions (5.5)  ]    *  Anaphylaxis [see  Warnings and Precautions (5.6)  ]    *  Neutropenia [see  Warnings and Precautions (5.7)  ]         EXCERPT:   The most common adverse reactions (incidence >=20%) are diarrhea, pyrexia, fatigue, nausea, cough, pneumonia, abdominal pain, chills, and rash (  6.1  ).",Neutropenia [ see is not a named entity
"*  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Severe Diarrhea or Colitis [see  Warnings and Precautions (5.2)  ]    *  Pneumonitis [see  Warnings and Precautions (5.3)  ]    *  Intestinal Perforation [see  Warnings and Precautions (5.4)  ]    *  Severe Cutaneous Reactions [see  Warnings and Precautions (5.5)  ]    *  Anaphylaxis [see  Warnings and Precautions (5.6)  ]    *  Neutropenia [see  Warnings and Precautions (5.7)  ]         EXCERPT:   The most common adverse reactions (incidence >=20%) are diarrhea, pyrexia, fatigue, nausea, cough, pneumonia, abdominal pain, chills, and rash (  6.1  ).",cough is an adverse reaction entity
"*  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Severe Diarrhea or Colitis [see  Warnings and Precautions (5.2)  ]    *  Pneumonitis [see  Warnings and Precautions (5.3)  ]    *  Intestinal Perforation [see  Warnings and Precautions (5.4)  ]    *  Severe Cutaneous Reactions [see  Warnings and Precautions (5.5)  ]    *  Anaphylaxis [see  Warnings and Precautions (5.6)  ]    *  Neutropenia [see  Warnings and Precautions (5.7)  ]         EXCERPT:   The most common adverse reactions (incidence >=20%) are diarrhea, pyrexia, fatigue, nausea, cough, pneumonia, abdominal pain, chills, and rash (  6.1  ).",pyrexia is an adverse reaction entity
"*  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Severe Diarrhea or Colitis [see  Warnings and Precautions (5.2)  ]    *  Pneumonitis [see  Warnings and Precautions (5.3)  ]    *  Intestinal Perforation [see  Warnings and Precautions (5.4)  ]    *  Severe Cutaneous Reactions [see  Warnings and Precautions (5.5)  ]    *  Anaphylaxis [see  Warnings and Precautions (5.6)  ]    *  Neutropenia [see  Warnings and Precautions (5.7)  ]         EXCERPT:   The most common adverse reactions (incidence >=20%) are diarrhea, pyrexia, fatigue, nausea, cough, pneumonia, abdominal pain, chills, and rash (  6.1  ).",", chills , is not a named entity"
"*  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Severe Diarrhea or Colitis [see  Warnings and Precautions (5.2)  ]    *  Pneumonitis [see  Warnings and Precautions (5.3)  ]    *  Intestinal Perforation [see  Warnings and Precautions (5.4)  ]    *  Severe Cutaneous Reactions [see  Warnings and Precautions (5.5)  ]    *  Anaphylaxis [see  Warnings and Precautions (5.6)  ]    *  Neutropenia [see  Warnings and Precautions (5.7)  ]         EXCERPT:   The most common adverse reactions (incidence >=20%) are diarrhea, pyrexia, fatigue, nausea, cough, pneumonia, abdominal pain, chills, and rash (  6.1  ).",Precautions ( 5.2 is not a named entity
"*  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Severe Diarrhea or Colitis [see  Warnings and Precautions (5.2)  ]    *  Pneumonitis [see  Warnings and Precautions (5.3)  ]    *  Intestinal Perforation [see  Warnings and Precautions (5.4)  ]    *  Severe Cutaneous Reactions [see  Warnings and Precautions (5.5)  ]    *  Anaphylaxis [see  Warnings and Precautions (5.6)  ]    *  Neutropenia [see  Warnings and Precautions (5.7)  ]         EXCERPT:   The most common adverse reactions (incidence >=20%) are diarrhea, pyrexia, fatigue, nausea, cough, pneumonia, abdominal pain, chills, and rash (  6.1  ).",reactions ( incidence is not a named entity
"*  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Severe Diarrhea or Colitis [see  Warnings and Precautions (5.2)  ]    *  Pneumonitis [see  Warnings and Precautions (5.3)  ]    *  Intestinal Perforation [see  Warnings and Precautions (5.4)  ]    *  Severe Cutaneous Reactions [see  Warnings and Precautions (5.5)  ]    *  Anaphylaxis [see  Warnings and Precautions (5.6)  ]    *  Neutropenia [see  Warnings and Precautions (5.7)  ]         EXCERPT:   The most common adverse reactions (incidence >=20%) are diarrhea, pyrexia, fatigue, nausea, cough, pneumonia, abdominal pain, chills, and rash (  6.1  ).",diarrhea is an adverse reaction entity
"*  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Severe Diarrhea or Colitis [see  Warnings and Precautions (5.2)  ]    *  Pneumonitis [see  Warnings and Precautions (5.3)  ]    *  Intestinal Perforation [see  Warnings and Precautions (5.4)  ]    *  Severe Cutaneous Reactions [see  Warnings and Precautions (5.5)  ]    *  Anaphylaxis [see  Warnings and Precautions (5.6)  ]    *  Neutropenia [see  Warnings and Precautions (5.7)  ]         EXCERPT:   The most common adverse reactions (incidence >=20%) are diarrhea, pyrexia, fatigue, nausea, cough, pneumonia, abdominal pain, chills, and rash (  6.1  ).",Anaphylaxis is an adverse reaction entity
"*  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Severe Diarrhea or Colitis [see  Warnings and Precautions (5.2)  ]    *  Pneumonitis [see  Warnings and Precautions (5.3)  ]    *  Intestinal Perforation [see  Warnings and Precautions (5.4)  ]    *  Severe Cutaneous Reactions [see  Warnings and Precautions (5.5)  ]    *  Anaphylaxis [see  Warnings and Precautions (5.6)  ]    *  Neutropenia [see  Warnings and Precautions (5.7)  ]         EXCERPT:   The most common adverse reactions (incidence >=20%) are diarrhea, pyrexia, fatigue, nausea, cough, pneumonia, abdominal pain, chills, and rash (  6.1  ).",( is not a named entity
"*  Hepatotoxicity [see  Warnings and Precautions (5.1)  ]    *  Severe Diarrhea or Colitis [see  Warnings and Precautions (5.2)  ]    *  Pneumonitis [see  Warnings and Precautions (5.3)  ]    *  Intestinal Perforation [see  Warnings and Precautions (5.4)  ]    *  Severe Cutaneous Reactions [see  Warnings and Precautions (5.5)  ]    *  Anaphylaxis [see  Warnings and Precautions (5.6)  ]    *  Neutropenia [see  Warnings and Precautions (5.7)  ]         EXCERPT:   The most common adverse reactions (incidence >=20%) are diarrhea, pyrexia, fatigue, nausea, cough, pneumonia, abdominal pain, chills, and rash (  6.1  ).",Cutaneous Reactions is an adverse reaction entity
"The most frequent (>=2%) serious adverse reactions reported for subjects treated with Zydelig were pneumonia (17%), pyrexia (9%), sepsis (8%), febrile neutropenia (5%) and diarrhea (5%).","% ) , is not a named entity"
"The most frequent (>=2%) serious adverse reactions reported for subjects treated with Zydelig were pneumonia (17%), pyrexia (9%), sepsis (8%), febrile neutropenia (5%) and diarrhea (5%).",pneumonia is an adverse reaction entity
"The most frequent (>=2%) serious adverse reactions reported for subjects treated with Zydelig were pneumonia (17%), pyrexia (9%), sepsis (8%), febrile neutropenia (5%) and diarrhea (5%).",% ) is not a named entity
"The most frequent (>=2%) serious adverse reactions reported for subjects treated with Zydelig were pneumonia (17%), pyrexia (9%), sepsis (8%), febrile neutropenia (5%) and diarrhea (5%).",reactions reported is not a named entity
"The most frequent (>=2%) serious adverse reactions reported for subjects treated with Zydelig were pneumonia (17%), pyrexia (9%), sepsis (8%), febrile neutropenia (5%) and diarrhea (5%).",sepsis is an adverse reaction entity
"The most frequent (>=2%) serious adverse reactions reported for subjects treated with Zydelig were pneumonia (17%), pyrexia (9%), sepsis (8%), febrile neutropenia (5%) and diarrhea (5%).",febrile neutropenia is an adverse reaction entity
"The most frequent (>=2%) serious adverse reactions reported for subjects treated with Zydelig were pneumonia (17%), pyrexia (9%), sepsis (8%), febrile neutropenia (5%) and diarrhea (5%).",pyrexia is an adverse reaction entity
"The most frequent (>=2%) serious adverse reactions reported for subjects treated with Zydelig were pneumonia (17%), pyrexia (9%), sepsis (8%), febrile neutropenia (5%) and diarrhea (5%).",diarrhea is an adverse reaction entity
"The most frequent (>=2%) serious adverse reactions reported for subjects treated with Zydelig were pneumonia (17%), pyrexia (9%), sepsis (8%), febrile neutropenia (5%) and diarrhea (5%).",8 % is not a named entity
"The most frequent (>=2%) serious adverse reactions reported for subjects treated with Zydelig were pneumonia (17%), pyrexia (9%), sepsis (8%), febrile neutropenia (5%) and diarrhea (5%).",serious is not a named entity
5.3 Pneumonitis      Fatal and serious pneumonitis occurred in patients treated with Zydelig.,patients treated is not a named entity
5.3 Pneumonitis      Fatal and serious pneumonitis occurred in patients treated with Zydelig.,Fatal is an adverse reaction entity
5.3 Pneumonitis      Fatal and serious pneumonitis occurred in patients treated with Zydelig.,pneumonitis is an adverse reaction entity
5.3 Pneumonitis      Fatal and serious pneumonitis occurred in patients treated with Zydelig.,Fatal and serious is not a named entity
( 5.2)   *  Fatal and serious pneumonitis can occur in Zydelig-treated patients.,pneumonitis is an adverse reaction entity
( 5.2)   *  Fatal and serious pneumonitis can occur in Zydelig-treated patients.,( is not a named entity
( 5.2)   *  Fatal and serious pneumonitis can occur in Zydelig-treated patients.,occur is not a named entity
( 5.2)   *  Fatal and serious pneumonitis can occur in Zydelig-treated patients.,Fatal is an adverse reaction entity
( 5.3)   *  Fatal and serious intestinal perforation can occur in Zydelig-treated patients across clinical trials.,serious is not a named entity
( 5.3)   *  Fatal and serious intestinal perforation can occur in Zydelig-treated patients across clinical trials.,intestinal perforation is an adverse reaction entity
( 5.3)   *  Fatal and serious intestinal perforation can occur in Zydelig-treated patients across clinical trials.,Fatal is an adverse reaction entity
( 5.3)   *  Fatal and serious intestinal perforation can occur in Zydelig-treated patients across clinical trials.,occur is not a named entity
5.7 Neutropenia      Treatment-emergent Grade 3 or 4 neutropenia occurred in 31% of Zydelig-treated patients across clinical trials [see  Adverse Reactions (6.1)  ].,neutropenia is an adverse reaction entity
5.7 Neutropenia      Treatment-emergent Grade 3 or 4 neutropenia occurred in 31% of Zydelig-treated patients across clinical trials [see  Adverse Reactions (6.1)  ].,3 or 4 is not a named entity
*  Fatal and/or serious hepatotoxicity occurred in 14% of Zydelig-treated patients.,Fatal is an adverse reaction entity
*  Fatal and/or serious hepatotoxicity occurred in 14% of Zydelig-treated patients.,of is not a named entity
*  Fatal and/or serious hepatotoxicity occurred in 14% of Zydelig-treated patients.,hepatotoxicity is an adverse reaction entity
*  Fatal and/or serious hepatotoxicity occurred in 14% of Zydelig-treated patients.,occurred is not a named entity
*  Fatal and serious intestinal perforation can occur in Zydelig-treated patients across clinical trials.,Fatal is an adverse reaction entity
*  Fatal and serious intestinal perforation can occur in Zydelig-treated patients across clinical trials.,intestinal perforation is an adverse reaction entity
*  Fatal and serious intestinal perforation can occur in Zydelig-treated patients across clinical trials.,and serious intestinal is not a named entity
*  Fatal and serious intestinal perforation can occur in Zydelig-treated patients across clinical trials.,perforation can occur is not a named entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Severe cutaneous reactions: Monitor patients for the development of severe cutaneous reactions and discontinue Zydelig.,EXCERPT : is not a named entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Severe cutaneous reactions: Monitor patients for the development of severe cutaneous reactions and discontinue Zydelig.,cutaneous reactions is an adverse reaction entity
"After resumption of treatment at a lower dose, 26% of patients had recurrence of ALT and AST elevations.",a lower dose is not a named entity
"After resumption of treatment at a lower dose, 26% of patients had recurrence of ALT and AST elevations.",recurrence ALT elevations is an adverse reaction entity
"After resumption of treatment at a lower dose, 26% of patients had recurrence of ALT and AST elevations.",recurrence AST elevations is an adverse reaction entity
"After resumption of treatment at a lower dose, 26% of patients had recurrence of ALT and AST elevations.",and AST elevations is not a named entity
"The most frequent serious adverse reactions that occurred were pneumonia (15%), diarrhea (11%), and pyrexia (9%).",pneumonia is an adverse reaction entity
"The most frequent serious adverse reactions that occurred were pneumonia (15%), diarrhea (11%), and pyrexia (9%).",diarrhea is an adverse reaction entity
"The most frequent serious adverse reactions that occurred were pneumonia (15%), diarrhea (11%), and pyrexia (9%).",pyrexia is an adverse reaction entity
"The most frequent serious adverse reactions that occurred were pneumonia (15%), diarrhea (11%), and pyrexia (9%).",serious adverse reactions is not a named entity
"The most frequent serious adverse reactions that occurred were pneumonia (15%), diarrhea (11%), and pyrexia (9%).",( is not a named entity
"The most frequent serious adverse reactions that occurred were pneumonia (15%), diarrhea (11%), and pyrexia (9%).",11 % is not a named entity
Elevations in ALT or AST greater than 5 times the upper limit of normal have occurred [see  Adverse Reactions (6.1)  ].,Elevations in AST is an adverse reaction entity
Elevations in ALT or AST greater than 5 times the upper limit of normal have occurred [see  Adverse Reactions (6.1)  ].,limit is not a named entity
Elevations in ALT or AST greater than 5 times the upper limit of normal have occurred [see  Adverse Reactions (6.1)  ].,Elevations in ALT is an adverse reaction entity
Elevations in ALT or AST greater than 5 times the upper limit of normal have occurred [see  Adverse Reactions (6.1)  ].,Reactions is not a named entity
5.4 Intestinal Perforation      Fatal and serious intestinal perforation occurred in Zydelig-treated patients.,occurred in Zydelig-treated is not a named entity
5.4 Intestinal Perforation      Fatal and serious intestinal perforation occurred in Zydelig-treated patients.,intestinal perforation is an adverse reaction entity
5.4 Intestinal Perforation      Fatal and serious intestinal perforation occurred in Zydelig-treated patients.,Perforation Fatal and is not a named entity
5.4 Intestinal Perforation      Fatal and serious intestinal perforation occurred in Zydelig-treated patients.,Fatal is an adverse reaction entity
Dose modifications       Adverse reactions that led to dose delays in more than 5% of patients in Studies 1 and 2 were neutropenia (14%) and peripheral sensory neuropathy (11%)  [see  Dosage and Administration (        2.2        )  ]  .,neutropenia is an adverse reaction entity
Dose modifications       Adverse reactions that led to dose delays in more than 5% of patients in Studies 1 and 2 were neutropenia (14%) and peripheral sensory neuropathy (11%)  [see  Dosage and Administration (        2.2        )  ]  .,patients in is not a named entity
Dose modifications       Adverse reactions that led to dose delays in more than 5% of patients in Studies 1 and 2 were neutropenia (14%) and peripheral sensory neuropathy (11%)  [see  Dosage and Administration (        2.2        )  ]  .,peripheral sensory neuropathy is an adverse reaction entity
Dose modifications       Adverse reactions that led to dose delays in more than 5% of patients in Studies 1 and 2 were neutropenia (14%) and peripheral sensory neuropathy (11%)  [see  Dosage and Administration (        2.2        )  ]  .,2 is not a named entity
"In Study 3, 67% of patients treated with ADCETRIS experienced any grade of neuropathy.",neuropathy is an adverse reaction entity
"In Study 3, 67% of patients treated with ADCETRIS experienced any grade of neuropathy.",grade is not a named entity
"However, based on its mechanism of action and findings in animals, ADCETRIS can cause fetal harm when administered to a pregnant woman.",", based on is not a named entity"
"However, based on its mechanism of action and findings in animals, ADCETRIS can cause fetal harm when administered to a pregnant woman.",fetal harm is an adverse reaction entity
"The most common serious adverse reactions experienced by patients with classical HL include peripheral motor neuropathy (4%), abdominal pain (3%), pulmonary embolism (2%), pneumonitis (2%), pneumothorax (2%), pyelonephritis (2%), and pyrexia (2%).",% ) is not a named entity
"The most common serious adverse reactions experienced by patients with classical HL include peripheral motor neuropathy (4%), abdominal pain (3%), pulmonary embolism (2%), pneumonitis (2%), pneumothorax (2%), pyelonephritis (2%), and pyrexia (2%).",pyelonephritis is an adverse reaction entity
"The most common serious adverse reactions experienced by patients with classical HL include peripheral motor neuropathy (4%), abdominal pain (3%), pulmonary embolism (2%), pneumonitis (2%), pneumothorax (2%), pyelonephritis (2%), and pyrexia (2%).",( 2 % is not a named entity
"The most common serious adverse reactions experienced by patients with classical HL include peripheral motor neuropathy (4%), abdominal pain (3%), pulmonary embolism (2%), pneumonitis (2%), pneumothorax (2%), pyelonephritis (2%), and pyrexia (2%).",pneumothorax is an adverse reaction entity
"The most common serious adverse reactions experienced by patients with classical HL include peripheral motor neuropathy (4%), abdominal pain (3%), pulmonary embolism (2%), pneumonitis (2%), pneumothorax (2%), pyelonephritis (2%), and pyrexia (2%).",common serious adverse is not a named entity
"The most common serious adverse reactions experienced by patients with classical HL include peripheral motor neuropathy (4%), abdominal pain (3%), pulmonary embolism (2%), pneumonitis (2%), pneumothorax (2%), pyelonephritis (2%), and pyrexia (2%).",most common serious is not a named entity
"The most common serious adverse reactions experienced by patients with classical HL include peripheral motor neuropathy (4%), abdominal pain (3%), pulmonary embolism (2%), pneumonitis (2%), pneumothorax (2%), pyelonephritis (2%), and pyrexia (2%).",abdominal pain is an adverse reaction entity
"The most common serious adverse reactions experienced by patients with classical HL include peripheral motor neuropathy (4%), abdominal pain (3%), pulmonary embolism (2%), pneumonitis (2%), pneumothorax (2%), pyelonephritis (2%), and pyrexia (2%).",motor neuropathy ( is not a named entity
"The most common serious adverse reactions experienced by patients with classical HL include peripheral motor neuropathy (4%), abdominal pain (3%), pulmonary embolism (2%), pneumonitis (2%), pneumothorax (2%), pyelonephritis (2%), and pyrexia (2%).",pulmonary embolism is an adverse reaction entity
"The most common serious adverse reactions experienced by patients with classical HL include peripheral motor neuropathy (4%), abdominal pain (3%), pulmonary embolism (2%), pneumonitis (2%), pneumothorax (2%), pyelonephritis (2%), and pyrexia (2%).",pyrexia is an adverse reaction entity
"The most common serious adverse reactions experienced by patients with classical HL include peripheral motor neuropathy (4%), abdominal pain (3%), pulmonary embolism (2%), pneumonitis (2%), pneumothorax (2%), pyelonephritis (2%), and pyrexia (2%).",") , pulmonary is not a named entity"
"The most common serious adverse reactions experienced by patients with classical HL include peripheral motor neuropathy (4%), abdominal pain (3%), pulmonary embolism (2%), pneumonitis (2%), pneumothorax (2%), pyelonephritis (2%), and pyrexia (2%).",pneumothorax ( is not a named entity
"The most common serious adverse reactions experienced by patients with classical HL include peripheral motor neuropathy (4%), abdominal pain (3%), pulmonary embolism (2%), pneumonitis (2%), pneumothorax (2%), pyelonephritis (2%), and pyrexia (2%).",pneumonitis is an adverse reaction entity
"The most common serious adverse reactions experienced by patients with classical HL include peripheral motor neuropathy (4%), abdominal pain (3%), pulmonary embolism (2%), pneumonitis (2%), pneumothorax (2%), pyelonephritis (2%), and pyrexia (2%).",peripheral motor neuropathy is an adverse reaction entity
5.7 Increased Toxicity in the Presence of Moderate or Severe Hepatic Impairment         The frequency of >=Grade 3 adverse reactions and deaths was greater in patients with moderate and severe hepatic impairment compared to patients with normal hepatic function.,deaths is an adverse reaction entity
5.7 Increased Toxicity in the Presence of Moderate or Severe Hepatic Impairment         The frequency of >=Grade 3 adverse reactions and deaths was greater in patients with moderate and severe hepatic impairment compared to patients with normal hepatic function.,adverse reactions is not a named entity
*   Tumor lysis syndrome : Closely monitor patients with rapidly proliferating tumor or high tumor burden  (5.5)  .,: Closely is not a named entity
*   Tumor lysis syndrome : Closely monitor patients with rapidly proliferating tumor or high tumor burden  (5.5)  .,Tumor lysis syndrome is an adverse reaction entity
"The most common adverse reactions (>=2%) associated with infusion-related reactions were nausea (4%), chills (4%), dyspnea (2%), headache (2%), pruritus (2%), rash (2%), back pain (2%), and vomiting (2%).",chills is an adverse reaction entity
"The most common adverse reactions (>=2%) associated with infusion-related reactions were nausea (4%), chills (4%), dyspnea (2%), headache (2%), pruritus (2%), rash (2%), back pain (2%), and vomiting (2%).",( is not a named entity
"The most common adverse reactions (>=2%) associated with infusion-related reactions were nausea (4%), chills (4%), dyspnea (2%), headache (2%), pruritus (2%), rash (2%), back pain (2%), and vomiting (2%).",were is not a named entity
"The most common adverse reactions (>=2%) associated with infusion-related reactions were nausea (4%), chills (4%), dyspnea (2%), headache (2%), pruritus (2%), rash (2%), back pain (2%), and vomiting (2%).",( 2 % is not a named entity
"The most common adverse reactions (>=2%) associated with infusion-related reactions were nausea (4%), chills (4%), dyspnea (2%), headache (2%), pruritus (2%), rash (2%), back pain (2%), and vomiting (2%).",pruritus is an adverse reaction entity
"The most common adverse reactions (>=2%) associated with infusion-related reactions were nausea (4%), chills (4%), dyspnea (2%), headache (2%), pruritus (2%), rash (2%), back pain (2%), and vomiting (2%).",", is not a named entity"
"The most common adverse reactions (>=2%) associated with infusion-related reactions were nausea (4%), chills (4%), dyspnea (2%), headache (2%), pruritus (2%), rash (2%), back pain (2%), and vomiting (2%).",) associated with is not a named entity
"The most common adverse reactions (>=2%) associated with infusion-related reactions were nausea (4%), chills (4%), dyspnea (2%), headache (2%), pruritus (2%), rash (2%), back pain (2%), and vomiting (2%).",2 % ) is not a named entity
"The most common adverse reactions (>=2%) associated with infusion-related reactions were nausea (4%), chills (4%), dyspnea (2%), headache (2%), pruritus (2%), rash (2%), back pain (2%), and vomiting (2%).",headache is an adverse reaction entity
"The most common adverse reactions (>=2%) associated with infusion-related reactions were nausea (4%), chills (4%), dyspnea (2%), headache (2%), pruritus (2%), rash (2%), back pain (2%), and vomiting (2%).",adverse reactions ( is not a named entity
"The most common adverse reactions (>=2%) associated with infusion-related reactions were nausea (4%), chills (4%), dyspnea (2%), headache (2%), pruritus (2%), rash (2%), back pain (2%), and vomiting (2%).",infusion-related reactions is an adverse reaction entity
"The most common adverse reactions (>=2%) associated with infusion-related reactions were nausea (4%), chills (4%), dyspnea (2%), headache (2%), pruritus (2%), rash (2%), back pain (2%), and vomiting (2%).",dyspnea is an adverse reaction entity
"The most common adverse reactions (>=2%) associated with infusion-related reactions were nausea (4%), chills (4%), dyspnea (2%), headache (2%), pruritus (2%), rash (2%), back pain (2%), and vomiting (2%).",back pain is an adverse reaction entity
"The most common adverse reactions (>=2%) associated with infusion-related reactions were nausea (4%), chills (4%), dyspnea (2%), headache (2%), pruritus (2%), rash (2%), back pain (2%), and vomiting (2%).",nausea is an adverse reaction entity
"The most common adverse reactions (>=2%) associated with infusion-related reactions were nausea (4%), chills (4%), dyspnea (2%), headache (2%), pruritus (2%), rash (2%), back pain (2%), and vomiting (2%).",rash is an adverse reaction entity
"The most common adverse reactions (>=2%) associated with infusion-related reactions were nausea (4%), chills (4%), dyspnea (2%), headache (2%), pruritus (2%), rash (2%), back pain (2%), and vomiting (2%).",2 is not a named entity
"The most common adverse reactions (>=2%) associated with infusion-related reactions were nausea (4%), chills (4%), dyspnea (2%), headache (2%), pruritus (2%), rash (2%), back pain (2%), and vomiting (2%).",vomiting is an adverse reaction entity
"The most common adverse reactions (>=2%) associated with infusion-related reactions were nausea (4%), chills (4%), dyspnea (2%), headache (2%), pruritus (2%), rash (2%), back pain (2%), and vomiting (2%).",infusion-related reactions were is not a named entity
5 WARNINGS AND PRECAUTIONS         EXCERPT:    *   Peripheral neuropathy : Monitor patients for neuropathy and institute dose modifications accordingly  (5.1)  .,dose is not a named entity
5 WARNINGS AND PRECAUTIONS         EXCERPT:    *   Peripheral neuropathy : Monitor patients for neuropathy and institute dose modifications accordingly  (5.1)  .,Peripheral neuropathy is an adverse reaction entity
"The most common serious adverse reactions experienced by patients with sALCL were septic shock (3%), supraventricular arrhythmia (3%), pain in extremity (3%), and urinary tract infection (3%).",pain in extremity is an adverse reaction entity
"The most common serious adverse reactions experienced by patients with sALCL were septic shock (3%), supraventricular arrhythmia (3%), pain in extremity (3%), and urinary tract infection (3%).",shock is not a named entity
"The most common serious adverse reactions experienced by patients with sALCL were septic shock (3%), supraventricular arrhythmia (3%), pain in extremity (3%), and urinary tract infection (3%).",urinary tract infection is an adverse reaction entity
"The most common serious adverse reactions experienced by patients with sALCL were septic shock (3%), supraventricular arrhythmia (3%), pain in extremity (3%), and urinary tract infection (3%).",supraventricular arrhythmia is an adverse reaction entity
"The most common serious adverse reactions experienced by patients with sALCL were septic shock (3%), supraventricular arrhythmia (3%), pain in extremity (3%), and urinary tract infection (3%).",shock ( is not a named entity
"The most common serious adverse reactions experienced by patients with sALCL were septic shock (3%), supraventricular arrhythmia (3%), pain in extremity (3%), and urinary tract infection (3%).",The most is not a named entity
"The most common serious adverse reactions experienced by patients with sALCL were septic shock (3%), supraventricular arrhythmia (3%), pain in extremity (3%), and urinary tract infection (3%).",septic shock is an adverse reaction entity
"The most common serious adverse reactions experienced by patients with sALCL were septic shock (3%), supraventricular arrhythmia (3%), pain in extremity (3%), and urinary tract infection (3%).",", is not a named entity"
"In Study 3, pulmonary toxicity was reported in 8 patients (5%) in the ADCETRIS-treated arm and 5 patients (3%) in the placebo arm.",3 % ) is not a named entity
"In Study 3, pulmonary toxicity was reported in 8 patients (5%) in the ADCETRIS-treated arm and 5 patients (3%) in the placebo arm.",pulmonary toxicity is an adverse reaction entity
"Adverse reactions that led to treatment discontinuation in 2 or more patients were peripheral sensory neuropathy (14%), peripheral motor neuropathy (7%), acute respiratory distress syndrome (1%), paraesthesia (1%) and vomiting (1%).",discontinuation in 2 is not a named entity
"Adverse reactions that led to treatment discontinuation in 2 or more patients were peripheral sensory neuropathy (14%), peripheral motor neuropathy (7%), acute respiratory distress syndrome (1%), paraesthesia (1%) and vomiting (1%).",peripheral sensory neuropathy is an adverse reaction entity
"Adverse reactions that led to treatment discontinuation in 2 or more patients were peripheral sensory neuropathy (14%), peripheral motor neuropathy (7%), acute respiratory distress syndrome (1%), paraesthesia (1%) and vomiting (1%).",2 or more is not a named entity
"Adverse reactions that led to treatment discontinuation in 2 or more patients were peripheral sensory neuropathy (14%), peripheral motor neuropathy (7%), acute respiratory distress syndrome (1%), paraesthesia (1%) and vomiting (1%).",sensory neuropathy is not a named entity
"Adverse reactions that led to treatment discontinuation in 2 or more patients were peripheral sensory neuropathy (14%), peripheral motor neuropathy (7%), acute respiratory distress syndrome (1%), paraesthesia (1%) and vomiting (1%).",acute respiratory distress syndrome is an adverse reaction entity
"Adverse reactions that led to treatment discontinuation in 2 or more patients were peripheral sensory neuropathy (14%), peripheral motor neuropathy (7%), acute respiratory distress syndrome (1%), paraesthesia (1%) and vomiting (1%).",( is not a named entity
"Adverse reactions that led to treatment discontinuation in 2 or more patients were peripheral sensory neuropathy (14%), peripheral motor neuropathy (7%), acute respiratory distress syndrome (1%), paraesthesia (1%) and vomiting (1%).",", paraesthesia ( is not a named entity"
"Adverse reactions that led to treatment discontinuation in 2 or more patients were peripheral sensory neuropathy (14%), peripheral motor neuropathy (7%), acute respiratory distress syndrome (1%), paraesthesia (1%) and vomiting (1%).",vomiting is an adverse reaction entity
"Adverse reactions that led to treatment discontinuation in 2 or more patients were peripheral sensory neuropathy (14%), peripheral motor neuropathy (7%), acute respiratory distress syndrome (1%), paraesthesia (1%) and vomiting (1%).",paraesthesia is an adverse reaction entity
"Adverse reactions that led to treatment discontinuation in 2 or more patients were peripheral sensory neuropathy (14%), peripheral motor neuropathy (7%), acute respiratory distress syndrome (1%), paraesthesia (1%) and vomiting (1%).",peripheral motor neuropathy is an adverse reaction entity
"5.4 Serious Infections and Opportunistic Infections      Serious infections and opportunistic infections such as pneumonia, bacteremia, and sepsis or septic shock (including fatal outcomes) have been reported in patients treated with ADCETRIS.",including fatal outcomes is not a named entity
"5.4 Serious Infections and Opportunistic Infections      Serious infections and opportunistic infections such as pneumonia, bacteremia, and sepsis or septic shock (including fatal outcomes) have been reported in patients treated with ADCETRIS.",pneumonia is an adverse reaction entity
"5.4 Serious Infections and Opportunistic Infections      Serious infections and opportunistic infections such as pneumonia, bacteremia, and sepsis or septic shock (including fatal outcomes) have been reported in patients treated with ADCETRIS.",septic shock is an adverse reaction entity
"5.4 Serious Infections and Opportunistic Infections      Serious infections and opportunistic infections such as pneumonia, bacteremia, and sepsis or septic shock (including fatal outcomes) have been reported in patients treated with ADCETRIS.",fatal outcomes is not a named entity
"5.4 Serious Infections and Opportunistic Infections      Serious infections and opportunistic infections such as pneumonia, bacteremia, and sepsis or septic shock (including fatal outcomes) have been reported in patients treated with ADCETRIS.",opportunistic infections is an adverse reaction entity
"5.4 Serious Infections and Opportunistic Infections      Serious infections and opportunistic infections such as pneumonia, bacteremia, and sepsis or septic shock (including fatal outcomes) have been reported in patients treated with ADCETRIS.",Serious is not a named entity
"5.4 Serious Infections and Opportunistic Infections      Serious infections and opportunistic infections such as pneumonia, bacteremia, and sepsis or septic shock (including fatal outcomes) have been reported in patients treated with ADCETRIS.",treated with ADCETRIS is not a named entity
"5.4 Serious Infections and Opportunistic Infections      Serious infections and opportunistic infections such as pneumonia, bacteremia, and sepsis or septic shock (including fatal outcomes) have been reported in patients treated with ADCETRIS.",sepsis is an adverse reaction entity
"5.4 Serious Infections and Opportunistic Infections      Serious infections and opportunistic infections such as pneumonia, bacteremia, and sepsis or septic shock (including fatal outcomes) have been reported in patients treated with ADCETRIS.",infections is an adverse reaction entity
"5.4 Serious Infections and Opportunistic Infections      Serious infections and opportunistic infections such as pneumonia, bacteremia, and sepsis or septic shock (including fatal outcomes) have been reported in patients treated with ADCETRIS.",shock is not a named entity
"5.4 Serious Infections and Opportunistic Infections      Serious infections and opportunistic infections such as pneumonia, bacteremia, and sepsis or septic shock (including fatal outcomes) have been reported in patients treated with ADCETRIS.",sepsis or is not a named entity
"5.4 Serious Infections and Opportunistic Infections      Serious infections and opportunistic infections such as pneumonia, bacteremia, and sepsis or septic shock (including fatal outcomes) have been reported in patients treated with ADCETRIS.",or septic shock is not a named entity
"5.4 Serious Infections and Opportunistic Infections      Serious infections and opportunistic infections such as pneumonia, bacteremia, and sepsis or septic shock (including fatal outcomes) have been reported in patients treated with ADCETRIS.",fatal is an adverse reaction entity
"5.4 Serious Infections and Opportunistic Infections      Serious infections and opportunistic infections such as pneumonia, bacteremia, and sepsis or septic shock (including fatal outcomes) have been reported in patients treated with ADCETRIS.",bacteremia is an adverse reaction entity
"*  Classical HL post-auto-HSCT consolidation: neutropenia, peripheral sensory neuropathy, thrombocytopenia, anemia, upper respiratory tract infection, fatigue, peripheral motor neuropathy, nausea, cough, and diarrhea  (6.1)  .","fatigue , is not a named entity"
"*  Classical HL post-auto-HSCT consolidation: neutropenia, peripheral sensory neuropathy, thrombocytopenia, anemia, upper respiratory tract infection, fatigue, peripheral motor neuropathy, nausea, cough, and diarrhea  (6.1)  .",cough is an adverse reaction entity
"*  Classical HL post-auto-HSCT consolidation: neutropenia, peripheral sensory neuropathy, thrombocytopenia, anemia, upper respiratory tract infection, fatigue, peripheral motor neuropathy, nausea, cough, and diarrhea  (6.1)  .",neuropathy is not a named entity
"*  Classical HL post-auto-HSCT consolidation: neutropenia, peripheral sensory neuropathy, thrombocytopenia, anemia, upper respiratory tract infection, fatigue, peripheral motor neuropathy, nausea, cough, and diarrhea  (6.1)  .",and diarrhea is not a named entity
"*  Classical HL post-auto-HSCT consolidation: neutropenia, peripheral sensory neuropathy, thrombocytopenia, anemia, upper respiratory tract infection, fatigue, peripheral motor neuropathy, nausea, cough, and diarrhea  (6.1)  .",diarrhea is an adverse reaction entity
"*  Classical HL post-auto-HSCT consolidation: neutropenia, peripheral sensory neuropathy, thrombocytopenia, anemia, upper respiratory tract infection, fatigue, peripheral motor neuropathy, nausea, cough, and diarrhea  (6.1)  .",peripheral motor neuropathy is an adverse reaction entity
"*  Classical HL post-auto-HSCT consolidation: neutropenia, peripheral sensory neuropathy, thrombocytopenia, anemia, upper respiratory tract infection, fatigue, peripheral motor neuropathy, nausea, cough, and diarrhea  (6.1)  .",peripheral sensory neuropathy is an adverse reaction entity
"*  Classical HL post-auto-HSCT consolidation: neutropenia, peripheral sensory neuropathy, thrombocytopenia, anemia, upper respiratory tract infection, fatigue, peripheral motor neuropathy, nausea, cough, and diarrhea  (6.1)  .",* Classical HL is not a named entity
"*  Classical HL post-auto-HSCT consolidation: neutropenia, peripheral sensory neuropathy, thrombocytopenia, anemia, upper respiratory tract infection, fatigue, peripheral motor neuropathy, nausea, cough, and diarrhea  (6.1)  .",upper respiratory tract infection is an adverse reaction entity
"*  Classical HL post-auto-HSCT consolidation: neutropenia, peripheral sensory neuropathy, thrombocytopenia, anemia, upper respiratory tract infection, fatigue, peripheral motor neuropathy, nausea, cough, and diarrhea  (6.1)  .",anemia is an adverse reaction entity
"*  Classical HL post-auto-HSCT consolidation: neutropenia, peripheral sensory neuropathy, thrombocytopenia, anemia, upper respiratory tract infection, fatigue, peripheral motor neuropathy, nausea, cough, and diarrhea  (6.1)  .",* Classical HL is not a named entity
"*  Classical HL post-auto-HSCT consolidation: neutropenia, peripheral sensory neuropathy, thrombocytopenia, anemia, upper respiratory tract infection, fatigue, peripheral motor neuropathy, nausea, cough, and diarrhea  (6.1)  .",", upper respiratory is not a named entity"
"*  Classical HL post-auto-HSCT consolidation: neutropenia, peripheral sensory neuropathy, thrombocytopenia, anemia, upper respiratory tract infection, fatigue, peripheral motor neuropathy, nausea, cough, and diarrhea  (6.1)  .",thrombocytopenia is an adverse reaction entity
"*  Classical HL post-auto-HSCT consolidation: neutropenia, peripheral sensory neuropathy, thrombocytopenia, anemia, upper respiratory tract infection, fatigue, peripheral motor neuropathy, nausea, cough, and diarrhea  (6.1)  .",Classical is not a named entity
"*  Classical HL post-auto-HSCT consolidation: neutropenia, peripheral sensory neuropathy, thrombocytopenia, anemia, upper respiratory tract infection, fatigue, peripheral motor neuropathy, nausea, cough, and diarrhea  (6.1)  .","infection , is not a named entity"
"*  Classical HL post-auto-HSCT consolidation: neutropenia, peripheral sensory neuropathy, thrombocytopenia, anemia, upper respiratory tract infection, fatigue, peripheral motor neuropathy, nausea, cough, and diarrhea  (6.1)  .",", fatigue is not a named entity"
"*  Classical HL post-auto-HSCT consolidation: neutropenia, peripheral sensory neuropathy, thrombocytopenia, anemia, upper respiratory tract infection, fatigue, peripheral motor neuropathy, nausea, cough, and diarrhea  (6.1)  .",fatigue is an adverse reaction entity
"*  Classical HL post-auto-HSCT consolidation: neutropenia, peripheral sensory neuropathy, thrombocytopenia, anemia, upper respiratory tract infection, fatigue, peripheral motor neuropathy, nausea, cough, and diarrhea  (6.1)  .",neutropenia is an adverse reaction entity
"*  Classical HL post-auto-HSCT consolidation: neutropenia, peripheral sensory neuropathy, thrombocytopenia, anemia, upper respiratory tract infection, fatigue, peripheral motor neuropathy, nausea, cough, and diarrhea  (6.1)  .",nausea is an adverse reaction entity
"*  Classical HL post-auto-HSCT consolidation: neutropenia, peripheral sensory neuropathy, thrombocytopenia, anemia, upper respiratory tract infection, fatigue, peripheral motor neuropathy, nausea, cough, and diarrhea  (6.1)  .",", cough , is not a named entity"
"Skin and subcutaneous tissue disorders  : Toxic epidermal necrolysis, including fatal outcomes  [see  Warnings and Precautions (5.11)  ]  .",", including fatal is not a named entity"
"Skin and subcutaneous tissue disorders  : Toxic epidermal necrolysis, including fatal outcomes  [see  Warnings and Precautions (5.11)  ]  .",fatal is an adverse reaction entity
"Skin and subcutaneous tissue disorders  : Toxic epidermal necrolysis, including fatal outcomes  [see  Warnings and Precautions (5.11)  ]  .",and Precautions ( is not a named entity
"Skin and subcutaneous tissue disorders  : Toxic epidermal necrolysis, including fatal outcomes  [see  Warnings and Precautions (5.11)  ]  .",Toxic epidermal necrolysis is an adverse reaction entity
5.1 Peripheral Neuropathy      ADCETRIS treatment causes a peripheral neuropathy that is predominantly sensory.,neuropathy that is not a named entity
5.1 Peripheral Neuropathy      ADCETRIS treatment causes a peripheral neuropathy that is predominantly sensory.,Neuropathy ADCETRIS is not a named entity
5.1 Peripheral Neuropathy      ADCETRIS treatment causes a peripheral neuropathy that is predominantly sensory.,peripheral neuropathy is an adverse reaction entity
5.1 Peripheral Neuropathy      ADCETRIS treatment causes a peripheral neuropathy that is predominantly sensory.,peripheral neuropathy sensory is an adverse reaction entity
Cases of pulmonary toxicity have also been reported in patients receiving ADCETRIS.,pulmonary toxicity is an adverse reaction entity
Cases of pulmonary toxicity have also been reported in patients receiving ADCETRIS.,Cases of is not a named entity
Adverse reactions that led to treatment discontinuation in 2 or more patients with classical HL or sALCL were peripheral sensory neuropathy (8%) and peripheral motor neuropathy (3%).,peripheral motor neuropathy is an adverse reaction entity
Adverse reactions that led to treatment discontinuation in 2 or more patients with classical HL or sALCL were peripheral sensory neuropathy (8%) and peripheral motor neuropathy (3%).,patients with is not a named entity
Adverse reactions that led to treatment discontinuation in 2 or more patients with classical HL or sALCL were peripheral sensory neuropathy (8%) and peripheral motor neuropathy (3%).,peripheral sensory neuropathy is an adverse reaction entity
Adverse reactions that led to treatment discontinuation in 2 or more patients with classical HL or sALCL were peripheral sensory neuropathy (8%) and peripheral motor neuropathy (3%).,sALCL is not a named entity
Infusion reactions       Two cases of anaphylaxis were reported in the dose-finding trials.,Infusion is not a named entity
Infusion reactions       Two cases of anaphylaxis were reported in the dose-finding trials.,anaphylaxis is an adverse reaction entity
*   Pulmonary Toxicity : Monitor patients for new or worsening symptoms  (5.10)  .,Pulmonary Toxicity is an adverse reaction entity
*   Pulmonary Toxicity : Monitor patients for new or worsening symptoms  (5.10)  .,( 5.10 ) is not a named entity
"Of the patients who reported neuropathy, 51% had residual neuropathy at the time of their last evaluation.",", is not a named entity"
"Of the patients who reported neuropathy, 51% had residual neuropathy at the time of their last evaluation.",neuropathy is an adverse reaction entity
"Of the patients who reported neuropathy, 51% had residual neuropathy at the time of their last evaluation.",residual neuropathy is an adverse reaction entity
"Of the patients who reported neuropathy, 51% had residual neuropathy at the time of their last evaluation.",time of is not a named entity
"5.2 Anaphylaxis and Infusion Reactions      Infusion-related reactions, including anaphylaxis, have occurred with ADCETRIS.",Infusion-related reactions is an adverse reaction entity
"5.2 Anaphylaxis and Infusion Reactions      Infusion-related reactions, including anaphylaxis, have occurred with ADCETRIS.",Anaphylaxis and is not a named entity
"5.2 Anaphylaxis and Infusion Reactions      Infusion-related reactions, including anaphylaxis, have occurred with ADCETRIS.",have is not a named entity
"5.2 Anaphylaxis and Infusion Reactions      Infusion-related reactions, including anaphylaxis, have occurred with ADCETRIS.",anaphylaxis is an adverse reaction entity
"JC virus infection resulting in PML and death can occur in patients receiving ADCETRIS   (5.9  ,   6.2)  .",patients receiving is not a named entity
"JC virus infection resulting in PML and death can occur in patients receiving ADCETRIS   (5.9  ,   6.2)  .",PML is an adverse reaction entity
"JC virus infection resulting in PML and death can occur in patients receiving ADCETRIS   (5.9  ,   6.2)  .",resulting in is not a named entity
"JC virus infection resulting in PML and death can occur in patients receiving ADCETRIS   (5.9  ,   6.2)  .",death is an adverse reaction entity
"JC virus infection resulting in PML and death can occur in patients receiving ADCETRIS   (5.9  ,   6.2)  .",and is not a named entity
"JC virus infection resulting in PML and death can occur in patients receiving ADCETRIS   (5.9  ,   6.2)  .",JC virus infection is an adverse reaction entity
*   Hematologic toxicities : Monitor complete blood counts prior to each dose of ADCETRIS.,Hematologic toxicities is an adverse reaction entity
*   Hematologic toxicities : Monitor complete blood counts prior to each dose of ADCETRIS.,each dose is not a named entity
Hepatobiliary disorders  : hepatotoxicity  [see  Warnings and Precautions (        5.8        )  ]  .,hepatotoxicity [ see is not a named entity
Hepatobiliary disorders  : hepatotoxicity  [see  Warnings and Precautions (        5.8        )  ]  .,hepatotoxicity is an adverse reaction entity
"Other important serious adverse reactions reported include PML, Stevens-Johnson syndrome, and tumor lysis syndrome.",tumor lysis syndrome is an adverse reaction entity
"Other important serious adverse reactions reported include PML, Stevens-Johnson syndrome, and tumor lysis syndrome.",PML is an adverse reaction entity
"Other important serious adverse reactions reported include PML, Stevens-Johnson syndrome, and tumor lysis syndrome.",Other is not a named entity
"Other important serious adverse reactions reported include PML, Stevens-Johnson syndrome, and tumor lysis syndrome.",syndrome is not a named entity
"Other important serious adverse reactions reported include PML, Stevens-Johnson syndrome, and tumor lysis syndrome.",Other is not a named entity
"Other important serious adverse reactions reported include PML, Stevens-Johnson syndrome, and tumor lysis syndrome.",Stevens-Johnson syndrome is an adverse reaction entity
"In Studies 1 and 2, the most common adverse reactions (>=20%), regardless of causality, were neutropenia, peripheral sensory neuropathy, fatigue, nausea, anemia, upper respiratory tract infection, diarrhea, pyrexia, rash, thrombocytopenia, cough, and vomiting.","nausea , anemia is not a named entity"
"In Studies 1 and 2, the most common adverse reactions (>=20%), regardless of causality, were neutropenia, peripheral sensory neuropathy, fatigue, nausea, anemia, upper respiratory tract infection, diarrhea, pyrexia, rash, thrombocytopenia, cough, and vomiting.",most common is not a named entity
"In Studies 1 and 2, the most common adverse reactions (>=20%), regardless of causality, were neutropenia, peripheral sensory neuropathy, fatigue, nausea, anemia, upper respiratory tract infection, diarrhea, pyrexia, rash, thrombocytopenia, cough, and vomiting.",anemia is an adverse reaction entity
"In Studies 1 and 2, the most common adverse reactions (>=20%), regardless of causality, were neutropenia, peripheral sensory neuropathy, fatigue, nausea, anemia, upper respiratory tract infection, diarrhea, pyrexia, rash, thrombocytopenia, cough, and vomiting.",rash is an adverse reaction entity
"In Studies 1 and 2, the most common adverse reactions (>=20%), regardless of causality, were neutropenia, peripheral sensory neuropathy, fatigue, nausea, anemia, upper respiratory tract infection, diarrhea, pyrexia, rash, thrombocytopenia, cough, and vomiting.",neuropathy is not a named entity
"In Studies 1 and 2, the most common adverse reactions (>=20%), regardless of causality, were neutropenia, peripheral sensory neuropathy, fatigue, nausea, anemia, upper respiratory tract infection, diarrhea, pyrexia, rash, thrombocytopenia, cough, and vomiting.",pyrexia is an adverse reaction entity
"In Studies 1 and 2, the most common adverse reactions (>=20%), regardless of causality, were neutropenia, peripheral sensory neuropathy, fatigue, nausea, anemia, upper respiratory tract infection, diarrhea, pyrexia, rash, thrombocytopenia, cough, and vomiting.",reactions ( is not a named entity
"In Studies 1 and 2, the most common adverse reactions (>=20%), regardless of causality, were neutropenia, peripheral sensory neuropathy, fatigue, nausea, anemia, upper respiratory tract infection, diarrhea, pyrexia, rash, thrombocytopenia, cough, and vomiting.",", upper is not a named entity"
"In Studies 1 and 2, the most common adverse reactions (>=20%), regardless of causality, were neutropenia, peripheral sensory neuropathy, fatigue, nausea, anemia, upper respiratory tract infection, diarrhea, pyrexia, rash, thrombocytopenia, cough, and vomiting.",thrombocytopenia is an adverse reaction entity
"In Studies 1 and 2, the most common adverse reactions (>=20%), regardless of causality, were neutropenia, peripheral sensory neuropathy, fatigue, nausea, anemia, upper respiratory tract infection, diarrhea, pyrexia, rash, thrombocytopenia, cough, and vomiting.",fatigue is an adverse reaction entity
"In Studies 1 and 2, the most common adverse reactions (>=20%), regardless of causality, were neutropenia, peripheral sensory neuropathy, fatigue, nausea, anemia, upper respiratory tract infection, diarrhea, pyrexia, rash, thrombocytopenia, cough, and vomiting.",cough is an adverse reaction entity
"In Studies 1 and 2, the most common adverse reactions (>=20%), regardless of causality, were neutropenia, peripheral sensory neuropathy, fatigue, nausea, anemia, upper respiratory tract infection, diarrhea, pyrexia, rash, thrombocytopenia, cough, and vomiting.",upper respiratory tract infection is an adverse reaction entity
"In Studies 1 and 2, the most common adverse reactions (>=20%), regardless of causality, were neutropenia, peripheral sensory neuropathy, fatigue, nausea, anemia, upper respiratory tract infection, diarrhea, pyrexia, rash, thrombocytopenia, cough, and vomiting.",peripheral sensory neuropathy is an adverse reaction entity
"In Studies 1 and 2, the most common adverse reactions (>=20%), regardless of causality, were neutropenia, peripheral sensory neuropathy, fatigue, nausea, anemia, upper respiratory tract infection, diarrhea, pyrexia, rash, thrombocytopenia, cough, and vomiting.",Studies is not a named entity
"In Studies 1 and 2, the most common adverse reactions (>=20%), regardless of causality, were neutropenia, peripheral sensory neuropathy, fatigue, nausea, anemia, upper respiratory tract infection, diarrhea, pyrexia, rash, thrombocytopenia, cough, and vomiting.",vomiting is an adverse reaction entity
"In Studies 1 and 2, the most common adverse reactions (>=20%), regardless of causality, were neutropenia, peripheral sensory neuropathy, fatigue, nausea, anemia, upper respiratory tract infection, diarrhea, pyrexia, rash, thrombocytopenia, cough, and vomiting.","fatigue , nausea is not a named entity"
"In Studies 1 and 2, the most common adverse reactions (>=20%), regardless of causality, were neutropenia, peripheral sensory neuropathy, fatigue, nausea, anemia, upper respiratory tract infection, diarrhea, pyrexia, rash, thrombocytopenia, cough, and vomiting.",neutropenia is an adverse reaction entity
"In Studies 1 and 2, the most common adverse reactions (>=20%), regardless of causality, were neutropenia, peripheral sensory neuropathy, fatigue, nausea, anemia, upper respiratory tract infection, diarrhea, pyrexia, rash, thrombocytopenia, cough, and vomiting.",=20 % ) is not a named entity
"In Studies 1 and 2, the most common adverse reactions (>=20%), regardless of causality, were neutropenia, peripheral sensory neuropathy, fatigue, nausea, anemia, upper respiratory tract infection, diarrhea, pyrexia, rash, thrombocytopenia, cough, and vomiting.",", cough is not a named entity"
"In Studies 1 and 2, the most common adverse reactions (>=20%), regardless of causality, were neutropenia, peripheral sensory neuropathy, fatigue, nausea, anemia, upper respiratory tract infection, diarrhea, pyrexia, rash, thrombocytopenia, cough, and vomiting.","fatigue , nausea is not a named entity"
"In Studies 1 and 2, the most common adverse reactions (>=20%), regardless of causality, were neutropenia, peripheral sensory neuropathy, fatigue, nausea, anemia, upper respiratory tract infection, diarrhea, pyrexia, rash, thrombocytopenia, cough, and vomiting.",nausea is an adverse reaction entity
"In Studies 1 and 2, the most common adverse reactions (>=20%), regardless of causality, were neutropenia, peripheral sensory neuropathy, fatigue, nausea, anemia, upper respiratory tract infection, diarrhea, pyrexia, rash, thrombocytopenia, cough, and vomiting.",", the is not a named entity"
"In Studies 1 and 2, the most common adverse reactions (>=20%), regardless of causality, were neutropenia, peripheral sensory neuropathy, fatigue, nausea, anemia, upper respiratory tract infection, diarrhea, pyrexia, rash, thrombocytopenia, cough, and vomiting.",", is not a named entity"
"In Studies 1 and 2, the most common adverse reactions (>=20%), regardless of causality, were neutropenia, peripheral sensory neuropathy, fatigue, nausea, anemia, upper respiratory tract infection, diarrhea, pyrexia, rash, thrombocytopenia, cough, and vomiting.",diarrhea is an adverse reaction entity
5.5 Tumor Lysis Syndrome      Patients with rapidly proliferating tumor and high tumor burden may be at increased risk of tumor lysis syndrome.,Lysis is not a named entity
5.5 Tumor Lysis Syndrome      Patients with rapidly proliferating tumor and high tumor burden may be at increased risk of tumor lysis syndrome.,tumor lysis syndrome is an adverse reaction entity
"There were no Grade 3 or 4 infusion-related reactions reported in Studies 1 and 2; however, Grade 1 or 2 infusion-related reactions were reported for 19 patients (12%).","however , is not a named entity"
"There were no Grade 3 or 4 infusion-related reactions reported in Studies 1 and 2; however, Grade 1 or 2 infusion-related reactions were reported for 19 patients (12%).",infusion-related reactions is an adverse reaction entity
"There were no Grade 3 or 4 infusion-related reactions reported in Studies 1 and 2; however, Grade 1 or 2 infusion-related reactions were reported for 19 patients (12%).",infusion-related reactions is an adverse reaction entity
"There were no Grade 3 or 4 infusion-related reactions reported in Studies 1 and 2; however, Grade 1 or 2 infusion-related reactions were reported for 19 patients (12%).",reactions were is not a named entity
*   Serious dermatologic reactions : Discontinue if Stevens-Johnson syndrome or toxic epidermal necrolysis occurs  (5.10)  .,dermatologic reactions is an adverse reaction entity
*   Serious dermatologic reactions : Discontinue if Stevens-Johnson syndrome or toxic epidermal necrolysis occurs  (5.10)  .,( 5.10 is not a named entity
"5.8 Hepatotoxicity         Serious cases of hepatotoxicity, including fatal outcomes, have occurred in patients receiving ADCETRIS.",fatal is an adverse reaction entity
"5.8 Hepatotoxicity         Serious cases of hepatotoxicity, including fatal outcomes, have occurred in patients receiving ADCETRIS.",ADCETRIS is not a named entity
"5.8 Hepatotoxicity         Serious cases of hepatotoxicity, including fatal outcomes, have occurred in patients receiving ADCETRIS.",in patients is not a named entity
"5.8 Hepatotoxicity         Serious cases of hepatotoxicity, including fatal outcomes, have occurred in patients receiving ADCETRIS.",hepatotoxicity is an adverse reaction entity
"*   Anaphylaxis and infusion reactions : If an infusion reaction occurs, interrupt the infusion.",: If is not a named entity
"*   Anaphylaxis and infusion reactions : If an infusion reaction occurs, interrupt the infusion.",infusion reactions is an adverse reaction entity
"*   Anaphylaxis and infusion reactions : If an infusion reaction occurs, interrupt the infusion.",occurs is not a named entity
"*   Anaphylaxis and infusion reactions : If an infusion reaction occurs, interrupt the infusion.",Anaphylaxis is an adverse reaction entity
"Of the patients who reported neuropathy, 59% had complete resolution and 41% had residual neuropathy (26% partial improvement, 15% no improvement) at the time of their last evaluation.",neuropathy is an adverse reaction entity
"Of the patients who reported neuropathy, 59% had complete resolution and 41% had residual neuropathy (26% partial improvement, 15% no improvement) at the time of their last evaluation.",26 % partial is not a named entity
"Of the patients who reported neuropathy, 59% had complete resolution and 41% had residual neuropathy (26% partial improvement, 15% no improvement) at the time of their last evaluation.",had is not a named entity
"Of the patients who reported neuropathy, 59% had complete resolution and 41% had residual neuropathy (26% partial improvement, 15% no improvement) at the time of their last evaluation.",residual neuropathy is an adverse reaction entity
"Adverse reactions that led to dose delays in more than 5% of ADCETRIS-treated patients in Study 3 were neutropenia (22%), peripheral sensory neuropathy (16%), upper respiratory tract infection (6%), and peripheral motor neuropathy (6%)  [see  Dosage and Administration (        2.2        )  ]  .",") , and is not a named entity"
"Adverse reactions that led to dose delays in more than 5% of ADCETRIS-treated patients in Study 3 were neutropenia (22%), peripheral sensory neuropathy (16%), upper respiratory tract infection (6%), and peripheral motor neuropathy (6%)  [see  Dosage and Administration (        2.2        )  ]  .",upper respiratory tract infection is an adverse reaction entity
"Adverse reactions that led to dose delays in more than 5% of ADCETRIS-treated patients in Study 3 were neutropenia (22%), peripheral sensory neuropathy (16%), upper respiratory tract infection (6%), and peripheral motor neuropathy (6%)  [see  Dosage and Administration (        2.2        )  ]  .",[ see Dosage is not a named entity
"Adverse reactions that led to dose delays in more than 5% of ADCETRIS-treated patients in Study 3 were neutropenia (22%), peripheral sensory neuropathy (16%), upper respiratory tract infection (6%), and peripheral motor neuropathy (6%)  [see  Dosage and Administration (        2.2        )  ]  .",peripheral sensory neuropathy is an adverse reaction entity
"Adverse reactions that led to dose delays in more than 5% of ADCETRIS-treated patients in Study 3 were neutropenia (22%), peripheral sensory neuropathy (16%), upper respiratory tract infection (6%), and peripheral motor neuropathy (6%)  [see  Dosage and Administration (        2.2        )  ]  .",neutropenia is an adverse reaction entity
"Adverse reactions that led to dose delays in more than 5% of ADCETRIS-treated patients in Study 3 were neutropenia (22%), peripheral sensory neuropathy (16%), upper respiratory tract infection (6%), and peripheral motor neuropathy (6%)  [see  Dosage and Administration (        2.2        )  ]  .",ADCETRIS-treated patients in is not a named entity
"Adverse reactions that led to dose delays in more than 5% of ADCETRIS-treated patients in Study 3 were neutropenia (22%), peripheral sensory neuropathy (16%), upper respiratory tract infection (6%), and peripheral motor neuropathy (6%)  [see  Dosage and Administration (        2.2        )  ]  .",5 % of is not a named entity
"Adverse reactions that led to dose delays in more than 5% of ADCETRIS-treated patients in Study 3 were neutropenia (22%), peripheral sensory neuropathy (16%), upper respiratory tract infection (6%), and peripheral motor neuropathy (6%)  [see  Dosage and Administration (        2.2        )  ]  .",peripheral motor neuropathy is an adverse reaction entity
5.9 Progressive Multifocal Leukoencephalopathy       JC virus infection resulting in PML and death has been reported in ADCETRIS-treated patients.,PML is an adverse reaction entity
5.9 Progressive Multifocal Leukoencephalopathy       JC virus infection resulting in PML and death has been reported in ADCETRIS-treated patients.,JC virus infection is an adverse reaction entity
5.9 Progressive Multifocal Leukoencephalopathy       JC virus infection resulting in PML and death has been reported in ADCETRIS-treated patients.,death is an adverse reaction entity
5.9 Progressive Multifocal Leukoencephalopathy       JC virus infection resulting in PML and death has been reported in ADCETRIS-treated patients.,death has been is not a named entity
5.9 Progressive Multifocal Leukoencephalopathy       JC virus infection resulting in PML and death has been reported in ADCETRIS-treated patients.,resulting in PML is not a named entity
5.9 Progressive Multifocal Leukoencephalopathy       JC virus infection resulting in PML and death has been reported in ADCETRIS-treated patients.,been reported is not a named entity
5.6 Increased Toxicity in the Presence of Severe Renal Impairment         The frequency of >=Grade 3 adverse reactions and deaths was greater in patients with severe renal impairment compared to patients with normal renal function.,deaths is an adverse reaction entity
5.6 Increased Toxicity in the Presence of Severe Renal Impairment         The frequency of >=Grade 3 adverse reactions and deaths was greater in patients with severe renal impairment compared to patients with normal renal function.,with normal is not a named entity
"Brentuximab vedotin caused embryo-fetal toxicities, including significantly decreased embryo viability and fetal malformations, in animals at maternal exposures that were similar to human exposures at the recommended doses for patients with classical HL and sALCL.",significantly is not a named entity
"Brentuximab vedotin caused embryo-fetal toxicities, including significantly decreased embryo viability and fetal malformations, in animals at maternal exposures that were similar to human exposures at the recommended doses for patients with classical HL and sALCL.",decreased embryo viability is an adverse reaction entity
"Brentuximab vedotin caused embryo-fetal toxicities, including significantly decreased embryo viability and fetal malformations, in animals at maternal exposures that were similar to human exposures at the recommended doses for patients with classical HL and sALCL.","malformations , in is not a named entity"
"Brentuximab vedotin caused embryo-fetal toxicities, including significantly decreased embryo viability and fetal malformations, in animals at maternal exposures that were similar to human exposures at the recommended doses for patients with classical HL and sALCL.",including significantly decreased is not a named entity
"Brentuximab vedotin caused embryo-fetal toxicities, including significantly decreased embryo viability and fetal malformations, in animals at maternal exposures that were similar to human exposures at the recommended doses for patients with classical HL and sALCL.",embryo-fetal toxicities is an adverse reaction entity
"Brentuximab vedotin caused embryo-fetal toxicities, including significantly decreased embryo viability and fetal malformations, in animals at maternal exposures that were similar to human exposures at the recommended doses for patients with classical HL and sALCL.",fetal malformations is an adverse reaction entity
"Pulmonary Toxicity       In a trial in patients with classical HL that studied ADCETRIS with bleomycin as part of a combination regimen, the rate of non-infectious pulmonary toxicity was higher than the historical incidence reported with ABVD (adriamycin, bleomycin, vinblastine, dacarbazine).",", dacarbazine ) is not a named entity"
"Pulmonary Toxicity       In a trial in patients with classical HL that studied ADCETRIS with bleomycin as part of a combination regimen, the rate of non-infectious pulmonary toxicity was higher than the historical incidence reported with ABVD (adriamycin, bleomycin, vinblastine, dacarbazine).",non-infectious pulmonary toxicity is an adverse reaction entity
Interstitial infiltration and/or inflammation were observed on radiographs and computed tomographic imaging of the chest.,imaging is not a named entity
Interstitial infiltration and/or inflammation were observed on radiographs and computed tomographic imaging of the chest.,Interstitial infiltration of the chest is an adverse reaction entity
Interstitial infiltration and/or inflammation were observed on radiographs and computed tomographic imaging of the chest.,Interstitial inflammation of the chest is an adverse reaction entity
Interstitial infiltration and/or inflammation were observed on radiographs and computed tomographic imaging of the chest.,on radiographs and is not a named entity
"The most common adverse reactions (>=20%), regardless of causality, were neutropenia, anemia, peripheral sensory neuropathy, fatigue, nausea, pyrexia, rash, diarrhea, and pain.",common adverse reactions is not a named entity
"The most common adverse reactions (>=20%), regardless of causality, were neutropenia, anemia, peripheral sensory neuropathy, fatigue, nausea, pyrexia, rash, diarrhea, and pain.",fatigue is an adverse reaction entity
"The most common adverse reactions (>=20%), regardless of causality, were neutropenia, anemia, peripheral sensory neuropathy, fatigue, nausea, pyrexia, rash, diarrhea, and pain.",and is not a named entity
"The most common adverse reactions (>=20%), regardless of causality, were neutropenia, anemia, peripheral sensory neuropathy, fatigue, nausea, pyrexia, rash, diarrhea, and pain.",( > is not a named entity
"The most common adverse reactions (>=20%), regardless of causality, were neutropenia, anemia, peripheral sensory neuropathy, fatigue, nausea, pyrexia, rash, diarrhea, and pain.",neutropenia is an adverse reaction entity
"The most common adverse reactions (>=20%), regardless of causality, were neutropenia, anemia, peripheral sensory neuropathy, fatigue, nausea, pyrexia, rash, diarrhea, and pain.",nausea is an adverse reaction entity
"The most common adverse reactions (>=20%), regardless of causality, were neutropenia, anemia, peripheral sensory neuropathy, fatigue, nausea, pyrexia, rash, diarrhea, and pain.",", fatigue is not a named entity"
"The most common adverse reactions (>=20%), regardless of causality, were neutropenia, anemia, peripheral sensory neuropathy, fatigue, nausea, pyrexia, rash, diarrhea, and pain.",rash is an adverse reaction entity
"The most common adverse reactions (>=20%), regardless of causality, were neutropenia, anemia, peripheral sensory neuropathy, fatigue, nausea, pyrexia, rash, diarrhea, and pain.",", peripheral sensory is not a named entity"
"The most common adverse reactions (>=20%), regardless of causality, were neutropenia, anemia, peripheral sensory neuropathy, fatigue, nausea, pyrexia, rash, diarrhea, and pain.",pyrexia is an adverse reaction entity
"The most common adverse reactions (>=20%), regardless of causality, were neutropenia, anemia, peripheral sensory neuropathy, fatigue, nausea, pyrexia, rash, diarrhea, and pain.",pain is an adverse reaction entity
"The most common adverse reactions (>=20%), regardless of causality, were neutropenia, anemia, peripheral sensory neuropathy, fatigue, nausea, pyrexia, rash, diarrhea, and pain.",anemia is an adverse reaction entity
"The most common adverse reactions (>=20%), regardless of causality, were neutropenia, anemia, peripheral sensory neuropathy, fatigue, nausea, pyrexia, rash, diarrhea, and pain.",> =20 is not a named entity
"The most common adverse reactions (>=20%), regardless of causality, were neutropenia, anemia, peripheral sensory neuropathy, fatigue, nausea, pyrexia, rash, diarrhea, and pain.","neuropathy , is not a named entity"
"The most common adverse reactions (>=20%), regardless of causality, were neutropenia, anemia, peripheral sensory neuropathy, fatigue, nausea, pyrexia, rash, diarrhea, and pain.",peripheral sensory neuropathy is an adverse reaction entity
"The most common adverse reactions (>=20%), regardless of causality, were neutropenia, anemia, peripheral sensory neuropathy, fatigue, nausea, pyrexia, rash, diarrhea, and pain.",", regardless is not a named entity"
"The most common adverse reactions (>=20%), regardless of causality, were neutropenia, anemia, peripheral sensory neuropathy, fatigue, nausea, pyrexia, rash, diarrhea, and pain.",diarrhea is an adverse reaction entity
"The most common adverse reactions (>=20%), regardless of causality, were neutropenia, anemia, peripheral sensory neuropathy, fatigue, nausea, pyrexia, rash, diarrhea, and pain.","rash , diarrhea is not a named entity"
Several patients discontinued GILENYA because of unexplained dyspnea during the extension (uncontrolled) studies.,dyspnea is an adverse reaction entity
Several patients discontinued GILENYA because of unexplained dyspnea during the extension (uncontrolled) studies.,dyspnea during the is not a named entity
5.3     Progressive Multifocal Leukoencephalopathy       A case of progressive multifocal leukoencephalopathy (PML) and a case of probable PML occurred in patients with MS who received GILENYA in the post marketing setting.,PML is an adverse reaction entity
5.3     Progressive Multifocal Leukoencephalopathy       A case of progressive multifocal leukoencephalopathy (PML) and a case of probable PML occurred in patients with MS who received GILENYA in the post marketing setting.,PML is an adverse reaction entity
5.3     Progressive Multifocal Leukoencephalopathy       A case of progressive multifocal leukoencephalopathy (PML) and a case of probable PML occurred in patients with MS who received GILENYA in the post marketing setting.,progressive multifocal leukoencephalopathy is an adverse reaction entity
5.3     Progressive Multifocal Leukoencephalopathy       A case of progressive multifocal leukoencephalopathy (PML) and a case of probable PML occurred in patients with MS who received GILENYA in the post marketing setting.,in the is not a named entity
5.3     Progressive Multifocal Leukoencephalopathy       A case of progressive multifocal leukoencephalopathy (PML) and a case of probable PML occurred in patients with MS who received GILENYA in the post marketing setting.,post is not a named entity
5.3     Progressive Multifocal Leukoencephalopathy       A case of progressive multifocal leukoencephalopathy (PML) and a case of probable PML occurred in patients with MS who received GILENYA in the post marketing setting.,Progressive Multifocal Leukoencephalopathy is not a named entity
Atrioventricular Blocks          Initiation of GILENYA treatment has resulted in transient AV conduction delays.,conduction is not a named entity
Atrioventricular Blocks          Initiation of GILENYA treatment has resulted in transient AV conduction delays.,AV conduction delays is an adverse reaction entity
The incidence of macular edema is also increased in MS patients with a history of uveitis.,macular edema is an adverse reaction entity
The incidence of macular edema is also increased in MS patients with a history of uveitis.,also increased in is not a named entity
"In a study of 697 patients with available 24-hour Holter monitoring data after their first dose (N=351 receiving GILENYA and N=346 on placebo), second-degree AV blocks (Mobitz Types I [Wenckebach] or 2:1 AV blocks) occurred in 4% (N=14) of patients receiving GILENYA and 2% (N=7) of patients on placebo.",2:1 AV blocks is an adverse reaction entity
"In a study of 697 patients with available 24-hour Holter monitoring data after their first dose (N=351 receiving GILENYA and N=346 on placebo), second-degree AV blocks (Mobitz Types I [Wenckebach] or 2:1 AV blocks) occurred in 4% (N=14) of patients receiving GILENYA and 2% (N=7) of patients on placebo.",AV blocks Mobitz Types I is an adverse reaction entity
"In a study of 697 patients with available 24-hour Holter monitoring data after their first dose (N=351 receiving GILENYA and N=346 on placebo), second-degree AV blocks (Mobitz Types I [Wenckebach] or 2:1 AV blocks) occurred in 4% (N=14) of patients receiving GILENYA and 2% (N=7) of patients on placebo.",with available is not a named entity
"In a study of 697 patients with available 24-hour Holter monitoring data after their first dose (N=351 receiving GILENYA and N=346 on placebo), second-degree AV blocks (Mobitz Types I [Wenckebach] or 2:1 AV blocks) occurred in 4% (N=14) of patients receiving GILENYA and 2% (N=7) of patients on placebo.",monitoring is not a named entity
"In a study of 697 patients with available 24-hour Holter monitoring data after their first dose (N=351 receiving GILENYA and N=346 on placebo), second-degree AV blocks (Mobitz Types I [Wenckebach] or 2:1 AV blocks) occurred in 4% (N=14) of patients receiving GILENYA and 2% (N=7) of patients on placebo.",with is not a named entity
"In a study of 697 patients with available 24-hour Holter monitoring data after their first dose (N=351 receiving GILENYA and N=346 on placebo), second-degree AV blocks (Mobitz Types I [Wenckebach] or 2:1 AV blocks) occurred in 4% (N=14) of patients receiving GILENYA and 2% (N=7) of patients on placebo.",second-degree AV blocks is an adverse reaction entity
"In a study of 697 patients with available 24-hour Holter monitoring data after their first dose (N=351 receiving GILENYA and N=346 on placebo), second-degree AV blocks (Mobitz Types I [Wenckebach] or 2:1 AV blocks) occurred in 4% (N=14) of patients receiving GILENYA and 2% (N=7) of patients on placebo.",AV blocks Wenckebach is an adverse reaction entity
"In a study of 697 patients with available 24-hour Holter monitoring data after their first dose (N=351 receiving GILENYA and N=346 on placebo), second-degree AV blocks (Mobitz Types I [Wenckebach] or 2:1 AV blocks) occurred in 4% (N=14) of patients receiving GILENYA and 2% (N=7) of patients on placebo.",AV blocks ) is not a named entity
"In 2-year placebo-controlled clinical trials, elevation of liver transaminases to 3-fold the upper limit of normal (ULN) or greater occurred in 14% of patients treated with GILENYA 0.5 mg and 3% of patients on placebo.",elevation of liver transaminases is an adverse reaction entity
"In 2-year placebo-controlled clinical trials, elevation of liver transaminases to 3-fold the upper limit of normal (ULN) or greater occurred in 14% of patients treated with GILENYA 0.5 mg and 3% of patients on placebo.",patients on placebo is not a named entity
"Prior and Concomitant Treatment with Antineoplastic, Immunosuppressive, or Immune-Modulating Therapies          In clinical studies, patients who received GILENYA did not receive concomitant treatment with antineoplastic, non-corticosteroid immunosuppressive, or immune-modulating therapies used for treatment of MS. Concomitant use of GILENYA with any of these therapies, and also with corticosteroids, would be expected to increase the risk of immunosuppression [see Drug Interactions (7)]  .",", is not a named entity"
"Prior and Concomitant Treatment with Antineoplastic, Immunosuppressive, or Immune-Modulating Therapies          In clinical studies, patients who received GILENYA did not receive concomitant treatment with antineoplastic, non-corticosteroid immunosuppressive, or immune-modulating therapies used for treatment of MS. Concomitant use of GILENYA with any of these therapies, and also with corticosteroids, would be expected to increase the risk of immunosuppression [see Drug Interactions (7)]  .",immunosuppression is an adverse reaction entity
"Cryptococcal infections          Cryptococcal infections, including cases of cryptococcal meningitis, have been reported with GILENYA in the postmarketing setting.",Cryptococcal infections is an adverse reaction entity
"Cryptococcal infections          Cryptococcal infections, including cases of cryptococcal meningitis, have been reported with GILENYA in the postmarketing setting.",cryptococcal meningitis is an adverse reaction entity
"Cryptococcal infections          Cryptococcal infections, including cases of cryptococcal meningitis, have been reported with GILENYA in the postmarketing setting.","cryptococcal meningitis , is not a named entity"
"Cryptococcal infections          Cryptococcal infections, including cases of cryptococcal meningitis, have been reported with GILENYA in the postmarketing setting.",in is not a named entity
"Vascular Events       Vascular events, including ischemic and hemorrhagic strokes, and peripheral arterial occlusive disease were reported in premarketing clinical trials in patients who received GILENYA doses (1.25-5 mg) higher than recommended for use in MS.",patients who received is not a named entity
"Vascular Events       Vascular events, including ischemic and hemorrhagic strokes, and peripheral arterial occlusive disease were reported in premarketing clinical trials in patients who received GILENYA doses (1.25-5 mg) higher than recommended for use in MS.",hemorrhagic strokes is an adverse reaction entity
"Vascular Events       Vascular events, including ischemic and hemorrhagic strokes, and peripheral arterial occlusive disease were reported in premarketing clinical trials in patients who received GILENYA doses (1.25-5 mg) higher than recommended for use in MS.",Vascular events is an adverse reaction entity
"Vascular Events       Vascular events, including ischemic and hemorrhagic strokes, and peripheral arterial occlusive disease were reported in premarketing clinical trials in patients who received GILENYA doses (1.25-5 mg) higher than recommended for use in MS.",peripheral arterial occlusive disease is an adverse reaction entity
"Vascular Events       Vascular events, including ischemic and hemorrhagic strokes, and peripheral arterial occlusive disease were reported in premarketing clinical trials in patients who received GILENYA doses (1.25-5 mg) higher than recommended for use in MS.",use in MS is not a named entity
"Vascular Events       Vascular events, including ischemic and hemorrhagic strokes, and peripheral arterial occlusive disease were reported in premarketing clinical trials in patients who received GILENYA doses (1.25-5 mg) higher than recommended for use in MS.",ischemic strokes is an adverse reaction entity
"Vascular Events       Vascular events, including ischemic and hemorrhagic strokes, and peripheral arterial occlusive disease were reported in premarketing clinical trials in patients who received GILENYA doses (1.25-5 mg) higher than recommended for use in MS.",in patients is not a named entity
"Vascular Events       Vascular events, including ischemic and hemorrhagic strokes, and peripheral arterial occlusive disease were reported in premarketing clinical trials in patients who received GILENYA doses (1.25-5 mg) higher than recommended for use in MS.",use is not a named entity
"Following the second dose, a further decrease in heart rate may occur when compared to the heart rate prior to the second dose, but this change is of a smaller magnitude than that observed following the first dose.",decrease in heart rate is an adverse reaction entity
"Following the second dose, a further decrease in heart rate may occur when compared to the heart rate prior to the second dose, but this change is of a smaller magnitude than that observed following the first dose.","dose , but is not a named entity"
(  5.3  )   *  Macular edema: Perform an examination of the fundus including the macula before and 3-4 months after treatment initiation.,Macular edema is an adverse reaction entity
(  5.3  )   *  Macular edema: Perform an examination of the fundus including the macula before and 3-4 months after treatment initiation.,edema : is not a named entity
All second degree AV blocks on placebo were Mobitz Type I and occurred after the first 12 hours postdose.,second degree AV blocks Mobitz Type I is an adverse reaction entity
All second degree AV blocks on placebo were Mobitz Type I and occurred after the first 12 hours postdose.,Type is not a named entity
Hypertension was reported as an adverse reaction in 8% of patients on GILENYA 0.5 mg and in 4% of patients on placebo.,and is not a named entity
Hypertension was reported as an adverse reaction in 8% of patients on GILENYA 0.5 mg and in 4% of patients on placebo.,Hypertension is an adverse reaction entity
Adverse events that led to treatment discontinuation and occurred in more than 1% of patients taking GILENYA 0.5 mg were serum transaminase elevations (4.7% compared to 1% on placebo) and basal cell carcinoma (1% compared to 0.5% on placebo).,basal cell carcinoma is an adverse reaction entity
Adverse events that led to treatment discontinuation and occurred in more than 1% of patients taking GILENYA 0.5 mg were serum transaminase elevations (4.7% compared to 1% on placebo) and basal cell carcinoma (1% compared to 0.5% on placebo).,more than is not a named entity
Adverse events that led to treatment discontinuation and occurred in more than 1% of patients taking GILENYA 0.5 mg were serum transaminase elevations (4.7% compared to 1% on placebo) and basal cell carcinoma (1% compared to 0.5% on placebo).,serum transaminase elevations is an adverse reaction entity
Adverse events that led to treatment discontinuation and occurred in more than 1% of patients taking GILENYA 0.5 mg were serum transaminase elevations (4.7% compared to 1% on placebo) and basal cell carcinoma (1% compared to 0.5% on placebo).,placebo ) is not a named entity
(  5.6  )   *  Liver injury: liver enzyme results should be available before initiation.,Liver injury is an adverse reaction entity
(  5.6  )   *  Liver injury: liver enzyme results should be available before initiation.,: liver enzyme is not a named entity
"In placebo-controlled trials, the most frequent adverse reactions (incidence >=10% and >placebo) for GILENYA 0.5 mg were headache, liver transaminase elevation, diarrhea, cough, influenza, sinusitis, back pain, abdominal pain, and pain in extremity.","sinusitis , back is not a named entity"
"In placebo-controlled trials, the most frequent adverse reactions (incidence >=10% and >placebo) for GILENYA 0.5 mg were headache, liver transaminase elevation, diarrhea, cough, influenza, sinusitis, back pain, abdominal pain, and pain in extremity.",liver transaminase elevation is an adverse reaction entity
"In placebo-controlled trials, the most frequent adverse reactions (incidence >=10% and >placebo) for GILENYA 0.5 mg were headache, liver transaminase elevation, diarrhea, cough, influenza, sinusitis, back pain, abdominal pain, and pain in extremity.",diarrhea is an adverse reaction entity
"In placebo-controlled trials, the most frequent adverse reactions (incidence >=10% and >placebo) for GILENYA 0.5 mg were headache, liver transaminase elevation, diarrhea, cough, influenza, sinusitis, back pain, abdominal pain, and pain in extremity.",pain is not a named entity
"In placebo-controlled trials, the most frequent adverse reactions (incidence >=10% and >placebo) for GILENYA 0.5 mg were headache, liver transaminase elevation, diarrhea, cough, influenza, sinusitis, back pain, abdominal pain, and pain in extremity.",were is not a named entity
"In placebo-controlled trials, the most frequent adverse reactions (incidence >=10% and >placebo) for GILENYA 0.5 mg were headache, liver transaminase elevation, diarrhea, cough, influenza, sinusitis, back pain, abdominal pain, and pain in extremity.",headache is an adverse reaction entity
"In placebo-controlled trials, the most frequent adverse reactions (incidence >=10% and >placebo) for GILENYA 0.5 mg were headache, liver transaminase elevation, diarrhea, cough, influenza, sinusitis, back pain, abdominal pain, and pain in extremity.",sinusitis is an adverse reaction entity
"In placebo-controlled trials, the most frequent adverse reactions (incidence >=10% and >placebo) for GILENYA 0.5 mg were headache, liver transaminase elevation, diarrhea, cough, influenza, sinusitis, back pain, abdominal pain, and pain in extremity.",0.5 is not a named entity
"In placebo-controlled trials, the most frequent adverse reactions (incidence >=10% and >placebo) for GILENYA 0.5 mg were headache, liver transaminase elevation, diarrhea, cough, influenza, sinusitis, back pain, abdominal pain, and pain in extremity.",influenza is an adverse reaction entity
"In placebo-controlled trials, the most frequent adverse reactions (incidence >=10% and >placebo) for GILENYA 0.5 mg were headache, liver transaminase elevation, diarrhea, cough, influenza, sinusitis, back pain, abdominal pain, and pain in extremity.","diarrhea , cough is not a named entity"
"In placebo-controlled trials, the most frequent adverse reactions (incidence >=10% and >placebo) for GILENYA 0.5 mg were headache, liver transaminase elevation, diarrhea, cough, influenza, sinusitis, back pain, abdominal pain, and pain in extremity.","placebo-controlled trials , is not a named entity"
"In placebo-controlled trials, the most frequent adverse reactions (incidence >=10% and >placebo) for GILENYA 0.5 mg were headache, liver transaminase elevation, diarrhea, cough, influenza, sinusitis, back pain, abdominal pain, and pain in extremity.",back pain is an adverse reaction entity
"In placebo-controlled trials, the most frequent adverse reactions (incidence >=10% and >placebo) for GILENYA 0.5 mg were headache, liver transaminase elevation, diarrhea, cough, influenza, sinusitis, back pain, abdominal pain, and pain in extremity.",abdominal pain is an adverse reaction entity
"In placebo-controlled trials, the most frequent adverse reactions (incidence >=10% and >placebo) for GILENYA 0.5 mg were headache, liver transaminase elevation, diarrhea, cough, influenza, sinusitis, back pain, abdominal pain, and pain in extremity.","elevation , is not a named entity"
"In placebo-controlled trials, the most frequent adverse reactions (incidence >=10% and >placebo) for GILENYA 0.5 mg were headache, liver transaminase elevation, diarrhea, cough, influenza, sinusitis, back pain, abdominal pain, and pain in extremity.",pain in extremity is an adverse reaction entity
"In placebo-controlled trials, the most frequent adverse reactions (incidence >=10% and >placebo) for GILENYA 0.5 mg were headache, liver transaminase elevation, diarrhea, cough, influenza, sinusitis, back pain, abdominal pain, and pain in extremity.",placebo is not a named entity
"In placebo-controlled trials, the most frequent adverse reactions (incidence >=10% and >placebo) for GILENYA 0.5 mg were headache, liver transaminase elevation, diarrhea, cough, influenza, sinusitis, back pain, abdominal pain, and pain in extremity.",cough is an adverse reaction entity
"In placebo-controlled trials, the most frequent adverse reactions (incidence >=10% and >placebo) for GILENYA 0.5 mg were headache, liver transaminase elevation, diarrhea, cough, influenza, sinusitis, back pain, abdominal pain, and pain in extremity.",> =10 is not a named entity
"Macular edema has also been reported in patients taking GILENYA 0.5 mg in the postmarketing setting, usually within the first 6 months of treatment.",Macular edema is an adverse reaction entity
"Macular edema has also been reported in patients taking GILENYA 0.5 mg in the postmarketing setting, usually within the first 6 months of treatment.",in patients is not a named entity
"Of the 14 patients receiving GILENYA, 7 patients had 2:1 AV block (5 patients within the first 6 hours postdose and 2 patients after 6 hours postdose).",GILENYA is not a named entity
"Of the 14 patients receiving GILENYA, 7 patients had 2:1 AV block (5 patients within the first 6 hours postdose and 2 patients after 6 hours postdose).",2:1 AV block is an adverse reaction entity
"Isolated delayed onset events, including transient asystole and unexplained death, have occurred within 24 hours of the first dose.",asystole is an adverse reaction entity
"Isolated delayed onset events, including transient asystole and unexplained death, have occurred within 24 hours of the first dose.",death is an adverse reaction entity
"Isolated delayed onset events, including transient asystole and unexplained death, have occurred within 24 hours of the first dose.",occurred within 24 is not a named entity
"Isolated delayed onset events, including transient asystole and unexplained death, have occurred within 24 hours of the first dose.",have is not a named entity
"In controlled clinical trials, adverse reactions of symptomatic bradycardia following the first dose were reported in 0.6% of patients receiving GILENYA 0.5 mg and in 0.1% of patients on placebo.",controlled is not a named entity
"In controlled clinical trials, adverse reactions of symptomatic bradycardia following the first dose were reported in 0.6% of patients receiving GILENYA 0.5 mg and in 0.1% of patients on placebo.",symptomatic bradycardia is an adverse reaction entity
5.5     Posterior Reversible Encephalopathy Syndrome      There have been rare cases of posterior reversible encephalopathy syndrome (PRES) reported in patients receiving GILENYA.,PRES is an adverse reaction entity
5.5     Posterior Reversible Encephalopathy Syndrome      There have been rare cases of posterior reversible encephalopathy syndrome (PRES) reported in patients receiving GILENYA.,of is not a named entity
5.5     Posterior Reversible Encephalopathy Syndrome      There have been rare cases of posterior reversible encephalopathy syndrome (PRES) reported in patients receiving GILENYA.,Syndrome There is not a named entity
5.5     Posterior Reversible Encephalopathy Syndrome      There have been rare cases of posterior reversible encephalopathy syndrome (PRES) reported in patients receiving GILENYA.,posterior reversible encephalopathy syndrome is an adverse reaction entity
"(  5.4  )   *  Posterior reversible encephalopathy syndrome (PRES): If suspected, discontinue GILENYA.",Posterior reversible encephalopathy syndrome is an adverse reaction entity
"(  5.4  )   *  Posterior reversible encephalopathy syndrome (PRES): If suspected, discontinue GILENYA.",* Posterior is not a named entity
"(  5.4  )   *  Posterior reversible encephalopathy syndrome (PRES): If suspected, discontinue GILENYA.",PRES is an adverse reaction entity
"(  5.4  )   *  Posterior reversible encephalopathy syndrome (PRES): If suspected, discontinue GILENYA.",If suspected is not a named entity
"In MS placebo-controlled trials, dyspnea was reported in 9% of patients receiving GILENYA 0.5 mg and 7% of patients receiving placebo.",dyspnea is an adverse reaction entity
"In MS placebo-controlled trials, dyspnea was reported in 9% of patients receiving GILENYA 0.5 mg and 7% of patients receiving placebo.",7 is not a named entity
Recurrence of liver transaminase elevations occurred with rechallenge in some patients.,liver transaminase elevations is an adverse reaction entity
Recurrence of liver transaminase elevations occurred with rechallenge in some patients.,Recurrence of is not a named entity
Macular Edema in Patients with History of Uveitis or Diabetes Mellitus        Patients with a history of uveitis and patients with diabetes mellitus are at increased risk of macular edema during GILENYA therapy.,or is not a named entity
Macular Edema in Patients with History of Uveitis or Diabetes Mellitus        Patients with a history of uveitis and patients with diabetes mellitus are at increased risk of macular edema during GILENYA therapy.,macular edema is an adverse reaction entity
5.6     Respiratory Effects       Dose-dependent reductions in forced expiratory volume over 1 second (FEV1) and diffusion lung capacity for carbon monoxide (DLCO) were observed in patients treated with GILENYA as early as 1 month after treatment initiation.,reductions in DLCO is an adverse reaction entity
5.6     Respiratory Effects       Dose-dependent reductions in forced expiratory volume over 1 second (FEV1) and diffusion lung capacity for carbon monoxide (DLCO) were observed in patients treated with GILENYA as early as 1 month after treatment initiation.,reductions in forced expiratory volume over 1 second is an adverse reaction entity
5.6     Respiratory Effects       Dose-dependent reductions in forced expiratory volume over 1 second (FEV1) and diffusion lung capacity for carbon monoxide (DLCO) were observed in patients treated with GILENYA as early as 1 month after treatment initiation.,reductions in diffusion lung capacity for carbon monoxide is an adverse reaction entity
5.6     Respiratory Effects       Dose-dependent reductions in forced expiratory volume over 1 second (FEV1) and diffusion lung capacity for carbon monoxide (DLCO) were observed in patients treated with GILENYA as early as 1 month after treatment initiation.,Respiratory Effects Dose-dependent is not a named entity
5.6     Respiratory Effects       Dose-dependent reductions in forced expiratory volume over 1 second (FEV1) and diffusion lung capacity for carbon monoxide (DLCO) were observed in patients treated with GILENYA as early as 1 month after treatment initiation.,diffusion is not a named entity
5.6     Respiratory Effects       Dose-dependent reductions in forced expiratory volume over 1 second (FEV1) and diffusion lung capacity for carbon monoxide (DLCO) were observed in patients treated with GILENYA as early as 1 month after treatment initiation.,over is not a named entity
5.6     Respiratory Effects       Dose-dependent reductions in forced expiratory volume over 1 second (FEV1) and diffusion lung capacity for carbon monoxide (DLCO) were observed in patients treated with GILENYA as early as 1 month after treatment initiation.,second is not a named entity
5.6     Respiratory Effects       Dose-dependent reductions in forced expiratory volume over 1 second (FEV1) and diffusion lung capacity for carbon monoxide (DLCO) were observed in patients treated with GILENYA as early as 1 month after treatment initiation.,reductions in FEV1 is an adverse reaction entity
"In 2-year placebo-controlled trials, the reduction from baseline in the percent of predicted values for FEV1 at the time of last assessment on drug was 2.8% for GILENYA 0.5 mg and 1.0% for placebo.",reduction for FEV1 is an adverse reaction entity
"In 2-year placebo-controlled trials, the reduction from baseline in the percent of predicted values for FEV1 at the time of last assessment on drug was 2.8% for GILENYA 0.5 mg and 1.0% for placebo.",drug was is not a named entity
Lymphomas       Cases of lymphoma have occurred in premarketing clinical trials and in the postmarketing setting.,lymphoma is an adverse reaction entity
Lymphomas       Cases of lymphoma have occurred in premarketing clinical trials and in the postmarketing setting.,Lymphomas Cases is not a named entity
"For DLCO, the reduction from baseline in percent of predicted values at the time of last assessment on drug was 3.3% for GILENYA 0.5 mg and 0.5% for placebo.",predicted is not a named entity
"For DLCO, the reduction from baseline in percent of predicted values at the time of last assessment on drug was 3.3% for GILENYA 0.5 mg and 0.5% for placebo.",DLCO reduction is an adverse reaction entity
5     WARNINGS AND PRECAUTIONS       EXCERPT:    *  Bradycardia and/or atrioventricular conduction after first dose: Monitor patients.,PRECAUTIONS is not a named entity
5     WARNINGS AND PRECAUTIONS       EXCERPT:    *  Bradycardia and/or atrioventricular conduction after first dose: Monitor patients.,PRECAUTIONS EXCERPT : is not a named entity
5     WARNINGS AND PRECAUTIONS       EXCERPT:    *  Bradycardia and/or atrioventricular conduction after first dose: Monitor patients.,atrioventricular conduction is an adverse reaction entity
5     WARNINGS AND PRECAUTIONS       EXCERPT:    *  Bradycardia and/or atrioventricular conduction after first dose: Monitor patients.,Bradycardia is an adverse reaction entity
The other patient developed probable PML after taking GILENYA for approximately 4 years.,PML is an adverse reaction entity
The other patient developed probable PML after taking GILENYA for approximately 4 years.,GILENYA is not a named entity
"In controlled clinical trials, first-degree AV block after the first dose occurred in 4.7% of patients receiving GILENYA and 1.6% of patients on placebo.",4.7 is not a named entity
"In controlled clinical trials, first-degree AV block after the first dose occurred in 4.7% of patients receiving GILENYA and 1.6% of patients on placebo.",first-degree AV block is an adverse reaction entity
"Herpes Viral Infections          In placebo-controlled trials, the rate of herpetic infections was 9% in patients receiving GILENYA 0.5 mg and 7% on placebo.",was 9 is not a named entity
"Herpes Viral Infections          In placebo-controlled trials, the rate of herpetic infections was 9% in patients receiving GILENYA 0.5 mg and 7% on placebo.",herpetic infections is an adverse reaction entity
"Because of the continuing pharmacodynamic effects of fingolimod, initiating other drugs during this period warrants the same considerations needed for concomitant administration (e.g., risk of additive immunosuppressant effects) [see Drug Interactions (7)]  .",for concomitant administration is not a named entity
"Because of the continuing pharmacodynamic effects of fingolimod, initiating other drugs during this period warrants the same considerations needed for concomitant administration (e.g., risk of additive immunosuppressant effects) [see Drug Interactions (7)]  .",immunosuppressant effects is an adverse reaction entity
"Symptoms reported included sudden onset of severe headache, altered mental status, visual disturbances, and seizure.",", visual disturbances is not a named entity"
"Symptoms reported included sudden onset of severe headache, altered mental status, visual disturbances, and seizure.",", is not a named entity"
"Symptoms reported included sudden onset of severe headache, altered mental status, visual disturbances, and seizure.",seizure is an adverse reaction entity
"Symptoms reported included sudden onset of severe headache, altered mental status, visual disturbances, and seizure.",Symptoms is not a named entity
"Symptoms reported included sudden onset of severe headache, altered mental status, visual disturbances, and seizure.",visual disturbances is an adverse reaction entity
"Symptoms reported included sudden onset of severe headache, altered mental status, visual disturbances, and seizure.",altered mental status is an adverse reaction entity
"Symptoms reported included sudden onset of severe headache, altered mental status, visual disturbances, and seizure.",", and seizure is not a named entity"
"Symptoms reported included sudden onset of severe headache, altered mental status, visual disturbances, and seizure.",headache is an adverse reaction entity
"GILENYA may therefore increase the risk of infections, some serious in nature [see Clinical Pharmacology (12.2)]  .",serious in is not a named entity
"GILENYA may therefore increase the risk of infections, some serious in nature [see Clinical Pharmacology (12.2)]  .",infections is an adverse reaction entity
"GILENYA may therefore increase the risk of infections, some serious in nature [see Clinical Pharmacology (12.2)]  .",infections is an adverse reaction entity
"GILENYA may therefore increase the risk of infections, some serious in nature [see Clinical Pharmacology (12.2)]  .",in nature [ is not a named entity
"On Day 1, the maximum decline in heart rate generally occurs within 6 hours and recovers, although not to baseline levels, by 8 to 10 hours postdose.",", by is not a named entity"
"On Day 1, the maximum decline in heart rate generally occurs within 6 hours and recovers, although not to baseline levels, by 8 to 10 hours postdose.",decline in heart rate is an adverse reaction entity
Symptoms of PRES are usually reversible but may evolve into ischemic stroke or cerebral hemorrhage.,of is not a named entity
Symptoms of PRES are usually reversible but may evolve into ischemic stroke or cerebral hemorrhage.,ischemic stroke is an adverse reaction entity
Symptoms of PRES are usually reversible but may evolve into ischemic stroke or cerebral hemorrhage.,are usually reversible is not a named entity
Symptoms of PRES are usually reversible but may evolve into ischemic stroke or cerebral hemorrhage.,cerebral hemorrhage is an adverse reaction entity
Symptoms of PRES are usually reversible but may evolve into ischemic stroke or cerebral hemorrhage.,may evolve is not a named entity
Symptoms of PRES are usually reversible but may evolve into ischemic stroke or cerebral hemorrhage.,PRES is an adverse reaction entity
"Patients who experienced bradycardia were generally asymptomatic, but some patients experienced hypotension, dizziness, fatigue, palpitations, and/or chest pain that usually resolved within the first 24 hours on treatment.",chest pain is an adverse reaction entity
"Patients who experienced bradycardia were generally asymptomatic, but some patients experienced hypotension, dizziness, fatigue, palpitations, and/or chest pain that usually resolved within the first 24 hours on treatment.",fatigue is an adverse reaction entity
"Patients who experienced bradycardia were generally asymptomatic, but some patients experienced hypotension, dizziness, fatigue, palpitations, and/or chest pain that usually resolved within the first 24 hours on treatment.",palpitations is an adverse reaction entity
"Patients who experienced bradycardia were generally asymptomatic, but some patients experienced hypotension, dizziness, fatigue, palpitations, and/or chest pain that usually resolved within the first 24 hours on treatment.",resolved within is not a named entity
"Patients who experienced bradycardia were generally asymptomatic, but some patients experienced hypotension, dizziness, fatigue, palpitations, and/or chest pain that usually resolved within the first 24 hours on treatment.",hypotension is an adverse reaction entity
"Patients who experienced bradycardia were generally asymptomatic, but some patients experienced hypotension, dizziness, fatigue, palpitations, and/or chest pain that usually resolved within the first 24 hours on treatment.","asymptomatic , but is not a named entity"
"Patients who experienced bradycardia were generally asymptomatic, but some patients experienced hypotension, dizziness, fatigue, palpitations, and/or chest pain that usually resolved within the first 24 hours on treatment.",Patients who experienced is not a named entity
"Patients who experienced bradycardia were generally asymptomatic, but some patients experienced hypotension, dizziness, fatigue, palpitations, and/or chest pain that usually resolved within the first 24 hours on treatment.",bradycardia is an adverse reaction entity
"Patients who experienced bradycardia were generally asymptomatic, but some patients experienced hypotension, dizziness, fatigue, palpitations, and/or chest pain that usually resolved within the first 24 hours on treatment.",who experienced bradycardia is not a named entity
"Patients who experienced bradycardia were generally asymptomatic, but some patients experienced hypotension, dizziness, fatigue, palpitations, and/or chest pain that usually resolved within the first 24 hours on treatment.",asymptomatic is not a named entity
"Patients who experienced bradycardia were generally asymptomatic, but some patients experienced hypotension, dizziness, fatigue, palpitations, and/or chest pain that usually resolved within the first 24 hours on treatment.",dizziness is an adverse reaction entity
"Patients who experienced bradycardia were generally asymptomatic, but some patients experienced hypotension, dizziness, fatigue, palpitations, and/or chest pain that usually resolved within the first 24 hours on treatment.",", dizziness is not a named entity"
"Serious, life-threatening events of disseminated varicella zoster and herpes simplex infections, including cases of encephalitis and multiorgan failure, have occurred with GILENYA 0.5 mg in the postmarketing setting.",herpes simplex infections is an adverse reaction entity
"Serious, life-threatening events of disseminated varicella zoster and herpes simplex infections, including cases of encephalitis and multiorgan failure, have occurred with GILENYA 0.5 mg in the postmarketing setting.",encephalitis is an adverse reaction entity
"Serious, life-threatening events of disseminated varicella zoster and herpes simplex infections, including cases of encephalitis and multiorgan failure, have occurred with GILENYA 0.5 mg in the postmarketing setting.",GILENYA 0.5 mg is not a named entity
"Serious, life-threatening events of disseminated varicella zoster and herpes simplex infections, including cases of encephalitis and multiorgan failure, have occurred with GILENYA 0.5 mg in the postmarketing setting.","infections , including is not a named entity"
"Serious, life-threatening events of disseminated varicella zoster and herpes simplex infections, including cases of encephalitis and multiorgan failure, have occurred with GILENYA 0.5 mg in the postmarketing setting.",disseminated varicella zoster infections is an adverse reaction entity
"Serious, life-threatening events of disseminated varicella zoster and herpes simplex infections, including cases of encephalitis and multiorgan failure, have occurred with GILENYA 0.5 mg in the postmarketing setting.",in the is not a named entity
"Serious, life-threatening events of disseminated varicella zoster and herpes simplex infections, including cases of encephalitis and multiorgan failure, have occurred with GILENYA 0.5 mg in the postmarketing setting.",events of is not a named entity
"Serious, life-threatening events of disseminated varicella zoster and herpes simplex infections, including cases of encephalitis and multiorgan failure, have occurred with GILENYA 0.5 mg in the postmarketing setting.",multiorgan failure is an adverse reaction entity
"Reduction in Heart Rate          After the first dose of GILENYA, the heart rate decrease starts within an hour.",in Heart Rate is not a named entity
"Reduction in Heart Rate          After the first dose of GILENYA, the heart rate decrease starts within an hour.",heart rate decrease is an adverse reaction entity
"Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes.",leading is not a named entity
"Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes.",PML is an adverse reaction entity
"Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes.",leading is not a named entity
"Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes.",changes in memory is an adverse reaction entity
"Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes.",personality changes is an adverse reaction entity
"Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes.","in thinking , is not a named entity"
"Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes.",clumsiness of limbs is an adverse reaction entity
"Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes.",", disturbance is not a named entity"
"Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes.",confusion is an adverse reaction entity
"Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes.",disturbance of vision is an adverse reaction entity
"Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes.",Typical symptoms associated is not a named entity
"Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes.",", and orientation is not a named entity"
"Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes.",and changes is not a named entity
"Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes.",symptoms is not a named entity
"Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes.",changes in orientation is an adverse reaction entity
"Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes.",days to weeks is not a named entity
"Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes.",changes in thinking is an adverse reaction entity
"Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes.",progressive weakness on one side of the body is an adverse reaction entity
(  5.5  )   *  Decrease in pulmonary function tests (PFT): Obtain PFT when clinically indicated.,* is not a named entity
(  5.5  )   *  Decrease in pulmonary function tests (PFT): Obtain PFT when clinically indicated.,Decrease in pulmonary function tests is an adverse reaction entity
(  5.5  )   *  Decrease in pulmonary function tests (PFT): Obtain PFT when clinically indicated.,Decrease in PFT is an adverse reaction entity
(  5.5  )   *  Decrease in pulmonary function tests (PFT): Obtain PFT when clinically indicated.,Obtain PFT is not a named entity
The diagnosis of probable PML was based on MRI findings and the detection of JCV DNA in the CSF in the absence of clinical signs or symptoms specific to PML.,signs or is not a named entity
The diagnosis of probable PML was based on MRI findings and the detection of JCV DNA in the CSF in the absence of clinical signs or symptoms specific to PML.,JCV DNA in is not a named entity
The diagnosis of probable PML was based on MRI findings and the detection of JCV DNA in the CSF in the absence of clinical signs or symptoms specific to PML.,PML is an adverse reaction entity
The diagnosis of probable PML was based on MRI findings and the detection of JCV DNA in the CSF in the absence of clinical signs or symptoms specific to PML.,PML is an adverse reaction entity
The diagnosis of probable PML was based on MRI findings and the detection of JCV DNA in the CSF in the absence of clinical signs or symptoms specific to PML.,of is not a named entity
The diagnosis of probable PML was based on MRI findings and the detection of JCV DNA in the CSF in the absence of clinical signs or symptoms specific to PML.,JCV in the CSF is an adverse reaction entity
"5.10     Immune System Effects Following GILENYA Discontinuation      Fingolimod remains in the blood and has pharmacodynamic effects, including decreased lymphocyte counts, for up to 2 months following the last dose of GILENYA.",System Effects Following is not a named entity
"5.10     Immune System Effects Following GILENYA Discontinuation      Fingolimod remains in the blood and has pharmacodynamic effects, including decreased lymphocyte counts, for up to 2 months following the last dose of GILENYA.",decreased lymphocyte counts is an adverse reaction entity
"In 2-year, double-blind, placebo-controlled studies in patients with multiple sclerosis, macular edema with or without visual symptoms occurred in 1.5% of patients (11/799) treated with fingolimod 1.25 mg, 0.5% of patients (4/783) treated with GILENYA 0.5 mg and 0.4% of patients (3/773) treated with placebo.",treated is not a named entity
"In 2-year, double-blind, placebo-controlled studies in patients with multiple sclerosis, macular edema with or without visual symptoms occurred in 1.5% of patients (11/799) treated with fingolimod 1.25 mg, 0.5% of patients (4/783) treated with GILENYA 0.5 mg and 0.4% of patients (3/773) treated with placebo.",macular edema is an adverse reaction entity
"In 2-year, double-blind, placebo-controlled studies in patients with multiple sclerosis, macular edema with or without visual symptoms occurred in 1.5% of patients (11/799) treated with fingolimod 1.25 mg, 0.5% of patients (4/783) treated with GILENYA 0.5 mg and 0.4% of patients (3/773) treated with placebo.",with is not a named entity
"In 2-year, double-blind, placebo-controlled studies in patients with multiple sclerosis, macular edema with or without visual symptoms occurred in 1.5% of patients (11/799) treated with fingolimod 1.25 mg, 0.5% of patients (4/783) treated with GILENYA 0.5 mg and 0.4% of patients (3/773) treated with placebo.",visual symptoms is an adverse reaction entity
EXCERPT:   The most common adverse reaction reported in 2% of patients treated with Besivance was conjunctival redness.,conjunctival redness is an adverse reaction entity
EXCERPT:   The most common adverse reaction reported in 2% of patients treated with Besivance was conjunctival redness.,common adverse reaction is not a named entity
"The most frequently reported ocular adverse reaction was conjunctival redness, reported in approximately 2% of patients.",adverse reaction was is not a named entity
"The most frequently reported ocular adverse reaction was conjunctival redness, reported in approximately 2% of patients.",conjunctival redness is an adverse reaction entity
"The most frequently reported ocular adverse reaction was conjunctival redness, reported in approximately 2% of patients.",ocular adverse reaction is an adverse reaction entity
"The most frequently reported ocular adverse reaction was conjunctival redness, reported in approximately 2% of patients.",in approximately is not a named entity
"Other adverse reactions reported in patients receiving Besivance occurring in approximately 1-2% of patients included: blurred vision, eye pain, eye irritation, eye pruritus and headache.",reactions reported is not a named entity
"Other adverse reactions reported in patients receiving Besivance occurring in approximately 1-2% of patients included: blurred vision, eye pain, eye irritation, eye pruritus and headache.",blurred vision is an adverse reaction entity
"Other adverse reactions reported in patients receiving Besivance occurring in approximately 1-2% of patients included: blurred vision, eye pain, eye irritation, eye pruritus and headache.",Besivance is not a named entity
"Other adverse reactions reported in patients receiving Besivance occurring in approximately 1-2% of patients included: blurred vision, eye pain, eye irritation, eye pruritus and headache.",", eye pruritus is not a named entity"
"Other adverse reactions reported in patients receiving Besivance occurring in approximately 1-2% of patients included: blurred vision, eye pain, eye irritation, eye pruritus and headache.",eye irritation is an adverse reaction entity
"Other adverse reactions reported in patients receiving Besivance occurring in approximately 1-2% of patients included: blurred vision, eye pain, eye irritation, eye pruritus and headache.",% is not a named entity
"Other adverse reactions reported in patients receiving Besivance occurring in approximately 1-2% of patients included: blurred vision, eye pain, eye irritation, eye pruritus and headache.",eye pain is an adverse reaction entity
"Other adverse reactions reported in patients receiving Besivance occurring in approximately 1-2% of patients included: blurred vision, eye pain, eye irritation, eye pruritus and headache.",headache is an adverse reaction entity
"Other adverse reactions reported in patients receiving Besivance occurring in approximately 1-2% of patients included: blurred vision, eye pain, eye irritation, eye pruritus and headache.",eye pruritus is an adverse reaction entity
"Other adverse reactions reported in patients receiving Besivance occurring in approximately 1-2% of patients included: blurred vision, eye pain, eye irritation, eye pruritus and headache.",", eye pain is not a named entity"
EXCERPT:   WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)       See full prescribing information for complete boxed warning         Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs.,agents is not a named entity
EXCERPT:   WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)       See full prescribing information for complete boxed warning         Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs.,NSF is an adverse reaction entity
EXCERPT:   WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)       See full prescribing information for complete boxed warning         Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs.,NSF is an adverse reaction entity
EXCERPT:   WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)       See full prescribing information for complete boxed warning         Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs.,NEPHROGENIC SYSTEMIC FIBROSIS is an adverse reaction entity
EXCERPT:   WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)       See full prescribing information for complete boxed warning         Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs.,) See is not a named entity
EXCERPT:   WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)       See full prescribing information for complete boxed warning         Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs.,the risk for is not a named entity
"*  The risk for NSF appears highest among patients with:Chronic, severe kidney disease (GFR < 30 mL/min/1.73m2), orAcute kidney injury.",NSF is an adverse reaction entity
"*  The risk for NSF appears highest among patients with:Chronic, severe kidney disease (GFR < 30 mL/min/1.73m2), orAcute kidney injury.",injury is not a named entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *    Nephrogenic Systemic Fibrosis has occurred in patients with impaired elimination of GBCAs.,has occurred in is not a named entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *    Nephrogenic Systemic Fibrosis has occurred in patients with impaired elimination of GBCAs.,Nephrogenic Systemic Fibrosis is an adverse reaction entity
"NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.",fibrosis is an adverse reaction entity
"NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.",NSF is an adverse reaction entity
"NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.",fatal is an adverse reaction entity
"NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.",muscle and internal is not a named entity
"NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.",debilitating is not a named entity
"NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.",debilitating fibrosis affecting is not a named entity
"The GBCA-associated NSF risk appears highest for patients with chronic, severe kidney disease (GFR < 30 mL/min/1.73m  2  ) as well as patients with acute kidney injury.",kidney is not a named entity
"The GBCA-associated NSF risk appears highest for patients with chronic, severe kidney disease (GFR < 30 mL/min/1.73m  2  ) as well as patients with acute kidney injury.",NSF is an adverse reaction entity
6 ADVERSE REACTIONS      *    The following serious adverse reactions are discussed elsewhere in labeling:   *    Nephrogenic Systemic Fibrosis (NSF) [see Boxed Warning and Warnings and Precautions (  5.1  )].,Warnings and Precautions is not a named entity
6 ADVERSE REACTIONS      *    The following serious adverse reactions are discussed elsewhere in labeling:   *    Nephrogenic Systemic Fibrosis (NSF) [see Boxed Warning and Warnings and Precautions (  5.1  )].,Nephrogenic Systemic Fibrosis is an adverse reaction entity
6 ADVERSE REACTIONS      *    The following serious adverse reactions are discussed elsewhere in labeling:   *    Nephrogenic Systemic Fibrosis (NSF) [see Boxed Warning and Warnings and Precautions (  5.1  )].,NSF is an adverse reaction entity
6 ADVERSE REACTIONS      *    The following serious adverse reactions are discussed elsewhere in labeling:   *    Nephrogenic Systemic Fibrosis (NSF) [see Boxed Warning and Warnings and Precautions (  5.1  )].,reactions are discussed is not a named entity
"NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.",fatal is an adverse reaction entity
"NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.",affecting the is not a named entity
"NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.",skin is not a named entity
"NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.",NSF is an adverse reaction entity
"NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.",fibrosis is an adverse reaction entity
"NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.",result is not a named entity
Monitor patients closely during and after administration of Gadavist (  5.2  )             5.1 Nephrogenic Systemic Fibrosis      Gadolinium-based contrast agents (GBCAs) increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs.,with impaired elimination is not a named entity
Monitor patients closely during and after administration of Gadavist (  5.2  )             5.1 Nephrogenic Systemic Fibrosis      Gadolinium-based contrast agents (GBCAs) increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs.,NSF is an adverse reaction entity
Monitor patients closely during and after administration of Gadavist (  5.2  )             5.1 Nephrogenic Systemic Fibrosis      Gadolinium-based contrast agents (GBCAs) increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs.,nephrogenic systemic fibrosis is an adverse reaction entity
Monitor patients closely during and after administration of Gadavist (  5.2  )             5.1 Nephrogenic Systemic Fibrosis      Gadolinium-based contrast agents (GBCAs) increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs.,of the drugs is not a named entity
"5.3 Acute Kidney Injury      In patients with chronic renal impairment, acute kidney injury sometimes requiring dialysis has been observed with the use of some GBCAs.",", acute is not a named entity"
"5.3 Acute Kidney Injury      In patients with chronic renal impairment, acute kidney injury sometimes requiring dialysis has been observed with the use of some GBCAs.",acute kidney injury is an adverse reaction entity
"Higher than recommended dosing or repeated dosing appears to increase the risk (  5.1  )   *    Anaphylactic and other hypersensitivity reactions with cardiovascular, respiratory or cutaneous manifestations, ranging from mild to severe, including death, have occurred.",respiratory manifestations is an adverse reaction entity
"Higher than recommended dosing or repeated dosing appears to increase the risk (  5.1  )   *    Anaphylactic and other hypersensitivity reactions with cardiovascular, respiratory or cutaneous manifestations, ranging from mild to severe, including death, have occurred.",Anaphylactic reactions is an adverse reaction entity
"Higher than recommended dosing or repeated dosing appears to increase the risk (  5.1  )   *    Anaphylactic and other hypersensitivity reactions with cardiovascular, respiratory or cutaneous manifestations, ranging from mild to severe, including death, have occurred.",hypersensitivity reactions is an adverse reaction entity
"Higher than recommended dosing or repeated dosing appears to increase the risk (  5.1  )   *    Anaphylactic and other hypersensitivity reactions with cardiovascular, respiratory or cutaneous manifestations, ranging from mild to severe, including death, have occurred.",the is not a named entity
"Higher than recommended dosing or repeated dosing appears to increase the risk (  5.1  )   *    Anaphylactic and other hypersensitivity reactions with cardiovascular, respiratory or cutaneous manifestations, ranging from mild to severe, including death, have occurred.",cutaneous manifestations is an adverse reaction entity
"Higher than recommended dosing or repeated dosing appears to increase the risk (  5.1  )   *    Anaphylactic and other hypersensitivity reactions with cardiovascular, respiratory or cutaneous manifestations, ranging from mild to severe, including death, have occurred.",cardiovascular manifestations is an adverse reaction entity
"Higher than recommended dosing or repeated dosing appears to increase the risk (  5.1  )   *    Anaphylactic and other hypersensitivity reactions with cardiovascular, respiratory or cutaneous manifestations, ranging from mild to severe, including death, have occurred.",ranging from is not a named entity
"Higher than recommended dosing or repeated dosing appears to increase the risk (  5.1  )   *    Anaphylactic and other hypersensitivity reactions with cardiovascular, respiratory or cutaneous manifestations, ranging from mild to severe, including death, have occurred.",death is an adverse reaction entity
"Higher than recommended dosing or repeated dosing appears to increase the risk (  5.1  )   *    Anaphylactic and other hypersensitivity reactions with cardiovascular, respiratory or cutaneous manifestations, ranging from mild to severe, including death, have occurred.",from mild is not a named entity
"Higher than recommended dosing or repeated dosing appears to increase the risk (  5.1  )   *    Anaphylactic and other hypersensitivity reactions with cardiovascular, respiratory or cutaneous manifestations, ranging from mild to severe, including death, have occurred.",or repeated dosing is not a named entity
"Higher than recommended dosing or repeated dosing appears to increase the risk (  5.1  )   *    Anaphylactic and other hypersensitivity reactions with cardiovascular, respiratory or cutaneous manifestations, ranging from mild to severe, including death, have occurred.",5.1 ) is not a named entity
"Higher than recommended dosing or repeated dosing appears to increase the risk (  5.1  )   *    Anaphylactic and other hypersensitivity reactions with cardiovascular, respiratory or cutaneous manifestations, ranging from mild to severe, including death, have occurred.",the risk is not a named entity
"EXCERPT:    *    Most common adverse reactions (incidence >= 0.5%) are headache, nausea, and dizziness (  6.1)          To report SUSPECTED ADVERSE REACTIONS, contact Bayer HealthCare Pharmaceuticals Inc. at 1-888-842-2937 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch             6.1 Clinical Trials Experience    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.",headache is an adverse reaction entity
"EXCERPT:    *    Most common adverse reactions (incidence >= 0.5%) are headache, nausea, and dizziness (  6.1)          To report SUSPECTED ADVERSE REACTIONS, contact Bayer HealthCare Pharmaceuticals Inc. at 1-888-842-2937 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch             6.1 Clinical Trials Experience    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.",nausea is an adverse reaction entity
"EXCERPT:    *    Most common adverse reactions (incidence >= 0.5%) are headache, nausea, and dizziness (  6.1)          To report SUSPECTED ADVERSE REACTIONS, contact Bayer HealthCare Pharmaceuticals Inc. at 1-888-842-2937 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch             6.1 Clinical Trials Experience    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.",Because is not a named entity
"EXCERPT:    *    Most common adverse reactions (incidence >= 0.5%) are headache, nausea, and dizziness (  6.1)          To report SUSPECTED ADVERSE REACTIONS, contact Bayer HealthCare Pharmaceuticals Inc. at 1-888-842-2937 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch             6.1 Clinical Trials Experience    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.",rates observed in is not a named entity
"EXCERPT:    *    Most common adverse reactions (incidence >= 0.5%) are headache, nausea, and dizziness (  6.1)          To report SUSPECTED ADVERSE REACTIONS, contact Bayer HealthCare Pharmaceuticals Inc. at 1-888-842-2937 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch             6.1 Clinical Trials Experience    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.",Clinical Trials is not a named entity
"EXCERPT:    *    Most common adverse reactions (incidence >= 0.5%) are headache, nausea, and dizziness (  6.1)          To report SUSPECTED ADVERSE REACTIONS, contact Bayer HealthCare Pharmaceuticals Inc. at 1-888-842-2937 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch             6.1 Clinical Trials Experience    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.",dizziness is an adverse reaction entity
"Other adverse reactions which occurred in 2-5% of subjects were eye irritation, headache, and nasopharyngitis.",eye irritation is an adverse reaction entity
"Other adverse reactions which occurred in 2-5% of subjects were eye irritation, headache, and nasopharyngitis.",nasopharyngitis is an adverse reaction entity
"Other adverse reactions which occurred in 2-5% of subjects were eye irritation, headache, and nasopharyngitis.",reactions which occurred is not a named entity
"Other adverse reactions which occurred in 2-5% of subjects were eye irritation, headache, and nasopharyngitis.",headache is an adverse reaction entity
"Other adverse reactions which occurred in 2-5% of subjects were eye irritation, headache, and nasopharyngitis.",% is not a named entity
"Other adverse reactions which occurred in 2-5% of subjects were eye irritation, headache, and nasopharyngitis.","headache , and is not a named entity"
"Other adverse reactions occurring in 2-5% of subjects were eye irritation, headache, and nasopharyngitis.",occurring is not a named entity
"Other adverse reactions occurring in 2-5% of subjects were eye irritation, headache, and nasopharyngitis.",eye irritation is an adverse reaction entity
"Other adverse reactions occurring in 2-5% of subjects were eye irritation, headache, and nasopharyngitis.",headache is an adverse reaction entity
"Other adverse reactions occurring in 2-5% of subjects were eye irritation, headache, and nasopharyngitis.",subjects is not a named entity
"Other adverse reactions occurring in 2-5% of subjects were eye irritation, headache, and nasopharyngitis.",nasopharyngitis is an adverse reaction entity
"Other adverse reactions occurring in 2-5% of subjects were eye irritation, headache, and nasopharyngitis.",reactions is not a named entity
"The hypersensitivity reactions include itching, body rash, and swelling of lips, tongue and/or throat.",tongue is not a named entity
"The hypersensitivity reactions include itching, body rash, and swelling of lips, tongue and/or throat.",reactions include itching is not a named entity
"The hypersensitivity reactions include itching, body rash, and swelling of lips, tongue and/or throat.",swelling of lips is an adverse reaction entity
"The hypersensitivity reactions include itching, body rash, and swelling of lips, tongue and/or throat.",of is not a named entity
"The hypersensitivity reactions include itching, body rash, and swelling of lips, tongue and/or throat.",and is not a named entity
"The hypersensitivity reactions include itching, body rash, and swelling of lips, tongue and/or throat.",swelling of tongue is an adverse reaction entity
"The hypersensitivity reactions include itching, body rash, and swelling of lips, tongue and/or throat.",swelling of throat is an adverse reaction entity
"The hypersensitivity reactions include itching, body rash, and swelling of lips, tongue and/or throat.","lips , is not a named entity"
"The hypersensitivity reactions include itching, body rash, and swelling of lips, tongue and/or throat.",body rash is an adverse reaction entity
"The hypersensitivity reactions include itching, body rash, and swelling of lips, tongue and/or throat.",hypersensitivity reactions is an adverse reaction entity
"The hypersensitivity reactions include itching, body rash, and swelling of lips, tongue and/or throat.",", is not a named entity"
"The hypersensitivity reactions include itching, body rash, and swelling of lips, tongue and/or throat.",itching is an adverse reaction entity
6 ADVERSE REACTIONS    EXCERPT:    The most common adverse reaction occurring in approximately 25% of patients was a mild taste following instillation.,REACTIONS EXCERPT : is not a named entity
6 ADVERSE REACTIONS    EXCERPT:    The most common adverse reaction occurring in approximately 25% of patients was a mild taste following instillation.,taste following instillation is an adverse reaction entity
"5.1 Spread of Toxin Effect      Postmarketing safety data from XEOMIN and other approved botulinum toxins suggest that botulinum toxin effects may, in some cases, be observed beyond the site of local injection.",toxin effects beyond the site of local injection is an adverse reaction entity
"5.1 Spread of Toxin Effect      Postmarketing safety data from XEOMIN and other approved botulinum toxins suggest that botulinum toxin effects may, in some cases, be observed beyond the site of local injection.",", is not a named entity"
Swallowing and breathing difficulties can be life threatening and there have been reports of death related to the spread of toxin effects.,death is an adverse reaction entity
Swallowing and breathing difficulties can be life threatening and there have been reports of death related to the spread of toxin effects.,threatening and there is not a named entity
Swallowing and breathing difficulties can be life threatening and there have been reports of death related to the spread of toxin effects.,can be is not a named entity
Swallowing and breathing difficulties can be life threatening and there have been reports of death related to the spread of toxin effects.,spread of toxin effects is an adverse reaction entity
Swallowing and breathing difficulties can be life threatening and there have been reports of death related to the spread of toxin effects.,Swallowing difficulties is an adverse reaction entity
Swallowing and breathing difficulties can be life threatening and there have been reports of death related to the spread of toxin effects.,and breathing difficulties is not a named entity
Swallowing and breathing difficulties can be life threatening and there have been reports of death related to the spread of toxin effects.,breathing difficulties is an adverse reaction entity
Swallowing and breathing difficulties can be life threatening and there have been reports of death related to the spread of toxin effects.,be is not a named entity
Patients with neuromuscular disorders may be at increased risk of clinically significant effects including severe dysphagia and respiratory compromise from typical doses of XEOMIN [See  Adverse Reactions (6.1)  ]  .,respiratory compromise is an adverse reaction entity
Patients with neuromuscular disorders may be at increased risk of clinically significant effects including severe dysphagia and respiratory compromise from typical doses of XEOMIN [See  Adverse Reactions (6.1)  ]  .,neuromuscular disorders may is not a named entity
Patients with neuromuscular disorders may be at increased risk of clinically significant effects including severe dysphagia and respiratory compromise from typical doses of XEOMIN [See  Adverse Reactions (6.1)  ]  .,doses of is not a named entity
Patients with neuromuscular disorders may be at increased risk of clinically significant effects including severe dysphagia and respiratory compromise from typical doses of XEOMIN [See  Adverse Reactions (6.1)  ]  .,dysphagia is an adverse reaction entity
"Adverse reactions reported in less than 1% of subjects were: facial paresis (brow ptosis), muscle disorder (elevation of eyebrow), injection site pain, and eyelid edema.",injection site pain is an adverse reaction entity
"Adverse reactions reported in less than 1% of subjects were: facial paresis (brow ptosis), muscle disorder (elevation of eyebrow), injection site pain, and eyelid edema.",elevation of eyebrow is an adverse reaction entity
"Adverse reactions reported in less than 1% of subjects were: facial paresis (brow ptosis), muscle disorder (elevation of eyebrow), injection site pain, and eyelid edema.",less than 1 is not a named entity
"Adverse reactions reported in less than 1% of subjects were: facial paresis (brow ptosis), muscle disorder (elevation of eyebrow), injection site pain, and eyelid edema.",( elevation is not a named entity
"Adverse reactions reported in less than 1% of subjects were: facial paresis (brow ptosis), muscle disorder (elevation of eyebrow), injection site pain, and eyelid edema.",( brow is not a named entity
"Adverse reactions reported in less than 1% of subjects were: facial paresis (brow ptosis), muscle disorder (elevation of eyebrow), injection site pain, and eyelid edema.",eyelid edema is an adverse reaction entity
"Adverse reactions reported in less than 1% of subjects were: facial paresis (brow ptosis), muscle disorder (elevation of eyebrow), injection site pain, and eyelid edema.",muscle disorder is an adverse reaction entity
"Adverse reactions reported in less than 1% of subjects were: facial paresis (brow ptosis), muscle disorder (elevation of eyebrow), injection site pain, and eyelid edema.",brow ptosis is an adverse reaction entity
"Adverse reactions reported in less than 1% of subjects were: facial paresis (brow ptosis), muscle disorder (elevation of eyebrow), injection site pain, and eyelid edema.",less than is not a named entity
"Adverse reactions reported in less than 1% of subjects were: facial paresis (brow ptosis), muscle disorder (elevation of eyebrow), injection site pain, and eyelid edema.",", injection site is not a named entity"
"Adverse reactions reported in less than 1% of subjects were: facial paresis (brow ptosis), muscle disorder (elevation of eyebrow), injection site pain, and eyelid edema.",than is not a named entity
"Adverse reactions reported in less than 1% of subjects were: facial paresis (brow ptosis), muscle disorder (elevation of eyebrow), injection site pain, and eyelid edema.",facial paresis is an adverse reaction entity
"5.3 Hypersensitivity Reactions      Hypersensitivity reactions have been reported with botulinum toxin products (anaphylaxis, serum sickness, urticaria, soft tissue edema, and dyspnea).",urticaria is an adverse reaction entity
"5.3 Hypersensitivity Reactions      Hypersensitivity reactions have been reported with botulinum toxin products (anaphylaxis, serum sickness, urticaria, soft tissue edema, and dyspnea).",toxin is not a named entity
"5.3 Hypersensitivity Reactions      Hypersensitivity reactions have been reported with botulinum toxin products (anaphylaxis, serum sickness, urticaria, soft tissue edema, and dyspnea).",dyspnea is an adverse reaction entity
"5.3 Hypersensitivity Reactions      Hypersensitivity reactions have been reported with botulinum toxin products (anaphylaxis, serum sickness, urticaria, soft tissue edema, and dyspnea).",been is not a named entity
"5.3 Hypersensitivity Reactions      Hypersensitivity reactions have been reported with botulinum toxin products (anaphylaxis, serum sickness, urticaria, soft tissue edema, and dyspnea).",Hypersensitivity reactions is an adverse reaction entity
"5.3 Hypersensitivity Reactions      Hypersensitivity reactions have been reported with botulinum toxin products (anaphylaxis, serum sickness, urticaria, soft tissue edema, and dyspnea).",", is not a named entity"
"5.3 Hypersensitivity Reactions      Hypersensitivity reactions have been reported with botulinum toxin products (anaphylaxis, serum sickness, urticaria, soft tissue edema, and dyspnea).",serum sickness is an adverse reaction entity
"5.3 Hypersensitivity Reactions      Hypersensitivity reactions have been reported with botulinum toxin products (anaphylaxis, serum sickness, urticaria, soft tissue edema, and dyspnea).",anaphylaxis is an adverse reaction entity
"5.3 Hypersensitivity Reactions      Hypersensitivity reactions have been reported with botulinum toxin products (anaphylaxis, serum sickness, urticaria, soft tissue edema, and dyspnea).",sickness is not a named entity
"5.3 Hypersensitivity Reactions      Hypersensitivity reactions have been reported with botulinum toxin products (anaphylaxis, serum sickness, urticaria, soft tissue edema, and dyspnea).",toxin products ( is not a named entity
"5.3 Hypersensitivity Reactions      Hypersensitivity reactions have been reported with botulinum toxin products (anaphylaxis, serum sickness, urticaria, soft tissue edema, and dyspnea).",soft tissue edema is an adverse reaction entity
"5.3 Hypersensitivity Reactions      Hypersensitivity reactions have been reported with botulinum toxin products (anaphylaxis, serum sickness, urticaria, soft tissue edema, and dyspnea).","urticaria , soft is not a named entity"
"The symptoms are consistent with the mechanism of action of botulinum toxin and may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties.",", is not a named entity"
"The symptoms are consistent with the mechanism of action of botulinum toxin and may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties.",dysarthria is an adverse reaction entity
"The symptoms are consistent with the mechanism of action of botulinum toxin and may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties.",asthenia is an adverse reaction entity
"The symptoms are consistent with the mechanism of action of botulinum toxin and may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties.",dysphagia is an adverse reaction entity
"The symptoms are consistent with the mechanism of action of botulinum toxin and may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties.",generalized muscle weakness is an adverse reaction entity
"The symptoms are consistent with the mechanism of action of botulinum toxin and may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties.",diplopia is an adverse reaction entity
"The symptoms are consistent with the mechanism of action of botulinum toxin and may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties.",and may is not a named entity
"The symptoms are consistent with the mechanism of action of botulinum toxin and may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties.",urinary incontinence is an adverse reaction entity
"The symptoms are consistent with the mechanism of action of botulinum toxin and may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties.","urinary incontinence , is not a named entity"
"The symptoms are consistent with the mechanism of action of botulinum toxin and may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties.",breathing difficulties is an adverse reaction entity
"The symptoms are consistent with the mechanism of action of botulinum toxin and may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties.",toxin and may is not a named entity
"The symptoms are consistent with the mechanism of action of botulinum toxin and may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties.","include asthenia , is not a named entity"
"The symptoms are consistent with the mechanism of action of botulinum toxin and may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties.",blurred vision is an adverse reaction entity
"The symptoms are consistent with the mechanism of action of botulinum toxin and may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties.",ptosis is an adverse reaction entity
"The symptoms are consistent with the mechanism of action of botulinum toxin and may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties.",dysphonia is an adverse reaction entity
"The symptoms are consistent with the mechanism of action of botulinum toxin and may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties.",weakness is not a named entity
"The symptoms are consistent with the mechanism of action of botulinum toxin and may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties.",", ptosis is not a named entity"
"The symptoms are consistent with the mechanism of action of botulinum toxin and may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties.","asthenia , is not a named entity"
"The symptoms are consistent with the mechanism of action of botulinum toxin and may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties.","blurred vision , is not a named entity"
"The symptoms are consistent with the mechanism of action of botulinum toxin and may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties.","ptosis , is not a named entity"
"5.6 Corneal Exposure, Corneal Ulceration, and Ectropion in Patients Treated with XEOMIN for Blepharospasm      Reduced blinking from injection of botulinum toxin products in the orbicularis muscle can lead to corneal exposure, persistent epithelial defect and corneal ulceration, especially in patients with VII nerve disorders.",Reduced blinking is an adverse reaction entity
"5.6 Corneal Exposure, Corneal Ulceration, and Ectropion in Patients Treated with XEOMIN for Blepharospasm      Reduced blinking from injection of botulinum toxin products in the orbicularis muscle can lead to corneal exposure, persistent epithelial defect and corneal ulceration, especially in patients with VII nerve disorders.",corneal exposure is an adverse reaction entity
"5.6 Corneal Exposure, Corneal Ulceration, and Ectropion in Patients Treated with XEOMIN for Blepharospasm      Reduced blinking from injection of botulinum toxin products in the orbicularis muscle can lead to corneal exposure, persistent epithelial defect and corneal ulceration, especially in patients with VII nerve disorders.",the is not a named entity
"5.6 Corneal Exposure, Corneal Ulceration, and Ectropion in Patients Treated with XEOMIN for Blepharospasm      Reduced blinking from injection of botulinum toxin products in the orbicularis muscle can lead to corneal exposure, persistent epithelial defect and corneal ulceration, especially in patients with VII nerve disorders.",and is not a named entity
"5.6 Corneal Exposure, Corneal Ulceration, and Ectropion in Patients Treated with XEOMIN for Blepharospasm      Reduced blinking from injection of botulinum toxin products in the orbicularis muscle can lead to corneal exposure, persistent epithelial defect and corneal ulceration, especially in patients with VII nerve disorders.",corneal persistent epithelial defect is an adverse reaction entity
"5.6 Corneal Exposure, Corneal Ulceration, and Ectropion in Patients Treated with XEOMIN for Blepharospasm      Reduced blinking from injection of botulinum toxin products in the orbicularis muscle can lead to corneal exposure, persistent epithelial defect and corneal ulceration, especially in patients with VII nerve disorders.",corneal ulceration is an adverse reaction entity
"5.6 Corneal Exposure, Corneal Ulceration, and Ectropion in Patients Treated with XEOMIN for Blepharospasm      Reduced blinking from injection of botulinum toxin products in the orbicularis muscle can lead to corneal exposure, persistent epithelial defect and corneal ulceration, especially in patients with VII nerve disorders.",in Patients Treated is not a named entity
"5.6 Corneal Exposure, Corneal Ulceration, and Ectropion in Patients Treated with XEOMIN for Blepharospasm      Reduced blinking from injection of botulinum toxin products in the orbicularis muscle can lead to corneal exposure, persistent epithelial defect and corneal ulceration, especially in patients with VII nerve disorders.",with XEOMIN is not a named entity
"In unapproved uses, including spasticity in children and adults, and in approved indications, symptoms consistent with spread of toxin effect have been reported at doses comparable to or lower than doses used to treat cervical dystonia.",children and adults is not a named entity
"In unapproved uses, including spasticity in children and adults, and in approved indications, symptoms consistent with spread of toxin effect have been reported at doses comparable to or lower than doses used to treat cervical dystonia.",spread of toxin effect is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions to XEOMIN are discussed in greater detail in other sections of the labeling:     *  Hypersensitivity [ see  Contraindications (4)  and  Warnings and Precautions (5.3)  ]    *  Dysphagia and Breathing Difficulties in Treatment of cervical dystonia [ see  Warnings and Precautions (5.4)   ]   *  Spread of Effects from Toxin [see  Warnings and Precautions (5.1)  ]         EXCERPT:     Cervical Dystonia:  The most commonly observed adverse reactions (>=5% of patients and > placebo) are dysphagia, neck pain, muscle weakness, injection site pain, and musculoskeletal pain (  6.1  ).",6 is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions to XEOMIN are discussed in greater detail in other sections of the labeling:     *  Hypersensitivity [ see  Contraindications (4)  and  Warnings and Precautions (5.3)  ]    *  Dysphagia and Breathing Difficulties in Treatment of cervical dystonia [ see  Warnings and Precautions (5.4)   ]   *  Spread of Effects from Toxin [see  Warnings and Precautions (5.1)  ]         EXCERPT:     Cervical Dystonia:  The most commonly observed adverse reactions (>=5% of patients and > placebo) are dysphagia, neck pain, muscle weakness, injection site pain, and musculoskeletal pain (  6.1  ).",musculoskeletal pain is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions to XEOMIN are discussed in greater detail in other sections of the labeling:     *  Hypersensitivity [ see  Contraindications (4)  and  Warnings and Precautions (5.3)  ]    *  Dysphagia and Breathing Difficulties in Treatment of cervical dystonia [ see  Warnings and Precautions (5.4)   ]   *  Spread of Effects from Toxin [see  Warnings and Precautions (5.1)  ]         EXCERPT:     Cervical Dystonia:  The most commonly observed adverse reactions (>=5% of patients and > placebo) are dysphagia, neck pain, muscle weakness, injection site pain, and musculoskeletal pain (  6.1  ).",> placebo is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions to XEOMIN are discussed in greater detail in other sections of the labeling:     *  Hypersensitivity [ see  Contraindications (4)  and  Warnings and Precautions (5.3)  ]    *  Dysphagia and Breathing Difficulties in Treatment of cervical dystonia [ see  Warnings and Precautions (5.4)   ]   *  Spread of Effects from Toxin [see  Warnings and Precautions (5.1)  ]         EXCERPT:     Cervical Dystonia:  The most commonly observed adverse reactions (>=5% of patients and > placebo) are dysphagia, neck pain, muscle weakness, injection site pain, and musculoskeletal pain (  6.1  ).",Hypersensitivity is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions to XEOMIN are discussed in greater detail in other sections of the labeling:     *  Hypersensitivity [ see  Contraindications (4)  and  Warnings and Precautions (5.3)  ]    *  Dysphagia and Breathing Difficulties in Treatment of cervical dystonia [ see  Warnings and Precautions (5.4)   ]   *  Spread of Effects from Toxin [see  Warnings and Precautions (5.1)  ]         EXCERPT:     Cervical Dystonia:  The most commonly observed adverse reactions (>=5% of patients and > placebo) are dysphagia, neck pain, muscle weakness, injection site pain, and musculoskeletal pain (  6.1  ).",Spread of Effects from Toxin is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions to XEOMIN are discussed in greater detail in other sections of the labeling:     *  Hypersensitivity [ see  Contraindications (4)  and  Warnings and Precautions (5.3)  ]    *  Dysphagia and Breathing Difficulties in Treatment of cervical dystonia [ see  Warnings and Precautions (5.4)   ]   *  Spread of Effects from Toxin [see  Warnings and Precautions (5.1)  ]         EXCERPT:     Cervical Dystonia:  The most commonly observed adverse reactions (>=5% of patients and > placebo) are dysphagia, neck pain, muscle weakness, injection site pain, and musculoskeletal pain (  6.1  ).",) is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions to XEOMIN are discussed in greater detail in other sections of the labeling:     *  Hypersensitivity [ see  Contraindications (4)  and  Warnings and Precautions (5.3)  ]    *  Dysphagia and Breathing Difficulties in Treatment of cervical dystonia [ see  Warnings and Precautions (5.4)   ]   *  Spread of Effects from Toxin [see  Warnings and Precautions (5.1)  ]         EXCERPT:     Cervical Dystonia:  The most commonly observed adverse reactions (>=5% of patients and > placebo) are dysphagia, neck pain, muscle weakness, injection site pain, and musculoskeletal pain (  6.1  ).",> placebo is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions to XEOMIN are discussed in greater detail in other sections of the labeling:     *  Hypersensitivity [ see  Contraindications (4)  and  Warnings and Precautions (5.3)  ]    *  Dysphagia and Breathing Difficulties in Treatment of cervical dystonia [ see  Warnings and Precautions (5.4)   ]   *  Spread of Effects from Toxin [see  Warnings and Precautions (5.1)  ]         EXCERPT:     Cervical Dystonia:  The most commonly observed adverse reactions (>=5% of patients and > placebo) are dysphagia, neck pain, muscle weakness, injection site pain, and musculoskeletal pain (  6.1  ).",neck pain is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions to XEOMIN are discussed in greater detail in other sections of the labeling:     *  Hypersensitivity [ see  Contraindications (4)  and  Warnings and Precautions (5.3)  ]    *  Dysphagia and Breathing Difficulties in Treatment of cervical dystonia [ see  Warnings and Precautions (5.4)   ]   *  Spread of Effects from Toxin [see  Warnings and Precautions (5.1)  ]         EXCERPT:     Cervical Dystonia:  The most commonly observed adverse reactions (>=5% of patients and > placebo) are dysphagia, neck pain, muscle weakness, injection site pain, and musculoskeletal pain (  6.1  ).",) ] is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions to XEOMIN are discussed in greater detail in other sections of the labeling:     *  Hypersensitivity [ see  Contraindications (4)  and  Warnings and Precautions (5.3)  ]    *  Dysphagia and Breathing Difficulties in Treatment of cervical dystonia [ see  Warnings and Precautions (5.4)   ]   *  Spread of Effects from Toxin [see  Warnings and Precautions (5.1)  ]         EXCERPT:     Cervical Dystonia:  The most commonly observed adverse reactions (>=5% of patients and > placebo) are dysphagia, neck pain, muscle weakness, injection site pain, and musculoskeletal pain (  6.1  ).",", is not a named entity"
"6 ADVERSE REACTIONS    The following adverse reactions to XEOMIN are discussed in greater detail in other sections of the labeling:     *  Hypersensitivity [ see  Contraindications (4)  and  Warnings and Precautions (5.3)  ]    *  Dysphagia and Breathing Difficulties in Treatment of cervical dystonia [ see  Warnings and Precautions (5.4)   ]   *  Spread of Effects from Toxin [see  Warnings and Precautions (5.1)  ]         EXCERPT:     Cervical Dystonia:  The most commonly observed adverse reactions (>=5% of patients and > placebo) are dysphagia, neck pain, muscle weakness, injection site pain, and musculoskeletal pain (  6.1  ).",Dysphagia is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions to XEOMIN are discussed in greater detail in other sections of the labeling:     *  Hypersensitivity [ see  Contraindications (4)  and  Warnings and Precautions (5.3)  ]    *  Dysphagia and Breathing Difficulties in Treatment of cervical dystonia [ see  Warnings and Precautions (5.4)   ]   *  Spread of Effects from Toxin [see  Warnings and Precautions (5.1)  ]         EXCERPT:     Cervical Dystonia:  The most commonly observed adverse reactions (>=5% of patients and > placebo) are dysphagia, neck pain, muscle weakness, injection site pain, and musculoskeletal pain (  6.1  ).",injection site pain is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions to XEOMIN are discussed in greater detail in other sections of the labeling:     *  Hypersensitivity [ see  Contraindications (4)  and  Warnings and Precautions (5.3)  ]    *  Dysphagia and Breathing Difficulties in Treatment of cervical dystonia [ see  Warnings and Precautions (5.4)   ]   *  Spread of Effects from Toxin [see  Warnings and Precautions (5.1)  ]         EXCERPT:     Cervical Dystonia:  The most commonly observed adverse reactions (>=5% of patients and > placebo) are dysphagia, neck pain, muscle weakness, injection site pain, and musculoskeletal pain (  6.1  ).",adverse reactions to is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions to XEOMIN are discussed in greater detail in other sections of the labeling:     *  Hypersensitivity [ see  Contraindications (4)  and  Warnings and Precautions (5.3)  ]    *  Dysphagia and Breathing Difficulties in Treatment of cervical dystonia [ see  Warnings and Precautions (5.4)   ]   *  Spread of Effects from Toxin [see  Warnings and Precautions (5.1)  ]         EXCERPT:     Cervical Dystonia:  The most commonly observed adverse reactions (>=5% of patients and > placebo) are dysphagia, neck pain, muscle weakness, injection site pain, and musculoskeletal pain (  6.1  ).",The is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions to XEOMIN are discussed in greater detail in other sections of the labeling:     *  Hypersensitivity [ see  Contraindications (4)  and  Warnings and Precautions (5.3)  ]    *  Dysphagia and Breathing Difficulties in Treatment of cervical dystonia [ see  Warnings and Precautions (5.4)   ]   *  Spread of Effects from Toxin [see  Warnings and Precautions (5.1)  ]         EXCERPT:     Cervical Dystonia:  The most commonly observed adverse reactions (>=5% of patients and > placebo) are dysphagia, neck pain, muscle weakness, injection site pain, and musculoskeletal pain (  6.1  ).",( 5.1 is not a named entity
"6 ADVERSE REACTIONS    The following adverse reactions to XEOMIN are discussed in greater detail in other sections of the labeling:     *  Hypersensitivity [ see  Contraindications (4)  and  Warnings and Precautions (5.3)  ]    *  Dysphagia and Breathing Difficulties in Treatment of cervical dystonia [ see  Warnings and Precautions (5.4)   ]   *  Spread of Effects from Toxin [see  Warnings and Precautions (5.1)  ]         EXCERPT:     Cervical Dystonia:  The most commonly observed adverse reactions (>=5% of patients and > placebo) are dysphagia, neck pain, muscle weakness, injection site pain, and musculoskeletal pain (  6.1  ).",muscle weakness is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions to XEOMIN are discussed in greater detail in other sections of the labeling:     *  Hypersensitivity [ see  Contraindications (4)  and  Warnings and Precautions (5.3)  ]    *  Dysphagia and Breathing Difficulties in Treatment of cervical dystonia [ see  Warnings and Precautions (5.4)   ]   *  Spread of Effects from Toxin [see  Warnings and Precautions (5.1)  ]         EXCERPT:     Cervical Dystonia:  The most commonly observed adverse reactions (>=5% of patients and > placebo) are dysphagia, neck pain, muscle weakness, injection site pain, and musculoskeletal pain (  6.1  ).",dysphagia is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse reactions to XEOMIN are discussed in greater detail in other sections of the labeling:     *  Hypersensitivity [ see  Contraindications (4)  and  Warnings and Precautions (5.3)  ]    *  Dysphagia and Breathing Difficulties in Treatment of cervical dystonia [ see  Warnings and Precautions (5.4)   ]   *  Spread of Effects from Toxin [see  Warnings and Precautions (5.1)  ]         EXCERPT:     Cervical Dystonia:  The most commonly observed adverse reactions (>=5% of patients and > placebo) are dysphagia, neck pain, muscle weakness, injection site pain, and musculoskeletal pain (  6.1  ).",Breathing Difficulties is an adverse reaction entity
"Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases.",transmission of viral diseases is an adverse reaction entity
"Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases.",and is not a named entity
"These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties.",", diplopia , is not a named entity"
"These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties.",", urinary incontinence is not a named entity"
"These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties.",generalized muscle weakness is an adverse reaction entity
"These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties.",blurred vision is an adverse reaction entity
"These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties.",diplopia is an adverse reaction entity
"These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties.",breathing difficulties is an adverse reaction entity
"These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties.",", is not a named entity"
"These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties.",asthenia is an adverse reaction entity
"These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties.","dysarthria , urinary is not a named entity"
"These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties.",may include is not a named entity
"These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties.",dysarthria is an adverse reaction entity
"These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties.",urinary incontinence is an adverse reaction entity
"These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties.",dysphagia is an adverse reaction entity
"These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties.",ptosis is an adverse reaction entity
"These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties.","diplopia , is not a named entity"
"These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties.",", blurred is not a named entity"
"These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties.",dysphonia is an adverse reaction entity
"These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties.",", is not a named entity"
"These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties.","dysphagia , dysphonia is not a named entity"
"These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties.",include is not a named entity
Aspiration may result from severe dysphagia and is a particular risk when treating patients in whom swallowing or respiratory function is already compromised.,treating is not a named entity
Aspiration may result from severe dysphagia and is a particular risk when treating patients in whom swallowing or respiratory function is already compromised.,is already compromised is not a named entity
Aspiration may result from severe dysphagia and is a particular risk when treating patients in whom swallowing or respiratory function is already compromised.,Aspiration is an adverse reaction entity
Aspiration may result from severe dysphagia and is a particular risk when treating patients in whom swallowing or respiratory function is already compromised.,dysphagia is an adverse reaction entity
"Blepharospasm:  The most commonly observed adverse reactions (>=5% of patients and > placebo) are eyelid ptosis, dry eye, dry mouth, diarrhea, headache, visual impairment, dyspnea, nasopharyngitis, and respiratory tract infection (  6.1  ).",headache is an adverse reaction entity
"Blepharospasm:  The most commonly observed adverse reactions (>=5% of patients and > placebo) are eyelid ptosis, dry eye, dry mouth, diarrhea, headache, visual impairment, dyspnea, nasopharyngitis, and respiratory tract infection (  6.1  ).",most commonly observed is not a named entity
"Blepharospasm:  The most commonly observed adverse reactions (>=5% of patients and > placebo) are eyelid ptosis, dry eye, dry mouth, diarrhea, headache, visual impairment, dyspnea, nasopharyngitis, and respiratory tract infection (  6.1  ).",diarrhea is an adverse reaction entity
"Blepharospasm:  The most commonly observed adverse reactions (>=5% of patients and > placebo) are eyelid ptosis, dry eye, dry mouth, diarrhea, headache, visual impairment, dyspnea, nasopharyngitis, and respiratory tract infection (  6.1  ).","headache , visual is not a named entity"
"Blepharospasm:  The most commonly observed adverse reactions (>=5% of patients and > placebo) are eyelid ptosis, dry eye, dry mouth, diarrhea, headache, visual impairment, dyspnea, nasopharyngitis, and respiratory tract infection (  6.1  ).","nasopharyngitis , is not a named entity"
"Blepharospasm:  The most commonly observed adverse reactions (>=5% of patients and > placebo) are eyelid ptosis, dry eye, dry mouth, diarrhea, headache, visual impairment, dyspnea, nasopharyngitis, and respiratory tract infection (  6.1  ).",dry mouth is an adverse reaction entity
"Blepharospasm:  The most commonly observed adverse reactions (>=5% of patients and > placebo) are eyelid ptosis, dry eye, dry mouth, diarrhea, headache, visual impairment, dyspnea, nasopharyngitis, and respiratory tract infection (  6.1  ).",", and respiratory is not a named entity"
"Blepharospasm:  The most commonly observed adverse reactions (>=5% of patients and > placebo) are eyelid ptosis, dry eye, dry mouth, diarrhea, headache, visual impairment, dyspnea, nasopharyngitis, and respiratory tract infection (  6.1  ).",nasopharyngitis is an adverse reaction entity
"Blepharospasm:  The most commonly observed adverse reactions (>=5% of patients and > placebo) are eyelid ptosis, dry eye, dry mouth, diarrhea, headache, visual impairment, dyspnea, nasopharyngitis, and respiratory tract infection (  6.1  ).",respiratory tract infection is an adverse reaction entity
"Blepharospasm:  The most commonly observed adverse reactions (>=5% of patients and > placebo) are eyelid ptosis, dry eye, dry mouth, diarrhea, headache, visual impairment, dyspnea, nasopharyngitis, and respiratory tract infection (  6.1  ).",visual impairment is an adverse reaction entity
"Blepharospasm:  The most commonly observed adverse reactions (>=5% of patients and > placebo) are eyelid ptosis, dry eye, dry mouth, diarrhea, headache, visual impairment, dyspnea, nasopharyngitis, and respiratory tract infection (  6.1  ).",", visual is not a named entity"
"Blepharospasm:  The most commonly observed adverse reactions (>=5% of patients and > placebo) are eyelid ptosis, dry eye, dry mouth, diarrhea, headache, visual impairment, dyspnea, nasopharyngitis, and respiratory tract infection (  6.1  ).",eyelid ptosis is an adverse reaction entity
"Blepharospasm:  The most commonly observed adverse reactions (>=5% of patients and > placebo) are eyelid ptosis, dry eye, dry mouth, diarrhea, headache, visual impairment, dyspnea, nasopharyngitis, and respiratory tract infection (  6.1  ).",dyspnea is an adverse reaction entity
"Blepharospasm:  The most commonly observed adverse reactions (>=5% of patients and > placebo) are eyelid ptosis, dry eye, dry mouth, diarrhea, headache, visual impairment, dyspnea, nasopharyngitis, and respiratory tract infection (  6.1  ).",and > placebo is not a named entity
"Blepharospasm:  The most commonly observed adverse reactions (>=5% of patients and > placebo) are eyelid ptosis, dry eye, dry mouth, diarrhea, headache, visual impairment, dyspnea, nasopharyngitis, and respiratory tract infection (  6.1  ).",Blepharospasm is not a named entity
"Blepharospasm:  The most commonly observed adverse reactions (>=5% of patients and > placebo) are eyelid ptosis, dry eye, dry mouth, diarrhea, headache, visual impairment, dyspnea, nasopharyngitis, and respiratory tract infection (  6.1  ).",dry eye is an adverse reaction entity
"Blepharospasm:  The most commonly observed adverse reactions (>=5% of patients and > placebo) are eyelid ptosis, dry eye, dry mouth, diarrhea, headache, visual impairment, dyspnea, nasopharyngitis, and respiratory tract infection (  6.1  ).",", dyspnea , is not a named entity"
"Blepharospasm:  The most commonly observed adverse reactions (>=5% of patients and > placebo) are eyelid ptosis, dry eye, dry mouth, diarrhea, headache, visual impairment, dyspnea, nasopharyngitis, and respiratory tract infection (  6.1  ).",", headache , is not a named entity"
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: eye swelling, eyelid edema, dysphagia, nausea, flu-like symptoms, injection site pain, injection site reaction, allergic dermatitis, localized allergic reactions like swelling, edema, erythema, pruritus or rash, herpes zoster, muscular weakness, muscle spasm, dysarthria, myalgia and hypersensitivity.",localized allergic reactions is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: eye swelling, eyelid edema, dysphagia, nausea, flu-like symptoms, injection site pain, injection site reaction, allergic dermatitis, localized allergic reactions like swelling, edema, erythema, pruritus or rash, herpes zoster, muscular weakness, muscle spasm, dysarthria, myalgia and hypersensitivity.",a is not a named entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: eye swelling, eyelid edema, dysphagia, nausea, flu-like symptoms, injection site pain, injection site reaction, allergic dermatitis, localized allergic reactions like swelling, edema, erythema, pruritus or rash, herpes zoster, muscular weakness, muscle spasm, dysarthria, myalgia and hypersensitivity.",localized rash is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: eye swelling, eyelid edema, dysphagia, nausea, flu-like symptoms, injection site pain, injection site reaction, allergic dermatitis, localized allergic reactions like swelling, edema, erythema, pruritus or rash, herpes zoster, muscular weakness, muscle spasm, dysarthria, myalgia and hypersensitivity.",and hypersensitivity is not a named entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: eye swelling, eyelid edema, dysphagia, nausea, flu-like symptoms, injection site pain, injection site reaction, allergic dermatitis, localized allergic reactions like swelling, edema, erythema, pruritus or rash, herpes zoster, muscular weakness, muscle spasm, dysarthria, myalgia and hypersensitivity.",frequency or establish is not a named entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: eye swelling, eyelid edema, dysphagia, nausea, flu-like symptoms, injection site pain, injection site reaction, allergic dermatitis, localized allergic reactions like swelling, edema, erythema, pruritus or rash, herpes zoster, muscular weakness, muscle spasm, dysarthria, myalgia and hypersensitivity.",localized pruritus is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: eye swelling, eyelid edema, dysphagia, nausea, flu-like symptoms, injection site pain, injection site reaction, allergic dermatitis, localized allergic reactions like swelling, edema, erythema, pruritus or rash, herpes zoster, muscular weakness, muscle spasm, dysarthria, myalgia and hypersensitivity.",eyelid edema is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: eye swelling, eyelid edema, dysphagia, nausea, flu-like symptoms, injection site pain, injection site reaction, allergic dermatitis, localized allergic reactions like swelling, edema, erythema, pruritus or rash, herpes zoster, muscular weakness, muscle spasm, dysarthria, myalgia and hypersensitivity.",myalgia and is not a named entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: eye swelling, eyelid edema, dysphagia, nausea, flu-like symptoms, injection site pain, injection site reaction, allergic dermatitis, localized allergic reactions like swelling, edema, erythema, pruritus or rash, herpes zoster, muscular weakness, muscle spasm, dysarthria, myalgia and hypersensitivity.",localized erythema is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: eye swelling, eyelid edema, dysphagia, nausea, flu-like symptoms, injection site pain, injection site reaction, allergic dermatitis, localized allergic reactions like swelling, edema, erythema, pruritus or rash, herpes zoster, muscular weakness, muscle spasm, dysarthria, myalgia and hypersensitivity.",dysarthria is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: eye swelling, eyelid edema, dysphagia, nausea, flu-like symptoms, injection site pain, injection site reaction, allergic dermatitis, localized allergic reactions like swelling, edema, erythema, pruritus or rash, herpes zoster, muscular weakness, muscle spasm, dysarthria, myalgia and hypersensitivity.",uncertain size is not a named entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: eye swelling, eyelid edema, dysphagia, nausea, flu-like symptoms, injection site pain, injection site reaction, allergic dermatitis, localized allergic reactions like swelling, edema, erythema, pruritus or rash, herpes zoster, muscular weakness, muscle spasm, dysarthria, myalgia and hypersensitivity.",estimate their is not a named entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: eye swelling, eyelid edema, dysphagia, nausea, flu-like symptoms, injection site pain, injection site reaction, allergic dermatitis, localized allergic reactions like swelling, edema, erythema, pruritus or rash, herpes zoster, muscular weakness, muscle spasm, dysarthria, myalgia and hypersensitivity.",always possible to is not a named entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: eye swelling, eyelid edema, dysphagia, nausea, flu-like symptoms, injection site pain, injection site reaction, allergic dermatitis, localized allergic reactions like swelling, edema, erythema, pruritus or rash, herpes zoster, muscular weakness, muscle spasm, dysarthria, myalgia and hypersensitivity.",localized edema is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: eye swelling, eyelid edema, dysphagia, nausea, flu-like symptoms, injection site pain, injection site reaction, allergic dermatitis, localized allergic reactions like swelling, edema, erythema, pruritus or rash, herpes zoster, muscular weakness, muscle spasm, dysarthria, myalgia and hypersensitivity.",always is not a named entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: eye swelling, eyelid edema, dysphagia, nausea, flu-like symptoms, injection site pain, injection site reaction, allergic dermatitis, localized allergic reactions like swelling, edema, erythema, pruritus or rash, herpes zoster, muscular weakness, muscle spasm, dysarthria, myalgia and hypersensitivity.",injection site pain is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: eye swelling, eyelid edema, dysphagia, nausea, flu-like symptoms, injection site pain, injection site reaction, allergic dermatitis, localized allergic reactions like swelling, edema, erythema, pruritus or rash, herpes zoster, muscular weakness, muscle spasm, dysarthria, myalgia and hypersensitivity.",flu-like symptoms is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: eye swelling, eyelid edema, dysphagia, nausea, flu-like symptoms, injection site pain, injection site reaction, allergic dermatitis, localized allergic reactions like swelling, edema, erythema, pruritus or rash, herpes zoster, muscular weakness, muscle spasm, dysarthria, myalgia and hypersensitivity.",not always possible is not a named entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: eye swelling, eyelid edema, dysphagia, nausea, flu-like symptoms, injection site pain, injection site reaction, allergic dermatitis, localized allergic reactions like swelling, edema, erythema, pruritus or rash, herpes zoster, muscular weakness, muscle spasm, dysarthria, myalgia and hypersensitivity.",voluntarily is not a named entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: eye swelling, eyelid edema, dysphagia, nausea, flu-like symptoms, injection site pain, injection site reaction, allergic dermatitis, localized allergic reactions like swelling, edema, erythema, pruritus or rash, herpes zoster, muscular weakness, muscle spasm, dysarthria, myalgia and hypersensitivity.",herpes zoster is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: eye swelling, eyelid edema, dysphagia, nausea, flu-like symptoms, injection site pain, injection site reaction, allergic dermatitis, localized allergic reactions like swelling, edema, erythema, pruritus or rash, herpes zoster, muscular weakness, muscle spasm, dysarthria, myalgia and hypersensitivity.",hypersensitivity is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: eye swelling, eyelid edema, dysphagia, nausea, flu-like symptoms, injection site pain, injection site reaction, allergic dermatitis, localized allergic reactions like swelling, edema, erythema, pruritus or rash, herpes zoster, muscular weakness, muscle spasm, dysarthria, myalgia and hypersensitivity.",nausea is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: eye swelling, eyelid edema, dysphagia, nausea, flu-like symptoms, injection site pain, injection site reaction, allergic dermatitis, localized allergic reactions like swelling, edema, erythema, pruritus or rash, herpes zoster, muscular weakness, muscle spasm, dysarthria, myalgia and hypersensitivity.","herpes zoster , is not a named entity"
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: eye swelling, eyelid edema, dysphagia, nausea, flu-like symptoms, injection site pain, injection site reaction, allergic dermatitis, localized allergic reactions like swelling, edema, erythema, pruritus or rash, herpes zoster, muscular weakness, muscle spasm, dysarthria, myalgia and hypersensitivity.",myalgia is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: eye swelling, eyelid edema, dysphagia, nausea, flu-like symptoms, injection site pain, injection site reaction, allergic dermatitis, localized allergic reactions like swelling, edema, erythema, pruritus or rash, herpes zoster, muscular weakness, muscle spasm, dysarthria, myalgia and hypersensitivity.",muscle spasm is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: eye swelling, eyelid edema, dysphagia, nausea, flu-like symptoms, injection site pain, injection site reaction, allergic dermatitis, localized allergic reactions like swelling, edema, erythema, pruritus or rash, herpes zoster, muscular weakness, muscle spasm, dysarthria, myalgia and hypersensitivity.",injection site reaction is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: eye swelling, eyelid edema, dysphagia, nausea, flu-like symptoms, injection site pain, injection site reaction, allergic dermatitis, localized allergic reactions like swelling, edema, erythema, pruritus or rash, herpes zoster, muscular weakness, muscle spasm, dysarthria, myalgia and hypersensitivity.",", it is not a named entity"
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: eye swelling, eyelid edema, dysphagia, nausea, flu-like symptoms, injection site pain, injection site reaction, allergic dermatitis, localized allergic reactions like swelling, edema, erythema, pruritus or rash, herpes zoster, muscular weakness, muscle spasm, dysarthria, myalgia and hypersensitivity.",muscular weakness is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: eye swelling, eyelid edema, dysphagia, nausea, flu-like symptoms, injection site pain, injection site reaction, allergic dermatitis, localized allergic reactions like swelling, edema, erythema, pruritus or rash, herpes zoster, muscular weakness, muscle spasm, dysarthria, myalgia and hypersensitivity.",dysphagia is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: eye swelling, eyelid edema, dysphagia, nausea, flu-like symptoms, injection site pain, injection site reaction, allergic dermatitis, localized allergic reactions like swelling, edema, erythema, pruritus or rash, herpes zoster, muscular weakness, muscle spasm, dysarthria, myalgia and hypersensitivity.",it is not a named entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: eye swelling, eyelid edema, dysphagia, nausea, flu-like symptoms, injection site pain, injection site reaction, allergic dermatitis, localized allergic reactions like swelling, edema, erythema, pruritus or rash, herpes zoster, muscular weakness, muscle spasm, dysarthria, myalgia and hypersensitivity.",erythema is not a named entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: eye swelling, eyelid edema, dysphagia, nausea, flu-like symptoms, injection site pain, injection site reaction, allergic dermatitis, localized allergic reactions like swelling, edema, erythema, pruritus or rash, herpes zoster, muscular weakness, muscle spasm, dysarthria, myalgia and hypersensitivity.",eye swelling is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: eye swelling, eyelid edema, dysphagia, nausea, flu-like symptoms, injection site pain, injection site reaction, allergic dermatitis, localized allergic reactions like swelling, edema, erythema, pruritus or rash, herpes zoster, muscular weakness, muscle spasm, dysarthria, myalgia and hypersensitivity.",it is not a named entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: eye swelling, eyelid edema, dysphagia, nausea, flu-like symptoms, injection site pain, injection site reaction, allergic dermatitis, localized allergic reactions like swelling, edema, erythema, pruritus or rash, herpes zoster, muscular weakness, muscle spasm, dysarthria, myalgia and hypersensitivity.",these reactions is not a named entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: eye swelling, eyelid edema, dysphagia, nausea, flu-like symptoms, injection site pain, injection site reaction, allergic dermatitis, localized allergic reactions like swelling, edema, erythema, pruritus or rash, herpes zoster, muscular weakness, muscle spasm, dysarthria, myalgia and hypersensitivity.",a is not a named entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: eye swelling, eyelid edema, dysphagia, nausea, flu-like symptoms, injection site pain, injection site reaction, allergic dermatitis, localized allergic reactions like swelling, edema, erythema, pruritus or rash, herpes zoster, muscular weakness, muscle spasm, dysarthria, myalgia and hypersensitivity.","size , it is not a named entity"
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: eye swelling, eyelid edema, dysphagia, nausea, flu-like symptoms, injection site pain, injection site reaction, allergic dermatitis, localized allergic reactions like swelling, edema, erythema, pruritus or rash, herpes zoster, muscular weakness, muscle spasm, dysarthria, myalgia and hypersensitivity.",allergic dermatitis is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: eye swelling, eyelid edema, dysphagia, nausea, flu-like symptoms, injection site pain, injection site reaction, allergic dermatitis, localized allergic reactions like swelling, edema, erythema, pruritus or rash, herpes zoster, muscular weakness, muscle spasm, dysarthria, myalgia and hypersensitivity.",", myalgia and is not a named entity"
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: eye swelling, eyelid edema, dysphagia, nausea, flu-like symptoms, injection site pain, injection site reaction, allergic dermatitis, localized allergic reactions like swelling, edema, erythema, pruritus or rash, herpes zoster, muscular weakness, muscle spasm, dysarthria, myalgia and hypersensitivity.",relationship to is not a named entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: eye swelling, eyelid edema, dysphagia, nausea, flu-like symptoms, injection site pain, injection site reaction, allergic dermatitis, localized allergic reactions like swelling, edema, erythema, pruritus or rash, herpes zoster, muscular weakness, muscle spasm, dysarthria, myalgia and hypersensitivity.",localized swelling is an adverse reaction entity
Patients with smaller neck muscle mass and patients who require bilateral injections into the sternocleidomastoid muscles have been reported to be at greater risk of dysphagia.,be at is not a named entity
Patients with smaller neck muscle mass and patients who require bilateral injections into the sternocleidomastoid muscles have been reported to be at greater risk of dysphagia.,dysphagia is an adverse reaction entity
Blepharospasm (  5.6  ):       *  Corneal exposure and ulceration   *  Injection of XEOMIN into the orbicularis oculi muscle may lead to reduced blinking and corneal exposure with possible ulceration or perforation.,orbicularis oculi muscle is not a named entity
Blepharospasm (  5.6  ):       *  Corneal exposure and ulceration   *  Injection of XEOMIN into the orbicularis oculi muscle may lead to reduced blinking and corneal exposure with possible ulceration or perforation.,reduced blinking is an adverse reaction entity
Blepharospasm (  5.6  ):       *  Corneal exposure and ulceration   *  Injection of XEOMIN into the orbicularis oculi muscle may lead to reduced blinking and corneal exposure with possible ulceration or perforation.,XEOMIN into the is not a named entity
Blepharospasm (  5.6  ):       *  Corneal exposure and ulceration   *  Injection of XEOMIN into the orbicularis oculi muscle may lead to reduced blinking and corneal exposure with possible ulceration or perforation.,muscle may is not a named entity
Blepharospasm (  5.6  ):       *  Corneal exposure and ulceration   *  Injection of XEOMIN into the orbicularis oculi muscle may lead to reduced blinking and corneal exposure with possible ulceration or perforation.,Corneal exposure is an adverse reaction entity
Blepharospasm (  5.6  ):       *  Corneal exposure and ulceration   *  Injection of XEOMIN into the orbicularis oculi muscle may lead to reduced blinking and corneal exposure with possible ulceration or perforation.,corneal exposure is an adverse reaction entity
Blepharospasm (  5.6  ):       *  Corneal exposure and ulceration   *  Injection of XEOMIN into the orbicularis oculi muscle may lead to reduced blinking and corneal exposure with possible ulceration or perforation.,corneal perforation is an adverse reaction entity
Blepharospasm (  5.6  ):       *  Corneal exposure and ulceration   *  Injection of XEOMIN into the orbicularis oculi muscle may lead to reduced blinking and corneal exposure with possible ulceration or perforation.,( is not a named entity
Blepharospasm (  5.6  ):       *  Corneal exposure and ulceration   *  Injection of XEOMIN into the orbicularis oculi muscle may lead to reduced blinking and corneal exposure with possible ulceration or perforation.,5.6 is not a named entity
Blepharospasm (  5.6  ):       *  Corneal exposure and ulceration   *  Injection of XEOMIN into the orbicularis oculi muscle may lead to reduced blinking and corneal exposure with possible ulceration or perforation.,Corneal ulceration is an adverse reaction entity
Blepharospasm (  5.6  ):       *  Corneal exposure and ulceration   *  Injection of XEOMIN into the orbicularis oculi muscle may lead to reduced blinking and corneal exposure with possible ulceration or perforation.,corneal ulceration is an adverse reaction entity
Blepharospasm (  5.6  ):       *  Corneal exposure and ulceration   *  Injection of XEOMIN into the orbicularis oculi muscle may lead to reduced blinking and corneal exposure with possible ulceration or perforation.,5.6 ) is not a named entity
5.4 Dysphagia and Breathing Difficulties in Treatment of Cervical Dystonia      Treatment with XEOMIN and other botulinum toxin products can result in swallowing or breathing difficulties.,Dystonia Treatment with is not a named entity
5.4 Dysphagia and Breathing Difficulties in Treatment of Cervical Dystonia      Treatment with XEOMIN and other botulinum toxin products can result in swallowing or breathing difficulties.,swallowing difficulties is an adverse reaction entity
5.4 Dysphagia and Breathing Difficulties in Treatment of Cervical Dystonia      Treatment with XEOMIN and other botulinum toxin products can result in swallowing or breathing difficulties.,breathing difficulties is an adverse reaction entity
5.4 Dysphagia and Breathing Difficulties in Treatment of Cervical Dystonia      Treatment with XEOMIN and other botulinum toxin products can result in swallowing or breathing difficulties.,and other botulinum is not a named entity
EXCERPT:     WARNING: DISTANT SPREAD OF TOXIN EFFECT       See full prescribing information for complete   boxed warning  .,SPREAD is not a named entity
EXCERPT:     WARNING: DISTANT SPREAD OF TOXIN EFFECT       See full prescribing information for complete   boxed warning  .,DISTANT SPREAD OF TOXIN EFFECT is an adverse reaction entity
A theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD) is also considered extremely remote.,also considered extremely is not a named entity
A theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD) is also considered extremely remote.,Creutzfeldt-Jakob disease is an adverse reaction entity
A theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD) is also considered extremely remote.,Creutzfeldt-Jakob disease ( is not a named entity
A theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD) is also considered extremely remote.,A theoretical is not a named entity
A theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD) is also considered extremely remote.,CJD is an adverse reaction entity
A theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD) is also considered extremely remote.,CJD is an adverse reaction entity
Cervical Dystonia (  5.4  ):       *  Patients with smaller neck muscle mass and patients who require bilateral injections into the sternocleidomastoid muscles are at greater risk of dysphagia.,risk is not a named entity
Cervical Dystonia (  5.4  ):       *  Patients with smaller neck muscle mass and patients who require bilateral injections into the sternocleidomastoid muscles are at greater risk of dysphagia.,dysphagia is an adverse reaction entity
"The adverse events occurring in >=5% of XEOMIN-treated patients and greater than placebo in the Phase 3 study were eyelid ptosis, dry eye, dry mouth, diarrhea, headache, visual impairment, dyspnea, nasopharyngitis, and respiratory tract infection.",ptosis is not a named entity
"The adverse events occurring in >=5% of XEOMIN-treated patients and greater than placebo in the Phase 3 study were eyelid ptosis, dry eye, dry mouth, diarrhea, headache, visual impairment, dyspnea, nasopharyngitis, and respiratory tract infection.",and respiratory tract is not a named entity
"The adverse events occurring in >=5% of XEOMIN-treated patients and greater than placebo in the Phase 3 study were eyelid ptosis, dry eye, dry mouth, diarrhea, headache, visual impairment, dyspnea, nasopharyngitis, and respiratory tract infection.",respiratory tract infection is an adverse reaction entity
"The adverse events occurring in >=5% of XEOMIN-treated patients and greater than placebo in the Phase 3 study were eyelid ptosis, dry eye, dry mouth, diarrhea, headache, visual impairment, dyspnea, nasopharyngitis, and respiratory tract infection.",were eyelid is not a named entity
"The adverse events occurring in >=5% of XEOMIN-treated patients and greater than placebo in the Phase 3 study were eyelid ptosis, dry eye, dry mouth, diarrhea, headache, visual impairment, dyspnea, nasopharyngitis, and respiratory tract infection.",nasopharyngitis is an adverse reaction entity
"The adverse events occurring in >=5% of XEOMIN-treated patients and greater than placebo in the Phase 3 study were eyelid ptosis, dry eye, dry mouth, diarrhea, headache, visual impairment, dyspnea, nasopharyngitis, and respiratory tract infection.",occurring is not a named entity
"The adverse events occurring in >=5% of XEOMIN-treated patients and greater than placebo in the Phase 3 study were eyelid ptosis, dry eye, dry mouth, diarrhea, headache, visual impairment, dyspnea, nasopharyngitis, and respiratory tract infection.","headache , visual is not a named entity"
"The adverse events occurring in >=5% of XEOMIN-treated patients and greater than placebo in the Phase 3 study were eyelid ptosis, dry eye, dry mouth, diarrhea, headache, visual impairment, dyspnea, nasopharyngitis, and respiratory tract infection.",diarrhea is an adverse reaction entity
"The adverse events occurring in >=5% of XEOMIN-treated patients and greater than placebo in the Phase 3 study were eyelid ptosis, dry eye, dry mouth, diarrhea, headache, visual impairment, dyspnea, nasopharyngitis, and respiratory tract infection.",dry eye is an adverse reaction entity
"The adverse events occurring in >=5% of XEOMIN-treated patients and greater than placebo in the Phase 3 study were eyelid ptosis, dry eye, dry mouth, diarrhea, headache, visual impairment, dyspnea, nasopharyngitis, and respiratory tract infection.",visual impairment is an adverse reaction entity
"The adverse events occurring in >=5% of XEOMIN-treated patients and greater than placebo in the Phase 3 study were eyelid ptosis, dry eye, dry mouth, diarrhea, headache, visual impairment, dyspnea, nasopharyngitis, and respiratory tract infection.","ptosis , is not a named entity"
"The adverse events occurring in >=5% of XEOMIN-treated patients and greater than placebo in the Phase 3 study were eyelid ptosis, dry eye, dry mouth, diarrhea, headache, visual impairment, dyspnea, nasopharyngitis, and respiratory tract infection.",Phase 3 is not a named entity
"The adverse events occurring in >=5% of XEOMIN-treated patients and greater than placebo in the Phase 3 study were eyelid ptosis, dry eye, dry mouth, diarrhea, headache, visual impairment, dyspnea, nasopharyngitis, and respiratory tract infection.",eyelid ptosis is an adverse reaction entity
"The adverse events occurring in >=5% of XEOMIN-treated patients and greater than placebo in the Phase 3 study were eyelid ptosis, dry eye, dry mouth, diarrhea, headache, visual impairment, dyspnea, nasopharyngitis, and respiratory tract infection.",dyspnea is an adverse reaction entity
"The adverse events occurring in >=5% of XEOMIN-treated patients and greater than placebo in the Phase 3 study were eyelid ptosis, dry eye, dry mouth, diarrhea, headache, visual impairment, dyspnea, nasopharyngitis, and respiratory tract infection.",dry mouth is an adverse reaction entity
"The adverse events occurring in >=5% of XEOMIN-treated patients and greater than placebo in the Phase 3 study were eyelid ptosis, dry eye, dry mouth, diarrhea, headache, visual impairment, dyspnea, nasopharyngitis, and respiratory tract infection.",in is not a named entity
"The adverse events occurring in >=5% of XEOMIN-treated patients and greater than placebo in the Phase 3 study were eyelid ptosis, dry eye, dry mouth, diarrhea, headache, visual impairment, dyspnea, nasopharyngitis, and respiratory tract infection.",headache is an adverse reaction entity
"The adverse events occurring in >=5% of XEOMIN-treated patients and greater than placebo in the Phase 3 study were eyelid ptosis, dry eye, dry mouth, diarrhea, headache, visual impairment, dyspnea, nasopharyngitis, and respiratory tract infection.",events is not a named entity
Swallowing and breathing difficulties can be life threatening and there have been reports of death.,there have been is not a named entity
Swallowing and breathing difficulties can be life threatening and there have been reports of death.,breathing difficulties is an adverse reaction entity
Swallowing and breathing difficulties can be life threatening and there have been reports of death.,reports of is not a named entity
Swallowing and breathing difficulties can be life threatening and there have been reports of death.,have is not a named entity
Swallowing and breathing difficulties can be life threatening and there have been reports of death.,Swallowing difficulties is an adverse reaction entity
Swallowing and breathing difficulties can be life threatening and there have been reports of death.,death is an adverse reaction entity
"Headache was the most common adverse reaction, reported for 57 subjects (7.1%), followed by injection site hematoma in 8 subjects (1.0%).",Headache is an adverse reaction entity
"Headache was the most common adverse reaction, reported for 57 subjects (7.1%), followed by injection site hematoma in 8 subjects (1.0%).",", is not a named entity"
"Headache was the most common adverse reaction, reported for 57 subjects (7.1%), followed by injection site hematoma in 8 subjects (1.0%).",( 7.1 % is not a named entity
"Headache was the most common adverse reaction, reported for 57 subjects (7.1%), followed by injection site hematoma in 8 subjects (1.0%).",injection site hematoma is an adverse reaction entity
Glabellar Lines:  The most commonly observed adverse reaction (>1% of patients and > placebo) is headache (  6.1  ).,( 6.1 is not a named entity
Glabellar Lines:  The most commonly observed adverse reaction (>1% of patients and > placebo) is headache (  6.1  ).,headache is an adverse reaction entity
